Subject,Relationship,Object
NCT03821493,involves,Healthy Participants
NCT03821493,evaluates,Itraconazole
NCT03821493,measures_primary,AUC (0-inf) PF-06651600
NCT03821493,measures_secondary,Maximum observed plasma concentration
NCT03821493,has_criteria,BMI 17.5 to 30.5 kg/m2
NCT03821493,has_criteria,total body weight >50 kg
NCT03821493,has_criteria,congestive heart failure
NCT03821493,has_criteria,hypersensitivity itraconazole
NCT03821493,has_criteria,Hepatitis B
NCT03821493,has_criteria,malignancy
NCT04544293,involves,Autoimmune Pulmonary Alveolar Proteinosis
NCT04544293,evaluates,Inhaled Molgramostim Nebulizer Solution
NCT04544293,measures_primary,Change from baseline in % predicted DLCO
NCT04544293,measures_secondary,St. Georges Respiratory Questionnaire Total score
NCT04544293,measures_secondary,SGRQ Activity component score
NCT04544293,has_criteria,From Baseline to Week 24
NCT04544293,has_criteria,From Baseline to Week 48
NCT03181893,involves,Dermatomyositis
NCT03181893,evaluates,Intravenous Sabirnetug
NCT03181893,measures_primary,CDASI activity score
NCT03181893,measures_secondary,Treatment Emergent Adverse Events
NCT03181893,has_criteria,Baseline and Week 12
NCT01328093,involves,Schizophrenia
NCT01328093,evaluates,LY2140023
NCT01328093,evaluates,Aripiprazole
NCT01328093,measures_primary,Body Weight Change
NCT01328093,measures_secondary,Barnes Akathisia Scale
NCT01328093,measures_secondary,Simpson-Angus Scale
NCT01328093,has_criteria,Baseline
NCT04732793,involves,Knee Osteoarthritis
NCT04732793,evaluates,Hyruan ONE
NCT04732793,measures_primary,WOMAC pain score
NCT04732793,measures_secondary,WOMAC stiffness
NCT04732793,measures_secondary,WOMAC function
NCT04732793,has_criteria,Baseline to 13 weeks post injection
NCT02240693,involves,Alzheimer Disease
NCT02240693,evaluates,BI 409306
NCT02240693,measures_primary,Change From Baseline
NCT02240693,measures_secondary,ADCS-MCI-ADL Total Score
NCT02240693,has_criteria,Activities of Daily Living
NCT06456593,involves,Crohn's Disease
NCT06456593,evaluates,Obefazimod
NCT06456593,measures_primary,Crohn's Disease Activity Index (CDAI)
NCT06456593,measures_primary,Change from baseline in CDAI score
NCT06456593,measures_secondary,Simple Endoscopic Score for Crohn's disease (SES-CD)
NCT06456593,measures_secondary,Endoscopic response
NCT06456593,measures_secondary,SES-CD ulcer subscore > 1
NCT06456593,measures_secondary,CDAI clinical remission
NCT06456593,measures_secondary,PRO-2 clinical remission
NCT06456593,measures_secondary,CDAI clinical response
NCT06456593,measures_secondary,PRO-2 clinical response
NCT06456593,has_criteria,Week 12
NCT06456593,has_criteria,Week 52
NCT05590793,involves,Advanced Cancer of the Prostate
NCT05590793,evaluates,Triptorelin Pamoate
NCT05590793,measures_primary,Castrate levels testosterone
NCT05590793,measures_secondary,Treatment emergent adverse event
NCT05590793,measures_secondary,Clinical laboratory tests
NCT05590793,measures_secondary,Physical examination
NCT05590793,measures_secondary,Electrocardiogram readings
NCT05590793,measures_secondary,Vital signs
NCT05590793,measures_secondary,Prostate specific antigen
NCT05590793,has_criteria,Adult Chinese participants
NCT05732454,involves,Atopic Dermatitis
NCT05732454,evaluates,Etrasimod
NCT05732454,measures_primary,IGA clear or almost clear
NCT05732454,measures_secondary,Hemoglobin
NCT05732454,measures_secondary,RBC
NCT05732454,measures_secondary,Platelets
NCT05732454,measures_secondary,WBC
NCT05732454,measures_secondary,TBNK panel
NCT05732454,measures_secondary,Hematocrit
NCT05732454,measures_secondary,Total bilirubin
NCT05732454,measures_secondary,Urea Nitrogen
NCT05732454,measures_secondary,Creatinine
NCT05732454,has_criteria,oral treatments
NCT02220933,involves,Spinal Progressive Multiple Sclerosis
NCT02220933,evaluates,MD1003
NCT02220933,measures_primary,EDSS or TW25
NCT02220933,measures_secondary,MSWS
NCT02220933,has_criteria,decreased EDSS
NCT03836287,involves,Axillary Hyperhidrosis
NCT03836287,evaluates,Sofpironium Bromide Gel
NCT03836287,measures_primary,Hyperhidrosis Disease Severity
NCT03836287,measures_secondary,Gravimetric Sweat Production
NCT03836287,has_criteria,11-15 weeks
NCT03068754,involves,Amyotrophic Lateral Sclerosis
NCT03068754,evaluates,Acthar Gel
NCT03068754,measures_primary,ALSFRS-R score
NCT03068754,measures_secondary,Spirometry
NCT03068754,has_criteria,Clinically significant changes
NCT06272487,involves,Hypertension
NCT06272487,evaluates,Zilebesiran
NCT06272487,measures_primary,Change from Baseline
NCT06272487,measures_secondary,Serum Angiotensinogen
NCT06272487,has_criteria,Standard of Care
NCT02438787,involves,Anti-TNF(Alpha) Refractory
NCT02438787,evaluates,Ustekinumab
NCT02438787,measures_primary,ASAS 40 Response
NCT02438787,measures_secondary,ASAS 20 Response
NCT02438787,has_criteria,Active Radiographic Axial Spondyloarthritis
NCT04053387,involves,Plaque Psoriasis
NCT04053387,evaluates,Tapinarof cream
NCT04053387,measures_primary,Median Time to First Worsening
NCT04053387,measures_secondary,Clinically Meaningful Changes
NCT04053387,has_criteria,PGA = 0 (Clear)
NCT05002933,involves,Type 2 Diabetes Mellitus
NCT05002933,evaluates,Insulin glargine U300
NCT05002933,measures_primary,Mean change HbA1c
NCT05002933,measures_secondary,Percentage achieving HbA1c target
NCT05002933,has_criteria,Adult patients age≥18 years
NCT05426733,involves,Biliary Atresia
NCT05426733,evaluates,Odevixibat
NCT05426733,measures_primary,Proportion alive
NCT05426733,measures_secondary,Change AST to platelet ratio index
NCT05426733,measures_secondary,Change Fibrosis-4 score
NCT05426733,measures_secondary,Change serum bile acids
NCT05426733,measures_secondary,Change height
NCT05426733,measures_secondary,Change weight
NCT05426733,measures_secondary,Change mid-arm circumference
NCT05426733,measures_secondary,Time to onset sentinel events
NCT05426733,measures_secondary,Change pediatric end-stage liver disease score
NCT05426733,has_criteria,Completion of 104-week Treatment Period
NCT05426733,has_criteria,Signed informed consent
NCT04437433,involves,Migraine
NCT04437433,evaluates,Oral Atogepant
NCT04437433,measures_primary,Treatment Emergent Adverse Event
NCT04437433,measures_secondary,Clinically Significant Laboratory Values
NCT04437433,measures_secondary,Clinically Significant ECG Findings
NCT04437433,measures_secondary,Clinically Significant Vital Sign Measurements
NCT04437433,measures_secondary,Columbia-Suicide Severity Rating Scale
NCT04437433,has_criteria,Completed Visit 7
NCT04479787,involves,Low Back Pain
NCT04479787,evaluates,Spinal Cord Stimulation
NCT04479787,evaluates,Medical Management
NCT04479787,measures_primary,Composite Responder Rate
NCT04479787,measures_secondary,NRS Relative Change
NCT04479787,measures_secondary,ODI Change
NCT04479787,measures_secondary,PCS Responder Rate
NCT04479787,has_criteria,≥ 50% decrease NRS
NCT00327587,involves,Hypertension
NCT00327587,evaluates,Valsartan
NCT00327587,evaluates,HCTZ
NCT00327587,evaluates,Amlodipine
NCT00327587,measures_primary,Diastolic blood pressure
NCT00327587,measures_primary,Systolic blood pressure
NCT00327587,measures_secondary,Blood pressure
NCT00327587,measures_secondary,Systolic blood pressure
NCT00327587,measures_secondary,Diastolic blood pressure
NCT00327587,has_criteria,MSDBP ≥ 100 mmHg and < 120 mmHg
NCT00327587,has_criteria,MSSBP ≥ 145 mmHg and < 200 mmHg
NCT00327587,has_criteria,MSSBP ≥ 180 mmHg and/or MSDBP ≥ 110 mmHg
NCT00327587,has_criteria,MSDBP ≥ 90 mmHg and < 110 mmHg
NCT00327587,has_criteria,MSSBP ≥ 140 mmHg and < 180 mmHg
NCT00327587,has_criteria,Arm circumference > 42 cm
NCT02618187,involves,Ulcerative Colitis
NCT02618187,evaluates,SER-287
NCT02618187,measures_primary,Clinical Remission
NCT02618187,measures_secondary,Microbiome Dynamics
NCT02618187,has_criteria,Total Modified Mayo Score
NCT01429987,involves,Chronic Idiopathic Constipation
NCT01429987,evaluates,Plecanatide
NCT01429987,measures_primary,12-week CSBM Frequency
NCT01429987,measures_secondary,Stool Consistency
NCT01429987,measures_secondary,Straining Score
NCT01429987,has_criteria,Age 18-75
NCT01429987,has_criteria,BMI 18-35
NCT01429987,has_criteria,Rome III criteria
NCT04158687,involves,Schizophrenia
NCT04158687,evaluates,CTP-692
NCT04158687,measures_primary,Change From Baseline
NCT04158687,measures_secondary,Clinical Global Impression-Severity Score
NCT04158687,measures_secondary,Personal and Social Performance Scale
NCT04158687,has_criteria,Adults
NCT01862887,involves,QTc interval
NCT01862887,evaluates,PH-797804
NCT01862887,measures_primary,QTcF Interval
NCT01862887,measures_secondary,AUC (0-t)
NCT01862887,measures_secondary,Cmax
NCT01862887,measures_secondary,Tmax
NCT01862887,has_criteria,Healthy male subjects
NCT01862887,has_criteria,Healthy female subjects
NCT01862887,has_criteria,Body Mass Index (BMI)
NCT01862887,has_criteria,total body weight
NCT01862887,has_criteria,clinically significant hematological
NCT01862887,has_criteria,clinically significant renal
NCT01862887,has_criteria,clinically significant endocrine
NCT01862887,has_criteria,clinically significant pulmonary
NCT01862887,has_criteria,clinically significant gastrointestinal
NCT01862887,has_criteria,clinically significant cardiovascular
NCT01862887,has_criteria,clinically significant hepatic
NCT01862887,has_criteria,clinically significant psychiatric
NCT01862887,has_criteria,clinically significant neurologic
NCT01862887,has_criteria,clinically significant allergic
NCT01862887,has_criteria,positive urine drug screen
NCT01862887,has_criteria,regular alcohol consumption
NCT00397033,involves,Schizoaffective Disorder
NCT00397033,evaluates,Paliperidone Extended Release
NCT00397033,measures_primary,PANSS Total Score
NCT00397033,measures_secondary,PANSS Positive Subscale Score
NCT00397033,has_criteria,30% or more reduction
NCT04172233,involves,Plaque Psoriasis
NCT04172233,evaluates,AK101
NCT04172233,measures_primary,PASI75
NCT04172233,measures_secondary,PASI90
NCT04172233,measures_secondary,Physician Global Assessment
NCT04172233,has_criteria,≥ 10% body surface area
NCT04172233,has_criteria,PASI ≥12
NCT04172233,has_criteria,Physicians Global Assessment score ≥3
NCT05522387,involves,Alzheimer's Disease
NCT05522387,evaluates,XPro1595
NCT05522387,measures_primary,Change from Baseline
NCT05522387,measures_secondary,Clinical Dementia Rating Scale
NCT05522387,has_criteria,defined criteria
NCT00848354,involves,Rheumatoid arthritis
NCT00848354,evaluates,Etanercept
NCT00848354,measures_primary,ACR50 response
NCT00848354,measures_secondary,HAQ Score
NCT00848354,measures_secondary,SF-36 Score
NCT00848354,has_criteria,Baseline and Week 24
NCT02674633,involves,ADHD
NCT02674633,evaluates,Software
NCT02674633,measures_primary,TOVA API
NCT02674633,measures_secondary,ADHD-RS Total
NCT02674633,has_criteria,DSM-IV
NCT00886587,involves,Atopic Dermatitis
NCT00886587,evaluates,Device
NCT00886587,measures_primary,EASI Score Day 43
NCT00886587,measures_secondary,IGADA Score Day 43
NCT00886587,measures_secondary,Itch Score Day 43
NCT00886587,has_criteria,Post-menarchal female
NCT00886587,has_criteria,Negative urine pregnancy test
NCT00886587,has_criteria,Diagnosed with AD
NCT00886587,has_criteria,Willing to provide consent
NCT05054387,involves,Fabry disease
NCT05054387,evaluates,Fabrazyme
NCT05054387,measures_primary,change of Fabry disease symptoms
NCT05054387,measures_secondary,eGFR
NCT05054387,has_criteria,8 years of age or older
NCT05054387,has_criteria,naive to agalsidase beta
NCT05054387,has_criteria,diagnosed with Fabry disease
NCT05054387,has_criteria,plasma or leukocyte αGAL activity deficient
NCT04360187,involves,Atopic Dermatitis
NCT04360187,evaluates,Crisaborole
NCT04360187,measures_primary,Eczema Area and Severity Index
NCT04360187,measures_secondary,Treatment-Emergent Adverse Events
NCT04360187,measures_secondary,Serious Adverse Events
NCT04360187,measures_secondary,Clinically Significant Changes
NCT04360187,has_criteria,≥2 Years of Age
NCT00678587,involves,Chronic Liver Disease
NCT00678587,involves,Thrombocytopenia
NCT00678587,evaluates,Eltrombopag
NCT00678587,measures_primary,Platelet Transfusion
NCT00678587,measures_secondary,WHO Bleeding Score
NCT00678587,has_criteria,Platelets <50 Gi/L
NCT01098487,involves,Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT01098487,evaluates,Eltrombopag
NCT01098487,measures_primary,MF Grade change
NCT01098487,measures_secondary,Collagen Level
NCT01098487,has_criteria,centrally-reviewed BM biopsy
NCT03772587,involves,Generalized Myasthenia Gravis
NCT03772587,evaluates,M281
NCT03772587,measures_primary,Number of TEAEs
NCT03772587,measures_secondary,Number of SAEs
NCT03772587,measures_secondary,Number of AESI
NCT03772587,has_criteria,Up to Day 113
NCT00876187,involves,Chronic Low Back Pain
NCT00876187,evaluates,Tanezumab
NCT00876187,measures_primary,LBPI score
NCT00876187,measures_secondary,RMDQ Total Score
NCT00876187,measures_secondary,Patient's Global Assessment
NCT00876187,has_criteria,Baseline Observation Carried Forward
NCT00660387,involves,Parkinson's Disease
NCT00660387,evaluates,Levodopa-Carbidopa Intestinal Gel
NCT00660387,measures_primary,Change From Baseline
NCT00660387,measures_primary,"Average Daily Normalized ""Off"" Time"
NCT00660387,measures_secondary,Change From Baseline
NCT00660387,measures_secondary,"Average Daily Normalized ""On"" Time"
NCT00660387,measures_secondary,Parkinson's Disease Questionnaire (PDQ-39) Summary Index
NCT00660387,has_criteria,Levodopa-Responsive
NCT01255787,involves,Major Depressive Disorder
NCT01255787,evaluates,Vortioxetine
NCT01255787,measures_primary,MADRS total score
NCT01255787,measures_secondary,MADRS Response
NCT01255787,measures_secondary,MADRS Remission
NCT01255787,measures_secondary,CGI-I Score
NCT01255787,has_criteria,Baseline value
NCT00877487,involves,Attention-Deficit/Hyperactivity Disorder
NCT00877487,evaluates,Vyvanse
NCT00877487,measures_primary,ADHD-RS total score
NCT00877487,measures_secondary,CGI-S score
NCT00877487,has_criteria,18-55 years old
NCT00877487,has_criteria,negative pregnancy test
NCT00877487,has_criteria,documented ADHD diagnosis
NCT00877487,has_criteria,ADHD-RS score < 22
NCT00877487,has_criteria,CGI-S score ≤3
NCT00877487,has_criteria,stable SPD489 treatment 6 months
NCT01524887,involves,Alzheimer's Disease
NCT01524887,evaluates,IGIV
NCT01524887,measures_primary,Cognitive Subscale ADAS-Cog
NCT01524887,measures_secondary,ADCS-Activities of Daily Living
NCT01524887,measures_secondary,ADCS-Clinical Global Impression of Change
NCT01524887,measures_secondary,Neuropsychiatric Inventory
NCT01524887,has_criteria,Baseline to 9 Months
NCT01617187,involves,Schizophrenia
NCT01617187,evaluates,Asenapine
NCT01617187,measures_primary,Change From Baseline
NCT01617187,measures_secondary,CGI-S Score
NCT01617187,measures_secondary,PANSS Responders
NCT01617187,has_criteria,Baseline and Day 42
NCT03465787,involves,Schizophrenia
NCT03465787,evaluates,Lurasidone HCL
NCT03465787,measures_primary,Total PANSS Score
NCT03465787,measures_secondary,CGI-S score
NCT03465787,has_criteria,aged 19-75 years
NCT03465787,has_criteria,DSM-5 schizophrenia
NCT03465787,has_criteria,CGI-S ≥ 4
NCT03465787,has_criteria,not pregnant or nursing
NCT03465787,has_criteria,off prior antipsychotics
NCT03465787,has_criteria,good physical health
NCT03465787,has_criteria,no chronic CNS disease
NCT03465787,has_criteria,no prior lurasidone trial
NCT03465787,has_criteria,no recent alcohol/drug abuse
NCT03465787,has_criteria,able to cooperate
NCT05865496,involves,Chronic Rhinosinusitis With Nasal Polyps
NCT05865496,evaluates,611
NCT05865496,measures_primary,Bilateral NPS
NCT05865496,measures_secondary,Nasal Congestion Symptom Severity Score
NCT05865496,measures_secondary,Lund Mackay Score
NCT05865496,measures_secondary,Total Nasal Symptom Score
NCT05865496,measures_secondary,UPSIT Score
NCT05865496,has_criteria,Up to 16 weeks
NCT03909516,involves,Anterior Cruciate Ligament Reconstruction
NCT03909516,evaluates,Iovera° Device
NCT03909516,measures_primary,Average Daily Pain
NCT03909516,measures_secondary,Area-Under-Effect
NCT03909516,measures_secondary,Single Assessment Numerical Evaluation
NCT03909516,measures_secondary,Knee Injury and Osteoarthritis Outcomes Score
NCT03909516,has_criteria,Baseline to 10 days post-surgery
NCT03909516,has_criteria,Baseline to 12 Week
NCT03836716,involves,Amyotropic Lateral Sclerosis
NCT03836716,evaluates,Arimoclomol
NCT03836716,measures_primary,Mean and Change
NCT03836716,measures_secondary,Standard hematology parameters
NCT03836716,has_criteria,first dose of IMP
NCT02111096,involves,Type 2 Diabetes Mellitus
NCT02111096,evaluates,LY2409021
NCT02111096,measures_primary,Hepatic Fat Fraction
NCT02111096,measures_secondary,Alanine Aminotransferase Levels
NCT02111096,measures_secondary,Fasting Lipids Levels
NCT02111096,measures_secondary,Fasting Blood Glucagon
NCT02111096,measures_secondary,Body Weight
NCT02111096,has_criteria,HbA1c stratum
NCT02046616,involves,Rheumatoid Arthritis
NCT02046616,evaluates,Tocilizumab
NCT02046616,measures_primary,Change From Baseline in CDAI
NCT02046616,measures_primary,Change From Baseline in DAS28-ESR Score
NCT02046616,measures_secondary,Percentage of Participants With American College of Rheumatology Response
NCT02046616,has_criteria,Inadequate Response to DMARDs
NCT01647516,involves,Ulcerative Colitis
NCT01647516,evaluates,Ozanimod
NCT01647516,measures_primary,Clinical Remission
NCT01647516,measures_secondary,Clinical Response
NCT01647516,has_criteria,Mayo score
NCT01058096,involves,Bipolar I Disorder
NCT01058096,evaluates,Cariprazine
NCT01058096,measures_primary,YMRS Total Score
NCT01058096,measures_secondary,CGI-S Total Score
NCT01058096,has_criteria,Informed consent
NCT02317016,involves,EGFRm+ Non-small Cell Lung Cancer
NCT02317016,evaluates,AZD9291
NCT02317016,measures_primary,Rosuvastatin Cmax
NCT02317016,measures_secondary,Rosuvastatin AUC
NCT02317016,measures_secondary,Rosuvastatin Tmax
NCT02317016,measures_secondary,Rosuvastatin AUC0-t
NCT04839016,involves,plaque psoriasis
NCT04839016,evaluates,SHR-1314
NCT04839016,measures_primary,PASI 90 at Week 12
NCT04839016,measures_secondary,sPGA of 0 or 1 at Week 12
NCT04839016,measures_secondary,PASI 75 at Week 12
NCT04839016,measures_secondary,PASI 100 at Week 12
NCT04839016,has_criteria,18 years or older
NCT04839016,has_criteria,chronic plaque-type psoriasis
NCT04839016,has_criteria,PASI score 12 or greater
NCT04839016,has_criteria,sPGA score 3 or greater
NCT04839016,has_criteria,BSA 10% or greater
NCT04839016,has_criteria,inadequately controlled by topical treatment
NCT04839016,has_criteria,inadequately controlled by phototherapy
NCT04839016,has_criteria,inadequately controlled by previous systemic therapy
NCT04839016,has_criteria,BMI 18 kg/m2 or above
NCT03971422,involves,Generalized Myasthenia Gravis
NCT03971422,evaluates,Rozanolixizumab
NCT03971422,measures_primary,Change From Baseline
NCT03971422,measures_secondary,Percentage of Participants Achieving MG-ADL Response
NCT03971422,has_criteria,Baseline and Day 43
NCT03845075,involves,Hypothalamic Injury-induced Obesity
NCT03845075,evaluates,Tesofensine
NCT03845075,evaluates,Metoprolol
NCT03845075,measures_primary,Number of adverse events
NCT03845075,measures_secondary,Serious adverse events
NCT03845075,measures_secondary,Systolic Blood Pressure
NCT03845075,measures_secondary,Diastolic Blood Pressure
NCT03845075,measures_secondary,Heart Rate
NCT03845075,measures_secondary,Hematology Parameters
NCT03845075,measures_secondary,Electrolytes and Creatinine
NCT03845075,measures_secondary,Liver and Kidney Function Tests
NCT03845075,has_criteria,Treatment emergent adverse events
NCT04507659,involves,Ankylosing Spondylitis
NCT04507659,evaluates,Jaktinib Hydrochloride Tablets
NCT04507659,measures_primary,ASAS 20 at Week 16
NCT04507659,measures_secondary,ASAS 20 at Week 2
NCT04507659,measures_secondary,ASAS 40 at Week 2
NCT04507659,measures_secondary,ASAS 70 at Week 2
NCT04507659,has_criteria,≥20% and ≥1 unit
NCT02868359,involves,Chronic Cervical Pain
NCT02868359,evaluates,Pregabalin
NCT02868359,measures_primary,Pain Related Sleep Interference
NCT02868359,measures_secondary,Neck Disability Index
NCT02868359,measures_secondary,Pain Numeric Rating Scale
NCT02868359,measures_secondary,Euro Qol- 5 Dimensions -5 Level
NCT02868359,has_criteria,rescue medication
NCT01649375,involves,Ankylosing Spondylitis
NCT01649375,evaluates,Secukinumab
NCT01649375,measures_primary,ASAS 20 response
NCT01649375,measures_secondary,ASAS 40 response
NCT01649375,measures_secondary,hsCRP
NCT01649375,has_criteria,Baseline up to 16 weeks
NCT00809159,involves,Ankylosing Spondylitis
NCT00809159,evaluates,AIN457
NCT00809159,measures_primary,ASAS20 Response
NCT00809159,measures_secondary,BASDAI Score
NCT00809159,has_criteria,Moderate to Severe
NCT00365859,involves,Autistic Disorder
NCT00365859,evaluates,Aripiprazole
NCT00365859,measures_primary,Simpson-Angus Scale
NCT00365859,measures_secondary,Abnormal Involuntary Movement Scale
NCT00365859,has_criteria,Screening to Week 52
NCT04312659,involves,Crohn's Disease
NCT04312659,evaluates,Infliximab
NCT04312659,measures_primary,Clinical Response
NCT04312659,measures_primary,Clinical Remission
NCT04312659,measures_secondary,Endoscopic Remission
NCT04312659,measures_secondary,Height Z-Scores
NCT04312659,has_criteria,Children
NCT04098575,involves,Type 2 Diabetes
NCT04098575,evaluates,Empagliflozin
NCT04731675,involves,Tenosynovial Giant Cell Tumor of the Knee
NCT04731675,evaluates,AMB-05X
NCT04731675,measures_primary,Tumor Response RECIST
NCT04731675,measures_secondary,Range of Motion
NCT04731675,measures_secondary,PROMIS Physical Function Score
NCT04731675,has_criteria,Treatment-emergent Adverse Events
NCT03881059,involves,Psoriatic Arthritis
NCT03881059,evaluates,BMS-986165
NCT03881059,measures_primary,ACR 20 Response
NCT03881059,measures_secondary,PASI 75 Response
NCT03881059,has_criteria,tender joints
NCT04680975,involves,Diffuse Cutaneous Systemic Sclerosis
NCT04680975,evaluates,Belumosudil
NCT04680975,measures_primary,CRISS Score
NCT04680975,measures_secondary,mRSS
NCT04680975,measures_secondary,FVC percent predicted
NCT04680975,measures_secondary,physician global assessment
NCT04680975,measures_secondary,patient global assessment
NCT04680975,measures_secondary,SHAQ-DI
NCT04680975,has_criteria,new onset renal crisis
NCT04680975,has_criteria,new onset lung fibrosis
NCT04680975,has_criteria,pulmonary arterial hypertension
NCT04680975,has_criteria,left ventricular failure
NCT01603459,involves,Spasticity
NCT01603459,evaluates,Botulinum Toxin Type A
NCT01603459,measures_primary,Ashworth Scale Score
NCT01603459,measures_secondary,Investigator's Global Assessment of Tolerability
NCT01603459,has_criteria,Injection Cycle
NCT00614575,involves,Parkinson's disease
NCT00614575,involves,depressive symptoms
NCT00614575,evaluates,pramipexole
NCT00614575,measures_primary,UPDRS Part III Total Score
NCT00614575,measures_secondary,Beck's Depression Inventory Total Score
NCT00614575,measures_secondary,UPDRS Part I Item 3 Score
NCT00614575,measures_secondary,Modified Hoehn & Yahr Rating Scale
NCT00614575,has_criteria,12 weeks
NCT02400775,involves,Essential Hypertension
NCT02400775,involves,Stable Angina
NCT02400775,involves,Dyslipidemia
NCT02400775,evaluates,Azilsartan
NCT02400775,measures_primary,Change in lipid pool
NCT02400775,measures_secondary,Change in fibrotic component
NCT02400775,measures_secondary,Change in calcified component
NCT02400775,measures_secondary,Change in number of microchannels
NCT02400775,measures_secondary,Change in thickness of fibrous cap
NCT02400775,has_criteria,office blood pressure
NCT02698475,involves,Chronic Plaque Psoriasis
NCT02698475,evaluates,Ustekinumab
NCT02698475,measures_primary,PGA Score Cleared
NCT02698475,measures_secondary,PASI 75 Response
NCT02698475,measures_secondary,CDLQI Score
NCT02698475,has_criteria,Treatment Failure
NCT01351675,involves,Chronic Kidney Disease
NCT01351675,involves,Type 2 Diabetes
NCT01351675,evaluates,Bardoxolone Methyl
NCT01351675,measures_primary,Time-to-first event
NCT01351675,measures_secondary,Rate of change eGFR
NCT01351675,measures_secondary,Time to first hospitalization
NCT01351675,measures_secondary,Time to first event
NCT01351675,has_criteria,eGFR ≥ 15.0 and < 30.0 mL/min/1.73 m2
NCT01351675,has_criteria,History of type 2 diabetes
NCT01351675,has_criteria,Age ≥ 18 years
NCT01351675,has_criteria,Treatment with ACE inhibitor and/or ARB
NCT01351675,has_criteria,Stable dose 2 weeks prior
NCT01351675,has_criteria,Mean systolic blood pressure ≤ 160 mmHg
NCT01351675,has_criteria,Mean systolic blood pressure ≥ 105 mmHg
NCT01351675,has_criteria,Mean diastolic blood pressure < 90 mm Hg
NCT03550859,involves,Chronic Kidney Disease
NCT03550859,involves,Proteinuria
NCT03550859,evaluates,HMG-CoA Reductase
NCT03550859,measures_primary,Urine Protein to Creatinine Ratio
NCT03550859,measures_secondary,Urine Albumin-to-Creatinine Ratio
NCT03550859,measures_secondary,estimated glomerular filtration rate
NCT03550859,measures_secondary,high-sensitivity CRP
NCT03550859,measures_secondary,HOMA-insulin resistance
NCT03550859,measures_secondary,24hr urine protein
NCT03550859,measures_secondary,MCP-1
NCT03550859,measures_secondary,urinary 8-isoprostane
NCT03550859,measures_secondary,urine nephrin
NCT03550859,measures_secondary,type IV collagen
NCT03550859,has_criteria,aged ≥ 19 years
NCT03550859,has_criteria,CKD stage G2 or G3
NCT03550859,has_criteria,urine PCR 300 mg/g ≤ 3000 mg/g
NCT03550859,has_criteria,hypertension
NCT03550859,has_criteria,written informed consent
NCT03550859,has_criteria,statin treatment for 4 weeks
NCT00951275,involves,Rheumatoid Arthritis
NCT00951275,evaluates,Tocilizumab
NCT00951275,measures_primary,Hemoglobin levels
NCT00951275,measures_secondary,FACIT-F Scores
NCT00951275,has_criteria,Moderate to Severe Active
NCT04793659,involves,Wandering
NCT04793659,evaluates,Fasudil
NCT04793659,measures_primary,Global Impression of Wandering
NCT04793659,measures_secondary,Weekly Wandering Report
NCT04793659,measures_secondary,Revised Algase Wandering Scale
NCT04793659,measures_secondary,Mini Mental State Examination
NCT04793659,measures_secondary,Neuropsychiatric Inventory-Questionnaire
NCT04793659,has_criteria,Caregiver distress
NCT02684370,involves,Chronic Plaque Psoriasis
NCT02684370,evaluates,Risankizumab
NCT02684370,measures_primary,PASI90 at Week 16
NCT02684370,measures_secondary,sPGA Score at Week 16
NCT02684370,has_criteria,Moderate to Severe
NCT03498170,involves,Healthy male participants
NCT03498170,evaluates,Itraconazole
NCT03498170,measures_primary,BCT197 exposure
NCT03498170,measures_secondary,Adverse events
NCT03498170,has_criteria,Healthy male participants
NCT03498170,has_criteria,Non-smokers
NCT03498170,has_criteria,BMI 18-30 kg/m2
NCT03498170,has_criteria,Barrier contraception
NCT03498170,has_criteria,No sperm donation
NCT03498170,has_criteria,No pre-existing skin disease
NCT03498170,has_criteria,No clinically significant lab values
NCT03498170,has_criteria,Normal liver function tests
NCT03498170,has_criteria,QTcF ≤450 msec
NCT03498170,has_criteria,No allergy to BCT197 excipients
NCT03498170,has_criteria,No hypersensitivity to itraconazole
NCT03498170,has_criteria,No QTc prolonging medications
NCT03498170,has_criteria,Negative for HIV
NCT03498170,has_criteria,No clinically significant illness 30 days prior
NCT03498170,has_criteria,Suitable for participation
NCT02200575,involves,Hypertension
NCT02200575,evaluates,drug
NCT02200575,measures_primary,blood pressure changes
NCT02200575,measures_secondary,treatment compliance
NCT02200575,has_criteria,age 18+
NCT03774875,involves,Plaque Psoriasis
NCT03774875,evaluates,Apremilast
NCT03774875,measures_primary,DLQI at Week 16
NCT03774875,measures_secondary,BSA Affected by Psoriasis
NCT03774875,measures_secondary,Itch NRS Score
NCT01644175,involves,Hypercholesterolemia
NCT01644175,involves,High Cardiovascular Risk
NCT01644175,evaluates,Alirocumab
NCT01644175,measures_primary,LDL-C at Week 24
NCT01644175,measures_secondary,Apolipoprotein B at Week 24
NCT03512275,involves,Hidradenitis Suppurativa
NCT03512275,evaluates,Bermekimab
NCT03512275,measures_primary,HiSCR at Week 12
NCT03512275,measures_secondary,Change From Baseline to Week 12 in VAS Score for Disease
NCT03512275,measures_secondary,Change From Baseline to Week 12 in VAS Score for Pain
NCT03512275,has_criteria,Predose at Days 14
NCT01126970,involves,Obesity
NCT01126970,evaluates,Velneperit
NCT01126970,evaluates,Orlistat
NCT01126970,measures_primary,change in body weight
NCT01126970,measures_secondary,waist circumference
NCT01126970,measures_secondary,hip circumference
NCT01126970,measures_secondary,BMI
NCT01126970,has_criteria,18 to 65 years old
NCT01126970,has_criteria,BMI 30.0 to 45.0 kg/m2
NCT06259175,involves,arterial hypertension
NCT06259175,evaluates,amlodipine/ indapamide/ perindopril
NCT06259175,measures_primary,Mean changes from baseline
NCT06259175,measures_secondary,Proportion of patients
NCT06259175,has_criteria,concomitant antihypertensive medicines
NCT01716975,involves,Schizophrenia
NCT01716975,evaluates,EVP-6124
NCT01716975,measures_primary,Change from Baseline
NCT01716975,measures_secondary,Safety and Tolerability
NCT01716975,has_criteria,Age 18 to 50 years
NCT02322775,involves,Asthma
NCT02322775,evaluates,Benralizumab
NCT02322775,measures_primary,FEV1 change
NCT02322775,measures_secondary,PEF change
NCT02322775,has_criteria,eosinophil count
NCT02322775,has_criteria,region
NCT01375075,involves,Hyperlipidemia
NCT01375075,evaluates,LY2484595
NCT01375075,measures_primary,Percent Change HDL-C
NCT01375075,measures_primary,Percent Change LDL-C
NCT01375075,measures_secondary,Area Under the Curve
NCT01375075,measures_secondary,Rash Episodes
NCT01375075,has_criteria,Baseline
NCT02549170,involves,Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT02549170,evaluates,HyQvia
NCT02549170,evaluates,Gammagard Liquid
NCT02549170,measures_primary,Relapse rate
NCT02549170,measures_secondary,Responder rate
NCT02549170,has_criteria,worsening of functional disability
NCT04981470,involves,Hypertension
NCT04981470,evaluates,baroloop System
NCT04981470,measures_primary,Composite MAE rate
NCT04981470,measures_secondary,Change in blood pressure
NCT04981470,measures_secondary,Change in 24-hour ABPM
NCT04981470,measures_secondary,Change in Office Blood Pressure
NCT04981470,measures_secondary,Change in antihypertensive drugs/dosages
NCT04981470,measures_secondary,Quality of Life Evaluation
NCT04981470,has_criteria,Aged 18-79 years
NCT06488170,involves,psoriasis
NCT06488170,involves,psoriatic arthritis
NCT06488170,evaluates,Tildrakizumab
NCT06488170,measures_primary,Change From Baseline
NCT06488170,measures_secondary,Dermatology Life Quality Index
NCT06488170,measures_secondary,Psoriasis Area and Severity Index
NCT06488170,measures_secondary,Relative PASI Score
NCT06488170,has_criteria,Baseline to Week 28
NCT03284970,involves,RRMS
NCT03284970,evaluates,Rebif
NCT03284970,evaluates,Tecfidera
NCT03284970,measures_primary,Percentage of Infections
NCT03284970,measures_secondary,Lymphocyte Levels
NCT03284970,measures_secondary,Lymphopenia Grades
NCT03284970,measures_secondary,CD4 and CD8 Counts
NCT03284970,measures_secondary,CD4 and CD8 Ratio
NCT03284970,measures_secondary,Adverse Events
NCT03284970,has_criteria,interferon beta 1a SC 44 micro-gram thrice a week
NCT03284970,has_criteria,dimethyl fumarate
NCT03284970,has_criteria,at least one year of laboratory values
NCT03284970,has_criteria,laboratory tests after January 1
NCT00445770,involves,Rheumatoid Arthritis
NCT00445770,evaluates,Etanercept
NCT00445770,evaluates,Methotrexate
NCT00445770,measures_primary,Change From Baseline in mTSS
NCT00445770,measures_secondary,Change From Baseline in Erosion Score
NCT00445770,measures_secondary,Change From Baseline in JSN Score
NCT00445770,has_criteria,Japanese Subjects
NCT04540770,evaluates,HuL001
NCT04540770,measures_primary,Frequency
NCT04540770,measures_secondary,Proportion of subjects who report clinically significant abnormal findings in physical examination
NCT04540770,measures_secondary,Change from baseline in blood pressure
NCT04540770,measures_secondary,Change from baseline in respiratory rate
NCT04540770,measures_secondary,Change from baseline in heart rate
NCT04540770,measures_secondary,Change from baseline in body temperature
NCT04540770,measures_secondary,Change from baseline in hematology assessments
NCT04540770,measures_secondary,Change from baseline in biochemistry assessments
NCT04540770,measures_secondary,Change from baseline in electrocardiogram (ECG) results
NCT02198170,involves,Healthy Volunteers
NCT02198170,evaluates,lenvatinib
NCT02198170,measures_primary,Pharmacokinetics
NCT02198170,measures_secondary,Safety
NCT02198170,has_criteria,Non-smoking
NCT02198170,has_criteria,age 18-55 years
NCT02198170,has_criteria,BMI 18-30 kg/m2
NCT02198170,has_criteria,negative pregnancy test
NCT01155570,involves,Psoriasis Vulgaris
NCT01155570,involves,Psoriatic Arthritis
NCT01155570,evaluates,Humira
NCT01155570,measures_primary,Physician's Global Assessment
NCT01155570,has_criteria,Japanese local regulations
NCT05593575,involves,Diabetic Kidney Disease
NCT05593575,evaluates,SPH3127 Tablets
NCT05593575,measures_primary,Percentage change UACR
NCT05593575,measures_secondary,Percentage change log-transformed UACR
NCT05593575,measures_secondary,Change trend eGFR
NCT05593575,has_criteria,Type 2 diabetes
NCT05593575,has_criteria,UACR 30 mg/g ≤ UACR \< 3000mg/g
NCT05593575,has_criteria,eGFR ≥ 45mL/min/1.73 m2
NCT05593575,has_criteria,AST and ALT ≤ 2 times ULN
NCT05593575,has_criteria,total bilirubin ≤ 1.5 times ULN
NCT05593575,has_criteria,hemoglobin ≥ 90 g/L
NCT05593575,has_criteria,Serum potassium 3.5 mmol/L ≤Serum potassium ≤ 4.8 mmol/L
NCT05593575,has_criteria,effective contraceptive measures
NCT05593575,has_criteria,informed consent
NCT06257875,involves,Ulcerative Colitis
NCT06257875,evaluates,Lutikizumab
NCT06257875,measures_primary,Endoscopic Improvement
NCT06257875,measures_secondary,Clinical Remission
NCT06257875,measures_secondary,Clinical Response
NCT06257875,has_criteria,Endoscopy subscore
NCT04244175,involves,Focal Onset Seizures
NCT04244175,evaluates,CVL-865
NCT04244175,measures_primary,Change From Baseline
NCT04244175,measures_secondary,Response Ratio
NCT04244175,measures_secondary,Percentage of Participants
NCT04244175,measures_secondary,Seizure-free Participants
NCT04244175,measures_secondary,Seizure Rate over Time
NCT04244175,measures_secondary,Patient's Global Impression
NCT04244175,measures_secondary,Change from Baseline in CGI-S
NCT04244175,has_criteria,Baseline up to Day 71
NCT05643170,involves,Schizophrenia
NCT05643170,evaluates,KarXT
NCT05643170,measures_primary,IAQ Scores
NCT05643170,measures_secondary,CGI-S Scores
NCT05643170,has_criteria,DSM-5 Diagnosis
NCT06546670,involves,Sickle Cell Disease
NCT06546670,evaluates,ITU512
NCT06546670,measures_primary,HbF%
NCT06546670,measures_secondary,AUC of ITU512
NCT06546670,measures_secondary,Cmax of ITU512
NCT06546670,measures_secondary,Tmax of ITU512
NCT06546670,has_criteria,Healthy Participants
NCT00811070,involves,Philadelphia chromosome positive leukemias
NCT00811070,evaluates,SKI-606
NCT00811070,measures_primary,Major Cytogenetic Response
NCT00811070,measures_secondary,Maximum Tolerated Dose
NCT00811070,has_criteria,Dose-Limiting Toxicity
NCT01968070,evaluates,LY3127760
NCT01968070,measures_primary,AUC 0-∞
NCT01968070,measures_secondary,Cmax
NCT01968070,has_criteria,Overtly healthy males
NCT01968070,has_criteria,Females
NCT01968070,has_criteria,Body mass index
NCT01968070,has_criteria,Normotensive
NCT06303570,involves,Dercum's Disease
NCT06303570,evaluates,CBL-514
NCT06303570,measures_primary,Complete Response
NCT06303570,measures_secondary,pain
NCT06303570,measures_secondary,partial response
NCT06303570,has_criteria,aged 18 to 64
NCT04545970,involves,Facial Lines
NCT04545970,evaluates,Cosmetic Product
NCT04545970,measures_primary,Investigator Clinical Grading
NCT04545970,measures_secondary,Subject Tolerability Assessment
NCT04545970,has_criteria,Baseline
NCT01951170,involves,Rheumatoid Arthritis
NCT01951170,evaluates,RoActemra/Actemra
NCT01951170,measures_primary,Change from baseline mTSS
NCT01951170,measures_secondary,DAS28-ESR Remission
NCT01951170,measures_secondary,ACR20/50/70 Responses
NCT01951170,has_criteria,Disease activity score 28-ESR
NCT02848170,involves,essential hypertension
NCT02848170,evaluates,CS-3150
NCT02848170,evaluates,Olmesartan
NCT02848170,measures_primary,blood pressure change
NCT02848170,measures_secondary,blood pressure control
NCT02848170,has_criteria,age ≥ 20 years
NCT02848170,has_criteria,mean 24 hour SBP ≥ 130 mmHg
NCT02848170,has_criteria,mean 24 hour DBP ≥ 80 mmHg
NCT02848170,has_criteria,Sitting SBP ≥ 140 mmHg
NCT02848170,has_criteria,Sitting SBP < 180 mmHg
NCT02848170,has_criteria,Sitting DBP ≥ 90 mmHg
NCT02848170,has_criteria,Sitting DBP < 110 mmHg
NCT02848170,has_criteria,no secondary hypertension
NCT02848170,has_criteria,no malignant hypertension
NCT02848170,has_criteria,no diabetes mellitus
NCT02848170,has_criteria,serum potassium 3.5-5.1 mEq/L
NCT02848170,has_criteria,normal day-night cycle
NCT02848170,has_criteria,eGFR ≥ 60 mL/min/1.73 m\^2
NCT04132570,involves,Rhinitis
NCT04132570,evaluates,Intranasal Budesonide Aqueous Spray
NCT04132570,measures_primary,rTNSS change
NCT04132570,measures_secondary,SGIC
NCT04132570,measures_secondary,Individual Nasal Symptoms Scores
NCT04132570,measures_secondary,Individual non-Nasal Symptoms Score
NCT04132570,has_criteria,Baseline up to 10 days
NCT03100942,involves,Sjogren's Syndrome
NCT03100942,evaluates,Filgotinib
NCT03100942,evaluates,Lanraplenib
NCT03100942,evaluates,Tirabrutinib
NCT03100942,measures_primary,Percentage of Participants Fulfilling Protocol-Specified Response Criteria at Week 12
NCT03100942,measures_secondary,Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 12
NCT03100942,measures_secondary,Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) at Week 12
NCT03100942,has_criteria,Improvement ≥ 20% in ≥ 3 of 5 participant-reported Sjogren's syndrome (SjS) related visual analogue score (VAS) measures
NCT02477670,involves,Schizophrenia
NCT02477670,evaluates,AVP-786
NCT02477670,measures_primary,Change From Baseline
NCT02477670,measures_secondary,Change From Baseline
NCT02477670,has_criteria,Baseline and Week 6
NCT00549770,involves,Essential Hypertension
NCT00549770,evaluates,LCZ696A
NCT00549770,measures_primary,Change in msDBP
NCT00549770,measures_primary,Change in msSBP
NCT00549770,measures_secondary,Change in maDBP
NCT00549770,measures_secondary,Change in maSBP
NCT00549770,measures_secondary,Daytime maDBP
NCT00549770,measures_secondary,Nighttime maDBP
NCT00549770,has_criteria,baseline
NCT03345342,involves,Schizophrenia
NCT03345342,evaluates,Paliperidone Palmitate
NCT03345342,measures_primary,Time to relapse
NCT03345342,measures_secondary,Change From Baseline in PANSS Total Score
NCT03345342,measures_secondary,Change From Baseline in CGI-S Score
NCT03345342,has_criteria,Psychiatric hospitalization
NCT06191042,involves,Psoriasis Vulgaris
NCT06191042,involves,Psoriatic Arthritis
NCT06191042,evaluates,si-544
NCT06191042,measures_primary,psoriasis area and severity index
NCT06191042,measures_secondary,PASI response rate
NCT06191042,has_criteria,Adults
NCT06122649,involves,Plaque-type Psoriasis
NCT06122649,evaluates,Apremilast
NCT06122649,measures_primary,PASI 75% reduction
NCT06122649,measures_secondary,sPGA score 0 or 1
NCT06122649,measures_secondary,Whole Body Itch Scale
NCT06122649,measures_secondary,Scalp Physician's Globa Assesment
NCT06122649,measures_secondary,Affected Body Surface Area
NCT06122649,measures_secondary,Dermatology Life Quality Index
NCT06122649,measures_secondary,Scalp Itch NRS
NCT06122649,has_criteria,Chinese participants aged ≥18
NCT06122649,has_criteria,Diagnosis of chronic
NCT06122649,has_criteria,sPGA score ≥ 3
NCT06122649,has_criteria,PASI score ≥ 12
NCT06122649,has_criteria,BSA involvement ≥ 10%
NCT01124370,involves,Heart Failure
NCT01124370,evaluates,remedē System
NCT01124370,measures_primary,AHI Change From Baseline
NCT01124370,measures_secondary,Epworth Sleepiness Scale Change
NCT01124370,measures_secondary,Minnesota Living With Heart Failure Questionnaire Change
NCT01124370,has_criteria,Up to 2 years
NCT00608842,involves,Superficial Lipomas
NCT00608842,evaluates,study material
NCT00608842,measures_primary,Complete Clearance
NCT00608842,measures_secondary,Adverse Events
NCT00608842,has_criteria,palpable lipomas
NCT03823300,involves,Neovascular Age-Related Macular Degeneration
NCT03823300,evaluates,Faricimab
NCT03823300,measures_primary,Change From Baseline BCVA
NCT03823300,measures_secondary,Best Corrected Visual Acuity
NCT03823300,has_criteria,Baseline BCVA
NCT02718300,involves,Myelofibrosis
NCT02718300,evaluates,INCB050465
NCT02718300,evaluates,Ruxolitinib
NCT02718300,measures_primary,Spleen Volume
NCT02718300,measures_secondary,Symptom Score
NCT02718300,has_criteria,Day 28
NCT06019000,involves,hyposmia
NCT06019000,evaluates,CYR-064
NCT06019000,measures_primary,Safety and Tolerability
NCT06019000,measures_secondary,NRS-11 Smell-PRO
NCT06019000,measures_secondary,NRS-11 Taste-PRO
NCT06019000,measures_secondary,Mean Change in NRS-11 Smell-PRO
NCT06019000,measures_secondary,Mean Change in NRS-11 Taste-PRO
NCT06019000,measures_secondary,Change in VRS scores
NCT06019000,has_criteria,written informed consent
NCT06019000,has_criteria,18-65 years of age
NCT06019000,has_criteria,no structural issues
NCT00254800,involves,Healthy Females
NCT00254800,evaluates,Exenatide
NCT00254800,measures_primary,Pharmacokinetics profile
NCT00254800,measures_secondary,Safety and Tolerability
NCT00254800,has_criteria,Pre-menopausal female
NCT02762370,involves,Osteoarthritis of the knee
NCT02762370,involves,Type 2 Diabetes
NCT02762370,evaluates,FX006
NCT02762370,evaluates,TCA IR
NCT02762370,measures_primary,Glycemic Variability
NCT02762370,measures_secondary,Area Under the Effect (AUE) Curves
NCT02762370,has_criteria,Willingness and ability to comply
NCT01606670,involves,Parkinson's Disease
NCT01606670,evaluates,Neupro
NCT01606670,measures_primary,Change in UPDRS Part II
NCT01606670,measures_primary,Change in UPDRS Part III
NCT01606670,has_criteria,maintenance dose
NCT03559270,involves,Atopic Dermatitis
NCT03559270,evaluates,Baricitinib
NCT03559270,measures_primary,EASI75
NCT03559270,measures_secondary,IGA 0/1
NCT03559270,measures_secondary,BSA ≤3%
NCT03559270,has_criteria,Body Surface Area
NCT03585270,involves,Delayed Cerebral Ischemia
NCT03585270,evaluates,Clazosentan
NCT03585270,measures_primary,Clinical Deterioration
NCT03585270,measures_secondary,Cerebral Infarction
NCT03585270,has_criteria,Clinical Deterioration
NCT04014270,involves,Chronic Stroke
NCT04014270,evaluates,Self-modulated Functional Electrical Stimulation
NCT04014270,measures_primary,Change FMA-UE
NCT04014270,measures_secondary,Change ARAT
NCT04014270,has_criteria,Upper Limb Paresis
NCT01789970,involves,Chronic Low Back Pain
NCT01789970,evaluates,Hydrocodone Bitartrate Extended-Release Tablets
NCT01789970,measures_primary,Weekly Average Pain Intensity
NCT01789970,measures_secondary,Weekly Average Pain Intensity
NCT01789970,has_criteria,Discontinuation of study drug
NCT00647270,involves,Rheumatoid Arthritis
NCT00647270,evaluates,Adalimumab
NCT00647270,measures_primary,ACR20 response
NCT00647270,measures_secondary,HAQ-DI
NCT00647270,has_criteria,ACR20 criteria
NCT05397470,involves,Facioscapulohumeral Muscular Dystrophy
NCT05397470,evaluates,Losmapimod
NCT05397470,measures_primary,Change from Baseline in RSA
NCT05397470,measures_secondary,Quality of Life in Neurologic Disorders
NCT05397470,measures_secondary,Patient's Global Impression of Change
NCT05397470,has_criteria,Baseline and at Week 48
NCT02281370,involves,Healthy Subjects
NCT02281370,evaluates,Eltrombopag
NCT02281370,evaluates,Cyclosporine
NCT02281370,measures_primary,Composite PK parameters
NCT02281370,measures_secondary,Vital signs
NCT02281370,measures_secondary,Clinical laboratory assessments
NCT02281370,measures_secondary,Adverse events
NCT02281370,measures_secondary,Electrocardiogram
NCT02281370,has_criteria,18 to 64 years old
NCT02281370,has_criteria,Healthy subjects
NCT02281370,has_criteria,Body weight >=60 kg
NCT02281370,has_criteria,BMI 24.7-32.0 kg/m^2
NCT03099200,involves,HER2 Positive Breast Cancer
NCT03099200,evaluates,Productivity and Health-Related Quality of Life
NCT03099200,measures_primary,Work Productivity
NCT03099200,measures_secondary,Health Related Quality of Life
NCT03099200,has_criteria,Baseline
NCT03129100,involves,Axial Spondyloarthritis
NCT03129100,evaluates,Ixekizumab
NCT03129100,measures_primary,Percentage of Participants Who do Not Experience a Flare
NCT03129100,measures_secondary,ASDAS
NCT03129100,has_criteria,ASDAS ≥2.1
NCT03104400,involves,Psoriatic Arthritis
NCT03104400,evaluates,Upadacitinib
NCT03104400,evaluates,Placebo
NCT03104400,evaluates,Adalimumab
NCT03104400,measures_primary,ACR20 response
NCT03104400,measures_secondary,Change HAQ-DI
NCT03104400,has_criteria,Inadequate response DMARD
NCT02996500,involves,Rheumatoid Arthritis
NCT02996500,evaluates,Pf-06650833
NCT02996500,measures_primary,Change From Baseline in SDAI
NCT02996500,measures_secondary,Change From Baseline in SDAI
NCT02996500,has_criteria,Inadequate Response To Methotrexate
NCT06406400,involves,Opioid Use Disorder
NCT06406400,evaluates,AZD4041
NCT06406400,measures_primary,Self-reported withdrawal symptoms
NCT06406400,measures_secondary,Adverse events
NCT06406400,has_criteria,Day 4 pre-dose value
NCT01177800,involves,Plaque-type Psoriasis
NCT01177800,evaluates,Infliximab
NCT01177800,measures_primary,PASI 75 response
NCT01177800,measures_secondary,DLQI at Week 10
NCT01177800,measures_secondary,Static PGA Score
NCT01177800,has_criteria,Baseline improvement in PASI scores
NCT02065700,involves,Rheumatoid Arthritis
NCT02065700,evaluates,GLPG0634
NCT02065700,measures_primary,ACR20 Response
NCT02065700,measures_secondary,Treatment-Emergent Adverse Events
NCT02065700,has_criteria,filgotinib start date
NCT01689337,involves,Cartilage Injury of the Knee
NCT01689337,evaluates,Sprifermin
NCT01689337,evaluates,Placebo
NCT01689337,measures_primary,Composition of Refilled Cartilage
NCT01689337,measures_secondary,Change From Baseline in KOOS
NCT01689337,has_criteria,6 months post-MFx surgery
NCT04533737,involves,Psoriasis
NCT04533737,evaluates,Brodalumab
NCT04533737,evaluates,Guselkumab
NCT04533737,measures_primary,PASI 100 Response
NCT04533737,measures_secondary,Time to PASI 100
NCT04533737,has_criteria,weight <=100 kg
NCT04533737,has_criteria,weight >100 kg
NCT03877237,involves,Heart Failure With Reduced Ejection Fraction
NCT03877237,evaluates,Dapagliflozin
NCT03877237,measures_primary,Change From Baseline in KCCQ-TSS
NCT03877237,measures_secondary,Change From Baseline in KCCQ-PLS
NCT03877237,has_criteria,randomization visit
NCT02357537,involves,Ulcerative Colitis
NCT02357537,evaluates,Combined Anti-inflammatory Diet
NCT02357537,measures_primary,Endoscopy Mayo Score
NCT02357537,measures_secondary,Patient Simple Clinical Colitis Activity Index
NCT02357537,measures_secondary,Adverse Events
NCT02357537,has_criteria,Dietary Compliance
NCT04047537,involves,Type 2 Diabetes
NCT04047537,evaluates,WBF-0011
NCT04047537,measures_primary,Hemoglobin A1c
NCT04047537,measures_secondary,3-hour blood glucose AUC
NCT04047537,measures_secondary,Fasting Lipid Panel
NCT04047537,measures_secondary,Body weight
NCT04047537,measures_secondary,Adverse Events
NCT04047537,measures_secondary,Change from baseline in Laboratory Chemistry Values
NCT04047537,measures_secondary,Change from baseline in Laboratory Complete Blood count Values
NCT05318937,involves,Parkinson's Disease Cognitive Impairment
NCT05318937,evaluates,SAGE-718
NCT05318937,measures_primary,WAIS-IV Coding Test Score
NCT05318937,measures_secondary,Percentage of Participants with at Least One Treatment-Emergent Adverse Event (TEAE)
NCT05318937,has_criteria,idiopathic Parkinson's disease
NCT05318937,has_criteria,Montreal Cognitive Assessment (MoCA) score
NCT05318937,has_criteria,modified Hoehn \& Yahr Stage I to III
NCT05318937,has_criteria,stable motor symptoms
NCT06054737,involves,Chronic Venous Insufficiency
NCT06054737,evaluates,Balneotherapy
NCT06054737,measures_primary,CIVIQ-2 score
NCT06054737,measures_secondary,Quality of Life
NCT06054737,measures_secondary,VAS leg pain
NCT06054737,measures_secondary,Adverse events
NCT06054737,has_criteria,From inclusion
NCT01446237,involves,Acne
NCT01446237,evaluates,Benzoyl Peroxide 2.5%
NCT01446237,measures_primary,Lesion Counts
NCT01446237,measures_secondary,ISGA Score
NCT01446237,has_criteria,2-grade Improvement
NCT04052737,involves,Mild to Moderate Alzheimer's Disease
NCT04052737,evaluates,PMZ-1620
NCT04052737,measures_primary,drug related adverse events
NCT04052737,measures_secondary,clinical progression
NCT04052737,measures_secondary,neuropsychiatric inventory Score
NCT04052737,measures_secondary,ADAS-Cog
NCT04052737,has_criteria,160 days
NCT01145352,involves,Juvenile Idiopathic Arthritis
NCT01145352,evaluates,Etanercept
NCT01145352,measures_primary,DAS28-based response
NCT01145352,measures_secondary,Treatment-related adverse events
NCT01145352,has_criteria,EULAR response criteria
NCT05103332,involves,Hypertension
NCT05103332,evaluates,Zilebesiran
NCT05103332,measures_primary,Change from Baseline
NCT05103332,measures_secondary,Proportion of Patients
NCT05103332,has_criteria,Standard of Care
NCT02045732,involves,Multiple Sclerosis
NCT02045732,evaluates,PF-06342674
NCT02045732,measures_primary,Treatment-Emergent AEs
NCT02045732,measures_secondary,Laboratory Abnormalities
NCT02045732,measures_secondary,Clinically Significant Changes
NCT02045732,has_criteria,Baseline through Day 127/Early Termination
NCT05046132,evaluates,Setmelanotide
NCT05046132,evaluates,Moxifloxacin
NCT05046132,measures_primary,QTcF change
NCT05046132,measures_secondary,Heart Rate change
NCT05046132,has_criteria,Healthy Participants
NCT05169515,involves,B-Cell Non-Hodgkin Lymphoma
NCT05169515,evaluates,Mosunetuzumab
NCT05169515,evaluates,Glofitamab
NCT05169515,evaluates,CC-220
NCT05169515,evaluates,CC-99282
NCT05169515,measures_primary,Best ORR
NCT05169515,measures_primary,Best CR rate
NCT05169515,measures_secondary,Duration of response
NCT05169515,measures_secondary,Progression-free survival
NCT05169515,measures_secondary,Event-free survival
NCT05169515,measures_secondary,Overall survival
NCT05169515,has_criteria,Lugano 2014
NCT00831415,involves,Major Depressive Disorder
NCT00831415,evaluates,Desvenlafaxine Succinate Sustained Release
NCT00831415,measures_primary,HAM-D17 Score
NCT00831415,measures_secondary,Percentage of Participants With Adverse Events
NCT00831415,has_criteria,Baseline (Extension Study) up to Day 308 or Final On-Therapy (FOT) Evaluation
NCT01844115,involves,Generalized Anxiety Disorder
NCT01844115,evaluates,Vilazodone
NCT01844115,measures_primary,Change From Baseline HAM-A
NCT01844115,measures_secondary,Change From Baseline SDS
NCT01844115,has_criteria,18-70 years of age
NCT01844115,has_criteria,DSM-IV-TR criteria
NCT01844115,has_criteria,Hamilton Rating Scale for Anxiety score 20
NCT06084988,involves,Knee Osteoarthritis
NCT06084988,evaluates,StromaForte
NCT06084988,measures_primary,Pain assessment VAS
NCT06084988,measures_secondary,Knee function KOOS
NCT06084988,has_criteria,Adverse events CTCAE
NCT01885078,involves,Rheumatoid Arthritis
NCT01885078,measures_primary,ACR20 response
NCT01885078,has_criteria,Baseline through 84 Months
NCT03649971,involves,Familial Adenomatous Polyposis
NCT03649971,evaluates,Guselkumab
NCT03649971,measures_primary,Percentage Change from Baseline
NCT03649971,measures_secondary,Change in InSiGHT Stage
NCT03649971,measures_secondary,Change in Spigelman Stage Score
NCT03649971,has_criteria,Baseline
NCT03649971,has_criteria,Baseline
NCT05996471,involves,Human Immunodeficiency Virus
NCT05996471,evaluates,VH3810109
NCT05996471,evaluates,Cabotegravir
NCT05996471,measures_primary,Plasma HIV-1 RNA
NCT05996471,measures_secondary,Serious Adverse Events
NCT05996471,measures_secondary,Deaths
NCT05996471,measures_secondary,Adverse Events
NCT05996471,measures_secondary,Grade 3-4 AEs
NCT05996471,measures_secondary,Laboratory Abnormalities
NCT05996471,measures_secondary,Injection Site Reactions
NCT05996471,measures_secondary,Confirmed Virologic Failure
NCT05996471,measures_secondary,HIV Disease Progression
NCT05996471,measures_secondary,CD4+ T-Cell Count
NCT05996471,measures_secondary,CD8+ T-Cell Count
NCT05996471,measures_secondary,Anti-VH3810109 Antibodies
NCT05996471,measures_secondary,Neutralizing Antibodies
NCT05996471,measures_secondary,Treatment-emergent Genotypic Resistance
NCT05996471,measures_secondary,Treatment-emergent Phenotypic Resistance
NCT05996471,has_criteria,Age
NCT01033071,involves,Hypertension
NCT01033071,evaluates,Azilsartan Medoxomil
NCT01033071,evaluates,Chlorthalidone
NCT01033071,evaluates,Olmesartan Medoxomil
NCT01033071,evaluates,Hydrochlorothiazide
NCT01033071,measures_primary,Systolic Blood Pressure
NCT01033071,measures_secondary,Diastolic Blood Pressure
NCT02845271,involves,Painful Osteoarthritis of the Knee
NCT02845271,evaluates,GZ389988
NCT02845271,evaluates,Placebo
NCT02845271,measures_primary,Change from baseline
NCT02845271,measures_secondary,Patient Global Assessment
NCT02845271,measures_secondary,Patient Global Impression of Change
NCT02845271,measures_secondary,Patient Global Assessment of Response to Therapy
NCT02845271,measures_secondary,Rate of response to therapy
NCT02845271,has_criteria,Symptomatic variables
NCT01545388,involves,Type 2 Diabetes Mellitus
NCT01545388,evaluates,Metformin
NCT01545388,measures_primary,Change From Baseline
NCT01545388,measures_secondary,Percentage of Participants Who Experienced at Least One Adverse Event
NCT01545388,has_criteria,HbA1c ≥ 6.0% and ≤ 9.0%
NCT01545388,has_criteria,HbA1c ≥ 6.5% and < 10.0%
NCT00447278,involves,Attention-Deficit/Hyperactivity Disorder
NCT00447278,evaluates,Atomoxetine
NCT00447278,measures_primary,Change From Baseline
NCT00447278,measures_secondary,CHIP-CE PRF Domain Scores
NCT00447278,has_criteria,Child and Adolescent
NCT04488978,involves,Essential Hypertension
NCT04488978,evaluates,Irbesartan
NCT04488978,evaluates,Amlodipine
NCT04488978,measures_primary,Mean Sitting Systolic Blood Pressure
NCT04488978,measures_secondary,Mean Sitting Diastolic Blood Pressure
NCT04488978,measures_secondary,Proportion of patients
NCT04488978,has_criteria,19 years or older
NCT04488978,has_criteria,75 years or younger
NCT04488978,has_criteria,Signed informed consent
NCT04488978,has_criteria,Essential Hypertension
NCT04488978,has_criteria,Orthostatic hypertension
NCT04225871,involves,Generalized Myasthenia Gravis
NCT04225871,evaluates,Zilucoplan
NCT04225871,measures_primary,Change from Baseline to Week 12 in the MG-ADL Score
NCT04225871,measures_secondary,Change from Baseline to Week 12 in the QMG Score
NCT04225871,measures_secondary,Change from Baseline to Week 12 in the MGC Score
NCT04225871,measures_secondary,Change from Baseline to Week 12 in the MG-QOL15r Score
NCT02463071,involves,hypertriglyceridemia
NCT02463071,evaluates,AZD0585
NCT02463071,measures_primary,Percent Change in Serum Triglycerides
NCT02463071,measures_secondary,Percent Change in Serum Lipid Profile
NCT02463071,measures_secondary,Percent Changes in Plasma Fatty Acids Profile
NCT02463071,measures_secondary,Percent Changes in Apolipoproteins Profile
NCT02463071,measures_secondary,Percent Changes in Small Dense LDL
NCT02463071,measures_secondary,Percent Changes in Lp(a)
NCT02463071,measures_secondary,Percent Changes in RLP-C
NCT02463071,measures_secondary,Percent Changes in PCSK9
NCT02463071,measures_secondary,Percent Changes in Hs-CRP
NCT02463071,has_criteria,Japanese men or women
NCT01185288,involves,Rheumatoid Arthritis
NCT01185288,evaluates,Methotrexate
NCT01185288,measures_primary,DAS28(CRP) score
NCT01185288,measures_secondary,Power Doppler Ultrasound
NCT01185288,has_criteria,ACR50 criteria
NCT03026088,involves,Chronic Heart Failure
NCT03026088,evaluates,Oral Bisoprolol
NCT03026088,measures_primary,Resting Heart Rate
NCT03026088,measures_secondary,Left Ventricular Ejection Fraction
NCT03026088,measures_secondary,Left Ventricular End-Systolic Dimension
NCT03026088,measures_secondary,Left Ventricular End-diastolic Dimension
NCT03026088,measures_secondary,Interventricular Septal Thickness
NCT03026088,measures_secondary,Ratio of Early (E) to Late (A) Ventricular Filling Velocities
NCT03026088,has_criteria,Clinically Relevant Blood Pressure
NCT04232878,evaluates,CVL-936
NCT04232878,measures_primary,C-SSRS SI severity
NCT04232878,measures_secondary,Simpson-Angus Scale
NCT04232878,measures_secondary,Abnormal Involuntary Movement Scale
NCT04232878,has_criteria,Healthy Subjects
NCT02460978,involves,Type 1 Diabetes
NCT02460978,evaluates,Dapagliflozin
NCT02460978,measures_primary,HbA1c at Week 24
NCT02460978,measures_secondary,Total Daily Insulin Dose
NCT02460978,measures_secondary,Body Weight
NCT02460978,measures_secondary,24-hour CGM Mean Value
NCT02460978,measures_secondary,24-hour CGM Mean Amplitude of Glycemic Excursion
NCT02460978,measures_secondary,Percent of 24-hour Glucose Readings
NCT00744978,involves,Alzheimer's Disease
NCT00744978,evaluates,Varenicline
NCT00744978,measures_primary,ADAS-Cog 75 at Week 6
NCT00744978,measures_secondary,ADAS-Cog 75 at Week 3
NCT00744978,measures_secondary,ADAS-Cog 70 at Week 3
NCT00744978,measures_secondary,ADAS-Cog 70 at Week 6
NCT05695378,involves,Multiple System Atrophy
NCT05695378,evaluates,KM-819
NCT05695378,measures_primary,putaminal [18F]FP-CIT binding
NCT05695378,measures_secondary,UMSARS scores
NCT05695378,has_criteria,subjects with MSA
NCT01502371,involves,Persistent Asthma
NCT01502371,evaluates,Mometasone Furoate Metered Dose Inhaler
NCT01502371,measures_primary,Change From Baseline in AM FEV1
NCT01502371,measures_secondary,Change From Baseline in AM PEF
NCT01502371,measures_secondary,PAQLQ(S) Total Score
NCT01502371,has_criteria,participating countries
NCT03214588,involves,Friedreich Ataxia
NCT03214588,evaluates,TAK-831
NCT03214588,measures_primary,9-HPT-1
NCT03214588,measures_secondary,FARS ADL
NCT03214588,has_criteria,ambulation status
NCT01821378,involves,psychotic disorders
NCT01821378,evaluates,Lurasidone
NCT01821378,measures_primary,PANSS Total Score
NCT01821378,measures_secondary,CGI-S Score
NCT01821378,measures_secondary,MADRS total score
NCT01821378,has_criteria,20% or greater improvement
NCT01078571,involves,Rheumatoid Arthritis
NCT01078571,evaluates,Adalimumab
NCT01078571,measures_primary,DAS 28 index change
NCT01078571,measures_secondary,DAS 28 index percentage change
NCT01078571,has_criteria,Baseline
NCT04752371,involves,Adult-onset Still's disease
NCT04752371,evaluates,Camoteskimab
NCT04752371,measures_primary,Absence of fever
NCT04752371,measures_secondary,C-Reactive Protein Reduction
NCT04752371,has_criteria,18 to 75 years old
NCT01859988,involves,Atopic Dermatitis
NCT01859988,evaluates,Dupilumab
NCT01859988,measures_primary,EASI score change
NCT01859988,measures_secondary,IGA response
NCT01859988,measures_secondary,Pruritus NRS
NCT01859988,has_criteria,Baseline to Week 16
NCT04573478,involves,IgA Nephropathy
NCT04573478,evaluates,Atrasentan
NCT04573478,measures_primary,Change in eGFR
NCT04573478,measures_secondary,Proteinuria
NCT04573478,measures_secondary,Adverse Events
NCT04573478,has_criteria,non-SGLT2i stratum
NCT01433978,involves,Chronic Immune Thrombocytopenia
NCT01433978,evaluates,OralE5501
NCT01433978,evaluates,E5501
NCT01433978,measures_primary,Change From Baseline
NCT01433978,measures_secondary,Platelet responses
NCT01433978,has_criteria,non-missing data
NCT00744471,involves,Osteoarthritis Of The Hip
NCT00744471,evaluates,Tanezumab
NCT00744471,measures_primary,WOMAC Pain Subscale Score
NCT00744471,measures_secondary,WOMAC Physical Function Subscale Score
NCT00744471,measures_secondary,Patient Global Assessment
NCT00744471,has_criteria,Baseline Observation Carried Forward
NCT03669588,involves,Myasthenia Gravis
NCT03669588,evaluates,ARGX-113
NCT03669588,measures_primary,MG-ADL responders
NCT03669588,measures_secondary,MG-ADL responders
NCT03669588,has_criteria,Day 63
NCT02557178,involves,Chronic Obstructive Pulmonary Disease
NCT02557178,evaluates,Home-Based Health Management
NCT02557178,measures_primary,Change in Number of Daily Steps
NCT02557178,measures_secondary,Change in Physical Quality of Life
NCT02557178,has_criteria,SenseWear Pro ArmBand
NCT01595009,involves,Neuroendocrine Tumors
NCT01595009,evaluates,Everolimus
NCT01595009,measures_primary,Progression Free Survival
NCT01595009,measures_secondary,EORTC QLQ-C30 Score
NCT01595009,has_criteria,advanced NETs
NCT03364309,involves,Plaque Psoriasis
NCT03364309,evaluates,Ixekizumab
NCT03364309,measures_primary,PASI 75
NCT03364309,measures_secondary,sPGA score
NCT03364309,has_criteria,Chinese participants
NCT04820907,involves,Essential Hypertension
NCT04820907,evaluates,HCP1904-1
NCT04820907,measures_primary,Change in systolic blood pressure
NCT04820907,measures_secondary,Change in diastolic blood pressure
NCT04820907,measures_secondary,Pulse blood pressure
NCT04820907,measures_secondary,Responder rate
NCT04820907,measures_secondary,Target blood pressure reach rate
NCT04820907,has_criteria,
NCT03312907,involves,Systemic Lupus Erythematosus
NCT03312907,evaluates,Belimumab
NCT03312907,evaluates,Rituximab
NCT03312907,measures_primary,Disease Control at Week 52
NCT03312907,measures_primary,Clinical Remission at Week 64
NCT03312907,measures_secondary,SLEDAI-2K score
NCT03312907,has_criteria,corticosteroids at a prednisone equivalent dose
NCT05166707,involves,Obsessive-Compulsive Disorder
NCT05166707,evaluates,ERP-based Mobile Intervention
NCT05166707,measures_primary,OCD symptoms
NCT05166707,measures_secondary,Global Improvement
NCT05166707,measures_secondary,Severity of illness
NCT05166707,measures_secondary,Depression
NCT05166707,measures_secondary,Anxiety
NCT05166707,has_criteria,Screening/Baseline
NCT00905307,involves,Acute Schizophrenia
NCT00905307,evaluates,OPC-34712
NCT00905307,evaluates,Aripiprazole
NCT00905307,measures_primary,Change From Baseline
NCT00905307,measures_secondary,PANSS Positive Subscale Score
NCT00905307,measures_secondary,PANSS Negative Subscale Score
NCT00905307,has_criteria,Baseline to Week 6
NCT02770807,involves,Ataxia Telangiectasia
NCT02770807,evaluates,Intra-Erythrocyte Dexamethasone Sodium Phosphate
NCT02770807,measures_primary,Change From Baseline in mICARS
NCT02770807,measures_secondary,Clinical Global Impression of Change (CGI-C)
NCT02770807,measures_secondary,Clinical Global Impression of Severity (CGI-S)
NCT02770807,has_criteria,Clinical interview and examination
NCT04833907,involves,Canavan Disease
NCT04833907,evaluates,rAAV-Olig001-ASPA Gene Therapy
NCT04833907,measures_primary,Myelination
NCT04833907,measures_secondary,N-Acetyl-Aspartate concentrations
NCT04833907,measures_secondary,Motor Function
NCT04833907,measures_secondary,Neurocognitive Function
NCT04833907,measures_secondary,Spasticity
NCT04833907,has_criteria,12 Months Post Dose
NCT03823378,involves,Rheumatoid Arthritis
NCT03823378,evaluates,ABBV-105
NCT03823378,measures_primary,DAS28-CRP
NCT03823378,measures_secondary,Adverse Events
NCT03823378,has_criteria,Study M16-063
NCT00545571,involves,Chronic Renal Anemia
NCT00545571,evaluates,Mircera
NCT00545571,measures_primary,Hb within target range
NCT00545571,measures_secondary,Mean Change in Hb
NCT00545571,has_criteria,Hemodialysis Participants
NCT03775278,involves,Overweight
NCT03775278,involves,Obese
NCT03775278,evaluates,PHP-303
NCT03775278,measures_primary,Adverse Events
NCT03775278,measures_secondary,ECG parameters
NCT03775278,measures_secondary,blood pressure
NCT03775278,measures_secondary,heart rate
NCT03775278,measures_secondary,body temperature
NCT03775278,measures_secondary,respiratory rate
NCT03775278,measures_primary,AUC
NCT03775278,measures_primary,Cmax
NCT03775278,measures_primary,Tmax
NCT03775278,measures_primary,t1/2
NCT03775278,has_criteria,≥ 18 to ≤ 60 years
NCT03775278,has_criteria,good general health
NCT03775278,has_criteria,clinically significant diseases
NCT03775278,has_criteria,clinically significant findings
NCT00843778,involves,Rheumatoid Arthritis
NCT00843778,evaluates,C87080
NCT00843778,measures_primary,DAS28[ESR] Remission
NCT00843778,measures_secondary,Treatment-emergent Adverse Event
NCT00843778,measures_secondary,Serious Adverse Event
NCT00843778,has_criteria,Disease Activity Score
NCT06603571,involves,Obesity
NCT06603571,involves,Overweight
NCT06603571,involves,Type 2 Diabetes
NCT06603571,evaluates,LY3841136
NCT06603571,evaluates,Tirzepatide
NCT06603571,measures_primary,Percent Change Body Weight
NCT06603571,measures_secondary,Percentage Participants Achieve ≥5% Body Weight Reduction
NCT06603571,measures_secondary,Percentage Participants Achieve ≥10% Body Weight Reduction
NCT06603571,measures_secondary,Change from baseline in Hemoglobin A1c
NCT06603571,measures_secondary,Pharmacokinetics LY3841136 AUC
NCT06603571,measures_secondary,Pharmacokinetics LY3841136 Cmax
NCT05774756,involves,Acquired Hypothalamic Obesity
NCT05774756,evaluates,Setmelanotide
NCT05774756,measures_primary,% change in BMI
NCT05774756,measures_secondary,hunger score
NCT05774756,measures_secondary,Symptoms of Hyperphagia
NCT05774756,has_criteria,≥18 years of age
NCT05774756,has_criteria,<18 years of age
NCT01721109,involves,HIV-1
NCT01721109,evaluates,Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate
NCT01721109,measures_primary,HIV-1 RNA < 50 Copies/mL
NCT01721109,measures_secondary,HIV-1 RNA < 400 Copies/mL
NCT01721109,measures_secondary,Change From Baseline in Plasma log10 HIV-1 RNA
NCT01721109,measures_secondary,Change From Baseline in CD4+ Cell Count
NCT01721109,measures_secondary,Change From Baseline in CD4 Percentage
NCT01721109,has_criteria,12 years to < 18 years of age
NCT01721109,has_criteria,written assent
NCT01721109,has_criteria,written informed consent
NCT01953809,evaluates,GSK1322322
NCT01953809,evaluates,Norethindrone
NCT01953809,evaluates,Ethinyl Estradiol
NCT01953809,measures_primary,Number of subjects with AEs
NCT01953809,measures_secondary,Concurrent medication assessment
NCT01953809,measures_secondary,Laboratory parameter assessment
NCT01953809,measures_secondary,Electrocardiogram assessment
NCT01953809,measures_secondary,Vital sign measurement
NCT01953809,has_criteria,8 weeks
NCT04685109,involves,Dry Eye Disease
NCT04685109,evaluates,ALOCROSS
NCT04685109,evaluates,VISMED
NCT04685109,measures_primary,change of OSS score
NCT04685109,measures_secondary,corneal fluorescein staining
NCT04685109,measures_secondary,conjunctival staining
NCT04685109,has_criteria,fluorescein corneal staining
NCT04777409,involves,Alzheimer's Disease
NCT04777409,evaluates,Semaglutide
NCT04777409,measures_primary,Change in CDR-SB
NCT04777409,measures_secondary,ADCS-ADLMCI score
NCT04777409,measures_secondary,Time to progression
NCT04777409,measures_secondary,Change in ADAS-Cog-13
NCT04777409,measures_secondary,Change in MoCA score
NCT04777409,has_criteria,MCI (CDR global equal to 0.5) at baseline
NCT04987307,involves,Ulcerative Colitis
NCT04987307,evaluates,Efavaleukin Alfa
NCT04987307,measures_primary,Clinical Remission at Week 12
NCT04987307,measures_secondary,Clinical Response at Week 12
NCT04987307,measures_secondary,Endoscopic Remission at Week 12
NCT04987307,measures_secondary,Symptomatic Remission at Week 12
NCT04987307,measures_secondary,Combined Endoscopic Remission and Histologic Remission
NCT04987307,measures_secondary,Clinically Significant Change in Histological Score
NCT04987307,measures_secondary,Treatment-emergent Adverse Events
NCT04987307,has_criteria,Informed consent
NCT04987307,has_criteria,Age ≥ 18 to < 80 years
NCT04987307,has_criteria,Diagnosis of UC established ≥ 3 months prior
NCT04987307,has_criteria,Modified Mayo score of 5 to 9
NCT04987307,has_criteria,Centrally read endoscopy subscore ≥ 2
NCT04987307,has_criteria,Surveillance colonoscopy within 12 months
NCT04987307,has_criteria,Colorectal cancer surveillance
NCT00647556,involves,Photodamage
NCT00647556,evaluates,Adapalene Gel 0.3%
NCT00647556,evaluates,Tretinoin 0.05% Emollient Cream
NCT00647556,measures_primary,Change From Baseline
NCT00647556,measures_secondary,Number of participants improved
NCT00647556,has_criteria,Decrease by at least one point
NCT03046056,involves,Small Bowel Crohn's Disease
NCT03046056,evaluates,Filgotinib
NCT03046056,measures_primary,Clinical Remission
NCT03046056,measures_secondary,MaRIA Score
NCT03046056,has_criteria,Week 24
NCT02690909,involves,Hypertension
NCT02690909,evaluates,Redy™ Renal Denervation System
NCT02690909,measures_primary,systolic daytime blood pressure
NCT02690909,measures_secondary,office systolic blood pressure
NCT02690909,measures_secondary,office diastolic blood pressure
NCT02690909,has_criteria,guideline based stable drug regimen
NCT02690909,has_criteria,office systolic blood pressure >150 mmHg
NCT02690909,has_criteria,average daytime systolic blood pressure >140 mmHg
NCT06168409,involves,Resistant Hypertension
NCT06168409,evaluates,baxdrostat
NCT06168409,measures_primary,Change from baseline SBP
NCT06168409,measures_secondary,Change from baseline DBP
NCT06168409,has_criteria,≥ 18 years old
NCT02079909,involves,Alzheimer's Disease
NCT02079909,evaluates,T-817MA
NCT02079909,measures_primary,ADAS-cog Change
NCT02079909,measures_secondary,ADCS-CGIC
NCT02079909,measures_secondary,ADCS-ADL Change
NCT02079909,has_criteria,Male or female
NCT00735709,involves,Major Depressive Disorder
NCT00735709,evaluates,Vortioxetine
NCT00735709,measures_primary,HAM-D24 total score
NCT00735709,measures_secondary,Sheehan Disability Scale
NCT00735709,measures_secondary,Clinical Global Impression-Global Improvement
NCT00735709,has_criteria,Baseline to Week 8
NCT01771809,involves,Ulcerative Colitis
NCT01771809,evaluates,PF-00547659
NCT01771809,measures_primary,Mucosal healing
NCT01771809,measures_secondary,Serum trough concentrations
NCT01771809,has_criteria,Baseline
NCT03972709,involves,Geographic Atrophy
NCT03972709,involves,Age-Related Macular Degeneration
NCT03972709,evaluates,Galegenimab
NCT03972709,measures_primary,Change in GA Area
NCT03972709,measures_secondary,Percentage of Participants With Ocular Adverse Events
NCT03972709,has_criteria,unfavorable and unintended sign
NCT03850509,involves,Crohn's Disease
NCT03850509,evaluates,OPS-2071
NCT03850509,measures_primary,Clinical Remission
NCT03850509,measures_secondary,Endoscopic Response
NCT03850509,has_criteria,Active Inflammation
NCT01929707,evaluates,LY3050258
NCT01929707,measures_primary,Maximum Concentration
NCT01929707,measures_secondary,Area Under the Concentration
NCT01929707,has_criteria,Healthy Participants
NCT01149707,involves,Distal Ulcerative Colitis
NCT01149707,evaluates,PUR 0110 Rectal Enema
NCT01149707,measures_primary,remission rate
NCT01149707,measures_primary,clinical response rate
NCT01149707,measures_primary,subject response
NCT01149707,measures_primary,remission rate
NCT01149707,measures_secondary,overall Mayo score
NCT01149707,measures_secondary,individual sub-scores
NCT01149707,measures_secondary,investigator assessment ulcerative colitis symptom score
NCT01149707,has_criteria,treatment-related adverse events
NCT06636656,involves,Ulcerative Colitis
NCT06636656,evaluates,BI 3032950
NCT06636656,measures_primary,clinical remission
NCT06636656,measures_secondary,Endoscopic remission
NCT06636656,measures_secondary,Clinical response
NCT06636656,measures_secondary,Endoscopic improvement
NCT06636656,measures_secondary,Modified Mayo Score change
NCT06636656,measures_secondary,Stool frequency subscore
NCT06636656,has_criteria,mSC of 0 to 2
NCT04421456,involves,Schizophrenia
NCT04421456,evaluates,GWP42003-P
NCT04421456,evaluates,Placebo
NCT04421456,measures_primary,PANSS-T Score
NCT04421456,measures_secondary,PANSS-P Score
NCT04421456,measures_secondary,PANSS-N Score
NCT04421456,has_criteria,Inadequate Response
NCT05889156,involves,Hypertriglyceridemia
NCT05889156,evaluates,NST-1024
NCT05889156,measures_primary,Percent Change in TG
NCT05889156,measures_secondary,Percent Change in Cholesterol
NCT05889156,has_criteria,18 to 79 years of age
NCT03903809,involves,NDD-CKD
NCT03903809,evaluates,Pegol-Sihematide
NCT03903809,measures_primary,change in hemoglobin
NCT03903809,measures_secondary,proportion of patients
NCT03903809,has_criteria,hemoglobin target range
NCT00863109,involves,Chronic Hepatitis C
NCT00863109,evaluates,MK-4031-336
NCT00863109,measures_primary,Change From Baseline
NCT00863109,measures_secondary,CLDQ-HCV Global
NCT00863109,has_criteria,Completed Treatment
NCT05636709,involves,Ulcerative Colitis
NCT05636709,involves,Crohn's Disease
NCT05636709,evaluates,GMA therapy
NCT05636709,measures_primary,steroid-free clinical remission
NCT05636709,measures_secondary,early clinical remission rate
NCT05636709,has_criteria,Total Mayo score ≤2
NCT05636709,has_criteria,Harvey-Bradshaw Index score ≤4
NCT04102007,involves,Plaque Psoriasis
NCT04102007,evaluates,Risankizumab
NCT04102007,measures_primary,sPGA 0/1
NCT04102007,measures_secondary,DLQI 0/1
NCT04102007,measures_secondary,PSS 0
NCT04102007,has_criteria,Suboptimal response
NCT00993109,involves,Essential Hypertension
NCT00993109,evaluates,Nifedipine-Valsartan Combination
NCT00993109,evaluates,Valsartan Monotherapy
NCT00993109,measures_primary,Response rate
NCT00993109,measures_secondary,Control rate
NCT00993109,measures_secondary,Change in pulse pressure
NCT00993109,measures_secondary,Reduction in Urinary microalbumin excretion
NCT00993109,has_criteria,microalbuminuria
NCT04594707,involves,Idiopathic Pulmonary Fibrosis
NCT04594707,evaluates,Recombinant Human Pentraxin-2
NCT04594707,measures_primary,Annual Rate of Change in FVC
NCT04594707,measures_primary,Annual Rate of Change in 6MWD
NCT04594707,measures_primary,Annual Rate of Change in FVC% Predicted
NCT04594707,measures_secondary,Change in Carbon Monoxide Diffusing Capacity
NCT04594707,measures_secondary,Time to Disease Progression
NCT04594707,measures_secondary,Survival
NCT04594707,measures_secondary,IPF-related Mortality
NCT04594707,measures_secondary,Respiratory-related Mortality
NCT04594707,has_criteria,Age ≥ 18 years
NCT00688909,involves,Breast Cancer
NCT00688909,evaluates,Anastrozole
NCT00688909,evaluates,Letrozole
NCT00688909,measures_primary,Time to Discontinuation
NCT00688909,measures_secondary,Percentage of Participants Discontinuing
NCT00688909,measures_secondary,Change in BPI Composite Score
NCT00688909,measures_secondary,Change in Disability Index
NCT00688909,has_criteria,Post-menopausal Women
NCT06124807,involves,Obesity
NCT06124807,involves,Overweight
NCT06124807,evaluates,LY3305677
NCT06124807,evaluates,Placebo
NCT06124807,measures_primary,Percent Change in Body Weight
NCT06124807,measures_secondary,Percentage of Participants Who Achieve ≥5% Body Weight Reduction
NCT06124807,measures_secondary,Percentage of Participants Who Achieve ≥10% Body Weight Reduction
NCT06124807,measures_secondary,Change from Baseline in BMI
NCT06124807,measures_secondary,Absolute Change from Baseline in Liver Fat Content by MRI-PDFF
NCT06124807,measures_secondary,Percent Change from Baseline in Liver Fat Content by MRI-PDFF
NCT06124807,measures_secondary,Pharmacokinetics (PK): Area Under the Curve (AUC) of LY3305677
NCT06124807,measures_secondary,PK: Maximum Concentration (Cmax) of LY3305677
NCT06124807,has_criteria,Adult Participants
NCT04779307,involves,Ulcerative Colitis
NCT04779307,evaluates,Vedolizumab
NCT04779307,measures_primary,Clinical Remission
NCT04779307,measures_secondary,Sustained Clinical Remission
NCT04779307,has_criteria,Week 54
NCT04779307,has_criteria,Week 14
NCT05789056,involves,Netherton Syndrome
NCT05789056,evaluates,QRX003 Lotion
NCT05789056,measures_primary,IGA reduction
NCT05789056,measures_secondary,NS surface area change
NCT05789056,measures_secondary,WI-NRS score change
NCT05789056,measures_secondary,TSQM score
NCT05789056,has_criteria,Up to week 16
NCT06554509,involves,Prurigo Nodularis
NCT06554509,evaluates,SHR-1819 Injection
NCT06554509,measures_primary,WI-NRS reduction
NCT06554509,measures_secondary,IGA CNPG-S score
NCT06554509,measures_secondary,DLQI score
NCT06554509,has_criteria,Adult Patients
NCT05125809,involves,Osteogenesis Imperfecta
NCT05125809,evaluates,Setrusumab
NCT05125809,measures_primary,Annualized Rate of Fractures
NCT05125809,measures_secondary,Percent Change in P1NP
NCT05125809,has_criteria,Baseline
NCT03721107,involves,Irritable Bowel Syndrome
NCT03721107,evaluates,study medication
NCT03721107,measures_primary,Overall Response
NCT03721107,measures_secondary,Treatment-Related TEAEs
NCT03721107,measures_secondary,Subject Global Assessment of Relief
NCT03721107,has_criteria,evaluable weeks of data
NCT00200356,involves,Acute Ischemic Stroke
NCT00200356,evaluates,Edaravone-Sodium Ozagrel
NCT00200356,measures_primary,mRS score 0-1
NCT00200356,measures_secondary,Barthel Index Score
NCT00200356,measures_secondary,NIH Stroke Scale Score
NCT00200356,has_criteria,3 months
NCT00200356,has_criteria,Baseline NIH Stroke Scale Score
NCT00200356,has_criteria,14 days
NCT00200356,has_criteria,1 Month
NCT05935956,involves,chemotherapy-induced neuropathy
NCT05935956,evaluates,Magnetic Peripheral Nerve Stimulation
NCT05935956,measures_primary,pain reduction at Day 90
NCT05935956,measures_secondary,Pain Disability Index
NCT05935956,measures_secondary,EuroQol Group Quality of Life Questionnaire
NCT05935956,has_criteria,therapy-related adverse events
NCT02097056,involves,Alzheimer's Disease
NCT02097056,evaluates,Donepezil HCl
NCT02097056,measures_primary,Change From Baseline MMSE
NCT02097056,measures_secondary,Change From Baseline NPI-Q
NCT02097056,has_criteria,Moderate to Severe
NCT00362856,involves,Celiac Disease
NCT00362856,evaluates,larazotide acetate
NCT00362856,measures_primary,urinary LAMA ratio
NCT00362856,measures_secondary,daily symptom diary
NCT00362856,measures_secondary,PGWBI
NCT00362856,measures_secondary,GSRS
NCT00362856,has_criteria,gluten-free diet
NCT00145509,involves,Bipolar Disorder
NCT00145509,evaluates,Asenapine
NCT00145509,measures_primary,Y-MRS Score
NCT00145509,measures_secondary,MADRS Score
NCT00145509,has_criteria,Adverse Events
NCT00669409,involves,Osteoarthritis Of The Knee
NCT00669409,evaluates,PF-04383119
NCT00669409,measures_primary,HVLT-R Total Score
NCT00669409,measures_secondary,HVLT-R Total Score
NCT00669409,has_criteria,Japanese Patients
NCT01718509,involves,Binge Eating Disorder
NCT01718509,evaluates,SPD489
NCT01718509,measures_primary,Binge Days Per Week
NCT01718509,measures_secondary,Percent of Participants With Improvement
NCT01718509,has_criteria,Adults Aged 18-55 Years
NCT00992407,involves,Schizophrenia
NCT00992407,involves,Schizoaffective Disorder
NCT00992407,evaluates,Long Acting Injectable Risperidone
NCT00992407,evaluates,Oral Risperidone
NCT00992407,measures_primary,Change From Baseline in PSP
NCT00992407,measures_primary,Change From Baseline in PANSS
NCT00992407,measures_primary,Change From Baseline in CGI-S
NCT00992407,measures_primary,Change From Baseline in SFS
NCT00992407,has_criteria,Baseline and Week 52
NCT01839656,involves,Spinal Muscular Atrophy
NCT01839656,evaluates,Nusinersen
NCT01839656,measures_primary,Motor Milestones
NCT01839656,measures_secondary,Event-free Survival
NCT01839656,has_criteria,Day 1352 or Early Termination
NCT03073109,involves,Rheumatoid Arthritis
NCT03073109,evaluates,Tofacitinib
NCT03073109,evaluates,Biological Disease-Modifying Antirheumatic Drugs
NCT03073109,measures_primary,RAPID3 Score
NCT03073109,measures_secondary,HAQ-DI Score
NCT03073109,has_criteria,daily living activities
NCT00101907,involves,Advanced Cancer
NCT00101907,evaluates,AMG 706
NCT00101907,measures_primary,Objective Tumor Response
NCT00101907,measures_secondary,Adverse Events
NCT00101907,has_criteria,Treatment-emergent
NCT02588807,involves,Amyotrophic Lateral Sclerosis
NCT02588807,evaluates,Food Supplement
NCT02588807,measures_primary,ALS Functional Rating Scale
NCT02588807,measures_secondary,Forced vital capacity
NCT02588807,measures_secondary,hand grip power
NCT02588807,has_criteria,8 months
NCT01138007,involves,Major Depressive Disorder
NCT01138007,evaluates,323U66 SR
NCT01138007,measures_primary,Change From Baseline
NCT01138007,measures_secondary,MADRS Total Score
NCT01138007,has_criteria,Baseline MADRS score
NCT03460756,involves,Postpartum Depression
NCT03460756,evaluates,Oral Ganaxolone
NCT03460756,measures_primary,Change From Baseline
NCT03460756,measures_secondary,Change From Baseline
NCT03460756,has_criteria,Day 1 assessment
NCT03790709,involves,Alzheimer's Disease
NCT03790709,involves,mild cognitive impairment
NCT03790709,involves,dementia
NCT03790709,evaluates,ANAVEX2-73
NCT03790709,measures_primary,cognitive decline
NCT03790709,measures_secondary,Activities of Daily Living
NCT03790709,measures_secondary,treatment-related adverse events
NCT03790709,has_criteria,age 60 to 85 years
NCT03790709,has_criteria,NIA-AA diagnosis
NCT03790709,has_criteria,MMSE score 20-28
NCT03790709,has_criteria,Free Recall score ≤17
NCT03790709,has_criteria,Total Recall score <40
NCT03790709,has_criteria,designated study partner
NCT04079088,involves,Relapsing Multiple Sclerosis
NCT04079088,evaluates,Oral BIIB061
NCT04079088,evaluates,Interferon-beta1
NCT04079088,evaluates,Glatiramer Acetate
NCT04079088,measures_primary,Overall Disability Response Score
NCT04079088,measures_secondary,Change from Baseline in Normalized Magnetization Transfer Ratio
NCT04079088,has_criteria,Baseline
NCT04441788,involves,Chronic Obstructive Pulmonary Disease
NCT04441788,involves,Chronic Bronchitis
NCT04441788,evaluates,ION-827359
NCT04441788,measures_primary,Change From Baseline in FEV1
NCT04441788,measures_secondary,Change From Baseline in EXACT
NCT04441788,measures_secondary,Change From Baseline in CAT
NCT04441788,has_criteria,Baseline measurement
NCT05399888,involves,Alzheimer's Disease
NCT05399888,involves,Mild Cognitive Impairment
NCT05399888,evaluates,BIIB080 Injections
NCT05399888,measures_primary,Change From Baseline to Week 76 on the CDR-SB
NCT05399888,measures_secondary,Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI)
NCT05399888,has_criteria,50 to 80 Years of Age
NCT02442778,involves,Dementia of the Alzheimer's Type
NCT02442778,evaluates,AVP-786
NCT02442778,measures_primary,Change From Baseline
NCT02442778,measures_secondary,Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change
NCT02442778,measures_secondary,Neuropsychiatric Inventory Agitation/Aggression Domain Score
NCT02442778,has_criteria,elderly participants
NCT02585778,involves,Hypercholesterolemia
NCT02585778,involves,Type 1 Diabetes
NCT02585778,involves,Type 2 Diabetes
NCT02585778,evaluates,Alirocumab
NCT02585778,measures_primary,Percent Change LDL-C
NCT02585778,measures_secondary,Treatment-Emergent Adverse Events
NCT02585778,has_criteria,Maximally Tolerated Lipid Lowering Therapy
NCT00505778,involves,Ulcerative Colitis
NCT00505778,evaluates,Once a Day Dose
NCT00505778,measures_primary,Remission at Month 6
NCT00505778,measures_secondary,Remission at Month 3
NCT00505778,measures_secondary,Remission at Month 12
NCT00505778,measures_secondary,Relapse/Flare Within 6 Months
NCT00505778,has_criteria,SCCAI < 5
NCT02372578,involves,Painful Diabetic Peripheral Neuropathy
NCT02372578,evaluates,ASP3662
NCT02372578,measures_primary,Change from Baseline pain intensity
NCT02372578,measures_secondary,Percentage of Responders
NCT02372578,measures_secondary,Change from Baseline pain score
NCT02372578,measures_secondary,Patient Global Impression Change
NCT02372578,measures_secondary,Clinical Global Impression of Change
NCT02372578,has_criteria,Baseline to Week 6/EOT
NCT00050778,involves,Multiple Sclerosis
NCT00050778,evaluates,Alemtuzumab
NCT00050778,evaluates,Rebif
NCT00050778,measures_primary,Sustained Accumulation of Disability
NCT00050778,measures_secondary,Annualized Relapse Rate
NCT00050778,measures_secondary,Relapse Free at 3 Years
NCT00050778,has_criteria,Baseline score of 0
NCT00050778,has_criteria,Baseline score of 1.0 or more
NCT00050778,has_criteria,at least 48 hours
NCT00050778,has_criteria,at least 30 days of clinical stability
NCT01363388,involves,ANCA-Associated Vasculitis
NCT01363388,evaluates,CCX168
NCT01363388,measures_primary,Disease Response at Day 85
NCT01363388,measures_secondary,Renal Response at Day 85
NCT01363388,measures_secondary,Disease Remission at Day 85
NCT01363388,measures_secondary,Percent Change From Baseline to Day 85 in BVAS
NCT01363388,measures_secondary,Change From Baseline to Day 85 in eGFR
NCT01363388,has_criteria,Baseline to Day 85
NCT00116688,involves,Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT00116688,evaluates,Romiplostim (AMG 531)
NCT00116688,measures_primary,Number of Participants With a Platelet Response
NCT00116688,measures_secondary,Duration of treatment
NCT00116688,has_criteria,concurrent ITP therapies
NCT01039688,involves,Rheumatoid Arthritis
NCT01039688,evaluates,CP-690
NCT01039688,evaluates,Methotrexate
NCT01039688,measures_primary,mTSS at Month 6
NCT01039688,measures_secondary,ACR70 Response at Month 6
NCT01039688,measures_secondary,Absolute Blood Pressure at Month 6
NCT01039688,has_criteria,Previously received MTX
NCT03198078,involves,Schizophrenia
NCT03198078,evaluates,Brexpiprazole
NCT03198078,measures_primary,PANSS Total Score
NCT03198078,measures_secondary,PANSS Positive Sub-Scales Scores
NCT03198078,measures_secondary,PANSS Negative Sub-Scales Scores
NCT03198078,has_criteria,Adolescents
NCT03785678,involves,Stroke
NCT03785678,evaluates,Tenecteplase
NCT03785678,measures_primary,mRS Score at Day 90
NCT03785678,measures_secondary,Functional Independence at Day 90
NCT03785678,measures_secondary,Recanalization at 24 Hours
NCT03785678,measures_secondary,Reperfusion at 24 Hours
NCT03785678,measures_secondary,Angiographic Reperfusion
NCT03785678,has_criteria,Day 4.5 to 24 Hours
NCT04084678,involves,WHO Group 1 PH
NCT04084678,evaluates,Ralinepag
NCT04084678,measures_primary,Change from Baseline in peak VO2
NCT04084678,measures_secondary,NT-proBNP
NCT04084678,measures_secondary,Minute Ventilation (VE)/Carbon Dioxide output (VCO2) slope
NCT04084678,measures_secondary,health-related quality of life
NCT04084678,measures_secondary,Time to First All-cause Non-elective Hospitalization
NCT04084678,has_criteria,At least 18 years of age
NCT04084678,has_criteria,Primary diagnosis of PAH
NCT04084678,has_criteria,diagnostic RHC performed
NCT06061471,involves,plaque psoriasis
NCT06061471,evaluates,AK111 Injection
NCT06061471,measures_primary,PASI 75
NCT06061471,measures_secondary,PASI 90
NCT06061471,has_criteria,age ≥18 years old
NCT06061471,has_criteria,PASI score ≥ 12
NCT06061471,has_criteria,BSA ≥ 10%
NCT06061471,has_criteria,sPGA ≥ 3
NCT00886288,involves,Hypertension
NCT00886288,involves,Albuminuria
NCT00886288,evaluates,Telmisartan
NCT00886288,measures_primary,Mean Difference in SBP
NCT00886288,measures_primary,Mean Difference in DBP
NCT00886288,measures_secondary,Percentage of Responders
NCT00886288,measures_secondary,Percentage of Patients With AE
NCT00886288,measures_secondary,Percentage of Patients With Albuminuria Shift
NCT00886288,has_criteria,chronic renal insufficiency
NCT00886288,has_criteria,macroalbuminuria
NCT00886288,has_criteria,diabetes
NCT04026178,involves,Generalized Lipodystrophy
NCT04026178,evaluates,Metreleptin
NCT04026178,measures_primary,Antibody titers
NCT04026178,measures_secondary,Adverse events
NCT04026178,has_criteria,Baseline and Months 1
NCT05165771,involves,Rheumatoid Arthritis
NCT05165771,evaluates,GS-5718
NCT05165771,measures_primary,DAS28 (CRP) at Week 12
NCT05165771,measures_secondary,ACR20 response at Week 12
NCT05165771,has_criteria,inadequate response to bDMARDs
NCT00445978,involves,Sickle Cell Disease
NCT00445978,evaluates,6R-BH4
NCT00445978,measures_primary,Peripheral Arterial Tonometry
NCT00445978,measures_secondary,Urine 8-Isoprostane
NCT00445978,measures_secondary,Urine Albumin to Creatinine Ratio
NCT00445978,measures_secondary,Tricuspid Regurgitant Velocity
NCT00445978,has_criteria,up to 16 weeks
NCT00915278,involves,Solid Tumors
NCT00915278,evaluates,PF-04605412
NCT00915278,measures_primary,Maximum Observed Serum Concentration
NCT00915278,measures_secondary,Area Under the Curve
NCT00915278,has_criteria,Grade 3 or 4 toxicity
NCT02393378,involves,Rheumatoid Arthritis
NCT02393378,evaluates,Namilumab
NCT02393378,evaluates,Adalimumab
NCT02393378,measures_primary,Change From Baseline
NCT02393378,measures_secondary,Disease Activity Score 28
NCT02393378,has_criteria,Inadequately Responding to Methotrexate
NCT01769378,involves,Type 2 Diabetes
NCT01769378,evaluates,Dulaglutide
NCT01769378,evaluates,Placebo
NCT01769378,measures_primary,HbA1c at 24 Weeks
NCT01769378,measures_secondary,Fasting Serum Glucose at 24 Weeks
NCT01769378,measures_secondary,Body Weight at 24 Weeks
NCT01769378,measures_secondary,Body Mass Index at 24 Weeks
NCT01769378,has_criteria,Sulfonylurea Therapy
NCT05332678,involves,Alzheimer's Disease
NCT05332678,evaluates,SLS-005
NCT05332678,measures_primary,Changes in brain imaging
NCT05332678,measures_secondary,Changes in CSF biomarkers
NCT05332678,measures_secondary,Changes in brain structures
NCT05332678,has_criteria,treatment period
NCT00907478,involves,Immune Thrombocytopenia Purpura
NCT00907478,evaluates,Romiplostim
NCT00907478,measures_primary,Percentage of Participants With Collagen Fibrosis
NCT00907478,measures_secondary,Increased Modified Bauermeister Grade
NCT00907478,has_criteria,12 weeks after romiplostim discontinuation
NCT01251588,involves,Symptomatic Articular Cartilage Defects of the Knee
NCT01251588,evaluates,MACI®
NCT01251588,measures_primary,Degree of Defect Fill
NCT01251588,measures_secondary,Proportion of Patients
NCT01251588,has_criteria,Baseline to Week 156
NCT01251588,has_criteria,Baseline and Week 260
NCT04882878,involves,Systemic Lupus Erythematosus
NCT04882878,evaluates,Nipocalimab
NCT04882878,measures_primary,SLE SRI-4 Composite Response
NCT04882878,measures_secondary,CLASI Activity Score
NCT04882878,measures_secondary,Active Joints
NCT04882878,measures_secondary,SLEDAI-2K
NCT04882878,has_criteria,Active Mucocutaneous Lupus Manifestations
NCT04882878,has_criteria,Arthritis
NCT04882878,has_criteria,4 Active Joints
NCT00714688,involves,Attention Deficit/Hyperactivity Disorder
NCT00714688,evaluates,Prolonged Release OROS Methylphenidate
NCT00714688,measures_primary,change in ADHD symptoms
NCT00714688,measures_secondary,CGI-S severity
NCT00714688,measures_secondary,CGI-C change
NCT00714688,measures_secondary,CAARS-S:S total score
NCT00714688,has_criteria,DSM-IV diagnosis
NCT03170388,involves,Acne Vulgaris
NCT03170388,evaluates,Vehicle Controlled
NCT03170388,measures_primary,Inflammatory Lesion Counts
NCT03170388,measures_secondary,Non-inflammatory Lesion Counts
NCT03170388,has_criteria,Baseline to Week 12
NCT00256178,involves,Primary Dyslipidemia
NCT00256178,evaluates,Lapaquistat Acetate
NCT00256178,evaluates,Simvastatin
NCT00256178,measures_primary,Change from Baseline in Low Density Lipoprotein cholesterol
NCT00256178,measures_secondary,Triglycerides
NCT00256178,measures_secondary,Total Cholesterol
NCT00256178,measures_secondary,High Density Lipoprotein cholesterol
NCT00256178,measures_secondary,Very Low Density Lipoprotein cholesterol
NCT00256178,measures_secondary,apolipoprotein A1
NCT00256178,measures_secondary,apolipoprotein B
NCT00256178,measures_secondary,non- High Density Lipoprotein cholesterol
NCT00256178,measures_secondary,Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol
NCT00256178,measures_secondary,Total Cholesterol/High Density Lipoprotein cholesterol
NCT00256178,measures_secondary,apolipoprotein A1/apolipoprotein B
NCT00256178,measures_secondary,high-sensitivity C-reactive protein
NCT00256178,measures_secondary,Low Density Lipoprotein cholesterol concentrations
NCT00256178,measures_secondary,Best corrected visual acuity
NCT00256178,measures_secondary,Adverse Events
NCT00256178,measures_secondary,Clinical Laboratory Tests
NCT00256178,measures_secondary,Vital Signs
NCT00256178,measures_secondary,12-lead Electrocardiogram
NCT00256178,measures_secondary,Physical Examination
NCT00256178,has_criteria,Females of childbearing potential
NCT01887678,involves,Osteoarthritis of the knee
NCT01887678,evaluates,Traumeel®-Zeel®
NCT01887678,evaluates,Placebo
NCT01887678,measures_primary,Pain Subscore
NCT01887678,measures_secondary,Pain Subscore
NCT01887678,has_criteria,Baseline value
NCT01687478,involves,Treatment-resistant Depression
NCT01687478,evaluates,Olanzapine
NCT01687478,evaluates,Fluoxetine
NCT01687478,measures_primary,MADRS total score
NCT01687478,measures_secondary,CGI-S scale
NCT01687478,measures_secondary,Simpson-Angus Scale
NCT01687478,measures_secondary,Short-Form 36 Health Survey
NCT01687478,has_criteria,Baseline + Treatment\*Visit.
NCT00642278,involves,Type 2 Diabetes
NCT00642278,evaluates,Canagliflozin
NCT00642278,evaluates,Sitagliptin
NCT00642278,measures_primary,Change in HbA1c
NCT00642278,measures_secondary,Change in Fasting Plasma Glucose
NCT00642278,measures_secondary,Percentage of Patients With Symptoms of Hypoglycemia
NCT00642278,measures_secondary,Change in Overnight Urine Glucose/Creatinine Ratio
NCT00642278,measures_secondary,Absolute Change in Body Weight
NCT00642278,measures_secondary,Percent Change in Body Weight
NCT01633788,involves,Meibomian gland dysfunction
NCT01633788,evaluates,AGN-195263
NCT01633788,measures_primary,Meibum quality response
NCT01633788,measures_secondary,Maximum Meibum Quality Score
NCT01633788,measures_secondary,Complete Overall Ocular Discomfort
NCT01633788,has_criteria,Meibomian gland dysfunction
NCT05257278,involves,Knee surgery
NCT05257278,evaluates,MonoPlus®
NCT05257278,measures_primary,functional performance
NCT05257278,measures_secondary,functional performance
NCT05257278,has_criteria,preoperatively
NCT05821478,involves,Hidradenitis Suppurativa
NCT05821478,evaluates,Antibiotherapy
NCT05821478,measures_primary,clinical remission
NCT05821478,measures_secondary,Physician Global Assessment
NCT05821478,measures_secondary,Modified Sartorius score
NCT05821478,measures_secondary,Hurley Score
NCT05821478,measures_secondary,Hidradenitis Suppurativa Severity Score
NCT05821478,measures_secondary,Hidradenitis Suppurativa Clinical Response
NCT05821478,has_criteria,Hurley Stage 2
NCT03920293,involves,Generalized Myasthenia Gravis
NCT03920293,evaluates,Ravulizumab
NCT03920293,measures_primary,Change From Baseline
NCT03920293,measures_secondary,Quantitative Myasthenia Gravis
NCT03920293,has_criteria,Baseline
NCT00904371,involves,Hypertensive Patients
NCT00904371,evaluates,Telmisartan
NCT00904371,measures_primary,Change From Baseline in SBP
NCT00904371,measures_primary,Change From Baseline in DBP
NCT00904371,measures_primary,Change From Baseline in SCORE
NCT00904371,measures_primary,Change From Baseline in Framingham CVD Risk Assessment Score
NCT00904371,measures_primary,Change From Baseline in Framingham Stroke Risk Assessment Score
NCT00904371,measures_primary,Change From Baseline in Risk Assessment According to ESH/ESC Guidelines
NCT00904371,measures_secondary,Percentage of Patients That Achieved Target BP Values
NCT00904371,measures_secondary,Additional Antihypertensive Treatment Pattern at Visit 3
NCT00904371,has_criteria,High Risk Hypertensive Patients
NCT00642993,involves,Obesity
NCT00642993,involves,Overweight
NCT00642993,evaluates,SCH 497079
NCT00642993,measures_primary,Body Weight at Week 12
NCT00642993,measures_secondary,Weight Loss ≥5% at Week 12
NCT00642993,measures_secondary,Weight Loss ≥10% at Week 12
NCT00642993,measures_secondary,Waist Circumference at Week 12
NCT00642993,measures_secondary,Body Mass Index (BMI) at Week 12
NCT00642993,has_criteria,BMI ≥30 kg/m\^2
NCT00642993,has_criteria,BMI ≤40 kg/m\^2
NCT00642993,has_criteria,BMI ≥27 kg/m\^2
NCT00642993,has_criteria,BMI <30 kg/m\^2
NCT03123471,involves,Plaque Psoriasis
NCT03123471,evaluates,Apremilast
NCT03123471,measures_primary,Scalp Physician Global Assessment
NCT03123471,measures_secondary,Whole Body Itch NRS
NCT03123471,measures_secondary,Scalp Itch NRS
NCT03123471,has_criteria,Moderate to Severe
NCT03971071,involves,Medication Overuse Headache
NCT03971071,evaluates,Erenumab
NCT03971071,measures_primary,Absence of MOH
NCT03971071,measures_secondary,Physical Impairment Domain Scores
NCT03971071,has_criteria,Mean monthly AHMD
NCT06636071,involves,Osteogenesis Imperfecta
NCT06636071,evaluates,Setrusumab
NCT06636071,measures_primary,Annualized Fracture Rate
NCT06636071,measures_secondary,DXA Bone Mineral Density
NCT06636071,has_criteria,Pediatric Japanese Subjects
NCT03216278,evaluates,Dapagliflozin/Metformin XR
NCT03216278,measures_primary,Area under the curve
NCT03216278,measures_primary,Peak Plasma Concentration
NCT03351478,involves,Type 2 Diabetes Mellitus
NCT03351478,evaluates,Sotagliflozin
NCT03351478,measures_primary,Change From Baseline in HbA1c
NCT03351478,measures_secondary,Change From Baseline in Sitting Systolic Blood Pressure
NCT03351478,measures_secondary,Change From Baseline in 2-hour Postprandial Glucose
NCT03351478,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT03351478,measures_secondary,Change From Baseline in Body Weight
NCT03351478,measures_secondary,Percentage of Participants With HbA1c <6.5%
NCT03351478,measures_secondary,Percentage of Participants With HbA1c <7.0%
NCT03351478,has_criteria,Type 2 Diabetes on Dipeptidyl peptidase-4 inhibitors
NCT03351478,has_criteria,stable dose for at least 12 weeks
NCT03351478,has_criteria,Signed written informed consent
NCT05151471,involves,Amyotrophic Lateral Sclerosis
NCT05151471,evaluates,Oral Edaravone
NCT05151471,measures_primary,Time to ALSFRS-R
NCT05151471,measures_secondary,CAFS score
NCT05151471,measures_secondary,ALSFRS-R score
NCT05151471,measures_secondary,ALSAQ-40 score
NCT05151471,has_criteria,Up to 96 weeks
NCT02152371,involves,Type II Diabetes
NCT02152371,evaluates,Dulaglutide
NCT02152371,measures_primary,HbA1c
NCT02152371,measures_secondary,Fasting Serum Glucose
NCT02152371,measures_secondary,7-Point Self Monitored Plasma Glucose
NCT02152371,measures_secondary,Body Weight
NCT02152371,measures_secondary,Daily Mean Insulin Glargine Dose
NCT00440271,involves,HIV
NCT00440271,evaluates,tipRanavir/r
NCT00440271,measures_primary,Viral load <50 copies/mL
NCT00440271,measures_secondary,CD4+ and CD8+ Cell Counts
NCT00440271,has_criteria,Race/Gender HIV+ Patients
NCT01646671,involves,Severe Hypertension
NCT01646671,evaluates,LCZ696
NCT01646671,measures_primary,Change in msSBP
NCT01646671,measures_primary,Change in msDBP
NCT01646671,measures_secondary,Percentage of Participants With Successful BP Control
NCT01646671,measures_secondary,Percentage of Participants Achieving Successful msSBP Control
NCT01646671,measures_secondary,Percentage of Participants Achieving Successful msDBP Control
NCT01646671,measures_secondary,Percentage of Participants With SBP Response
NCT01646671,measures_secondary,Percentage of Participants With DBP Response
NCT01646671,has_criteria,Japanese Patients
NCT06307093,evaluates,RPH-075
NCT06307093,evaluates,Keytruda
NCT06307093,involves,Malignant Neoplasms
NCT06307093,measures_primary,AUC(0-504)
NCT06307093,measures_primary,Cmax
NCT06307093,measures_primary,Cmax ss
NCT06307093,measures_primary,Cmin ss
NCT06307093,measures_primary,AUCtau ss
NCT06307093,measures_secondary,Incidence of Adverse Reactions
NCT06307093,measures_secondary,Incidence of Treatment-Emergent Adverse Events
NCT06307093,measures_secondary,Incidence of Immune-mediated adverse reactions
NCT01512693,involves,Moderate Hepatic Insufficiency
NCT01512693,evaluates,Odanacatib
NCT01512693,measures_primary,AUC0-∞
NCT01512693,measures_secondary,Cmax
NCT01512693,measures_secondary,Tmax
NCT01512693,measures_secondary,t1/2
NCT01512693,has_criteria,BMI of ≤ 39 kg/m\^2
NCT01709578,involves,Rheumatoid Arthritis
NCT01709578,evaluates,SAR153191
NCT01709578,evaluates,REGN88
NCT01709578,measures_primary,ACR20 at Week 24
NCT01709578,measures_secondary,HAQ-DI at Week 12
NCT01709578,has_criteria,Anti-TNF intolerant
NCT01709578,has_criteria,Not responding to Anti-TNF
NCT03806478,involves,Alzheimer's Disease
NCT03806478,evaluates,APH-1105
NCT03806478,measures_primary,Cognition Change
NCT03806478,measures_secondary,Cognitive Functioning
NCT03806478,has_criteria,Baseline through 30 days post final treatment dose
NCT00764478,involves,Bipolar 1 Disorder
NCT00764478,evaluates,Asenapine
NCT00764478,measures_primary,Change From Baseline
NCT00764478,measures_secondary,CGI-BP-S Overall Score
NCT00764478,has_criteria,Y-MRS responders
NCT03577171,involves,Chronic Hepatitis B Virus Infection
NCT03577171,evaluates,ABI-H0731+ Entecavir
NCT03577171,evaluates,Entecavir
NCT03577171,measures_primary,Change in HBV DNA
NCT03577171,measures_secondary,Number of Adverse Events
NCT03577171,measures_secondary,Premature Study Discontinuation
NCT03577171,measures_secondary,Abnormal Safety Laboratory Result
NCT03577171,measures_secondary,Electrocardiogram Abnormality
NCT03577171,measures_secondary,Change in Vital Signs
NCT03577171,measures_secondary,Abnormal Alanine Aminotransferase
NCT03577171,measures_secondary,Decline in Viral DNA
NCT03577171,measures_secondary,Median Time to Viral Suppression
NCT03577171,has_criteria,Viremic HBeAg-positive
NCT01937871,involves,Benign Prostatic Hyperplasia
NCT01937871,involves,Erectile Dysfunction
NCT01937871,evaluates,Tadalafil
NCT01937871,measures_primary,Change From Baseline
NCT01937871,measures_secondary,International Index of Erectile Function
NCT01937871,has_criteria,Erectile dysfunction severity
NCT06042478,involves,Chronic Spontaneous Urticaria
NCT06042478,evaluates,Remibrutinib
NCT06042478,measures_primary,UAS7=0 Week 12
NCT06042478,measures_secondary,absolute change UAS7
NCT06042478,measures_secondary,absolute change ISS7
NCT06042478,measures_secondary,absolute change HSS7
NCT06042478,has_criteria,adult ≥18 years
NCT06042478,has_criteria,CSU duration ≥6 months
NCT06042478,has_criteria,inadequately controlled CSU
NCT02921971,involves,Diffuse Systemic Sclerosis
NCT02921971,evaluates,SAR156597
NCT02921971,measures_primary,Change From Baseline in mRSS
NCT02921971,measures_secondary,Health Assessment Questionnaire Disability Index Score
NCT02921971,measures_secondary,Mean Observed Forced Vital Capacity
NCT02921971,measures_secondary,Mean Observed Diffusing Lung Capacity for Carbon Monoxide
NCT05524571,involves,Thyroid Eye Disease
NCT05524571,evaluates,Batoclimab
NCT05524571,measures_primary,proptosis responder
NCT05524571,measures_secondary,Clinical Activity Score
NCT05524571,measures_secondary,Gorman score for diplopia
NCT05524571,has_criteria,TSHR antibody
NCT00734071,involves,Generalized Anxiety Disorder
NCT00734071,evaluates,Vortioxetine
NCT00734071,measures_primary,Change From Baseline
NCT00734071,measures_secondary,Hospital Anxiety and Depression Anxiety Subscale
NCT00734071,measures_secondary,Clinical Global Impression Scale-Global Improvement
NCT00734071,measures_secondary,Sheehan Disability Scale Total Score
NCT00734071,has_criteria,Baseline to Week 8
NCT03496571,involves,Eosinophilic Gastritis
NCT03496571,involves,Eosinophilic Gastroenteritis
NCT03496571,evaluates,AK002
NCT03496571,measures_primary,Percent Change in Eosinophils
NCT03496571,measures_secondary,PRO Total Symptom Score
NCT03496571,has_criteria,≥18 and ≤80 years
NCT03496571,has_criteria,Average weekly score ≥3
NCT03496571,has_criteria,Eosinophilia ≥30 eosinophils/HPF
NCT03496571,has_criteria,Failed standard-of-care treatments
NCT04127578,involves,Parkinson's Disease
NCT04127578,evaluates,PR001
NCT04127578,measures_primary,Change from baseline
NCT04127578,measures_secondary,Immunogenicity
NCT04127578,has_criteria,Body weight range
NCT06431971,involves,Parkinson disease
NCT06431971,evaluates,Talineuren
NCT06431971,measures_primary,MDS-UPDRS score
NCT06431971,measures_secondary,PDQ-39 score
NCT06431971,measures_secondary,Montreal Cognitive Assessment score
NCT06431971,measures_secondary,Levodopa equivalent daily dose
NCT06431971,has_criteria,Informed consent
NCT06431971,has_criteria,Age 30-85 years
NCT06431971,has_criteria,Confirmed PD
NCT06431971,has_criteria,Hoehn and Yahr Stage 0-2.5
NCT06431971,has_criteria,Stable dopaminergic treatment
NCT05586971,involves,Gout
NCT05586971,evaluates,Tigulixostat
NCT05586971,measures_primary,sUA levels <6.0 mg/dL
NCT05586971,measures_secondary,Gout flare
NCT05586971,measures_secondary,Tophi resolution
NCT05586971,has_criteria,Age 18-85 years
NCT05586971,has_criteria,Hyperuricemia
NCT05586971,has_criteria,ACR/EULAR 2015 criteria
NCT05586971,has_criteria,sUA ≥6.0 mg/dL
NCT05586971,has_criteria,sUA ≥7.0 mg/dL
NCT05586971,has_criteria,BMI ≤50 kg/m2
NCT05586971,has_criteria,eGFR ≥30 mL/min/1.73 m2
NCT05586971,has_criteria,No secondary hyperuricemia
NCT05586971,has_criteria,No acute gout attack
NCT05586971,has_criteria,No pegloticase use
NCT00613171,involves,Systemic Sclerosis
NCT00613171,evaluates,STI571
NCT00613171,measures_primary,Change From Baseline in Modified Rodnan Skin Score (MRSS)
NCT00613171,measures_secondary,Number of Participants With Adverse Events (AE's)
NCT00613171,measures_secondary,Number of Participants With Non-response
NCT00613171,has_criteria,equal to or older than 18 years of age
NCT02002871,involves,Eczema
NCT02002871,evaluates,Blue Light
NCT02002871,measures_primary,Change From Baseline
NCT02002871,measures_secondary,Inflammation (Erythema)
NCT02002871,measures_secondary,Patient Rating of Itching
NCT02002871,has_criteria,Good health
NCT02014571,involves,Chronic Hepatitis C
NCT02014571,evaluates,GSK2878175
NCT02014571,measures_primary,HCV RNA viral load
NCT02014571,measures_secondary,HCV RNA maximum change
NCT02014571,has_criteria,HCV subjects
NCT02596893,involves,Crohn's Disease
NCT02596893,evaluates,Mongersen
NCT02596893,measures_primary,Clinical Remission
NCT02596893,measures_secondary,Endoscopic Response-50
NCT02596893,has_criteria,CDAI score \< 150
NCT01766778,involves,Type 2 Diabetes
NCT01766778,evaluates,Vildagliptin
NCT01766778,measures_primary,Change HbA1c
NCT01766778,measures_secondary,Fasting Plasma Glucose
NCT01766778,measures_secondary,Percentage Achieving Good Glycemic Control
NCT01766778,measures_secondary,Percentage Overall Drug Compliance
NCT01766778,has_criteria,age
NCT01885871,involves,benign solar lentigines
NCT01885871,evaluates,Laser Removal
NCT01885871,measures_primary,VAS Improvement Score
NCT01885871,measures_secondary,Percent of Participants With Improvement Score
NCT01885871,has_criteria,Fitzpatrick Skin Type I-III
NCT01885871,has_criteria,18 to 60 years of age
NCT01885871,has_criteria,at least 5 lesions
NCT01885871,has_criteria,no topical creams
NCT01283971,involves,Rheumatoid Arthritis
NCT01283971,evaluates,RoActemra
NCT01283971,evaluates,Actemra
NCT01283971,evaluates,Tocilizumab
NCT01283971,evaluates,Adalimumab
NCT01283971,evaluates,Methotrexate
NCT01283971,measures_primary,DAS28 Remission
NCT01283971,measures_secondary,ACR20 Response
NCT01283971,measures_secondary,ACR50 Response
NCT01283971,has_criteria,Inadequate response to TNF-inhibitor
NCT03002571,involves,atopic dermatitis
NCT03002571,evaluates,IDP-124 Lotion
NCT03002571,measures_primary,IGA 2-grade reduction
NCT03002571,measures_secondary,EASI 75
NCT03002571,has_criteria,Baseline to Week 6
NCT03002571,has_criteria,Baseline to Week 10
NCT05196971,involves,Treatment-Resistant Depression
NCT05196971,evaluates,HS-10345
NCT05196971,measures_primary,Change from Baseline in C-SSRS
NCT05196971,measures_secondary,Change from Baseline in CADSS
NCT05196971,measures_secondary,Change From pre-dosing in MOAA/S
NCT05196971,has_criteria,7 weeks after discharge
NCT04744493,involves,Parkinson's Disease
NCT04744493,evaluates,MRGuided FUS Subthalamotomy
NCT04744493,measures_primary,MDS-UPDRS motor score
NCT04744493,measures_secondary,MDS-UPDRS parts I
NCT04744493,has_criteria,Levodopa equivalent medication usage
NCT03465878,involves,Type 1 Diabetes Mellitus
NCT03465878,evaluates,LY900014
NCT03465878,measures_primary,Insulin Lispro AUC
NCT03465878,measures_secondary,Glucose Concentration
NCT03465878,has_criteria,glycated hemoglobin less than 10 percent
NCT03465878,has_criteria,age 6-64 years
NCT03465878,has_criteria,T1DM for at least 1 year
NCT03465878,has_criteria,no other diabetes medication
NCT03465878,has_criteria,no severe hypoglycemia
NCT03465878,has_criteria,no clinically significant hematologic
NCT03465878,has_criteria,no liver disease
NCT03465878,has_criteria,no history of renal impairment
NCT00289978,involves,Relapsing-remitting Multiple Sclerosis
NCT00289978,evaluates,Fingolimod
NCT00289978,measures_primary,Annualized Relapse Rate
NCT00289978,measures_secondary,Disability Progression
NCT00289978,measures_secondary,New or Enlarged T2 Lesions
NCT00289978,has_criteria,Baseline EDSS score 0-5.0
NCT00289978,has_criteria,Baseline EDSS score 5.5 or above
NCT01621178,involves,Type 2 Diabetes
NCT01621178,involves,Chronic Kidney Disease
NCT01621178,evaluates,Dulaglutide
NCT01621178,evaluates,Insulin Glargine
NCT01621178,measures_primary,Change in HbA1c
NCT01621178,measures_secondary,Percentage of Participants Whose HbA1c Was <7.0%
NCT01621178,measures_secondary,Percentage of Participants Whose HbA1c Was <8.0%
NCT01621178,measures_secondary,Change From Baseline in 8-Point Self-Monitored Plasma Glucose
NCT01621178,measures_secondary,Change From Baseline in Fasting Glucose
NCT01621178,has_criteria,Baseline
NCT00939471,involves,Pediatric Sinusitis
NCT00939471,evaluates,Balloon Sinuplasty
NCT00939471,measures_primary,Sinus Symptom Scores
NCT00939471,measures_secondary,Medication Usage
NCT00939471,measures_secondary,Post-operative Interventions
NCT00939471,has_criteria,Subjects less than 12 years
NCT00939471,has_criteria,Subjects 12 years or greater
NCT02024971,involves,Type 2 Diabetes Mellitus
NCT02024971,evaluates,Pioglitazone/Metformin Hydrochloride Combination Tablets
NCT02024971,measures_primary,Change From Baseline in Glycosylated Hemoglobin (HbA1c)
NCT02024971,measures_secondary,Change From Baseline in Fasting Blood Glucose
NCT02024971,measures_secondary,Change From Baseline in Fasting Insulin
NCT02024971,has_criteria,Patients with type 2 diabetes
NCT04032171,involves,Multiple Sclerosis
NCT04032171,evaluates,Evobrutinib
NCT04032171,measures_primary,Time to EDSS progression
NCT04032171,measures_secondary,Change From Baseline in Patient Reported Outcomes Measurement Information Syste...
NCT04032171,has_criteria,Baseline up to 96 weeks
NCT01563978,involves,Rheumatoid Arthritis
NCT01563978,evaluates,Fostamatinib
NCT01563978,measures_primary,Change From Baseline
NCT01563978,measures_secondary,Mean Daytime and Night-time SBP
NCT01563978,measures_secondary,Mean Awake SBP
NCT01563978,measures_secondary,Mean Sleeping SBP
NCT01563978,measures_secondary,Mean Clinic SBP
NCT01563978,measures_secondary,Mean Morning Pre-dose Home SBP
NCT01563978,has_criteria,twice daily
NCT01670071,involves,Schizophrenia
NCT01670071,evaluates,Oral Paliperidone Extended-Release
NCT01670071,evaluates,Oral Risperidone Immediate-Release
NCT01670071,measures_primary,Change in category fluency
NCT01670071,measures_secondary,Modified Wisconsin Card Sorting Test
NCT01670071,measures_secondary,Continuous Performance Test
NCT06568471,involves,Hypercholesterolemia
NCT06568471,evaluates,HST101
NCT06568471,measures_primary,LDL-C change
NCT06568471,measures_secondary,Free PCSK9 change
NCT06568471,measures_secondary,Other Lipid parameters change
NCT06568471,measures_secondary,Percentage of patients achieving LDL-C goals
NCT06568471,measures_secondary,Incidence of treatment-emergent adverse events
NCT06568471,has_criteria,LDL-C\<2.6 mmol/L
NCT06568471,has_criteria,LDL-C\<1.8 mmol/L
NCT06568471,has_criteria,LDL-C\<1.4 mmol/L
NCT05258071,involves,Parkinson's Disease
NCT05258071,evaluates,Pirepemat
NCT05258071,measures_primary,Falls frequency
NCT05258071,measures_secondary,MDS-UPDRS part 2
NCT05258071,measures_secondary,NPI Item G
NCT05258071,measures_secondary,Caregiver distress
NCT05258071,has_criteria,55-85 years old
NCT05258071,has_criteria,idiopathic Parkinson's disease
NCT05258071,has_criteria,MoCA score 10-26
NCT05258071,has_criteria,Hoehn & Yahr score ≥2.5
NCT05258071,has_criteria,recurrent falls 3 months
NCT05258071,has_criteria,2 falls 4 weeks
NCT01204593,involves,Type 1 Diabetes Mellitus
NCT01204593,evaluates,basal bolus therapy
NCT01204593,measures_primary,Change in HbA1c
NCT01204593,measures_secondary,Percentage of patients with HbA1c < 7%
NCT01204593,measures_secondary,Fasting Blood Glucose
NCT01204593,measures_secondary,7-point SMBG
NCT01204593,measures_secondary,Daily dose for insulin glulisine
NCT01204593,measures_secondary,Daily dose for insulin glargine
NCT01204593,measures_secondary,Symptomatic hypoglycemias
NCT01204593,has_criteria,insulin glulisine
NCT01204593,has_criteria,insulin glargine
NCT02318719,involves,Post-herpetic Neuralgia
NCT02318719,evaluates,DS-5565
NCT02318719,measures_primary,Change in ADPS
NCT02318719,measures_secondary,Change in VAS pain
NCT02318719,has_criteria,pain present for more than 3 months
NCT02318719,has_criteria,pain scale of ≥ 40 mm
NCT04597918,involves,Diabetic Macular Edema
NCT04597918,evaluates,Faricimab
NCT04597918,measures_primary,ETDRS DRSS improvement
NCT04597918,measures_secondary,Best-Corrected Visual Acuity
NCT04597918,has_criteria,Treatment-Naïve
NCT01309841,involves,Non-cancer-related Pain
NCT01309841,involves,Opioid-induced Constipation
NCT01309841,evaluates,Study Drug
NCT01309841,measures_primary,Responder/Non-responder
NCT01309841,measures_secondary,Time to First Post-dose Laxation
NCT01309841,measures_secondary,Change From Baseline in Mean Number of Days
NCT01309841,measures_secondary,Change From Baseline in Degree of Straining
NCT01309841,measures_secondary,Change From Baseline in Stool Consistency
NCT01309841,has_criteria,Baseline (Week 1) to end of treatment (Week 12)
NCT02481141,involves,Type II diabetes mellitus
NCT02481141,evaluates,5-ALA-SFC
NCT02481141,measures_primary,Change From Baseline in Fasting Blood Glucose
NCT02481141,measures_secondary,Change From Baseline in 2 Hour Post Meal Glucose Level
NCT02481141,measures_secondary,Change From Baseline in Body Weight
NCT02481141,measures_secondary,Change From Baseline in HbA1c
NCT02481141,measures_secondary,Change From Baseline in Total Cholesterol
NCT02481141,measures_secondary,Change From Baseline LDL
NCT02481141,measures_secondary,Change From Baseline in HDL
NCT02481141,measures_secondary,Change From Baseline in Triglycerides
NCT02481141,has_criteria,Males and females residing in Bahrain
NCT02481141,has_criteria,aged 20 to 75 years old
NCT02481141,has_criteria,diagnosed with type II diabetes mellitus
NCT02481141,has_criteria,HbA1c >6.5 and <10%
NCT00819741,involves,Type 2 Diabetes
NCT00819741,evaluates,Repaglinide
NCT00819741,measures_primary,Change in HbA1c
NCT00819741,measures_secondary,Fasting Plasma Glucose
NCT00819741,measures_secondary,2-hour Postprandial Plasma Glucose
NCT00819741,measures_secondary,7-point Plasma Glucose Profile
NCT00819741,measures_secondary,Fasting Serum Insulin
NCT00819741,measures_secondary,2-hour Postprandial Serum Insulin
NCT00819741,measures_secondary,Fasting Serum C-peptide
NCT00819741,measures_secondary,2-hour Postprandial Serum C-peptide
NCT00819741,measures_secondary,Hypoglycaemic Episodes
NCT00819741,has_criteria,Oral Sugar-lowering Drugs
NCT04461119,involves,Chronic Schizophrenia
NCT04461119,evaluates,Evenamide
NCT04461119,measures_primary,PANSS total score
NCT04461119,measures_secondary,CGI-S score
NCT04461119,measures_secondary,CGI-C
NCT04461119,has_criteria,plasma drug concentrations
NCT03852719,involves,Chronic Hepatitis Delta
NCT03852719,evaluates,Bulevirtide
NCT03852719,measures_primary,Combined response at Week 48
NCT03852719,measures_secondary,Undetectable HDV RNA at Week 48
NCT03852719,measures_secondary,ALT normalization at Week 48
NCT03852719,measures_secondary,Change From Baseline in Liver Stiffness
NCT03852719,measures_secondary,Percentage Who Prematurely Discontinued
NCT03852719,has_criteria,Adverse Event (AE)
NCT05183919,involves,ADHD
NCT05183919,evaluates,AKL-T01
NCT05183919,measures_primary,TOVA ACS
NCT05183919,measures_secondary,ADHD Rating Scale-IV
NCT05183919,has_criteria,adult prompts
NCT03434041,involves,Treatment-resistant Depression
NCT03434041,evaluates,Intranasal Esketamine
NCT03434041,measures_primary,Change From Baseline in MADRS Total Score
NCT03434041,measures_secondary,Change From Baseline in Depressive Symptoms
NCT03434041,measures_secondary,Change From Baseline in SDS Total Score
NCT03434041,has_criteria,Baseline up to end of double-blind treatment phase
NCT01300819,involves,Parkinson's Disease
NCT01300819,evaluates,Rotigotine
NCT01300819,measures_primary,Change From Baseline
NCT01300819,measures_secondary,Unified Parkinson's Disease Rating Scale
NCT01300819,measures_secondary,Health-related Quality of Life
NCT01300819,has_criteria,12-week Maintenance
NCT00389519,involves,Hypertension
NCT00389519,evaluates,Ramipril
NCT00389519,measures_primary,Systolic Blood Pressure
NCT00389519,measures_secondary,Diastolic Blood Pressure
NCT00389519,measures_secondary,Serum Creatinine
NCT00389519,measures_secondary,Serum Potassium
NCT00389519,measures_secondary,Schwartz Formula GFR
NCT00389519,has_criteria,Previous hypertension diagnosis
NCT00389519,has_criteria,Age 6 to 16 years
NCT00389519,has_criteria,Weight ≥ 20 kg
NCT00141219,involves,Peripheral Neuropathic Pain
NCT00141219,evaluates,Pregabalin
NCT00141219,measures_primary,Mean Pain Score
NCT00141219,measures_secondary,30% Responders
NCT00141219,measures_secondary,50% Responders
NCT00141219,measures_secondary,Weekly Mean Pain Score
NCT00141219,has_criteria,Week 8 or Early Discontinuation
NCT02433119,involves,Essential Hypertension
NCT02433119,evaluates,OROSARTAN
NCT02433119,evaluates,CODIOVAN
NCT02433119,measures_primary,Change from baseline MSDBP
NCT02433119,measures_secondary,Control rate blood pressure
NCT02433119,measures_secondary,Responder rate blood pressure
NCT02433119,has_criteria,aged or over
NCT02433119,has_criteria,diagnosed essential hypertension
NCT02433119,has_criteria,understood objective
NCT02433119,has_criteria,written informed consent
NCT02433119,has_criteria,severe hypertension
NCT02433119,has_criteria,difference blood pressure
NCT02433119,has_criteria,secondary hypertension
NCT02433119,has_criteria,history hypersensitivity CCB
NCT02433119,has_criteria,history hypersensitivity ARB
NCT02433119,has_criteria,history hypersensitivity sulfonamide
NCT04669041,involves,Primary Hypercholesterolemia
NCT04669041,evaluates,Ezetimibe/Rosuvastatin
NCT04669041,measures_primary,Percent change LDL-C
NCT04669041,measures_secondary,Proportion lipid goal
NCT04669041,measures_secondary,Percent change TC
NCT04669041,measures_secondary,Percent change TG
NCT04669041,measures_secondary,Percent change HDL-C
NCT04669041,measures_secondary,Number adverse events
NCT04669041,has_criteria,at least 18 years old
NCT04669041,has_criteria,primary hypercholesterolemia
NCT04669041,has_criteria,not adequately controlled
NCT05056441,involves,Crohn's Disease
NCT05056441,evaluates,VDZ
NCT05056441,evaluates,UST
NCT05056441,measures_primary,Clinical Remission
NCT05056441,measures_primary,Clinical Response
NCT05056441,has_criteria,Baseline up to 36 months
NCT00667719,involves,Essential Hypertension
NCT00667719,evaluates,Aliskiren/ Amlodipine / Hydrochlorothiazide
NCT00667719,measures_primary,Change From Baseline in msDBP
NCT00667719,measures_primary,Change From Baseline in msSBP
NCT00667719,has_criteria,sitting diastolic pressures
NCT02652819,evaluates,FG-4592
NCT02652819,involves,Anemia
NCT02652819,involves,Chronic Kidney Disease
NCT02652819,measures_primary,Change in Hb
NCT02652819,measures_secondary,Proportion Hb response
NCT02652819,measures_secondary,Mean Hb ≥10.0 g/dL
NCT02652819,measures_secondary,LDL cholesterol
NCT02652819,measures_secondary,Iron metabolism
NCT02652819,measures_secondary,SF-36 Physical Functioning
NCT02652819,measures_secondary,SF-36 vitality subscore
NCT02652819,measures_secondary,Mean arterial blood pressure
NCT02652819,measures_secondary,Rescue therapy
NCT02652819,measures_secondary,Treatment-emergent adverse events
NCT02652819,has_criteria,Subjects not on dialysis
NCT02554019,involves,Systemic Lupus Erythematosus
NCT02554019,evaluates,BT063
NCT02554019,measures_primary,Swollen/tender joints
NCT02554019,measures_secondary,Skin improvement
NCT02554019,has_criteria,Joint assessment
NCT02078219,involves,Gout
NCT02078219,involves,Asymptomatic Hyperuricemia
NCT02078219,evaluates,RDEA3170
NCT02078219,evaluates,Placebo
NCT02078219,measures_primary,Percent Change sUA
NCT02078219,measures_secondary,Percentage Subjects sUA ≤6.0 mg/dL
NCT02078219,measures_secondary,Absolute Change sUA
NCT02078219,has_criteria,sUA ≤10.0 mg/dL
NCT02078219,has_criteria,sUA level >7.0 mg/dL
NCT02078219,has_criteria,gout
NCT02078219,has_criteria,sUA level ≥8.0 mg/dL
NCT02078219,has_criteria,hypertension
NCT02078219,has_criteria,ischemic heart disease
NCT02078219,has_criteria,diabetes
NCT02078219,has_criteria,metabolic syndrome
NCT02078219,has_criteria,sUA level ≥9.0 mg/dL
NCT02078219,has_criteria,no gout
NCT02078219,has_criteria,no complications
NCT02078219,has_criteria,no acute gout flare
NCT02078219,has_criteria,no history kidney stones
NCT02078219,has_criteria,creatinine clearance ≥60 mL/min
NCT02078219,has_criteria,no CYP3A inhibitors
NCT03713619,involves,Hidradenitis Suppurativa
NCT03713619,evaluates,Secukinumab
NCT03713619,measures_primary,HiSCR50 at Week 16
NCT03713619,measures_secondary,HS Flares
NCT03713619,measures_secondary,NRS30
NCT03713619,has_criteria,at least 50% decrease
NCT01529619,involves,Alzheimer's Disease
NCT01529619,evaluates,Rivastigmine Patch
NCT01529619,measures_primary,Change in ADAS-J cog
NCT01529619,measures_secondary,Disability Assessment for Dementia
NCT01529619,measures_secondary,Mini-Mental State Examination
NCT01529619,measures_secondary,Japanese version of the Clinical global impression of change
NCT01529619,has_criteria,Switched From Cholinesterase Inhibitors
NCT03103919,involves,Parkinson's Disease
NCT03103919,evaluates,Wearable Devices
NCT03103919,measures_primary,Change From Baseline
NCT03103919,measures_secondary,Kinesia-ONE™ Variable
NCT03103919,has_criteria,Baseline (Visit 1/Week 1)
NCT02733419,involves,Human Immunodeficiency Virus-1 Infection
NCT02733419,evaluates,Enfuvirtide
NCT02733419,measures_primary,virologic failure
NCT02733419,measures_secondary,viral load
NCT02733419,has_criteria,treatment-experienced
NCT03115619,involves,IPF
NCT03115619,evaluates,Pirfenidone
NCT03115619,measures_primary,Quality of Life
NCT03115619,measures_secondary,Dyspnoea
NCT03115619,measures_secondary,Forced Vital Capacity
NCT03115619,measures_secondary,Diffusing Lung Capacity
NCT03115619,measures_secondary,Acute IPF Exacerbations
NCT03115619,measures_secondary,Treatment compliance
NCT03115619,measures_secondary,Adverse Events
NCT03115619,has_criteria,Adult participants
NCT03115619,has_criteria,prescribed pirfenidone
NCT03115619,has_criteria,no more than 4 weeks prior to enrollment
NCT05824416,involves,Acquired Brain Injury
NCT05824416,evaluates,ALBA® Device
NCT05824416,measures_primary,Upper Extremity Motor Function
NCT05824416,measures_secondary,Cognitive Function
NCT05824416,measures_secondary,Muscle Strength
NCT05824416,has_criteria,Subacute and Chronic
NCT03712124,involves,Diabetic Gastroparesis
NCT03712124,evaluates,CNSA-001
NCT03712124,measures_primary,Maximal Tolerated Volume
NCT03712124,measures_secondary,Gastroparesis Cardinal Symptom Index
NCT03712124,has_criteria,Baseline (Day 1)
NCT02252224,involves,Adverse event
NCT02252224,evaluates,Forxiga
NCT02252224,measures_primary,HbA1c
NCT02252224,measures_secondary,FPG
NCT02252224,has_criteria,received at least one dose
NCT00806416,involves,Osteoporosis
NCT00806416,evaluates,Alendronate
NCT00806416,evaluates,Vitamin D
NCT00806416,measures_primary,Urinary excretion
NCT00806416,measures_secondary,AUC0-120 hr
NCT00806416,measures_secondary,Cmax
NCT00806416,has_criteria,Age 18 to 65 years
NCT02389816,involves,Major Depressive Disorder
NCT02389816,evaluates,Lu AA21004
NCT02389816,measures_primary,Change From Baseline
NCT02389816,measures_secondary,MADRS Response at Week 8
NCT02389816,measures_secondary,MADRS Remission at Week 8
NCT02389816,has_criteria,Baseline to Week 8
NCT02181816,involves,Hypertension
NCT02181816,evaluates,Azilsartan/Amlodipine Combination Tablets
NCT02181816,measures_primary,Systolic Office Blood Pressure
NCT02181816,measures_secondary,Diastolic Office Blood Pressure
NCT02181816,has_criteria,Hypertensive patients
NCT02181816,has_criteria,Hypersensitivity to azilsartan/amlodipine
NCT02181816,has_criteria,Pregnant or possibilities of pregnancy
NCT02181816,has_criteria,Diabetic patients taking aliskiren fumarate
NCT03041116,involves,Pantothenate Kinase-Associated Neurodegeneration
NCT03041116,evaluates,Fosmetpantotenate
NCT03041116,measures_primary,PKAN-ADL Total Score
NCT03041116,measures_secondary,Treatment-emergent Adverse Event
NCT03041116,has_criteria,age group
NCT02302716,involves,Type 2 Diabetes Mellitus
NCT02302716,evaluates,LY2963016
NCT02302716,evaluates,LANTUS
NCT02302716,measures_primary,Change From Baseline in HbA1c
NCT02302716,measures_secondary,Change From Baseline in 7-point SMBG Values
NCT02302716,measures_secondary,Intra-Participant Variability in Fasting Blood Glucose
NCT02302716,has_criteria,Baseline HbA1c
NCT02302716,has_criteria,country
NCT02302716,has_criteria,sulfonylurea use
NCT02302716,has_criteria,basal insulin status at study entry
NCT02094924,evaluates,GSK587323
NCT02094924,measures_primary,PK parameters
NCT02094924,measures_secondary,Vital sign assessment
NCT02094924,measures_secondary,Adverse event
NCT02094924,has_criteria,Up to 39 days
NCT02289716,involves,Osteoarthritis
NCT02289716,evaluates,Fulranumab
NCT02289716,measures_primary,WOMAC pain score
NCT02289716,measures_secondary,WOMAC physical function
NCT02289716,measures_secondary,Patient Global Assessment
NCT02289716,measures_secondary,WOMAC Stiffness
NCT02289716,measures_secondary,daily numerical rating scale
NCT02289716,has_criteria,Baseline
NCT00537316,involves,Ulcerative Colitis
NCT00537316,evaluates,Infliximab
NCT00537316,measures_primary,Steroid-free Remission
NCT00537316,measures_secondary,Mucosal Healing
NCT00537316,has_criteria,Week 16
NCT02618616,involves,Plaque Psoriasis
NCT02618616,evaluates,ZPL-3893787
NCT02618616,measures_primary,PASI at Week 12
NCT02618616,measures_secondary,IGA at Week 12
NCT02618616,measures_secondary,NRS for Pruritus
NCT02618616,has_criteria,From baseline to week 12
NCT02388724,involves,Erosive Esophagitis
NCT02388724,evaluates,Vonoprazan
NCT02388724,measures_primary,Endoscopic healing
NCT02388724,measures_secondary,Adverse Event
NCT02388724,has_criteria,Los Angeles classification
NCT03877224,involves,Heart Failure With Preserved Ejection Fraction
NCT03877224,evaluates,Dapagliflozin
NCT03877224,measures_primary,Change From Baseline in KCCQ-TSS
NCT03877224,measures_secondary,Change From Baseline in KCCQ-PLS
NCT03877224,has_criteria,baseline value
NCT05016024,involves,Irritable Bowel Syndrome
NCT05016024,evaluates,Molecular Complex of Resins
NCT05016024,measures_primary,IBS-SSS score
NCT05016024,measures_secondary,Abdominal pain intensity
NCT05016024,measures_secondary,Overall symptom relief
NCT05016024,measures_secondary,Time to relief
NCT05016024,measures_secondary,Severity score of each symptom
NCT05016024,has_criteria,End of treatment (up to 5 months)
NCT00758524,involves,Essential Hypertension
NCT00758524,evaluates,LCI699
NCT00758524,measures_primary,Change in MSDBP
NCT00758524,measures_primary,Change in MSSBP
NCT00758524,measures_secondary,Number of Participants
NCT00758524,has_criteria,Adverse Event
NCT01604824,involves,Autosomal Dominant Hypercholesterolemia
NCT01604824,involves,Gain-of-Function Mutations
NCT01604824,involves,Loss-of-Function Mutations
NCT01604824,evaluates,Alirocumab
NCT01604824,measures_primary,Percent Change LDL-C
NCT01604824,measures_secondary,Percent Change Apo B100
NCT01604824,measures_secondary,Percent Change Non-HDL-C
NCT01604824,measures_secondary,Percent Change Total Cholesterol
NCT01604824,measures_secondary,Percent Change Apo B100/ApoA-1 Ratio
NCT01604824,has_criteria,18 to 70 years
NCT01604824,has_criteria,PCSK9 GOFm
NCT01604824,has_criteria,ApoB LOFm
NCT01604824,has_criteria,LDL-Cholesterol ≥70 mg/dL
NCT01604824,has_criteria,lipid-lowering therapy
NCT01604824,has_criteria,Serum triglycerides ≤350 mg/dL
NCT03441516,involves,Alzheimer's dementia
NCT03441516,involves,dementia of the Alzheimer type
NCT03441516,evaluates,Choline Alphoscerate
NCT03441516,measures_primary,ADAS-cog
NCT03441516,measures_secondary,K-MMSE
NCT03441516,measures_secondary,FAB
NCT03441516,measures_secondary,S-IADL
NCT03441516,measures_secondary,CGA-NPI
NCT03441516,measures_secondary,Changes in brain metabolism
NCT03441516,has_criteria,50 - 90 years of age
NCT03441516,has_criteria,DSM-IV criteria
NCT03441516,has_criteria,NIA-AA criteria
NCT03441516,has_criteria,K-MMSE score of 12 - 26
NCT03441516,has_criteria,CDR score of 0.5 - 2
NCT03441516,has_criteria,donepezil 10 mg per day
NCT03441516,has_criteria,stable dose of donepezil
NCT03441516,has_criteria,no other brain pills including choline alfoscerate
NCT03441516,has_criteria,stable dose of other drugs for 2 weeks
NCT05646524,involves,Paroxysmal Nocturnal Hemoglobinuria
NCT05646524,evaluates,NM8074
NCT05646524,measures_primary,Change from Baseline Hemoglobin
NCT05646524,measures_secondary,Lactate Dehydrogenase
NCT05646524,measures_secondary,Packed Red Blood Cell Transfusions
NCT05646524,measures_secondary,Membrane Attack Complex
NCT05646524,measures_secondary,Complement Component C3b
NCT05646524,measures_secondary,Reticulocyte Count
NCT05646524,measures_secondary,Bilirubin
NCT05646524,measures_secondary,Quality of Life
NCT05646524,has_criteria,Naive to Complement Inhibitor Therapy
NCT03227224,involves,Major Depressive Disorder
NCT03227224,evaluates,JNJ-42847922
NCT03227224,measures_primary,Change From Baseline
NCT03227224,measures_secondary,Treatment-emergent Adverse Events
NCT03227224,measures_secondary,Clinically Significant Laboratory Abnormalities
NCT03227224,has_criteria,Responded Inadequately
NCT01179516,involves,Major Depressive Disorder
NCT01179516,evaluates,Vortioxetine
NCT01179516,measures_primary,Change From Baseline in MADRS Total Score
NCT01179516,measures_secondary,Percentage of Participants With a MADRS Response at Week 8
NCT01179516,measures_secondary,Mean Clinical Global Impression Scale - Improvement (CGI-I) Score at Week 8
NCT01179516,has_criteria,Baseline Hamilton Anx...
NCT00320216,involves,plaque-type psoriasis
NCT00320216,evaluates,CNTO 1275
NCT00320216,measures_primary,PASI 75% Improvement
NCT00320216,measures_secondary,Physician's Global Assessment
NCT00320216,has_criteria,plaque-type psoriasis
NCT00320216,has_criteria,10% body surface areas
NCT00320216,has_criteria,Psoriasis area-and-severity index
NCT06646016,involves,Immune-related Colitis
NCT06646016,evaluates,Extracorporeal Photopheresis
NCT06646016,measures_primary,Remission of ir-colitis
NCT06646016,measures_secondary,Diarrhea frequency
NCT06646016,measures_secondary,Colonic mucosal endoscopy score
NCT06646016,has_criteria,Diarrhea improves
NCT06538116,involves,Alzheimer's Disease
NCT06538116,evaluates,Mevidalen
NCT06538116,measures_primary,Change from Baseline in iADRS
NCT06538116,measures_secondary,Change from Baseline in ADAS-Cog13
NCT06538116,measures_secondary,Change from Baseline in Verbal Fluency Test
NCT06538116,measures_secondary,Change from Baseline in Category Fluency Test
NCT06538116,measures_secondary,Change from Baseline in Digit Symbol Coding Test
NCT06538116,has_criteria,Baseline
NCT06126224,involves,Psychosis Associated With Alzheimer's Disease
NCT06126224,evaluates,KarXT
NCT06126224,measures_primary,Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) score
NCT06126224,measures_secondary,Change from Baseline to End of Treatment in the Cohen-Mansfield Agitation Inventory (CMAI) score
NCT06126224,measures_secondary,Change from Baseline to End of Treatment in the Clinical Global Impressions-Severity (CGI-S) scale
NCT06126224,has_criteria,aged 55 to 90 years
NCT06126224,has_criteria,understand the nature of the trial
NCT06126224,has_criteria,Meets clinical criteria for Possible AD or Probable AD
NCT06126224,has_criteria,living at the same home or residential assisted-living facility for a minimum of 6 weeks before
NCT03739216,involves,nasal symptoms
NCT03739216,evaluates,ClariFix device
NCT03739216,measures_primary,change from baseline
NCT03739216,measures_secondary,Patient Global Impression of Change
NCT03739216,measures_secondary,Clinical Global Impression - Improvement
NCT03739216,has_criteria,treatment with ClariFix device
NCT03739216,has_criteria,provide consent
NCT03739216,has_criteria,adhere to study schedule
NCT03739216,has_criteria,additional treatment
NCT03739216,has_criteria,additional nasal treatments
NCT05216224,involves,Hidradenitis Suppurativa
NCT05216224,evaluates,ATI-450
NCT05216224,measures_primary,inflammatory nodule/abscess count
NCT05216224,measures_secondary,Hidradenitis Suppurativa Clinical Response
NCT05216224,measures_secondary,International Hidradenitis Suppurativa Severity Score System
NCT05216224,measures_secondary,Patient's Global Assessment of Skin Pain
NCT05216224,measures_secondary,Hidradenitis Suppurativa-Physician Global Assessment
NCT05216224,measures_secondary,Dermatology Life Quality Index
NCT05216224,measures_secondary,adverse events
NCT05216224,has_criteria,Baseline through Week 12
NCT01316224,involves,Psoriatic Arthritis
NCT01316224,involves,Psoriasis
NCT01316224,evaluates,Adalimumab
NCT01316224,measures_primary,PsA development
NCT01316224,measures_secondary,PsA signs/symptoms
NCT01316224,measures_secondary,PASI score
NCT01316224,measures_secondary,Quality of Life
NCT01316224,has_criteria,inflamed joints >0
NCT01316224,has_criteria,CASPAR score >=3
NCT01395524,involves,Non-cancer-related Pain
NCT01395524,involves,Opioid-induced Constipation
NCT01395524,evaluates,NKTR-118
NCT01395524,measures_primary,Change From Baseline
NCT01395524,measures_secondary,Change From Baseline
NCT01395524,has_criteria,Baseline (Week 0)
NCT03703024,involves,Osteoarthritis
NCT03703024,evaluates,Raspberry Leaf Extract
NCT03703024,measures_primary,Change in Pain Scores
NCT03703024,measures_secondary,WOMAC stiffness sub-score
NCT03703024,measures_secondary,WOMAC physical function sub-score
NCT03703024,has_criteria,12-13 weeks
NCT02986724,involves,Ulcerative Colitis
NCT02986724,involves,Crohn's Disease
NCT02986724,evaluates,Vedolizumab
NCT02986724,measures_primary,Clinical Response
NCT02986724,measures_primary,Clinical Remission
NCT02986724,has_criteria,Biologically Naive
NCT04204616,involves,Prurigo Nodularis
NCT04204616,evaluates,Nemolizumab
NCT04204616,measures_primary,IGA Success
NCT04204616,measures_secondary,Peak Pruritus
NCT04204616,measures_secondary,Disease Activity State
NCT04204616,has_criteria,Baseline
NCT05972616,involves,low back pain
NCT05972616,evaluates,Natural Matrix Protein™
NCT05972616,measures_primary,radiographic fusion rate
NCT05972616,measures_secondary,Oswestry Disability Index
NCT05972616,measures_secondary,12-Item Short Form Survey
NCT05972616,measures_secondary,Visual Analogue Scale
NCT05972616,has_criteria,CT grade 3A
NCT05972616,has_criteria,less than 3 degrees of motion
NCT01894516,involves,Rheumatoid Arthritis
NCT01894516,evaluates,GLPG0634
NCT01894516,measures_primary,ACR20 Response
NCT01894516,measures_secondary,ACR50 Response
NCT01894516,has_criteria,Active Rheumatoid Arthritis
NCT04414124,involves,COVID-19
NCT04414124,evaluates,KB109
NCT04414124,measures_primary,COVID-19 symptom score
NCT04414124,measures_secondary,Time to resolution of fever
NCT04414124,measures_secondary,Proportion of patients with decreased oxygen saturation
NCT04414124,measures_secondary,Effect of COVID-19 symptoms on physical activities
NCT04414124,measures_secondary,Proportion of patients requiring hospitalization
NCT04414124,measures_secondary,Time to resolution of overall 13 COVID-19 related symptoms
NCT04414124,has_criteria,Mild-to-moderate COVID-19
NCT03628924,involves,Hidradenitis Suppurativa
NCT03628924,evaluates,Guselkumab
NCT03628924,measures_primary,HiSCR at Week 16
NCT03628924,measures_secondary,Dermatology Life Quality Index (DLQI)
NCT03628924,measures_secondary,Hidradenitis Suppurativa (HS)-Related Pain Symptom Score
NCT03628924,has_criteria,Moderate to Severe HS
NCT01979016,involves,Atopic Dermatitis
NCT01979016,evaluates,Dupilumab
NCT01979016,measures_primary,EASI score
NCT01979016,measures_secondary,IGA score
NCT01979016,measures_secondary,Pruritus NRS
NCT01979016,has_criteria,rescue medication
NCT02392624,involves,Chronic Idiopathic Urticaria
NCT02392624,evaluates,Omalizumab
NCT02392624,measures_primary,Time to Clinical Worsening
NCT02392624,measures_secondary,Percentage of Participants Who Experienced Clinical Worsening
NCT02392624,has_criteria,UAS7 >= 12
NCT04493424,involves,Palmoplantar Pustulosis
NCT04493424,evaluates,Spesolimab
NCT04493424,measures_primary,Percent Change PPP ASI
NCT04493424,measures_secondary,Proportion of Patients PPP ASI50
NCT04493424,has_criteria,Previous Spesolimab studies
NCT02094716,involves,scabies
NCT02094716,evaluates,Permethrin Foam
NCT02094716,evaluates,Permethrin Foam
NCT02094716,measures_primary,treatment success
NCT02094716,measures_secondary,Signs/Symptoms
NCT02094716,has_criteria,Investigator's Global Assessment
NCT06544616,involves,Preclinical Alzheimer's Disease
NCT06544616,evaluates,JNJ-64042056
NCT06544616,measures_primary,Change From Baseline in PACC-5
NCT06544616,measures_secondary,Change from baseline in brain tau burden
NCT06544616,measures_secondary,Time to Event of Clinical Progression
NCT06544616,has_criteria,Baseline up to Week 206
NCT03934216,involves,Ulcerative Colitis
NCT03934216,evaluates,Deucravacitinib
NCT03934216,measures_primary,Clinical Remission Response Rate
NCT03934216,measures_secondary,Clinical Response Rate
NCT03934216,measures_secondary,Endoscopic Response
NCT03934216,has_criteria,moderate to severe disease
NCT04684524,involves,Allergic Fungal Rhinosinusitis
NCT04684524,evaluates,Dupilumab
NCT04684524,measures_primary,Change from baseline in sinus opacifications
NCT04684524,measures_secondary,Nasal congestion/obstruction score
NCT04684524,measures_secondary,anterior/posterior rhinorrhea score
NCT04684524,measures_secondary,endoscopic NPS
NCT04684524,measures_secondary,SNOT-22 total score
NCT04684524,has_criteria,systemic corticosteroids
NCT05456724,involves,Open-Angle Glaucoma
NCT05456724,involves,Ocular Hypertension
NCT05456724,evaluates,TO-O-1001
NCT05456724,measures_primary,mean IOP
NCT05456724,measures_secondary,Best Corrected Visual Acuity
NCT05456724,has_criteria,18 - 59-year-old
NCT02475317,involves,Overweight
NCT02475317,involves,Obese
NCT02475317,evaluates,LUM001
NCT02475317,evaluates,SHP626
NCT02475317,measures_primary,Fecal bile acid excretion
NCT02475317,measures_secondary,Treatment Emergent Adverse Events
NCT02475317,measures_secondary,Vital Signs
NCT02475317,measures_secondary,Blood Pressure
NCT02475317,measures_secondary,12-lead Electrocardiogram
NCT02475317,has_criteria,Baseline
NCT03921541,involves,Arginase 1 Deficiency
NCT03921541,evaluates,pegzilarginase
NCT03921541,measures_primary,change in plasma arginine
NCT03921541,measures_secondary,2 Minute Walk Test
NCT03921541,measures_secondary,GMFM-E
NCT03921541,measures_secondary,plasma arginine levels
NCT03921541,measures_secondary,plasma arginine levels
NCT03921541,measures_secondary,ornithine and guanidino compounds
NCT03921541,measures_secondary,GMFM-D
NCT03921541,measures_secondary,Functional Mobility Scale
NCT03921541,has_criteria,Baseline through week 24
NCT03921541,has_criteria,Baseline and week 24
NCT03921541,has_criteria,Week 24
NCT03921541,has_criteria,Baseline
NCT03921541,has_criteria,Baseline
NCT00873041,involves,Non-transfusion Dependent Thalassemia
NCT00873041,evaluates,Deferasirox
NCT00873041,measures_primary,Change in LIC
NCT00873041,measures_secondary,Change in Serum Ferritin
NCT00873041,has_criteria,Iron Overload
NCT01799941,involves,Pseudobulbar Affect
NCT01799941,evaluates,Nuedexta
NCT01799941,measures_primary,CNS-LS Score
NCT01799941,measures_secondary,CNS-LS Score
NCT01799941,has_criteria,Day 90
NCT04572841,involves,Primary Sjögren's Syndrome
NCT04572841,evaluates,SAR441344
NCT04572841,measures_primary,Change in ESSDAI
NCT04572841,measures_secondary,ESSPRI
NCT04572841,measures_secondary,Multidimensional Fatigue Inventory
NCT04572841,has_criteria,Baseline to Week 24
NCT00960141,involves,Seasonal Allergic Rhinitis
NCT00960141,evaluates,Montelukast
NCT00960141,measures_primary,Daytime Nasal Symptoms Score
NCT00960141,measures_secondary,Nighttime Symptoms Score
NCT00960141,measures_secondary,Daytime Eye Symptoms Score
NCT00960141,measures_secondary,Patient's Global Evaluation
NCT00960141,measures_secondary,Physician's Global Evaluation
NCT00960141,measures_secondary,Rhinoconjunctivitis Quality-of-Life Score
NCT01632241,involves,Systemic Lupus Erythematosus
NCT01632241,evaluates,Belimumab
NCT01632241,measures_primary,SRI Response Rate
NCT01632241,measures_secondary,SLEDAI-2K
NCT01632241,has_criteria,Baseline SS score
NCT03559517,involves,Crohn's Disease
NCT03559517,evaluates,Ontamalimab
NCT03559517,measures_primary,Clinical Remission
NCT03559517,measures_secondary,Endoscopic Response
NCT03559517,has_criteria,Clinical remission
NCT00756041,involves,Diabetic Peripheral Neuropathy
NCT00756041,evaluates,TAK-128
NCT00756041,measures_primary,composite nerve conduction velocities
NCT00756041,measures_secondary,electrophysiologic parameters
NCT00756041,measures_secondary,vibration perception threshold
NCT00756041,measures_secondary,neurological examination
NCT00756041,measures_secondary,pain scores
NCT00756041,measures_secondary,quality of life index
NCT00756041,has_criteria,Treatment-emergent adverse events
NCT03759041,involves,Ulcerative Colitis
NCT03759041,evaluates,SER-287
NCT03759041,measures_primary,Clinical Remission
NCT03759041,measures_secondary,Endoscopic Improvement
NCT03759041,has_criteria,Active mild-to-moderate UC
NCT05333419,involves,Open Angle Glaucoma
NCT05333419,involves,Ocular Hypertension
NCT05333419,evaluates,PA5346 Latanoprost FA SR Ocular Implant
NCT05333419,measures_primary,IOP control
NCT05333419,measures_secondary,biodegradation
NCT05333419,measures_secondary,safety
NCT05333419,measures_secondary,tolerability
NCT05333419,has_criteria,adults with OAG or OHT
NCT01929317,involves,Parkinson's Disease
NCT01929317,evaluates,Ropinirole
NCT01929317,measures_primary,UPDRS Part III Score
NCT01929317,measures_secondary,Mean Change From Baseline
NCT01929317,has_criteria,Dose Increase Effect Verification Phase
NCT03926117,involves,Chronic Renal Disease
NCT03926117,evaluates,Antibody Mediated IL-6 Inhibition
NCT03926117,measures_primary,Percent change from baseline
NCT03926117,measures_secondary,Percentage of Participants With TEAEs
NCT03926117,measures_secondary,Percentage of Participants With TIMI Major Bleeding Events
NCT03926117,has_criteria,From week 0 to week 32
NCT03320941,involves,Obesity
NCT03320941,evaluates,LIK066
NCT03320941,measures_primary,Body Weight at Week 12
NCT03320941,measures_secondary,Waist Circumference
NCT03320941,measures_secondary,Hemoglobin A1c
NCT03320941,measures_secondary,Fasting Plasma Glucose
NCT03320941,has_criteria,Japanese Patients
NCT05216341,involves,Osteoarthritis
NCT05216341,evaluates,OLP-1002
NCT05216341,measures_primary,Safety and tolerability
NCT05216341,measures_secondary,Physical examination abnormalities
NCT05216341,has_criteria,moderate to severe pain
NCT01590641,involves,Chronic Hepatitis B
NCT01590641,evaluates,GS-9620
NCT01590641,measures_primary,HBV viral load
NCT01590641,measures_secondary,HBsAg
NCT01590641,has_criteria,Chronic HBV infection
NCT04001517,involves,Dementia With Lewy Bodies
NCT04001517,evaluates,Neflamapimod
NCT04001517,measures_primary,Composite z-score NTB
NCT04001517,measures_secondary,CDR-SB score
NCT04001517,has_criteria,Baseline to Week 16
NCT04143217,involves,ADHD
NCT04143217,evaluates,SPN-812
NCT04143217,measures_primary,Incidence of Adverse Events
NCT04143217,measures_secondary,Change from baseline AISRS Total score
NCT04143217,has_criteria,Safety Population
NCT02087917,involves,Primary Hypercholesterolemia
NCT02087917,evaluates,HS-25
NCT02087917,measures_primary,LDL-C change
NCT02087917,measures_secondary,adverse events
NCT02087917,has_criteria,LDL-C 130-189 mg/dL
NCT02087917,has_criteria,TG ≤ 350 mg/dL
NCT02087917,has_criteria,age 18-65 years
NCT01529541,involves,Type 2 Diabetes Mellitus
NCT01529541,evaluates,CWP-0403
NCT01529541,evaluates,Sitagliptin
NCT01529541,measures_primary,Change in HbA1c
NCT01529541,measures_secondary,Fasting plasma glucose
NCT01529541,measures_secondary,Fasting serum insulin
NCT01529541,measures_secondary,Fasting serum pro-insulin
NCT01529541,measures_secondary,Fasting serum c-peptide
NCT01529541,measures_secondary,HOMA-β
NCT01529541,measures_secondary,HOMA-IR
NCT01529541,has_criteria,Diagnosed with type 2 DM
NCT01529541,has_criteria,Age 19 to 75 years
NCT01529541,has_criteria,FPG ≤ 270 mg/dL
NCT01529541,has_criteria,Written Informed Consent
NCT01529541,has_criteria,Type 1 DM or secondary diabetes
NCT01529541,has_criteria,Oral anti-hyperglycemic drugs
NCT01529541,has_criteria,Body mass index 20 to 40 kg/m2
NCT00765817,involves,Type 2 Diabetes Mellitus
NCT00765817,evaluates,Exenatide
NCT00765817,measures_primary,Change in HbA1c
NCT00765817,measures_secondary,Percentage of Patients Achieving HbA1c <=7%
NCT00765817,measures_secondary,Percentage of Patients Achieving HbA1c <=6.5%
NCT00765817,measures_secondary,Change in Fasting Serum Glucose
NCT00765817,measures_secondary,Change in 7-point Self-monitored Blood Glucose (SMBG) Profile
NCT00765817,measures_secondary,Change in Total Cholesterol
NCT00765817,measures_secondary,Change in Low Density Lipoprotein (LDL) Cholesterol
NCT00765817,measures_secondary,Change in High Density Lipoprotein (HDL) Cholesterol
NCT00765817,has_criteria,baseline and 30 weeks
NCT03051217,involves,Psoriasis
NCT03051217,evaluates,Certolizumab Pegol
NCT03051217,measures_primary,PASI75 response
NCT03051217,measures_secondary,PGA Clear or Almost Clear
NCT03051217,measures_secondary,PASI90 response
NCT03051217,has_criteria,moderate to severe chronic plaque Psoriasis
NCT05260541,involves,Post-Traumatic Stress Disorder
NCT05260541,evaluates,PRAX-114
NCT05260541,measures_primary,CAPS-5 total score
NCT05260541,measures_secondary,CGI-S score
NCT05260541,measures_secondary,CGI-I score
NCT05260541,has_criteria,Clinician experience
NCT03833141,involves,Severe Eosinophilic Asthma
NCT03833141,evaluates,benralizumab
NCT03833141,measures_primary,change in ACQ-6
NCT03833141,measures_secondary,exacerbations
NCT03833141,measures_secondary,concomitant medications
NCT03833141,measures_secondary,serious adverse events
NCT03833141,measures_secondary,hospitalizations
NCT03833141,measures_secondary,Asthma Quality of Life Questionnaire
NCT03833141,has_criteria,at least 0.5 units
NCT06039241,involves,Atopic Dermatitis
NCT06039241,evaluates,Dupilumab
NCT06039241,measures_primary,EASI ≤ 7
NCT06039241,measures_primary,peak pruritus NRS ≤ 4
NCT06039241,measures_primary,DLQI ≤ 5
NCT06039241,measures_secondary,ADCT score
NCT06039241,measures_secondary,RECAP score
NCT06039241,has_criteria,≥6 years
NCT05403541,involves,Generalized Myasthenia Gravis
NCT05403541,evaluates,Batoclimab
NCT05403541,measures_primary,Change from Baseline in MG-ADL score
NCT05403541,measures_secondary,Change from Baseline in QMG score
NCT05403541,has_criteria,AChR Ab seropositive
NCT06275841,evaluates,Esomeprazole
NCT06275841,evaluates,Vepdegestrant
NCT06275841,measures_primary,Cmax of vepdegestrant
NCT06275841,measures_primary,AUCinf of vepdegestrant
NCT06275841,measures_secondary,treatment-emergent adverse events
NCT06275841,measures_secondary,serious adverse events
NCT05388916,involves,Pediatric Plaque Psoriasis
NCT05388916,evaluates,Secukinumab
NCT05388916,measures_primary,PASI 75 response
NCT05388916,measures_secondary,IGA mod 2011 0 or 1 response
NCT05388916,measures_secondary,PASI 90/100 response
NCT05388916,measures_secondary,PASI 75/90/100 response/IGA mod 2011 0 or 1 response
NCT05950516,involves,Type 2 Diabetes
NCT05950516,evaluates,Semaglutide Ingection
NCT05950516,measures_primary,Change in HbA1c
NCT05950516,measures_secondary,Change in Fasting Glucose
NCT05950516,measures_secondary,Change in Body Weight
NCT05950516,measures_secondary,Percentage of Participants That Achieved Body Weight Loss ≥5%
NCT05950516,has_criteria,age ≥ 18 years and ≤75 years old
NCT05950516,has_criteria,diagnosed with type 2 diabetes for at least 6 months
NCT05950516,has_criteria,received stable treatment with only metformin ≥ 1500 mg/day
NCT05950516,has_criteria,receive combination metformin (dose ≥ 750 mg/day) and another OAD
NCT05950516,has_criteria,HbA1c ≥ 7.0% and ≤ 11.0%（local lab）
NCT05950516,has_criteria,HbA1c ≥ 7.0% and ≤10.0%（local lab）
NCT05950516,has_criteria,BMI≥18.5kg/m2 and ≤35 kg/m2
NCT05950516,has_criteria,voluntarily participate in this research
NCT05950516,has_criteria,can communicate well with researchers
NCT05950516,has_criteria,willing to maintain the same diet and exercise habits
NCT05950516,has_criteria,sign an informed consent form (ICF)
NCT05950516,has_criteria,HbAlc ≥ 7.0% and ≤ 11.0%（cental lab）
NCT01815424,involves,plaque psoriasis
NCT01815424,evaluates,CP-690
NCT01815424,measures_primary,PGA score at Week 16
NCT01815424,measures_secondary,PASI75 at Week 16
NCT01815424,measures_secondary,Percent Change BSA at Week 16
NCT01815424,has_criteria,Asian subjects
NCT01815424,has_criteria,moderate to severe
NCT01371734,involves,Major Depressive Disorder
NCT01371734,evaluates,DVS SR
NCT01371734,measures_primary,Change From Baseline
NCT01371734,measures_secondary,CGI-S Score
NCT01371734,has_criteria,Children and Adolescent Outpatients
NCT06046534,involves,Systemic Lupus Erythematosus
NCT06046534,evaluates,Anifrolumab
NCT06046534,measures_primary,SLE remission
NCT06046534,measures_secondary,Proportion of patients
NCT06046534,has_criteria,SLEDAI = 0
NCT02017717,involves,Glioblastoma
NCT02017717,evaluates,Nivolumab
NCT02017717,evaluates,Bevacizumab
NCT02017717,evaluates,Ipilimumab
NCT02017717,measures_primary,Drug-related adverse events
NCT02017717,measures_secondary,Adverse events
NCT02017717,measures_secondary,Serious adverse events
NCT02017717,measures_secondary,Liver function tests
NCT02017717,has_criteria,Four doses
NCT00496834,involves,Essential Hypertension
NCT00496834,evaluates,Losartan
NCT00496834,measures_primary,PWV Changes
NCT00496834,measures_secondary,SBP Mean Changes
NCT00496834,measures_secondary,DBP Mean Changes
NCT00496834,has_criteria,Mean SBP ≥ 140 mm Hg
NCT00496834,has_criteria,Mean DBP ≥ 90 mm Hg
NCT00496834,has_criteria,Patient is willing to sign informed consent
NCT05562934,involves,Resistant Hypertension
NCT05562934,evaluates,XXB750
NCT05562934,measures_primary,Change from baseline in mean 24hr SBP at Week 12
NCT05562934,measures_secondary,Proportions of participants achieving blood pressure control
NCT05562934,has_criteria,≥ 18 years old
NCT05562934,has_criteria,Uncontrolled BP with an office msSBP ≥ 140 mmHg
NCT05562934,has_criteria,Stable doses of three or four antihypertensive drugs
NCT00840034,involves,Major Depressive Disorder
NCT00840034,evaluates,Adjunctive Treatment
NCT00840034,measures_primary,Change From Baseline
NCT00840034,measures_secondary,QIDS-SR16 Total Score
NCT00840034,measures_secondary,QIDS-SR16 Individual Items
NCT00840034,has_criteria,Adults
NCT00985517,involves,Parkinson's Disease
NCT00985517,evaluates,CERE-120
NCT00985517,measures_primary,Change From Baseline
NCT00985517,measures_secondary,UPDRS Part III
NCT00985517,has_criteria,age 35 to 70 years
NCT00635219,involves,Major Depressive Disorder
NCT00635219,evaluates,Vortioxetine
NCT00635219,measures_primary,MADRS Total Score
NCT00635219,measures_secondary,HAM-D-24 Total Score
NCT00635219,measures_secondary,CGI-I Score
NCT00635219,has_criteria,Baseline HAM-A Total Score
NCT00488319,involves,Adolescent Schizophrenia
NCT00488319,evaluates,Paliperidone ER
NCT00488319,measures_primary,PANSS Scores
NCT00488319,measures_secondary,PANSS Scores
NCT00488319,has_criteria,Open-label Baseline
NCT06248619,involves,Thyroid Eye Disease
NCT06248619,evaluates,Teprotumumab
NCT06248619,measures_primary,Proptosis responder rate
NCT06248619,measures_secondary,Overall responder rate
NCT06248619,measures_secondary,CAS value
NCT06248619,measures_secondary,Diplopia responder rate
NCT06248619,measures_secondary,Complete diplopia responder rate
NCT06248619,measures_secondary,GO-QoL questionnaire score
NCT06248619,has_criteria,Graves' disease
NCT06248619,has_criteria,CAS ≥ 3
NCT06248619,has_criteria,moderate-to-severe active TED
NCT06248619,has_criteria,lid retraction ≥ 2 mm
NCT01855919,involves,Chronic Low Back Pain
NCT01855919,evaluates,Duloxetine
NCT01855919,measures_primary,Change From Baseline
NCT01855919,measures_secondary,Patient Global Impression
NCT01855919,has_criteria,Baseline
NCT06473519,involves,Respiratory syncytial virus
NCT06473519,evaluates,RSVpreF
NCT06473519,measures_primary,Geometric mean titer ratio
NCT06473519,measures_secondary,Local reactions
NCT06473519,measures_secondary,Systemic events
NCT06473519,measures_secondary,Adverse events
NCT06473519,has_criteria,Healthy Female Adults
NCT01439919,involves,Persistent Cancer Pain
NCT01439919,evaluates,SSR411298
NCT01439919,measures_primary,Change from baseline pain
NCT01439919,measures_secondary,BPI-SF scores
NCT01439919,measures_secondary,Responder rates
NCT01439919,measures_secondary,Breakthrough pain frequency
NCT01439919,measures_secondary,Opioid consumption
NCT01439919,measures_secondary,Rescue medication consumption
NCT01439919,measures_secondary,Mood disorders
NCT01439919,has_criteria,reduction from baseline
NCT03945019,involves,Crohn's Disease
NCT03945019,evaluates,CT-P13
NCT03945019,measures_primary,Clinical Remission
NCT03945019,measures_secondary,Endoscopic Response
NCT03945019,measures_secondary,CDAI-100 Response
NCT03945019,has_criteria,dose adjustment
NCT05494619,involves,Guillain-Barré Syndrome
NCT05494619,evaluates,Crovalimab
NCT05494619,measures_primary,Functional Grade Score
NCT05494619,measures_secondary,GBS-DS score
NCT05494619,measures_secondary,10-Meter Walk Test
NCT05494619,has_criteria,Week 24
NCT05494619,has_criteria,Week 8
NCT06597019,involves,Heterozygous Familial Hypercholesterolemia
NCT06597019,evaluates,Inclisiran
NCT06597019,measures_primary,LDL-C percent change
NCT06597019,measures_secondary,PCSK9 percent change
NCT06597019,measures_secondary,total cholesterol percent change
NCT06597019,measures_secondary,Apo B percent change
NCT06597019,measures_secondary,non-HDL-C percent change
NCT06597019,has_criteria,Baseline and Day 330
NCT00195819,involves,Ankylosing Spondylitis
NCT00195819,evaluates,Adalimumab
NCT00195819,measures_primary,ASAS 20 Response
NCT00195819,measures_secondary,mSASSS
NCT00195819,has_criteria,ASAS 20 responders
NCT00150618,involves,Attention Deficit Hyperactivity Disorder
NCT00150618,evaluates,SPD503
NCT00150618,measures_primary,Change From Baseline
NCT00150618,measures_secondary,Conner's Parent Rating Scale-revised Short Version
NCT00150618,measures_secondary,Clinical Global Impression-Improvement
NCT00150618,measures_secondary,Parent Global Assessment
NCT00150618,measures_secondary,Child Health Questionnaire-Parent Form
NCT00150618,has_criteria,Aged 6-17
NCT01968018,involves,Chronic Cancer Pain
NCT01968018,evaluates,Ultracet
NCT01968018,measures_primary,Change from Baseline in BPI Pain Severity
NCT01968018,measures_secondary,Analgesic Effect as Assessed by BPI Item 5 Score
NCT01968018,measures_secondary,Number of Participants With Adverse Events
NCT01968018,measures_secondary,Number of Doses of Rescue Medication Over Time
NCT01968018,measures_secondary,Number of Participants With Patient Global Assessment
NCT01968018,has_criteria,Untoward medical event
NCT00251641,involves,Psoriasis
NCT00251641,evaluates,Infliximab
NCT00251641,evaluates,Methotrexate
NCT00251641,measures_primary,PASI75 Response
NCT00251641,measures_secondary,PGA Score
NCT00251641,has_criteria,Adult male and female subjects
NCT04799418,involves,Parkinson's disease
NCT04799418,evaluates,STEM-PD
NCT04799418,measures_primary,Change from baseline
NCT04799418,measures_secondary,Clinical Global Impression
NCT04799418,has_criteria,Completion of study activities
NCT04613518,involves,Ulcerative Colitis
NCT04613518,evaluates,BMS-986165
NCT04613518,measures_primary,Clinical Response
NCT04613518,measures_secondary,Adverse Events
NCT04613518,measures_secondary,Serious Adverse Events
NCT04613518,has_criteria,modified Mayo score
NCT01390441,evaluates,MK-8808
NCT01390441,measures_primary,AUC0-84day
NCT01390441,measures_secondary,Adverse Event
NCT01390441,has_criteria,Up to 52 weeks
NCT01727141,involves,COPD
NCT01727141,evaluates,Indacaterol Maleate / Glycopyrronium Bromide
NCT01727141,measures_primary,FEV1 AUC0-12
NCT01727141,measures_secondary,SGRQ Total Score
NCT01727141,has_criteria,moderate to severe airflow limitation
NCT05079919,involves,Severe Hypertriglyceridemia
NCT05079919,evaluates,Olezarsen
NCT05079919,measures_primary,Percent Change in Fasting TG
NCT05079919,measures_secondary,Proportion of Participants Achieving Fasting TG < 500 mg/dL
NCT05079919,has_criteria,≥ 2 Events of Adjudicated Acute Pancreatitis
NCT00236119,involves,Psoriasis
NCT00236119,evaluates,CEP-701
NCT00236119,measures_primary,PSGA Change from Baseline
NCT00236119,measures_secondary,Psoriasis Area and Severity Index (PASI)
NCT00236119,has_criteria,severe
NCT00636818,involves,Attention-Deficit/Hyperactivity Disorder
NCT00636818,evaluates,Atomoxetine
NCT00636818,measures_primary,CAARS-Inv:SV Total Score
NCT00636818,measures_secondary,CGI-ADHD-S
NCT00636818,measures_secondary,CAARS-S:SV Total Score
NCT00636818,measures_secondary,HAMD-17
NCT00636818,has_criteria,Asian Subjects
NCT00427219,involves,Benign prostatic hyperplasia
NCT00427219,evaluates,Ozarelix
NCT00427219,measures_primary,International Prostate Symptom Score
NCT00427219,measures_secondary,IPSS-QOL
NCT00427219,measures_secondary,BPH Impact Index
NCT00427219,measures_secondary,LUTS Global Assessment Question
NCT00427219,measures_secondary,International Index of Erectile Function-15
NCT00427219,measures_secondary,Maximum Urinary Flow Rate
NCT00427219,has_criteria,IPSS QOL
NCT00269919,involves,Schizophrenia
NCT00269919,evaluates,Risperidone Microspheres
NCT00269919,measures_primary,Change From Baseline PANSS
NCT00269919,measures_secondary,Change From Baseline CGI-S
NCT00269919,measures_secondary,Change From Baseline GAF
NCT00269919,measures_secondary,Change From Baseline WHOQOL
NCT00269919,has_criteria,Baseline and Week 96
NCT00600119,involves,Opioid-Induced Constipation
NCT00600119,evaluates,NKTR-118
NCT00600119,measures_primary,Change From Baseline in SBMs/Week
NCT00600119,measures_secondary,Change From Baseline in PAC-QOL Questionnaire
NCT00600119,has_criteria,2-week OIC screening
NCT01808118,involves,Non-Radiographic Axial Spondyloarthritis
NCT01808118,evaluates,Adalimumab
NCT01808118,measures_primary,ASDAS Inactive Disease
NCT01808118,measures_secondary,Number of Participants
NCT01808118,has_criteria,2 consecutive study visits
NCT01143818,involves,Hypogonadal Men
NCT01143818,measures_primary,Percent Change From Baseline
NCT01143818,measures_secondary,International Index of Erectile Function Total Score
NCT01143818,measures_secondary,Multidimensional Fatigue Inventory Total Score
NCT06602219,involves,Plaque Psoriasis
NCT06602219,evaluates,LY4100511
NCT06602219,measures_primary,PASI 75
NCT06602219,measures_secondary,sPGA Score 0 or 1
NCT06602219,measures_secondary,PASI 50
NCT06602219,measures_secondary,PASI 75
NCT06602219,measures_secondary,PASI 90
NCT06602219,measures_secondary,PASI 100
NCT06602219,measures_secondary,sPGA Score 0 or 1
NCT06602219,measures_secondary,Mean Change PASI Score
NCT06602219,measures_secondary,Percent Change PASI Score
NCT06602219,measures_secondary,Mean Change BSA Affected
NCT06602219,measures_secondary,Percent Change BSA Affected
NCT06602219,has_criteria,Adult Participants
NCT03319719,involves,Nasolabial Folds
NCT03319719,evaluates,Belotero® Balance With Integral Lidocaine
NCT03319719,measures_primary,Pain Using VAS
NCT03319719,measures_secondary,Merz NLF Scale
NCT03319719,measures_secondary,Treatment Emergent Adverse Events
NCT03319719,measures_secondary,Serious Adverse Events
NCT03319719,measures_secondary,Common Treatment Site Response
NCT03319719,measures_secondary,CTR Severity
NCT03319719,has_criteria,Baseline up to Week 6
NCT02686619,involves,Renal Transplant
NCT02686619,evaluates,Mycophenolate Mofetil
NCT02686619,evaluates,Sirolimus
NCT02686619,evaluates,Cyclosporine
NCT02686619,measures_primary,Creatinine Clearance
NCT02686619,measures_secondary,Adverse Events
NCT02686619,measures_secondary,Serious Adverse Events
NCT02686619,measures_secondary,Cancers
NCT02686619,measures_secondary,Premature Discontinuations
NCT02686619,measures_secondary,24-Hour Urinary Protein
NCT02686619,has_criteria,cadaveric kidney graft
NCT02686619,has_criteria,antilymphocyte antibodies
NCT02686619,has_criteria,panel reactive antibodies
NCT02686619,has_criteria,Cold ischaemia time
NCT02055118,involves,Hunter Syndrome
NCT02055118,involves,Early Cognitive Impairment
NCT02055118,evaluates,Idursulfase-IT
NCT02055118,evaluates,Elaprase
NCT02055118,measures_primary,DAS-II GCA Standard Score
NCT02055118,measures_secondary,VABS-II ABC Score
NCT02055118,has_criteria,Pediatric Patients
NCT05970718,involves,Healthy Adult Participants
NCT05970718,evaluates,REGN7544
NCT05970718,measures_primary,Incidence of TEAEs
NCT05970718,measures_primary,Severity of TEAEs
NCT05970718,measures_secondary,Changes from baseline in SBP
NCT05970718,measures_secondary,Changes from baseline in DBP
NCT05970718,measures_secondary,Changes from baseline in MAP
NCT05970718,measures_secondary,Changes from baseline in PP
NCT05970718,measures_secondary,Concentrations of REGN7544 in serum
NCT05970718,measures_secondary,Incidence of treatment-emergent ADA
NCT05970718,measures_secondary,Titer of ADA
NCT05795517,involves,Hypercholesterolemia
NCT05795517,involves,Nonalcoholic Fatty Liver Disease
NCT05795517,evaluates,HSK31679
NCT05795517,measures_primary,Percentage change in LDL-C
NCT05795517,measures_secondary,Percentage change in MRI-PDFF
NCT05795517,measures_secondary,Proportion of patients with LDL-C<3.34mmol/L
NCT05795517,measures_secondary,Percentage change in fasting TG
NCT05795517,measures_secondary,Percentage change in fasting TC
NCT05795517,measures_secondary,Percentage change in fasting HDL-C
NCT05795517,measures_secondary,Percentage change in body weight
NCT05795517,has_criteria,aged 18 ≤ age \< 65
NCT03932019,involves,Spondyloarthritis
NCT03932019,evaluates,Jitongning Tablet
NCT03932019,measures_primary,ASAS 20 response
NCT03932019,measures_secondary,BASDAI
NCT03932019,measures_secondary,BASFI
NCT03932019,measures_secondary,Spinal pain
NCT03932019,measures_secondary,PGA
NCT03932019,measures_secondary,TCM syndrome scores
NCT05192941,involves,Hypercholesterolemia
NCT05192941,evaluates,Inclisiran
NCT05192941,measures_primary,LDL-C target
NCT05192941,measures_secondary,Muscle-related adverse event
NCT05192941,measures_secondary,self-reported pain
NCT05192941,measures_secondary,pain diary
NCT05192941,measures_secondary,SF-BPI pain severity
NCT05192941,measures_secondary,SF-BPI pain interference
NCT05192941,has_criteria,individual LDL-C target
NCT00744341,involves,Worsening Heart Failure
NCT00744341,evaluates,SLV320
NCT00744341,measures_primary,Change in serum creatinine
NCT00744341,measures_secondary,Dyspnea
NCT00744341,measures_secondary,eGFR
NCT00744341,measures_secondary,Subject Global Clinical Assessment Score
NCT00744341,measures_secondary,Urine Osmolality
NCT00744341,measures_secondary,Serum Osmolality
NCT00744341,has_criteria,four SLV320 doses
NCT00744341,has_criteria,placebo
NCT05137041,involves,Acute Low Back Pain
NCT05137041,evaluates,FIRTECH
NCT05137041,measures_primary,NRS Responders
NCT05137041,measures_secondary,SPID0-5
NCT05137041,measures_secondary,RMDQ Score
NCT05137041,has_criteria,≥30% decrease
NCT03344341,involves,T2DM
NCT03344341,measures_primary,HbA1c change at Week 24
NCT03344341,measures_secondary,HbA1c reduction ≥0.5%
NCT03344341,measures_secondary,HbA1c<7.0%
NCT03344341,measures_secondary,fasting plasma glucose (FPG) change
NCT03344341,measures_secondary,2h postprandial glucose (PPG) change
NCT03344341,measures_secondary,body weight change
NCT03344341,measures_secondary,SBP change
NCT03344341,has_criteria,drug-naive patients
NCT04011241,involves,Healthy male subjects
NCT04011241,evaluates,Itraconazole
NCT04011241,measures_primary,AUC0-tz
NCT04011241,measures_primary,Cmax
NCT04011241,measures_primary,AUC0-∞
NCT04011241,has_criteria,Healthy male subjects
NCT04011241,has_criteria,Age 18 to 50 years
NCT04011241,has_criteria,BMI 18.5 to 29.9 kg/m2
NCT04011241,has_criteria,Signed informed consent
NCT02348619,involves,Obstructive Sleep Apnea
NCT02348619,evaluates,JZP-110
NCT02348619,measures_primary,Change in MWT
NCT02348619,measures_secondary,Change in ESS score
NCT02348619,has_criteria,Week 4 to Week 6
NCT02348619,measures_secondary,Patient Global Impression of Change
NCT02348619,measures_secondary,Clinical Global Impression of Change
NCT02348619,measures_secondary,Change in FOSQ-10
NCT05039619,involves,Lupus Nephritis
NCT05039619,evaluates,Obinutuzumab
NCT05039619,measures_primary,CRR (Complete Renal Response)
NCT05039619,measures_secondary,Adverse Events
NCT05039619,has_criteria,Active Class III or IV
NCT02897219,involves,Type 1 Diabetes Mellitus
NCT02897219,evaluates,ASP1941
NCT02897219,measures_primary,Change from baseline in HbA1c
NCT02897219,measures_secondary,Fasting plasma glucose
NCT02897219,measures_secondary,self-monitored blood glucose level
NCT02897219,measures_secondary,leptin
NCT02897219,measures_secondary,glycoalbumin
NCT02897219,measures_secondary,adiponectin
NCT02897219,measures_secondary,glucagon
NCT02897219,measures_secondary,number of units of insulin administered
NCT02897219,measures_secondary,body weight
NCT02897219,measures_secondary,waist circumference
NCT02897219,has_criteria,diagnosed with type 1 diabetes mellitus
NCT02897219,has_criteria,receiving insulin therapy
NCT02897219,has_criteria,not switched insulin product
NCT02897219,has_criteria,HbA1c value between 7.5% and 11.0%
NCT02897219,has_criteria,fasting blood C-peptide level < 0.6 ng/mL
NCT02897219,has_criteria,body mass index (BMI) be
NCT06561841,involves,Paroxysmal Nocturnal Hemoglobinuria
NCT06561841,evaluates,HSK39297
NCT06561841,measures_primary,hemoglobin levels
NCT06561841,measures_secondary,LDH
NCT06561841,measures_secondary,reticulocyte count
NCT06561841,measures_secondary,Indirect bilirubin
NCT06561841,measures_secondary,free hemoglobin
NCT06561841,measures_secondary,RBC transfusions
NCT06561841,measures_secondary,RBC transfused
NCT06561841,measures_secondary,PNH RBC clone size
NCT06561841,measures_secondary,C3 fragment deposition
NCT06561841,measures_secondary,FACIT-Fatigue score
NCT06561841,has_criteria,red blood cell transfusions
NCT00610441,involves,Attention-Deficit/Hyperactivity Disorder
NCT00610441,evaluates,MK-8777
NCT00610441,measures_primary,Change in AISRS Score
NCT00610441,measures_secondary,Percentage of Participants
NCT00610441,has_criteria,Baseline score
NCT00973141,involves,Osteoarthritis-related Pain
NCT00973141,evaluates,JNJ-42160443
NCT00973141,measures_primary,Change from baseline
NCT00973141,measures_secondary,Pain
NCT00973141,measures_secondary,Pain severity
NCT00973141,has_criteria,double-blind efficacy phase
NCT02448641,involves,Ischemic Stroke
NCT02448641,evaluates,SB623
NCT02448641,measures_primary,FMMS improvement
NCT02448641,measures_secondary,Modified Rankin Scale
NCT02448641,has_criteria,≥10 points improvement
NCT01506141,involves,Hunter Syndrome
NCT01506141,involves,Cognitive Impairment
NCT01506141,evaluates,Idursulfase-IT
NCT01506141,evaluates,Elaprase
NCT01506141,measures_primary,AUC0-infinity
NCT01506141,measures_primary,AUC0-t
NCT01506141,measures_primary,Cmax
NCT01506141,has_criteria,Pediatric Participants
NCT05684341,involves,Type 2 Diabetes
NCT05684341,evaluates,Connected Solution
NCT05684341,measures_primary,Change from baseline in HbA1c
NCT05684341,measures_secondary,Time to first reach fSMBG target range
NCT05684341,measures_secondary,Insulin compliance
NCT05684341,measures_secondary,Insulin discontinuation rate
NCT05684341,measures_secondary,Change from baseline in total daily insulin dose
NCT05684341,measures_secondary,Change from baseline in body weight
NCT05684341,measures_secondary,Change from baseline in DTSQs score
NCT05684341,measures_secondary,Scores of DTSQc
NCT05684341,measures_secondary,Change from baseline in EQ-5D-3L score
NCT05684341,measures_secondary,Number of participants experiencing hypoglycemia
NCT05684341,measures_secondary,Number of hypoglycemic events per patient-year
NCT05684341,has_criteria,Adult participants
NCT05684341,has_criteria,Basal insulin
NCT01746017,involves,Diabetes
NCT01746017,evaluates,LY2922470
NCT01746017,measures_primary,Blood Glucose AUEC(0-24)
NCT01746017,measures_secondary,C-Peptide AUEC(0-6)
NCT00746941,involves,Progressive Multifocal Leukoencephalopathy
NCT00746941,evaluates,Mefloquine
NCT00746941,measures_primary,JC Virus Load in CSF
NCT00746941,measures_secondary,Expanded Disability Status Scale Score
NCT00746941,measures_secondary,Karnofsky Performance Status Index Score
NCT00746941,has_criteria,measurable baseline values
NCT01922141,involves,Hypertension
NCT01922141,evaluates,Aliskiren
NCT01922141,measures_primary,MSSBP change
NCT01922141,measures_secondary,Hyperkalemia
NCT01922141,measures_secondary,Hypotension
NCT01922141,measures_secondary,eGFR reduction
NCT01922141,has_criteria,age less than 75
NCT01543919,involves,Chronic Obstructive Pulmonary Disease
NCT01543919,evaluates,PH-797804
NCT01543919,measures_primary,Change from baseline
NCT01543919,measures_secondary,Chronic Obstructive Pulmonary Disease symptoms
NCT01543919,has_criteria,Adults with COPD
NCT01302041,involves,Prostate Cancer
NCT01302041,evaluates,Enzalutamide
NCT01302041,measures_primary,PSA response at Week 25
NCT01302041,measures_secondary,Adverse Events
NCT01302041,has_criteria,unknown or missing response
NCT02384941,involves,Type 1 Diabetes Mellitus
NCT02384941,evaluates,Sotagliflozin
NCT02384941,measures_primary,Change From Baseline in A1C
NCT02384941,measures_secondary,Percentage of Participants With A1C <7.0%
NCT02384941,measures_secondary,Absolute Change From Baseline in Body Weight
NCT02384941,measures_secondary,Change From Baseline in Mean Daily Bolus Insulin Dose
NCT02384941,has_criteria,Inadequate Glycemic Control
NCT00121641,involves,Type 2 diabetes
NCT00121641,evaluates,saxagliptin
NCT00121641,measures_primary,HbA1c Changes
NCT00121641,measures_secondary,Fasting Plasma Glucose
NCT00121641,measures_secondary,Postprandial Glucose AUC
NCT00121641,has_criteria,Drug naive
NCT00121641,has_criteria,HbA1c ≥7.0%
NCT00121641,has_criteria,HbA1c ≤10.0%
NCT00121641,has_criteria,Fasting C-peptide ≥1 ng/mL
NCT00121641,has_criteria,Body mass index ≤40 kg/m2
NCT00432341,involves,Cervical Dystonia
NCT00432341,evaluates,Botulinum Toxin Type A
NCT00432341,measures_primary,TDTS at Week 4
NCT00432341,measures_secondary,TWSTRS Total Score
NCT00432341,has_criteria,Baseline
NCT00528541,involves,Cervical Dystonia
NCT00528541,evaluates,Botulinum Toxin Type A
NCT00528541,measures_primary,Dysphagia Incidence
NCT00528541,measures_secondary,TWSTRS Total Score
NCT00528541,has_criteria,Physician Assessment
NCT04393441,involves,Dry Eye Disease
NCT04393441,evaluates,Artificial Tear Formulation
NCT04393441,measures_primary,Change From Baseline
NCT04393441,measures_secondary,Current Symptom Survey
NCT04393441,has_criteria,Corneal and conjunctival staining scores
NCT02782741,involves,Late-onset Pompe Disease
NCT02782741,evaluates,Avalglucosidase Alfa
NCT02782741,evaluates,Alglucosidase Alfa
NCT02782741,measures_primary,Percent Predicted FVC
NCT02782741,measures_primary,Total Distance Walked
NCT02782741,measures_primary,Percent Predicted MIP
NCT02782741,measures_secondary,Maximal Inspiratory Pressure
NCT02782741,has_criteria,Previously Treated
NCT06109441,involves,Ulcerative Colitis
NCT06109441,evaluates,ALTB-268
NCT06109441,measures_primary,mMS at week 12
NCT06109441,measures_primary,proportion of subjects with clinical response
NCT06109441,measures_secondary,proportion of subjects with clinical remission
NCT06109441,measures_secondary,proportion of subjects with endoscopic improvement
NCT06109441,has_criteria,refractory to biologics
NCT01254019,involves,Duchenne Muscular Dystrophy
NCT01254019,evaluates,GSK2402968
NCT01254019,measures_primary,Change From Baseline
NCT01254019,measures_secondary,Linearized North Star Ambulatory Assessment
NCT01254019,has_criteria,randomization assessment
NCT03530917,involves,Healthy Participants
NCT03530917,evaluates,RO7020531
NCT03530917,measures_primary,Cmax
NCT03530917,measures_secondary,AUClast
NCT03530917,has_criteria,up to 1 year
NCT01308619,involves,Rosacea
NCT01308619,evaluates,Oracea
NCT01308619,measures_primary,Inflammatory Lesion Counts
NCT01308619,measures_secondary,Biochemical Markers of Rosacea
NCT01308619,has_criteria,Aged 18 to 70 years
NCT05764317,involves,Arterial Hypertension
NCT05764317,involves,Dyslipidemia
NCT05764317,evaluates,amlodipine/atorvastatin/perindopril
NCT05764317,measures_primary,Systolic blood pressure
NCT05764317,measures_primary,Diastolic blood pressure
NCT05764317,measures_primary,LDL-C
NCT05764317,measures_secondary,quality of life
NCT05764317,has_criteria,12 weeks
NCT06049017,involves,Ulcerative Colitis
NCT06049017,evaluates,JNJ-77242113
NCT06049017,measures_primary,Clinical Response
NCT06049017,measures_secondary,Clinical Remission
NCT06049017,measures_secondary,Symptomatic Remission
NCT06049017,measures_secondary,Endoscopic Improvement
NCT06049017,measures_secondary,Histologic-endoscopic Mucosal Improvement
NCT06049017,measures_secondary,Adverse Events
NCT06049017,has_criteria,Week 12
NCT02661217,involves,Heart Failure with Reduced Ejection Fraction
NCT02661217,evaluates,LCZ696
NCT02661217,measures_primary,Target Dose of LCZ696
NCT02661217,measures_secondary,LCZ696 Maintenance
NCT02661217,measures_secondary,LCZ696 Discontinuation
NCT02661217,has_criteria,Acute Decompensation Event
NCT03595618,involves,Knee Osteoarthritis
NCT03595618,evaluates,GLPG1972/S201086
NCT03595618,measures_primary,Cartilage Thickness
NCT03595618,measures_secondary,WOMAC Total Score
NCT03595618,measures_secondary,Pain Assessment
NCT03595618,has_criteria,8% cartilage loss
NCT04150341,involves,Allergic Asthma
NCT04150341,evaluates,Inhaled TD-8236
NCT04150341,measures_primary,FEV1 AUC change
NCT04150341,measures_secondary,Maximum FEV1 decline
NCT04150341,measures_secondary,Maximum % FEV1 decline
NCT04150341,has_criteria,Treatment-emergent Adverse Event
NCT02693119,involves,Leber's Hereditary Optic Neuropathy
NCT02693119,evaluates,Elamipretide Topical Ophthalmic Solution
NCT02693119,measures_primary,Best Corrected Visual Acuity
NCT02693119,measures_secondary,Ocular TEAEs
NCT02693119,has_criteria,Baseline
NCT01316419,involves,Hypertension
NCT01316419,evaluates,Twynsta
NCT01316419,measures_primary,Mean SBP change
NCT01316419,measures_primary,Mean DBP change
NCT01316419,measures_secondary,Target blood pressure
NCT01316419,measures_secondary,DBP response
NCT01316419,measures_secondary,SBP response
NCT01316419,measures_secondary,Quality of Life
NCT01316419,has_criteria,Baseline visit
NCT00670319,involves,Osteoporosis
NCT00670319,evaluates,Raloxifene Hydrochloride
NCT00670319,measures_primary,vertebral fractures
NCT00670319,measures_secondary,bone mineral density
NCT00670319,measures_secondary,bone mineral content
NCT00670319,measures_secondary,nonvertebral fractures
NCT00670319,measures_secondary,biochemical markers
NCT00670319,has_criteria,postmenopausal women
NCT00274118,involves,Diabetes
NCT00274118,evaluates,Telmisartan Enalapril
NCT00274118,measures_primary,Change from baseline GFR
NCT00274118,measures_secondary,Percentage change albumin excretion
NCT00274118,measures_secondary,Change from baseline creatinine
NCT00274118,measures_secondary,Incidence clinical endpoints
NCT00274118,measures_secondary,Incidence all cause mortality
NCT00274118,measures_secondary,Changes vital signs
NCT00274118,measures_secondary,Number patients Adverse Events
NCT00274118,measures_secondary,Physical examination
NCT00274118,measures_secondary,Clinical laboratory parameters
NCT00274118,measures_secondary,Resting 12-lead ECG
NCT00274118,has_criteria,Baseline 1 2 3 4 years
NCT03170518,involves,Type 2 Diabetes Mellitus
NCT03170518,evaluates,Canagliflozin
NCT03170518,measures_primary,Change in HbA1c
NCT03170518,measures_secondary,Fasting Plasma Glucose
NCT03170518,measures_secondary,Adverse Events
NCT03170518,has_criteria,>=10 to <18 Years
NCT00571519,involves,Type 2 Diabetes Mellitus
NCT00571519,evaluates,Rivoglitazone
NCT00571519,measures_primary,Change in A1c
NCT00571519,measures_secondary,Fasting Plasma Glucose
NCT00571519,measures_secondary,Total Cholesterol
NCT00571519,has_criteria,Baseline up to week 2
NCT02238119,involves,Chronic Obstructive Pulmonary Disease
NCT02238119,evaluates,Free Combination of Tiotropium + Formoterol
NCT02238119,evaluates,Formoterol
NCT02238119,measures_primary,FEV1 AUC0-12h
NCT02238119,measures_secondary,FEV1 AUC0-24h
NCT02238119,measures_secondary,FEV1 AUC12-24h
NCT02238119,measures_secondary,FVC AUC0-12h
NCT02238119,measures_secondary,FVC AUC0-24h
NCT02238119,measures_secondary,FVC AUC12-24h
NCT02238119,measures_secondary,peak FEV1 response
NCT02238119,measures_secondary,trough FEV1 response
NCT02238119,measures_secondary,peak FVC response
NCT02238119,measures_secondary,trough FVC response
NCT02238119,measures_secondary,PEFR
NCT02238119,measures_secondary,rescue salbutamol therapy
NCT02238119,measures_secondary,daytime COPD symptom score
NCT02238119,measures_secondary,nighttime COPD symptom score
NCT02238119,has_criteria,stable moderate to severe airway obstruction
NCT02238119,has_criteria,FEV1 ≤ 60% of predicted
NCT00078819,involves,Psoriasis
NCT00078819,evaluates,Etanercept
NCT00078819,measures_primary,PASI 75 at Week 12
NCT00078819,measures_secondary,PASI 50 at Week 12
NCT00078819,measures_secondary,sPGA score at Week 12
NCT00078819,has_criteria,Baseline and week 12
NCT06105619,involves,sGBM/IDH Mutant Glioblastoma
NCT06105619,evaluates,PLB1001 Enteric Capsules
NCT06105619,measures_primary,Overall survival
NCT06105619,measures_secondary,Objective Response Rate
NCT06105619,measures_secondary,Progression Free Survival
NCT06105619,measures_secondary,Quality of Life
NCT06105619,measures_secondary,Karnofsky Performance Status
NCT06105619,has_criteria,5 years
NCT04791319,involves,Atopic Dermatitis
NCT04791319,evaluates,Bermekimab
NCT04791319,measures_primary,EASI-75 response
NCT04791319,measures_secondary,vIGA-AD
NCT04791319,measures_secondary,Eczema-Related Itch NRS
NCT04791319,has_criteria,Baseline Itch Value >=4
NCT01819818,involves,schizophrenia
NCT01819818,evaluates,Paliperidone Palmitate
NCT01819818,measures_primary,CGI-S scale scores
NCT01819818,measures_secondary,PSP scale scores
NCT01819818,has_criteria,diagnosed with schizophrenia
NCT01819818,has_criteria,prescribed paliperidone palmitate
NCT06073119,involves,plaque psoriasis
NCT06073119,evaluates,SAR441566
NCT06073119,measures_primary,PASI75 at week 12
NCT06073119,measures_secondary,sPGA score at week 12
NCT06073119,measures_secondary,Treatment-Emergent Adverse Events
NCT06073119,has_criteria,moderate to severe plaque psoriasis
NCT06073119,has_criteria,PASI ≥ 12 points
NCT06073119,has_criteria,sPGA score ≥ 3 points
NCT06073119,has_criteria,BSA score ≥ 10%
NCT02756819,involves,Arterial Hypertension
NCT02756819,evaluates,Azilsartan Medoxomil
NCT02756819,measures_primary,Change in SBP
NCT02756819,measures_secondary,Change in DBP
NCT02756819,has_criteria,overweight or obese
NCT03564119,involves,Papularpustular Rosacea
NCT03564119,evaluates,S5G4T-1
NCT03564119,measures_primary,IGA score clear/almost clear
NCT03564119,measures_secondary,Inflammatory Lesion Counts
NCT03564119,has_criteria,IRB approved consent
NCT05879718,involves,Cutaneous Lupus Erythematosus
NCT05879718,involves,Systemic Lupus Erythematosus
NCT05879718,evaluates,PF-06823859
NCT05879718,measures_primary,CLASI-A score
NCT05879718,measures_secondary,Physician global assessment
NCT05879718,has_criteria,Active CLE or SLE
NCT06241118,involves,Atopic Dermatitis
NCT06241118,evaluates,Amlitelimab
NCT06241118,measures_primary,vIGA-AD 0 or 1
NCT06241118,measures_primary,reduction from baseline ≥2 points
NCT06241118,measures_secondary,EASI75
NCT06241118,measures_secondary,SD-NRS
NCT06241118,has_criteria,prior biologic therapy
NCT06241118,has_criteria,oral JAK inhibitor
NCT01289119,involves,Type 2 Diabetes
NCT01289119,evaluates,Alogliptin
NCT01289119,measures_primary,Change From Baseline in HbA1c
NCT01289119,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT01289119,has_criteria,Baseline and Week 16
NCT06626919,involves,Non-oncology Plasma Cell-related Diseases
NCT06626919,evaluates,Anitocabtagene Autoleucel
NCT06626919,measures_primary,MG ADL score
NCT06626919,measures_secondary,QMG score
NCT06626919,measures_secondary,MGC scale
NCT06626919,has_criteria,24 months
NCT03683719,involves,Chronic Hand Eczema
NCT03683719,evaluates,Delgocitinib Cream
NCT03683719,measures_primary,IGA-CHE Treatment Success
NCT03683719,measures_secondary,Hand Eczema Severity Index
NCT03683719,has_criteria,IGA-CHE Score 0 or 1
NCT00817219,involves,Psoriasis Vulgaris
NCT00817219,evaluates,TACLONEX Ointment
NCT00817219,measures_primary,Controlled Disease
NCT00817219,measures_secondary,Serum Cortisol Concentration
NCT00817219,measures_secondary,Change in Albumin Corrected Serum Calcium
NCT00817219,measures_secondary,Change in Urinary Calcium:Creatinine Ratio
NCT00817219,measures_secondary,Percentage Change in PASI
NCT00817219,has_criteria,Adolescent Patients
NCT00454818,involves,Heart Failure
NCT00454818,evaluates,Genetically Targeted Enzyme Replacement Therapy
NCT00454818,measures_primary,6-minute Walk Test
NCT00454818,measures_secondary,NYHA Class
NCT00454818,measures_secondary,MLWHFQ Score
NCT00454818,has_criteria,Cardiovascular-related Hospitalizations
NCT01163318,involves,Rheumatoid Arthritis
NCT01163318,evaluates,Humira
NCT01163318,measures_primary,DAS28-4ESR < 2.6
NCT01163318,measures_secondary,MHAQ Score ≤ 0.5
NCT01163318,has_criteria,Baseline Week 0
NCT05215418,involves,Overweight
NCT05215418,involves,Obese
NCT05215418,involves,hypertension
NCT05215418,involves,dyslipidemia
NCT05215418,involves,Type 2 diabetes mellitus
NCT05215418,involves,prediabetes
NCT05215418,involves,obstructive sleep apnea
NCT05215418,evaluates,VI-0521
NCT05215418,measures_primary,Systolic Blood Pressure
NCT05215418,measures_primary,Diastolic Blood Pressure
NCT05215418,measures_secondary,Blood Pressure
NCT05215418,has_criteria,BMI ≥ 27 kg/m2
NCT05215418,has_criteria,18-75 years of age
NCT05215418,has_criteria,ambulatory
NCT05215418,has_criteria,ABPM monitor
NCT02446418,involves,Asthma
NCT02446418,evaluates,Fluticasone Furoate/Vilanterol Inhalation Powder
NCT02446418,measures_primary,Change From Baseline in ACT Total Score
NCT02446418,measures_secondary,Percentage of Participants With Correct Use of Device
NCT02446418,has_criteria,Not Making Any Critical or Non-critical Errors
NCT05355818,involves,Chronic Hand Eczema
NCT05355818,evaluates,Delgocitinib Cream
NCT05355818,measures_primary,IGA-CHE treatment success
NCT05355818,measures_secondary,HECSI-90
NCT05355818,measures_secondary,HESD itch score
NCT05355818,measures_secondary,HESD pain score
NCT05355818,has_criteria,Adolescents 12-17 Years
NCT00141518,involves,Parkinson's disease
NCT00141518,evaluates,Duodopa
NCT00141518,measures_primary,UPDRS Total Score
NCT00141518,measures_secondary,EQ-5D Summary Index Score
NCT00141518,measures_secondary,EQ-5D VAS Score
NCT00141518,has_criteria,Baseline (Month -3)
NCT00141518,has_criteria,Month 12
NCT00996918,involves,Alzheimer Disease
NCT00996918,evaluates,Bapineuzumab
NCT00996918,measures_primary,ADAS-Cog/11 score
NCT00996918,measures_secondary,ADAS-Cog/11 score
NCT00996918,has_criteria,Study Baseline
NCT04375813,involves,Bladder Cancer
NCT04375813,evaluates,Encapsulated Rapamycin
NCT04375813,measures_primary,Recurrence Free Survival
NCT04375813,measures_secondary,Urinary Quality of Life
NCT04375813,measures_secondary,Cognitive Function
NCT04375813,has_criteria,Enrollment
NCT02327013,involves,Adult ADHD
NCT02327013,evaluates,Vortioxetine
NCT02327013,measures_primary,AISRS Total Score
NCT02327013,measures_secondary,BRIEF-A Using Metacognition Index
NCT02327013,measures_secondary,BRIEF-A Using Global Executive Composite Score
NCT02327013,measures_secondary,Sheehan Disability Scale Total Score
NCT02327013,has_criteria,Baseline to Week 6
NCT03668613,involves,Plaque Psoriasis
NCT03668613,evaluates,Secukinumab
NCT03668613,measures_primary,PASI 75 Response
NCT03668613,measures_secondary,IGA Mod 2011
NCT03668613,measures_secondary,PASI 90 Response
NCT03668613,has_criteria,Age 6 to <18 Years
NCT03118713,involves,Type 2 Diabetes Mellitus
NCT03118713,evaluates,Ipragliflozin
NCT03118713,measures_primary,Percentage change UACR
NCT03118713,measures_secondary,Estimated glomerular filtration rate
NCT03118713,measures_secondary,Hemoglobin A1c
NCT03118713,measures_secondary,Fasting Plasma Glucose
NCT03118713,measures_secondary,body weight
NCT03118713,measures_secondary,blood pressure
NCT03118713,measures_secondary,Uric Acid
NCT03118713,measures_secondary,EQ-5D-5L
NCT03118713,measures_secondary,EQ VAS
NCT03118713,measures_secondary,Quality of Life
NCT03118713,has_criteria,Albuminuria
NCT06149013,involves,Mild Cognitive Impairment
NCT06149013,involves,Mild Dementia
NCT06149013,evaluates,Digital Behavioral Activation Therapy
NCT06149013,measures_primary,Overall quality of life
NCT06149013,measures_secondary,Activity Level
NCT06149013,measures_secondary,Disorder-specific quality of life
NCT06149013,has_criteria,3 months
NCT01732536,involves,Recurrent Nasal Polyps
NCT01732536,evaluates,Steroid-Releasing S8 Sinus Implant
NCT01732536,measures_primary,Nasal Obstruction Score
NCT01732536,measures_secondary,Bilateral Polyp Grade
NCT01732536,measures_secondary,Ethmoid Sinus Obstruction
NCT01732536,measures_secondary,Bilateral Polyp Grade
NCT01732536,measures_secondary,Nasal Obstruction Symptom Evaluation (NOSE) Score
NCT01732536,has_criteria,Sinus surgeons
NCT04772313,involves,Gout
NCT04772313,evaluates,Pegloticase
NCT04772313,evaluates,Methotrexate
NCT04772313,measures_primary,sUA responders
NCT04772313,measures_secondary,Infusion Reaction
NCT04772313,measures_secondary,Urate Deposition Volume
NCT04772313,measures_secondary,HAQ-DI Score
NCT04772313,has_criteria,sUA < 6 mg/dL
NCT04772313,has_criteria,80% of the time
NCT01242813,involves,TNF-receptor Associated Periodic Syndrome (TRAPS)
NCT01242813,evaluates,ACZ885
NCT01242813,measures_primary,Complete or Almost Complete Response
NCT01242813,measures_secondary,Clinical Remission
NCT01242813,has_criteria,Physician's Global Assessment
NCT00313313,involves,Type 2 Diabetes
NCT00313313,evaluates,Saxagliptin
NCT00313313,measures_primary,Change From Baseline in A1C
NCT00313313,measures_secondary,Fasting Plasma Glucose
NCT00313313,has_criteria,Inadequate blood sugar control
NCT00313313,has_criteria,Treated with a sulfonylurea
NCT00313313,has_criteria,No major heart
NCT04193436,evaluates,PF-06835919
NCT04193436,measures_primary,AUCinf of PF-06835919
NCT04193436,measures_primary,Cmax of PF-06835919
NCT04193436,measures_primary,AUCinf
NCT04193436,measures_primary,Cmax
NCT04193436,measures_primary,fu of PF-06835919
NCT04193436,measures_secondary,Number of Participants Reporting Treatment-emergent Adverse Events (AEs)
NCT04193436,has_criteria,temporally associated with the use of study intervention
NCT05787236,involves,Plaque Psoriasis
NCT05787236,evaluates,Secukinumab
NCT05787236,measures_primary,PASI score <1
NCT05787236,measures_primary,PASI score <2
NCT05787236,measures_primary,PASI score <3
NCT05787236,measures_primary,PASI score <5
NCT05787236,measures_primary,PASI 75 response
NCT05787236,measures_primary,PASI 90 response
NCT05787236,measures_secondary,DLQI 0/1
NCT05787236,has_criteria,Moderate-to-severe
NCT02422836,involves,Photodamage
NCT02422836,evaluates,Anti-Aging Treatment Regimen
NCT02422836,measures_primary,Glogau Photodamage Scale
NCT02422836,measures_secondary,Dryness and Flaking
NCT02422836,measures_secondary,Dyschromia
NCT02422836,measures_secondary,Stinging and Burning
NCT02422836,has_criteria,8 weeks
NCT01083849,involves,Chronic Kidney Disease
NCT01083849,evaluates,Paricalcitol
NCT01083849,measures_primary,iPTH levels target range
NCT01083849,measures_secondary,Hypercalcemia
NCT01083849,measures_secondary,Hyperphosphatemia
NCT01083849,measures_secondary,Elevated Calcium-Phosphorus Product
NCT01083849,has_criteria,serum calcium level
NCT00077636,involves,Chronic Hepatitis C Infection
NCT00077636,evaluates,PEGASYS
NCT00077636,evaluates,COPEGUS
NCT00077636,measures_primary,Sustained Virological Response
NCT00077636,measures_secondary,Virological Response
NCT00077636,measures_secondary,Virological Response 12 Weeks Post-Treatment
NCT00077636,measures_secondary,Adverse Events
NCT00077636,has_criteria,Interferon-Naive
NCT01154036,involves,High Cardiovascular Risk
NCT01154036,involves,High Cholesterol
NCT01154036,evaluates,MK0653C
NCT01154036,measures_primary,Percent Change LDL-C
NCT01154036,measures_secondary,Percentage Participants Reach Target LDL-C
NCT01154036,measures_secondary,Percent Change Total Cholesterol
NCT01154036,has_criteria,Average value measurements
NCT02407236,involves,Ulcerative Colitis
NCT02407236,evaluates,Ustekinumab
NCT02407236,measures_primary,Clinical Remission
NCT02407236,measures_secondary,Mayo score
NCT02407236,has_criteria,Week 8
NCT02964936,involves,Chronic Kidney Disease
NCT02964936,involves,Anemia
NCT02964936,evaluates,ASP1517
NCT02964936,measures_primary,Hb response rate
NCT02964936,measures_secondary,Average Hb
NCT02964936,measures_secondary,Proportion target Hb
NCT02964936,measures_secondary,Rate of rise Hb
NCT02964936,measures_secondary,Proportion measurement points
NCT02964936,measures_secondary,Proportion participants target Hb
NCT02964936,measures_secondary,Time achieve lower Hb
NCT02964936,measures_secondary,Change from baseline Hb
NCT02964936,measures_secondary,Quality of life
NCT02964936,measures_secondary,Number participants abnormal
NCT02964936,measures_secondary,Safety assessed body weight
NCT02964936,measures_secondary,Safety assessed adverse events
NCT02964936,measures_secondary,Safety assessed electrocardiogram
NCT02964936,measures_secondary,Number participants abnormal
NCT02964936,measures_secondary,Plasma concentration ASP1517
NCT02964936,measures_secondary,Average hematocrit level
NCT02964936,measures_secondary,Average reticulocyte level
NCT02964936,measures_secondary,Average iron level
NCT02964936,measures_secondary,Average ferritin level
NCT02964936,measures_secondary,Average transferrin level
NCT02964936,measures_secondary,Average total iron binding capacity level
NCT00635349,involves,Knee Osteoarthritis
NCT00635349,evaluates,Tramadol Hydrochloride Plus Acetaminophen Tablets
NCT00635349,evaluates,Non-Steroidal Anti-Inflammatory Drugs
NCT00635349,measures_primary,Change From Day 29
NCT00635349,measures_primary,WOMAC Total Score
NCT00635349,measures_secondary,Pain Intensity Score
NCT00635349,measures_secondary,Number of Participants With Pain Relief
NCT00635349,measures_secondary,Number of Participants With Overall Assessment
NCT00635349,has_criteria,Day 29
NCT03777436,involves,Genital Psoriasis
NCT03777436,evaluates,Apremilast
NCT03777436,measures_primary,sPGA-G Response
NCT03777436,measures_secondary,sPGA Response
NCT03777436,measures_secondary,GPI-NRS Response
NCT03777436,has_criteria,Baseline at Week 16
NCT00961636,involves,Dyslipidemia
NCT00961636,evaluates,ERN/LRPT
NCT00961636,measures_primary,Days per week with GFSS ≥4
NCT00961636,measures_secondary,Maximum GFSS ≥4
NCT00961636,has_criteria,unlikely to conceive
NCT05835336,involves,ADHD
NCT05835336,evaluates,Non-pharmacological Intervention
NCT05835336,measures_primary,Change in ADHD-RS
NCT05835336,measures_secondary,Change in BRIEF
NCT05835336,measures_secondary,Change in CPT-3
NCT05835336,measures_secondary,CGI-I
NCT05835336,has_criteria,Documented history of ADHD diagnosis
NCT05835336,has_criteria,Age 12-17 y
NCT05835336,has_criteria,Written informed consent
NCT05835336,has_criteria,Able and willing to complete assessments
NCT05835336,has_criteria,No current psychiatric/neurological comorbidity
NCT05835336,has_criteria,No ADHD Medications
NCT02435836,involves,Chronic Schizophrenia
NCT02435836,evaluates,Aripiprazole
NCT02435836,measures_primary,PANSS Total Score
NCT02435836,measures_secondary,PANSS Positive Sub-scale Score
NCT02435836,measures_secondary,PANSS Negative Sub-scale Score
NCT02703636,involves,Alzheimer's disease
NCT02703636,evaluates,Rivastigmine patch
NCT02703636,measures_primary,MMSE Total Score
NCT02703636,measures_secondary,Safety
NCT02703636,has_criteria,ChEIs failed
NCT01815736,involves,HIV-1
NCT01815736,evaluates,TAF-Containing FDC
NCT01815736,measures_primary,HIV-1 RNA < 50 copies/mL
NCT01815736,measures_secondary,Hip Bone Mineral Density
NCT01815736,measures_secondary,Spine BMD
NCT01815736,measures_secondary,Serum Creatinine
NCT01815736,measures_secondary,EFV-related Symptom Assessment Score
NCT01815736,has_criteria,EFV/FTC/TDF prior treatment
NCT01508936,involves,Asthma
NCT01508936,evaluates,Reslizumab
NCT01508936,measures_primary,Change From Baseline in FEV1
NCT01508936,measures_secondary,Change From Baseline in ACQ
NCT01508936,has_criteria,blood eosinophil count
NCT01536236,involves,Diabetic Polyneuropathy
NCT01536236,evaluates,Spinal Cord Stimulation
NCT01536236,measures_primary,Neuropathy Impairment
NCT01536236,measures_secondary,Device related adverse events
NCT01536236,has_criteria,HbA1c levels
NCT00792636,involves,Migraine Headaches
NCT00792636,evaluates,Sumatriptan and Naproxen Sodium Combination Tablet
NCT00792636,evaluates,Sumatriptan Tablet
NCT00792636,evaluates,Naproxen Sodium Tablet
NCT00792636,measures_primary,Blood Pressure
NCT00792636,measures_secondary,Blood Pressure
NCT00762736,involves,Type 2 Diabetes Mellitus
NCT00762736,evaluates,Pioglitazone
NCT00762736,evaluates,Azilsartan
NCT00762736,measures_primary,glycosylated hemoglobin
NCT00762736,measures_secondary,fasting plasma glucose
NCT00762736,measures_secondary,total cholesterol
NCT00762736,measures_secondary,high-density lipoprotein
NCT00762736,measures_secondary,low-density lipoprotein
NCT00762736,measures_secondary,triglycerides
NCT00762736,measures_secondary,body weight
NCT00762736,measures_secondary,systolic blood pressure
NCT00762736,measures_secondary,diastolic blood pressure
NCT00762736,measures_secondary,edema
NCT00762736,measures_secondary,microalbuminuria
NCT00762736,measures_secondary,C-reactive protein
NCT00762736,measures_secondary,matrix metalloproteinase-9
NCT00762736,has_criteria,hemoglobin value
NCT00762736,has_criteria,type 2 diabetes
NCT00762736,has_criteria,adequate contraception
NCT00762736,has_criteria,stable antihypertensive therapy
NCT00762736,has_criteria,clinical laboratory evaluations
NCT00523549,involves,Hypertension
NCT00523549,involves,Diastolic Dysfunction
NCT00523549,evaluates,Valsartan
NCT00523549,evaluates,Amlodipine
NCT00523549,measures_primary,Lateral Mitral Relaxation Velocity
NCT00523549,measures_secondary,Left Atrial Size
NCT00523549,measures_secondary,E Wave Velocity/E
NCT00523549,measures_secondary,Vascular Stiffness
NCT00523549,measures_secondary,Mean Sitting Systolic Blood Pressure
NCT00523549,measures_secondary,Mean Sitting Diastolic Blood Pressure
NCT00523549,measures_secondary,Estimated Central Aortic Pressure
NCT00523549,has_criteria,Age 45 years or older
NCT00523549,has_criteria,Post-menopausal
NCT00523549,has_criteria,Uncontrolled systolic hypertension
NCT00523549,has_criteria,Maximum two antihypertensive medications
NCT02270736,involves,Chronic Troublesome Drooling
NCT02270736,evaluates,NT 201
NCT02270736,evaluates,Placebo
NCT02270736,measures_primary,Change From Baseline in uSFR
NCT02270736,measures_secondary,Global Impression of Change Scale
NCT02270736,measures_secondary,Occurrence of Treatment Emergent Adverse Events
NCT02270736,has_criteria,6 to 17 years
NCT01601236,involves,Diabetic Nephropathy
NCT01601236,evaluates,Acthar
NCT01601236,measures_primary,Percent Change eGFR
NCT01601236,measures_secondary,Proteinuria Remission
NCT01601236,has_criteria,Inclusion Criteria
NCT02053116,involves,Type 2 Diabetes Mellitus
NCT02053116,evaluates,PF-05175157
NCT02053116,measures_primary,Change from baseline WMDG
NCT02053116,measures_secondary,fasting plasma glucose
NCT02053116,measures_secondary,Glycosylated Hemoglobin
NCT02053116,measures_secondary,fasting total cholesterol
NCT02053116,measures_secondary,glucose AUC(0-5)
NCT02053116,measures_secondary,insulin AUC(0-5)
NCT02053116,measures_secondary,C-peptide AUC(0-5)
NCT02053116,measures_secondary,ratio of AUC(0-5) insulin to AUC(0-5) glucose
NCT02053116,measures_secondary,ratio of AUC(0-5) C-peptide to AUC(0-5) glucose
NCT02053116,measures_secondary,HOMA IR
NCT02053116,measures_secondary,HOMA B
NCT02053116,measures_secondary,low density lipoprotein cholesterol
NCT02053116,measures_secondary,body weight
NCT02053116,measures_secondary,high density lipoprotein cholesterol
NCT02053116,measures_secondary,triglycerides
NCT02053116,measures_secondary,non-HDL cholesterol
NCT02053116,measures_secondary,very low density lipoprotein
NCT02053116,has_criteria,Type 2 Diabetes Mellitus
NCT02053116,has_criteria,metformin 1000mg
NCT02202616,involves,COPD
NCT02202616,evaluates,QVA149
NCT02202616,measures_primary,Change From Baseline in Trough FEV1
NCT02202616,measures_secondary,Change in Baseline Dyspnea Index
NCT02202616,measures_secondary,Transitional Dyspnea Index
NCT02202616,has_criteria,CAT score >10
NCT01754116,evaluates,GSK1265744
NCT01754116,measures_primary,AUC 0-wk12
NCT01754116,measures_primary,Cwk12
NCT01754116,measures_primary,Cmax
NCT01754116,measures_secondary,AUC(0-infinity)
NCT01754116,measures_secondary,AUC(0-wk4)
NCT01754116,measures_secondary,Cwk4
NCT01754116,measures_secondary,AUC(0-wk8)
NCT01754116,measures_secondary,Cwk8
NCT01754116,measures_secondary,t½
NCT01754116,measures_secondary,tmax
NCT01754116,measures_secondary,CL/F
NCT00655824,involves,rheumatoid arthritis
NCT00655824,evaluates,Ofatumumab
NCT00655824,measures_primary,Minimum Change From Baseline in DAS28
NCT00655824,measures_secondary,DAS28(CRP)
NCT00655824,has_criteria,clinical status
NCT03102424,involves,Type 2 Diabetes Mellitus
NCT03102424,evaluates,DW1330
NCT03102424,measures_primary,HbA1c < 7%
NCT03102424,measures_secondary,Fasting plasma glucose
NCT03102424,measures_secondary,body weight
NCT03102424,measures_secondary,OAD drugs
NCT03102424,has_criteria,age 30 through 80 years
NCT03102424,has_criteria,stable oral anti-diabetic drugs
NCT03102424,has_criteria,HbA1c 7.5 to 10%
NCT03567824,involves,Type 2 diabetes mellitus
NCT03567824,evaluates,MLD10
NCT03567824,measures_primary,Change in Serum Magnesium Concentration
NCT03567824,measures_secondary,Change from baseline in fasting blood glucose
NCT03567824,measures_secondary,Change from baseline in insulin sensitivity
NCT03567824,measures_secondary,Change from baseline in insulin resistance
NCT03567824,measures_secondary,Change from baseline in HbA1c
NCT03567824,has_criteria,Body Mass Index 18 to 40 kg/m2
NCT03567824,has_criteria,Hypomagnesemia serum magnesium ≤ 1.5 mg/dL
NCT03567824,has_criteria,Females non-pregnant non-lactating negative serum pregnancy test
NCT03567824,has_criteria,History of clinically significant GI renal hepatic neurologic hematologic endocrine other than Type 2 diabetes mellitus oncologic pulmonary immunologic psychiatric or cardiovascular disease
NCT02215616,involves,Huntington's Disease
NCT02215616,evaluates,Laquinimod
NCT02215616,measures_primary,UHDRS-TMS at Week 52
NCT02215616,measures_secondary,Caudate Volume
NCT02215616,has_criteria,prior positive genetic testing for HD
NCT04781816,involves,Cutaneous Lupus Erythematosus
NCT04781816,evaluates,SAR443122
NCT04781816,measures_primary,CLASI-A Sub-Score
NCT04781816,measures_secondary,PhysGA- Disease Activity
NCT04781816,measures_secondary,Itch-NRS
NCT04781816,has_criteria,Baseline (Day 1)
NCT05394116,involves,Fibrodysplasia Ossificans Progressiva
NCT05394116,evaluates,Garetosmab
NCT05394116,evaluates,Placebo
NCT05394116,measures_primary,Number of new HO lesions
NCT05394116,measures_secondary,Incidence of adverse events
NCT05394116,measures_secondary,Clinician-assessed flare-ups
NCT05394116,measures_secondary,Patient-reported flare-ups
NCT05394116,measures_secondary,Total volume of new HO lesions
NCT05394116,measures_secondary,Change in joint function
NCT05394116,has_criteria,Adult Participants
NCT02667496,involves,Mild Cognitive Impairment Due to Alzheimer's Disease
NCT02667496,evaluates,Sargramostim
NCT02667496,measures_primary,Change from baseline
NCT02667496,measures_secondary,CSF analysis
NCT02667496,measures_secondary,MRI
NCT02667496,measures_secondary,antidrug antibody levels
NCT02667496,has_criteria,MCI due to AD
NCT02667496,has_criteria,sporadic or familial inheritance pattern
NCT02667496,has_criteria,ADAS-cog ≥1.5 SD
NCT02667496,has_criteria,no definite impairment(s) in ADLs
NCT02667496,has_criteria,positive amyloid PET scan
NCT01744496,involves,Parkinson's Disease
NCT01744496,evaluates,Rotigotine
NCT01744496,measures_primary,Change From Baseline
NCT01744496,measures_secondary,PDQ-8 Sum Score
NCT01744496,has_criteria,2-Point Reduction
NCT06656416,involves,Bipolar Disorder
NCT06656416,involves,Depression
NCT06656416,evaluates,ALTO-100
NCT06656416,evaluates,placebo
NCT06656416,measures_primary,MADRS total score
NCT06656416,measures_secondary,PHQ-9
NCT06656416,measures_secondary,CGI-S
NCT06656416,has_criteria,pre-defined subgroup
NCT00442416,involves,Anemia
NCT00442416,evaluates,Subcutaneous Mircera
NCT00442416,measures_primary,Mean Change Hb Concentration
NCT00442416,measures_secondary,Percentage of Participants
NCT00442416,has_criteria,Adequate iron status
NCT02963116,evaluates,AZD5718
NCT02963116,measures_primary,AUC of Rosuvastatin
NCT02963116,measures_secondary,Cmax of Rosuvastatin
NCT02963116,measures_secondary,t½ of Rosuvastatin
NCT02963116,measures_secondary,tmax of rosuvastatin
NCT02963116,measures_secondary,AUC of AZD5718
NCT02963116,measures_secondary,AUC(0-last) of AZD5718
NCT02963116,measures_secondary,Cmax of AZD5718
NCT02655016,involves,Advanced Ovarian Cancer
NCT02655016,evaluates,Niraparib
NCT02655016,measures_primary,Progression Free Survival
NCT02655016,measures_secondary,Overall Survival
NCT02655016,measures_secondary,Time to First Subsequent Therapy
NCT02655016,measures_secondary,Progression-Free Survival-2
NCT02655016,measures_secondary,Change From Baseline in Participant Reported Outcome
NCT02655016,has_criteria,Platinum-Based Chemotherapy
NCT03769116,involves,Duchenne Muscular Dystrophy
NCT03769116,evaluates,Delandistrogene Moxeparvovec
NCT03769116,measures_primary,Dystrophin protein expression
NCT03769116,measures_secondary,North Star Ambulatory Assessment
NCT03769116,has_criteria,age group
NCT01867216,involves,Diabetes
NCT01867216,evaluates,LY2922470
NCT01867216,measures_primary,HbA1c at Day 28
NCT01867216,measures_secondary,Blood Glucose AUEC₀-₂₄
NCT01867216,measures_secondary,C-Peptide AUEC₀-₁₂
NCT01867216,has_criteria,type 2 diabetes
NCT01867216,has_criteria,HbA1c 6.5% to 11%
NCT01867216,has_criteria,no diabetes treatment change
NCT01867216,has_criteria,BMI 18.0 to 45.0 kg/m\^2
NCT00922116,involves,Chronic renal anemia
NCT00922116,evaluates,Mircera
NCT00922116,measures_primary,Hemoglobin Concentration
NCT00922116,measures_secondary,Dose Adjustments
NCT00922116,has_criteria,adult patients
NCT02203916,involves,Hypertension
NCT02203916,evaluates,Azilsartan Medoxomil
NCT02203916,measures_primary,Trough clinic SBP
NCT02203916,measures_primary,Trough clinic DBP
NCT02203916,measures_secondary,Clinic DBP response
NCT02203916,measures_secondary,Clinic SBP response
NCT02203916,has_criteria,Baseline sitting clinic SBP
NCT02203916,has_criteria,Baseline sitting clinic DBP
NCT00797316,involves,Metabolic Syndrome
NCT00797316,involves,Stage 2 Systolic Hypertension
NCT00797316,evaluates,Aliskiren Plus HCTZ
NCT00797316,evaluates,Aliskiren
NCT00797316,measures_primary,Change in msSBP
NCT00797316,measures_secondary,Change in msDBP
NCT00797316,measures_secondary,Percentage of Participants With Blood Pressure Response
NCT00797316,measures_secondary,Percentage of Patients Achieving Blood Pressure Control
NCT00797316,measures_secondary,Change in Pulse Pressure
NCT00797316,has_criteria,stage 2 systolic hypertension
NCT00797316,has_criteria,msSBP ≥160 mmHg
NCT00797316,has_criteria,msSBP \<200 mmHg
NCT00797316,has_criteria,Abdominal obesity
NCT00797316,has_criteria,waist circumference > 102 cm for men
NCT00797316,has_criteria,waist circumference > 88 cm for women
NCT00797316,has_criteria,Current triglycerides ≥ 150 mg/dL
NCT00797316,has_criteria,Fasting glucose > 100 mg/dL
NCT00797316,has_criteria,Fasting glucose < 126 mg/dL
NCT01703624,involves,Chronic Obstructive Pulmonary Disease
NCT01703624,evaluates,Glycopyrronium Bromide
NCT01703624,measures_primary,FEV1 Area Under the Curve
NCT01703624,measures_secondary,Adverse event monitoring
NCT01703624,has_criteria,informed consent
NCT04237116,involves,Plaque Psoriasis
NCT04237116,involves,Non-alcoholic Fatty Liver Disease
NCT04237116,evaluates,Secukinumab
NCT04237116,measures_primary,PASI 90 response
NCT04237116,measures_secondary,ALT score
NCT04237116,measures_secondary,DLQI
NCT04237116,has_criteria,liver function
NCT04446416,involves,Recurrent GBM
NCT04446416,evaluates,NaviFUS System
NCT04446416,evaluates,Bevacizumab
NCT04446416,measures_primary,Progression-free survival
NCT04446416,measures_secondary,Tumor shrinkage
NCT04446416,measures_secondary,Objective response rate
NCT04446416,measures_secondary,PET uptake
NCT04446416,measures_secondary,Overall survival
NCT04446416,measures_secondary,Degree of BBB opening
NCT04446416,measures_secondary,Corticosteroid consumption
NCT04446416,measures_secondary,Quality of life
NCT04446416,has_criteria,38 weeks
NCT06079216,involves,Alzheimer's Disease
NCT06079216,has_criteria,aged 55+
NCT06079216,has_criteria,speak/read English
NCT06079216,has_criteria,at least 18 years old
NCT06079216,has_criteria,work within a residential care facility
NCT06079216,has_criteria,speak and read English
NCT06079216,has_criteria,diagnosed with dementia
NCT01493024,involves,Chronic Kidney Disease
NCT01493024,involves,Moderate Kidney Dysfunction
NCT01493024,involves,Hyperkalemia
NCT01493024,evaluates,Zirconium Silicate
NCT01493024,measures_primary,Exponential Rate of Change
NCT01493024,measures_secondary,Serum Potassium
NCT01493024,has_criteria,S-K levels 3.5 to 4.9 mmol/L
NCT01448824,evaluates,LY2484595
NCT01448824,measures_primary,Maximum Observed Plasma Concentration
NCT01448824,measures_secondary,Time of Maximum Observed Plasma Concentration
NCT01448824,has_criteria,Healthy Participants
NCT01560624,involves,Pulmonary Arterial Hypertension
NCT01560624,evaluates,UT-15C
NCT01560624,measures_primary,Time to First Clinical Worsening Event
NCT01560624,measures_secondary,Change in 6-Minute Walk Distance
NCT01560624,measures_secondary,Change in Plasma NT-proBNP
NCT01560624,has_criteria,Background Oral Monotherapy
NCT05547035,involves,Major Depression Disorders
NCT05547035,evaluates,Wearable Monitor
NCT05547035,measures_primary,MADRS total score
NCT05547035,measures_secondary,Hospital Anxiety and Depression total score
NCT05547035,measures_secondary,CGI scale
NCT05547035,has_criteria,physiological measurements
NCT02671435,evaluates,Durvalumab
NCT02671435,evaluates,Monalizumab
NCT02671435,measures_primary,Change From Baseline in SBP
NCT02671435,measures_primary,Change From Baseline in DBP
NCT02671435,measures_primary,Change From Baseline in RR
NCT02671435,measures_primary,Change From Baseline in PR
NCT02671435,measures_primary,Change From Baseline in BT
NCT02671435,measures_primary,Change From Baseline in OS
NCT00770835,involves,Type 2 Diabetes Mellitus
NCT00770835,evaluates,Pioglitazone
NCT00770835,measures_primary,Endothelial Progenitor Cells
NCT00770835,measures_secondary,Circulating Progenitor Cells
NCT00770835,measures_secondary,Flow Mediated Dilation
NCT00770835,measures_secondary,Glucose Control
NCT00770835,measures_secondary,Lipid Parameters
NCT00770835,measures_secondary,insulin sensitivity
NCT00770835,measures_secondary,Inflammation Markers
NCT00770835,measures_secondary,Adipokines
NCT00770835,measures_secondary,Oxidative Stress
NCT00770835,measures_secondary,Urinary albumin excretion
NCT00770835,has_criteria,glycosylated hemoglobin
NCT02482935,involves,healthy participants
NCT02482935,evaluates,Abemaciclib
NCT02482935,measures_primary,AUC [0-inf]
NCT02482935,measures_secondary,Cmax
NCT02482935,measures_secondary,Tmax
NCT02482935,has_criteria,BMI 18 to 32 kg/m\^2
NCT01868035,involves,Non-Hodgkin's Lymphoma
NCT01868035,evaluates,Iodine-131 Anti-B1 Antibody
NCT01868035,measures_primary,Complete Response
NCT01868035,measures_secondary,Partial Response
NCT01868035,has_criteria,Grade 4 toxicities
NCT04730635,involves,Alzheimer's Disease
NCT04730635,involves,mild cognitive impairment
NCT04730635,involves,mild Alzheimer's Disease
NCT04730635,evaluates,donepezil
NCT04730635,evaluates,placebo
NCT04730635,measures_primary,Percentage Change OCL
NCT04730635,measures_secondary,Standard Deviation OCL
NCT04730635,has_criteria,MMSE score 18-28
NCT04730635,has_criteria,MHIS score ≤4
NCT04730635,has_criteria,reliable study partner
NCT04730635,has_criteria,Apolipoprotein E genotyping
NCT04730635,has_criteria,able to speak
NCT04730635,has_criteria,able to adhere to schedule
NCT04730635,has_criteria,adequate visual acuity
NCT04183335,involves,Prurigo Nodularis
NCT04183335,evaluates,Dupilumab
NCT04183335,measures_primary,WI-NRS improvement
NCT04183335,measures_secondary,IGA PN-S scores
NCT04183335,has_criteria,Topical therapies
NCT03482635,involves,Ulcerative Colitis
NCT03482635,evaluates,SPESOLIMAB
NCT03482635,measures_primary,Clinical Remission
NCT03482635,measures_secondary,Clinical Response
NCT03482635,measures_secondary,Endoscopic Improvement
NCT03482635,measures_secondary,Combined Endoscopic Improvement and Histologic Remission
NCT03482635,has_criteria,modified Mayo Clinical Score
NCT03035058,involves,Primary Sclerosing Cholangitis
NCT03035058,involves,Inflammatory Bowel Disease
NCT03035058,evaluates,Vedolizumab
NCT03035058,measures_primary,No Worsening Ishak
NCT03035058,measures_secondary,Serum Alkaline Phosphatase
NCT03035058,measures_secondary,Ishak Necroinflammatory
NCT03035058,has_criteria,Underlying IBD
NCT02417935,involves,Diabetic Peripheral Neuropathic Pain
NCT02417935,evaluates,Duloxetine
NCT02417935,measures_primary,Change From Baseline
NCT02417935,measures_secondary,Patient Global Impression
NCT02417935,has_criteria,Duration of DPNP
NCT01567735,involves,Chronic Hepatitis C Virus Genotype-4
NCT01567735,evaluates,TMC435
NCT01567735,measures_primary,SVR12
NCT01567735,measures_secondary,SVR24
NCT01567735,measures_secondary,on-treatment virologic response
NCT01567735,measures_secondary,on-treatment virologic failure
NCT01567735,measures_secondary,viral breakthrough rate
NCT01567735,measures_secondary,viral relapse rate
NCT01567735,has_criteria,treatment-naïve
NCT01567735,has_criteria,previous relapsers
NCT01567735,has_criteria,previous non-responders
NCT04499235,involves,Bullous Pemphigoid
NCT04499235,evaluates,AKST4290
NCT04499235,measures_primary,Disease Control
NCT04499235,measures_secondary,Time to Disease Control
NCT04499235,measures_secondary,Time to Rescue Therapy
NCT04499235,has_criteria,Disease control
NCT02426086,involves,Myelofibrosis
NCT02426086,evaluates,Imetelstat
NCT02426086,measures_primary,Spleen response rate
NCT02426086,measures_secondary,Symptom response rate
NCT02426086,measures_secondary,Overall Response Rate
NCT02426086,has_criteria,Previously Treated With JAK Inhibitor
NCT01473563,involves,Advanced Nonsquamous Non-Small Cell Lung Cancer
NCT01473563,evaluates,Pemetrexed
NCT01473563,measures_primary,Adherence to treatment
NCT01473563,measures_secondary,Change From Baseline in EQ-5D VAS
NCT01473563,measures_secondary,Change From Baseline in EQ-5D Index Score
NCT01473563,has_criteria,Cycle 1
NCT05130463,involves,Type 2 Diabetes Mellitus
NCT05130463,evaluates,Esgliteo
NCT05130463,measures_primary,Change from baseline HbA1c
NCT05130463,measures_secondary,fasting plasma glucose
NCT05130463,measures_secondary,body weight
NCT05130463,measures_secondary,systolic blood pressure
NCT05130463,measures_secondary,diastolic blood pressure
NCT05130463,has_criteria,Korean Patients
NCT01359735,involves,Mohs Micrographic Surgery
NCT01359735,evaluates,HP802-247
NCT01359735,evaluates,bacitracin ointment
NCT01359735,measures_primary,Investigator's Global Assessment
NCT01359735,measures_secondary,Complete wound closure
NCT01359735,measures_secondary,Time in Days to Wound Closure
NCT01359735,measures_secondary,Investigator Reported Signs and Symptoms
NCT01359735,measures_secondary,Subject Reported Signs and Symptoms
NCT01359735,has_criteria,12 weeks or until wound closure
NCT05620563,involves,Osteoarthritis Pain
NCT05620563,evaluates,LY3857210
NCT05620563,measures_primary,Change From Baseline
NCT05620563,measures_secondary,WOMAC Pain Subscale
NCT05620563,measures_secondary,WOMAC Stiffness Subscale
NCT05620563,has_criteria,Baseline
NCT04809363,involves,Crohn's Disease
NCT04809363,evaluates,CDPATH™
NCT04809363,measures_primary,Decisional Conflict Scale
NCT04809363,measures_secondary,Work Productivity and Activity Impairment Questionnaire - CD Version
NCT04809363,has_criteria,risk category
NCT03400163,involves,Non-Alcoholic Steatohepatitis
NCT03400163,evaluates,BMS-986036
NCT03400163,measures_primary,Hepatic Fat Fraction
NCT03400163,measures_secondary,Adverse Events
NCT03400163,measures_secondary,Serious Adverse Events
NCT03400163,measures_secondary,Injection Site Reactions
NCT03400163,measures_secondary,Adverse Events Leading to Discontinuation
NCT03400163,measures_secondary,Deaths
NCT03400163,measures_secondary,Marked Laboratory Abnormalities
NCT03400163,measures_secondary,Vital Sign Abnormalities
NCT03400163,measures_secondary,Electrocardiogram
NCT00475735,involves,Attention Deficit Hyperactivity Disorder
NCT00475735,evaluates,MK0249
NCT00475735,measures_primary,AISRS Total Score Responder Rate
NCT00475735,measures_secondary,CGI-S Score
NCT00475735,has_criteria,DSM-IV criteria
NCT02843035,involves,Gaucher Disease Type 3
NCT02843035,involves,Gaucher Disease Type 1
NCT02843035,evaluates,Venglustat
NCT02843035,evaluates,Cerezyme
NCT02843035,measures_primary,plasma lyso-GL1
NCT02843035,measures_primary,plasma GL1
NCT02843035,measures_secondary,CSF lyso-GL1
NCT02843035,measures_secondary,CSF GL1
NCT02843035,measures_secondary,Cmax
NCT02843035,measures_secondary,Tmax
NCT02843035,measures_secondary,AUC
NCT02843035,measures_secondary,Ctrough
NCT02843035,has_criteria,≥18 years of age
NCT02843035,has_criteria,written informed consent
NCT02843035,has_criteria,Gaucher disease Type 1
NCT02843035,has_criteria,Gaucher disease Type 3
NCT01244035,involves,Hypertension
NCT01244035,evaluates,MK-8266
NCT01244035,measures_primary,AUC(0-8 Hours)
NCT01244035,measures_secondary,Cmax
NCT01244035,has_criteria,Dosing Regimens
NCT00701935,involves,Type 2 Diabetes
NCT00701935,evaluates,Exenatide
NCT00701935,measures_primary,Percentage change in abdominal visceral fat
NCT00701935,measures_secondary,Percentage change in total abdominal fat
NCT00701935,measures_secondary,Percentage change in subcutaneous abdominal fat
NCT00701935,measures_secondary,Change in HbA1c from baseline to 6 months
NCT00701935,measures_secondary,Percentage of patients with HbA1c values <= 7.0% measured at 6 months
NCT00701935,measures_secondary,Change in Fasting plasma glucose
NCT00701935,measures_secondary,Change in weight
NCT00701935,measures_secondary,Change in Systolic blood pressure
NCT00701935,measures_secondary,Change in Diastolic blood pressure
NCT00701935,measures_secondary,Change in total cholesterol
NCT00701935,measures_secondary,Change in triglycerides
NCT00701935,measures_secondary,Change in HDL cholesterol
NCT00701935,measures_secondary,Event Rate of Treatment-Emergent Hypoglycemic Event
NCT00701935,has_criteria,Pretreated With Metformin
NCT05152563,involves,Eosinophilic Gastritis
NCT05152563,involves,Eosinophilic Duodenitis
NCT05152563,evaluates,AK002
NCT05152563,measures_primary,Proportion of Responders
NCT05152563,measures_secondary,Mean absolute change in TSS
NCT05152563,measures_secondary,Percent change in tissue eosinophils
NCT05152563,measures_secondary,Number of treatment responders
NCT05152563,measures_secondary,Proportion of subjects achieving mean eosinophil count
NCT05152563,measures_secondary,Proportion of subjects who show ≥50% reduction in TSS
NCT05152563,measures_secondary,Proportion of subjects who show ≥70% reduction in TSS
NCT05152563,measures_secondary,Change in weekly TSS
NCT05152563,has_criteria,≥18 and ≤80 years
NCT05152563,has_criteria,≥30 eosinophils/hpf in at least 5 hpf
NCT05152563,has_criteria,≥30 eosinophils/hpf in at least 3 hpf
NCT05152563,has_criteria,weekly average score of abdominal pain
NCT04770818,involves,Lateral Ankle Ligament Reconstruction
NCT04770818,evaluates,InternalBrace™ Augmentation
NCT04770818,measures_primary,Return to Work
NCT04770818,measures_secondary,Visual Analog Scale
NCT04770818,measures_secondary,Veterans Rand
NCT04770818,measures_secondary,Foot and Ankle Ability Measure
NCT04770818,has_criteria,Pre-operative
NCT00549718,involves,Acute Schizophrenia
NCT00549718,evaluates,Lurasidone HCl
NCT00549718,measures_primary,Change in PANSS Score
NCT00549718,measures_secondary,CGI-S From Baseline
NCT00549718,has_criteria,6 weeks
NCT00622713,involves,Alzheimer's Disease
NCT00622713,evaluates,Rivastigmine Patch
NCT00622713,measures_primary,patch tolerance
NCT00622713,measures_secondary,Clinical Global Impression
NCT00622713,measures_secondary,Instrumental Activities of Daily Living
NCT00622713,measures_secondary,Mini-Mental State Examination
NCT00622713,has_criteria,target patch size
NCT01651936,involves,Rheumatoid Arthritis
NCT01651936,evaluates,MK-8457
NCT01651936,measures_primary,DAS28-CRP at Week 12
NCT01651936,measures_secondary,ACR20 Response at Week 12
NCT01651936,has_criteria,Baseline and Week 12
NCT04462536,involves,Acute Ischemic Stroke
NCT04462536,evaluates,Nerinetide
NCT04462536,measures_primary,independent functioning
NCT04462536,measures_secondary,Mortality rate
NCT04462536,measures_secondary,Worsening of stroke
NCT04462536,has_criteria,Endovascular Thrombectomy
NCT04462536,has_criteria,Excluding Thrombolysis
NCT02856113,involves,Type 2 Diabetes
NCT02856113,evaluates,Alogliptin
NCT02856113,measures_primary,Change From Baseline in HbA1c
NCT02856113,measures_secondary,Clinically Significant Physical Examination Findings
NCT02856113,measures_secondary,Abnormal Vital Signs Values
NCT02856113,measures_secondary,Abnormal 12-lead ECG Findings
NCT02856113,measures_secondary,Treatment-emergent Adverse Events
NCT02856113,has_criteria,From Day 1 to end of treatment period
NCT02873936,involves,Rheumatoid Arthritis
NCT02873936,evaluates,Filgotinib
NCT02873936,measures_primary,ACR20 response
NCT02873936,measures_secondary,HAQ-DI score
NCT02873936,has_criteria,Inadequate response to DMARDs
NCT01391013,involves,HIV-1 infection
NCT01391013,evaluates,Darunavir/Ritonavir 800/100 mg
NCT01391013,evaluates,Triple Combination Therapy
NCT01391013,measures_primary,Change in FMD (%)
NCT01391013,measures_secondary,Circulating Endothelial Cells
NCT01391013,measures_secondary,Precursors of Circulating Endothelial Cells
NCT01391013,measures_secondary,Low-density Lipoprotein Cholesterol
NCT01391013,measures_secondary,High-density Lipoprotein Cholesterol
NCT01391013,measures_secondary,Triglycerides
NCT01391013,measures_secondary,Insulin Sensitivity
NCT01391013,has_criteria,HIV-RNA greater than or equal to 50 Copies/mL
NCT01393613,involves,Acute Schizophrenia
NCT01393613,evaluates,OPC-34712
NCT01393613,measures_primary,PANSS Total Score
NCT01393613,measures_secondary,CGI-S Score
NCT01393613,measures_secondary,PSP Score
NCT01393613,has_criteria,Baseline
NCT02531113,involves,Crohn's Disease
NCT02531113,evaluates,RPC1063
NCT02531113,measures_primary,SES-CD at Week 12
NCT02531113,measures_secondary,Treatment Emergent Adverse Events
NCT02531113,has_criteria,Treatment Emergent Adverse Events
NCT02975336,involves,Systemic Lupus Erythematosus
NCT02975336,evaluates,M2951
NCT02975336,measures_primary,SRI-4 response
NCT02975336,measures_secondary,SRI-6 response
NCT02975336,has_criteria,SLEDAI-2K score
NCT03605836,involves,Attention-deficit/Hyperactivity Disorder
NCT03605836,evaluates,Centanafadine Sustained-release Tablets
NCT03605836,measures_primary,Change From Baseline
NCT03605836,measures_secondary,Clinical Global Impression-Severity of Illness Scale
NCT03605836,has_criteria,DSM-5 criteria for ADHD
NCT00488618,involves,Acute Mania
NCT00488618,evaluates,Cariprazine
NCT00488618,measures_primary,Change From Baseline
NCT00488618,measures_secondary,Clinical Global Impression-Severity
NCT00488618,has_criteria,Baseline
NCT01636713,involves,COPD
NCT01636713,evaluates,GSK573719/GW642444
NCT01636713,measures_primary,Change From Baseline FEV1
NCT01636713,measures_secondary,Transition Dyspnea Index
NCT01636713,has_criteria,smoking status
NCT01562613,involves,Hypertension
NCT01562613,evaluates,Eprosartan
NCT01562613,measures_primary,BP levels achieved
NCT01562613,measures_secondary,Framingham Stroke Risk Profile Scores
NCT01562613,has_criteria,age
NCT01638013,involves,Rheumatoid Arthritis
NCT01638013,evaluates,ASP015K
NCT01638013,measures_primary,ACR20 response
NCT01638013,measures_secondary,ACR50-CRP response
NCT01638013,has_criteria,completed Phase IIb or III
NCT00663936,involves,Alzheimer's disease
NCT00663936,evaluates,T-817MA
NCT00663936,measures_primary,cognitive function
NCT00663936,measures_secondary,activities of daily living
NCT00663936,measures_secondary,global assessment
NCT00663936,has_criteria,Mild to moderate Alzheimer's disease
NCT00663936,has_criteria,receiving Donepezil
NCT00663936,has_criteria,Age 50 to 90
NCT00663936,has_criteria,living in the community
NCT00663936,has_criteria,eligible informant
NCT00663936,has_criteria,read and understand English
NCT00663936,has_criteria,clinically significant cardiac
NCT00663936,has_criteria,clinically significant hepatic
NCT00663936,has_criteria,clinically significant renal
NCT00663936,has_criteria,dementia not of Alzheimer's type
NCT00663936,has_criteria,taking donepezil
NCT00663936,has_criteria,taking drug other than donepezil
NCT03483636,involves,alcohol interaction
NCT03483636,evaluates,Lemborexant
NCT03483636,measures_primary,body sway
NCT03483636,measures_secondary,Power of Attention
NCT03483636,has_criteria,single-dose treatment period
NCT03393013,involves,systemic lupus erythematous
NCT03393013,involves,Lupus Nephritis
NCT03393013,evaluates,zetomipzomib
NCT03393013,measures_primary,treatment-related adverse event
NCT03393013,measures_secondary,UPCR reduction
NCT03393013,measures_secondary,Partial Renal Response
NCT03393013,has_criteria,adult patients
NCT06167213,involves,heart failure
NCT06167213,evaluates,SAPIEN X4 Transcatheter Heart Valve
NCT06167213,measures_primary,death or stroke
NCT06167213,measures_secondary,Kansas City Cardiomyopathy Questionnaire score
NCT06167213,measures_secondary,New York Heart Association functional class
NCT06167213,has_criteria,Inclusion Criteria
NCT03867318,involves,Coronary Heart Disease
NCT03867318,involves,Multiple Cardiovascular Risk Factors
NCT03867318,evaluates,Ezetimibe
NCT03867318,evaluates,Atorvastatin
NCT03867318,measures_primary,LDL-C levels
NCT03867318,measures_secondary,Adverse Event
NCT03867318,measures_secondary,Discontinuation
NCT03867318,has_criteria,Target LDL-C level
NCT02971618,involves,Type 2 Diabetes Mellitus
NCT02971618,evaluates,dapagliflozin
NCT02971618,measures_primary,HbA1c reduction
NCT02971618,measures_secondary,fasting blood glucose
NCT02971618,measures_secondary,body weight
NCT02971618,measures_secondary,systolic blood pressure
NCT02971618,measures_secondary,diastolic blood pressure
NCT02971618,has_criteria,age 18-65 years
NCT02971618,has_criteria,first prescription
NCT04349449,involves,Crohn's Disease
NCT04349449,evaluates,ENTYVIO
NCT04349449,measures_primary,HBI less than 5
NCT04349449,measures_secondary,Change From Baseline in HBI
NCT04349449,measures_secondary,Change From Baseline in PGA
NCT04349449,measures_secondary,Change From Baseline in PRO-2
NCT04349449,has_criteria,Bio-naive Patients
NCT01436149,involves,Major Depressive Disorder
NCT01436149,evaluates,SPD489
NCT01436149,measures_primary,MADRS total score
NCT01436149,measures_secondary,Sheehan Disability Scale
NCT01436149,has_criteria,Adults
NCT01709149,involves,Amyotrophic Lateral Sclerosis
NCT01709149,evaluates,CK-2017357
NCT01709149,measures_primary,ALSFRS-R Total Score
NCT01709149,measures_secondary,Maximum Voluntary Ventilation
NCT01709149,measures_secondary,Sniff Nasal Inspiratory Pressure
NCT01709149,measures_secondary,Slow Vital Capacity
NCT01709149,has_criteria,Baseline
NCT02989649,involves,diabetes mellitus
NCT02989649,evaluates,Alogliptin
NCT02989649,measures_primary,Change From Baseline in HbA1c Level at Month 6
NCT02989649,measures_secondary,Percentage of Participants With a Decrease in HbA1c Level by <7.0%
NCT02989649,measures_secondary,Percentage of Participants With a Decrease in HbA1c Level by >0.3% and No Tolerability Findings
NCT02989649,measures_secondary,Change From Baseline in Fasting Plasma Glucose (FPG) Level Over Time
NCT02989649,has_criteria,glycosylated hemoglobin (HbA1c) ≥6.5%
NCT00314249,involves,Fibromyalgia
NCT00314249,evaluates,Milnacipran
NCT00314249,measures_primary,Composite Syndrome Responder Status
NCT00314249,measures_secondary,Time-Weighted Average Pain Scores
NCT00314249,has_criteria,Stable dose treatment phase
NCT01364649,involves,Major Depressive Disorder With Sexual Dysfunction
NCT01364649,evaluates,Vortioxetine
NCT01364649,measures_primary,Change From Baseline
NCT01364649,measures_secondary,CSFQ-14 Total Score
NCT01364649,has_criteria,Baseline CSFQ-14 total score
NCT01087970,involves,Squamous Cell Head and Neck Cancer
NCT01087970,measures_primary,Progression-Free Survival
NCT01087970,measures_secondary,Overall Survival
NCT01087970,measures_secondary,Percentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR)
NCT01087970,has_criteria,RECIST criteria version 1.0
NCT03682770,involves,Peanut Allergy
NCT03682770,evaluates,Dupilumab
NCT03682770,measures_primary,DBPCFC Pass Rate
NCT03682770,measures_secondary,Cumulative Tolerated Dose
NCT03682770,has_criteria,Post-randomization values
NCT02395042,involves,Interstitial Cystitis With Hunner's Lesions
NCT02395042,evaluates,LiRIS®
NCT02395042,measures_primary,Change From Baseline in Daily Average Bladder Pain
NCT02395042,measures_secondary,Change From Baseline in Number of Hunner's Lesions
NCT02395042,measures_secondary,Change From Baseline in Composite Score of Hunner's Lesions
NCT02395042,has_criteria,Diagnosis of interstitial cystitis with Hunner's lesions/ulcers
NCT02395042,has_criteria,Previous treatment with LiRIS®
NCT00357370,involves,Type 2 Diabetes
NCT00357370,evaluates,BMS-512148
NCT00357370,measures_primary,Adjusted Mean Change
NCT00357370,measures_secondary,Fasting Plasma Glucose
NCT00357370,measures_secondary,Therapeutic Glycemic Response
NCT00357370,has_criteria,insulin uptitration
NCT00644670,involves,Dyslipidemia
NCT00644670,involves,High cholesterol
NCT00644670,involves,Coronary heart disease
NCT00644670,evaluates,Atorvastatin
NCT00644670,measures_primary,LDL-C target
NCT00644670,measures_secondary,HDL-C
NCT00644670,measures_secondary,non-HDL-C
NCT00644670,measures_secondary,triglycerides
NCT00644670,measures_secondary,total cholesterol
NCT00644670,measures_secondary,apolipoprotein B
NCT00644670,measures_secondary,hemoglobin A1c
NCT00644670,has_criteria,Dyslipidemia
NCT00644670,has_criteria,High risk
NCT00644670,has_criteria,statin use
NCT00644670,has_criteria,Uncontrolled diabetes
NCT00644670,has_criteria,high blood pressure
NCT00644670,has_criteria,Impaired liver function
NCT02537470,involves,Type 2 Diabetes
NCT02537470,evaluates,Biphasic Remogliflozin Etabonate
NCT02537470,measures_primary,HbA1c at Week 12
NCT02537470,measures_secondary,Fasting plasma glucose
NCT02537470,measures_secondary,Insulin
NCT02537470,measures_secondary,C-peptide
NCT02537470,measures_secondary,Total Cholesterol
NCT02537470,measures_secondary,LDL-c
NCT02537470,measures_secondary,HDL-c
NCT02537470,measures_secondary,Serum Triglycerides
NCT02537470,measures_secondary,Body Weight
NCT02537470,measures_secondary,Waist Circumference
NCT02537470,measures_secondary,Adverse Events
NCT02537470,has_criteria,written informed consent
NCT02537470,has_criteria,clinical diagnosis type 2 diabetes
NCT02537470,has_criteria,HbA1c 7.0 - 10.5%
NCT02537470,has_criteria,history metabolic acidosis
NCT02537470,has_criteria,current active renal disease
NCT02537470,has_criteria,use investigational device or drug
NCT04867616,involves,Mild Cognitive Impairment
NCT04867616,involves,Alzheimer's Disease
NCT04867616,evaluates,Bepranemab
NCT04867616,measures_primary,CDR-SB total score
NCT04867616,measures_secondary,Incidence of TEAEs
NCT04867616,measures_secondary,Incidence of TESAEs
NCT04867616,has_criteria,From Baseline to Week 80
NCT05688696,involves,Systemic Lupus Erythematosus
NCT05688696,evaluates,Orelabrutinib
NCT05688696,measures_primary,SLE Responder Index
NCT05688696,measures_secondary,British Isles Lupus Assessment Group-based Composite Lupus Assessment
NCT05688696,measures_secondary,Time to 1st flare
NCT05688696,measures_secondary,Prednisone dose reduction
NCT05688696,measures_secondary,Complement C3
NCT05688696,measures_secondary,Complement C4
NCT05688696,measures_secondary,Anti-dsDNA antibody
NCT05688696,has_criteria,≥25% prednisone reduction
NCT05353816,involves,Heart Failure
NCT05353816,evaluates,Corheart 6 Left Ventricular Assist System
NCT05353816,measures_primary,Device implantation success
NCT05353816,measures_secondary,Functional status
NCT05353816,measures_secondary,Quality of Life
NCT05353816,has_criteria,3 months post-implantation
NCT03374475,involves,Major Depressive Disorder
NCT03374475,evaluates,JNJ-42847922
NCT03374475,measures_primary,Change From Baseline HDRS17
NCT03374475,measures_secondary,Change From Baseline HDRS17 Sleep Item-Adjusted Total Score
NCT03374475,measures_secondary,Change From Baseline HDRS17 Anxiety/Somatization Factor Score
NCT03374475,has_criteria,Baseline up to Day 57
NCT00409175,involves,Familial Amyloidosis
NCT00409175,evaluates,Fx-1006A
NCT00409175,measures_primary,NIS-LL score
NCT00409175,measures_secondary,QOL-DN TQOL Score
NCT00409175,has_criteria,Change From Baseline
NCT01135459,involves,Systemic Lupus Erythematosus
NCT01135459,evaluates,CEP-33457
NCT01135459,measures_primary,SRI response at Week 24
NCT01135459,measures_secondary,SLEDAI-2K score
NCT01135459,has_criteria,SLEDAI-2K score reduction
NCT00583375,involves,Foot and Ankle Fusion
NCT00583375,evaluates,Augment® Bone Graft
NCT00583375,measures_primary,Pain on Weight Bearing
NCT00583375,measures_secondary,Foot Function Index
NCT00583375,has_criteria,24 weeks
NCT01451775,evaluates,Empagliflozin
NCT01451775,measures_primary,Area Under the Curve
NCT01451775,measures_secondary,Maximum Measured Concentration
NCT01451775,has_criteria,Healthy male and female subjects
NCT01451775,has_criteria,Any relevant deviation from healthy conditions
NCT05181475,involves,Alzheimer's Disease
NCT05181475,evaluates,GV-971
NCT05181475,measures_primary,ADAS-cog/11 score
NCT05181475,measures_secondary,MMSE score
NCT05181475,measures_secondary,ADCS-ADL score
NCT05181475,has_criteria,Aged 50 to 85 years
NCT05181475,has_criteria,NIA-AA diagnostic criteria
NCT05181475,has_criteria,MMSE scores 11 to 26
NCT05181475,has_criteria,received GV-971 treatment
NCT00658775,involves,Erosive Gastroesophageal Reflux Disease
NCT00658775,evaluates,Rabeprazole Extended-Release
NCT00658775,evaluates,Esomeprazole
NCT00658775,measures_primary,Endoscopically-confirmed Healing
NCT00658775,measures_secondary,Diary-recorded Sustained Resolution of Heartburn
NCT00658775,has_criteria,Los Angeles classification
NCT00725075,involves,Schizophrenia
NCT00725075,evaluates,MK-8435
NCT00725075,measures_primary,Change From Baseline
NCT00725075,measures_secondary,Total Score PANSS
NCT00725075,measures_secondary,Calgary Depression Scale
NCT00725075,has_criteria,Baseline and Week 12
NCT01076959,involves,Rheumatoid Arthritis
NCT01076959,evaluates,Humira
NCT01076959,measures_primary,Patient Effectiveness
NCT01076959,measures_secondary,DAS 28
NCT01076959,has_criteria,EULAR response
NCT06052059,involves,Ulcerative Colitis
NCT06052059,evaluates,Tulisokibart
NCT06052059,measures_primary,Clinical Remission
NCT06052059,measures_secondary,Adverse Events
NCT06052059,has_criteria,Moderately to Severely Active
NCT02163759,involves,Ulcerative Colitis
NCT02163759,evaluates,Etrolizumab
NCT02163759,evaluates,Adalimumab
NCT02163759,evaluates,Placebo
NCT02163759,measures_primary,Remission at Week 10
NCT02163759,measures_secondary,Disease activity
NCT02163759,has_criteria,MCS ≤9/MCS ≥10
NCT01358175,involves,Ankylosing Spondylitis
NCT01358175,evaluates,Secukinumab
NCT01358175,measures_primary,ASAS 20 response
NCT01358175,measures_primary,ASAS 40 response
NCT01358175,measures_primary,ASAS 5/6 response
NCT01358175,measures_secondary,Change From Baseline in hsCRP
NCT01358175,measures_secondary,Change From Baseline in BASDAI
NCT02319759,involves,Psoriatic Arthritis
NCT02319759,evaluates,Guselkumab
NCT02319759,measures_primary,ACR 20 response
NCT02319759,measures_secondary,PASI-75 response
NCT02319759,has_criteria,Treatment Failure
NCT03696459,evaluates,JNJ-53718678
NCT03696459,measures_primary,Placebo-corrected change
NCT03696459,measures_secondary,Adverse Events
NCT03696459,has_criteria,Healthy Adult Participants
NCT00930059,involves,Alzheimer's Disease
NCT00930059,evaluates,PF-04447943
NCT00930059,measures_primary,Change From Baseline in ADAS-Cog 70
NCT00930059,measures_secondary,Change From Baseline in ADAS-Cog 70
NCT00930059,has_criteria,Mild To Moderate
NCT00950170,involves,Hemophilia A
NCT00950170,evaluates,ReFacto AF
NCT00950170,measures_primary,Annualized Bleeding Rate
NCT00950170,measures_secondary,Total Number of Infusions
NCT00950170,has_criteria,Previously Untreated
NCT01105975,involves,High LDL-C
NCT01105975,involves,Low HDL-C
NCT01105975,evaluates,LY2484595
NCT01105975,measures_primary,Percent Change HDL-C
NCT01105975,measures_primary,Percent Change LDL-C
NCT01105975,has_criteria,Baseline
NCT04292275,involves,Heart Failure
NCT04292275,evaluates,Remote Monitoring
NCT04292275,measures_primary,Time to change therapy
NCT04292275,measures_secondary,Health-ITUES-HCP Scores
NCT04292275,measures_secondary,Health-ITUES-Subject Scores
NCT04292275,measures_secondary,Subject Satisfaction
NCT04292275,measures_secondary,KCCQ-23 Scores
NCT04292275,has_criteria,Dose is optimal
NCT04428775,involves,ALS Disease
NCT04428775,evaluates,ALZT-OP1a
NCT04428775,measures_primary,ALS disease progression
NCT04428775,measures_secondary,pulmonary function
NCT04428775,measures_secondary,incidence adverse event
NCT04428775,has_criteria,treatment arm
NCT01768559,involves,Type 2 Diabetes
NCT01768559,evaluates,Lixisenatide
NCT01768559,evaluates,Insulin Glulisine
NCT01768559,measures_primary,Change in HbA1c
NCT01768559,measures_secondary,Change in Body Weight
NCT01768559,measures_secondary,Percentage of Participants With HbA1c Level <7% and ≤6.5% at Week 26
NCT01768559,measures_secondary,Percentage of Participants With no Weight Gain at Week 26
NCT01768559,measures_secondary,Change in Average 7-point SMPG Profiles
NCT02392559,involves,Genetic Low-Density Lipoprotein (LDL) Disorders
NCT02392559,evaluates,Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition
NCT02392559,measures_primary,Percent Change From Baseline to Week 24 in LDL-C
NCT02392559,measures_secondary,Percent Change From Baseline to Mean of Weeks 22 and 24 in LDL-C
NCT02392559,measures_secondary,Percent Change From Baseline to Week 24 in Non-HDL-C
NCT02392559,measures_secondary,Percent Change From Baseline to Week 24 in Apoliprotein-B (ApoB)
NCT02392559,measures_secondary,Percent Change From Baseline to Week 24 in Total Cholesterol/HDL-C Ratio
NCT02842359,involves,Type 2 Diabetes
NCT02842359,involves,Hyperlipidemia
NCT02842359,involves,Hypertension
NCT02842359,evaluates,Irbesartan/Atorvastatin
NCT02842359,measures_primary,flow mediated dilatation
NCT02842359,measures_secondary,nytrotyrosine marker
NCT02842359,measures_secondary,Intercellular Adhesion Molecule-1
NCT02842359,measures_secondary,Interleukin-6
NCT02842359,measures_secondary,C-reactive protein
NCT02842359,measures_secondary,blood pressure
NCT02842359,measures_secondary,low density lipoprotein-C
NCT02842359,measures_secondary,total cholesterol
NCT02842359,measures_secondary,high density lipoprotein-C
NCT02842359,measures_secondary,triglycerides
NCT02842359,measures_secondary,apolipoprotein-A1
NCT02842359,measures_secondary,apolipoprotein-B
NCT02842359,measures_secondary,immunosenescence T cell fractionation
NCT02842359,measures_secondary,T-cell
NCT02642159,involves,Type 2 Diabetes
NCT02642159,involves,Mixed Dyslipidemia
NCT02642159,evaluates,Alirocumab
NCT02642159,measures_primary,Percent Change Non-HDL-C
NCT02642159,measures_secondary,Percent Change LDL-C
NCT02642159,has_criteria,Maximally Tolerated Statin
NCT06263270,involves,Primary Osteoarthritis of the Knee
NCT06263270,evaluates,CYT-108
NCT06263270,measures_primary,WOMAC Scores
NCT06263270,measures_secondary,Time of Onset
NCT06263270,has_criteria,mild to moderate knee OA
NCT02632175,involves,Ulcerative Colitis
NCT02632175,evaluates,Adalimumab
NCT02632175,measures_primary,clinical remission
NCT02632175,measures_secondary,PUCAI response
NCT02632175,measures_secondary,clinical response
NCT02632175,measures_secondary,PUCAI remission
NCT02632175,measures_secondary,Full Mayo score
NCT02632175,has_criteria,available Full Mayo score data
NCT00992459,involves,Urea Cycle Disorders
NCT00992459,evaluates,HPN-100
NCT00992459,measures_primary,24-hour NH3 AUC
NCT00992459,measures_secondary,Ammonia Values
NCT00992459,has_criteria,Maximum Ammonia Values
NCT03210259,involves,Plaque Psoriasis
NCT03210259,evaluates,BI 695501
NCT03210259,measures_primary,PASI75 Response
NCT03210259,measures_secondary,AUCτ
NCT03210259,measures_secondary,Cmax
NCT03210259,measures_secondary,Cmin
NCT03210259,measures_secondary,Tmax
NCT02513459,involves,Crohn's Disease
NCT02513459,evaluates,Risankizumab
NCT02513459,measures_primary,CDAI Clinical Remission
NCT02513459,measures_secondary,CDAI Clinical Response
NCT02513459,has_criteria,CDAI score < 150
NCT06631170,involves,Atopic Dermatitis
NCT06631170,evaluates,Roflumilast Cream
NCT06631170,measures_primary,vIGA-AD success
NCT06631170,measures_secondary,WI-NRS reduction
NCT06631170,measures_secondary,EASI-75 reduction
NCT06631170,has_criteria,moderate AD severity
NCT06631170,has_criteria,WI-NRS ≥ 4 at baseline
NCT00904670,involves,Attention Deficit Hyperactivity Disorder
NCT00904670,evaluates,Quillivant Oral Suspension
NCT00904670,measures_primary,SKAMP-Combined Score
NCT00904670,measures_secondary,SKAMP Attention Subscale Score
NCT00904670,has_criteria,Hour 4 post-dose
NCT03764475,involves,Chronic Plaque Psoriasis
NCT03764475,evaluates,ARQ-151 Cream
NCT03764475,measures_primary,IGA score clear
NCT03764475,measures_secondary,Duration of Response
NCT03764475,has_criteria,Intertriginous area involvement
NCT02949375,involves,Chronic Liver Disease
NCT02949375,evaluates,GRI-0621
NCT02949375,measures_primary,Change in serum ALT
NCT02949375,measures_secondary,Change in serum AST
NCT02949375,measures_secondary,Serum CK-18 levels
NCT02949375,measures_secondary,NKT cell activity
NCT02949375,has_criteria,Elevated serum levels of ALT
NCT02065570,involves,Crohn's Disease
NCT02065570,evaluates,Two Drug Regimens
NCT02065570,measures_primary,Percentage of Participants
NCT02065570,measures_secondary,Endoscopic Response
NCT02065570,has_criteria,Treatment-Emergent Adverse Events
NCT01338870,involves,Type 2 Diabetes
NCT01338870,evaluates,PF-04991532
NCT01338870,measures_primary,Change From Baseline in HbA1c
NCT01338870,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT01338870,measures_secondary,Percentage of Participants Achieving Less Than (<) 6.5% or <7% Glycosylated Hemoglobin (HbA1c) Levels
NCT01338870,measures_secondary,Change From Baseline in Body Weight
NCT03908970,involves,Atopic Dermatitis Syndrome
NCT03908970,evaluates,OPA-15406 Ointment
NCT03908970,measures_primary,Responder Rate IGA
NCT03908970,measures_secondary,EASI Score
NCT03908970,has_criteria,Japanese Dermatological Association's criteria
NCT01931475,involves,Chronic Pain Due to Osteoarthritis
NCT01931475,evaluates,Duloxetine
NCT01931475,measures_primary,Change From Baseline
NCT01931475,measures_secondary,Patient Global Impressions of Improvement Score
NCT01931475,measures_secondary,Western Ontario and McMaster Universities Arthritis Index Total and Subscale Scores
NCT01931475,has_criteria,Baseline
NCT01156675,involves,Lumbar Spinal Stenosis
NCT01156675,evaluates,FLEXUS(TM) Interspinous Spacer
NCT01156675,measures_primary,Zurich Claudication Questionnaire
NCT01156675,measures_secondary,Neurological status
NCT01156675,has_criteria,Successful Neurologic Status
NCT04287075,involves,Chronic Neuropathic Pain
NCT04287075,evaluates,Surgical Treatment
NCT04287075,measures_primary,Change in VAS
NCT04287075,measures_secondary,PROMIS - Pain Related Measures
NCT04287075,has_criteria,1 year
NCT04287075,has_criteria,Serious Adverse Events
NCT04617275,involves,Type 2 Diabetes Mellitus
NCT04617275,involves,Obesity
NCT04617275,evaluates,PF-06882961
NCT04617275,measures_primary,Safety
NCT04617275,measures_primary,Tolerability
NCT04617275,measures_primary,Pharmacodynamics
NCT04617275,has_criteria,Supine SBP <90 mmHg
NCT04617275,has_criteria,Supine DBP <50 mmHg
NCT04617275,has_criteria,Supine pulse rate <40 or >120 bpm
NCT04617275,has_criteria,Change from baseline SBP >=30 mmHg
NCT04617275,has_criteria,Change from baseline DBP >=20 mmHg
NCT05953012,involves,Neovascular Age-related Macular Degeneration
NCT05953012,evaluates,PMC-403
NCT05953012,measures_primary,Maximum tolerated dose
NCT05953012,measures_secondary,Adverse events
NCT05953012,has_criteria,Baseline upto 4 weeks
NCT04905212,involves,IgA nephropathy
NCT04905212,evaluates,Telitacicept
NCT04905212,measures_primary,24-hour urine protein
NCT04905212,measures_secondary,eGFR
NCT04905212,measures_secondary,UPCR
NCT04905212,measures_secondary,UACR
NCT04905212,measures_secondary,immunological parameters
NCT04905212,has_criteria,pathological biopsy
NCT04905212,has_criteria,aged ≥ 18 years
NCT04905212,has_criteria,urine total protein
NCT04905212,has_criteria,GFR > 30 mL/min
NCT04905212,has_criteria,stabilized AEI/ARB
NCT02419612,involves,Type 2 Diabetes
NCT02419612,evaluates,Saxagliptin
NCT02419612,evaluates,Dapagliflozin
NCT02419612,evaluates,Glimepiride
NCT02419612,measures_primary,Change From Baseline in HbA1c
NCT02419612,measures_secondary,Change From Baseline in Total Body Weight
NCT02419612,measures_secondary,Percentage of Subjects Achieving a Therapeutic Glycemic Response
NCT02419612,measures_secondary,Change From Baseline in Systolic Blood Pressure
NCT02419612,measures_secondary,Percentage of Subjects With Treatment Intensification
NCT02419612,has_criteria,Inadequate Glycemic Control
NCT00827112,involves,HIV-Infected Patients
NCT00827112,evaluates,Maraviroc + Ritonavir Boosted Atazanavir
NCT00827112,measures_primary,HIV-1 RNA Levels
NCT00827112,measures_secondary,TLOVR
NCT00827112,has_criteria,Treatment Naive
NCT06250946,involves,Obesity
NCT06250946,evaluates,HRS-7535 Tablets
NCT06250946,measures_primary,Percent change in body weight
NCT06250946,measures_secondary,Weight loss ≥5%
NCT06250946,has_criteria,BMI 28.0-40.0 kg/m2
NCT06250946,has_criteria,Diet and exercise control
NCT06250946,has_criteria,<5% self-reported weight change
NCT06250946,has_criteria,Age 18-65 years
NCT05543369,involves,Healthy Participants
NCT05543369,evaluates,Elafibranor
NCT05543369,measures_primary,AUCτ at steady state
NCT05543369,measures_secondary,Cmax at steady state
NCT05543369,measures_secondary,Percentage of participants with clinically significant change in laboratory parameters
NCT05543369,has_criteria,Clinically significant changes in Laboratory Parameters
NCT04208412,involves,Hereditary Angioedema Type I or II
NCT04208412,evaluates,KVD900
NCT04208412,measures_primary,time to conventional treatment
NCT04208412,measures_secondary,Proportion of HAE Attacks
NCT04208412,has_criteria,Adult Subjects
NCT00360412,involves,Parkinson's Disease
NCT00360412,evaluates,E2007
NCT00360412,measures_primary,OFF time (hours)
NCT00360412,measures_secondary,ON time (hours)
NCT00360412,measures_secondary,UPDRS Part II
NCT00360412,measures_secondary,UPDRS Part III
NCT00360412,has_criteria,Levodopa treated
NCT01710046,involves,Psoriasis
NCT01710046,evaluates,CP-690
NCT01710046,measures_primary,PASI75 at Week 12
NCT01710046,measures_secondary,Physician's Global Assessment
NCT01710046,has_criteria,Moderate to Severe Chronic Plaque Psoriasis
NCT06456346,involves,Essential Thrombocythemia
NCT06456346,evaluates,Bomedemstat
NCT06456346,evaluates,Hydroxyurea
NCT06456346,measures_primary,Durable Clinicohematologic Response Rate
NCT06456346,measures_secondary,Change From Baseline in MFSAF v4.0 Individual Fatigue Symptom Item Score
NCT06456346,measures_secondary,Change From Baseline in PROMIS Fatigue SF-7a Total Fatigue Score
NCT06456346,measures_secondary,Change From Baseline in MFSAF v4.0 Total Symptom Score
NCT06456346,measures_secondary,Duration of Hematologic Remission
NCT06456346,has_criteria,platelet count to ≤400 × 10\^9/L
NCT06456346,has_criteria,absence of white blood cell (WBC) count elevation to \>10 × 10\^9/L
NCT00460746,involves,HIV
NCT00460746,evaluates,Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125
NCT00460746,measures_primary,Plasma HIV Viral Load
NCT00460746,measures_secondary,CD4+ Cell Count
NCT00460746,has_criteria,HIV-1 positive
NCT00460746,has_criteria,drug resistance
NCT00460746,has_criteria,antiretroviral failure
NCT00460746,has_criteria,PI containing regimen
NCT00317369,involves,Crohn's Disease
NCT00317369,evaluates,OPC-6535
NCT00317369,measures_primary,Clinical Improvement Rate
NCT00317369,measures_secondary,Remission Rate
NCT00317369,measures_secondary,Mean Change From Baseline in Total CDAI Score
NCT00317369,measures_secondary,Mean Change From the Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Score
NCT00317369,has_criteria,CDAI score improved
NCT03811912,involves,Alopecia Areata
NCT03811912,evaluates,CTP-543
NCT03811912,measures_primary,Relative Change SALT
NCT03811912,measures_secondary,Percentage SALT reduction
NCT03811912,measures_secondary,Absolute Change SALT
NCT03811912,measures_secondary,Satisfaction Hair Coverage
NCT03811912,has_criteria,Age 18 years
NCT02249312,involves,Bronchial Asthma
NCT02249312,evaluates,BIIL 284 BS
NCT02249312,measures_primary,FEV1 by spirometry
NCT02249312,measures_secondary,FVC by spirometry
NCT02249312,measures_secondary,FEF 25-70% by spirometry
NCT02249312,measures_secondary,FEF50% by spirometry
NCT02249312,measures_secondary,FEF 75% by spirometry
NCT02249312,measures_secondary,PEFR a.m. versus p.m.
NCT02249312,measures_secondary,Physician's global evaluation
NCT02249312,measures_secondary,Adverse Events
NCT02249312,has_criteria,Written informed consent
NCT02249312,has_criteria,Males and females aged 18-65 years
NCT02752412,involves,Type 2 Diabetes Mellitus
NCT02752412,evaluates,LixiLan
NCT02752412,evaluates,Insulin Glargine
NCT02752412,measures_primary,Change from baseline HbA1c
NCT02752412,measures_secondary,2-hour postprandial plasma glucose
NCT02752412,measures_secondary,blood glucose excursion
NCT02752412,measures_secondary,self-monitoring plasma glucose
NCT02752412,measures_secondary,body weight
NCT02752412,measures_secondary,Fasting Plasma Glucose
NCT02752412,measures_secondary,daily dose of insulin glargine
NCT02752412,measures_secondary,HbA1c <7%
NCT02752412,measures_secondary,hypoglycemia
NCT02752412,measures_secondary,anti-lixisenatide antibodies
NCT02752412,measures_secondary,anti-insulin antibodies
NCT02752412,has_criteria,Type 2 Diabetes Mellitus
NCT02752412,has_criteria,basal insulin regimen
NCT02752412,has_criteria,oral anti-diabetic drugs
NCT05607446,involves,Persistent Allergic Rhinitis
NCT05607446,evaluates,TQC3564 Tablets
NCT05607446,measures_primary,Total nasal symptom Score
NCT05607446,measures_secondary,Change in TNSS from baseline
NCT05607446,has_criteria,Age 18-65 years old
NCT02079246,involves,Alzheimer's Disease
NCT02079246,evaluates,Idalopirdine
NCT02079246,measures_primary,Change in Cognition
NCT02079246,measures_secondary,Clinical Global Impression Score
NCT02079246,measures_secondary,Change in Daily Functioning
NCT02079246,has_criteria,Baseline II
NCT05434546,involves,Tourette syndrome
NCT05434546,evaluates,Sepranolone
NCT05434546,measures_primary,total tic score
NCT05434546,measures_secondary,impairment score
NCT05434546,has_criteria,randomization day 1
NCT06338995,involves,Chronic Rhinosinusitis and Nasal Polyps
NCT06338995,evaluates,Lebrikizumab (LY3650150)
NCT06338995,measures_primary,Nasal Congestion Score
NCT06338995,measures_secondary,Endoscopic Nasal Polyp Score
NCT06338995,measures_secondary,Lund Mackay score
NCT06338995,measures_secondary,Forced Expiratory Volume in 1 Second
NCT06338995,measures_secondary,Severity of Loss of Smell
NCT06338995,has_criteria,Intranasal Corticosteroids
NCT01958281,involves,HCV Infection
NCT01958281,evaluates,Sofosbuvir Plus Ribavirin
NCT01958281,evaluates,Ledipasvir/Sofosbuvir
NCT01958281,measures_primary,SVR12
NCT01958281,measures_secondary,Treatment-Emergent Adverse Events
NCT01958281,measures_secondary,Treatment-Emergent Laboratory Abnormalities
NCT01958281,measures_secondary,Clinically Significant ECG Abnormalities
NCT01958281,measures_secondary,Treatment-Emergent Adverse Events Associated With Vital Sign Abnormalities
NCT01958281,has_criteria,Renal Insufficiency
NCT01148810,involves,Polymyositis
NCT01148810,involves,Dermatomyositis
NCT01148810,evaluates,BAF312
NCT01148810,measures_primary,Disease Activity Scores
NCT01148810,measures_secondary,Health-related Quality of Life
NCT01148810,measures_secondary,Steroids Use
NCT01148810,has_criteria,12 weeks
NCT01008410,involves,Ulcerative Proctitis
NCT01008410,involves,Proctosigmoiditis
NCT01008410,evaluates,Budesonide Foam
NCT01008410,measures_primary,Remission at Week 6
NCT01008410,measures_secondary,Rectal Bleeding MMDAI Subscale Score
NCT01008410,has_criteria,Active disease
NCT05039710,involves,Japanese Participants
NCT05039710,evaluates,JNJ-75220795
NCT05039710,measures_primary,Percent Change in Liver Fat Content
NCT05039710,measures_secondary,Number of Participants With Change From Baseline in Vital Signs Abnormalities
NCT05039710,measures_secondary,Number of Participants With Change From Baseline in Clinical Laboratory Abnormalities
NCT05039710,measures_secondary,Number of Participants With Change From Baseline in Physical Examination Abnormalities
NCT05039710,measures_secondary,Number of Participants With Change From Baseline in Electrocardiogram (ECG) Abnormalities
NCT05039710,has_criteria,Baseline
NCT05888610,involves,Alzheimer's disease
NCT05888610,involves,dementias
NCT05888610,evaluates,Digital Outpost
NCT05888610,measures_primary,Usability at 2 weeks
NCT05888610,measures_secondary,Clinical Assessments
NCT05888610,has_criteria,Caregiver of Duke patient
NCT05888610,has_criteria,Age > 18 years
NCT05888610,has_criteria,English speaker
NCT02234310,involves,Hemophilia B
NCT02234310,evaluates,rFIXFc
NCT02234310,measures_primary,Annualized Bleeding Rate
NCT02234310,measures_secondary,Annualized Spontaneous Joint Bleeding Episodes
NCT02234310,has_criteria,Previously Untreated Males
NCT06000410,involves,Osteoarthritis of the Knee
NCT06000410,evaluates,Amniotic Suspension Allograft
NCT06000410,measures_primary,WOMAC Pain scale
NCT06000410,measures_secondary,WOMAC Function
NCT06000410,measures_secondary,OMERACT-OARSI responder rate
NCT06000410,has_criteria,Males or females 18 years
NCT05301712,involves,Stroke
NCT05301712,evaluates,Naloxone HCI IV
NCT05301712,measures_primary,mRS score Day 90
NCT05301712,measures_secondary,Modified Barthel Index
NCT05301712,measures_secondary,EuroQol five dimensions questionnaire
NCT05301712,measures_secondary,Korean Mini-Mental State Examination
NCT05301712,measures_secondary,Global Deterioration Scale
NCT05301712,has_criteria,Day 90
NCT01926912,involves,Schizophrenia
NCT01926912,evaluates,Paliperidone Palmitate
NCT01926912,measures_primary,Change from baseline ESRS score
NCT01926912,measures_secondary,Change from baseline BPRS score
NCT01926912,measures_secondary,Clinical Global Impression - Severity (CGI-S) scale score
NCT01926912,measures_secondary,Clinical Global Impression - Change (CGI-C) scale score
NCT00277212,involves,Bipolar I Disorder
NCT00277212,evaluates,Aripiprazole
NCT00277212,evaluates,Lamotrigine
NCT00277212,measures_primary,Relapse Through Week 52
NCT00277212,measures_secondary,Discontinuation for Any Reason
NCT00277212,measures_secondary,Deaths
NCT00277212,measures_secondary,Serious Adverse Events
NCT00277212,measures_secondary,Adverse Events
NCT00277212,has_criteria,Any new untoward medical occurrence
NCT00420212,involves,Relapsing-Remitting Multiple Sclerosis
NCT00420212,evaluates,Oral BG00012
NCT00420212,measures_primary,Proportion of Relapses
NCT00420212,measures_secondary,T2 Hyperintense Lesions
NCT00420212,measures_secondary,Gadolinium-enhancing Lesions
NCT00420212,measures_secondary,Subjects With Gd-Enhancing Lesions
NCT00420212,measures_secondary,Annualized Relapse Rate
NCT00420212,has_criteria,protocol-defined relapse
NCT05952869,involves,Heterozygous Familial Hypercholesterolemia
NCT05952869,evaluates,Enlicitide Decanoate
NCT05952869,measures_primary,LDL-C percent change
NCT05952869,measures_secondary,non-HDL-C percent change
NCT05952869,measures_secondary,ApoB percent change
NCT05952869,measures_secondary,Lp(a) percent change
NCT05952869,has_criteria,Up to ~60 weeks
NCT05952869,has_criteria,Up to ~52 weeks
NCT00663169,involves,Acute Gout
NCT00663169,evaluates,Canakinumab
NCT00663169,measures_primary,Gout improvement
NCT00663169,measures_secondary,Time to recurrence
NCT00663169,measures_secondary,Time to walk independently
NCT00663169,measures_secondary,Discontinuation due to adverse events
NCT00663169,measures_secondary,Change in CRP
NCT00663169,measures_secondary,Change in SAA
NCT00663169,has_criteria,Hospitalized patients
NCT00734162,involves,Chronic Hepatitis B Infection
NCT00734162,evaluates,Tenofovir Disoproxil Fumarate
NCT00734162,measures_primary,decrease in spine BMD
NCT00734162,measures_secondary,HBV DNA < 400 Copies/mL
NCT00734162,has_criteria,baseline age
NCT00853762,involves,Multiple Sclerosis
NCT00853762,evaluates,Atacicept
NCT00853762,measures_primary,Change From Baseline
NCT00853762,measures_secondary,Pulse Rate
NCT00853762,measures_secondary,Temperature
NCT00853762,measures_secondary,Electrocardiogram
NCT00853762,has_criteria,Baseline
NCT00797862,involves,Hypertension
NCT00797862,evaluates,Aliskiren
NCT00797862,evaluates,Amlodipine
NCT00797862,measures_primary,msSBP at Week 24
NCT00797862,measures_secondary,msDBP at Week 32
NCT00797862,has_criteria,Baseline
NCT03627091,involves,Crohn's Disease
NCT03627091,evaluates,Ontamalimab
NCT03627091,measures_primary,Clinical Remission
NCT03627091,measures_secondary,Endoscopic Response
NCT03627091,has_criteria,Week 52
NCT02616380,involves,Rheumatoid Arthritis
NCT02616380,evaluates,Adalimumab
NCT02616380,measures_primary,HAQ-DI score
NCT02616380,measures_secondary,SF-36 Physical Component Summary
NCT02616380,measures_secondary,SF-36 Mental Component Summary
NCT02616380,measures_secondary,EQ-5D-3L Index
NCT02616380,has_criteria,Baseline and Week 24
NCT01139762,involves,Benign Prostatic Hyperplasia
NCT01139762,evaluates,Tadalafil
NCT01139762,evaluates,Finasteride
NCT01139762,measures_primary,Change in IPSS
NCT01139762,measures_secondary,IPSS storage subscore
NCT01139762,measures_secondary,IPSS voiding subscore
NCT01139762,has_criteria,Enlarged Prostates
NCT01139762,has_criteria,Urinary Symptoms
NCT05657691,involves,Major Depressive Disorder
NCT05657691,involves,Impaired Cognition
NCT05657691,evaluates,Xanamem
NCT05657691,measures_primary,Attention Composite
NCT05657691,measures_primary,Change from Baseline
NCT05657691,measures_secondary,Depressive Symptoms
NCT05657691,has_criteria,Age 18-75
NCT05657691,has_criteria,MDD diagnosis
NCT05657691,has_criteria,HAM-D ≥ 17
NCT05657691,has_criteria,Cognitive abilities
NCT05657691,has_criteria,Stable antidepressant dose
NCT05657691,has_criteria,Nicotine abstinence
NCT03459391,evaluates,XC221
NCT03459391,measures_primary,AUC0-inf
NCT03459391,measures_primary,Cmax
NCT03459391,has_criteria,Healthy Volunteers
NCT03341962,involves,Ulcerative Colitis
NCT03341962,evaluates,IMU-838
NCT03341962,measures_primary,Symptomatic Remission
NCT03341962,measures_primary,Endoscopic Healing
NCT03341962,measures_secondary,Time to Achieving Symptomatic Remission
NCT03341962,measures_secondary,Proportion of Patients With Clinical Response
NCT03341962,measures_secondary,Proportion of Patients With Endoscopic Healing
NCT03341962,measures_secondary,Proportion of Patients With Symptomatic Response
NCT03341962,has_criteria,30 mg/day
NCT03341962,has_criteria,45 mg/day
NCT06497491,involves,Adult-onset Still's Disease
NCT06497491,evaluates,GNR-086
NCT06497491,evaluates,Ilaris
NCT06497491,measures_primary,DAS28-ESR/CRP score
NCT06497491,measures_secondary,ACR30/50/70/90/100 response
NCT06497491,has_criteria,fever associated with the underlying disease
NCT03655691,involves,Crow's Feet wrinkles
NCT03655691,evaluates,ET-01
NCT03655691,measures_primary,IGA-C Score
NCT03655691,measures_secondary,SSA-C Score
NCT03655691,has_criteria,25-65 years of age
NCT03655691,has_criteria,minimal to moderate Crow's Feet wrinkles
NCT03655691,has_criteria,moderate to severe Crow's Feet wrinkles
NCT03655691,has_criteria,willingness to refrain
NCT03655691,has_criteria,female subjects not pregnant
NCT03655691,has_criteria,not lactating
NCT01519791,involves,Rheumatoid Arthritis
NCT01519791,evaluates,Certolizumab Pegol
NCT01519791,measures_primary,Sustained Remission
NCT01519791,measures_primary,Sustained Low Disease Activity
NCT01519791,measures_secondary,Change From Baseline in mTSS
NCT01519791,measures_secondary,Percentage of Subjects With Radiographic Non-progression
NCT01519791,measures_secondary,Change From Baseline in the Joint Erosion Score
NCT01519791,has_criteria,DMARD-naïve Adults
NCT04391894,involves,Dry Eye Disease
NCT04391894,evaluates,ECF843
NCT04391894,evaluates,Vehicle
NCT04391894,measures_primary,SANDE score
NCT04391894,measures_secondary,Corneal Fluorescein Staining Score
NCT04391894,measures_secondary,Central Corneal Fluorescein Staining
NCT00937794,involves,Hunter Syndrome
NCT00937794,evaluates,Elaprase
NCT00937794,measures_primary,General Conceptual Ability
NCT00937794,measures_secondary,Adaptive Behavior
NCT00937794,has_criteria,Male
NCT03572062,involves,Respiratory Syncytial Virus
NCT03572062,evaluates,Adjuvanted RSV Vaccine
NCT03572062,measures_primary,Local Reactions Within 14 Days
NCT03572062,measures_secondary,Systemic Events Within 14 Days
NCT03572062,measures_secondary,Adverse Events Within 1 Month
NCT03572062,has_criteria,Healthy Older Adults
NCT04217291,involves,Type 2 Diabetes Mellitus
NCT04217291,evaluates,SY-004
NCT04217291,measures_primary,Glycosylated Hemoglobin A1c
NCT04217291,measures_secondary,fasting blood glucose
NCT04217291,measures_secondary,postprandial blood glucose auc0-2h
NCT04217291,measures_secondary,abdominal weight
NCT04217291,has_criteria,age ≥ 18 years old
NCT04217291,has_criteria,age ≥ 75 years old
NCT04217291,has_criteria,type 2 diabetes
NCT04383691,involves,bipolar I disorder
NCT04383691,evaluates,Lurasidone
NCT04383691,evaluates,Placebo
NCT04383691,measures_primary,MADRS total score
NCT04383691,measures_primary,CGI-BP-S (depression) score
NCT04383691,has_criteria,written voluntary consent
NCT04383691,has_criteria,aged 18 through 65 years
NCT04383691,has_criteria,bipolar I disorder
NCT04383691,has_criteria,depressed episode
NCT04383691,has_criteria,no rapid cycling
NCT04383691,has_criteria,no psychotic features
NCT02117791,involves,Chronic Thromboembolic Pulmonary Hypertension
NCT02117791,evaluates,Riociguat
NCT02117791,measures_primary,6MWD after 4 months
NCT02117791,measures_primary,Pulmonary Vascular Resistance after 4 months
NCT02117791,measures_primary,TRPG after 4 months
NCT02117791,measures_primary,BNP/NT-pro BNP after 4 months
NCT02117791,measures_primary,WHO functional class after 4 months
NCT02117791,measures_secondary,Time to Clinical Worsening
NCT02117791,has_criteria,Treated with Riociguat for CTEPH
NCT02117791,has_criteria,Not contraindicated based on product label
NCT05021991,involves,Essential Tremor
NCT05021991,evaluates,PRAX-944
NCT05021991,measures_primary,Change from baseline
NCT05021991,measures_secondary,CGI-S score
NCT05021991,measures_secondary,CGI-I score
NCT05021991,measures_secondary,TETRAS-ADL score
NCT05021991,has_criteria,56 days
NCT01026194,involves,Type 2 Diabetes
NCT01026194,evaluates,MP-513
NCT01026194,measures_primary,Change From Baseline in HbA1c
NCT01026194,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT01026194,measures_secondary,Change From Baseline in AUC0-2h for Postprandial Plasma Glucose
NCT01026194,measures_secondary,Change From Baseline in 2-hour Postprandial Plasma Glucose
NCT01026194,has_criteria,20 - 75 years old
NCT01026194,has_criteria,Dietary management
NCT01026194,has_criteria,Therapeutic exercise for diabetes
NCT01026194,has_criteria,HbA1c 6.5% - 10.0%
NCT01026194,has_criteria,Thiazolidinedione for diabetes
NCT02886494,involves,Alzheimer's Disease
NCT02886494,involves,Vascular Dementia
NCT02886494,evaluates,BAC
NCT02886494,measures_primary,ADAS-cog Score
NCT02886494,measures_secondary,CIBIC-plus Score
NCT02886494,has_criteria,Screening
NCT05914194,involves,Narcolepsy Type 1
NCT05914194,evaluates,NLS-2
NCT05914194,measures_primary,Cataplexy episodes
NCT05914194,measures_secondary,PROMIS-SRI
NCT05914194,measures_secondary,PROMIS-SD
NCT05914194,measures_secondary,Epworth Sleepiness Scale
NCT05914194,has_criteria,8 weeks
NCT01354691,involves,Alzheimer's Disease
NCT01354691,evaluates,Ladostigil
NCT01354691,measures_primary,ADAS-Cog
NCT01354691,measures_secondary,Neuropsychiatric Inventory
NCT01354691,measures_secondary,Cornell Scale for Depression in Dementia
NCT01240694,involves,Systemic Lupus Erythematosus
NCT01240694,evaluates,CEP-33457
NCT01240694,measures_primary,Clinical Response SRI
NCT01240694,measures_secondary,SLEDAI-2K score
NCT01240694,has_criteria,Baseline up to Week 72
NCT01268891,involves,Parkinson's Disease
NCT01268891,evaluates,Azilect
NCT01268891,measures_primary,OFF Time
NCT01268891,measures_secondary,CGI-I Score
NCT01268891,measures_secondary,UPDRS-ADL Score
NCT01268891,measures_secondary,UPDRS Motor Score
NCT01268891,has_criteria,Levodopa-treated
NCT03172494,involves,Type 2 Diabetes
NCT03172494,evaluates,Insulin Degludec/Liraglutide
NCT03172494,evaluates,Insulin Degludec
NCT03172494,evaluates,Liraglutide
NCT03172494,measures_primary,Change in HbA1c
NCT03172494,measures_secondary,Change in Body Weight
NCT03172494,measures_secondary,Number of Hypoglycaemic Episodes
NCT03172494,has_criteria,Oral Antidiabetic Drugs
NCT04329676,involves,Parkinson's Disease
NCT04329676,evaluates,directSTIM Deep Brain Stimulation System
NCT04329676,measures_primary,UPDRS III score
NCT04329676,measures_secondary,Therapeutic Window
NCT04329676,has_criteria,6 months post-implant
NCT03819660,involves,Spinal Muscular Atrophy 3
NCT03819660,evaluates,Amifampridine Phosphate
NCT03819660,measures_primary,Quality of life
NCT03819660,measures_secondary,Number of subjects with TEAE
NCT03819660,has_criteria,SMA-001 study
NCT03819660,has_criteria,written informed consent
NCT03819660,has_criteria,negative pregnancy test
NCT03819660,has_criteria,contraceptive regimen
NCT03819660,has_criteria,overall health
NCT03813160,involves,Dermatomyositis
NCT03813160,evaluates,Lenabasum
NCT03813160,measures_primary,Total Improvement Score
NCT03813160,measures_secondary,CDASI activity score
NCT03813160,measures_secondary,Forced vital capacity
NCT03813160,has_criteria,Definition of Improvement
NCT03664960,involves,Eosinophilic Gastritis
NCT03664960,involves,Eosinophilic Duodenitis
NCT03664960,evaluates,AK002
NCT03664960,measures_primary,Percent Change TSS
NCT03664960,measures_secondary,Number of Eosinophils
NCT03664960,has_criteria,Completed Study AK002-003
NCT03664960,has_criteria,Written informed consent
NCT03664960,has_criteria,Pre-existing dietary restrictions
NCT03664960,has_criteria,Able to comply with procedures
NCT03349060,involves,Atopic Dermatitis
NCT03349060,evaluates,PF-04965842
NCT03349060,measures_primary,IGA response at Week 12
NCT03349060,measures_secondary,EASI response at Week 12
NCT03349060,has_criteria,Aged 12 years and older
NCT00311376,involves,Neurogenic Overactive Bladder
NCT00311376,evaluates,Botulinum Toxin Type A
NCT00311376,measures_primary,Change in incontinence episodes
NCT00311376,measures_secondary,Maximum Cystometric Capacity
NCT00311376,measures_secondary,Maximum Detrusor Pressure
NCT00311376,measures_secondary,Incontinence Quality of Life
NCT00311376,has_criteria,spinal cord injury
NCT00311376,has_criteria,multiple sclerosis
NCT00311376,has_criteria,inadequate response to anticholinergic medication
NCT00960076,involves,Type 2 Diabetes
NCT00960076,evaluates,Saxagliptin
NCT00960076,measures_primary,Change in HbA1c
NCT00960076,measures_secondary,Change in 2-hour PPG
NCT00960076,measures_secondary,Change in FPG
NCT00960076,measures_secondary,Percent of Subjects Reaching Goal
NCT00960076,has_criteria,Type 2 diabetics
NCT00960076,has_criteria,A1c 7.5-11%
NCT00960076,has_criteria,BMI less than or equal to 45 kg/m2
NCT00960076,has_criteria,Significant cardiovascular history
NCT00960076,has_criteria,Active liver disease
NCT00960076,has_criteria,renal impairment
NCT02526160,involves,X-linked Hypophosphatemia
NCT02526160,evaluates,KRN23
NCT02526160,measures_primary,Serum Phosphorus Levels
NCT02526160,measures_secondary,Brief Pain Inventory
NCT02526160,measures_secondary,WOMAC Stiffness Score
NCT02526160,has_criteria,Baseline through Week 24
NCT03287960,involves,Leptin Receptor (LEPR) Deficiency Obesity
NCT03287960,evaluates,setmelanotide
NCT03287960,measures_primary,Weight Loss Threshold
NCT03287960,measures_secondary,Hunger Score
NCT03287960,measures_secondary,Waist Circumference
NCT03287960,has_criteria,≥12 years of age
NCT03008460,involves,Bowel Cleansing
NCT03008460,evaluates,Eziclen®/Izinova®
NCT03008460,evaluates,Klean-prep®
NCT03008460,measures_primary,Cleansing Score
NCT03008460,measures_secondary,Boston Bowel Preparation Scale
NCT03008460,has_criteria,colonoscopy visit
NCT04270760,involves,Atherosclerotic cardiovascular disease
NCT04270760,evaluates,Olpasiran
NCT04270760,measures_primary,Percentage Change From Baseline
NCT04270760,measures_secondary,Low Density Lipoprotein Cholesterol
NCT04270760,measures_secondary,Apolipoprotein B
NCT04270760,has_criteria,Age 18 to 80 years
NCT04270760,has_criteria,Lipoprotein(a) > 150 nmol/L
NCT03487276,involves,Hidradenitis Suppurativa
NCT03487276,evaluates,IFX-1
NCT03487276,measures_primary,HiSCR at Week 16
NCT03487276,measures_secondary,Flares
NCT03487276,has_criteria,≥ 25% increase in AN count
NCT06333860,involves,Moderate Plaque Psoriasis
NCT06333860,evaluates,Risankizumab
NCT06333860,evaluates,Deucravacitinib
NCT06333860,measures_primary,PASI 90
NCT06333860,measures_primary,sPGA 0 or 1
NCT06333860,measures_secondary,PASI 90 ITT_B_NR
NCT06333860,has_criteria,Systemic Treatment
NCT03796676,involves,Atopic Dermatitis
NCT03796676,evaluates,JAK1 Inhibitor
NCT03796676,measures_primary,IGA Response 'Clear' or 'Almost Clear
NCT03796676,measures_secondary,EASI Response ≥ 75% Improvement
NCT03796676,measures_secondary,Peak Pruritis Numeric Rating Scale (PP-NRS)
NCT03796676,measures_secondary,Change From Baseline in PSAAD
NCT03796676,has_criteria,Baseline to Week 12
NCT01266876,involves,Heterozygous Familial Hypercholesterolemia
NCT01266876,evaluates,REGN727/SAR236553
NCT01266876,measures_primary,Percent Change LDL-C
NCT01266876,measures_secondary,Total Cholesterol
NCT01266876,measures_secondary,High Density Lipoprotein Cholesterol
NCT02825160,involves,Pulmonary Arterial Hypertension
NCT02825160,evaluates,Ventavis
NCT02825160,measures_primary,Pulmonary Vascular Resistance
NCT02825160,measures_secondary,6-Minute Walking Distance
NCT02825160,measures_secondary,tricuspid regurgitation pressure gradient
NCT02825160,measures_secondary,brain natriuretic peptide / N-terminal pro-brain natriuretic peptide
NCT02825160,measures_secondary,WHO functional class
NCT02825160,measures_secondary,Time to Clinical Worsening
NCT02825160,has_criteria,Patients diagnosed with PAH
NCT02825160,has_criteria,Patients for whom the decision to initiate treatment with Ventavis was made as per investigator's routine treatment practice
NCT00219076,involves,Hypertensive Non Responders
NCT00219076,evaluates,Aliskiren and Amlodipine
NCT00219076,measures_primary,Change in blood pressure
NCT00219076,measures_secondary,Change in blood pressure
NCT00219076,has_criteria,essential hypertension
NCT00219076,has_criteria,Severe hypertension
NCT00219076,has_criteria,secondary hypertension
NCT00219076,has_criteria,Hypertensive encephalopathy
NCT00219076,has_criteria,cerebrovascular accident
NCT01487460,involves,Dyslipidemia
NCT01487460,evaluates,TAP311
NCT01487460,measures_primary,Adverse events
NCT01487460,measures_secondary,Vital signs
NCT01487460,measures_secondary,ECG
NCT01487460,measures_secondary,Clinical labs
NCT01487460,has_criteria,Healthy subjects
NCT01487460,has_criteria,Dyslipidemic patients
NCT01316276,involves,Cystic Fibrosis
NCT01316276,evaluates,Liposomal Amikacin
NCT01316276,measures_primary,Pulmonary Function Test
NCT01316276,measures_secondary,Respiratory Rate
NCT01316276,measures_secondary,Heart Rate
NCT01316276,measures_secondary,Systolic BP
NCT01316276,measures_secondary,Diastolic BP
NCT01316276,measures_secondary,Body Temperature
NCT01316276,measures_secondary,Oxygen Saturation
NCT01316276,has_criteria,Chronic Pseudomonas Aeruginosa
NCT05092776,involves,Familial Mediterranean Fever
NCT05092776,evaluates,RPH-104
NCT05092776,measures_primary,complete response
NCT05092776,measures_secondary,Time to recurrent attack
NCT05092776,has_criteria,colchicine inefficacy
NCT02521376,involves,Adults With Normal and Impaired Liver Function
NCT02521376,evaluates,Entospletinib
NCT02521376,measures_primary,AUCtau of ENTO
NCT02521376,measures_secondary,Cmax of ENTO
NCT02521376,measures_secondary,Percentage of Participants Experiencing TEAEs
NCT02521376,measures_secondary,Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
NCT02521376,has_criteria,Any adverse events with onset date of on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug or Any AEs leading to premature discontinuation of study drug
NCT02521376,has_criteria,values that increase at least one toxicity grade from baseline
NCT05367960,involves,Fragile X Syndrome
NCT05367960,evaluates,BPN14770
NCT05367960,measures_primary,Treatment Emergent Adverse Events
NCT05367960,measures_secondary,NIH- Toolbox Cognitive Battery
NCT05367960,has_criteria,24 months
NCT03915860,involves,Acne Vulgaris
NCT03915860,evaluates,Trifarotene 50 μg/g Cream
NCT03915860,measures_primary,DLQI Total Score
NCT03915860,measures_primary,C-DLQI Score
NCT03915860,measures_primary,CompAQ Total Score
NCT03915860,has_criteria,aged >16 years
NCT03915860,has_criteria,aged <=16 years
NCT00800176,involves,Diabetes Mellitus
NCT00800176,evaluates,RO4998452
NCT00800176,measures_primary,Absolute Change in HbA1c
NCT00800176,measures_secondary,Fasting Plasma Glucose
NCT00800176,measures_secondary,Mean Daily Glucose Concentration
NCT00800176,measures_secondary,Fructosamine Concentration
NCT00800176,measures_secondary,Meal Tolerance Test: 0-3h Mean Glucose Concentration
NCT00800176,measures_secondary,Meal Tolerance Test: 0-3h Mean Insulin Concentration
NCT00800176,measures_secondary,Meal Tolerance Test: 0-3h Urinary Glucose Excretion
NCT00800176,measures_secondary,Body Weight
NCT00800176,measures_secondary,Percentage of Participants Treated to Target HbA1c
NCT00800176,measures_secondary,Percentage of Participants Treated to Target HbA1c
NCT00800176,measures_secondary,Percentage of Participants With at Least One Adverse Event
NCT00800176,has_criteria,adult patients
NCT00800176,has_criteria,type 2 diabetes
NCT00800176,has_criteria,treated with diet
NCT00800176,has_criteria,treated with diet and exercise alone
NCT00800176,has_criteria,type 1 diabetes mellitus
NCT00800176,has_criteria,treated with an oral or injectable anti-diabetic agent
NCT00800176,has_criteria,treated with any PPARgamma agonist
NCT00800176,has_criteria,uncontrolled hypertension
NCT00800176,has_criteria,significant pre-diagnosed diabetic complications
NCT01302860,involves,Cryopyrin-associated Periodic Syndromes
NCT01302860,involves,Familial Cold Autoinflammatory Syndrome
NCT01302860,involves,Muckle-Wells Syndrome
NCT01302860,involves,Neonatal Onset Multisystem Inflammatory Disease
NCT01302860,evaluates,ACZ885
NCT01302860,measures_primary,Complete Response at Week 56
NCT01302860,measures_secondary,Physician global assessment
NCT01302860,measures_secondary,Skin disease
NCT01302860,has_criteria,Aged 4 Years or Younger
NCT01302860,has_criteria,Aged 2 Years or Younger
NCT02145676,involves,Upper Limb Spasticity
NCT02145676,evaluates,OnabotulinumtoxinA
NCT02145676,measures_primary,Change From Baseline
NCT02145676,measures_secondary,Pain
NCT02145676,has_criteria,baseline pain score >0
NCT02565576,involves,Myasthenia Gravis
NCT02565576,evaluates,CFZ533
NCT02565576,measures_primary,QMG score at week 25
NCT02565576,measures_secondary,MGC score
NCT02565576,has_criteria,moderate to severe
NCT01924182,involves,Pain
NCT01924182,involves,Opioid-related Side Effects
NCT01924182,evaluates,Intrathecal Morphine
NCT01924182,evaluates,Conventional Medical Management
NCT01924182,measures_primary,Pain intensity
NCT01924182,measures_secondary,Toxicity score
NCT01924182,has_criteria,Baseline to Month 3
NCT00740831,involves,Uterine Myomas
NCT00740831,evaluates,PGL4001
NCT00740831,evaluates,GnRH-agonist
NCT00740831,measures_primary,PBAC Score < 75
NCT00740831,measures_primary,Serum Estradiol Levels
NCT00740831,measures_secondary,Hot Flushes
NCT00740831,has_criteria,Week 13 Visit
NCT05032482,involves,Alzheimer's disease dementia
NCT05032482,evaluates,WeArable Neuromodulation DeVice
NCT05032482,measures_primary,Change from baseline ADAS-Cog-14
NCT05032482,measures_secondary,Change from baseline ADCS-iADL
NCT05032482,measures_secondary,Change from baseline ADCS-CGIC
NCT05032482,has_criteria,Adult participants aged 65-85 years
NCT05032482,has_criteria,diagnosed with probable Alzheimer's disease dementia
NCT05032482,has_criteria,willing and able to comply
NCT05032482,has_criteria,have a study partner
NCT00316082,involves,Type 2 Diabetes
NCT00316082,evaluates,BMS-477118
NCT00316082,measures_primary,Change From Baseline in A1C
NCT00316082,measures_secondary,Change From Baseline in FPG
NCT00316082,measures_secondary,Percentage of Participants Achieving A1C < 7%
NCT00316082,measures_secondary,Changes From Baseline in PPG AUC
NCT00316082,has_criteria,Inadequate blood sugar control
NCT00316082,has_criteria,Type 2 diabetes
NCT00316082,has_criteria,Previous treatment for diabetes
NCT00316082,has_criteria,Current treatment with other medications to lower blood sugar
NCT00316082,has_criteria,Major heart
NCT00316082,has_criteria,Women who are pregnant or breastfeeding
NCT01583582,involves,hypertension
NCT01583582,evaluates,Peptides Derived From Coldwater Shrimp
NCT01583582,measures_primary,change in systolic blood pressure
NCT01583582,measures_secondary,change in diastolic blood pressure
NCT01583582,has_criteria,systolic blood pressure 130 - 160 mmHg
NCT01583582,has_criteria,diastolic blood pressure ≤ 100 mmHg
NCT01583582,has_criteria,age 30 - 75 years
NCT01583582,has_criteria,body weight ≥ 60 kg
NCT05344482,involves,plaque psoriasis
NCT05344482,evaluates,secukinumab
NCT05344482,measures_primary,PASI ≤3 at week 52
NCT05344482,measures_secondary,PASI75
NCT05344482,measures_secondary,PASI90
NCT05344482,measures_secondary,PASI100
NCT05344482,has_criteria,moderate to severe
NCT01290731,evaluates,TMC435
NCT01290731,involves,Hepatitis C
NCT01290731,measures_primary,SVR12
NCT01290731,measures_secondary,SVR24
NCT01290731,measures_secondary,HCV RNA drop
NCT01290731,has_criteria,Genotype 1
NCT06650631,involves,Osteoarthritis
NCT06650631,evaluates,Heat Treatment
NCT06650631,measures_primary,Pain intensity change
NCT06650631,measures_secondary,Functional levels
NCT06650631,has_criteria,Patient-reported outcome
NCT06648031,involves,Overweight
NCT06648031,involves,Obese
NCT06648031,involves,Pre-diabetes
NCT06648031,involves,Type 2 Diabetes
NCT06648031,evaluates,DehydraTECH-CBD
NCT06648031,evaluates,DehydraTECH-GLP1 Agonists
NCT06648031,measures_primary,HbA1c decrease
NCT06648031,measures_primary,bodyweight decrease
NCT06648031,measures_secondary,laboratory parameters
NCT06648031,measures_secondary,fasting glucose
NCT06648031,measures_secondary,insulin cholesterol
NCT06648031,measures_secondary,inflammation
NCT06648031,measures_secondary,glomerular filtration rate
NCT06648031,measures_secondary,liver enzymes
NCT06648031,has_criteria,treatment-emergent adverse events
NCT06648031,has_criteria,Serious adverse events
NCT03802682,evaluates,Apalutamide
NCT03802682,measures_primary,Maximum Plasma Concentration
NCT03802682,measures_secondary,Area Under the Plasma Concentration-time Curve
NCT03802682,has_criteria,Body mass index (BMI)
NCT03802682,has_criteria,Blood pressure
NCT03802682,has_criteria,Nonsmoker
NCT04529473,involves,Insulin Sensitivity
NCT04529473,involves,Glycaemic Control
NCT04529473,evaluates,Eubacterium Hallii
NCT04529473,measures_primary,2-hour blood glucose AUC
NCT04529473,measures_primary,2-hour insulin AUC
NCT04529473,measures_primary,Post-prandial insulin sensitivity
NCT04529473,measures_primary,Glycated haemoglobin
NCT04529473,measures_secondary,Glycaemic Variability
NCT04529473,measures_secondary,Glycaemic Control
NCT04529473,measures_secondary,GV during sleeping hours
NCT04529473,measures_secondary,Fasting Blood Glucose
NCT04529473,measures_secondary,Blood Pressure
NCT04529473,has_criteria,treatment groups
NCT04529473,has_criteria,placebo
NCT03290131,involves,Multiple Sclerosis
NCT03290131,evaluates,Arbaclofen Extended-Release Tablets
NCT03290131,measures_primary,Change From Baseline
NCT03290131,measures_secondary,Clinical Global Impression of Change
NCT03290131,has_criteria,18 to 65 years of age
NCT00772031,involves,Chronic Migraine
NCT00772031,evaluates,propranolol
NCT00772031,evaluates,placebo
NCT00772031,measures_primary,Headache Days
NCT00772031,measures_secondary,Depression Inventory
NCT00772031,measures_secondary,Migraine Disability Assessment
NCT00772031,measures_secondary,Migraine Specific Quality of Life
NCT00772031,has_criteria,28 day diary period
NCT01254331,involves,Rheumatoid Arthritis
NCT01254331,evaluates,Tocilizumab
NCT01254331,measures_primary,DAS28 less than 3.2
NCT01254331,measures_secondary,DAS28 less than 2.6
NCT01254331,measures_secondary,ACR 20
NCT01254331,has_criteria,Local Environment
NCT03557931,involves,Schizophrenia
NCT03557931,evaluates,ASP4345
NCT03557931,measures_primary,MCCB Neurocognitive Composite Score
NCT03557931,measures_secondary,Adverse Event
NCT03557931,has_criteria,Stable Doses Antipsychotic Medication
NCT01839331,involves,Osteoarthritis of the Knee
NCT01839331,evaluates,Intra-Articular Ampion Injection
NCT01839331,measures_primary,Change in Knee Pain
NCT01839331,measures_secondary,Change in Knee Function
NCT01839331,measures_secondary,Change in Knee Stiffness
NCT01839331,measures_secondary,Change in Patient's Global Assessment
NCT01839331,has_criteria,Able to provide written informed consent
NCT01839331,has_criteria,Willing and able to comply
NCT01839331,has_criteria,40 years to 85 years old
NCT01839331,has_criteria,Ambulatory
NCT01839331,has_criteria,Symptomatic for greater than 6 months
NCT01839331,has_criteria,Clinical diagnosis of osteoarthritis
NCT01839331,has_criteria,Radiological evidence Kellgren Lawrence Grade II to IV
NCT01737931,involves,Application Site Reaction
NCT01737931,evaluates,SPM962
NCT01737931,measures_primary,Skin Irritation Score
NCT01737931,measures_secondary,Itching of Application Site
NCT01737931,has_criteria,Body-mass index 18-28 kg/m2
NCT00765882,involves,Chronic Constipation
NCT00765882,evaluates,Linaclotide
NCT00765882,measures_primary,CSBM overall responders
NCT00765882,measures_secondary,Stool Consistency
NCT00765882,measures_secondary,Severity of Straining
NCT00765882,measures_secondary,Abdominal Discomfort
NCT00765882,measures_secondary,Bloating
NCT00765882,has_criteria,Change from Baseline to Week 12
NCT01677182,involves,Bipolar 1 Disorder
NCT01677182,evaluates,Ramelteon
NCT01677182,measures_primary,Change From Baseline in MADRS Total Score
NCT01677182,measures_secondary,Change From Baseline in YMRS Total Score
NCT01677182,measures_secondary,CGI-I Score
NCT01677182,measures_secondary,Change From Baseline in CGI-S
NCT01677182,has_criteria,Baseline and Week 6
NCT03359473,involves,Chronic Obstructive Pulmonary Disease
NCT03359473,evaluates,GSK2881078
NCT03359473,measures_primary,Change From Baseline
NCT03359473,measures_secondary,Heart Rate
NCT03359473,measures_secondary,PR Interval
NCT03359473,measures_secondary,QRS Duration
NCT03359473,measures_secondary,QT Interval
NCT03359473,measures_secondary,QTcF
NCT03359473,measures_secondary,QTcB
NCT03359473,has_criteria,randomized participants
NCT00577473,involves,Ulcerative colitis
NCT00577473,evaluates,Asacol
NCT00577473,measures_primary,Treatment Success
NCT00577473,measures_secondary,Physician's Global Assessment
NCT00577473,has_criteria,ITT Population
NCT04448431,involves,Depression
NCT04448431,evaluates,Vortioxetine
NCT04448431,evaluates,Desvenlafaxine
NCT04448431,measures_primary,MADRS total score
NCT04448431,measures_secondary,Remission
NCT04448431,measures_secondary,Response
NCT04448431,measures_secondary,Change in MADRS anhedonia factor score
NCT04448431,measures_secondary,Change in DSST total score
NCT04448431,has_criteria,Baseline to Week 8
NCT02551731,involves,Infantile Spasms
NCT02551731,evaluates,Cannabidiol Oral Solution
NCT02551731,measures_primary,Complete Responders at Day 14
NCT02551731,measures_secondary,Absence of Infantile Spasms
NCT02551731,measures_secondary,Absence of Hypsarrhythmia
NCT02551731,measures_secondary,Reduction in Seizure-burden
NCT02551731,measures_secondary,Parent Impression of Efficacy
NCT02551731,measures_secondary,Percentage of Participants With a Partial Response
NCT02551731,measures_secondary,Percentage of Complete Responders With Relapse
NCT02551731,has_criteria,Complete response
NCT02579473,involves,Parkinson's Disease
NCT02579473,evaluates,SER-214
NCT02579473,measures_primary,Fluctuation Index
NCT02579473,measures_secondary,Safety
NCT02579473,has_criteria,initial sc dose
NCT01519882,involves,Parkinson's Disease
NCT01519882,measures_primary,Sleep Efficiency Index
NCT01519882,measures_secondary,Parkinson's Disease Sleep Scale Score Version 2
NCT03495973,involves,Crohn's Disease
NCT03495973,evaluates,Ustekinumab
NCT03495973,measures_primary,Clinical Response
NCT03495973,measures_secondary,Clinical Remission
NCT03495973,has_criteria,Harvey Bradshaw Index
NCT01502631,involves,Acute Spinal Cord Injury
NCT01502631,evaluates,SUN13837 Injection
NCT01502631,measures_primary,SCIM III Score
NCT01502631,measures_secondary,Total Motor Score
NCT01502631,has_criteria,Adult Subjects
NCT01568073,involves,Idiopathic Parkinson's Disease
NCT01568073,evaluates,BIA 9-1067
NCT01568073,measures_primary,OFF-time change
NCT01568073,measures_secondary,UPDRS SCORE
NCT01568073,measures_secondary,Parkinson's Disease Sleep Scale
NCT01568073,measures_secondary,Non-motor Symptoms Scale
NCT01568073,has_criteria,end-of-dose motor fluctuations
NCT04422431,involves,Wilson Disease
NCT04422431,evaluates,ALXN1840
NCT04422431,measures_primary,Liver Cu Concentration
NCT04422431,measures_secondary,NASH CRN Fibrosis Stage
NCT04422431,measures_secondary,Metavir Fibrosis Score
NCT04422431,measures_secondary,Ishak Fibrosis Score
NCT04422431,has_criteria,Baseline values
NCT04740931,involves,Macular Edema
NCT04740931,evaluates,Faricimab
NCT04740931,measures_primary,Change From Baseline in BCVA
NCT04740931,measures_secondary,Best Corrected Visual Acuity
NCT04740931,has_criteria,baseline BCVA (≤34
NCT06256731,involves,Multiple sclerosis
NCT06256731,involves,MS disease severity
NCT06256731,evaluates,ETNA-MS device
NCT06256731,measures_primary,EDSS score
NCT06256731,measures_secondary,test-retest reliability
NCT06256731,measures_secondary,Symbol Digit Modalities Test
NCT06256731,measures_secondary,Brief International Cognitive Assessment for MS
NCT06256731,has_criteria,certified neurologist
NCT02031276,involves,Crohn's Disease
NCT02031276,evaluates,Risankizumab
NCT02031276,measures_primary,CDAI Clinical Remission
NCT02031276,measures_secondary,CDAI Clinical Response
NCT02031276,has_criteria,Week 12
NCT00266227,involves,Rheumatoid Arthritis
NCT00266227,evaluates,Rituximab
NCT00266227,measures_primary,ACR20 response
NCT00266227,measures_secondary,Tender joint count
NCT00266227,measures_secondary,Swollen joint count
NCT00266227,measures_secondary,Physician's Global Assessment
NCT00266227,measures_secondary,Patient's Global Assessment
NCT00266227,measures_secondary,Patient's Assessment of Pain
NCT00266227,measures_secondary,Health Assessment Questionnaire
NCT00266227,measures_secondary,erythrocyte sedimentation rate
NCT00266227,has_criteria,American College of Rheumatology
NCT00700427,involves,Attention-Deficit/Hyperactivity Disorder
NCT00700427,evaluates,Medication
NCT00700427,measures_primary,Response Maintenance
NCT00700427,measures_secondary,Number of Days Until Relapse
NCT00700427,has_criteria,Response criteria
NCT01422876,involves,Type 2 Diabetes
NCT01422876,evaluates,Empagliflozin / Linagliptin
NCT01422876,measures_primary,Change From Baseline in HbA1c
NCT01422876,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT01422876,measures_secondary,Change From Baseline in Body Weight
NCT01422876,has_criteria,Treatment naive or Metformin treated
NCT01681576,involves,essential hypertension
NCT01681576,evaluates,LCZ696
NCT01681576,evaluates,valsartan
NCT01681576,measures_primary,Sodium Excretion
NCT01681576,measures_secondary,Urine Volume
NCT01681576,has_criteria,Males and females
NCT01681576,has_criteria,non-childbearing potential
NCT01681576,has_criteria,Asian patients
NCT01681576,has_criteria,untreated or antihypertensive therapy
NCT01681576,has_criteria,up to two drugs
NCT00568776,involves,Alzheimer's Disease
NCT00568776,evaluates,ELND005
NCT00568776,measures_primary,Neuropsychological Test Battery Z-score
NCT00568776,measures_secondary,Alzheimer's Disease Cooperative Study - Activities of Daily Living Score
NCT00568776,has_criteria,Mild to Moderate
NCT00744627,involves,Generalized Anxiety Disorder
NCT00744627,evaluates,Vortioxetine
NCT00744627,measures_primary,Change From Baseline
NCT00744627,measures_secondary,Hospital Anxiety and Depression
NCT00744627,has_criteria,Baseline to Week 8
NCT00363727,involves,Parkinson's disease
NCT00363727,evaluates,REQUIP CR
NCT00363727,measures_primary,Change from Baseline
NCT00363727,measures_secondary,UPDRS motor score
NCT00363727,has_criteria,time to dyskinesia
NCT04418427,involves,Diabetic Macular Edema
NCT04418427,evaluates,ADVM-022 Intravitreal Gene Therapy
NCT04418427,measures_primary,Time to worsening DME
NCT04418427,measures_secondary,Incidence ocular adverse events
NCT04418427,measures_secondary,Change from Baseline in CST
NCT04418427,measures_secondary,Change from Baseline in BCVA
NCT04418427,measures_secondary,Frequency of rescue aflibercept
NCT04418427,measures_secondary,Incidence improvement DRSS score
NCT04418427,measures_secondary,Incidence worsening DRSS score
NCT04418427,measures_secondary,Occurrence vision threatening complication
NCT04418427,measures_secondary,Incidence CST <300 μm
NCT04418427,measures_secondary,Incidence clinically significant findings
NCT04418427,has_criteria,96 weeks
NCT00424476,involves,Systemic Lupus Erythematosus
NCT00424476,evaluates,Belimumab
NCT00424476,measures_primary,SRI Response Rate
NCT00424476,measures_secondary,SELENA SLEDAI score
NCT00424476,measures_secondary,PGA
NCT00424476,measures_secondary,SF-36 PCS
NCT00424476,has_criteria,≥ 4 point reduction
NCT00424476,has_criteria,no worsening PGA
NCT00424476,has_criteria,no new BILAG A
NCT00424476,has_criteria,no new BILAG B
NCT03782376,involves,Crohn's Disease
NCT03782376,evaluates,Ustekinumab
NCT03782376,measures_primary,Clinical Response
NCT03782376,measures_secondary,Clinical Remission
NCT03782376,has_criteria,CD-related surgery
NCT01215227,involves,Hypertension
NCT01215227,evaluates,[MISSING]
NCT01215227,measures_primary,Systolic Blood Pressure
NCT01215227,measures_primary,Diastolic Blood Pressure
NCT01215227,measures_secondary,Alanine Aminotransferase
NCT01215227,measures_secondary,Aspartate Aminotransferase
NCT01215227,measures_secondary,Suicidality
NCT01215227,has_criteria,[MISSING]
NCT04501627,involves,Gastroesophageal Reflux Disease
NCT04501627,evaluates,Vonoprazan
NCT04501627,measures_primary,Endoscopic Healing of RE
NCT04501627,measures_secondary,Percentage of Participants Reporting AEs
NCT04501627,has_criteria,Baseline up to Week 4
NCT04980027,involves,Type 2 Diabetes Mellitus
NCT04980027,evaluates,Insulin Glargine 300 U/ml
NCT04980027,measures_primary,Change in HbA1c
NCT04980027,measures_secondary,Percentage of participants with hypoglycemia
NCT04980027,has_criteria,Insulin-naïve patients
NCT00151827,involves,Hypertension
NCT00151827,involves,Renal Impairment
NCT00151827,evaluates,Olmesartan Medoxomil
NCT00151827,measures_primary,Diastolic blood pressure
NCT00151827,measures_secondary,Systolic blood pressure
NCT00151827,measures_secondary,Creatinine clearance
NCT00151827,measures_secondary,Proteinuria
NCT00151827,measures_secondary,Serum creatinine
NCT00151827,has_criteria,Mean sitting BP 140-180/90-109 mmHg
NCT00151827,has_criteria,Renal impairment mild to moderate
NCT00151827,has_criteria,No malignant hypertension
NCT00151827,has_criteria,No severe heart failure
NCT00151827,has_criteria,No severe renal disease
NCT02965573,involves,Myasthenia Gravis
NCT02965573,evaluates,ARGX-113
NCT02965573,measures_primary,Vital Signs
NCT02965573,measures_secondary,Vital Signs
NCT02965573,has_criteria,Generalized Muscle Weakness
NCT01860976,involves,Psoriatic Arthritis
NCT01860976,evaluates,Subcutaneous Abatacept
NCT01860976,measures_primary,ACR 20 Responders
NCT01860976,measures_secondary,HAQ Responders
NCT01860976,has_criteria,TNFi-naïve
NCT00358527,involves,Seasonal Allergic Rhinitis
NCT00358527,evaluates,Mometasone Furoate
NCT00358527,measures_primary,Nasal Symptoms Severity
NCT00358527,measures_secondary,Sleep Problems Index II
NCT00358527,has_criteria,Age >= 18 years
NCT05296473,involves,ADHD
NCT05296473,evaluates,Guided ADHD Therapy
NCT05296473,measures_primary,TOVA Attention Comparison Score
NCT05296473,measures_secondary,ADHD-RS-5 Inattention Subscale
NCT05296473,measures_secondary,Token Search
NCT05296473,measures_secondary,Spatial Span
NCT05296473,has_criteria,Study Day 0 to Study Day 63
NCT05620576,involves,Diabetic Peripheral Neuropathic Pain
NCT05620576,evaluates,LY3857210
NCT05620576,measures_primary,Change From Baseline
NCT05620576,measures_secondary,Pain Interference
NCT05620576,has_criteria,Baseline
NCT02994927,involves,ANCA-associated vasculitis
NCT02994927,evaluates,CCX168
NCT02994927,evaluates,Avacopan
NCT02994927,measures_primary,Disease Remission
NCT02994927,measures_secondary,Glucocorticoid Toxicity
NCT02994927,has_criteria,BVAS of 0
NCT02994927,has_criteria,glucocorticoids
NCT02994927,has_criteria,disease relapse
NCT00909727,involves,Cystic Fibrosis
NCT00909727,evaluates,Ivacaftor
NCT00909727,measures_primary,FEV1 Percent Predicted
NCT00909727,measures_secondary,CFQ-R Respiratory Domain Score
NCT00909727,measures_secondary,Sweat Chloride Concentration
NCT00909727,measures_secondary,Weight
NCT00909727,has_criteria,Weighing at least 15 kg
NCT00909727,has_criteria,G551D mutation
NCT00909727,has_criteria,Forced expiratory volume in 1 second (FEV1)
NCT02983227,involves,Rheumatoid Arthritis
NCT02983227,evaluates,GDC-0853
NCT02983227,measures_primary,ACR50 Response
NCT02983227,measures_secondary,Adverse Events
NCT02983227,has_criteria,8 weeks after last dose
NCT02958527,involves,Depression
NCT02958527,evaluates,Effexor
NCT02958527,measures_primary,Change from baseline
NCT02958527,measures_secondary,MADRS Total Scores
NCT02958527,has_criteria,Adverse Drug Reactions
NCT01562327,involves,Rheumatoid Arthritis
NCT01562327,evaluates,Tocilizumab
NCT01562327,measures_primary,Tender Joint Count
NCT01562327,measures_primary,Swollen Joint Count
NCT01562327,has_criteria,experienced at least one condition
NCT01562327,has_criteria,stopped DMARDs
NCT01562327,has_criteria,stopped Biologic Agents
NCT02174627,involves,Chronic Kidney Disease
NCT02174627,evaluates,Roxadustat
NCT02174627,measures_primary,Mean Change in Hb
NCT02174627,measures_secondary,Hb Response
NCT02174627,has_criteria,Baseline Hb ≥ 8.0 g/dL
NCT05801627,involves,Type 2 diabetes
NCT05801627,evaluates,SAL067
NCT05801627,measures_primary,HbA1c change
NCT05801627,measures_secondary,FPG change
NCT05801627,has_criteria,BMI 19kg/m2 to 35kg/m2
NCT05801627,has_criteria,metformin≥ 1500mg/day
NCT05801627,has_criteria,HbA1c 7.5% to 10.5%
NCT05801627,has_criteria,HbA1c 7.0% to 10.0%
NCT05801627,has_criteria,fasting blood glucose \<=13.9mmol/L
NCT01613027,involves,Rheumatoid Arthritis
NCT01613027,evaluates,MabThera
NCT01613027,measures_primary,DAS28-ESR at Month 6
NCT01613027,measures_primary,DAS28-ESR at Month 12
NCT01613027,measures_secondary,EULAR Response at Month 6
NCT01613027,measures_secondary,EULAR Response at Month 12
NCT01613027,measures_secondary,Swollen Joint Count at Month 6
NCT01613027,measures_secondary,Swollen Joint Count at Month 12
NCT01613027,has_criteria,Baseline
NCT05013060,involves,Irritable Bowel Syndrome
NCT05013060,evaluates,Sodium Butyrate
NCT05013060,evaluates,Probiotics
NCT05013060,measures_primary,IBS symptom severity
NCT05013060,measures_secondary,Global Improvement Scale
NCT05013060,measures_secondary,IBS-Adequate Relief
NCT05013060,measures_secondary,Quality of Life
NCT05013060,has_criteria,7 days symptom change
NCT00873860,involves,Asthma
NCT00873860,evaluates,CAT-354
NCT00873860,measures_primary,Change From Baseline in Mean ACQ Score
NCT00873860,measures_secondary,Forced Expiratory Volume in 1 Second (FEV1)
NCT00873860,has_criteria,Study Day 1
NCT02633527,involves,Attention-Deficit/Hyperactivity Disorder
NCT02633527,evaluates,SPN-812
NCT02633527,measures_primary,ADHD-RS-IV Total score
NCT02633527,measures_secondary,CGI-I Scale score
NCT02633527,measures_secondary,CGI-S Scale score
NCT02633527,has_criteria,Baseline to Week 8
NCT01754727,involves,Ankylosing Spondylitis
NCT01754727,evaluates,Adalimumab
NCT01754727,measures_primary,BASDAI 50 at Month 12
NCT01754727,measures_secondary,ASDAS Score From Baseline
NCT01754727,has_criteria,self-reported questionnaire
NCT02317627,involves,Psoriasis Vulgaris
NCT02317627,evaluates,KD025
NCT02317627,measures_primary,PASI 75
NCT02317627,measures_secondary,PASI 50
NCT02317627,has_criteria,first-line therapy
NCT05501327,involves,scar
NCT05501327,evaluates,SLI-F06
NCT05501327,measures_primary,Scarless Labs Observer Scale
NCT05501327,measures_secondary,Patient and Observer Scar Assessment Scale
NCT05501327,measures_secondary,Scarless Labs Patient Scale
NCT05501327,has_criteria,Healthy subjects
NCT05501327,has_criteria,Body Mass Index
NCT05501327,has_criteria,symmetrically located scapular lines
NCT05501327,has_criteria,follow study instructions
NCT03624127,involves,Psoriasis
NCT03624127,evaluates,BMS-986165
NCT03624127,measures_primary,sPGA 0/1
NCT03624127,measures_secondary,PASI 75
NCT03624127,has_criteria,randomization visit
NCT00996476,involves,Hepatitis-C
NCT00996476,evaluates,TMC435
NCT00996476,measures_primary,HCV RNA levels
NCT00996476,measures_secondary,Undetectable HCV RNA
NCT00996476,measures_secondary,Decrease HCV RNA
NCT01447576,involves,Major Depressive Disorder
NCT01447576,evaluates,OPC-34712
NCT01447576,measures_primary,Change From Baseline in CGI-S
NCT01447576,measures_secondary,Mean Clinical Global Impression - Improvement (CGI-I) Scale Score
NCT01447576,has_criteria,Informed Consent Form
NCT00490776,involves,Cutaneous T-Cell Lymphoma
NCT00490776,evaluates,Oral LBH589
NCT00490776,measures_primary,Overall Response Rate
NCT00490776,measures_secondary,Physician's Global Assessment
NCT00490776,has_criteria,Refractory/Resistant
NCT06553027,involves,Parkinson's Disease
NCT06553027,evaluates,CVN424
NCT06553027,measures_primary,OFF time on motor diaries
NCT06553027,measures_secondary,ON time without troublesome dyskinesia
NCT06553027,measures_secondary,MDS-UPDRS Part II
NCT06553027,measures_secondary,CGI-S
NCT01809327,involves,Type 2 Diabetes Mellitus
NCT01809327,evaluates,Canagliflozin
NCT01809327,measures_primary,Change in HbA1c
NCT01809327,measures_secondary,Percent Change in Body Weight
NCT01809327,measures_secondary,Percentage of Participants With HbA1c Less Than 7 Percent
NCT01809327,measures_secondary,Change in Systolic Blood Pressure
NCT01809327,measures_secondary,Percent Change in HDL-C
NCT01809327,measures_secondary,Percent Change in Triglycerides
NCT01809327,measures_secondary,Number of Participants With Treatment Emergent Adverse Events
NCT01809327,has_criteria,Inadequate Glycemic Control
NCT00170976,involves,Hypertension
NCT00170976,evaluates,Valsartan
NCT00170976,evaluates,Amlodipine
NCT00170976,measures_primary,Diastolic blood pressure
NCT00170976,measures_primary,Systolic blood pressure
NCT00170976,measures_secondary,Standing blood pressure
NCT00170976,measures_secondary,Pulse
NCT00170976,has_criteria,Successful completion VAA489A2307
NCT00170976,has_criteria,Visit 7 blood pressure
NCT00170976,has_criteria,Adverse events drug related
NCT00377676,involves,Type 2 diabetes
NCT00377676,evaluates,Cycloset
NCT00377676,measures_primary,Change in HbA1c
NCT00377676,measures_secondary,cardiovascular SAE
NCT00377676,has_criteria,age 30-80 years
NCT00377676,has_criteria,body mass index \< 43 kg/m2
NCT00377676,has_criteria,HbA1c ≤ 10%
NCT00377676,has_criteria,stable diabetes
NCT00117676,involves,Chronic Hepatitis B
NCT00117676,evaluates,Tenofovir Disoproxil Fumarate
NCT00117676,evaluates,Adefovir Dipivoxil
NCT00117676,measures_primary,HBV DNA < 400 copies/mL
NCT00117676,measures_primary,Histological Improvement
NCT00117676,measures_secondary,HBV DNA < 400 copies/mL
NCT00117676,measures_secondary,Histological Response
NCT00117676,has_criteria,HBeAg-Negative
NCT00868127,involves,Hypercholesterolemia
NCT00868127,evaluates,Lapaquistat Acetate
NCT00868127,measures_primary,Percent change LDL-C
NCT00868127,measures_secondary,Percent change Non-HDL-C
NCT00868127,measures_secondary,Percent change Total Cholesterol
NCT00868127,measures_secondary,Percent change Triglycerides
NCT00868127,measures_secondary,Percent change HDL-C
NCT00868127,measures_secondary,Derived ratios
NCT00868127,has_criteria,Completed prior study
NCT00868127,has_criteria,Contraception
NCT00868127,has_criteria,Laboratory evaluations
NCT00868127,has_criteria,Low cholesterol diet
NCT00868127,has_criteria,Continue lipid-altering medication
NCT01254227,involves,Cardiac Iron Overload
NCT01254227,evaluates,Deferasirox
NCT01254227,measures_primary,Change in Cardiac Iron Content
NCT01254227,measures_secondary,Left Ventricular Ejection Fraction
NCT01254227,measures_secondary,Right Ventricular Ejection Fraction
NCT01254227,has_criteria,baseline T2\* value
NCT06087627,involves,Chronic Nodular Prurigo
NCT06087627,evaluates,Dupilumab
NCT06087627,measures_primary,IGA-CPG-S score
NCT06087627,measures_secondary,WI-NRS improvement
NCT06087627,has_criteria,atopic comorbidities
NCT04761627,involves,Plaque Psoriasis
NCT04761627,evaluates,ABP 654
NCT04761627,measures_primary,PASI Percent Improvement
NCT04761627,measures_secondary,AUCtau
NCT04761627,has_criteria,Moderate to Severe
NCT03457727,evaluates,Danirixin
NCT03457727,measures_primary,AUC [0-inf]
NCT03457727,measures_secondary,Number of Participants
NCT03457727,measures_secondary,Adverse Event
NCT03457727,measures_secondary,Serious Adverse Events
NCT03457727,measures_secondary,Vital Signs
NCT03457727,measures_secondary,Electrocardiogram
NCT03457727,has_criteria,Up to 29 days
NCT00679627,involves,Alzheimer's Disease
NCT00679627,evaluates,Galantamine
NCT00679627,measures_primary,Change From Baseline in MMSE Score
NCT00679627,measures_secondary,Number of Deaths Reported
NCT00679627,has_criteria,Up to 2 years
NCT00328627,involves,Type 2 Diabetes Mellitus
NCT00328627,evaluates,Alogliptin
NCT00328627,evaluates,Pioglitazone
NCT00328627,measures_primary,Change From Baseline to Week 26 in HbA1c
NCT00328627,measures_secondary,Change From Baseline to Week 4 in HbA1c
NCT00328627,measures_secondary,Change From Baseline to Week 8 in HbA1c
NCT00328627,measures_secondary,Change From Baseline to Week 12 in HbA1c
NCT00328627,measures_secondary,Change From Baseline to Week 16 in HbA1c
NCT00328627,measures_secondary,Change From Baseline to Week 20 in HbA1c
NCT00328627,has_criteria,baseline metformin dose
NCT00328627,has_criteria,baseline HbA1c
NCT02347176,involves,Atopic Dermatitis
NCT02347176,evaluates,Tralokinumab
NCT02347176,measures_primary,EASI Total Score
NCT02347176,measures_secondary,IGA Response
NCT02347176,has_criteria,prohibited medications
NCT05349227,involves,Cancer survivorship
NCT05349227,evaluates,digital health coaching intervention
NCT05349227,measures_primary,Retention rate
NCT05349227,measures_secondary,Self-Efficacy
NCT05349227,measures_secondary,Physical Function
NCT05349227,measures_secondary,Quality of Life
NCT05349227,has_criteria,6 months engagement
NCT02123927,evaluates,TAK-438
NCT02123927,measures_primary,AUC(0-48)
NCT02123927,measures_secondary,Body Weight
NCT02123927,has_criteria,Healthy Male Participants
NCT05583227,involves,Eosinophilic Esophagitis
NCT05583227,evaluates,Tezepelumab
NCT05583227,measures_primary,Histologic response
NCT05583227,measures_primary,EoE EREFS
NCT05583227,measures_primary,EoE-HSS grade
NCT05583227,measures_primary,EoE-HSS stage
NCT05583227,measures_secondary,DSQ score
NCT05583227,has_criteria,esophageal biopsies
NCT00253227,involves,Alzheimer's Disease
NCT00253227,evaluates,Galantamine
NCT00253227,measures_primary,ADAS-cog/11 score
NCT00253227,measures_primary,CIBIC-plus score
NCT00253227,measures_secondary,ADAS-cog/13 score
NCT00253227,measures_secondary,DAD score
NCT00253227,measures_secondary,NPI score
NCT00253227,measures_secondary,Adverse events
NCT00253227,measures_secondary,Pittsburgh Sleep Scale score
NCT00253227,has_criteria,NINCDS-ADRDA criteria
NCT00253227,has_criteria,MMSE score 11-24
NCT00253227,has_criteria,ADAS-cog score ≥12
NCT00253227,has_criteria,6 months cognitive decline
NCT00253227,has_criteria,Consistent informant
NCT01484327,involves,Heart Failure
NCT01484327,evaluates,Carvedilol
NCT01484327,measures_primary,LVEF (%)
NCT01484327,measures_secondary,Adverse Events
NCT01484327,has_criteria,Cardedilol dosage
NCT05212727,involves,Multiple sclerosis
NCT05212727,evaluates,eye-tracking software
NCT05212727,measures_primary,MSFC score
NCT05212727,measures_secondary,SDMT score
NCT05212727,measures_secondary,BICAMS score
NCT05212727,measures_secondary,MoCA score
NCT05212727,has_criteria,Baseline
NCT03053427,involves,Restless Legs Syndrome
NCT03053427,evaluates,Gabapentin Enacarbil
NCT03053427,measures_primary,Change From Baseline in IRLS Score
NCT03053427,measures_secondary,Percentage of Participants With an Investigator-rated Clinical Global Impression (ICGI) Response
NCT03053427,measures_secondary,Percentage of Participants With a Patient-rated Clinical Global Impression (PCGI) Response
NCT03053427,measures_secondary,Change From Baseline in Pittsburgh Sleep Quality Index Total Score (PSQI)
NCT03053427,measures_secondary,Change From Baseline in Athens Insomnia Scale
NCT03053427,has_criteria,age category
NCT03053427,has_criteria,estimated creatinine clearance category
NCT03924427,involves,Psoriasis
NCT03924427,evaluates,BMS-986165
NCT03924427,measures_primary,sPGA 0/1 Response
NCT03924427,measures_secondary,PASI 75 Response
NCT03924427,has_criteria,Stable plaque psoriasis
NCT03924427,has_criteria,Moderate to severe disease
NCT03924427,has_criteria,Candidate for phototherapy or systemic therapy
NCT05729373,involves,Generalized Anxiety Disorder
NCT05729373,evaluates,SEP-363856
NCT05729373,measures_primary,Change from Baseline
NCT05729373,measures_secondary,Clinical Global Impression-Severity
NCT05729373,has_criteria,DSM-5 criteria
NCT05729373,has_criteria,18 to 65 years of age
NCT05729373,has_criteria,willing to comply
NCT02090673,involves,Type 2 diabetes mellitus
NCT02090673,evaluates,Exenatide
NCT02090673,measures_primary,Hemoglobin A1c
NCT02090673,measures_secondary,Body weight
NCT02090673,measures_secondary,Fasting plasma glucose
NCT02090673,measures_secondary,subjective measures
NCT02090673,has_criteria,at least 18 years of age
NCT02090673,has_criteria,initiate Exenatide treatment
NCT02090673,has_criteria,comply with recommendations
NCT02090673,has_criteria,not participating in other studies
NCT02090673,has_criteria,not pregnant or planning pregnancy
NCT02090673,has_criteria,no contraindications
NCT01415531,involves,essential hypertension
NCT01415531,evaluates,Nebivolol
NCT01415531,measures_primary,Change in DBP
NCT01415531,measures_secondary,Change in SBP
NCT01415531,has_criteria,age 18-54 years
NCT02986373,involves,Psoriatic Arthritis
NCT02986373,evaluates,Risankizumab
NCT02986373,measures_primary,mTSS change
NCT02986373,measures_secondary,erosion scores
NCT02986373,measures_secondary,joint space narrowing
NCT02986373,has_criteria,Week 24 visit
NCT01083173,involves,HIV-1
NCT01083173,evaluates,Kaletra
NCT01083173,measures_primary,Viral Load Below 400 Copies/mL
NCT01083173,measures_primary,Viral Load Below 50 Copies/mL
NCT01083173,measures_secondary,Change From Baseline in CD4 Cell Counts
NCT01083173,has_criteria,initiation of Kaletra treatment
NCT00300573,involves,HIV
NCT00300573,evaluates,Dexelvucitabine
NCT00300573,evaluates,Lamivudine
NCT00300573,measures_primary,viral load decrease
NCT00300573,measures_secondary,viral load suppression
NCT00300573,measures_secondary,CD4+ cell count
NCT00300573,has_criteria,NRTI resistance
NCT00300573,has_criteria,PI resistance
NCT00300573,has_criteria,NNRTI resistance
NCT06177431,involves,Motor Neurone Disease
NCT06177431,evaluates,Monepantel
NCT06177431,measures_primary,Serum NfL chain levels
NCT06177431,measures_secondary,Urinary p75 levels
NCT06177431,measures_secondary,ALS Functional Rating Scale
NCT06177431,measures_secondary,Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen
NCT06177431,has_criteria,Baseline to End of Treatment
NCT02280473,involves,Dry Eye Disease
NCT02280473,evaluates,Refresh Optive® Gel Drops
NCT02280473,measures_primary,OSDI Score change
NCT02280473,measures_secondary,Tear Break-up Time
NCT02280473,measures_secondary,Corneal and Conjunctival Staining
NCT01291173,involves,Binge Eating Disorder
NCT01291173,evaluates,SPD489
NCT01291173,measures_primary,Change From Baseline
NCT01291173,measures_secondary,Binge Episodes Per Week
NCT01291173,has_criteria,Baseline and week 11
NCT05357573,involves,TIO
NCT05357573,evaluates,KRN23
NCT05357573,measures_primary,Change from Baseline in mean serum phosphorus level
NCT05357573,measures_secondary,Proportion of patients achieving serum phosphorus level above the lower limit of normal
NCT05357573,has_criteria,Adult Chinese Patients
NCT01225731,involves,Chronic Plaque Psoriasis
NCT01225731,evaluates,Tildrakizumab
NCT01225731,measures_primary,PASI 75 Response
NCT01225731,measures_secondary,Adverse Events
NCT01225731,has_criteria,Up to 72 weeks
NCT05635331,involves,Heart Failure with reduced Ejection Fraction
NCT05635331,evaluates,dapagliflozin
NCT05635331,measures_primary,KCCQ score change
NCT05635331,measures_secondary,Time to discontinuation
NCT05635331,measures_secondary,Number of discontinuation reasons
NCT05635331,measures_secondary,Number of treatment changes
NCT05635331,measures_secondary,Time to other HF medication discontinuation
NCT05635331,measures_secondary,Number of other HF treatment dosage changes
NCT05635331,measures_secondary,Number of other HF treatment initiation
NCT05635331,has_criteria,newly prescribed dapagliflozin
NCT06311331,involves,Talus Replacement
NCT06311331,evaluates,restor3d device
NCT06311331,measures_primary,safety and probable benefit
NCT06311331,measures_secondary,Change in perceived pain
NCT06311331,measures_secondary,Change in FAOS Composite score
NCT06311331,measures_secondary,Change in FAOS pain subscale score
NCT06311331,measures_secondary,Change in FAOS other symptoms subscale score
NCT06311331,measures_secondary,Change in FAOS activities of daily living (ADL) subscale score
NCT06311331,has_criteria,device-related SAE
NCT06311331,has_criteria,subsequent secondary surgical intervention (SSSI)
NCT02740231,involves,Knee Osteoarthritis
NCT02740231,evaluates,Visco-antalgic Intra-articular Administration
NCT02740231,measures_primary,WOMAC Pain Subscale
NCT02740231,measures_secondary,WOMAC Osteoarthritis Index
NCT02740231,has_criteria,Baseline and Month 6
NCT02905331,involves,Plaque-Type Psoriasis
NCT02905331,evaluates,Guselkumab
NCT02905331,measures_primary,IGA cleared or minimal
NCT02905331,measures_secondary,PASI 90 Response
NCT02905331,has_criteria,treatment failure rules
NCT02549573,involves,Parkinson's Disease
NCT02549573,evaluates,Outpatient Physical Therapy
NCT02549573,measures_primary,Change From Baseline
NCT02549573,measures_secondary,Change From Baseline
NCT02549573,has_criteria,APOKYN®  use
NCT04169373,involves,Axial Spondyloarthritis
NCT04169373,evaluates,Upadacitinib
NCT04169373,measures_primary,ASAS40 Response
NCT04169373,measures_secondary,ASAS40 Response
NCT04169373,has_criteria,≥ 40% relative to Baseline
NCT04704531,involves,Dry Eye Disease
NCT04704531,evaluates,Lagricel® Ofteno Ophthalmic Solution
NCT04704531,measures_primary,Change in OSDI
NCT04704531,measures_secondary,Change in tear break-up time
NCT04704531,measures_secondary,Change in conjunctival and corneal staining
NCT04704531,has_criteria,Presence/absence adverse events
NCT04811131,involves,Non-Segmental Facial Vitiligo
NCT04811131,evaluates,ARQ-252 Cream 0.3%
NCT04811131,measures_primary,F-VASI75 at Week 24
NCT04811131,measures_secondary,Percentage Change From Baseline in F-VASI Score
NCT04811131,measures_secondary,Change From Baseline in F-BSA Score
NCT04811131,measures_secondary,Change From Baseline in Vitiligo Noticeability Scale (VNS) Score
NCT04811131,has_criteria,early study termination
NCT02428231,involves,Gastrointestinal Adverse Events
NCT02428231,evaluates,DMF
NCT02428231,measures_primary,Average Change in GSRS
NCT02428231,measures_secondary,Time to First Worsening
NCT02428231,has_criteria,Baseline to Week 14
NCT06649773,involves,Type 2 Diabetes
NCT06649773,evaluates,Noiiglutide Injection
NCT06649773,measures_primary,HbA1c at Week 24
NCT06649773,measures_secondary,Fasting plasma glucose
NCT06649773,measures_secondary,Fasting body weight
NCT06649773,measures_secondary,Plasma glucose levels
NCT06649773,measures_secondary,7-point SMBG spectrum
NCT06649773,measures_secondary,Blood pressure
NCT06649773,measures_secondary,Fasting insulin
NCT06649773,measures_secondary,C-peptide
NCT06649773,measures_secondary,Insulin levels
NCT06649773,measures_secondary,C-peptide levels
NCT06649773,measures_secondary,Adverse events
NCT06649773,has_criteria,SHR20004
NCT04820673,involves,Acne Vulgaris
NCT04820673,evaluates,Sarecycline
NCT04820673,measures_primary,ASIS Domain Score
NCT04820673,measures_secondary,Facial IGA Success
NCT04820673,has_criteria,Facial IGA Success
NCT00907673,involves,Chronic Congestive Heart Failure
NCT00907673,evaluates,Automated Fluid Shunt
NCT00907673,measures_primary,NT-proBNP change
NCT00907673,measures_secondary,functional capacity
NCT00907673,measures_secondary,LV volumes
NCT00907673,measures_secondary,LVEF
NCT00907673,measures_secondary,ascites
NCT00907673,measures_secondary,hydrothorax
NCT00907673,measures_secondary,leg edema
NCT00907673,measures_secondary,renal function
NCT00907673,measures_secondary,quality of life
NCT00907673,has_criteria,ascites
NCT00907673,has_criteria,diuretic resistance
NCT02186873,involves,Ankylosing Spondylitis
NCT02186873,evaluates,Golimumab
NCT02186873,measures_primary,ASAS 20 at Week 16
NCT02186873,measures_secondary,ASAS 40 at Week 16
NCT02186873,measures_secondary,BASDAI at Week 16
NCT02186873,has_criteria,20% improvement from baseline
NCT03986073,involves,Type 2 Diabetes Mellitus
NCT03986073,evaluates,TQ-F3083 Capsules
NCT03986073,measures_primary,HbA1c reduction
NCT03986073,measures_secondary,Fasting plasma glucose
NCT03986073,measures_secondary,2 hours-postprandial blood sugar
NCT03986073,measures_secondary,Weight
NCT03986073,measures_secondary,DPP-4 activity
NCT03986073,measures_secondary,GLP-1 concentrations
NCT03986073,has_criteria,12 weeks of treatment
NCT04958031,involves,Dementia-Related Apathy
NCT04958031,evaluates,CVL-871
NCT04958031,measures_primary,DAIR score change
NCT04958031,measures_secondary,Electrocardiogram changes
NCT04958031,measures_secondary,Clinical laboratory changes
NCT04958031,measures_secondary,Vital sign changes
NCT04958031,measures_secondary,Physical/neurological changes
NCT04958031,measures_secondary,Suicidality (C-SSRS)
NCT04958031,has_criteria,Baseline up to Week 16
NCT01724931,involves,Rheumatoid Arthritis
NCT01724931,evaluates,Aminopterin
NCT01724931,measures_primary,ACR20 at week 84
NCT01724931,measures_secondary,ACR20 at week 84
NCT01724931,has_criteria,>18 years of age
NCT01724931,has_criteria,ACR/EULAR 2010 criteria
NCT01724931,has_criteria,>1 joint with synovitis
NCT01724931,has_criteria,ACR 1992 functional criteria
NCT01724931,has_criteria,RA active
NCT01724931,has_criteria,Adequate contraception
NCT01724931,has_criteria,Negative pregnancy test
NCT01724931,has_criteria,Negative hepatitis B/C serology
NCT06633731,involves,Fitzpatrick Skin Types V and VI
NCT06633731,evaluates,Topical Facial Treatment
NCT06633731,measures_primary,Investigator Clinical Efficacy Grading
NCT06633731,measures_secondary,Clinical Photography
NCT06633731,measures_secondary,Self-Assessment Questionnaires
NCT06633731,has_criteria,Healthy Females
NCT03322631,involves,Type 2 Diabetes
NCT03322631,evaluates,Tirzepatide
NCT03322631,measures_primary,Fasting Plasma Glucose
NCT03322631,has_criteria,T2DM controlled diet and exercise
NCT03322631,has_criteria,single oral antidiabetic medication
NCT03322631,has_criteria,body mass index 20.0 to 35.0 kg/m^2
NCT03322631,has_criteria,allergies to tirzepatide
NCT03322631,has_criteria,allergies to GLP-1 analogs
NCT02172573,involves,Parkinson's disease
NCT02172573,evaluates,Pramipexole
NCT02172573,evaluates,Bromocriptine
NCT02172573,evaluates,L-dopa
NCT02172573,measures_primary,Change from baseline
NCT02172573,measures_secondary,Modified Hoehn & Yahr stage
NCT02172573,has_criteria,Patients with Parkinson's disease
NCT02172573,has_criteria,At least 20 years of age
NCT02172573,has_criteria,In- or outpatients
NCT02172573,has_criteria,Either sex
NCT03963973,involves,Psychiatric disorders
NCT03963973,evaluates,RDN-929
NCT03963973,measures_primary,AUC RDN-929
NCT03963973,measures_secondary,Cmax RDN-929
NCT03963973,has_criteria,Age 55-85 years
NCT03963973,has_criteria,Healthy adults
NCT03963973,has_criteria,No major psychiatric disorders
NCT03963973,has_criteria,ALT/AST ≤1.5 ULN
NCT03963973,has_criteria,No clinically significant abnormalities
NCT03963973,has_criteria,No clinically significant vital signs abnormalities
NCT00662831,involves,Neuroischaemic Foot Ulcers
NCT00662831,involves,Diabetic Patients
NCT00662831,evaluates,Fragmin
NCT00662831,measures_primary,Ulcer Surface Area
NCT00662831,measures_secondary,Wound infection
NCT00662831,measures_secondary,Ischemia
NCT00662831,has_criteria,Toe pressure
NCT00662831,has_criteria,UT grade
NCT00662831,has_criteria,UT stage
NCT04880031,involves,Nonalcoholic Steatohepatitis
NCT04880031,evaluates,BOS-580
NCT04880031,measures_primary,Safety and tolerability
NCT04880031,measures_secondary,Blood pressure
NCT04880031,measures_secondary,Heart rate
NCT04880031,has_criteria,Obese subjects
NCT01534273,evaluates,LY2886721
NCT01534273,measures_primary,Percent Change CSF Amyloid
NCT01534273,measures_secondary,Percent Change CSF Amyloid
NCT01350973,involves,Hypertriglyceridemia
NCT01350973,evaluates,TAK-085
NCT01350973,measures_primary,Percent Change From Baseline in Triglyceride Level at the Final Visit
NCT01350973,measures_secondary,Percent Change From Baseline in Low-Density Lipoprotein - Cholesterol (LDL-C) Level Over Time
NCT01350973,measures_secondary,Percent Change From Baseline in Total Cholesterol Over Time
NCT01350973,measures_secondary,Percent Change From Baseline in High-Density Lipoprotein - Cholesterol (HDL-C) Level Over Time
NCT01350973,measures_secondary,Percent Change From Baseline in Non-High-Density Lipoprotein - Cholesterol Level Over Time
NCT01350973,measures_secondary,Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT05132231,involves,Plaque Psoriasis
NCT05132231,evaluates,Brodalumab
NCT05132231,measures_primary,DLQI change
NCT05132231,measures_secondary,WPAI:PSO
NCT05132231,measures_secondary,HUI2
NCT05132231,has_criteria,employed at time
NCT05802173,involves,Androgenetic Alopecia
NCT05802173,evaluates,TDM-105795
NCT05802173,measures_primary,non-vellus TAHC
NCT05802173,measures_secondary,hair growth index
NCT05802173,has_criteria,male 18-55 years old
NCT05802173,has_criteria,written informed consent
NCT05802173,has_criteria,mild to moderate AGA
NCT05802173,has_criteria,Modified Norwood-Hamilton Scale IIIv
NCT06159673,involves,Alzheimer's Disease Psychosis
NCT06159673,evaluates,ACP-204
NCT06159673,measures_primary,CGI-I-ADP score
NCT06159673,measures_secondary,SAPS-H+D total score
NCT06159673,has_criteria,≥55 and ≤95 years of age
NCT06159673,has_criteria,MMSE score ≥6 and ≤24
NCT06159673,has_criteria,Psychotic symptoms for at least 2 months
NCT00947531,involves,Vascular Dementia
NCT00947531,evaluates,Cerebrolysin
NCT00947531,measures_primary,ADAS-cog+ score
NCT00947531,measures_secondary,CIBIC+ Score
NCT00947531,has_criteria,baseline and week 24
NCT01103960,involves,Hypertension
NCT01103960,evaluates,T80+A5
NCT01103960,evaluates,A5 Monotherapy
NCT01103960,measures_primary,Change From Baseline in DBP
NCT01103960,measures_secondary,Change From Baseline in SBP
NCT01103960,measures_secondary,DBP and SBP Control
NCT01103960,has_criteria,Treatment Failure
NCT01753076,involves,Amyotrophic Lateral Sclerosis
NCT01753076,evaluates,Ozanezumab
NCT01753076,evaluates,Placebo
NCT01753076,measures_primary,ALSFRS-R Score
NCT01753076,measures_secondary,Overall Survival
NCT01753076,has_criteria,Change From Baseline
NCT02174276,involves,Chronic Hepatitis B
NCT02174276,evaluates,GS-4774
NCT02174276,measures_primary,Mean Change in HBsAg
NCT02174276,measures_secondary,Percentage of Participants With HBsAg Loss
NCT02174276,has_criteria,ALT levels
NCT01736176,involves,Parkinson's Disease
NCT01736176,evaluates,Levodopa-carbidopa Intestinal Gel
NCT01736176,measures_primary,Change From Baseline
NCT01736176,measures_secondary,Healthcare Resources
NCT01736176,has_criteria,PEG-J procedure
NCT04825860,involves,Schizophrenia
NCT04825860,evaluates,SEP-363856
NCT04825860,measures_primary,PANSS total score
NCT04825860,measures_secondary,CGI-S score
NCT04825860,has_criteria,Informed consent
NCT04825860,has_criteria,18 to 65 years
NCT04825860,has_criteria,DSM 5 criteria
NCT04825860,has_criteria,CGI S score ≥ 4
NCT04825860,has_criteria,PANSS total score ≥ 80
NCT03852160,involves,Treatment-resistant Depression
NCT03852160,evaluates,Esketamine Nasal Spray
NCT03852160,measures_primary,Remission at Week 8
NCT03852160,measures_secondary,Remission without relapse
NCT03852160,has_criteria,MADRS total score <= 10
NCT01702376,evaluates,Retosiban
NCT01702376,evaluates,Moxifloxacin
NCT01702376,measures_primary,Change from baseline in QTcF
NCT01702376,measures_primary,Change from baseline in QTcB
NCT01702376,measures_primary,Change from baseline in QTci/QTciL interval
NCT01702376,has_criteria,Healthy Volunteers
NCT00491894,involves,Cerebral Palsy
NCT00491894,involves,Neurologic Conditions
NCT00491894,evaluates,Glycopyrrolate Liquid
NCT00491894,measures_primary,Patient response status
NCT00491894,measures_secondary,Parent/Caregiver's Assessment
NCT00491894,has_criteria,Pediatric Patients 3 to 18 Years of Age
NCT04860960,involves,Niemann-Pick Disease Type C1
NCT04860960,evaluates,Trappsol(R) Cyclo(TM)
NCT04860960,measures_primary,Change from Baseline in 4-Domain NPC Severity Score
NCT04860960,measures_primary,Change from Baseline in 5-Domain NPC Severity Score
NCT04860960,measures_secondary,Ataxia
NCT04860960,measures_secondary,Adaptive behavior
NCT04860960,measures_secondary,Swallow function
NCT04860960,has_criteria,Confirmed diagnosis of NPC1
NCT04860960,has_criteria,Annual Severity Increment Score
NCT04860960,has_criteria,Treated or Not Treated with Miglustat
NCT04860960,has_criteria,Body weight
NCT04860960,has_criteria,Neurological symptom
NCT04860960,has_criteria,Written informed consent
NCT01054976,involves,Alzheimer's Disease
NCT01054976,evaluates,Galantamine
NCT01054976,measures_primary,Simple Reaction Time
NCT01054976,measures_primary,Choice Reaction Time
NCT01054976,measures_primary,ADAS-Cog
NCT01054976,measures_primary,DAD-K
NCT01054976,measures_primary,S-IADL
NCT01054976,has_criteria,Baseline
NCT02058160,involves,Type 2 Diabetes
NCT02058160,evaluates,Insulin Glargine/Lixisenatide
NCT02058160,evaluates,Insulin Glargine
NCT02058160,measures_primary,Change in HbA1c
NCT02058160,measures_secondary,Change in 2-hour Plasma Glucose Excursion
NCT02058160,measures_secondary,Change in Body Weight
NCT02058160,measures_secondary,Mean Change in 7-point SMPG Profile
NCT02058160,measures_secondary,Percentage of Participants Reaching HbA1c <7.0%
NCT02058160,measures_secondary,Change in Daily Insulin Glargine Dose
NCT02058160,has_criteria,HbA1c <7.0%
NCT02058160,has_criteria,No Body Weight Gain
NCT05911360,involves,Human Immunodeficiency Virus
NCT05911360,evaluates,DTG/3TC FDC
NCT05911360,measures_primary,Plasma HIV-1 RNA
NCT05911360,measures_secondary,CD4+ Cells Count
NCT05911360,measures_secondary,CD4:CD8 Ratio
NCT05911360,has_criteria,Virologic Suppression
NCT05911360,has_criteria,ART-Experienced
NCT05911360,has_criteria,≥50 Years of Age
NCT00663260,involves,Type 2 Diabetes Mellitus
NCT00663260,involves,Moderate Renal Impairment
NCT00663260,evaluates,Dapagliflozin
NCT00663260,measures_primary,HbA1c at Week 24
NCT00663260,measures_secondary,Fasting Plasma Glucose
NCT00663260,measures_secondary,Total Body Weight
NCT00663260,has_criteria,last assessment prior
NCT01083160,involves,Rheumatoid Arthritis
NCT01083160,evaluates,Adalimumab
NCT01083160,measures_primary,DAS28 score
NCT01083160,measures_secondary,Tender Joint Count
NCT01083160,measures_secondary,Swollen Joint Count
NCT01083160,measures_secondary,Severity of Pain
NCT01083160,has_criteria,Missed doses
NCT03406260,involves,Healthy Elderly Participants
NCT03406260,evaluates,Lasmiditan
NCT03406260,measures_primary,Systolic Blood Pressure
NCT03406260,measures_secondary,Mean 24-hour systolic blood pressure
NCT03406260,has_criteria,BMI 19.0 to 35.0 kg/m²
NCT01371994,involves,Urinary Continence
NCT01371994,evaluates,Solifenacin Succinate
NCT01371994,measures_primary,Time to Continence
NCT01371994,measures_secondary,Average Daily Pad Usage
NCT01371994,has_criteria,Robotic Assisted Radical Prostatectomy
NCT00347360,involves,Hypertension
NCT00347360,evaluates,carvedilol CR
NCT00347360,evaluates,lisinopril
NCT00347360,measures_primary,24 hr Mean DBP
NCT00347360,measures_secondary,Trough to Peak Ratios DBP
NCT00347360,has_criteria,once-daily criteria
NCT01963260,involves,Immune Thrombocytopenia Purpura
NCT01963260,evaluates,MK-8723
NCT01963260,measures_primary,Platelet Response
NCT01963260,measures_secondary,AUC0-∞
NCT01963260,has_criteria,Baseline platelet count
NCT03122860,involves,Knee Osteoarthritis
NCT03122860,evaluates,SM04690
NCT03122860,measures_primary,Change From Baseline OA Pain
NCT03122860,measures_secondary,WOMAC Pain
NCT03122860,has_criteria,Moderately to Severely Symptomatic
NCT03249376,involves,Bipolar I disorder
NCT03249376,involves,Bipolar II disorder
NCT03249376,evaluates,Lumateperone
NCT03249376,measures_primary,Change From Baseline
NCT03249376,measures_secondary,Clinical Global Impression Scale
NCT03249376,measures_secondary,Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form
NCT03249376,has_criteria,age 18-75
NCT03249376,has_criteria,male or female
NCT03249376,has_criteria,written informed consent
NCT03249376,has_criteria,current major depressive episode
NCT00602472,involves,Type 2 Diabetes
NCT00602472,evaluates,BI 1356
NCT00602472,measures_primary,HbA1c Change
NCT00602472,measures_secondary,FPG Change
NCT00602472,has_criteria,baseline HbA1c
NCT01029704,involves,Type 2 Diabetes Mellitus
NCT01029704,evaluates,EGT0001442
NCT01029704,measures_primary,Change in FPG
NCT01029704,measures_secondary,Change in Body Weight
NCT01029704,measures_secondary,Change in HbA1c
NCT01852604,involves,Chronic Hepatitis C Infection
NCT01852604,evaluates,Samatasvir
NCT01852604,measures_primary,SVR4
NCT01852604,measures_secondary,RVR
NCT01852604,measures_secondary,EVR
NCT01852604,measures_secondary,SVR8
NCT01852604,measures_secondary,SVR12
NCT01852604,measures_secondary,SVR24
NCT01852604,has_criteria,Genotype 1a
NCT01852604,has_criteria,documented clinical history
NCT01852604,has_criteria,HCV treatment-naïve or interferon/RBV-treatment relapsed
NCT01852604,has_criteria,acceptable double method of birth control
NCT04921969,involves,Atopic Dermatitis
NCT04921969,evaluates,Ruxolitinib Cream
NCT04921969,measures_primary,IGA-TS at Week 8
NCT04921969,measures_secondary,Itch NRS Score
NCT04921969,measures_secondary,Itch NRS Score
NCT04921969,measures_secondary,Itch NRS Score
NCT04921969,has_criteria,Baseline to Week 8
NCT04921969,has_criteria,Baseline to Day 7 (Week 1)
NCT04921969,has_criteria,Baseline to Day 3
NCT03192969,involves,Giant Cell Arteritis
NCT03192969,evaluates,Subcutaneous Abatacept
NCT03192969,measures_primary,Physician's Global Assessment
NCT03192969,measures_secondary,Short Form questionnaire-36
NCT03192969,measures_secondary,Time from Week 12
NCT03192969,measures_secondary,Erythrocyte sedimentation rate
NCT03192969,measures_secondary,C-reactive protein
NCT03192969,measures_secondary,All adverse events
NCT03192969,measures_secondary,Laboratory test abnormalities
NCT03192969,has_criteria,sustained remission
NCT00812812,involves,Major depressive disorder
NCT00812812,evaluates,Paxil
NCT00812812,measures_primary,Change From Baseline in CDRS-R Total Score
NCT00812812,measures_secondary,Number of CGI-GI Responders
NCT00812812,has_criteria,Children and adolescents
NCT01258712,involves,Rheumatoid Arthritis
NCT01258712,evaluates,Tocilizumab
NCT01258712,evaluates,Methotrexate
NCT01258712,measures_primary,ACR20 response
NCT01258712,measures_secondary,ACR50 response
NCT01258712,measures_secondary,ACR70 response
NCT01258712,measures_secondary,Swollen joint count
NCT01258712,measures_secondary,Tender joint count
NCT01258712,measures_secondary,DAS28
NCT01258712,measures_secondary,DAS28 remission
NCT01258712,measures_secondary,Adverse event incidence
NCT01258712,measures_secondary,Vital signs
NCT01258712,measures_secondary,Electrocardiogram
NCT01258712,measures_secondary,Hematological exam results
NCT01258712,measures_secondary,Biochemical exam results
NCT01258712,measures_secondary,Serum lipid exam results
NCT01258712,measures_secondary,Urinalysis results
NCT01258712,has_criteria,Moderate-to-severe rheumatoid arthritis
NCT01258712,has_criteria,American College of Rheumatology criteria
NCT01258712,has_criteria,DMARD treatment failure
NCT01682512,involves,Rheumatoid Arthritis
NCT01682512,evaluates,BI 695500
NCT01682512,evaluates,Rituxan
NCT01682512,measures_primary,DAS28 score
NCT01682512,measures_secondary,AUC0-tz
NCT01682512,has_criteria,Full first and second dose
NCT01692912,involves,Psoriatic Arthritis
NCT01692912,evaluates,Intensive Care
NCT01692912,evaluates,Routine Care
NCT01692912,measures_primary,DAS28<2.6 at Month 9
NCT01692912,measures_secondary,Time to DAS28<2.6
NCT01692912,measures_secondary,Absolute change in DAS28
NCT01692912,measures_secondary,Percentage of Patients achieving ACR 20/50/70
NCT01692912,measures_secondary,Percentage of patients achieving PsARC
NCT01692912,measures_secondary,Absolute change in HAQ-DI
NCT01692912,has_criteria,DAS28<2.6
NCT01692912,has_criteria,ACR 20/50/70
NCT01692912,has_criteria,PsARC
NCT00698646,involves,Hypertension
NCT00698646,evaluates,Valsartan/Hydrochlorothiazide
NCT00698646,evaluates,Valsartan
NCT00698646,evaluates,Hydrochlorothiazide
NCT00698646,measures_primary,Change in MSSBP
NCT00698646,measures_secondary,Change in MSDBP
NCT00698646,measures_secondary,Blood Pressure Control
NCT00698646,measures_secondary,Blood Pressure Goal
NCT00698646,has_criteria,Age 70 years or older
NCT00698646,has_criteria,Hypertension prior to randomization
NCT00698646,has_criteria,Office cuff MSSBP 140-200 mmHg
NCT00698646,has_criteria,Ability to communicate
NCT00698646,has_criteria,Written informed consent
NCT00698646,has_criteria,No other investigational drugs
NCT00698646,has_criteria,No hypersensitivity to study drugs
NCT00698646,has_criteria,Mean MSDBP < 120 mmHg
NCT00698646,has_criteria,No more than 2 antihypertensive drugs
NCT04829669,involves,Major Depressive Disorder
NCT04829669,measures_primary,Change From Baseline in Severity of Depression
NCT04829669,measures_secondary,Change From Baseline in Severity of Suicidality
NCT04829669,measures_secondary,Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 (Clinician-rated Frequency of Suicidal Thinking [FoST]) Score
NCT04829669,has_criteria,Baseline
NCT06557772,involves,Nonresponsive Celiac Disease
NCT06557772,evaluates,Subcutaneous Amlitelimab
NCT06557772,measures_primary,Vh:Cd ratio
NCT06557772,measures_secondary,Celiac Disease Symptom Diary
NCT06557772,measures_secondary,TEAEs
NCT06557772,measures_secondary,PCSA
NCT06557772,measures_secondary,discontinued due to TEAEs
NCT06557772,measures_secondary,Serum amlitelimab concentrations
NCT06557772,measures_secondary,Incidence of antidrug antibodies
NCT00871572,involves,Type 2 Diabetes Mellitus
NCT00871572,measures_primary,Change in HbA1c
NCT00871572,measures_secondary,Fasting Blood Glucose
NCT00871572,measures_secondary,Glucose AUC
NCT00871572,measures_secondary,Fasting Triglycerides
NCT00871572,measures_secondary,Diabetes Symptom Checklist-Revised
NCT00871572,has_criteria,Baseline
NCT00500604,involves,essential hypertension
NCT00500604,evaluates,Irbesartan/Hydrochlorothiazide
NCT00500604,evaluates,Valsartan/Hydrochlorothiazide
NCT00500604,measures_primary,Reduction in SBP
NCT00500604,measures_secondary,Reduction in DBP
NCT00500604,measures_secondary,Number of normalised patients
NCT00500604,has_criteria,Untreated or treated hypertension
NCT00500604,has_criteria,Office SBP ≥ 160 mmHg
NCT00500604,has_criteria,Office SBP ≥ 140 mmHg
NCT00500604,has_criteria,Previous antihypertensive therapy
NCT00500604,has_criteria,ACE inhibitor / calcium channel blocker
NCT00500604,has_criteria,Beta blocker / calcium channel blocker
NCT00500604,has_criteria,Beta blocker / low dose diuretic
NCT00500604,has_criteria,ACE inhibitor / low dose diuretic
NCT00500604,has_criteria,SBP ≥ 180 mmHg
NCT00500604,has_criteria,DBP ≥ 110 mmHg
NCT00500604,has_criteria,Secondary hypertension
NCT00500604,has_criteria,Bilateral renal artery stenosis
NCT00500604,has_criteria,Renal artery stenosis in a solitary kidney
NCT00500604,has_criteria,Renal transplant
NCT00500604,has_criteria,One functioning kidney
NCT00500604,has_criteria,Type 1 diabetes mellitus
NCT00500604,has_criteria,Cardiovascular disease
NCT00500604,has_criteria,Neurological disease
NCT00500604,has_criteria,Endocrine disease
NCT00500604,has_criteria,Renal disease
NCT00500604,has_criteria,Metabolic disease
NCT00500604,has_criteria,Gastrointestinal disease
NCT00500604,has_criteria,Malignancy
NCT04308304,involves,Alzheimer's Disease
NCT04308304,evaluates,MK-1942
NCT04308304,measures_primary,Number of Participants
NCT04308304,measures_secondary,Clinically Significant Abnormalities
NCT04308304,measures_secondary,Abnormal Neurological Exams
NCT04308304,measures_secondary,Suicidal Ideation
NCT04308304,has_criteria,Up to Day 42
NCT04308304,has_criteria,Up to Day 28
NCT04308304,has_criteria,Up to Day 29
NCT04338204,involves,Ulcerative Colitis
NCT04338204,evaluates,Tofacitinib
NCT04338204,measures_primary,Partial Mayo Score
NCT04338204,measures_secondary,Total Mayo Score
NCT04338204,measures_secondary,Clinical Response
NCT04338204,has_criteria,Steroid-Free Clinical Remission
NCT00643604,involves,Pulmonary Hypertension
NCT00643604,evaluates,Remodulin
NCT00643604,measures_primary,Six Minute Walk Distance
NCT00643604,measures_secondary,WHO Functional Classification
NCT00643604,measures_secondary,Borg Dyspnea Score
NCT00643604,measures_secondary,CAMPHOR Score
NCT00643604,measures_secondary,Treatment Satisfaction Questionnaire
NCT00643604,has_criteria,Outpatient Clinic
NCT01188772,involves,Hepatitis C
NCT01188772,evaluates,Sofosbuvir
NCT01188772,measures_primary,Change in HCV RNA
NCT01188772,measures_secondary,Rapid virologic response
NCT01188772,measures_secondary,Complete early virologic response
NCT01188772,measures_secondary,Extended rapid virologic response
NCT01188772,measures_secondary,Virologic Response at the End of Treatment
NCT01188772,measures_secondary,Sustained Virologic Response at Post-treatment Week 12
NCT01188772,measures_secondary,Sustained Virologic Response at Post-treatment Week 24
NCT01188772,has_criteria,Treatment-Naive
NCT01785472,involves,Essential Hypertension
NCT01785472,evaluates,LCZ696
NCT01785472,evaluates,Olmesartan
NCT01785472,measures_primary,msSBP
NCT01785472,measures_primary,msDBP
NCT01785472,measures_primary,msPP
NCT01785472,measures_primary,maSBP
NCT01785472,measures_primary,maDBP
NCT01785472,has_criteria,baseline
NCT01785472,has_criteria,8 weeks
NCT04768972,involves,Amyotrophic Lateral Sclerosis
NCT04768972,evaluates,ION363
NCT04768972,measures_primary,Functional impairment
NCT04768972,measures_secondary,Amyotrophic Lateral Sclerosis Specific Quality of Life
NCT04768972,measures_secondary,Survival
NCT04768972,measures_secondary,Ventilation Assistance-Free Survival
NCT04768972,measures_secondary,Slow Vital Capacity
NCT04768972,measures_secondary,Handheld Dynamometry
NCT04768972,measures_secondary,Neurofilament Light Concentration
NCT00420004,involves,Major Depression
NCT00420004,measures_primary,Change From Baseline
NCT00420004,measures_secondary,Response and Remission Rates
NCT00420004,has_criteria,50% reduction in HAMD-17 total score
NCT00087568,involves,Chronic Hepatitis C
NCT00087568,evaluates,PEGASYS
NCT00087568,evaluates,Ribavirin
NCT00087568,measures_primary,undetectable HCV RNA
NCT00087568,measures_primary,>=2-log10 decrease HCV RNA
NCT00087568,measures_secondary,Serum Alanine Transaminase
NCT00087568,has_criteria,viremia after 12 weeks
NCT01811472,involves,NAFLD
NCT01811472,evaluates,LCQ908
NCT01811472,measures_primary,Change From Baseline in Percentage of Fat in the Liver
NCT01811472,measures_secondary,Percentage of Responders
NCT01811472,has_criteria,reduction of ≥ 30% from baseline in liver fat
NCT01811472,has_criteria,reduction of ≥ 50% from baseline in liver fat
NCT01811472,has_criteria,Liver fat content \< 10%
NCT01811472,has_criteria,Liver fat content \< 5.6%
NCT06345404,involves,Atopic dermatitis
NCT06345404,evaluates,Soquelitinib
NCT06345404,measures_primary,percent change EASI
NCT06345404,measures_secondary,vIGA 0 or 1
NCT06345404,has_criteria,adult ≥18 years
NCT01317004,involves,Multiple Sclerosis
NCT01317004,evaluates,MS Therapy Change
NCT01317004,measures_primary,Treatment Satisfaction
NCT01317004,measures_secondary,Activities of Daily Living
NCT01317004,measures_secondary,Fatigue
NCT01317004,has_criteria,Relapse Remitting
NCT05118672,involves,Common cold
NCT05118672,evaluates,Paracetamol /Fexofenadine /Phenylephrine
NCT05118672,measures_primary,overall symptom score
NCT05118672,measures_secondary,nasal congestion
NCT05118672,has_criteria,moderate to severe nasal congestion
NCT05118672,has_criteria,moderate to severe runny nose
NCT05118672,has_criteria,moderate to severe symptoms
NCT03721172,involves,Plaque Psoriasis
NCT03721172,evaluates,Apremilast
NCT03721172,measures_primary,sPGA response
NCT03721172,measures_secondary,Affected BSA
NCT03721172,measures_secondary,PASI Score
NCT03721172,has_criteria,Baseline and Week 16
NCT02799472,involves,Rheumatoid Arthritis
NCT02799472,evaluates,GSK3196165
NCT02799472,evaluates,Methotrexate
NCT02799472,measures_primary,Change From Baseline
NCT02799472,measures_secondary,Predictive Biomarkers
NCT02799472,has_criteria,disease duration
NCT00694304,involves,Major Depressive Disorder
NCT00694304,evaluates,Vortioxetine
NCT00694304,measures_primary,Change From Baseline
NCT00694304,measures_secondary,Change From Baseline
NCT00694304,has_criteria,Long-term Treatment
NCT01236404,involves,Type 2 Diabetes Mellitus
NCT01236404,evaluates,PB1023 Injection
NCT01236404,measures_primary,Fasting plasma glucose
NCT01236404,measures_secondary,Glucose levels
NCT01236404,has_criteria,Males or post menopausal females
NCT00442104,involves,Infantile spasms
NCT00442104,evaluates,ganaxolone
NCT00442104,measures_primary,Change From Baseline
NCT00442104,measures_secondary,Number of Participants
NCT00442104,has_criteria,Day 0 assessment
NCT06164704,involves,Chronic Rhinosinusitis With Nasal Polyps
NCT06164704,evaluates,Verekitug
NCT06164704,measures_primary,Change From Baseline in NPS
NCT06164704,measures_secondary,Nasal Congestion Score
NCT06164704,measures_secondary,Opacification of Sinuses
NCT06164704,measures_secondary,Mean Difficulty With Sense of Smell
NCT06164704,has_criteria,Systemic Corticosteroids or NP Surgery
NCT03942172,involves,Parkinson's disease
NCT03942172,evaluates,SpotOn Balance Glasses
NCT03942172,measures_primary,Unified Parkinson's disease rating scale
NCT03942172,measures_secondary,TIMED UP AND GO (TUG)
NCT03942172,measures_secondary,Berg Balance Scale (BBS)
NCT03942172,measures_secondary,Non-Motor Symptoms Scale (NMSS)
NCT03942172,measures_secondary,39-item Parkinson's Disease Questionnaire (PDQ-39)
NCT03942172,measures_secondary,Freeze of gait (FOG) Questionnaire
NCT03942172,has_criteria,Age: ≥ 30 years
NCT03942172,has_criteria,Parkinson's disease
NCT03942172,has_criteria,Gait disturbances
NCT04466904,involves,T2DM
NCT04466904,evaluates,IBI362
NCT04466904,measures_primary,Treatment-Emergent Adverse Events
NCT04466904,measures_secondary,Fasting Blood Glucose
NCT04466904,measures_secondary,Glucagon
NCT04466904,measures_secondary,Insulin
NCT04466904,measures_secondary,C-peptide
NCT04466904,has_criteria,Male or female 18 to 75 years
NCT04466904,has_criteria,T2D patients with poorly controlled blood glucose
NCT04466904,has_criteria,HbA1c 7.5% ≤ 11.0%
NCT04466904,has_criteria,Body mass index 20 ≤ BMI ≤ 35 kg/m2
NCT02252172,involves,Multiple Myeloma
NCT02252172,evaluates,Daratumumab
NCT02252172,evaluates,Lenalidomide
NCT02252172,evaluates,Dexamethasone
NCT02252172,measures_primary,Progression-free Survival
NCT02252172,measures_secondary,Complete Response
NCT02252172,has_criteria,Previously Untreated
NCT05176704,involves,Alzheimer disease
NCT05176704,involves,dementias
NCT05176704,evaluates,Eye-Tracking Software Application
NCT05176704,measures_primary,CDR score
NCT05176704,measures_secondary,MoCA score
NCT05176704,measures_secondary,MMSE score
NCT05176704,has_criteria,Informed consent
NCT05176704,has_criteria,Aged 18 years or older
NCT05176704,has_criteria,Read French or English
NCT05176704,has_criteria,Visual acuity 20/100
NCT02855892,involves,BPH
NCT02855892,evaluates,GV1001
NCT02855892,measures_primary,IPSS scores
NCT02855892,measures_secondary,prostate volume
NCT02855892,measures_secondary,Qmax
NCT02855892,measures_secondary,IIEF
NCT02855892,measures_secondary,PSA
NCT02855892,measures_secondary,residual urine volume
NCT02855892,measures_secondary,hormones
NCT02855892,has_criteria,Transrectal Ultrasonography
NCT01565889,evaluates,Sofosbuvir
NCT01565889,involves,HIV
NCT01565889,involves,Hepatitis C Virus
NCT01565889,measures_primary,SVR12
NCT01565889,measures_secondary,Adverse Events
NCT01565889,measures_secondary,SVR4
NCT01565889,measures_secondary,SVR24
NCT01565889,has_criteria,HCV RNA \< LLOQ
NCT00518089,involves,Bacterial Conjunctivitis
NCT00518089,evaluates,Gatifloxacin
NCT00518089,measures_primary,Clinical Success
NCT00518089,measures_secondary,Microbiological Cure
NCT00518089,measures_secondary,Clinical Improvement
NCT00518089,has_criteria,Day 1 Baseline
NCT06500689,involves,essential hypertension
NCT06500689,evaluates,Allisartan Isoproxil/Sustained-Release Indapamide
NCT06500689,measures_primary,change in msSBP
NCT06500689,measures_secondary,proportion of responders
NCT06500689,has_criteria,18-75 years old
NCT04103892,involves,Major Depressive Disorder
NCT04103892,evaluates,CLE-100
NCT04103892,measures_primary,sleepiness
NCT04103892,measures_secondary,sedation
NCT04103892,measures_secondary,dissociative symptoms
NCT04103892,measures_secondary,suicidal ideation
NCT04103892,measures_secondary,suicidal behavior
NCT04103892,measures_secondary,psychotic symptoms
NCT04103892,has_criteria,treatment-emergent
NCT01323192,involves,Attention-Deficit Hyperactivity Disorder
NCT01323192,evaluates,JNS001
NCT01323192,measures_primary,Change From Baseline
NCT01323192,measures_secondary,Clinical Global Impression
NCT01323192,has_criteria,Baseline (Day 0) to Endpoint (Week 8)
NCT01922089,involves,Heart Failure
NCT01922089,evaluates,LCZ696
NCT01922089,measures_primary,Treatment success
NCT01922089,measures_secondary,Hypotension
NCT01922089,measures_secondary,Renal Dysfunction
NCT01922089,measures_secondary,Hyperkalemia
NCT01922089,measures_secondary,Angioedema
NCT01922089,has_criteria,RAAS Stratum
NCT01922089,has_criteria,Valsartan dose
NCT01922089,has_criteria,Enalapril dose
NCT01922089,has_criteria,ACEI/ARB use
NCT00484289,involves,Rheumatoid Arthritis
NCT00484289,evaluates,Abatacept
NCT00484289,measures_primary,ACR 20 response
NCT00484289,measures_secondary,Abnormal Laboratory Changes
NCT00484289,measures_secondary,Vital Signs
NCT00484289,has_criteria,20% reduction
NCT00761189,involves,Acute Schizophrenia
NCT00761189,evaluates,PaliperidoNe Extended-Release
NCT00761189,measures_primary,CGI-I Scale
NCT00761189,measures_secondary,PSP Scale Score
NCT00761189,has_criteria,Intent-to-treat
NCT03412929,involves,Chronic Wounds
NCT03412929,evaluates,Honey Impregnated Dressing
NCT03412929,measures_primary,Percent change in necrotic tissue
NCT03412929,measures_secondary,Wound Closure
NCT03412929,measures_secondary,Infections
NCT03412929,measures_secondary,Odor
NCT03412929,measures_secondary,Pain Score
NCT03412929,measures_secondary,Bates-Jensen Wound Assessment Tool Score
NCT03412929,has_criteria,initial date of application
NCT03901092,involves,Alzheimer's Disease
NCT03901092,evaluates,Flortaucipir F 18 Positron Emission Tomography (PET)
NCT03901092,measures_primary,Diagnostic Performance
NCT03901092,measures_primary,Sensitivity and specificity
NCT03901092,measures_primary,NFT Score
NCT03901092,measures_primary,NIA-AA Autopsy Diagnosis
NCT03901092,measures_primary,High ADNC
NCT02092389,involves,Ulcerative Colitis
NCT02092389,evaluates,Adalimumab
NCT02092389,measures_primary,fC level ≤ 150 µg/g
NCT02092389,measures_secondary,Workability
NCT02092389,measures_secondary,Quality of Life
NCT02092389,has_criteria,enrollment
NCT04681729,involves,Chronic Inducible Cold Urticaria
NCT04681729,evaluates,Dupilumab
NCT04681729,measures_primary,Negative Ice Cube Provocation Test
NCT04681729,measures_secondary,Urticaria Control Test Score
NCT04681729,has_criteria,H1-antihistamine use
NCT06064929,involves,Lupus Nephritis
NCT06064929,evaluates,Felzartamab
NCT06064929,measures_primary,Urine Protein:Creatinine Ratio
NCT06064929,measures_secondary,Complete Renal Response
NCT06064929,measures_secondary,Overall Complete and Partial Renal Response
NCT06064929,measures_secondary,Serum Creatinine
NCT06064929,measures_secondary,Urine Protein
NCT06064929,measures_secondary,Estimated Glomerular Filtration Rate
NCT06064929,measures_secondary,eGFR Slope
NCT06064929,measures_secondary,Lupus Serologic Markers
NCT06064929,has_criteria,Baseline
NCT05680129,involves,T2DM
NCT05680129,evaluates,XW003
NCT05680129,evaluates,Dulaglutide
NCT05680129,measures_primary,Change from baseline in HbA1c
NCT05680129,measures_secondary,fasting plasma glucose
NCT05680129,measures_secondary,lipid panel
NCT05680129,measures_secondary,body weight
NCT05680129,measures_secondary,plasma trough level of XW003
NCT05680129,has_criteria,Ability and willingness to participate
NCT05680129,has_criteria,Sex: male or female
NCT05680129,has_criteria,Age: 18 to 75 years
NCT05680129,has_criteria,BMI: 20.0 kg/m\^2 to 35.0 kg/m\^2
NCT05680129,has_criteria,Diagnosed with T2DM for at least 3 months
NCT05680129,has_criteria,Treated with metformin (≥1500 mg/day)
NCT05680129,has_criteria,HbA1c ranging from 7.5% to 11.0%
NCT05680129,has_criteria,FPG ≤13.9 mmol/L
NCT05680129,has_criteria,History of type 1 or other types of diabetes mellitus
NCT05680129,has_criteria,Use of insulin during the 6 months preceding screening
NCT05680129,has_criteria,History of proliferative diabetic retinopathy
NCT05680129,has_criteria,History of acute or chronic pancreatitis
NCT05680129,has_criteria,Personal or family history of medullary thyroid carcinoma
NCT05680129,has_criteria,History of stomach surgeries
NCT05680129,has_criteria,History of heart attack
NCT00716092,involves,Type 2 diabetes mellitus
NCT00716092,evaluates,Linagliptin
NCT00716092,measures_primary,WMG Change From Baseline
NCT00716092,measures_secondary,GLP-1 AUEC (0-2h) Change
NCT00716092,measures_secondary,Fasting Plasma Glucose (FPG) Change
NCT00716092,measures_secondary,Plasma Glucose AUEC (0-3h) Change
NCT00716092,has_criteria,Male and female patients
NCT00716092,has_criteria,HbA1c 6.5 to 10.0%
NCT00716092,has_criteria,previously treated with not more than one drug
NCT00716092,has_criteria,Myocardial infarction
NCT00716092,has_criteria,Renal insufficiency with creatinine clearance \< 50 mL/min
NCT00716092,has_criteria,Treatment with rosiglitazone
NCT04976192,involves,Chronic Idiopathic Urticaria
NCT04976192,evaluates,TEV-45779
NCT04976192,evaluates,XOLAIR
NCT04976192,measures_primary,Change from baseline in ISS7
NCT04976192,measures_secondary,Relative potency of TEV 45779 and XOLAIR
NCT04976192,measures_secondary,Change from baseline in the UAS7
NCT04976192,measures_secondary,Percentage of patients with a UAS7 ≤6
NCT04976192,measures_secondary,Percentage of complete responders (UAS7=0)
NCT04976192,measures_secondary,Change from baseline in the physician's (in-clinic) assessment of UAS7
NCT04976192,measures_secondary,Change from baseline in the weekly number of wheals score
NCT04976192,measures_secondary,Change from baseline in the weekly size of the largest wheals score
NCT04976192,has_criteria,Baseline and week 12
NCT00790192,involves,schizophrenia
NCT00790192,evaluates,Lurasidone HCL
NCT00790192,measures_primary,PANSS total score
NCT00790192,measures_secondary,CGI-S
NCT00790192,has_criteria,aged 18-75 years
NCT00428389,involves,Alzheimer's disease
NCT00428389,evaluates,switching from donepezil to rivastigmine patch
NCT00428389,measures_primary,discontinued due any reason
NCT00428389,measures_secondary,discontinued due adverse event
NCT00428389,measures_secondary,discontinued due any reason
NCT00428389,measures_secondary,CGIC score
NCT00428389,has_criteria,Baseline through week 5
NCT00428389,has_criteria,Baseline through end of study
NCT00428389,has_criteria,week 5 through end of extension phase
NCT01987492,involves,Severe asthma
NCT01987492,evaluates,Lebrikizumab
NCT01987492,measures_primary,Relative Change OCS Dose
NCT01987492,measures_secondary,Percentage OCS Dose Reduction
NCT01987492,measures_secondary,Percentage Participants Discontinuing OCS
NCT01987492,has_criteria,Severe asthma specialist follow-up
NCT00320489,involves,Schizophrenia
NCT00320489,evaluates,Olanzapine Pamoate Depot
NCT00320489,evaluates,Oral Olanzapine
NCT00320489,measures_primary,Median Time to Discontinuation
NCT00320489,measures_secondary,Heinrich-Carpenter QLS Total Score
NCT00320489,measures_secondary,36-Item Short Form Health Survey
NCT00320489,measures_secondary,EuroQol: 5 Dimensions Questionnaire
NCT00320489,has_criteria,Baseline up to 104 weeks
NCT03259789,involves,Type 2 Diabetes
NCT03259789,evaluates,Bexagliflozin
NCT03259789,evaluates,Placebo
NCT03259789,measures_primary,Change From Baseline in HbA1c at Week 24
NCT03259789,measures_secondary,Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
NCT03259789,measures_secondary,Change From Baseline in Systolic Blood Pressure (SBP) at Week 24
NCT03259789,measures_secondary,Proportion of Subjects Achieving HbA1c < 7% Over Time
NCT03259789,has_criteria,Baseline to week 24
NCT00105989,involves,Major Depressive Disorder
NCT00105989,evaluates,Duloxetine
NCT00105989,measures_primary,Recurrence Count
NCT00105989,measures_secondary,Worsening
NCT00105989,measures_secondary,Loss of Response
NCT00105989,measures_secondary,HAMD-17 Total Score
NCT00105989,has_criteria,re-emergence criteria
NCT04776629,involves,Psoriasis
NCT04776629,involves,Cardiometabolic Risk Factors
NCT04776629,evaluates,Orticumab
NCT04776629,measures_primary,Percent change PASI
NCT04776629,measures_secondary,sIGA Score
NCT04776629,measures_secondary,PASI75
NCT04776629,measures_secondary,PASI50
NCT04776629,measures_secondary,BSA involvement
NCT04776629,has_criteria,Treatment success
NCT00992589,involves,Gastroesophageal Erosive Reflux Disease
NCT00992589,evaluates,Rabeprazole
NCT00992589,measures_primary,Change in Regurgitation
NCT00992589,measures_secondary,Weight-for-Age Z-Score
NCT00992589,measures_secondary,I-GERQ-R Total Score
NCT00992589,measures_secondary,Weekly Average I-GERQ-DD Total Score
NCT00992589,has_criteria,Baseline Observation Carried Forward
NCT01438489,involves,Systemic Lupus Erythematosus
NCT01438489,evaluates,MEDI-546
NCT01438489,measures_primary,SRI (4) Response
NCT01438489,measures_secondary,Type I Interferon
NCT01438489,has_criteria,SLEDAI-2K score
NCT00850889,involves,nasolabial folds
NCT00850889,evaluates,Juvederm Ultra With Lidocaine
NCT00850889,evaluates,Restylane
NCT00850889,measures_primary,Procedural Pain Score
NCT00850889,measures_secondary,Comparative Pain
NCT00850889,measures_secondary,Investigator Assessment of Improvement
NCT00850889,measures_secondary,Subject Assessment of Improvement
NCT00850889,has_criteria,moderate to severe nasolabial folds
NCT00850889,has_criteria,same pre-treatment NLF severity score
NCT00850889,has_criteria,negative urine pregnancy test result
NCT00850889,has_criteria,reliable method of contraception
NCT03633929,involves,Opioid Use Disorder
NCT03633929,evaluates,mHealth
NCT03633929,measures_primary,Opioid use reported
NCT03633929,measures_secondary,Depression Score
NCT03633929,measures_secondary,World Health Organization Quality of Life
NCT03633929,has_criteria,self-reported in app
NCT01559129,involves,Systemic Sclerosis With Interstitial Lung Disease
NCT01559129,evaluates,Pomalidomide
NCT01559129,measures_primary,Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52
NCT01559129,has_criteria,From the start of study drug to 28 days after last dose
NCT01620489,involves,Type 2 Diabetes
NCT01620489,evaluates,Liraglutide
NCT01620489,measures_primary,HbA1c (%)
NCT01620489,measures_secondary,Weight Gain
NCT01620489,measures_secondary,Hypoglycaemic Episodes
NCT01620489,measures_secondary,Self-measured Plasma Glucose
NCT01620489,measures_secondary,Body Mass Index
NCT04285229,involves,Radiographic Axial Spondyloarthritis
NCT04285229,evaluates,Ixekizumab
NCT04285229,measures_primary,ASAS40 Response
NCT04285229,has_criteria,bDMARD-naïve
NCT03756129,involves,treatment-resistant depression
NCT03756129,evaluates,MIJ821
NCT03756129,measures_primary,Change From Baseline
NCT03756129,measures_secondary,Change From Baseline
NCT03756129,has_criteria,single dose administration
NCT01253629,involves,Fragile X Syndrome
NCT01253629,evaluates,AFQ056
NCT01253629,measures_primary,ABC-C Total score
NCT01253629,measures_secondary,CGI-I scale
NCT01253629,has_criteria,partially methylated
NCT01754129,involves,Parkinson's disease
NCT01754129,evaluates,LevoDopa/Carbidopa
NCT01754129,measures_primary,"Mean change ""off"" time"
NCT01754129,measures_secondary,UPDRS IV score
NCT01754129,has_criteria,"off"" times"
NCT01216072,involves,Relapsing Forms of Multiple Sclerosis
NCT01216072,evaluates,Fingolimod
NCT01216072,measures_primary,Global Satisfaction
NCT01216072,measures_secondary,Patient-reported Activities of Daily Living
NCT01216072,has_criteria,Change From Baseline
NCT02277704,involves,Military-Related PTSD
NCT02277704,evaluates,TNX-102 SL
NCT02277704,measures_primary,CAPS-5 score change
NCT02277704,measures_secondary,Sleep Disturbance
NCT02277704,measures_secondary,CGI-I Responder Rate
NCT02277704,measures_secondary,Sheehan Disability Scale
NCT02277704,has_criteria,18 to 65 years old
NCT03139604,involves,Acute Graft-Versus-Host Disease
NCT03139604,evaluates,Itacitinib
NCT03139604,measures_primary,Overall Response Rate
NCT03139604,measures_secondary,Nonrelapse Mortality
NCT03139604,measures_secondary,Duration of Response
NCT03139604,measures_secondary,Cmax of Itacitinib
NCT03139604,measures_secondary,Cmin of Itacitinib
NCT03139604,measures_secondary,Tmax of Itacitinib
NCT03139604,measures_secondary,AUC of Itacitinib
NCT03139604,measures_secondary,CL/F of Itacitinib
NCT03139604,measures_secondary,Time to Response
NCT03139604,measures_secondary,Relapse Rate of Malignant and Nonmalignant Hematologic Disease
NCT03139604,measures_secondary,Malignancy Relapse-related Mortality Rate
NCT03139604,has_criteria,Randomization through end of Study
NCT05014204,involves,Type II Diabetes
NCT05014204,evaluates,Novel Therapy
NCT05014204,measures_primary,Serious adverse events
NCT05014204,measures_secondary,HbA1c
NCT05014204,measures_secondary,Fasting plasma glucose
NCT05014204,measures_secondary,Insulin resistance
NCT05014204,measures_secondary,Post-prandial glucose
NCT05014204,measures_secondary,Weight
NCT05014204,measures_secondary,Blood pressure
NCT05014204,measures_secondary,Alanine aminotransferase
NCT05014204,measures_secondary,Aspartate aminotransferase
NCT05014204,measures_secondary,Glucose-lowering medication usage
NCT05014204,has_criteria,Age 22-65 years
NCT05014204,has_criteria,Diagnosis of T2D
NCT05014204,has_criteria,T2D history 3-10 years
NCT05014204,has_criteria,HbA1C 7.5-10.0%
NCT05014204,has_criteria,BMI 24-40 kg/m2
NCT05014204,has_criteria,Two to three glucose lowering medications
NCT05014204,has_criteria,Weight stability
NCT05014204,has_criteria,No blood donation
NCT05014204,has_criteria,Study compliance
NCT05014204,has_criteria,Informed Consent Form
NCT05014204,has_criteria,Women of childbearing potential
NCT03446001,involves,Alzheimer's Disease
NCT03446001,evaluates,TRx0237
NCT03446001,measures_primary,Change from Baseline on ADAS-cog11
NCT03446001,measures_primary,Change from Baseline on ADCS-ADL23
NCT03446001,measures_primary,Number of adverse events
NCT03446001,measures_secondary,Change in annualized rate of whole brain atrophy
NCT03446001,measures_secondary,Change in Standardized Uptake Value Ratio (SUVR)
NCT03446001,measures_secondary,Change in annualized rate of temporal and parietal lobe atrophy
NCT01193101,involves,Essential Hypertension
NCT01193101,evaluates,LCZ696
NCT01193101,measures_primary,Change From Baseline
NCT01193101,measures_secondary,Mean Sitting Diastolic Blood Pressure
NCT01193101,measures_secondary,Mean Sitting Systolic Blood Pressure
NCT01193101,measures_secondary,24 Hour Mean Ambulatory DBP and SBP
NCT01193101,measures_secondary,Daytime Mean Ambulatory DBP and SBP
NCT01193101,measures_secondary,Nighttime Mean Ambulatory DBP and SBP
NCT01193101,measures_secondary,Mean Sitting Pulse Pressure
NCT01193101,has_criteria,Baseline
NCT01193101,has_criteria,8 weeks
NCT03793712,involves,Schizophrenia
NCT03793712,evaluates,Lu AF11167
NCT03793712,measures_primary,BNSS total score
NCT03793712,measures_secondary,PSP score
NCT03793712,measures_secondary,PANSS total score
NCT03793712,measures_secondary,PANSS Marder Negative Symptom Factor score
NCT00595946,involves,Opioid-induced Bowel Dysfunction
NCT00595946,evaluates,Lubiprostone
NCT00595946,measures_primary,Spontaneous Bowel Movements
NCT00595946,measures_secondary,Straining
NCT00595946,measures_secondary,Stool Consistency
NCT00595946,measures_secondary,Constipation Severity
NCT00595946,measures_secondary,Abdominal Bloating
NCT00595946,measures_secondary,Abdominal Discomfort
NCT00595946,measures_secondary,Bowel Habit Regularity
NCT00595946,has_criteria,at least 8 weeks
NCT00595946,has_criteria,at least 3 SBMs
NCT05376969,involves,Type 2 Diabetes Mellitus
NCT05376969,evaluates,DWP16001
NCT05376969,measures_primary,HbA1c reduction
NCT05376969,measures_secondary,Fasting Plasma Glucose
NCT05376969,has_criteria,Prior phase 3 study participation
NCT02624869,involves,Familial Hypercholesterolemia
NCT02624869,evaluates,Evolocumab
NCT02624869,measures_primary,LDL-C Percent Change
NCT02624869,measures_secondary,Non-HDL-C Percent Change
NCT02624869,has_criteria,Baseline value
NCT01340872,involves,Iron Deficiency Anaemia
NCT01340872,involves,Ulcerative Colitis
NCT01340872,evaluates,Oral Ferric Iron
NCT01340872,measures_primary,Change in Hb Concentration
NCT01340872,measures_secondary,Proportion of Subjects That Achieved ≥1 g/dL Change From Baseline in Hb Concentration at Week 12
NCT01340872,measures_secondary,Proportion of Subjects That Achieved ≥2 g/dL Change From Baseline in Hb Concentration at Week 12
NCT01340872,measures_secondary,Proportion of Subjects That Achieved Hb Concentration Within Normal Range at Week 12
NCT01340872,has_criteria,Randomisation Visit
NCT00841672,involves,Hypertension
NCT00841672,evaluates,Aliskiren
NCT00841672,evaluates,Amlodipine
NCT00841672,measures_primary,Systolic Blood Pressure Response
NCT00841672,measures_secondary,Diastolic Blood Pressure Response
NCT00841672,measures_secondary,Blood Pressure Control
NCT00841672,has_criteria,≥ 18 years of age
NCT00841672,has_criteria,msSBP ≥ 160 mmHg
NCT00841672,has_criteria,msSBP < 200 mmHg
NCT00841672,has_criteria,serum potassium ≥ 5.3 mEq/L
NCT00650104,involves,Parkinson's Disease
NCT00650104,evaluates,Ropinirole XL
NCT00650104,measures_primary,UPDRS Total Activities
NCT00650104,measures_secondary,Adverse Events
NCT00650104,has_criteria,Long-term treatment
NCT03781804,involves,Chronic Rhinosinusitis
NCT03781804,involves,Nasal Polyps
NCT03781804,evaluates,OPN-375
NCT03781804,measures_primary,Change From Baseline
NCT03781804,measures_secondary,Percent volume opacified
NCT03781804,measures_secondary,SNOT-22 Total Score
NCT03781804,has_criteria,Subject Symptoms and Functioning
NCT05303701,involves,Alzheimer's Disease
NCT05303701,evaluates,GV1001
NCT05303701,measures_primary,SIB score
NCT05303701,measures_secondary,CIBIC-plus score
NCT05303701,has_criteria,dementia patient
NCT01585272,involves,Alzheimer's dementia
NCT01585272,evaluates,Rivastigmine
NCT01585272,measures_primary,Change From Baseline
NCT01585272,measures_secondary,Discontinuation Rate
NCT01585272,has_criteria,Intolerance of patch treatment
NCT06029972,involves,Ulcerative Colitis
NCT06029972,evaluates,Tilpisertib Fosmecarbil
NCT06029972,measures_primary,Clinical Response
NCT06029972,measures_secondary,Clinical Remission
NCT06029972,has_criteria,Week 12
NCT00962104,involves,Attention-Deficit/Hyperactivity Disorder
NCT00962104,evaluates,Atomoxetine
NCT00962104,measures_primary,Change From Baseline
NCT00962104,measures_secondary,AAQoL Scores
NCT00962104,measures_secondary,EQ-5D Health State Score
NCT00962104,has_criteria,Asian Adult Patients
NCT03519204,involves,Lip Enhancement
NCT03519204,evaluates,JUVÉDERM® VOLBELLA® With Lidocaine
NCT03519204,measures_primary,Lip Fullness Scale
NCT03519204,measures_secondary,Overall Lip Volume
NCT03519204,has_criteria,Chinese Adults
NCT03320304,involves,Major Depressive Episode
NCT03320304,evaluates,VNS Therapy
NCT03320304,measures_primary,MADRS response
NCT03320304,measures_secondary,Duration of response
NCT03320304,measures_secondary,Change in MADRS
NCT03320304,measures_secondary,Cumulative response
NCT03320304,measures_secondary,Cumulative remission
NCT03320304,has_criteria,MADRS score 20
NCT01743001,involves,Eisenmenger Syndrome
NCT01743001,evaluates,Macitentan
NCT01743001,measures_primary,Exercise Capacity
NCT01743001,measures_secondary,WHO Functional Class
NCT01743001,measures_secondary,Dyspnea
NCT01743001,measures_secondary,Quality of Life
NCT01743001,has_criteria,From baseline to Week 16
NCT04564872,involves,Type 2 diabetes mellitus
NCT04564872,evaluates,Metformin
NCT04564872,measures_primary,HbA1c Change
NCT04564872,measures_secondary,Incidence of Treatment-Emergent Adverse Events
NCT04564872,has_criteria,Age ≥ 18 and ≤ 75 years
NCT04564872,has_criteria,Type 2 diabetes mellitus
NCT04564872,has_criteria,Insufficient glycaemic control
NCT04564872,has_criteria,HbA1c ≥7.5 to ≤11.0%
NCT04564872,has_criteria,FPG \< 15 mmol/L
NCT04564872,has_criteria,BMI ≥ 18.0 kg/m² to ≤ 35.0 kg/m²
NCT04564872,has_criteria,Diabetic ketoacidosis
NCT04564872,has_criteria,hyperglycemia hypertonic state
NCT04564872,has_criteria,serious complications of diabetes
NCT01933672,involves,Type 2 Diabetes
NCT01933672,evaluates,PF-04937319
NCT01933672,evaluates,Sitagliptin
NCT01933672,measures_primary,Change From Baseline in WMDG
NCT01933672,measures_primary,Change From Baseline in FPG
NCT01933672,measures_secondary,Change From Baseline in C-Peptide
NCT01933672,measures_secondary,Change From Baseline in Insulin
NCT01933672,measures_secondary,Incidence of All Causality Treatment-Emergent Adverse Event
NCT01933672,measures_secondary,Frequency of Laboratory Test Abnormalities
NCT01933672,measures_secondary,Change From Baseline in Body Weight
NCT01933672,has_criteria,Potential Clinical Concern
NCT00109772,involves,Complex Regional Pain Syndrome Type 1
NCT00109772,evaluates,Lenalidomide
NCT00109772,measures_primary,CRPS Pain Intensity
NCT00109772,measures_secondary,Short Form McGill Pain Questionnaire
NCT00109772,has_criteria,12 weeks of treatment
NCT03447704,involves,Ankylosing Spondylitis
NCT03447704,evaluates,BCD-085
NCT03447704,measures_primary,ASAS40 rate
NCT03447704,measures_secondary,BASDAI
NCT03447704,measures_secondary,ASDAS-CRP
NCT03447704,measures_secondary,SF-36
NCT03447704,measures_secondary,Frequency of AE/SAE
NCT03447704,has_criteria,Active disease
NCT03447704,has_criteria,BASDAI score
NCT03447704,has_criteria,Mean backache intensity
NCT03823404,involves,Alzheimer's Disease
NCT03823404,evaluates,COR388
NCT03823404,measures_primary,ADAS-Cog 11 Total Score
NCT03823404,measures_secondary,ADCS-ADL Inventory Score
NCT03823404,measures_secondary,CDR-SB Sum of Boxes
NCT03823404,measures_secondary,MMSE Total Score
NCT03823404,measures_secondary,NPI Total Score
NCT03823404,has_criteria,Key Inclusion Criteria
NCT02479204,evaluates,ACT-334441
NCT02479204,measures_primary,PR intervals
NCT02479204,measures_primary,Heart rate
NCT02479204,measures_primary,AUC
NCT02479204,measures_primary,Cmax
NCT02479204,measures_primary,tmax
NCT02479204,measures_primary,t(1/2)
NCT02479204,has_criteria,diltiazem
NCT02479204,has_criteria,atenolol
NCT00700401,involves,Chronic Hepatitis C
NCT00700401,evaluates,PEGASYS
NCT00700401,evaluates,Copegus
NCT00700401,measures_primary,Sustained Virological Response
NCT00700401,measures_secondary,Rapid Virological Response
NCT00700401,measures_secondary,Virological Response
NCT00700401,measures_secondary,Virological Relapse
NCT00700401,measures_secondary,Positive Predictive Value
NCT00700401,has_criteria,undetectable HCV RNA
NCT00449072,involves,Perennial Allergic Rhinitis
NCT00449072,evaluates,Triamcinolone Acetonide
NCT00449072,measures_primary,Growth Velocity
NCT00449072,measures_secondary,Instantaneous Total Nasal Symptom Score
NCT00449072,measures_secondary,Four Individual Nasal Symptom Scores
NCT00449072,has_criteria,Ages 3 to 9
NCT04507204,involves,Attention-Deficit/Hyperactivity Disorder
NCT04507204,evaluates,Adhansia XR
NCT04507204,measures_primary,ADHD-RS-5 Total Score
NCT04507204,measures_secondary,Time Sensitive ADHD Symptom Scale
NCT04507204,measures_secondary,Clinical Global Impression-Severity
NCT04507204,measures_secondary,Clinical Global Impression-Improvement
NCT04507204,measures_secondary,Treatment Satisfaction
NCT04507204,has_criteria,DSM-5 criteria
NCT02584504,involves,Hypercholesterolemia
NCT02584504,evaluates,Alirocumab
NCT02584504,measures_primary,Percent Change LDL-C
NCT02584504,measures_secondary,Apolipoprotein B
NCT02584504,has_criteria,Non-statin lipid modifying therapy
NCT02116972,involves,Osteoarthritis of the Knee
NCT02116972,evaluates,FX006
NCT02116972,evaluates,Normal Saline
NCT02116972,measures_primary,Pain Intensity Scores
NCT02116972,measures_secondary,WOMAC C
NCT02116972,measures_secondary,Patient Global Impression of Change
NCT02116972,has_criteria,Willingness to comply
NCT02175472,involves,Parkinson's Disease
NCT02175472,evaluates,Light Therapy
NCT02175472,measures_primary,MDS-UPDRS change
NCT02175472,measures_secondary,CGI-I
NCT02175472,measures_secondary,PDQ-39 score
NCT02175472,has_criteria,Six Months
NCT03217604,evaluates,PF-06852231
NCT03217604,measures_primary,Treatment Emergent AEs
NCT03217604,measures_secondary,Laboratory Abnormalities
NCT03217604,measures_secondary,Clinically Significant Change
NCT03217604,measures_secondary,Change From Baseline
NCT03217604,measures_secondary,Electrocardiogram Findings
NCT03217604,has_criteria,Healthy Subjects
NCT00538304,involves,Glaucoma
NCT00538304,involves,Ocular Hypertension
NCT00538304,evaluates,Bimatoprost
NCT00538304,measures_primary,Change From Baseline in Mean Peak Macroscopic Conjunctival Hyperemia at Month 1
NCT00538304,measures_secondary,Change from Baseline in mean Intraocular Pressure (IOP) at Month 1
NCT00538304,measures_secondary,Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye at Month 1
NCT00538304,measures_secondary,Percentage of Physicians Who Were Very or Extremely Willing to Continue Patient on Drug
NCT00538304,has_criteria,Baseline
NCT00863304,involves,Osteoarthritis
NCT00863304,evaluates,Tanezumab
NCT00863304,measures_primary,Change From Baseline
NCT00863304,measures_secondary,Change From Baseline
NCT00863304,has_criteria,Baseline Observation Carried Forward
NCT06010004,involves,Type 2 Diabetes
NCT06010004,evaluates,Orforglipron
NCT06010004,measures_primary,Change from Baseline in HbA1c
NCT06010004,measures_secondary,Percentage of Participants who Achieve HbA1c <7.0%
NCT06010004,measures_secondary,Percentage of Participants who Achieve HbA1c ≤6.5%
NCT06010004,measures_secondary,Percentage of Participants who Achieve HbA1c <5.7%
NCT06010004,measures_secondary,Change from Baseline in Fasting Serum Glucose
NCT06010004,measures_secondary,Change from Baseline in Body Weight
NCT06010004,measures_secondary,Percentage of Participants who Achieve Weight Loss of ≥5%
NCT06010004,measures_secondary,Percentage of Participants who Achieve Weight Loss of ≥10%
NCT06010004,measures_secondary,Percentage of Participants who Achieve Weight Loss of ≥15%
NCT06010004,measures_secondary,Change from Baseline in Waist Circumference
NCT06010004,measures_secondary,Change from Baseline in Body Mass Index
NCT06010004,measures_secondary,Change from Baseline in Daily Average 7-Point SMBG
NCT06010004,has_criteria,Have Type 2 Diabetes
NCT06010004,has_criteria,Have HbA1c ≥7.0% to ≤10.5%
NCT06010004,has_criteria,Are of stable weight (±5%)
NCT06010004,has_criteria,Have a BMI ≥23.0 kg/m²
NCT06010004,has_criteria,Do not have Type 1 Diabetes
NCT02334501,evaluates,Lansoprazole
NCT02334501,evaluates,Neratinib
NCT02334501,measures_primary,AUC(0-t)
NCT02334501,measures_primary,AUC(0-inf)
NCT02334501,measures_primary,Cmax
NCT02334501,measures_secondary,Adverse events
NCT02334501,has_criteria,Healthy
NCT02334501,has_criteria,18 to 55 years
NCT02334501,has_criteria,BMI 18.5 to 32.0
NCT02334501,has_criteria,Non to moderate smokers
NCT01173601,involves,Major Depressive Disorder
NCT01173601,evaluates,Adjunctive Treatment
NCT01173601,measures_primary,Change From Randomization to Week 8 in MADRS Total Score
NCT01173601,measures_secondary,Sheehan Disability Scale Global Functional Impairment Scale
NCT01173601,measures_secondary,Fatigue Associated With Depression (FAsD) Impact Subscale Score
NCT01173601,has_criteria,Randomization
NCT03928704,involves,Nonradiographic Axial Spondyloarthritis
NCT03928704,evaluates,Bimekizumab
NCT03928704,measures_primary,ASAS40 response
NCT03928704,measures_secondary,BASDAI change
NCT03928704,has_criteria,ASAS40 criteria
NCT01885104,involves,Constipation
NCT01885104,evaluates,Oral Polyethylene Glycol (PEG 3350) Solution
NCT01885104,measures_primary,Inflammation of mucosa
NCT01885104,measures_secondary,Inflammation of mucosa
NCT01885104,has_criteria,Functional constipation
NCT02896192,involves,POMC Deficiency Obesity
NCT02896192,evaluates,setmelanotide
NCT02896192,measures_primary,Weight loss threshold
NCT02896192,measures_secondary,Hunger score
NCT02896192,measures_secondary,Percent change in body weight
NCT02896192,has_criteria,≥12 years of age
NCT00151892,involves,Ulcerative Colitis
NCT00151892,evaluates,SPD476
NCT00151892,measures_primary,Endoscopic Remission
NCT00151892,measures_secondary,UCDAI Score
NCT00151892,measures_secondary,SIBDQ Total Score
NCT00151892,has_criteria,Withdrawal Due to Relapse
NCT02383589,involves,Pemphigus Vulgaris
NCT02383589,evaluates,Rituximab
NCT02383589,evaluates,Mycophenolate Mofetil
NCT02383589,measures_primary,Sustained Complete Remission
NCT02383589,measures_secondary,Oral Corticosteroid Dose
NCT02383589,measures_secondary,Disease Flares
NCT02383589,measures_secondary,Time to Remission
NCT02383589,measures_secondary,Time to Flare
NCT02383589,measures_secondary,Health-Related Quality of Life
NCT02383589,has_criteria,three or more new lesions
NCT01337089,involves,Chronic Cancer Related Pain
NCT01337089,evaluates,Sativex Oromucosal Spray
NCT01337089,measures_primary,Change From Baseline In Mean NRS Average Pain
NCT01337089,measures_secondary,Change From Baseline In Mean Sleep Disruption NRS
NCT01337089,has_criteria,Baseline
NCT04718389,involves,Severe Asthma
NCT04718389,evaluates,GSK3511294
NCT04718389,evaluates,Mepolizumab
NCT04718389,evaluates,Benralizumab
NCT04718389,measures_primary,exacerbations rate
NCT04718389,measures_secondary,SGRQ total score
NCT04718389,measures_secondary,ACQ-5 score
NCT04718389,measures_secondary,FEV1
NCT04718389,has_criteria,Adult and adolescent participants
NCT01199289,involves,Asthma
NCT01199289,evaluates,AMG 827
NCT01199289,measures_primary,Change From Baseline
NCT01199289,measures_secondary,Pre- and Post-Bronchodilator FEV1
NCT01199289,measures_secondary,Peak Expiratory Flow Rate
NCT01199289,measures_secondary,Rescue Short Acting β-Agonist Use
NCT01199289,measures_secondary,Daily Asthma Symptom Score
NCT01199289,has_criteria,Inadequately Controlled Asthma
NCT01290029,involves,Chronic Kidney Disease
NCT01290029,evaluates,Cinacalcet
NCT01290029,measures_primary,Intact Parathyroid Hormone
NCT01290029,measures_secondary,Total Calcium
NCT04152629,involves,ADHD
NCT04152629,evaluates,FOQUEST
NCT04152629,measures_primary,Change in ADHD Rating Scale Total Score
NCT04152629,measures_secondary,Change from Baseline ADHD Rating Scale Total Score at 4 Months
NCT04152629,has_criteria,Pediatric: Male or non-pregnant
NCT01118780,involves,Generalized Anxiety Disorder
NCT01118780,evaluates,Duloxetine
NCT01118780,measures_primary,Change From Baseline
NCT01118780,measures_secondary,Sheehan Disability Scale
NCT01118780,has_criteria,age category
NCT00336492,involves,Ulcerative Colitis
NCT00336492,evaluates,Infliximab
NCT00336492,measures_primary,Clinical Response
NCT00336492,measures_secondary,PUCAI Remission
NCT00336492,has_criteria,Moderately to severely active ulcerative colitis
NCT00336492,has_criteria,Diagnosed with ulcerative colitis
NCT00336492,has_criteria,Sexually active
NCT00336492,has_criteria,Adequate birth control
NCT00336492,has_criteria,History of latent or active TB
NCT00336492,has_criteria,Live viral or bacterial vaccination
NCT00336492,has_criteria,Serious infections
NCT00336492,has_criteria,Prior treatment with infliximab
NCT04657289,involves,Neovascular Age-Related Macular Degeneration
NCT04657289,evaluates,Ranibizumab
NCT04657289,measures_primary,Change from baseline BCVA
NCT04657289,measures_secondary,Percentage participants BCVA 69 letters
NCT04657289,measures_secondary,Percentage participants BCVA 38 letters
NCT04657289,measures_secondary,Patient preference ranibizumab
NCT04657289,measures_secondary,Treatment satisfaction
NCT04657289,has_criteria,Baseline to Week 72
NCT00751829,involves,Isolated Systolic Hypertension
NCT00751829,measures_primary,Change in mean sitting systolic BP
NCT00751829,measures_secondary,Change in mean standing systolic BP
NCT00751829,has_criteria,Age 65 or older
NCT02154529,involves,HER2-Positive Metastatic Breast Cancer
NCT02154529,evaluates,Tesevatinib
NCT02154529,evaluates,Trastuzumab
NCT02154529,measures_primary,Mean Serum Cmax
NCT02154529,measures_secondary,Median Serum Tmax
NCT02154529,measures_secondary,Mean Serum AUC(0-t)
NCT02154529,has_criteria,Up to 8 months
NCT00251680,involves,Hyperlipidemia
NCT00251680,evaluates,Lapaquistat Acetate
NCT00251680,measures_primary,Change from Baseline in LDL cholesterol
NCT00251680,measures_secondary,Triglycerides
NCT00251680,measures_secondary,Total Cholesterol
NCT00251680,measures_secondary,HDL cholesterol
NCT00251680,measures_secondary,VLDL cholesterol
NCT00251680,measures_secondary,apolipoprotein A1
NCT00251680,measures_secondary,apolipoprotein B
NCT00251680,measures_secondary,non-HDL cholesterol
NCT00251680,measures_secondary,LDL/HDL ratio
NCT00251680,measures_secondary,Total Cholesterol/HDL ratio
NCT00251680,measures_secondary,apoA1/apoB ratio
NCT00251680,measures_secondary,high-sensitivity C-reactive protein
NCT00251680,measures_secondary,LDL cholesterol < 1.81 mmol/L
NCT00251680,measures_secondary,LDL cholesterol < 2.59 mmol/L
NCT00251680,measures_secondary,LDL cholesterol < 3.37 mmol/L
NCT00251680,measures_secondary,Best corrected visual acuity
NCT00251680,measures_secondary,Adverse Events
NCT00251680,measures_secondary,Clinical Laboratory Tests
NCT00251680,measures_secondary,Vital Signs
NCT00251680,measures_secondary,12-lead Electrocardiogram
NCT00251680,measures_secondary,Physical Examination
NCT00251680,has_criteria,Lipid-Lowering Therapy
NCT03172780,involves,Osteoarthritis Knee
NCT03172780,evaluates,Diclofenac sodium gel of 1% of Mylan Inc.
NCT03172780,evaluates,Voltaren® Gel 1% of Novartis Consumer Health
NCT03172780,measures_primary,Change From Baseline
NCT03172780,measures_secondary,WOMAC pain subscale score
NCT03172780,has_criteria,week 4
NCT06141980,involves,Type 2 Diabetes Mellitus
NCT06141980,evaluates,DWP16001
NCT06141980,measures_primary,Change of HbA1c
NCT06141980,measures_secondary,Change of FPG
NCT06141980,has_criteria,age 19 under 80 years
NCT06141980,has_criteria,HbA1c 7% ≤ 11%
NCT06141980,has_criteria,FPG \<270 mg/dl
NCT06141980,has_criteria,received metformin gemigliptin 8 weeks
NCT03226392,involves,Asthma
NCT03226392,evaluates,QAW039
NCT03226392,measures_primary,Change From Baseline in FEV1
NCT03226392,measures_secondary,Daytime Asthma Symptom Score
NCT03226392,measures_secondary,Number of Puffs of SABA Taken Per Day
NCT03226392,measures_secondary,Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ+12) Score
NCT03226392,has_criteria,diagnosis of asthma
NCT02566889,involves,Inflammatory Bowel Disease
NCT02566889,evaluates,Infliximab
NCT02566889,measures_primary,Clinical Response
NCT02566889,measures_secondary,Mayo Score
NCT02566889,has_criteria,Dose escalation
NCT03581929,involves,Mild Cognitive Impairment
NCT03581929,evaluates,Memormax
NCT03581929,measures_primary,global cognitive performance
NCT03581929,measures_secondary,variations of cognitive performance
NCT03581929,has_criteria,6 months treatment
NCT02626689,involves,β-thalassemia
NCT02626689,evaluates,Standard of Care
NCT02626689,measures_primary,Change in PSC
NCT02626689,measures_primary,Change in MCS
NCT02626689,measures_secondary,Change in total scores
NCT02626689,has_criteria,Transfusion Dependent
NCT02626689,has_criteria,Non-transfusion Dependent
NCT02473289,involves,Major Depressive Disorder
NCT02473289,evaluates,Sirukumab
NCT02473289,measures_primary,Change From Baseline in HDRS-17 Total Score at Week 12
NCT02473289,measures_secondary,Change From Baseline in HDRS-17 Total Score at Weeks 1
NCT02473289,measures_secondary,Percentage of Participants With Remission as Assessed by HDRS-17 Total Score at Week 12
NCT02473289,has_criteria,Baseline and Week 12
NCT05591989,involves,Chronic Rhinitis
NCT05591989,evaluates,NEUROMARK System
NCT05591989,measures_primary,rTNSS total score
NCT05591989,measures_secondary,mini-RQLQ score
NCT05591989,measures_secondary,CGI-I score
NCT05591989,measures_secondary,NRS score
NCT05591989,has_criteria,≥18 years of age
NCT05591989,has_criteria,rhinitis symptoms 6 months
NCT05591989,has_criteria,moderate to severe runny nose
NCT05591989,has_criteria,mild to severe nasal congestion
NCT05591989,has_criteria,total rTNSS score 5
NCT05591989,has_criteria,allergy test 5 years
NCT05352529,involves,Alzheimer's disease
NCT05352529,involves,dementia
NCT05352529,evaluates,Assistive Technology
NCT05352529,measures_primary,ADCS-ADL score
NCT05352529,measures_primary,MBRC Caregiver Strain
NCT05352529,measures_secondary,QoL-18
NCT05352529,measures_secondary,SS-2
NCT05352529,has_criteria,diagnosed with ADRD
NCT05352529,has_criteria,primary caregiver
NCT05352529,has_criteria,proficient in English
NCT03544229,involves,Gastroparesis
NCT03544229,evaluates,TAK-906
NCT03544229,measures_primary,ANMS GCSI-DD score
NCT03544229,measures_secondary,Percentage of Participants
NCT03544229,has_criteria,Adult Participants
NCT00623480,involves,Hemophilia A
NCT00623480,evaluates,rFVIII Therapy
NCT00623480,measures_primary,Bleeding Frequency
NCT00623480,measures_secondary,MRI Scale
NCT00623480,measures_secondary,Colorado Adult Joint Assessment Scale
NCT00623480,has_criteria,Males aged 12 to 50 years
NCT00623480,has_criteria,Males aged 18 to 50 years
NCT00623480,has_criteria,severe hemophilia A
NCT00623480,has_criteria,FVIII:C baseline levels
NCT00550680,involves,Chronic Renal Anemia
NCT00550680,evaluates,Mircera
NCT00550680,measures_primary,Hb within target range
NCT00550680,measures_secondary,Mean Change in Hb
NCT00550680,has_criteria,Weeks -4 to 0
NCT01452529,involves,Chronic Low Back Pain
NCT01452529,evaluates,Hydrocodone Bitartrate
NCT01452529,measures_primary,Pain Intensity
NCT01452529,measures_secondary,Sleep Disturbance
NCT01452529,has_criteria,≥ 30% Reduction in Pain
NCT02171429,involves,Ulcerative Colitis
NCT02171429,evaluates,Etrolizumab
NCT02171429,evaluates,Adalimumab
NCT02171429,evaluates,Placebo
NCT02171429,measures_primary,Remission at Week 10
NCT02171429,measures_secondary,Disease activity
NCT02171429,has_criteria,Tumor Necrosis Factor Inhibitors
NCT05772429,involves,Epilepsy
NCT05772429,evaluates,Epidyolex
NCT05772429,measures_primary,Seizure Frequency
NCT05772429,measures_secondary,Behavior Rating Inventory
NCT05772429,has_criteria,Age ≤5 Years
NCT05772429,has_criteria,Age 6 to 18 Years
NCT01070329,involves,Depression
NCT01070329,involves,Painful Physical Symptoms
NCT01070329,evaluates,Treatment
NCT01070329,measures_primary,Change From Baseline
NCT01070329,measures_secondary,Montgomery-Asberg Depression Rating Scale Total Score
NCT01070329,measures_secondary,Sheehan Disability Scale Total and Item Scores
NCT01070329,measures_secondary,Percentage of Participants Achieving Remission
NCT01070329,has_criteria,Baseline
NCT00805480,involves,Chronic Plaque-type Psoriasis
NCT00805480,evaluates,AIN457
NCT00805480,measures_primary,Change From Baseline in PASI Scores
NCT00805480,measures_secondary,Percentage of Participants Who Had Not Relapsed
NCT00805480,measures_secondary,Percentage of Participants With at Least 50% Improvement From Baseline in PASI
NCT00805480,measures_secondary,Percentage of Participants With at Least 75% or 90% Improvement From Baseline in PASI
NCT00805480,has_criteria,Baseline
NCT02470429,involves,Dry Eye
NCT02470429,evaluates,SYSTANE® HYDRATION
NCT02470429,measures_primary,Change From Baseline TOSS Score
NCT02470429,measures_secondary,IDEEL Treatment Effectiveness Score
NCT02470429,measures_secondary,IDEEL Treatment Inconvenience Score
NCT02470429,measures_secondary,Tear Film Break-up Time
NCT02470429,has_criteria,Use of non-BAK artificial tears
NCT01018680,involves,Osteoarthritis
NCT01018680,evaluates,Duloxetine
NCT01018680,evaluates,Placebo
NCT01018680,measures_primary,Pain Score at 8 Weeks
NCT01018680,measures_secondary,Patient Global Impression of Improvement
NCT01018680,measures_secondary,Western Ontario and McMaster Universities Index of Osteoarthritis
NCT01018680,has_criteria,Nonsteroidal Anti-inflammatory Drug
NCT05972629,involves,Phenylketonuria
NCT05972629,evaluates,SAR444836
NCT05972629,measures_primary,Plasma Phe<360 μmol/L
NCT05972629,measures_secondary,Change from baseline
NCT05972629,has_criteria,Adult males
NCT05972629,has_criteria,18-65 years of age
NCT05972629,has_criteria,uncontrolled classical PKU
NCT05972629,has_criteria,PAH deficiency
NCT04333329,involves,Alzheimer's Disease
NCT04333329,evaluates,Transcranial Pulse Stimulation (TPS)
NCT04333329,measures_primary,CERAD Total Score
NCT04333329,measures_secondary,Mini-Mental-State Examination (MMSE)
NCT04333329,measures_secondary,Clock Drawing Test (CDT)
NCT04333329,has_criteria,Age
NCT02808780,involves,Ulcerative Colitis
NCT02808780,measures_primary,Partial Mayo Score
NCT02808780,measures_secondary,Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Score
NCT02808780,measures_secondary,EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) Score
NCT02808780,has_criteria,less than 30 years
NCT04127669,involves,Stroke
NCT04127669,evaluates,OSU6162
NCT04127669,measures_primary,Clinical Global Impression of Change
NCT04127669,measures_secondary,Frenchay Activity Index
NCT04127669,measures_secondary,Mental Fatigue Scale
NCT04127669,measures_secondary,Fatigue Severity Scale
NCT04127669,has_criteria,Residual Symptoms
NCT02552212,involves,axSpA
NCT02552212,evaluates,Certolizumab Pegol
NCT02552212,measures_primary,ASDAS-MI Response
NCT02552212,measures_secondary,ASAS40 Response
NCT02552212,has_criteria,X-ray Evidence of AS
NCT05164172,involves,Chronic Migraine
NCT05164172,involves,Episodic Migraine
NCT05164172,evaluates,Eptinezumab
NCT05164172,measures_primary,PedMIDAS Score
NCT05164172,has_criteria,Completed Week12 visit
NCT05164172,has_criteria,Adverse event
NCT05164172,has_criteria,Hypersensitivity reaction
NCT05164172,has_criteria,ALT value >5 times
NCT05164172,has_criteria,AST value >5 times
NCT05164172,has_criteria,ALT value >3 times
NCT05164172,has_criteria,Bilirubin value >2 times
NCT01696604,involves,Healthy Male Subjects
NCT01696604,evaluates,GSK2849466
NCT01696604,measures_primary,Adverse Events
NCT01696604,measures_primary,electrocardiogram
NCT01696604,measures_primary,blood pressure
NCT01696604,measures_primary,heart rate
NCT01696604,has_criteria,single ascending doses
NCT01696604,has_criteria,repeat doses
NCT00527072,involves,plaque psoriasis
NCT00527072,evaluates,Remicade
NCT00527072,measures_primary,PGA score minimal
NCT00527072,measures_secondary,PASI 50 Response
NCT00527072,has_criteria,plaque psoriasis etanercept treatment  PGA score  methotrexate cyclosporine  infliximab adalimumab hypersensitivity  granulomatous infection
NCT03728504,involves,Chronic Hand Eczema
NCT03728504,evaluates,ASN002
NCT03728504,measures_primary,Percent Change mTLSS
NCT03728504,measures_secondary,Physician Global Assessment
NCT03728504,measures_secondary,Patient Global Assessment
NCT03728504,has_criteria,History of severe CHE 6 months prior
NCT03728504,has_criteria,Refractory to topical corticosteroids
NCT03728504,has_criteria,Moderate to severe CHE PGA 3 or 4
NCT03728504,has_criteria,Emollient use 1 week prior
NCT03728504,has_criteria,BMI ≤ 38 kg/m2
NCT03728504,has_criteria,Negative pregnancy test
NCT02058368,involves,Benign Prostatic Hyperplasia
NCT02058368,evaluates,Dutasteride
NCT02058368,evaluates,Tamsulosin
NCT02058368,evaluates,Tamsulosin Monotherapy
NCT02058368,measures_primary,Change From Baseline
NCT02058368,measures_secondary,Percent Change in Prostate Volume
NCT02058368,has_criteria,Moderate to Severe
NCT02019472,involves,Rheumatoid Arthritis
NCT02019472,evaluates,Sirukumab
NCT02019472,evaluates,Adalimumab
NCT02019472,measures_primary,DAS28 (ESR)
NCT02019472,measures_secondary,ACR 50 Response
NCT02019472,measures_secondary,DAS28 (ESR)
NCT02019472,has_criteria,American College of Rheumatology
NCT02326272,involves,Plaque Psoriasis
NCT02326272,evaluates,Certolizumab Pegol
NCT02326272,measures_primary,PASI75 response
NCT02326272,measures_secondary,PGA Clear or Almost Clear
NCT02326272,measures_secondary,PASI90 response
NCT06648772,involves,Plaque Psoriasis
NCT06648772,evaluates,Roflumilast Cream 0.3%
NCT06648772,measures_primary,IGA treatment success
NCT06648772,measures_primary,PASI-75
NCT06648772,measures_primary,PASI-90
NCT06648772,measures_secondary,Time to PASI-50
NCT06648772,has_criteria,≥ 2 points improvement
NCT01478204,involves,Alzheimer's Disease
NCT01478204,measures_primary,Sleep Quality
NCT01478204,measures_secondary,Daytime Sleepiness
NCT01478204,has_criteria,NINCDS-ADRDA criteria
NCT01478204,has_criteria,MMSE score
NCT05636904,involves,Androgenetic Alopecia
NCT05636904,evaluates,Topical DLQ01
NCT05636904,measures_primary,Change from baseline in TAHC
NCT05636904,measures_secondary,Cumulative hair thickness density
NCT05636904,measures_secondary,Anagen/telogen ratio
NCT05636904,has_criteria,clinically significant
NCT01001572,involves,Essential Hypertension
NCT01001572,evaluates,Valsartan/Amlodipine
NCT01001572,measures_primary,Change in MSDBP
NCT01001572,measures_secondary,Percentage of Participants With Diastolic Blood Pressure Response
NCT01001572,measures_secondary,Percentage of Participants With Diastolic Blood Pressure Control
NCT01001572,has_criteria,Baseline and Week 8
NCT06165172,involves,Amyotrophic Lateral Sclerosis
NCT06165172,evaluates,MyoRegulator
NCT06165172,measures_primary,Improvement in Functionality
NCT06165172,measures_primary,Change in ALSFRS-R score
NCT06165172,measures_primary,Change in ROADS score
NCT06165172,measures_primary,Change in ALSAQ-40 score
NCT06165172,has_criteria,Up to 4 weeks
NCT00925704,involves,Healthy volunteers
NCT00925704,evaluates,Rocaltrol
NCT00925704,evaluates,Fosrenol
NCT00925704,evaluates,Renvela
NCT00925704,measures_primary,AUC 0-48
NCT00925704,measures_primary,Cmax
NCT00925704,measures_primary,Tmax
NCT00925704,has_criteria,Healthy volunteers
NCT00925704,has_criteria,age 19-45 years
NCT00925704,has_criteria,no clinically significant abnormalities
NCT00925704,has_criteria,no current or recurrent disease
NCT00517868,involves,Painful Bladder Syndrome
NCT00517868,involves,Interstitial Cystitis
NCT00517868,evaluates,URG101
NCT00517868,measures_primary,Daytime Bladder Pain Intensity
NCT00517868,measures_secondary,Question 3 PORIS
NCT00517868,measures_secondary,Total Symptom Score
NCT00517868,measures_secondary,Daytime Urinary Urgency Score
NCT00517868,has_criteria,12 hours post-dose
NCT00984568,involves,ulcerative colitis
NCT00984568,evaluates,Infliximab
NCT00984568,measures_primary,Mayo score
NCT00984568,measures_secondary,Steroid-free remission
NCT00984568,has_criteria,moderate-to-severe active
NCT05270668,involves,Systemic Sclerosis Associated With Interstitial Lung Disease
NCT05270668,evaluates,Tulisokibart
NCT05270668,measures_primary,Change from Baseline in FVC
NCT05270668,measures_secondary,Change from Baseline in HRCT QILD-WL
NCT05270668,measures_secondary,Percentage of Participants with an Improvement in the Revised CRISS Score
NCT01084668,involves,Psoriasis
NCT01084668,evaluates,Adalimumab
NCT01084668,measures_primary,PASI75
NCT01084668,measures_secondary,Dermatology Life Quality Index Score
NCT01084668,measures_secondary,Nail Psoriasis Severity Index Score
NCT01084668,has_criteria,Inclusion visit
NCT00915772,involves,Type 2 Diabetes
NCT00915772,evaluates,Linagliptin 2.5 mg Bid + Metformin
NCT00915772,measures_primary,Change in HbA1c
NCT00915772,measures_secondary,Frequency of AEs
NCT00915772,has_criteria,Signed informed consent
NCT01011868,involves,Type 2 Diabetes
NCT01011868,evaluates,BI 10773
NCT01011868,measures_primary,Change in HbA1c
NCT01011868,measures_secondary,Fasting Plasma Glucose
NCT01011868,has_criteria,Signed and dated
NCT05966272,involves,Type 2 diabetes mellitus
NCT05966272,evaluates,HRS9531 Injection
NCT05966272,measures_primary,Change From Baseline in HbA1c
NCT05966272,measures_secondary,Proportion of subjects reaching HbA1c targets
NCT05966272,has_criteria,Male or female subjects
NCT05966272,has_criteria,18-65 years of age
NCT05966272,has_criteria,Type 2 diabetes mellitus
NCT05966272,has_criteria,treated with metformin
NCT05966272,has_criteria,HbA1c 7.5-10.5%
NCT00434967,involves,Hypertension
NCT00434967,evaluates,Candesartan/HCT 32/25 mg
NCT00434967,measures_primary,Change in DBP
NCT00434967,measures_primary,Change in SBP
NCT00434967,measures_secondary,DBP control rate
NCT00434967,measures_secondary,SBP control rate
NCT00434967,measures_secondary,DBP responder rate
NCT00434967,has_criteria,Sitting DBP <90 mmHg
NCT00999167,involves,Cirrhosis
NCT00999167,involves,Episodic Hepatic Encephalopathy
NCT00999167,evaluates,HPN-100
NCT00999167,measures_primary,Rate of AEs
NCT00999167,measures_secondary,Total HE events
NCT00999167,measures_secondary,Time to first HE episode
NCT00999167,has_criteria,WH Grade ≥2
NCT00999167,has_criteria,WH Grade 1 and asterixis grade increase of 1
NCT00105040,involves,Partial Onset Seizures
NCT00105040,evaluates,Levetiracetam
NCT00105040,measures_primary,Change from Baseline
NCT00105040,measures_secondary,Wide Range Assessment of Memory and Learning-Second Edition
NCT00105040,has_criteria,Baseline to Week 12
NCT04167540,involves,Parkinson's disease
NCT04167540,evaluates,GDNF Gene Therapy
NCT04167540,measures_primary,Change from baseline in MDS-UPDRS
NCT04167540,measures_secondary,Change from baseline in NMSS
NCT04167540,measures_secondary,Percentage and absolute changes in Ioflupane retention
NCT04167540,has_criteria,Male and female adults 35-75 years of age
NCT04167540,has_criteria,Diagnosed with Parkinson's disease
NCT01721044,involves,Rheumatoid Arthritis
NCT01721044,evaluates,Baricitinib
NCT01721044,measures_primary,ACR20 Response
NCT01721044,measures_secondary,HAQ-DI Score
NCT01721044,measures_secondary,DAS-28 hsCRP
NCT01721044,has_criteria,tender joint count
NCT01721044,has_criteria,swollen joint count
NCT01721044,has_criteria,hsCRP
NCT01721044,has_criteria,Patient's Global Assessment
NCT05594667,involves,Major Depressive Disorder
NCT05594667,evaluates,SSRIs
NCT05594667,measures_primary,QIDS-SR-16 response
NCT05594667,measures_secondary,QIDS-SR-16 remission
NCT05594667,measures_secondary,Montgomery and Asberg Depression Rating Scale
NCT05594667,measures_secondary,Number of adverse-events
NCT05594667,measures_secondary,Number of serious adverse events
NCT05594667,has_criteria,SSRI treatment
NCT05594667,has_criteria,QIDS-SR-16 score ≥6
NCT05594667,has_criteria,19 to 65 years
NCT05594667,has_criteria,Fluent in English
NCT03927040,involves,Alzheimer's Disease
NCT03927040,evaluates,Transcranial Electromagnetic Treatment
NCT03927040,measures_primary,Adverse Event Assessment
NCT03927040,measures_secondary,ADAS-cog score
NCT03927040,measures_secondary,Rey AVLT score
NCT03927040,measures_secondary,Digit span score
NCT03927040,measures_secondary,MMSE score
NCT03927040,measures_secondary,Global Deterioration score
NCT03927040,measures_secondary,Trails A & B score
NCT03927040,measures_secondary,Clock draw score
NCT03927040,has_criteria,MMSE score 16 to 26
NCT03927040,has_criteria,mild or moderate stage
NCT03927040,has_criteria,NINCDS-ADRDA criteria
NCT02172040,involves,Hypertension
NCT02172040,evaluates,Celecoxib
NCT02172040,evaluates,Amlodipine
NCT02172040,measures_primary,Mean Change in SBPday
NCT02172040,measures_secondary,Mean Change in SBPday
NCT02172040,has_criteria,Adult 40 to 75 years
NCT06454240,involves,Chronic Rhinosinusitis With Nasal Polyps
NCT06454240,evaluates,Lunsekimig
NCT06454240,evaluates,Placebo
NCT06454240,measures_primary,Change in NPS
NCT06454240,measures_secondary,Change in nasal congestion/obstruction score
NCT06454240,measures_secondary,Change in Lund-Mackay CT score
NCT06454240,measures_secondary,Change in maxillary sinus volume
NCT06454240,measures_secondary,Change in SNOT-22 total score
NCT06454240,measures_secondary,Change in patient-reported total symptom score
NCT06454240,measures_secondary,Change in anterior rhinorrhea and posterior rhinorrhea score
NCT06454240,measures_secondary,Change in rhinosinusitis VAS
NCT06454240,has_criteria,Adults
NCT04571944,involves,Delirium
NCT04571944,evaluates,Suvorexant
NCT04571944,measures_primary,Percentage of Delirium
NCT04571944,measures_secondary,Adverse Events
NCT04571944,measures_secondary,Discontinuation due AE
NCT04571944,has_criteria,DSM-5 criteria
NCT01967940,involves,HIV-1
NCT01967940,evaluates,Tenofovir Alafenamide
NCT01967940,evaluates,Placebo
NCT01967940,evaluates,Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
NCT01967940,evaluates,Atazanavir
NCT01967940,measures_primary,Plasma HIV-1 RNA
NCT01967940,measures_secondary,Laboratory Abnormalities
NCT01967940,measures_secondary,Treatment-Emergent Adverse Event
NCT01967940,has_criteria,Failing Regimen
NCT02318667,involves,Ulcerative Colitis
NCT02318667,evaluates,Golimumab
NCT02318667,measures_primary,Endoscopic Activity
NCT02318667,measures_secondary,Histological Activity
NCT02318667,has_criteria,moderate to severe
NCT01602367,involves,Uncontrolled High Blood Pressure
NCT01602367,evaluates,BMS-823778
NCT01602367,measures_primary,24-hour ambulatory diastolic blood pressure
NCT01602367,measures_secondary,24-hour ambulatory systolic blood pressure
NCT01602367,has_criteria,Seated blood pressure ≥90 and ≤105 mmHg diastolic AND ≤155 mmHg systolic
NCT01602367,has_criteria,Mean 24-hour diastolic blood pressure ≥85 mmHg
NCT01602367,has_criteria,BMI ≥27 kg/m2
NCT01602367,has_criteria,Stable dose of anti-hyperglycemic or cholesterol lowering medication for at least 6 weeks
NCT01602367,has_criteria,History of Cushing's disease or syndrome
NCT01602367,has_criteria,Glycosylated hemoglobin (HbA1c) ≥10%
NCT01602367,has_criteria,Cerebrovascular insult
NCT01602367,has_criteria,History of impaired renal or hepatic function
NCT01602367,has_criteria,BMI ≥50 kg/m2
NCT01602367,has_criteria,Injectable antihyperglycemic agent (such as insulin) within 16 weeks
NCT01602367,has_criteria,More than one class of antihypertensive agents within 4 weeks
NCT01602367,has_criteria,Daily use of nonsteroidal anti-inflammatory agents within 1 week
NCT01602367,has_criteria,Androgen medications
NCT01602367,has_criteria,Diagnosis or history of breast cancer
NCT04124367,involves,stroke
NCT04124367,evaluates,IMPULSE
NCT04124367,measures_primary,Action Research Arm Test
NCT04124367,measures_secondary,Nine-Hole Peg Test
NCT04124367,measures_secondary,Hand grip dynamometry
NCT04124367,measures_secondary,National Institutes of Health Stroke Scale
NCT04124367,has_criteria,18-80 years of age
NCT04124367,has_criteria,first-ever hemispheric subcortical ischemic stroke
NCT04124367,has_criteria,Pre-stroke modified Rankin Scale 0 or 1
NCT04124367,has_criteria,Action Research Arm Test score 13-50
NCT04124367,has_criteria,Shoulder Abduction Finger Extension score ≥5
NCT01461967,involves,Healthy Volunteers
NCT01461967,evaluates,RO5508887
NCT01461967,measures_primary,Adverse event incidence
NCT01461967,measures_secondary,Plasma concentrations
NCT01461967,measures_secondary,Urine levels
NCT01461967,measures_secondary,Amyloid deposition
NCT01461967,has_criteria,Healthy status
NCT01461967,has_criteria,Body Mass Index
NCT01461967,has_criteria,Contraception
NCT01461967,has_criteria,Drug abuse
NCT01461967,has_criteria,Smoking
NCT01461967,has_criteria,Hepatitis B
NCT01461967,has_criteria,Hepatitis C
NCT01461967,has_criteria,HIV infection
NCT01461967,has_criteria,Hypersensitivity
NCT01461967,has_criteria,Drug reaction
NCT01461967,has_criteria,Investigational drug
NCT01809340,involves,Depression
NCT01809340,evaluates,Minocycline
NCT01809340,measures_primary,Change in MADRS
NCT01809340,measures_secondary,Change in MADRS
NCT01809340,has_criteria,Day 54
NCT01437540,involves,Chronic Obstructive Pulmonary Disease
NCT01437540,evaluates,Aclidinium Bromide/Formoterol Fumarate
NCT01437540,evaluates,Formoterol Fumarate
NCT01437540,measures_primary,Treatment-emergent Adverse Event
NCT01437540,measures_secondary,Clinical Laboratory Values
NCT01437540,measures_secondary,Pulse Rate
NCT01437540,measures_secondary,Blood Pressure
NCT01437540,measures_secondary,ECG
NCT01437540,has_criteria,Potentially Clinically Significant
NCT05650567,involves,Dermatomyositis
NCT05650567,involves,Polymyositis
NCT05650567,evaluates,M5049
NCT05650567,measures_primary,ACR/EULAR TIS at Week 24
NCT05650567,measures_secondary,Treatment-Emergent Adverse Events
NCT05650567,measures_secondary,Clinically Significant Changes
NCT05650567,measures_secondary,ACR/EULAR TIS >= 20
NCT05650567,measures_secondary,Total Improvement Score (TIS)
NCT05650567,measures_secondary,Core Set Measures (CSM)
NCT05650567,measures_secondary,Muscle-associated Enzyme
NCT05650567,measures_secondary,Core Set Measures (CSM)
NCT05650567,measures_secondary,International Myositis Assessment and Clinical Studies (IMACS) Response
NCT05650567,measures_secondary,Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
NCT05650567,measures_secondary,Investigator's Global Assessment (IGA) Skin Activity
NCT06470048,involves,Diffuse Cutaneous Systemic Sclerosis
NCT06470048,evaluates,Ianalumab
NCT06470048,measures_primary,rCRISS25 response
NCT06470048,measures_secondary,Change from baseline in FVC% predicted
NCT06470048,measures_secondary,Change from baseline in mRSS
NCT06470048,measures_secondary,Change from baseline in HAQ-DI
NCT06470048,has_criteria,>= 18 and <= 70 years
NCT06470048,has_criteria,Diagnosis of systemic sclerosis
NCT04860830,involves,Schizophrenia
NCT04860830,evaluates,Iclepertin
NCT04860830,measures_primary,Change from baseline
NCT04860830,measures_secondary,SCoRS interviewer total score
NCT04860830,measures_secondary,VRFCAT total time
NCT04860830,measures_secondary,Tower of London
NCT04860830,measures_secondary,PRECIS total score
NCT04860830,has_criteria,Signed informed consent
NCT04860830,has_criteria,Male
NCT01174030,involves,Rosacea
NCT01174030,evaluates,CD07805/47 Topical Gel
NCT01174030,measures_primary,CEA Success
NCT01174030,measures_secondary,PSA-5 Success
NCT01174030,has_criteria,18 years or older
NCT01174030,has_criteria,clinical diagnosis of rosacea
NCT01174030,has_criteria,CEA score of 3
NCT01174030,has_criteria,PSA-5 score of 3
NCT01174030,has_criteria,PSA-11 score of 5
NCT01174030,has_criteria,facial inflammatory lesions
NCT01174030,has_criteria,Raynaud's syndrome
NCT01174030,has_criteria,thromboangiitis obliterans
NCT01174030,has_criteria,orthostatic hypotension
NCT01174030,has_criteria,severe cardiovascular disease
NCT01174030,has_criteria,cerebral or coronary insufficiency
NCT01174030,has_criteria,renal or hepatic impairment
NCT01174030,has_criteria,scleroderma
NCT01174030,has_criteria,Sjögren's syndrome
NCT01174030,has_criteria,depression
NCT01174030,has_criteria,allergies to study medications
NCT02641730,involves,Palmoplantar pustulosis
NCT02641730,evaluates,Guselkumab
NCT02641730,measures_primary,PPPASI Total Score
NCT02641730,measures_secondary,PPSI Total Score
NCT02641730,has_criteria,treatment failure
NCT04508530,involves,Pediatric Acute-onset Neuropsychiatric Syndrome
NCT04508530,evaluates,Panzyga
NCT04508530,measures_primary,CY-BOCS score
NCT04508530,measures_secondary,Clinical Global Impression
NCT04508530,has_criteria,9 weeks
NCT04508530,has_criteria,18 weeks
NCT00300430,involves,Mixed Dyslipidemia
NCT00300430,evaluates,ABT-335
NCT00300430,measures_primary,Percent Change in Triglycerides
NCT00300430,measures_secondary,Percent Change in HDL-C
NCT00300430,measures_secondary,Percent Change in LDL-C
NCT00300430,measures_secondary,Percent Change in Non-HDL-C
NCT00300430,measures_secondary,Percent Change in VLDL-C
NCT00300430,measures_secondary,Percent Change in Total Cholesterol
NCT00300430,measures_secondary,Percent Change in Apo B
NCT00300430,measures_secondary,Percent Change in hsCRP
NCT00300430,has_criteria,Adult subjects
NCT00675948,involves,Cancer Related Pain
NCT00675948,evaluates,Sativex
NCT00675948,measures_primary,Pain Severity Score
NCT00675948,measures_secondary,Global Health Status
NCT00675948,has_criteria,0 - 657 days
NCT01353248,involves,Hepatitis C Virus (HCV) Infection
NCT01353248,evaluates,GS-5885
NCT01353248,measures_primary,Sustained virologic response
NCT01353248,measures_secondary,Viral breakthrough
NCT01353248,measures_secondary,Viral relapse
NCT01353248,has_criteria,24 weeks of off-treatment
NCT04624230,involves,Ulcerative Colitis
NCT04624230,evaluates,Oral Tofacitinib
NCT04624230,measures_primary,Mayo score
NCT04624230,measures_secondary,Partial Mayo Score
NCT04624230,has_criteria,Children Aged 2-17
NCT02754830,involves,Alzheimer's Disease
NCT02754830,evaluates,LY3303560
NCT02754830,measures_primary,Mean Change From Baseline
NCT02754830,measures_secondary,QT/QT Corrected (QTc) Interval
NCT02754830,has_criteria,Overtly healthy males or females
NCT05896748,involves,Human Immunodeficiency Virus (HIV-1) Infection
NCT05896748,evaluates,Cabotegravir (CAB)
NCT05896748,evaluates,Rilpivirine (RPV)
NCT05896748,measures_primary,Number of Participants With Adverse Events
NCT05896748,measures_secondary,Injection Site Reactions
NCT05896748,measures_secondary,Severity of AEs of special interest
NCT05896748,measures_secondary,Severity of ISRs
NCT05896748,measures_secondary,Percentage of participants who discontinue treatment
NCT05896748,has_criteria,Adult Participants
NCT05153148,involves,Psoriatic Arthritis
NCT05153148,evaluates,NDI-034858
NCT05153148,measures_primary,ACR20 Response
NCT05153148,measures_secondary,ACR-50 Response
NCT05153148,has_criteria,Active Psoriatic Arthritis
NCT04678830,involves,Long COVID-19
NCT04678830,evaluates,Leronlimab
NCT04678830,measures_primary,Symptom Severity Score
NCT04678830,measures_secondary,Duration of Symptoms
NCT04678830,has_criteria,COVID-19 related symptoms
NCT05326230,involves,Hypertension
NCT05326230,evaluates,Paradise™ Renal Denervation System
NCT05326230,measures_primary,24-hour systolic ABPM
NCT05326230,measures_secondary,change in blood pressure
NCT05326230,has_criteria,antihypertensive treatment
NCT04387448,involves,Diabetic Nephropathy
NCT04387448,involves,Focal Segmental Glomerulosclerosis
NCT04387448,involves,Treatment-Resistant Minimal Change Disease
NCT04387448,evaluates,TRPC5 Channel Inhibitor
NCT04387448,measures_primary,Urine Protein-to-Creatinine Ratio
NCT04387448,measures_primary,Urine Albumin-to-Creatinine Ratio
NCT04387448,measures_secondary,modified partial remission
NCT04387448,measures_secondary,complete remission
NCT04387448,measures_secondary,24-hour urine protein excretion
NCT04387448,measures_secondary,24-hour urine albumin excretion
NCT04387448,measures_secondary,UACR/UPCR decrease
NCT04387448,measures_secondary,adverse events
NCT04387448,measures_secondary,electrocardiogram parameters
NCT04387448,measures_secondary,vital signs measurements
NCT04387448,measures_secondary,laboratory parameters
NCT04387448,measures_secondary,plasma pharmacokinetics
NCT04387448,has_criteria,age 18-75 years
NCT04387448,has_criteria,eGFR ≥ 30 mL/min/1.73 m2
NCT04387448,has_criteria,ACE inhibitor or ARB
NCT04387448,has_criteria,type 2 diabetes
NCT04387448,has_criteria,HbA1c level ≤11%
NCT04387448,has_criteria,UACR ≥ 150 mg/g
NCT04387448,has_criteria,FSGS diagnosis
NCT02891148,evaluates,BI 690517
NCT02891148,measures_primary,AUC0-infinity
NCT02891148,measures_secondary,Cmax
NCT02891148,has_criteria,Healthy male subjects
NCT02891148,has_criteria,Age 18 to 50 years
NCT02891148,has_criteria,BMI 18.5 to 29.9 kg/m2
NCT02891148,has_criteria,Signed informed consent
NCT02914548,involves,Atopic Dermatitis
NCT02914548,evaluates,OPA-15406 Ointment
NCT02914548,measures_primary,Responder Rate IGA
NCT02914548,measures_secondary,EASI Score
NCT02914548,measures_secondary,VAS for Pruritus
NCT02914548,has_criteria,Baseline and Week4
NCT03321526,involves,Major Depressive Disorder
NCT03321526,evaluates,JNJ-42847922
NCT03321526,evaluates,Quetiapine Extended-Release
NCT03321526,measures_primary,Time to discontinuation
NCT03321526,measures_secondary,Sustained Remission
NCT03321526,measures_secondary,Sustained Response
NCT03321526,has_criteria,Responded inadequately
NCT04088357,involves,Acute Induced Wounds
NCT04088357,evaluates,Topical TolaSure
NCT04088357,measures_primary,Time-to-closure
NCT04088357,measures_secondary,Percent Area Reduction
NCT04088357,measures_secondary,Wound Pain Control
NCT04088357,measures_secondary,Quality of Healing
NCT04088357,measures_secondary,Cutaneous Tolerability
NCT04088357,has_criteria,Healthy Participants
NCT02065557,involves,Ulcerative Colitis
NCT02065557,evaluates,Adalimumab
NCT02065557,measures_primary,Clinical Remission
NCT02065557,measures_primary,Clinical Remission
NCT02065557,measures_secondary,Clinical Response
NCT02065557,has_criteria,Week 8 Responders
NCT02065557,has_criteria,Week 52 Responders
NCT05394857,involves,Graves' Orbitopathy
NCT05394857,evaluates,SHR-1314
NCT05394857,measures_primary,proptosis responder rate
NCT05394857,measures_secondary,reduction of clinical activity score
NCT05394857,measures_secondary,Overall responder rate
NCT05394857,measures_secondary,CAS value of 0 or 1
NCT05394857,measures_secondary,proptosis measurement
NCT05394857,measures_secondary,Diplopia response rate
NCT05394857,measures_secondary,GO-QoL score
NCT05394857,has_criteria,understand and communicate
NCT05394857,has_criteria,18 to 70 years old
NCT05394857,has_criteria,active GO symptoms
NCT00861757,involves,Benign Prostatic Hyperplasia
NCT00861757,evaluates,Tadalafil
NCT00861757,measures_primary,Change From Baseline in IPSS
NCT00861757,measures_secondary,IPSS Obstructive Subscore
NCT00861757,measures_secondary,IPSS Irritative Subscore
NCT00861757,measures_secondary,IPSS Quality of Life
NCT00861757,measures_secondary,Benign Prostatic Hyperplasia Impact Index
NCT00861757,has_criteria,prior alpha blocker use
NCT00861757,has_criteria,country
NCT00861757,has_criteria,baseline value
NCT04154826,involves,Nontuberculous Mycobacterial Lung Disease
NCT04154826,evaluates,Recombinant Interleukin-7
NCT04154826,measures_primary,Acid Fast Bacilli sputum culture conversion
NCT04154826,measures_secondary,6-minute walk distance
NCT04154826,measures_secondary,oxygen saturation
NCT04154826,measures_secondary,Forced expiratory volume
NCT04154826,measures_secondary,lung involved by CT
NCT04154826,measures_secondary,Health-related Quality of Life
NCT04154826,measures_secondary,hospital readmissions
NCT04154826,has_criteria,refractory
NCT02684357,involves,Chronic Plaque Psoriasis
NCT02684357,evaluates,Risankizumab
NCT02684357,measures_primary,PASI90 at Week 16
NCT02684357,measures_secondary,sPGA Score at Week 16
NCT02684357,has_criteria,Baseline PASI score
NCT03487848,involves,Chronic Hepatitis C
NCT03487848,evaluates,Daclatasvir
NCT03487848,evaluates,Sofosbuvir
NCT03487848,measures_primary,Number of Participants Experiencing Adverse Events
NCT03487848,measures_secondary,Laboratory Abnormalities
NCT03487848,has_criteria,worst toxicity grade 3 or higher
NCT03927157,involves,Asthma
NCT03927157,evaluates,Tezepelumab
NCT03927157,measures_primary,Change from baseline FEV1
NCT03927157,measures_secondary,Asthma Control Questionnaire-6 Score
NCT03927157,measures_secondary,Asthma Symptom Diary score
NCT03927157,measures_secondary,AQLQ(S)+12 total score
NCT03927157,has_criteria,Randomization
NCT04423757,involves,Depression
NCT04423757,evaluates,BI 1358894
NCT04423757,measures_primary,Change from baseline
NCT04423757,measures_secondary,STAI Scores
NCT04423757,has_criteria,≥ 50% MADRS reduction
NCT06398626,involves,Ulcerative Colitis
NCT06398626,evaluates,Etrasimod
NCT06398626,measures_primary,Symptomatic remission
NCT06398626,measures_secondary,Symptomatic response
NCT06398626,measures_secondary,Clinical remission
NCT06398626,measures_secondary,Steroid-free symptomatic remission
NCT06398626,measures_secondary,Steroid-free clinical remission
NCT06398626,measures_secondary,Fatigue
NCT06398626,measures_secondary,Bowel urgency
NCT06398626,has_criteria,Adult patients
NCT01787357,involves,Healthy Volunteers
NCT01787357,evaluates,Canagliflozin
NCT01787357,evaluates,JNJ-28431754
NCT01787357,evaluates,moxifloxacin
NCT01787357,measures_primary,QTc intervals
NCT01787357,measures_secondary,Adverse events
NCT01787357,measures_secondary,Plasma concentrations
NCT01787357,has_criteria,BMI 18-35 kg/m2
NCT01787357,has_criteria,normal cardiac conduction
NCT01787357,has_criteria,non-smokers
NCT00666757,involves,Severe Depression
NCT00666757,evaluates,Duloxetine
NCT00666757,measures_primary,Remission probability
NCT00666757,measures_secondary,Change From Baseline
NCT00666757,has_criteria,QIDS-SR total score
NCT00666757,involves,Depression
NCT00666757,evaluates,SSRIs
NCT00666757,measures_primary,Remission probability
NCT00666757,measures_secondary,Change From Baseline
NCT00666757,has_criteria,HAMD-17 total score
NCT01107457,involves,Psoriasis
NCT01107457,measures_primary,PASI 75 Improvement
NCT01107457,measures_secondary,PASI Improvement
NCT04765657,involves,Atherosclerotic Cardiovascular Disease
NCT04765657,evaluates,Inclisiran
NCT04765657,measures_primary,LDL-C percentage change
NCT04765657,measures_secondary,Adverse Events
NCT04765657,measures_secondary,Serious Adverse Events
NCT04765657,has_criteria,ASCVD risk
NCT04765657,has_criteria,Elevated LDL-C
NCT03135548,involves,Palmoplantar Pustulosis
NCT03135548,evaluates,BI 655130
NCT03135548,measures_primary,ppPASI50
NCT03135548,measures_secondary,ppPASI75
NCT03135548,has_criteria,Week 16
NCT00683657,involves,Type 2 Diabetes
NCT00683657,evaluates,Saxagliptin
NCT00683657,measures_primary,Change From Baseline in MWG
NCT00683657,measures_secondary,Change From Baseline in 4-Hour Mean Weighted Postprandial Plasma Glucose
NCT00683657,measures_secondary,Change From Baseline in 2-Hour Postprandial Plasma Glucose After the Evening Meal
NCT00683657,measures_secondary,Change From Baseline in Mean Daily Glucose
NCT00683657,has_criteria,Baseline
NCT03669757,involves,Chronic Plaque Psoriasis
NCT03669757,evaluates,Anti-inflammatory Substance
NCT03669757,measures_primary,Number of adverse events
NCT03669757,measures_secondary,Change from baseline
NCT03669757,has_criteria,treatment-emergent
NCT00444626,involves,Nasolabial Folds
NCT00444626,evaluates,Dermal Gel Extra
NCT00444626,evaluates,FDA Approved Device
NCT00444626,measures_primary,Change in NLF wrinkle severity
NCT00444626,measures_secondary,Participant Pain Assessment
NCT00444626,has_criteria,Initial Treatment Visit
NCT00444626,measures_primary,Change in NLF wrinkle severity
NCT00444626,measures_secondary,Number of Participants With at Least a 1 Point Improvement From Baseline in the Blinded Evaluator's Assessment of Wrinkle Severity at Week 24
NCT01138657,involves,Uveitis
NCT01138657,evaluates,Adalimumab
NCT01138657,measures_primary,Change in AC Cell Grade
NCT01138657,measures_secondary,Change in Vitreous Haze Grade
NCT01138657,has_criteria,≥ 1 eye
NCT00907257,involves,facial acne vulgaris
NCT00907257,evaluates,Two Acne Treatments
NCT00907257,measures_primary,Change From Baseline
NCT00907257,measures_secondary,Inflammatory Lesion Count
NCT00907257,has_criteria,Minimum of 20 inflammatory lesions
NCT00907257,has_criteria,Minimum of 30 non-inflammatory lesions
NCT00907257,has_criteria,Investigator Global severity scale
NCT04847557,involves,Heart Failure With Preserved Ejection Fraction
NCT04847557,involves,Obesity
NCT04847557,evaluates,Tirzepatide
NCT04847557,measures_primary,Change from Baseline in KCCQ-CSS
NCT04847557,measures_secondary,Occurrence of Composite Endpoint
NCT04847557,measures_secondary,Change from Baseline in Exercise Capacity
NCT04847557,measures_secondary,Percent Change from Baseline in Body Weight
NCT04847557,measures_secondary,Change from Baseline in hsCRP
NCT04847557,measures_secondary,Hierarchical Composite of All-Cause Mortality
NCT04847557,measures_secondary,Percentage of Participants with NYHA Class Change
NCT04847557,has_criteria,Baseline
NCT04964557,involves,Hyperlipidaemia
NCT04964557,evaluates,AZD8233
NCT04964557,measures_primary,Percentage Change LDL-C
NCT04964557,measures_secondary,Number of Subjects With Adverse Events
NCT04964557,has_criteria,On-study includes adverse events
NCT04006457,involves,Alopecia Areata
NCT04006457,evaluates,PF-06651600
NCT04006457,measures_primary,SALT Score <=10
NCT04006457,measures_secondary,SALT Score <=20
NCT04006457,measures_secondary,Change from baseline SALT score
NCT04006457,measures_secondary,75% improvement SALT score
NCT04006457,has_criteria,Tetanus booster response
NCT04777357,involves,Bipolar I Disorder
NCT04777357,evaluates,Cariprazine
NCT04777357,measures_primary,Change in SAS
NCT04777357,measures_secondary,Change in AIMS
NCT04777357,has_criteria,Pediatric Participants
NCT02525094,involves,Atopic Dermatitis
NCT02525094,evaluates,MEDI9929
NCT02525094,measures_primary,EASI 50 at Week 12
NCT02525094,measures_secondary,EASI 75 at Week 12
NCT02525094,measures_secondary,Mean Change EASI
NCT02525094,has_criteria,Baseline (Day 1) and Week 12
NCT00438360,involves,Chronic Plaque Psoriasis
NCT00438360,evaluates,Cyclosporine A Microemulsion
NCT00438360,measures_primary,Relapse Rate
NCT00438360,measures_secondary,Change From Baseline in PASI Score
NCT00438360,measures_secondary,Change From Baseline in BSA Affected by Psoriasis
NCT00438360,has_criteria,PASI score >75%
NCT01377194,involves,Major Depressive Disorder
NCT01377194,evaluates,Levomilnacipran ER
NCT01377194,measures_primary,Change in MADRS
NCT01377194,measures_secondary,Change in SDS
NCT01377194,has_criteria,18-75 years old
NCT01377194,has_criteria,DSM-IV-TR criteria
NCT01377194,has_criteria,6 weeks duration
NCT01377194,has_criteria,reliable birth control
NCT01377194,has_criteria,no suicide risk
NCT01377194,has_criteria,no manic episode
NCT01377194,has_criteria,no psychotic disorder
NCT01377194,has_criteria,no obsessive-compulsive disorder
NCT02593760,involves,Myelofibrosis (MF)
NCT02593760,evaluates,Vismodegib
NCT02593760,evaluates,Ruxolitinib
NCT02593760,measures_primary,Spleen Volume Reduction
NCT02593760,measures_secondary,Complete Remission
NCT02593760,measures_secondary,Partial Remission
NCT02593760,measures_secondary,Overall Response Rate
NCT02593760,has_criteria,IWG-MRT Revised Response Criteria
NCT04069260,involves,Nephropathic Cystinosis
NCT04069260,evaluates,ELX-02
NCT04069260,measures_primary,WBC cystine levels
NCT04069260,measures_secondary,Area under the plasma concentration curve
NCT04069260,has_criteria,18 years of age or older
NCT04069260,has_criteria,biallelic CTNS mutations
NCT04069260,has_criteria,estimated glomerular filtration rate ≥40 mL/min/1.73m2
NCT04069260,has_criteria,Body mass index of 19.0 to 30.0 kg/m2
NCT04069260,has_criteria,stable graft function
NCT01577160,involves,Schizophrenia
NCT01577160,evaluates,Paliperidone Extended Release
NCT01577160,measures_primary,Percentage of Responders
NCT01577160,measures_secondary,Change From Baseline in CGI-S Score
NCT01577160,measures_secondary,Number of Participants With CGI-I Score
NCT01577160,measures_secondary,Change From Baseline in PSP Score
NCT01577160,has_criteria,Baseline state at Week 12
NCT02847260,involves,Pulmonary Arterial Hypertension
NCT02847260,evaluates,Remodulin
NCT02847260,measures_primary,Six Minute Walk Distance
NCT02847260,measures_secondary,Borg Dyspnea Score
NCT02847260,measures_secondary,NT-proBNP Concentrations
NCT02847260,measures_secondary,WHO Functional Classification
NCT02847260,has_criteria,Baseline to week 16
NCT06228560,involves,Chronic spontaneous urticaria
NCT06228560,evaluates,LP-003
NCT06228560,measures_primary,UAS7 = 0
NCT06228560,measures_secondary,HSS7 = 0
NCT06228560,has_criteria,Aged 18 to 75 years
NCT06228560,has_criteria,Wheals with itching for ≥ 6 weeks
NCT06228560,has_criteria,Double or more H1 antihistamines
NCT06228560,has_criteria,UAS7 ≥16
NCT06228560,has_criteria,ISS7 ≥8
NCT04577794,involves,Ulcerative Colitis
NCT04577794,evaluates,GLPG3970
NCT04577794,measures_primary,Total MCS at Week 6
NCT04577794,measures_secondary,Treatment-Emergent Adverse Events
NCT04577794,has_criteria,Documented diagnosis of UC of ≥3 months
NCT04487860,involves,Vitiligo
NCT04487860,evaluates,AS012
NCT04487860,measures_primary,Vitiligo Area Scoring Index score
NCT04487860,measures_secondary,Vitiligo Extent Score
NCT04487860,measures_secondary,Vitiligo Impact Patient scale
NCT04487860,measures_secondary,Physician's global assessment scores
NCT04487860,measures_secondary,Dermatology Life Quality Index
NCT04487860,has_criteria,≥ 18 years of age
NCT04487860,has_criteria,Stable or unstable vitiligo
NCT04487860,has_criteria,VASI of ≥ 4
NCT04728360,involves,plaque-type psoriasis
NCT04728360,evaluates,BAT2206
NCT04728360,evaluates,Stelara
NCT04728360,measures_primary,PASI score
NCT04728360,measures_secondary,PASI-50/75/90/100
NCT04728360,measures_secondary,sPGA score
NCT04728360,has_criteria,≥ 18 years old
NCT04728360,has_criteria,plaque-type psoriasis
NCT04728360,has_criteria,PASI ≥ 12
NCT04728360,has_criteria,sPGA ≥ 3
NCT04728360,has_criteria,body surface area ≥ 10%
NCT04728360,has_criteria,failed systemic therapies
NCT04728360,has_criteria,contraindication systemic therapies
NCT04728360,has_criteria,intolerance systemic therapies
NCT04728360,has_criteria,contraceptive precaution
NCT00577460,involves,Parkinson's Disease
NCT00577460,evaluates,pramipexole ER
NCT00577460,measures_primary,UPDRS II+III Change
NCT00577460,measures_secondary,Number of Participants With UPDRS II+III Response
NCT00577460,measures_secondary,Percentage Off Time During Waking Hours Total Score
NCT00577460,has_criteria,successfully switched
NCT00768560,evaluates,Nifedipine
NCT00768560,measures_primary,Change of Sitting Blood Pressure
NCT00768560,measures_secondary,Differences of Systolic Blood Pressure Profile
NCT00768560,measures_secondary,Differences of Diastolic Blood Pressure Profile
NCT00768560,has_criteria,Elderly subjects (≥65 years)
NCT00768560,has_criteria,Non-elderly subjects (<65 years)
NCT00768560,has_criteria,Subjects with diabetes mellitus or chronic renal disorders
NCT03602560,involves,Primary Biliary Cholangitis
NCT03602560,evaluates,Seladelpar
NCT03602560,measures_primary,Normalized ALP levels
NCT03602560,measures_secondary,Pruritus NRS
NCT03602560,has_criteria,18 to 75 years old
NCT05177094,involves,Diabetic Peripheral Neuropathic Pain
NCT05177094,evaluates,LY3526318
NCT05177094,measures_primary,Pain Intensity
NCT05177094,measures_secondary,Pain Interference
NCT05177094,has_criteria,Baseline
NCT03055494,involves,Plaque Psoriasis
NCT03055494,evaluates,Secukinumab
NCT03055494,evaluates,Placebo
NCT03055494,measures_primary,Psoriasis Area and Severity Index 90
NCT03055494,measures_secondary,Response of Psoriasis Skin Lesions
NCT03055494,measures_secondary,Systolic Blood Pressure
NCT03055494,measures_secondary,Diastolic Blood Pressure
NCT03055494,measures_secondary,Body Weight
NCT03055494,measures_secondary,Glucose Level
NCT03055494,measures_secondary,Insulin Level
NCT03055494,measures_secondary,High-sensitivity C-reactive Protein
NCT03055494,measures_secondary,Homeostatic Model Assessment of Insulin Resistance
NCT03055494,has_criteria,Healthy Range
NCT04007991,involves,Tourette's Syndrome
NCT04007991,evaluates,Ecopipam Tablets
NCT04007991,measures_primary,Change From Baseline
NCT04007991,measures_secondary,Clinical Global Impression
NCT04007991,has_criteria,≥ 6 and < 18 years
NCT04007991,has_criteria,≥ 18 kg
NCT04007991,has_criteria,TS diagnosis
NCT04007991,has_criteria,motor and vocal tics
NCT04007991,has_criteria,YGTSS-Total Tic Score
NCT04007991,has_criteria,no medications
NCT04007991,has_criteria,Effective contraception
NCT06280391,involves,Non-cystic Fibrosis Bronchiectasis
NCT06280391,evaluates,Itepekimab
NCT06280391,measures_primary,Annualized rate of PEs
NCT06280391,measures_secondary,Percentage of participants PE free
NCT06280391,has_criteria,Baseline up to End of Treatment
NCT01241591,involves,Chronic Plaque Psoriasis
NCT01241591,evaluates,CP-690
NCT01241591,evaluates,Etanercept
NCT01241591,measures_primary,PGA response at Week 12
NCT01241591,measures_primary,PASI75 response at Week 12
NCT01241591,has_criteria,Moderate to Severe
NCT06506994,involves,Heart Failure
NCT06506994,evaluates,HRS-9057
NCT06506994,measures_primary,Lower limb edema change
NCT06506994,measures_secondary,Jugular venous distension change
NCT06506994,measures_secondary,Pulmonary congestion change
NCT06506994,measures_secondary,New York Heart Association (NYHA) classification change
NCT06506994,has_criteria,age 18-70 years
NCT06506994,has_criteria,diagnosed chronic heart failure
NCT03546894,involves,Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC)
NCT03546894,evaluates,ALK Inhibitors
NCT03546894,measures_primary,Progression-free Survival
NCT03546894,measures_secondary,Quality of Life Status
NCT03546894,measures_secondary,Daily Function Status
NCT03546894,has_criteria,Baseline up to disease progression
NCT00246194,involves,Schizophrenia
NCT00246194,evaluates,Long-Acting Risperidone Injection
NCT00246194,measures_primary,Clinical Global Impression of Severity
NCT00246194,measures_secondary,Clinical Global Impression of Change
NCT00246194,measures_secondary,Global Assessment of Function
NCT00246194,measures_secondary,Personal and Social Performance
NCT00246194,measures_secondary,Strauss-Carpenter Levels of Function
NCT00246194,has_criteria,Baseline (Month 0) to 24 months
NCT04229394,involves,Knee Osteoarthritis
NCT04229394,evaluates,2ccPA
NCT04229394,measures_primary,20% improvement WOMAC
NCT04229394,measures_secondary,50% improvement WOMAC
NCT04229394,measures_secondary,70% improvement WOMAC
NCT04229394,has_criteria,Symptomatic knee OA
NCT03535194,involves,Plaque Psoriasis
NCT03535194,evaluates,Mirikizumab
NCT03535194,evaluates,Secukinumab
NCT03535194,evaluates,Placebo
NCT03535194,measures_primary,sPGA 0 or 1
NCT03535194,measures_primary,PASI 90
NCT03535194,measures_secondary,PASI 75
NCT03535194,has_criteria,Moderate to Severe
NCT00530348,involves,Multiple Sclerosis
NCT00530348,evaluates,Alemtuzumab
NCT00530348,evaluates,Rebif
NCT00530348,measures_primary,Sustained Accumulation of Disability
NCT00530348,measures_secondary,Annualized Relapse Rate
NCT00530348,measures_secondary,Relapse Free at Year 2
NCT00530348,has_criteria,Baseline score of 0
NCT00530348,has_criteria,Baseline score of 1.0 or more
NCT00530348,has_criteria,at least 48 hours
NCT00530348,has_criteria,at least 30 days of clinical stability
NCT06146530,involves,Generalized Anxiety Disorder
NCT06146530,evaluates,Cerina-A
NCT06146530,measures_primary,anxiety severity
NCT06146530,measures_secondary,depression symptoms
NCT06146530,measures_secondary,functional impairment
NCT06146530,measures_secondary,usability
NCT06146530,has_criteria,baseline
NCT04683848,involves,Acute Traumatic Cervical Spinal Cord Injury
NCT04683848,evaluates,MT-3921
NCT04683848,measures_primary,Change in UEMS
NCT04683848,measures_secondary,Change in SCIM III score
NCT04683848,measures_secondary,Change in GRASSP score
NCT04683848,measures_secondary,Change in SCAR
NCT04683848,measures_secondary,Proportion of responders
NCT00436748,involves,Chronic Kidney Disease
NCT00436748,evaluates,Darbepoetin Alfa
NCT00436748,measures_primary,Hemoglobin ≥ 10.0 g/dL
NCT00436748,measures_secondary,Weight-adjusted Darbepoetin Alfa Dose
NCT00436748,has_criteria,Pediatric Patients
NCT00881530,involves,Type Two Diabetes
NCT00881530,evaluates,Empagliflozin
NCT00881530,measures_primary,Change From Baseline
NCT00881530,measures_secondary,HbA1c
NCT00881530,has_criteria,Hypoglycemic events
NCT04161430,involves,Type 2 Diabetes Mellitus
NCT04161430,evaluates,DBPR108
NCT04161430,measures_primary,Change from baseline HbA1c
NCT04161430,measures_secondary,Percentage of subjects HbA1c≤6.5%
NCT04161430,measures_secondary,Percentage of subjects HbA1c≤7%
NCT04161430,has_criteria,WHO (1999) criteria
NCT04161430,has_criteria,18 ≤ age ≤ 75 years
NCT04161430,has_criteria,19kg/m\^2 ≤ Body Mass Index
NCT02611830,involves,Ulcerative Colitis
NCT02611830,evaluates,Vedolizumab
NCT02611830,measures_primary,Clinical Remission
NCT02611830,measures_secondary,Mucosal Healing
NCT02611830,measures_secondary,Durable Clinical Response
NCT02611830,has_criteria,Mayo score ≤ 2 points
NCT01154348,involves,Type 2 Diabetes Mellitus
NCT01154348,evaluates,S-707106
NCT01154348,evaluates,Metformin
NCT01154348,measures_primary,Safety pharmacokinetics
NCT01154348,measures_secondary,Pharmacokinetics
NCT01154348,has_criteria,Body mass index 25.0-38 kg/m2
NCT01154348,has_criteria,Stable dose metformin BID
NCT01154348,has_criteria,Hemoglobin A1c level ≤10.5
NCT04369430,involves,Parkinson's Disease
NCT04369430,evaluates,AKST4290
NCT04369430,measures_primary,Change in motor function
NCT04369430,measures_secondary,Incidence of adverse events
NCT04369430,has_criteria,Stable dopaminergic treatment
NCT06336330,involves,Heart Failure
NCT06336330,evaluates,Dapagliflozin
NCT06336330,measures_primary,Time to discontinuation
NCT06336330,measures_secondary,Reasons for discontinuation
NCT06336330,has_criteria,Baseline to 12 months
NCT02833857,involves,Secondary Hyperparathyroidism
NCT02833857,evaluates,etelcalcetide
NCT02833857,measures_primary,Change From Baseline in Serum Corrected Calcium Concentration
NCT02833857,measures_secondary,Change From Baseline in Serum Phosphorus Concentration
NCT02833857,measures_secondary,Change From Baseline in Serum Potassium Concentration
NCT02833857,measures_secondary,Change From Baseline in Intact Parathyroid Hormone (iPTH) Levels
NCT02833857,measures_secondary,Change From Baseline in Heart Rate
NCT02833857,measures_secondary,Change From Baseline in Temperature
NCT02833857,measures_secondary,Change From Baseline in Blood Pressure
NCT02833857,measures_secondary,Change From Baseline in PR Interval
NCT02833857,measures_secondary,Change From Baseline in QRS Interval
NCT02833857,measures_secondary,Change From Baseline in QT Interval
NCT02833857,measures_secondary,Change From Baseline in Corrected (Bazett) QT Interval
NCT02833857,measures_secondary,Change From Baseline in Corrected (Fridericia) QT Interval
NCT02833857,has_criteria,Paediatric Patients Aged 2 to Less Than 18 Years
NCT02833857,has_criteria,Receiving Haemodialysis
NCT04802057,involves,Cold Agglutinin Disease
NCT04802057,evaluates,SAR445088
NCT04802057,measures_primary,Total bilirubin change
NCT04802057,measures_secondary,Hemoglobin change
NCT04802057,measures_secondary,Lactate dehydrogenase change
NCT04802057,measures_secondary,Reticulocyte count change
NCT04802057,measures_secondary,Complement System Classical Pathway Levels
NCT04802057,measures_secondary,Complement System Alternative Pathway Levels
NCT04802057,measures_secondary,CH50
NCT04802057,measures_secondary,Total Complement Factor C4 Levels
NCT04802057,has_criteria,Previously treated
NCT01939548,involves,Schizophrenia
NCT01939548,evaluates,PF-02545920
NCT01939548,measures_primary,PANSS Total Score
NCT01939548,measures_secondary,Personal and Social Performance Scale Total Score
NCT01939548,has_criteria,Sub-Optimally Controlled Symptoms
NCT04808648,evaluates,Itraconazole
NCT04808648,evaluates,Rifampicin
NCT04808648,measures_primary,Cmax
NCT04808648,measures_primary,AUC(0-last)
NCT04808648,measures_primary,AUC(0-∞)
NCT04808648,has_criteria,Healthy male volunteers
NCT04808648,has_criteria,18 to 45 years old
NCT04808648,has_criteria,50.0 to 80.0 kg
NCT04808648,has_criteria,19.0 to 26.0 kg/m2
NCT04808648,has_criteria,normal physical findings
NCT04808648,has_criteria,non-clinically significant abnormality
NCT04808648,has_criteria,promise not to smoke
NCT04808648,has_criteria,promise not to drink alcohol
NCT04808648,has_criteria,promise not to drink caffeinated beverages
NCT04808648,has_criteria,able to communicate with researcher
NCT04808648,has_criteria,male subjects of reproductive potential
NCT01221948,involves,Parkinson's Disease
NCT01221948,evaluates,Vercise Implantable Stimulator
NCT01221948,measures_primary,UPDRS III Score
NCT01221948,measures_secondary,UPDRS II Score
NCT01221948,has_criteria,Meds Off
NCT03671148,involves,Psoriatic Arthritis
NCT03671148,evaluates,Risankizumab
NCT03671148,evaluates,Placebo
NCT03671148,measures_primary,ACR20 Response
NCT03671148,measures_secondary,HAQ-DI Change
NCT03671148,measures_secondary,PASI 90 Response
NCT03671148,has_criteria,Inadequate Response
NCT03671148,has_criteria,Intolerance Biologic Therapy
NCT02911948,involves,Type 2 Diabetes Mellitus
NCT02911948,evaluates,Insulin Degludec/Liraglutide
NCT02911948,evaluates,Insulin Degludec
NCT02911948,measures_primary,Change in HbA1c
NCT02911948,measures_secondary,Change in Body Weight
NCT02911948,measures_secondary,Change in Fasting Plasma Glucose
NCT02911948,measures_secondary,Number of Hypoglycaemic Episodes
NCT02911948,has_criteria,Inadequately Controlled
NCT02947048,involves,Autism
NCT02947048,evaluates,L1-79
NCT02947048,measures_primary,Change From Baseline in Clinical Global Impression Scale (CGI)
NCT02947048,measures_secondary,Change From Baseline in Vineland Adaptive Behavior Scale - 2nd Edition Socialization Standard Score
NCT02947048,has_criteria,Adolescent and Adult Males
NCT04115748,involves,Psoriatic Arthritis
NCT04115748,evaluates,Filgotinib
NCT04115748,measures_primary,ACR20 response
NCT04115748,measures_secondary,PASDAS
NCT04115748,has_criteria,Biologic DMARD naive
NCT05316220,involves,Ulcerative Colitis
NCT05316220,evaluates,Mesalamine Capsules
NCT05316220,measures_primary,Clinical Remission
NCT05316220,measures_secondary,Endoscopic Remission
NCT05316220,measures_secondary,Symptomatic Remission
NCT05316220,has_criteria,Stable dose of mesalamine
NCT05316220,has_criteria,Remission for at least 30 days
NCT05316220,has_criteria,Abnormal clinical results
NCT01746420,involves,Lateral Epicondylitis
NCT01746420,evaluates,rhPDGF-BB Injection
NCT01746420,measures_primary,Grip Strength Test
NCT01746420,measures_secondary,Visual Analog Scale
NCT01746420,measures_secondary,DASH
NCT01746420,measures_secondary,PRTEE
NCT01746420,has_criteria,Treated Subjects
NCT01807520,involves,Nail Psoriasis
NCT01807520,evaluates,Secukinumab
NCT01807520,measures_primary,Percent Change NAPSI
NCT01807520,measures_secondary,PASI75
NCT01807520,has_criteria,Moderate to Severe
NCT03700320,involves,Episodic Migraine
NCT03700320,evaluates,Atogepant
NCT03700320,measures_primary,Treatment Emergent Adverse Event
NCT03700320,measures_secondary,Clinically Significant Laboratory Values
NCT03700320,measures_secondary,Clinically Significant ECG Findings
NCT03700320,measures_secondary,Clinically Significant Vital Sign Measurements
NCT03700320,has_criteria,first dose up to the end of study
NCT04684420,evaluates,GXR RM 500 Milligram
NCT04684420,measures_primary,AUClast of Metformin
NCT04684420,measures_secondary,Cmax of Metformin
NCT04684420,has_criteria,Treatment-Emergent Adverse Events
NCT02566031,involves,COPD
NCT02566031,evaluates,QVA149
NCT02566031,measures_primary,Trough FEV1
NCT02566031,measures_secondary,Transitional Dyspnea Index
NCT02566031,measures_secondary,COPD Assessment Test
NCT02566031,has_criteria,Symptomatic Mild to Moderate
NCT01507831,involves,Hypercholesterolemia
NCT01507831,involves,Cardiovascular disease
NCT01507831,evaluates,Alirocumab
NCT01507831,evaluates,Placebo
NCT01507831,measures_primary,Percent Change LDL-C
NCT01507831,measures_secondary,Percent Change LDL-C
NCT01507831,measures_secondary,Percent Change LDL-C
NCT01507831,has_criteria,High Cardiovascular Risk
NCT01965431,involves,Cardiac Safety
NCT01965431,evaluates,BI 207127
NCT01965431,evaluates,Faldaprevir
NCT01965431,measures_primary,QTcN change from baseline
NCT01965431,measures_secondary,HR change from baseline
NCT00620282,involves,Type 2 Diabetes Mellitus
NCT00620282,evaluates,Liraglutide
NCT00620282,measures_primary,Change in ACh-mediated FBF
NCT00620282,measures_secondary,Change in SNP-mediated FBF
NCT00620282,measures_secondary,Change in HbA1c
NCT00620282,measures_secondary,Change in Fasting Plasma Glucose
NCT00620282,measures_secondary,Change in Mean Postprandial Glucose
NCT00620282,measures_secondary,Change in Body Weight
NCT00620282,measures_secondary,Change in Total Cholesterol
NCT00620282,measures_secondary,Change in LDL-C
NCT00620282,measures_secondary,Change in HDL-C
NCT00620282,measures_secondary,Change in Triglycerides
NCT00620282,measures_secondary,Change in TNF-alpha
NCT00620282,has_criteria,serum BUN values
NCT05155020,involves,Asthma
NCT05155020,evaluates,AK120
NCT05155020,measures_primary,Change in FEV1
NCT05155020,measures_secondary,Annualized exacerbation events
NCT05155020,measures_secondary,FeNO
NCT05155020,measures_secondary,ACQ-5 scores
NCT05155020,measures_secondary,AQLQ-s scores
NCT05155020,has_criteria,Age 18-75 years
NCT05155020,has_criteria,Asthma diagnosis 12+ months
NCT05155020,has_criteria,Stable inhaled glucocorticoids
NCT05155020,has_criteria,Blood eosinophils ≥200 cells/µL
NCT05155020,has_criteria,FEV1 40-80% predicted
NCT05155020,has_criteria,Inadequate asthma control
NCT01166282,involves,Enthesitis Related Arthritis
NCT01166282,evaluates,Adalimumab
NCT01166282,measures_primary,Percent Change in Active Joints
NCT01166282,measures_secondary,Number of Sites of Enthesitis
NCT01166282,measures_secondary,Tender Joint Count
NCT01166282,measures_secondary,Swollen Joint Count
NCT01166282,measures_secondary,Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response
NCT01166282,has_criteria,last nonmissing value prior to first dose of study drug
NCT03120520,involves,Chronic Idiopathic Constipation
NCT03120520,evaluates,Plecanatide
NCT03120520,measures_primary,Proportion of Responders
NCT03120520,measures_secondary,Change From Baseline in Weekly Average Stool Consistency
NCT03120520,measures_secondary,Change From Baseline in the Weekly Rate of Spontaneous Bowel Movements
NCT03120520,has_criteria,Adolescents 12 to <18 Years of Age
NCT01627782,involves,Treatment-resistant Depression
NCT01627782,evaluates,Ketamine
NCT01627782,measures_primary,MADRS Total Score
NCT01627782,measures_secondary,Number of Responders
NCT01627782,measures_secondary,Number of Remitters
NCT01627782,has_criteria,Baseline (Day 1)
NCT01079182,involves,Ankylosing Spondylitis
NCT01079182,evaluates,Adalimumab
NCT01079182,measures_primary,BASDAI score
NCT01079182,measures_secondary,BASFI score
NCT01079182,has_criteria,drug-related AEs
NCT03464682,involves,Primary Hypercholesterolemia
NCT03464682,evaluates,HS-25
NCT03464682,measures_primary,Percent change LDL-C
NCT03464682,measures_secondary,Percent change Non-HDL-C
NCT03464682,measures_secondary,Percent change HDL-C
NCT03464682,measures_secondary,Percent change TC
NCT03464682,measures_secondary,Percent change TG
NCT03464682,measures_secondary,Percent change Apo B
NCT03464682,measures_secondary,Percent change Apo Al
NCT03464682,has_criteria,18 to 70 years old
NCT03464682,has_criteria,LDL-C 3.36mmol/L to 4.88 mmol/L
NCT03464682,has_criteria,no lipid modifying drug treatment
NCT03464682,has_criteria,Liver transaminases ≤ 1.5 x upper limit of normal
NCT03025282,involves,Psoriasis Vulgaris
NCT03025282,evaluates,CD10367
NCT03025282,measures_primary,AUC of TSS
NCT03025282,measures_secondary,AUC of Individual Clinical Scores
NCT03025282,has_criteria,Day 1 to Day 19
NCT01734382,involves,Systemic Juvenile Arthritis
NCT01734382,evaluates,RoActemra/Actemra
NCT01734382,measures_primary,JADAS-71 score
NCT01734382,measures_secondary,JIA flare
NCT01734382,has_criteria,Disease flare definition
NCT05274425,involves,Asthma
NCT05274425,evaluates,Enerzair
NCT05274425,measures_primary,Change from baseline in FEV1
NCT05274425,measures_secondary,Change from baseline in ACT score
NCT05274425,measures_secondary,Effective rate
NCT05274425,has_criteria,age (<65 vs. ≥65 years)
NCT05274425,has_criteria,male vs. female
NCT05274425,has_criteria,pregnancy (yes vs. no)
NCT05274425,has_criteria,family history (yes vs. no)
NCT05274425,has_criteria,exacerbation history (0 vs. above 1)
NCT05274425,has_criteria,smoking history (yes vs. no)
NCT05274425,has_criteria,comorbidity (yes vs. no)
NCT05274425,has_criteria,concomitant medication/ therapy (yes vs. no)
NCT03451422,involves,Systemic Lupus Erythematosus
NCT03451422,evaluates,Efavaleukin Alfa
NCT03451422,measures_primary,Number of Participants
NCT03451422,measures_secondary,Anti-AMG 592 Antibodies
NCT03451422,measures_secondary,Anti-IL-2 Antibodies
NCT03451422,has_criteria,maximum of 18 weeks
NCT06230822,involves,Idiopathic Pulmonary Fibrosis
NCT06230822,evaluates,VUM02 Injection
NCT06230822,measures_primary,DLCO changes
NCT06230822,measures_secondary,FVC changes
NCT06230822,measures_secondary,Exercise capacity changes
NCT06230822,measures_secondary,St. George's Respiratory Questionnaire
NCT06230822,measures_secondary,Symptoms of dyspnea
NCT06230822,measures_secondary,Symptoms of cough
NCT06230822,has_criteria,Maximum tolerated dose
NCT05596422,involves,Inflammatory Bowel Disease
NCT05596422,evaluates,Vedolizumab
NCT05596422,measures_primary,IBD Relapse
NCT05596422,measures_secondary,Clinical Response
NCT05596422,measures_secondary,Clinical Remission
NCT05596422,has_criteria,Biologics Discontinuation
NCT00668525,involves,Major Depressive Disorder
NCT00668525,evaluates,Escitalopram
NCT00668525,measures_primary,MADRS total score
NCT00668525,measures_secondary,HAM-D total score
NCT00668525,has_criteria,DSM-IV-TR criteria
NCT00668525,has_criteria,8 weeks duration
NCT00668525,has_criteria,reliable birth control
NCT00668525,has_criteria,no manic episode
NCT00668525,has_criteria,no psychotic disorder
NCT00668525,has_criteria,no obsessive-compulsive
NCT00805025,involves,Bronchiectasis
NCT00805025,evaluates,Quality of Life Questionnaire-Bronchiectasis (QOL-B)
NCT00805025,measures_primary,Respiratory symptoms
NCT00805025,measures_secondary,Convergent validity
NCT00805025,has_criteria,Day -14 to Day 0
NCT00437125,involves,Parkinson's Disease
NCT00437125,evaluates,Duloxetine
NCT00437125,measures_primary,Change From Baseline to 12 Weeks on the UPDRS Total Score
NCT00437125,measures_secondary,Change From Baseline to 12 Weeks on the UKU Side Effect Rating Scale
NCT00437125,measures_secondary,Change From Baseline on the Pittsburgh Sleep Quality Index
NCT00437125,has_criteria,baseline through 12 weeks
NCT00767325,involves,Rheumatoid Arthritis
NCT00767325,evaluates,Abatacept+MTX
NCT00767325,measures_primary,Global PDUS score
NCT00767325,measures_secondary,Earliest Time Point
NCT00767325,has_criteria,MCP 2-5 Joints
NCT06429722,involves,Bipolar II Disorder
NCT06429722,evaluates,NMRA-335140
NCT06429722,measures_primary,Change from Baseline
NCT06429722,measures_secondary,Snaith-Hamilton Pleasure Scale
NCT06429722,has_criteria,Baseline and up to Week 6
NCT01782222,involves,Parkinson's Disease
NCT01782222,evaluates,Rotigotine
NCT01782222,measures_primary,Change From Baseline
NCT01782222,measures_secondary,Unified Parkinson's Disease Rating Scale
NCT01782222,has_criteria,Baseline (Visit 2) until End of the Maintenance Period
NCT06559722,involves,Type 2 Diabetes
NCT06559722,evaluates,Insulin Degludec/Liraglutide Injection
NCT06559722,measures_primary,Change from baseline HbA1c
NCT06559722,measures_secondary,Proportion subjects HbA1c<7%
NCT06559722,measures_secondary,Proportion subjects HbA1c≤6.5%
NCT06559722,measures_secondary,Change from baseline FPG
NCT06559722,measures_secondary,Change from baseline SMBG
NCT06559722,measures_secondary,Change from baseline body weight
NCT06559722,measures_secondary,Number treatment emergent adverse events
NCT06559722,measures_secondary,Number treatment emergent hypoglycaemic episodes
NCT06559722,measures_secondary,Number participants injection site reactions
NCT06559722,measures_secondary,Incidence anti-drug antibodies
NCT06559722,measures_secondary,Plasma concentrations degludec
NCT06559722,has_criteria,Baseline
NCT02462122,involves,plaque psoriasis
NCT02462122,evaluates,IDP-118
NCT02462122,measures_primary,Treatment Success
NCT02462122,measures_secondary,Treatment Success
NCT02462122,has_criteria,at least 18 years of age
NCT02462122,has_criteria,BSA of at least 3%
NCT02462122,has_criteria,IGA score of 3 or 4
NCT02462122,has_criteria,clinical diagnosis of psoriasis
NCT05108922,involves,Alzheimer's disease
NCT05108922,evaluates,Donanemab
NCT05108922,evaluates,Aducanumab
NCT05108922,measures_primary,Amyloid plaque clearance
NCT05108922,measures_secondary,Brain amyloid plaque
NCT05108922,has_criteria,Centiloid value <24.1
NCT04083222,involves,essential hypertension
NCT04083222,evaluates,IONIS-AGT-LRx
NCT04083222,measures_primary,Percent Change AGT
NCT04083222,measures_secondary,Change From Baseline SBP
NCT04083222,has_criteria,BMI ≤ 35.0 kg/m²
NCT03131648,involves,Atopic Dermatitis
NCT03131648,evaluates,Tralokinumab
NCT03131648,measures_primary,Eczema Area and Severity Index
NCT03131648,measures_secondary,Worst Daily Pruritus
NCT03131648,measures_secondary,SCORAD
NCT03131648,measures_secondary,DLQI
NCT03131648,has_criteria,Investigator's Global Assessment
NCT01555125,involves,Chronic Plaque-type Psoriasis
NCT01555125,evaluates,Secukinumab
NCT01555125,measures_primary,PASI 75
NCT01555125,measures_secondary,IGA
NCT01555125,has_criteria,Moderate to Severe
NCT03532022,involves,Congenital Adrenal Hyperplasia
NCT03532022,evaluates,Chronocort®
NCT03532022,measures_primary,Biochemical control
NCT03532022,measures_secondary,Responder rate
NCT03532022,measures_secondary,Fertility markers
NCT03532022,measures_secondary,Hirsutism
NCT03532022,measures_secondary,Acne
NCT03532022,measures_secondary,HbA1c levels
NCT03532022,measures_secondary,Waist circumference
NCT03532022,measures_secondary,Body weight
NCT03532022,has_criteria,17 OHP and A4
NCT02737722,involves,Diabetic Ulcer
NCT02737722,evaluates,Bisphosphocin Nu-3
NCT02737722,measures_primary,Diabetic Ulcer Severity Score
NCT02737722,measures_secondary,Diabetic Foot Ulcer Wound Infection Score
NCT02737722,has_criteria,Type I or II Diabetes Mellitus
NCT01377922,involves,Lambert Eaton Myasthenic Syndrome
NCT01377922,evaluates,Amifampridine Phosphate
NCT01377922,measures_primary,Change From Baseline QMG
NCT01377922,measures_secondary,Change in SGI Score
NCT01377922,measures_secondary,Change From Baseline T25FW
NCT01377922,has_criteria,Baseline and Day 14
NCT03607422,involves,Atopic Dermatitis
NCT03607422,evaluates,Upadacitinib
NCT03607422,measures_primary,EASI 75 at Week 16
NCT03607422,measures_secondary,vIGA-AD at Week 16
NCT03607422,has_criteria,Moderate to Severe
NCT03795922,involves,Glabellar Lines
NCT03795922,evaluates,MT10109L
NCT03795922,measures_primary,≥2-grade improvement
NCT03795922,measures_secondary,Duration of treatment effect
NCT03795922,has_criteria,≥2-grade improvement
NCT03334422,involves,Atopic Dermatitis
NCT03334422,evaluates,Baricitinib
NCT03334422,measures_primary,IGA 0 or 1
NCT03334422,measures_secondary,EASI75
NCT03334422,measures_secondary,EASI90
NCT03334422,has_criteria,moderate to severe AD
NCT03998722,involves,Vaginal Atrophy
NCT03998722,evaluates,VagiVital®
NCT03998722,measures_primary,Change in VA symptom
NCT03998722,measures_secondary,Vaginal pH
NCT03998722,measures_secondary,Quality of Life
NCT03998722,measures_secondary,Number of AEs
NCT03998722,measures_secondary,Blood pressure
NCT03998722,measures_secondary,Heart rate
NCT03998722,has_criteria,self-identified
NCT01160822,involves,Osteoarthritis
NCT01160822,evaluates,Canakinumab
NCT01160822,measures_primary,Pain Using VAS
NCT01160822,measures_secondary,WOMAC Pain Subscale
NCT01160822,has_criteria,Baseline VAS pain score
NCT06046222,involves,Eosinophilic Granulomatosis With Polyangiitis
NCT06046222,evaluates,NS-229
NCT06046222,evaluates,Placebo
NCT06046222,measures_primary,Proportion of subjects in remission
NCT06046222,measures_secondary,Time to first relapse of EGPA
NCT06046222,measures_secondary,Time to first worsening of EGPA
NCT06046222,has_criteria,BVAS of 0
NCT06046222,has_criteria,OGC dose of prednisolone/prednisone ≤4 mg/day
NCT06046222,has_criteria,OGC dose of prednisolone/prednisone ≤7.5 mg/day
NCT06046222,has_criteria,BVAS of >0
NCT00293722,involves,Psoriatic Arthritis
NCT00293722,evaluates,Etanercept
NCT00293722,measures_primary,Percent BSA Affected
NCT00293722,measures_secondary,DAS 28
NCT00293722,has_criteria,Rheumatologists treated
NCT06339086,involves,Type 2 Diabetes
NCT06339086,evaluates,Semaglutide Injection
NCT06339086,measures_primary,Change in HbA1c
NCT06339086,measures_secondary,Change from baseline to week 20 in HbA1c
NCT06339086,measures_secondary,Change from baseline to week 20 in FPG
NCT06339086,measures_secondary,Proportion of participants who achieved HbA1c<7.0%
NCT06339086,measures_secondary,Proportion of participants who achieved HbA1c<7.0%
NCT06339086,measures_secondary,Proportion of participants who achieved HbA1c<7.0%
NCT06339086,measures_secondary,Change in Body Weight
NCT06339086,measures_secondary,Proportion of participants with Weight Loss≥5%
NCT06339086,measures_secondary,Change in Diastolic and Systolic Blood Pressure
NCT06339086,measures_secondary,Changes in Blood Lipids
NCT06339086,measures_secondary,Incidence and severity of Adverse Events
NCT06339086,has_criteria,≥18 years old
NCT06339086,has_criteria,≤75 years old
NCT06339086,has_criteria,Diagnosis of type 2 diabetes
NCT06339086,has_criteria,Use a stable dose of metformin
NCT06339086,has_criteria,Glycosylated Hemoglobin(HbA1c) >7
NCT02946463,involves,Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT02946463,evaluates,Ravulizumab
NCT02946463,evaluates,Eculizumab
NCT02946463,measures_primary,Normalization of LDH
NCT02946463,measures_secondary,Transfusion Avoidance
NCT02946463,measures_secondary,Breakthrough Hemolysis
NCT02946463,measures_secondary,Percent Change in LDH Levels
NCT02946463,measures_secondary,Change in Quality of Life
NCT02946463,has_criteria,Transfusion free
NCT06611163,involves,Genital Psoriasis
NCT06611163,evaluates,Subcutaneous Tildrakizumab
NCT06611163,measures_primary,sPGA-G score
NCT06611163,measures_secondary,GPI-NRS
NCT06611163,measures_secondary,Body Surface Area
NCT06611163,measures_secondary,DLQI item 9 score
NCT06611163,measures_secondary,DLQI total score
NCT06611163,measures_secondary,GPSS total score
NCT06611163,has_criteria,moderate to severe
NCT01525563,involves,Cycle Regularization
NCT01525563,evaluates,Duphaston
NCT01525563,measures_primary,Percentage of Regular Cycles
NCT01525563,measures_secondary,Change in Cycle Duration
NCT01525563,measures_secondary,Amount of Menstrual Bleeding
NCT01525563,measures_secondary,Evolution of Pain During Menstruation
NCT01525563,measures_secondary,Overall Patient Satisfaction
NCT01525563,measures_secondary,Evolution of Duration of Menstrual Bleeding
NCT01525563,measures_secondary,Overall Clinical Response
NCT01525563,has_criteria,cycle duration 21 to 35 days
NCT01890863,evaluates,ROTAHALER Device
NCT01890863,measures_primary,Number of participants with AEs
NCT01890863,measures_secondary,Laboratory parameters
NCT01890863,measures_secondary,Vital sign measurement
NCT01890863,has_criteria,Males and females aged 18-65 years
NCT01890863,has_criteria,Healthy as determined by physician
NCT01682863,involves,COPD
NCT01682863,evaluates,QVA149
NCT01682863,evaluates,QAB149
NCT01682863,measures_primary,Change From Baseline in FEV1
NCT01682863,measures_secondary,Time to Premature Discontinuation
NCT01682863,measures_secondary,Change From Baseline in 1 Hour Post-dose FEV1
NCT01682863,measures_secondary,Change From Baseline in FVC Measurement
NCT01682863,has_criteria,Moderate to Severe Airflow Limitation
NCT02274363,involves,Psoriasis
NCT02274363,measures_primary,Psoriasis area and severity index (PASI) score
NCT02274363,measures_secondary,dermatology life quality index (DLQI)
NCT02274363,measures_secondary,body surface area (BSA)
NCT02274363,has_criteria,PASI score greater than 10
NCT02274363,has_criteria,PASI score less than or equal to 10
NCT02274363,has_criteria,Time from disease diagnosis
NCT01862263,involves,Type II Diabetes
NCT01862263,evaluates,Vildagliptin
NCT01862263,measures_primary,Glucose variability
NCT01862263,measures_secondary,Hypoglycemia
NCT01862263,measures_secondary,Hyperglycemia
NCT01862263,has_criteria,Body weight
NCT01862263,has_criteria,Blood pressure
NCT01862263,has_criteria,Fasting plasma glucose
NCT01862263,has_criteria,Hemoglobin A1C
NCT01862263,has_criteria,Creatinine
NCT01862263,has_criteria,C-peptide
NCT01862263,has_criteria,alanine aminotransferase
NCT01862263,has_criteria,aspartate aminotransferase
NCT01862263,has_criteria,Direct bilirubin
NCT04397263,involves,Crohn's Disease
NCT04397263,evaluates,Guselkumab
NCT04397263,measures_primary,Change from Baseline in CDAI Score
NCT04397263,measures_secondary,Change from Baseline in PRO-2 Score
NCT04397263,measures_secondary,Change from Baseline in SES-CD Score
NCT04397263,measures_secondary,Serum Concentation of Guselkumab
NCT04397263,measures_secondary,Number of Participants with Anti-Guselkumab Antibodies
NCT04397263,measures_secondary,Change from Baseline in C-reactive protein (CRP)
NCT04397263,measures_secondary,Change from Baseline in Fecal Calprotectin (FC) Levels
NCT04397263,has_criteria,Up to Week 48
NCT04146363,involves,Atopic Dermatitis
NCT04146363,evaluates,Lebrikizumab
NCT04146363,measures_primary,IGA score 0 or 1
NCT04146363,measures_primary,EASI-75
NCT04146363,measures_secondary,IGA score 0 or 1
NCT04146363,has_criteria,Baseline to Week 16
NCT04146363,has_criteria,Baseline to Week 2
NCT06598163,involves,Mild Cognitive Impairment
NCT06598163,evaluates,Five Lives MED
NCT06598163,measures_primary,Cognitive Function
NCT06598163,measures_secondary,Behavioral Impairment
NCT06598163,measures_secondary,Instrumental Activities of Daily Living
NCT06598163,has_criteria,Baseline and Study Exit (12 weeks)
NCT02709486,involves,Osteoarthritis
NCT02709486,evaluates,Subcutaneous Tanezumab
NCT02709486,measures_primary,WOMAC Pain Subscale
NCT02709486,measures_secondary,WOMAC Physical Function Subscale
NCT02709486,measures_secondary,Patient's Global Assessment
NCT02709486,has_criteria,Baseline
NCT00674986,involves,Type 2 Diabetes
NCT00674986,evaluates,Episodic
NCT00674986,measures_primary,Change From Baseline in HbA1c
NCT00674986,measures_secondary,Change From Baseline in Depression Severity
NCT00674986,measures_secondary,Change From Baseline in the Diabetes Distress Scale
NCT00674986,has_criteria,Non-insulin Treated
NCT02544763,involves,Tuberous Sclerosis Complex
NCT02544763,evaluates,Cannabidiol
NCT02544763,measures_primary,Percent Change in Seizures
NCT02544763,measures_secondary,Caregiver Global Impression of Change
NCT02544763,has_criteria,≥ 50% reduction in seizure frequency
NCT01555463,involves,Papulopustular rosacea
NCT01555463,evaluates,Azelaic Acid Foam
NCT01555463,measures_primary,Inflammatory Lesion Count
NCT01555463,measures_secondary,Erythema Intensity
NCT01555463,has_criteria,up to 12 weeks
NCT06268886,involves,Alzheimer's Disease
NCT06268886,evaluates,BMS-986446
NCT06268886,measures_primary,CDR-SB score
NCT06268886,measures_secondary,brain tau deposition
NCT06268886,measures_secondary,iADRS score
NCT06268886,measures_secondary,ADASCog14 score
NCT06268886,measures_secondary,ADCS-iADL score
NCT06268886,measures_secondary,MMSE score
NCT06268886,has_criteria,Mild cognitive impairment
NCT06268886,has_criteria,CDR score
NCT06268886,has_criteria,CDR-Memory Box score
NCT06268886,has_criteria,AD pathology
NCT06268886,has_criteria,episodic memory impairment
NCT06268886,has_criteria,MMSE score
NCT02804763,involves,Systemic Lupus Erythematosus
NCT02804763,evaluates,Dapirolizumab Pegol
NCT02804763,measures_primary,BICLA response
NCT02804763,measures_secondary,SLEDAI-2K
NCT02804763,has_criteria,BILAG 2004 improvement
NCT02804763,has_criteria,SLEDAI-2K
NCT02804763,has_criteria,Physician's Global Assessment of Disease Activity
NCT02804763,has_criteria,concomitant medications
NCT06260163,involves,Ulcerative Colitis
NCT06260163,evaluates,Guselkumab
NCT06260163,measures_primary,Clinical Remission
NCT06260163,measures_secondary,Clinical Response
NCT06260163,measures_secondary,PUCAI Remission
NCT06260163,has_criteria,induction responders
NCT04092686,involves,Schizophrenia
NCT04092686,evaluates,Investigational Drug
NCT04092686,measures_primary,Change from Baseline
NCT04092686,measures_secondary,Clinical Global Impressions - Severity
NCT04092686,has_criteria,Acute exacerbation of psychotic symptoms
NCT04092686,has_criteria,DSM-5 criteria for schizophrenia
NCT04092686,has_criteria,CGI-S score ≥ 4
NCT04092686,has_criteria,PANSS total score ≥ 80
NCT04092686,has_criteria,PANSS item score ≥ 4
NCT04092686,has_criteria,Marked deterioration of functioning
NCT03299686,involves,Severe Asthma
NCT03299686,evaluates,CJM112
NCT03299686,measures_primary,Change From Baseline FEV1
NCT03299686,measures_secondary,Change From Baseline FEV1 % predicted
NCT03299686,measures_secondary,Change From Baseline ACQ6 Score
NCT03299686,measures_secondary,Change From Baseline ACQ7 Score
NCT03299686,has_criteria,Inadequately Controlled
NCT02422186,involves,Treatment-resistant Depression
NCT02422186,evaluates,Intranasal Esketamine
NCT02422186,measures_primary,Change From Baseline MADRS
NCT02422186,measures_secondary,Change From Baseline MADRS
NCT02422186,has_criteria,Elderly Participants
NCT04820686,involves,Chronic Hepatitis B Infection
NCT04820686,evaluates,Vebicorvir
NCT04820686,measures_primary,Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) On-Treatment
NCT04820686,measures_secondary,Number of Participants With One or More Adverse Events (AEs)
NCT04820686,measures_secondary,Number of Participants With Premature Treatment Discontinuation Due to AEs
NCT04820686,measures_secondary,Number of Participants With One or More Abnormal Laboratory Result
NCT04820686,measures_secondary,Number of Participants With Serum HBsAg Below the Lower Limit of Quantitation (<LLOQ)
NCT04820686,measures_secondary,Number of Participants With HBV Deoxyribonucleic Acid (DNA) Not Detected (<5 IU/mL)
NCT04820686,measures_secondary,Number of Participants With HBV Ribonucleic Acid (RNA) <LLOQ
NCT04820686,measures_secondary,Change From Baseline in Mean log10 HBV RNA On-Treatment
NCT04820686,measures_secondary,Change From Baseline in Mean log10 Hepatitis B Core-related Antigen (HBcrAg) On-Treatment
NCT04820686,measures_secondary,Number of Participants With HBsAg Seroconversion
NCT05599763,involves,Diaper Rash
NCT05599763,evaluates,2% aqueous eosin
NCT05599763,measures_primary,Percentage of patients cured
NCT05599763,measures_secondary,Change of SSDDS score
NCT05599763,has_criteria,Children under 24 months
NCT05599763,has_criteria,Diaper rash
NCT05599763,has_criteria,SSDDS score >= 3/6
NCT05599763,has_criteria,Not requiring hospitalization
NCT05599763,has_criteria,Written consent of parent
NCT05599763,has_criteria,Affiliated with social security
NCT02348086,involves,Rheumatoid arthritis
NCT02348086,evaluates,Adipose stem cells
NCT02348086,measures_primary,Change from Baseline
NCT02348086,measures_secondary,Overall Health
NCT02348086,measures_secondary,Overall Pain
NCT02348086,measures_secondary,Overall Global Activity
NCT02348086,has_criteria,Subjects diagnosed with rheumatoid arthritis
NCT02348086,has_criteria,Subjects scheduled for stem cell/SVF treatment
NCT02348086,has_criteria,Subjects willing and able to sign informed consent
NCT02348086,has_criteria,Subjects willing and able to perform follow-up interviews and surveys
NCT05487963,involves,atopic dermatitis
NCT05487963,evaluates,CGB-500 Topical Ointment
NCT05487963,measures_primary,Percent change EASI score
NCT05487963,measures_secondary,Investigator's Global Assessment
NCT05487963,has_criteria,age 18 years or older
NCT05487963,has_criteria,atopic dermatitis diagnosis 6 months
NCT05487963,has_criteria,clinically stable atopic dermatitis
NCT05487963,has_criteria,IGA score 2 or 3
NCT05487963,has_criteria,EASI score 1.1 to 12.0
NCT05487963,has_criteria,atopic dermatitis 2-12% BSA
NCT03753763,involves,Multiple System Atrophy
NCT03753763,evaluates,safinamide
NCT03753763,measures_primary,anterior displacement
NCT03753763,measures_secondary,lateral displacement
NCT03753763,measures_secondary,UMSARS Part II
NCT03753763,has_criteria,ITT Population
NCT03222622,involves,Psoriasis
NCT03222622,evaluates,Icotinib Hydrochloride Cream
NCT03222622,measures_primary,PASI 50 score
NCT03222622,measures_secondary,PASI 75 score
NCT03222622,has_criteria,Mild to Moderate
NCT01397422,involves,Levodopa-Induced Dyskinesia
NCT01397422,evaluates,Extended Release Amantadine
NCT01397422,measures_primary,Change in UDysRS
NCT01397422,measures_secondary,Change in FSS
NCT01397422,measures_secondary,Change in UDysRS Total Objective Score
NCT01397422,measures_secondary,Change in ON Time Without Troublesome Dyskinesia
NCT01397422,measures_secondary,Change in MDS-UPDRS Combined Scores
NCT01397422,has_criteria,Baseline (Day 1) and Week 8
NCT00508157,involves,Schizophrenia
NCT00508157,involves,Metabolic Syndrome
NCT00508157,evaluates,Aripiprazole
NCT00508157,evaluates,Other Atypical Antipsychotics
NCT00508157,measures_primary,Percent Change in Non-HDL Cholesterol
NCT00508157,measures_secondary,Number of Participants Remaining
NCT00508157,measures_secondary,Fasting Lipid Parameters
NCT00508157,measures_secondary,Fasting Glucose Levels
NCT00508157,measures_secondary,Body Weight
NCT00508157,measures_secondary,Body Mass Index
NCT00508157,measures_secondary,Clinical Global Impression-Severity
NCT00508157,measures_secondary,Subjective Well-Being Under Neuroleptics
NCT00508157,has_criteria,waist \>102 cm in males
NCT00508157,has_criteria,waist \>88 cm in females
NCT00508157,has_criteria,systolic BP ≥130
NCT00508157,has_criteria,diastolic BP ≥85 mm Hg
NCT00508157,has_criteria,fasting HDL \<40 mg/dL in males
NCT00508157,has_criteria,fasting HDL \<50 mg/dL in females
NCT00508157,has_criteria,fasting triglycerides ≥150 mg/dL
NCT00508157,has_criteria,fasting glucose ≥100 mg/dL
NCT05816057,involves,Type 2 Diabetes Mellitus
NCT05816057,evaluates,Semaglutide Injection
NCT05816057,measures_primary,Change in HbA1c
NCT05816057,measures_secondary,Fasting Plasma Glucose
NCT05816057,measures_secondary,Body Weight
NCT05816057,has_criteria,Stable daily dose metformin
NCT05816057,has_criteria,Age 18-75 years
NCT05816057,has_criteria,HbA1c 7.0% to 11.0%
NCT03485157,involves,Osteoarthritis of the Knee
NCT03485157,evaluates,Micronized dHACM
NCT03485157,evaluates,Saline
NCT03485157,measures_primary,Change From Baseline in VAS for Pain
NCT03485157,measures_primary,Change From Baseline in WOMAC Osteoarthritis Index
NCT03485157,measures_secondary,Change From Baseline in VAS
NCT03485157,has_criteria,90 days
NCT03485157,has_criteria,365 days
NCT06345157,involves,RRMS
NCT06345157,evaluates,Ofatumumab
NCT06345157,measures_primary,Annualized relapse rate
NCT06345157,measures_secondary,SDMT
NCT06345157,measures_secondary,Fatigue Severity Scale
NCT06345157,measures_secondary,Quality of life
NCT06345157,has_criteria,Baseline
NCT04157257,involves,Chronic Hepatitis b
NCT04157257,evaluates,QL-007 Tablets
NCT04157257,measures_primary,HBsAg levels at week 24
NCT04157257,measures_secondary,HBsAg and HBeAg levels
NCT04157257,measures_secondary,HBsAg and HBeAg serological clearance
NCT04157257,measures_secondary,ALT level
NCT04157257,has_criteria,aged 18-70 years
NCT04157257,has_criteria,received entecavir or tenofovir
NCT04157257,has_criteria,HBsAg > 250 IU/mL
NCT04157257,has_criteria,ALT ≤ 2×ULN
NCT04157257,has_criteria,no HIV
NCT00844857,involves,Bipolar Depression
NCT00844857,measures_primary,Change From Baseline
NCT00844857,measures_secondary,Percentage of Participants With Remission
NCT00844857,has_criteria,Ages 10-17
NCT00762957,involves,Type 2 Diabetes Mellitus
NCT00762957,evaluates,TAK-559
NCT00762957,measures_primary,Change from baseline in glycosylated hemoglobin
NCT00762957,measures_secondary,Change from baseline in fasting plasma glucose
NCT00762957,measures_secondary,Change from baseline in serum insulin
NCT00762957,measures_secondary,Change from baseline in C-peptide
NCT00762957,measures_secondary,Change from baseline in triglycerides
NCT00762957,measures_secondary,Change from baseline in total cholesterol
NCT00762957,measures_secondary,Change from baseline in high-density lipoprotein
NCT00762957,measures_secondary,Change from baseline in low-density lipoprotein
NCT00762957,measures_secondary,Change from baseline in very-low-density lipoprotein
NCT00762957,measures_secondary,Change from baseline in apolipoproteins A1 and B 100
NCT00762957,measures_secondary,Change from baseline in free fatty acids
NCT00762957,measures_secondary,Change from baseline in plasminogen activator inhibitor-1
NCT00762957,measures_secondary,Change from baseline in fibrinogen
NCT00762957,measures_secondary,Change from baseline in Interleukin-6
NCT00762957,measures_secondary,Change from baseline in C-reactive protein
NCT00762957,measures_secondary,Change from baseline in urinary albumin to creatinine ratio
NCT00762957,has_criteria,diagnosed with type 2 diabetes mellitus
NCT00762957,has_criteria,stable dose of an oral antidiabetic monotherapy
NCT00762957,has_criteria,glycosylated hemoglobin level greater than or equal to 8.0% and less than or equal to 10.0%
NCT00479557,involves,Alzheimer's Disease
NCT00479557,evaluates,ACC-001
NCT00479557,measures_primary,Geometric Mean Titers
NCT00479557,measures_secondary,Anti-A-beta Immunoglobulin
NCT00479557,has_criteria,mild to moderate
NCT02612857,involves,Dermatomyositis
NCT02612857,evaluates,IMO-8400
NCT02612857,measures_primary,CDASI Activity Score
NCT02612857,measures_secondary,mCDASI v2-Activity score
NCT02612857,has_criteria,definite or probable DM
NCT02612857,has_criteria,CDASI-Activity score ≥15
NCT02612857,has_criteria,muscle weakness
NCT02612857,has_criteria,diagnostic evaluation for cancer
NCT02612857,has_criteria,dysphagia
NCT02612857,has_criteria,hypersensitivity to oligodeoxynucleotide
NCT02612857,has_criteria,drug or alcohol abuse
NCT02612857,has_criteria,body weight >140 kg
NCT03282357,involves,Nasolabial Folds
NCT03282357,evaluates,Radiesse
NCT03282357,measures_primary,Treatment success
NCT03282357,measures_secondary,GAIS Score
NCT03282357,has_criteria,Moderate or severe NLFs
NCT00880048,involves,Major Depressive Disorder
NCT00880048,evaluates,Orvepitant
NCT00880048,measures_primary,Change From Baseline
NCT00880048,measures_secondary,Percentage of Participants
NCT00880048,has_criteria,Baseline and up to Week 6
NCT04099563,evaluates,PF-04965842
NCT04099563,measures_primary,AUCinf
NCT04099563,measures_primary,Cmax
NCT04099563,measures_primary,Tmax
NCT04099563,measures_secondary,Number of Participants With Adverse Events
NCT04099563,measures_secondary,Number of Participants With Clinically Significant Change From Baseline in Laboratory Tests
NCT04099563,measures_secondary,Number of Pariticipants With Clinically Significant Change From Baseline in Vital Signs
NCT04099563,has_criteria,Screening up to follow up
NCT03028363,involves,Acne Vulgaris
NCT03028363,evaluates,Olumacostat Glasaretil Gel
NCT03028363,measures_primary,Acne Lesion Counts
NCT03028363,measures_secondary,Investigator Global Assessment
NCT03028363,has_criteria,At least 20 inflammatory lesions
NCT03028363,has_criteria,At least 20 non-inflammatory lesions
NCT03028363,has_criteria,Investigator Global Assessment 3 or greater
NCT03809663,involves,Atopic Dermatitis
NCT03809663,evaluates,Tezepelumab
NCT03809663,measures_primary,IGA 0/1 at Week 16
NCT03809663,measures_secondary,EASI 75 at Week 16
NCT03809663,measures_secondary,EASI 50/90 at Week 16
NCT03809663,measures_secondary,Time to EASI 50/75/90
NCT03809663,has_criteria,rescue medication
NCT01480596,involves,Myasthenia Gravis
NCT01480596,evaluates,Belimumab
NCT01480596,measures_primary,QMG score at 24
NCT01480596,measures_secondary,Improvement by >=3 points
NCT01480596,has_criteria,Baseline score (less than or equal to median)
NCT04963296,involves,Systemic Lupus Erythematosus
NCT04963296,evaluates,Obinutuzumab
NCT04963296,measures_primary,SRI(4) at Week 52
NCT04963296,measures_secondary,SRI(6) at Week 52
NCT04963296,measures_secondary,Sustained Corticosteroid Control
NCT04963296,measures_secondary,Time to First BILAG Flare
NCT04963296,measures_secondary,Sustained SRI(4) Response
NCT04963296,measures_secondary,BICLA at Week 52
NCT04963296,has_criteria,Prednisone >= 10 mg/day
NCT05432596,involves,Atopic Dermatitis
NCT05432596,evaluates,ATI-1777
NCT05432596,measures_primary,EASI score change
NCT05432596,measures_secondary,IGA-TS
NCT05432596,has_criteria,12 to 65 years old
NCT03009396,involves,Crohn's Disease
NCT03009396,evaluates,Anti-MAP
NCT03009396,measures_primary,CDAI score reduction
NCT03009396,measures_secondary,Weeks to remission
NCT03009396,measures_secondary,Weeks in remission
NCT03009396,measures_secondary,Weeks to response
NCT03009396,measures_secondary,Weeks in response
NCT03009396,has_criteria,CDAI less than 150
NCT00145496,involves,Schizophrenia
NCT00145496,evaluates,Asenapine
NCT00145496,evaluates,Olanzapine
NCT00145496,measures_primary,Negative Symptoms
NCT00145496,measures_secondary,Quality of Life
NCT00145496,measures_secondary,Body Weight
NCT00145496,has_criteria,Schizophrenia diagnosis
NCT00145496,has_criteria,Persistent negative symptoms
NCT00145496,has_criteria,Caregiver required
NCT00145496,has_criteria,Uncontrolled medical condition
NCT00145496,has_criteria,No other psychiatric disorder
NCT01294696,involves,Osteoarthritis
NCT01294696,evaluates,MK-0663-140
NCT01294696,measures_primary,Pain Relief
NCT01294696,measures_secondary,Joint Stiffness
NCT01294696,has_criteria,Baseline pain score
NCT01597596,involves,Infantile-Onset Pompe Disease
NCT01597596,evaluates,Alglucosidase Alfa
NCT01597596,measures_primary,Cardiac function at Week 52
NCT01597596,measures_secondary,Motor Development Status at Week 52
NCT01597596,has_criteria,GAA enzyme deficiency
NCT05052996,involves,HIV
NCT05052996,evaluates,Islatravir
NCT05052996,evaluates,Lenacapavir
NCT05052996,measures_primary,HIV-1 RNA ≥ 50 Copies/mL
NCT05052996,measures_secondary,CD4+ Cell Count
NCT05052996,measures_secondary,Adverse Events
NCT05052996,measures_secondary,Cmax of Islatravir
NCT05052996,measures_secondary,Tmax of Islatravir
NCT05052996,measures_secondary,Ctau of Islatravir
NCT05052996,measures_secondary,AUCtau of Islatravir
NCT05052996,measures_secondary,t1/2 of Islatravir
NCT04777396,involves,Alzheimer's Disease
NCT04777396,evaluates,Semaglutide
NCT04777396,measures_primary,Change in CDR-SB
NCT04777396,measures_secondary,ADCS-ADL-MCI
NCT04777396,measures_secondary,Time to progression
NCT04777396,measures_secondary,Change in ADCOMS
NCT04777396,measures_secondary,Change in MMSE
NCT04777396,has_criteria,MCI (CDR global equal to 0.5) at baseline
NCT02822235,involves,Inflammatory Bowel Disease
NCT02822235,involves,Crohn's Disease
NCT02822235,involves,Ulcerative Colitis
NCT02822235,evaluates,Harvey Bradshaw Index
NCT02822235,evaluates,Crohn's Disease Activity Index
NCT02822235,measures_primary,Number of Participants
NCT02822235,measures_secondary,Partial Mayo Score
NCT02822235,has_criteria,Age
NCT02093663,involves,Ulcerative Colitis
NCT02093663,evaluates,MMX Mesalamine/Mesalazine
NCT02093663,measures_primary,UC-DAI score
NCT02093663,measures_secondary,rectal bleeding
NCT02093663,measures_secondary,stool frequency
NCT02093663,measures_secondary,PGA
NCT02093663,has_criteria,clinical response
NCT06532435,involves,Cognitive Improvement
NCT06532435,evaluates,DHA & ARA Candy
NCT06532435,measures_primary,WISC-IV-Chinese score
NCT06532435,measures_secondary,Conners TRS score
NCT06532435,measures_secondary,sick leave days
NCT06532435,has_criteria,preschool children
NCT02819635,involves,Ulcerative Colitis
NCT02819635,evaluates,Upadacitinib
NCT02819635,measures_primary,Clinical Remission
NCT02819635,measures_secondary,Adapted Mayo Score
NCT02819635,has_criteria,Moderately to Severely Active
NCT01075763,involves,Alzheimer's Disease
NCT01075763,evaluates,Interferon Beta-1a
NCT01075763,measures_primary,ADAS-Cog Score
NCT01075763,measures_secondary,MMSE Score
NCT01075763,has_criteria,Baseline and Week 52
NCT01075763,has_criteria,Week 12 and 28
NCT02748863,involves,Psoriasis
NCT02748863,evaluates,Secukinumab
NCT02748863,measures_primary,PASI 75 response
NCT02748863,measures_secondary,IGA mod 2011
NCT02748863,measures_secondary,PASI 90 response
NCT02748863,measures_secondary,PASI 100 response
NCT02748863,has_criteria,PASI 75 response
NCT02748863,has_criteria,IGA mod 2011 0 or 1
NCT05267535,involves,Alzheimer's Disease
NCT05267535,evaluates,Piromelatine
NCT05267535,measures_primary,ADAS-cog 14
NCT05267535,measures_secondary,ADCS-iADL
NCT05267535,measures_secondary,ADCS-CGIC
NCT02620163,involves,Hypertension
NCT02620163,evaluates,YH22162
NCT02620163,evaluates,Telmisartan/Amlodipine
NCT02620163,measures_primary,Change From Baseline in MSSBP
NCT02620163,measures_secondary,Patients Achieving Blood Pressure Control
NCT02620163,measures_secondary,Reduction From Baseline in MSBP
NCT02620163,has_criteria,Signed Informed Consent
NCT02620163,has_criteria,Men and women ≥ 19 years of age
NCT02620163,has_criteria,Essential hypertensive patients
NCT02620163,has_criteria,mean sitting systolic blood pressure (MSSBP) 140 mmHg ≤ MSSBP \< 200 mmHg
NCT02620163,has_criteria,mean sitting systolic blood pressure (MSSBP) 160 mmHg ≤ MSSBP \< 200 mmHg
NCT02914522,involves,Ulcerative Colitis
NCT02914522,evaluates,Filgotinib
NCT02914522,measures_primary,EBS Remission
NCT02914522,measures_secondary,MCS Remission
NCT02914522,has_criteria,Moderately to Severely Active
NCT03420222,involves,Intermittent Explosive Disorder
NCT03420222,evaluates,AVP-786
NCT03420222,measures_primary,OAS-M Total Aggression Score
NCT03420222,measures_secondary,OAS-M Total Irritability Score
NCT03420222,has_criteria,Baseline; Week 12
NCT04951622,involves,Generalized Myasthenia Gravis
NCT04951622,evaluates,Nipocalimab
NCT04951622,measures_primary,Average Change MG-ADL
NCT04951622,measures_secondary,Quantitative Myasthenia Gravis (QMG) Score
NCT04951622,has_criteria,Baseline up to Week 24
NCT00763022,involves,Type 2 Diabetes Mellitus
NCT00763022,evaluates,TAK-559
NCT00763022,measures_primary,Glycosylated hemoglobin
NCT00763022,measures_secondary,Fasting Plasma Glucose
NCT00763022,measures_secondary,Serum insulin
NCT00763022,measures_secondary,C-peptide
NCT00763022,measures_secondary,Lipids
NCT00763022,measures_secondary,Apolipoproteins Al and B100
NCT00763022,measures_secondary,Free fatty acids
NCT00763022,measures_secondary,Markers of thrombosis
NCT00763022,measures_secondary,Markers of inflammation
NCT00763022,measures_secondary,Urinary albumin/creatinine ratio
NCT00763022,has_criteria,stable dose of oral anti-diabetic monotherapy
NCT00763022,has_criteria,glycosylated hemoglobin level
NCT00763022,has_criteria,fasting plasma glucose
NCT00763022,has_criteria,stable dose of glyburide
NCT00763022,has_criteria,stable or worsening self-monitoring blood glucose
NCT00763022,has_criteria,low-density lipoprotein
NCT04184622,involves,Obesity
NCT04184622,involves,Overweight
NCT04184622,evaluates,Tirzepatide
NCT04184622,evaluates,LY3298176
NCT04184622,measures_primary,Percent Change From Baseline
NCT04184622,measures_primary,Body Weight
NCT04184622,measures_secondary,Percentage of Participants
NCT04184622,measures_secondary,Body Weight Reduction
NCT04184622,measures_secondary,Waist Circumference
NCT04184622,measures_secondary,Body Mass Index
NCT04184622,has_criteria,prediabetes status
NCT06623422,involves,Non-small Cell Lung Cancer
NCT06623422,evaluates,Pembrolizumab
NCT06623422,evaluates,V940
NCT06623422,measures_primary,Disease-Free Survival
NCT06623422,measures_secondary,Overall Survival
NCT06623422,measures_secondary,Distant Metastasis-Free Survival
NCT06623422,measures_secondary,Disease-Free Survival 2
NCT06623422,measures_secondary,Lung Cancer Specific Survival
NCT06623422,measures_secondary,Change from Baseline in EORTC-QLQ-C30 Global Health Status/Quality of Life
NCT06623422,has_criteria,randomization
NCT03517722,involves,Systemic Lupus Erythematosus
NCT03517722,evaluates,Ustekinumab
NCT03517722,measures_primary,SRI-4 response
NCT03517722,measures_secondary,Time to First Flare
NCT03517722,has_criteria,SLEDAI-2K total score
NCT05649722,involves,Pulmonary Hypertension Associated With Interstitial Lung Disease
NCT05649722,evaluates,Treprostinil Palmitil Inhalation Powder
NCT05649722,measures_primary,6-Minute Walk Distance
NCT05649722,measures_secondary,Forced Vital Capacity
NCT05649722,measures_secondary,Percent Predicted FVC
NCT05649722,measures_secondary,Forced Expiratory Volume in 1 Second
NCT05649722,measures_secondary,Percent Predicted FEV1
NCT05649722,measures_secondary,Forced Expiratory Flow Between 25% and 75% of Forced Vital Capacity
NCT05649722,measures_secondary,Lung Diffusion Capacity for Carbon Monoxide
NCT05649722,measures_secondary,N-Terminal Fragment B-Type Natriuretic Peptide
NCT05649722,has_criteria,Pre-OLE Baseline
NCT02065622,involves,Ulcerative Colitis
NCT02065622,evaluates,Adalimumab
NCT02065622,measures_primary,Clinical Remission
NCT02065622,measures_primary,Clinical Remission
NCT02065622,measures_secondary,Endoscopic Improvement
NCT02065622,has_criteria,Full Mayo Score
NCT01101022,involves,Attention-Deficit/Hyperactivity Disorder
NCT01101022,evaluates,SPD489
NCT01101022,measures_primary,BRIEF-A GEC T-score
NCT01101022,measures_secondary,AIM-A Multi-Item Scales
NCT01101022,measures_secondary,Informant-reported BRIEF-A T-scores
NCT01101022,measures_secondary,Subject-reported BRIEF-A T-scores
NCT03938922,involves,Parkinson's disease dementia
NCT03938922,evaluates,ENT-01
NCT03938922,measures_primary,Cognition Improvement
NCT03938922,measures_secondary,Montreal Cognitive Assessment
NCT03938922,measures_secondary,Symptoms Adapted for Parkinson's Disease
NCT03938922,measures_secondary,Neuropsychiatric Inventory
NCT03938922,has_criteria,repeated oral doses
NCT03538522,involves,Alzheimer's Disease
NCT03538522,evaluates,NA-831
NCT03538522,measures_primary,CDR-SB score
NCT03538522,measures_secondary,ADCS-ADL MCI
NCT03538522,has_criteria,Change from baseline
NCT04795622,involves,Skin Laxity
NCT04795622,evaluates,Ulthera® DeepSEE® System
NCT04795622,measures_primary,Skin Laxity Improvement
NCT04795622,measures_secondary,iGAIS
NCT04795622,measures_secondary,sGAIS
NCT04795622,measures_secondary,FACE-Q Satisfaction
NCT04795622,has_criteria,Day 90 photographs
NCT05963022,involves,Type 2 Diabetes
NCT05963022,evaluates,Tirzepatide
NCT05963022,measures_primary,Change from Baseline HbA1c
NCT05963022,measures_secondary,Fasting Serum Glucose
NCT05963022,measures_secondary,Body Weight
NCT05963022,measures_secondary,Daily Average 7-Point SMBG
NCT05963022,measures_secondary,Weight loss
NCT05963022,has_criteria,Chinese Participants
NCT03342963,involves,Healthy male adults
NCT03342963,evaluates,ASC-01
NCT03342963,measures_primary,Peak Plasma Concentration
NCT03342963,measures_secondary,Area Under the Plasma Concentration Versus Time Curve 168h
NCT03342963,has_criteria,Age 20-40 years
NCT03342963,has_criteria,BMI 18.5-25.0 kg/m2
NCT03342963,has_criteria,Written informed consent
NCT03342963,has_criteria,No clinically significant abnormality
NCT00830063,involves,Osteoarthritis of knee
NCT00830063,evaluates,Tanezumab
NCT00830063,measures_primary,WOMAC Pain Subscale
NCT00830063,measures_secondary,WOMAC Physical Function Subscale
NCT00830063,measures_secondary,Patient Global Assessment of Osteoarthritis
NCT00830063,has_criteria,Baseline Observation Carried Forward
NCT05192863,involves,Crohn's Disease
NCT05192863,evaluates,Vedolizumab
NCT05192863,measures_primary,Complete Remission
NCT05192863,measures_secondary,Corticosteroid-free Clinical Remission
NCT05192863,has_criteria,corticosteroid-free
NCT04184063,involves,Progressive Supranuclear Palsy
NCT04184063,involves,Multiple System Atrophy
NCT04184063,evaluates,NBMI
NCT04184063,measures_primary,PSPRS individual scales
NCT04184063,measures_secondary,FAB individual scales
NCT04184063,has_criteria,PSP patients
NCT05084963,involves,Active Eosinophilic Esophagitis
NCT05084963,evaluates,IRL201104
NCT05084963,measures_primary,peak esophageal eosinophil count
NCT05084963,measures_secondary,Dysphagia Symptom Questionnaire score
NCT05084963,has_criteria,< 15 eos/hpf
NCT02026063,involves,Carcinoid Syndrome
NCT02026063,evaluates,Telotristat Etiprate
NCT02026063,measures_primary,Change From Baseline
NCT02026063,measures_secondary,Gastrointestinal Symptoms
NCT02026063,has_criteria,First dose of study drug
NCT05646563,involves,Paroxysmal Nocturnal Hemoglobinuria
NCT05646563,evaluates,NM8074
NCT05646563,measures_primary,Hemoglobin Levels
NCT05646563,measures_secondary,Lactate Dehydrogenase
NCT05646563,measures_secondary,Packed Red Blood Cell Transfusions
NCT05646563,measures_secondary,Membrane Attack Complex
NCT05646563,measures_secondary,Complement Component C3b
NCT05646563,measures_secondary,Reticulocyte Count
NCT05646563,measures_secondary,Bilirubin Levels
NCT05646563,measures_secondary,Quality of Life
NCT05646563,has_criteria,Inadequate Response to Soliris
NCT02289963,evaluates,Alirocumab
NCT02289963,involves,Hypercholesterolemia
NCT02289963,measures_primary,LDL-C at Week 24
NCT02289963,measures_secondary,Apolipoprotein (Apo) B at Week 24
NCT02289963,has_criteria,High Cardiovascular Risk
NCT00817635,involves,Resistant Hypertension
NCT00817635,evaluates,LCI699
NCT00817635,measures_primary,Change From Baseline in MSSBP
NCT00817635,measures_secondary,Percentage of Participants With a MSSBP Response
NCT00817635,measures_secondary,Percentage of Participants With a MSDBP Response
NCT00817635,has_criteria,Baseline
NCT00487994,involves,Primary Dyslipidemia
NCT00487994,evaluates,Lapaquistat Acetate
NCT00487994,measures_primary,Low Density Lipoprotein cholesterol
NCT00487994,measures_secondary,High Density Lipoprotein cholesterol
NCT00487994,measures_secondary,Total Cholesterol
NCT00487994,measures_secondary,Triglycerides
NCT00487994,measures_secondary,Very Low Density Lipoprotein cholesterol
NCT00487994,measures_secondary,Apolipoprotein A1
NCT00487994,measures_secondary,Apolipoprotein B
NCT00487994,has_criteria,low density lipoprotein cholesterol
NCT00487994,has_criteria,triglyceride
NCT00487994,has_criteria,fasting low density lipoprotein cholesterol
NCT00487994,has_criteria,physical and mental health
NCT00487994,has_criteria,surgical sterilization
NCT01074294,involves,Attention Deficit/Hyperactivity Disorder
NCT01074294,evaluates,OPC-34712
NCT01074294,measures_primary,Change From Baseline
NCT01074294,measures_secondary,WRAADDS Total Score
NCT01074294,has_criteria,Adult
NCT04923594,involves,Narcolepsy
NCT04923594,evaluates,NLS-2
NCT04923594,measures_primary,Change in ESS Score
NCT04923594,measures_secondary,Patient Global Impression of Change
NCT04923594,has_criteria,Males and females between 18 and 65 years
NCT04923594,has_criteria,Diagnosis of narcolepsy
NCT04923594,has_criteria,Body mass index from 18 to 40 kg/m2
NCT04923594,has_criteria,Consent to use a medically acceptable method of contraception
NCT04923594,has_criteria,Willing and able to provide written informed consent
NCT04923594,has_criteria,Female subjects who are pregnant
NCT04923594,has_criteria,Any other clinically relevant medical
NCT04923594,has_criteria,History or presence of bipolar disorder
NCT04923594,has_criteria,Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness
NCT00992394,involves,Plaque Psoriasis
NCT00992394,evaluates,Etanercept
NCT00992394,measures_primary,AUC PGA Psoriasis
NCT00992394,measures_secondary,DLQI
NCT00992394,measures_secondary,PSSQ
NCT03285594,involves,Type 2 Diabetes Mellitus
NCT03285594,evaluates,Sotagliflozin
NCT03285594,measures_primary,Change From Baseline in HbA1c
NCT03285594,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT03285594,measures_secondary,Change From Baseline in Body Weight
NCT03285594,measures_secondary,Change From Baseline in Systolic Blood Pressure
NCT03285594,has_criteria,Participants with Type 2 Diabetes Mellitus
NCT03285594,has_criteria,using basal insulin alone or in combination with up to 2 OADs
NCT03285594,has_criteria,given written informed consent
NCT01473394,involves,Major Depressive Disorder
NCT01473394,evaluates,Vilazodone
NCT01473394,measures_primary,Change From Baseline
NCT01473394,measures_secondary,Clinical Global Impressions-Severity Score
NCT01473394,has_criteria,18-70 years of age
NCT03982394,involves,Chronic Plaque Psoriasis
NCT03982394,measures_primary,PASI 90
NCT03982394,measures_secondary,sPGA 0/1
NCT03982394,measures_secondary,Static Physician Global Assessment
NCT03982394,measures_secondary,PASI 75
NCT03982394,measures_secondary,PASI 100
NCT03982394,measures_secondary,Absolute PASI<=5
NCT03982394,has_criteria,Moderate to Severe
NCT03983980,involves,Plaque Psoriasis
NCT03983980,evaluates,Tapinarof
NCT03983980,measures_primary,PGA score 0 or 1
NCT03983980,measures_secondary,PASI improvement
NCT03983980,has_criteria,Baseline to Week 12
NCT05931380,involves,Obesity Disease
NCT05931380,evaluates,Orforglipron
NCT05931380,measures_primary,Mean Percent Change in Body Weight
NCT05931380,measures_secondary,Percentage of Participants Who Achieve ≥5% Body Weight Reduction
NCT05931380,measures_secondary,Percentage of Participants Who Achieve ≥10% Body Weight Reduction
NCT05931380,measures_secondary,Percentage of Participants Who Achieve ≥15% Body Weight Reduction
NCT05931380,measures_secondary,Percentage of Participants Who Achieve ≥20% Body Weight Reduction
NCT05931380,measures_secondary,Mean Change from Baseline in Body Mass Index (BMI)
NCT05931380,measures_secondary,Percentage of Participants Who Had Improvements in Hypertension
NCT05931380,measures_secondary,Percentage of Participants Who Had Improvements in Dyslipidemia
NCT05931380,measures_secondary,Percentage of Participants Who Achieve HbA1c Target value
NCT05931380,measures_secondary,Mean Change from Baseline in Visceral Adipose Tissue (VAT)
NCT05931380,measures_secondary,Mean Change from Baseline in Waist Circumference at Umbilical Level
NCT05931380,measures_secondary,Mean Change from Baseline in Systolic Blood Pressure (SBP)
NCT05931380,measures_secondary,Mean Change from Baseline in non-High Density Lipoprotein (HDL)
NCT05931380,measures_secondary,Mean Change from Baseline in HDL
NCT05931380,measures_secondary,Mean Change from Baseline in Triglycerides
NCT05931380,measures_secondary,Mean Change from Baseline in Fasting Glucose
NCT05931380,measures_secondary,Mean Change from Baseline in Hemoglobin A1c (HbA1c)
NCT05931380,measures_secondary,Mean Change from Baseline in High-sensitivity C-reactive Protein
NCT05931380,measures_secondary,Mean Change from Baseline in Short Form 36 Version 2 (SF-36v2) Acute Form Domain Scores
NCT05931380,measures_secondary,Mean Change from Baseline in IMPACT of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function
NCT05931380,measures_secondary,Time to Onset of Type 2 Diabetes (T2D)
NCT01911780,evaluates,Telmisartan/Hydrochlorothiazide
NCT01911780,evaluates,Telmisartan/Hydrochlorothiazide Plus Amlodipine
NCT01911780,measures_primary,Change From Baseline in Mean Seated DBP
NCT01911780,measures_primary,Change from baseline in mean seated systolic blood pressure
NCT01911780,measures_primary,The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg
NCT01911780,measures_primary,The Number of Patients With DBP<90 mmHg and SBP<140 mmHg
NCT01911780,measures_secondary,Change From Baseline in Mean DBP Pressure at Trough After 52 Week
NCT04440592,involves,Diffuse Cutaneous Systemic Sclerosis
NCT04440592,evaluates,MT-7117
NCT04440592,measures_primary,ACR CRISS composite score
NCT04440592,measures_secondary,Health Assessment Questionnaire Disability Index
NCT04440592,measures_secondary,percent predicted forced vital capacity
NCT04440592,measures_secondary,Patient Global Assessment
NCT04440592,measures_secondary,Physician Global Assessment
NCT04440592,has_criteria,52 weeks
NCT02745080,involves,Psoriatic Arthritis
NCT02745080,evaluates,Secukinumab
NCT02745080,evaluates,Adalimumab
NCT02745080,measures_primary,ACR20 response
NCT02745080,measures_secondary,PASI-90 Response
NCT02745080,measures_secondary,ACR50 Response
NCT02745080,has_criteria,no permanent discontinuation
NCT02745080,has_criteria,no use of cDMARDs
NCT00171080,involves,Hypertension
NCT00171080,evaluates,Valsartan
NCT00171080,evaluates,Irbesartan
NCT00171080,measures_primary,Systolic blood pressure
NCT00171080,measures_secondary,Diastolic blood pressure
NCT00171080,measures_secondary,Ambulatory blood pressure
NCT00171080,has_criteria,MSSBP ≥ 140 mmHG
NCT00171080,has_criteria,MSSBP < 180 mmHG
NCT00171080,has_criteria,Chronic hemodialysis
NCT00171080,has_criteria,Stable hematocrit
NCT00171080,has_criteria,epoetin treatment
NCT00171080,has_criteria,Atrial fibrillation
NCT02248480,involves,Chronic Osteoarthritis
NCT02248480,evaluates,Duloxetine
NCT02248480,measures_primary,Change From Baseline
NCT02248480,measures_secondary,Patient Global Impression
NCT02248480,measures_secondary,Clinical Global Impression
NCT02248480,has_criteria,Baseline
NCT02279173,involves,Immune Thrombocytopenia
NCT02279173,evaluates,Romiplostim
NCT02279173,measures_primary,Platelet response
NCT02279173,measures_secondary,Collagen development
NCT02279173,measures_secondary,Modified Bauermeister Grade
NCT02279173,has_criteria,Platelet count ≥ 50 x 10⁹/L
NCT05206773,involves,Fabry Disease
NCT05206773,evaluates,Venglustat Tablets
NCT05206773,measures_primary,Percent change in symptom
NCT05206773,measures_secondary,Rescue pain medication use
NCT05206773,has_criteria,≥16 Years of Age
NCT01426373,involves,Subcutaneous Fat
NCT01426373,evaluates,Deoxycholic Acid
NCT01426373,measures_primary,Submental Fat Rating Scale
NCT01426373,measures_secondary,Patient-Reported Submental Fat Scale
NCT01426373,has_criteria,Serious Adverse Events
NCT00637273,involves,Type 2 Diabetes
NCT00637273,evaluates,Exenatide
NCT00637273,measures_primary,Change in HbA1c
NCT00637273,measures_secondary,Body Weight
NCT00637273,has_criteria,Metformin treated
NCT00789373,involves,Advanced Non-squamous Non-Small Cell Lung Cancer
NCT00789373,measures_primary,Progression-free Survival
NCT00789373,measures_secondary,Overall Survival
NCT00789373,measures_secondary,Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score
NCT00789373,has_criteria,Response Evaluation Criteria In Solid Tumors (RECIST)
NCT00697073,involves,Friedreich's ataxia
NCT00697073,evaluates,Idebenone
NCT00697073,measures_primary,ICARS score
NCT00697073,measures_secondary,FARS score
NCT00697073,has_criteria,Body weight ≥ 25kg/55 lbs
NCT00697073,has_criteria,Negative urine pregnancy test
NCT00697073,has_criteria,Patients able to comply
NCT03196427,involves,Ulcerative Colitis
NCT03196427,involves,Crohn's Disease
NCT03196427,evaluates,Vedolizumab
NCT03196427,measures_primary,Complete Mayo Score
NCT03196427,measures_secondary,SES-CD Score
NCT03196427,measures_secondary,CDAI
NCT03196427,has_criteria,Treatment-emergent Adverse Events
NCT00687973,involves,Essential Hypertension
NCT00687973,evaluates,Amlodipine/Valsartan
NCT00687973,measures_primary,Central Systolic Blood Pressure
NCT00687973,measures_secondary,Augmentation Index
NCT00687973,measures_secondary,Pulse Wave Velocity
NCT00687973,measures_secondary,Brachial SBP/DBP
NCT00687973,measures_secondary,Brachial Pulse Pressure
NCT00687973,measures_secondary,SBP/DBP
NCT00687973,measures_secondary,Pulse Pressure
NCT00687973,has_criteria,Hypertension defined
NCT04684394,involves,Neovascular Age-related Macular Degeneration
NCT04684394,evaluates,GEM103
NCT04684394,measures_primary,Letters From Baseline
NCT04684394,measures_secondary,Ocular TEAEs
NCT04684394,measures_secondary,Non-ocular TEAEs
NCT04684394,measures_secondary,Abnormal Ophthalmic Examination Findings
NCT04684394,has_criteria,Baseline up to Week 48
NCT06322394,involves,Acute Ischaemic Stroke
NCT06322394,evaluates,BXOS110 Injection
NCT06322394,measures_primary,mRS score 0-2
NCT06322394,measures_secondary,mRS score 0-1
NCT06322394,measures_secondary,mRS Displacement
NCT02722694,involves,Rheumatoid Arthritis
NCT02722694,evaluates,Abatacept
NCT02722694,measures_primary,ACR 20 at 24 weeks
NCT02722694,measures_primary,HAQ-DI improvement
NCT02722694,measures_secondary,ACR 50 at 24 weeks
NCT02722694,measures_secondary,ACR 70 at 24 weeks
NCT02722694,has_criteria,Inadequate Response to Methotrexate
NCT03905694,involves,Primary Hyperoxaluria Type 1
NCT03905694,evaluates,Lumasiran
NCT03905694,measures_primary,Percentage Change in Spot Urinary Oxalate:Creatinine Ratio
NCT03905694,measures_secondary,Percentage Change in Urinary Oxalate Excretion
NCT03905694,has_criteria,genetic confirmation of PH1
NCT03905694,has_criteria,urinary oxalate excretion requirements
NCT03905694,has_criteria,stable Vitamin B6 regimen
NCT03905694,has_criteria,serum creatinine
NCT03905694,has_criteria,estimated glomerular filtration rate
NCT04059094,involves,Cystic Fibrosis
NCT04059094,evaluates,BI 1265162
NCT04059094,measures_primary,Change From Baseline FEV1
NCT04059094,measures_secondary,Lung Clearance Index
NCT04059094,measures_secondary,Cystic Fibrosis Questionnaire Revised (CFQ-R) Total Score
NCT04059094,has_criteria,Adolescents and Adults
NCT00573794,involves,Ulcerative Colitis
NCT00573794,evaluates,Adalimumab
NCT00573794,measures_primary,Partial Mayo Score
NCT00573794,measures_secondary,Mayo Score
NCT00573794,measures_secondary,Percentage of Participants With Remission
NCT00573794,measures_secondary,Mayo Endoscopy Subscore
NCT00573794,measures_secondary,Mayo Rectal Bleeding Subscore
NCT00573794,has_criteria,Baseline (Week 0)
NCT05924594,involves,ADHD
NCT05924594,evaluates,CTx-1301
NCT05924594,measures_primary,Change from baseline
NCT05924594,measures_secondary,Onset and duration
NCT05924594,measures_secondary,CGI-S
NCT05924594,has_criteria,6-12 years old
NCT01954394,evaluates,Alirocumab
NCT01954394,measures_primary,LDL-C at Weeks
NCT01954394,measures_secondary,LDL-C at Weeks
NCT01954394,has_criteria,treatment-emergent period
NCT03312894,involves,Treatment-Resistant Depression
NCT03312894,evaluates,TAK-653
NCT03312894,measures_primary,MADRS Total Score
NCT03312894,measures_secondary,CGI-S Score
NCT03312894,measures_secondary,QIDS-SR16 Total Score
NCT03312894,has_criteria,Baseline up to Day 57
NCT00281580,evaluates,Telmisartan
NCT00281580,evaluates,Amlodipine
NCT00281580,measures_primary,Change From Baseline
NCT00281580,measures_secondary,Change From Baseline
NCT00537680,involves,Friedreich's Ataxia
NCT00537680,evaluates,idebenone
NCT00537680,measures_primary,ICARS score change
NCT00537680,measures_secondary,FARS score change
NCT00537680,measures_secondary,ADL score change
NCT00537680,has_criteria,6 months treatment
NCT01933880,involves,Attention Deficit Hyperactivity Disorder
NCT01933880,evaluates,Methylphenidate
NCT01933880,measures_primary,IOWA Conners Behavior Rating Scale - I/O Score
NCT01933880,measures_secondary,Change From Baseline in Digit Span Test Total Score
NCT01933880,has_criteria,Baseline and Week 12
NCT05059080,involves,Coronavirus Disease 2019
NCT05059080,evaluates,RO7496998
NCT05059080,measures_primary,COVID-19 symptoms
NCT05059080,measures_secondary,Dyspnea Symptoms Assessment Score
NCT05059080,has_criteria,Baseline assessment
NCT01640080,involves,Major Depressive Disorder
NCT01640080,evaluates,Intravenous Esketamine
NCT01640080,measures_primary,MADRS total score
NCT01640080,measures_secondary,MADRS total score
NCT01640080,has_criteria,Treatment-Resistant Depression
NCT00553280,involves,Diabetic Peripheral Neuropathy
NCT00553280,evaluates,Pregabalin
NCT00553280,measures_primary,Change From Baseline
NCT00553280,measures_secondary,Change From Baseline
NCT00553280,has_criteria,From baseline to 52 weeks
NCT02371980,involves,Major Depressive Disorder
NCT02371980,evaluates,Vortioxetine
NCT02371980,measures_primary,Time to relapse
NCT02371980,measures_secondary,Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
NCT02371980,has_criteria,Double-blind Baseline (BL) II
NCT03542994,involves,Psoriasis
NCT03542994,involves,Atopic Dermatitis
NCT03542994,evaluates,EDP1066
NCT03542994,measures_primary,Psoriasis-area-and-severity index score
NCT03542994,measures_primary,Eczema-area-and-severity index score
NCT03542994,measures_secondary,Adverse Events
NCT03542994,measures_secondary,laboratory values
NCT03542994,measures_secondary,ECG parameters
NCT03542994,measures_secondary,physical examination
NCT03542994,has_criteria,body mass index
NCT01455194,involves,Asthma
NCT01455194,evaluates,High Dose Ciclesonide
NCT01455194,measures_primary,ACQ Score
NCT01455194,measures_secondary,Asthma Control
NCT01455194,has_criteria,Baseline ACQ Score
NCT02938494,involves,Acne Vulgaris
NCT02938494,evaluates,IDP-123 Lotion
NCT02938494,measures_primary,Noninflammatory Lesion Count
NCT02938494,measures_secondary,Inflammatory Lesion Count
NCT02938494,has_criteria,at least 12 years old
NCT04605094,involves,Atopic Dermatitis
NCT04605094,evaluates,Benralizumab
NCT04605094,measures_primary,IGA 0/1 at Week 16
NCT04605094,measures_secondary,EASI-75 at Week 16
NCT04605094,has_criteria,Baseline (Week 0)
NCT00312494,involves,Acute Mania
NCT00312494,evaluates,Ziprasidone
NCT00312494,measures_primary,YMRS Change
NCT00312494,measures_secondary,MADRS Total Scores
NCT00312494,has_criteria,Baseline
NCT04450394,involves,Type 2 Diabetes Mellitus
NCT04450394,evaluates,LY3209590
NCT04450394,measures_primary,Change From Baseline in HbA1c
NCT04450394,measures_secondary,Change From Baseline in Fasting Serum Glucose
NCT04450394,measures_secondary,Rate of Documented Hypoglycemia
NCT04450394,has_criteria,type 2 diabetes mellitus
NCT04450394,has_criteria,metformin
NCT04450394,has_criteria,DPPIV inhibitor
NCT04450394,has_criteria,SGLT2 inhibitor
NCT01625494,involves,essential hypertension
NCT01625494,evaluates,Irbesartan/Amlodipine
NCT01625494,measures_primary,controlled OBPM
NCT01625494,measures_secondary,Mean change in OBPM
NCT01625494,measures_secondary,Number of patients with adverse events
NCT01625494,measures_secondary,Number of patients discontinue
NCT01625494,measures_secondary,Number of patients with abnormal liver function
NCT01625494,has_criteria,≥18 years old
NCT01625494,has_criteria,uncontrolled systolic BP
NCT01625494,has_criteria,treated with irbesartan
NCT01625494,has_criteria,treated with amlodipine
NCT01625494,has_criteria,signed written informed consent
NCT01625494,has_criteria,bilateral artery stenosis
NCT01625494,has_criteria,renal artery stenosis
NCT01625494,has_criteria,renal transplant
NCT01625494,has_criteria,one functioning kidney
NCT01625494,has_criteria,known contraindications
NCT05496894,involves,relapsing multiple sclerosis
NCT05496894,evaluates,Mitoxantrone Hydrochloride Liposome Injection
NCT05496894,measures_primary,Annualized Relapse Rate
NCT05496894,measures_secondary,Number of Relapses
NCT05496894,measures_secondary,Time to Onset of Confirmed Disability Progression
NCT05496894,measures_secondary,Time to Onset of Confirmed Disability Progression
NCT05496894,measures_secondary,Proportion of participants with ≥ 20% improvement
NCT05496894,measures_secondary,Change from baseline in T25FW walking speed
NCT05496894,measures_secondary,Number of new or enlarged T2 lesions
NCT05496894,measures_secondary,Change from baseline in brain MRI Gd-enhancing T1 lesion volume
NCT05496894,measures_secondary,Change from baseline in brain MRI T2 lesion volume
NCT05496894,measures_secondary,Number of participants with treatment-related adverse events
NCT05496894,has_criteria,18 to 55 years of age
NCT05496894,has_criteria,Diagnosis of relapsing multiple sclerosis
NCT05496894,has_criteria,Disease duration of secondary progressive multiple sclerosis
NCT05496894,has_criteria,Expanded disability status scale (EDSS) score
NCT02335294,involves,Pain After Abdominoplasty
NCT02335294,evaluates,TRV130
NCT02335294,measures_primary,Time Weighted Average Change From Baseline in Pain Score Over 24 Hours
NCT02335294,measures_secondary,Pain intensity
NCT02335294,has_criteria,>=18 and <65 years of age
NCT02335294,has_criteria,Plans to undergo an abdominoplasty procedure with no additional collateral procedures
NCT02335294,has_criteria,Is able to understand and comply with the procedures and study requirements
NCT02335294,has_criteria,ASA Physical Status Classification System classification of P3 or worse
NCT02335294,has_criteria,Has surgical or post-surgical complications
NCT02335294,has_criteria,Has clinically significant medical conditions or history of such conditions that may interfere with the interpretation of efficacy
NCT02335294,has_criteria,Has previously participated in another TRV130 clinical study
NCT02198794,involves,Tardive Dyskinesia
NCT02198794,evaluates,study drug
NCT02198794,measures_primary,Total Motor AIMS Score
NCT02198794,measures_secondary,Treatment-Emergent AEs
NCT02198794,has_criteria,Baseline to end of follow-up
NCT00942994,involves,Stage 2 hypertension
NCT00942994,evaluates,Aliskiren/Amlodipine/Hydrochlorothiazide
NCT00942994,evaluates,Aliskiren/Amlodipine
NCT00942994,measures_primary,Change From Baseline in MSSBP
NCT00942994,measures_secondary,Change From Baseline in MSDBP
NCT00942994,measures_secondary,Percentage of Patients Achieving Blood Pressure Control
NCT00942994,measures_secondary,Percentage of Responders
NCT00942994,has_criteria,newly diagnosed or history of hypertension
NCT02685462,evaluates,Cenicriviroc
NCT02685462,evaluates,HMG-CoA Reductase Inhibitors
NCT02685462,evaluates,Caffeine
NCT02685462,evaluates,Digoxin
NCT02685462,measures_primary,maximum plasma concentration
NCT02685462,measures_primary,minimum plasma concentration
NCT02685462,measures_primary,area under the plasma concentration-time curve
NCT02685462,measures_secondary,Changes from Baseline
NCT02685462,has_criteria,Baseline and 23 days
NCT01650194,involves,Bone Metastatic Castration-Resistant Prostate Cancer
NCT01650194,evaluates,Enzalutamide
NCT01650194,evaluates,Abiraterone Acetate
NCT01650194,measures_primary,Testosterone Concentration
NCT01650194,measures_secondary,Dihydrotestosterone Concentration
NCT01650194,measures_secondary,Cortisol
NCT01650194,measures_secondary,Androstenedione
NCT01650194,measures_secondary,Progesterone
NCT02783573,involves,Mild Alzheimer's Disease Dementia
NCT02783573,evaluates,Lanabecestat
NCT02783573,measures_primary,Change From Baseline in ADAS-Cog13 Score
NCT02783573,measures_secondary,Change From Baseline in ADCS-iADL
NCT02783573,measures_secondary,Change From Baseline in Functional Activities Questionnaire Score
NCT02783573,has_criteria,AChEI use at baseline
NCT03169894,involves,Crohn's Disease
NCT03169894,involves,Ulcerative Colitis
NCT03169894,evaluates,MDGN-002
NCT03169894,measures_primary,Change From Baseline in SES-CD
NCT03169894,measures_secondary,Change From Baseline in CDAI
NCT03169894,measures_secondary,Change From Baseline in IBD-Q
NCT03169894,has_criteria,Moderate to Severe Active
NCT00685373,involves,Cryopyrin-associated Periodic Syndromes
NCT00685373,involves,Familial Cold Autoinflammatory Syndrome
NCT00685373,involves,Muckle-Wells Syndrome
NCT00685373,involves,Neonatal Onset Multisystem Inflammatory Disease
NCT00685373,evaluates,ACZ885
NCT00685373,measures_primary,Disease Relapse
NCT00685373,measures_secondary,Injection Site Reactions
NCT00685373,has_criteria,complete response
NCT02329327,involves,Acute Major Bleeding
NCT02329327,evaluates,Andexanet Alfa
NCT02329327,measures_primary,Hemostatic Efficacy
NCT02329327,measures_secondary,Percent Change
NCT02329327,has_criteria,FXa inhibitor
NCT04173494,involves,Myelofibrosis
NCT04173494,evaluates,Momelotinib
NCT04173494,evaluates,Danazol
NCT04173494,measures_primary,TSS Response Rate
NCT04173494,measures_secondary,Transfusion Independence
NCT04173494,measures_secondary,Splenic Response Rate
NCT04173494,has_criteria,red blood cell transfusion
NCT04173494,has_criteria,hemoglobin level
NCT00612573,involves,moderate to severe facial acne vulgaris
NCT00612573,evaluates,tetracycline-class antibiotics
NCT00612573,measures_primary,IGA score at Week 12
NCT00612573,measures_secondary,Inflammatory Lesion Count
NCT00612573,measures_secondary,NonInflammatory Lesion Count
NCT00612573,measures_secondary,Total Lesion Count
NCT00612573,has_criteria,12 to 45 years of age
NCT00612573,has_criteria,moderate to severe facial acne vulgaris
NCT00612573,has_criteria,no more than two nodules
NCT00612573,has_criteria,allergic to tetracycline-class antibiotics
NCT00612573,has_criteria,history of pseudomembranous colitis
NCT00612573,has_criteria,history of hepatitis or liver damage
NCT00612573,has_criteria,renal impairment
NCT03859973,involves,Schizophrenia
NCT03859973,evaluates,BI 425809
NCT03859973,measures_primary,Change in Neurocognitive Function
NCT03859973,measures_secondary,Change in Cognitive Function
NCT03859973,has_criteria,Brain Training Using a Computer
NCT04126473,involves,Cystic Fibrosis
NCT04126473,evaluates,ELX-02
NCT04126473,measures_primary,sweat chloride concentration
NCT04126473,measures_secondary,ppFEV1
NCT04126473,measures_secondary,ppFVC
NCT04126473,measures_secondary,ppFEF25-75
NCT04126473,has_criteria,G542X Allele
NCT00884273,involves,Prostate Cancer
NCT00884273,evaluates,Degarelix
NCT00884273,measures_primary,Change From Baseline in Prostate Size
NCT00884273,measures_secondary,Total International Prostate Symptom Score
NCT00884273,measures_secondary,Serum Testosterone Levels
NCT00884273,measures_secondary,Prostate-Specific Antigen Levels
NCT00884273,measures_secondary,Quality of Life
NCT00884273,has_criteria,After treatment of 12 weeks
NCT00884273,has_criteria,After treatment of 4 and 8 weeks
NCT00884273,has_criteria,After treatment of 4
NCT01146860,involves,Acute Rhinosinusitis
NCT01146860,evaluates,Dry Extract BNO 1016
NCT01146860,measures_primary,Major Symptom Score
NCT01146860,measures_secondary,SNOT 20 Symptom Scores
NCT01146860,has_criteria,4-point rating scale
NCT05083260,involves,Parkinson's Disease
NCT05083260,evaluates,NE3107
NCT05083260,measures_primary,Change from baseline
NCT05083260,measures_secondary,OFF time
NCT05083260,measures_secondary,Average Motor disease society- Unified Parkinson's disease rating scale Part III total score
NCT03451760,involves,Behavioral Symptoms in Dementia
NCT03451760,evaluates,Feru-guard
NCT03451760,measures_primary,Change from Baseline NPI-Q
NCT03451760,measures_secondary,Caregiver Distress subscale score
NCT03451760,has_criteria,direct contact > 2 days/week
NCT04944576,involves,Total Ankle Prosthesis
NCT04944576,evaluates,EasyMove®
NCT04944576,measures_primary,Revision rate
NCT04944576,measures_secondary,AOFAS score
NCT04944576,measures_secondary,FAAM score
NCT04944576,measures_secondary,Range of motion
NCT04944576,has_criteria,preop
NCT04944576,has_criteria,4-6 weeks postop
NCT04944576,has_criteria,1 year postop
NCT04944576,has_criteria,2 years postop
NCT04944576,has_criteria,5 years postop
NCT06291376,involves,Immunoglobulin A Nephropathy
NCT06291376,evaluates,Ravulizumab
NCT06291376,measures_primary,Change from Baseline in Proteinuria
NCT06291376,measures_secondary,Glomerular Filtration Rate
NCT06291376,has_criteria,Baseline
NCT00216476,involves,Schizophrenia
NCT00216476,involves,Schizoaffective Disorder
NCT00216476,evaluates,Risperidone LAI
NCT00216476,evaluates,Quetiapine Tablets
NCT00216476,evaluates,Aripiprazole
NCT00216476,measures_primary,Mean Relapse Free Period
NCT00216476,measures_secondary,PANSS Score
NCT00216476,measures_secondary,CGI Score
NCT00216476,has_criteria,predefined criteria
NCT01009060,involves,Schizophrenia
NCT01009060,evaluates,GSK239512
NCT01009060,measures_primary,Change From Baseline
NCT01009060,measures_secondary,MCCB composite T scores
NCT01009060,has_criteria,Baseline and up to Week 7
NCT02608476,involves,Facial Acne Vulgaris
NCT02608476,evaluates,CB-03-01 Cream
NCT02608476,measures_primary,IGA success
NCT02608476,measures_secondary,Non-inflammatory Lesion Counts
NCT02608476,measures_secondary,Inflammatory Lesion Counts
NCT02608476,measures_secondary,Total Lesion Counts
NCT02608476,has_criteria,9 years of age or older
NCT02608476,has_criteria,post-menopausal
NCT02608476,has_criteria,surgically sterile
NCT02608476,has_criteria,highly effective birth control
NCT02608476,has_criteria,negative pregnancy test
NCT06087276,involves,Essential Tremor
NCT06087276,evaluates,Ulixacaltamide
NCT06087276,measures_primary,change in mADL11
NCT06087276,measures_secondary,Adverse Events
NCT06087276,has_criteria,Week 8 baseline
NCT03348527,involves,Prostate Cancer
NCT03348527,evaluates,Liproca Depot
NCT03348527,measures_primary,PSA level decrease
NCT03348527,measures_secondary,Prostate Volume
NCT03348527,measures_secondary,Lesions
NCT03348527,measures_secondary,Quality of Life
NCT03348527,measures_secondary,Micturition Status
NCT03348527,measures_secondary,Adverse Events
NCT03348527,measures_secondary,Testosterone Levels
NCT03348527,has_criteria,Transrectal injection
NCT00719576,involves,Symptomatic Articular Cartilage Defects
NCT00719576,evaluates,MACI®
NCT00719576,evaluates,Microfracture Treatment
NCT00719576,measures_primary,KOOS Pain and Function
NCT00719576,measures_secondary,ICRS II overall assessment score
NCT00719576,measures_secondary,MRI degree of defect fill
NCT00719576,has_criteria,Knee Injury and Osteoarthritis Outcome Score
NCT05789576,involves,plaque psoriasis
NCT05789576,evaluates,VTAMA® (Tapinarof) Cream
NCT05789576,measures_primary,PGA score of Clear (0) or Almost Clear (1)
NCT05789576,measures_secondary,Time to achieve PGA score
NCT05789576,has_criteria,18 years of age or older
NCT05789576,has_criteria,clinical diagnosis of plaque psoriasis
NCT05789576,has_criteria,stable disease in head and neck region
NCT05789576,has_criteria,PGA (target lesion) score of 2 (Mild)
NCT03019627,involves,Dry Eye
NCT03019627,evaluates,NGF Eye Drops Solution
NCT03019627,measures_primary,SANDE Scores
NCT03019627,measures_secondary,Cornea Vital Staining
NCT03019627,has_criteria,week 8
NCT01090427,involves,Psoriasis
NCT01090427,evaluates,Ustekinumab
NCT01090427,measures_primary,PGA score 0 or 1
NCT01090427,measures_secondary,PASI 75 response
NCT01090427,measures_secondary,CDLQI score
NCT01090427,has_criteria,Adolescent patients
NCT05699460,involves,Parkinson's Disease
NCT05699460,involves,Multiple System Atrophy
NCT05699460,evaluates,Gene Therapy
NCT05699460,measures_primary,Change from baseline
NCT05699460,measures_primary,Change from baseline
NCT05699460,measures_secondary,Quality of life
NCT05699460,measures_secondary,Quality of life
NCT05699460,has_criteria,Diagnosis of Idiopathic PD
NCT01770860,involves,Wounds
NCT01770860,evaluates,Bandages
NCT01770860,measures_primary,Time to healing
NCT01770860,measures_secondary,Forced Rank Score
NCT01770860,measures_secondary,Erythema
NCT01770860,measures_secondary,Edema
NCT01770860,measures_secondary,Maceration
NCT01770860,has_criteria,within 14 days
NCT02242760,involves,Acne Vulgaris
NCT02242760,evaluates,SB204 Gel
NCT02242760,measures_primary,Absolute Change in Inflammatory Lesion Counts
NCT02242760,measures_primary,Change in inflammatory lesion count from Baseline to Week 12
NCT02242760,measures_primary,Proportion of Success According to the Dichotomized Investigator Global Assessment
NCT02242760,measures_secondary,Absolute Change in Non-inflammatory Lesion Counts
NCT02242760,measures_secondary,Percent Change in Inflammatory Lesion Count From Baseline to Week 12
NCT02242760,measures_secondary,Percent Change in Non-inflammatory Lesion Count From Baseline to Week 12
NCT02242760,measures_secondary,Median Time to Improvement
NCT02242760,has_criteria,Modera...
NCT05469360,involves,Early Alzheimer's Disease
NCT05469360,evaluates,NIO752
NCT05469360,measures_primary,Change in cerebrospinal total tau
NCT05469360,measures_secondary,Total tau protein levels
NCT05469360,has_criteria,30 to 74 years old
NCT05737160,involves,Generalized Myasthenia Gravis
NCT05737160,evaluates,Telitacicept
NCT05737160,measures_primary,Change from baseline in MG-ADL
NCT05737160,measures_secondary,Change from baseline in QMG
NCT05737160,has_criteria,Stable MG SoC regimen
NCT05737160,has_criteria,MGFA Class II
NCT05737160,has_criteria,AChR-Ab or MuSK-Ab positive
NCT05737160,has_criteria,QMG ≥ 8
NCT05737160,has_criteria,A total MG-ADL score of ≥ 6
NCT02895360,involves,Advanced Solid Tumors
NCT02895360,involves,Recurrent Glioblastoma
NCT02895360,evaluates,BAL101553
NCT02895360,measures_primary,Safety and Tolerability
NCT02895360,measures_secondary,Pharmacokinetics
NCT02895360,has_criteria,Dose limiting toxicities
NCT06550076,involves,Plaque Psoriasis
NCT06550076,evaluates,TAK-279
NCT06550076,measures_primary,PASI-75 Score
NCT06550076,measures_secondary,sPGA
NCT06550076,has_criteria,Baseline up to Week 52
NCT05602727,involves,Alzheimer's Disease
NCT05602727,evaluates,MK-1942
NCT05602727,measures_primary,ADAS-Cog11 score
NCT05602727,measures_secondary,Adverse Event
NCT05602727,has_criteria,Up to ~ 14 Weeks
NCT01850160,involves,arterial hypertension
NCT01850160,evaluates,Valsartan plus Chlorthalidone
NCT01850160,measures_primary,Systolic Blood Pressure
NCT01850160,measures_primary,Diastolic Blood Pressure
NCT01850160,measures_secondary,blood pressure values
NCT01850160,has_criteria,Systolic blood pressure greater or equal
NCT01903460,involves,Alagille Syndrome
NCT01903460,involves,cholestasis
NCT01903460,involves,pruritus
NCT01903460,evaluates,LUM001
NCT01903460,measures_primary,Fasting Serum Bile Acid Level
NCT01903460,measures_primary,Liver Enzymes
NCT01903460,measures_primary,Pruritus
NCT01903460,measures_secondary,alanine aminotransferase
NCT01903460,measures_secondary,aspartate aminotransferase
NCT01903460,measures_secondary,alkaline phosphatase
NCT01903460,has_criteria,Diagnosis of Alagille Syndrome
NCT01903460,has_criteria,Evidence of cholestasis
NCT01903460,has_criteria,Moderate to severe pruritus
NCT01903460,has_criteria,Ability to understand and willingness to sign informed consent/assent
NCT01903460,has_criteria,prior to initiation of any study procedures
NCT00510276,involves,Attention-Deficit/Hyperactivity Disorder
NCT00510276,evaluates,Atomoxetine
NCT00510276,measures_primary,CAARS-Inv:SV Total Score
NCT00510276,measures_secondary,AAQOL-29 Total Score
NCT00510276,measures_secondary,AAQOL-29 Relationship Subscale
NCT00510276,has_criteria,Young Adults
NCT00642460,involves,Systemic Juvenile Idiopathic Arthritis
NCT00642460,evaluates,RoActemra/Actemra
NCT00642460,measures_primary,ACR core set
NCT00642460,measures_secondary,Oral Corticosteroid Dose
NCT00642460,has_criteria,≥30% improvement
NCT05422976,involves,Osteoarthritis
NCT05422976,evaluates,EVI-01
NCT05422976,measures_primary,Change in pain intensity
NCT05422976,measures_secondary,Change in WOMAC index
NCT05422976,measures_secondary,Patient satisfaction
NCT05422976,measures_secondary,Physician satisfaction
NCT05422976,has_criteria,Eighteen (18) years old
NCT02205476,involves,scar revision surgery
NCT02205476,evaluates,study drug
NCT02205476,measures_primary,clinically significant vital sign abnormalities
NCT02205476,measures_secondary,clinical laboratory abnormalities
NCT02205476,measures_secondary,treatment-emergent adverse events
NCT02205476,has_criteria,initial scar revision surgery
NCT04680676,involves,Psoriatic Arthritis
NCT04680676,evaluates,BI 730357
NCT04680676,measures_primary,ACR 20 response
NCT04680676,measures_secondary,ACR 50 response
NCT04680676,measures_secondary,ACR 70 response
NCT04680676,measures_secondary,Tender Joint Count
NCT04680676,measures_secondary,Swollen Joint Count
NCT04680676,measures_secondary,HAQ-DI
NCT04680676,measures_secondary,PASI75 response
NCT04680676,has_criteria,Age ≥ 18
NCT00251927,involves,Gastroesophageal reflux disease
NCT00251927,evaluates,Esomeprazole
NCT00251927,evaluates,Surgery
NCT00251927,measures_primary,Los Angeles Grade
NCT00251927,measures_secondary,Heartburn Severity
NCT00251927,measures_secondary,Microscopic Reflux-related Changes
NCT00251927,measures_secondary,Percentage Time With pH<4
NCT00251927,has_criteria,biopsy at 5 years visit
NCT03181594,involves,Chronic Rhinitis
NCT03181594,evaluates,ClariFix™ Cryotherapy Device
NCT03181594,measures_primary,Change From Baseline
NCT03181594,measures_secondary,Rhinoconjunctivitis Quality of Life Questionnaire
NCT03181594,has_criteria,>21 years of age
NCT03181594,has_criteria,moderate to severe rhinorrhea
NCT03181594,has_criteria,mild to severe congestion
NCT03181594,has_criteria,minimum TNSS score of 4
NCT03181594,has_criteria,symptoms present for >6 months
NCT01068860,involves,Impaired Glucose Tolerance
NCT01068860,involves,Type 2 Diabetes
NCT01068860,evaluates,Canakinumab
NCT01068860,measures_primary,Meal Stimulated Insulin Secretion Rate
NCT01068860,measures_primary,Insulin Secretion Rate
NCT01068860,measures_secondary,Glucose
NCT01068860,has_criteria,Baseline Diabetes Therapies
NCT01658176,involves,advanced breast cancer
NCT01658176,evaluates,PF-04691502
NCT01658176,evaluates,Exemestane
NCT01658176,measures_primary,Progression-Free Survival
NCT01658176,measures_secondary,Objective tumor response
NCT01658176,measures_secondary,Clinical benefit response
NCT01658176,measures_secondary,Overall Survival
NCT01658176,has_criteria,estrogen receptor positive
NCT01658176,has_criteria,Her-2 negative
NCT01658176,has_criteria,previously treated
NCT01658176,has_criteria,aromatase inhibitor
NCT01658176,has_criteria,hormone resistance
NCT01658176,has_criteria,acceptable glucose control
NCT01658176,has_criteria,acceptable bone marrow
NCT01658176,has_criteria,acceptable liver function
NCT01658176,has_criteria,acceptable kidney function
NCT06030076,involves,Plaque Psoriasis
NCT06030076,evaluates,Tildrakizumab
NCT06030076,measures_primary,PASI Score
NCT06030076,measures_secondary,PGA Score
NCT06030076,measures_secondary,WHO-5 Score
NCT06030076,measures_secondary,TSQM-11 Score
NCT06030076,has_criteria,Adult Participants
NCT02795676,involves,Fabry disease
NCT02795676,evaluates,PRX-102
NCT02795676,evaluates,Agalsidase Beta
NCT02795676,measures_primary,annualized change eGFR
NCT02795676,measures_secondary,Lyso-Gb3
NCT02795676,measures_secondary,Pain at Its Worst
NCT02795676,has_criteria,at least 4 eGFR observations
NCT05318976,involves,Early Alzheimer's Disease
NCT05318976,evaluates,XPro1595
NCT05318976,measures_primary,Change in EMACC
NCT05318976,measures_secondary,Change in CDR
NCT05318976,measures_secondary,Change in CDR-SB
NCT05318976,measures_secondary,Change in AFD
NCT05318976,measures_secondary,Change in E-Cog
NCT05318976,has_criteria,early ADi
NCT00825227,involves,Fatigue
NCT00825227,evaluates,Armodafinil
NCT00825227,measures_primary,Worst fatigue severity
NCT00825227,measures_secondary,Percentage of days with severe fatigue
NCT00825227,has_criteria,Business decision
NCT02243176,involves,T2D
NCT02243176,evaluates,Saxagliptin
NCT02243176,evaluates,Acarbose
NCT02243176,measures_primary,Absolute Change HbA1c
NCT02243176,measures_secondary,GI Adverse Events
NCT02243176,measures_secondary,Therapeutic Glycemic Response
NCT02243176,measures_secondary,HbA1c<7.0% without GI Adverse Events
NCT02243176,measures_secondary,Change From Baseline FPG
NCT02243176,measures_secondary,2H Postprandial Glucose
NCT02243176,has_criteria,Inadequately controlled with metformin
NCT05156827,involves,Acute Ischemic Stroke
NCT05156827,evaluates,TB006
NCT05156827,measures_primary,Recovery Success
NCT05156827,measures_primary,NIHSS
NCT05156827,measures_secondary,mRS
NCT05156827,measures_secondary,MoCA Total Score
NCT05156827,has_criteria,Day 90
NCT05156827,has_criteria,Baseline
NCT05156827,has_criteria,Day 85
NCT00573443,involves,PBA
NCT00573443,evaluates,AVP-923
NCT00573443,measures_primary,PBA Episode Rate Ratio
NCT00573443,measures_secondary,CNS-LS Total Score
NCT00573443,measures_secondary,NPI-Q Frequency and Severity Score
NCT00573443,has_criteria,ALS or MS
NCT03837743,involves,plaque psoriasis
NCT03837743,evaluates,DUR-928 Topical Solution
NCT03837743,measures_primary,Change From Baseline
NCT03837743,measures_secondary,Local Psoriasis Severity Index
NCT03837743,has_criteria,stable mild to moderate
NCT06127043,involves,Ulcerative Colitis
NCT06127043,evaluates,Rosnilimab
NCT06127043,measures_primary,modified Mayo Score
NCT06127043,measures_secondary,clinical remission
NCT06127043,measures_secondary,endoscopic treatment improvement
NCT06127043,measures_secondary,clinical response
NCT06127043,has_criteria,moderate to severe
NCT06127043,has_criteria,clinical diagnosis of UC
NCT06127043,has_criteria,surveillance colonoscopy
NCT06127043,has_criteria,no dysplasia or colon cancer
NCT06127043,has_criteria,inadequate response to 3 or more UC therapies
NCT03745638,involves,Atopic Dermatitis
NCT03745638,evaluates,Ruxolitinib Cream
NCT03745638,measures_primary,IGA-TS at Week 8
NCT03745638,measures_secondary,EASI75
NCT03745638,measures_secondary,Itch NRS Score
NCT03745638,has_criteria,≥ 8 years of age
NCT05635838,involves,Hidradenitis Suppurativa
NCT05635838,evaluates,Ruxolitinib Cream
NCT05635838,measures_primary,Change from baseline in AN count
NCT05635838,measures_secondary,Proportion of participants achieving AN50
NCT05635838,measures_secondary,Proportion of participants achieving AN75
NCT05635838,measures_secondary,Proportion of participants achieving AN90
NCT05635838,measures_secondary,Proportion of participants achieving AN100
NCT05635838,measures_secondary,Change from baseline in Skin Pain NRS
NCT05635838,measures_secondary,Change from baseline in Itch NRS
NCT05635838,measures_secondary,Proportion of participants who achieve HiSCR
NCT05635838,measures_secondary,Change from baseline in IHS4 score
NCT05635838,measures_secondary,Number of Treatment Emergent Adverse Events
NCT05635838,has_criteria,Diagnosis of HS
NCT06328608,involves,Fabry Disease
NCT06328608,evaluates,PRX-102
NCT06328608,measures_primary,Incidence TEAEs
NCT06328608,measures_primary,Incidence IRRs
NCT06328608,measures_primary,Incidence ISRs
NCT06328608,measures_secondary,Change in Tanner stage
NCT06328608,measures_secondary,Change from baseline ECG
NCT06328608,measures_secondary,Incidence ADAs
NCT06328608,measures_secondary,Incidence premedication use
NCT06328608,measures_secondary,Pharmacokinetics tmax
NCT06328608,measures_secondary,Pharmacokinetics AUC0 t
NCT06328608,measures_secondary,Pharmacokinetics AUC0-2wk
NCT06328608,has_criteria,Children and Adolescents
NCT01895543,involves,Chronic Idiopathic Constipation
NCT01895543,evaluates,Treatment Period
NCT01895543,measures_primary,Global Evaluation of Constipation Severity
NCT01895543,measures_secondary,Laboratory parameters
NCT01895543,measures_secondary,Electrocardiograms
NCT01895543,measures_secondary,Body Weight
NCT01895543,measures_secondary,Vital Signs
NCT01895543,measures_secondary,Concomitant Medications
NCT01895543,has_criteria,Informed Consent
NCT05226143,involves,Atopic Dermatitis
NCT05226143,evaluates,Eczema Spot Treatment
NCT05226143,measures_primary,Rajka and Langeland Severity Index Score
NCT05226143,measures_secondary,Dryness of Target Lesion
NCT05226143,measures_secondary,Tactile Roughness of Target Lesion
NCT05226143,measures_secondary,Erythema of Target Lesion
NCT05226143,has_criteria,Up to 14 days
NCT06088043,involves,Plaque Psoriasis
NCT06088043,evaluates,TAK-279
NCT06088043,measures_primary,sPGA of Clear or Almost Clear
NCT06088043,measures_secondary,PASI-75 Response
NCT06088043,measures_secondary,PASI-90 Response
NCT06088043,has_criteria,52 Weeks of Treatment
NCT06034743,involves,Hypertension
NCT06034743,evaluates,Baxdrostat
NCT06034743,measures_primary,seated systolic blood pressure
NCT06034743,measures_secondary,seated diastolic blood pressure
NCT06034743,has_criteria,≥ 18 years old
NCT06428838,involves,Migraine
NCT06428838,evaluates,Eptinezumab
NCT06428838,measures_primary,Number of migraine days
NCT06428838,measures_secondary,Readmission to ED
NCT06428838,has_criteria,Baseline to Month 3
NCT06428838,measures_secondary,Generalized Anxiety Disorder 7-item
NCT06428838,measures_secondary,Headache Impact Test 6
NCT06428838,measures_secondary,Patient Health Questionnaire 9
NCT00784238,involves,Schizophrenia
NCT00784238,evaluates,Paliperidone ER
NCT00784238,measures_primary,Change From Baseline
NCT00784238,measures_secondary,Mental Functioning
NCT00784238,has_criteria,transition to Paliperidone ER
NCT01969838,involves,Myelofibrosis
NCT01969838,evaluates,Momelotinib
NCT01969838,evaluates,Ruxolitinib
NCT01969838,measures_primary,Splenic response rate
NCT01969838,measures_primary,Total Symptom Score Response Rate
NCT01969838,measures_secondary,Rate of Red Blood Cell Transfusions
NCT01969838,measures_secondary,RBC Transfusion Independence Rate
NCT01969838,has_criteria,≥35% spleen volume reduction
NCT01969838,has_criteria,≥50% TSS reduction
NCT01969838,has_criteria,≥20 daily TSS available
NCT01969838,has_criteria,Hemoglobin Level Below 8 g/dL
NCT02682238,involves,Palmar Hyperhidrosis
NCT02682238,evaluates,BBI-4000 Gel
NCT02682238,measures_primary,HDSS decrease
NCT02682238,measures_secondary,Gravimetrically Measured Sweat Production
NCT02682238,has_criteria,Baseline to Day 29
NCT00381238,involves,Alzheimer's Disease
NCT00381238,evaluates,Rosiglitazone
NCT00381238,measures_primary,MMSE Total Score
NCT00381238,measures_secondary,Number of SAEs
NCT00381238,has_criteria,Mild To Moderate
NCT00599638,involves,Post-Herpetic Neuralgia
NCT00599638,evaluates,Pregabalin/PF-00489791 Combination
NCT00599638,evaluates,Pregabalin
NCT00599638,measures_primary,Mean Pain Score
NCT00599638,measures_secondary,Patient Global Impression of Change
NCT00599638,measures_secondary,Pain Visual Analogue Scale
NCT00599638,has_criteria,End of treatment period
NCT00777608,involves,Alzheimer's Disease
NCT00777608,evaluates,Donepezil
NCT00777608,measures_primary,CogState Composite Score
NCT00777608,measures_secondary,ADAS-Cog Score
NCT00777608,has_criteria,mild-to-moderate
NCT04204603,involves,Rheumatoid Arthritis
NCT04204603,evaluates,CKD-506
NCT04204603,measures_primary,Change from baseline
NCT04204603,measures_secondary,ACR20
NCT04204603,has_criteria,Methotrexate response
NCT01964443,involves,Psoriasis
NCT01964443,evaluates,Hospital Anxiety and Depression Scale
NCT01964443,measures_primary,psoriasis disease severity
NCT01964443,measures_secondary,anxiety and depression
NCT01964443,has_criteria,psoriasis disease duration
NCT00261443,involves,Bipolar Mania
NCT00261443,evaluates,Aripiprazole
NCT00261443,measures_primary,Relapse to Any Mood Episode
NCT00261443,measures_secondary,Clinical Global Impression Scale
NCT00261443,has_criteria,worsening disease
NCT01354938,involves,Acute Exacerbation of Chronic Bronchitis
NCT01354938,evaluates,Klaricid XL
NCT01354938,measures_primary,SGRQ Total Score
NCT01354938,measures_secondary,Adverse Event
NCT01354938,has_criteria,treatment duration of 10 days
NCT01258738,involves,Early Spondyloarthritis
NCT01258738,evaluates,Etanercept
NCT01258738,measures_primary,ASAS 40 Response
NCT01258738,measures_secondary,ASAS 20 Response
NCT01258738,measures_secondary,ASAS 5/6 Response
NCT01258738,has_criteria,X-ray Structural Changes
NCT03743038,involves,acne vulgaris
NCT03743038,evaluates,Topicals
NCT03743038,measures_primary,IGA score improvement
NCT03743038,measures_secondary,Inflammatory Lesion Count
NCT03743038,measures_secondary,Non-Inflammatory Lesion Count
NCT03743038,has_criteria,IGA score
NCT06192108,involves,Type 2 Diabetes
NCT06192108,evaluates,Orforglipron
NCT06192108,evaluates,Dapagliflozin
NCT06192108,measures_primary,Change from Baseline in HbA1c
NCT06192108,measures_secondary,Percentage of Participants Who Achieved HbA1c <7.0%
NCT06192108,measures_secondary,Percentage of Participants Who Achieved HbA1c ≤6.5%
NCT06192108,measures_secondary,Percentage Change from Baseline in Body Weight
NCT06192108,measures_secondary,Percentage Change from Baseline in non-HDL-Cholesterol
NCT06192108,measures_secondary,Percentage Change from Baseline in Triglycerides
NCT06192108,measures_secondary,Change from Baseline in Systolic Blood Pressure
NCT06192108,measures_secondary,Change from Baseline in Fasting Serum Glucose
NCT06192108,measures_secondary,Percentage of Participants Who Achieved Weight Loss of ≥5% from Baseline
NCT06192108,measures_secondary,Percentage of Participants Who Achieved Weight Loss of ≥10% from baseline
NCT06192108,measures_secondary,Percentage of Participants Who Achieved Weight Loss of ≥15% from baseline
NCT06192108,measures_secondary,Change from Baseline in Diastolic Blood Pressure
NCT06192108,measures_secondary,Percentage Change from Baseline in Total Cholesterol
NCT06192108,measures_secondary,Change from Baseline in Short Form 36 Version 2 (SF-36-v2) Acute Form Domain Summary Scores
NCT06192108,measures_secondary,Change from Baseline in Diabetes Treatment Satisfaction Questionnaire-Change (DTSQc) Scores
NCT06192108,has_criteria,Inadequate Glycemic Control With Metformin
NCT04815603,involves,Anemia of Aging
NCT04815603,evaluates,BGE-117
NCT04815603,measures_primary,Hemoglobin Change
NCT04815603,measures_secondary,FACIT-Fatigue Score
NCT04815603,measures_secondary,SPPB Score
NCT04815603,measures_secondary,6-minute Walk Test
NCT04815603,measures_secondary,SF-36
NCT04815603,has_criteria,eGFR ≥ 60 mL/min/1.73 m2
NCT04815603,has_criteria,eGFR ≥ 30 and < 60 mL/min/ 1.73 m2
NCT00851903,involves,Type 2 Diabetes
NCT00851903,evaluates,Insulin Glargine
NCT00851903,evaluates,Sitagliptin
NCT00851903,measures_primary,HbA1c Response Rate
NCT00851903,measures_secondary,Self-Monitored Fasting Plasma Glucose Mean
NCT00851903,measures_secondary,7-point Plasma Glucose Profile
NCT00851903,measures_secondary,Insulin Dose
NCT00851903,measures_secondary,Number of Patients With at Least One Episode of Symptomatic Hypoglycemia
NCT00851903,measures_secondary,Change in Body Weight From Baseline to Study Endpoint
NCT00851903,has_criteria,premature discontinuation
NCT04442503,involves,Postpartum Depression
NCT04442503,evaluates,SAGE-217
NCT04442503,measures_primary,Change From Baseline
NCT04442503,measures_secondary,Change From Baseline
NCT04442503,has_criteria,Severe Postpartum Depression
NCT00117143,evaluates,Amgen Megakaryopoiesis Protein 2 (AMG 531)
NCT00117143,involves,Immune Thrombocytopenic Purpura
NCT00117143,measures_primary,Targeted therapeutic platelet response
NCT00117143,measures_secondary,Increase in platelet count
NCT00117143,measures_secondary,Peak platelet counts
NCT04704843,involves,Celiac Disease
NCT04704843,evaluates,Guselkumab
NCT04704843,measures_primary,Vh:Cd ratio
NCT04704843,measures_secondary,IELs
NCT04704843,measures_secondary,Marsh-Oberhuber Scores
NCT04704843,has_criteria,Clinically significant
NCT01887938,involves,Metachromatic Leukodystrophy
NCT01887938,evaluates,HGT-1110
NCT01887938,measures_primary,Change From Baseline in Motor Function
NCT01887938,measures_secondary,Adaptive Behavior Composite Standard Score
NCT01887938,has_criteria,Baseline to Week 628
NCT02046603,involves,Rheumatoid Arthritis
NCT02046603,evaluates,Tocilizumab
NCT02046603,evaluates,Methotrexate
NCT02046603,measures_primary,DAS28-ESR at Week 2
NCT02046603,measures_primary,DAS28-ESR at Week 4
NCT02046603,measures_primary,DAS28-ESR at Week 8
NCT02046603,has_criteria,Inadequate Response to DMARDs
NCT02046603,has_criteria,Anti-TNF Biologic Agent
NCT06194838,involves,K2-level Amputees
NCT06194838,evaluates,Non-Powered Prosthetic Knees
NCT06194838,measures_primary,step count
NCT06194838,measures_secondary,Activities-Specific Balance Confidence scale
NCT06194838,measures_secondary,Prosthesis Evaluation Questionnaire - Well Being
NCT06194838,has_criteria,trained certified prosthetist
NCT05521438,involves,Netherton Syndrome
NCT05521438,evaluates,QRX003 Lotion
NCT05521438,measures_primary,1-point IGA
NCT05521438,measures_secondary,2-point IGA
NCT05521438,measures_secondary,NS Sign
NCT05521438,measures_secondary,BSA
NCT05521438,measures_secondary,WI-NRS score
NCT05521438,measures_secondary,TSQM
NCT05521438,measures_secondary,Rescue Therapy
NCT05521438,has_criteria,at least 14 years old
NCT05521438,has_criteria,post-menopausal
NCT05521438,has_criteria,surgically sterile
NCT05521438,has_criteria,effective birth control
NCT00123903,involves,Hypertension
NCT00123903,involves,Microalbuminuria
NCT00123903,evaluates,COREG MR
NCT00123903,evaluates,TOPROL-XL
NCT00123903,measures_primary,urine albumin: creatinine ratio
NCT00123903,measures_secondary,normoalbuminuria
NCT00123903,measures_secondary,macroalbuminuria
NCT00123903,measures_secondary,hs-CRP
NCT00123903,measures_secondary,lipids
NCT00123903,measures_secondary,blood pressure
NCT00123903,measures_secondary,heart rate
NCT00123903,measures_secondary,add-on therapy
NCT00123903,measures_secondary,clinical chemistry parameters
NCT00123903,measures_secondary,hematology parameters
NCT00123903,measures_secondary,vital signs
NCT00123903,has_criteria,Documented history of hypertension
NCT00123903,has_criteria,ACE inhibitor
NCT00123903,has_criteria,Persistent microalbuminuria
NCT00123903,has_criteria,History of heart attack
NCT00123903,has_criteria,History of stroke
NCT00123903,has_criteria,History of congestive heart failure
NCT00123903,has_criteria,History of arrhythmia
NCT00123903,has_criteria,History of type 1 diabetes mellitus
NCT00123903,has_criteria,History of type 2 diabetes mellitus
NCT00123903,has_criteria,History of liver disease
NCT00123903,has_criteria,History of renal disease
NCT03950843,involves,Atrial Fibrillation
NCT03950843,evaluates,CKD-825
NCT03950843,measures_primary,24-h mHR
NCT03950843,measures_secondary,resting HR
NCT03950843,measures_secondary,modified EHRA score
NCT03950843,has_criteria,≥ 19 years
NCT03950843,has_criteria,persistent or permanent Atrial Fibrillation
NCT03950843,has_criteria,modified EHRA score ≥ 2a
NCT03950843,has_criteria,resting HR ≥ 80 bpm
NCT03950843,has_criteria,24-h mHR ≥ 80 bpm
NCT03950843,has_criteria,no antiarrhythmics within 2 weeks
NCT03950843,has_criteria,no pacemaker or ICD
NCT03950843,has_criteria,no catheter ablation within 12 weeks
NCT03950843,has_criteria,no heart failure NYHA class 4
NCT03950843,has_criteria,no myocardial infarction within 12 weeks
NCT03950843,has_criteria,no unstable angina pectoris within 12 weeks
NCT03519243,involves,Chronic Kidney Disease
NCT03519243,evaluates,BCD-131
NCT03519243,evaluates,Mircera
NCT03519243,measures_primary,Change in Hemoglobin
NCT03519243,measures_secondary,Proportion of Patients
NCT03519243,has_criteria,Anemia on Dialysis
NCT03660943,involves,Osteoarthritis Knee Pain
NCT03660943,evaluates,CNTX-4975-05
NCT03660943,measures_primary,Change From Baseline
NCT03660943,measures_secondary,WOMAC B Stiffness
NCT03660943,has_criteria,Baseline
NCT02337738,involves,Parkinson's Disease
NCT02337738,evaluates,TVP-1012
NCT02337738,measures_primary,Change From Baseline in Mean Daily OFF-time
NCT02337738,measures_secondary,Change From Baseline to Week 26 in Mean Daily OFF-time
NCT02337738,measures_secondary,Change From Baseline in MDS-UPDRS Part II Total Score
NCT02337738,measures_secondary,Change From Baseline in MDS-UPDRS Part III Total Score
NCT02337738,measures_secondary,Change From Baseline in Parkinson's Disease Questionnaire-39 Summary Index Score
NCT02337738,has_criteria,Levodopa Treated
NCT04627038,involves,Osteoarthritis
NCT04627038,evaluates,LY3556050
NCT04627038,measures_primary,Pain Intensity
NCT04627038,measures_secondary,WOMAC Pain Subscale
NCT04627038,measures_secondary,WOMAC Stiffness Subscale
NCT04627038,has_criteria,Baseline
NCT02077803,evaluates,Canagliflozin and Metformin Extended Release
NCT02077803,measures_primary,Plasma concentration
NCT02077803,measures_secondary,Adverse events
NCT02077803,has_criteria,Healthy Fed Participants
NCT02566603,involves,ITP
NCT02566603,evaluates,PRTX-100
NCT02566603,measures_primary,Overall platelet response
NCT02566603,measures_secondary,Complete platelet response
NCT02566603,measures_secondary,Time to platelet response
NCT02566603,measures_secondary,Durability of platelet response
NCT02566603,measures_secondary,Concomitant ITP medication use
NCT02566603,has_criteria,Toxicity Grading Criteria
NCT01552343,involves,Nocturia
NCT01552343,evaluates,Nocturia Impact Diary
NCT01552343,measures_primary,Nocturia Impact
NCT01552343,measures_secondary,Overall Impact Question
NCT01552343,has_criteria,Baseline voids
NCT03758443,involves,Ulcerative Colitis
NCT03758443,evaluates,TD-1473
NCT03758443,measures_primary,Change From Baseline
NCT03758443,measures_secondary,Clinical Remission
NCT03758443,measures_secondary,Clinical Response
NCT03758443,has_criteria,Adapted Mayo score
NCT03029143,involves,Ulcerative Colitis
NCT03029143,evaluates,Vedolizumab
NCT03029143,measures_primary,Mucosal Healing
NCT03029143,measures_primary,Clinical Remission
NCT03029143,measures_primary,Clinical Response
NCT03029143,measures_secondary,Clinical Response
NCT03029143,has_criteria,Mayo score ≤2 points
NCT06402838,involves,Alzheimer's Disease
NCT06402838,evaluates,RO7269162
NCT06402838,measures_primary,amyloid load
NCT06402838,measures_secondary,Aβ37 in CSF
NCT06402838,measures_secondary,Aβ38 in CSF
NCT06402838,measures_secondary,Aβ40 in CSF
NCT06402838,measures_secondary,Aβ42 in CSF
NCT06402838,measures_secondary,Aβ40 in plasma
NCT06402838,measures_secondary,Aβ42 in plasma
NCT06402838,measures_secondary,RO7269162 plasma
NCT06402838,measures_secondary,RO7269162 CSF
NCT06402838,has_criteria,Body Mass Index
NCT06402838,has_criteria,MCI due to AD
NCT06402838,has_criteria,CDR-GS score
NCT06402838,has_criteria,amyloid PET scan
NCT06402838,has_criteria,study partner
NCT00676143,involves,Alzheimer Disease
NCT00676143,evaluates,Bapineuzumab
NCT00676143,measures_primary,Change From Baseline
NCT00676143,measures_secondary,Disability Assessment for Dementia
NCT00676143,has_criteria,trained and certified psychometric rater
NCT05889143,evaluates,CREZET Tablet
NCT05889143,measures_primary,Rate of change in LDL-C
NCT05889143,measures_secondary,Change in HbA1c
NCT05889143,measures_secondary,Change in FPG
NCT05889143,measures_secondary,Change in lipid variable
NCT05889143,measures_secondary,Change in AST
NCT05889143,measures_secondary,Change in ALT
NCT05889143,measures_secondary,Percentage of subjects who reached LDL-C target
NCT05889143,has_criteria,dyslipidemia
NCT05889143,has_criteria,over 19 years of age
NCT03861143,involves,Ulcerative Colitis
NCT03861143,evaluates,BT-11
NCT03861143,measures_primary,Clinical Remission
NCT03861143,measures_secondary,Clinical remission rate
NCT03861143,has_criteria,UC for at least 3 months
NCT03861143,has_criteria,total Mayo Score 4 to 10
NCT03861143,has_criteria,MES 2
NCT03861143,has_criteria,aged 18 to 75 years
NCT03861143,has_criteria,able to participate fully
NCT03861143,has_criteria,written informed consent
NCT03861143,has_criteria,no CD or indeterminate colitis
NCT03861143,has_criteria,no fistula with CD
NCT03861143,has_criteria,no Modified Truelove and Witts criteria
NCT03861143,has_criteria,no disease activity limited to distal 15 cm
NCT03861143,has_criteria,no immunosuppressant treatment within 25 days
NCT03861143,has_criteria,able to attend study visits
NCT03861143,has_criteria,not concurrently participating in other studies
NCT03861143,has_criteria,not previously enrolled in current study
NCT02670538,involves,Bipolar I Disorder
NCT02670538,evaluates,Cariprazine
NCT02670538,evaluates,Placebo
NCT02670538,measures_primary,Change From Baseline in MADRS
NCT02670538,measures_secondary,Change From Baseline in CGI-S Score
NCT02670538,has_criteria,DSM-5 criteria
NCT01406938,involves,Psoriasis
NCT01406938,evaluates,Secukinumab
NCT01406938,measures_primary,PASI 75 response
NCT01406938,measures_secondary,PASI 50/75/90/100
NCT01406938,measures_secondary,IGA 2011 Score
NCT01406938,has_criteria,Moderate to Severe Chronic Plaque-type Psoriasis
NCT03484143,involves,Alzheimer's Disease
NCT03484143,evaluates,Neuro RX Gamma
NCT03484143,measures_primary,Change in SIB score
NCT03484143,measures_secondary,ADCS-ADL-Sev
NCT03484143,measures_secondary,EQ-5D
NCT02068443,involves,Type 2 Diabetes
NCT02068443,evaluates,Metformin Hydrochloride
NCT02068443,measures_primary,Change From Baseline HbA1c
NCT02068443,measures_secondary,Percentage of Participants Achieving Target HbA1c
NCT02068443,has_criteria,Inadequate Glycemic Control
NCT01213043,involves,Alpha1-Antitrypsin Deficiency
NCT01213043,evaluates,Prolastin-C
NCT01213043,measures_primary,AUC0-7days
NCT01213043,measures_secondary,Mean Trough
NCT01213043,has_criteria,Treatment-Emergent Adverse Events
NCT03064438,involves,Acne Rosacea
NCT03064438,evaluates,ACU-D1
NCT03064438,measures_primary,Total Lesion Count
NCT03064438,measures_secondary,Investigator's Global Assessment
NCT03064438,has_criteria,Treatment responders
NCT06645938,involves,Healthy Adults
NCT06645938,evaluates,Vepdegestrant
NCT06645938,measures_primary,Maximum Observed Plasma Concentration
NCT06645938,measures_primary,Area Under the Curve
NCT06645938,measures_secondary,Number of Participants With Treatment-Emergent Adverse Events
NCT06645938,measures_secondary,Number of Participants With Clinical Laboratory Abnormalities
NCT06645938,measures_secondary,Number of Participants With Clinically Significant Change From Baseline in Vital Signs
NCT06645938,measures_secondary,Number of Participants With Electrocardiogram Abnormalities
NCT06645938,has_criteria,informed consent
NCT01683838,involves,Spasticity
NCT01683838,involves,Spinal Cord Injury
NCT01683838,evaluates,Fampridine-Sustained Release
NCT01683838,measures_primary,Ashworth Score
NCT01683838,measures_secondary,Mean Subject's Global Impression
NCT01683838,measures_secondary,Spasm Frequency/Severity
NCT01683838,has_criteria,Baseline average score
NCT04567303,involves,Neovascular Age-Related Macular Degeneration
NCT04567303,evaluates,Zifibancimig
NCT04567303,measures_primary,ETDRS-BCVA Score
NCT04567303,measures_secondary,Adverse Events
NCT04567303,has_criteria,Baseline up to Week 24
NCT04920903,evaluates,COR588
NCT04920903,measures_primary,AUC
NCT04920903,measures_primary,Cmax
NCT04920903,measures_primary,Tmax
NCT04920903,has_criteria,Healthy male and female subjects
NCT04920903,has_criteria,Body mass index
NCT04920903,has_criteria,clinically significant abnormal screening results
NCT04920903,has_criteria,normal limits
NCT04076943,involves,Chemotherapy Induced Anemia
NCT04076943,evaluates,Roxadustat
NCT04076943,measures_primary,Maximum Change in Hb
NCT04076943,measures_secondary,Mean Change in Hb Level
NCT04076943,measures_secondary,Change in Hb From Baseline
NCT04076943,measures_secondary,Percentage of Participants Who Achieved a ≥1 g/dL Increase in Hb
NCT04076943,measures_secondary,Time to Achieve a ≥1 g/dL Increase in Hb
NCT04076943,has_criteria,Baseline Hb
NCT02094443,involves,Chronic Hepatitis C
NCT02094443,evaluates,Alisporivir
NCT02094443,measures_primary,HCV RNA viral load
NCT02094443,measures_secondary,Alanine Aminotransferase
NCT02094443,has_criteria,Written informed consent
NCT01696643,involves,Opioid-Induced Constipation
NCT01696643,evaluates,CB-5945
NCT01696643,measures_primary,Change From Baseline
NCT01696643,measures_secondary,Patient Assessment of Constipation-Quality of Life
NCT01696643,has_criteria,Baseline through Week 56
NCT01117480,involves,Rheumatoid Arthritis
NCT01117480,evaluates,HUMIRA
NCT01117480,measures_primary,DAS28 < 2.6
NCT01117480,measures_secondary,HAQ-DI
NCT01117480,measures_secondary,RADAI
NCT01117480,has_criteria,Disease Activity Score
NCT02711462,evaluates,PF-06687234
NCT02711462,measures_primary,Maximum Observed Plasma Concentration
NCT02711462,measures_secondary,Time to Reach Maximum Observed Plasma Concentration
NCT02711462,measures_secondary,Area Under the Curve From Time Zero to Extrapolated Infinite Time
NCT02653391,involves,Fuchs' Corneal Endothelial Dystrophy
NCT02653391,evaluates,Elamipretide Topical Ophthalmic Solution
NCT02653391,measures_primary,Incidence of ocular TEAEs
NCT02653391,measures_secondary,Severity of ocular TEAEs
NCT02653391,measures_secondary,Change From Baseline in SLE
NCT02653391,measures_secondary,Change From Baseline in IOP
NCT02653391,measures_secondary,Change From Baseline in Central Corneal Thickness
NCT02653391,has_criteria,Screening Visit
NCT05190991,involves,Familial Mediterranean Fever
NCT05190991,evaluates,RPH-104
NCT05190991,measures_primary,PGA of disease activity
NCT05190991,measures_secondary,Serological remission
NCT05190991,measures_secondary,SAA levels
NCT05190991,has_criteria,PGA score ≥ 2
NCT04134091,involves,Nonalcoholic Steatohepatitis
NCT04134091,evaluates,LPCN 1144
NCT04134091,measures_primary,Hepatic Fat Fraction
NCT04134091,measures_secondary,Resolution of NASH
NCT04134091,has_criteria,hepatic fat fraction ≥ 5%
NCT02725580,involves,Variant Late Infantile Neuronal Ceroid Lipofuscinosis 6
NCT02725580,evaluates,AT-GTX-501
NCT02725580,measures_primary,Hamburg Motor + Language aggregate score
NCT02725580,measures_secondary,Unified Batten Disease Rating Scale
NCT02725580,has_criteria,Screening Day -30 up to -2
NCT01031680,involves,Type 2 Diabetes Mellitus
NCT01031680,involves,Cardiovascular Disease
NCT01031680,involves,Hypertension
NCT01031680,evaluates,dapagliflozin
NCT01031680,measures_primary,Adjusted Mean Change in HbA1c
NCT01031680,measures_secondary,Proportion of Responders
NCT01031680,measures_secondary,Adjusted Mean Change in Seated Systolic Blood Pressure (SBP)
NCT01031680,measures_secondary,Adjusted Mean Percent Change in Body Weight
NCT01031680,measures_secondary,Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 24
NCT01031680,measures_secondary,Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m²
NCT01031680,has_criteria,BMI baseline ≥27 kg/m2
NCT01155362,involves,Crohn's Disease
NCT01155362,evaluates,PDA001
NCT01155362,measures_primary,CDAI reduction
NCT01155362,measures_secondary,CDAI remission
NCT01155362,has_criteria,age 18-75 years
NCT00838591,involves,Asthma
NCT00838591,evaluates,MN-221
NCT00838591,measures_primary,FEV1 at Hour 3
NCT00838591,measures_secondary,Change from baseline FEV1
NCT00838591,measures_secondary,Change from baseline PEFR
NCT00838591,measures_secondary,Improvement in Dyspnea index
NCT00838591,has_criteria,Acute Exacerbation of Asthma
NCT00910091,involves,Endometrial Cancer
NCT00910091,evaluates,BN83495
NCT00910091,evaluates,Megestrol Acetate
NCT00910091,measures_primary,Progression Free Survival
NCT00910091,measures_secondary,Adverse Event
NCT00910091,measures_secondary,Quality of Life
NCT00910091,has_criteria,Age >65 Years
NCT02173691,involves,Chronic Obstructive Bronchitis
NCT02173691,evaluates,Tiotropium
NCT02173691,evaluates,Salmeterol
NCT02173691,evaluates,Placebo
NCT02173691,measures_primary,FEV1 response
NCT02173691,measures_secondary,Transition Dyspnoea Index
NCT02173691,measures_secondary,FVC response
NCT02173691,measures_secondary,Peak expiratory flow rates
NCT02173691,measures_secondary,COPD symptom scores
NCT02173691,measures_secondary,St. George's Hospital Respiratory Questionnaire
NCT02173691,measures_secondary,Mahler Dyspnoea Index
NCT02173691,has_criteria,COPD
NCT06481891,involves,Hypertrophic Cardiomyopathy
NCT06481891,evaluates,Sotagliflozin
NCT06481891,measures_primary,KCCQ CSS
NCT06481891,measures_secondary,NYHA Functional Class
NCT06481891,has_criteria,Baseline to Week 26
NCT01665391,involves,Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
NCT01665391,evaluates,Fresolimumab
NCT01665391,measures_primary,Percentage of patients achieving PR or CR
NCT01665391,measures_secondary,Change from baseline in Up/c ratio
NCT01665391,measures_secondary,Number of patients reporting AEs
NCT01665391,measures_secondary,Time to first PR or CR
NCT01665391,measures_secondary,Change from baseline in eGFR
NCT01665391,has_criteria,Up to Day 112
NCT04532294,involves,COVID-19
NCT04532294,evaluates,BGB-DXP593
NCT04532294,measures_primary,Number of TEAEs
NCT04532294,measures_secondary,Clinically Relevant Changes
NCT04532294,has_criteria,Healthy Participants
NCT00422162,involves,Major Depressive Disorder
NCT00422162,evaluates,Duloxetine
NCT00422162,measures_primary,Change in MADRS
NCT00422162,measures_secondary,Change in HAMD-6
NCT00422162,has_criteria,minimum 50% response
NCT00818662,involves,Alzheimer´s Disease
NCT00818662,evaluates,Immune Globulin Intravenous (IGIV 10%)
NCT00818662,measures_primary,Change From Baseline
NCT00818662,measures_secondary,Activities of Daily Living
NCT00818662,has_criteria,Mild-to-Moderate
NCT04669262,evaluates,BGB-DXP604
NCT04669262,evaluates,BGB-DXP593
NCT04669262,measures_primary,Number of Participants
NCT04669262,measures_secondary,Clinically Meaningful Changes
NCT04669262,measures_secondary,Vital Signs
NCT04669262,measures_secondary,12-Lead ECG Parameters
NCT04669262,measures_secondary,Laboratory Findings
NCT04669262,measures_secondary,Maximum Observed Serum Concentration
NCT04669262,measures_secondary,Area Under the Concentration Time Curve
NCT04167462,involves,Plaque Psoriasis
NCT04167462,evaluates,BMS-986165
NCT04167462,measures_primary,sPGA Response
NCT04167462,measures_secondary,PASI 75 Response
NCT04167462,has_criteria,2-point improvement
NCT03491462,involves,Amyotrophic Lateral Sclerosis
NCT03491462,evaluates,Arimoclomol
NCT03491462,measures_primary,CAFS score
NCT03491462,measures_secondary,Percent Predicted Slow Vital Capacity
NCT03491462,has_criteria,Time to PAV
NCT03912805,involves,Crow's Feet wrinkles
NCT03912805,evaluates,ET-01
NCT03912805,measures_primary,Change in IGA-C
NCT03912805,measures_secondary,Change in SSA-C
NCT03912805,has_criteria,females 25-65 years
NCT03901105,involves,Alzheimer's Disease
NCT03901105,evaluates,flortaucipir F 18 PET imaging
NCT03901105,measures_primary,CDR-SB worsening
NCT03901105,measures_secondary,MMSE
NCT03901105,measures_secondary,ADAS-Cog11
NCT03901105,measures_secondary,FAQ
NCT03901105,measures_secondary,CDR global
NCT03901105,has_criteria,clinically meaningful deterioration
NCT00227305,involves,Schizophrenia
NCT00227305,involves,Bipolar I Disorder
NCT00227305,evaluates,Quetiapine Fumarate
NCT00227305,measures_primary,Simpson-Angus Scale
NCT00227305,measures_secondary,Barnes Akathisia Rating Scale
NCT00227305,measures_secondary,Weight
NCT00227305,has_criteria,Open label
NCT00227305,has_criteria,26 weeks
NCT05543187,involves,Progressive Familial Intrahepatic Cholestasis
NCT05543187,evaluates,TAK-625
NCT05543187,measures_primary,ItchRO Severity Score
NCT05543187,measures_secondary,ItchRO Frequency Score
NCT05543187,has_criteria,Baseline to Week 26
NCT01576887,involves,End-Stage Renal Disease
NCT01576887,involves,Type 2 Diabetes Mellitus
NCT01576887,evaluates,Residual Renal Function
NCT01576887,measures_primary,Change in Residual Renal Function
NCT01576887,measures_secondary,Number of Adverse Events
NCT01576887,has_criteria,ESRD on PD for >3 months
NCT01576887,has_criteria,Diagnosis of T2DM prior to dialysis
NCT01576887,has_criteria,RRF ≥ 25 Liters/week/1.73 m2
NCT01576887,has_criteria,RRF ≥ 25 Liters/week/1.73 m2 at Screen A and B
NCT01576887,has_criteria,RRF at Screen B ≥ 50% of Screen A
NCT01576887,has_criteria,Age ≥ 18 years
NCT01576887,has_criteria,Mean SBP ≤ 160 mmHg and ≥ 90 mmHg
NCT01576887,has_criteria,Mean DBP < 100 mmHg and ≥ 40 mmHg
NCT01464333,involves,Crohn's Disease
NCT01464333,evaluates,Humira
NCT01464333,measures_primary,Change in CDAI Score
NCT01464333,measures_secondary,Work Productivity
NCT01464333,has_criteria,first dose of Humira
NCT00545233,involves,Chronic Hepatitis C
NCT00545233,involves,Insulin Resistance
NCT00545233,evaluates,PEGASYS
NCT00545233,evaluates,COPEGUS
NCT00545233,evaluates,Pioglitazone
NCT00545233,measures_primary,Virologic Response
NCT00545233,measures_primary,log10 HCV RNA
NCT00545233,measures_secondary,≥ 2 log10 Decrease
NCT00545233,measures_secondary,Virological Relapse
NCT00545233,has_criteria,Treatment-Naive
NCT02531633,involves,Giant Cell Arteritis
NCT02531633,evaluates,Sirukumab
NCT02531633,measures_primary,Sustained Remission
NCT02531633,measures_secondary,Cumulative Prednisone Dose
NCT02531633,has_criteria,Completed Week 52 visit
NCT04252287,involves,Heart Failure
NCT04252287,evaluates,Canagliflozin
NCT04252287,measures_primary,Change From Baseline in KCCQ-TSS
NCT04252287,measures_secondary,Change From Baseline in Total Daily Step Count
NCT04252287,measures_secondary,Change From Baseline in KCCQ Individual Domain Scores
NCT04252287,has_criteria,Baseline
NCT01206387,involves,Plaque Psoriasis
NCT01206387,evaluates,Desoximetasone Spray 0.25%
NCT01206387,measures_primary,PGA change from baseline
NCT01206387,measures_secondary,TLSS change from baseline
NCT01206387,has_criteria,[TRUNCATED]
NCT03463187,involves,Plaque Psoriasis
NCT03463187,evaluates,SHR-1314
NCT03463187,measures_primary,PASI 75
NCT03463187,measures_secondary,Anti-SHR-1314 antibodies
NCT03463187,has_criteria,evaluable participants
NCT02807987,involves,Hypertension
NCT02807987,involves,Renal Impairment
NCT02807987,evaluates,CS-3150
NCT02807987,measures_primary,Blood pressure change
NCT02807987,measures_secondary,Blood pressure control
NCT02807987,has_criteria,Aged 20 to 80 years
NCT02807987,has_criteria,Hypertension
NCT02807987,has_criteria,ARB or ACE inhibitor
NCT02807987,has_criteria,eGFR 30 to 60 mL/min/1.73 m2
NCT02807987,has_criteria,No secondary hypertension
NCT02807987,has_criteria,No diabetes mellitus
NCT02807987,has_criteria,No insulin treatment
NCT02807987,has_criteria,No hemodialysis
NCT02807987,has_criteria,Serum potassium 3.5 to 4.8 mEq/L
NCT03784287,involves,Mucopolysaccharidosis Type IIIB
NCT03784287,evaluates,AX 250
NCT03784287,measures_primary,cognitive function
NCT03784287,measures_secondary,Heparan sulfate levels
NCT03784287,measures_secondary,brain structure
NCT03784287,measures_secondary,adaptive function
NCT03784287,has_criteria,completed 48 weeks
NCT00587587,involves,Keloid
NCT00587587,evaluates,Apligraf
NCT00587587,measures_primary,Keloid Recurrence
NCT00587587,measures_secondary,Scar Firmness
NCT00587587,has_criteria,Baseline to Week 52
NCT00384033,involves,Major Depressive Disorder
NCT00384033,evaluates,Desvenlafaxine Succinate Sustained Release
NCT00384033,measures_primary,Change From Baseline
NCT00384033,measures_secondary,CGI-Improvement Score
NCT00384033,measures_secondary,CGI-Severity Score
NCT00384033,measures_secondary,MADRS Total Score
NCT00384033,measures_secondary,Lassitude Item of MADRS
NCT00384033,has_criteria,Baseline and Week 8
NCT01636687,involves,Psoriasis
NCT01636687,evaluates,securkinumab
NCT01636687,measures_primary,PASI 75 Response
NCT01636687,measures_secondary,IGA mod 2011
NCT01636687,has_criteria,moderate to severe
NCT03178487,involves,Ankylosing Spondylitis
NCT03178487,evaluates,Upadacitinib
NCT03178487,measures_primary,ASAS 40 Response
NCT03178487,measures_secondary,ASDAS
NCT03178487,has_criteria,Active Ankylosing Spondylitis
NCT02946333,involves,Multiple Myeloma
NCT02946333,measures_primary,Health-related Quality of Life
NCT02946333,measures_secondary,Direct Healthcare Costs
NCT02946333,has_criteria,Not Candidates for ASCT
NCT03370133,involves,Chronic Plaque Psoriasis
NCT03370133,evaluates,Bimekizumab
NCT03370133,evaluates,Placebo
NCT03370133,evaluates,Active Comparator
NCT03370133,measures_primary,PASI90 Response
NCT03370133,measures_secondary,Investigator's Global Assessment
NCT03370133,has_criteria,Adult Subjects
NCT05150587,involves,Papulopustular Rosacea
NCT05150587,evaluates,Rifaximin
NCT05150587,measures_primary,Change in lesions
NCT05150587,measures_secondary,IGA score
NCT05150587,has_criteria,≥11 and ≤70 facial papules
NCT00993187,involves,Type 2 Diabetes Mellitus
NCT00993187,evaluates,Sitagliptin/Metformin
NCT00993187,measures_primary,Change in HbA1C
NCT00993187,measures_secondary,Adverse Event
NCT00993187,measures_secondary,Discontinuation due to AE
NCT00993187,measures_secondary,Fasting Plasma Glucose
NCT00993187,measures_secondary,Hypoglycemia
NCT00993187,measures_secondary,Body Weight
NCT00993187,has_criteria,Up to 32 weeks
NCT00993187,has_criteria,Up to 30 weeks
NCT02654587,involves,Advanced NSCLC
NCT02654587,evaluates,OSE2101
NCT02654587,measures_primary,Overall Survival
NCT02654587,measures_secondary,Post-Progression Survival
NCT02654587,measures_secondary,Time to Worsening ECOG PS
NCT02654587,measures_secondary,Mean Changes in Functional Subscales
NCT02654587,has_criteria,ICI secondary resistance
NCT04773587,involves,Atopic Dermatitis
NCT04773587,evaluates,Roflumilast
NCT04773587,measures_primary,vIGA-AD Success
NCT04773587,measures_secondary,WI-NRS
NCT04773587,has_criteria,Baseline WI-NRS ≥ 4
NCT04149587,involves,Psoriasis
NCT04149587,evaluates,Brodalumab
NCT04149587,measures_primary,PASI 100 Response
NCT04149587,measures_secondary,sPGA Score
NCT04149587,has_criteria,Inadequate Response
NCT03482011,involves,Plaque Psoriasis
NCT03482011,evaluates,Mirikizumab
NCT03482011,measures_primary,sPGA 0
NCT03482011,measures_secondary,PASI 90
NCT03482011,measures_secondary,PASI 75
NCT03482011,has_criteria,moderate-to-severe PsO
NCT04805411,involves,Atopic Dermatitis
NCT04805411,evaluates,CM310
NCT04805411,measures_primary,EASI-75 at Week 16
NCT04805411,measures_secondary,IGA 0/1 at week 16
NCT04805411,measures_secondary,EASI-90 at week 16
NCT04805411,measures_secondary,EASI-50 at week 16
NCT04805411,measures_secondary,NRS pruritus at week 16
NCT04805411,measures_secondary,BSA at Week 24
NCT04805411,measures_secondary,DLQI at Week 24
NCT04805411,has_criteria,EASI score ≥16
NCT04805411,has_criteria,IGA score ≥3
NCT04805411,has_criteria,≥10% BSA of AD
NCT06005428,involves,Catecholaminergic Polymorphic Ventricular Tachycardia
NCT06005428,evaluates,CRD-4730
NCT06005428,measures_primary,Change in Ventricular Arrhythmia
NCT06005428,measures_secondary,Laboratory Assessments
NCT06005428,measures_secondary,Vital Signs Measurement
NCT06005428,measures_secondary,Physical Exam
NCT06005428,measures_secondary,Electrocardiogram Measurements
NCT06005428,has_criteria,Baseline to Day 22
NCT02683928,involves,Atopic Dermatitis
NCT02683928,evaluates,GBR 830
NCT02683928,measures_primary,Eczema Area and Severity Index
NCT02683928,measures_secondary,Thickness of Lesional Skin Biopsies
NCT02683928,measures_secondary,Ratio of Active Atopic Dermatitis mRNA Expression
NCT02683928,has_criteria,Moderate-to-severe
NCT06624228,involves,Psoriatic Arthritis
NCT06624228,evaluates,Bimekizumab
NCT06624228,measures_primary,ACR50 at Week 16
NCT06624228,measures_secondary,PASI100 response
NCT06624228,has_criteria,5 or more MDA criteria
NCT00583128,involves,Non-Constipating Irritable Bowel Syndrome
NCT00583128,evaluates,AST-120
NCT00583128,measures_primary,Days with abdominal pain
NCT00583128,measures_secondary,IBS QOL score
NCT00583128,measures_secondary,HADS score
NCT00583128,measures_secondary,Bristol Scale score
NCT00583128,measures_secondary,IBS Symptom Severity
NCT00583128,measures_secondary,Durability of effect
NCT00583128,measures_secondary,Clinical laboratory tests
NCT00583128,measures_secondary,Adverse event
NCT00583128,has_criteria,8 weeks
NCT03530293,involves,Tourette Syndrome
NCT03530293,evaluates,NBI-98854
NCT03530293,measures_primary,Time to Loss of Treatment Response
NCT03530293,measures_secondary,Change From Randomization Baseline
NCT03530293,has_criteria,Randomization (Week 8
NCT01451411,involves,Euvolemic Hyponatremia
NCT01451411,involves,Hypervolemic Hyponatremia
NCT01451411,evaluates,Intravenous Conivaptan
NCT01451411,measures_primary,Serum Sodium Change
NCT01451411,measures_secondary,Effective Water Clearance
NCT01451411,measures_secondary,Free Water Clearance
NCT01451411,has_criteria,Pediatric Subjects
NCT02193711,involves,Osteoarthritis of the Knee
NCT02193711,evaluates,Delivra Joint Health Cream
NCT02193711,measures_primary,change in pain score
NCT02193711,measures_secondary,WOMAC
NCT02193711,has_criteria,three weeks
NCT00762411,involves,Alzheimer's Disease
NCT00762411,evaluates,LY450139
NCT00762411,measures_primary,ADAS-Cog11 score
NCT00762411,measures_secondary,ADCS-ADL score
NCT00762411,has_criteria,Baseline (randomization)
NCT05411211,involves,Polyarticular Juvenile Idiopathic Arthritis
NCT05411211,evaluates,Adalimumab
NCT05411211,measures_primary,Change in Physician's Global Assessment
NCT05411211,measures_secondary,Participants Experiencing Joint Pain
NCT05411211,measures_secondary,Participants Experiencing Joint Swelling
NCT05411211,measures_secondary,Number of Active Joints Count
NCT05411211,measures_secondary,Number of joints with limitation of passive motion
NCT05411211,measures_secondary,Number of joints with pain on passive motion
NCT05411211,measures_secondary,Change from Baseline of C-Reactive Protein
NCT05411211,measures_secondary,Change from Baseline of Erythrocyte Sedimentation Rate
NCT05411211,measures_secondary,Change from Baseline in Parent's or Child's Global Assessment
NCT05411211,measures_secondary,Change from Baseline in Physical function
NCT05411211,measures_secondary,Change from baseline in dosage of corticosteroid
NCT05411211,measures_secondary,Number of Participants with Adverse Events
NCT05411211,has_criteria,Chinese Pediatric Participants
NCT05481411,involves,Hepatic Impairment
NCT05481411,evaluates,Olpasiran
NCT05481411,measures_primary,Maximum Observed Serum Concentration
NCT05481411,measures_secondary,Area Under the Plasma Concentration-time Curve
NCT05481411,has_criteria,Body mass index between 18.0 and 40.0 kg/m\^2
NCT05481411,has_criteria,between 18 and 75 years of age
NCT01714661,involves,Schizophrenia
NCT01714661,evaluates,EVP-6124
NCT01714661,measures_primary,Change from Baseline
NCT01714661,measures_secondary,Safety and Tolerability
NCT01714661,has_criteria,Age 18 to 50 years
NCT01575561,involves,Bipolar I Disorder
NCT01575561,evaluates,Lurasidone
NCT01575561,measures_primary,Change From Baseline
NCT01575561,measures_secondary,PANSS P Score
NCT01575561,has_criteria,Subjects With Bipolar I
NCT01608061,involves,Mild Probable Alzheimer's Disease
NCT01608061,evaluates,ADvance DBS-f
NCT01608061,measures_primary,ADAS-Cog 13
NCT01608061,measures_secondary,CDR-SB
NCT01608061,has_criteria,45-85 years of age
NCT05082428,involves,Ulcerative Colitis
NCT05082428,evaluates,Tofacitinib
NCT05082428,measures_primary,Age at Diagnosis
NCT05082428,measures_primary,Duration of Ulcerative Colitis
NCT05082428,measures_primary,Extent of Colonic Involvement
NCT05082428,measures_primary,Mayo Score at Initiation
NCT05082428,has_criteria,Age at diagnosis
NCT05082428,has_criteria,Date of initiation
NCT00570128,involves,Down Syndrome
NCT00570128,evaluates,Donepezil Hydrochloride
NCT00570128,measures_primary,V-Scale Composite Score
NCT00570128,measures_secondary,V-Scale Composite Score
NCT00570128,has_criteria,age and a national sample
NCT01458028,evaluates,BAY85-3934
NCT01458028,measures_primary,Area under curve
NCT01458028,measures_secondary,Maximum drug concentration
NCT01458028,measures_secondary,Safety and tolerability
NCT01458028,measures_secondary,Erythropoietin change
NCT01458028,measures_secondary,Reticulocytes change
NCT01458028,measures_secondary,Hemoglobin change
NCT01458028,measures_secondary,Hematocrit change
NCT01458028,measures_secondary,VEGF change
NCT01458028,has_criteria,No specific disease
NCT01458028,has_criteria,Good general health
NCT01458028,has_criteria,Male or female
NCT01458028,has_criteria,18 to 45 years
NCT01458028,has_criteria,65 to 85 years
NCT01458028,has_criteria,Caucasian
NCT00604383,involves,Diabetic Retinopathy
NCT00604383,evaluates,Protein Kinase C (PKC) Inhibitor
NCT00604383,measures_primary,Percentage of SMVL
NCT00604383,measures_secondary,Center Involved DME
NCT00604383,measures_secondary,Proliferative Diabetic Retinopathy
NCT00604383,measures_secondary,NEI-VFQ-25 score
NCT00604383,has_criteria,Baseline through 36 months
NCT05476783,involves,Alzheimer's Disease
NCT05476783,evaluates,TB006
NCT05476783,measures_primary,CDR SB score
NCT05476783,measures_secondary,Columbia Suicide Severity Rating Scale
NCT05476783,has_criteria,Clinically Significant
NCT02971683,involves,Idiopathic Inflammatory Myopathy
NCT02971683,evaluates,Abatacept
NCT02971683,measures_primary,IMACS DOI
NCT02971683,measures_secondary,HAQ-DI
NCT02971683,has_criteria,24 weeks after first dose
NCT03796728,evaluates,Juvéderm® VOLIFT™ With Lidocaine
NCT03796728,measures_primary,Lip Fullness Scale
NCT03796728,measures_secondary,Oral Commissures Severity Scale
NCT03796728,measures_secondary,FACE-Q Lips Questionnaire
NCT03796728,has_criteria,Baseline (Prior to Treatment)
NCT04630028,involves,Ulcerative Colitis
NCT04630028,evaluates,Ustekinumab
NCT04630028,measures_primary,Clinical Remission
NCT04630028,measures_secondary,Adverse Events
NCT04630028,measures_secondary,Serious Adverse Events
NCT04630028,measures_secondary,Discontinuation
NCT04630028,measures_secondary,Laboratory Abnormalities
NCT04630028,has_criteria,Moderately to Severely Active
NCT03746483,involves,Cystic Fibrosis
NCT03746483,evaluates,MS1819-SD
NCT03746483,measures_primary,Coefficient of Fat Absorption
NCT03746483,measures_secondary,Stool Weights
NCT03746483,measures_secondary,Signs and Symptoms of Malabsorption
NCT03746483,measures_secondary,Coefficient of Nitrogen Absorption
NCT03746483,has_criteria,Cystic fibrosis
NCT03746483,has_criteria,stable dose porcine PERT
NCT03746483,has_criteria,fair or better nutritional status
NCT03746483,has_criteria,fecal elastase <100 µg/g
NCT02419183,involves,Mild Cognitive Impairment
NCT02419183,involves,Dementia
NCT02419183,involves,Alzheimer's disease
NCT02419183,evaluates,SAMSTAR
NCT02419183,measures_primary,cognitive screening feasibility
NCT02419183,measures_secondary,participant experience
NCT02419183,measures_secondary,clinical staff attitudes
NCT02419183,has_criteria,normal visual acuity
NCT02419183,has_criteria,normal hearing acuity
NCT02419183,has_criteria,Dementia Screening Interview (AD8) score 0-1
NCT02419183,has_criteria,MoCA score 28 or higher
NCT02419183,has_criteria,English-speaking
NCT02419183,has_criteria,informed consent
NCT04701983,involves,Chronic Obstructive Pulmonary Disease
NCT04701983,evaluates,SAR440340/REGN3500/Itepekimab
NCT04701983,measures_primary,Annualized rate AECOPD
NCT04701983,measures_secondary,Change from baseline FEV1
NCT04701983,has_criteria,Baseline to Week 52
NCT02670083,involves,Alzheimer's Disease
NCT02670083,evaluates,Crenezumab
NCT02670083,measures_primary,Change From Baseline
NCT02670083,measures_secondary,Change From Baseline
NCT02670083,has_criteria,Baseline
NCT05454683,involves,Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT05454683,evaluates,Melatonin and Zinc
NCT05454683,measures_primary,Self-reported fatigue
NCT05454683,measures_secondary,Health-related quality of life
NCT05454683,measures_secondary,Sleep disturbances
NCT05454683,has_criteria,Dietary therapy
NCT01246583,involves,Chronic Plaque Psoriasis
NCT01246583,evaluates,CP-690-550 Ointment
NCT01246583,measures_primary,Percent Change TPSS
NCT01246583,measures_secondary,Change From Baseline TPSS
NCT01246583,measures_secondary,Percentage of Participants With Treatment Area Overall Severity of Psoriasis Response
NCT01246583,has_criteria,Target plaque severity
NCT02616328,involves,Rheumatoid Arthritis
NCT02616328,evaluates,Tocilizumab
NCT02616328,measures_primary,DAS28 < 2.6
NCT02616328,measures_secondary,Adverse Events
NCT02616328,measures_secondary,Tender Joint Count
NCT02616328,measures_secondary,Swollen Joint Count
NCT02616328,measures_secondary,C-Reactive Protein
NCT02616328,measures_secondary,Participant Global Health
NCT02616328,measures_secondary,Clinical Disease Activity Index
NCT02616328,measures_secondary,DAS28
NCT02616328,measures_secondary,CDAI
NCT05731128,involves,Ulcerative Colitis
NCT05731128,evaluates,Dupilumab
NCT05731128,measures_primary,Clinical remission
NCT05731128,measures_secondary,Clinical response
NCT05731128,has_criteria,Aged ≥18 Years
NCT02510261,involves,Transthyretin (TTR)-Mediated Amyloidosis
NCT02510261,evaluates,Patisiran (ALN-TTR02)
NCT02510261,measures_primary,Change From Baseline in NIS
NCT02510261,measures_secondary,Change From Baseline in mNIS +7 Composite Score
NCT02510261,measures_secondary,Change From Baseline in NIS+7 Total Score
NCT01704261,involves,Type 2 Diabetes Mellitus
NCT01704261,evaluates,Omarigliptin
NCT01704261,measures_primary,Change From Baseline in Hemoglobin A1c
NCT01704261,measures_secondary,Percentage of Participants Who Experienced at Least One Adverse Event
NCT01704261,measures_secondary,Percentage of Participants Who Discontinued From the Study Due to an AE
NCT01704261,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT01704261,measures_secondary,Percentage of Participants Attaining A1C Glycemic Goals of <7% and <6.5% at Week 24
NCT01704261,has_criteria,Inadequate Glycemic Control
NCT03526861,involves,Atopic Dermatitis
NCT03526861,evaluates,Tralokinumab
NCT03526861,measures_primary,IGA Score 0 or 1
NCT03526861,measures_primary,EASI75 at Week 16
NCT03526861,measures_primary,Pruritus NRS reduction
NCT03526861,measures_primary,SCORAD change
NCT03526861,measures_secondary,CDLQI change
NCT03526861,has_criteria,Investigator's Global Assessment
NCT03340961,involves,papulopustular rosacea
NCT03340961,evaluates,DFD-29 Extended Release Capsules
NCT03340961,measures_primary,IGA 'treatment success
NCT03340961,measures_secondary,Total Inflammatory Lesion Count Reduction
NCT03340961,measures_secondary,RosaQoL Score
NCT03340961,has_criteria,age 18 years and above
NCT03340961,has_criteria,Fitzpatrick skin type I - III
NCT03340961,has_criteria,good general health
NCT03340961,has_criteria,clinical diagnosis rosacea
NCT03340961,has_criteria,IGA grade 2 - 4
NCT03340961,has_criteria,10 - 40 inflammatory lesions
NCT02960893,involves,Spinocerebellar Ataxia
NCT02960893,evaluates,study drug
NCT02960893,measures_primary,Change in SARA score
NCT02960893,measures_secondary,Deaths
NCT02960893,has_criteria,First dose of study drug
NCT03926611,involves,Chronic Spontaneous Urticaria
NCT03926611,evaluates,LOU064
NCT03926611,measures_primary,UAS7 score change
NCT03926611,measures_secondary,UAS7=0 response rate
NCT03926611,measures_secondary,Cumulative Number of Weeks With an AAS7=0 Response
NCT03926611,has_criteria,Inadequately Controlled CSU
NCT00867828,involves,Alzheimer's disease
NCT00867828,evaluates,Neptune Krill Oil
NCT00867828,measures_primary,Neurological Test Battery change
NCT00867828,measures_secondary,change in DAD
NCT00867828,measures_secondary,change in NTB
NCT00867828,measures_secondary,change in GDS
NCT00867828,measures_secondary,change in MMSE
NCT00867828,has_criteria,age 50 years or older
NCT00867828,has_criteria,NINCDS-ADRDA criteria
NCT00867828,has_criteria,MMSE score 20-26
NCT00867828,has_criteria,decline in cognitive function
NCT00867828,has_criteria,Ham-D score < 9
NCT00867828,has_criteria,stable antidepressant dose
NCT00867828,has_criteria,no fish oil supplements
NCT00867828,has_criteria,living at home
NCT00867828,has_criteria,responsible caregiver
NCT00867828,has_criteria,stable cholinesterase inhibitor dose
NCT00867828,has_criteria,stable concomitant medication dose
NCT00867828,has_criteria,written informed consent
NCT00675428,involves,Multiple Myeloma
NCT00675428,evaluates,Natalizumab
NCT00675428,measures_primary,Objective Response Rate
NCT00675428,measures_secondary,Adverse Events
NCT00675428,has_criteria,grade 3 toxicity
NCT02670928,involves,Type 2 Diabetes
NCT02670928,involves,Obesity
NCT02670928,evaluates,Active Weight Management
NCT02670928,measures_primary,Clinically Significant Weight Reduction
NCT02670928,measures_secondary,Blood Pressure
NCT02670928,measures_secondary,Cholesterol
NCT02670928,measures_secondary,Triglycerides
NCT02670928,measures_secondary,Lipid Protein
NCT02670928,measures_secondary,Quality of Life
NCT02670928,has_criteria,Baseline values
NCT03907878,involves,Chronic Spontaneous Urticaria
NCT03907878,evaluates,Ligelizumab
NCT03907878,measures_primary,UAS7 Change From Baseline
NCT03907878,measures_secondary,HSS7 Change From Baseline
NCT03907878,has_criteria,H1- Antihistamines
NCT00763971,involves,Attention Deficit Hyperactivity Disorder
NCT00763971,evaluates,Lisdexamfetamine Dimesylate
NCT00763971,measures_primary,ADHD-RS-IV Total Score
NCT00763971,measures_secondary,CGI-I Scores
NCT00763971,measures_secondary,CPRS-R Total Score
NCT00763971,measures_secondary,HUI-2 Scores
NCT00763971,measures_secondary,CHIP-CE:PRF Global T-score
NCT00763971,has_criteria,up to 7 weeks
NCT04832971,involves,Mixed Dyslipidemia
NCT04832971,evaluates,ARO-ANG3
NCT04832971,measures_primary,Percent Change TG
NCT04832971,measures_secondary,Percent Change Non-HDL-C
NCT04832971,measures_secondary,Percent Change ApoB
NCT04832971,measures_secondary,Percent Change LDL-C
NCT04832971,measures_secondary,Percent Change ANGPTL3
NCT04832971,measures_secondary,Percent Change HDL-C
NCT04832971,has_criteria,IP administration
NCT01863771,involves,Ulcerative Colitis
NCT01863771,evaluates,Golimumab
NCT01863771,measures_primary,Mayo Score
NCT01863771,measures_secondary,Clinical Remission
NCT01863771,measures_secondary,Mucosal Healing
NCT01863771,has_criteria,Maintenance-Week 54
NCT05290493,involves,22q11 Deletion Syndrome
NCT05290493,evaluates,NB-001
NCT05290493,measures_primary,CGI-I Scale
NCT05290493,measures_primary,CGI-S Scale
NCT05290493,measures_secondary,Pediatric Anxiety Rating Scale
NCT05290493,has_criteria,anxiety as defined
NCT01963611,involves,multiple sclerosis
NCT01963611,evaluates,Plovamer Acetate
NCT01963611,measures_primary,Annualized Relapse Rate
NCT01963611,measures_secondary,Percentage of Subjects Remaining Relapse-Free
NCT01963611,has_criteria,neurological symptoms
NCT04437511,involves,Alzheimer's Disease
NCT04437511,evaluates,Donanemab
NCT04437511,measures_primary,Change From Baseline
NCT04437511,measures_secondary,Mini Mental State Examination
NCT04437511,has_criteria,age at baseline
NCT03153111,involves,Heart Failure With Preserved Ejection Fraction
NCT03153111,involves,Pulmonary Vascular Disease
NCT03153111,evaluates,Macitentan
NCT03153111,measures_primary,NT-proBNP change
NCT03153111,measures_secondary,Clinical Summary Score
NCT03153111,measures_secondary,Accelerometer-assessed activity
NCT03153111,measures_secondary,Worsening of Heart Failure events
NCT03153111,has_criteria,Baseline to Week 24
NCT06106828,involves,Thyroid Eye Disease
NCT06106828,evaluates,Satralizumab
NCT06106828,measures_primary,Proptosis reduction
NCT06106828,measures_secondary,Diplopia improvement
NCT06106828,measures_secondary,Motility-induced pain
NCT06106828,measures_secondary,Spontaneous pain
NCT06106828,measures_secondary,GO-QoL score
NCT06106828,measures_secondary,Overall response
NCT06106828,measures_secondary,Clinical Activity Score
NCT06106828,has_criteria,Baseline proptosis
NCT01920893,involves,Nasal Polyposis
NCT01920893,involves,Chronic Sinusitis
NCT01920893,evaluates,Dupilumab
NCT01920893,measures_primary,Bilateral Endoscopic NPS
NCT01920893,measures_secondary,Participant Reported Symptoms
NCT01920893,measures_secondary,Visual Analogue Scale
NCT01920893,measures_secondary,Nasal Peak Inspiratory Flow
NCT01920893,measures_secondary,Smell Test
NCT01920893,has_criteria,Baseline
NCT05840211,involves,Hormone Receptor-positive/Human Epidermal Growth Factor 2 Negative Metastatic Breast Cancer
NCT05840211,evaluates,Sacituzumab Govitecan
NCT05840211,measures_primary,Progression Free Survival
NCT05840211,measures_secondary,Overall Survival
NCT05840211,measures_secondary,Objective Response Rate
NCT05840211,measures_secondary,Change from Baseline in the Physical Functioning Domain
NCT05840211,measures_secondary,Time to Deterioration in Version 3.0 EORTC-QLQ-C30 Scores
NCT05840211,has_criteria,Received Endocrine Therapy
NCT00883493,involves,Bipolar Depression
NCT00883493,evaluates,Quetiapine
NCT00883493,evaluates,Lithium
NCT00883493,measures_primary,MADRS Total Score
NCT00883493,measures_secondary,HAM-D Total Score
NCT00883493,measures_secondary,HAM-A Total Score
NCT00883493,has_criteria,Baseline
NCT04090411,involves,Ulcerative Colitis
NCT04090411,evaluates,PF-06480605
NCT04090411,measures_primary,Clinical remission
NCT04090411,measures_secondary,Adverse events
NCT04090411,has_criteria,Week 14
NCT05250011,involves,Heart Failure with reduced Ejection Fraction
NCT05250011,evaluates,dapagliflozin
NCT05250011,measures_primary,Health-Related Quality of Life
NCT05250011,measures_secondary,Medication Adherence
NCT05250011,has_criteria,Age equal or above 18 years old
NCT05250011,has_criteria,dapagliflozin treatment
NCT05250011,has_criteria,ejection fraction of 40 percent or less
NCT01920711,involves,Heart Failure
NCT01920711,evaluates,LCZ696
NCT01920711,evaluates,Valsartan
NCT01920711,measures_primary,CV death and HF hospitalization
NCT01920711,measures_secondary,Change in KCCQ score
NCT01920711,measures_secondary,NYHA Functional Class
NCT01920711,has_criteria,preserved ejection fraction
NCT01920711,has_criteria,NYHA Class II-IV
NCT00931411,involves,Atopic Dermatitis
NCT00931411,evaluates,Formulation 609580 20
NCT00931411,evaluates,Formulation 609209
NCT00931411,measures_primary,SCORAD score
NCT00931411,measures_secondary,Global Efficacy
NCT00931411,measures_secondary,Quality of Life
NCT00931411,measures_secondary,Cosmetic Acceptability
NCT00931411,has_criteria,Children with atopic dermatitis
NCT06446193,involves,ASD
NCT06446193,involves,SCD
NCT06446193,evaluates,NDTx-01
NCT06446193,measures_primary,Adaptive Behavior
NCT06446193,measures_secondary,Social Responsiveness
NCT06446193,measures_secondary,Parenting Relationship
NCT03033511,involves,Extensive Stage Small Cell Lung Cancer
NCT03033511,evaluates,Rovalpituzumab Tesirine
NCT03033511,measures_primary,Overall Survival
NCT03033511,measures_secondary,Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) Physical Functioning Domain Over Time
NCT03033511,has_criteria,DLL3high
NCT04032093,involves,Respiratory Syncytial Virus
NCT04032093,evaluates,RSV vaccine
NCT04032093,measures_primary,Percentage of Maternal Participants
NCT04032093,measures_secondary,Systemic Events
NCT04032093,has_criteria,Prespecified Local Reactions
NCT05123911,involves,seborrheic dermatitis
NCT05123911,evaluates,shampoo
NCT05123911,evaluates,conditioner
NCT05123911,evaluates,combining cream
NCT05123911,measures_primary,Score of Scalp Residue
NCT05123911,measures_primary,Score of Topical Tolerability
NCT05123911,measures_secondary,Score of Scalp Residue
NCT05123911,has_criteria,Affected Area Criteria
NCT05123911,has_criteria,Severity Criteria
NCT01148511,involves,Choroidal Neovascularisation
NCT01148511,involves,Age-related Macular Degeneration
NCT01148511,evaluates,Labeled Regimen
NCT01148511,evaluates,"Treat and Extend"" Regimen"
NCT01148511,measures_primary,Change in BCVA
NCT01148511,measures_primary,Change in Letter Count
NCT01148511,measures_secondary,Number of Visits
NCT01148511,measures_secondary,Follow-up Duration
NCT01148511,measures_secondary,Change in Central Retinal Thickness
NCT01148511,measures_secondary,Quality of Life
NCT01148511,has_criteria,Baseline to Month 12
NCT01291511,involves,Schizophrenia
NCT01291511,evaluates,study medication
NCT01291511,measures_primary,PANSS Total Score
NCT01291511,measures_secondary,CGI-S
NCT01291511,measures_secondary,SDS Total Score
NCT01291511,has_criteria,Up to 26 weeks post-randomization
NCT01088711,involves,Obesity
NCT01088711,involves,Type 2 Diabetes
NCT01088711,evaluates,Omarigliptin
NCT01088711,measures_primary,Percent DPP-4 inhibition
NCT01088711,measures_secondary,WAA Active GLP-1 Concentration
NCT01088711,measures_secondary,WAA Total GLP-1 Concentration
NCT01088711,measures_secondary,Plasma Glucose Concentration
NCT01088711,has_criteria,Obese Participants
NCT01088711,has_criteria,Participants With Type 2 Diabetes
NCT01256411,involves,Essential Hypertension
NCT01256411,evaluates,LCZ696
NCT01256411,measures_primary,Change in Blood Pressure
NCT01256411,measures_secondary,Adverse Events
NCT01256411,has_criteria,Completed protocol No. CLCZ696A2219
NCT01256411,has_criteria,Good medication compliance
NCT01256411,has_criteria,Able to communicate and comply
NCT00532311,involves,Hypercholesterolemia
NCT00532311,evaluates,Lapaquistat Acetate
NCT00532311,measures_primary,Change from Baseline in LDL cholesterol
NCT00532311,measures_secondary,Change from Baseline in Triglycerides
NCT00532311,measures_secondary,Change from Baseline in Total Cholesterol
NCT00532311,measures_secondary,Change from Baseline in HDL cholesterol
NCT00532311,measures_secondary,Change from Baseline in VLDL cholesterol
NCT00532311,measures_secondary,Change from Baseline in apolipoprotein A1
NCT00532311,measures_secondary,Change from Baseline in apolipoprotein B
NCT00532311,measures_secondary,Change from Baseline in non-HDL cholesterol
NCT00532311,measures_secondary,Change from Baseline in LDL/HDL ratio
NCT00532311,measures_secondary,Change from Baseline in Total Cholesterol/HDL ratio
NCT00532311,measures_secondary,Change from Baseline in apolipoprotein A1/apolipoprotein B
NCT00532311,measures_secondary,Change from Baseline in high-sensitivity C-reactive protein
NCT00532311,measures_secondary,Percentage of subjects who achieve LDL cholesterol concentrations less than 1.81 mmol/L (70 mg/dL)
NCT00532311,measures_secondary,Percentage of subjects who achieve LDL cholesterol concentrations less than 2.59 mmol/L (100 mg/dL)
NCT00532311,measures_secondary,Percentage of subjects who achieve LDL cholesterol concentrations less than 3.37 mmol/L (130 mg/dL)
NCT00532311,has_criteria,Females of childbearing potential who are sexually active must agree to use adequate contraception from screening throughout the duration of the study and for 30 days following the last dose
NCT00532311,has_criteria,Has been on a stable dose of statin for at least 3 months prior to Screening
NCT04020211,involves,Chronic Knee Pain
NCT04020211,evaluates,HF10
NCT04020211,measures_primary,Oxford Knee Score
NCT04020211,measures_secondary,Disability and Functioning
NCT04020211,measures_secondary,Walking distance
NCT04020211,measures_secondary,Global Assessment of Functioning
NCT04020211,measures_secondary,Visual Analog Scale (VAS)
NCT04020211,measures_secondary,Short-Form McGill Pain Questionnaire (SF-MPQ-2)
NCT04020211,has_criteria,Responders
NCT02993783,involves,Acute Intestinal Graft-Versus-Host Disease
NCT02993783,evaluates,Vedolizumab
NCT02993783,measures_primary,Overall Response at Day 28
NCT02993783,measures_secondary,Serious Adverse Events
NCT02993783,has_criteria,Allo-HSCT
NCT02270983,involves,Opioid-Induced Constipation
NCT02270983,evaluates,Linaclotide
NCT02270983,measures_primary,Change From Baseline in 8-Week SBM Frequency Rate
NCT02270983,measures_secondary,Time to First SBM After the First Dose of Investigational Product
NCT02270983,measures_secondary,Percentage of Participants Meeting 6/8 Week Spontaneous Bowel Movement (SBM) 3 + 1 Responder Criteria
NCT02270983,measures_secondary,Change From Baseline in 8-Week Stool Consistency
NCT02270983,measures_secondary,Change From Baseline in 8-Week Straining
NCT02270983,measures_secondary,Change From Baseline in 8-Week Abdominal Bloating
NCT02270983,has_criteria,Baseline (Day 0) up to 8 weeks
NCT02871297,involves,Major Depressive Disorder
NCT02871297,evaluates,Vortioxetine
NCT02871297,measures_primary,Change From Baseline
NCT02871297,measures_secondary,Time to First Relapse
NCT02871297,has_criteria,7 to 18 Years of Age
NCT03561883,involves,Gastroesophageal Reflux Disease
NCT03561883,evaluates,IW-3718
NCT03561883,measures_primary,Change From Baseline in WHSS
NCT03561883,measures_secondary,Change From Baseline in WRFS
NCT03561883,measures_secondary,Percentage of Participants Who Were Overall Heartburn Responders
NCT03561883,has_criteria,4 of the 8 treatment weeks
NCT02104583,involves,Ventricular Arrhythmia
NCT02104583,evaluates,Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator
NCT02104583,measures_primary,Change From Baseline in PVC Count
NCT02104583,measures_secondary,Change From Baseline in nsVT Count
NCT02104583,measures_secondary,Overall Occurrence of VT/VF
NCT02104583,has_criteria,Randomization up to 24 weeks
NCT02811783,involves,mycosis fungoides
NCT02811783,involves,Sézary syndrome
NCT02811783,evaluates,Naloxone Hydrochloride
NCT02811783,measures_primary,Change from Baseline
NCT02811783,measures_secondary,Numeric Rating Scale for Sleep
NCT02811783,measures_secondary,Categorical Rating Scale for Skin Integrity
NCT02811783,measures_secondary,Pruritus Quality of Life Score
NCT02811783,has_criteria,21 years of age
NCT02811783,has_criteria,signed informed consent
NCT02811783,has_criteria,histological criteria
NCT01879683,involves,Interstitial Cystitis
NCT01879683,involves,Hunner's Lesions
NCT01879683,evaluates,LiRIS
NCT01879683,measures_primary,Appearance of Hunner's Lesions
NCT01879683,measures_secondary,Patient Report...
NCT02151383,involves,Acute Heart Failure
NCT02151383,evaluates,Serelaxin
NCT02151383,measures_primary,Pharmacokinetic Concentration
NCT02151383,measures_secondary,Change From Baseline
NCT02151383,has_criteria,Pediatric Patients
NCT02616783,involves,HIV-1 infection
NCT02616783,evaluates,Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
NCT02616783,measures_primary,Percent Change in Spine BMD
NCT02616783,measures_primary,Percent Change in Hip BMD
NCT02616783,measures_secondary,Percentage of Participants With HIV-1 RNA < 50 Copies/mL
NCT02616783,measures_secondary,Change From Baseline in CD4+ Cell Count
NCT02616783,has_criteria,Aged ≥ 60 Years
NCT00265083,involves,Ankylosing Spondylitis
NCT00265083,evaluates,Golimumab
NCT00265083,measures_primary,20% improvement
NCT00265083,measures_secondary,Bath Ankylosing Spondylitis Functional Index
NCT00265083,measures_secondary,Bath Ankylosing Spondylitis Metrology Index
NCT00265083,has_criteria,Definite AS
NCT00265083,has_criteria,BASDAI score
NCT00265083,has_criteria,Total Back Pain score
NCT00072683,involves,Hyponatremia
NCT00072683,evaluates,Tolvaptan
NCT00072683,measures_primary,serum sodium level
NCT00072683,measures_secondary,fluid restriction
NCT00072683,has_criteria,Hyponatremia euvolemic
NCT03997383,involves,Transthyretin Amyloidosis With Cardiomyopathy
NCT03997383,evaluates,Patisiran
NCT03997383,measures_primary,Composite Endpoint
NCT03997383,measures_secondary,Change From Baseline
NCT03997383,has_criteria,baseline tafamidis use
NCT03230383,evaluates,PF-06865571
NCT03230383,measures_primary,Maximum Observed Plasma Concentration
NCT03230383,measures_primary,AUCtau
NCT03230383,measures_primary,Time to Reach Maximum Observed Concentration
NCT03230383,measures_secondary,Dose normalized Cmax
NCT03230383,measures_secondary,Amount of unchanged drug recovered in urine
NCT05052983,involves,Prurigo Nodularis
NCT05052983,evaluates,Nemolizumab
NCT05052983,measures_primary,Time to relapse
NCT05052983,measures_secondary,IGA Success
NCT05052983,has_criteria,Baseline up to Week 24
NCT04994483,involves,Alzheimer's Disease
NCT04994483,evaluates,Simufilam 100 Mg
NCT04994483,measures_primary,Change from baseline
NCT04994483,measures_secondary,Change from baseline
NCT04994483,has_criteria,Baseline (Study Day 1) to Week 52
NCT06137183,involves,Ulcerative Colitis
NCT06137183,evaluates,Vixarelimab
NCT06137183,measures_primary,Clinical Remission
NCT06137183,measures_primary,Clinical Response
NCT06137183,measures_primary,Endoscopic Improvement
NCT06137183,measures_primary,Endoscopic Remission
NCT06137183,measures_secondary,Adverse Events
NCT06137183,measures_secondary,Serum Concentration
NCT06137183,measures_secondary,Anti-drug Antibodies
NCT06137183,has_criteria,Moderate to Severe
NCT01806597,involves,Palmoplantar Psoriasis
NCT01806597,evaluates,Secukinumab
NCT01806597,measures_primary,ppIGA 0 or 1 response
NCT01806597,measures_secondary,ppIGA response
NCT01806597,has_criteria,ppIGA scale reduction
NCT02460497,involves,Thinning Hair
NCT02460497,involves,Female Pattern Hair Loss
NCT02460497,involves,Androgenic Alopecia
NCT02460497,evaluates,Minoxidil 2% Solution
NCT02460497,evaluates,Botanical Hair Regimen
NCT02460497,measures_primary,Change From Baseline
NCT02460497,measures_secondary,Participant Rating
NCT02460497,measures_secondary,Shed Hair Count
NCT02460497,has_criteria,Subject Satisfaction Questionnaire
NCT00709683,evaluates,NovoMix® 30 FlexPen®
NCT00709683,measures_primary,serious adverse drug reactions
NCT00709683,measures_secondary,serious adverse events
NCT00709683,measures_secondary,hypoglycaemic events
NCT00709683,measures_secondary,Weight (BMI) change
NCT00709683,measures_secondary,HbA1c change
NCT00709683,measures_secondary,HbA1c target
NCT00709683,measures_secondary,fasting plasma glucose level
NCT00709683,measures_secondary,post-meal plasma glucose level
NCT01939197,involves,Hepatitis C Virus
NCT01939197,involves,Human Immunodeficiency Virus
NCT01939197,evaluates,ABT-450/r/ABT-267
NCT01939197,evaluates,ABT-333
NCT01939197,evaluates,Ribavirin
NCT01939197,measures_primary,SVR12
NCT01939197,measures_secondary,SVR12
NCT01939197,has_criteria,Genotype 1 or 4
NCT03421197,involves,plaque psoriasis
NCT03421197,evaluates,PPC-06
NCT03421197,measures_primary,PASI-75 at Week 24
NCT03421197,measures_secondary,Investigator's Global Assessment (IGA)
NCT03421197,has_criteria,age ≥18 years
NCT03421197,has_criteria,stable plaque psoriasis
NCT00268697,involves,Primary Dyslipidemia
NCT00268697,evaluates,Lapaquistat Acetate
NCT00268697,evaluates,Ezetimibe
NCT00268697,measures_primary,Low Density Lipoprotein cholesterol
NCT00268697,measures_secondary,Triglycerides
NCT00268697,measures_secondary,Total Cholesterol
NCT00268697,measures_secondary,High Density Lipoprotein cholesterol
NCT00268697,measures_secondary,Very Low Density Lipoprotein cholesterol
NCT00268697,measures_secondary,apolipoprotein A1
NCT00268697,measures_secondary,apolipoprotein B
NCT00268697,measures_secondary,non- High Density Lipoprotein cholesterol
NCT00268697,measures_secondary,Low Density Lipoprotein cholesterol/High Density Lipoprotein cholesterol ratio
NCT00268697,measures_secondary,Total Cholesterol/High Density Lipoprotein cholesterol ratio
NCT00268697,measures_secondary,apolipoprotein A1/apolipoprotein B ratio
NCT00268697,measures_secondary,high-sensitivity C-reactive protein
NCT00268697,measures_secondary,Low Density Lipoprotein cholesterol concentrations
NCT00268697,measures_secondary,Best corrected visual acuity
NCT00268697,measures_secondary,Adverse Events
NCT00268697,measures_secondary,Clinical Laboratory Tests
NCT00268697,measures_secondary,Vital Signs
NCT00268697,measures_secondary,12-lead Electrocardiogram
NCT00268697,measures_secondary,Physical Examination
NCT03558997,involves,allergic rhinitis
NCT03558997,evaluates,Dupilumab
NCT03558997,measures_primary,Change From Baseline in TNSS AUC
NCT03558997,measures_secondary,Change From Baseline in TNSS AUC
NCT03558997,has_criteria,SCIT vs. Dupilumab + SCIT
NCT01718483,involves,Binge Eating Disorder
NCT01718483,evaluates,SPD489
NCT01718483,measures_primary,Binge Days Per Week
NCT01718483,measures_secondary,CGI-I Scores
NCT01718483,measures_secondary,Body Weight
NCT01718483,measures_secondary,Y-BOCS-BE Total Score
NCT01718483,measures_secondary,Fasting Triglyceride Levels
NCT01718483,measures_secondary,Fasting Total Cholesterol Levels
NCT01718483,measures_secondary,Hemoglobin A1c Levels
NCT01718483,has_criteria,Adults Aged 18-55
NCT03550183,involves,Parkinson's Disease
NCT03550183,evaluates,Umbilical Cord Derived Mesenchymal Stem Cells Therapy
NCT03550183,measures_primary,Unified Parkinson's Disease Rating Scale
NCT03550183,measures_secondary,Hoehn and Yahr staging
NCT03550183,measures_secondary,Mini-Mental State Examination
NCT03550183,measures_secondary,Hamilton depression scales 24
NCT03550183,measures_secondary,Hamilton Anxiety Scale 14
NCT03550183,has_criteria,Age 40 to 60 years
NCT06534983,involves,Muscle-Invasive Urothelial Carcinoma
NCT06534983,evaluates,Autogene Cevumeran
NCT06534983,evaluates,Nivolumab
NCT06534983,measures_primary,Disease Free Survival
NCT06534983,measures_primary,Overall Survival
NCT06534983,measures_primary,Distant Metastasis-Free Survival
NCT06534983,measures_secondary,Number of Participants with Adverse Events
NCT06534983,measures_secondary,Change From Baseline in Participant-reported Pain
NCT06534983,measures_secondary,Physical Function
NCT06534983,measures_secondary,Role Function
NCT06534983,measures_secondary,Quality of Life
NCT06534983,has_criteria,High-Risk
NCT02659397,evaluates,ETC-1002
NCT02659397,measures_primary,Percent change LDL-cholesterol
NCT02659397,measures_secondary,hsCRP
NCT02659397,measures_secondary,total cholesterol
NCT02659397,measures_secondary,non-HDL-cholesterol
NCT02659397,measures_secondary,apolipoprotein B
NCT02659397,has_criteria,2 week treatment
NCT02659397,has_criteria,4 week treatment
NCT03161483,involves,Systemic Lupus Erythematosus
NCT03161483,evaluates,CC-220
NCT03161483,measures_primary,SRI(4) Response
NCT03161483,measures_secondary,SLEDAI 2K score
NCT03161483,measures_secondary,CLASI Activity Score
NCT03161483,has_criteria,SLEDAI 2K score
NCT03161483,has_criteria,BILAG 2004 Index
NCT03161483,has_criteria,Physician's Global Assessment
NCT04643483,involves,Crohn's Disease
NCT04643483,evaluates,Certolizumab Pegol
NCT04643483,measures_primary,Clinical remission
NCT04643483,measures_secondary,Clinical response
NCT04643483,has_criteria,PCDAI score ≤10
NCT03328897,involves,Chronic Spontaneous Urticaria
NCT03328897,evaluates,Xolair
NCT03328897,measures_primary,Change From Baseline ISS7
NCT03328897,measures_secondary,Change From Baseline UAS7
NCT03328897,measures_secondary,Change From Baseline NHS7
NCT03328897,has_criteria,Baseline ISS7
NCT01582061,involves,Cushing's Disease
NCT01582061,evaluates,Pasireotide s.c.
NCT01582061,measures_primary,Percentage of Patients With Mean UFC ≤ ULN
NCT01582061,measures_secondary,Percentage of Patients Achieving a Reduction of Mean UFC ≥ 50% From Baseline
NCT01582061,has_criteria,Baseline up to approximately 256 weeks
NCT04620161,involves,Functional Constipation
NCT04620161,evaluates,Pradigastat
NCT04620161,measures_primary,Number change SBM
NCT04620161,measures_secondary,Responder rate
NCT04620161,measures_secondary,Constipation symptom score
NCT04620161,has_criteria,Aged 18-70 years
NCT04620161,has_criteria,Written informed consent
NCT04620161,has_criteria,ROME IV criteria
NCT02083783,involves,Attention Deficit Hyperactivity Disorder
NCT02083783,evaluates,study medication
NCT02083783,measures_primary,PERMP questions answered
NCT02083783,measures_secondary,SKAMP-Combined Scores
NCT02083783,has_criteria,Children aged 6 to 12 years
NCT02234583,involves,Fibromyalgia
NCT02234583,evaluates,DS-5565
NCT02234583,measures_primary,Average Daily Pain Score
NCT02234583,measures_secondary,Patient-Rated Global Impression of Change
NCT02234583,measures_secondary,Hospital Anxiety Depression Scale
NCT02234583,measures_secondary,EuroQol Five Dimensions Questionnaire
NCT02234583,measures_secondary,Short Form-36
NCT01226797,involves,Chronic Hepatitis C Infection
NCT01226797,evaluates,PF-4136309
NCT01226797,measures_primary,ALT response at Week 4
NCT01226797,measures_secondary,AST response at Week 4
NCT01226797,has_criteria,Abnormal Liver Enzymes
NCT03260205,involves,Attention-deficit/Hyperactivity Disorder
NCT03260205,evaluates,ADHD-RS-IV Preschool Version
NCT03260205,measures_primary,ADHD-RS-IV Preschool Version
NCT03260205,measures_secondary,Clinical Global Impressions Global Improvement
NCT03260205,has_criteria,DSM-IV-TR criteria
NCT01134705,involves,Perennial Allergic Rhinitis
NCT01134705,measures_primary,rTNSS change
NCT01134705,measures_secondary,iTNSS change
NCT01134705,measures_secondary,RQLQ
NCT01134705,has_criteria,Baseline (Days -3 to 0) and Days 1-43
NCT05331183,involves,Cystic Fibrosis
NCT05331183,evaluates,Elexacaftor/Tezacaftor/Ivacaftor
NCT05331183,measures_primary,ppFEV1 change
NCT05331183,measures_secondary,Sweat Chloride
NCT05331183,measures_secondary,CFQ-R RD Score
NCT05331183,measures_secondary,Body Mass Index
NCT05331183,measures_secondary,Weight
NCT05331183,measures_secondary,Pulmonary Exacerbations
NCT05331183,has_criteria,Subjects Without F508del
NCT02016183,evaluates,Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets
NCT02016183,measures_primary,Changes From Baseline in SBP
NCT02016183,measures_primary,Changes From Baseline in DBP
NCT02016183,measures_primary,Changes From Baseline in Pulse Rate
NCT02016183,has_criteria,Adverse Drug Reactions
NCT02674997,involves,Hemophilia
NCT02674997,evaluates,GAS-Hem
NCT02674997,measures_primary,GAS-Hem responsiveness
NCT02674997,measures_secondary,SF-36
NCT02674997,measures_secondary,PedQL
NCT02674997,has_criteria,Baseline; weeks 6 and 12
NCT02054897,involves,Type 2 Diabetes
NCT02054897,evaluates,Semaglutide
NCT02054897,measures_primary,Change in HbA1c
NCT02054897,measures_secondary,Change in Body Weight
NCT02054897,measures_secondary,Change in Fasting Plasma Glucose
NCT02054897,measures_secondary,Change in Systolic and Diastolic Blood Pressure
NCT02054897,has_criteria,drug-naïve subjects
NCT04895605,involves,autistic disorder
NCT04895605,evaluates,Low Level Laser Light Therapy
NCT04895605,measures_primary,ABC Irritability Subscale score
NCT04895605,has_criteria,aged 5 to 12 years
NCT04895605,has_criteria,DSM-V diagnosis
NCT04895605,has_criteria,ADI-R confirmed
NCT04895605,has_criteria,irritable behaviors
NCT04895605,has_criteria,ABC Irritability Subscale score >=18
NCT04895605,has_criteria,CGI-S scale score >=4
NCT01191983,involves,Diabetic Nephropathy
NCT01191983,evaluates,Methoxy Polyethylene Glycol-Epoetin Beta
NCT01191983,measures_primary,Hemoglobin levels
NCT01191983,measures_secondary,Adverse Events
NCT01191983,measures_secondary,Red Blood Cell Transfusion
NCT01191983,measures_secondary,anti-epoetin antibodies
NCT01191983,measures_secondary,Short Form-36 Health Survey
NCT01191983,has_criteria,Baseline (Week -2 up to Week 0)
NCT01191983,has_criteria,Week 17 up to Week 24
NCT01191983,has_criteria,Week 0 up to Week 24
NCT02987205,involves,Nasolabial Folds
NCT02987205,evaluates,Revanesse® Ultra
NCT02987205,evaluates,Restylane®
NCT02987205,measures_primary,Wrinkle Severity Rating Scale
NCT02987205,measures_secondary,Responder Rate
NCT02987205,measures_secondary,Nasolabial Folds
NCT02987205,has_criteria,22 years of age or older
NCT02987205,has_criteria,bilateral nasolabial folds
NCT02987205,has_criteria,Wrinkle Severity Rating Scale Score 3 or 4
NCT02152605,involves,Chronic Obstructive Pulmonary Disease
NCT02152605,evaluates,Umeclidinium/Vilanterol
NCT02152605,measures_primary,Change From Baseline
NCT02152605,measures_secondary,Trough Forced Expiratory Volume
NCT02152605,has_criteria,Baseline SGRQ total score
NCT00159783,involves,Bipolar Disorder
NCT00159783,evaluates,Asenapine
NCT00159783,evaluates,Olanzapine
NCT00159783,measures_primary,Abnormal Physical Examination Findings
NCT00159783,measures_secondary,Electrocardiogram
NCT00159783,measures_secondary,Body Weight
NCT00159783,measures_secondary,Extrapyramidal Symptoms
NCT00159783,measures_secondary,Concomitant Medications
NCT00159783,has_criteria,Adverse Event(s)
NCT02851797,involves,Duchenne Muscular Dystrophy
NCT02851797,evaluates,Givinostat
NCT02851797,measures_primary,4 Standard Stairs Climb
NCT02851797,measures_secondary,Time to Rise From Floor
NCT02851797,measures_secondary,Six-minute Walking Test
NCT02851797,measures_secondary,Total North Star Ambulatory Assessment Score
NCT02851797,has_criteria,Ambulant Patients
NCT00116805,involves,Chronic Hepatitis B
NCT00116805,evaluates,Tenofovir Disoproxil Fumarate
NCT00116805,evaluates,Adefovir Dipivoxil
NCT00116805,measures_primary,HBV DNA < 400
NCT00116805,measures_primary,Histological response
NCT00116805,measures_secondary,HBV DNA < 400
NCT00116805,measures_secondary,Knodell necroinflammatory score
NCT00116805,has_criteria,HBV DNA value
NCT02367183,involves,Crohn's Disease
NCT02367183,evaluates,GED-0301
NCT02367183,measures_primary,Change in SES-CD Score
NCT02367183,measures_secondary,Proportion of subjects achieving clinical remission
NCT02367183,has_criteria,Diagnosis of Crohn's Disease
NCT02595983,involves,Transthyretin (TTR)-Mediated Amyloidosis
NCT02595983,evaluates,Revusiran (ALN-TTRSC)
NCT02595983,measures_primary,Percentage Change in Serum TTR
NCT02595983,measures_secondary,Modified Neurological Impairment Score (mNIS +7) Composite Score
NCT02595983,measures_secondary,Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) Questionnaire Score
NCT02595983,measures_secondary,Number of Participants in Each Polyneuropathy Disability (PND) Stage
NCT02595983,has_criteria,Disease Has Continued to Worsen Following Liver Transplant
NCT03301883,involves,Systemic Juvenile Idiopathic Arthritis
NCT03301883,evaluates,Tocilizumab
NCT03301883,measures_primary,JIA ACR30 Response
NCT03301883,measures_secondary,Inactive Disease
NCT03301883,has_criteria,Wallace et. al. 2011 Criteria
NCT04467697,involves,Hypogonadal Men
NCT04467697,evaluates,Oral Testosterone Undecanoate
NCT04467697,evaluates,SOV2012-F1
NCT04467697,measures_primary,Change from baseline
NCT04467697,measures_secondary,Ambulatory Systolic Blood Pressure
NCT04467697,measures_secondary,Ambulatory Diastolic Blood Pressure
NCT04467697,measures_secondary,Ambulatory Heart Rate
NCT04467697,has_criteria,Plasma and Serum Testosterone
NCT01034397,involves,Rheumatoid Arthritis
NCT01034397,evaluates,Tocilizumab
NCT01034397,measures_primary,Synovitis change
NCT01034397,measures_secondary,OMERACT RAMRIS Score
NCT01034397,has_criteria,Inadequate response
NCT01130597,involves,Heart Failure
NCT01130597,involves,Chronic Kidney Disease
NCT01130597,evaluates,Patiromer
NCT01130597,measures_primary,Serum Potassium
NCT01130597,measures_secondary,Patiromer Dose
NCT01130597,has_criteria,spironolactone therapy
NCT01130597,has_criteria,Age 18 years
NCT01130597,has_criteria,serum potassium
NCT01130597,has_criteria,eGFR < 60 mL/min/1.73m2
NCT04159805,involves,Generalized Myasthenia Gravis
NCT04159805,evaluates,TAK-079
NCT04159805,measures_primary,Change From Baseline
NCT04159805,measures_secondary,Quantitative Myasthenia Gravis Scale Score
NCT04159805,has_criteria,Informed consent form
NCT02660983,involves,Dementia
NCT02660983,involves,Cerebrovascular Disease
NCT02660983,evaluates,Donepezil Hydrochloride
NCT02660983,measures_primary,ADAS-cog Score
NCT02660983,measures_secondary,CIBIC-plus Score
NCT02660983,measures_secondary,MMSE Score
NCT02660983,measures_secondary,Executive Function Test
NCT02660983,has_criteria,Baseline and Week 24
NCT06588283,involves,Plaque Psoriasis
NCT06588283,involves,Obesity
NCT06588283,involves,Overweight
NCT06588283,evaluates,Ixekizumab
NCT06588283,evaluates,Tirzepatide
NCT06588283,measures_primary,PASI 100 and weight reduction
NCT06588283,measures_secondary,PASI 75 and weight reduction
NCT06588283,has_criteria,Moderate-to-Severe Plaque Psoriasis
NCT03738397,involves,Atopic Dermatitis
NCT03738397,evaluates,Upadacitinib
NCT03738397,evaluates,Dupilumab
NCT03738397,measures_primary,EASI 75
NCT03738397,measures_secondary,Worst Pruritus NRS
NCT03738397,measures_secondary,EASI 100
NCT03738397,has_criteria,Moderate to Severe
NCT00626197,involves,Systemic Lupus Erythematosus
NCT00626197,evaluates,Ocrelizumab
NCT00626197,measures_primary,Complete Renal Response
NCT00626197,measures_secondary,Overall Response
NCT00626197,has_criteria,serum creatinine
NCT06196905,involves,systemic vasculitis
NCT06196905,evaluates,MT-2990
NCT06196905,measures_secondary,Change from baseline BVAS
NCT06196905,measures_secondary,Change from baseline VDI
NCT06196905,measures_secondary,Patient Global Impression of Change
NCT06196905,measures_secondary,Clinical Global Impression of Change
NCT00678561,involves,Chronic Plaque Psoriasis
NCT00678561,evaluates,CP-690
NCT00678561,measures_primary,Percent Change TPSS
NCT00678561,measures_secondary,PGA of Psoriasis
NCT00678561,has_criteria,Administration Site Adverse Events
NCT00570661,involves,Systemic Juvenile Idiopathic Arthritis
NCT00570661,evaluates,ITF2357
NCT00570661,measures_primary,Number of patients completing
NCT00570661,measures_secondary,Patient Global Assessment
NCT00570661,measures_secondary,Physician Global Assessment
NCT00570661,measures_secondary,Number of Joints With Active Arthritis
NCT00570661,measures_secondary,Number of Joints With Limitation
NCT00570661,has_criteria,Treatment-limiting toxicity
NCT04474405,involves,Cognitive impairment
NCT04474405,involves,Healthy volunteers
NCT04474405,evaluates,Flortaucipir Injection
NCT04474405,measures_primary,Flortaucipir uptake
NCT04474405,measures_secondary,Cognitive function
NCT04474405,has_criteria,Age 18-75 years
NCT01000805,involves,Major Depressive Disorder
NCT01000805,evaluates,Duloxetine
NCT01000805,measures_primary,Change From Baseline
NCT01000805,measures_secondary,Montgomery Asberg Depression Rating Scale
NCT01000805,measures_secondary,Sheehan Disability Scale
NCT01000805,measures_secondary,Percentage of Participants Achieving Remission
NCT01000805,has_criteria,Baseline
NCT06235905,involves,Major Depressive Disorder
NCT06235905,evaluates,SPN-820
NCT06235905,measures_primary,HAM-D6 score
NCT06235905,measures_secondary,MADRS score
NCT06235905,has_criteria,aged 18 to 65 years
NCT06235905,has_criteria,Diagnosis of MDD
NCT06235905,has_criteria,MADRS total score ≥22
NCT06235905,has_criteria,CGI-S score ≥4
NCT03882905,involves,Primary Hypercholesterolemia
NCT03882905,involves,Coronary Heart Disease
NCT03882905,involves,Cardiovascular Risk Factors
NCT03882905,evaluates,SCH 58235
NCT03882905,evaluates,Ezetimibe
NCT03882905,measures_primary,Percentage Change from Baseline
NCT03882905,measures_secondary,Percentage Participants with Consecutive Elevations
NCT03882905,has_criteria,statin therapy
NCT00960661,involves,Type 2 Diabetes
NCT00960661,evaluates,Basal Insulin/Glargine
NCT00960661,evaluates,Basal Insulin/Glargine
NCT00960661,measures_primary,Change in HbA1c
NCT00960661,measures_secondary,Percentage of Participants Achieving HbA1C < 7.0%
NCT00960661,measures_secondary,Percent of Participants Achieving HbA1c ≤ 6.5%
NCT00960661,measures_secondary,Change in Fasting Blood Glucose
NCT00960661,measures_secondary,Change in Total Cholesterol
NCT00960661,measures_secondary,Change in High Density Lipoprotein
NCT00960661,measures_secondary,Change in Low Density Lipoprotein
NCT00960661,has_criteria,Baseline
NCT01913405,involves,Hemophilia A
NCT01913405,evaluates,BAX 855
NCT01913405,measures_primary,Global Hemostatic Efficacy
NCT01913405,measures_secondary,Intraoperative Blood Loss
NCT01913405,measures_secondary,Postoperative Blood Loss
NCT01913405,has_criteria,Surgical Procedures
NCT00617305,involves,Pulmonary Arterial Hypertension
NCT00617305,evaluates,Ambrisentan
NCT00617305,measures_primary,Change From Baseline in PVR
NCT00617305,measures_secondary,Change From Baseline in mPAP
NCT00617305,measures_secondary,Change From Baseline in mRAP
NCT00617305,measures_secondary,Change From Baseline in Cardiac Output
NCT00617305,measures_secondary,Change From Baseline in 6MWD
NCT00617305,measures_secondary,Change in Dyspnea Index
NCT00617305,has_criteria,sub-optimal response to PDE-5i monotherapy
NCT05215561,involves,Psoriasis vulgaris
NCT05215561,involves,Psoriatic arthritis
NCT05215561,involves,GPP
NCT05215561,evaluates,Cosentyx
NCT05215561,measures_primary,Change from baseline
NCT05215561,measures_secondary,Incidence of serious adverse events
NCT05215561,measures_secondary,Incidence of SAEs
NCT05215561,has_criteria,IGA mod 2011
NCT05215561,has_criteria,PASI 75/90/100 response
NCT05215561,has_criteria,CDLQI
NCT05215561,has_criteria,C-HAQ
NCT01294683,involves,Primary Hypercholesterolemia
NCT01294683,involves,Mixed Dyslipidemia
NCT01294683,evaluates,MK-0524B
NCT01294683,evaluates,Extended-Release Niacin
NCT01294683,evaluates,Laropiprant
NCT01294683,evaluates,Simvastatin
NCT01294683,measures_primary,Change From Baseline
NCT01294683,measures_secondary,Percentage of Participants
NCT01294683,has_criteria,Baseline
NCT02959983,involves,Irritable Bowel Syndrome With Diarrhea
NCT02959983,evaluates,Eluxadoline
NCT02959983,measures_primary,Composite Responder
NCT02959983,measures_secondary,Stool Consistency Responder
NCT02959983,measures_secondary,Pain Responder
NCT02959983,has_criteria,Prior Loperamide Use
NCT04978597,involves,Parkinson's Disease
NCT04978597,evaluates,L-DOPA/DDCI
NCT04978597,measures_primary,MDS-UPDRS Part III
NCT04978597,measures_secondary,MDS-UPDRS Part IV
NCT04978597,has_criteria,30 to 80 years
NCT04978597,has_criteria,idiopathic PD
NCT04978597,has_criteria,Hoehn & Yahr staging
NCT04978597,has_criteria,MDS-UPDRS Part III score ≥20
NCT03187197,involves,atrial fibrillation
NCT03187197,evaluates,Pradaxa
NCT03187197,measures_primary,PACT-Q2 Scores
NCT03187197,measures_secondary,convenience dimension score
NCT03187197,measures_secondary,satisfaction dimension score
NCT03187197,has_criteria,treatment ongoing
NCT00171405,involves,Hypertension
NCT00171405,evaluates,Aliskiren 300 mg
NCT00171405,evaluates,Hydrochlorothiazide 25 mg
NCT00171405,measures_primary,Diastolic blood pressure
NCT00171405,measures_primary,Systolic blood pressure
NCT00171405,measures_primary,Standing blood pressure
NCT00171405,has_criteria,CSPP100A2302 core study
NCT00171405,has_criteria,aliskiren 300 mg
NCT00171405,has_criteria,HCTZ 25 mg
NCT00171405,has_criteria,severe adverse events
NCT00445705,involves,Fibromyalgia Syndrome
NCT00445705,evaluates,AGN 203818
NCT00445705,measures_primary,Change From Baseline
NCT00445705,measures_secondary,Short Form Brief Pain Inventory
NCT00445705,measures_secondary,Fibromyalgia Impact Questionnaire
NCT00445705,has_criteria,Baseline
NCT02335983,involves,Multiple Myeloma
NCT02335983,evaluates,Carfilzomib
NCT02335983,measures_primary,Change From Baseline
NCT02335983,measures_secondary,Maximum Plasma Concentration
NCT02335983,has_criteria,serious adverse event
NCT03608397,involves,Cervical Dystonia
NCT03608397,evaluates,DaxibotulinumtoxinA
NCT03608397,measures_primary,Change from Baseline TWSTRS-total score
NCT03608397,measures_secondary,Duration of effect
NCT03608397,has_criteria,Adults 18 to 80 years
NCT01259297,involves,Major Cardiovascular Events
NCT01259297,evaluates,Aliskiren
NCT01259297,measures_primary,SAGE scale
NCT01259297,measures_secondary,Composite CV endpoint
NCT01259297,has_criteria,Elderly People
NCT01399697,involves,Rheumatoid Arthritis
NCT01399697,evaluates,RoActemra/Actemra
NCT01399697,evaluates,Methotrexate
NCT01399697,measures_primary,DAS28 Score < 2.6
NCT01399697,measures_secondary,CDAI < 2.8
NCT01399697,measures_secondary,SDAI < 3.3
NCT01399697,has_criteria,Inadequate response to Methotrexate
NCT00478205,involves,Alzheimer's disease
NCT00478205,evaluates,Donepezil Sustained Release
NCT00478205,evaluates,Donepezil Immediate Release
NCT00478205,measures_primary,SIB Total Score
NCT00478205,measures_secondary,Modified CIBIC+
NCT00478205,measures_secondary,ADCS-ADL Total Score
NCT00478205,measures_secondary,MMSE Total Score
NCT00478205,has_criteria,Adult patients
NCT00478205,has_criteria,non-child-bearing potential
NCT00478205,has_criteria,diagnostic evidence of probable Alzheimer's disease
NCT00761605,involves,Schizophrenia
NCT00761605,evaluates,Paliperidone Extended-Release
NCT00761605,measures_primary,Change From Baseline
NCT00761605,measures_secondary,Total Personal and Social Performance
NCT00761605,measures_secondary,Subjective Well-being Under Neuroleptic
NCT00761605,has_criteria,transition to Paliperidone ER
NCT02598297,involves,Myelofibrosis
NCT02598297,evaluates,Ruxolitinib
NCT02598297,measures_primary,Progression Free Survival
NCT02598297,measures_secondary,Time to Primary Progression
NCT02598297,measures_secondary,Percentage Change in Spleen Volume
NCT02598297,measures_secondary,Percentage Change in Symptoms
NCT02598297,measures_secondary,Number of Participants With Specific Subscale Scores
NCT02598297,has_criteria,High Molecular Risk Mutations
NCT01597297,involves,Multiple Sclerosis
NCT01597297,evaluates,Fampridine
NCT01597297,measures_primary,walking disability
NCT01597297,measures_secondary,static balance
NCT01597297,measures_secondary,dynamic balance
NCT01597297,measures_secondary,subjective well-being
NCT01597297,measures_secondary,global impression
NCT01597297,has_criteria,informed consent
NCT01597297,has_criteria,diagnosis Multiple Sclerosis
NCT01597297,has_criteria,EDSS 4 to 7
NCT01597297,has_criteria,contraception
NCT01597297,has_criteria,no allergy pyridine
NCT03085797,involves,Nasal Polyps
NCT03085797,evaluates,Mepolizumab
NCT03085797,measures_primary,Change From Baseline
NCT03085797,measures_secondary,Nasal Obstruction VAS
NCT03085797,has_criteria,Early discontinuation from IP
NCT00706797,involves,Rheumatoid Arthritis
NCT00706797,evaluates,Etanercept
NCT00706797,evaluates,Methotrexate
NCT00706797,measures_primary,Change From Baseline
NCT00706797,measures_secondary,Erosions
NCT00706797,measures_secondary,Joint Space Narrowing
NCT00706797,measures_secondary,Radiographic Progression
NCT00706797,has_criteria,Moderate RA Subjects
NCT02265705,involves,Rheumatoid Arthritis
NCT02265705,evaluates,Baricitinib
NCT02265705,measures_primary,ACR20 response
NCT02265705,measures_secondary,HAQ-DI Score
NCT02265705,measures_secondary,DAS28-hsCRP
NCT02265705,has_criteria,≥20% improvement
NCT05527405,involves,Alzheimer's Disease
NCT05527405,evaluates,Caregiver Training Program
NCT05527405,measures_primary,Change in Zarit Burden
NCT05527405,measures_secondary,Change in ADCS-ADL
NCT05527405,measures_secondary,Change in QoL-18
NCT05527405,has_criteria,cognitive impairment
NCT04804605,involves,atopic dermatitis
NCT04804605,evaluates,ARQ-151 cream
NCT04804605,measures_primary,vIGA-AD success
NCT04804605,measures_secondary,WI-NRS score
NCT04804605,measures_secondary,EASI score
NCT04804605,has_criteria,legally competent
NCT04804605,has_criteria,informed consent
NCT04804605,has_criteria,ages 2 years and older
NCT04804605,has_criteria,atopic dermatitis
NCT01467505,involves,HCV Infection
NCT01467505,evaluates,Telaprevir
NCT01467505,measures_primary,SVR12
NCT01467505,measures_secondary,SVR24
NCT01467505,measures_secondary,RVR
NCT01467505,measures_secondary,eRVR
NCT01467505,has_criteria,undetectable HCV RNA
NCT02096705,involves,type 2 diabetes
NCT02096705,evaluates,Insulin
NCT02096705,measures_primary,HbA1c change
NCT02096705,measures_secondary,Fasting Plasma Glucose
NCT02096705,measures_secondary,Body Weight
NCT02096705,measures_secondary,Total Daily Dose of Insulin
NCT02096705,has_criteria,HbA1c ≥ 7.5% and ≤ 11.0%
NCT02096705,has_criteria,stable mean dose of ≥ 20 IU injectable insulin daily
NCT02096705,has_criteria,HbA1c ≥ 7.5 and ≤ 10.5%
NCT02096705,has_criteria,Treatment with more than two oral antidiabetic agents within 6 weeks of Enrollment
NCT02096705,has_criteria,History of diabetic ketoacidosis of hyperosmolar nonketotic coma
NCT02096705,has_criteria,Clinically diagnosed Type 1 diabetes mellitus
NCT02096705,has_criteria,Congestive heart failure defined as NYHA stage III and IV
NCT02096705,has_criteria,Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg
NCT02096705,has_criteria,History of unstable or rapidly progressing renal disease
NCT02096705,has_criteria,History of severe hepatobiliary disease
NCT02096705,has_criteria,Mallingancy within 5 years of the screening/enrollment visit
NCT05819398,involves,Hidradenitis Suppurativa
NCT05819398,evaluates,Spesolimab
NCT05819398,measures_primary,dT count change
NCT05819398,measures_secondary,IHS4 value change
NCT05819398,measures_secondary,TEAEs occurrence
NCT05819398,has_criteria,Moderate to severe HS
NCT05819398,has_criteria,Lesions in 2+ areas
NCT05819398,has_criteria,Biologic naive or TNFi-exposed
NCT05819398,has_criteria,Inadequate response to antibiotics
NCT05819398,has_criteria,AN count ≥5
NCT05819398,has_criteria,dT count ≥1
NCT01903005,involves,Opioid Dependence
NCT01903005,evaluates,OX219
NCT01903005,measures_primary,COWS score
NCT01903005,measures_secondary,SOWS score
NCT01903005,has_criteria,bioavailability BNX
NCT01617005,involves,Rheumatoid Arthritis
NCT01617005,evaluates,Tocilizumab
NCT01617005,measures_primary,EULAR response
NCT01617005,measures_secondary,Treatment discontinuation
NCT01617005,has_criteria,Moderate to severe active RA
NCT01462305,involves,Seasonal Affective Disorder
NCT01462305,evaluates,Light Exposure
NCT01462305,measures_primary,SIGH-ADS Score
NCT01462305,measures_secondary,Q-LES-Q-SF
NCT01462305,has_criteria,SIGH-ADS score 20 or greater
NCT03984305,involves,Parkinson's Disease
NCT03984305,evaluates,PKG
NCT03984305,measures_primary,MDS-UPDRS score
NCT03984305,measures_secondary,PDQ-39
NCT03984305,has_criteria,Baseline to 4 month
NCT04740905,involves,Macular Edema
NCT04740905,evaluates,Faricimab
NCT04740905,measures_primary,BCVA at Week 24
NCT04740905,measures_secondary,BCVA at specified timepoints
NCT04740905,has_criteria,baseline BCVA (≥55 and ≤54 letters)
NCT04102111,involves,Crohn's Disease
NCT04102111,measures_primary,Change From Baseline in CDAI Score
NCT04102111,measures_secondary,Change From Baseline in SES-CD
NCT04102111,has_criteria,incomplete data missing
NCT01923311,involves,HIV-1
NCT01923311,evaluates,Elvitegravir
NCT01923311,measures_primary,AUCtau of EVG
NCT01923311,measures_primary,Cmax of EVG
NCT01923311,measures_primary,Ctau of EVG
NCT01923311,measures_primary,CL/F of EVG
NCT01923311,measures_primary,Vz/F of EVG
NCT01923311,measures_secondary,Treatment-emergent Adverse Events
NCT01923311,measures_secondary,Laboratory Abnormalities
NCT01923311,has_criteria,HIV-1 RNA > 1000 copies/mL
NCT01923311,has_criteria,HIV-1 RNA < 50 copies/mL
NCT01923311,has_criteria,age 6 to < 18 Years
NCT01923311,has_criteria,age 6 to < 12 Years
NCT03826628,involves,Tuberous Sclerosis Complex
NCT03826628,evaluates,Topical Rapamycin Cream
NCT03826628,measures_primary,Time to Treatment Success
NCT03826628,measures_secondary,Change From Baseline in IGA
NCT03826628,measures_secondary,Change From Baseline in FASI
NCT03826628,has_criteria,Facial Angiofibroma severity
NCT06331728,involves,Adverse Events
NCT06331728,evaluates,IGNX001
NCT06331728,measures_primary,Incidence of TEAE
NCT06331728,measures_secondary,Serious Adverse Events
NCT06331728,has_criteria,Clinically significant changes
NCT04596293,involves,Ulcerative Colitis
NCT04596293,evaluates,BBT-401-1S
NCT04596293,measures_primary,Clinical Response
NCT04596293,measures_primary,Clinical Remission
NCT04596293,measures_primary,Endoscopic Remission
NCT04596293,measures_secondary,Change from baseline
NCT04596293,has_criteria,Day 57
NCT00714493,involves,Rheumatoid Arthritis
NCT00714493,measures_primary,EULAR response at Week 10
NCT00714493,measures_secondary,Change from baseline in physical function (HAQ)
NCT00714493,has_criteria,DAS28 score
NCT04978493,involves,Crohn's Disease
NCT04978493,evaluates,BI 706321
NCT04978493,evaluates,Ustekinumab
NCT04978493,measures_primary,SES-CD reduction
NCT04978493,measures_secondary,Endoscopic response
NCT04978493,measures_secondary,Endoscopic remission
NCT04978493,measures_secondary,Biological remission
NCT04978493,measures_secondary,Clinical remission
NCT04978493,has_criteria,induction baseline SES-CD
NCT00501293,involves,Attention Deficit Hyperactivity Disorder
NCT00501293,evaluates,Methylphenidate Transdermal System
NCT00501293,measures_primary,ADHD-RS-IV Scores
NCT00501293,measures_secondary,Conner's Parent Rating Scale
NCT00501293,measures_secondary,Clinical Global Impression-Improvement
NCT00501293,has_criteria,Adolescents Aged 13-17
NCT01000493,involves,Adult Post Traumatic Stress Disorder
NCT01000493,evaluates,Orvepitant
NCT01000493,measures_primary,Change From Baseline
NCT01000493,measures_secondary,Percentage of Participants Responding
NCT01000493,has_criteria,Baseline (Day 1 pre-dose)
NCT04706793,involves,Ulcerative Colitis
NCT04706793,evaluates,Oral Etrasimod
NCT04706793,measures_primary,Clinical Remission
NCT04706793,measures_secondary,Endoscopic Improvement
NCT04706793,measures_secondary,Symptomatic Remission
NCT04706793,measures_secondary,Mucosal Healing
NCT04706793,has_criteria,Japanese Participants
NCT02565511,involves,Alzheimer's Disease
NCT02565511,evaluates,CAD106
NCT02565511,evaluates,CNP520
NCT02565511,measures_primary,Time to Event
NCT02565511,measures_secondary,Change in APCC Test Score
NCT02565511,measures_secondary,Change in CDR-SOB Score
NCT02565511,has_criteria,Risk for Onset of Clinical Symptoms
NCT05342428,involves,Plaque Psoriasis
NCT05342428,evaluates,TLL018
NCT05342428,measures_primary,PASI score decrease
NCT05342428,measures_secondary,PASI 50 PASI 75 PASI 90 PASI 100
NCT05342428,has_criteria,Baseline to Week 4
NCT03054428,involves,Atopic Dermatitis
NCT03054428,evaluates,Dupilumab
NCT03054428,measures_primary,IGA 0 or 1
NCT03054428,measures_secondary,EASI-75
NCT03054428,has_criteria,≥12 to <18 years
NCT02553928,involves,Alzheimer's disease
NCT02553928,evaluates,Memantine
NCT02553928,measures_primary,ADCS - CGIC Score
NCT02553928,measures_secondary,Adverse Events
NCT02553928,has_criteria,Mini Mental State Examination score
NCT01795911,involves,Hepatitis C virus
NCT01795911,evaluates,Pegylated Interferon Lambda
NCT01795911,measures_primary,SVR12
NCT01795911,measures_secondary,eRVR
NCT01795911,measures_secondary,cytopenic abnormalities
NCT01795911,measures_secondary,interferon-associated flu-like symptoms
NCT01795911,measures_secondary,interferon-associated musculoskeletal symptoms
NCT01795911,measures_secondary,SVR24
NCT01795911,measures_secondary,deaths
NCT01795911,measures_secondary,Serious adverse events
NCT01795911,measures_secondary,drug related Adverse events
NCT01795911,has_criteria,non-cirrhotic HCV GT-1b subjects
NCT01435928,involves,Schizophrenia
NCT01435928,evaluates,PEARL
NCT01435928,measures_primary,Time to First Relapse Event
NCT01435928,measures_secondary,Time to All-cause Discontinuation
NCT01435928,measures_secondary,Change From Double-blind Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
NCT01435928,measures_secondary,Change From Double-blind Baseline in Clinical Global Impression - Severity of Illness Scale (CGI-S) Score
NCT01435928,measures_secondary,Change From Double-blind Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT05732428,involves,ER+/HER2- Advanced Breast Cancer
NCT05732428,evaluates,Vepdegestrant
NCT05732428,measures_primary,Objective Response Rate
NCT05732428,measures_secondary,Clinical Benefit
NCT05732428,has_criteria,RECIST v1.1
NCT00689728,involves,Rheumatoid Arthritis
NCT00689728,evaluates,Methotrexate
NCT00689728,measures_primary,ACR50 Response
NCT00689728,measures_secondary,SF-36
NCT00689728,has_criteria,Inadequate Response
NCT00691028,involves,Rheumatoid Arthritis
NCT00691028,evaluates,TA-650(Infliximab)
NCT00691028,measures_primary,ACR-N response
NCT00691028,measures_secondary,ACR20
NCT00691028,has_criteria,Tender Joint Counts
NCT04134728,involves,Rheumatoid Arthritis
NCT04134728,evaluates,GSK3196165
NCT04134728,evaluates,Placebo
NCT04134728,evaluates,Sarilumab
NCT04134728,measures_primary,HAQ-DI Change
NCT04134728,measures_secondary,ACR20
NCT04134728,has_criteria,Inadequate response
NCT01270828,involves,Postherpetic Neuralgia
NCT01270828,evaluates,Pregabalin
NCT01270828,measures_primary,30% pain reduction
NCT01270828,measures_secondary,5 day rolling average
NCT01270828,measures_secondary,50% pain reduction
NCT01270828,has_criteria,loss of therapeutic response
NCT01188928,involves,Psoriasis Vulgaris
NCT01188928,evaluates,LEO 80185
NCT01188928,measures_primary,Controlled disease
NCT01188928,measures_secondary,Mean Percentage Change in PASI
NCT01188928,has_criteria,moderate or mild disease
NCT05199961,involves,Diffuse Large B-cell Lymphoma
NCT05199961,evaluates,Tisagenlecleucel
NCT05199961,measures_primary,Quality of Life
NCT05199961,measures_secondary,Self-efficacy
NCT05199961,has_criteria,Enrollment
NCT06353828,involves,Ulcerative Colitis
NCT06353828,evaluates,IcBD-01 Enema
NCT06353828,measures_primary,Change from baseline
NCT06353828,measures_secondary,Partial Mayo Score
NCT06353828,measures_secondary,PRO-UC Diary
NCT06353828,measures_secondary,Endoscopic Mayo subscore
NCT06353828,measures_secondary,Length of inflamed colon
NCT06353828,has_criteria,Age ≥18 years
NCT06353828,has_criteria,Diagnosis of UC
NCT06353828,has_criteria,Not treated rectally
NCT06353828,has_criteria,Active disease
NCT06353828,has_criteria,Stable doses of biologics
NCT06353828,has_criteria,Stable doses of steroids
NCT06353828,has_criteria,Stable dose of oral mesalazine
NCT06353828,has_criteria,Full Mayo score ≥4 to < 9
NCT06353828,has_criteria,Did not respond to Mesalamine treatment
NCT06353828,has_criteria,Non-pregnant women
NCT06353828,has_criteria,No intention to become pregnant
NCT06353828,has_criteria,Male subject with female partner(s)
NCT06353828,has_criteria,Use contraception
NCT01787461,involves,Sun Exposure
NCT01787461,evaluates,Oral Dietary Supplement
NCT01787461,measures_primary,Change From Baseline
NCT01787461,measures_secondary,Photographic Assessment
NCT01787461,has_criteria,Healthy Adult Women
NCT04973228,involves,Seborrheic Dermatitis
NCT04973228,evaluates,Roflumilast
NCT04973228,measures_primary,IGA success at Week 8
NCT04973228,measures_secondary,WI-NRS success at Week 8
NCT04973228,has_criteria,weekly average baseline pruritus score
NCT00723528,involves,Plaque Psoriasis
NCT00723528,evaluates,Ustekinumab
NCT00723528,measures_primary,PASI score improvement
NCT00723528,measures_secondary,DLQI score
NCT00723528,has_criteria,Baseline visit Week 0
NCT06581328,involves,Ulcerative Colitis
NCT06581328,involves,Crohn's Disease
NCT06581328,evaluates,Vedolizumab
NCT06581328,measures_primary,PRO-2 Remission
NCT06581328,measures_secondary,Clinical Response
NCT06581328,measures_secondary,Endoscopic Response
NCT06581328,has_criteria,2-item PRO-2
NCT06151561,involves,Glabellar Lines
NCT06151561,evaluates,AGN-151586
NCT06151561,measures_primary,Facial Wrinkle Scale
NCT06151561,measures_secondary,Facial Wrinkle Scale
NCT06151561,has_criteria,good health
NCT06151561,has_criteria,moderate GL
NCT06151561,has_criteria,severe GL
NCT06468228,involves,Hidradenitis Suppurativa
NCT06468228,evaluates,Lutikizumab
NCT06468228,measures_primary,HiSCR 75
NCT06468228,measures_secondary,Numeric Rating Scale 30
NCT06468228,measures_secondary,Dermatology Life Quality Index
NCT06468228,measures_secondary,Hidradenitis Suppurativa Impact Assessment
NCT06468228,measures_secondary,Hidradenitis Suppurativa Symptom Assessment
NCT06468228,has_criteria,Adult and Adolescent
NCT02696798,involves,Radiographic Axial Spondyloarthritis
NCT02696798,evaluates,Ixekizumab
NCT02696798,measures_primary,ASAS40 Response
NCT02696798,measures_secondary,ASAS20 Response
NCT02696798,has_criteria,TNF Inhibitor Experienced
NCT00844545,involves,aHUS
NCT00844545,evaluates,eculizumab
NCT00844545,measures_primary,platelet count change
NCT00844545,measures_secondary,Hematologic Normalization
NCT00844545,measures_secondary,Complete TMA Response
NCT00844545,measures_secondary,TMA Intervention Rate
NCT00844545,has_criteria,plasma therapy-resistant
NCT00859898,involves,Type 2 Diabetes
NCT00859898,evaluates,Dapagliflozin
NCT00859898,evaluates,Metformin XR
NCT00859898,measures_primary,HbA1c at Week 24
NCT00859898,measures_secondary,Fasting Plasma Glucose at Week 24
NCT01677598,involves,Plaque Psoriasis
NCT01677598,evaluates,Ustekinumab
NCT01677598,measures_primary,Change from baseline PASI
NCT01677598,measures_secondary,Change from baseline NAPSI
NCT01677598,measures_secondary,Change from baseline EQ-5D
NCT01677598,has_criteria,label-recommended interval
NCT03480698,involves,Stroke
NCT03480698,evaluates,Cerebrolysin
NCT03480698,measures_primary,mRS at 3 months
NCT03480698,measures_secondary,NIHSS at 21 days
NCT03480698,measures_secondary,NIHSS at 3 months
NCT03480698,measures_secondary,Proportion of patients with excellent recovery
NCT03480698,measures_secondary,Proportion of patients with functional independence
NCT03480698,has_criteria,3 months after stroke onset
NCT03480698,has_criteria,21 days after stroke onset
NCT01148498,involves,Alzheimer's Disease
NCT01148498,involves,dementia
NCT01148498,evaluates,solanezumab
NCT01148498,measures_primary,change in plasma levels
NCT01148498,measures_secondary,change in plasma levels
NCT01148498,has_criteria,age 45-90 years
NCT01148498,has_criteria,female of childbearing potential
NCT01148498,has_criteria,not breastfeeding
NCT01148498,has_criteria,negative pregnancy test
NCT01148498,has_criteria,birth control
NCT01148498,has_criteria,CDR rating of 0.5 or 1
NCT01148498,has_criteria,florbetapir PET imaging
NCT01482845,involves,Alzheimer's Disease
NCT01482845,evaluates,ABT-126
NCT01482845,measures_primary,Safety and tolerability
NCT01482845,measures_secondary,Pharmacokinetic evaluation
NCT01482845,has_criteria,Age 55-90 years
NCT01482845,has_criteria,NINCDS/ADRDA criteria
NCT01482845,has_criteria,MMSE 16-26
NCT01482845,has_criteria,MHIS ≤ 4
NCT01482845,has_criteria,Stable donepezil or rivastigmine
NCT01482845,has_criteria,Computerized tomography or MRI
NCT01482845,has_criteria,No alternative etiology for dementia
NCT02097745,involves,Rheumatoid Arthritis
NCT02097745,evaluates,Rituximab
NCT02097745,measures_primary,ACR20 Response
NCT02097745,measures_secondary,DAS28
NCT02097745,has_criteria,Inadequate response
NCT01204398,involves,Hypertension
NCT01204398,evaluates,Telmisartan+Amlodipine Fixed Dose Combination
NCT01204398,measures_primary,Change From Baseline in ABPM
NCT01204398,measures_secondary,Change From Baseline to End of Study in DBP and SBP
NCT01204398,has_criteria,Aged at least 18 years
NCT00603798,involves,Actinic Keratoses
NCT00603798,evaluates,Imiquimod Creams
NCT00603798,measures_primary,Complete clearance
NCT00603798,measures_secondary,Percent Change
NCT00603798,has_criteria,Good general health
NCT00603798,has_criteria,5 to 20 AKs
NCT00603798,has_criteria,Negative pregnancy test
NCT00603798,has_criteria,Frequent visits
NCT00603798,has_criteria,Not pregnant
NCT03771898,involves,Metachromatic Leukodystrophy
NCT03771898,evaluates,Intrathecal SHP611
NCT03771898,measures_primary,Loss of locomotion
NCT03771898,measures_secondary,Gross Motor Function
NCT03771898,has_criteria,Baseline up to Week 106
NCT02107898,involves,Heterozygous Familial Hypercholesterolemia
NCT02107898,involves,Hypercholesterolemia
NCT02107898,evaluates,Alirocumab
NCT02107898,measures_primary,Percent Change LDL-C
NCT02107898,measures_secondary,Apolipoprotein B
NCT02107898,has_criteria,Lipid Modifying Therapy
NCT01795898,involves,Osteoarthritis
NCT01795898,involves,Chronic Low Back Pain
NCT01795898,evaluates,Fentanyl Transdermal Patch
NCT01795898,measures_primary,Change From Baseline
NCT01795898,measures_secondary,Number of Participants Requiring Rescue Medication
NCT01795898,measures_secondary,Number of Participants With Clinical Global Impression-Improvement Score
NCT01795898,has_criteria,Filipino Participants
NCT00720798,involves,Multiple Myeloma
NCT00720798,evaluates,Tocilizumab
NCT00720798,measures_primary,Percentage of Adverse Events
NCT00720798,measures_secondary,Percentage Withdrew From Treatment
NCT00720798,measures_secondary,Percentage With Concomitant Therapy
NCT00720798,has_criteria,50% improvement tender joint count
NCT00720798,has_criteria,50% improvement swollen joint count
NCT00720798,has_criteria,20%
NCT00720798,has_criteria,tender joint counts
NCT00720798,has_criteria,swollen joint counts
NCT02478398,involves,Ragweed-Induced Rhinoconjunctivitis
NCT02478398,involves,Asthma
NCT02478398,evaluates,RAGWITEK™
NCT02478398,measures_primary,Total Combined Score
NCT02478398,measures_secondary,Total Combined Score
NCT02478398,has_criteria,ragweed pollen counts
NCT00863798,involves,Major Depressive Disorder
NCT00863798,evaluates,Desvenlafaxine Succinate Sustained Release
NCT00863798,measures_primary,HAM-D17 Total Score
NCT00863798,measures_secondary,CGI-Improvement
NCT00863798,measures_secondary,CGI-S
NCT00863798,measures_secondary,MADRS Total Score
NCT00863798,measures_secondary,HAM-D6 Total Score
NCT00863798,has_criteria,Adults
NCT03520998,involves,Alzheimer's Disease
NCT03520998,evaluates,GRF6019
NCT03520998,measures_primary,Changes in MMSE
NCT03520998,measures_secondary,Changes in ADASCog/11
NCT03520998,measures_secondary,Changes in CDR-SOB
NCT03520998,measures_secondary,Changes in ADCS-ADL23
NCT03520998,measures_secondary,Changes in ADCS-CGIC
NCT03520998,has_criteria,Mild to Moderate
NCT01254305,involves,Major Depressive Disorder
NCT01254305,evaluates,Levomilnacipran ER
NCT01254305,measures_primary,Change in CGI-S
NCT01254305,measures_secondary,Change in PGI-S
NCT01254305,measures_secondary,Change in CPFQ
NCT01254305,has_criteria,18-65 years old
NCT05175105,involves,Pyruvate Kinase Deficiency
NCT05175105,evaluates,Mitapivat
NCT05175105,measures_primary,Hemoglobin Response
NCT05175105,measures_secondary,Change in Hb Concentration
NCT05175105,measures_secondary,Change From Baseline in Estradiol Concentration
NCT05175105,measures_secondary,Change From Baseline in Estrone Concentration
NCT05175105,measures_secondary,Change From Baseline in Total Testosterone Concentration
NCT05175105,measures_secondary,Change From Baseline in Free Testosterone Concentration
NCT05175105,measures_secondary,Change From Baseline in Luteinizing Hormone Concentration
NCT05175105,measures_secondary,Change From Baseline in Sexual Maturity Rating
NCT05175105,measures_secondary,Number of Female Participants With Development of Ovarian Cysts
NCT05175105,measures_secondary,Change From Baseline in the Size of Ovarian Cysts
NCT05175105,measures_secondary,Change From Baseline in Height-for-age Z-score
NCT05175105,measures_secondary,Change From Baseline in Weight-for-age Z-score
NCT05175105,has_criteria,Not Regularly Transfused
NCT01588405,involves,Pulmonary Hypertension
NCT01588405,evaluates,Oral Treprostinil
NCT01588405,measures_primary,Six-minute Walk Distance
NCT01588405,measures_secondary,Borg Dyspnea Score
NCT01588405,measures_secondary,Quality of Life
NCT01588405,has_criteria,Transition to oral
NCT06008405,evaluates,TQB2928 Injection Combination Therapy
NCT06008405,measures_primary,Incidence of Adverse Events
NCT06008405,measures_secondary,Severity of serious adverse events
NCT06008405,measures_secondary,Incidence of serious adverse events
NCT06008405,measures_secondary,Area under the curve (AUC)
NCT06008405,measures_secondary,Peak concentration (Cmax)
NCT06008405,measures_secondary,Peak Time (Tmax)
NCT06008405,measures_secondary,Incidence of anti-drug antibody (ADA)
NCT06008405,has_criteria,AML: Objective Response Rate (ORR)
NCT04506905,involves,Schizophrenia
NCT04506905,evaluates,MK-8189
NCT04506905,measures_primary,Number of AEs
NCT04506905,measures_secondary,Discontinuing treatment
NCT04506905,has_criteria,Up to approximately 27 days
NCT00787605,involves,Systolic Hypertension
NCT00787605,involves,Diabetes Mellitus
NCT00787605,evaluates,Aliskiren HCTZ
NCT00787605,evaluates,Amlodipine
NCT00787605,measures_primary,Change in msSBP
NCT00787605,measures_secondary,Change in msDBP
NCT00787605,measures_secondary,Percentage of Responders
NCT00787605,measures_secondary,Percentage of Patients Achieving Blood Pressure Control
NCT00787605,measures_secondary,Biomarker Measurements
NCT00787605,measures_secondary,Percentage of patients with Adverse Event
NCT00787605,has_criteria,≥ 18 years old
NCT00787605,has_criteria,stage 2 hypertension
NCT00787605,has_criteria,Type 2 diabetes mellitus
NCT00787605,has_criteria,stable anti-diabetic regimen
NCT00787605,has_criteria,stable diet and exercise
NCT00787605,has_criteria,written informed consent
NCT00787605,has_criteria,office cuff msSBP ≥ 160 mmHg
NCT00787605,has_criteria,office cuff msSBP \< 200 mmHg
NCT00787605,has_criteria,msDBP ≥ 110 mmHg
NCT00757705,involves,Schizophrenia
NCT00757705,evaluates,Paliperidone Extended-Release
NCT00757705,measures_primary,PANSS Total Score
NCT00757705,measures_secondary,PANSS Marder Subscale Scores
NCT00757705,measures_secondary,Percentage Improvement PANSS
NCT00757705,has_criteria,Baseline
NCT02970305,involves,Schizophrenia
NCT02970305,evaluates,Pimavanserin
NCT02970305,measures_primary,Change From Baseline to Week 26 in the Negative Symptom Assessment-16 (NSA-16) Total Score
NCT02970305,measures_secondary,Change From Baseline to Week 26 in the Personal and Social Performance Scale (PSP) Score
NCT02970305,measures_secondary,Proportion of Negative Symptom Assessment-16 (NSA-16) Responders at Week 26
NCT02970305,has_criteria,From baseline to Week 26
NCT06642961,involves,Asthma
NCT06642961,evaluates,GR1802 Injection
NCT06642961,measures_primary,Change from baseline FEV1
NCT06642961,measures_secondary,Percent change FEV1
NCT06642961,measures_secondary,Annualized asthma exacerbations
NCT06642961,measures_secondary,Time to first exacerbation
NCT06642961,measures_secondary,Annualized rate LOAC
NCT06642961,measures_secondary,Time to first LOAC
NCT06642961,measures_secondary,Change in lung function measures
NCT06642961,measures_secondary,Asthma Control Questionnaire score
NCT06642961,has_criteria,Moderate to Severe Asthma
NCT02291861,involves,Tardive Dyskinesia
NCT02291861,evaluates,[TRUNCATED]
NCT02291861,measures_primary,Change in AIMS score
NCT02291861,measures_secondary,Percentage of Treatment Success
NCT02291861,has_criteria,[TRUNCATED]
NCT02182661,involves,Bronchial Asthma
NCT02182661,evaluates,Ba253BINEB
NCT02182661,measures_primary,Change from baseline in symptom score
NCT02182661,measures_secondary,Change from baseline in treatment score
NCT02182661,measures_secondary,Change from baseline in asthma score
NCT02182661,measures_secondary,Change from baseline in daily life score
NCT02182661,measures_secondary,Change from baseline in nocturnal sleep score
NCT02182661,measures_secondary,Change from baseline in Peak expiratory flow rate
NCT02182661,measures_secondary,Physician's global evaluation
NCT02182661,measures_secondary,Patient's impression
NCT02182661,measures_secondary,Change from baseline in FEV1
NCT02182661,measures_secondary,Change from baseline in FVC
NCT04338061,involves,Multiple Sclerosis
NCT04338061,evaluates,Evobrutinib
NCT04338061,measures_primary,Annualized Relapse Rate
NCT04338061,measures_secondary,Disability Progression
NCT04338061,measures_secondary,Patient Reported Outcomes
NCT04338061,has_criteria,qualified relapses
NCT01606761,involves,Rheumatoid Arthritis
NCT01606761,evaluates,CNTO 136
NCT01606761,measures_primary,ACR 20 Response
NCT01606761,measures_secondary,Health Assessment Questionnaire Disability Index Score
NCT01606761,has_criteria,Anti-TNF-Alpha Therapy
NCT04019561,involves,NAFLD/NASH
NCT04019561,involves,Obesity
NCT04019561,evaluates,MEDI0382
NCT04019561,evaluates,Placebo
NCT04019561,measures_primary,Hepatic Fat Fraction
NCT04019561,measures_primary,Liver Volume
NCT04019561,measures_primary,Liver Fat Volume
NCT04019561,measures_secondary,TEAE
NCT04019561,measures_secondary,SAE
NCT04019561,measures_secondary,ADA Titer
NCT04019561,has_criteria,Obese Subjects
NCT02345161,involves,Chronic Obstructive Pulmonary Disease
NCT02345161,evaluates,Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate
NCT02345161,evaluates,Budesonide/Formoterol
NCT02345161,measures_primary,Change From Baseline in FEV1
NCT02345161,measures_secondary,Change From Baseline in FEV1
NCT02345161,has_criteria,randomized subjects
NCT04640961,involves,Osteoarthritis of Shoulder Joint
NCT04640961,evaluates,Cingal®
NCT04640961,measures_primary,NRS Pain Score
NCT04640961,measures_secondary,DASH score
NCT04640961,measures_secondary,Patient Global Assessment (PGA) Score
NCT04640961,measures_secondary,OMERACT-OARSI Responder Index
NCT04640961,has_criteria,6 Months
NCT02914561,involves,Crohn's Disease
NCT02914561,evaluates,Filgotinib
NCT02914561,measures_primary,Clinical Remission
NCT02914561,measures_secondary,Endoscopic Response
NCT02914561,has_criteria,CDAI score
NCT01514461,involves,Familial Chylomicronemia Syndrome
NCT01514461,evaluates,LCQ908
NCT01514461,measures_primary,Percent Change Triglycerides
NCT01514461,measures_secondary,Percentage Patients Responding
NCT01514461,has_criteria,fasting triglyceride values
NCT01712061,involves,Type 2 Diabetes
NCT01712061,involves,Overt Nephropathy
NCT01712061,evaluates,Chemokine CCR2/5 Receptor Antagonist
NCT01712061,measures_primary,Percent Reduction UACR
NCT01712061,measures_secondary,Change From Baseline UACR
NCT01712061,measures_secondary,Change From Baseline UPCR
NCT01712061,measures_secondary,Change From Baseline eGFR
NCT01712061,measures_secondary,Change From Baseline eGFR Cystatin
NCT01712061,measures_secondary,Change From Baseline Serum Creatinine
NCT01712061,has_criteria,Baseline and Week 12
NCT01712061,has_criteria,Baseline
NCT01712061,has_criteria,Baseline
NCT01712061,has_criteria,Baseline
NCT01712061,has_criteria,Baseline
NCT01712061,has_criteria,Baseline
NCT00418561,involves,Late Infantile Metachromatic Leukodystrophy
NCT00418561,evaluates,Metazym
NCT00418561,measures_primary,Change From Baseline in GMFM
NCT00418561,measures_secondary,Change From Baseline in CSF Sulfatide
NCT00418561,measures_secondary,Number of Participants With Shift From Baseline to Week 26 in Sulfatide Levels in Urine
NCT00418561,has_criteria,Baseline up to Week 26
NCT05157061,involves,Irritable Bowel Syndrome
NCT05157061,evaluates,GOS
NCT05157061,measures_primary,IBS symptom severity
NCT05157061,measures_secondary,Abdominal pain
NCT05157061,measures_secondary,Bloating
NCT05157061,measures_secondary,Global IBS improvement
NCT05157061,measures_secondary,Stool consistency
NCT05157061,measures_secondary,Defecation frequency
NCT05157061,has_criteria,Baseline to end of study
NCT06236061,involves,Hypertension
NCT06236061,evaluates,LCZ696/Amlodipine
NCT06236061,measures_primary,Change in msSBP
NCT06236061,measures_primary,Change in maSBP
NCT06236061,measures_primary,Proportion of patients achieving blood pressure control
NCT06236061,measures_secondary,Change in msDBP
NCT06236061,measures_secondary,Change in maDBP
NCT06236061,measures_secondary,Proportion of patients achieving msSBP response
NCT06236061,measures_secondary,Proportion of patients achieving msDBP response
NCT06236061,measures_secondary,Change in daytime
NCT06236061,measures_secondary,Change in daytime
NCT06236061,has_criteria,Uncontrolled by LCZ696
NCT02059161,involves,Type 1 Diabetes Mellitus
NCT02059161,evaluates,MK-1293
NCT02059161,evaluates,Lantus
NCT02059161,measures_primary,Change From Baseline in A1C
NCT02059161,measures_primary,Change From Baseline in A1C
NCT02059161,measures_secondary,Percentage of Participants With Any Confirmed Positive Anti-insulin Antibody
NCT02059161,measures_secondary,Percentage of Participants With Negative AIA at Baseline Who Develop Confirmed Positive AIA
NCT02059161,measures_secondary,Change From Baseline in AIA Titer
NCT02059161,measures_secondary,Percentage of Participants Who Develop Insulin Neutralizing Antibodies
NCT02059161,has_criteria,Total insulin dose
NCT02317861,involves,Gout
NCT02317861,involves,Asymptomatic Hyperuricemia
NCT02317861,evaluates,RDEA3170
NCT02317861,evaluates,Febuxostat
NCT02317861,measures_primary,Change in Serum uric acid
NCT02317861,measures_secondary,Urinary excretion of uric acid
NCT02317861,measures_secondary,Renal clearance of uric acid
NCT02317861,measures_secondary,Fractional excretion of uric acid
NCT02317861,measures_secondary,Maximum plasma concentration
NCT02317861,measures_secondary,Time to reach maximum concentration
NCT02317861,measures_secondary,Area under the concentration-time curve
NCT02317861,measures_secondary,Half life
NCT02317861,measures_secondary,Incidence of adverse events
NCT02317861,has_criteria,Day 1 and Day 7
NCT02317861,has_criteria,Day 1 and Day 8
NCT02401061,involves,ITP
NCT02401061,evaluates,PRTX-100
NCT02401061,measures_primary,Platelet response
NCT02401061,measures_secondary,Complete platelet response
NCT02401061,measures_secondary,Time to platelet response
NCT02401061,measures_secondary,Durability of platelet response
NCT02401061,has_criteria,platelet count ≥ 30
NCT02401061,has_criteria,baseline platelet count \< 30
NCT02401061,has_criteria,platelet count ≥ 50
NCT02401061,has_criteria,platelet count \> 100
NCT02401061,has_criteria,platelet count ≥ 100
NCT03980483,involves,Rheumatoid Arthritis
NCT03980483,evaluates,GSK3196165
NCT03980483,evaluates,Placebo
NCT03980483,evaluates,Tofacitinib
NCT03980483,measures_primary,ACR20 at Week 12
NCT03980483,measures_secondary,CDAI <=10 at Week 12
NCT03980483,has_criteria,Inadequate response to Methotrexate
NCT00798161,involves,Type 2 Diabetes
NCT00798161,evaluates,Linagliptin
NCT00798161,evaluates,Metformin
NCT00798161,measures_primary,HbA1c Change
NCT00798161,measures_secondary,FPG Change
NCT00798161,has_criteria,baseline HbA1c
NCT04091061,evaluates,PF-06865571
NCT04091061,involves,Hepatic Impairment
NCT04091061,measures_primary,Number of TEAEs
NCT04091061,measures_secondary,Clinical Laboratory Abnormalities
NCT04091061,has_criteria,treatment-emergent
NCT01540461,involves,Hepatocellular Carcinoma
NCT01540461,evaluates,Brivanib
NCT01540461,measures_primary,objective response rate
NCT01540461,measures_secondary,disease control rate
NCT01540461,has_criteria,Chinese subjects
NCT03082261,involves,chronic pain
NCT03082261,evaluates,Multiple Waveform Enabled Neurostimulator
NCT03082261,measures_primary,Mean Change in Pain
NCT03082261,measures_secondary,Quality of Life
NCT03082261,measures_secondary,Pain Catastrophizing
NCT03082261,has_criteria,Baseline to 6 Months
NCT03730961,involves,Heart Failure
NCT03730961,involves,Reduced Heart Function
NCT03730961,evaluates,BMS-986231
NCT03730961,measures_primary,Urinary output
NCT03730961,measures_secondary,FeNa
NCT03730961,measures_secondary,FeK
NCT03730961,has_criteria,HFrEF
NCT00434161,involves,Multiple Myeloma
NCT00434161,evaluates,Palifermin
NCT00434161,measures_primary,Oral Mucositis severity
NCT00434161,measures_secondary,Cataract Development
NCT00434161,has_criteria,WHO Grades 0/1
NCT02805361,involves,Type II Diabetes Mellitus
NCT02805361,evaluates,Dapagliflozin
NCT02805361,measures_primary,HbAlc change from baseline
NCT02805361,measures_secondary,Total body weight
NCT02805361,measures_secondary,Total cholesterol
NCT02805361,measures_secondary,Systolic Blood Pressures
NCT02805361,measures_secondary,LDL-C
NCT02805361,measures_secondary,non-HDL-C
NCT02805361,measures_secondary,triglycerides
NCT02805361,measures_secondary,Diastolic Blood Pressures
NCT02805361,has_criteria,Fasting blood glucose ≥ 126mg/dL
NCT02805361,has_criteria,2-hour glucose level ≥ 200 mg/dL
NCT02805361,has_criteria,HbA1c ≥ 6.5%
NCT02805361,has_criteria,Dapagliflozin treatment ≥ 4 weeks
NCT02805361,has_criteria,Dapagliflozin treatment ≤ 16 weeks
NCT02805361,has_criteria,CrCl > 60 ml/min
NCT02805361,has_criteria,eGFR > 60 ml/min/1.73 m2
NCT03563183,involves,Frailty
NCT03563183,evaluates,ZOSTER-006
NCT03563183,evaluates,ZOSTER-022
NCT03563183,measures_primary,Frailty Index
NCT03563183,measures_secondary,Short Form 36
NCT03563183,measures_secondary,EuroQol 5D
NCT03563183,has_criteria,FI score
NCT00661661,involves,Rheumatoid Arthritis
NCT00661661,evaluates,CP-690
NCT00661661,measures_primary,ACR20 response
NCT00661661,measures_secondary,ACR50 response
NCT00661661,has_criteria,Baseline up to Week 288
NCT04969861,involves,Head and Neck Squamous Cell Carcinoma
NCT04969861,evaluates,bempegaldesleukin
NCT04969861,evaluates,pembrolizumab
NCT04969861,measures_primary,Progression-Free Survival
NCT04969861,measures_secondary,Overall Survival
NCT04969861,measures_secondary,Time to Deterioration
NCT04969861,measures_secondary,Change in Global Health Status/Quality of Life
NCT04969861,has_criteria,≥ 10-point decrease
NCT04971161,involves,CVU
NCT04971161,evaluates,Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells
NCT04971161,measures_primary,Wound size change
NCT04971161,measures_secondary,Time to complete wound closure
NCT04971161,has_criteria,Day 1-2
NCT02022761,involves,Chronic Asthma
NCT02022761,evaluates,Laninamivir octanoate
NCT02022761,measures_primary,Safety and tolerability
NCT02022761,measures_secondary,Pharmacokinetics
NCT02022761,has_criteria,BMI 19.0 to 33.0 kg/m2
NCT01370005,involves,Hypertensive Patients With Type 2 Diabetes Mellitus
NCT01370005,evaluates,Empagliflozin (BI 10773)
NCT01370005,measures_primary,HbA1c Change From Baseline
NCT01370005,measures_secondary,Mean 24-hour Systolic Blood Pressure Change From Baseline
NCT01370005,measures_secondary,Mean 24-hour Diastolic Blood Pressure Change From Baseline
NCT01370005,measures_secondary,Proportion of Patients With HbA1c <7%
NCT01370005,measures_secondary,Fasting Plasma Glucose (FPG) Change From Baseline
NCT01370005,measures_secondary,Body Weight Change From Baseline
NCT01370005,measures_secondary,Daytime Mean Systolic Blood Pressure (SBP) Change From Baseline
NCT01370005,measures_secondary,Daytime Mean Diastolic Blood Pressure (DBP) Change From Baseline
NCT01370005,measures_secondary,Nighttime Mean Systolic Blood Pressure (SBP) Change From Baseline
NCT01370005,measures_secondary,Nighttime Mean Diastolic Blood Pressure (DBP) Change From Baseline
NCT01370005,measures_secondary,Trough Mean Seated Systolic Blood Pressure (SBP) Change From Baseline
NCT01370005,measures_secondary,Trough Mean Seated Diastolic Blood Pressure (DBP) Change From Baseline
NCT01370005,measures_secondary,Proportion of Patients Reaching Blood Pressure <130/80 mmHg
NCT03403205,involves,Wilson Disease
NCT03403205,evaluates,ALXN1840
NCT03403205,measures_primary,Change from Baseline in UWDRS Part II Total Score at Week 48
NCT03403205,measures_secondary,Number of Participants With Treatment-emergent Adverse Events
NCT03403205,has_criteria,Baseline to Week 48
NCT06415305,involves,Acne
NCT06415305,evaluates,Clascoterone Cream 1%
NCT06415305,measures_primary,Clear or almost clear
NCT06415305,measures_secondary,Lesion change
NCT06415305,measures_secondary,Inflammatory lesion reduction
NCT06415305,measures_secondary,Non-inflammatory lesion reduction
NCT06415305,measures_secondary,Erythema
NCT06415305,measures_secondary,Dryness
NCT06415305,measures_secondary,Peeling
NCT06415305,measures_secondary,Skin oiliness
NCT06415305,measures_secondary,Pruritus
NCT06415305,measures_secondary,Burning/stinging
NCT06415305,has_criteria,Outpatient subjects
NCT06415305,has_criteria,Fitzpatrick skin types
NCT06415305,has_criteria,12 years or older
NCT01715805,involves,Major Depressive Disorder
NCT01715805,evaluates,Cariprazine
NCT01715805,measures_primary,Change From Baseline MADRS
NCT01715805,measures_secondary,Change From Baseline SDS
NCT01715805,has_criteria,Antidepressant Therapy
NCT02079805,involves,Essential Hypertension
NCT02079805,involves,Type 2 Diabetes Mellitus
NCT02079805,evaluates,Azilsartan
NCT02079805,evaluates,Telmisartan
NCT02079805,measures_primary,Change in HOMA-R
NCT02079805,measures_secondary,Change in Fasting Blood Glucose
NCT02079805,measures_secondary,Change in Fasting Insulin
NCT02079805,measures_secondary,Change in HbA1c
NCT02079805,measures_secondary,Change in HOMA-β
NCT02079805,measures_secondary,Change in 1
NCT02079805,has_criteria,Baseline and Week 12
NCT00239005,involves,Gastrointestinal Symptoms
NCT00239005,evaluates,Enteric-Coated Mycophenolate Sodium
NCT00239005,measures_primary,Dose maintenance at week 13
NCT00239005,measures_secondary,Gastrointestinal Symptom Rating Scale
NCT00239005,measures_secondary,Gastrointestinal Quality of Life Index
NCT00239005,has_criteria,Kidney transplant recipient
NCT00239005,has_criteria,MMF immunosuppression
NCT00239005,has_criteria,GI side effects on MMF
NCT00239005,has_criteria,At least 18 years old
NCT00239005,has_criteria,Informed consent
NCT04035005,involves,Primary Progressive Multiple Sclerosis
NCT04035005,evaluates,Ocrelizumab
NCT04035005,measures_primary,Time to Upper Limb Disability Progression
NCT04035005,measures_secondary,EDSS Score
NCT04035005,has_criteria,EDSS score 3.0 to 8.0
NCT06233461,involves,Crohn's Disease
NCT06233461,evaluates,TAK-279
NCT06233461,measures_primary,Endoscopic Response
NCT06233461,measures_secondary,Clinical Remission
NCT06233461,measures_secondary,Clinical Response
NCT06233461,measures_secondary,Endoscopic Remission
NCT06233461,measures_secondary,Clinical Remission
NCT06233461,measures_secondary,Clinical Response
NCT06233461,has_criteria,Moderately to Severely Active
NCT02229461,evaluates,Naproxen Sodium/ASA
NCT02229461,measures_primary,Inhibition (%)
NCT02229461,measures_secondary,Platelet aggregation
NCT01101061,involves,Postmenopausal Women
NCT01101061,evaluates,Romosozumab
NCT01101061,measures_primary,P1NP levels
NCT01101061,measures_secondary,CTX levels
NCT01101061,has_criteria,Japanese and Non-Japanese
NCT05407961,involves,Type 2 Diabetes Mellitus
NCT05407961,evaluates,LY3532226
NCT05407961,measures_primary,Change from Baseline in cDI
NCT05407961,measures_secondary,Insulin Secretion Rate
NCT05407961,measures_secondary,β-cell Glucose Sensitivity
NCT05407961,measures_secondary,Hyperinsulinemic Euglycemic Clamp M-value
NCT05407961,measures_secondary,Fasting and Post meal Glucose
NCT05407961,measures_secondary,Glycosylated Haemoglobin
NCT05407961,measures_secondary,Glucagon Concentration
NCT05407961,has_criteria,type 2 diabetes mellitus
NCT06226883,involves,Crohn's Disease
NCT06226883,evaluates,MORF-057
NCT06226883,measures_primary,Endoscopic response
NCT06226883,measures_secondary,Clinical response
NCT06226883,measures_secondary,Clinical remission
NCT06226883,has_criteria,Signs/symptoms of CD
NCT06226883,has_criteria,CDAI score 220 to 450
NCT06226883,has_criteria,Average daily stool subscore ≥4
NCT06226883,has_criteria,Average daily abdominal pain subscore ≥2
NCT06226883,has_criteria,SES-CD score ≥6
NCT06226883,has_criteria,Inadequate response to corticosteroids
NCT06226883,has_criteria,Inadequate response to Immunosuppressants
NCT06226883,has_criteria,Inadequate response to advanced therapies
NCT01029405,involves,plaque type psoriasis
NCT01029405,evaluates,Ointment
NCT01029405,measures_primary,OTPSS reduction
NCT01029405,measures_secondary,OTPSS reduction
NCT01029405,has_criteria,age >18 years
NCT00704405,involves,Hepatitis C Virus
NCT00704405,evaluates,Vaniprevir
NCT00704405,measures_primary,SVR24
NCT00704405,measures_secondary,Adverse Event
NCT00704405,measures_secondary,Discontinuing
NCT00704405,has_criteria,non-cirrhotic
NCT02649205,involves,Chronic kidney disease
NCT02649205,evaluates,Ketosteril
NCT02649205,measures_primary,Patient compliance
NCT02649205,measures_secondary,CKD stage
NCT02649205,has_criteria,protein restricted diet
NCT01084005,involves,Type 2 Diabetes
NCT01084005,evaluates,Linagliptin
NCT01084005,measures_primary,HbA1c Change
NCT01084005,measures_secondary,FPG Change
NCT01084005,has_criteria,Elderly Patients
NCT04154605,involves,Rhinitis
NCT04154605,evaluates,ClariFix
NCT04154605,measures_primary,rTNSS Responder Rate
NCT04154605,measures_secondary,Mean change rTNSS
NCT04154605,measures_secondary,Change in Total RQLQ(S)
NCT04154605,measures_secondary,Patient Satisfaction Questionnaire
NCT04154605,has_criteria,30% reduction rTNSS
NCT00730405,involves,Distal Subungual Onychomycosis
NCT00730405,evaluates,Oral Albaconazole
NCT00730405,measures_primary,Effective Treatment
NCT00730405,measures_primary,Clinical Cure
NCT00730405,measures_primary,Mycological Cure
NCT00730405,measures_primary,Complete Cure
NCT00730405,has_criteria,Week 52
NCT00735787,involves,Psoriasis
NCT00735787,evaluates,Humira
NCT00735787,measures_primary,PGA of Clear
NCT00735787,measures_secondary,ESIF
NCT00735787,has_criteria,Physician's Global Assessment
NCT02573077,involves,Hyponatremia
NCT02573077,evaluates,Observation
NCT02573077,measures_primary,Change in serum [Na+]
NCT02573077,measures_secondary,EQ-5D
NCT02573077,measures_secondary,EORTC QLQ-C30
NCT02573077,measures_secondary,ECOG PS
NCT02573077,measures_secondary,MMSE
NCT02573077,has_criteria,Moderate to Severe
NCT04136977,involves,Eustachian tube dysfunction
NCT04136977,evaluates,balloon dilation
NCT04136977,measures_primary,ETDQ-7 score change
NCT04136977,measures_secondary,complication rate
NCT04136977,measures_secondary,revision dilation
NCT04136977,measures_secondary,surgical interventions
NCT04136977,measures_secondary,participant satisfaction
NCT04136977,measures_secondary,work productivity
NCT00400777,involves,Hypertension
NCT00400777,evaluates,Valsartan
NCT00400777,measures_primary,Diastolic BP control
NCT00400777,measures_primary,Systolic BP control
NCT00400777,measures_secondary,Diastolic responders
NCT00400777,measures_secondary,Mean change in Diastolic BP
NCT00400777,measures_secondary,Mean change in Systolic BP
NCT00400777,has_criteria,Systolic BP ≥140 mmHg
NCT00400777,has_criteria,Diastolic BP ≥90 mmHg
NCT00400777,has_criteria,Systolic BP ≥130 mmHg
NCT00400777,has_criteria,Diastolic BP ≥85 mmHg
NCT00400777,has_criteria,Systolic BP ≥130 mmHg
NCT00400777,has_criteria,Diastolic BP ≥80 mmHg
NCT00400777,has_criteria,Systolic BP ≥160 mmHg
NCT00400777,has_criteria,Diastolic BP ≥100 mmHg
NCT00449553,involves,Type 2 Diabetes
NCT00449553,evaluates,Pioglitazone
NCT00449553,measures_primary,Change in HbA1C
NCT00449553,measures_secondary,Body Weight
NCT00449553,measures_secondary,Clinical Laboratory Tests
NCT00449553,measures_secondary,beta-cell function
NCT00449553,measures_secondary,insulin resistance
NCT00449553,measures_secondary,fasting lipoproteins
NCT00449553,has_criteria,Treatment with pioglitazone
NCT00449553,has_criteria,Oral antidiabetic medications
NCT04634253,involves,Rheumatoid Arthritis
NCT04634253,evaluates,LY3462817
NCT04634253,measures_primary,DAS28-hsCRP
NCT04634253,measures_secondary,ACR20
NCT04634253,measures_secondary,ACR70
NCT04634253,has_criteria,previous RA therapy
NCT05491447,involves,Atopic Dermatitis
NCT05491447,evaluates,BMX-010
NCT05491447,measures_primary,Change from Baseline
NCT05491447,measures_secondary,Eczema Area and Severity Index-50
NCT05491447,measures_secondary,Eczema Area and Severity Index-75
NCT05491447,measures_secondary,Body Surface Area
NCT05491447,has_criteria,active AD
NCT01664247,involves,Type 2 Diabetes
NCT01664247,evaluates,Insulin Degludec
NCT01664247,measures_primary,Change From Baseline in HbA1c (%)
NCT01664247,measures_secondary,Change from baseline in FPG
NCT01664247,measures_secondary,Number of Responders for HbA1c
NCT01664247,measures_secondary,Change From Baseline in Mean Pre-breakfast Measurements
NCT01664247,measures_secondary,Change From Baseline in 8-point Profile
NCT01664247,measures_secondary,Change From Baseline in Mean of the 8-point Profile
NCT01664247,measures_secondary,Number of Hypoglycaemic Episodes
NCT01664247,has_criteria,Qualifying for Treatment Intensification
NCT05621447,involves,Healthy adult male subjects
NCT05621447,evaluates,TAS-303
NCT05621447,measures_primary,Radioactivity excretion
NCT05621447,measures_secondary,Adverse events
NCT05621447,has_criteria,Aged 18-40 years
NCT05621447,has_criteria,Body weight ≥50 kg
NCT05621447,has_criteria,BMI 18.5-25.0
NCT05621447,has_criteria,Systolic blood pressure 90-139 mmHg
NCT05621447,has_criteria,Diastolic blood pressure 40-89 mmHg
NCT04551053,involves,Myelofibrosis
NCT04551053,evaluates,Parsaclisib
NCT04551053,evaluates,Ruxolitinib
NCT04551053,measures_primary,Spleen Volume Reduction
NCT04551053,measures_secondary,Total Symptom Score
NCT04551053,has_criteria,Suboptimal Response
NCT00621153,involves,Stage II essential hypertension
NCT00621153,evaluates,Candesartan
NCT00621153,measures_primary,Mean DBP change
NCT00621153,measures_secondary,Mean SBP change
NCT00621153,has_criteria,Untreated hypertension
NCT00621153,has_criteria,Serum creatinine ≤3 mg/dL
NCT00621153,has_criteria,Serum potassium ≤5.5 mmol/L
NCT04350177,involves,Parkinson's Disease
NCT04350177,evaluates,IkT-148009
NCT04350177,measures_primary,AUC of IkT-148009
NCT04350177,measures_secondary,Cmax
NCT04350177,has_criteria,Healthy Elderly Participants
NCT03675477,involves,Ulcerative Colitis
NCT03675477,measures_primary,Clinical Response
NCT03675477,measures_secondary,Clinical Remission
NCT03675477,has_criteria,9-point modified Mayo score
NCT03436953,involves,Parkinson's Disease
NCT03436953,evaluates,CX-8998
NCT03436953,measures_primary,MDS-UPDRS Tremor Score
NCT03436953,measures_secondary,TETRAS Activity of Daily Living
NCT03436953,measures_secondary,accelerometry score
NCT03436953,measures_secondary,Incidence of Treatment-Emergent Adverse Events
NCT03436953,has_criteria,Baseline through completion of study treatment period
NCT01193153,involves,Schizoaffective Disorder
NCT01193153,evaluates,Paliperidone Palmitate
NCT01193153,measures_primary,Relapse Percentage
NCT01193153,measures_secondary,PSP Total Score
NCT01193153,has_criteria,Double blind relapse prevention
NCT03373253,involves,Treatment Resistant Depression
NCT03373253,measures_primary,Depression severity
NCT03373253,measures_secondary,Clinical Global Impression
NCT03373253,has_criteria,socio-demographic characteristics
NCT04090047,evaluates,Itraconazole
NCT04090047,measures_primary,AUClast of PF-06700841
NCT04090047,measures_secondary,Cmax of PF-06700841
NCT04090047,measures_secondary,Incidence of TEAE
NCT04090047,measures_secondary,Incidence of SAE
NCT04090047,measures_secondary,AEs leading to Discontinuation
NCT04090047,measures_secondary,Clinically significant abnormalities in vital signs
NCT04090047,measures_secondary,Clinically significant abnormalities in ECG
NCT04090047,measures_secondary,Clinically significant abnormalities in clinical laboratory values
NCT04090047,has_criteria,For male and women of non-childbearing potential (WONCBP)
NCT04090047,has_criteria,For women of childbearing potential (WOCBP)
NCT02125877,involves,Iron Overload
NCT02125877,evaluates,Deferasirox
NCT02125877,measures_primary,Adverse Events
NCT02125877,measures_secondary,Laboratory Values
NCT02125877,has_criteria,Baseline values
NCT04914377,involves,COVID-19
NCT04914377,evaluates,TQ Formula
NCT04914377,measures_primary,Time to Sustained Clinical Response
NCT04914377,measures_secondary,Viral Load
NCT04914377,measures_secondary,Viral Clearance
NCT04914377,measures_secondary,Covid Symptoms
NCT04914377,has_criteria,Randomization
NCT01128153,involves,type 2 diabetes
NCT01128153,evaluates,Saxagliptin Triple Oral Therapy
NCT01128153,measures_primary,Change in HbA1c
NCT01128153,measures_secondary,Change in 2-hour Postprandial Glucose
NCT01128153,measures_secondary,Change in Fasting Plasma Glucose
NCT01128153,has_criteria,HbA1c ≥ 7% and ≤ 10%
NCT01128153,has_criteria,BMI ≤ 40 kg/m2
NCT01581177,involves,bronchodilator effect
NCT01581177,evaluates,Albuterol DPI
NCT01581177,measures_primary,FEV1 AUC change
NCT01581177,measures_secondary,FEV1 volume change
NCT01581177,measures_secondary,Tonset
NCT01581177,measures_secondary,Fmax
NCT01581177,measures_secondary,tmax
NCT01581177,measures_secondary,Duration of effect
NCT01581177,measures_secondary,R percent
NCT01581177,has_criteria,greater than or equal to 12 percent
NCT00606177,involves,Bipolar Disorder
NCT00606177,evaluates,Aripiprazole
NCT00606177,measures_primary,YMRS total scores
NCT00606177,measures_secondary,CGI-BP severity of illness
NCT00606177,has_criteria,age 18 or above and below 65
NCT03180853,involves,Multiple Myeloma
NCT03180853,measures_primary,Overall Response Rate
NCT03180853,measures_secondary,Time to Next Treatment
NCT03180853,measures_secondary,Overall Survival
NCT03180853,measures_secondary,Survival Time
NCT03180853,measures_secondary,European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 Score
NCT03180853,has_criteria,International Myeloma Working Group 2016 criteria
NCT02584777,involves,Myelofibrosis
NCT02584777,evaluates,Pacritinib
NCT02584777,measures_primary,spleen volume reduction
NCT02584777,measures_secondary,total symptom score
NCT02584777,has_criteria,platelet count <100
NCT06510777,involves,Venous Leg Ulcers
NCT06510777,evaluates,PICO
NCT06510777,measures_primary,Confirmed healed VLUs
NCT06510777,measures_secondary,Relative Wound Area Reduction
NCT06510777,measures_secondary,Time to achieve 100% healthy granulation tissue
NCT06510777,measures_secondary,Changes in quality of life
NCT06510777,has_criteria,complete closure
NCT05076877,evaluates,Lazertinib
NCT05076877,measures_primary,Plasma Concentration
NCT05076877,measures_secondary,Adverse Events
NCT05076877,measures_secondary,Laboratory Test Results
NCT05076877,measures_secondary,Electrocardiograms
NCT05076877,measures_secondary,Vital Signs
NCT05076877,has_criteria,Up to 56 days
NCT00402077,involves,Obesity
NCT00402077,involves,Overweight
NCT00402077,evaluates,Pramlintide
NCT00402077,measures_primary,Absolute change in body weight
NCT00402077,measures_secondary,Percent change in body weight
NCT00402077,measures_secondary,Weight loss from baseline
NCT00402077,measures_secondary,Anthropometric measurements
NCT00402077,measures_secondary,Fasting serum lipids
NCT00402077,measures_secondary,Patient reported outcome questionnaires
NCT00402077,has_criteria,BMI >=30 kg/m^2
NCT00402077,has_criteria,BMI >=27 kg/m^2
NCT00402077,has_criteria,Other risk factors
NCT00402077,has_criteria,Stable treatment regimen
NCT01345253,involves,Systemic Lupus Erythematosus
NCT01345253,evaluates,Belimumab
NCT01345253,measures_primary,SLE Responder Index
NCT01345253,measures_secondary,SELENA SLEDAI score
NCT01345253,has_criteria,Baseline value
NCT03810677,involves,Varicose Veins
NCT03810677,evaluates,ELVeS® Radial® 2ring Slim Fiber
NCT03810677,measures_primary,Anatomic success
NCT03810677,measures_primary,Clinical success
NCT03810677,measures_secondary,Pain scoring
NCT03810677,measures_secondary,Post-operative adverse events
NCT03810677,has_criteria,index-procedure
NCT03810677,has_criteria,Venous Clinical Severity Score
NCT01561053,involves,Alzheimer's Disease
NCT01561053,evaluates,Albumin
NCT01561053,measures_primary,ADAS-Cog total score
NCT01561053,measures_secondary,ADCS-ADL total score
NCT01561053,has_criteria,Baseline and 14 Months
NCT01052077,involves,Major Depressive Disorder
NCT01052077,evaluates,OPC-34712
NCT01052077,measures_primary,MADRS Total Score
NCT01052077,measures_secondary,Sheehan Disability Scale (SDS) Score
NCT01052077,has_criteria,Baseline (end of week 8) to Week 14
NCT05933577,involves,High-Risk Melanoma
NCT05933577,evaluates,V940
NCT05933577,evaluates,Pembrolizumab
NCT05933577,measures_primary,Recurrence-Free Survival
NCT05933577,measures_secondary,Distant Metastasis-Free Survival
NCT05933577,measures_secondary,Overall-Survival
NCT05933577,measures_secondary,Number of Participants Who Experience an Adverse Event
NCT05933577,measures_secondary,Number of Participants Who Discontinue Study Treatment Due to an AE
NCT05933577,measures_secondary,Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score
NCT05933577,has_criteria,Up to approximately 74 months
NCT05933577,has_criteria,Up to approximately 85 months
NCT05933577,has_criteria,Up to approximately 68 weeks
NCT05933577,has_criteria,Up to approximately 56 weeks
NCT00550953,involves,Hypertension
NCT00550953,evaluates,Telmisartan
NCT00550953,measures_primary,Seated Diastolic BP
NCT00550953,measures_secondary,Seated Systolic BP
NCT00550953,measures_secondary,Seated Trough Diastolic BP
NCT00550953,measures_secondary,Seated Trough Systolic BP
NCT00550953,measures_secondary,Adequate Response Diastolic BP
NCT00550953,measures_secondary,Adequate Response Systolic BP
NCT00550953,measures_secondary,Optimal Blood Pressure
NCT00550953,has_criteria,Seated trough blood pressure
NCT04770753,involves,Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
NCT04770753,evaluates,Mitapivat
NCT04770753,measures_primary,Hb response
NCT04770753,measures_secondary,FACIT-Fatigue Score
NCT04770753,has_criteria,Hb 1.5+ response
NCT02058147,involves,Type 2 Diabetes Mellitus
NCT02058147,evaluates,Insulin Glargine/Lixisenatide
NCT02058147,measures_primary,Change in HbA1c
NCT02058147,measures_secondary,Plasma glucose excursion
NCT02058147,measures_secondary,Body weight
NCT02058147,measures_secondary,Fasting Plasma Glucose
NCT02058147,measures_secondary,Self-monitored Plasma Glucose
NCT02058147,has_criteria,Baseline
NCT02221947,involves,Alzheimer's Disease
NCT02221947,evaluates,Bryostatin 1
NCT02221947,measures_primary,HVLT-R delayed recall
NCT02221947,measures_secondary,RBANS figure recall
NCT02221947,measures_secondary,Digit Symbol Coding
NCT02221947,measures_secondary,CDR-SB
NCT02221947,has_criteria,48 hours post infusion
NCT04640077,involves,Alzheimer's Disease
NCT04640077,evaluates,Donanemab
NCT04640077,measures_primary,ADAS-Cog13
NCT04640077,measures_secondary,ADCS-ADL
NCT04640077,measures_secondary,ADCS-iADL
NCT04640077,measures_secondary,MMSE Score
NCT04640077,has_criteria,PAIR 1
NCT01392677,involves,Type 2 diabetes mellitus
NCT01392677,evaluates,Dapagliflozin
NCT01392677,measures_primary,HbA1c Levels
NCT01392677,measures_secondary,Fasting plasma glucose
NCT01392677,measures_secondary,Total body weight
NCT01392677,measures_secondary,Seated Systolic Blood Pressure
NCT01392677,has_criteria,Stable dose combination
NCT01392677,has_criteria,HbA1c ≥7.7%
NCT01392677,has_criteria,HbA1c ≤11.0%
NCT02296853,involves,Hepatic Impairment
NCT02296853,evaluates,Tenofovir Alafenamide
NCT02296853,measures_primary,AUCinf of TAF
NCT02296853,measures_primary,Cmax of TAF
NCT02296853,measures_primary,AUClast of TAF
NCT02296853,measures_secondary,Percentage of Participants Experiencing Treatment-Emergent Adverse Events
NCT02296853,measures_secondary,Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities
NCT02296853,has_criteria,Screening laboratory parameters
NCT02296853,has_criteria,Creatinine clearance ≥ 60 mL/min
NCT03199053,involves,Type 2 Diabetes Mellitus
NCT03199053,evaluates,Dapagliflozin
NCT03199053,evaluates,Saxagliptin
NCT03199053,measures_primary,HbA1c at Week 26
NCT03199053,measures_secondary,HbA1c at Week 26
NCT03199053,has_criteria,Aged 10 to Below 18
NCT03342053,involves,Huntington's Disease
NCT03342053,evaluates,RO7234292
NCT03342053,measures_primary,CSF mHTT Protein
NCT03342053,measures_secondary,Ventricular Volume
NCT03342053,measures_secondary,Caudate Volume
NCT03342053,measures_secondary,Whole Brain Volume
NCT03342053,measures_secondary,EEG Parameters
NCT03342053,measures_secondary,Huntington's Disease Cognitive Assessment Battery
NCT03434353,involves,Chronic Hepatitis B
NCT03434353,evaluates,Inarigivir Soproxil
NCT03434353,evaluates,Tenofovir Alafenamide
NCT03434353,measures_primary,HBsAg decline
NCT03434353,measures_secondary,HBeAg loss
NCT03434353,measures_secondary,HBeAg seroconversion
NCT03434353,has_criteria,Baseline
NCT03359577,involves,Psoriasis
NCT03359577,evaluates,Psorax35
NCT03359577,measures_primary,Change in PASI
NCT03359577,measures_secondary,PASI<3
NCT03359577,has_criteria,Baseline to 32 weeks
NCT01042977,involves,Type 2 Diabetes Mellitus
NCT01042977,involves,Cardiovascular Disease
NCT01042977,evaluates,dapagliflozin 10 mg
NCT01042977,measures_primary,HbA1c change from baseline
NCT01042977,measures_secondary,Proportion of Responders
NCT01042977,measures_secondary,Percent Change in Body Weight
NCT01042977,measures_secondary,Reduction From Baseline in Body Weight
NCT01042977,measures_secondary,Change in Systolic Blood Pressure
NCT01042977,has_criteria,BMI baseline ≥27 kg/m²
NCT03395353,involves,Depressive Disorder
NCT03395353,evaluates,Duloxetine
NCT03395353,measures_primary,Change From Baseline
NCT03395353,measures_secondary,CGI-S
NCT03395353,has_criteria,Japanese Children Adolescents
NCT02787551,involves,Type 2 Diabetes
NCT02787551,evaluates,Insulin Glargine/Lixisenatide Fixed Ratio Combination
NCT02787551,measures_primary,Change in HbA1c
NCT02787551,measures_secondary,Fasting Plasma Glucose
NCT02787551,measures_secondary,Self-monitored Plasma Glucose
NCT02787551,has_criteria,available HbA1c assessment
NCT04573153,involves,Covid-19
NCT04573153,evaluates,hydroxychloroquine
NCT04573153,measures_primary,hospitalization rate
NCT04573153,measures_secondary,Adverse Event
NCT04573153,measures_secondary,Serious Adverse Event
NCT04573153,has_criteria,14 days
NCT02106351,involves,Upper Limb Spasticity
NCT02106351,evaluates,Dysport
NCT02106351,measures_primary,MAS Score
NCT02106351,measures_secondary,Physician's Global Assessment
NCT02106351,measures_secondary,Goal Attainment Scale
NCT02106351,has_criteria,Children
NCT04343651,involves,COVID-19
NCT04343651,evaluates,Leronlimab
NCT04343651,measures_primary,Time to Clinical Resolution
NCT04343651,measures_secondary,Incidence of Hospitalization
NCT04343651,measures_secondary,Duration (Days) of Hospitalization
NCT04343651,measures_secondary,Incidence of Mechanical Ventilation
NCT04343651,measures_secondary,Duration of Mechanical Ventilation Supply
NCT04343651,measures_secondary,Incidence of Oxygen Use
NCT04343651,has_criteria,first exposure to treatment
NCT03598751,involves,Psoriatic Arthritis
NCT03598751,evaluates,BCD-085
NCT03598751,measures_primary,ACR 20
NCT03598751,measures_secondary,PsARC
NCT03598751,has_criteria,History psoriatic arthritis
NCT03928353,evaluates,PB2452
NCT03928353,measures_primary,Number of Participants
NCT03928353,measures_secondary,Diastolic Blood Pressure
NCT03928353,measures_secondary,Systolic Blood Pressure
NCT03928353,measures_secondary,Oral Body Temperature
NCT03928353,has_criteria,Healthy Younger
NCT03928353,has_criteria,Older
NCT03928353,has_criteria,Elderly
NCT02424253,involves,Atopic Dermatitis
NCT02424253,evaluates,ZPL-3893787
NCT02424253,measures_primary,Change From Baseline in Pruritus
NCT02424253,measures_secondary,Change From Baseline in EASI Score
NCT02424253,has_criteria,Eczema Area and Severity Index (EASI) of ≥12 and \<48
NCT02424253,has_criteria,Investigator's Global Assessment (IGA) score ≥ 3
NCT02424253,has_criteria,mean pruritus score of ≥ 5
NCT02424253,has_criteria,Males and females aged 18-65 years inclusive
NCT02424253,has_criteria,physician documented history or diagnosis of atopic dermatitis for at least 12 months prior to screening
NCT00950651,involves,Osteoarthritis of the Knee
NCT00950651,evaluates,Tramadol HCl / Contramid® Tablets
NCT00950651,evaluates,Tramadol HCl (SR)
NCT00950651,measures_primary,Percentage of Change
NCT00950651,measures_secondary,WOMAC Stiffness Subscale Score
NCT00950651,measures_secondary,WOMAC Physical Function Subscale Score
NCT00950651,measures_secondary,WOMAC Total Score
NCT00950651,has_criteria,Baseline to week 12
NCT02457351,evaluates,Roniciclib
NCT02457351,measures_primary,Adverse events
NCT02457351,measures_secondary,Complete blood count
NCT02457351,measures_secondary,Complete chemistry panel
NCT02457351,measures_secondary,Coagulation panel
NCT02457351,measures_secondary,Virology
NCT02457351,measures_secondary,Urinalysis
NCT02457351,measures_secondary,Pregnancy test
NCT02457351,measures_secondary,ECOG performance status
NCT02457351,measures_secondary,Electrocardiogram
NCT02457351,measures_secondary,Physical examination
NCT02457351,has_criteria,up to 15 months
NCT02177253,involves,Chronic Obstructive Pulmonary Disease
NCT02177253,evaluates,Ipratropium Bromide/Salbutamol
NCT02177253,evaluates,Ipratropium Bromide Respimat®
NCT02177253,evaluates,COMBIVENT® Inhalation Aerosol
NCT02177253,evaluates,Placebo
NCT02177253,measures_primary,FEV1 TAUC0-6
NCT02177253,measures_secondary,Peak FEV1
NCT02177253,measures_secondary,Change from baseline in Peak FEV1 response
NCT02177253,measures_secondary,Area under the FEV1 curve
NCT02177253,measures_secondary,Onset of therapeutic FEV1 response
NCT02177253,measures_secondary,Duration of therapeutic FEV1 response
NCT02177253,measures_secondary,Time to peak FEV1 response
NCT02177253,measures_secondary,TAUC0-8
NCT02177253,measures_secondary,peak FVC
NCT02177253,measures_secondary,Amount of beta agonist therapy
NCT02177253,measures_secondary,Number of patients using concomitant medication
NCT02177253,measures_secondary,Weekly means of daily symptom scores
NCT02177253,measures_secondary,Number of patients with at least one COPD exacerbation
NCT02177253,measures_secondary,Number of COPD exacerbations
NCT02177253,measures_secondary,Physician's Global Evaluation
NCT02177253,measures_secondary,Trough PEFR
NCT02177253,measures_secondary,Number of patients with adverse events
NCT02177253,measures_secondary,Incidence of paradoxical bronchoconstriction
NCT02177253,measures_secondary,Number of COPD exacerbation days
NCT02177253,measures_secondary,Number of patients with clinically significant changes in vital signs
NCT02177253,measures_secondary,Number of patients with abnormal changes in laboratory parameters
NCT02177253,measures_secondary,Number of patients with abnormal changes in 12-lead electrocardiogram (ECG) parameters
NCT02177253,has_criteria,adults
NCT05995353,involves,Crohn's Disease
NCT05995353,evaluates,Risankizumab
NCT05995353,measures_primary,PCDAI Clinical Remission
NCT05995353,measures_secondary,Endoscopic Response
NCT05995353,has_criteria,Pediatric Participants
NCT01354353,involves,Schizophrenia
NCT01354353,evaluates,LY2140023
NCT01354353,measures_primary,Maximum Concentration (Cmax)
NCT01354353,measures_secondary,Area Under the Concentration - Time Curve (AUC)
NCT01354353,has_criteria,Baseline up to Day 21
NCT03611751,involves,Plaque Psoriasis
NCT03611751,evaluates,BMS-986165
NCT03611751,measures_primary,sPGA 0/1
NCT03611751,measures_secondary,PASI 75
NCT03611751,has_criteria,Discontinue treatment
NCT04587453,involves,Atopic Dermatitis
NCT04587453,evaluates,Tralokinumab
NCT04587453,measures_primary,IGA Score at Week 16
NCT04587453,measures_primary,EASI75 at Week 16
NCT04587453,measures_secondary,Change in SCORAD Total Score
NCT04587453,measures_secondary,Change in DLQI Score
NCT04587453,has_criteria,Japanese Subjects
NCT05366751,involves,Essential Tremor
NCT05366751,evaluates,SAGE-324
NCT05366751,measures_primary,Percentage of Participants
NCT05366751,measures_secondary,Change from Baseline
NCT05366751,has_criteria,Baseline up to approximately 5 years
NCT03131453,involves,Alzheimer's Disease
NCT03131453,evaluates,CNP520
NCT03131453,measures_primary,Time to Event
NCT03131453,measures_secondary,Change in APCC Test Score
NCT03131453,measures_secondary,Change in CDR-SOB Score
NCT03131453,has_criteria,Risk for Onset of Clinical Symptoms
NCT05061953,involves,Multiple Sclerosis
NCT05061953,evaluates,Functional Eye-Tracking Software Application
NCT05061953,measures_primary,Change from Baseline
NCT05061953,measures_secondary,Change from Baseline
NCT05061953,has_criteria,Able to provide informed consent
NCT00546351,involves,Painful Distal Diabetic Neuropathy
NCT00546351,evaluates,Lacosamide
NCT00546351,measures_primary,Number of Participants
NCT00546351,measures_secondary,Average Daily Pain Score
NCT00546351,has_criteria,From entry Visit 1 through end of treatment
NCT02352753,involves,Osteogenesis Imperfecta
NCT02352753,evaluates,Denosumab
NCT02352753,measures_primary,Lumbar spine BMD Z-score
NCT02352753,measures_secondary,Proximal femur BMD Z-score
NCT02352753,measures_secondary,Vertebral Fracture
NCT02352753,has_criteria,Age
NCT05059353,involves,Mild Cognitive Impairment
NCT05059353,evaluates,Digitally Based Multidomain Intervention
NCT05059353,measures_primary,Processing speed
NCT05059353,measures_primary,Executive functioning
NCT05059353,measures_primary,Mood
NCT05059353,measures_primary,Overall cognition
NCT05059353,measures_primary,QoL
NCT05059353,has_criteria,Petersen's criteria
NCT05059353,has_criteria,NIA-AA criteria
NCT05059353,has_criteria,CDR score
NCT05059353,has_criteria,MMSE
NCT05059353,has_criteria,Education
NCT04148651,involves,Vulvar Lichen Sclerosus
NCT04148651,evaluates,CO2RE® System
NCT04148651,measures_primary,Average severity grade
NCT04148651,measures_secondary,Average severity grade
NCT04148651,has_criteria,baseline score >0
NCT00922987,involves,Epilepsy
NCT00922987,evaluates,Lyrica
NCT00922987,measures_primary,Partial Seizure Frequency
NCT00922987,measures_secondary,Visual Analog Scale of Anxiety Scores
NCT00922987,has_criteria,Baseline through week 16 or ET
NCT05877547,involves,Nonalcoholic Steatohepatitis (NASH)
NCT05877547,evaluates,Efinopegdutide
NCT05877547,measures_primary,NASH Resolution
NCT05877547,measures_secondary,Adverse Event
NCT05877547,measures_secondary,Discontinuing Medication
NCT05877547,has_criteria,Fibrosis Stage
NCT03828747,involves,Alzheimer's Disease
NCT03828747,evaluates,Semorinemab
NCT03828747,measures_primary,Cognitive Function
NCT03828747,measures_secondary,Functional Capacities
NCT03828747,measures_secondary,CDR-SB
NCT03828747,has_criteria,Baseline to Week 49
NCT02907177,involves,Multiple sclerosis
NCT02907177,evaluates,Ponesimod
NCT02907177,measures_primary,Annualized Confirmed Relapse Rate
NCT02907177,measures_secondary,12-Week Confirmed Disability Accumulation
NCT02907177,has_criteria,Baseline EDSS score
NCT06278077,involves,Short-Term Insomnia
NCT06278077,evaluates,investigational drug
NCT06278077,measures_primary,Change from baseline in Sleep Efficiency
NCT06278077,measures_secondary,Number of Awakenings
NCT06278077,measures_secondary,daytime performance
NCT06278077,has_criteria,Screening Visit
NCT00322153,involves,Alzheimer's Disease
NCT00322153,evaluates,Memantine
NCT00322153,measures_primary,Change From Baseline
NCT00322153,measures_secondary,CIBIC-Plus
NCT00322153,measures_secondary,ADCS-ADL19
NCT01204853,involves,Pulmonary Arterial Hypertension
NCT01204853,evaluates,Sitaxentan Sodium
NCT01204853,measures_primary,6-minute Walk Distance
NCT01204853,measures_secondary,WHO Functional Class
NCT01204853,measures_secondary,Haemodynamics Parameters
NCT01204853,measures_secondary,NT-pro BNP
NCT01204853,has_criteria,Clinical Worsening
NCT04667377,involves,Overweight
NCT04667377,involves,Obesity
NCT04667377,evaluates,BI 456906
NCT04667377,measures_primary,Weight Loss ≥5%
NCT04667377,measures_secondary,Weight Loss ≥10%
NCT04667377,has_criteria,Baseline Weight
NCT02045277,involves,plaque psoriasis
NCT02045277,evaluates,IDP 118
NCT02045277,measures_primary,IGA score improvement
NCT02045277,measures_secondary,IGA score
NCT02045277,has_criteria,at least 18 years of age
NCT02045277,has_criteria,BSA of at least 3%
NCT02045277,has_criteria,IGA score of 3 or 4
NCT01660477,evaluates,Lopinavir/Ritonavir
NCT01660477,evaluates,Isavuconazole
NCT01660477,measures_primary,Safety and tolerability
NCT01660477,measures_secondary,PK profile
NCT01660477,has_criteria,Body weight ≥ 45 kg
NCT01660477,has_criteria,BMI 18 to 32 kg/m2
NCT01660477,has_criteria,AST and ALT normal
NCT01660477,has_criteria,Bilirubin normal
NCT01660477,has_criteria,Lipase normal
NCT01660477,has_criteria,Amylase normal
NCT01660477,has_criteria,Glucose normal
NCT01660477,has_criteria,Triglycerides normal
NCT01646177,involves,Psoriasis
NCT01646177,evaluates,Ixekizumab
NCT01646177,measures_primary,sPGA (0
NCT01646177,measures_secondary,PASI 75
NCT01646177,measures_secondary,sPGA (0)
NCT01646177,measures_secondary,PASI 90
NCT01646177,has_criteria,Moderate to Severe
NCT01730053,evaluates,Alirocumab
NCT01730053,evaluates,Rosuvastatin
NCT01730053,measures_primary,Percent Change LDL-C
NCT01730053,measures_secondary,Apolipoprotein B
NCT01730053,has_criteria,on- or off-treatment
NCT01538251,involves,Ulcerative Colitis
NCT01538251,evaluates,Propionyl-L-Carnitine Hydrochloride
NCT01538251,measures_primary,Proportion of remissions
NCT01538251,measures_secondary,Rectal bleeding evaluation
NCT01538251,measures_secondary,stool frequency evaluation
NCT01538251,measures_secondary,Histological response
NCT01538251,measures_secondary,C-reactive protein
NCT01538251,measures_secondary,Fibrinogen
NCT01538251,measures_secondary,quality of life
NCT01538251,has_criteria,active ulcerative colitis
NCT01538251,has_criteria,Disease Activity Index 3-6
NCT01538251,has_criteria,rectal bleeding sub-score 1
NCT01369277,evaluates,PF-04991532
NCT01369277,measures_primary,Maximum Plasma Concentration
NCT01369277,measures_secondary,Time for Cmax
NCT01369277,has_criteria,Healthy male and female subjects
NCT01369277,has_criteria,18 to 55 years old
NCT01369277,has_criteria,BMI 17.5 to 30.5 kg/m2
NCT01369277,has_criteria,Body weight > 50 kg
NCT01369277,has_criteria,Japanese subjects with four Japanese grandparents
NCT01369277,has_criteria,Mean body weight within ±10% of Japanese subjects
NCT01369277,has_criteria,No clinically significant disease
NCT01369277,has_criteria,Screening supine blood pressure <140/90 mm Hg
NCT02159053,involves,Ankylosing Spondylitis
NCT02159053,evaluates,Secukinumab
NCT02159053,measures_primary,ASAS20 response
NCT02159053,measures_secondary,ASAS40 response
NCT02159053,has_criteria,16 weeks
NCT05063253,involves,Type 2 diabetes
NCT05063253,evaluates,TG103 Injection
NCT05063253,measures_primary,Glycosylated hemoglobin
NCT05063253,measures_secondary,Body weight
NCT05063253,measures_secondary,Body mass index
NCT05063253,measures_secondary,Waist circumference
NCT05063253,measures_secondary,Waist-hip ratio
NCT05063253,measures_secondary,Blood pressure
NCT05063253,measures_secondary,Blood lipid
NCT05063253,measures_secondary,Weight loss
NCT05063253,measures_secondary,Adverse events
NCT05063253,measures_secondary,Plasma drug concentration
NCT05063253,measures_secondary,Fasting blood glucose
NCT05063253,measures_secondary,Postprandial blood glucose
NCT05063253,measures_secondary,Anti-drug antibodies
NCT05063253,has_criteria,Type 2 diabetes diagnosis
NCT05063253,has_criteria,Age 18-75 years
NCT05063253,has_criteria,BMI ≥ 24.0 kg/m^2
NCT05063253,has_criteria,Stable body weight
NCT00136851,involves,Hypertension
NCT00136851,evaluates,Amlodipine Besylate/Benazepril
NCT00136851,evaluates,Amlodipine
NCT00136851,measures_primary,Blood pressure goal
NCT00136851,measures_secondary,Swelling in legs or arms
NCT00136851,measures_secondary,Systolic blood pressure
NCT00136851,measures_secondary,Diastolic blood pressure
NCT00136851,has_criteria,Diagnosis of severe hypertension
NCT00136851,has_criteria,Diastolic blood pressure < 60 mm Hg
NCT00136851,has_criteria,Serum potassium < 3.5 or > 5.5 mEq/L
NCT00136851,has_criteria,Refractory hypertension
NCT04850651,evaluates,Fluconazole
NCT04850651,measures_primary,Cmax of Pyrotinib
NCT04850651,measures_secondary,AUC0-t of Pyrotinib
NCT04850651,measures_secondary,AUC0-Inf of Pyrotinib
NCT04850651,measures_secondary,Tmax of Pyrotinib
NCT04850651,measures_secondary,t1/2 of Pyrotinib
NCT04850651,measures_secondary,Incidence of AEs
NCT04850651,has_criteria,Written informed consent
NCT04850651,has_criteria,Ability to complete study
NCT04850651,has_criteria,Healthy male or female
NCT04850651,has_criteria,Age 18 to 45
NCT04850651,has_criteria,Male weight ≥ 50 kg
NCT04850651,has_criteria,Female weight ≥ 45 kg
NCT04071847,involves,Parkinson's disease
NCT04071847,evaluates,Abbott DBS
NCT04071847,measures_primary,disease-specific motor rating scale
NCT04071847,measures_secondary,disease-specific motor rating scale
NCT04071847,has_criteria,Parkinson's disease
NCT01499251,involves,Recurrent Glioblastoma
NCT01499251,evaluates,Macitentan
NCT01499251,evaluates,Temozolomide
NCT01499251,measures_primary,Dose-Limiting Toxicity
NCT01499251,measures_secondary,Treatment-emergent AEs
NCT01499251,measures_secondary,Serious AEs
NCT01499251,measures_secondary,Premature discontinuation
NCT01499251,measures_secondary,Laboratory abnormalities
NCT01499251,measures_secondary,ECG abnormalities
NCT01499251,measures_secondary,Vital signs
NCT01499251,measures_secondary,ALT and AST elevation
NCT01499251,has_criteria,Baseline to 28 days
NCT00798577,involves,bacterial conjunctivitis
NCT00798577,evaluates,Antibiotic
NCT00798577,measures_primary,subjective visual change
NCT00798577,measures_secondary,clinical resolution
NCT00798577,has_criteria,symptoms less than or equal to 24 hours
NCT01828177,involves,Rosacea
NCT01828177,evaluates,PDI-320
NCT01828177,measures_primary,IGA Score Success Rate
NCT01828177,measures_secondary,inflammatory lesion count
NCT01828177,measures_secondary,erythema severity
NCT01828177,measures_secondary,telangiectasia severity
NCT01828177,has_criteria,moderate to severe papulopustular rosacea
NCT01828177,has_criteria,mild erythema
NCT01828177,has_criteria,mild telangiectasia
NCT01828177,has_criteria,willing to apply medication
NCT01828177,has_criteria,comply with study instructions
NCT04924153,involves,KCNT1-Related Epilepsy
NCT04924153,measures_primary,Number of Seizures
NCT04924153,measures_secondary,Head Circumference
NCT04924153,measures_secondary,CGI-S Scale Scores
NCT04924153,measures_secondary,CGI-C Scale Scores
NCT04924153,measures_secondary,Participant-Specific VAS
NCT04924153,has_criteria,Under 18 years of age
NCT05084053,involves,Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT05084053,involves,Multifocal Motor Neuropathy
NCT05084053,evaluates,TAK-771
NCT05084053,measures_primary,Change in Maximum Grip Strength
NCT05084053,measures_secondary,Number of Participants with TEAEs
NCT05084053,measures_secondary,Number of Participants with SAEs
NCT05084053,measures_secondary,Number of Participants with Serious and Nonserious Adverse Reactions
NCT05084053,measures_secondary,Number of Participants with SAEs Associated with Infusions
NCT05084053,measures_secondary,Number of Participants with TEAEs Associated with Infusions
NCT05084053,measures_secondary,Number of Participants with AEs Temporally Associated with Infusions
NCT05084053,has_criteria,baseline measurement point
NCT04638153,involves,Achondroplasia
NCT04638153,evaluates,Recifercept
NCT04638153,measures_primary,Height Growth at Month
NCT04638153,measures_secondary,Change From Baseline Pulse Rate
NCT04638153,measures_secondary,Change From Baseline Respiratory Rate
NCT04638153,has_criteria,28 to 35 days after last dose
NCT00842153,involves,Psoriasis
NCT00842153,evaluates,Clobetasol Propionate Foam
NCT00842153,evaluates,Vehicle Foam
NCT00842153,measures_primary,TLGI Score
NCT00842153,measures_secondary,Pruritus (Overall) Score
NCT00842153,has_criteria,Baseline condition
NCT01571453,involves,Major Depressive Disorder
NCT01571453,evaluates,Vortioxetine
NCT01571453,measures_primary,MADRS Total Score
NCT01571453,measures_secondary,CGI-S Score
NCT01571453,measures_secondary,CGI-I Score
NCT01571453,measures_secondary,HAM-A Total Score
NCT01571453,has_criteria,Asian Countries
NCT02035553,involves,Alzheimer's Disease Psychosis
NCT02035553,evaluates,Pimavanserin
NCT02035553,measures_primary,Change in NPI-NH psychosis score
NCT02035553,measures_secondary,
NCT02035553,has_criteria,
NCT00643851,involves,Type 2 Diabetes
NCT00643851,evaluates,BMS-512148
NCT00643851,measures_primary,Adjusted Mean Change HbA1c
NCT00643851,measures_secondary,Fasting Plasma Glucose
NCT00643851,measures_secondary,Percentage of Participants Achieving a Therapeutic Glycemic Response
NCT00643851,has_criteria,last assessment prior to first dose
NCT04991753,involves,Rheumatoid Arthritis
NCT04991753,evaluates,Nipocalimab
NCT04991753,measures_primary,Change from Baseline in DAS28-CRP
NCT04991753,measures_secondary,Percentage of Participants who Achieve ACR20 at Week 12
NCT04991753,measures_secondary,Percentage of Participants who Achieve ACR50 at Week 12
NCT04991753,has_criteria,Baseline to Week 12
NCT01939353,involves,Attention-Deficit Hyperactivity Disorder
NCT01939353,evaluates,EB-1020 Sustained Release
NCT01939353,measures_primary,Change From Baseline-2
NCT01939353,measures_secondary,Behavior Rating Inventory of Executive Function
NCT01939353,has_criteria,Adult Males
NCT01423253,involves,Major Depressive Disorder With Mixed Features
NCT01423253,measures_primary,MADRS Total Scores
NCT01423253,measures_secondary,CGI-S Score
NCT01423253,measures_secondary,YMRS Total Score
NCT01423253,measures_secondary,HAM-A Total Score
NCT06150014,involves,Chronic Hepatitis B
NCT06150014,evaluates,TQA3605 Tablets
NCT06150014,measures_primary,HBV DNA levels
NCT06150014,measures_secondary,HBsAg
NCT06150014,measures_secondary,HBeAg
NCT06150014,measures_secondary,Serologic clearance
NCT06150014,measures_secondary,Virological breakthrough rate
NCT06150014,has_criteria,treatment naive
NCT00751114,involves,Type 2 Diabetes
NCT00751114,evaluates,Insulin Glargine
NCT00751114,evaluates,Sitagliptin
NCT00751114,measures_primary,HbA1c Change
NCT00751114,measures_primary,HbA1c Response Rate
NCT00751114,measures_secondary,Self-monitored Fasting Plasma Glucose
NCT00751114,measures_secondary,7-point Plasma Glucose Profile
NCT00751114,measures_secondary,Insulin Dose
NCT00751114,measures_secondary,Lipid Profile
NCT01149655,involves,Schizophrenia
NCT01149655,evaluates,Oral Aripiprazole
NCT01149655,measures_primary,Overall relapse rate
NCT01149655,measures_secondary,Percentage of responders
NCT01149655,has_criteria,CGI-I score
NCT01617655,involves,Heterozygous Familial Hypercholesterolemia
NCT01617655,evaluates,Alirocumab
NCT01617655,measures_primary,Percent Change LDL-C
NCT01617655,measures_secondary,Apolipoprotein B
NCT06053255,involves,Low Back Pain
NCT06053255,involves,Sacroiliitis
NCT06053255,evaluates,Neurolyser XR
NCT06053255,measures_primary,Change in pain
NCT06053255,measures_secondary,Quality of life
NCT06053255,measures_secondary,Analgesic/opiate usage
NCT06053255,has_criteria,Aged 18 and older
NCT06053255,has_criteria,BPI < 40
NCT06053255,has_criteria,Able to consent
NCT00311155,involves,Hypertension
NCT00311155,evaluates,Olmesartan
NCT00311155,measures_primary,Normalized blood pressure
NCT00311155,measures_secondary,Diastolic responders
NCT00311155,measures_secondary,Systolic responders
NCT00311155,has_criteria,Baseline to ≤20 weeks
NCT06655155,involves,Systemic Sclerosis
NCT06655155,evaluates,Efgartigimod PH20 SC
NCT06655155,measures_primary,Change from baseline mRSS
NCT06655155,measures_secondary,Incidence of adverse events
NCT06655155,measures_secondary,Proportion of participants CRISS-25
NCT06655155,measures_secondary,Change from baseline HAQ-DI
NCT06655155,measures_secondary,Change from baseline PGA
NCT06655155,has_criteria,Up to 24 weeks
NCT06655155,has_criteria,Up to 48 weeks
NCT06655155,has_criteria,Up to 55 weeks
NCT00775814,involves,Hypertension
NCT00775814,involves,Insulin Resistance
NCT00775814,involves,Obesity
NCT00775814,evaluates,Candesartan
NCT00775814,measures_primary,Diastolic Blood Pressure
NCT00775814,measures_secondary,Adiponectin
NCT00775814,measures_secondary,C-Reactive Protein
NCT00775814,measures_secondary,Fasting Plasma Glucose
NCT00775814,measures_secondary,Fasting Plasma Insulin
NCT00775814,measures_secondary,Insulin Resistance
NCT00775814,measures_secondary,Lipid Parameters
NCT00775814,measures_secondary,Fibrinogen
NCT00775814,measures_secondary,Prospective Cardiovascular Münster risk score
NCT00775814,measures_secondary,24-hour mean blood pressure
NCT00775814,measures_secondary,Daytime mean blood pressure
NCT00775814,measures_secondary,Night-time mean blood pressure
NCT00775814,measures_secondary,Systolic Blood Pressure
NCT00775814,has_criteria,Abdominal obesity
NCT00775814,has_criteria,Body mass index
NCT00775814,has_criteria,Hypertension
NCT00775814,has_criteria,Homeostasis Model Assessment Insulin Resistance
NCT00775814,has_criteria,Hyperlipidemia
NCT01207414,involves,Schizophrenia
NCT01207414,evaluates,Iloperidone
NCT01207414,measures_primary,I-CGI-C at Week 12
NCT01207414,measures_secondary,Change From Baseline in TSQM at Week 12
NCT01207414,has_criteria,Adverse event
NCT06588855,involves,Ulcerative Colitis
NCT06588855,evaluates,RO7790121
NCT06588855,measures_primary,Clinical Remission
NCT06588855,measures_secondary,Partial Modified Mayo Score
NCT06588855,measures_secondary,Endoscopic Improvement
NCT06588855,measures_secondary,Endoscopic Remission
NCT06588855,measures_secondary,Clinical Response
NCT06588855,has_criteria,Moderately to Severely Active
NCT03882255,evaluates,Ponesimod
NCT03882255,measures_primary,Maximum Decrease from Baseline
NCT03882255,measures_secondary,Minimum of the Mean Hourly HR
NCT03882255,measures_secondary,Minimum of the Mean Arterial Blood Pressure
NCT03882255,measures_secondary,Change from Baseline in Average Heart Rate
NCT03882255,measures_secondary,Change from Baseline in Average PR Interval
NCT03882255,measures_secondary,Maximum Observed Plasma Analyte Concentration
NCT03887455,involves,Alzheimer's Disease
NCT03887455,evaluates,Lecanemab
NCT03887455,measures_primary,CDR-SB at 18 Months
NCT03887455,measures_secondary,Number of TEAEs
NCT03887455,has_criteria,Mild Cognitive Impairment
NCT01485614,involves,Type 2 Diabetes Mellitus
NCT01485614,evaluates,Sitagliptin
NCT01485614,measures_primary,Change From Baseline in A1C
NCT01485614,measures_secondary,Number of Participants Who Experienced ≥1 Adverse Event
NCT01485614,has_criteria,Pediatric Participants
NCT04885114,involves,Huntington's Disease
NCT04885114,evaluates,VY-HTT01
NCT04885114,measures_primary,Level of VY-HTT01
NCT04885114,measures_secondary,Unified Huntington Disease Rating Scale
NCT04885114,measures_secondary,Clinical Global Impression
NCT04885114,measures_secondary,Huntington's Disease Quality of Life
NCT04885114,measures_secondary,EuroQol 5 Dimension 5 Level
NCT05357755,involves,Plaque Psoriasis
NCT05357755,evaluates,JNJ-77242113
NCT05357755,measures_primary,PASI 75 score
NCT05357755,measures_secondary,Adverse Events
NCT05357755,measures_secondary,Serious Adverse Events
NCT05357755,measures_secondary,Change from Baseline in PASI Total Score
NCT05357755,has_criteria,Up to Week 24
NCT01784614,involves,Transient Insomnia
NCT01784614,evaluates,LY2624803
NCT01784614,measures_primary,Wake After Sleep Onset
NCT01784614,measures_secondary,Latency to Persistent Sleep
NCT01784614,measures_secondary,Total Sleep Time
NCT01784614,has_criteria,overtly healthy males or females
NCT00589914,involves,Schizophrenia
NCT00589914,evaluates,Paliperidone Palmitate
NCT00589914,evaluates,RISPERDAL CONSTA
NCT00589914,measures_primary,PANSS Total Score
NCT00589914,measures_secondary,CGI-S Score
NCT00589914,measures_secondary,PSP Score
NCT00589914,has_criteria,DSM-IV criteria
NCT04993755,involves,C9ORF72 amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD)
NCT04993755,evaluates,TPN-101
NCT04993755,measures_primary,ALSFRS-R score
NCT04993755,measures_secondary,neurofilament light (NfL)
NCT04993755,has_criteria,hexanucleotide repeat expansion (HRE)
NCT01306214,involves,Type 2 Diabetes Mellitus
NCT01306214,evaluates,BI 10773
NCT01306214,measures_primary,Change From Baseline in HbA1c
NCT01306214,measures_secondary,Change From Baseline in Insulin Dose
NCT01306214,measures_secondary,Change From Baseline in Body Weight
NCT01306214,measures_secondary,Change From Baseline in HbA1c
NCT01306214,has_criteria,Diagnosis of T2DM
NCT01306214,has_criteria,Male and female patients
NCT01306214,has_criteria,Multiple daily injections
NCT01306214,has_criteria,Stable metformin therapy
NCT01306214,has_criteria,HbA1c >=7.5% and <=10%
NCT01306214,has_criteria,Uncontrolled hyperglycemia
NCT01306214,has_criteria,Glucose level >240 mg/dl
NCT01306214,has_criteria,Acute coronary syndrome
NCT01306214,has_criteria,Stroke or TIA within 3 months
NCT00983814,involves,Attention Deficit Hyperactivity Disorder
NCT00983814,evaluates,Droxidopa
NCT00983814,measures_primary,Change From Baseline
NCT00983814,measures_secondary,Adult ADHD Self-Report Scale
NCT00983814,measures_secondary,Clinician Global Impression
NCT00983814,has_criteria,18-55 years old
NCT00983814,has_criteria,DSM-IV criteria
NCT00983814,has_criteria,social anxiety disorder
NCT00983814,has_criteria,dysthymia
NCT01986114,involves,Bipolar I Disorder
NCT01986114,evaluates,SM-13496
NCT01986114,measures_primary,Change from baseline
NCT01986114,measures_secondary,Recurrence/Relapse
NCT01986114,has_criteria,Clinical stability of Bipolar Disorder
NCT03533114,involves,Idiopathic Hypersomnia
NCT03533114,evaluates,JZP-258
NCT03533114,measures_primary,Change in ESS Score
NCT03533114,measures_secondary,Percentage of Participants Reported as Worse on the Patient Global Impression of Change (PGIc)
NCT03533114,has_criteria,Stable Dose Period
NCT01438814,involves,Type 2 Diabetes Mellitus
NCT01438814,evaluates,Linagliptin
NCT01438814,evaluates,Metformin
NCT01438814,measures_primary,HbA1c <7.0%
NCT01438814,measures_primary,no GI side effects
NCT01438814,measures_secondary,Fasting Plasma Glucose
NCT01438814,has_criteria,treatment naive patients
NCT01291914,involves,Osteoarthritis of the knee
NCT01291914,evaluates,FX005
NCT01291914,measures_primary,Change from baseline
NCT01291914,measures_secondary,WOMAC A score
NCT01291914,has_criteria,≥40 years of age
NCT01291914,has_criteria,American College of Rheumatology Criteria
NCT01291914,has_criteria,Kellgren-Lawrence grades
NCT01291914,has_criteria,WOMAC A subscale
NCT02462603,involves,Parkinson's Disease
NCT02462603,evaluates,PTC-589
NCT02462603,measures_primary,MDS-UPDRS Score
NCT02462603,measures_secondary,NMSS Total Score
NCT02462603,has_criteria,Baseline up to 30 days
NCT00402103,involves,High Blood Pressure
NCT00402103,evaluates,Aliskiren / Amlodipine
NCT00402103,measures_primary,Change in msDBP
NCT00402103,measures_secondary,Percentage of Patients Achieving a Blood Pressure Control Target of <140/90 mmHg
NCT00402103,measures_secondary,Percentage of Patients Achieving a Response in msDBP
NCT03971643,involves,Pyoderma Gangrenosum
NCT03971643,evaluates,IFX-1
NCT03971643,measures_primary,Proportion of patients
NCT03971643,measures_secondary,Time to complete closure
NCT03971643,has_criteria,Physician's Global Assessment
NCT02976038,involves,Primary Mitochondrial Myopathy
NCT02976038,evaluates,Elamipretide
NCT02976038,measures_primary,Distance Walked
NCT02976038,measures_secondary,EuroQol 5 Dimensions 5 Levels
NCT02976038,measures_secondary,Euroquol Visual Analog Scale
NCT02976038,measures_secondary,NeuroQOL Fatigue Questionnaire
NCT02976038,has_criteria,Genetically Confirmed
NCT02790138,involves,Chronic Pouchitis
NCT02790138,evaluates,Vedolizumab
NCT02790138,measures_primary,Clinically Relevant Remission
NCT02790138,measures_secondary,Clinically Relevant Remission
NCT02790138,has_criteria,mPDAI score \<5
NCT03367403,involves,Early Symptomatic Alzheimer's Disease
NCT03367403,evaluates,LY3002813
NCT03367403,measures_primary,Change From Baseline in iADRS Score
NCT03367403,measures_secondary,Change From Baseline in ADAS-Cog13 Score
NCT03367403,has_criteria,Baseline
NCT02466243,involves,Dermatomyositis
NCT02466243,evaluates,JBT-101
NCT02466243,measures_primary,CDASI score change
NCT02466243,measures_secondary,Patient-reported Outcomes
NCT02466243,has_criteria,CDASI activity score ≥ 14
NCT02466243,has_criteria,No difficulty lifting or walking
NCT02466243,has_criteria,Creatine phosphokinase or aldolase
NCT02466243,has_criteria,Failed hydroxychloroquine treatment
NCT02466243,has_criteria,Stable dermatomyositis treatment
NCT02527343,involves,Familial Partial Lipodystrophy
NCT02527343,evaluates,Volanesorsen
NCT02527343,measures_primary,Percent Change Fasting TG
NCT02527343,measures_secondary,Hepatic Steatosis
NCT02527343,has_criteria,Baseline to Month 3
NCT05869708,involves,Major Depressive Disorder
NCT05869708,evaluates,Neurofeedback Training
NCT05869708,measures_primary,Anhedonic Symptoms
NCT05869708,measures_secondary,Depression Severity
NCT05869708,has_criteria,Eligibility Criteria
NCT03384290,evaluates,PRS-060
NCT03384290,measures_primary,Change in blood pressure
NCT03384290,measures_secondary,Change in heart rate
NCT03384290,measures_secondary,Change in body temperature
NCT03384290,measures_secondary,Change in electrocardiograms
NCT03384290,measures_secondary,Change in FEV1
NCT03384290,measures_secondary,Change in FEV6
NCT03384290,measures_secondary,Change in PEFR
NCT03384290,measures_secondary,Change in FVC
NCT03384290,has_criteria,Healthy Subjects
NCT03505190,involves,Healthy Chinese Volunteers
NCT03505190,evaluates,RO7062931
NCT03505190,measures_primary,Percentage of Participants
NCT03505190,measures_secondary,Adverse Events
NCT03505190,measures_secondary,Laboratory Abnormalities
NCT03505190,measures_secondary,Electrocardiogram Abnormalities
NCT03505190,measures_secondary,T-wave Abnormalities
NCT03505190,has_criteria,standard reference range
NCT05953090,involves,Vulvovaginal Atrophy
NCT05953090,measures_primary,Change in VSQ score
NCT05953090,measures_secondary,Change in VQLI score
NCT03096990,involves,Psoriatic Arthritis
NCT03096990,evaluates,Apremilast
NCT03096990,measures_primary,PsARC response
NCT03096990,measures_secondary,Baseline|Change from baseline
NCT03096990,has_criteria,age
NCT03483103,involves,Diffuse Large B-cell Lymphoma
NCT03483103,evaluates,Lisocabtagene Maraleucel
NCT03483103,measures_primary,Overall Response Rate
NCT03483103,measures_secondary,Number of Participants With Any Treatment-Emergent Adverse Events
NCT03483103,has_criteria,Hematology Laboratory Results
NCT04721808,involves,Rheumatoid Arthritis
NCT04721808,evaluates,Tofacitinib
NCT04721808,measures_primary,LDA (CDAI <=10)
NCT04721808,measures_secondary,LDA (CDAI <=10)
NCT04721808,has_criteria,Tofa Initiators
NCT00909038,involves,Hypertension
NCT00909038,evaluates,Telmisartan 80mg+Hydrochlorothiazide 25 mg
NCT00909038,measures_primary,Rate of BP Control
NCT00909038,measures_secondary,Mean SBP
NCT00909038,has_criteria,Treated for at least 8 weeks
NCT03813238,involves,Dyskinesia
NCT03813238,involves,Cerebral Palsy
NCT03813238,evaluates,TEV-50717
NCT03813238,evaluates,Deutetrabenazine
NCT03813238,measures_primary,Change From Baseline
NCT03813238,measures_secondary,Change From Baseline
NCT03813238,has_criteria,Children and Adolescents
NCT04693455,involves,Safety and tolerability
NCT04693455,evaluates,ZD03 Capsule
NCT04693455,measures_primary,Clinically significant Vital sign abnormalities
NCT04693455,measures_primary,Clinically significant 12-lead electrocardiograms abnormalities
NCT04693455,measures_primary,Clinically significant physical examination abnormalities
NCT04693455,measures_primary,Clinically significant haematology assessment abnormalities
NCT04693455,has_criteria,Screening
NCT02831855,involves,Rheumatoid Arthritis
NCT02831855,evaluates,Tofacitinib Modified Release Formulation
NCT02831855,measures_primary,DAS28-4 ESR
NCT02831855,measures_secondary,DAS28-4 ESR
NCT02831855,has_criteria,Week 24
NCT00300755,involves,Gastroesophageal Reflux Disease
NCT00300755,evaluates,Pantoprazole
NCT00300755,measures_primary,Change in WGSS
NCT00300755,measures_secondary,Change in Individual Weekly Mean Frequency Score
NCT00300755,measures_secondary,Change in Individual Weekly Mean Score
NCT00300755,measures_secondary,"Number of Patients With ""Healed"" Erosive Esophagitis"
NCT00300755,has_criteria,modified Hetzel-Dent score
NCT02091414,involves,Heart Transplant Rejection
NCT02091414,evaluates,CellCept
NCT02091414,measures_primary,Biopsy Proven Acute Rejection
NCT02091414,measures_secondary,Graft Loss
NCT02091414,measures_secondary,Immunosuppressant Use
NCT02091414,measures_secondary,Discontinuing MMF
NCT02091414,measures_secondary,Lost To Follow Up
NCT02091414,measures_secondary,Serum Creatinine
NCT02091414,has_criteria,Baseline Values
NCT01634555,evaluates,Ramucirumab (IMC-1121B)
NCT01634555,measures_primary,AUC(0-∞)
NCT01634555,measures_secondary,Cmax
NCT01634555,has_criteria,Treatment Emergent Anti-Drug Antibodies (TE-ADA)
NCT03956355,involves,Plaque Psoriasis
NCT03956355,evaluates,Tapinarof
NCT03956355,measures_primary,PGA score 0 or 1
NCT03956355,measures_secondary,PASI improvement
NCT03956355,has_criteria,Baseline to Week 12
NCT05327114,involves,Chronic Inflammatory Demyelinating Polyneuropathy
NCT05327114,evaluates,Nipocalimab
NCT05327114,measures_primary,Time to first relapse
NCT05327114,measures_secondary,Percentage of Responders
NCT05327114,measures_secondary,Change from Baseline INCAT
NCT05327114,measures_secondary,Change from Baseline MRC
NCT05327114,measures_secondary,Change from Baseline I-RODS
NCT05327114,has_criteria,Up to 52 weeks
NCT05327114,has_criteria,12 weeks
NCT01915914,involves,Atopic Dermatitis
NCT01915914,evaluates,Fluticasone Propionate 0.05% Cream
NCT01915914,measures_primary,Time to First Relapse
NCT01915914,measures_secondary,Numbers of Recurrent Participants
NCT01915914,has_criteria,PSGA exacerbation score \>=2
NCT01327014,involves,Hyperlipidemia
NCT01327014,evaluates,XueZhiKang
NCT01327014,measures_primary,LDL-C level
NCT01327014,measures_secondary,Total cholesterol
NCT01327014,measures_secondary,HDL-C level
NCT01327014,measures_secondary,Triglyceride level
NCT01327014,measures_secondary,Non-HDL cholesterol
NCT01327014,measures_secondary,Apo A-I
NCT01327014,measures_secondary,Apo-B
NCT01327014,measures_secondary,Apo-B/Apo A-I ratio
NCT01327014,measures_secondary,TC/HDL-C ratio
NCT01327014,measures_secondary,LDL-C level
NCT01327014,has_criteria,fasting levels of TC ≥ 240 mg/dl
NCT01327014,has_criteria,LDL-C ≥ 160 mg/dl
NCT01327014,has_criteria,LDL-C < 190 mg/dl
NCT01327014,has_criteria,TG < 400 mg/dl
NCT02175355,involves,Isolated Systolic Hypertension
NCT02175355,evaluates,Micardis
NCT02175355,evaluates,Hydrochlorothiazide
NCT02175355,measures_primary,systolic blood pressure
NCT02175355,measures_secondary,urine albumine excretion
NCT02175355,measures_secondary,pulse wave velocity
NCT02175355,measures_secondary,augmentation index
NCT02175355,measures_secondary,adverse events
NCT02175355,measures_secondary,physical examination
NCT02175355,measures_secondary,Heart Rate
NCT02175355,measures_secondary,laboratory parameters
NCT02175355,measures_secondary,12-lead electrocardiogram
NCT02175355,has_criteria,age 35-85 years
NCT02175355,has_criteria,SBP ≥ 150 mm Hg
NCT02175355,has_criteria,DBP < 90 mm Hg
NCT02175355,has_criteria,not on antihypertensive therapy
NCT02175355,has_criteria,informed consent
NCT02175355,has_criteria,not pre-menopausal
NCT02175355,has_criteria,surgically sterile
NCT02175355,has_criteria,not nursing
NCT02175355,has_criteria,acceptable birth control
NCT02681055,involves,NASH
NCT02681055,involves,NAFLD
NCT02681055,evaluates,MN-001
NCT02681055,measures_primary,Cholesterol Efflux Capacity
NCT02681055,measures_secondary,Triglyceride Levels
NCT02681055,has_criteria,hypertriglyceridemia
NCT00763555,involves,Plaque-type Psoriasis
NCT00763555,evaluates,CD 2027 Spray
NCT00763555,measures_primary,Success Rate 1
NCT00763555,measures_secondary,Success Rate 2
NCT00763555,measures_secondary,Dermatologic Sum Score
NCT00763555,measures_secondary,Erythema
NCT00763555,measures_secondary,Scaling
NCT00763555,measures_secondary,Plaque Elevation
NCT00763555,has_criteria,last observation carried forward
NCT02564055,involves,Atopic Dermatitis
NCT02564055,evaluates,GSK2894512 Cream
NCT02564055,measures_primary,IGA score clear/almost clear
NCT02564055,measures_primary,2 grade improvement IGA
NCT02564055,measures_secondary,Mean Change Itch/Pruritus NRS
NCT02564055,measures_secondary,Percent Change Itch/Pruritus NRS
NCT02564055,has_criteria,randomized participants
NCT01227655,involves,Idiopathic Parkinson's Disease
NCT01227655,evaluates,BIA 9-1067
NCT01227655,measures_primary,OFF-time at end of DB period
NCT01227655,measures_secondary,UPDRS Total SCORE
NCT01227655,has_criteria,end-of-dose motor fluctuations
NCT05164055,involves,Pompe Disease
NCT05164055,evaluates,Avalglucosidase Alfa
NCT05164055,measures_primary,distance walked meters
NCT05164055,measures_secondary,quick motor function test
NCT05164055,measures_secondary,pulmonary function tests
NCT05164055,has_criteria,late-onset Pompe disease
NCT05164055,has_criteria,infantile-onset Pompe disease
NCT01234350,involves,Advanced Prostate Cancer
NCT01234350,evaluates,FIRMAGON
NCT01234350,measures_primary,Incidence Rate of AESI
NCT01234350,measures_secondary,Change in Hepatic Enzymes
NCT01234350,measures_secondary,Change in Serum Glucose
NCT01234350,has_criteria,An ADR was defined as an AE assessed
NCT06559150,involves,Non-Cystic Fibrosis Bronchiectasis
NCT06559150,evaluates,Ensifentrine
NCT06559150,measures_primary,pulmonary exacerbations
NCT06559150,measures_secondary,Respiratory Symptoms
NCT06559150,measures_secondary,Saint George's Respiratory Questionnaire
NCT06559150,measures_secondary,quality of life - bronchiectasis questionnaire
NCT06559150,measures_secondary,Chronic Airways Assessment Test
NCT06559150,measures_secondary,Percent of the predicted forced expiratory volume over 1 second
NCT06559150,measures_secondary,quality of life - bronchiectasis questionnaire
NCT06559150,measures_secondary,Adverse Events
NCT06559150,has_criteria,Through study completion
NCT02930655,involves,Fabry Disease
NCT02930655,evaluates,Lucerastat
NCT02930655,measures_primary,Change from baseline
NCT02930655,measures_secondary,Plasma biomarkers
NCT02930655,has_criteria,Up to Week 12
NCT04279314,involves,Rett Syndrome
NCT04279314,evaluates,Trofinetide
NCT04279314,measures_primary,Potentially Clinically Important Changes
NCT04279314,measures_secondary,ECG
NCT04279314,has_criteria,≥7% from baseline
NCT02467855,involves,Hypertension
NCT02467855,evaluates,Index Treatment
NCT02467855,measures_primary,Percentage of Participants
NCT02467855,measures_secondary,Dose of Current Medications
NCT02467855,has_criteria,Age above 18 years
NCT02467855,has_criteria,Essential hypertension
NCT04495855,involves,Endometriosis
NCT04495855,evaluates,Visanne
NCT04495855,measures_primary,Endometriosis Associated Pelvic Pain
NCT04495855,measures_secondary,Endometriosis Health Profile-5 score
NCT04495855,measures_secondary,Patient satisfaction
NCT04495855,measures_secondary,Physician satisfaction
NCT04495855,has_criteria,Chinese Participants
NCT02651155,involves,Chronic Idiopathic Constipation
NCT02651155,evaluates,Lubiprostone
NCT02651155,measures_primary,SBM Frequency
NCT02651155,measures_secondary,Straining Score
NCT02651155,measures_secondary,Stool Consistency Score
NCT02651155,has_criteria,Up to 24 hours after first dose
NCT05925114,involves,Obesity
NCT05925114,evaluates,S-309309
NCT05925114,measures_primary,Percent Change Body Weight
NCT05925114,measures_secondary,Weight Loss ≥ 5%
NCT05925114,measures_secondary,Weight Loss ≥ 10%
NCT05925114,measures_secondary,Weight Loss ≥ 15%
NCT05925114,measures_secondary,Weight Loss ≥ 20%
NCT05925114,measures_secondary,Waist Circumference
NCT05925114,measures_secondary,Hip/Waist Ratio
NCT05925114,measures_secondary,BMI
NCT05925114,measures_secondary,Glucose Metabolism
NCT05925114,measures_secondary,Fasting Plasma Glucose
NCT05925114,measures_secondary,Cardiovascular Risk Factors
NCT05925114,measures_secondary,Total Fat Mass
NCT05925114,measures_secondary,Lean Mass
NCT05925114,measures_secondary,Visceral Fat Mass
NCT05925114,measures_secondary,Adiponectin
NCT05925114,measures_secondary,High Sensitivity C-reactive Protein
NCT05925114,measures_secondary,Leptin
NCT05925114,has_criteria,BMI ≥ 30 kg/m^2
NCT05925114,has_criteria,Stable body weight
NCT05925114,has_criteria,Unsuccessful dietary effort
NCT05925114,has_criteria,Non-childbearing potential
NCT05925114,has_criteria,Contraceptive method
NCT04250350,involves,Atopic Dermatitis
NCT04250350,evaluates,Lebrikizumab
NCT04250350,measures_primary,EASI-75
NCT04250350,measures_secondary,IGA score
NCT04250350,measures_secondary,Percentage Change From Baseline in EASI Score
NCT04250350,has_criteria,Adolescent participants
NCT04844450,evaluates,JNJ-75220795
NCT04844450,measures_primary,Percent change from baseline in liver fat content
NCT04844450,measures_secondary,Number of Participants With Treatment-Emergent Signs and Symptoms
NCT04844450,measures_secondary,Number of participants with change from baseline in vital signs abnormalities
NCT04844450,measures_secondary,Number of participants with change from baseline in clinical laboratory abnormalities
NCT04844450,measures_secondary,Number of participants with change from baseline in physical examination abnormalities
NCT04844450,measures_secondary,Number of participants with change from baseline in Electrocardiogram (ECG) abnormalities
NCT04844450,has_criteria,Baseline
NCT04844450,has_criteria,Baseline
NCT04844450,has_criteria,Baseline
NCT04844450,has_criteria,SAD: Predose
NCT00757523,involves,Acne Vulgaris
NCT00757523,evaluates,Duac Akne Gel
NCT00757523,evaluates,Epiduo Gel
NCT00757523,measures_primary,Percent change in lesions
NCT00757523,measures_secondary,ISGA success
NCT00757523,measures_secondary,Time to ISGA success
NCT00757523,has_criteria,Improvement of 2 grades
NCT00241150,involves,Hypertension
NCT00241150,involves,Metabolic Syndrome
NCT00241150,evaluates,Valsartan
NCT00241150,evaluates,Amlodipine
NCT00241150,measures_primary,flow-mediated vasodilatation
NCT00241150,measures_secondary,brachial artery flow
NCT00241150,measures_secondary,Circulating markers
NCT00241150,measures_secondary,Adverse events
NCT00241150,has_criteria,Non-smoking female
NCT00241150,has_criteria,postmenopausal
NCT00241150,has_criteria,blood pressure 130-149/85-94
NCT00241150,has_criteria,BMI 26-41 kg/m2
NCT00241150,has_criteria,no diet/exercise change
NCT00241150,has_criteria,informed consent
NCT05118750,involves,Major Depressive Disorder
NCT05118750,evaluates,ALTO-300
NCT05118750,measures_primary,change from baseline
NCT05118750,measures_primary,change from baseline
NCT05118750,has_criteria,diagnosis of MDD
NCT05118750,has_criteria,moderate to severe depression
NCT05118750,has_criteria,stable dose of SSRI
NCT05118750,has_criteria,stable dose of SNRI
NCT05118750,has_criteria,stable dose of bupropion
NCT00721955,involves,bipolar 1 disorder
NCT00721955,involves,agitation
NCT00721955,evaluates,Staccato Loxapine
NCT00721955,measures_primary,PANSS Excited Component Score
NCT00721955,measures_secondary,Clinical Global Impression-Improvement Score
NCT00721955,has_criteria,PANSS-EC ≥14
NCT00721955,has_criteria,CGI-I score 1 or 2
NCT02418455,involves,Mucopolysaccharidosis Type 7
NCT02418455,evaluates,UX003 Recombinant Human Beta-Glucuronidase
NCT02418455,measures_primary,uGAG Excretion
NCT02418455,measures_secondary,Standing Height
NCT02418455,has_criteria,Less Than 5 Years of Age
NCT06649955,involves,Amyotrophic Lateral Sclerosis
NCT06649955,evaluates,multi-site DCS
NCT06649955,measures_primary,ALS Functional Rating Scale
NCT06649955,measures_secondary,Rasch Overall ALS Disability Scale
NCT06649955,has_criteria,treatment day
NCT01347255,involves,Psoriasis Vulgaris
NCT01347255,evaluates,LEO 90100
NCT01347255,measures_primary,Total Clinical Score
NCT01347255,measures_secondary,Echo-poor Band Thickness
NCT01347255,measures_secondary,Total Skin Thickness
NCT01347255,has_criteria,Age 18 years or above
NCT01347255,has_criteria,Diagnosis of psoriasis vulgaris
NCT01347255,has_criteria,Lesions on arms
NCT01347255,has_criteria,Either sex
NCT01347255,has_criteria,All skin types
NCT01849055,evaluates,LY3023703
NCT01849055,measures_primary,Change From Baseline
NCT01849055,measures_secondary,Blood Pressure
NCT01849055,has_criteria,normotensive
NCT00425308,involves,Renal Transplant
NCT00425308,evaluates,Everolimus
NCT00425308,evaluates,Cyclosporine Microemulsion
NCT00425308,evaluates,Mycophenolate Sodium
NCT00425308,measures_primary,iohexol plasmatic clearance
NCT00425308,measures_secondary,Creatinine Clearance
NCT00425308,measures_secondary,Proteinuria
NCT00425308,measures_secondary,Biopsy-proven Acute Rejection
NCT00425308,measures_secondary,Graft Loss/Re-transplantation
NCT00425308,measures_secondary,Death
NCT00425308,measures_secondary,Lost to Follow-up
NCT00425308,has_criteria,Adult Renal Transplant Patients
NCT02467608,involves,Pulmonary Tuberculosis
NCT02467608,evaluates,HUEXC030
NCT02467608,measures_primary,ALT AUC change
NCT02467608,measures_secondary,ATDH incidence
NCT02467608,has_criteria,high risk genotypes
NCT01515423,involves,Schizophrenia
NCT01515423,evaluates,Paliperidone Palmitate
NCT01515423,measures_primary,PANSS Total Score
NCT01515423,measures_secondary,PANSS Positive Subscale
NCT01515423,measures_secondary,PANSS Negative Subscale
NCT01515423,measures_secondary,PANSS General Psychopathology Subscale
NCT01515423,has_criteria,Relapse defined
NCT00931723,involves,Bipolar Mania
NCT00931723,measures_primary,Change in YMRS
NCT00931723,measures_secondary,Clinically Significant Response
NCT00931723,measures_secondary,Clinically Significant Remission
NCT00931723,has_criteria,Days 8 to 43
NCT02539550,evaluates,PF-06266047
NCT02539550,measures_primary,Maximum Observed Plasma Concentration
NCT02539550,measures_primary,Time to Reach Maximum Observed Plasma Concentration
NCT02539550,measures_primary,Area Under the Curve From Time Zero to Last Quantifiable Concentration
NCT02539550,measures_primary,Area Under the Curve From Time Zero to Extrapolated Infinite Time
NCT02539550,has_criteria,Baseline up to 1 day of dosing
NCT01215955,involves,Type 2 Diabetes
NCT01215955,evaluates,Insulin Lispro
NCT01215955,measures_primary,Change in HbA1c
NCT01215955,measures_secondary,Body Weight
NCT01215955,measures_secondary,Time to HbA1c target
NCT01215955,has_criteria,Sulfonylurea/meglitinide use
NCT04599855,involves,Treatment-resistant Depression
NCT04599855,evaluates,Esketamine Nasal Spray
NCT04599855,measures_primary,MADRS Total Score
NCT04599855,measures_secondary,MADRS Total Score
NCT04599855,has_criteria,DSM-5 diagnostic criteria
NCT04599855,has_criteria,nonresponse to oral antidepressants
NCT04599855,has_criteria,IDS-C30 total score >=34
NCT03138655,involves,Ulcerative Colitis
NCT03138655,involves,Crohn's Disease
NCT03138655,evaluates,Vedolizumab IV
NCT03138655,measures_primary,Clinical Response
NCT03138655,measures_secondary,CDAI
NCT03138655,has_criteria,Baseline (Day 1)
NCT00207714,involves,Rheumatoid Arthritis
NCT00207714,evaluates,CNTO 148 Subcutaneous Injection
NCT00207714,measures_primary,ACR 20 response
NCT00207714,measures_secondary,ACR-N index
NCT00207714,has_criteria,active Rheumatoid Arthritis
NCT00207714,has_criteria,6 or more swollen joints
NCT00207714,has_criteria,6 or more tender joints
NCT00207714,has_criteria,laboratory criteria
NCT00207714,has_criteria,Diagnosis of RA
NCT03530514,evaluates,REGN4461
NCT03530514,measures_primary,Number of TEAEs
NCT03530514,measures_secondary,Concentrations of REGN4461
NCT03530514,measures_secondary,Percent change in body weight
NCT03530514,measures_secondary,Absolute change in body weight
NCT03530514,measures_secondary,Change from baseline in caloric intake
NCT03530514,measures_secondary,Change in lipid-regulating protein levels
NCT03530514,measures_secondary,Incidence of anti-drug antibodies
NCT03530514,measures_secondary,AUClast
NCT03530514,measures_secondary,AUCo-τ
NCT03530514,measures_secondary,Cmax
NCT03530514,measures_secondary,tmax
NCT03530514,measures_secondary,CL
NCT03530514,measures_secondary,Ctrough
NCT03530514,has_criteria,Males and females 18 to 50 years of age
NCT03530514,has_criteria,BMI from 18.5 to <30.0 kg/m^2
NCT03530514,has_criteria,Good health and free from major comorbidities
NCT03530514,has_criteria,Males and females 18 to 65 years of age
NCT03530514,has_criteria,BMI from 25.0 to 40.0 kg/m^2
NCT03511755,involves,Psoriasis
NCT03511755,evaluates,TEN
NCT03511755,measures_primary,PASI change from Baseline
NCT03511755,measures_secondary,IGA change from Baseline
NCT03511755,measures_secondary,DLQI change from Baseline
NCT03511755,measures_secondary,PQOL-12 change from Baseline
NCT03511755,has_criteria,Week 4
NCT02730455,involves,Acute Ischemic Stroke
NCT02730455,evaluates,Intravenous Natalizumab
NCT02730455,measures_primary,Composite Global Measure
NCT02730455,measures_secondary,mRS Score
NCT02730455,measures_secondary,BI Score
NCT02730455,has_criteria,Day 90
NCT00616655,involves,Generalized Anxiety Disorder
NCT00616655,evaluates,SEP-225441
NCT00616655,measures_primary,Change From Baseline
NCT00616655,measures_secondary,Change in Individual Item Scores
NCT00616655,has_criteria,Baseline to Week 8
NCT05413655,involves,Alzheimer disease dementia
NCT05413655,evaluates,EX039
NCT05413655,measures_primary,Change in ADAS-cog
NCT05413655,measures_secondary,Change in CDR-SB
NCT05413655,measures_secondary,CIBIC-Plus
NCT05413655,has_criteria,Aged 50-80 years
NCT05413655,has_criteria,NINCDS/ADRDA criteria
NCT05413655,has_criteria,MMSE 10-26
NCT05413655,has_criteria,CDR score 1
NCT05413655,has_criteria,AST
NCT05413655,has_criteria,CK concentration > 3 times upper limit of normal
NCT05413655,has_criteria,Serum creatinine ≦ upper limit of normal
NCT00374855,involves,mild hypertension
NCT00374855,evaluates,LY518674
NCT00374855,measures_primary,24-hour mean SBP
NCT00374855,measures_secondary,DBP
NCT00374855,has_criteria,age 18-70 years
NCT00374855,has_criteria,signed consent
NCT00374855,has_criteria,mild essential hypertension
NCT00374855,has_criteria,untreated or monotherapy
NCT00374855,has_criteria,no secondary hypertension
NCT00374855,has_criteria,no hyperlipidemia
NCT00374855,has_criteria,no cardiovascular disease
NCT00374855,has_criteria,no diabetes
NCT01562314,involves,Ulcerative Colitis
NCT01562314,evaluates,GWP42003
NCT01562314,measures_primary,Mayo Score 2 or less
NCT01562314,has_criteria,Baseline to End of Treatment
NCT03905655,involves,Chronic Hepatitis B
NCT03905655,evaluates,Nitazoxanide
NCT03905655,evaluates,Placebo
NCT03905655,measures_primary,Quantitative Hepatitis B Surface Antigen (qHBsAg)
NCT03905655,measures_secondary,HBsAg Loss
NCT03905655,measures_secondary,HBsAg Seroconversion
NCT03905655,measures_secondary,Hepatitis B Virus DNA Suppression
NCT03905655,measures_secondary,Change in Fibrosis-4 (FIB-4) Score
NCT03905655,has_criteria,HBeAG-Negative
NCT05375955,involves,Atopic Dermatitis
NCT05375955,involves,Plaque Psoriasis
NCT05375955,evaluates,PF-07038124
NCT05375955,measures_primary,IGA score clear/almost clear
NCT05375955,measures_primary,Reduction from baseline >=2 points
NCT05375955,measures_secondary,PGA score clear/almost clear
NCT05375955,measures_secondary,Reduction from baseline >=2 points
NCT05375955,has_criteria,Mild to Moderate AD
NCT05375955,has_criteria,Mild to Severe Plaque Psoriasis
NCT01365455,involves,Psoriasis
NCT01365455,evaluates,Subcutaneous Secukinumab
NCT01365455,measures_primary,PASI 75
NCT01365455,measures_secondary,IGA score
NCT01365455,has_criteria,moderate to severe
NCT02136914,involves,Levodopa Induced Dyskinesia
NCT02136914,evaluates,ADS-5102
NCT02136914,measures_primary,Change From Baseline
NCT02136914,measures_secondary,Movement Disorder Society Unified Parkinson's Disease Rating Scale
NCT02136914,has_criteria,Baseline to Week 12
NCT02136914,has_criteria,Baseline to Week 24
NCT01251614,involves,Chronic Plaque Psoriasis
NCT01251614,evaluates,Adalimumab
NCT01251614,evaluates,Methotrexate
NCT01251614,measures_primary,PASI 75 Response
NCT01251614,measures_secondary,"PGA of ""Cleared"" or ""Minimal"
NCT01251614,measures_secondary,PASI 90 Response
NCT01251614,has_criteria,Pediatric Subjects
NCT00415623,involves,Hypertension
NCT00415623,evaluates,Amlodipine
NCT00415623,measures_primary,Change in SBP
NCT00415623,measures_secondary,Change in DBP
NCT00415623,has_criteria,Target blood pressure reduction
NCT01313650,involves,COPD
NCT01313650,evaluates,GSK573719/Vilanterol
NCT01313650,measures_primary,Change From Baseline FEV1
NCT01313650,measures_secondary,Transition Dyspnea Index
NCT01313650,has_criteria,smoking status
NCT01349803,involves,chronic obstructive pulmonary disease
NCT01349803,evaluates,PT003 MDI
NCT01349803,evaluates,PT005 MDI
NCT01349803,evaluates,PT001 MDI
NCT01349803,evaluates,Foradil Aerolizer
NCT01349803,measures_primary,Change From Baseline in 24-Hour Mean Heart Rate
NCT01349803,measures_secondary,Change From Baseline in Mean FEV1 Trough
NCT01349803,measures_secondary,maximum 24-hour heart rate
NCT01349803,measures_secondary,mean night-time heart rate
NCT01349803,measures_secondary,mean day-time heart rate
NCT01349803,measures_secondary,ventricular ectopic events
NCT01349803,measures_secondary,ventricular couplets
NCT01349803,measures_secondary,ventricular runs
NCT01349803,measures_secondary,supraventricular runs
NCT01349803,measures_secondary,sustained ventricular tachycardia
NCT01349803,measures_secondary,supraventricular ectopic events
NCT01349803,has_criteria,moderate to severe
NCT00703755,involves,Metabolic Syndrome
NCT00703755,evaluates,Fenofibrate
NCT00703755,evaluates,Metformin
NCT00703755,evaluates,Combination of Fenofibrate and Metformin
NCT00703755,evaluates,Placebo
NCT00703755,measures_primary,Fasting glucose
NCT00703755,measures_primary,TG
NCT00703755,measures_primary,HDL-C
NCT00703755,measures_secondary,HbA1c
NCT00703755,measures_secondary,Insulin sensitivity
NCT00703755,measures_secondary,Lipid parameters
NCT00703755,measures_secondary,PAI-1 activity
NCT00703755,measures_secondary,hsCRP
NCT00703755,measures_secondary,Fibrinogen
NCT00703755,measures_secondary,TNF alpha
NCT00703755,measures_secondary,IL1
NCT00703755,measures_secondary,IL6
NCT00703755,measures_secondary,BMI
NCT00703755,measures_secondary,Waist circumference
NCT00703755,measures_secondary,Hip circumference
NCT00703755,measures_secondary,Waist to hip ratio
NCT00703755,measures_secondary,Blood pressure
NCT00703755,measures_secondary,MetS criteria
NCT00703755,has_criteria,18 to 75 years old
NCT00703755,has_criteria,3 of 5 criteria
NCT03055650,involves,Meibomian Gland Dysfunction
NCT03055650,evaluates,iLux Treatment
NCT03055650,measures_primary,Change in MGS Total Score
NCT03055650,measures_secondary,Change in TBUT
NCT03055650,measures_secondary,Change in SPEED Total Score
NCT03055650,has_criteria,Baseline (Day 0 pretreatment)
NCT05122650,involves,Essential Tremor
NCT05122650,evaluates,JZP385
NCT05122650,measures_primary,TETRAS composite score
NCT05122650,measures_secondary,CGI-S
NCT05122650,measures_secondary,CGI-C
NCT05122650,has_criteria,Adults with ET
NCT02932150,involves,Chronic Hepatitis B Virus Infection
NCT02932150,evaluates,Tenofovir Alafenamide
NCT02932150,measures_primary,Plasma HBV DNA < 20 IU/mL
NCT02932150,measures_secondary,Treatment-Emergent SAEs
NCT02932150,has_criteria,Participants from Cohort 2 Part A
NCT05481450,involves,Dry Eye Syndrome
NCT05481450,evaluates,Nutritears®
NCT05481450,measures_primary,Schirmer's Test
NCT05481450,measures_secondary,OSDI score
NCT05481450,measures_secondary,Tear Film Break-Up Time
NCT05481450,measures_secondary,SPEED score
NCT05481450,has_criteria,Baseline
NCT00527514,involves,Hypertension
NCT00527514,evaluates,Olmesartan and Amlodipine
NCT00527514,measures_primary,Change in Systolic BP
NCT00527514,measures_secondary,Change in Systolic BP
NCT00527514,has_criteria,mean seated systolic blood pressure
NCT03439514,involves,Dilated Cardiomyopathy
NCT03439514,evaluates,ARRY-371797
NCT03439514,measures_primary,Change From Baseline in 6 MWT
NCT03439514,measures_secondary,Kansas City Cardiomyopathy Questionnaire
NCT03439514,has_criteria,Lamin A/C Gene Mutation
NCT04202679,involves,Prurigo Nodularis
NCT04202679,evaluates,Dupilumab
NCT04202679,measures_primary,WI-NRS improvement
NCT04202679,measures_secondary,IGA PN-S score
NCT04202679,has_criteria,Topical prescription therapies
NCT04569084,involves,Amyotrophic Lateral Sclerosis
NCT04569084,evaluates,Oral Edaravone
NCT04569084,measures_primary,ALSFRS-R score
NCT04569084,measures_secondary,% slow vital capacity
NCT04569084,measures_secondary,ALSAQ-40
NCT04569084,has_criteria,≥ 18 to 75 years
NCT04569084,has_criteria,Definite ALS
NCT04569084,has_criteria,Probable ALS
NCT04569084,has_criteria,ALSFRS-R score ≥ 2
NCT04569084,has_criteria,%forced vital capacity ≥ 70%
NCT04569084,has_criteria,8 weeks decline ALSFRS-R
NCT04569084,has_criteria,first symptom within 2 years
NCT00604279,involves,Schizophrenia
NCT00604279,evaluates,Paliperidone Palmitate
NCT00604279,evaluates,Risperidone Long Acting Injection
NCT00604279,measures_primary,Change From Baseline
NCT00604279,measures_secondary,Personal and Social Performance
NCT00604279,measures_secondary,Clinical Global Impression-Severity
NCT00604279,has_criteria,Baseline
NCT03894579,involves,plaque psoriasis
NCT03894579,evaluates,SNK01
NCT03894579,measures_primary,dose-limiting toxicity
NCT03894579,measures_secondary,Non-DLT adverse events
NCT03894579,has_criteria,Informed consent obtained
NCT03894579,has_criteria,Diagnosis of plaque psoriasis
NCT03894579,has_criteria,at least one psoriatic plaque
NCT04501679,involves,Prurigo Nodularis
NCT04501679,evaluates,Nemolizumab
NCT04501679,measures_primary,PP NRS improvement
NCT04501679,measures_secondary,IGA success
NCT04501679,has_criteria,rescue therapy
NCT02182479,involves,bronchial asthma
NCT02182479,evaluates,Berodual® Respimat®
NCT02182479,evaluates,Berodual® MDI
NCT02182479,measures_primary,FEV1 (Forced expiratory volume in one second)
NCT02182479,measures_secondary,Time to onset of therapeutic response
NCT02182479,measures_secondary,Duration of therapeutic response
NCT02182479,measures_secondary,Time to peak FEV1
NCT02182479,measures_secondary,Change in averaged weekly morning and evening pre-dose PEFR
NCT02182479,measures_secondary,Extent of use of rescue medication
NCT02182479,measures_secondary,Change in night-time and daytime symptom scores
NCT02182479,measures_secondary,Overall incidence of adverse events
NCT02182479,measures_secondary,Number of patients with clinically significant changes in Heart rate
NCT02182479,measures_secondary,Number of patients with clinically significant changes in Blood pressure
NCT02182479,measures_secondary,Number of patients with clinically significant changes from baseline in laboratory investigations
NCT02182479,measures_secondary,Incidence of paradoxical bronchoconstriction
NCT02182479,has_criteria,Diagnosis of bronchial asthma
NCT02182479,has_criteria,Age: 18 - 65 years
NCT02182479,has_criteria,Screening FEV1: 40 - 80 % of predicted normal
NCT02182479,has_criteria,Airway obstruction reversibility: increase in FEV1 12% from baseline and ≥ 200 ml from baseline at 30 minutes after 2 puffs of Berodual® MDI
NCT02182479,has_criteria,Current non-smoker or ex-smoker (with a smoking history of ≤ 10 pack-years) with cessation of smoking ≥ 1 year prior to
NCT03426384,involves,Systemic Lupus Erythematosus
NCT03426384,measures_primary,Change from baseline
NCT03426384,measures_secondary,Change from baseline
NCT04770779,involves,Transfusion-Dependent Alpha- or Beta-Thalassemia
NCT04770779,evaluates,Mitapivat
NCT04770779,measures_primary,Transfusion Reduction Response
NCT04770779,measures_secondary,Transfusion-Independence
NCT04770779,measures_secondary,Change From Baseline
NCT04770779,has_criteria,Baseline up to Week 48
NCT00622284,involves,Type 2 Diabetes
NCT00622284,evaluates,BI 1356
NCT00622284,measures_primary,HbA1c Change From Baseline
NCT00622284,measures_primary,HbA1c Change From Baseline
NCT00622284,measures_secondary,Body Weight Change From Baseline
NCT00622284,measures_secondary,Body Weight Change From Baseline
NCT00622284,measures_secondary,Incidence of Hypoglycaemic Events
NCT00622284,measures_secondary,Fasting Plasma Glucose Change From Baseline
NCT00622284,has_criteria,previous anti-diabetic medications
NCT00721279,involves,Primary Restless Legs Syndrome
NCT00721279,evaluates,Sifrol
NCT00721279,measures_primary,Change in IRLS
NCT00721279,measures_secondary,Global Clinical Impression - Improvement
NCT00721279,has_criteria,Inclusion Criteria
NCT00445679,involves,Major Depressive Disorder
NCT00445679,evaluates,DVS SR
NCT00445679,measures_primary,HAM-D17 score
NCT00445679,measures_secondary,CGI-I Scores
NCT00445679,measures_secondary,CGI-S Scores
NCT00445679,measures_secondary,MADRS Total Score
NCT00445679,measures_secondary,VAS-PI Score
NCT00445679,has_criteria,Outpatients
NCT01987479,involves,Rheumatoid Arthritis
NCT01987479,evaluates,Tocilizumab
NCT01987479,measures_primary,DAS28-ESR Score
NCT01987479,measures_secondary,ACR20 Response
NCT01987479,has_criteria,American College of Rheumatology Criteria 20
NCT03956979,involves,Parkinson's Disease
NCT03956979,evaluates,JM-010
NCT03956979,measures_primary,UDysRS total score
NCT03956979,measures_secondary,MDS-UPDRS Part III score
NCT03956979,measures_secondary,CGI-C score
NCT03956979,measures_secondary,Hauser diary
NCT03956979,has_criteria,able to read consent
NCT02489279,involves,Attention-Deficit Hyperactivity Disorder
NCT02489279,evaluates,Training
NCT02489279,measures_primary,Change in CPT RT
NCT02489279,measures_secondary,Nelson-Denny Reading Comprehension
NCT02489279,measures_secondary,Adult Attention-Deficit Hyperactivity Disorder Self-Report Scale - Inattentive Subscale
NCT02489279,has_criteria,Baseline and 10 weeks
NCT01107379,involves,Sinus disease
NCT01107379,evaluates,Balloon Catheter Tools
NCT01107379,measures_primary,SNOT-20 score change
NCT01107379,measures_secondary,Lund-Mackay CT score
NCT01107379,has_criteria,Procedure Tolerability
NCT06096779,involves,Hepatocellular Carcinoma
NCT06096779,involves,Cirrhosis
NCT06096779,evaluates,Atezolizumab
NCT06096779,evaluates,Bevacizumab
NCT06096779,measures_primary,Objective Response Rate
NCT06096779,measures_secondary,Duration of Response
NCT06096779,measures_secondary,Progression Free Survival
NCT06096779,measures_secondary,Overall Survival
NCT06096779,measures_secondary,Change From Baseline in EORTC QLQ-C30 Scores
NCT06096779,has_criteria,Child-Pugh B7
NCT06096779,has_criteria,Child-Pugh B8
NCT00955279,involves,Sarcoidosis
NCT00955279,evaluates,Ustekinumab
NCT00955279,evaluates,Golimumab
NCT00955279,measures_primary,Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 16
NCT00955279,measures_secondary,Change From Baseline in 6-minute Walk Distance at Week 28
NCT00955279,measures_secondary,Change From Baseline in the St. George's Respiratory Questionnaire (SGRQ) Total Score at Week 28
NCT00955279,measures_secondary,Percentage of Responders With a Score of Less Than or Equal to 1 on Skin Physician's Global Assessment (SPGA) Scale
NCT00955279,has_criteria,Baseline (Day 1) and Week 16
NCT00955279,has_criteria,Baseline (Day 1) and Week 28
NCT03977584,involves,Autosomal-Dominant Alzheimer's Disease
NCT03977584,evaluates,crenezumab
NCT03977584,measures_primary,annualized rate of change
NCT03977584,measures_secondary,tau burden
NCT03977584,has_criteria,enrolled in main Study NCT01998841
NCT01579084,involves,Erythema Associated With Rosacea
NCT01579084,evaluates,AGN-199201
NCT01579084,measures_primary,Percentage of Responders
NCT01579084,measures_secondary,Erythema severity
NCT01579084,has_criteria,2-grade decrease
NCT06572384,involves,Interstitial Lung Disease
NCT06572384,involves,Connective Tissue Disease
NCT06572384,evaluates,Belimumab
NCT06572384,measures_primary,Absolute Change in FVC
NCT06572384,measures_secondary,Time to ILD Progression
NCT06572384,measures_secondary,FACIT-Fatigue Score
NCT06572384,measures_secondary,L-PF Total Symptom Score
NCT06572384,has_criteria,Baseline and Week 52
NCT01104779,involves,Schizophrenia
NCT01104779,evaluates,Cariprazine
NCT01104779,measures_primary,PANSS Total Score
NCT01104779,measures_secondary,CGI-S
NCT01104779,has_criteria,DSM-IV-TR criteria
NCT00791479,involves,Type 2 Diabetes
NCT00791479,evaluates,LY2189265
NCT00791479,measures_primary,Change From Baseline in HbA1c
NCT00791479,measures_secondary,Fasting Blood Glucose
NCT00791479,measures_secondary,Percentage of Participants Achieve HbA1c <7% or ≤6.5%
NCT00791479,measures_secondary,Change From Baseline in Daily Mean Blood Glucose Values From the 7-point Self Monitored Blood Glucose (SMBG) Profiles
NCT00791479,has_criteria,Baseline
NCT01189279,involves,Alopecia
NCT01189279,evaluates,Bimatoprost
NCT01189279,measures_primary,Maximum Plasma Level
NCT01189279,measures_secondary,Clinically Significant ECG Findings
NCT01189279,measures_secondary,Local Scalp Tolerability
NCT01189279,has_criteria,Single Dose
NCT01189279,has_criteria,Multiple Doses
NCT01381679,involves,Coronary Heart Disease
NCT01381679,evaluates,ezetimibe
NCT01381679,measures_primary,LDL-C target level
NCT01381679,measures_secondary,Total Cholesterol
NCT01381679,measures_secondary,High-density Lipoprotein Cholesterol
NCT01381679,measures_secondary,Triglycerides
NCT01381679,has_criteria,LDL-cholesterol target levels not achieved
NCT01381679,has_criteria,physician decision to initiate treatment
NCT01381679,has_criteria,LDL cholesterol levels ≤113 mg/dl
NCT05784779,involves,NASH
NCT05784779,involves,NAFLD
NCT05784779,evaluates,GH509
NCT05784779,evaluates,Placebo
NCT05784779,measures_primary,Change in liver fat
NCT05784779,measures_secondary,Proportion of MRI-PDFF responders
NCT05784779,measures_secondary,Change in liver enzymes
NCT05784779,measures_secondary,Change in glycemic control
NCT05784779,measures_secondary,Change in weight control
NCT05784779,measures_secondary,Tolerability and safety
NCT05784779,has_criteria,BMI ≥ 18 kg/m2
NCT05784779,has_criteria,≥ 18 years of age
NCT05784779,has_criteria,\< 75 years old
NCT05784779,has_criteria,Histologically confirmed NASH
NCT05784779,has_criteria,stage 2-3 fibrosis
NCT00699179,involves,Type 1 Diabetes Mellitus
NCT00699179,involves,Type 2 Diabetes Mellitus
NCT00699179,evaluates,NovoMix® 30
NCT00699179,measures_primary,Change in HbA1c
NCT00699179,measures_secondary,Change in FPG
NCT00699179,measures_secondary,Change in PPG
NCT00699179,measures_secondary,Change in insulin dose
NCT00699179,measures_secondary,Change in oral antidiabetic drug therapy
NCT00699179,measures_secondary,Change in body weight
NCT00699179,measures_secondary,Change in waist circumference
NCT00699179,measures_secondary,Change in number of hypoglycaemic events
NCT00699179,measures_secondary,Number of adverse drug reactions
NCT00699179,has_criteria,HbA1c greater than 7%
NCT00699179,has_criteria,Informed Consent
NCT00699179,has_criteria,Type 1 or Type 2 Diabetes Mellitus
NCT00699179,has_criteria,inadequately controlled on human insulin therapy
NCT00699179,has_criteria,lasting for at least 6 months
NCT00699179,has_criteria,hypersensitivity to biphasic insulin aspart 30
NCT00699179,has_criteria,other limiting conditions
NCT00699179,has_criteria,pregnant
NCT01361308,involves,Vasomotor Symptoms
NCT01361308,evaluates,Brisdelle
NCT01361308,measures_primary,Mean change VMS
NCT01361308,measures_secondary,Hot Flash Severity
NCT01361308,has_criteria,Patient Global Improvement
NCT05987423,involves,Thyroid Eye Disease
NCT05987423,evaluates,Satralizumab
NCT05987423,measures_primary,Proptosis reduction
NCT05987423,measures_secondary,Diplopia improvement
NCT05987423,measures_secondary,Motility-induced pain
NCT05987423,measures_secondary,Spontaneous pain
NCT05987423,measures_secondary,GO-QoL score
NCT05987423,measures_secondary,Overall Response
NCT05987423,measures_secondary,Clinical Activity Score
NCT05987423,has_criteria,≥ 2 millimeters (mm) increase
NCT02093923,involves,Hereditary Angioedema
NCT02093923,evaluates,DX-2930
NCT02093923,measures_primary,Serious Adverse Events
NCT02093923,measures_secondary,Treatment-Emergent Adverse Events
NCT02093923,has_criteria,≥2 HAE attacks per year
NCT02618408,involves,ADHD
NCT02618408,evaluates,SPN-810
NCT02618408,measures_primary,percent change IA
NCT02618408,measures_secondary,CGI-I
NCT02618408,measures_secondary,CGI-S
NCT02618408,has_criteria,non-missing IA
NCT03995108,involves,WHIM Syndrome
NCT03995108,evaluates,Mavorixafor
NCT03995108,measures_primary,Composite Clinical Efficacy
NCT03995108,measures_secondary,Total Warts Score
NCT03995108,measures_secondary,Total Infection Score
NCT03995108,measures_secondary,Time to Early Release
NCT03995108,has_criteria,Lymphopenia
NCT00882908,involves,Hepatitis C Virus
NCT00882908,evaluates,TMC435
NCT00882908,measures_primary,SVRW72
NCT00882908,measures_secondary,HCV RNA levels
NCT00882908,has_criteria,Never received treatment
NCT00675623,involves,Alzheimer's Disease
NCT00675623,evaluates,Dimebon
NCT00675623,measures_primary,cognition and memory
NCT00675623,measures_primary,global function
NCT00675623,measures_secondary,self care and daily function
NCT00675623,measures_secondary,behavior
NCT00675623,has_criteria,Mild-to-Moderate Alzheimer's disease
NCT00675623,has_criteria,Probable AD
NCT00675623,has_criteria,MMSE score 10-24
NCT00675623,has_criteria,Computerized tomography (CT) san or magnetic resonance imaging (MRI) consistent with AD
NCT00675623,has_criteria,Caregiver who cares for the patient at least 5 days per week
NCT00675623,has_criteria,Anti-dementia drugs including cholinesterase-inhibitors or N-methyl-D-aspartate receptor (NMDA) receptor antagonists within 90 days
NCT00675623,has_criteria,Other causes of dementia
NCT00675623,has_criteria,Other primary psychiatric or neurological disorders
NCT00675623,has_criteria,Unstable medical illnesses or significant hepatic or renal disease
NCT05919823,involves,Schizophrenia
NCT05919823,evaluates,KarXT
NCT05919823,measures_primary,PANSS total score
NCT05919823,measures_secondary,PANSS positive score
NCT05919823,measures_secondary,PANSS negative score
NCT05919823,measures_secondary,PANSS Negative Marder Factor score
NCT05919823,measures_secondary,CGI-S score
NCT05919823,has_criteria,Chinese Adult Subjects
NCT04268823,involves,Chronic Obstructive Pulmonary Disease
NCT04268823,evaluates,QBW251
NCT04268823,measures_primary,Fibrinogen plasma concentration
NCT04268823,measures_secondary,Total Bacteria Load
NCT04268823,measures_secondary,COPD Assessment Test
NCT04268823,measures_secondary,Euro Quality of Life-5 Dimensions-3 Level
NCT04268823,has_criteria,Baseline
NCT02913508,involves,Ulcerative Colitis
NCT02913508,involves,Crohn's Disease
NCT02913508,evaluates,Vedolizumab Subcutaneous
NCT02913508,evaluates,Vedolizumab Intravenous
NCT02913508,measures_primary,Average Concentration
NCT02913508,measures_secondary,Percentage of Participants
NCT02913508,measures_secondary,Percent Saturation of MAdCAM-1
NCT02913508,has_criteria,positive HAHA
NCT06315608,involves,Amyotrophic Lateral Sclerosis
NCT06315608,evaluates,MRG-001
NCT06315608,measures_primary,Change in disease progression
NCT06315608,measures_secondary,Stem Cell Mobilization
NCT06315608,measures_secondary,Regulatory T-cell Mobilization
NCT06315608,has_criteria,Written informed consent
NCT06315608,has_criteria,Age 18-75 years
NCT06315608,has_criteria,ALS diagnosis
NCT06315608,has_criteria,Time since onset ≤ 48 months
NCT06315608,has_criteria,Vital Capacity ≥ 50%
NCT06315608,has_criteria,Riluzole stable dose
NCT03345823,involves,Crohn's Disease
NCT03345823,evaluates,Upadacitinib
NCT03345823,measures_primary,Clinical Remission
NCT03345823,measures_secondary,Endoscopic Response
NCT03345823,measures_secondary,Adverse Events
NCT03345823,measures_secondary,Patient-Reported Outcomes
NCT03345823,measures_secondary,Clinical Response 100
NCT03345823,measures_secondary,Endoscopic Remission
NCT03345823,has_criteria,CDAI < 150
NCT01237223,involves,Essential Hypertension
NCT01237223,evaluates,SPA100
NCT01237223,measures_primary,Change in msDBP
NCT01237223,measures_primary,Change in msSBP
NCT01237223,measures_secondary,Percentage of Participants Achieving Blood Pressure Control at Endpoint
NCT01237223,measures_secondary,Percentage of Participants Achieving a Successful Response Rate
NCT01237223,measures_secondary,Number of Participants With Adverse Events
NCT01237223,has_criteria,msDBP < 90 mmHg
NCT01237223,has_criteria,msSBP < 140 mmHg
NCT04135508,involves,Ankylosing Spondylitis
NCT04135508,evaluates,BAT1406
NCT04135508,evaluates,Humira
NCT04135508,measures_primary,ASAS20 treatment response
NCT04135508,measures_secondary,ASAS40 treatment response
NCT04135508,measures_secondary,ASAS5/6 treatment response
NCT04135508,measures_secondary,BASDAI50 treatment response
NCT04135508,measures_secondary,performance status score
NCT04135508,measures_secondary,spinal pain score
NCT04135508,measures_secondary,morning stiffness duration
NCT04135508,measures_secondary,ASDAS
NCT04135508,measures_secondary,BASDAI
NCT04135508,measures_secondary,BASFI
NCT03653208,involves,Healthy male volunteers
NCT03653208,evaluates,hzVSF-v13
NCT03653208,measures_primary,Safety
NCT03653208,measures_secondary,Tolerability
NCT03653208,has_criteria,BMI 18-27 kg/m2
NCT03653208,has_criteria,Age 19-45 years
NCT03653208,has_criteria,Weight 55-90 kg
NCT03653208,has_criteria,Clinically healthy
NCT03653208,has_criteria,Dual contraception
NCT02423408,involves,Tension-Type Headache
NCT02423408,evaluates,TNX-201 Capsules
NCT02423408,measures_primary,Number of Subjects Pain Free
NCT02423408,measures_secondary,Rescue Medication
NCT02423408,has_criteria,2-category Improvement
NCT03614923,involves,Chronic Rhinosinusitis With Nasal Polyps
NCT03614923,evaluates,Etokimab
NCT03614923,measures_primary,Change From Baseline in NPS
NCT03614923,measures_secondary,Change From Baseline in SNOT-22 Score
NCT03614923,has_criteria,Nasal polyp score ≥ 4
NCT03614923,has_criteria,SNOT-22 score > 15
NCT03614923,has_criteria,Nasal blockade/obstruction/congestion
NCT03614923,has_criteria,Nasal discharge
NCT03614923,has_criteria,Facial pain/pressure
NCT03614923,has_criteria,Reduction or loss of smell
NCT03614923,has_criteria,BMI 18 to 42 kg/m\^2
NCT03614923,has_criteria,Total body weight > 50 kg
NCT05509023,involves,Atopic Dermatitis
NCT05509023,evaluates,ADX-914
NCT05509023,measures_primary,EASI score change
NCT05509023,measures_secondary,SCORAD score change
NCT05509023,measures_secondary,EASI reduction
NCT05509023,measures_secondary,vIGA-AD score
NCT05509023,has_criteria,serious adverse events
NCT01305408,involves,Major Depression
NCT01305408,evaluates,Armodafinil
NCT01305408,measures_primary,Change from baseline
NCT01305408,measures_secondary,Percentage of Responders
NCT01305408,measures_secondary,Participants in Remission
NCT01305408,has_criteria,Adults With Bipolar I Disorder
NCT02068508,involves,type 2 diabetes mellitus
NCT02068508,evaluates,Pioglitazone Tablets
NCT02068508,measures_primary,Change From Baseline in Fasting Blood Glucose
NCT02068508,measures_secondary,Change From Baseline in Glycosylated Hemoglobin
NCT02068508,measures_secondary,Change From Baseline in Fasting Triglycerides
NCT02068508,measures_secondary,Change From Baseline in HDL Cholesterol
NCT02068508,measures_secondary,Change From Baseline in LDL Cholesterol
NCT02068508,has_criteria,insulin resistance
NCT02068508,has_criteria,treated with insulin product
NCT02068508,has_criteria,started Actos Tablets
NCT01272908,involves,Rheumatoid Arthritis
NCT01272908,evaluates,MabThera
NCT01272908,measures_primary,ACR20/50/70
NCT01272908,measures_secondary,Complete clinical response
NCT01272908,has_criteria,Prior Anti-TNF Therapy
NCT00113308,involves,Rheumatoid Arthritis
NCT00113308,evaluates,COX-2 Inhibitor
NCT00113308,measures_primary,ACR20 Responders
NCT00113308,measures_secondary,tender/painful joint count
NCT00113308,measures_secondary,swollen joint count
NCT00113308,measures_secondary,patient's pain assessment
NCT00113308,measures_secondary,physician's global assessment
NCT00113308,measures_secondary,patient's global assessment
NCT00113308,measures_secondary,functional disability index
NCT00113308,measures_secondary,Short Form - McGill Pain Questionnaire
NCT00113308,measures_secondary,C-reactive protein
NCT00113308,measures_secondary,vital signs
NCT00113308,measures_secondary,heart rate
NCT00113308,measures_secondary,weight
NCT00113308,measures_secondary,BMI
NCT00113308,measures_secondary,pedal oedema
NCT00113308,measures_secondary,12-lead electrocardiograms
NCT01061723,involves,Ankylosing Spondylitis
NCT01061723,evaluates,SAR153191
NCT01061723,measures_primary,ASAS20 response at Week 12
NCT01061723,measures_primary,ASAS40 response at Week 12
NCT01061723,measures_secondary,Partial Remission at Week 12
NCT01061723,has_criteria,ASAS20 criteria
NCT01061723,has_criteria,ASAS40 criteria
NCT04586023,involves,Relapsing Multiple Sclerosis
NCT04586023,evaluates,Fenebrutinib
NCT04586023,evaluates,Teriflunomide
NCT04586023,measures_primary,Annualized Relapse Rate
NCT04586023,measures_primary,Time to Onset of cCDP12
NCT04586023,measures_primary,Time to Onset of cCDP24
NCT04586023,measures_primary,Time to Onset of CDP12
NCT04586023,measures_primary,Time to Onset of CDP24
NCT04586023,measures_primary,Total Number of Gd+ Lesions
NCT04586023,measures_primary,Percentage Change in Brain Volume
NCT04586023,measures_primary,Change in MSIS-29 Physical Score
NCT04586023,measures_secondary,Time to Onset of 12-week Confirmed 4-point Worsening in SDMT Score
NCT04586023,has_criteria,Minimum of 96 weeks
NCT06534723,involves,Alzheimer's Dementia
NCT06534723,involves,Syndrome of Deficiency of Spleen and Kidney
NCT06534723,evaluates,Wujia Yizhi Granules
NCT06534723,measures_primary,Change from baseline to endpoint
NCT06534723,measures_secondary,Clinical Dementia Rating-Sum of Boxes
NCT06534723,measures_secondary,ADAS-Cog12
NCT06534723,measures_secondary,ADCS-ADL scale
NCT06534723,has_criteria,Change from baseline to Month 12
NCT02192190,involves,Osteoarthritis Knee Pain
NCT02192190,evaluates,LY2951742
NCT02192190,measures_primary,WOMAC Pain Subscale
NCT02192190,measures_primary,WOMAC Physical Function Subscale
NCT02192190,measures_secondary,Patient's Global Assessment
NCT02192190,has_criteria,Baseline
NCT02224690,involves,Lennox-Gastaut Syndrome
NCT02224690,evaluates,Cannabidiol
NCT02224690,measures_primary,Drop Seizure Frequency
NCT02224690,measures_secondary,Total Seizure Frequency
NCT02224690,has_criteria,≥50% reduction
NCT04308590,involves,Cortisol-Secreting Adrenal Adenomas
NCT04308590,evaluates,Relacorilant
NCT04308590,measures_primary,Mean change in SBP
NCT04308590,measures_secondary,Mean change in AUCglucose
NCT04308590,measures_secondary,Mean change in DBP
NCT04308590,measures_secondary,Mean change in HR
NCT04308590,measures_secondary,Mean change in HbA1c
NCT04308590,measures_secondary,Proportion of patients who achieved 2-hour oGTT glucose less than 140 mg/dL
NCT04308590,has_criteria,Baseline greater than 5.7%
NCT03037203,involves,Parkinson's Disease
NCT03037203,involves,Excessive Sleepiness
NCT03037203,evaluates,JZP-110
NCT03037203,measures_primary,Epworth Sleepiness Scale
NCT03037203,measures_secondary,Change from Baseline
NCT03037203,has_criteria,Idiopathic PD
NCT03037203,has_criteria,Hoehn and Yahr stage
NCT03037203,has_criteria,ESS scores >11
NCT03037203,has_criteria,Usual nightly time in bed >=6 hours
NCT03037203,has_criteria,No other degenerative Parkinsonian syndromes
NCT03037203,has_criteria,No untreated or inadequately treated OSA
NCT03037203,has_criteria,No severe cognitive impairment
NCT05409079,involves,neuromuscular conditions
NCT05409079,evaluates,device intervention
NCT05409079,measures_primary,Change from Baseline
NCT05409079,measures_secondary,Change from Baseline
NCT05409079,has_criteria,Subjects between 10 and 99 years of age
NCT06411379,involves,Hidradenitis Suppurativa
NCT06411379,evaluates,Sonelokimab
NCT06411379,measures_primary,Hidradenitis Suppurativa Clinical Response 75
NCT06411379,measures_secondary,Hidradenitis Suppurativa Clinical Response 50
NCT06411379,measures_secondary,Change in IHS4
NCT06411379,measures_secondary,Dermatology Life Quality Index
NCT06411379,measures_secondary,Reduction from NRS30 & NRS50 in Patient's Global Assessment of Skin Pain
NCT06411379,measures_secondary,Patient Global Impression - Severity of Illness - Hidradenitis Suppurativa at Week 16
NCT06411379,has_criteria,Adult participants
NCT06411379,has_criteria,Moderate to Severe
NCT03781479,involves,Spinal Muscular Atrophy Type 3
NCT03781479,evaluates,Amifampridine Phosphate
NCT03781479,measures_primary,HFMSE change from baseline
NCT03781479,measures_secondary,HFMSE
NCT03781479,has_criteria,Age 6-50 years
NCT03781479,has_criteria,Genetically confirmed SMA Type 3
NCT03781479,has_criteria,Able to walk independently
NCT03781479,has_criteria,Not taking Nusinersen
NCT03781479,has_criteria,Able to swallow oral medication
NCT05125679,involves,Plaque Psoriasis
NCT05125679,evaluates,Guselkumab
NCT05125679,measures_primary,Change from Baseline in CFR
NCT05125679,measures_secondary,Global Longitudinal Strain
NCT05125679,measures_secondary,carotid-femoral Pulse Wave Velocity
NCT05125679,has_criteria,CFR in the Ranges of 2 to 2.49
NCT05125679,has_criteria,Nicotine Users and Non-users
NCT01980290,involves,Chronic Hepatitis C
NCT01980290,evaluates,Telaprevir
NCT01980290,measures_primary,SVR12
NCT01980290,measures_secondary,HCV RNA
NCT01980290,has_criteria,adherence to telaprevir
NCT04197479,involves,Non Alcoholic Fatty Liver Disease
NCT04197479,evaluates,Resmetirom
NCT04197479,measures_primary,percent change LDL-C
NCT04197479,measures_secondary,percent change ApoB
NCT04197479,measures_secondary,hepatic fat fraction
NCT04197479,measures_secondary,percent change triglycerides
NCT04197479,has_criteria,baseline TG > 150 mg/dL
NCT04102579,involves,Huntington Disease
NCT04102579,evaluates,Valbenazine
NCT04102579,measures_primary,TMC score
NCT04102579,measures_secondary,CGI-C Responders
NCT04102579,measures_secondary,PGI-C Responders
NCT04102579,measures_secondary,Neuro-QoL T-Score
NCT04102579,has_criteria,Baseline
NCT04848779,involves,Infantile-onset Pompe Disease
NCT04848779,evaluates,Alglucosidase Alfa
NCT04848779,measures_primary,alive and free ventilation
NCT04848779,measures_secondary,alive at 12 months
NCT04848779,has_criteria,≤6 Months of Age
NCT01551290,involves,Ulcerative Colitis
NCT01551290,evaluates,Infliximab
NCT01551290,measures_primary,Mayo score decrease
NCT01551290,measures_secondary,Clinical remission
NCT01551290,measures_secondary,Mucosal healing
NCT01551290,has_criteria,Active Ulcerative Colitis
NCT05431803,involves,Acromegaly
NCT05431803,evaluates,Lanreotide Autogel
NCT05431803,measures_primary,fasting GH ≤ 2.5 μg/L
NCT05431803,measures_primary,IGF-1 normalization
NCT05431803,measures_secondary,fasting GH < 1 μg/L
NCT05431803,measures_secondary,IGF-1 ≤1.3 ULN
NCT05431803,measures_secondary,Mean change in fasting GH
NCT05431803,measures_secondary,Mean change in IGF-1
NCT05431803,measures_secondary,Mean change in symptoms
NCT05431803,measures_secondary,Mean change in QoL scores
NCT05431803,measures_secondary,Treatment utilisation
NCT05431803,measures_secondary,Incidence of AEs
NCT05431803,measures_secondary,Mean change in BMI
NCT05431803,measures_secondary,Mean change in blood pressure
NCT05431803,measures_secondary,Mean change in heart rate
NCT05431803,measures_secondary,Mean change in clinical lab assessments
NCT05462990,involves,Knee Osteoarthritis
NCT05462990,evaluates,QUC398
NCT05462990,measures_primary,Change from baseline
NCT05462990,measures_secondary,Cartilage volume
NCT05462990,has_criteria,Weight ≥ 50 kg
NCT02466490,involves,Essential Hypertension
NCT02466490,evaluates,Fimasartan
NCT02466490,evaluates,HCTZ
NCT02466490,measures_primary,Blood Pressure Change
NCT02466490,measures_secondary,Treatment Response Rate
NCT02466490,measures_secondary,Adverse Event Incidence
NCT02466490,has_criteria,Baseline to Treatment Week 24
NCT01543490,involves,Blepharitis
NCT01543490,evaluates,ISV-305
NCT01543490,evaluates,Vehicle
NCT01543490,measures_primary,Reduction in score
NCT01543490,measures_secondary,Eyelid irritation resolution
NCT01543490,has_criteria,Decrease in score by 2 units
NCT03468790,involves,Allergic Asthma
NCT03468790,evaluates,Anti-IgE Monoclonal Antibody
NCT03468790,measures_primary,Asthma exacerbations
NCT03468790,measures_secondary,Asthma symptom scores
NCT03468790,measures_secondary,Asthma Control Test
NCT03468790,measures_secondary,Asthma Quality of Life Questionnaire
NCT03468790,measures_secondary,Global Evaluation of Treatment Effectiveness
NCT03468790,measures_secondary,Rescue medication use
NCT03468790,measures_secondary,Lung function parameters
NCT03468790,has_criteria,at least one exacerbation
NCT00974090,involves,Type 2 Diabetes
NCT00974090,evaluates,MP-513
NCT00974090,measures_primary,Change From Baseline in HbA1c
NCT00974090,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT00974090,measures_secondary,Change From Baseline in AUC0-2h for Postprandial Plasma Glucose
NCT00974090,measures_secondary,Change From Baseline in 2-hour Postprandial Plasma Glucose
NCT00974090,has_criteria,20 - 75 years old
NCT00974090,has_criteria,dietary management
NCT00974090,has_criteria,therapeutic exercise
NCT00974090,has_criteria,HbA1c 7.0% - 10.0%
NCT00974090,has_criteria,Sulfonylurea 12 weeks
NCT02469090,involves,Parkinson's Disease
NCT02469090,evaluates,APL-130277
NCT02469090,measures_primary,MDS-UPDRS Part III score
NCT02469090,measures_secondary,Patient-related Full 'ON' Response
NCT02469090,has_criteria,standard dose of oral L-dopa
NCT04718103,involves,Severe Asthma
NCT04718103,evaluates,GSK3511294
NCT04718103,measures_primary,Annualized exacerbations
NCT04718103,measures_secondary,Saint George's Respiratory Questionnaire
NCT04718103,measures_secondary,Asthma Control Questionnaire-5
NCT04718103,measures_secondary,FEV1
NCT04718103,has_criteria,Adults >=12 years old
NCT01817790,involves,Ocular Allergy Symptoms
NCT01817790,evaluates,Fluticasone Propionate
NCT01817790,measures_primary,Mean Change From Baseline
NCT01817790,measures_secondary,Mean Change From Baseline
NCT01817790,has_criteria,Baseline to 14 days
NCT04877990,involves,Crohn's Disease
NCT04877990,involves,Ulcerative Colitis
NCT04877990,evaluates,Deucravacitinib
NCT04877990,measures_primary,Number of TEAEs
NCT04877990,measures_secondary,Number of participants experiencing AEs
NCT04877990,measures_secondary,Number of participants experiencing SAEs
NCT04877990,measures_secondary,Number of participants experiencing AEs leading to study discontinuation
NCT04877990,measures_secondary,Number of participants experiencing AEIs
NCT04877990,has_criteria,first dose of study treatment
NCT02359903,involves,Ankylosing Spondylitis
NCT02359903,evaluates,BCD-055
NCT02359903,evaluates,Remicade
NCT02359903,measures_primary,ASAS20
NCT02359903,measures_primary,ASAS40
NCT02359903,measures_secondary,BASDAI Score
NCT02359903,measures_secondary,BASMI Score
NCT02359903,measures_secondary,BASFI Score
NCT02359903,measures_secondary,MASES Score
NCT02359903,measures_secondary,SF36 Score
NCT02359903,measures_secondary,Chest Expansion
NCT02359903,has_criteria,at least 1 injection
NCT01988103,involves,Psoriasis
NCT01988103,evaluates,Apremilast
NCT01988103,measures_primary,PASI-75 response
NCT01988103,measures_secondary,sPGA score
NCT01988103,has_criteria,Baseline to Week 16
NCT03447990,evaluates,MYK-491
NCT03447990,measures_primary,Number of Participants
NCT03447990,measures_secondary,Change From Baseline
NCT03447990,has_criteria,last non-missing value
NCT03976323,involves,Metastatic Non-squamous Non-Small-Cell Lung Cancer
NCT03976323,evaluates,Pembrolizumab
NCT03976323,measures_primary,Progression-free survival
NCT03976323,measures_secondary,Overall survival
NCT03976323,measures_secondary,Adverse Event
NCT03976323,measures_secondary,Discontinuing Study Treatment
NCT03976323,has_criteria,Up to approximately 3 years
NCT03976323,has_criteria,Up to approximately 5 years
NCT02570750,involves,Psoriasis
NCT02570750,evaluates,Etanercept
NCT02570750,measures_primary,Change From Baseline PASI
NCT02570750,measures_secondary,Dermatology Life Quality Index
NCT02570750,measures_secondary,Percentage of Participants PASI75 Response
NCT02570750,has_criteria,Baseline
NCT02570750,has_criteria,Baseline
NCT05367050,involves,Total Joint Replacement Surgery
NCT05367050,evaluates,Behavioral Tele-health Program
NCT05367050,measures_primary,Change in KOOS
NCT05367050,measures_primary,Change in HOOS
NCT05367050,measures_secondary,Change in Pain Catastrophizing
NCT05367050,measures_secondary,Change in Depression Scores
NCT05367050,measures_secondary,Change in Anxiety Scores
NCT05367050,has_criteria,Up to 4 months
NCT01448850,involves,Chronic Obstructive Pulmonary Disease
NCT01448850,evaluates,MEDI8968
NCT01448850,measures_primary,exacerbations/year
NCT01448850,measures_secondary,Time to First Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease
NCT01448850,has_criteria,Day 1 up to 393
NCT02694523,involves,Psoriasis
NCT02694523,evaluates,Risankizumab
NCT02694523,evaluates,Adalimumab
NCT02694523,measures_primary,PASI90
NCT02694523,measures_secondary,sPGA
NCT02694523,has_criteria,Moderate to Severe
NCT04119050,involves,Warm Autoimmune Hemolytic Anemia
NCT04119050,evaluates,M281
NCT04119050,measures_primary,Durable Response of Improvement in Hemoglobin
NCT04119050,measures_secondary,Change From Baseline in the Total Score From the FACIT-Fatigue Scale
NCT04119050,measures_secondary,Change from Baseline in Average Daily Dose of Prednisone or Equivalent
NCT04119050,measures_secondary,Number of Participants That Simultaneously Attain Normal Lactate Dehydrogenase
NCT04119050,has_criteria,Baseline (Day 1
NCT03235050,involves,Overweight and Obese Subjects With Type 2 Diabetes
NCT03235050,evaluates,cotadutide
NCT03235050,measures_primary,Change in HbA1c
NCT03235050,measures_secondary,Percent Change in Body Weight
NCT03235050,has_criteria,100
NCT02513550,involves,Plaque Psoriasis
NCT02513550,evaluates,Ixekizumab
NCT02513550,measures_primary,sPGA 0 or 1
NCT02513550,measures_secondary,PASI 75
NCT02513550,has_criteria,clinical response criteria
NCT03318523,involves,Parkinson's Disease
NCT03318523,evaluates,BIIB054
NCT03318523,measures_primary,Change From Baseline in MDS-UPDRS Total Score
NCT03318523,measures_secondary,Change From Baseline in MDS-UPDRS Total Score
NCT03318523,has_criteria,Not specified
NCT00969150,involves,Major Depressive Disorder
NCT00969150,evaluates,Levomilnacipran ER
NCT00969150,measures_primary,Change in MADRS
NCT00969150,measures_secondary,Change in SDS
NCT00969150,has_criteria,18-80 years old
NCT00969150,has_criteria,DSM-IV-TR criteria
NCT00969150,has_criteria,depressive episode 4 weeks
NCT00969150,has_criteria,no pregnancy or breastfeeding
NCT00969150,has_criteria,reliable birth control
NCT00969150,has_criteria,no history manic episode
NCT00969150,has_criteria,no history psychotic disorder
NCT00969150,has_criteria,no history obsessive-compulsive disorder
NCT00969150,has_criteria,no suicide risk
NCT02202850,involves,Ankylosing Spondylitis
NCT02202850,evaluates,Etanercept
NCT02202850,measures_primary,ASAS Partial Remission
NCT02202850,measures_secondary,ASAS 5/6 Remission
NCT02202850,measures_secondary,ASAS 60 Remission
NCT02202850,has_criteria,Less than or equal to 2
NCT02202850,has_criteria,Greater than or equal to 20 percent
NCT02202850,has_criteria,Greater than or equal to 60 percent
NCT02202850,has_criteria,Absolute change greater than or equal to 2
NCT00264550,involves,Rheumatoid Arthritis
NCT00264550,evaluates,Golimumab
NCT00264550,measures_primary,ACR 20 response
NCT00264550,measures_secondary,Health Assessment Questionnaire (HAQ) Score
NCT00264550,measures_secondary,Disease Activity Index Score 28 (DAS 28)
NCT00264550,has_criteria,tender joint count
NCT00264550,has_criteria,swollen joint count
NCT00264550,has_criteria,C-reactive protein
NCT00264550,has_criteria,global assessment of disease activity
NCT02322450,involves,Essential Hypertension
NCT02322450,evaluates,QGC001
NCT02322450,measures_primary,Change from Period 1
NCT02322450,measures_secondary,24h ABPM
NCT02322450,measures_secondary,Self BP measurements
NCT02322450,measures_secondary,Office BP measurements
NCT02322450,measures_secondary,Hormonal measurements
NCT02322450,has_criteria,minimum of 24 measurements
NCT03388255,involves,localized scleroderma diseases
NCT03388255,evaluates,PLACENTEX ® i.m.
NCT03388255,measures_primary,tele-thermographic profile
NCT03388255,measures_secondary,ultrasound profile
NCT03388255,measures_secondary,histology improvement
NCT03388255,measures_secondary,Dermatology Life Quality Index (DLQI)
NCT03388255,has_criteria,inactive stage of disease
NCT02833350,involves,Rheumatoid Arthritis
NCT02833350,evaluates,GDC-0853
NCT02833350,evaluates,Placebo
NCT02833350,evaluates,Adalimumab
NCT02833350,measures_primary,ACR50 response
NCT02833350,measures_secondary,Adverse Events
NCT02833350,has_criteria,Day 84
NCT02833350,has_criteria,Day 1 up to 8 weeks
NCT04675450,involves,Metastatic Breast Cancer
NCT04675450,evaluates,NBP
NCT04675450,measures_primary,EORTC QLQ-CIPN20 Sensory Subscale
NCT04675450,measures_secondary,Number of Participants Requiring Rescue Medication
NCT04675450,measures_secondary,Days Free of Rescue Medication
NCT04675450,measures_secondary,Mean Change from Baseline in the Brief Pain Inventory Short Form (mBPI-SF) score
NCT04675450,measures_secondary,Number of Participants with Treatment-Emergent Adverse Events
NCT04675450,measures_secondary,Area Under the Curve (AUC) for NBP
NCT04675450,measures_secondary,Cmax for NBP
NCT04675450,measures_secondary,Tmax for NBP
NCT04675450,measures_secondary,Area Under the Curve for Paclitaxel
NCT06254950,involves,Ulcerative Colitis
NCT06254950,evaluates,TAK-279
NCT06254950,measures_primary,Clinical Remission
NCT06254950,measures_secondary,Clinical Response
NCT06254950,measures_secondary,Symptomatic Remission
NCT06254950,measures_secondary,Endoscopic Improvement
NCT06254950,measures_secondary,Endoscopic Remission
NCT06254950,measures_secondary,Bowel Urgency
NCT06254950,measures_secondary,Abdominal Pain
NCT06254950,measures_secondary,IBDQ Total Score
NCT06254950,has_criteria,Moderately to Severely Active
NCT02762955,involves,Plaque Psoriasis
NCT02762955,evaluates,adalimumab
NCT02762955,measures_primary,PASI Improvement (%)
NCT02762955,measures_secondary,BSA Improvement (%)
NCT02762955,measures_secondary,Change in SF-36
NCT02762955,measures_secondary,Change in DQLI
NCT02762955,has_criteria,16 weeks of therapy
NCT02546908,involves,Prostate Cancer
NCT02546908,measures_primary,Overall Survival
NCT02546908,measures_secondary,Prostate Cancer-related Mortality
NCT02546908,measures_secondary,Metastasis-free survival
NCT02546908,measures_secondary,Progression-free Survival
NCT02546908,measures_secondary,Time to PSA Progression
NCT02546908,measures_secondary,European Quality of Life-5 Dimensions
NCT02546908,has_criteria,up to 5 years
NCT05809908,involves,Alzheimer's Disease
NCT05809908,evaluates,Tricaprilin
NCT05809908,measures_primary,Change From Baseline ADAS-Cog
NCT05809908,measures_secondary,ADCS-CGIC
NCT05809908,measures_secondary,Number of Subjects with Treatment Related Adverse Events
NCT05809908,measures_secondary,Change From Baseline ADCS-ADL score
NCT05809908,has_criteria,Mini Mental State Exam score 14 to 24
NCT05809908,has_criteria,NIA-AA criteria
NCT05809908,has_criteria,Magnetic resonance imaging compatible with probable AD
NCT05809908,has_criteria,cholinesterase inhibitors
NCT05809908,has_criteria,medium chain triglyceride -containing products
NCT05809908,has_criteria,less than 6 years of formal education
NCT05809908,has_criteria,medical or neurological condition other than AD
NCT05809908,has_criteria,modified Hachinski Ischaemia score > 4
NCT04201808,involves,Chronic Hepatitis B
NCT04201808,evaluates,TAF
NCT04201808,measures_primary,HBV DNA viral suppression
NCT04201808,measures_secondary,Adverse events
NCT04201808,measures_secondary,ALT levels within normal limit
NCT04201808,measures_secondary,AST levels within normal limit
NCT04201808,has_criteria,Suboptimal response
NCT01790503,involves,Glioblastoma
NCT01790503,evaluates,PLX3397
NCT01790503,evaluates,Radiation Therapy
NCT01790503,evaluates,Temozolomide
NCT01790503,measures_primary,Progression-free Survival
NCT01790503,measures_secondary,Karnofsky Performance Status
NCT01790503,has_criteria,Response Assessment in Neuro-Oncology
NCT00360308,involves,Parkinson's Disease
NCT00360308,evaluates,E2007
NCT00360308,measures_primary,Total Daily OFF Time
NCT00360308,measures_secondary,UPDRS Part II
NCT00360308,measures_secondary,UPDRS Part III
NCT00360308,measures_secondary,Total Daily ON Time
NCT00360308,has_criteria,Levodopa Treated
NCT00430508,involves,Essential Hypertension
NCT00430508,evaluates,Olmesartan and Hydrochlorothiazide
NCT00430508,measures_primary,Change in Diastolic Blood Pressure
NCT00430508,measures_secondary,Change in Systolic Blood Pressure
NCT00430508,has_criteria,moderate to severe hypertension
NCT04936308,involves,Psoriatic Arthritis
NCT04936308,evaluates,Guselkumab
NCT04936308,measures_primary,ACR 20 Response
NCT04936308,measures_secondary,Psoriasis Response
NCT04936308,has_criteria,Prior Anti-TNF Agent
NCT00742508,involves,Chronic Heart Failure
NCT00742508,evaluates,SK&F-105517-D
NCT00742508,measures_primary,Mean Change Albumin
NCT00742508,measures_secondary,Mean Change Alkaline Phosphatase
NCT00742508,measures_secondary,Mean Change Alanine Aminotransferase
NCT00742508,measures_secondary,Mean Change Aspartate Aminotransferase
NCT00742508,measures_secondary,Mean Change Creatine Kinase
NCT00742508,measures_secondary,Mean Change Gamma Glutamyl Transferase
NCT00742508,measures_secondary,Mean Change Amylase
NCT00742508,measures_secondary,Mean Change Total Bilirubin
NCT00742508,measures_secondary,Mean Change Creatinine
NCT00742508,measures_secondary,Mean Change Uric Acid
NCT00742508,measures_secondary,Mean Change Calcium
NCT00742508,measures_secondary,Mean Change Chloride
NCT00742508,measures_secondary,Mean Change Glucose
NCT00742508,measures_secondary,Mean Change Potassium
NCT00742508,measures_secondary,Mean Change Sodium
NCT00742508,measures_secondary,Mean Change Urea/Blood Urea Nitrogen
NCT00742508,measures_secondary,Mean Change Creatine Kinase BB Percentage
NCT00742508,measures_secondary,Mean Change Creatine Kinase MB Percentage
NCT00742508,measures_secondary,Mean Change Creatine Kinase MM Percentage
NCT06475508,involves,Rheumatoid Arthritis
NCT06475508,evaluates,Complarate
NCT06475508,evaluates,Actemra
NCT06475508,measures_primary,ACR20 response
NCT06475508,measures_secondary,ACR50 response
NCT06475508,measures_secondary,ACR70 response
NCT06475508,measures_secondary,Time to ACR20
NCT06475508,measures_secondary,DAS28
NCT06475508,has_criteria,28 assessed joints
NCT06475508,has_criteria,CRP or ESR
NCT06475508,has_criteria,PtGDA
NCT06475508,has_criteria,PGDA
NCT06347016,involves,Hypertriglyceridemia
NCT06347016,evaluates,Plozasiran
NCT06347016,measures_primary,Percent Change in TG
NCT06347016,measures_secondary,Proportion of Subjects Who Achieve Fasting TG Levels of < 500 mg/dL
NCT06347016,measures_secondary,Adjudicated Abdominal Clinical Event Rate
NCT06347016,measures_secondary,Proportion of Subjects Who Achieve Fasting TG Levels of <150mg/dL
NCT06347016,measures_secondary,Number of Subjects with Adverse Events
NCT06347016,measures_secondary,Incidence Rates of New-Onset Diabetes Mellitus
NCT06347016,measures_secondary,Incidence Rates of Impaired Glucose Tolerance
NCT06347016,measures_secondary,Incidence Rates of Worsening of Existing Diabetes
NCT06347016,measures_secondary,Change from Baseline in Hemoglobin A1c
NCT06347016,measures_secondary,Change from Baseline in Fasting Blood Glucose
NCT06347016,measures_secondary,Change from Baseline in C-Peptide
NCT06347016,measures_secondary,Change from Baseline in Homeostatic Model Assessment for Insulin Resistance
NCT02020616,involves,Type 2 Diabetes
NCT02020616,evaluates,LY3053102
NCT02020616,measures_primary,Change From Baseline in HbA1c
NCT02020616,measures_secondary,Percentage of Participants Achieving HbA1c <7.0% or HbA1c ≤6.5%
NCT02020616,measures_secondary,Percentage of Participants That Require Rescue Therapy
NCT02020616,measures_secondary,Change From Baseline in Body Weight
NCT02020616,measures_secondary,Change From Baseline in 7-Point Blood Glucose Profile
NCT02020616,has_criteria,Baseline HbA1c category
NCT02020616,has_criteria,metformin use
NCT02020616,has_criteria,washout of second OAM
NCT06108024,involves,Seborrheic Keratosis
NCT06108024,evaluates,SM-020 Gel 1.0%
NCT06108024,measures_primary,PLA score of 0
NCT06108024,measures_secondary,Application Site Reactions
NCT06108024,has_criteria,Seborrheic Keratosis Target Lesion
NCT02201524,involves,Psoriasis
NCT02201524,evaluates,PF-04965842
NCT02201524,measures_primary,PASI score at Week 4
NCT02201524,measures_secondary,Percent Change From Baseline in PASI Score at Week 1
NCT02201524,has_criteria,Baseline
NCT02201524,has_criteria,Baseline
NCT01933334,involves,Systemic Sclerosis-Related Interstitial Lung Disease
NCT01933334,evaluates,Pirfenidone
NCT01933334,measures_primary,Percentage of AEs
NCT01933334,measures_secondary,Serious Adverse Events
NCT01933334,has_criteria,Treatment-emergent
NCT05700734,evaluates,MK-8510
NCT05700734,involves,Human Immunodeficiency Virus Type 1
NCT05700734,measures_primary,Change from Baseline in Plasma HIV-1 RNA
NCT05700734,measures_secondary,Percentage of Participants Who Experience an Adverse Event
NCT05700734,measures_secondary,Percentage of Participants Who Discontinued from Study Due to an Adverse Event
NCT05700734,measures_secondary,Area Under the Concentration-Time Curve of MK-8558 From Time 0 to 168 Hours (AUC0-168 hr)
NCT05700734,measures_secondary,Area Under the Concentration-Time Curve of MK-8558 From Time 0 to last (AUC0-last)
NCT05700734,measures_secondary,Concentration at 168 Hours Post-dose (C168) of MK-8558
NCT05700734,measures_secondary,Maximum Concentration (Cmax) of MK-8558
NCT05700734,has_criteria,Up to 36 days
NCT01235234,involves,Dry Eye Disease
NCT01235234,evaluates,CF101
NCT01235234,measures_primary,Corneal FS Score
NCT01235234,measures_secondary,Schirmer Test Tearing
NCT01235234,measures_secondary,OSDI
NCT01235234,has_criteria,Corneal FS score
NCT06085534,involves,Ankylosing Spondylitis
NCT06085534,evaluates,LNK01001 Capsule
NCT06085534,measures_primary,ASAS40 response
NCT06085534,has_criteria,≥ 40% improvement
NCT01527916,involves,Alzheimer's Disease
NCT01527916,evaluates,ABT-126
NCT01527916,measures_primary,Alzheimer's Disease Assessment Scale
NCT01527916,measures_secondary,Activities of Daily Living
NCT01527916,measures_secondary,Mini Mental Status Exam
NCT01527916,measures_secondary,DEMentia Quality of Life
NCT01527916,measures_secondary,Clinician Interview-Based Impression of Change
NCT01527916,measures_secondary,Neuropsychiatry Inventory
NCT01527916,measures_secondary,Partner-Patient Questionnaire for Shared Activities
NCT01527916,measures_secondary,Resource Use in Dementia
NCT01527916,measures_secondary,EuroQol-5D Questionnaires
NCT01527916,measures_secondary,Wechsler Memory Scale-III Working Memory Index
NCT01527916,has_criteria,informed consent
NCT01527916,has_criteria,age 55-90 years
NCT03779334,involves,Spinal Muscular Atrophy
NCT03779334,evaluates,Risdiplam
NCT03779334,measures_primary,Percentage Sitting
NCT03779334,measures_secondary,Time to Ventilation
NCT03779334,has_criteria,SMN2 gene copies
NCT01231334,involves,Severe Facial Acne
NCT01231334,evaluates,Aczone® Plus Differin®
NCT01231334,evaluates,Duac® Plus Differin®
NCT01231334,measures_primary,GAAS at Week 12
NCT01231334,measures_secondary,Overall Disease Severity
NCT01231334,has_criteria,Baseline
NCT01585324,involves,Chronic Hepatitis C
NCT01585324,evaluates,Copegus
NCT01585324,evaluates,Pegasys
NCT01585324,measures_primary,SVR 24 weeks
NCT01585324,measures_secondary,Change in hemoglobin
NCT01585324,measures_secondary,Lowest hemoglobin
NCT01585324,has_criteria,Baseline and Week 12
NCT01936324,involves,Acne
NCT01936324,evaluates,DRM01B Topical Gel
NCT01936324,measures_primary,Acne Lesion Counts
NCT01936324,measures_secondary,Investigator Global Assessment of Acne
NCT01936324,has_criteria,Good health
NCT03250624,involves,Atopic Dermatitis
NCT03250624,evaluates,CD5024 0.3% Cream
NCT03250624,measures_primary,EASI score
NCT03250624,measures_secondary,IGA score
NCT03250624,has_criteria,Last Observation Carried Forward
NCT06501534,involves,Gout
NCT06501534,evaluates,IBI128
NCT06501534,measures_primary,serum uric acid levels
NCT06501534,measures_secondary,gout flares
NCT06501534,measures_secondary,Adverse Event
NCT06501534,has_criteria,Chinese subjects
NCT03775434,involves,atopic dermatitis
NCT03775434,evaluates,B244
NCT03775434,measures_primary,Number of TEAEs
NCT03775434,measures_secondary,Clinically Significant Changes
NCT03775434,measures_secondary,Mean Change in Blood Pressure
NCT03775434,measures_secondary,Mean Change in Pulse Rate
NCT03775434,measures_secondary,Mean Change in Body Temperature
NCT03775434,has_criteria,2 to 17 years of age
NCT03775434,has_criteria,confirmed diagnosis of atopic dermatitis
NCT03775434,has_criteria,Hanifin and Rajka criteria
NCT01922258,involves,Agitation Associated With Dementia of the Alzheimer's Type
NCT01922258,evaluates,Brexpiprazole
NCT01922258,measures_primary,Change in CMAI score
NCT01922258,measures_secondary,CGI-S Score
NCT01922258,has_criteria,Screening to week 12
NCT03638258,involves,Chronic Plaque Psoriasis
NCT03638258,evaluates,ARQ-151 Cream
NCT03638258,measures_primary,IGA score at Week 6
NCT03638258,measures_secondary,mPASI score
NCT03638258,has_criteria,Base...
NCT05418296,involves,Alzheimer's Disease
NCT05418296,involves,ADRD
NCT05418296,evaluates,Novel Virtual Environment
NCT05418296,measures_primary,Activities of Daily Living
NCT05418296,measures_secondary,Neuropsychiatric Inventory
NCT05418296,measures_secondary,Approaches to Dementia Questionnaire
NCT05418296,measures_secondary,Sense of Competence in Dementia Care Staff
NCT05418296,has_criteria,Diagnosis of AD/ADRD
NCT04799496,involves,Ulcerative Colitis
NCT04799496,involves,Crohn's Disease
NCT04799496,involves,Chronic Pouchitis
NCT04799496,evaluates,Kynteles Injection
NCT04799496,evaluates,Vedolizumab
NCT04799496,measures_primary,Clinical Response
NCT04799496,measures_primary,Clinical Remission
NCT04799496,has_criteria,Baseline up to 56 weeks
NCT00861016,involves,Hypertension
NCT00861016,evaluates,Metoprolol Succinate Prolonged-Release Tablet
NCT00861016,measures_primary,blood pressure target
NCT00861016,measures_secondary,blood pressure reduction
NCT00861016,has_criteria,newly diagnosed essential hypertension
NCT00861016,has_criteria,not received anti-hypertensive treatment
NCT00861016,has_criteria,SiDBP \<110mmHg
NCT00861016,has_criteria,SiSBP \<180mmHg
NCT00861016,has_criteria,Resting HR is \< 55bpm
NCT00402324,involves,Mixed Bipolar Disorder
NCT00402324,evaluates,Olanzapine
NCT00402324,measures_primary,Mixed Onset of Action
NCT00402324,measures_primary,Mixed Response
NCT00402324,measures_secondary,YMRS total scores
NCT00402324,measures_secondary,HAMD total scores
NCT00402324,measures_secondary,CGI-BP Severity
NCT00402324,has_criteria,25% reduction HAMD
NCT00402324,has_criteria,25% reduction YMRS
NCT00402324,has_criteria,50% reduction HAMD
NCT00402324,has_criteria,50% reduction YMRS
NCT01175824,involves,Type 2 diabetes
NCT01175824,evaluates,Insulin intensification strategies
NCT01175824,measures_primary,Change in HbA1c
NCT01175824,measures_secondary,Fasting plasma glucose
NCT06277934,involves,Obesity
NCT06277934,evaluates,RGT001-075
NCT06277934,measures_primary,Percent change in body weight
NCT06277934,measures_secondary,Change in body weight
NCT06277934,measures_secondary,Change in BMI
NCT06277934,measures_secondary,Change in waist circumference
NCT06277934,has_criteria,BMI ≥27 kg/m²
NCT06277934,has_criteria,BMI ≤ 45 kg/m²
NCT06277934,has_criteria,Stable body weight
NCT03943134,involves,Acute Trauma of the Upper Extremity
NCT03943134,evaluates,Avive® Soft Tissue Membrane
NCT03943134,measures_primary,QuickDASH score
NCT03943134,measures_secondary,PROMIS Pediatric Upper Extremity/Parent Proxy Upper Extremity (PUE/PPUE)
NCT03943134,has_criteria,Adult subjects only
NCT03943134,has_criteria,Pediatric subjects only
NCT01947816,involves,Ulcerative Colitis
NCT01947816,evaluates,Humira
NCT01947816,measures_primary,Change From Baseline in Mayo Score
NCT01947816,measures_secondary,Change From Baseline in CRP Levels
NCT01947816,measures_secondary,Mayo Endoscopic Sub-Score
NCT01947816,measures_secondary,Change From Baseline in Partial Mayo Score
NCT01947816,has_criteria,company criteria
NCT03566316,involves,Hypertension
NCT03566316,involves,Hyperlipidemia
NCT03566316,evaluates,Telmisartan/Amlodipine/Rosuvastatin
NCT03566316,measures_primary,Percentage of change LDL-Cholesterol
NCT03566316,measures_secondary,Systolic blood pressure
NCT03566316,measures_secondary,Diastolic blood pressure
NCT03566316,measures_secondary,HDL-Cholesterol
NCT03566316,measures_secondary,Total Cholesterol
NCT03566316,measures_secondary,Triglyceride
NCT03566316,measures_secondary,Apolipoprotein B
NCT03566316,measures_secondary,HDL-Cholesterol/LDL-Cholesterol ratio
NCT03566316,measures_secondary,Total cholesterol/HDL-Cholesterol ratio
NCT03566316,measures_secondary,Patients reaching treatment goals
NCT03566316,has_criteria,19 years old or above
NCT03566316,has_criteria,Essential hypertension
NCT03566316,has_criteria,Hyperlipidemia
NCT03566316,has_criteria,Anti-hypertensive/anti-hyperlipidemic drugs
NCT03566316,has_criteria,Sit systolic blood pressure ≥ 140mmHg
NCT03566316,has_criteria,LDL-Cholesterol ≥ 100mg/dL
NCT03566316,has_criteria,Agree to participate
NCT03566316,has_criteria,Severe hypertension
NCT03566316,has_criteria,Systolic blood pressure ≥ 180 mm Hg
NCT03566316,has_criteria,Diastolic blood pressure ≥ 110 mm Hg
NCT04323124,evaluates,PF-07059013
NCT04323124,measures_primary,Number of Participants
NCT04323124,measures_secondary,Laboratory Test Findings
NCT04323124,measures_secondary,Vital Signs Findings
NCT04323124,has_criteria,Screening visit
NCT02301624,involves,Generalized Myasthenia Gravis
NCT02301624,evaluates,Eculizumab
NCT02301624,measures_primary,MG-ADL total score
NCT02301624,measures_secondary,Treatment-emergent adverse events
NCT02301624,has_criteria,Completed Study ECU-MG-301
NCT02301624,has_criteria,Written informed consent
NCT02301624,has_criteria,Comply with protocol
NCT02301624,has_criteria,Negative pregnancy test
NCT05625334,evaluates,Acetylsalicylic Acid Powder
NCT05625334,evaluates,Non-enteric-coated Chewable Aspirin
NCT05625334,measures_primary,TxB2 suppression
NCT05625334,measures_secondary,Platelet aggregation
NCT05625334,has_criteria,Age 18-55 years
NCT02010216,involves,Rheumatoid Arthritis
NCT02010216,evaluates,RoActemra
NCT02010216,evaluates,Actemra
NCT02010216,evaluates,Tocilizumab
NCT02010216,measures_primary,Change From Baseline
NCT02010216,measures_secondary,ACR20/50/70 Responses
NCT02010216,has_criteria,Baseline
NCT01600716,involves,Multiple Sclerosis
NCT01600716,involves,Urinary Incontinence
NCT01600716,evaluates,OnabotulinumtoxinA
NCT01600716,measures_primary,Change in Frequency
NCT01600716,measures_secondary,Maximum Cystometric Capacity
NCT01600716,measures_secondary,Maximum Detrusor Pressure
NCT01600716,measures_secondary,Incontinence Quality of Life
NCT01600716,has_criteria,Non-Catheterizing
NCT06297616,involves,Obesity
NCT06297616,involves,Overweight
NCT06297616,evaluates,LY3841136
NCT06297616,evaluates,Tirzepatide
NCT06297616,measures_primary,Body Weight Change
NCT06297616,measures_secondary,AUC
NCT06297616,measures_secondary,Cmax
NCT06297616,has_criteria,BMI 27-40 kg/m²
NCT06297616,has_criteria,Stable weight 3 months
NCT02775916,involves,Primary Sjögren's Syndrome
NCT02775916,evaluates,CDZ173
NCT02775916,measures_primary,ESSPRI score
NCT02775916,measures_secondary,ESSDAI score
NCT02775916,has_criteria,Day 85
NCT05139316,involves,Glycogen Storage Disease Type Ia
NCT05139316,evaluates,Adeno-Associated Virus Serotype 8-Mediated Gene Transfer
NCT05139316,measures_primary,Percent Change Cornstarch Intake
NCT05139316,measures_secondary,Time to Hypoglycemia
NCT05139316,has_criteria,Baseline
NCT01161524,involves,Adolescents
NCT01161524,evaluates,Perampanel
NCT01161524,measures_primary,Cognition CDR System
NCT01161524,measures_secondary,Power of Attention T-score
NCT01161524,has_criteria,Baseline (Visit 2/Week 0 Evaluation)
NCT04955834,involves,Type 2 diabetes
NCT04955834,evaluates,Insulin Degludec Injection
NCT04955834,measures_primary,Change value of HbA1c
NCT04955834,measures_secondary,Change value of fasting blood glucose
NCT04955834,has_criteria,Aged ≥18 and ≤70 years old
NCT04955834,has_criteria,Type 2 diabetes diagnosed clinically
NCT04955834,has_criteria,Stable dose of oral hypoglycemic agents
NCT04955834,has_criteria,HbA1c 7.5%-11.0%
NCT04955834,has_criteria,BMI ≥18 kg/m2 and ≤40kg/m2
NCT04398134,involves,Chronic Hepatitis B Virus Infection
NCT04398134,evaluates,ABI-H2158
NCT04398134,measures_primary,Change From Baseline in Mean log10 HBV DNA
NCT04398134,measures_secondary,Percentage of Participants With Adverse Events
NCT04398134,measures_secondary,Percentage of Participants With Premature Treatment Discontinuation
NCT04398134,measures_secondary,Percentage of Participants With Abnormal Laboratory Results
NCT04398134,has_criteria,Up to 72 weeks
NCT04481724,involves,Neuropathy
NCT04481724,evaluates,Gamma-linolenic Acid
NCT04481724,measures_primary,Body weight
NCT04481724,measures_secondary,Neuropathy symptoms
NCT04481724,measures_secondary,Health-related quality of life
NCT04481724,measures_secondary,Perceived control over eating
NCT04481724,measures_secondary,Body image and satisfaction
NCT04481724,measures_secondary,Medication prescriptions
NCT04481724,measures_secondary,Hemoglobin A1c
NCT04481724,measures_secondary,Ketones
NCT04481724,measures_secondary,Blood glucose
NCT04481724,has_criteria,Age greater than or equal to 18 yrs
NCT04481724,has_criteria,Weight loss greater than or equal to 7%
NCT04481724,has_criteria,BMI > 25 kg/m2
NCT04209634,involves,CHAPLE Disease
NCT04209634,evaluates,Pozelimab
NCT04209634,measures_primary,Normalization of serum albumin
NCT04209634,measures_secondary,Improvement in clinical outcomes
NCT04209634,has_criteria,Active disease at baseline
NCT04486716,involves,Relapsing Multiple Sclerosis
NCT04486716,evaluates,Ofatumumab
NCT04486716,measures_primary,gadolinium enhancing lesions
NCT04486716,measures_secondary,CD19+ B cell counts
NCT04486716,measures_secondary,CD3+CD20+ T cell counts
NCT04486716,measures_secondary,Treatment Satisfaction Questionnaire
NCT04486716,measures_secondary,Columbia-Suicide Severity Rating Scale
NCT04486716,has_criteria,Baseline up to 12 months
NCT04155424,involves,Relapsing Neuromyelitis Optica Spectrum Disorder
NCT04155424,evaluates,Eculizumab
NCT04155424,measures_primary,Change in ARR
NCT04155424,measures_secondary,EDSS Score
NCT04155424,measures_secondary,HAI Score
NCT04155424,measures_secondary,PedsQL Score
NCT04155424,has_criteria,Baseline ARR
NCT00887224,involves,Major Depressive Disorder
NCT00887224,evaluates,Desvenlafaxine Succinate Sustained Release
NCT00887224,measures_primary,Time to Relapse
NCT00887224,measures_secondary,CGI-I Score
NCT00887224,measures_secondary,CGI-S Score
NCT00887224,measures_secondary,HAM-D17 Score
NCT00887224,has_criteria,Unsatisfactory response
NCT05970224,involves,Spontaneous Intracerebral Haemorrhage
NCT05970224,evaluates,Ixodes Ricinus-Contact Phase Inhibitor
NCT05970224,measures_primary,hematoma volume
NCT05970224,measures_secondary,perihematomal oedema
NCT05970224,has_criteria,Adult Patients
NCT03941834,involves,Trigeminal Neuralgia
NCT03941834,evaluates,DBT
NCT03941834,measures_primary,Average Daily Pain Score
NCT03941834,measures_secondary,Sheehan Suicidality Tracking Scale
NCT03941834,has_criteria,All-Causality Serious Adverse Events
NCT05789524,involves,Hemophilia A
NCT05789524,involves,Hemophilia B
NCT05789524,evaluates,SerpinPC
NCT05789524,measures_primary,Annualized Bleeding Rate
NCT05789524,measures_secondary,Total Coagulation Factor
NCT05789524,measures_secondary,Pharmacokinetic Plasma Concentrations
NCT05789524,measures_secondary,Haemophilia-specific QoL Instrument
NCT05789524,has_criteria,Male participants
NCT05789524,has_criteria,≥12 and ≤65 years
NCT05789524,has_criteria,written informed consent
NCT05789524,has_criteria,factor VIII less than 0.01 IU/mL
NCT03053024,involves,Mantle Cell Lymphoma
NCT03053024,evaluates,Bortezomib
NCT03053024,measures_primary,Treatment response
NCT03053024,measures_secondary,Prognostic Index Score
NCT03053024,has_criteria,Eastern Cooperative Oncology Group Performance Status
NCT00905424,involves,Major Depressive Disorder
NCT00905424,evaluates,SPD489
NCT00905424,measures_primary,Change From Augmentation Baseline
NCT00905424,measures_secondary,Hamilton Depression Scale Total Score
NCT00905424,measures_secondary,Sheehan Disability Scale Total Score
NCT00905424,measures_secondary,Clinical Global Impression-Improvement (CGI-I)
NCT00905424,has_criteria,Augmentation Baseline
NCT02047734,involves,Relapsing Multiple Sclerosis
NCT02047734,evaluates,Ozanimod
NCT02047734,measures_primary,Adjusted ARR
NCT02047734,measures_secondary,New or Enlarging Lesions
NCT02047734,has_criteria,Age
NCT00851318,involves,Rheumatoid Arthritis
NCT00851318,evaluates,Certolizumab Pegol
NCT00851318,measures_primary,ACR20 Response
NCT00851318,measures_secondary,arthritis pain
NCT00851318,measures_secondary,disease activity
NCT00851318,has_criteria,tender joint count
NCT00851318,has_criteria,swollen joint count
NCT03183518,evaluates,Cosmetic Facial Product
NCT03183518,measures_primary,Skin Irritation Scores
NCT03183518,measures_secondary,Superficial Irritation Scores
NCT03183518,has_criteria,Healthy Participants
NCT01030718,involves,Chronic Myeloid Leukemia
NCT01030718,involves,Ph+ Acute Lymphoblastic Leukemia
NCT01030718,evaluates,BMS-354825
NCT01030718,measures_primary,Cytogenetic Response
NCT01030718,measures_secondary,Adverse Events
NCT01030718,has_criteria,Ph+ metaphases
NCT01722318,involves,Irritable Bowel Syndrome With Constipation
NCT01722318,evaluates,Plecanatide
NCT01722318,measures_primary,Change in CSBM frequency
NCT01722318,measures_secondary,Abdominal Pain Intensity
NCT01722318,measures_secondary,Stool Consistency
NCT01722318,measures_secondary,Straining
NCT01722318,has_criteria,Age 18-75
NCT01722318,has_criteria,BMI 18-35 kg/m2
NCT01722318,has_criteria,Rome III criteria
NCT01610713,involves,Multiple Sclerosis
NCT01610713,evaluates,Delta-9-tetrahydrocannabinol
NCT01610713,evaluates,Cannabidiol
NCT01610713,measures_primary,Visual Analogue Scale Score
NCT01610713,measures_secondary,Guy's Neurological Disability Scale Score
NCT01610713,has_criteria,double-blind therapy
NCT01094613,involves,Crohn's Disease
NCT01094613,evaluates,Delayed Release 6MP
NCT01094613,measures_primary,Proportion of clinical response
NCT01094613,measures_secondary,Time to clinical response
NCT01094613,has_criteria,CDAI score 220-450
NCT01969136,involves,Alzheimer's Disease
NCT01969136,evaluates,EVP-6124
NCT01969136,measures_primary,Change from Baseline in ADAS-Cog-13
NCT01969136,measures_secondary,Change from Baseline in CDR-SB
NCT01969136,measures_secondary,Change from Baseline in activities of daily living
NCT01969136,measures_secondary,Change from Baseline in psychiatric and behavioral symptoms
NCT01969136,measures_secondary,Change from Baseline in MMSE
NCT01969136,measures_secondary,Change from Baseline in COWAT
NCT01969136,has_criteria,Ages ≥55 and ≤85 years
NCT01969136,has_criteria,Informed consent form
NCT01969136,has_criteria,Clinical diagnosis of dementia due to probable AD
NCT01969136,has_criteria,Clinical decline within 12 months before screening
NCT04307836,involves,Hypertension
NCT04307836,evaluates,Renal Denervation Therapy
NCT04307836,measures_primary,average daytime ambulatory systolic blood pressure
NCT04307836,measures_secondary,average 24hr ambulatory systolic blood pressure
NCT04307836,measures_secondary,average office systolic blood pressure
NCT04307836,has_criteria,aged 19 to 75 years old
NCT04307836,has_criteria,0 to 3 antihypertensive medications
NCT04307836,has_criteria,140 mmHg ≤ average office SBP
NCT04307836,has_criteria,90 mmHg ≤ office DBP
NCT04307836,has_criteria,135 mmHg ≤ average daytime ambulatory SBP
NCT04307836,has_criteria,85 mmHg ≤ average daytime ambulatory DBP
NCT03028636,involves,fecal incontinence
NCT03028636,evaluates,Eclipse System
NCT03028636,measures_primary,St. Mark's score
NCT03028636,measures_secondary,Patient Global Impression
NCT03028636,has_criteria,completed 12-month visit
NCT03028636,has_criteria,elected to continue use
NCT03028636,has_criteria,electronic informed consent
NCT04700449,involves,Ulcerative Colitis
NCT04700449,evaluates,CBP-307
NCT04700449,measures_primary,Change in adapted Mayo score
NCT04700449,measures_secondary,Change in complete Mayo score
NCT04700449,has_criteria,decrease of ≥ 2 points
NCT01190436,involves,Hypertensive Subjects With Diabetes
NCT01190436,evaluates,Bisoprolol
NCT01190436,measures_primary,Mean Change in BP
NCT01190436,measures_secondary,Percentage of Participants With Controlled BP
NCT01190436,measures_secondary,Response to Study Drug
NCT01190436,measures_secondary,Mean Change From Baseline in Heart Rate
NCT01190436,measures_secondary,Percentage of Participants With Decrease in Heart Rate
NCT01190436,measures_secondary,Percentage of Participants With Increased HbA1c
NCT01190436,measures_secondary,Mean Change From Baseline in HbA1c
NCT01190436,measures_secondary,Percentage of Participants With Increased Fasting Blood Sugar
NCT01190436,measures_secondary,Mean Change From Baseline in Fasting Blood Sugar
NCT01190436,measures_secondary,Mean Change From Baseline in Total Cholesterol
NCT01190436,has_criteria,Filipino
NCT03617536,involves,Chronic Kidney Disease
NCT03617536,involves,Pruritus
NCT03617536,evaluates,CR845
NCT03617536,measures_primary,Change From Baseline
NCT03617536,measures_secondary,Skindex-10 Score
NCT03617536,measures_secondary,5-D Itch Scale Score
NCT03617536,has_criteria,stage III
NCT02307513,involves,Behçet's Disease
NCT02307513,evaluates,Apremilast
NCT02307513,measures_primary,AUC W0-12
NCT02307513,measures_secondary,Oral Ulcer Pain
NCT02307513,measures_secondary,Disease Activity
NCT02307513,has_criteria,Baseline to week 12
NCT02467413,involves,Alzheimer's Disease
NCT02467413,involves,Vascular Dementia
NCT02467413,evaluates,BAC
NCT02467413,measures_primary,ADAS-cog score
NCT02467413,measures_secondary,CIBIC-plus score
NCT02467413,measures_secondary,Activities of Daily Living score
NCT02467413,measures_secondary,Mini-Mental State Examination score
NCT02467413,measures_secondary,Neuropsychiatric Inventory score
NCT02467413,has_criteria,Weeks 12
NCT02467413,has_criteria,Weeks 4
NCT04253236,involves,Warm Autoimmune Hemolytic Anemia
NCT04253236,evaluates,RVT-1401
NCT04253236,measures_primary,Number of Responders
NCT04253236,measures_secondary,Time to Response
NCT04253236,measures_secondary,Time to Achieving Hb Levels
NCT04253236,measures_secondary,Number of Participants With Change in FACIT-F Score
NCT04253236,has_criteria,Hb \>=10 g/dL
NCT00857649,involves,Alzheimer's Disease
NCT00857649,evaluates,Memantine
NCT00857649,measures_primary,Change from Baseline in Neuropsychiatric Inventory (NPI) total score
NCT00857649,measures_primary,Change from Baseline in Severe Impairment Battery (SIB) total score
NCT00857649,measures_primary,Improvement evaluated with reference to Baseline
NCT00857649,has_criteria,Moderate to Severe Dementia of the Alzheimer's Type
NCT00857649,has_criteria,Outpatients
NCT01857713,involves,extraesophageal reflux
NCT01857713,evaluates,Reza Band UES Assist Device
NCT01857713,measures_primary,Percent Change in RSI
NCT01857713,measures_secondary,SF-36 Short Form Health Survey
NCT01857713,measures_secondary,Functional Outcomes of Sleep Questionnaire
NCT01857713,has_criteria,18 years of age or older
NCT01857713,has_criteria,informed consent
NCT01857713,has_criteria,understand clinical study requirements
NCT01857713,has_criteria,able to comply with follow-up schedule
NCT01857713,has_criteria,clinically diagnosed with esophagopharyngeal reflux
NCT01422213,involves,Major Depressive Disorder
NCT01422213,evaluates,Vortioxetine
NCT01422213,measures_primary,DSST (Number of Correct Symbols)
NCT01422213,measures_primary,RAVLT (Acquisition and Delayed Recall)
NCT01422213,has_criteria,Adult Patients
NCT03345836,involves,Crohn's Disease
NCT03345836,evaluates,Upadacitinib
NCT03345836,measures_primary,Clinical Remission
NCT03345836,measures_secondary,Endoscopic Response
NCT03345836,has_criteria,Biologic Therapy
NCT02291549,involves,Chronic Sinusitis
NCT02291549,involves,Recurrent Nasal Polyps
NCT02291549,evaluates,S8 Sinus Implant
NCT02291549,measures_primary,Nasal Obstruction/Congestion Score
NCT02291549,measures_secondary,Bilateral Polyp Grade
NCT02291549,measures_secondary,Percentage of Patients Indicated for Repeat Endoscopic Sinus Surgery
NCT02291549,measures_secondary,Ethmoid Sinus Obstruction
NCT02291549,has_criteria,nasal obstruction/congestion
NCT02291549,has_criteria,postnasal discharge
NCT02291549,has_criteria,facial pain/pressure/fullness
NCT02291549,has_criteria,altered sense of smell/taste
NCT02291549,has_criteria,nasal polyps
NCT02291549,has_criteria,systemic steroid
NCT01169818,involves,Type 2 Diabetes Mellitus
NCT01169818,evaluates,Physician Versus Patient-led
NCT01169818,measures_primary,Change in HbA1c
NCT01169818,measures_secondary,Percentage of patients achieving HbA1c levels < 7.0% without experiencing severe hypoglycemia
NCT01169818,has_criteria,Diagnosed with T2DM duration of T2DM > 2 years
NCT01169818,has_criteria,Insulin naïve
NCT01169818,has_criteria,Continuous treatment with stable doses of 2 OADs for > three months prior to randomization
NCT01169818,has_criteria,HbA1c levels 7% and 11 %
NCT01169818,has_criteria,Body mass index (BMI) 20 and 40 kg/m2
NCT01169818,has_criteria,Willing and able to perform blood glucose monitoring using a blood glucose meter
NCT02438813,involves,Submental Fullness
NCT02438813,evaluates,SMF reduction treatment
NCT02438813,measures_primary,Change From Baseline
NCT02438813,measures_secondary,Patient-Reported Submental Fat Impact Scale
NCT02438813,has_criteria,Baseline (Day 1)
NCT04482413,involves,Alzheimer's Disease
NCT04482413,evaluates,AstroStem
NCT04482413,measures_primary,CDR-SB score
NCT04482413,measures_secondary,ADAS-Cog-11 score
NCT04482413,measures_secondary,MMSE
NCT04482413,measures_secondary,ADCS-ADL-MCI
NCT04482413,measures_secondary,C-SSRS
NCT04482413,has_criteria,Baseline and 52 Weeks
NCT06209736,involves,C3G
NCT06209736,involves,ICGN
NCT06209736,evaluates,OMS906
NCT06209736,measures_primary,Change in proteinuria
NCT06209736,measures_secondary,eGFR
NCT06209736,measures_secondary,serum creatinine
NCT06209736,has_criteria,48 weeks
NCT03794336,involves,Type 2 Diabetes Mellitus
NCT03794336,evaluates,Alogliptin
NCT03794336,evaluates,Acarbose
NCT03794336,measures_primary,HbA1c <7%
NCT03794336,measures_secondary,Gastrointestinal tolerability
NCT03794336,measures_secondary,Hypoglycemia events
NCT03794336,measures_secondary,Other Adverse Events
NCT03794336,measures_secondary,Overall tolerability
NCT03794336,has_criteria,High CV Risk
NCT03794336,has_criteria,CHD
NCT03794336,has_criteria,Metformin Monotherapy
NCT03794336,has_criteria,Drug Naive
NCT01432236,involves,Fibromyalgia
NCT01432236,involves,Depression
NCT01432236,evaluates,Pregabalin
NCT01432236,measures_primary,Mean NRS Pain Score
NCT01432236,measures_secondary,Fibromyalgia Impact Questionnaire Score
NCT01432236,has_criteria,Comorbid Depression
NCT02842736,involves,Heavy Menstrual Bleeding
NCT02842736,evaluates,CeRene Device
NCT02842736,measures_primary,Reduction in Menstrual Bleeding
NCT02842736,measures_secondary,Dysmenorrhea
NCT02842736,has_criteria,PBLAC Score of ≤75
NCT04015518,involves,Palmoplantar Pustulosis
NCT04015518,evaluates,BI 655130
NCT04015518,measures_primary,PPP ASI change
NCT04015518,measures_secondary,Palmoplantar Pustulosis Pain VAS
NCT04015518,has_criteria,least square means
NCT02284113,involves,Pain
NCT02284113,evaluates,Iovera° Device
NCT02284113,measures_primary,Change in Pain
NCT02284113,measures_secondary,Length of Hospital Stay
NCT02284113,measures_secondary,Change in WOMAC Scores
NCT02284113,measures_secondary,Change in Active Range of Motion
NCT02284113,has_criteria,Total Knee Arthroplasty
NCT04039113,involves,COPD
NCT04039113,evaluates,tezepelumab
NCT04039113,measures_primary,exacerbation rate ratio
NCT04039113,measures_secondary,FEV1 change
NCT04039113,measures_secondary,SGRQ Total Score
NCT04039113,has_criteria,moderate or severe COPD
NCT01475136,evaluates,LY2140023
NCT01475136,measures_primary,AUC(0-∞)
NCT01475136,measures_secondary,Cmax
NCT01475136,measures_secondary,Tmax
NCT01475136,has_criteria,Body mass index
NCT01475136,has_criteria,Clinical laboratory tests
NCT01475136,has_criteria,Venous access
NCT03221036,involves,Ulcerative Colitis
NCT03221036,evaluates,Vedolizumab IV
NCT03221036,measures_primary,Clinical Response
NCT03221036,measures_primary,Clinical Remission
NCT03221036,measures_secondary,Mucosal Healing
NCT03221036,has_criteria,Week 10
NCT03221036,has_criteria,Week 60
NCT01183013,involves,Type 2 Diabetes
NCT01183013,evaluates,Linagliptin
NCT01183013,evaluates,Pioglitazone
NCT01183013,measures_primary,HbA1c Change
NCT01183013,measures_secondary,Treat to Target Efficacy Response
NCT01183013,measures_secondary,Relative Efficacy Response
NCT01183013,measures_secondary,Fasting Plasma Glucose (FPG) Change
NCT01183013,has_criteria,Baseline HbA1c
NCT01183013,has_criteria,prior anti-diabetic medication
NCT05766813,involves,Parkinson's Disease
NCT05766813,evaluates,Lenrispodun
NCT05766813,measures_primary,MDS-UPDRS score
NCT05766813,measures_secondary,Hauser Diary
NCT05766813,has_criteria,Age 40-80 years
NCT05766813,has_criteria,BMI 19.0-40.0 kg/m2
NCT05766813,has_criteria,UKPDS Brain Bank criteria
NCT05766813,has_criteria,Hoehn and Yahr stage 2 or 3
NCT05766813,has_criteria,Stable levodopa dose
NCT02848313,involves,Intermediate Age-Related Macular Degeneration
NCT02848313,evaluates,Subcutaneous Elamipretide
NCT02848313,measures_primary,Change From Baseline in Mean Standard Luminance BCVA
NCT02848313,measures_secondary,Change from Baseline in Mean Low Luminance BCVA
NCT02848313,measures_secondary,Change From Baseline in Mean Dark Adaptometry
NCT02848313,measures_secondary,Mean Treatment Compliance (%) of Administration of Subcutaneous Elamipretide
NCT02848313,has_criteria,Baseline to Day 7
NCT04874636,involves,Chronic Low Back Pain
NCT04874636,evaluates,LY3556050
NCT04874636,measures_primary,Change From Baseline
NCT04874636,measures_secondary,Roland Morris Disability Questionnaire
NCT04874636,measures_secondary,Patient's Global Impression of Change
NCT04874636,has_criteria,Baseline
NCT05021536,involves,Amyotrophic Lateral Sclerosis
NCT05021536,evaluates,AMX0035
NCT05021536,measures_primary,ALSFRS-R Slope Change
NCT05021536,measures_secondary,Participant Quality of Life
NCT05021536,measures_secondary,Long-Term Survival
NCT05021536,measures_secondary,Rate of Decline in SVC
NCT05021536,has_criteria,at least 18 years of age
NCT05021536,has_criteria,Diagnosis of ALS
NCT02542813,involves,Healthy Female Volunteers
NCT02542813,evaluates,Oxytocin (GR121619)
NCT02542813,measures_primary,Safety and Tolerability
NCT02542813,measures_secondary,Pharmacokinetics
NCT02542813,has_criteria,Up to 16 weeks
NCT03760913,involves,Pain
NCT03760913,evaluates,OLP-1002
NCT03760913,measures_primary,Supine Blood Pressure
NCT03760913,measures_secondary,Supine Pulse Rate
NCT01709513,involves,Primary Hypercholesterolemia
NCT01709513,involves,Cardiovascular Risk
NCT01709513,evaluates,Alirocumab
NCT01709513,measures_primary,LDL-C at Week 24
NCT01709513,measures_secondary,Apolipoprotein B at Week 24
NCT01709513,has_criteria,Intolerant to Statins
NCT01968213,involves,High Grade Serous or Endometrioid Ovarian Cancer
NCT01968213,evaluates,Rucaparib
NCT01968213,measures_primary,Progression-free survival
NCT01968213,measures_secondary,Overall Survival
NCT01968213,has_criteria,Platinum resistant
NCT00540436,involves,Pulmonary Arterial Hypertension
NCT00540436,evaluates,GSK1325760A
NCT00540436,measures_primary,Six Minutes Walk Distance
NCT00540436,measures_secondary,Borg Dyspnea Index
NCT00540436,measures_secondary,World Health Organization Functional Classification
NCT00540436,measures_secondary,Time to Clinical Worsening
NCT00540436,has_criteria,Pulmonary Arterial Hypertension
NCT02314936,involves,Functional Constipation
NCT02314936,evaluates,Polydextrose Supplement
NCT02314936,measures_primary,Colonic Transit Time
NCT02314936,measures_secondary,Constipation Symptoms
NCT02314936,measures_secondary,Constipation Quality of Life
NCT02314936,has_criteria,Rome II criteria
NCT02714036,involves,Amyotrophic Lateral Sclerosis
NCT02714036,evaluates,MN-166
NCT02714036,measures_primary,SUVR change from baseline
NCT02714036,measures_secondary,blood biomarkers
NCT02714036,measures_secondary,ALSFRS-R score
NCT02714036,has_criteria,eligible participants
NCT01209949,involves,Acne Vulgaris
NCT01209949,evaluates,Adapalene BPO Gel
NCT01209949,measures_primary,Clear or Almost Clear
NCT01209949,measures_secondary,Lesion Counts
NCT01209949,has_criteria,Facial acne IGA 2 or 3
NCT01209949,has_criteria,10 inflammatory lesions
NCT01209949,has_criteria,Aged 16 to 25 years
NCT05197049,involves,Crohn's Disease
NCT05197049,evaluates,Guselkumab
NCT05197049,measures_primary,Clinical Remission
NCT05197049,measures_secondary,Endoscopic Response
NCT05197049,has_criteria,Moderate to severe CD
NCT05197049,has_criteria,Intolerance to therapy
NCT05197049,has_criteria,Diagnosis of Crohn's disease
NCT06282549,involves,Essential Hypertension
NCT06282549,evaluates,TEL/AML/CTD
NCT06282549,measures_primary,Mean Systolic Blood Pressure
NCT06282549,measures_secondary,Percentage of MACCE
NCT06282549,has_criteria,over 65-year-old
NCT06282549,has_criteria,essential hypertension
NCT06282549,has_criteria,3 or more antihypertensive medication
NCT06282549,has_criteria,no MACCE within 6 months
NCT06282549,has_criteria,voluntarily signed informed consent
NCT02305849,involves,Rheumatoid Arthritis
NCT02305849,evaluates,ASP015K
NCT02305849,measures_primary,ACR20 response
NCT02305849,measures_secondary,mTSS
NCT02305849,has_criteria,Inadequate response to MTX
NCT02851849,involves,Type 2 Diabetes Mellitus
NCT02851849,evaluates,LGD-6972
NCT02851849,measures_primary,Change from baseline in HbA1c
NCT02851849,measures_secondary,Change from baseline in fasting glucose
NCT02851849,measures_secondary,Change from baseline values for fasting glucagon
NCT02851849,measures_secondary,Change from baseline values for fasting GLP-1
NCT02851849,measures_secondary,Change from baseline values for fasting insulin
NCT02851849,measures_secondary,Change from baseline values for fasting lipids
NCT02851849,measures_secondary,Change from baseline in blood pressure
NCT02851849,measures_secondary,Change from baseline in body weight
NCT02851849,has_criteria,Female subjects surgically sterile
NCT02851849,has_criteria,Male subjects vasectomy or contraception
NCT02851849,has_criteria,Written informed consent
NCT02851849,has_criteria,Diagnosis of T2DM
NCT02851849,has_criteria,Stable metformin therapy
NCT06425549,involves,Plaque Psoriasis
NCT06425549,evaluates,Bimekizumab
NCT06425549,evaluates,Ustekinumab
NCT06425549,measures_primary,PASI90 response
NCT06425549,measures_secondary,IGA response
NCT06425549,has_criteria,6 years to less than 18 years
NCT04946318,involves,Uncontrolled Asthma
NCT04946318,evaluates,CSJ117
NCT04946318,measures_primary,Number of AEs
NCT04946318,measures_secondary,Participant deaths
NCT04946318,has_criteria,drug free follow-up
NCT03292406,involves,Cutaneous T-Cell Lymphoma
NCT03292406,evaluates,CD11301
NCT03292406,measures_primary,Overall Response
NCT03292406,measures_secondary,mSWAT Score
NCT03292406,has_criteria,Target treated lesions
NCT02561806,involves,Plaque Psoriasis
NCT02561806,evaluates,Ixekizumab
NCT02561806,measures_primary,PASI 90
NCT02561806,measures_secondary,PASI 75
NCT02561806,measures_secondary,PASI 100
NCT02176499,involves,Hypertension
NCT02176499,evaluates,Telmisartan
NCT02176499,measures_primary,Blood pressure
NCT02176499,measures_secondary,Sodium loss
NCT02176499,has_criteria,Mild-to-moderate hypertension
NCT02970942,involves,Non-alcoholic Steatohepatitis
NCT02970942,evaluates,Subcutaneous Semaglutide
NCT02970942,measures_primary,NASH Resolution
NCT02970942,measures_secondary,Liver Fibrosis Improvement
NCT02970942,has_criteria,Fibrosis stages 0-4
NCT06646042,evaluates,Carbamazepine
NCT06646042,evaluates,Ibuzatrelvir
NCT06646042,measures_primary,Cmax of ibuzatrelvir
NCT06646042,measures_primary,AUCinf of ibuzatrelvir
NCT06646042,measures_primary,AUClast of ibuzatrelvir
NCT06646042,measures_secondary,Treatment Emergent AEs
NCT06646042,measures_secondary,Clinically Significant Change in Laboratory Abnormalities
NCT06646042,measures_secondary,Clinically Significant Change in Vital Signs
NCT04366349,evaluates,Melrilimab
NCT04366349,measures_primary,AUC[0-t]
NCT04366349,measures_primary,AUC[0-infinity]
NCT04366349,measures_primary,Cmax
NCT04366349,measures_primary,Tmax
NCT04366349,has_criteria,randomized participants
NCT01124149,involves,Ulcerative Colitis
NCT01124149,evaluates,MMX Mesalamine
NCT01124149,measures_primary,Complete Remission
NCT01124149,measures_secondary,Clinical Remission
NCT01124149,measures_secondary,Mucosal Healing
NCT01124149,has_criteria,alternative treatment
NCT02081599,involves,Type 2 Diabetes
NCT02081599,evaluates,Teneligliptin
NCT02081599,measures_primary,Change From Baseline in HbA1c
NCT02081599,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT02081599,measures_secondary,Change From Baseline in AUC0-2h for Postprandial Plasma Glucose
NCT02081599,measures_secondary,Change From Baseline in 2-hour Postprandial Plasma Glucose
NCT02081599,has_criteria,stable dose of insulin
NCT02081599,has_criteria,dietary management
NCT02081599,has_criteria,therapeutic exercise
NCT02081599,has_criteria,HbA1c 7.5% to 10.5%
NCT01614899,involves,Schizophrenia
NCT01614899,evaluates,SM-13496
NCT01614899,measures_primary,Change From Baseline in PANSS Total Score at Week 6
NCT01614899,measures_secondary,Change From Baseline in CGI-S Score at Week 6
NCT01614899,measures_secondary,Change From Baseline in PANSS Positive Subscale Scores at Week 6
NCT01614899,has_criteria,Baseline and 6 week
NCT02334306,involves,Primary Sjögren's Syndrome
NCT02334306,evaluates,AMG 557/MEDI5872
NCT02334306,measures_primary,Change From Baseline
NCT02334306,measures_secondary,Peripheral Blood Biomarkers
NCT02334306,measures_secondary,Minor Salivary Gland Tissue Biomarkers
NCT02334306,measures_secondary,Focus Score
NCT02334306,has_criteria,Baseline (Day 1 predose)
NCT04944706,involves,Chronic Heart Failure With Preserved Ejection Fraction
NCT04944706,evaluates,Qishenyiqi Dripping Pills
NCT04944706,measures_primary,6-Minutes-Walking-Test distance
NCT04944706,measures_secondary,NT-proBNP
NCT04944706,measures_secondary,left atrial volume index
NCT04944706,measures_secondary,mitral inflow velocity
NCT04944706,measures_secondary,left ventricular ejection fraction
NCT04944706,measures_secondary,tricuspid regurgitation velocity
NCT04944706,measures_secondary,Hospitalizations for heart failure
NCT04944706,measures_secondary,deaths from cardiovascular disease
NCT04944706,measures_secondary,NYHA classification
NCT04944706,measures_secondary,Minnesota Living With Heart Failure Questionnaire(MLHFQ) Score
NCT04944706,has_criteria,aged ≥ 18 years
NCT04944706,has_criteria,chronic heart failure
NCT04944706,has_criteria,LVEF≥50%
NCT04944706,has_criteria,BNP > 35 ng/L
NCT04944706,has_criteria,NT-proBNP > 125 ng/L
NCT01660906,involves,Chronic Myeloid Leukemia
NCT01660906,evaluates,Dasatinib
NCT01660906,measures_primary,Change in AE severity
NCT01660906,measures_secondary,MDASI-CML Score
NCT01660906,measures_secondary,EORTC QLQ Score
NCT01660906,has_criteria,Imatinib-related AEs
NCT04745299,involves,Amyotrophic Lateral Sclerosis
NCT04745299,evaluates,Mutiple Lenzumestrocel
NCT04745299,measures_primary,Joint rank score
NCT04745299,measures_secondary,ALSFRS-R score
NCT04745299,has_criteria,period from randomization
NCT02348606,involves,Obstructive Sleep Apnea
NCT02348606,evaluates,JZP-110
NCT02348606,measures_primary,Change in MWT
NCT02348606,measures_secondary,Patient Global Impression of Change
NCT02348606,has_criteria,Baseline to Week 12
NCT03393806,involves,Moderate to Severe Asthma
NCT03393806,involves,Allergic Fungal Airway Disease
NCT03393806,evaluates,GSK3772847
NCT03393806,measures_primary,Percent Change From Baseline
NCT03393806,measures_secondary,Fractional Exhaled Nitric Oxide
NCT03393806,measures_secondary,Serum Concentrations GSK3772847
NCT03393806,measures_secondary,Serum Levels Free ST2
NCT03393806,has_criteria,Baseline (Day 1
NCT00249899,involves,Hypercholesterolemia
NCT00249899,evaluates,Lapaquistat Acetate
NCT00249899,measures_primary,Low Density Lipoprotein cholesterol
NCT00249899,measures_secondary,Adverse Events
NCT00249899,has_criteria,Woman of childbearing potential
NCT01870999,involves,Schizophrenia
NCT01870999,evaluates,Aripiprazole IM Depot
NCT01870999,measures_primary,Number of AEs
NCT01870999,measures_secondary,Aripiprazole Css
NCT01870999,measures_secondary,Aripiprazole Css
NCT01870999,measures_secondary,Aripiprazole AUCτ
NCT01870999,has_criteria,Adult Patients
NCT03596099,involves,Prehypertension
NCT03596099,evaluates,Mizkan rice vinegar
NCT03596099,measures_primary,Systolic Blood Pressure
NCT03596099,measures_secondary,Diastolic Blood Pressure
NCT03596099,measures_secondary,Blood Biomarkers
NCT03596099,measures_secondary,Vascular Reactivity
NCT03596099,has_criteria,SBP 120-139mmHg
NCT03596099,has_criteria,DBP 80-89mmHg
NCT03596099,has_criteria,30-65 years
NCT03596099,has_criteria,BMI 18.5-34.9 kg/m2
NCT03596099,has_criteria,stable body weight
NCT05020249,involves,Plaque Psoriasis
NCT05020249,evaluates,Bimekizumab
NCT05020249,measures_primary,PASI90 response
NCT05020249,measures_secondary,Investigator's Global Assessment
NCT05020249,has_criteria,Adult Korean Study Participants
NCT01375049,involves,Pseudomonas Infection
NCT01375049,evaluates,Aztreonam Lysine
NCT01375049,measures_primary,Percentage of PA-negative Cultures
NCT01375049,measures_secondary,Change From Baseline in FEV1% Predicted
NCT01375049,measures_secondary,Change From Baseline in CFQ-R RSS Score
NCT01375049,measures_secondary,Percentage of Participants With PA-negative Cultures
NCT01375049,measures_secondary,Use of Additional (Non-study) Antipseudomonal Antibiotics
NCT01375049,measures_secondary,Change From Baseline in Weight
NCT01375049,has_criteria,≥ 6 years of age
NCT02550106,involves,Chronic Spontaneous Urticaria
NCT02550106,evaluates,Omalizumab
NCT02550106,measures_primary,Percent of Participants With UCT score
NCT02550106,measures_secondary,UAS7≤6
NCT02550106,has_criteria,Adult Patients With CSU
NCT05605899,involves,High-risk Large B-cell Lymphoma
NCT05605899,evaluates,Axicabtagene Ciloleucel
NCT05605899,measures_primary,Event-free Survival
NCT05605899,measures_primary,Progression-free Survival
NCT05605899,measures_primary,Overall Survival
NCT05605899,measures_secondary,Complete Response Rate
NCT05605899,measures_secondary,Treatment-emergent Adverse Events
NCT05605899,measures_secondary,Serious Adverse Events
NCT05605899,measures_secondary,Deaths
NCT05605899,measures_secondary,Clinically Significant Changes
NCT05605899,measures_secondary,European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire-30 Score
NCT05605899,has_criteria,First dose date
NCT03100149,involves,Parkinson's Disease
NCT03100149,evaluates,Prasinezumab
NCT03100149,measures_primary,Change From Baseline in MDS-UPDRS Total Score
NCT03100149,measures_secondary,Change From Baseline in MDS-UPDRS Part IA
NCT03100149,measures_secondary,Change From Baseline in MDS-UPDRS Part IB
NCT03100149,measures_secondary,Change From Baseline in MDS-UPDRS Part I Total
NCT03100149,measures_secondary,Change From Baseline in MDS-UPDRS Part II Total
NCT03100149,measures_secondary,Change From Baseline in MDS-UPDRS Part III Total
NCT03100149,has_criteria,From baseline to Week 52
NCT03989349,involves,Atopic Dermatitis
NCT03989349,evaluates,Nemolizumab
NCT03989349,measures_primary,IGA Success
NCT03989349,measures_secondary,EASI-75
NCT03989349,has_criteria,rescue therapy
NCT01140906,involves,Major Depressive Disorder
NCT01140906,evaluates,Vortioxetine
NCT01140906,measures_primary,MADRS Total Score
NCT01140906,measures_secondary,CGI-I Score
NCT01140906,measures_secondary,SDS Total Score
NCT01140906,has_criteria,Baseline HAM-A Total Score
NCT05766306,involves,Stress
NCT05766306,evaluates,Probiotic
NCT05766306,measures_primary,Change in stress
NCT05766306,measures_secondary,Sleep quality
NCT05766306,has_criteria,Moderately Stressed Teens
NCT03847506,involves,Hypertension
NCT03847506,evaluates,Ezetimibe/Rosuvastatin
NCT03847506,evaluates,Candesartan Cilexetil/Amlodipine Besylate
NCT03847506,measures_primary,Change in siSBP
NCT03847506,measures_secondary,Percentage change in LDL-C levels
NCT03847506,has_criteria,Baseline siSBP
NCT01124006,involves,Lumbar Disc Degeneration
NCT01124006,evaluates,rhGDF-5
NCT01124006,measures_primary,Clinically Significant Abnormal results
NCT01124006,measures_secondary,Treatment Emergent Adverse Events
NCT01124006,measures_secondary,Oswestry Disability Index Change
NCT01124006,has_criteria,Early Stage
NCT03606499,involves,Inflammatory Bowel Disease
NCT03606499,involves,Crohn's Disease
NCT03606499,involves,Ulcerative Colitis
NCT03606499,involves,Extra-intestinal Manifestations
NCT03606499,involves,Immune-mediated Inflammatory Diseases
NCT03606499,evaluates,Ustekinumab
NCT03606499,measures_primary,Clinical Response
NCT03606499,measures_secondary,Harvey-Bradshaw Index
NCT03606499,measures_secondary,Remission
NCT03606499,has_criteria,Baseline Week 16 Week 24
NCT05046899,involves,Psoriasis
NCT05046899,evaluates,BiopH+Psoriasis Medical Bath
NCT05046899,measures_primary,PASI score
NCT05046899,measures_secondary,Dermatology Life Quality Index
NCT05046899,has_criteria,Baseline and week 8
NCT00880399,involves,Major Depressive Disorder
NCT00880399,evaluates,Orvepitant
NCT00880399,measures_primary,Change from Baseline
NCT00880399,measures_secondary,Percentage of Responders
NCT00880399,has_criteria,Baseline (Day 1)
NCT01281306,involves,Systolic Hypertension
NCT01281306,evaluates,AHU377
NCT01281306,evaluates,Valsartan
NCT01281306,measures_primary,Change From Baseline in msSBP
NCT01281306,measures_primary,Change From Baseline in msDBP
NCT01281306,measures_primary,Change From Baseline in maSBP
NCT01281306,measures_primary,Change From Baseline in maDBP
NCT01281306,measures_secondary,Change From Baseline in Daytime maSBP
NCT01281306,measures_secondary,Change From Baseline in Daytime maDBP
NCT01281306,measures_secondary,Change From Baseline in Nighttime maSBP
NCT01281306,measures_secondary,Change From Baseline in Nighttime maDBP
NCT01281306,measures_secondary,Change From Baseline in Mean Sitting Pulse Pressure
NCT01281306,measures_secondary,Change From Baseline in Mean Ambulatory Pulse Pressure
NCT01281306,has_criteria,Baseline
NCT03690206,involves,Short Bowel Syndrome
NCT03690206,evaluates,Glepaglutide
NCT03690206,measures_primary,Change in PS Volume
NCT03690206,measures_secondary,Clinical Response
NCT03690206,measures_secondary,Days Off PS
NCT03690206,measures_secondary,Weaned Off PS
NCT03690206,measures_secondary,Energy Content
NCT03690206,measures_secondary,Days on PS
NCT03690206,measures_secondary,Change in PS Volume Per Week
NCT03690206,measures_secondary,Patient Global Impression of Change Scale
NCT03690206,has_criteria,20% reduction in PS volume
NCT02905006,involves,Chronic Plaque Psoriasis
NCT02905006,evaluates,Bimekizumab
NCT02905006,measures_primary,PASI90 response
NCT02905006,measures_secondary,Investigator's Global Assessment
NCT02905006,has_criteria,Psoriasis severity
NCT00098306,involves,HIV-1 infection
NCT00098306,evaluates,Maraviroc
NCT00098306,measures_primary,Change in HIV-1 RNA
NCT00098306,measures_secondary,CD4 cell count
NCT00098306,has_criteria,pre-dose measurements
NCT04790006,involves,Type 2 Diabetes
NCT04790006,evaluates,TG103
NCT04790006,measures_primary,glycosylated hemoglobin (HbA1c)
NCT04790006,measures_secondary,Adverse events
NCT04790006,has_criteria,BMI 18.5-35 kg/m2
NCT04790006,has_criteria,Age 18-75 years
NCT04790006,has_criteria,Diagnosed type 2 diabetes
NCT04374136,involves,Frontotemporal Dementia
NCT04374136,evaluates,AL001
NCT04374136,measures_primary,Change in CGI-S Score
NCT04374136,measures_secondary,Change in CGI-I Score
NCT04374136,measures_secondary,Change in RBANS Score
NCT01453049,involves,Type 2 Diabetes
NCT01453049,evaluates,Rosiglitazone/Glimepiride
NCT01453049,measures_primary,Change From Baseline HbA1c
NCT01453049,measures_primary,Change From Baseline FPG
NCT01453049,measures_secondary,Number HbA1c Responders
NCT01453049,measures_secondary,Number FPG Responders
NCT01453049,measures_secondary,Number Participants HbA1c <7%
NCT01453049,measures_secondary,Change From Baseline Proinsulin
NCT01453049,has_criteria,Baseline (Week 0)
NCT05317013,involves,Osteopenia
NCT05317013,evaluates,CBD
NCT05317013,measures_primary,Serum CTx
NCT05317013,measures_secondary,Serum P1NP
NCT05317013,has_criteria,female aged 50-80 years
NCT01287936,involves,Ischemic Stroke
NCT01287936,evaluates,Modified Stem Cells
NCT01287936,measures_primary,Change in ESS Total Score
NCT01287936,measures_secondary,Change in ESS Motor Function Score
NCT01287936,has_criteria,6 months
NCT01662336,evaluates,Kaletra Adherence Support Assistance (KASA) Program
NCT01662336,measures_primary,Change From Baseline in Adherence Summative Score
NCT01662336,measures_secondary,Change From Baseline in Adherence Integration Subscale Score
NCT02082249,involves,Parkinson's Disease
NCT02082249,evaluates,ABT-SLV187
NCT02082249,measures_primary,Change in PGIC scores
NCT02082249,measures_secondary,Change in UPDRS score
NCT02082249,measures_secondary,Change in PDQ-39 scores
NCT02082249,measures_secondary,"Change in ""On"" time without dyskinesia"
NCT02082249,measures_secondary,"Change in ""Off"" time"
NCT02082249,measures_secondary,Change in CGI-C scores
NCT02082249,has_criteria,Optimized Treatment
NCT03345849,involves,Crohn's Disease
NCT03345849,evaluates,Upadacitinib
NCT03345849,measures_primary,Clinical Remission
NCT03345849,measures_primary,Clinical Remission
NCT03345849,measures_secondary,Patient-Reported Outcomes
NCT03345849,has_criteria,Conventional Therapies
NCT03345849,has_criteria,Biologic Therapies
NCT00731549,involves,Schizophrenia
NCT00731549,evaluates,Intramuscular Depot Formulation of Aripiprazole
NCT00731549,measures_primary,Stable participants at endpoint
NCT00731549,measures_secondary,Exacerbation of Psychotic Symptoms/Impending Relapse Criteria
NCT00731549,has_criteria,Outpatient status; PANSS total score ≤ 80; Lack of specific psychotic symptoms on the PANSS  as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): 1) conceptual disorganization 2) suspiciousness 3) hallucinatory behavior 4) unusual thought content; Clinical Global Impression of Severity (CGI-S) ≤ 4 (moderately ill); and Clinical Global Impression for Severity of Suicidality (CGI-SS) ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2.
NCT02607306,involves,Type 2 Diabetes Mellitus
NCT02607306,evaluates,Insulin Degludec/Liraglutide
NCT02607306,evaluates,Insulin Degludec
NCT02607306,evaluates,Liraglutide
NCT02607306,measures_primary,Change From Baseline in HbA1c
NCT02607306,measures_secondary,Change from baseline in Body Weight
NCT02607306,measures_secondary,Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
NCT02607306,has_criteria,Week 0
NCT02607306,has_criteria,Week 52
NCT01192399,involves,Paroxysmal Nocturnal Hemoglobinuria
NCT01192399,evaluates,Eculizumab
NCT01192399,measures_primary,Change From Baseline in Lactate Dehydrogenase
NCT01192399,measures_primary,Change From Baseline in PNH Red Blood Cell Count
NCT01192399,measures_primary,Change From Baseline in Lactate Dehydrogenase AUC
NCT01192399,measures_secondary,Change From Baseline in Plasma Free Hemoglobin
NCT01192399,measures_secondary,Change From Baseline in FACIT-Fatigue Scale Total Score
NCT01192399,measures_secondary,Number of Units of Packed Red Blood Cells Transfused
NCT01192399,measures_secondary,Change From Baseline in EORTC QLQ-C30 Score
NCT01192399,has_criteria,12 weeks prior to first dose
NCT01192399,has_criteria,baseline
NCT01192399,has_criteria,12 weeks after first dose
NCT05683249,involves,Attention Deficit Hyperactivity Disorder
NCT05683249,evaluates,NRCT-101SR
NCT05683249,measures_primary,PERMP-C score
NCT05683249,measures_secondary,AISRS score
NCT05683249,measures_secondary,BRIEF-A GEC score
NCT05683249,measures_secondary,HADS score
NCT05683249,has_criteria,Adult
NCT02965599,involves,Rheumatoid Arthritis
NCT02965599,evaluates,GSK3117391
NCT02965599,measures_primary,DAS28 score
NCT02965599,measures_secondary,Serious Adverse Events
NCT02965599,measures_secondary,Non-SAEs
NCT02965599,has_criteria,at least one dose
NCT04738942,involves,Ulcerative Colitis
NCT04738942,involves,Crohn's Disease
NCT04738942,evaluates,Intravenous Vedolizumab
NCT04738942,measures_primary,Clinical Response
NCT04738942,measures_secondary,Clinical Remission
NCT04738942,has_criteria,Week 12
NCT06016842,involves,Primary Biliary Cholangitis
NCT06016842,evaluates,Elafibranor
NCT06016842,measures_primary,Event-free survival
NCT06016842,measures_secondary,Treatment Emergent Adverse Events
NCT06016842,measures_secondary,Serious Adverse Events
NCT06016842,measures_secondary,Adverse Events of Special Interests
NCT06016842,measures_secondary,clinically significant changes in physical examination findings
NCT06016842,measures_secondary,clinically significant changes in vital signs
NCT06016842,measures_secondary,clinically significant changes in Electrocardiogram readings
NCT06016842,measures_secondary,clinically significant changes in laboratory parameters
NCT06016842,has_criteria,randomisation
NCT02888106,involves,Chronic Viral Hepatitis B With Delta-agent
NCT02888106,evaluates,Myrcludex B
NCT02888106,evaluates,Peginterferon Alfa-2a
NCT02888106,measures_primary,Negative HDV RNA
NCT02888106,measures_secondary,ALT normalization
NCT02888106,measures_secondary,Combined response
NCT02888106,measures_secondary,HBsAg response
NCT02888106,measures_secondary,HBsAg negativation
NCT02888106,measures_secondary,Negative HBV DNA
NCT02888106,measures_secondary,Liver fibrosis
NCT02888106,has_criteria,HDV RNA value below LLoD
NCT02888106,has_criteria,ALT within normal range
NCT01224106,involves,Prodromal Alzheimer's Disease
NCT01224106,evaluates,Gantenerumab
NCT01224106,measures_primary,CDR-SOB Total Score
NCT01224106,measures_secondary,ADAS-Cog-11 Scores
NCT01224106,has_criteria,Baseline up until 5 years
NCT06104306,involves,HIV-1 Infection
NCT06104306,evaluates,B/F/TAF
NCT06104306,measures_primary,Grade 3 or 4 Drug-related Adverse Events
NCT06104306,measures_primary,Grade 3 or 4 Laboratory Abnormalities
NCT06104306,measures_secondary,HIV-1 RNA
NCT06104306,measures_secondary,Plasma Concentrations of Bictegravir
NCT06104306,measures_secondary,Plasma Concentrations of Cabotegravir
NCT06104306,measures_secondary,Plasma Concentrations of Rilpivirine
NCT06104306,has_criteria,Switching From CAB + RPV
NCT05018806,involves,Atopic Dermatitis
NCT05018806,evaluates,Rilzabrutinib
NCT05018806,measures_primary,EASI score change
NCT05018806,measures_secondary,IGA score
NCT05018806,has_criteria,Baseline to Week 16
NCT02749799,involves,plaque-type psoriasis
NCT02749799,evaluates,DFD-01
NCT02749799,measures_primary,Investigator's Global Assessment
NCT02749799,measures_secondary,Percent Body Surface Area
NCT02749799,measures_secondary,Dermatology Life Quality Index
NCT02749799,has_criteria,18 years of age
NCT02749799,has_criteria,stable plaque-type psoriasis
NCT02749799,has_criteria,at least 3% Body Surface Area
NCT01483599,involves,Plaque-type Psoriasis
NCT01483599,evaluates,CNTO 1959
NCT01483599,measures_primary,PGA score at Week 16
NCT01483599,measures_secondary,PASI 75 Response
NCT01483599,has_criteria,Week 16
NCT03246399,involves,Degenerative Disc Disease
NCT03246399,evaluates,SM04690 Injectable Suspension
NCT03246399,measures_primary,TEAEs
NCT03246399,measures_secondary,ECG parameters
NCT03246399,measures_secondary,physical examination
NCT03246399,measures_secondary,clinical laboratory tests
NCT03246399,measures_secondary,vital signs
NCT03246399,measures_secondary,DLTs
NCT03246399,measures_primary,Cmax
NCT03246399,measures_secondary,tmax
NCT03246399,measures_secondary,AUC
NCT03246399,has_criteria,single intradiscal injection
NCT04320342,involves,COPD
NCT04320342,evaluates,CHF 5993
NCT04320342,evaluates,CHF 1535
NCT04320342,measures_primary,Change from baseline in FEV1
NCT04320342,measures_secondary,Rate of COPD exacerbations
NCT04320342,measures_secondary,SGRQ response
NCT04320342,has_criteria,2-week run-in period
NCT01780506,involves,HIV-1
NCT01780506,evaluates,E/C/F/TAF
NCT01780506,evaluates,E/C/F/TDF
NCT01780506,measures_primary,HIV-1 RNA < 50
NCT01780506,measures_secondary,CD4+ Cell Count
NCT01780506,measures_secondary,Hip BMD
NCT01780506,has_criteria,Antiretroviral Treatment-Naive
NCT02068599,involves,Primary Osteoarthritis
NCT02068599,evaluates,TV-45070
NCT02068599,measures_primary,Average Evening Pain Intensity
NCT02068599,measures_secondary,Daily WOMAC Pain Subscale Score
NCT02068599,has_criteria,Baseline (day -5 to day -1)
NCT00624442,involves,Heart Failure
NCT00624442,evaluates,CK-1827452
NCT00624442,measures_primary,Systolic Ejection Time
NCT00624442,measures_secondary,Fractional Shortening
NCT00624442,has_criteria,male or female of non-childbearing potential
NCT00624442,has_criteria,negative urine pregnancy test
NCT00624442,has_criteria,18 years old or greater
NCT00624442,has_criteria,signed informed consent
NCT02652806,involves,Chronic Kidney Disease
NCT02652806,evaluates,FG-4592
NCT02652806,measures_primary,Hb mean change
NCT02652806,measures_secondary,LDL cholesterol
NCT02652806,measures_secondary,Hb response
NCT02652806,measures_secondary,iron metabolism
NCT02652806,measures_secondary,hypertension exacerbation
NCT02652806,measures_secondary,treatment-emergent adverse events
NCT02652806,measures_secondary,vital signs
NCT02652806,measures_secondary,ECG findings
NCT02652806,measures_secondary,clinical laboratory values
NCT02652806,has_criteria,anti-hypertensive medication use
NCT02652806,has_criteria,hypertension adverse event
NCT02652806,has_criteria,blood pressure increase
NCT01370499,involves,Major Depression Disorder
NCT01370499,evaluates,LY2216684
NCT01370499,measures_primary,Change From Baseline
NCT01370499,measures_secondary,Suicidal Behaviors
NCT01370499,has_criteria,Baseline through 52 weeks
NCT05941442,involves,Panic Disorder
NCT05941442,evaluates,Darigabat
NCT05941442,measures_primary,Panic Attacks Free
NCT05941442,measures_secondary,PDSS Total Score
NCT05941442,measures_secondary,Panic Attack Frequency
NCT05941442,measures_secondary,CGI-S Score
NCT05941442,measures_secondary,HAM-A Total Score
NCT05941442,has_criteria,Primary diagnosis of panic
NCT00124449,involves,Rheumatoid Arthritis
NCT00124449,evaluates,Abatacept
NCT00124449,evaluates,Placebo
NCT00124449,measures_primary,Number of Participants
NCT00124449,measures_secondary,Radiographic Erosion
NCT00124449,measures_secondary,Joint Space Narrowing
NCT00124449,has_criteria,ARA criteria
NCT00077649,involves,Chronic Hepatitis C Infection
NCT00077649,evaluates,PEGASYS
NCT00077649,evaluates,COPEGUS
NCT00077649,measures_primary,Virological Response
NCT00077649,measures_secondary,Predicted Sustained Virological Response
NCT00077649,measures_secondary,Sustained Virological Response
NCT00077649,has_criteria,Interferon-Naive Patients
NCT05518149,involves,Major Depressive Disorder
NCT05518149,evaluates,Aticaprant
NCT05518149,measures_primary,Suicidal Ideation
NCT05518149,measures_secondary,Adverse Events
NCT05518149,measures_secondary,Abnormal Body Weight
NCT05518149,measures_secondary,Abnormal Body Mass Index
NCT05518149,has_criteria,18.5 and 25 kg/m\^2
NCT01222949,involves,Healthy Volunteers
NCT01222949,evaluates,Eurartesim™
NCT01222949,measures_primary,PK profile
NCT01222949,measures_secondary,Adverse Events
NCT01222949,has_criteria,Caucasian or Asian healthy subjects
NCT01222949,has_criteria,aged 18-50 years
NCT01222949,has_criteria,BMI 19.0-27.0 kg/m2
NCT01079806,involves,Chronic Hepatitis B Virus Infection
NCT01079806,evaluates,Entecavir
NCT01079806,measures_primary,HBV DNA Suppression
NCT01079806,measures_secondary,Hepatitis B e Antigen Seroconversion
NCT01079806,measures_secondary,Serum Alanine Aminotransferase
NCT01079806,measures_secondary,Hepatitis B Virus DNA
NCT01079806,has_criteria,Pediatric Patients
NCT06525506,involves,Thyroid Eye Disease
NCT06525506,evaluates,IBI311
NCT06525506,measures_primary,proptosis change
NCT06525506,measures_secondary,CAS change
NCT06525506,has_criteria,proptosis reduction
NCT02196506,involves,Major Depressive Disorder
NCT02196506,evaluates,Brexpiprazole
NCT02196506,measures_primary,MADRS Total Score
NCT02196506,measures_secondary,Sheehan Disability Scale
NCT02196506,has_criteria,Adults With Anxious Distress
NCT01838499,involves,Hidradenitis suppurativa
NCT01838499,evaluates,MEDI8968
NCT01838499,measures_primary,Clinically Relevant Response
NCT01838499,measures_secondary,Patient's Global Impression of Change
NCT01838499,measures_secondary,Pain Numerical Rating Scale
NCT01838499,has_criteria,Hidradenitis suppurativa
NCT01838499,has_criteria,At least 1 year diagnosis
NCT01838499,has_criteria,At least 5 active lesions
NCT01838499,has_criteria,Stable dose antibiotics
NCT01838499,has_criteria,Average pain score 3-9
NCT02405442,involves,Crohn's Disease
NCT02405442,evaluates,Andecaliximab
NCT02405442,measures_primary,Clinical Response
NCT02405442,measures_primary,Endoscopic Response
NCT02405442,measures_primary,CDAI Remission
NCT02405442,has_criteria,Week 8
NCT01243242,involves,Attention-Deficit Hyperactivity Disorder
NCT01243242,evaluates,Metadoxine (MG01CI)
NCT01243242,measures_primary,CAARS Total ADHD Symptoms Score
NCT01243242,measures_secondary,TOVA ADHD Score
NCT01243242,measures_secondary,AAQoL Total Score
NCT01243242,has_criteria,Adult
NCT00487942,involves,Schizophrenia
NCT00487942,evaluates,Armodafinil
NCT00487942,measures_primary,Composite T-Score
NCT00487942,measures_secondary,Speed of Processing
NCT00487942,has_criteria,Cognitive Deficits
NCT00906399,involves,Relapsing Multiple Sclerosis
NCT00906399,evaluates,Peginterferon Beta-1a
NCT00906399,measures_primary,Annualized Relapse Rate
NCT00906399,measures_secondary,Number of T2 lesions
NCT00906399,measures_secondary,Proportion of Participants Relapsed
NCT00906399,measures_secondary,Proportion of Participants With Sustained Disability Progression
NCT00906399,has_criteria,EDSS score
NCT00906399,has_criteria,age
NCT00906399,has_criteria,relapse rate
NCT03662542,involves,Ulcerative Colitis
NCT03662542,evaluates,Guselkumab
NCT03662542,evaluates,Golimumab
NCT03662542,measures_primary,Clinical Response
NCT03662542,measures_primary,Clinical Remission
NCT03662542,has_criteria,Moderately to severely active
NCT05516342,involves,Dementia
NCT05516342,evaluates,LEAD IT!
NCT05516342,measures_primary,Quality of Life
NCT05516342,measures_secondary,Engagement
NCT05516342,has_criteria,mild to moderate dementia
NCT02139306,involves,Nonsense Mutation Cystic Fibrosis
NCT02139306,evaluates,Ataluren
NCT02139306,measures_primary,ppFEV1 at Week 48
NCT02139306,measures_secondary,Pulmonary Exacerbations
NCT02139306,measures_secondary,CFQ-R Respiratory Domain
NCT02139306,has_criteria,expanded Fuchs criteria
NCT02381444,involves,Parkinson's Disease
NCT02381444,evaluates,levodopa-carbidopa intestinal gel
NCT02381444,evaluates,Standard of Care
NCT02381444,measures_primary,PDQ-39 summary index
NCT02381444,measures_secondary,Health Related Quality of Life
NCT02381444,measures_secondary,Unified Parkinson's disease Rating Scale part III
NCT02381444,measures_secondary,Activities of daily living
NCT02381444,measures_secondary,Healthcare Resource Utilization
NCT02381444,measures_secondary,ON-dyskinesia
NCT02381444,measures_secondary,Non-motor symptoms
NCT02381444,measures_secondary,Caregiver burden
NCT02381444,has_criteria,LCIG eligibility
NCT03028740,involves,Nonalcoholic Steatohepatitis
NCT03028740,evaluates,Cenicriviroc
NCT03028740,measures_primary,Fibrosis improvement
NCT03028740,measures_secondary,Time to first event
NCT03028740,has_criteria,Liver disease severity
NCT01176240,involves,Parkinson's Disease
NCT01176240,evaluates,Droxidopa
NCT01176240,measures_primary,OHQ composite score
NCT01176240,measures_secondary,Dizziness/Lightheadedness
NCT01176240,has_criteria,Baseline
NCT01176240,has_criteria,Baseline
NCT01176240,has_criteria,Baseline
NCT01176240,has_criteria,Baseline
NCT05099640,involves,Phenylketonuria
NCT05099640,evaluates,PTC923
NCT05099640,measures_primary,Blood Phe Level
NCT05099640,measures_secondary,Percentage of Participants
NCT05099640,has_criteria,Phe Reduction From Baseline ≥30% During Part 1
NCT06655740,involves,Type-2 Diabetes
NCT06655740,evaluates,Duodenal Mucosal RF Vapor Ablation
NCT06655740,measures_primary,Percentage of patients free of insulin
NCT06655740,measures_secondary,HbA1c
NCT06655740,has_criteria,Insulin free
NCT03579940,evaluates,Lasmiditan
NCT03579940,measures_primary,AUC[0-∞]
NCT03579940,measures_secondary,Cmax
NCT03579940,has_criteria,body mass index
NCT03579940,has_criteria,known allergies
NCT03579940,has_criteria,previously received
NCT03579940,has_criteria,abnormal supine blood pressure
NCT03579940,has_criteria,history of syncope
NCT05332340,involves,Diseases that interfere with the absorption
NCT05332340,evaluates,BZ371A
NCT05332340,measures_primary,Safety
NCT05332340,measures_secondary,Adverse effect evaluation
NCT05332340,has_criteria,Body mass index > 19 and < 28.5 Kg/m2
NCT05332340,has_criteria,Is able to understand the Informed Consent Form (ICF)
NCT05332340,has_criteria,Women in their menstrual period
NCT05332340,has_criteria,History or presence of hepatic or renal diseases
NCT05332340,has_criteria,Presence of active genital lesions or sexually transmitted disease (STD)
NCT01116440,involves,Endometriosis
NCT01116440,evaluates,BGS649
NCT01116440,measures_primary,Numeric Rating Scale Pelvic Pain Score
NCT01116440,measures_secondary,Percentage of Patients Achieving a Response
NCT01116440,has_criteria,surgical diagnosis of endometriosis
NCT01584440,involves,Alzheimer's Disease
NCT01584440,evaluates,AVP-923
NCT01584440,measures_primary,Change in NPI
NCT01584440,measures_secondary,Change in Total NPI
NCT01584440,has_criteria,clinically meaningful agitation
NCT03759340,involves,Alopecia Areata
NCT03759340,involves,Alopecia Universalis
NCT03759340,involves,Alopecia Totalis
NCT03759340,evaluates,ATI-502 Topical Solution
NCT03759340,measures_primary,Mean Relative Percent Change
NCT03759340,measures_secondary,Proportion of Subjects Achieving a SALT50
NCT03759340,measures_secondary,Proportion of Subjects Achieving a SALT75
NCT03759340,has_criteria,Baseline to Week 24
NCT03056040,involves,Paroxysmal Nocturnal Hemoglobinuria
NCT03056040,evaluates,ALXN1210
NCT03056040,evaluates,Eculizumab
NCT03056040,measures_primary,Percent Change LDH
NCT03056040,measures_secondary,Breakthrough Hemolysis
NCT03056040,measures_secondary,FACIT-Fatigue Scores
NCT03056040,has_criteria,packed red blood cells transfusion
NCT03386344,involves,Type 2 Diabetes Mellitus
NCT03386344,evaluates,Sotagliflozin
NCT03386344,measures_primary,Change From Baseline in HbA1c
NCT03386344,measures_secondary,Percent Change From Baseline in BMD
NCT03386344,measures_secondary,Change From Baseline in Body Weight
NCT03386344,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT03386344,measures_secondary,Change From Baseline in Systolic Blood Pressure
NCT03386344,measures_secondary,Percentage of Participants With HbA1c <7.0%
NCT03386344,measures_secondary,Percentage of Participants With Adverse Events
NCT03386344,has_criteria,diet and exercise only
NCT03386344,has_criteria,stable antidiabetes regimen
NCT03386344,has_criteria,written informed consent
NCT03386344,has_criteria,age >=55 years
NCT03386344,has_criteria,postmenopausal for >=5 years
NCT03386344,has_criteria,not Type 1 diabetes
NCT00085644,involves,Ankylosing Spondylitis
NCT00085644,evaluates,Adalimumab
NCT00085644,measures_primary,mSASSS change
NCT00085644,measures_secondary,ASAS 20 responders
NCT00085644,has_criteria,ASAS 20 response
NCT00390689,involves,Restless Legs Syndrome
NCT00390689,evaluates,Pramipexole
NCT00390689,measures_primary,change in IRLS score
NCT00390689,measures_secondary,Pittsburgh Sleep Quality Index
NCT00390689,measures_secondary,Japanese Version of the Epworth Sleepiness Scale
NCT00390689,has_criteria,decrease in IRLS score
NCT05086289,involves,Chronic Low Back Pain
NCT05086289,evaluates,LY3526318
NCT05086289,measures_primary,Pain Intensity
NCT05086289,measures_secondary,Roland Morris Disability
NCT05086289,has_criteria,Back pain
NCT00455429,involves,Atopic Dermatitis
NCT00455429,evaluates,JNJ-26113100
NCT00455429,measures_primary,IGA Score at Week 6
NCT00455429,measures_secondary,EASI Score at Week 6
NCT00455429,measures_secondary,VAS Score for Pruritus at Week 6
NCT01652729,involves,Type 2 Diabetes Mellitus
NCT01652729,evaluates,Exenatide
NCT01652729,evaluates,Sitagliptin
NCT01652729,evaluates,Placebo
NCT01652729,measures_primary,Change in HbA1c
NCT01652729,measures_secondary,Percentage of Subjects Achieving HbA1c <7%
NCT01652729,measures_secondary,Change in Fasting Plasma Glucose Concentrations
NCT01652729,measures_secondary,Change in Body Weight
NCT01652729,measures_secondary,Change in 2-hour Postprandial Glucose Concentrations
NCT01652729,has_criteria,At least 18 years old
NCT01652729,has_criteria,Diagnosed with type 2 diabetes mellitus
NCT01652729,has_criteria,HbA1c 7.1% to 11.0%
NCT01652729,has_criteria,Stable body weight
NCT01652729,has_criteria,Fasting plasma glucose concentration \<280 mg/dL
NCT01652729,has_criteria,Body mass index of \<45
NCT03329989,involves,EFP
NCT03329989,evaluates,EN3835
NCT03329989,measures_primary,2-level responders
NCT03329989,measures_secondary,1-level responders
NCT03329989,measures_secondary,Subject Satisfaction
NCT03329989,has_criteria,female
NCT06100289,involves,Ulcerative Colitis
NCT06100289,involves,Crohn's Disease
NCT06100289,evaluates,Vedolizumab
NCT06100289,measures_primary,Steady-state Median Plasma Concentration
NCT06100289,measures_secondary,Percentage of Participants with Positive Antivedolizumab Antibody
NCT06100289,measures_secondary,Percentage of Participants with Positive Neutralizing AVA
NCT06100289,has_criteria,weigh ≥10 kg
NCT06100289,has_criteria,diagnosed at least 1 month before screening
NCT06100289,has_criteria,moderately to severely active disease
NCT06100289,has_criteria,failed
NCT06100289,has_criteria,failed
NCT06100289,has_criteria,failed
NCT06100289,has_criteria,evidence of UC extending proximal to the rectum
NCT06100289,has_criteria,extensive colitis or pancolitis of >8 years' duration
NCT03559192,involves,Depression
NCT03559192,evaluates,JNJ-67953964
NCT03559192,measures_primary,MADRS Total Score
NCT03559192,measures_secondary,TEAEs
NCT03559192,has_criteria,Non-Responders
NCT00893789,involves,Traumatic Brain Injury
NCT00893789,evaluates,Armodafinil
NCT00893789,measures_primary,Change From Baseline
NCT00893789,measures_secondary,Percentage of Responders
NCT00893789,has_criteria,Excessive Sleepiness
NCT01281189,involves,Amyotrophic Lateral Sclerosis
NCT01281189,evaluates,Dexpramipexole
NCT01281189,measures_primary,CAFS at 12 Months
NCT01281189,measures_secondary,Death up to 12 Months
NCT01281189,measures_secondary,Change From Baseline in ALSFRS-R at 12 Months
NCT01281189,measures_secondary,Death or Respiratory Insufficiency up to Month 18
NCT01281189,has_criteria,12-18 months
NCT01782729,involves,atopic dermatitis
NCT01782729,evaluates,Tacrolimus Ointment
NCT01782729,measures_primary,Physician's Global Evaluation
NCT01782729,measures_secondary,Eczema Area and Severity Index
NCT01782729,measures_secondary,Participant's Assessment of Treatment Effects
NCT01782729,measures_secondary,Participant's Assessment of Itch
NCT01782729,has_criteria,Hanifin and Rajka Criteria
NCT00469092,involves,Type 2 Diabetes
NCT00469092,evaluates,Biphasic Insulin Aspart 30
NCT00469092,evaluates,Insulin Glargine
NCT00469092,measures_primary,Glycosylated Haemoglobin A1c
NCT00469092,measures_secondary,9-point Self-measured Plasma Glucose Profiles
NCT00469092,measures_secondary,Treatment Satisfaction
NCT00469092,measures_secondary,Number of Hypoglycaemic Episodes
NCT00469092,has_criteria,Metformin and Glimepiride
NCT04434092,involves,Paroxysmal Nocturnal Hemoglobinuria
NCT04434092,evaluates,Crovalimab
NCT04434092,evaluates,Eculizumab
NCT04434092,measures_primary,Transfusion Avoidance
NCT04434092,measures_secondary,hemolysis control
NCT04434092,measures_secondary,Breakthrough Hemolysis
NCT04434092,measures_secondary,Stabilization of Hemoglobin
NCT04434092,measures_secondary,Mean Change in Fatigue
NCT04434092,measures_secondary,Adverse Events
NCT04434092,measures_secondary,Injection-Site Reactions
NCT04434092,measures_secondary,Infusion-Related Reactions
NCT04434092,measures_secondary,Hypersensitivity
NCT04434092,measures_secondary,Infections
NCT04434092,measures_secondary,Adverse Events leading to Discontinuation
NCT04434092,has_criteria,complement inhibitors
NCT00791492,involves,Transthyretin Amyloid Polyneuropathy
NCT00791492,evaluates,Fx-1006A
NCT00791492,measures_primary,NIS-LL at Month 6
NCT00791492,measures_primary,NIS-LL at Month 12
NCT00791492,measures_secondary,Norfolk QOL-DN TQOL Score
NCT00791492,has_criteria,diabetic neuropathy
NCT00196989,involves,Type 2 Diabetes
NCT00196989,measures_primary,Percentage change HbA1c
NCT00196989,measures_secondary,fasting HbA1c
NCT00196989,measures_secondary,fasting plasma glucose
NCT00196989,measures_secondary,fasting fructosamine
NCT00196989,has_criteria,Baseline (Day 1)
NCT01855789,involves,Rheumatoid arthritis
NCT01855789,evaluates,Methotrexate
NCT01855789,evaluates,Tocilizumab
NCT01855789,measures_primary,DAS28 change
NCT01855789,measures_secondary,ACR20 response
NCT01855789,measures_secondary,ACR50 response
NCT01855789,has_criteria,20% improvement
NCT01519089,involves,Plaque Psoriasis
NCT01519089,involves,Psoriatic Arthritis
NCT01519089,evaluates,CP-690
NCT01519089,measures_primary,PASI75 Response
NCT01519089,measures_secondary,Physician Global Assessment
NCT01519089,measures_secondary,ACR20 Response
NCT01519089,has_criteria,Moderate to Severe
NCT00940589,involves,Alzheimer Disease
NCT00940589,evaluates,Circadin 2 mg
NCT00940589,measures_primary,ADAS-cog score
NCT00940589,measures_secondary,iADL score
NCT00940589,measures_secondary,MMSE score
NCT00940589,has_criteria,mild to moderate
NCT05357989,involves,Early PD
NCT05357989,evaluates,Buntanetap
NCT05357989,evaluates,Placebo
NCT05357989,measures_primary,Change From Baseline
NCT05357989,measures_primary,MDS-UPDRS Part II
NCT05357989,measures_secondary,Change in the Score
NCT05357989,measures_secondary,MDS-UPDRS Parts II+III
NCT05357989,measures_secondary,Activities of Daily Living
NCT05357989,measures_secondary,MDS-UPDRS Total Score
NCT05357989,has_criteria,From consent to end of trial
NCT00683592,involves,Major Depressive Disorder
NCT00683592,evaluates,Vilazodone
NCT00683592,measures_primary,MADRS total score
NCT00683592,measures_secondary,HAM-D 17 total score
NCT00683592,measures_secondary,CGI-I score
NCT00683592,has_criteria,Baseline
NCT01032889,involves,Submental Fat
NCT01032889,evaluates,Deoxycholic Acid Injection
NCT01032889,measures_primary,Change From Baseline
NCT01032889,measures_secondary,Submental Fat Volume
NCT01032889,has_criteria,Baseline and 12 weeks
NCT05247489,involves,Vitiligo
NCT05247489,evaluates,Ruxolitinib Cream
NCT05247489,measures_primary,Change from Baseline
NCT05247489,measures_secondary,Number of adverse events
NCT05247489,measures_secondary,Percentage achieving F-VASI50/75/90
NCT05247489,measures_secondary,Percentage achieving T-VASI50/75/90
NCT05247489,measures_secondary,Percentage change from baseline in F-VASI
NCT05247489,has_criteria,Approximately 14 months
NCT03959189,involves,Myotonic Dystrophy Type 1
NCT03959189,evaluates,ERX-963
NCT03959189,measures_primary,Stanford Sleepiness Scale
NCT03959189,measures_secondary,Patient Global Impression
NCT03959189,has_criteria,single dose
NCT01378429,involves,Perennial Allergic Rhinitis
NCT01378429,evaluates,Ciclesonide Nasal Aerosol
NCT01378429,measures_primary,Serum Cortisol AUC
NCT01378429,measures_secondary,Urinary Free Cortisol
NCT01378429,has_criteria,Subjects 6-11 years
NCT02673489,involves,Hepatitis C Infection
NCT02673489,evaluates,Daclatasvir
NCT02673489,evaluates,Sofosbuvir
NCT02673489,evaluates,Ribavirin
NCT02673489,measures_primary,SVR12
NCT02673489,measures_secondary,HCV RNA < LLOQ
NCT02673489,has_criteria,Baseline NS5A
NCT00701389,involves,Migraine
NCT00701389,evaluates,Sumatriptan
NCT00701389,evaluates,MK-0974
NCT00701389,evaluates,Telcagepant
NCT00701389,measures_primary,Time-weighted MAP
NCT00701389,measures_secondary,Blood Pressure
NCT00701389,has_criteria,Semi-recumbent BP
NCT03782792,involves,Generalized Pustular Psoriasis
NCT03782792,evaluates,Spesolimab
NCT03782792,measures_primary,GPPGA pustulation subscore 0
NCT03782792,measures_secondary,GPPGA score 0 or 1
NCT03782792,measures_secondary,GPPASI 75 at Week 4
NCT03782792,has_criteria,Generalized Pustular Psoriasis flare-up
NCT05107492,evaluates,PF-06480605
NCT05107492,measures_primary,Number of TEAEs
NCT05107492,measures_secondary,Serious Adverse Events
NCT05107492,has_criteria,Treatment Emergent Adverse Events
NCT02794792,involves,Type 2 Diabetes Mellitus
NCT02794792,evaluates,Ipragliflozin
NCT02794792,measures_primary,Change from baseline in HbA1c
NCT02794792,measures_secondary,Fasting plasma glucose
NCT02794792,has_criteria,Inadequate Glycemic Control
NCT01878292,involves,Major Depressive Disorder
NCT01878292,evaluates,Vilazodone
NCT01878292,measures_primary,CDRS-R Total Score
NCT01878292,measures_secondary,CGI-S Score
NCT01878292,has_criteria,age 12-17 years
NCT01878292,has_criteria,CDRS-R score 40 or greater
NCT01878292,has_criteria,CGI-S score 4 or greater
NCT06295692,involves,Generalized Pustular Psoriasis
NCT06295692,involves,Erythrodermic Psoriasis
NCT06295692,evaluates,JNJ-77242113
NCT06295692,measures_primary,Treatment Success
NCT06295692,measures_secondary,JDA Severity Index
NCT06295692,has_criteria,Week 16
NCT06295692,has_criteria,Week 156
NCT00952289,involves,Myelofibrosis
NCT00952289,evaluates,Oral JAK Inhibitor
NCT00952289,measures_primary,Spleen volume reduction
NCT00952289,measures_secondary,Symptom score reduction
NCT00952289,has_criteria,≥ 35% reduction
NCT05437289,evaluates,AZD7442
NCT05437289,measures_primary,Incidence of adverse events
NCT05437289,measures_secondary,Incidence of serious adverse events
NCT05437289,measures_secondary,Incidence of adverse event of special interests
NCT05437289,measures_secondary,Number of participants with abnormal laboratory test results
NCT05437289,measures_secondary,Number of participants with abnormal Coagulation test results
NCT05437289,measures_secondary,Number of participants with abnormal urinalysis
NCT05437289,measures_secondary,Number of participants with abnormal ECG readings
NCT05437289,measures_secondary,Number of participants with abnormal vital signs
NCT05437289,has_criteria,healthy Chinese participants 18 to 55 years of age
NCT00128492,involves,Cystic Fibrosis
NCT00128492,involves,Pseudomonas Aeruginosa
NCT00128492,evaluates,Aztreonam
NCT00128492,measures_primary,FEV1 decline
NCT00128492,measures_secondary,Heart Rate
NCT00128492,measures_secondary,Blood Pressure
NCT00128492,has_criteria,<15% or ≥15% decline
NCT01364389,involves,Polymyalgia Rheumatica
NCT01364389,evaluates,AIN457
NCT01364389,evaluates,ACZ885
NCT01364389,evaluates,Corticosteroids
NCT01364389,measures_primary,Time to Partial Clinical Response
NCT01364389,measures_primary,Time to Complete Clinical Response
NCT01364389,measures_primary,Time to First Flare
NCT01364389,measures_secondary,PMR-AS
NCT01364389,has_criteria,CRP values at Day 15
NCT06456580,involves,Generalized Myasthenia Gravis
NCT06456580,evaluates,Telitacicept
NCT06456580,measures_primary,Change from baseline MG-ADL
NCT06456580,measures_secondary,Change from baseline QMG
NCT06456580,measures_secondary,Change from baseline MG-QOL15r
NCT06456580,has_criteria,Baseline score
NCT03960580,involves,Chronic Rhinosinusitis
NCT03960580,evaluates,OPN-375
NCT03960580,measures_primary,Change From Baseline
NCT03960580,measures_secondary,Percent volume opacified
NCT03960580,has_criteria,Subjects With CRS
NCT04938180,involves,Tenosynovial Giant Cell Tumor
NCT04938180,evaluates,Intravenous AMB 05X
NCT04938180,measures_primary,Overall Tumor Response
NCT04938180,measures_secondary,Tumor Volume Score
NCT04938180,measures_secondary,Mean Change From Baseline Range of Motion
NCT04938180,has_criteria,6 months
NCT04938180,has_criteria,12 weeks
NCT04938180,has_criteria,24 weeks
NCT04097080,involves,Parkinson's Disease
NCT04097080,evaluates,Xenon
NCT04097080,measures_primary,UPDRS from baseline
NCT04097080,measures_secondary,
NCT04097080,has_criteria,Age over 18 years old
NCT04097080,has_criteria,Idiopathic Parkinson's disease
NCT04097080,has_criteria,Stage III Hoehn and Yahr
NCT04097080,has_criteria,Stable dopaminergic dosage
NCT04097080,has_criteria,Signed consent form
NCT04254380,involves,Type 1 Diabetes
NCT04254380,evaluates,Biosimilar
NCT04254380,measures_primary,Percentage of subjects
NCT04254380,measures_secondary,Mean change in AIA titers
NCT04254380,has_criteria,AIA titers
NCT05351580,involves,Parkinson's Disease
NCT05351580,evaluates,Kinesia ONE
NCT05351580,measures_primary,UPDRS Part III
NCT05351580,measures_secondary,PDQ-39
NCT05351580,measures_secondary,Montreal Cognitive Assessment
NCT05351580,measures_secondary,MANAGE-PD questionnaire
NCT05351580,has_criteria,oral medications
NCT04160091,involves,Glenohumeral Osteoarthritis
NCT04160091,involves,Shoulder Adhesive Capsulitis
NCT04160091,evaluates,FX006
NCT04160091,measures_primary,Change From Baseline
NCT04160091,measures_secondary,SPADI Pain Subscale
NCT04160091,measures_secondary,SPADI Disability Subscale
NCT04160091,measures_secondary,Patient Global Impression of Change
NCT04160091,measures_secondary,Range of Motion
NCT04160091,has_criteria,Baseline to 12 weeks
NCT03831191,involves,Atopic Dermatitis
NCT03831191,evaluates,LY3375880
NCT03831191,measures_primary,vIGA-AD 0 or 1
NCT03831191,measures_primary,EASI-75
NCT03831191,measures_primary,SCORAD-75
NCT03831191,has_criteria,Moderate-to-Severe
NCT00819091,involves,Type 2 Diabetes
NCT00819091,evaluates,Linagliptin
NCT00819091,measures_primary,Change From Baseline in HbA1c
NCT00819091,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT00819091,measures_secondary,Percentage of Patients With Absolute Efficacy Response
NCT00819091,measures_secondary,Percentage of Patients With Absolute Efficacy Response
NCT00819091,measures_secondary,Percentage of Patients With HbA1c Lowering by at Least 0.5% From Baseline
NCT00819091,has_criteria,Insufficient Glycaemic Control
NCT03018691,involves,Atopic Dermatitis
NCT03018691,evaluates,OPA-15406 Ointment
NCT03018691,measures_primary,Responder Rate IGA
NCT03018691,measures_secondary,Change From Baseline EASI Score
NCT03018691,measures_secondary,Change From Baseline VAS Pruritus Score
NCT03018691,has_criteria,Week 0-4
NCT01114880,involves,Ankylosing Spondylitis
NCT01114880,evaluates,Adalimumab
NCT01114880,measures_primary,ASAS20 Response Criteria
NCT01114880,measures_secondary,ASAS40 Response Criteria
NCT01114880,has_criteria,Active Ankylosing Spondylitis
NCT05243680,involves,Asthma
NCT05243680,evaluates,GSK3511294
NCT05243680,measures_primary,Asthma Control Questionnaire
NCT05243680,measures_secondary,Saint George's Respiratory Questionnaire
NCT05243680,measures_secondary,FEV1
NCT05243680,has_criteria,Adverse events
NCT05243680,has_criteria,Immunogenicity
NCT01701362,involves,Post-traumatic Peripheral Neuropathic Pain
NCT01701362,evaluates,Pregabalin
NCT01701362,measures_primary,Pain diary score
NCT01701362,measures_secondary,Sleep Interference Score
NCT01701362,has_criteria,Baseline Mean Pain Score
NCT01566162,involves,Schizophrenia
NCT01566162,measures_primary,Change in PANSS
NCT01566162,measures_secondary,Change in CGI-S Score
NCT01566162,measures_secondary,Change From Baseline in MADRS Total Score
NCT01566162,measures_secondary,Short Form-12 Health Survey
NCT04872491,involves,Ulcerative Colitis
NCT04872491,involves,Crohn's Disease
NCT04872491,evaluates,Vedolizumab
NCT04872491,measures_primary,Clinical Response
NCT04872491,measures_primary,Clinical Remission
NCT04872491,has_criteria,Partial Mayo Score
NCT04872491,has_criteria,Harvey-Bradshaw Index
NCT00923091,involves,Hypertension
NCT00923091,evaluates,Olmesartan
NCT00923091,evaluates,Amlodipine
NCT00923091,evaluates,Hydrochlorothiazid
NCT00923091,measures_primary,Change in SeDBP
NCT00923091,measures_secondary,Number of Subjects Reaching Blood Pressure Goal
NCT00923091,has_criteria,mean trough seated blood pressure
NCT00787891,involves,Gastroesophageal Reflux Disease
NCT00787891,evaluates,Rabeprazole
NCT00787891,measures_primary,Healing by Week 12
NCT00787891,measures_primary,Change From Baseline in Hetzel and Dent score
NCT00787891,measures_primary,Change From Baseline in GERD Symptom and Severity Score
NCT00787891,has_criteria,Pediatric Patients
NCT03605680,involves,Attention-deficit/Hyperactivity Disorder
NCT03605680,evaluates,Centanafadine Sustained-release Tablets
NCT03605680,measures_primary,Change From Baseline
NCT03605680,measures_secondary,Change From Baseline
NCT03605680,has_criteria,DSM-5 criteria for ADHD
NCT03765762,involves,Severe Alzheimer's Disease
NCT03765762,evaluates,GRF6019
NCT03765762,measures_primary,MMSE Score
NCT03765762,measures_primary,SIB Total Score
NCT03765762,measures_primary,ADCS-ADL-Severe
NCT03765762,measures_secondary,ADCS-CGIC
NCT03765762,has_criteria,Severe Impairment
NCT02537691,involves,Severe Asthma
NCT02537691,evaluates,
NCT02537691,measures_primary,Mean Number of Asthma Exacerbations
NCT02537691,measures_secondary,Change From Baseline in FEV1
NCT02537691,has_criteria,
NCT03662191,evaluates,PF-6291826
NCT03662191,measures_primary,AUCinf
NCT03662191,measures_primary,Cmax
NCT03662191,measures_primary,AUC24
NCT03662191,measures_primary,AUClast
NCT03662191,measures_primary,Tmax
NCT03662191,has_criteria,Body Mass Index
NCT03662191,has_criteria,hematological disease
NCT03662191,has_criteria,renal disease
NCT03662191,has_criteria,endocrine disease
NCT03662191,has_criteria,pulmonary disease
NCT03662191,has_criteria,gastrointestinal disease
NCT03662191,has_criteria,cardiovascular disease
NCT03662191,has_criteria,hepatic disease
NCT03662191,has_criteria,psychiatric disease
NCT03662191,has_criteria,neurological disease
NCT03662191,has_criteria,allergic disease
NCT03662191,has_criteria,blood pressure
NCT03662191,has_criteria,drug use
NCT03662191,has_criteria,fertile male
NCT04876391,involves,Hidradenitis Suppurativa
NCT04876391,evaluates,Spesolimab
NCT04876391,measures_primary,Percentage change in AN count
NCT04876391,measures_secondary,Percentage change in DF count
NCT04876391,measures_secondary,Hidradenitis Suppurativa Clinical Response
NCT04876391,measures_secondary,IHS4 score
NCT04876391,measures_secondary,HS-PGA score
NCT04876391,has_criteria,Completed previous trial
NCT06122662,involves,Progressive Supranuclear Palsy
NCT06122662,evaluates,AMX0035
NCT06122662,measures_primary,PSPRS Score
NCT06122662,measures_secondary,MDS-UPDRS Part II Score
NCT06122662,has_criteria,Age 40 to 80 years
NCT06122662,has_criteria,Diagnosis of possible or probable PSP Richardson Syndrome
NCT06122662,has_criteria,Presence of PSP symptoms for <5 years
NCT06122662,has_criteria,Score <40 on PSPRS
NCT06122662,has_criteria,Able to walk independently or with minimal assistance
NCT06122662,has_criteria,Minimum score of 24 on MMSE
NCT06122662,has_criteria,Reside outside skilled nursing facility
NCT06122662,has_criteria,Have study partner
NCT06122662,has_criteria,Capable of providing informed consent
NCT06122662,has_criteria,Capable and willing to comply with trial procedures
NCT01436162,involves,Major Depressive Disorder
NCT01436162,evaluates,SPD489
NCT01436162,measures_primary,MADRS Total Score
NCT01436162,measures_secondary,Sheehan Disability Scale
NCT01436162,measures_secondary,ABAC-A Composite T-Scores
NCT01436162,has_criteria,Lead-in Baseline
NCT02437162,involves,Radiographic Axial Spondyloarthritis
NCT02437162,evaluates,Ustekinumab
NCT02437162,measures_primary,ASAS 40 Response
NCT02437162,measures_secondary,ASAS 20 Response
NCT02437162,has_criteria,Anti-TNFα Naive
NCT03729362,involves,Late-onset Pompe Disease
NCT03729362,evaluates,cipaglucosidase alfa/miglustat
NCT03729362,measures_primary,6 Minute Walk Distance
NCT03729362,measures_secondary,Sitting Forced Vital Capacity
NCT03729362,measures_secondary,Manual Muscle Test Score
NCT03729362,has_criteria,Adult Subjects
NCT04700280,involves,Primary Sjögren's Syndrome
NCT04700280,evaluates,GLPG3970
NCT04700280,measures_primary,ESSDAI score
NCT04700280,measures_secondary,Treatment Emergent Adverse Events
NCT04700280,has_criteria,Adults with pSS
NCT00262080,involves,Hereditary Angioedema
NCT00262080,evaluates,DX-88
NCT00262080,measures_primary,Treatment Outcome Score
NCT00262080,measures_secondary,Mean Symptom Complex Severity
NCT00262080,has_criteria,baseline
NCT06442462,involves,Schizophrenia
NCT06442462,evaluates,SPG302
NCT06442462,measures_primary,PANSS Score
NCT06442462,measures_secondary,smooth pursuit eye tracking
NCT06442462,measures_secondary,Global Impressions Improvement scale
NCT06442462,measures_secondary,MATRICS Consensus Cognitive Battery scale
NCT06442462,has_criteria,treatment related adverse events
NCT01204762,involves,Hepatitis B
NCT01204762,evaluates,Pegylated Interferon Lambda
NCT01204762,measures_primary,HBeAg seroconversion
NCT01204762,measures_secondary,Serious adverse events
NCT01204762,measures_secondary,ALT normalization
NCT01204762,has_criteria,Positive for HBeAg
NCT02591862,involves,Paroxysmal Nocturnal Haemoglobinuria
NCT02591862,evaluates,Coversin
NCT02591862,measures_primary,LDH AUC
NCT02591862,measures_secondary,Haemoglobin
NCT02591862,measures_secondary,Haptoglobin
NCT02591862,measures_secondary,Lactate Dehydrogenase
NCT02591862,measures_secondary,FACIT Score
NCT02591862,has_criteria,2 years
NCT05386680,involves,Spinal Muscular Atrophy
NCT05386680,evaluates,OAV101
NCT05386680,measures_primary,HFMSE total score
NCT05386680,measures_secondary,RULM total Score
NCT05386680,has_criteria,Discontinued Nusinersen or Risdiplam
NCT06054880,involves,Ureteral Patency
NCT06054880,evaluates,Indigotindisulfonate Sodium Injection
NCT06054880,measures_primary,Conspicuity score
NCT06054880,measures_secondary,Adverse events
NCT06054880,has_criteria,>=1 point improvement
NCT04267380,involves,Rheumatoid arthritis
NCT04267380,evaluates,Tofacitinib
NCT04267380,measures_primary,Change in CDAI
NCT04267380,measures_secondary,Number of Participants Achieving Remission
NCT04267380,has_criteria,Baseline Up to 6 Months
NCT05627362,involves,Primary Sclerosing Cholangitis
NCT05627362,evaluates,Elafibranor
NCT05627362,measures_primary,Clinically Significant Changes
NCT05627362,measures_secondary,Clinically Significant Changes
NCT05627362,has_criteria,Adult Participants
NCT00640562,involves,Depression Symptoms
NCT00640562,evaluates,Quetiapine Extended Release
NCT00640562,measures_primary,Change From Baseline
NCT00640562,measures_secondary,HAM-D Score
NCT00640562,measures_secondary,PANSS Score
NCT00640562,measures_secondary,CGI- Severity of Illness
NCT00640562,has_criteria,12 weeks from baseline
NCT00661362,involves,Type 2 Diabetes
NCT00661362,evaluates,Saxagliptin
NCT00661362,measures_primary,HbA1c change
NCT00661362,measures_secondary,Fasting Plasma Glucose
NCT00661362,measures_secondary,PPG AUC
NCT00661362,has_criteria,Adult Patients
NCT01248780,involves,Rheumatoid Arthritis
NCT01248780,evaluates,Subcutaneous Golimumab
NCT01248780,measures_primary,ACR 20 response
NCT01248780,measures_secondary,DAS28 response
NCT01248780,has_criteria,Methotrexate Therapy
NCT03798080,involves,Type 2 Diabetes
NCT03798080,evaluates,Insulin Glargine/Lixisenatide
NCT03798080,measures_primary,Change in HbA1c
NCT03798080,measures_secondary,Change in glycated hemoglobin
NCT03798080,has_criteria,HbA1c <7.0%
NCT01034462,involves,Major Depressive Disorder
NCT01034462,evaluates,Levomilnacipran ER
NCT01034462,measures_primary,MADRS Total Score
NCT01034462,measures_secondary,SDS Total Score
NCT01034462,has_criteria,18-80 years old
NCT01034462,has_criteria,DSM-IV-TR criteria
NCT01034462,has_criteria,depressive episode 4 weeks
NCT04849780,involves,Dry Eye Symptoms
NCT04849780,evaluates,Silicone Hydrogel Daily Disposable Contact Lens
NCT04849780,measures_primary,Change From Baseline Comfort Score
NCT04849780,measures_secondary,Change From Baseline CLDEQ-8 Score
NCT04849780,has_criteria,CLDEQ total score ≥15
NCT05248880,involves,Glabellar Lines
NCT05248880,evaluates,AGN-151586
NCT05248880,measures_primary,Facial Wrinkle Scale
NCT05248880,measures_secondary,Adverse Events
NCT05248880,measures_secondary,Vital Sign Measurements
NCT05248880,measures_secondary,ECG parameters
NCT05248880,measures_secondary,laboratory evaluations
NCT05248880,measures_secondary,antidrug antibodies
NCT05248880,has_criteria,Toxin-Naïve Adult
NCT00496080,involves,Fibroid Related Bleeding
NCT00496080,evaluates,Doppler-Guided Uterine Artery Occlusion (DUAO) Device
NCT00496080,measures_primary,PBLAC score reduction
NCT00496080,measures_secondary,Health Related Quality of Life (HRQOL) Scores
NCT00496080,measures_secondary,Maintenance of Menses
NCT00496080,measures_secondary,Procedural Satisfaction
NCT00496080,measures_secondary,Decrease in Fibroid Bulk
NCT00496080,has_criteria,surgical re-intervention
NCT01073462,involves,Chronic Kidney Disease
NCT01073462,evaluates,Paricalcitol
NCT01073462,measures_primary,iPTH Level
NCT01073462,measures_secondary,Hypercalcemia
NCT01073462,measures_secondary,Hyperphosphatemia
NCT01073462,has_criteria,CKD Stage 5
NCT04931667,involves,Osteoarthritis of the Knee
NCT04931667,evaluates,Lorecivivint
NCT04931667,measures_primary,pain numeric rating scale
NCT04931667,measures_secondary,WOMAC Function
NCT04931667,has_criteria,40 to 80 years age
NCT01632540,involves,Perennial Allergic Rhinitis
NCT01632540,evaluates,Beclomethasone Dipropionate Nasal Aerosol
NCT01632540,measures_primary,Change in RCAT Score
NCT01632540,measures_secondary,TSQM-9 score
NCT01632540,measures_secondary,WPAI-CIQ-AS score
NCT01632540,measures_secondary,PSQI score
NCT01514240,involves,Crohn's Disease
NCT01514240,evaluates,D9421-C
NCT01514240,measures_primary,Remission after 8 weeks
NCT01514240,measures_secondary,Remission after 2 weeks
NCT01514240,measures_secondary,Remission after 4 weeks
NCT01514240,measures_secondary,Change in CDAI Scores
NCT01514240,has_criteria,CDAI score 180 to 400
NCT02229240,involves,Type 2 Diabetes Mellitus
NCT02229240,evaluates,Albiglutide
NCT02229240,measures_primary,HbA1c change
NCT02229240,measures_secondary,body weight
NCT02229240,has_criteria,HbA1c >=7.5%
NCT02229240,has_criteria,HbA1c <=10.0%
NCT02229240,has_criteria,basal-bolus insulin
NCT01059344,involves,Ulcerative Colitis
NCT01059344,evaluates,Asacol™ 4.8 g/Day
NCT01059344,measures_primary,Clinical Remission
NCT01059344,measures_secondary,Endoscopic Remission
NCT01059344,measures_secondary,Improvement
NCT01059344,has_criteria,modified UC-DAI score of 4-10
NCT01059344,has_criteria,sigmoidoscopy component score ≥ 2
NCT01059344,has_criteria,rectal bleeding component score ≥ 1
NCT01059344,has_criteria,18 years of age or older
NCT01059344,has_criteria,documented diagnosis of UC
NCT01059344,has_criteria,disease extending at least 15 cm
NCT01059344,has_criteria,written informed consent
NCT01059344,has_criteria,previously failed treatment with a mesalazine dose of > 2.0 g/day
NCT01059344,has_criteria,current relapse lasting > 6 weeks
NCT01059344,has_criteria,treatment with 5-ASA at a dose of >2.0g/day within 1 week prior to randomisation
NCT01490840,involves,Relapsing-remitting Multiple Sclerosis
NCT01490840,evaluates,Physical ACtivity
NCT01490840,measures_primary,Change From Baseline in Fatigue
NCT01490840,measures_secondary,Isometric and Dynamic Muscular Strength
NCT01490840,measures_secondary,Leg Strength Endurance
NCT01490840,measures_secondary,Quality of Life
NCT01490840,has_criteria,baseline
NCT06176040,involves,Atopic Dermatitis
NCT06176040,evaluates,TAVO101
NCT06176040,measures_primary,EASI 50 at Week 16
NCT06176040,measures_primary,EASI 75 at Week 16
NCT06176040,measures_primary,SCORAD at Week 16
NCT06176040,measures_secondary,Pruritus NRS at Week 16
NCT06176040,measures_secondary,IGA Score at Week 16
NCT06176040,has_criteria,Baseline to Week 16
NCT02905240,involves,Knee Osteoarthritis
NCT02905240,evaluates,nSTRIDE APS
NCT02905240,evaluates,Saline
NCT02905240,measures_primary,WOMAC Pain score
NCT02905240,measures_secondary,VAS Pain Change
NCT02905240,measures_secondary,OMERACT-OARSI Responders
NCT02905240,measures_secondary,WOMAC Stiffness Subscale
NCT02905240,measures_secondary,EQ-5D
NCT02905240,has_criteria,improvement of ≥50%
NCT00782340,involves,Neurogenic Orthostatic Hypotension
NCT00782340,evaluates,Droxidopa
NCT00782340,measures_primary,Change in OHQ Score
NCT00782340,measures_secondary,Change in OHDAS Composite Score
NCT00782340,measures_secondary,Change in OHSA Composite Score
NCT00782340,measures_secondary,Change in Activities Involving Standing a Short Time
NCT00782340,has_criteria,randomization
NCT00220740,involves,Chronic Inflammatory Demyelinating Polyneuropathy
NCT00220740,evaluates,Immune Globulin Intravenous
NCT00220740,measures_primary,Responder rates
NCT00220740,measures_secondary,Mean Change in Amplitude
NCT00220740,has_criteria,progressive motor and sensory dysfunction
NCT03617367,involves,Isolated Cervical Dystonia
NCT03617367,evaluates,DaxibotulinumtoxinA
NCT03617367,measures_primary,Clinician Global Impression
NCT03617367,measures_secondary,TWSTRS Total Score
NCT03617367,has_criteria,isolated CD severity
NCT01061567,involves,Parkinson's Disease
NCT01061567,evaluates,Pramipexole Extended Release
NCT01061567,measures_primary,Change From Baseline in UPDRS
NCT01061567,measures_secondary,Clinical Global Impression of Improvement
NCT01061567,measures_secondary,Change From Baseline in VAS of Patient Satisfaction
NCT01061567,measures_secondary,Change From Baseline in Morisky Medication Adherence Scale 4 Item Score
NCT01061567,has_criteria,Baseline and the end of study (up to 16 weeks)
NCT00621140,involves,Type 2 Diabetes
NCT00621140,evaluates,BI 1356
NCT00621140,measures_primary,HbA1c Change
NCT00621140,measures_secondary,FPG Change
NCT00621140,has_criteria,Insufficient Glycemic Control
NCT02998840,involves,Elevated Blood Pressure
NCT02998840,evaluates,B244
NCT02998840,measures_primary,Difference in Systolic BP
NCT02998840,measures_primary,Difference in Diastolic BP
NCT02998840,measures_secondary,Ambulatory Blood Pressure
NCT02998840,has_criteria,≥18 years of age
NCT02998840,has_criteria,Good general health
NCT02998840,has_criteria,Elevated Blood Pressure
NCT00034840,involves,Hypertension
NCT00034840,evaluates,Telmisartan
NCT00034840,evaluates,Valsartan
NCT00034840,measures_primary,Change in DBP
NCT00034840,measures_primary,Change in SBP
NCT00034840,measures_secondary,Responder rates
NCT00034840,has_criteria,Baseline mean seated DBP
NCT00034840,has_criteria,24-hour ABPM mean DBP
NCT00034840,has_criteria,Pre-menopausal women
NCT00034840,has_criteria,Child-bearing potential
NCT00034840,has_criteria,Night shift workers
NCT02343744,involves,Generalized Pustular Psoriasis
NCT02343744,involves,Erythrodermic Psoriasis
NCT02343744,evaluates,CNTO1959
NCT02343744,evaluates,Guselkumab
NCT02343744,measures_primary,Treatment Success
NCT02343744,measures_secondary,DLQI Score
NCT02343744,has_criteria,Baseline Week 16
NCT03293992,involves,Primary open-angle glaucoma
NCT03293992,involves,Ocular hypertension
NCT03293992,evaluates,RO7058584
NCT03293992,measures_primary,Change From Baseline in Mean Intraocular pressure
NCT03293992,measures_secondary,Incidence of Abnormal Laboratory Findings
NCT03293992,measures_secondary,Incidence of Blood Pressure Abnormalities
NCT03293992,measures_secondary,Incidence of Pulse Rate Abnormalities
NCT03293992,measures_secondary,Incidence of Electrocardiogram (ECG) Findings
NCT03293992,has_criteria,18 to 90 years of age
NCT03789292,involves,Rheumatoid Arthritis
NCT03789292,evaluates,CT-P17
NCT03789292,evaluates,Humira
NCT03789292,measures_primary,ACR20 Response Rate
NCT03789292,measures_primary,ACR50 Response Rate
NCT03789292,measures_primary,ACR70 Response Rate
NCT03789292,measures_secondary,Mean Change From Baseline
NCT03789292,has_criteria,28 joint count
NCT03789292,has_criteria,General Health
NCT03789292,has_criteria,erythrocyte sedimentation rate
NCT03789292,has_criteria,C-reactive protein
NCT06216392,involves,Atopic Dermatitis
NCT06216392,evaluates,GR1802 Injection
NCT06216392,measures_primary,EASI-75 at week 16
NCT06216392,measures_primary,IGA score 0 or 1
NCT06216392,measures_secondary,Percent change EASI score
NCT06216392,measures_secondary,Percent change NRS score
NCT06216392,measures_secondary,Body surface area
NCT06216392,measures_secondary,Changes DLQI
NCT06216392,measures_secondary,Incidence adverse events
NCT06216392,has_criteria,Baseline up to Week 52
NCT01217892,evaluates,Dapagliflozin
NCT01217892,measures_primary,Adjusted Mean Change in HbA1c
NCT01217892,measures_secondary,Adjusted Percent Change in Body Weight
NCT01217892,measures_secondary,Adjusted Mean Change in Fasting Plasma Glucose
NCT01217892,measures_secondary,Proportion of Participants With HbA1c<7.0% at Week 16
NCT01217892,has_criteria,Provision of informed consent
NCT02452892,involves,Treatment-Resistant Depression
NCT02452892,evaluates,Low Field Magnetic Stimulation
NCT02452892,measures_primary,HAM-D6 Total Score
NCT02452892,measures_secondary,Response to LFMS
NCT02452892,has_criteria,Non-responders to LFMS
NCT02434744,involves,Type 2 Diabetes Mellitus
NCT02434744,evaluates,KD026
NCT02434744,measures_primary,HbA1c decrease
NCT02434744,measures_secondary,Fasting Plasma Glucose
NCT02434744,measures_secondary,Insulin
NCT02434744,measures_secondary,HOMA-IR
NCT02434744,measures_secondary,Body Weight
NCT02434744,measures_secondary,AUC
NCT02434744,measures_secondary,Lipids
NCT02434744,measures_secondary,Blood Pressure
NCT02434744,measures_secondary,Waist Circumference
NCT02434744,measures_secondary,Body Mass Index
NCT02434744,measures_secondary,Plasma Levels of KD026
NCT02434744,measures_secondary,Serum Levels of Non-Esterified Free Fatty Acids
NCT02434744,has_criteria,HbA1c ≥ 7.0% and ≤ 11.0%
NCT02434744,has_criteria,metformin for at least
NCT03981744,involves,Polymyositis
NCT03981744,involves,Dermatomyositis
NCT03981744,evaluates,Ustekinumab
NCT03981744,measures_primary,IMACS TIS at Week 24
NCT03981744,measures_secondary,FI-2 at Week 24
NCT03981744,has_criteria,IMACS core set measures
NCT00732992,involves,Advanced Solid Malignancies
NCT00732992,evaluates,Sunitinib
NCT00732992,evaluates,Pemetrexed
NCT00732992,measures_primary,Sunitinib Relative Dose Intensity
NCT00732992,measures_secondary,Adverse Events
NCT00732992,measures_secondary,Trough Concentration
NCT00732992,measures_secondary,Maximum Concentration
NCT00732992,has_criteria,Cycle 2 Day 1
NCT00552344,involves,Crohn's Disease
NCT00552344,evaluates,Certolizumab Pegol
NCT00552344,measures_primary,HBI Remission
NCT00552344,measures_secondary,IBDQ Remission
NCT00552344,has_criteria,up to 272 weeks
NCT01633944,involves,Opioid-naive subjects
NCT01633944,evaluates,Buprenorphine HCl Buccal Film
NCT01633944,measures_primary,Change in pain intensity
NCT01633944,measures_secondary,Responder
NCT01633944,has_criteria,Baseline
NCT06501144,involves,Erectile Dysfunction
NCT06501144,evaluates,Digital Health Application
NCT06501144,measures_primary,IIEF-5 points
NCT06501144,measures_secondary,PGI-I
NCT06501144,measures_secondary,QOL-Med
NCT06501144,has_criteria,3 months (± 1 week)
NCT03802344,involves,Psoriasis
NCT03802344,evaluates,MC2-01 Cream
NCT03802344,measures_primary,Percentage Change in mPASI
NCT03802344,measures_secondary,Psoriasis Treatment Convenience Scale
NCT03802344,has_criteria,Baseline minus Week 8
NCT03733444,involves,Idiopathic Pulmonary Fibrosis
NCT03733444,evaluates,GLPG1690
NCT03733444,measures_primary,Annual Rate of Decline in FVC
NCT03733444,measures_secondary,Percentage of Participants With Disease Progression
NCT03733444,measures_secondary,Percentage of Participants With Respiratory-Related Hospitalization
NCT03733444,measures_secondary,Change From Baseline in SGRQ Total Score
NCT03733444,has_criteria,Baseline up to week 52
NCT03088267,involves,ADHD
NCT03088267,evaluates,Dyanavel® XR
NCT03088267,measures_primary,Change in SKAMP-C
NCT03088267,measures_secondary,PERMP-C Score
NCT03088267,has_criteria,school children
NCT00769067,involves,Non-Small Cell Lung Cancer
NCT00769067,evaluates,PF-00299804
NCT00769067,evaluates,Erlotinib
NCT00769067,measures_primary,Progression-Free Survival
NCT00769067,measures_secondary,European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
NCT00769067,has_criteria,One or Two Prior Chemotherapy Regimen
NCT06310967,involves,Hyperuricemia
NCT06310967,involves,Chronic Kidney Disease
NCT06310967,evaluates,IG3018
NCT06310967,measures_primary,serum uric acid
NCT06310967,measures_secondary,Gouty Attacks
NCT06310967,measures_secondary,Urinary Albumin/Creatinine Ration
NCT06310967,has_criteria,Baseline through study completion
NCT04781140,involves,Attention-Deficit/Hyperactivity Disorder
NCT04781140,evaluates,SPN-812
NCT04781140,measures_primary,Change from Baseline ADHD-RS-IV-P Total Score
NCT04781140,measures_secondary,Change from Baseline CGI-S Score
NCT04781140,has_criteria,DSM-IV-TR criteria
NCT00406640,involves,major depression
NCT00406640,evaluates,Desvenlafaxine Succinate Sustained Release
NCT00406640,evaluates,Escitalopram
NCT00406640,measures_primary,HAM-D17 score change
NCT00406640,measures_secondary,Response to Treatment
NCT00406640,measures_secondary,Remission
NCT00406640,has_criteria,Postmenopausal Women
NCT00348140,involves,Alzheimer's Disease
NCT00348140,evaluates,Rosiglitazone
NCT00348140,measures_primary,ADAS-Cog Total Score
NCT00348140,measures_secondary,APOE ε4 Status
NCT00348140,has_criteria,APOE4 Negatives Cohort
NCT05087940,involves,Resistant hypertension
NCT05087940,measures_primary,Blood pressure normalization
NCT05087940,measures_secondary,Systolic blood pressure reduction
NCT05087940,measures_secondary,Diastolic blood pressure reduction
NCT05087940,measures_secondary,Adverse events rate
NCT05087940,measures_secondary,Treatment withdrawal rate
NCT05087940,has_criteria,Resistant hypertension definition
NCT05087940,has_criteria,Aged 18 years or above
NCT05087940,has_criteria,Home blood pressure monitoring
NCT05087940,has_criteria,Pregnancy exclusion
NCT02200640,involves,Hypertension
NCT02200640,evaluates,MICARDIS
NCT02200640,evaluates,COZAAR
NCT02200640,measures_primary,Change in blood pressure
NCT02200640,measures_secondary,Responder rates
NCT02200640,has_criteria,Mean seated diastolic blood pressure
NCT02200640,has_criteria,24-mean DBP
NCT02200640,has_criteria,Age 18 years or older
NCT02200640,has_criteria,Ability to stop antihypertensive therapy
NCT02200640,has_criteria,Written informed consent
NCT05936567,involves,Chronic Spontaneous Urticaria
NCT05936567,evaluates,Povorcitinib
NCT05936567,measures_primary,UAS7 score at week 12
NCT05936567,measures_secondary,Proportion of participants achieving UAS7 ≤ 6
NCT05936567,measures_secondary,Time to first achievement of UAS7 ≤ 6
NCT05936567,measures_secondary,Proportion of participants with UAS7 = 0
NCT05936567,has_criteria,CSU diagnosis for ≥ 3 months
NCT05936567,has_criteria,CSU refractory to second-generation H1 antihistamines
NCT05936567,has_criteria,Stable dose of second-generation H1 antihistamine
NCT05936567,has_criteria,Willingness to comply with study protocol
NCT02852967,involves,Chronic Plaque Psoriasis
NCT02852967,evaluates,Belumosudil
NCT02852967,measures_primary,PASI 75 at Week 16
NCT02852967,measures_secondary,Mean Change PASI Score
NCT02852967,has_criteria,16 weeks
NCT00960440,involves,Rheumatoid Arthritis
NCT00960440,evaluates,CP-690
NCT00960440,measures_primary,ACR20 response
NCT00960440,measures_secondary,HAQ-DI Score
NCT00960440,measures_secondary,DAS28-4 (ESR)
NCT00960440,has_criteria,inadequate response
NCT04033367,involves,Atopic Dermatitis
NCT04033367,evaluates,Dupilumab
NCT04033367,measures_primary,Percent Change From Baseline
NCT04033367,measures_secondary,Peak Pruritus NRS
NCT04033367,measures_secondary,SCORAD Total Score
NCT04033367,has_criteria,affected body surface area
NCT04345367,involves,Atopic Dermatitis
NCT04345367,evaluates,Abrocitinib
NCT04345367,evaluates,Dupilumab
NCT04345367,measures_primary,PP-NRS4 response
NCT04345367,measures_secondary,EASI-90 response
NCT04345367,has_criteria,Moderate to Severe AD
NCT00422240,involves,Acne Vulgaris
NCT00422240,evaluates,Adapalene/Benzoyl Peroxide Topical Gel
NCT00422240,measures_primary,Percent Clear/Almost Clear
NCT00422240,measures_secondary,Inflammatory Lesion Count
NCT00422240,measures_secondary,Noninflammatory Lesion Count
NCT00422240,has_criteria,Baseline to Week 12
NCT03669640,involves,Schizophrenia
NCT03669640,involves,Schizoaffective Disorder
NCT03669640,evaluates,RO6889450
NCT03669640,evaluates,Ralmitaront
NCT03669640,measures_primary,BNSS Avolition/Apathy
NCT03669640,measures_primary,CGI-S Overall Scores
NCT03669640,measures_primary,CGI-S Negative Symptoms
NCT03669640,has_criteria,Baseline to Week 12
NCT03669640,has_criteria,Baseline to week 12
NCT03669640,has_criteria,Baseline to week 12
NCT00146640,involves,Rheumatoid Arthritis
NCT00146640,evaluates,Prednisone Timed-Release Tablet
NCT00146640,evaluates,Immediate-Release Prednisone
NCT00146640,measures_primary,Duration of morning stiffness
NCT00146640,measures_secondary,28-Joint Disease Activity Score
NCT00146640,measures_secondary,Percentage of Participants With Recurrence of Joint Stiffness
NCT00146640,measures_secondary,Pain Intensity
NCT00146640,has_criteria,Baseline
NCT04178967,involves,Atopic Dermatitis
NCT04178967,evaluates,Lebrikizumab
NCT04178967,measures_primary,IGA score 0 or 1
NCT04178967,measures_secondary,EASI-75
NCT04178967,has_criteria,Baseline to Week 16
NCT06063967,involves,Crohn's Disease
NCT06063967,evaluates,Risankizumab
NCT06063967,measures_primary,CDAI Clinical Remission
NCT06063967,measures_secondary,Endoscopic Response
NCT06063967,measures_secondary,Clinical Remission
NCT06063967,measures_secondary,Endoscopic Remission
NCT06063967,measures_secondary,Ulcer-Free Endoscopy
NCT06063967,measures_secondary,FACIT-Fatigue
NCT06063967,has_criteria,CDAI < 150
NCT03706040,involves,Atopic Dermatitis
NCT03706040,evaluates,Risankizumab
NCT03706040,measures_primary,EASI 75 at Week 16
NCT03706040,measures_secondary,vIGA-AD Score at Week 16
NCT03706040,has_criteria,Baseline and Week 16
NCT01916967,involves,Chronic Urticaria
NCT01916967,evaluates,Desloratadine
NCT01916967,measures_primary,Change from Baseline
NCT01916967,measures_secondary,Adverse Event
NCT01916967,has_criteria,Up to 4 weeks
NCT01096667,involves,Type 2 Diabetes
NCT01096667,involves,Hypertension
NCT01096667,evaluates,Ertugliflozin
NCT01096667,evaluates,PF-04971729
NCT01096667,evaluates,MK-8835
NCT01096667,measures_primary,24-hour Average SBP
NCT01096667,measures_secondary,Daytime Average SBP
NCT01096667,measures_secondary,Nighttime Average SBP
NCT01096667,measures_secondary,Seated
NCT01096667,has_criteria,Baseline 24-hour Average SBP
NCT03197740,involves,Alzheimer's disease
NCT03197740,evaluates,Donepezil Transdermal Patch
NCT03197740,measures_primary,ADAS-cog Change
NCT03197740,measures_secondary,CIBIC-plus score
NCT03197740,has_criteria,Age 50 to 85
NCT03197740,has_criteria,DSM-IV diagnosis
NCT03197740,has_criteria,MMSE score 10 to 26
NCT03197740,has_criteria,CDR score 0.5
NCT03197740,has_criteria,Capable of cognitive tests
NCT03197740,has_criteria,Donepezil naive
NCT03197740,has_criteria,Donepezil 10mg/day treatment
NCT03197740,has_criteria,Donepezil 5mg/day treatment
NCT03197740,has_criteria,Reliable caregiver
NCT02274740,involves,Type 2 diabetes
NCT02274740,evaluates,Lixisenatide
NCT02274740,measures_primary,Change in plasma triglycerides
NCT02274740,measures_secondary,Change from baseline in plasma cholesterol
NCT02274740,measures_secondary,Change from baseline in APO B48
NCT02274740,measures_secondary,Change from baseline in free fatty acid levels
NCT02274740,measures_secondary,Change from baseline in lipoprotein distribution
NCT02274740,measures_secondary,Change from baseline in LDL oxidation
NCT02274740,measures_secondary,Change from baseline in postprandial plasma glucose
NCT02274740,measures_secondary,Change from baseline in insulin
NCT02274740,measures_secondary,Change from baseline in C-peptide
NCT02274740,measures_secondary,Change in baseline coronary flow reserve
NCT02274740,has_criteria,BMI >30 kg/m^2
NCT02274740,has_criteria,Waist circumference >102 cm in men
NCT02274740,has_criteria,Waist circumference >88 cm in women
NCT02274740,has_criteria,HbA1c ≥7 and ≤8.5%
NCT01439867,involves,Chronic Kidney Disease
NCT01439867,involves,Secondary Hyperparathyroidism
NCT01439867,evaluates,Cinacalcet
NCT01439867,measures_primary,Corrected Serum Calcium
NCT01439867,measures_secondary,Intact Parathyroid Hormone
NCT01439867,measures_secondary,Serum Phosphorous
NCT01439867,measures_secondary,Calcium Phosphorus Product
NCT01439867,has_criteria,Corrected serum calcium
NCT00984867,involves,type 2 diabetes
NCT00984867,evaluates,dapagliflozin
NCT00984867,measures_primary,Adjusted Mean Change in HbA1c
NCT00984867,measures_secondary,Adjusted Mean Change in Body Weight
NCT00984867,measures_secondary,Adjusted Mean Change in HbA1c
NCT00984867,measures_secondary,Adjusted Mean Change in Fasting Plasma Glucose
NCT00984867,measures_secondary,Adjusted Mean Change in Seated Systolic Blood Pressure
NCT00984867,measures_secondary,Adjusted Mean Change in 2-hour Post Liquid Meal Glucose Rise
NCT00984867,measures_secondary,Proportion of Participants Achieving a Therapeutic Glycemic Response
NCT00984867,has_criteria,Patients with type 2 diabetes
NCT00984867,has_criteria,Patients who are not receiving treatment
NCT00553267,involves,Resistant Hypertension
NCT00553267,evaluates,Telmisartan/Amlodipine (80/10)
NCT00553267,evaluates,Telmisartan/Amlodipine (40/10)
NCT00553267,evaluates,amlodipine10
NCT00553267,measures_primary,Change From Baseline in Trough Seated Diastolic Blood Pressure
NCT00553267,measures_secondary,Change from baseline to the end of study in trough DBP
NCT00553267,measures_secondary,Change From Baseline in Trough Seated Systolic Blood Pressure
NCT00553267,measures_secondary,Change from baseline to the end of study in trough SBP
NCT00553267,has_criteria,diagnosis of essential hypertension
NCT06489340,involves,Diabetic Kidney Disease
NCT06489340,evaluates,2-HPβCD
NCT06489340,measures_primary,Percent change UACR
NCT06489340,measures_secondary,Incidence Treatment-Emergent Adverse Events
NCT06489340,has_criteria,Capable of giving Informed Consent
NCT01730040,evaluates,Alirocumab
NCT01730040,measures_primary,Percent Change LDL-C
NCT01730040,measures_secondary,Percent Change LDL-C
NCT01730040,has_criteria,on- or off-treatment
NCT00502840,involves,Rheumatoid Arthritis
NCT00502840,evaluates,MabThera
NCT00502840,measures_primary,DAS28 Score
NCT00502840,measures_secondary,EULAR Response
NCT00502840,has_criteria,Inadequate Response
NCT06623240,involves,Juvenile Idiopathic Arthritis
NCT06623240,evaluates,HB-adMSCs
NCT06623240,measures_primary,ACR Pedi 30
NCT06623240,measures_secondary,ACR Pedi 50
NCT06623240,measures_secondary,ACR Pedi 70
NCT06623240,measures_secondary,C-reactive protein
NCT06623240,measures_secondary,erythrocyte sedimentation rate
NCT06623240,measures_secondary,PedsQL
NCT06623240,has_criteria,Baseline (Week 0) up to Week 72
NCT02346240,involves,Plaque Psoriasis
NCT02346240,evaluates,Certolizumab Pegol
NCT02346240,measures_primary,PASI75 response
NCT02346240,measures_secondary,PGA Clear or Almost Clear
NCT02346240,measures_secondary,PASI90 response
NCT02346240,has_criteria,Week 12
NCT01441440,involves,Major Depressive Disorder
NCT01441440,evaluates,Venlafaxine ER
NCT01441440,measures_primary,HAM-D17 Total Score
NCT01441440,measures_secondary,MADRS Total Score
NCT01441440,measures_secondary,CGI-S
NCT01441440,has_criteria,Baseline
NCT06256367,involves,Bipolar I Disorder
NCT06256367,evaluates,Cariprazine
NCT06256367,measures_primary,Change from baseline MADRS
NCT06256367,measures_secondary,Change from baseline FAST
NCT06256367,has_criteria,Physician-confirmed BP-I diagnosis
NCT00917267,involves,Type 2 Diabetes
NCT00917267,evaluates,Exenatide Once-Weekly Injection
NCT00917267,measures_primary,Change in HbA1c
NCT00917267,measures_secondary,Fasting Serum Glucose
NCT00917267,measures_secondary,Body Weight
NCT00917267,measures_secondary,Total Cholesterol
NCT00917267,measures_secondary,High-Density Lipoprotein
NCT00917267,measures_secondary,Triglycerides
NCT00917267,measures_secondary,Blood Pressure
NCT00917267,has_criteria,Asian Subjects
NCT05572567,involves,Rheumatoid Arthritis
NCT05572567,evaluates,Tofacitinib
NCT05572567,measures_primary,CDAI
NCT05572567,measures_secondary,J-HAQ
NCT05572567,measures_secondary,patient pain VAS
NCT05572567,has_criteria,90 days after therapy
NCT01112267,involves,Chronic Low-Back Pain
NCT01112267,evaluates,Extended Release Tramadol Hydrochloride/Acetaminophen
NCT01112267,measures_primary,Pain Intensity Reduction
NCT01112267,measures_secondary,Pain Relief
NCT01112267,measures_secondary,Short Form (SF)-36 Score
NCT01112267,has_criteria,Baseline up to Day 29
NCT01624467,involves,Advanced Solid Tumors
NCT01624467,evaluates,Necitumumab
NCT01624467,measures_primary,Change From Time-Matched Baseline in QTcF interval
NCT01624467,measures_secondary,Change From Time-Matched Baseline in PR Interval
NCT01624467,measures_secondary,Change From Time-Matched Baseline in Heart Rate
NCT01624467,measures_secondary,AUC[0-∞] of Necitumumab
NCT01624467,measures_secondary,Cmax of Necitumumab
NCT01624467,measures_secondary,Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR)
NCT01624467,has_criteria,Change From Time-Matched Baseline ≥ 25% and Absolute Value of QRS >110 Msec
NCT01980940,involves,Osteoarthritis
NCT01980940,evaluates,Etoricoxib Gel
NCT01980940,measures_primary,WOMAC Pain
NCT01980940,measures_secondary,AUC0-last
NCT01980940,has_criteria,Single Dosing
NCT03018340,involves,Major Depressive Disorder
NCT03018340,evaluates,Pimavanserin
NCT03018340,measures_primary,Change From Baseline
NCT03018340,measures_secondary,SDS Total Score
NCT03018340,measures_secondary,CGI-S Total Score
NCT03018340,has_criteria,Baseline
NCT00466440,involves,Prostate Cancer
NCT00466440,evaluates,Enzastaurin
NCT00466440,measures_primary,Objective Tumor Response
NCT00466440,measures_secondary,PSA Decline
NCT00466440,has_criteria,Baseline up to 3 years
NCT01675167,involves,Opioid Use Disorder
NCT01675167,evaluates,Buprenorphine HCl Buccal Film
NCT01675167,measures_primary,Pain intensity scores
NCT01675167,measures_secondary,Opioid rescue medication use
NCT01675167,measures_secondary,Time to optimal dose
NCT01675167,has_criteria,Opioid-experienced subjects
NCT02953639,involves,Cognitive Impairment Associated With Schizophrenia
NCT02953639,evaluates,Basmisanil
NCT02953639,measures_primary,Change From Baseline to Week 24 in MATRICS Consensus Cognitive Battery (MCCB) Neurocognitive Composite Score
NCT02953639,measures_secondary,Change From Baseline to Week 24 in MCCB Cognitive Domain Scores
NCT02953639,measures_secondary,Change From Baseline to Week 24 in Wechsler Memory Scale Fourth Edition
NCT02953639,has_criteria,Baseline up to Week 24
NCT04539639,involves,atopic dermatitis
NCT04539639,evaluates,Jaktinib
NCT04539639,measures_primary,EASI 50 response
NCT04539639,measures_secondary,IGA 0 or 1
NCT04539639,has_criteria,inadequate topical response
NCT05895786,involves,Idiopathic Inflammatory Myopathies
NCT05895786,involves,Dermatomyositis
NCT05895786,involves,Polymyositis
NCT05895786,evaluates,PF-06823859
NCT05895786,measures_primary,Total Improvement Score
NCT05895786,measures_secondary,Manual Muscle Testing
NCT05895786,measures_secondary,Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score
NCT05895786,measures_secondary,Investigator Global Assessment severity scale
NCT05895786,measures_secondary,Patient-Reported Outcomes Measurement Information System - Physical Function
NCT05895786,measures_secondary,5-D Itch Scale Score
NCT05895786,has_criteria,baseline CDASI-A score >14
NCT05895786,has_criteria,baseline IGA ≥2
NCT00686686,involves,Palmoplantar Psoriasis
NCT00686686,evaluates,Infliximab
NCT00686686,measures_primary,PPPASI improvement
NCT00686686,measures_secondary,PGA score
NCT00686686,measures_secondary,DLQI
NCT00686686,has_criteria,Infusion response
NCT06041386,involves,Asthma
NCT06041386,evaluates,Mepolizumab
NCT06041386,measures_primary,4-Component Clinical Remission
NCT06041386,measures_secondary,Clinically Significant Asthma Exacerbations
NCT06041386,measures_secondary,Oral corticosteroids (OCS) Sparing Remission
NCT06041386,measures_secondary,3-Component Clinical Remission
NCT06041386,measures_secondary,Mini-Asthma Quality of Life Questionnaire (AQLQ) Overall Score
NCT06041386,has_criteria,Confirmed asthma diagnosis
NCT06041386,has_criteria,NUCALA prescribed
NCT06041386,has_criteria,No NUCALA use 6 months prior
NCT04090086,evaluates,JNJ-64417184
NCT04090086,evaluates,JNJ-53718678
NCT04090086,measures_primary,Number of Participants
NCT04090086,measures_secondary,Adverse Events
NCT04090086,has_criteria,BMI 18.0-30.0 kg/m^2
NCT01252563,evaluates,Amlodipine Tablets
NCT01252563,evaluates,Amlodipine OD Tablets
NCT01252563,measures_primary,Ambulatory Blood Pressure Goal
NCT01252563,measures_secondary,Ambulatory Systolic Blood Pressure
NCT01252563,measures_secondary,Ambulatory Diastolic Blood Pressure
NCT01252563,has_criteria,10 mg/day
NCT00919763,involves,Atopic Dermatitis
NCT00919763,evaluates,CD2027 Ointment
NCT00919763,measures_primary,Change From Baseline
NCT00919763,measures_secondary,Investigator's Global Assessment
NCT00919763,has_criteria,Baseline
NCT01817582,involves,Keratoconjunctivitis Sicca
NCT01817582,evaluates,Lotemax Gel 0.5%
NCT01817582,evaluates,Restasis 0.05%
NCT01817582,measures_primary,Corneal Fluorescein Staining
NCT01817582,measures_secondary,Ocular Surface Disease Index
NCT01817582,has_criteria,Baseline
NCT00122382,involves,Rheumatoid Arthritis
NCT00122382,measures_primary,DAS 28 CRP remission
NCT00122382,measures_secondary,Radiographic Total Score
NCT00122382,has_criteria,DAS 28 CRP score
NCT03742973,involves,Primary Biliary Cholangitis
NCT03742973,evaluates,Baricitinib
NCT03742973,measures_primary,Change From Baseline in ALP
NCT03742973,measures_secondary,Itch NRS
NCT03742973,measures_secondary,Fatigue NRS
NCT03742973,has_criteria,Elevated ALP levels
NCT03742973,has_criteria,Antimitochondrial antibodies
NCT03742973,has_criteria,Liver biopsy
NCT03742973,has_criteria,ALP ≥1.67 x ULN
NCT03742973,has_criteria,ALP ≤6 x ULN
NCT03742973,has_criteria,Taking UDCA
NCT03222973,involves,Relapsing Multiple Sclerosis
NCT03222973,evaluates,BIIB033
NCT03222973,measures_primary,Overall Response Score
NCT03222973,measures_secondary,Adverse Events
NCT03222973,has_criteria,Baseline to Week 72
NCT02697773,involves,Osteoarthritis
NCT02697773,evaluates,Tanezumab
NCT02697773,measures_primary,WOMAC Pain Subscale
NCT02697773,measures_secondary,WOMAC Physical Function Subscale
NCT02697773,measures_secondary,Patient's Global Assessment
NCT02697773,has_criteria,moderate to severe
NCT06149494,involves,COPD
NCT06149494,involves,Human Rhinovirus/Enterovirus Upper Respiratory Infection
NCT06149494,evaluates,Vapendavir
NCT06149494,measures_primary,Peak total LRSS
NCT06149494,measures_secondary,COPD Specific Respiratory Symptoms
NCT06149494,measures_secondary,Upper Respiratory Symptoms
NCT06149494,measures_secondary,Overall Symptom severity
NCT06149494,has_criteria,Day of treatment commencement to Day 42
NCT03391882,involves,Parkinson's Disease
NCT03391882,evaluates,Investigational Drug
NCT03391882,measures_primary,Change in MDS-UPDRS
NCT03391882,measures_secondary,Durability of Effect
NCT03391882,has_criteria,Motor Fluctuations
NCT04481139,involves,Ankylosing Spondylitis
NCT04481139,evaluates,SHR0302
NCT04481139,measures_primary,ASAS20 response
NCT04481139,measures_secondary,ASAS40 response
NCT04481139,measures_secondary,ASAS5/6 response
NCT04481139,measures_secondary,BASDAI
NCT04481139,has_criteria,>= 20% improvement
NCT01127139,involves,Essential Hypertension
NCT01127139,evaluates,Tarka
NCT01127139,measures_primary,Change in Blood Pressure
NCT01127139,measures_secondary,Percentage of Patients Achieving Blood Pressure < 140/90 mmHg
NCT01127139,measures_secondary,Number and Type of Antihypertensive Drugs Added to Fixed Combination Tarka to Reach Blood Pressure Goal
NCT01127139,has_criteria,blood pressure goal of less than 140/90 mmHg
NCT06589986,involves,Ulcerative Colitis
NCT06589986,evaluates,RO7790121
NCT06589986,measures_primary,Clinical Remission
NCT06589986,measures_primary,Partial Modified Mayo Score
NCT06589986,measures_secondary,Endoscopic Improvement
NCT06589986,measures_secondary,Endoscopic Remission
NCT06589986,has_criteria,Moderately to Severely Active
NCT02466386,involves,Attention-deficit/Hyperactivity Disorder
NCT02466386,evaluates,SPD489
NCT02466386,measures_primary,Change From Baseline
NCT02466386,measures_secondary,Electrocardiogram Parameters
NCT02466386,has_criteria,Preschool Children Aged 4-5 Years
NCT05194839,involves,Palmoplantar Pustulosis
NCT05194839,evaluates,RIST4721
NCT05194839,measures_primary,Absolute Change From Baseline in PPPASI
NCT05194839,measures_secondary,Absolute Change From Baseline in PPPGA
NCT05194839,has_criteria,Moderate or severe PPP
NCT05194839,has_criteria,Males and females must be willing to use birth control as indicated
NCT05194839,has_criteria,Moderate to severe psoriasis covering ≥10% of total body surface area (BSA) at screening
NCT05194839,has_criteria,Breastfeeding or pregnant
NCT05194839,has_criteria,Known immunodeficiency or subject is immunocompromised
NCT05194839,has_criteria,Active/latent infection with HBV
NCT05194839,has_criteria,Any topical medications for PPP excluding emollients within two weeks of randomization and systemic therapies (including phototherapy) within 4 weeks of randomization
NCT00487539,involves,Ulcerative Colitis
NCT00487539,evaluates,Golimumab
NCT00487539,measures_primary,Mayo score
NCT00487539,measures_secondary,IBDQ Score
NCT00487539,has_criteria,Moderately to Severely Active
NCT04115839,involves,Psoriatic Arthritis
NCT04115839,evaluates,Filgotinib
NCT04115839,measures_primary,ACR20 response
NCT04115839,measures_secondary,PASDAS
NCT04115839,has_criteria,Biologic DMARD Therapy
NCT05003986,involves,Proteinuric Glomerular Diseases
NCT05003986,evaluates,Sparsentan
NCT05003986,measures_primary,UP/C at week 108
NCT05003986,measures_secondary,Change from baseline in UP/C
NCT05003986,measures_secondary,Urine albumin/creatinine ratio
NCT05003986,measures_secondary,Estimated glomerular filtration rate
NCT05003986,measures_secondary,Proportion of subjects achieving complete remission of proteinuria
NCT05003986,measures_secondary,Proportion of subjects with FSGS and/or MCD histological patterns achieving partial remission
NCT05003986,has_criteria,Oral s...
NCT06450886,involves,Inclusion Body Myositis
NCT06450886,evaluates,Ulviprubart
NCT06450886,measures_primary,incidence TEAEs
NCT06450886,measures_secondary,IBMFRS
NCT06450886,has_criteria,From Baseline (Day 1)
NCT06111586,involves,Type 1 diabetes
NCT06111586,evaluates,FrexalimAB
NCT06111586,measures_primary,Change in C-peptide
NCT06111586,measures_secondary,Time in range
NCT06111586,has_criteria,Insulin therapy
NCT01724086,involves,Chronic Genotype 1 Hepatitis C Virus
NCT01724086,evaluates,TMC647055
NCT01724086,evaluates,TMC435
NCT01724086,evaluates,GSK23336805
NCT01724086,evaluates,Ribavirin
NCT01724086,measures_primary,SVR12
NCT01724086,measures_secondary,adverse events
NCT01724086,measures_secondary,serious adverse events
NCT01724086,has_criteria,undetectable HCV RNA
NCT05430386,involves,Non-small cell lung cancer
NCT05430386,evaluates,HS-10241
NCT05430386,evaluates,Almonertinib
NCT05430386,measures_primary,Objective response rate
NCT05430386,measures_secondary,Adverse events
NCT05430386,has_criteria,Maximum tolerated dose
NCT06431763,involves,Atherosclerotic Cardiovascular Disease
NCT06431763,evaluates,Inclisiran
NCT06431763,evaluates,Bempedoic Acid
NCT06431763,measures_primary,Percent change from baseline
NCT06431763,measures_primary,LDL-C levels
NCT06431763,measures_secondary,Number of participants
NCT06431763,measures_secondary,Individual responsiveness
NCT06431763,has_criteria,maximally tolerated HI statin dose
NCT05809986,involves,Multiple Sclerosis
NCT05809986,evaluates,Ofatumumab
NCT05809986,measures_primary,NEDA-3
NCT05809986,measures_secondary,MSIS-29
NCT05809986,measures_secondary,FSIQ-RMS
NCT05809986,has_criteria,relapsing types
NCT00914186,involves,Atopic Dermatitis
NCT00914186,evaluates,TS-022
NCT00914186,measures_primary,Pruritis VAS
NCT00914186,measures_secondary,Investigator's Global Assessment
NCT00914186,measures_secondary,Five Point Pruritus Scale
NCT00914186,measures_secondary,Eczema Area and Severity Index
NCT00914186,has_criteria,Adult Patients
NCT01281839,involves,Hepatitis C
NCT01281839,evaluates,TMC435
NCT01281839,measures_primary,SVR12
NCT01281839,measures_primary,SVRW72
NCT01281839,measures_primary,SVR24
NCT01281839,measures_primary,SVR4
NCT01281839,measures_secondary,Change From Baseline
NCT01281839,measures_secondary,Actual Values of log10 HCV RNA
NCT01281839,has_criteria,Genotype 1 Hepatitis C
NCT06215586,involves,Chronic Heart Failure With Preserved Ejection Fraction
NCT06215586,evaluates,Tovinontrine
NCT06215586,measures_primary,NT-proBNP change
NCT06215586,measures_secondary,cGMP change
NCT06215586,measures_secondary,BNP change
NCT06215586,measures_secondary,KCQ-23 Clinical Summary Score
NCT06215586,measures_secondary,New York Heart Association Classification
NCT06215586,measures_secondary,Treatment Emergent Adverse Events
NCT06215586,has_criteria,Baseline to Week 12
NCT01733186,involves,Articular Cartilage Defects
NCT01733186,evaluates,CARTISTEM
NCT01733186,measures_primary,IKDC Score
NCT01733186,measures_secondary,VAS
NCT01733186,measures_secondary,Lysholm Score
NCT01733186,has_criteria,NSAIDs discontinuation
NCT04214639,involves,Acne Vulgaris
NCT04214639,evaluates,IDP-126 Gel
NCT04214639,measures_primary,Inflammatory Lesion Count
NCT04214639,measures_secondary,Noninflammatory Lesion Count
NCT04214639,has_criteria,9 years of age
NCT04214639,has_criteria,Informed consent
NCT04214639,has_criteria,Evaluator's Global Severity Score 3 or 4
NCT04214639,has_criteria,30 to 100 inflammatory lesions
NCT04214639,has_criteria,35 to 150 noninflammatory lesions
NCT04214639,has_criteria,2 or fewer nodules
NCT03518086,involves,Ulcerative Colitis
NCT03518086,evaluates,Mirikizumab
NCT03518086,measures_primary,Clinical Remission
NCT03518086,measures_secondary,Clinical Response
NCT03518086,has_criteria,Moderately to Severely Active
NCT02486939,involves,Rheumatoid Arthritis
NCT02486939,evaluates,CHS-0214-05
NCT02486939,measures_primary,ACR20 response
NCT02486939,measures_secondary,PASI-50 response
NCT02486939,has_criteria,ACR20 responder
NCT01418339,involves,Tourette's Disorder
NCT01418339,evaluates,Aripiprazole
NCT01418339,measures_primary,YGTSS Total Tic Score
NCT01418339,measures_secondary,CGI-TS Score
NCT01418339,measures_secondary,GTS-QOL Total Score
NCT01418339,has_criteria,Baseline to Week 8
NCT01979939,involves,Chronic Hepatitis C Virus Genotype 1 Infection
NCT01979939,evaluates,Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325
NCT01979939,measures_primary,SVR12
NCT01979939,measures_secondary,HCV RNA <LOQ TD/TND
NCT01979939,has_criteria,chronic HCV infection
NCT03039686,involves,Duchenne muscular dystrophy
NCT03039686,evaluates,RO7239361
NCT03039686,measures_primary,NSAA Total Score
NCT03039686,measures_secondary,4 Stair Climb Velocity
NCT03039686,has_criteria,Ambulatory boys
NCT00960986,involves,Major Depressive Disorder
NCT00960986,evaluates,Duloxetine
NCT00960986,measures_primary,Mean Change From Baseline
NCT00960986,measures_secondary,Common Adverse Events Score
NCT00960986,has_criteria,incidence >5%
NCT01059539,involves,Bipolar I Disorder
NCT01059539,evaluates,Cariprazine
NCT01059539,measures_primary,Change From Baseline
NCT01059539,measures_secondary,Change From Baseline
NCT01059539,has_criteria,DSM-IV-TR criteria
NCT03448939,involves,Papulopustular Rosacea
NCT03448939,evaluates,S5G4T-1
NCT03448939,measures_primary,IGA Score Clear/Almost Clear
NCT03448939,measures_secondary,Inflammatory Lesion Counts
NCT03448939,has_criteria,18 years of age and older
NCT03448939,has_criteria,moderate to severe rosacea
NCT03448939,has_criteria,15 to 70 total inflammatory lesions
NCT06302439,involves,ENPP1 Deficiency
NCT06302439,involves,ABCC6 Deficiency
NCT06302439,evaluates,
NCT06302439,measures_primary,Patient Functional changes
NCT06302439,measures_secondary,Health-Related Quality-of-Life
NCT06302439,has_criteria,
NCT04456686,involves,Osteoarthritis
NCT04456686,evaluates,LY3016859
NCT04456686,measures_primary,Change From Baseline
NCT04456686,measures_secondary,WOMAC® Pain Subscale
NCT04456686,has_criteria,Baseline
NCT02172586,involves,Hypertension
NCT02172586,evaluates,Telmisartan
NCT02172586,evaluates,Hydrochlorothiazide
NCT02172586,evaluates,Losartan
NCT02172586,measures_primary,Change from baseline DBP
NCT02172586,measures_secondary,Change from baseline SBP
NCT02172586,has_criteria,Age ≥ 18 years
NCT02172586,has_criteria,DBP ≥ 95 mmHg
NCT02172586,has_criteria,DBP < 110 mmHg
NCT02172586,has_criteria,SBP < 180 mmHg
NCT02172586,has_criteria,Written informed consent
NCT02172586,has_criteria,Nursing
NCT02172586,has_criteria,Secondary hypertension
NCT02172586,has_criteria,Malignant hypertension
NCT02172586,has_criteria,Clinically significant sodium depletion
NCT00671086,involves,Chronic Insomnia
NCT00671086,evaluates,Ramelteon
NCT00671086,measures_primary,Subjective Total Sleep Time
NCT00671086,measures_secondary,Subjective Sleep Latency
NCT00671086,has_criteria,long-term insomnia treatment
NCT04766086,involves,Group B Streptococcus
NCT04766086,evaluates,Multivalent Group B Streptococcus Vaccine
NCT04766086,measures_primary,Local reactions
NCT04766086,measures_secondary,Systemic reactions
NCT04766086,has_criteria,Healthy Nonpregnant Women
NCT04639986,involves,HR+/HER2- Metastatic Breast Cancer
NCT04639986,evaluates,Sacituzumab Govitecan
NCT04639986,measures_primary,Progression-free Survival
NCT04639986,measures_secondary,Overall Survival
NCT04639986,measures_secondary,Objective Response Rate
NCT04639986,measures_secondary,Duration of Response
NCT04639986,measures_secondary,Clinical Benefit Rate
NCT04639986,measures_secondary,Percentage of Participants Experiencing Adverse Events
NCT04639986,measures_secondary,Percentage of Participants Experiencing Serious Adverse Events
NCT04639986,measures_secondary,Change From Baseline of the EORTC QLQ-C30 Score
NCT04639986,has_criteria,randomization
NCT02570139,involves,Incontinence Associated Dermatitis
NCT02570139,evaluates,Barrier Film
NCT02570139,measures_primary,Percent decrease IAD score
NCT02570139,measures_secondary,Pain Scores
NCT02570139,has_criteria,Up to 21 days hospitalization
NCT01762839,involves,Cardiac Safety
NCT01762839,evaluates,Oritavancin
NCT01762839,measures_primary,QTcF change
NCT01762839,measures_secondary,QTcB change
NCT01762839,measures_secondary,HR
NCT01762839,measures_secondary,RR
NCT01762839,measures_secondary,PR
NCT01762839,measures_secondary,QRS interval
NCT01762839,has_criteria,Healthy participants
NCT01762839,has_criteria,18-60 years old
NCT01762839,has_criteria,BMI 18-30 kg/m^2
NCT01762839,has_criteria,Normal ECG
NCT01762839,has_criteria,Normal lab results
NCT01276639,involves,Chronic Plaque Psoriasis
NCT01276639,evaluates,CP-690
NCT01276639,measures_primary,PGA score at Week 16
NCT01276639,measures_secondary,PASI 75 Response
NCT01276639,measures_secondary,Percent Change in BSA
NCT01276639,has_criteria,Moderate to Severe
NCT00614939,involves,Type 2 Diabetes
NCT00614939,involves,Renal Impairment
NCT00614939,evaluates,Saxagliptin
NCT00614939,measures_primary,HbA1c Level
NCT00614939,measures_secondary,Fasting Plasma Glucose
NCT00614939,has_criteria,Renal Impairment Subgroup
NCT01292239,involves,Hepatitis C
NCT01292239,evaluates,TMC435
NCT01292239,measures_primary,SVR12
NCT01292239,measures_secondary,SVR24
NCT01292239,measures_secondary,HCV RNA drop
NCT01292239,has_criteria,Treatment-naive
NCT01292239,has_criteria,Genotype 1
NCT05245539,involves,Schizophrenia
NCT05245539,evaluates,CVL-231
NCT05245539,measures_primary,24-hour ambulatory SBP
NCT05245539,measures_secondary,ambulatory SBP daytime
NCT05245539,measures_secondary,ambulatory SBP nighttime
NCT05245539,measures_secondary,24-hour ambulatory DBP
NCT05245539,measures_secondary,24-hour ambulatory HR
NCT05245539,has_criteria,treatment-emergent adverse events
NCT05245539,has_criteria,electrocardiograms
NCT05245539,has_criteria,clinical laboratory assessments
NCT05245539,has_criteria,vital sign measurements
NCT05245539,has_criteria,physical examination results
NCT05245539,has_criteria,neurological examination results
NCT05245539,has_criteria,C-SSRS
NCT05245539,has_criteria,SAS
NCT05245539,has_criteria,AIMS
NCT05245539,has_criteria,BARS
NCT05245539,has_criteria,CVL-231 Peak Plasma Concentration
NCT02402686,involves,Rheumatoid Arthritis
NCT02402686,evaluates,Tocilizumab Subcutaneous
NCT02402686,measures_primary,DAS28 from Baseline
NCT02402686,measures_secondary,CDAI Score from Baseline
NCT02402686,has_criteria,failing DMARDs
NCT06095986,involves,Primary Sclerosing Cholangitis
NCT06095986,evaluates,Aramchol Meglumine
NCT06095986,measures_primary,Change from Baseline in ALP
NCT06095986,measures_secondary,Hepatobiliary fibrosis
NCT06095986,measures_secondary,Enhanced liver fibrosis (ELF)
NCT06095986,measures_secondary,MRCP
NCT06095986,measures_secondary,Quantitative liver function
NCT06095986,measures_secondary,5D-itch scale
NCT06095986,measures_secondary,PROMIS-19 score
NCT06095986,measures_secondary,Mayo IBD symptom severity score
NCT06095986,has_criteria,48 weeks
NCT01945086,involves,Atopic Dermatitis
NCT01945086,evaluates,Ustekinumab
NCT01945086,measures_primary,Eczema Area Severity Index
NCT01945086,measures_secondary,Investigator's Global Assessment
NCT01945086,measures_secondary,Atopic Dermatitis Itch Scale
NCT01945086,has_criteria,Adult Japanese Participants
NCT03997786,involves,Chronic Plaque Psoriasis
NCT03997786,evaluates,Tildrakizumab
NCT03997786,measures_primary,PASI 75 response
NCT03997786,measures_secondary,PGA score
NCT03997786,has_criteria,Children aged 2-15 years
NCT02260986,involves,Atopic Dermatitis
NCT02260986,evaluates,Dupilumab
NCT02260986,measures_primary,IGA score 0 or 1
NCT02260986,measures_secondary,EASI-75
NCT02260986,measures_secondary,Pruritus NRS
NCT02260986,has_criteria,Moderate-to-Severe AD
NCT01555762,involves,Metastatic Colorectal Cancer
NCT01555762,evaluates,Avastin
NCT01555762,measures_primary,Progression-Free Survival
NCT01555762,measures_secondary,Overall Survival
NCT01555762,measures_secondary,Percentage of Participants With Bevacizumab Administration
NCT01555762,measures_secondary,Percentage of Participants With Adverse Events
NCT01555762,measures_secondary,Percentage of Participants With Activities of Daily Living
NCT01555762,has_criteria,Up to 53 months
NCT01555762,has_criteria,Up to 36 months
NCT01555762,has_criteria,Baseline
NCT04201262,involves,NMOSD
NCT04201262,evaluates,Ravulizumab
NCT04201262,measures_primary,Annualized Relapse Rate
NCT04201262,measures_secondary,Clinically Important Change
NCT04201262,has_criteria,Baseline up to 2.25 years
NCT03656562,involves,Systemic Lupus Erythematosus
NCT03656562,evaluates,VAY736
NCT03656562,evaluates,CFZ533
NCT03656562,measures_primary,SRI-4 response
NCT03656562,measures_primary,reduced steroid dose
NCT03656562,measures_secondary,Physician's global assessment
NCT03656562,has_criteria,rescue medication
NCT03656562,has_criteria,prohibited medication
NCT02005562,involves,Kidney Transplant
NCT02005562,evaluates,CellCept
NCT02005562,measures_primary,BPAR Before Week 12
NCT02005562,measures_secondary,Serum Creatinine
NCT02005562,measures_secondary,Creatinine Clearance
NCT02005562,has_criteria,Acute Subclinical Rejection
NCT00730691,involves,Generalized Anxiety Disorder
NCT00730691,evaluates,Vortioxetine
NCT00730691,measures_primary,Change From Baseline
NCT00730691,measures_secondary,Hospital Anxiety and Depression
NCT00730691,has_criteria,Baseline to Week 8
NCT05363891,involves,Rheumatoid Arthritis
NCT05363891,evaluates,Natrunix
NCT05363891,evaluates,Placebo
NCT05363891,measures_primary,ACR 20 response
NCT05363891,measures_primary,ACR 50 response
NCT05363891,measures_secondary,NRS-pain
NCT05363891,has_criteria,Weight > 40 kg
NCT05363891,has_criteria,moderate to severe RA
NCT05363891,has_criteria,methotrexate-inadequate responders
NCT05363891,has_criteria,persistent moderate to severe RA
NCT05363891,has_criteria,≥6 swollen joints
NCT05363891,has_criteria,≥6 tender joints
NCT03538691,involves,Major Depressive Disorder
NCT03538691,evaluates,Brexpiprazole
NCT03538691,measures_primary,Time-to-Relapse
NCT03538691,measures_secondary,Sheehan Disability Scale
NCT03538691,has_criteria,Relapse criteria
NCT02185794,involves,Chronic Hepatitis C Virus Infection
NCT02185794,evaluates,Voxilaprevir
NCT02185794,measures_primary,Change From Baseline in Plasma HCV RNA
NCT02185794,measures_secondary,Absolute HCV RNA Level Through Week 48
NCT02185794,measures_secondary,Number of Participants Achieving Reductions From Baseline in HCV RNA
NCT02185794,measures_secondary,Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected
NCT04321980,evaluates,OP-101
NCT04321980,measures_primary,Cmax of OP-101
NCT04321980,measures_secondary,Tmax of OP-101
NCT04321980,measures_secondary,AUC0-last of OP-101
NCT04321980,measures_secondary,AUC0-48 of OP-101
NCT03175562,involves,Cosmetic facial product
NCT03175562,evaluates,Human Repeat Insult Patch Test
NCT03175562,measures_primary,Skin Irritation Scores
NCT03175562,measures_secondary,Superficial Irritation Scores
NCT03175562,has_criteria,Healthy Participants
NCT02004691,involves,Acid Sphingomyelinase Deficiency
NCT02004691,evaluates,Olipudase Alfa
NCT02004691,measures_primary,Spleen Volume (MN)
NCT02004691,measures_secondary,Splenomegaly-Related Score (SRS)
NCT02004691,has_criteria,Spleen volume (MN)
NCT01196091,involves,Systemic Lupus Erythematosus
NCT01196091,evaluates,LY2127399
NCT01196091,measures_primary,SLE Responder Index
NCT01196091,measures_secondary,SELENA SLEDAI score
NCT01196091,measures_secondary,PGA
NCT01196091,measures_secondary,BILAG organ domain
NCT01196091,has_criteria,prednisone dose decrease
NCT01196091,has_criteria,BILAG C score
NCT01196091,has_criteria,no BILAG A or B flares
NCT02791191,involves,Mild Alzheimer's Disease Dementia
NCT02791191,evaluates,LY3202626
NCT02791191,measures_primary,Change in ¹⁸F-AV-1451 SUVr
NCT02791191,measures_secondary,Emergent MRI Findings
NCT02791191,measures_secondary,Amyloid-Related Imaging Abnormalities
NCT02791191,measures_secondary,Suicidal Ideation and Behaviors
NCT02791191,has_criteria,Age at baseline
NCT01037062,involves,Chronic Hepatitis B Infection
NCT01037062,evaluates,Entecavir
NCT01037062,measures_primary,Loss of HBeAg
NCT01037062,measures_secondary,HBV DNA levels
NCT01037062,has_criteria,completed previous trials
NCT02091362,involves,Type 2 Diabetes Mellitus
NCT02091362,evaluates,LY2409021
NCT02091362,measures_primary,Change From Baseline
NCT02091362,measures_secondary,Change From Baseline
NCT02091362,measures_secondary,Change From Baseline
NCT02091362,has_criteria,Baseline
NCT02059291,involves,Hereditary Periodic Fevers
NCT02059291,evaluates,Canakinumab
NCT02059291,measures_primary,Resolution of initial flare
NCT02059291,measures_secondary,Serologic Remission
NCT02059291,measures_secondary,Normalized SAA Level
NCT02059291,has_criteria,Patient's written informed consent
NCT02059291,has_criteria,Male and female patients
NCT05165394,involves,Major Depressive Disorder
NCT05165394,evaluates,NBI-1065846
NCT05165394,measures_primary,Change in DARS Score
NCT05165394,measures_secondary,Change in MADRS Score
NCT05165394,measures_secondary,CGI-S Scores
NCT05165394,has_criteria,Aged 18 to 65 years
NCT05165394,has_criteria,Primary diagnosis of MDD
NCT05165394,has_criteria,≥1 antidepressant medication(s)
NCT05434091,evaluates,PF-07291177
NCT05434091,measures_primary,Plasma Concentration
NCT05434091,measures_secondary,AUClast
NCT05434091,measures_secondary,AUCinf
NCT05434091,measures_secondary,Tmax
NCT05434091,measures_secondary,t1/2
NCT05434091,has_criteria,18 to 60 years
NCT03823391,involves,Rheumatoid Arthritis
NCT03823391,evaluates,ABBV-3373
NCT03823391,measures_primary,Change From Baseline
NCT03823391,measures_secondary,Clinical Disease Activity Index
NCT03823391,measures_secondary,Simplified Disease Activity Index
NCT03823391,has_criteria,Moderate to Severe
NCT01564862,involves,Major Depressive Disorder
NCT01564862,evaluates,Lu AA21004
NCT01564862,measures_primary,Change From Baseline to Week 8
NCT01564862,measures_secondary,Perceived Deficits Questionnaire
NCT01564862,has_criteria,Baseline and Week 8
NCT02858362,involves,Duchenne Muscular Dystrophy
NCT02858362,evaluates,SMT C1100
NCT02858362,measures_primary,Change From Baseline in MRS FF
NCT02858362,measures_secondary,Change From Baseline in MRS WTRT
NCT02858362,measures_secondary,Observed Trough Plasma Concentration
NCT02858362,measures_secondary,Simulated Maximum Plasma Concentration
NCT02858362,measures_secondary,Simulated Average Plasma Concentration
NCT02858362,measures_secondary,Number of Participants Reporting TEAEs
NCT02858362,has_criteria,Boys
NCT05883462,involves,Recurrent Chronic Rhinosinusitis
NCT05883462,involves,Nasal Polyps
NCT05883462,evaluates,Paclitaxel-Coated Nasal Balloon
NCT05883462,measures_primary,Freedom from target lesion reintervention
NCT05883462,measures_secondary,Symptom-driven reintervention
NCT05883462,measures_secondary,Change in SNOT-22 score
NCT05883462,measures_secondary,Lund-Kennedy Endoscopic Scores
NCT05883462,measures_secondary,Lund-Mackay computed tomography score
NCT05883462,measures_secondary,Health-related quality -of- life
NCT05883462,has_criteria,30 days
NCT05883462,has_criteria,6 months
NCT05883462,has_criteria,12 months
NCT03474562,involves,ASCVD
NCT03474562,involves,IFG
NCT03474562,involves,Hypertension
NCT03474562,evaluates,High-Dose Statin
NCT03474562,evaluates,Telmisartan
NCT03474562,evaluates,Amlodipine
NCT03474562,measures_primary,HOMA-IR
NCT03474562,measures_secondary,fasting plasma glucose
NCT03474562,measures_secondary,insulin level
NCT03474562,measures_secondary,HOMA-B
NCT03474562,measures_secondary,hemoglobin A1c
NCT03474562,measures_secondary,total cholesterol
NCT03474562,measures_secondary,triglycerides
NCT03474562,measures_secondary,HDL-C
NCT03474562,measures_secondary,LDL-C
NCT03474562,measures_secondary,C-reactive protein
NCT03474562,has_criteria,Written informed consent
NCT03474562,has_criteria,Aged 19 to 75 years
NCT03474562,has_criteria,ASCVD requiring high-intensity statin therapy
NCT03474562,has_criteria,antihypertensive drugs
NCT03474562,has_criteria,SBP > 140mmHg
NCT03474562,has_criteria,DBP > 90mmHg
NCT03474562,has_criteria,impaired fasting glucose
NCT03474562,has_criteria,impaired glucose tolerance
NCT05059262,involves,Tenosynovial Giant Cell Tumor
NCT05059262,evaluates,Vimseltinib
NCT05059262,measures_primary,Objective Response Rate
NCT05059262,measures_secondary,Range of motion
NCT05059262,measures_secondary,Physical function
NCT05059262,measures_secondary,Worst stiffness
NCT05059262,measures_secondary,Quality of life
NCT05059262,measures_secondary,Worst pain
NCT05059262,has_criteria,≥18 years of age
NCT05059262,has_criteria,tumor biopsy
NCT05059262,has_criteria,moderate pain
NCT05059262,has_criteria,moderate stiffness
NCT01506362,involves,Ulcerative Colitis
NCT01506362,evaluates,BL-7040
NCT01506362,measures_primary,Clinical Response
NCT01506362,measures_secondary,Mucosal Healing
NCT01506362,has_criteria,Age 18-70
NCT06559891,involves,Hypertension
NCT06559891,evaluates,TIVUS™ Renal Denervation System
NCT06559891,measures_primary,Ambulatory systolic BP
NCT06559891,measures_secondary,Major Adverse Events
NCT06559891,measures_secondary,Home systolic BP
NCT06559891,measures_secondary,Office systolic BP
NCT06559891,measures_secondary,Daytime ambulatory diastolic BP
NCT06559891,measures_secondary,24-hr ambulatory systolic BP
NCT06559891,measures_secondary,Home diastolic BP
NCT06559891,measures_secondary,Office diastolic BP
NCT06559891,measures_secondary,Systolic Blood Pressure
NCT06559891,measures_secondary,Systolic Blood Pressure
NCT06559891,measures_secondary,Ambulatory systolic BP
NCT06559891,has_criteria,hypertensive medication
NCT06302491,involves,β-thalassemia
NCT06302491,evaluates,AND017
NCT06302491,measures_primary,Hb levels
NCT06302491,measures_secondary,red blood cell count
NCT06302491,measures_secondary,reticulocyte count
NCT06302491,measures_secondary,mean corpuscular volume
NCT06302491,measures_secondary,mean corpuscular hemoglobin
NCT06302491,has_criteria,oral doses
NCT03965091,involves,Fibromyalgia
NCT03965091,evaluates,Fremanezumab
NCT03965091,measures_primary,Change From Baseline in PI-NRS
NCT03965091,measures_secondary,Change From Baseline in FIQR
NCT03965091,measures_secondary,Responder Rate PGIC
NCT03965091,has_criteria,last 14 days before first dose
NCT02109562,involves,Schizophrenia
NCT02109562,evaluates,RBP-7000
NCT02109562,measures_primary,PANSS Total Score
NCT02109562,measures_secondary,CGI-S
NCT02109562,has_criteria,Day 1 prior to treatment
NCT04856891,involves,Eosinophilic Duodenitis
NCT04856891,evaluates,Lirentelimab
NCT04856891,measures_primary,Tissue eosinophil responders
NCT04856891,measures_secondary,PRO Total Symptom Score
NCT04856891,has_criteria,Eosinophil count <=15 cells/HPF
NCT01805791,involves,Ulcerative Colitis
NCT01805791,evaluates,HMPL-004
NCT01805791,measures_primary,Clinical Remission
NCT01805791,measures_secondary,Clinical Response
NCT01805791,measures_secondary,Mucosal Healing
NCT01805791,has_criteria,modified Mayo Score 4-10
NCT01805791,has_criteria,endoscopy score activity 2-3
NCT01805791,has_criteria,modified Mayo endoscopy score >2
NCT01805791,has_criteria,Age ≥ 18 years
NCT02769091,involves,Nonalcoholic Steatohepatitis
NCT02769091,involves,Type 2 Diabetes
NCT02769091,measures_primary,ALT response
NCT02769091,measures_secondary,liver fat response
NCT02769091,measures_secondary,Percentage of Adverse Events
NCT02769091,has_criteria,female or male
NCT02769091,has_criteria,18 to 65 years
NCT02769091,has_criteria,Type 2 Diabetes Mellitus
NCT02769091,has_criteria,stable medication for diabetes
NCT02769091,has_criteria,NASH Activity Score ≥4
NCT02769091,has_criteria,steatosis score ≥1
NCT02769091,has_criteria,lobular inflammation score ≥1
NCT02769091,has_criteria,hepatocyte ballooning score ≥1
NCT02769091,has_criteria,historical diagnosis of NASH
NCT02769091,has_criteria,ALT level 45 to 105 IU/L
NCT05377580,involves,Ulcerative Colitis
NCT05377580,evaluates,IBI112
NCT05377580,measures_primary,clinical remission
NCT05377580,measures_secondary,clinical response
NCT05377580,measures_secondary,symptom relief
NCT05377580,measures_secondary,endoscopic remission
NCT05377580,measures_secondary,mucosal healing
NCT05377580,has_criteria,moderately to severely active
NCT03891862,involves,Tardive Dyskinesia
NCT03891862,evaluates,Valbenazine
NCT03891862,measures_primary,Change From Randomization
NCT03891862,measures_secondary,EQ-5D-5L Health State Index
NCT03891862,measures_secondary,EQ-5D-5L VAS
NCT03891862,has_criteria,childbearing potential
NCT03891862,has_criteria,clinical diagnoses
NCT03199391,involves,Implant survivorship
NCT03199391,evaluates,BioWick SureLock
NCT03199391,measures_primary,Implant survivorship
NCT03199391,measures_secondary,ASES Patient Self-Evaluation Score
NCT03199391,measures_secondary,VAS Pain Score
NCT03199391,has_criteria,Preoperative
NCT03199391,has_criteria,3 months
NCT03199391,has_criteria,6 months
NCT03199391,has_criteria,1 year
NCT01261494,involves,Type 2 Diabetes Mellitus
NCT01261494,evaluates,GFT505
NCT01261494,measures_primary,HbA1c level
NCT01261494,measures_secondary,OGTT parameters
NCT01261494,measures_secondary,Fasting Plasma Glucose
NCT01261494,measures_secondary,insulin resistance index
NCT01261494,has_criteria,Body Mass Index
NCT01261494,has_criteria,Drug-Naive patients
NCT01261494,has_criteria,HbA1c
NCT01261494,has_criteria,hormonal replacement therapy
NCT02187562,involves,Platelet Aggregation
NCT02187562,evaluates,Meloxicam
NCT02187562,measures_primary,Thromboxane B2 production
NCT02187562,measures_secondary,Adverse events
NCT02187562,measures_secondary,Laboratory parameters
NCT02187562,measures_secondary,Electrocardiogram
NCT02187562,measures_secondary,Vital signs
NCT02187562,has_criteria,Aspirin intake
NCT00569062,involves,Depression
NCT00569062,evaluates,GW856553X
NCT00569062,measures_primary,Change from Randomization
NCT00569062,measures_secondary,IDS-C total score
NCT00569062,has_criteria,Week 6 assessment
NCT00435162,involves,High Blood Pressure
NCT00435162,evaluates,Valsartan
NCT00435162,measures_primary,Change in MSSBP
NCT00435162,measures_secondary,Change in MSDBP
NCT00435162,has_criteria,Children 6 Months - 5 Years
NCT01810380,involves,Schizophrenia
NCT01810380,evaluates,Brexpiprazole
NCT01810380,measures_primary,Change From Baseline
NCT01810380,measures_secondary,CGI-S Score
NCT01810380,measures_secondary,CGI-I Score
NCT01810380,measures_secondary,PANSS Positive Subscale Score
NCT01810380,has_criteria,Baseline and Week 6
NCT00701662,involves,Multifocal Motor Neuropathy
NCT00701662,evaluates,Purified Human Antibodies
NCT00701662,measures_primary,Muscle Strength
NCT00701662,measures_secondary,Disability
NCT00701662,has_criteria,MRC sum score
NCT02737891,involves,Type 2 Diabetes Mellitus
NCT02737891,evaluates,Tesofensine/Metoprolol
NCT02737891,measures_primary,Change From Baseline to End of Treatment in HbA1c
NCT02737891,measures_secondary,Change From Baseline to End of Treatment in Body Weight
NCT02737891,has_criteria,Males and females
NCT02737891,has_criteria,Confirmed diagnosis of T2DM
NCT02737891,has_criteria,18-70 years of age
NCT02737891,has_criteria,HbA1c ≥7.0%
NCT02737891,has_criteria,Hypersensitivity to tesofensine/metoprolol
NCT02737891,has_criteria,Heart failure class II or greater
NCT02737891,has_criteria,History of myocardial infarction
NCT02737891,has_criteria,History of coronary revascularisation
NCT02737891,has_criteria,History of angioplasty
NCT02737891,has_criteria,Patients reporting angina
NCT02737891,has_criteria,Treatment with insulin
NCT02737891,has_criteria,Treatment with other injectable anti-diabetic medications
NCT02737891,has_criteria,Treatment with TZDs
NCT02737891,has_criteria,Any clinically significant cardiac arrhythmia
NCT01739491,involves,Chronic Lymphocytic Leukemia
NCT01739491,evaluates,Bendamustine Hydrochloride
NCT01739491,measures_primary,complete remission
NCT01739491,measures_secondary,partial remission
NCT01739491,measures_secondary,stable disease
NCT01739491,measures_secondary,disease progression
NCT01739491,measures_secondary,lack of effect
NCT01739491,has_criteria,Adult Filipino patients
NCT01739491,has_criteria,cytologically-diagnosed chronic lymphocytic leukaemia
NCT01739491,has_criteria,World health organization performance Status 0
NCT00752622,involves,Crohn's Disease
NCT00752622,evaluates,Infliximab
NCT00752622,measures_primary,CDAI score decrease
NCT00752622,measures_secondary,Harvey-Bradshaw Index
NCT00752622,has_criteria,Disease progression/lack of response
NCT00418522,involves,Type 2 Diabetes Mellitus
NCT00418522,evaluates,Inhaled Insulin
NCT00418522,measures_primary,Change From Baseline in HbA1c
NCT00418522,measures_secondary,Percentage of Subjects Achieving Glycemic Control
NCT00418522,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT00418522,measures_secondary,Change From Baseline in Fasting and Postprandial Blood Glucose
NCT00418522,measures_secondary,Change From Baseline in Postprandial Blood Glucose
NCT00418522,measures_secondary,Change From Baseline in Lipids
NCT03903822,involves,Atopic Dermatitis
NCT03903822,evaluates,PF-06700841 Topical Cream
NCT03903822,measures_primary,EASI score at Week 6
NCT03903822,measures_secondary,IGA score at Week 6
NCT03903822,has_criteria,Mild or Moderate AD
NCT05301322,involves,Respiratory syncytial virus
NCT05301322,evaluates,RSVpreF
NCT05301322,measures_primary,Percentage of Participants
NCT05301322,measures_secondary,Systemic events
NCT05301322,has_criteria,Enrolled participants
NCT00098722,involves,HIV-1 infection
NCT00098722,evaluates,Maraviroc
NCT00098722,measures_primary,Change in HIV-1 RNA
NCT00098722,measures_secondary,CD4 cell count
NCT00098722,measures_secondary,CD8 cell count
NCT00098722,has_criteria,HIV-1 RNA levels
NCT00144222,involves,Essential Hypertension
NCT00144222,evaluates,Telmisartan
NCT00144222,evaluates,Hydrochlorothiazide
NCT00144222,measures_primary,Change in mean seated trough DBP
NCT00144222,measures_secondary,Change in seated trough SBP
NCT00144222,measures_secondary,Seated DBP control rate
NCT00144222,measures_secondary,Seated DBP response rate V2
NCT00144222,measures_secondary,Seated DBP response rate V3
NCT00144222,measures_secondary,Seated SBP response rate V2
NCT00144222,measures_secondary,Seated SBP response rate V3
NCT00144222,measures_secondary,Change in trough pulse pressure
NCT00144222,measures_secondary,Plasma concentrations of Telmisartan and HCTZ
NCT00144222,has_criteria,Mean seated DBP >= 95 and <= 114 mmHg
NCT00144222,has_criteria,Mean seated SBP >= 140 and <= 200 mmHg
NCT00144222,has_criteria,Mean seated DBP >= 90 and <= 114 mmHg
NCT00144222,has_criteria,Mean seated SBP <= 200 mmHg
NCT00144222,has_criteria,Patients taking 4 or more anti-hypertensive medications
NCT00144222,has_criteria,Patients with known or suspected secondary hypertension
NCT03298022,involves,Ulcerative Colitis
NCT03298022,evaluates,ALTB-168
NCT03298022,measures_primary,Clinical Response
NCT03298022,measures_secondary,Clinical Remission
NCT03298022,has_criteria,Anti-TNF Alpha and/or Anti-integrin Refractory
NCT02177422,involves,Hypertension
NCT02177422,evaluates,Telmisartan
NCT02177422,measures_primary,blood pressure <90 mmHg
NCT02177422,measures_secondary,blood pressure at months 3
NCT02177422,measures_secondary,heart rate
NCT02177422,has_criteria,mean seated diastolic blood pressure ≥ 95 mmHg
NCT02177422,has_criteria,mean seated systolic blood pressure ≥ 140 mmHg
NCT02177422,has_criteria,24-hour mean diastolic blood pressure ≥ 85 mmHg
NCT02177422,has_criteria,age 18 or older
NCT01890122,involves,Type 2 Diabetes
NCT01890122,evaluates,Alogliptin and Metformin
NCT01890122,measures_primary,Change From Baseline in HbA1c
NCT01890122,measures_secondary,Change From Baseline in FPG
NCT01890122,measures_secondary,Time to Hyperglycemic Rescue Event
NCT01890122,measures_secondary,Percentage of Participants Requiring Hyperglycemic Rescue
NCT01890122,has_criteria,FPG ≥275 mg/dL
NCT01890122,has_criteria,FPG ≥250 mg/dL
NCT01890122,has_criteria,FPG ≥225 mg/dL
NCT01890122,has_criteria,HbA1c ≥8.5%
NCT04338022,involves,Multiple Sclerosis
NCT04338022,evaluates,Evobrutinib
NCT04338022,measures_primary,Annualized Relapse Rate
NCT04338022,measures_secondary,Time to First Occurrence of CDP
NCT04338022,measures_secondary,Change From Baseline in PROMIS MS Physical Function
NCT04338022,measures_secondary,Change From Baseline in PROMIS MS Fatigue
NCT04338022,has_criteria,qualified relapses
NCT05348122,involves,Type 2 Diabetes
NCT05348122,evaluates,TG103 Injection
NCT05348122,measures_primary,HbA1c from baseline
NCT05348122,measures_secondary,Fasting plasma glucose
NCT05348122,measures_secondary,Weight
NCT05348122,measures_secondary,Postprandial blood glucose
NCT05348122,measures_secondary,Blood lipids
NCT05348122,measures_secondary,Remedial therapy
NCT05348122,measures_secondary,TEAEs and SAEs
NCT05348122,has_criteria,Baseline through Day113
NCT00724048,involves,Huntington's Disease
NCT00724048,evaluates,Pridopidine
NCT00724048,measures_primary,Change From Baseline in mMS
NCT00724048,measures_secondary,Change From Baseline in TMS
NCT00724048,measures_secondary,Number of Participants in Each of the Ratings of the CGI-C Scale
NCT00724048,measures_secondary,Change From Baseline in Stroop Word Reading Test
NCT00724048,has_criteria,Baseline
NCT03000348,involves,Cystic Fibrosis Exacerbations
NCT03000348,evaluates,Oral Cysteamine
NCT03000348,measures_primary,Change From Baseline in Sputum Bacterial Load
NCT03000348,measures_secondary,Change from baseline in neutrophil elastase levels
NCT03000348,measures_secondary,Change From Baseline in Sputum IL8
NCT03000348,measures_secondary,Change From Baseline in FEV1
NCT03000348,measures_secondary,Change From Baseline in BMI
NCT03000348,measures_secondary,Change From Baseline in C-Reactive Protein
NCT03000348,measures_secondary,Change From Baseline in Blood Leukocyte Count
NCT03000348,measures_secondary,Change From Baseline in CFRSD-CRISS
NCT03000348,has_criteria,Adult Patients
NCT02090348,involves,Relapsing Remitting Multiple Sclerosis
NCT02090348,evaluates,Dimethyl Fumarate
NCT02090348,measures_primary,fatigue as assessed by FSMC
NCT02090348,measures_secondary,fatigue as assessed by FSS
NCT02090348,measures_secondary,work productivity as assessed by WPAI-MS
NCT02090348,measures_secondary,quality of life
NCT02090348,has_criteria,Baseline and 1
NCT01059448,involves,Rheumatoid Arthritis
NCT01059448,evaluates,AMG 827
NCT01059448,measures_primary,ACR 20 Response
NCT01059448,measures_secondary,ACR 50 Response
NCT01059448,has_criteria,Baseline in parent study 20090061
NCT00757848,involves,Cystic Fibrosis
NCT00757848,evaluates,AZD9668
NCT00757848,measures_primary,Ratio of Sputum Absolute Neutrophil Count
NCT00757848,measures_secondary,Sputum Percentage Neutrophil Count
NCT00757848,measures_secondary,24-hour Sputum Weight
NCT00757848,measures_secondary,Forced Expiratory Volume in 1 Second (FEV1)
NCT00757848,measures_secondary,Slow Vital Capacity (SVC)
NCT00757848,measures_secondary,Forced Expiratory Flow Between 25 and 75% of Forced Vital Capacity (FEF25-75%)
NCT00757848,measures_secondary,Forced Vital Capacity (FVC)
NCT00757848,measures_secondary,Morning Peak Expiratory Flow (PEF)
NCT00757848,measures_secondary,Evening Peak Expiratory Flow (PEF)
NCT00757848,measures_secondary,Bronkotest Diary Card Signs and Symptoms
NCT05526248,involves,Prostate Cancer
NCT05526248,evaluates,Darolutamide
NCT05526248,evaluates,Enzalutamide
NCT05526248,measures_primary,Change in testosterone
NCT05526248,measures_secondary,Serum PSA
NCT05526248,measures_secondary,Adverse Event
NCT05526248,measures_secondary,Quality of life
NCT05526248,has_criteria,Informed Consent Form
NCT05771948,involves,Knee Osteoarthritis
NCT05771948,evaluates,CCoat Intra-Articular Injections
NCT05771948,measures_primary,Change from baseline in KOOS pain
NCT05771948,measures_secondary,Change in NRS Pain Score
NCT05771948,measures_secondary,Change in Patient's Global Assessment (PGA)
NCT05771948,has_criteria,at least 8 points or ≥ 20% from baseline
NCT02864082,involves,Congenital Ichthyosis
NCT02864082,evaluates,PAT-001
NCT02864082,measures_primary,IGA score improvement
NCT02864082,measures_secondary,Erythema
NCT02864082,has_criteria,Medical intervention
NCT04156620,involves,axSpA
NCT04156620,evaluates,Secukinumab
NCT04156620,measures_primary,ASAS40
NCT04156620,measures_secondary,ASDAS-CRP
NCT04156620,has_criteria,Baseline to Week 16
NCT05919082,involves,Plaque Psoriasis
NCT05919082,evaluates,LEO 90100
NCT05919082,evaluates,Daivobet® Ointment
NCT05919082,measures_primary,PGA score
NCT05919082,measures_primary,mPASI-75
NCT05919082,measures_primary,mPASI-90
NCT05919082,has_criteria,Physician's Global Assessment
NCT02713282,involves,Schizophrenia
NCT02713282,evaluates,Paliperidone Palmitate
NCT02713282,measures_primary,Symptomatic Remission
NCT02713282,measures_secondary,PANSS score
NCT02713282,has_criteria,Stabilized on Paliperidone Palmitate 1-Month Formulation
NCT05027282,involves,Photoaging
NCT05027282,evaluates,CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment
NCT05027282,measures_primary,Improvement in Photoaging Damage Appearance
NCT05027282,measures_secondary,Improvement in Photoaging Damage Appearance
NCT05027282,has_criteria,18 to 65 years of age
NCT05027282,has_criteria,Written informed consent
NCT05027282,has_criteria,Glogau Photodamage Scale Mild (I) to Moderate (II)
NCT05027282,has_criteria,Fitzpatrick skin types I-VI
NCT05027282,has_criteria,Fitzpatrick wrinkle & elastosis scale class I-II
NCT02236182,involves,Chronic Obstructive Pulmonary Disease
NCT02236182,evaluates,Ipratropium Bromide
NCT02236182,measures_primary,FEV1
NCT02236182,measures_secondary,AUC0-4
NCT02236182,has_criteria,FEV1 <=65% predicted normal
NCT02236182,has_criteria,FEV1 <=70% FVC
NCT02236182,has_criteria,Age >=40 years
NCT02236182,has_criteria,Smoking history >10 pack-years
NCT06072482,involves,ANCA-associated Vasculitis
NCT06072482,evaluates,Avacopan
NCT06072482,measures_primary,Time to Relapse
NCT06072482,measures_secondary,Sustained Remission
NCT06072482,has_criteria,Remission at Month 12
NCT05372939,involves,Ulcerative Colitis
NCT05372939,evaluates,AMT-101
NCT05372939,measures_primary,UC-100 Score
NCT05372939,measures_secondary,Robarts Histopathology Index
NCT05372939,measures_secondary,Mayo Clinic Score
NCT05372939,measures_secondary,fecal calprotectin
NCT05372939,measures_secondary,high-sensitivity C-reactive protein
NCT05372939,measures_secondary,RHI
NCT05372939,measures_secondary,Clinical remission rate
NCT05372939,measures_secondary,Clinical response rate
NCT05372939,has_criteria,Moderate to severe UC
NCT05372939,has_criteria,Eligible for Humira
NCT05372939,has_criteria,Women of childbearing potential
NCT05372939,has_criteria,Written informed consent
NCT05372939,has_criteria,Aged 18 to 75 years
NCT05397639,involves,Dementia of the Alzheimer's type
NCT05397639,evaluates,Masupirdine
NCT05397639,measures_primary,Change in CMAI items score
NCT05397639,measures_secondary,Change in mADCS-CGI-C
NCT05397639,has_criteria,diagnosis of dementia of the Alzheimer's type
NCT05397639,has_criteria,confirmed agitation
NCT05397639,has_criteria,MMSE score 8-24
NCT05397639,has_criteria,not predominantly non-Alzheimer's dementia
NCT05397639,has_criteria,agitation secondary to Alzheimer's disease
NCT06461286,involves,OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy
NCT06461286,evaluates,PYC-001
NCT06461286,measures_primary,Incidence of TEAEs
NCT06461286,measures_secondary,Change from baseline
NCT06461286,has_criteria,Hematology Screening parameters
NCT00817063,involves,Severe Chronic Hand Eczema
NCT00817063,evaluates,Retinoid
NCT00817063,measures_primary,PGA at Week 24
NCT00817063,measures_secondary,mTLSS at Week 24
NCT00817063,has_criteria,Baseline (Week 0)
NCT06260722,involves,Type 2 Diabetes
NCT06260722,evaluates,Retatrutide
NCT06260722,evaluates,Semaglutide
NCT06260722,measures_primary,Change from Baseline in HbA1c (%)
NCT06260722,measures_secondary,Percentage of Participants Who Achieve HbA1c ≤ 6.5%
NCT06260722,measures_secondary,Percentage of Participants Who Achieve HbA1c < 5.7%
NCT06260722,measures_secondary,Percent Change from Baseline in Body Weight
NCT06260722,measures_secondary,Percentage of Participants Who Achieve Weight Reduction of ≥ 5%
NCT06260722,measures_secondary,Percentage of Participants Who Achieve Weight Reduction of ≥ 10%
NCT06260722,measures_secondary,Percentage of Participants Who Achieve Weight Reduction of ≥ 15%
NCT06260722,measures_secondary,Percentage of Participants Who Achieve HbA1c ≤ 6.5% and ≥ 10% Weight Reduction
NCT06260722,measures_secondary,Percent Change from Baseline in Triglycerides
NCT06260722,measures_secondary,Percent Change from Baseline in Non-HDL Cholesterol
NCT06260722,measures_secondary,Change from Baseline in Systolic Blood Pressure
NCT03727139,involves,Parkinson's disease
NCT03727139,evaluates,Rasagiline Tablets
NCT03727139,measures_primary,Change From Baseline
NCT03727139,measures_secondary,Adverse Events
NCT03727139,measures_secondary,Adverse Drug Reactions
NCT03727139,has_criteria,Parkinson's disease
NCT03727139,has_criteria,contraindications
NCT02129439,involves,Ulcerative Colitis
NCT02129439,evaluates,SB012
NCT02129439,measures_primary,Total Mayo score
NCT02129439,measures_secondary,Endoscopic Mayo score
NCT02129439,measures_secondary,Glucocorticoid consumption
NCT02129439,has_criteria,Baseline (Visit 2) to day 28 (Visit 7)
NCT02129439,has_criteria,Baseline (Visit 2) to End-of-Study Visit10 (56 days)
NCT02129439,has_criteria,Baseline (Visit 2) to Visit 7 and Visit 10 (28 and 56 days)
NCT02129439,has_criteria,Baseline (Visit 2) to day 56 End of Study Visit 10 (56 days)
NCT00503139,involves,Rheumatoid arthritis
NCT00503139,evaluates,Etanercept
NCT00503139,measures_primary,DAS28-4 (ESR)
NCT00503139,measures_secondary,Erythrocyte Sedimentation Rate
NCT02956486,involves,Early Alzheimer's Disease
NCT02956486,evaluates,Elenbecestat
NCT02956486,measures_primary,CDR-SB Score
NCT02956486,measures_secondary,Treatment-emergent Adverse Events
NCT02956486,has_criteria,Baseline (Day 1)
NCT06082986,involves,Crohn's Disease
NCT06082986,evaluates,Ustekinumab
NCT06082986,measures_primary,Endoscopic Remission
NCT06082986,measures_secondary,Endoscopic Response
NCT06082986,measures_secondary,Clinical Remission
NCT06082986,has_criteria,Bio-naive participants
NCT01433263,involves,Lung Cancer
NCT01433263,involves,Pancreatic Cancer
NCT01433263,evaluates,BYM338
NCT01433263,measures_primary,Thigh Muscle Volume
NCT01433263,measures_secondary,Body Weight
NCT01433263,measures_secondary,Total Lean Body Mass
NCT01433263,measures_secondary,Bone Mineral Density
NCT01433263,has_criteria,Muscle TMV loss
NCT03370263,involves,Systemic Lupus Erythematosus
NCT03370263,evaluates,BENLYSTA
NCT03370263,measures_primary,Change from Baseline
NCT03370263,measures_secondary,Physician's Global Assessment
NCT03370263,measures_secondary,Lupus Impact Tracker
NCT03370263,measures_secondary,Number of subjects with abnormal
NCT03370263,measures_secondary,Number of subjects with adverse events
NCT03370263,has_criteria,Baseline and up to 52 weeks
NCT04701086,involves,Dry Eye Disease
NCT04701086,evaluates,Cationorm Pro
NCT04701086,evaluates,VISMED
NCT04701086,measures_primary,change of OSS score
NCT04701086,measures_secondary,change of ocular stainings
NCT04701086,measures_secondary,corneal fluorescein staining
NCT04701086,measures_secondary,conjunctival staining
NCT04701086,has_criteria,fluorescein corneal staining
NCT00804986,involves,Type 2 Diabetes Mellitus
NCT00804986,evaluates,LY2428757
NCT00804986,measures_primary,Change in HbA1c
NCT00804986,measures_secondary,Change in VAS
NCT00804986,measures_secondary,Number of Participants
NCT00804986,measures_secondary,Total Average Concentration
NCT00804986,has_criteria,baseline through 16 weeks
NCT01480063,involves,Multiple Sclerosis
NCT01480063,evaluates,Fampyra
NCT01480063,measures_primary,Change from Baseline in Physician's Clinical Global Impression of Improvement (CGI-I) of Walking Ability
NCT01480063,measures_secondary,Participants' Assessment of Physical and Psychological Impact of Multiple Sclerosis Using the Multiple Sclerosis Impact Scale-29 Items (MSIS-29)
NCT01480063,has_criteria,newly prescribed Fampyra but not yet started the treatment
NCT01480063,has_criteria,≥18 years of age
NCT01480063,has_criteria,willing and able to provide written informed consent
NCT02052739,involves,Status Epilepticus
NCT02052739,evaluates,SAGE-547 Injection
NCT02052739,measures_primary,Change From Baseline (CFB) in NIH-SS Total Score
NCT02052739,measures_secondary,Change From Baseline in Vital Sign Parameter: Body Weight
NCT02052739,measures_secondary,Change From Baseline in Vital Sign Parameter: Heart Rate
NCT02052739,has_criteria,Baseline (Screening) to infusion at 0-24
NCT04999839,involves,Plaque Psoriasis
NCT04999839,evaluates,NDI-034858
NCT04999839,measures_primary,PASI-75 at Week 12
NCT04999839,measures_secondary,PGA Score at Week 12
NCT04999839,has_criteria,moderate to severe
NCT03408639,involves,ESRD
NCT03408639,evaluates,CinnaGen Beta Erythropoietin
NCT03408639,evaluates,Eprex
NCT03408639,measures_primary,Mean Hb change
NCT03408639,measures_primary,Mean weekly epoetin dosage
NCT03408639,measures_secondary,Proportion of patients with any permanent or transient dose change
NCT03408639,measures_secondary,Proportion of patients with any Hb measurement outside the target range
NCT03408639,measures_secondary,Proportion of patients needed blood transfusions
NCT03408639,measures_secondary,Proportion of patients with treatment success
NCT03408639,measures_secondary,Proportion of patients with maintenance success
NCT03408639,measures_secondary,Percentage of patients with Hb measurements more than 10.0 g/dl
NCT03408639,measures_secondary,Percentage of patients with hematocrit measurements more than 30%
NCT03408639,has_criteria,Hb level within 10-12 g/dl
NCT02511886,involves,Alcohol Use Disorder
NCT02511886,evaluates,Arbaclofen Placarbil
NCT02511886,measures_primary,Maximum Observed Plasma Concentration
NCT02511886,measures_secondary,Time to Maximum Observed Plasma Concentration
NCT02511886,measures_secondary,Area Under the Concentration-Time Curve
NCT03073486,involves,Acne Vulgaris
NCT03073486,evaluates,Olumacostat Glasaretil Gel
NCT03073486,measures_primary,Acne Lesion Counts
NCT03073486,measures_secondary,Investigator Global Assessment
NCT03073486,has_criteria,At least 20 inflammatory lesions
NCT03073486,has_criteria,At least 20 non-inflammatory lesions
NCT03073486,has_criteria,Investigator Global Assessment 3 or greater
NCT01976663,involves,Nasolabial Folds
NCT01976663,evaluates,JUVÉDERM VOLIFT® XC
NCT01976663,measures_primary,Nasolabial Fold Severity
NCT01976663,measures_secondary,Overall Nasolabial Folds FACE-Q Score
NCT01976663,has_criteria,Moderate to Severe Nasolabial Folds
NCT00382863,involves,Heart Failure
NCT00382863,evaluates,Elastic Restraint
NCT00382863,measures_primary,Peak VO2
NCT00382863,measures_secondary,6MW Distance
NCT00382863,measures_secondary,MLWHF Score
NCT00382863,measures_secondary,Participant Deaths
NCT00382863,measures_secondary,NYHA Functional Class
NCT00382863,measures_secondary,KCCQ Score
NCT00382863,has_criteria,baseline to 6 months
NCT00219063,involves,essential hypertension
NCT00219063,evaluates,Aliskiren
NCT00219063,evaluates,Ramipril
NCT00219063,measures_primary,Diastolic blood pressure
NCT00219063,measures_primary,Systolic blood pressure
NCT00219063,measures_secondary,Diastolic blood pressure
NCT00219063,measures_secondary,Systolic blood pressure
NCT00219063,has_criteria,Patients with essential hypertension
NCT00219063,has_criteria,Eligible and able to participate
NCT00219063,has_criteria,Severe hypertension
NCT00219063,has_criteria,Secondary hypertension
NCT00219063,has_criteria,Hypertensive encephalopathy
NCT00219063,has_criteria,Cerebrovascular accident
NCT02039063,involves,Crohn's Disease
NCT02039063,evaluates,E6011
NCT02039063,measures_primary,Clinically Significant Change
NCT02039063,measures_secondary,Treatment-emergent Adverse Events
NCT02039063,has_criteria,Japanese Subjects
NCT05099263,involves,Nasal Obstruction
NCT05099263,evaluates,Vivaer Procedure
NCT05099263,measures_primary,NOSE Scale score
NCT05099263,measures_secondary,Responder Percent
NCT05099263,measures_secondary,Adverse Events
NCT05099263,has_criteria,Age 22 to 85 years
NCT05099263,has_criteria,Nasal obstruction treatment
NCT05099263,has_criteria,NOSE score ≥ 55
NCT05099263,has_criteria,SSB hypertrophy
NCT02800863,involves,Post-permanent Implant
NCT02800863,evaluates,DRG implantable pulse generator
NCT02800863,measures_primary,Percent Change VAS
NCT02800863,measures_secondary,Change From Baseline PROMIS-29
NCT02800863,has_criteria,12 month study
NCT01662648,involves,Schizophrenia
NCT01662648,evaluates,Paliperidone Extended-Release
NCT01662648,measures_primary,PANSS Total Score
NCT01662648,measures_secondary,PANSS Total Positive Subscale Score
NCT01662648,has_criteria,switched from other antipsychotic drugs
NCT06294925,involves,Ulcerative Colitis
NCT06294925,evaluates,Etrasimod
NCT06294925,measures_primary,symptomatic remission
NCT06294925,measures_secondary,clinical response
NCT06294925,has_criteria,≥18 and <65 years of age
NCT05156125,involves,Ulcerative Colitis
NCT05156125,evaluates,VTX002
NCT05156125,measures_primary,Clinical remission
NCT05156125,measures_secondary,Endoscopic improvement
NCT05156125,measures_secondary,Symptomatic remission
NCT05156125,measures_secondary,Histologic remission
NCT05156125,measures_secondary,Endoscopic improvement-histologic remission
NCT05156125,has_criteria,Active UC confirmed by endoscopy
NCT05156125,has_criteria,Diagnosed with UC ≥ 3 months prior to Screening
NCT05156125,has_criteria,Severe extensive colitis
NCT00505622,involves,Parkinson's Disease
NCT00505622,evaluates,Perampanel
NCT00505622,measures_primary,Total Daily OFF Time
NCT00505622,measures_secondary,UPDRS Part II Score
NCT00505622,measures_secondary,UPDRS Part III Score
NCT00505622,measures_secondary,Total Daily ON Time
NCT00505622,has_criteria,Levodopa Treated
NCT02182830,involves,Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
NCT02182830,evaluates,Empagliflozin (BI 10773)
NCT02182830,measures_primary,Change From Baseline in Glycated Haemoglobin (HbA1c) (%) at 24 Weeks
NCT02182830,measures_secondary,Change from baseline in mean 24-hour ambulatory Systolic blood pressure SBP at Week 12
NCT02182830,measures_secondary,Changes From Baseline in Trough Mean Ambulatory SBP at Week 12
NCT02182830,measures_secondary,Change From Baseline in Body Weight at Week 24
NCT02182830,measures_secondary,Change From Baseline in Trough Seated SBP at Week 12
NCT02182830,measures_secondary,Change From Baseline in Mean 24-hour Ambulatory SBP (mmHg) at Week 24
NCT02182830,has_criteria,last observation prior to randomisation
NCT03172325,involves,Rheumatoid arthritis
NCT03172325,evaluates,CinnoRA
NCT03172325,evaluates,Humira
NCT03172325,measures_primary,DAS28-EULAR response
NCT03172325,measures_secondary,ACR20 Response Rate
NCT03172325,measures_secondary,ACR50 Response Rate
NCT03172325,measures_secondary,ACR70 Response Rate
NCT03172325,measures_secondary,HAQ Disability Index
NCT03172325,has_criteria,DAS28-ESR
NCT00980330,involves,Chronic Hepatitis C
NCT00980330,evaluates,TMC435
NCT00980330,measures_primary,SVR24
NCT00980330,measures_secondary,HCV RNA drop
NCT00980330,has_criteria,Failed standard treatment
NCT05499130,involves,Ulcerative Colitis
NCT05499130,involves,Crohn's Disease
NCT05499130,evaluates,TEV-48574
NCT05499130,measures_primary,clinical remission
NCT05499130,measures_primary,endoscopic response
NCT05499130,measures_primary,clinical response
NCT05499130,measures_primary,Endoscopic improvement
NCT05499130,measures_primary,Endoscopic remission
NCT05499130,measures_secondary,2-item patient-reported outcome
NCT05499130,has_criteria,moderate to severe
NCT00171730,involves,Acromegaly
NCT00171730,evaluates,Pasireotide
NCT00171730,measures_primary,Time to tumor response
NCT00171730,measures_secondary,Pituitary Tumor Volumes
NCT00171730,measures_secondary,Symptoms of Acromegaly
NCT00171730,has_criteria,Growth Hormone (GH) and IGF-1
NCT01917825,involves,Lumbosacral Radiculopathy
NCT01917825,evaluates,MDT-15
NCT01917825,measures_primary,Change in Radicular Leg Pain
NCT01917825,measures_secondary,Change in Physical Function
NCT01917825,measures_secondary,Change in Back Pain
NCT01917825,measures_secondary,Change in Neuropathic Type Symptoms
NCT01917825,measures_secondary,Change in Medical Outcomes study - Sleep Scale
NCT01917825,measures_secondary,Change in Emotional Function
NCT01917825,measures_secondary,Change in Work Function
NCT01917825,has_criteria,escalating sequential doses
NCT05715125,involves,Psoriatic Arthritis
NCT05715125,evaluates,VTX958
NCT05715125,measures_primary,ACR20 at Week 16
NCT05715125,measures_secondary,TEAEs
NCT05715125,measures_secondary,HAQ-DI scores
NCT05715125,measures_secondary,PASI75 score
NCT05715125,measures_secondary,SF-36 PCS
NCT05715125,has_criteria,3% BSA involvement
NCT01382225,involves,Dry Eye Syndrome
NCT01382225,evaluates,Sodium Hyaluronate Ophthalmic Solution
NCT01382225,measures_primary,Change From Baseline in LGS Total Score
NCT01382225,measures_secondary,Change From Baseline in GSF Total Score
NCT01382225,measures_secondary,Percentage Change From Baseline in CFS Total Score
NCT01382225,has_criteria,Baseline
NCT01382225,has_criteria,Baseline
NCT01298648,involves,Crohn's Disease
NCT01298648,evaluates,adalimumab
NCT01298648,measures_primary,CDAI at Week 4
NCT01298648,measures_secondary,CDAI at Week 8
NCT01298648,has_criteria,CDAI scores below 150
NCT06258148,involves,Type 2 Diabetes Mellitus
NCT06258148,evaluates,TG103 Injection
NCT06258148,measures_primary,HbA1c at 24 weeks
NCT06258148,measures_secondary,HbA1c at 52 weeks
NCT06258148,measures_secondary,HbA1c percentage
NCT06258148,measures_secondary,Fasting plasma glucose
NCT06258148,measures_secondary,Weight
NCT06258148,measures_secondary,2h-postprandial plasma glucose
NCT06258148,measures_secondary,Mean blood glucose curve
NCT06258148,measures_secondary,Postprandial blood glucose increment
NCT06258148,measures_secondary,Blood lipids
NCT06258148,measures_secondary,Remedial therapy
NCT06258148,measures_secondary,Adverse events
NCT06258148,measures_secondary,TG103 blood concentrations
NCT06258148,measures_secondary,TG103 antibodies
NCT06258148,has_criteria,Type 2 Diabetes diagnosis
NCT06258148,has_criteria,Age 18-75 years
NCT06258148,has_criteria,BMI 18.5-40
NCT06258148,has_criteria,No hypoglycemic drugs
NCT06258148,has_criteria,Insulin use ≤14 days
NCT04476030,involves,Major Depressive Disorder
NCT04476030,evaluates,Sage-217
NCT04476030,measures_primary,Change From Baseline
NCT04476030,measures_secondary,Change From Baseline
NCT04476030,has_criteria,Adults with MDD
NCT00734630,involves,hypertension
NCT00734630,evaluates,Nebivolol
NCT00734630,measures_primary,SBP at Week 12
NCT00734630,measures_secondary,DBP at Week 12
NCT00734630,has_criteria,Male or female 18-85 years old
NCT00734630,has_criteria,history of hypertension
NCT00734630,has_criteria,qualifying laboratory results
NCT00734630,has_criteria,severe hypertension
NCT00734630,has_criteria,chronic kidney disease
NCT00734630,has_criteria,congestive heart failure
NCT00734630,has_criteria,clinically significant respiratory
NCT00734630,has_criteria,liver or heart disease
NCT00734630,has_criteria,history of stroke
NCT00734630,has_criteria,history of heart attack
NCT00734630,has_criteria,history of heart surgery
NCT00734630,has_criteria,history of hypersensitivity to nebivolol
NCT00117325,involves,Vasomotor Rhinitis
NCT00117325,measures_primary,Mean Change rTNSS
NCT00117325,measures_secondary,Mean Change iTNSS
NCT00117325,has_criteria,Baseline 4 days prior
NCT03941548,involves,Alopecia Areata
NCT03941548,evaluates,CTP-543
NCT03941548,measures_primary,Relative Change SALT
NCT03941548,measures_secondary,Percentage Reduction SALT
NCT03941548,measures_secondary,Absolute Change SALT
NCT03941548,has_criteria,Adults
NCT02013622,involves,Early-Episode Schizophrenia
NCT02013622,evaluates,Brexpiprazole
NCT02013622,measures_primary,PANSS Total Score
NCT02013622,measures_secondary,CGI-S Score
NCT02013622,has_criteria,clinical experience
NCT01978730,involves,Dementia
NCT01978730,evaluates,SaiLuoTong Capsule
NCT01978730,measures_primary,V-ADAS-cog
NCT01978730,measures_secondary,ADCS-CGIC
NCT01978730,measures_secondary,ADCS - ADL
NCT01978730,measures_secondary,MMSE
NCT01978730,measures_secondary,CDR scale
NCT01978730,measures_secondary,CLOX
NCT01978730,measures_secondary,C-EXIT25
NCT01978730,measures_secondary,NPI
NCT01978730,measures_secondary,CDR-sb
NCT01978730,has_criteria,40 years old or above
NCT01978730,has_criteria,Education≥primary-school
NCT01978730,has_criteria,DSM-IV criteria
NCT01978730,has_criteria,VaD diagnosed
NCT01479530,involves,Parkinson's Disease
NCT01479530,evaluates,Azilect
NCT01479530,measures_primary,OFF time
NCT01479530,measures_secondary,CGI-I Score
NCT01479530,measures_secondary,UPDRS-ADL Score
NCT01479530,measures_secondary,UPDRS Motor Score
NCT01479530,has_criteria,Levodopa-treated
NCT04963725,involves,Ulcerative Colitis
NCT04963725,evaluates,Ustekinumab
NCT04963725,measures_primary,Rectal Bleeding Score
NCT04963725,measures_secondary,Stool Frequency Score
NCT04963725,measures_secondary,Partial Mayo Score
NCT04963725,has_criteria,Induction Dose
NCT02588625,involves,Diffuse Cutaneous Systemic Sclerosis
NCT02588625,evaluates,BMS-986020
NCT02588625,evaluates,Placebo
NCT02588625,measures_primary,modified Rodnan skin score
NCT02588625,measures_secondary,physical function
NCT02588625,measures_secondary,forced vital capacity
NCT02588625,measures_secondary,global assessment
NCT02588625,has_criteria,≥ 20%
NCT01453725,involves,Axial Spondyloarthritis
NCT01453725,evaluates,Golimumab
NCT01453725,measures_primary,ASAS 20 Response
NCT01453725,measures_secondary,Adverse Event
NCT01453725,has_criteria,20% improvement
NCT00503425,involves,Rheumatoid Arthritis
NCT00503425,evaluates,MabThera
NCT00503425,measures_primary,DAS28 at Week 24
NCT00503425,measures_secondary,Adverse Events
NCT00503425,has_criteria,Inadequate Response to DMARD
NCT03625622,involves,Alzheimer's disease
NCT03625622,evaluates,AR1001
NCT03625622,measures_primary,ADAS-Cog 13
NCT03625622,measures_secondary,ADCS-CGIC
NCT03625622,measures_secondary,MMSE-2
NCT03625622,measures_secondary,NPI
NCT03625622,measures_secondary,GDS
NCT03625622,measures_secondary,C-SSRS
NCT03625622,measures_secondary,QOL-AD
NCT03625622,has_criteria,age 55-80 years
NCT03625622,has_criteria,diagnosis probable Alzheimer's disease
NCT03625622,has_criteria,MMSE Score 16-26
NCT01277822,involves,Uncontrolled High Blood Pressure
NCT01277822,evaluates,Losartan
NCT01277822,evaluates,Amlodipine
NCT01277822,measures_primary,Change in MSDBP
NCT01277822,measures_primary,Change in MSSBP
NCT01277822,measures_secondary,Percentage of Participants Who Achieve Target Blood Pressure
NCT01277822,has_criteria,sitting diastolic BP \<90mmHg
NCT01277822,has_criteria,sitting systolic BP \<140mmHg
NCT01277822,has_criteria,sitDBP change more than 10mmHg
NCT01277822,has_criteria,sitSBP change more than 20mmHg
NCT01814722,involves,HIV infection
NCT01814722,evaluates,Raltegravir
NCT01814722,measures_primary,Change From Baseline
NCT01814722,measures_secondary,Depression
NCT01814722,measures_secondary,HIV Symptom Index
NCT01814722,has_criteria,Week 4 Follow-up
NCT03725722,involves,Atopic Dermatitis
NCT03725722,evaluates,Delgocitinib Cream
NCT03725722,measures_primary,EASI Score
NCT03725722,measures_secondary,vIGA-AD TS
NCT03725722,has_criteria,Age 18 years
NCT03725722,has_criteria,Diagnosis of AD
NCT03725722,has_criteria,History of AD ≥1 year
NCT03725722,has_criteria,AD involvement 5-50%
NCT00557622,involves,Posttraumatic Stress Disorder
NCT00557622,evaluates,BRL29060A
NCT00557622,measures_primary,CAPS-SX total score
NCT00557622,measures_secondary,regional blood flow
NCT00557622,has_criteria,Baseline and Week 12
NCT02174848,involves,Pantothenate Kinase-Associated Neurodegeneration
NCT02174848,evaluates,deferiprone
NCT02174848,measures_primary,Change in BAD score
NCT02174848,measures_secondary,frequency of adverse events
NCT02174848,measures_secondary,frequency of serious adverse events
NCT02174848,has_criteria,Baseline and Month 18
NCT03801330,involves,Obstructive airways disease
NCT03801330,evaluates,Inspiration Point-A Digital Pulmonary Rehabilitation Tool
NCT03801330,measures_primary,6 Minute Walk Test
NCT03801330,measures_secondary,Modified Medical Research Council Dyspnea Scale
NCT03801330,measures_secondary,Medical Outcomes Scale VR-12
NCT03801330,measures_secondary,St Georges Respiratory Questionnaire
NCT03801330,has_criteria,Obstructive airways disease
NCT01072630,involves,Major Depression
NCT01072630,involves,Bipolar I Disorder
NCT01072630,evaluates,Armodafinil
NCT01072630,measures_primary,Change from baseline
NCT01072630,measures_secondary,Percentage of Responders
NCT01072630,measures_secondary,Percentage in Remission
NCT01072630,has_criteria,Adults
NCT02605525,involves,IgA Nephropathy
NCT02605525,evaluates,SM101
NCT02605525,measures_primary,Percent change proteinuria
NCT02605525,measures_secondary,eGFR change
NCT02605525,has_criteria,Baseline proteinuria
NCT01012622,involves,Attention Deficit Hyperactivity Disorder
NCT01012622,evaluates,OSmotic Release Oral System (OROS) Methylphenidate
NCT01012622,measures_primary,Change From Baseline in K-ARS Total Score
NCT01012622,measures_secondary,Number of Participants With Response
NCT01012622,measures_secondary,Number of Participants With Remission
NCT01012622,has_criteria,K-ARS Total score of 18 or less
NCT01012622,has_criteria,"Very much improved"" or ""Much improved"" in CGI-I"
NCT05774639,involves,Chronic Idiopathic Urticaria
NCT05774639,evaluates,ADL-018
NCT05774639,evaluates,XOLAIR
NCT05774639,measures_primary,Change from baseline
NCT05774639,measures_secondary,Relative potency
NCT05774639,has_criteria,Change from baseline
NCT02699086,involves,Attention-Deficit Hyperactivity Disorder
NCT02699086,evaluates,PDC-1421
NCT02699086,measures_primary,ADHD-RS-IV total score
NCT02699086,measures_secondary,CAARS-S:S T-score
NCT03343639,involves,plaque psoriasis
NCT03343639,evaluates,Serlopitant
NCT03343639,measures_primary,WI-NRS 4-point Responder Rate
NCT03343639,measures_secondary,Change from baseline to day 7
NCT03343639,has_criteria,age 18-80 years
NCT03343639,has_criteria,diagnosis of plaque psoriasis
NCT03343639,has_criteria,pruritus 4 weeks' duration
NCT00603239,involves,Type 2 Diabetes
NCT00603239,evaluates,Exenatide
NCT00603239,measures_primary,Change in HbA1c
NCT00603239,measures_secondary,Change in Fasting Serum Glucose
NCT00603239,measures_secondary,Change in Body Weight
NCT00603239,measures_secondary,Change in Waist Circumference
NCT00603239,measures_secondary,Change in Beta-cell Function
NCT00603239,measures_secondary,Change in Insulin Sensitivity
NCT00603239,measures_secondary,Number of Subjects Who Experienced an Episode of Minor Hypoglycemia
NCT00603239,measures_secondary,Change in Impact of Weight on Quality of Life (IWQOL)-Lite Score
NCT00603239,has_criteria,26 weeks
NCT04594239,involves,infraorbital hollow
NCT04594239,evaluates,Belotero Balance® (+) Lidocaine
NCT04594239,measures_primary,Responder Rate at Week 8
NCT04594239,measures_secondary,Global Aesthetic Improvement Scale
NCT04594239,has_criteria,MIHAS score
NCT04027439,involves,COPD
NCT04027439,evaluates,RPL554
NCT04027439,measures_primary,Change From Baseline FEV1
NCT04027439,measures_secondary,Average FEV1
NCT04027439,has_criteria,Single dose
NCT06029439,involves,Depression
NCT06029439,evaluates,NMRA-335140-501
NCT06029439,measures_primary,MADRS total score
NCT06029439,measures_secondary,SHAPS total score
NCT06029439,has_criteria,Baseline and Week 54
NCT01217086,involves,Rheumatoid arthritis
NCT01217086,evaluates,cT-p13
NCT01217086,measures_primary,ACR criteria comparison
NCT01217086,measures_secondary,Time to ACR20 response
NCT01217086,has_criteria,active rheumatoid arthritis
NCT01217086,has_criteria,methotrexate treatment
NCT01217086,has_criteria,allergies to infliximab
NCT01009086,involves,Psoriatic Arthritis
NCT01009086,evaluates,Ustekinumab
NCT01009086,measures_primary,ACR 20 response
NCT01009086,measures_secondary,Disability Index Score
NCT01009086,has_criteria,>= 3% BSA Psoriatic Involvement
NCT06157086,involves,Multiple Sclerosis
NCT06157086,evaluates,ofatumumab
NCT06157086,measures_primary,quality of life
NCT06157086,measures_secondary,treatment satisfaction
NCT06157086,measures_secondary,professional activity
NCT06157086,has_criteria,adult patients
NCT01681186,evaluates,LY2940680
NCT01681186,measures_primary,Cmax
NCT01681186,measures_secondary,AUC(0-tlast)
NCT01681186,measures_secondary,Tmax
NCT06235086,involves,Type 2 Diabetes Mellitus
NCT06235086,evaluates,TG103 Injection
NCT06235086,measures_primary,Changes in HbA1c
NCT06235086,measures_secondary,Change in fasting plasma glucose
NCT06235086,measures_secondary,Change in weight
NCT06235086,measures_secondary,Change in 2h-postprandial plasma glucose
NCT06235086,measures_secondary,Mean 7 point blood glucose curve
NCT06235086,measures_secondary,Change in blood lipids
NCT06235086,measures_secondary,Proportion of subjects receiving remedial therapy
NCT06235086,measures_secondary,Incidence of adverse events
NCT06235086,measures_secondary,Blood concentrations of TG103
NCT06235086,measures_secondary,The occurrence of TG103 anti-drug antibodies
NCT06235086,has_criteria,diagnosed with type 2 diabetes
NCT06235086,has_criteria,Aged 18 to 75 years
NCT06235086,has_criteria,Body Mass Index (BMI) 18.5≤BMI≤40
NCT06235086,has_criteria,Received stable dose of metformin hydrochloride monotherapy
NCT06235086,has_criteria,HbA1c 7.5% ≤ HbA1c ≤ 11.0%
NCT01853839,involves,Hypertension
NCT01853839,evaluates,Ramadan
NCT01853839,measures_primary,Blood pressure achievement
NCT01853839,measures_secondary,Cardiovascular Events
NCT01853839,has_criteria,Blood pressure <140/90 mmHg
NCT02436239,involves,Major Depressive Disorder
NCT02436239,evaluates,Vilazodone
NCT02436239,measures_primary,Change From Baseline
NCT02436239,measures_secondary,CGI-S Score
NCT02436239,measures_secondary,CGI-I
NCT02436239,has_criteria,Male or Female
NCT06609239,involves,Asthma
NCT06609239,evaluates,Lunsekimig
NCT06609239,measures_primary,Annualized rate exacerbation
NCT06609239,measures_secondary,Change from baseline FEV1
NCT06609239,measures_secondary,Change from baseline ACQ-5
NCT06609239,measures_secondary,Proportion ACQ-5 responders
NCT06609239,has_criteria,Adult participants
NCT01066039,involves,Type II Diabetes
NCT01066039,evaluates,Bisoprolol
NCT01066039,measures_primary,Change From Baseline in HbA1c
NCT01066039,measures_secondary,Systolic Blood Pressure
NCT01066039,measures_secondary,Diastolic Blood Pressure
NCT01066039,measures_secondary,Mean Blood Pressure
NCT01066039,measures_secondary,Homeostasis Model Assessment of Insulin Resistance
NCT01066039,measures_secondary,Insulin Level
NCT01066039,measures_secondary,C-Peptide Level
NCT01066039,has_criteria,Suboptimal Blood Pressure Control
NCT04658186,involves,Parkinson's Disease
NCT04658186,evaluates,UCB0599
NCT04658186,measures_primary,MDS-UPDRS Parts I-III
NCT04658186,measures_secondary,MDS-UPDRS Part III
NCT04658186,has_criteria,early-stage Parkinson's disease
NCT01614886,involves,Alzheimer's Disease
NCT01614886,evaluates,Rivastigmine Patch
NCT01614886,measures_primary,AE leading to discontinuation
NCT01614886,measures_secondary,ADAS-J Cog
NCT01614886,measures_secondary,MMSE
NCT01614886,measures_secondary,J-CGIC
NCT01614886,measures_secondary,Treatment Retention
NCT01614886,has_criteria,MMSE 10-20
NCT00445939,involves,Crohn's Disease
NCT00445939,evaluates,Adalimumab
NCT00445939,measures_primary,Clinical Remission
NCT00445939,measures_secondary,Clinical Response
NCT00445939,has_criteria,CDAI score 220-450
NCT03052322,involves,Rheumatoid Arthritis
NCT03052322,evaluates,MSB11022
NCT03052322,measures_primary,ACR20 Response
NCT03052322,measures_secondary,Anti-Drug Antibodies
NCT03052322,has_criteria,Hypersensitivity
NCT01331239,involves,Cushing's Disease
NCT01331239,evaluates,LCI699
NCT01331239,measures_primary,Percentage of Responders
NCT01331239,measures_secondary,Change in UFC
NCT01331239,has_criteria,mean UFC level
NCT03382639,involves,Schizophrenia
NCT03382639,evaluates,Luvadaxistat
NCT03382639,measures_primary,PANSS NSFS at Week 12
NCT03382639,measures_secondary,BNSS Total Score
NCT03382639,has_criteria,Adults with negative symptoms
NCT01190839,involves,Crohn's Disease
NCT01190839,evaluates,REMICADE
NCT01190839,evaluates,Placebo
NCT01190839,measures_primary,Clinical Recurrence
NCT01190839,measures_secondary,Endoscopic Recurrence
NCT01190839,has_criteria,CDAI score increase
NCT01190839,has_criteria,CDAI score >=200
NCT01190839,has_criteria,Rutgeerts score >=i2
NCT01190839,has_criteria,C. difficile toxin
NCT01190839,has_criteria,draining external fistula
NCT01190839,has_criteria,re-opening fistula
NCT01190839,has_criteria,internal fistula
NCT01190839,has_criteria,perianal abscess
NCT01190839,has_criteria,intra-abdominal abscess
NCT01190839,has_criteria,prohibited CD medication
NCT01190839,has_criteria,surgery for CD
NCT02091739,involves,Chronic Troublesome Sialorrhea
NCT02091739,involves,Neurological Conditions
NCT02091739,evaluates,NT 201
NCT02091739,evaluates,Placebo
NCT02091739,measures_primary,Unstimulated Salivary Flow Rate
NCT02091739,measures_primary,Global Impression of Change Scale
NCT02091739,measures_secondary,Global Impression of Change Scale
NCT02091739,has_criteria,Documented diagnosis
NCT02091739,has_criteria,Chronic troublesome sialorrhea
NCT03630939,involves,plaque psoriasis
NCT03630939,evaluates,Topical ESR-114
NCT03630939,measures_primary,Total Lesion Severity Score
NCT03630939,measures_secondary,Physician Global Assessment
NCT03630939,measures_secondary,PASI75
NCT03630939,has_criteria,history of plaque psoriasis
NCT03630939,has_criteria,PGA of mild or moderate
NCT03630939,has_criteria,total LSS of ≥6
NCT03630939,has_criteria,plaque psoriasis-affected BSA
NCT03630939,has_criteria,used topical therapy within 2 weeks
NCT00308139,involves,Type 2 Diabetes Mellitus
NCT00308139,evaluates,Exenatide Long-Acting Release
NCT00308139,measures_primary,Change in HbA1c
NCT00308139,measures_secondary,Percentage of Subjects Achieving HbA1c Target of <7%
NCT00308139,has_criteria,Day -3
NCT03879239,involves,Chronic Idiopathic Constipation
NCT03879239,evaluates,Vibrant Capsule
NCT03879239,measures_primary,CSBM1 Success Rate
NCT03879239,measures_secondary,CSBM2 Success Rate
NCT03879239,has_criteria,aged 22 years and older
NCT03879239,has_criteria,Rome III criteria
NCT04046939,involves,Eosinophilic Asthma
NCT04046939,evaluates,Dexpramipexole
NCT04046939,measures_primary,Change in AEC
NCT04046939,measures_secondary,Change in FEV1
NCT04046939,measures_secondary,Change in ACQ-6 Score
NCT04046939,has_criteria,Baseline
NCT01655186,involves,Chronic Kidney Disease
NCT01655186,involves,Type 2 Diabetes Mellitus
NCT01655186,evaluates,Bardoxolone Methyl
NCT01655186,measures_primary,Mean change in body weight
NCT01655186,measures_secondary,Change in fat mass
NCT01655186,measures_secondary,Change in visceral fat mass
NCT01655186,measures_secondary,Change in hepatic fat mass
NCT01655186,measures_secondary,Change in left ventricular structure
NCT01655186,measures_secondary,Change in gait speed
NCT01655186,has_criteria,eGFR ≥ 15.0 and \< 30.0 mL/min/1.73 m2
NCT01655186,has_criteria,history of type 2 diabetes mellitus
NCT01655186,has_criteria,at least 30 years of age
NCT01655186,has_criteria,Treatment with an ACE inhibitor and/or an ARB
NCT02786186,involves,plaque psoriasis
NCT02786186,evaluates,Treatment
NCT02786186,measures_primary,PASI 50/75/90/100
NCT02786186,measures_secondary,Work Productivity
NCT02786186,measures_secondary,Hospital Anxiety
NCT02786186,measures_secondary,Psoriasis Symptom
NCT02786186,measures_secondary,Treatment Satisfaction
NCT02786186,measures_secondary,Dermatology Life Quality
NCT02786186,measures_secondary,Psoriasis Epidemiology
NCT02786186,has_criteria,written informed consent
NCT02786186,has_criteria,18 years of age
NCT02786186,has_criteria,chronic plaque psoriasis
NCT01029886,involves,Type 2 Diabetes
NCT01029886,evaluates,Exenatide Once Weekly
NCT01029886,evaluates,Liraglutide
NCT01029886,measures_primary,Change in HbA1c
NCT01029886,measures_secondary,Change in Fasting Serum Glucose
NCT01029886,measures_secondary,Change in Body Weight
NCT01029886,measures_secondary,Change in Total Cholesterol
NCT01029886,measures_secondary,Change in HDL-C
NCT01029886,measures_secondary,Ratio of Fasting Triglycerides
NCT01029886,measures_secondary,Change in Systolic Blood Pressure
NCT01029886,measures_secondary,Change in Diastolic Blood Pressure
NCT01029886,measures_secondary,Hypoglycemic Events
NCT03425539,involves,Fabry Disease
NCT03425539,evaluates,Lucerastat
NCT03425539,measures_primary,Neuropathic Pain Monthly Score
NCT03425539,measures_secondary,Abdominal Pain Monthly Score
NCT03425539,measures_secondary,Number of Days With Diarrhea
NCT03425539,has_criteria,Male or female adult subjects
NCT03425539,has_criteria,FD diagnosis confirmed
NCT03425539,has_criteria,Fabry-associated neuropathic pain
NCT03425539,has_criteria,Enzyme replacement therapy (ERT) status
NCT03565939,involves,Ulcerative Colitis
NCT03565939,evaluates,Trichuris Suis Ova
NCT03565939,measures_primary,Full Mayo score
NCT03565939,measures_secondary,Endoscopic remission
NCT03565939,measures_secondary,Symptomatic remission
NCT03565939,has_criteria,18-75 years of age
NCT03565939,has_criteria,Established diagnosis of UC
NCT01032239,involves,Stroke
NCT01032239,evaluates,ITB
NCT01032239,evaluates,BMT
NCT01032239,measures_primary,Change in AS
NCT01032239,measures_secondary,FIM Score
NCT01032239,has_criteria,Baseline and month 6
NCT03459586,involves,Parkinson's Disease
NCT03459586,evaluates,9 zest app
NCT03459586,measures_primary,Sit-To-Stand test
NCT03459586,measures_primary,Timed Up and Go Test
NCT03459586,measures_primary,Parkinson's Disease Questionnaire-39 mobility subscale
NCT03459586,has_criteria,12 week measurement point
NCT05564039,involves,Type 2 Diabetes
NCT05564039,evaluates,Tirzepatide
NCT05564039,measures_primary,HbA1c
NCT05564039,measures_secondary,Fasting Serum Glucose
NCT05564039,has_criteria,Adult Participants
NCT06524739,involves,Post-COVID-19 POTS
NCT06524739,evaluates,IgPro20
NCT06524739,measures_primary,orthostatic intolerance
NCT06524739,measures_secondary,COMPASS-31 score
NCT06524739,measures_secondary,heart rate increase
NCT06524739,has_criteria,diagnostic criteria
NCT03090139,involves,Inflammatory Bowel Disease
NCT03090139,involves,UC
NCT03090139,involves,CD
NCT03090139,evaluates,anti-TNF therapy
NCT03090139,measures_primary,Incidence rate
NCT03090139,measures_secondary,Treatment Patterns
NCT03090139,measures_secondary,Number of Participants With Response to Treatment
NCT03090139,has_criteria,Clinical Response
NCT03090139,has_criteria,Harvey Bradshaw Index (HBI)
NCT02109939,involves,DEpression
NCT02109939,evaluates,GeneSight Psychotropic
NCT02109939,measures_primary,Percent Change HAM-D17
NCT02109939,measures_secondary,Percent Change QIDS-C16
NCT02109939,measures_secondary,Percentage of Responders HAM-D17
NCT02109939,measures_secondary,Percentage of Responders HAM-D17
NCT02109939,measures_secondary,Percentage of Remitters HAM-D17
NCT00382239,involves,Type 2 Diabetes
NCT00382239,evaluates,exenatide
NCT00382239,measures_primary,Change in HbA1c
NCT00382239,measures_secondary,Proportion of subjects achieving HbA1c <7% at Week 12
NCT00382239,measures_secondary,Total number of subjects achieving HbA1c \<7% at Week 12
NCT00382239,measures_secondary,Changes in fasting blood glucose
NCT00382239,measures_secondary,Change in Serum lipids
NCT00382239,measures_secondary,Changes in body weight
NCT00382239,measures_secondary,waist size
NCT00382239,measures_secondary,waist/hip ratio
NCT00382239,has_criteria,Diagnosed with type 2 diabetes
NCT00382239,has_criteria,Body weight >=50 kg
NCT00382239,has_criteria,Received treatment within the last 30 days
NCT00382239,has_criteria,Participated in this study previously
NCT00382239,has_criteria,Treated with any exogenous insulin
NCT00382239,has_criteria,Continuously treated with any of the following excluded medications within 3 months of screening
NCT01948791,involves,Alzheimer's Disease
NCT01948791,evaluates,Exelon
NCT01948791,measures_primary,ADAS-cog score
NCT01948791,measures_secondary,ADCS-ADL Score
NCT01948791,has_criteria,Chinese patients
NCT04417894,involves,Atopic Hand and Foot Dermatitis
NCT04417894,evaluates,Dupilumab
NCT04417894,measures_primary,Hand and Foot IGA
NCT04417894,measures_secondary,Pruritus NRS
NCT04417894,measures_secondary,mTLSS
NCT04417894,has_criteria,Adult and Adolescent
NCT05643794,involves,Fibromyalgia Syndrome
NCT05643794,evaluates,Rozanolixizumab
NCT05643794,measures_primary,BPI-SF average interference score
NCT05643794,measures_secondary,Percentage of participants with TEAEs
NCT05643794,has_criteria,Adult Study Participants
NCT00727194,involves,Generalized Myasthenia Gravis
NCT00727194,evaluates,Eculizumab
NCT00727194,measures_primary,QMG Total Score
NCT00727194,measures_secondary,MGFA Post-Intervention Status
NCT00727194,measures_secondary,MG-Activity of Daily Living Profile
NCT00727194,has_criteria,16 weeks
NCT05526391,involves,Multiple System Atrophy
NCT05526391,evaluates,TAK-341
NCT05526391,measures_primary,Change from Baseline
NCT05526391,measures_secondary,UMSARS Part I
NCT05526391,has_criteria,Up to 52 weeks
NCT02379091,involves,Rheumatoid Arthritis
NCT02379091,evaluates,Namilumab
NCT02379091,evaluates,Methotrexate
NCT02379091,measures_primary,DAS28-CRP at Week 12
NCT02379091,measures_secondary,ACR20
NCT02379091,measures_secondary,ACR50
NCT02379091,measures_secondary,ACR70
NCT02379091,has_criteria,Moderate to Severe
NCT05183594,involves,Tourette Syndrome
NCT05183594,evaluates,TSUPPORT
NCT05183594,measures_primary,YGTSS total tic score
NCT05183594,measures_secondary,YGTSS tic-related impairment
NCT05183594,measures_secondary,TS-CGI severity
NCT05183594,has_criteria,≥ 30% reduction
NCT06297291,involves,Hypertension
NCT06297291,evaluates,Global Paradise System
NCT06297291,measures_primary,Group Mean BP reduction
NCT06297291,measures_secondary,Subject Responder
NCT06297291,has_criteria,Signed informed consent
NCT00357994,involves,Parkinson's Disease
NCT00357994,evaluates,Levodopa-Carbidopa Intestinal Gel
NCT00357994,measures_primary,"Change in ""Off"" Time"
NCT00357994,measures_secondary,"Change in ""On"" Time Without Troublesome Dyskinesia"
NCT00357994,measures_secondary,Parkinson's Disease Questionnaire (PDQ-39) Summary Index
NCT00357994,has_criteria,Levodopa-Responsive
NCT01553591,involves,Diarrhea-Predominant Irritable Bowel Syndrome
NCT01553591,evaluates,Eluxadoline
NCT01553591,measures_primary,Composite Responder
NCT01553591,measures_secondary,Daily Worst Abdominal Pain
NCT01553591,measures_secondary,Daily Stool Consistency
NCT01553591,has_criteria,≥30% improvement
NCT03710694,involves,Clostridium difficile Infection
NCT03710694,evaluates,DAV132
NCT03710694,measures_primary,Proportion of patients with CDI
NCT03710694,measures_secondary,Proportion of patients with AAD
NCT03710694,measures_secondary,Plasma levels of FQs
NCT03710694,measures_secondary,Level of free fecal concentrations of FQs
NCT03710694,measures_secondary,Level of α-diversity of the intestinal microbiota
NCT03710694,measures_secondary,Change from D1 of α-diversity of the intestinal microbiota
NCT03710694,measures_secondary,Levels of β-diversity of the intestinal microbiota
NCT03710694,has_criteria,Duration of treatment with FQs
NCT05261191,involves,HIV-1
NCT05261191,evaluates,MGD020
NCT05261191,evaluates,MGD014
NCT05261191,measures_primary,adverse events
NCT05261191,measures_primary,serious adverse events
NCT05261191,measures_primary,treatment discontinuation
NCT05261191,has_criteria,antiretroviral therapy
NCT04538794,involves,Chronic Spontaneous Urticaria
NCT04538794,evaluates,CDX-0159
NCT04538794,measures_primary,Urticaria Activity Score
NCT04538794,measures_secondary,Hives Severity Score
NCT04538794,measures_secondary,Itch Severity Score
NCT04538794,measures_secondary,Urticaria Control Test
NCT04538794,has_criteria,18-75 years old
NCT04538794,has_criteria,Chronic Spontaneous Urticaria
NCT04538794,has_criteria,H1-antihistamines
NCT04538794,has_criteria,6 months diagnosis
NCT04736394,involves,Non-muscle Invasive Bladder Cancer
NCT04736394,evaluates,APL-1202
NCT04736394,evaluates,Epirubicin Hydrochloride
NCT04736394,measures_primary,Event-free survival
NCT04736394,measures_secondary,Overall survival
NCT04736394,measures_secondary,Recurrence-free rate
NCT04736394,measures_secondary,Progression-free rate
NCT04736394,measures_secondary,Clinical benefit rates
NCT04736394,measures_secondary,Change from Baseline in EORTC-QLQ-C30 Global Health Status/Quality of Life Total Score
NCT04736394,measures_secondary,Change from Baseline in EORTC-QLQ-Non-muscle Invasive Bladder Cancer Module 24 Total Score
NCT04736394,has_criteria,naïve Intermediate-risk
NCT03228394,involves,Postpartum Depression
NCT03228394,evaluates,Intravenous Ganaxolone
NCT03228394,measures_primary,Change From Baseline HAMD17 Total Score
NCT03228394,measures_secondary,Change From Baseline HAMD17 Total Score
NCT03228394,has_criteria,Day 1 assessment
NCT02562573,involves,Type 2 Diabetes
NCT02562573,evaluates,PBI-4050
NCT02562573,measures_primary,waist circumference
NCT02562573,measures_secondary,biomarkers
NCT02562573,measures_secondary,antidiabetic treatment
NCT02562573,measures_secondary,triglycerides
NCT02562573,measures_secondary,BP
NCT02562573,measures_secondary,HDL-C
NCT02562573,measures_secondary,fasting plasma glucose
NCT02562573,has_criteria,Metabolic Syndrome
NCT04204473,involves,Non-small Cell Lung Cancer
NCT04204473,evaluates,TY-9591
NCT04204473,measures_primary,Maximum Tolerated Dose
NCT04204473,measures_secondary,Overall Response Rate
NCT04204473,has_criteria,EGFR Positive Mutation
NCT06335173,involves,Early Alzheimer's Disease
NCT06335173,evaluates,Intravenous Sabirnetug
NCT06335173,measures_primary,Change from Baseline in iADRS Score
NCT06335173,measures_secondary,Change from Baseline in ADCS-iADL Score
NCT06335173,measures_secondary,Change from Baseline in ADAS-Cog13 Score
NCT06335173,has_criteria,Baseline up to Week 80
NCT01722331,involves,Chronic Plaque Psoriasis
NCT01722331,evaluates,MK-3222
NCT01722331,measures_primary,PASI-75 Response
NCT01722331,measures_secondary,PGA Score
NCT01722331,has_criteria,Adverse Event
NCT03371082,involves,Type 1 Diabetes
NCT03371082,evaluates,Insulin Glargine
NCT03371082,measures_primary,Change in HbA1c
NCT03371082,measures_secondary,TI-AIA development
NCT03371082,has_criteria,Male or nonpregnant
NCT02524782,involves,Type 2 Diabetes
NCT02524782,evaluates,MEDI4166
NCT02524782,measures_primary,glucose AUC
NCT02524782,measures_secondary,LDL-C
NCT02524782,has_criteria,43 days post dosing
NCT01968031,involves,Parkinson's Disease
NCT01968031,evaluates,Oral Istradefylline
NCT01968031,measures_primary,Hours of OFF State
NCT01968031,measures_secondary,Hours of ON Time
NCT01968031,has_criteria,Moderate to Severe
NCT02016482,involves,Chronic Plaque Psoriasis
NCT02016482,involves,Nail Psoriasis
NCT02016482,evaluates,Adalimumab
NCT02016482,measures_primary,mNAPSI 75 Response
NCT02016482,measures_secondary,PGA-F
NCT02016482,measures_secondary,Percent Change NAPSI
NCT02016482,has_criteria,United States
NCT02074982,involves,Plaque-type Psoriasis
NCT02074982,evaluates,Secukinumab
NCT02074982,evaluates,Ustekinumab
NCT02074982,measures_primary,PASI 90 at Week 16
NCT02074982,measures_secondary,PASI 75 at Week 4
NCT02074982,measures_secondary,PASI 90 at Week 52
NCT02074982,has_criteria,Moderate to Severe Plaque Psoriasis
NCT01881282,involves,Hemorrhoids
NCT01881282,evaluates,Compound Carraghenates Cream
NCT01881282,evaluates,Mayinglong Musk Hemorrhoid Ointment
NCT01881282,measures_primary,Pain Acting Time
NCT01881282,measures_secondary,Pain Intensity Score
NCT01881282,measures_secondary,Daily Duration of Symptoms
NCT01881282,measures_secondary,Frequency of Defecation
NCT01881282,measures_secondary,Participants' Satisfaction
NCT01881282,measures_secondary,Assessment of Other Symptoms
NCT01881282,has_criteria,Day 1 up to Day 7
NCT04528082,involves,Behçet's Disease
NCT04528082,evaluates,Apremilast
NCT04528082,measures_primary,AUCw0-12
NCT04528082,measures_secondary,Change from Week 0 to Week 12 in the Pain of Oral Ulcers
NCT04528082,measures_secondary,Complete Response Rate for Oral Ulcers
NCT04528082,measures_secondary,Proportion of Participants at Week 12 Whose Number of Oral Ulcers is Reduced by Greater Than or Equal to 50% from Week 0
NCT04528082,measures_secondary,Complete Response Rate for Genital Ulcers
NCT04528082,measures_secondary,Change from Week 0 to Week 12 in Disease Activity
NCT04528082,has_criteria,oral ulcers
NCT01648582,involves,Type 2 Diabetes Mellitus
NCT01648582,evaluates,Dulaglutide
NCT01648582,evaluates,Insulin Glargine
NCT01648582,measures_primary,Change From Baseline in HbA1c
NCT01648582,measures_secondary,Percentage of Participants Attaining HbA1c of <7% or ≤6.5%
NCT01648582,measures_secondary,Change From Baseline in Fasting Blood Glucose
NCT01648582,measures_secondary,Change From Baseline in 7-point Self-monitored Blood Glucose Profiles
NCT01648582,has_criteria,7-point SMBG profiles
NCT04637282,involves,CLN3 disease
NCT04637282,evaluates,PLX-200
NCT04637282,measures_primary,motor score change
NCT04637282,measures_secondary,overall decline status
NCT04637282,has_criteria,escalating oral doses
NCT03985982,involves,Glabellar Lines
NCT03985982,evaluates,Botulinum Toxin
NCT03985982,measures_primary,Facial Wrinkle Scale score
NCT03985982,measures_secondary,Percentage of responders
NCT03985982,has_criteria,Inclusion Criteria
NCT06637631,involves,Crohn's Disease
NCT06637631,evaluates,SAR441566
NCT06637631,measures_primary,Endoscopic response
NCT06637631,measures_secondary,Clinical remission
NCT06637631,measures_secondary,Patient-Reported Outcome
NCT06637631,has_criteria,CDAI score <150
NCT03770182,involves,Alzheimer's disease
NCT03770182,evaluates,ADAS
NCT03770182,measures_primary,cognitive efficacy
NCT03770182,measures_secondary,behavioral dysfunctions
NCT03770182,has_criteria,cognitive impairment
NCT02947620,involves,Type II Diabetes
NCT02947620,involves,Dyslipidemia
NCT02947620,evaluates,Metformin 1500 mg
NCT02947620,evaluates,Atorvastatin 40 mg
NCT02947620,measures_primary,Change in HbA1c
NCT02947620,measures_primary,Change in LDL-C
NCT02947620,measures_secondary,Change in HbA1c after 16 weeks
NCT02947620,measures_secondary,Change in LDL-C after 16 weeks
NCT02947620,measures_secondary,Percentage of subjects reaching LDL-C treatment goal
NCT02947620,measures_secondary,Percentage of subjects reaching HbA1c <7.0% and <6.5%
NCT02947620,measures_secondary,Change in lipid variables
NCT02947620,measures_secondary,Change in average fasting plasma glucose
NCT02947620,has_criteria,NCEP ATP III guideline
NCT03393520,involves,Alzheimer's Disease
NCT03393520,evaluates,AVP-786
NCT03393520,measures_primary,Change from Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score
NCT03393520,measures_secondary,Change from Baseline to Week 12 in the Clinical Global Impression of Severity (CGIS)-Agitation Domain Score
NCT03393520,has_criteria,Diagnosis of probable Alzheimer's Disease according to the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) working groups criteria
NCT03393520,has_criteria,clinically significant
NCT03393520,has_criteria,Clinical Global Impression of Severity of Illness scale for Agitation (CGIS-Agitation) score of ≥ 4 (moderately ill)
NCT03393520,has_criteria,reliable caregiver
NCT01294982,involves,Overactive Bladder
NCT01294982,evaluates,AOBO-001
NCT01294982,measures_primary,Change in micturitions
NCT01294982,measures_secondary,Urge incontinence episodes
NCT01294982,measures_secondary,Volume voided per micturition
NCT01294982,measures_secondary,Intensity of urgency episodes
NCT01294982,measures_secondary,Daytime and sleeptime micturitions
NCT01294982,measures_secondary,Weekly urge incontinence episodes
NCT01294982,measures_secondary,PPBC score
NCT01294982,has_criteria,Treatment-emergent adverse events
NCT05915182,involves,Chronic Obstructive Pulmonary Disease
NCT05915182,evaluates,Budesonide
NCT05915182,measures_primary,Change from baseline CAT
NCT05915182,measures_secondary,Percentage of CAT responders
NCT05915182,has_criteria,Dual LAMA/LABA or ICS/LABA
NCT02422940,involves,chronic post-ischemic stroke
NCT02422940,evaluates,dalfampridine-ER
NCT02422940,measures_primary,Serious Adverse Events
NCT02422940,measures_secondary,Two-Minute Walk Test
NCT02422940,measures_secondary,10 Meter Walk Test
NCT02422940,measures_secondary,Timed up and Go Test
NCT02422940,measures_secondary,Walking Impact Scale
NCT02422940,has_criteria,completed placebo-controlled study
NCT02300844,involves,Overweight
NCT02300844,involves,Obese
NCT02300844,involves,Normal weight
NCT02300844,evaluates,NNC0174-0833
NCT02300844,measures_primary,Number of TEAEs
NCT02300844,measures_secondary,Area under the curve
NCT02300844,measures_secondary,Maximum concentration
NCT02300844,measures_secondary,Time to maximum concentration
NCT02300844,has_criteria,BMI 20.0-35.0 kg/m^2
NCT02300844,has_criteria,Age 22-64 years
NCT02300844,has_criteria,Male
NCT02300844,has_criteria,reproductive age
NCT01838044,involves,Chronic Low Back Pain
NCT01838044,involves,Neuropathic Component
NCT01838044,evaluates,Celecoxib
NCT01838044,evaluates,Pregabalin
NCT01838044,evaluates,Celecoxib Monotherapy
NCT01838044,measures_primary,Pain Numeric Rating Scale
NCT01838044,measures_secondary,Benefit
NCT01838044,measures_secondary,Satisfaction
NCT01838044,measures_secondary,Willingness to Continue
NCT01838044,has_criteria,Baseline and Week 5
NCT01838044,has_criteria,Week 5 and Week 10
NCT01838044,has_criteria,Baseline and Week 10
NCT00044044,involves,Schizophrenia
NCT00044044,evaluates,Study Drug
NCT00044044,evaluates,Placebo
NCT00044044,evaluates,Haloperidol
NCT00044044,measures_primary,BPRS Total Score
NCT00044044,measures_primary,PANSS Scores
NCT00044044,measures_primary,CGI-S Scores
NCT00044044,measures_primary,MADRS Scores
NCT00044044,has_criteria,Baseline and 6 weeks
NCT00111540,involves,Type 2 Diabetes
NCT00111540,evaluates,Exenatide
NCT00111540,measures_primary,Change in HbA1c
NCT00111540,measures_secondary,Change in body weight
NCT00111540,measures_secondary,Change in fasting plasma glucose
NCT00111540,measures_secondary,Change in lipids
NCT00111540,has_criteria,HbA1c value <=11.0%
NCT00111540,has_criteria,BMI 25 kg/m^2 to 45 kg/m^2
NCT01661140,involves,Rheumatoid Arthritis
NCT01661140,evaluates,RoActemra
NCT01661140,evaluates,Methotrexate
NCT01661140,measures_primary,DAS28 score at Week 60
NCT01661140,measures_secondary,DAS28 score at Week 72
NCT01661140,has_criteria,Disease Activity Score In 28 Joints
NCT02724644,involves,Edematous Fibrosclerotic Panniculopathy
NCT02724644,evaluates,EN3835
NCT02724644,measures_primary,Composite Responders
NCT02724644,measures_secondary,Composite Responders
NCT02724644,has_criteria,2-level improvement
NCT00202644,involves,Essential Thrombocythemia
NCT00202644,evaluates,Anagrelide
NCT00202644,evaluates,Hydroxyurea
NCT00202644,measures_primary,Change From Baseline in LVEF
NCT00202644,measures_secondary,Platelet Count at Month 6
NCT00202644,measures_secondary,Percentage of Participants With Complete Response
NCT00202644,measures_secondary,Percentage of Participants With Partial Response
NCT00202644,measures_secondary,Time to Complete Response
NCT00202644,measures_secondary,Time to Partial Response
NCT00202644,measures_secondary,Number of Participants With Thrombotic and Haemorrhagic Events
NCT00202644,has_criteria,Platelet count of less than 400x10\^9/Liter
NCT00202644,has_criteria,platelet count of 400-600 x 10\^9/Liter
NCT00202644,has_criteria,reduction in platelet count of at least 200 x 10\^9/Liter from baseline
NCT06397144,involves,Healthy Participants
NCT06397144,evaluates,Nirmatrelvir Plus Ritonavir
NCT06397144,measures_primary,AUC from time zero
NCT06397144,measures_secondary,Cmax for nirmatrelvir
NCT06397144,has_criteria,Overtly healthy
NCT06397144,has_criteria,BMI 16-32 kg/m2
NCT05686044,involves,Alzheimer's Disease
NCT05686044,evaluates,Buntanetap
NCT05686044,measures_primary,ADAS-Cog 11
NCT05686044,measures_secondary,ADCS-CGIC
NCT05686044,has_criteria,Mild to Moderate AD
NCT00378092,involves,Schizophrenia
NCT00378092,evaluates,Risperidone Long-Acting Injection
NCT00378092,measures_primary,Time to Relapse
NCT00378092,measures_secondary,Change From Baseline
NCT00378092,has_criteria,24 Months Treatment
NCT01458340,involves,Attention-Deficit/Hyperactivity Disorder
NCT01458340,evaluates,TD-9855
NCT01458340,measures_primary,Change From Baseline
NCT01458340,measures_secondary,Change From Baseline
NCT01458340,has_criteria,Adults
NCT01252940,evaluates,Emtricitabine/Rilpivirine/Tenofovir DF
NCT01252940,measures_primary,HIV-1 RNA < 50 copies/mL
NCT01252940,measures_secondary,CD4 count
NCT01252940,measures_secondary,Fasting total cholesterol
NCT02660944,involves,Systemic Lupus Erythematosus
NCT02660944,evaluates,RSLV-132
NCT02660944,measures_primary,CLASI Improvement
NCT02660944,measures_secondary,Percentage of Participants Achieving a 50% Improvement in CLASI Activity Score
NCT02660944,has_criteria,CLASI score greater than or equal to 10 at Baseline
NCT02660944,has_criteria,Positive for one or more RNA autoantibodies
NCT02660944,has_criteria,severe
NCT02660944,has_criteria,severe renal involvement at Screening
NCT02660944,has_criteria,use of cyclophosphamide within 3 months of the Baseline visit
NCT02660944,has_criteria,use of rituximab within 6 months of the Baseline visit
NCT02660944,has_criteria,use of belimumab within 3 months of the Baseline visit
NCT02660944,has_criteria,use of background medications within 1 month of Baseline in excess of: i. mycophenolate mofetil \> 3 g/day; ii. azathioprine \> 200 mg/day; iii. methotrexate \> 25 mg/day; iv. hydroxychloroquine \> 400 mg/day; v. prednisone (or equivalent) \> 15 mg/day
NCT02660944,has_criteria,use of an intravenous steroid pulse within 2 months of Baseline
NCT04830644,involves,Primary Sjogren's Syndrome
NCT04830644,evaluates,Iguratimod
NCT04830644,evaluates,Placebo
NCT04830644,measures_primary,Change From Baseline in ESSDAI
NCT04830644,measures_secondary,Change From Baseline in ESSPRI
NCT04830644,measures_secondary,Change From Baseline in Unstimulated Salivary Flow
NCT04830644,measures_secondary,Change From Baseline in Schirmer's Test
NCT04830644,measures_secondary,Change From Baseline in IgG
NCT04830644,measures_secondary,Change From Baseline in IgA
NCT04830644,measures_secondary,Change From Baseline in IgM
NCT04830644,measures_secondary,Change From Baseline in RF
NCT04830644,has_criteria,Active Primary Sjogren's Syndrome
NCT00359944,involves,Alzheimer's Disease
NCT00359944,evaluates,AC-3933
NCT00359944,measures_primary,ADAS-COG total score
NCT00359944,measures_secondary,CIBIC-Plus
NCT00359944,measures_secondary,Disability Assessment for Dementia
NCT00359944,has_criteria,Mild to moderate Alzheimer's
NCT02677844,evaluates,Abemaciclib
NCT02677844,measures_primary,ΔΔQTcF
NCT02677844,measures_secondary,Cmax
NCT02677844,measures_secondary,AUC(0-tlast)
NCT02677844,has_criteria,Healthy Participants
NCT01186744,involves,Chronic Plaque Psoriasis
NCT01186744,evaluates,CP-690
NCT01186744,measures_primary,PASI75 Response
NCT01186744,measures_secondary,Physician's Global Assessment
NCT01186744,has_criteria,Greater Than 50% Reduction
NCT01098240,involves,Major Depression
NCT01098240,evaluates,CP-601
NCT01098240,measures_primary,MADRS Total Score
NCT01098240,measures_secondary,HAM-D25 Total Score
NCT01098240,measures_secondary,Bech Melancholia Subscale Score
NCT01098240,has_criteria,double-blind baseline
NCT02757144,involves,Healthy Male Volunteers
NCT02757144,evaluates,DWP14012
NCT02757144,measures_primary,Number of Adverse Events
NCT02757144,measures_secondary,Clinically Significant Vital Sign findings
NCT02757144,measures_secondary,Clinically Significant Electrocardiogram findings
NCT02757144,measures_secondary,Clinically Significant Laboratory results
NCT02757144,has_criteria,Day -2(Randomization) to Day 11~18(Post-study visit)
NCT00844844,involves,aHUS
NCT00844844,evaluates,eculizumab
NCT00844844,measures_primary,platelet count change
NCT00844844,measures_secondary,Hematologic Normalization
NCT00844844,measures_secondary,Complete TMA Response
NCT00844844,measures_secondary,TMA Intervention Rate
NCT00844844,has_criteria,plasma therapy-resistant
NCT05260073,involves,Actinic Keratosis
NCT05260073,evaluates,Tirbanibulin
NCT05260073,measures_primary,IGA success
NCT05260073,measures_secondary,Skindex-16 score
NCT05260073,has_criteria,Clinically typical AK lesions
NCT00509873,involves,Bacterial Conjunctivitis
NCT00509873,evaluates,Gatifloxacin
NCT00509873,measures_primary,Clearing of Conjunctivitis
NCT00509873,measures_secondary,Microbiological Cure
NCT00509873,measures_secondary,Clinical Improvement
NCT00509873,measures_secondary,Clinical Improvement of Ocular Symptoms
NCT00509873,has_criteria,Conjunctival Hyperemia
NCT02567773,evaluates,GSK2881078
NCT02567773,measures_primary,AUC0-t
NCT02567773,measures_secondary,Blood pressure
NCT02567773,measures_secondary,Heart rate
NCT02567773,measures_secondary,Cardiac telemetry
NCT02567773,measures_secondary,Electrocardiogram
NCT02567773,measures_secondary,Adverse events
NCT02567773,has_criteria,Up to Day 70
NCT02567773,has_criteria,Up to Day 28
NCT02567773,has_criteria,Up to Day 14-15
NCT02567773,has_criteria,Up to Day 28-30
NCT04707573,involves,Chronic Kidney Disease
NCT04707573,evaluates,AKB-6548
NCT04707573,measures_primary,Clinically Significant Changes
NCT04707573,measures_secondary,Adverse Events
NCT04707573,has_criteria,Stages 3 and 4
NCT05423873,involves,Facial Hyperpigmentation
NCT05423873,involves,Photodamaged Skin
NCT05423873,evaluates,Dual Skincare Regimen Treatment
NCT05423873,measures_primary,Investigator Clinical Grading
NCT05423873,measures_secondary,Adverse events
NCT05423873,has_criteria,Extrinsic Factors of Aging
NCT01551173,involves,Primary Hypercholesterolemia
NCT01551173,involves,Mixed Dyslipidemia
NCT01551173,evaluates,Fluvastatin Sodium Extended Release Tablets
NCT01551173,measures_primary,Percent Change LDL-C
NCT01551173,measures_secondary,Proportion Achieving LDL-C Goal
NCT01551173,has_criteria,LDL-C levels
NCT05295173,involves,Acute Ischemic Stroke
NCT05295173,evaluates,r-PA
NCT05295173,measures_primary,Functional handicap
NCT05295173,measures_primary,mRS 0 to 1
NCT05295173,measures_secondary,Neurological Improvement
NCT05295173,measures_secondary,NIHSS score ≤1
NCT05295173,measures_secondary,Barthel Index score ≥95
NCT05295173,has_criteria,90th day after treatment
NCT05984927,involves,Wet Age-Related Macular Degeneration
NCT05984927,evaluates,NG101 AAV Gene Therapy
NCT05984927,measures_primary,Best Corrected Visual Acuity
NCT05984927,measures_secondary,Cumulative Number of Rescue Therapy Injections
NCT05984927,has_criteria,age 50-89 years
NCT00757627,involves,Osteoarthritis
NCT00757627,evaluates,Etoricoxib
NCT00757627,measures_primary,Pain intensity decrease
NCT00757627,measures_secondary,WOMAC domain scores
NCT00757627,measures_secondary,Physicians' Global Assessment
NCT00757627,has_criteria,IGART categories
NCT00757627,has_criteria,EQ-5D categories
NCT03714373,involves,Prader-Willi Syndrome
NCT03714373,evaluates,DCCR
NCT03714373,measures_primary,HQ-CT Total Score
NCT03714373,measures_secondary,Body Fat Mass
NCT03714373,measures_secondary,Clinical Global Impression of Improvement
NCT03714373,measures_secondary,Clinical Global Impression of Severity
NCT03714373,has_criteria,at least one dose
NCT02281773,involves,Schizophrenia
NCT02281773,evaluates,BI 409306
NCT02281773,measures_primary,MCCB composite score
NCT02281773,measures_secondary,Serious Adverse Events
NCT02281773,measures_secondary,Protocol-specified Adverse Events of Special Interest
NCT02281773,measures_secondary,Dramatic Worsening of Disease State
NCT02281773,has_criteria,Stable Antipsychotic Treatment
NCT05322473,involves,Hidradenitis Suppurativa
NCT05322473,evaluates,Sonelokimab
NCT05322473,measures_primary,HiSCR75
NCT05322473,measures_secondary,IHS4
NCT05322473,measures_secondary,DLQI
NCT05322473,measures_secondary,Reduction NRS30 PGA Skin Pain
NCT05322473,has_criteria,≥18 years of age
NCT05236673,involves,Chronic Heart Failure
NCT05236673,evaluates,Jardiance
NCT05236673,measures_primary,Hospitalization for heart failure
NCT05236673,measures_secondary,Cardiovascular death
NCT05236673,measures_secondary,NYHA functional class
NCT05236673,measures_secondary,Ejection fraction
NCT05236673,measures_secondary,BNP or NT-proBNP
NCT05236673,measures_secondary,HbA1c
NCT05236673,measures_secondary,Fasting Plasma Glucose
NCT03462173,evaluates,DAG181
NCT03462173,measures_primary,Cmax
NCT03462173,measures_primary,Tmax
NCT03462173,measures_primary,AUC
NCT03462173,measures_primary,T1/2
NCT03462173,has_criteria,Healthy subjects
NCT03462173,has_criteria,18-45 years
NCT03462173,has_criteria,BMI 19-25 kg/m2
NCT03462173,has_criteria,No gastric acid inhibitors
NCT03462173,has_criteria,No immune system disease
NCT00559273,involves,Chronic Kidney Disease
NCT00559273,evaluates,Mircera
NCT00559273,measures_primary,Hemoglobin Response
NCT00559273,measures_secondary,Time to Hb response
NCT00559273,has_criteria,Anemia
NCT03627065,involves,Primary Sjögren's Syndrome
NCT03627065,evaluates,INCB050465
NCT03627065,measures_primary,Salivary Gland Ultrasound Score
NCT03627065,measures_secondary,Salivary CXCL13 Levels
NCT03627065,measures_secondary,Number of Participants With Treatment-emergent Adverse Events
NCT03627065,measures_secondary,Change in Whole Salivary Flow
NCT03627065,measures_secondary,Change in EULAR Sjögren's Syndrome Disease Activity Index
NCT03627065,measures_secondary,Change in EULAR Sjögren's Syndrome Patient Reported Index
NCT03627065,has_criteria,Up to 21 weeks
NCT01649765,involves,Systemic lupus erythematosus
NCT01649765,evaluates,Belimumab
NCT01649765,measures_primary,SRI response
NCT01649765,measures_secondary,PRINTO/ACR Juvenile SLE Response Evaluation
NCT01649765,has_criteria,SLEDAI score <=12
NCT02254265,involves,Keratoconjunctivitis Sicca
NCT02254265,evaluates,OTX-101
NCT02254265,measures_primary,Lissamine green score
NCT02254265,measures_secondary,Global symptom score
NCT02254265,measures_secondary,Tear Film Break up Time
NCT02254265,measures_secondary,Corneal Staining Score
NCT02254265,measures_secondary,Schirmer's Test
NCT02254265,measures_secondary,Patient Satisfaction
NCT02254265,has_criteria,Age 18 years or older
NCT01628965,involves,Early Parkinson's Disease
NCT01628965,evaluates,SPM 962
NCT01628965,measures_primary,UPDRS Part 2 sum score
NCT01628965,measures_primary,UPDRS Part 3 sum score
NCT01628965,measures_secondary,Adverse Events
NCT01628965,measures_secondary,Vital Signs
NCT01628965,measures_secondary,Laboratory Parameters
NCT01628965,has_criteria,Completed trial 243-07-001
NCT01628965,has_criteria,Discontinued trial 243-07-001
NCT01628965,has_criteria,Serious adverse event
NCT01649466,involves,Type 2 Diabetes Mellitus
NCT01649466,evaluates,Vildagliptin
NCT01649466,evaluates,NPH insulin add-on to glimepiride
NCT01649466,measures_primary,HbA1c below 7.0% without hypoglycemia
NCT01649466,measures_primary,weight gain
NCT01649466,measures_secondary,confirmed hypoglycemic events
NCT01649466,measures_secondary,severe hypoglycemic events
NCT01649466,measures_secondary,symptomatic hypoglycemic events
NCT01649466,measures_secondary,body weight
NCT01649466,measures_secondary,HbA1c
NCT01649466,has_criteria,24 weeks
NCT02931565,involves,Achalasia
NCT02931565,evaluates,IW-1701
NCT02931565,measures_primary,Supine BFT
NCT02931565,measures_secondary,Upright BFT
NCT02931565,has_criteria,Type I or II
NCT02194465,involves,Hypertension
NCT02194465,evaluates,LY2623091
NCT02194465,measures_primary,Change in SBP
NCT02194465,measures_primary,Change in DBP
NCT02194465,measures_primary,Change in ABPM
NCT02194465,measures_primary,Change in Serum Potassium
NCT02194465,measures_secondary,Cmax of LY2623091
NCT02194465,has_criteria,History of hypertension
NCT02194465,has_criteria,Seated SBP
NCT02194465,has_criteria,Stable antihypertensive dose
NCT04124965,involves,Generalized Myasthenia Gravis
NCT04124965,evaluates,Rozanolixizumab
NCT04124965,measures_primary,Change From Baseline
NCT04124965,measures_secondary,Percentage of Participants With TEAEs
NCT04124965,has_criteria,Adult Patients
NCT01360866,involves,Major Depressive Disorder
NCT01360866,evaluates,OPC-34712
NCT01360866,measures_primary,CGI-S Score
NCT01360866,measures_secondary,CGI-I Score
NCT01360866,measures_secondary,Sheehan Disability Scale
NCT01360866,has_criteria,screening to week 52/early termination
NCT00846365,involves,Hypertension
NCT00846365,evaluates,Azilsartan Medoxomil
NCT00846365,evaluates,Chlorthalidone
NCT00846365,measures_primary,Systolic blood pressure
NCT00846365,measures_secondary,Diastolic blood pressure
NCT00846365,has_criteria,Baseline and Week 8
NCT00846365,has_criteria,Baseline and Week 4
NCT00846365,has_criteria,Baseline
NCT06206265,involves,Irritable Bowel Syndrome
NCT06206265,evaluates,Psilocybin
NCT06206265,measures_primary,Stool consistency
NCT06206265,measures_secondary,Stool frequency
NCT06206265,measures_secondary,Abdominal pain
NCT06206265,has_criteria,IBS-Diarrhea
NCT06206265,has_criteria,IBS-Mixed
NCT06206265,has_criteria,IBS-Constipation
NCT03615066,involves,Chronic Hepatitis B
NCT03615066,evaluates,Selgantolimod
NCT03615066,measures_primary,qHBsAg decline
NCT03615066,measures_secondary,Treatment-Emergent Adverse Events
NCT03615066,measures_secondary,Treatment-Emergent Laboratory Abnormalities
NCT03615066,has_criteria,Viremic adult participants
NCT02295865,involves,Plaque-type Psoriasis
NCT02295865,evaluates,Toreforant
NCT02295865,measures_primary,PASI 75 Response
NCT02295865,measures_secondary,Investigator's Global Assessment
NCT02295865,measures_secondary,PASI 50
NCT02295865,measures_secondary,PASI 75
NCT02295865,measures_secondary,PASI 90
NCT02295865,measures_secondary,PASI 100
NCT02295865,has_criteria,moderate to severe
NCT01890265,involves,Idiopathic Pulmonary Fibrosis
NCT01890265,evaluates,FG-3019
NCT01890265,measures_primary,FVC (% predicted)
NCT01890265,measures_secondary,HRCT Quantitative Lung Fibrosis Score
NCT01890265,has_criteria,IPF progression events
NCT00762073,involves,Eosinophilic Esophagitis
NCT00762073,evaluates,Oral Viscous Budesonide
NCT00762073,measures_primary,Percent of Response
NCT00762073,measures_secondary,Histologic Response
NCT00762073,measures_secondary,Histologic Remission
NCT00762073,has_criteria,≤6 eosinophils/high power field
NCT02406027,involves,Early Alzheimer's Disease
NCT02406027,evaluates,JNJ-54861911
NCT02406027,measures_primary,Percent Change CSF ABeta
NCT02406027,measures_secondary,Treatment-emergent Adverse Events
NCT02406027,has_criteria,Cognitively and functionally normal
NCT05418673,involves,Parkinson's Disease
NCT05418673,evaluates,BIIB122 Tablets
NCT05418673,measures_primary,Time to Confirmed Worsening
NCT05418673,measures_secondary,Number of Participants With TEAEs and SAEs
NCT05418673,has_criteria,LRRK2 genetic variants
NCT02181673,involves,Psoriatic Arthritis
NCT02181673,evaluates,Golimumab
NCT02181673,measures_primary,ACR 20 Response
NCT02181673,measures_secondary,HAQ-DI Score
NCT02181673,has_criteria,swollen joint count
NCT04456673,involves,COPD
NCT04456673,evaluates,Dupilumab
NCT04456673,measures_primary,Annual rate AECOPD
NCT04456673,measures_secondary,Change pre-bronchodilator FEV1
NCT04456673,measures_secondary,Change SGRQ total score
NCT04456673,has_criteria,Moderate to severe COPD
NCT01757873,involves,Postherpetic Neuralgia
NCT01757873,evaluates,Z160
NCT01757873,measures_primary,Pain Intensity-Numeric Rating Scale
NCT01757873,measures_secondary,Neuropathic Pain Scale
NCT01757873,measures_secondary,Patient Global Impression of Change
NCT01757873,measures_secondary,Profile of Mood States
NCT01757873,measures_secondary,Daily Sleep Interference Scale
NCT01757873,measures_secondary,Short Form 36
NCT01757873,has_criteria,Baseline to Week 6
NCT04022473,involves,Gastrointestinal symptoms
NCT04022473,evaluates,Bafiertam™
NCT04022473,evaluates,Tecfidera
NCT04022473,measures_primary,MOGISS composite score
NCT04022473,measures_secondary,Number of days with GI symptom
NCT04022473,measures_secondary,AUC in MOGISS total score
NCT04022473,has_criteria,Males or non-pregnant females
NCT02415127,involves,Friedreich's Ataxia
NCT02415127,evaluates,ACTIMMUNE®
NCT02415127,measures_primary,Change From Baseline
NCT02415127,measures_secondary,Activities of Daily Living
NCT02415127,measures_secondary,Timed 25-Foot Walk
NCT02415127,has_criteria,Dose Escalation
NCT01987427,involves,Overweight
NCT01987427,involves,Obese
NCT01987427,evaluates,Lorcaserin
NCT01987427,evaluates,Phentermine-HCl
NCT01987427,measures_primary,Body Weight
NCT01987427,measures_secondary,Waist Circumference
NCT01987427,measures_secondary,Hip Circumference
NCT01987427,measures_secondary,Waist to Hip Ratio
NCT01987427,has_criteria,Adults
NCT05251727,involves,Metastatic Colorectal Cancer
NCT05251727,evaluates,ART-123
NCT05251727,evaluates,FOLFOX
NCT05251727,evaluates,Bevacizumab
NCT05251727,measures_primary,Treatment-emergent Adverse Events
NCT05251727,measures_secondary,Serious TEAEs
NCT05251727,measures_secondary,TEAEs Leading to Death
NCT05251727,measures_secondary,TEAEs Leading to IMP Discontinuation
NCT05251727,measures_secondary,Bleeding Events
NCT05251727,measures_secondary,Serious Bleeding Events
NCT05251727,measures_secondary,Dose Limiting Toxicity
NCT05251727,has_criteria,IMP dose
NCT03141073,involves,T2DM
NCT03141073,evaluates,HMS5552
NCT03141073,measures_primary,Change from baseline HbA1c
NCT03141073,measures_secondary,2h-PPG from baseline
NCT03141073,measures_secondary,Fasting plasma glucose from baseline
NCT03141073,measures_secondary,HbA1c < 7.0%
NCT03141073,has_criteria,T2DM subjects
NCT02294227,involves,Psoriatic Arthritis
NCT02294227,evaluates,Secukinumab
NCT02294227,measures_primary,ACR20 response
NCT02294227,measures_secondary,DAS-CRP score change
NCT02294227,measures_secondary,PASI75
NCT02294227,measures_secondary,SF-36-PCS
NCT02294227,has_criteria,Swollen and tender joint count
NCT00822744,involves,Major Depressive Disorder
NCT00822744,evaluates,SSR411298
NCT00822744,measures_primary,HAM-D total score
NCT00822744,measures_secondary,MADRS total score
NCT00822744,measures_secondary,CGI scores
NCT00822744,measures_secondary,HAM-D depressed mood
NCT00822744,measures_secondary,Geriatric Depression Scale
NCT00822744,measures_secondary,Sheehan Disability Scale
NCT00822744,measures_secondary,Hamilton Anxiety Rating scale
NCT05583344,involves,NASH
NCT05583344,evaluates,GSK4532990
NCT05583344,measures_primary,Histological Fibrosis
NCT05583344,measures_secondary,Pro-C3
NCT05583344,measures_secondary,Liver fat
NCT05583344,measures_secondary,Liver stiffness
NCT05583344,measures_secondary,ELF Score
NCT05583344,has_criteria,Clinical research network
NCT00856544,involves,Rheumatoid Arthritis
NCT00856544,evaluates,CP-690
NCT00856544,evaluates,Placebo
NCT00856544,measures_primary,ACR20 response
NCT00856544,measures_secondary,HAQ-DI Score
NCT00856544,has_criteria,other arthritis medications
NCT00783692,involves,Crohn's Disease
NCT00783692,evaluates,Vedolizumab
NCT00783692,measures_primary,Clinical Remission
NCT00783692,measures_secondary,Enhanced Clinical Response
NCT00783692,has_criteria,moderate to severe
NCT00461292,involves,Neurogenic Overactive Bladder
NCT00461292,evaluates,Botulinum Toxin Type A
NCT00461292,measures_primary,Change in incontinence episodes
NCT00461292,measures_secondary,Maximum Cystometric Capacity
NCT00461292,measures_secondary,Maximum Detrusor Pressure
NCT00461292,measures_secondary,Incontinence Quality of Life
NCT00461292,has_criteria,spinal cord injury
NCT00461292,has_criteria,multiple sclerosis
NCT00461292,has_criteria,inadequate response
NCT05169580,involves,sickle cell disease
NCT05169580,evaluates,FTX-6058
NCT05169580,measures_primary,%HbF biomarkers
NCT05169580,measures_secondary,Reticulocytes
NCT05169580,measures_secondary,Absolute Reticulocyte Count
NCT05169580,measures_secondary,Red cell distribution width
NCT05169580,measures_secondary,unconjugated bilirubin
NCT05169580,has_criteria,18 to 65 years old
NCT05169580,has_criteria,SCD pain crisis
NCT01377844,involves,Type 2 Diabetes Mellitus
NCT01377844,evaluates,EGT0001442
NCT01377844,measures_primary,Change From Baseline in HbA1c
NCT01377844,measures_secondary,Changes in Systolic and Diastolic Blood Pressure
NCT01377844,measures_secondary,Changes in Body Weight
NCT01377844,has_criteria,Male or female subjects
NCT01377844,has_criteria,≥18 years old
NCT01377844,has_criteria,HbA1c 7 to 10%
NCT01377844,has_criteria,FPG \<250 mg/dL
NCT01377844,has_criteria,Diet and exercise only
NCT01377844,has_criteria,One approved oral anti-diabetic agent
NCT02229344,involves,Ulcerative Colitis
NCT02229344,measures_primary,Total Number of Relapses
NCT02229344,measures_secondary,Percentage of Participants With Sustained Remission
NCT02229344,has_criteria,increase in Mayo or partial Mayo score
NCT01516892,involves,chronic migraine
NCT01516892,evaluates,BOTOX
NCT01516892,measures_primary,Headache Days
NCT01516892,measures_secondary,HIT-6 Total Score
NCT01516892,has_criteria,Diagnosis of chronic migraine
NCT01516892,has_criteria,≥15 days per month
NCT01516892,has_criteria,headache lasting 4 hours
NCT01516892,has_criteria,Exclusion Criteria
NCT01516892,has_criteria,myasthenia gravis
NCT01516892,has_criteria,Eaton-Lambert Syndrome
NCT01516892,has_criteria,amyotrophic lateral sclerosis
NCT01516892,has_criteria,Headache attributed to another disorder
NCT01516892,has_criteria,Infection or skin disorder
NCT01516892,has_criteria,Previous treatment with botulinum toxin
NCT02291029,involves,Primary Sjögren's Syndrome
NCT02291029,evaluates,CFZ533
NCT02291029,measures_primary,Change in ESSDAI
NCT02291029,measures_secondary,ESSPRI
NCT02291029,measures_secondary,Physician Global Assessment
NCT02291029,measures_secondary,Patient's Global Assessment
NCT02291029,measures_secondary,SF-36 Physical Component Score
NCT02291029,has_criteria,Baseline and Week 12
NCT02587065,involves,Convenience Satisfaction
NCT02587065,evaluates,Plegridy
NCT02587065,measures_primary,Change From Baseline
NCT02587065,measures_secondary,Number of Participants
NCT02587065,has_criteria,Adherence to Study Treatment
NCT01959165,involves,Ulcerative Colitis
NCT01959165,evaluates,MEDI7183
NCT01959165,measures_primary,Remission at Week 8
NCT01959165,measures_secondary,Response at Week 8
NCT01959165,measures_secondary,Mucosal Healing at Week 8
NCT01959165,measures_secondary,Response at Week 12
NCT01959165,has_criteria,Moderate to severe active UC
NCT01959165,has_criteria,inadequate response to immunomodulators
NCT01959165,has_criteria,intolerance to Anti- TNF-α agents
NCT00797966,involves,Major Depressive Disorder
NCT00797966,evaluates,OPC-34712
NCT00797966,measures_primary,MADRS Total Score
NCT00797966,measures_secondary,CGI-S Score
NCT00797966,measures_secondary,QLES-Q-SF Subscale Score
NCT00797966,has_criteria,Week 8 to Week 14
NCT01163266,involves,Major Depressive Disorder
NCT01163266,evaluates,Vortioxetine
NCT01163266,measures_primary,MADRS Total Score
NCT01163266,measures_secondary,CGI-I Score
NCT01163266,has_criteria,Baseline Hami...
NCT04469465,involves,Paroxysmal Nocturnal Hemoglobinuria
NCT04469465,evaluates,Danicopan
NCT04469465,measures_primary,Change From Baseline in Hgb
NCT04469465,measures_secondary,Percentage of Participants With Hgb Increase
NCT04469465,measures_secondary,Percentage of Participants With Transfusion Avoidance
NCT04469465,has_criteria,≥2 Grams/Deciliter increase in Hgb
NCT04469465,has_criteria,transfusion free during the 12-Week TP1
NCT04469465,has_criteria,transfusion free from Week 1 through Week 12
NCT03760965,involves,Type 2 Diabetes Mellitus
NCT03760965,evaluates,Sotagliflozin
NCT03760965,measures_primary,Change in HbA1c
NCT03760965,measures_secondary,Change in 2-hour PPG
NCT03760965,measures_secondary,Change in fasting plasma glucose
NCT03760965,measures_secondary,Change in body weight
NCT03760965,measures_secondary,Change in systolic blood pressure
NCT03760965,has_criteria,Chinese patients
NCT03760965,has_criteria,Diet and exercise
NCT03760965,has_criteria,Signed informed consent
NCT03760965,has_criteria,Age ≥18 years
NCT03760965,has_criteria,Type 2 Diabetes
NCT03760965,has_criteria,HbA1c 7-10%
NCT03760965,has_criteria,Fasting plasma glucose 15-270 mg/dL
NCT03760965,has_criteria,BMI 20-45 kg/m²
NCT04722666,involves,Major Depressive Disorder
NCT04722666,evaluates,MIJ821
NCT04722666,measures_primary,MADRS total score
NCT04722666,measures_secondary,treatment-emergent adverse events
NCT04722666,measures_secondary,adverse events of special interest
NCT04722666,has_criteria,≥50% reduction
NCT04722666,has_criteria,sustained response
NCT02255266,involves,Type 2 Diabetes
NCT02255266,evaluates,liraglutide
NCT02255266,measures_primary,HbA1c reduction
NCT02255266,measures_secondary,body weight
NCT02255266,has_criteria,age above 18 years
NCT01852565,evaluates,Diltiazem
NCT01852565,measures_primary,AUC(0-24h) darapladib
NCT01852565,measures_primary,Cmax darapladib
NCT01852565,measures_secondary,Number of adverse events
NCT01852565,measures_secondary,12-Lead electrocardiogram
NCT01852565,measures_secondary,Vital signs
NCT01852565,measures_secondary,Safety laboratory tests
NCT01852565,has_criteria,Up to 32 days
NCT01852565,has_criteria,Up to 70 days
NCT01852565,has_criteria,Up to 42 days
NCT01822665,involves,Gastrointestinal disease
NCT01822665,evaluates,Paracetamol Tablet
NCT01822665,evaluates,Ibuprofen Capsule
NCT01822665,evaluates,Ibuprofen Tablet
NCT01822665,evaluates,Placebo Tablet
NCT01822665,measures_primary,GMD Scores
NCT01822665,measures_primary,DMD Scores
NCT01822665,measures_secondary,Incidence of Gastric and/or Duodenal Mucosal Injury
NCT01822665,measures_secondary,Incidence of Fecal Occult Blood
NCT01822665,has_criteria,Body Mass Index 18-30 kg/m\^2
NCT01822665,has_criteria,Body Weight 60-80 kg
NCT01822665,has_criteria,normal stomach mucosa
NCT01822665,has_criteria,normal duodenum mucosa
NCT01822665,has_criteria,no gastrointestinal disease
NCT01822665,has_criteria,no history of renal disease
NCT01822665,has_criteria,no history of pulmonary edema
NCT01822665,has_criteria,no history of cardiomyopathy
NCT01822665,has_criteria,no history of liver disease
NCT01822665,has_criteria,no history of coagulation defects
NCT01822665,has_criteria,no history of bleeding diseases
NCT01822665,has_criteria,no history of anticoagulant therapy
NCT02850965,involves,Psoriasis
NCT02850965,evaluates,BI 695501
NCT02850965,evaluates,Humira
NCT02850965,measures_primary,PASI 75 Response
NCT02850965,measures_secondary,PASI 75 Response
NCT02850965,has_criteria,moderate to severe
NCT01725282,involves,Major Depressive Disorder
NCT01725282,evaluates,Quetiapine Extended Release (XR) (FK949E)
NCT01725282,measures_primary,Change From Baseline in MADRS Total Score
NCT01725282,measures_secondary,Change From Baseline in HAM-D17
NCT01725282,measures_secondary,Percentage of Participants With Improvement in CGI-I
NCT01725282,measures_secondary,Change From Baseline in SF-36
NCT01725282,has_criteria,Baseline and Week 6
NCT04531982,involves,Schizophrenia
NCT04531982,evaluates,Pimavanserin
NCT04531982,measures_primary,NSA-16 total score
NCT04531982,measures_secondary,CGI-SCH-S score
NCT04531982,measures_secondary,CGI-SCH-I score
NCT04531982,measures_secondary,PSP scale score
NCT04531982,has_criteria,26 Weeks Treatment Duration
NCT04663282,involves,Type 2 Diabetes
NCT04663282,evaluates,INS068
NCT04663282,measures_primary,Change in HbA1c
NCT04663282,measures_secondary,Proportion of subjects reaching HbA1c targets
NCT04663282,has_criteria,One or Two Oral Antidiabetics
NCT04251182,involves,Mild-to-moderate AD
NCT04251182,evaluates,T3D-959
NCT04251182,measures_primary,Change in cognition
NCT04251182,measures_secondary,Change in global function
NCT04251182,measures_secondary,Change in executive function
NCT04251182,measures_secondary,Change in Aβ 42/40 ratio
NCT04251182,has_criteria,reliable caregiver
NCT04251182,has_criteria,clinical diagnosis
NCT04251182,has_criteria,mild-to-moderate AD
NCT01224782,involves,Secondary Hyperparathyroidism
NCT01224782,evaluates,Zemplar Capsules
NCT01224782,measures_primary,iPTH decrease
NCT01224782,measures_secondary,Hypercalcemia
NCT01224782,measures_secondary,Mean weekly dose
NCT01224782,has_criteria,Baseline iPTH values
NCT05889182,involves,Hidradenitis Suppurativa
NCT05889182,evaluates,Oral Upadacitinib
NCT05889182,measures_primary,HiSCR 50
NCT05889182,measures_primary,HiSCR 75
NCT05889182,measures_secondary,NRS30
NCT05889182,measures_secondary,HS Flare
NCT05889182,measures_secondary,HSSA
NCT05889182,has_criteria,Anti-TNF Therapy
NCT03875482,involves,Plaque Psoriasis
NCT03875482,evaluates,Risankizumab
NCT03875482,measures_primary,PASI 90 at Week 16
NCT03875482,measures_secondary,sPGA of Clear or Almost Clear at Week 16
NCT03875482,measures_secondary,PASI 100 at Week 16
NCT03875482,has_criteria,Moderate to Severe
NCT02151682,involves,Pain
NCT02151682,evaluates,Tapentadol Tablets
NCT02151682,measures_primary,Pain reduction
NCT02151682,measures_secondary,Constipation
NCT02151682,has_criteria,Responder criteria
NCT02914665,involves,Heart Failure
NCT02914665,evaluates,Elamipretide
NCT02914665,measures_primary,Change in NT-proBNP
NCT02914665,measures_secondary,Number of patients staying in the same functional renal function class
NCT02914665,has_criteria,History of chronic heart failure
NCT02914665,has_criteria,Treated with furosemide or bumetanide or torasemide
NCT02914665,has_criteria,In-hospital observation/admission and treatment
NCT02442765,involves,Dementia of the Alzheimer's Type
NCT02442765,evaluates,AVP-786
NCT02442765,measures_primary,Change From Baseline
NCT02442765,measures_secondary,mADCS-CGIC-Agitation Score
NCT02442765,has_criteria,Baseline CMAI Total score
NCT03257865,involves,Bipolar I Disorder
NCT03257865,evaluates,Brexpiprazole
NCT03257865,measures_primary,YMRS score
NCT03257865,measures_secondary,CGI-BP Severity
NCT03257865,has_criteria,18 to 65 years
NCT04248465,involves,Amyotrophic Lateral Sclerosis
NCT04248465,evaluates,Ravulizumab
NCT04248465,measures_primary,ALSFRS-R Total Score
NCT04248465,measures_secondary,Ventilator Assistance-free Survival
NCT04248465,measures_secondary,Percent Predicted Slow Vital Capacity
NCT04248465,has_criteria,Treatment-emergent Adverse Events
NCT03175120,involves,Type 2 Diabetes Mellitus
NCT03175120,evaluates,Insulin Degludec/Liraglutide
NCT03175120,evaluates,Insulin Degludec
NCT03175120,measures_primary,Change in HbA1c
NCT03175120,measures_secondary,Change in Body Weight
NCT03175120,measures_secondary,Number of Hypoglycaemic Episodes
NCT03175120,measures_secondary,Change in Fasting Plasma Glucose
NCT03175120,measures_secondary,Change in Waist Circumference
NCT03175120,measures_secondary,Change in Mean of SMPG Profile
NCT03175120,has_criteria,Basal Insulin Therapy
NCT03175120,has_criteria,Metformin
NCT03175120,has_criteria,One Other OAD
NCT01258920,involves,Schizophrenia
NCT01258920,evaluates,Paliperidone Palmitate
NCT01258920,measures_primary,PANSS total score
NCT01258920,measures_secondary,CGI-S score
NCT01258920,has_criteria,DSM-IV-TR diagnosis
NCT04925674,involves,End-Stage Renal Disease
NCT04925674,evaluates,HEC53856
NCT04925674,measures_primary,Hemoglobin response
NCT04925674,measures_secondary,Changes in mean hemoglobin
NCT04925674,measures_secondary,Serum lipid
NCT04925674,measures_secondary,Indicators of iron
NCT04925674,measures_secondary,High-sensitivity C-reactive protein
NCT04925674,measures_secondary,Reticulocytes
NCT04925674,measures_secondary,VEGF
NCT04925674,has_criteria,Dialysis
NCT02252965,involves,Type 2 Diabetes
NCT02252965,evaluates,Metformin Extended Release
NCT02252965,evaluates,Metformin Immediate Release
NCT02252965,measures_primary,Change From Baseline in HbA1c
NCT02252965,measures_secondary,Overall Gastrointestinal Tolerability
NCT02252965,measures_secondary,Fasting Plasma Glucose Level
NCT02252965,measures_secondary,2-Hour Postprandial Plasma Glucose Level
NCT02252965,measures_secondary,Percentage of Subjects With Hypoglycemia
NCT02252965,has_criteria,Baseline up to Week 16
NCT02597920,involves,deep venous thrombosis
NCT02597920,involves,pulmonary embolism
NCT02597920,involves,atrial fibrillation
NCT02597920,evaluates,Pradaxa®
NCT02597920,evaluates,VKA
NCT02597920,measures_primary,PACT-Q2 Scores
NCT02597920,measures_secondary,convenience dimension score
NCT02597920,measures_secondary,satisfaction dimension score
NCT02597920,has_criteria,treatment ongoing
NCT03737474,involves,Major Depressive Disorder
NCT03737474,evaluates,Brexpiprazole
NCT03737474,measures_primary,MADRS Total Scores
NCT03737474,measures_secondary,CGI-I Scale
NCT03737474,measures_secondary,CGI-S Scale
NCT03737474,has_criteria,Treatment-emergent adverse events
NCT01855074,involves,Schizophrenia
NCT01855074,involves,Schizophreniform Disorder
NCT01855074,involves,Schizoaffective Disorder
NCT01855074,evaluates,Risperidone Long-Acting Microspheres
NCT01855074,measures_primary,Change From Baseline
NCT01855074,measures_secondary,Clinical Global Impressions
NCT01855074,measures_secondary,Short Form-36
NCT01855074,measures_secondary,Global Assessment of Functioning
NCT01855074,has_criteria,Baseline and Week 26
NCT02958865,involves,Ulcerative Colitis
NCT02958865,evaluates,PF-06651600
NCT02958865,evaluates,PF-06700841
NCT02958865,evaluates,Placebo
NCT02958865,measures_primary,Total Mayo Score
NCT02958865,measures_secondary,Number of Participants With AEs
NCT02958865,measures_secondary,Number of Participants With SAEs
NCT02958865,measures_secondary,Discontinuation Due to AEs
NCT02958865,measures_secondary,Number of Participants With Laboratory Test Abnormalities
NCT02958865,has_criteria,pre-specified criteria
NCT02186665,involves,plaque psoriasis
NCT02186665,evaluates,Investigator's Global Assessment (IGA)
NCT02186665,measures_primary,IGA improvement 2 grades
NCT02186665,measures_secondary,severity rating
NCT02186665,has_criteria,2 to 12 years of age
NCT02186665,has_criteria,stable mild to moderate
NCT02186665,has_criteria,other forms of psoriasis
NCT02186665,has_criteria,hypercalcemia
NCT02186665,has_criteria,past history of kidney stones
NCT02186665,has_criteria,vitamin D deficiency
NCT02186665,has_criteria,other concomitant dermatological disease
NCT02634320,involves,Schizophrenia
NCT02634320,evaluates,Aripiprazole Lauroxil
NCT02634320,measures_primary,CGI-S score
NCT02634320,measures_secondary,BPRS score
NCT02634320,measures_secondary,Adverse Events
NCT02634320,measures_secondary,QLS
NCT02634320,has_criteria,Up to 7 months
NCT04897074,involves,ADHD
NCT04897074,evaluates,AKL-T01
NCT04897074,measures_primary,TOVA-Attention Comparison Score
NCT04897074,measures_secondary,ADHD Rating Scale-5
NCT04897074,has_criteria,clinician-administered questionnaire
NCT00301574,involves,Alzheimer's Disease
NCT00301574,evaluates,Galantamine
NCT00301574,measures_primary,ADAS-J cog
NCT00301574,measures_secondary,CIBIC plus-J
NCT00301574,measures_secondary,DAD
NCT00301574,measures_secondary,Behave-AD
NCT00301574,measures_secondary,MENFIS
NCT00301574,has_criteria,NINCDS-ADRDA criteria
NCT00301574,has_criteria,MMSE score 10-22
NCT00301574,has_criteria,ADAS-J cog score at least 18
NCT00301574,has_criteria,cognitive dysfunction 6 months
NCT00301574,has_criteria,neurodegenerative diseases other than Alzheimer's disease
NCT00301574,has_criteria,cognitive dysfunction due to cerebral damage
NCT00301574,has_criteria,multi-infarct dementia
NCT00301574,has_criteria,active cerebrovascular disease
NCT00301574,has_criteria,clinically significant cardiovascular disease
NCT00301574,has_criteria,cholinesterase inhibitors
NCT01323374,involves,fibromyalgia
NCT01323374,evaluates,droxidopa
NCT01323374,evaluates,droxidopa/carbidopa
NCT01323374,measures_primary,fibromyalgia pain
NCT01323374,measures_secondary,quality of life
NCT01323374,measures_secondary,signs and symptoms
NCT01323374,has_criteria,18 years or over
NCT01323374,has_criteria,American College of Rheumatology criteria
NCT02581865,involves,Tourette Syndrome
NCT02581865,evaluates,NBI-98854
NCT02581865,measures_primary,YGTSS TTS
NCT02581865,measures_secondary,CGI-TS-Improvement Score
NCT02581865,measures_secondary,CGI-Tics-Severity Score
NCT02581865,measures_secondary,RTRS Total Score
NCT02581865,has_criteria,Baseline
NCT01903265,involves,Fibromyalgia
NCT01903265,evaluates,TNX-102 SL
NCT01903265,measures_primary,Weekly average pain
NCT01903265,measures_secondary,PROMIS T-score
NCT01903265,measures_secondary,Patient Global Impression
NCT01903265,has_criteria,30% improvement
NCT06473974,involves,Facial Hyperpigmentation
NCT06473974,measures_primary,Overall hyperpigmentation score
NCT06473974,measures_secondary,Skin condition improvement
NCT06473974,measures_secondary,Satisfaction with test product
NCT06473974,has_criteria,Mild-to-moderate
NCT00516074,involves,Type 2 Diabetes
NCT00516074,evaluates,Exenatide
NCT00516074,measures_primary,Change in Heart Rate
NCT00516074,measures_secondary,Change in Systolic Blood Pressure
NCT00516074,measures_secondary,Change in Diastolic Blood Pressure
NCT00516074,measures_secondary,Change in HbA1c
NCT00516074,has_criteria,Diagnosed with type 2 diabetes
NCT00516074,has_criteria,Treated with metformin
NCT00516074,has_criteria,HbA1c between 6.5% and 9.5%
NCT00516074,has_criteria,BMI > 25 kg/m^2
NCT00516074,has_criteria,BMI < 40 kg/m^2
NCT00516074,has_criteria,Have not received exenatide
NCT00516074,has_criteria,Not participated in interventional study
NCT00516074,has_criteria,Not receiving beta blockers
NCT00348374,involves,Type 2 Diabetes
NCT00348374,evaluates,Exubera
NCT00348374,evaluates,Lispro
NCT00348374,measures_primary,Change From Baseline in HbA1c
NCT00348374,measures_secondary,Change in mean glycosylated hemoglobin A1c
NCT00348374,measures_secondary,Subjects That Attained Glycosylated Hemoglobin A1c
NCT00348374,measures_secondary,Subjects That Attained Glycosylated Hemoglobin A1c Target Levels
NCT00348374,measures_secondary,Change From Baseline in Fasting and 2-hour Postprandial Glucose
NCT00348374,measures_secondary,Change From Baseline in Fasting and Postprandial Plasma Glucose
NCT00348374,has_criteria,Subjects That Attained Glycosylated Hemoglobin A1c
NCT03888365,involves,Pulmonary Arterial Hypertension
NCT03888365,evaluates,Inhaled Treprostinil
NCT03888365,measures_primary,PGI-S Score
NCT03888365,measures_secondary,Shortness of breath
NCT03888365,measures_secondary,Fatigue
NCT03888365,has_criteria,Severity rating
NCT00313820,involves,Post-Stroke Central Neuropathic Pain
NCT00313820,evaluates,Pregabalin
NCT00313820,measures_primary,Mean Pain Score
NCT00313820,measures_secondary,30% Responder
NCT00313820,has_criteria,Baseline
NCT01294020,involves,Pediatric Allograft Recipients
NCT01294020,evaluates,Tacrolimus
NCT01294020,measures_primary,AUC0-24h Tacrolimus
NCT01294020,measures_secondary,Cmax Tacrolimus
NCT01294020,measures_secondary,tmax Tacrolimus
NCT01294020,measures_secondary,C24 Tacrolimus
NCT01294020,measures_secondary,Acute Rejections
NCT01294020,has_criteria,Stable Pediatric Allograft Recipients
NCT02585674,involves,Type 2 Diabetes Mellitus
NCT02585674,evaluates,MyStar DoseCoach
NCT02585674,measures_primary,Fasting SMPG target
NCT02585674,measures_secondary,FPG target range
NCT02585674,measures_secondary,FSMPG glucose change
NCT02585674,measures_secondary,HbA1c change
NCT02585674,measures_secondary,Hypoglycemic events
NCT02585674,measures_secondary,Adverse events
NCT02585674,has_criteria,Inclusion criteria
NCT00686374,involves,Crohn's disease
NCT00686374,evaluates,Adalimumab
NCT00686374,measures_primary,PCDAI clinical remission
NCT00686374,measures_secondary,CDAI clinical remission
NCT00686374,has_criteria,PCDAI ≤ 10
NCT03431974,involves,Psoriasis
NCT03431974,evaluates,Aminopterin
NCT03431974,measures_primary,PASI score
NCT03431974,measures_secondary,Static Physician Global Assessment
NCT03431974,has_criteria,>=75% reduction in PASI
NCT04845620,involves,Atopic Dermatitis
NCT04845620,evaluates,Roflumilast
NCT04845620,measures_primary,IGA Success
NCT04845620,measures_secondary,EASI-75
NCT04845620,has_criteria,vIGA-AD score
NCT01678820,involves,Type 2 Diabetes Mellitus
NCT01678820,evaluates,MK-0431D
NCT01678820,measures_primary,Change From Baseline in A1C
NCT01678820,measures_secondary,Number of Participants Who Experienced at Least One Adverse Event
NCT01678820,measures_secondary,Number of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01678820,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT01678820,has_criteria,Inadequate Glycemic Control on Metformin Monotherapy
NCT01583374,involves,Ankylosing Spondylitis
NCT01583374,evaluates,Apremilast
NCT01583374,measures_primary,ASAS 20 response
NCT01583374,measures_secondary,BASFI score
NCT01583374,has_criteria,Active Ankylosing Spondylitis
NCT05543174,involves,Alagille Syndrome
NCT05543174,evaluates,TAK-625
NCT05543174,measures_primary,Change in sBA
NCT05543174,measures_secondary,Pruritus Severity
NCT05543174,has_criteria,Baseline to Week 18
NCT02807974,involves,Hypertensive Patients
NCT02807974,involves,Type 2 Diabetes
NCT02807974,involves,Albuminuria
NCT02807974,evaluates,CS-3150
NCT02807974,measures_primary,Change in blood pressure
NCT02807974,measures_secondary,Proportion of patients achieving blood pressure control
NCT02807974,measures_secondary,Change rate in urine-albumin-to-creatinine ratio
NCT02807974,measures_secondary,Time course of urine-albumin-to-creatinine ratio
NCT02807974,has_criteria,Age 20 to 80 years
NCT02807974,has_criteria,Type 2 diabetes
NCT02807974,has_criteria,Albuminuria urine albumin-to-creatinine ratio ≥ 30
NCT02807974,has_criteria,Hypertension Sitting SBP ≥ 140 mmHg
NCT02807974,has_criteria,Treatment with ARB or ACE inhibitor
NCT02807974,has_criteria,eGFR ≥ 30 mL/min/1.73m\^2
NCT02807974,has_criteria,Exclusion: Secondary hypertension
NCT02807974,has_criteria,Exclusion: Malignant hypertension
NCT02807974,has_criteria,Exclusion: Type 1 diabetes
NCT02807974,has_criteria,Exclusion: Secondary glucose intolerance
NCT02807974,has_criteria,Exclusion: Non-diabetic nephropathy
NCT02807974,has_criteria,Exclusion: Serum potassium level \< 3.5 or ≥ 4.8 mEq/L
NCT01475474,involves,Accidental Bowel Leakage
NCT01475474,evaluates,Renew Insert
NCT01475474,measures_primary,Relative Percentage Change
NCT01475474,measures_primary,Wexner Score Reduction
NCT01475474,measures_secondary,Wexner Score
NCT01475474,has_criteria,Minimum Wexner score of 12
NCT01475474,has_criteria,Weekly leakage of stool
NCT01475474,has_criteria,No greater than 50% with daily uncontrolled gas
NCT01006265,involves,Relapsing-remitting Multiple Sclerosis
NCT01006265,evaluates,ACT-128800
NCT01006265,measures_primary,Annualized Relapse Rate
NCT01006265,measures_secondary,Number of Participants With First Confirmed Relapse
NCT01006265,has_criteria,Confirmed relapse EDSS score
NCT03855865,involves,Major Depressive Disorder
NCT03855865,evaluates,Rapastinel
NCT03855865,measures_primary,MADRS Total Score
NCT03855865,measures_secondary,MADRS Total Score
NCT03855865,has_criteria,DSM-5 criteria for MDD
NCT03855865,has_criteria,8 weeks to 18 months duration
NCT03855865,has_criteria,inadequate response to antidepressants
NCT03855865,has_criteria,female of childbearing potential
NCT03855865,has_criteria,negative serum β-hCG pregnancy test
NCT03855865,has_criteria,no other DSM-5 disorder
NCT03855865,has_criteria,no lifetime history of schizophrenia
NCT03855865,has_criteria,no lifetime history of bipolar disorder
NCT03855865,has_criteria,no lifetime history of major neurocognitive disorder
NCT03745820,involves,Cognitive Impairment Associated With Schizophrenia
NCT03745820,evaluates,BIIB104
NCT03745820,measures_primary,Change From Baseline in MCCB Working Memory Domain Score at Week 12
NCT03745820,measures_secondary,Number of Participants With Adverse Events
NCT03745820,has_criteria,From first dose of study drug through end of the study (up to Week 14)
NCT06616974,involves,Pulmonary Hypertension
NCT06616974,involves,Heart Failure With Preserved Ejection Fraction
NCT06616974,evaluates,TX000045
NCT06616974,measures_primary,Mean Pulmonary Vascular Resistance
NCT06616974,measures_secondary,6-minute walk test distance
NCT06616974,measures_secondary,Pulmonary capillary wedge pressure
NCT06616974,has_criteria,PVR greater than or equal to 3 wood units
NCT00739674,involves,Hypertension
NCT00739674,evaluates,Losartan
NCT00739674,measures_primary,Target Blood Pressure
NCT00739674,measures_secondary,Systolic Blood Pressure
NCT00739674,measures_secondary,Diastolic Blood Pressure
NCT00739674,has_criteria,Newly Diagnosed Hypertension
NCT00739674,has_criteria,Untreated Hypertension
NCT00551174,involves,Post-Menopausal Osteoporosis
NCT00551174,evaluates,Bonviva
NCT00551174,measures_primary,Relative Percent Change
NCT00551174,measures_secondary,Serum C-telopeptide
NCT00551174,has_criteria,Previous Bonviva Treatment
NCT04256174,involves,Atopic Dermatitis
NCT04256174,evaluates,AK120
NCT04256174,measures_primary,Change from baseline
NCT04256174,measures_secondary,Maximum observed serum concentration
NCT04256174,measures_secondary,Area under the concentration-time curve
NCT04256174,measures_secondary,Anti-drug antibodies
NCT04256174,measures_secondary,Investigator global assessment
NCT04256174,measures_secondary,Pruritus-Numeric Rating Scale
NCT04256174,has_criteria,From signing of informed consent
NCT05198674,involves,Hypertension
NCT05198674,evaluates,Symplicity Spyral RDN System
NCT05198674,measures_primary,Office Systolic Blood Pressure change
NCT05198674,measures_secondary,Home Blood Pressure change
NCT05198674,measures_secondary,24-hour ABPM
NCT05198674,measures_secondary,blood pressure control
NCT05198674,measures_secondary,anti-hypertensive medications
NCT05198674,has_criteria,systolic blood pressure ≥140 mmHg
NCT05198674,has_criteria,diastolic blood pressure ≥ 90 mmHg
NCT05198674,has_criteria,average systolic home blood pressure ≥135 mmHg
NCT00666965,involves,Restless Legs Syndrome
NCT00666965,evaluates,SPM 962
NCT00666965,measures_primary,IRLS Score Change
NCT00666965,measures_secondary,CGI Severity
NCT00666965,measures_secondary,PGI Improvement
NCT00666965,measures_secondary,PSQI
NCT00666965,has_criteria,Baseline
NCT06068465,involves,Parkinson's Disease Psychosis
NCT06068465,evaluates,Pimavanserin
NCT06068465,measures_primary,change in SAPS-PD
NCT06068465,measures_secondary,Antipsychotic Efficacy
NCT06068465,has_criteria,age 40 or older
NCT06068465,has_criteria,Parkinson's disease 1 year duration
NCT06068465,has_criteria,psychotic symptoms after diagnosis
NCT06068465,has_criteria,hallucinations and/or delusions
NCT06068465,has_criteria,psychotic symptoms 1 month duration
NCT06068465,has_criteria,symptoms severe enough for antipsychotic
NCT06068465,has_criteria,SAPS Hallucinations or Delusions score ≥3
NCT06068465,has_criteria,stable anti-Parkinson's medication 1 month
NCT04752566,involves,Guillain-Barré Syndrome
NCT04752566,evaluates,Eculizumab
NCT04752566,measures_primary,Time to FG <=1
NCT04752566,measures_secondary,Number of Participants With A Hughes Functional Grade (FG) Score <=1
NCT04752566,has_criteria,Hughes Functional Grade Score
NCT02386566,involves,Multiple Sclerosis
NCT02386566,evaluates,Natalizumab
NCT02386566,measures_primary,EDSS change
NCT02386566,measures_secondary,MusiQoL
NCT02386566,measures_secondary,EQ-5D
NCT02386566,measures_secondary,FSMC
NCT02386566,measures_secondary,MSISQ-19
NCT02386566,has_criteria,clinical disease-free
NCT04501666,involves,Prurigo Nodularis
NCT04501666,evaluates,Nemolizumab
NCT04501666,measures_primary,Peak Pruritus NRS
NCT04501666,measures_secondary,Investigator Global Assessment
NCT04501666,has_criteria,rescue therapy
NCT02322866,involves,Acne
NCT02322866,evaluates,Sarecycline
NCT02322866,measures_primary,Inflammatory Lesion Counts
NCT02322866,measures_secondary,Investigator's Global Assessment
NCT02322866,has_criteria,Baseline to Week 12
NCT04162366,involves,Uncontrolled Blood Pressure
NCT04162366,involves,Chronic Kidney Disease
NCT04162366,evaluates,Aprocitentan
NCT04162366,measures_primary,Systolic blood pressure
NCT04162366,measures_primary,Diastolic blood pressure
NCT04162366,measures_secondary,Urine albumin-to-creatinine ratio
NCT04162366,has_criteria,Anti-hypertensive medications
NCT04162366,has_criteria,Diuretic
NCT04162366,has_criteria,Uncontrolled blood pressure
NCT04162366,has_criteria,Chronic Kidney Disease stage 3 or 4
NCT04162366,has_criteria,Estimated Glomerular Filtration Rate
NCT04162366,has_criteria,Pregnancy test
NCT04162366,has_criteria,Contraception
NCT04162366,has_criteria,Mean sitting systolic blood pressure
NCT04162366,has_criteria,Mean sitting diastolic blood pressure
NCT04162366,has_criteria,Renal function hospitalization
NCT04162366,has_criteria,eGFR decline
NCT04512066,involves,Schizophrenia
NCT04512066,involves,Schizoaffective Disorder
NCT04512066,evaluates,RO6889450
NCT04512066,evaluates,Placebo
NCT04512066,measures_primary,PANSS Total Score
NCT04512066,measures_secondary,PANSS Factor Scores
NCT04512066,has_criteria,Acute Exacerbation
NCT01467726,involves,hypertension
NCT01467726,involves,hypercholesterolemia
NCT01467726,involves,diabetes mellitus
NCT01467726,involves,osteoarthritis
NCT01467726,evaluates,velusetrag
NCT01467726,measures_primary,tolerability
NCT01467726,measures_secondary,bowel movement frequency
NCT01467726,has_criteria,reasonably good health
NCT01467726,has_criteria,controlled disease
NCT01467726,has_criteria,mild deviations
NCT04707157,involves,Diabetic Peripheral Neuropathic Pain
NCT04707157,evaluates,LY3556050
NCT04707157,measures_primary,Change From Baseline
NCT04707157,measures_secondary,Brief Pain Inventory-Short Form Modified Total Pain Interference Score
NCT04707157,measures_secondary,Patient's Global Impression of Change
NCT04707157,has_criteria,Baseline
NCT04673357,involves,Crohn's Disease
NCT04673357,evaluates,Ustekinumab
NCT04673357,measures_primary,Clinical Remission
NCT04673357,measures_secondary,Adverse Events
NCT04673357,measures_secondary,Serious Adverse Events
NCT04673357,has_criteria,Pediatric Crohn's Disease
NCT02060526,involves,MPS IIIA Disease
NCT02060526,evaluates,rhHNS
NCT02060526,measures_primary,Overall Response
NCT02060526,measures_secondary,Serious Adverse Events
NCT02060526,measures_secondary,Treatment Emergent Adverse Events
NCT02060526,has_criteria,Early Stage
NCT01392326,involves,Psoriatic Arthritis
NCT01392326,evaluates,Secukinumab
NCT01392326,measures_primary,PASI 75
NCT01392326,measures_primary,PASI 90
NCT01392326,measures_secondary,DAS28-CRP
NCT01392326,has_criteria,≥3% Skin Involvement
NCT05318326,involves,Type 2 diabetes
NCT05318326,evaluates,Yogliptin Tablets
NCT05318326,measures_primary,HbA1c change from baseline
NCT05318326,measures_secondary,FPG Change From Baseline
NCT05318326,has_criteria,aged 18 to 75 years old
NCT05318326,has_criteria,HbA1c 7.5% to 11%
NCT05318326,has_criteria,FPG≤15.0mmol/L
NCT05318326,has_criteria,BMI 19.0kg/m2 to 35.0kg/m2
NCT04750226,involves,Parkinson's Disease
NCT04750226,evaluates,ABBV-951
NCT04750226,measures_primary,Percentage of AEs
NCT04750226,measures_secondary,Infusion Site Evaluation Scale
NCT04750226,has_criteria,Adult Participants
NCT01137526,involves,Alzheimer's Disease
NCT01137526,evaluates,ABT-384
NCT01137526,measures_primary,ADAS-cog total score
NCT01137526,measures_secondary,MMSE score
NCT01137526,measures_secondary,CIBIC-plus score
NCT01137526,measures_secondary,NPI score
NCT01137526,measures_secondary,ADCS-ADL score
NCT01137526,has_criteria,age 55-90 years
NCT01137526,has_criteria,NINCDS/ADRDA criteria
NCT01137526,has_criteria,MMSE score 10-24
NCT01137526,has_criteria,CSDD score ≤10
NCT01137526,has_criteria,good health
NCT01137526,has_criteria,postmenopausal 2 years
NCT01137526,has_criteria,surgically sterile
NCT01137526,has_criteria,reliable caregiver
NCT06177457,involves,Healthy Adult
NCT06177457,evaluates,PF-07293893
NCT06177457,measures_primary,Plasma Concentration
NCT06177457,measures_secondary,Area under curve
NCT06177457,has_criteria,Baseline up to 35 days
NCT03608657,involves,Psoriatic Arthritis
NCT03608657,evaluates,Apremilast
NCT03608657,measures_primary,Low Disease Activity
NCT03608657,measures_secondary,Tender Joint Count
NCT03608657,measures_secondary,Swollen Joint Count
NCT03608657,measures_secondary,Leeds Enthesitis Index
NCT03608657,measures_secondary,Leeds Dactylitis Index
NCT03608657,measures_secondary,Body Surface Area
NCT03608657,measures_secondary,Health Assessment Questionnaire Disability Index
NCT05626257,involves,Chronic Rhinosinusitis With Nasal Polyps
NCT05626257,evaluates,Xolair
NCT05626257,measures_primary,Change from baseline in SNOT-22
NCT05626257,measures_secondary,Incidences of AEs/ADRs
NCT05626257,has_criteria,Subject characteristics
NCT02626026,involves,Rheumatoid Arthritis
NCT02626026,evaluates,GS-4059
NCT02626026,measures_primary,Treatment-Emergent Adverse Events
NCT02626026,measures_secondary,Treatment-Emergent Laboratory Abnormalities
NCT02626026,measures_secondary,12-Lead Electrocardiogram Abnormalities
NCT02626026,measures_primary,Cmax
NCT02626026,has_criteria,Healthy Volunteers
NCT02626026,has_criteria,Participants With Rheumatoid Arthritis
NCT05254457,involves,Plantar Fibromatosis
NCT05254457,evaluates,EN3835
NCT05254457,measures_primary,Change from baseline
NCT05254457,measures_secondary,Pain Intensity Numerica...
NCT05254457,has_criteria,participants treated
NCT00934648,involves,Rheumatoid Arthritis
NCT00934648,evaluates,MabThera
NCT00934648,measures_primary,DAS28 response
NCT00934648,measures_secondary,Bone Density
NCT00934648,has_criteria,adult patients
NCT02093026,involves,Rheumatoid Arthritis
NCT02093026,evaluates,Rituximab
NCT02093026,measures_primary,ACR20 Response
NCT02093026,measures_secondary,Health Assessment Questionnaire
NCT02093026,has_criteria,Baseline
NCT02172326,involves,Chronic Obstructive Bronchitis
NCT02172326,evaluates,tiotropium
NCT02172326,measures_primary,FEV1 change
NCT02172326,measures_secondary,FVC change
NCT02172326,has_criteria,FEV1 ≤ 65% predicted
NCT02715726,involves,Hypercholesterolemia
NCT02715726,involves,Cardiovascular disease
NCT02715726,evaluates,Alirocumab
NCT02715726,evaluates,Ezetimibe
NCT02715726,measures_primary,Low Density Lipoprotein Cholesterol
NCT02715726,measures_secondary,Apolipoprotein B
NCT02715726,has_criteria,High cardiovascular risk
NCT00736957,involves,Chronic Pain
NCT00736957,evaluates,Tramadol Hydrochloride Plus Acetaminophen
NCT00736957,measures_primary,Change From Baseline
NCT00736957,measures_secondary,Pain Intensity Difference
NCT00736957,measures_secondary,Pain Relief
NCT00736957,has_criteria,Japanese Participants
NCT01767857,involves,Advanced Colorectal Cancer
NCT01767857,evaluates,Xilonix
NCT01767857,measures_primary,Overall Survival
NCT01767857,measures_secondary,Lean Body Mass
NCT01767857,measures_secondary,Symptom Scale
NCT01767857,measures_secondary,Global Health Status
NCT01767857,measures_secondary,Platelet Counts
NCT01767857,has_criteria,Up to 18 months
NCT00544557,involves,Ankylosing Spondylitis
NCT00544557,evaluates,Etanercept
NCT00544557,measures_primary,Partial Remission
NCT00544557,measures_secondary,Serious Adverse Events
NCT00544557,has_criteria,ASAS criteria
NCT01739348,involves,Alzheimer's Disease
NCT01739348,evaluates,Verubecestat
NCT01739348,measures_primary,ADAS-Cog score
NCT01739348,measures_secondary,ADCS-ADL score
NCT01739348,has_criteria,Baseline and week 78
NCT00304226,involves,Hypertension
NCT00304226,evaluates,Valsartan
NCT00304226,evaluates,Amlodipine
NCT00304226,measures_primary,Blood pressure < 140/90 mmHg
NCT00304226,measures_secondary,Time to < 140/90 mmHg
NCT00304226,measures_secondary,Change in blood pressure
NCT00304226,measures_secondary,Adverse events
NCT00304226,has_criteria,Stage/grade 1 or 2 hypertension
NCT00304226,has_criteria,MSSBP ≥ 140 mm Hg
NCT00304226,has_criteria,MSDBP ≥ 90 mm Hg
NCT00304226,has_criteria,Uncontrolled hypertension
NCT00304226,has_criteria,Blood pressure ≤ 160/100 mm Hg
NCT00304226,has_criteria,No current CCB treatment
NCT00304226,has_criteria,MSSBP < 180 mm Hg
NCT00304226,has_criteria,MSDBP < 110 mm Hg
NCT05718557,involves,Solid Tumors
NCT05718557,evaluates,PYX-106
NCT05718557,measures_primary,Objective Response Rate
NCT05718557,measures_secondary,Progression Free Survival
NCT05718557,has_criteria,relapsed
NCT04889157,involves,Type 2 Diabetes Mellitus
NCT04889157,evaluates,PF-06882961
NCT04889157,measures_primary,AUC24 of PF-06882961
NCT04889157,measures_primary,Cmax of PF-06882961
NCT04889157,measures_secondary,Clinically Significant Change
NCT04889157,has_criteria,Clinically Significant Change
NCT01706926,involves,Rheumatoid Arthritis
NCT01706926,evaluates,Mavrilimumab
NCT01706926,measures_primary,DAS28 (CRP) score
NCT01706926,measures_secondary,ACR20 Responses
NCT01706926,has_criteria,Treatment-Emergent Adverse Events
NCT05536726,involves,Plaque Psoriasis
NCT05536726,evaluates,Recombinant Anti-IL-17A Humanized Monoclonal Antibody
NCT05536726,measures_primary,PASI 75
NCT05536726,measures_secondary,PASI 90
NCT05536726,has_criteria,Chinese Participants
NCT03438266,involves,cheek augmentation
NCT03438266,evaluates,JUVÉDERM VOLUMA® XC Injectable Gel
NCT03438266,measures_primary,Change From Baseline in MFVDS Score
NCT03438266,measures_secondary,Percentage of Participants With at Least a 1-Point Improvement in MFVDS Score
NCT03438266,measures_secondary,Change From Baseline in FACE-Q Satisfaction With Cheeks Questionnaire Score
NCT03438266,measures_secondary,Number of Participants With Treatment-Emergent Adverse Events
NCT03438266,has_criteria,Baseline (Screening) to Month 1
NCT04033926,involves,Polymyositis
NCT04033926,involves,Dermatomyositis
NCT04033926,evaluates,Zetomipzomib
NCT04033926,evaluates,KZR-616
NCT04033926,measures_primary,Mean change TIS
NCT04033926,measures_secondary,TIS Response
NCT04033926,measures_secondary,IMACS DOI
NCT04033926,measures_secondary,Mean percent change CSAMs
NCT04033926,has_criteria,≥ 20 points TIS
NCT02477020,involves,Schizophrenia
NCT02477020,evaluates,TAK-063
NCT02477020,measures_primary,Change From Baseline
NCT02477020,measures_secondary,PANSS Total Score
NCT02477020,has_criteria,Acute Exacerbation
NCT00240474,involves,Systolic Hypertension
NCT00240474,evaluates,Telmisartan + Hydrochlorothiazide
NCT00240474,evaluates,Amlodipine + Hydrochlorothiazide
NCT00240474,measures_primary,Change from baseline SBP
NCT00240474,measures_secondary,Change from baseline DBP
NCT00240474,measures_secondary,Change from baseline pulse pressure
NCT00240474,measures_secondary,Change from baseline HRQL
NCT00240474,measures_secondary,Proportion of patients achieving target response
NCT00240474,measures_secondary,Proportion of patients achieving SBP control
NCT00240474,measures_secondary,Proportion of patients achieving normal blood pressure
NCT00240474,measures_secondary,Proportion of patients achieving high-normal blood pressure
NCT00240474,has_criteria,aged at least 60 years old
NCT00240474,has_criteria,mean SBP greater than 140 mmHg
NCT00240474,has_criteria,mean DBP less than or equal to 95 mmHg
NCT00240474,has_criteria,24-hour mean ambulatory SBP greater than 125 mmHg
NCT00240474,has_criteria,hypertensive patients not on current antihypertensive therapy
NCT00240474,has_criteria,willing and able to provide written informed consent
NCT01900665,involves,Mild Alzheimer's Disease
NCT01900665,evaluates,Solanezumab
NCT01900665,measures_primary,ADAS-Cog14
NCT01900665,measures_secondary,ADCS-iADL
NCT01900665,measures_secondary,ADAS-Cog11
NCT01104766,involves,Schizophrenia
NCT01104766,evaluates,Cariprazine
NCT01104766,measures_primary,PANSS Total Score
NCT01104766,measures_secondary,CGI-S
NCT01104766,has_criteria,Informed consent
NCT02230566,involves,Mucopolysaccharidosis Type 7
NCT02230566,evaluates,UX003 Recombinant Human Betaglucuronidase
NCT02230566,measures_primary,Multi-Domain Responder Index
NCT02230566,measures_secondary,Percentage Change From Baseline
NCT02230566,has_criteria,Baseline to 24 weeks
NCT06174766,involves,Essential Hypertension
NCT06174766,evaluates,HGP2102
NCT06174766,measures_primary,Change from baseline
NCT06174766,measures_secondary,Blood pressure control
NCT06174766,has_criteria,sitSBP\<180 mmHg
NCT01727726,involves,Major Depressive Disorder
NCT01727726,evaluates,brexpiprazole
NCT01727726,measures_primary,MADRS Total Score
NCT01727726,measures_secondary,Sheehan Disability Scale
NCT01727726,has_criteria,Randomization Visit
NCT05905926,involves,IBS-C
NCT05905926,evaluates,Tenapanor
NCT05905926,measures_primary,% adverse events
NCT05905926,measures_secondary,ALT serum chemistry
NCT05905926,measures_secondary,AST serum chemistry
NCT05905926,measures_secondary,serum creatinine
NCT05905926,has_criteria,Pediatric Patients
NCT05905926,has_criteria,6 to Less Than 18 Years Old
NCT03095066,involves,Traumatic Brain Injury
NCT03095066,evaluates,AVP-786
NCT03095066,measures_primary,Change from Baseline to Week 12 in the Composite of the Clinical Impression Severity Scores on the Neuropsychiatric Inventory Clinician Rating Scale (NPI-C) Subscales of Aggression
NCT03095066,measures_secondary,Change from Baseline to Week 12 in Modified Clinical Global Impression of Change (mCGI-C) Raw Scores
NCT03095066,measures_secondary,Change from Baseline to Week 12 in NPI-C Rating Scale Subscales Scores for Aggression
NCT03095066,measures_secondary,Change from Baseline to Week 12 in Modified Clinical Global Impression of Severity (mCGI-S) Scale Scores
NCT03095066,has_criteria,Baseline; Week 12
NCT06163326,involves,Nonsegmental Vitiligo
NCT06163326,evaluates,Ritlecitinib
NCT06163326,measures_primary,T-VASI75 response
NCT06163326,measures_secondary,F-VASI75 response
NCT06163326,has_criteria,Screening up to at least 30 days
NCT04668157,involves,Hypertension
NCT04668157,evaluates,TAK-536
NCT04668157,measures_primary,Diastolic blood pressure
NCT04668157,measures_primary,Systolic blood pressure
NCT04668157,measures_secondary,Target blood pressure
NCT04668157,has_criteria,Informed consent
NCT04668157,has_criteria,Diagnosis hypertension
NCT03837457,involves,Mycosis Fungoides
NCT03837457,evaluates,Cobomarsen
NCT03837457,measures_primary,Progression-free survival
NCT03837457,measures_secondary,Pruritis Numerical Rating Scale
NCT03837457,measures_secondary,Skindex-29 Dermatological Survey
NCT03837457,measures_secondary,Pain Numerical Rating Scale
NCT03837457,measures_secondary,Difference in drug tolerability
NCT03837457,measures_secondary,Duration of composite global response
NCT03837457,has_criteria,Completed the SOLAR Study
NCT00911157,involves,Deep Vein Thrombosis
NCT00911157,evaluates,Fondaparinux Sodium
NCT00911157,measures_primary,Recurrent VTE
NCT00911157,measures_secondary,Perfusion Lung Scan
NCT00911157,measures_secondary,Bleeding Event
NCT00911157,has_criteria,Day 5 to Day 10
NCT02023866,involves,Mitochondrial Disease
NCT02023866,evaluates,RP103
NCT02023866,measures_primary,Change From Baseline in NPMDS
NCT02023866,measures_secondary,Glutathione
NCT02023866,measures_secondary,Glutathione Disulfide
NCT02023866,measures_secondary,Lactic Acid
NCT02023866,measures_secondary,6 Minute Walk Test
NCT02023866,has_criteria,two most preeminent symptoms
NCT00349466,involves,Keratoconjunctivitis Sicca
NCT00349466,evaluates,CF101
NCT00349466,measures_primary,Change From Baseline
NCT00349466,measures_secondary,Tear Break-Up Time
NCT00349466,measures_secondary,Fluorescein Staining
NCT00349466,measures_secondary,Dry Eye Symptom Score
NCT00349466,has_criteria,>25% Improvement
NCT02509026,involves,Non-radiographic axial spondyloarthritis
NCT02509026,evaluates,Etanercept
NCT02509026,measures_primary,Time to Flare
NCT02509026,measures_secondary,Percentage of Participants With Ankylosing Spondylitis Disease Activity Score (ASDAS) C-Reactive Protein (CRP) Less Than (<)1.3
NCT02509026,has_criteria,ASDAS-ESR level of >=2.1
NCT02246426,involves,Schizophrenia
NCT02246426,evaluates,Treatment
NCT02246426,measures_primary,Spatial Cognition
NCT02246426,measures_primary,UCSD Performance-based Skills Assessment
NCT02246426,measures_secondary,Emotion Recognition
NCT02246426,measures_secondary,Prosody Identification
NCT02246426,measures_secondary,Facial Memory
NCT02246426,measures_secondary,Emotional Intelligence
NCT02246426,measures_secondary,Empathic Accuracy
NCT02246426,measures_secondary,Household Chores
NCT02246426,measures_secondary,Communication
NCT02246426,measures_secondary,Finance
NCT02246426,measures_secondary,Transportation
NCT02246426,measures_secondary,Planning Recreational Activities
NCT02246426,has_criteria,schizophrenia patients
NCT05287126,involves,Ulcerative Colitis
NCT05287126,evaluates,Etrasimod
NCT05287126,measures_primary,Clinical Remission
NCT05287126,measures_secondary,Endoscopic Improvement
NCT05287126,measures_secondary,Symptomatic Remission
NCT05287126,has_criteria,Corticosteroids
NCT02537626,involves,Alzheimer's Disease
NCT02537626,evaluates,Low Level Laser Light Therapy
NCT02537626,measures_primary,ADAS-Cog Score
NCT02537626,measures_secondary,ADCS-ADL
NCT02537626,has_criteria,4 months
NCT03653026,involves,Ulcerative Colitis
NCT03653026,evaluates,Upadacitinib
NCT03653026,measures_primary,Clinical Remission
NCT03653026,measures_secondary,Endoscopic Improvement
NCT03653026,measures_secondary,Endoscopic Remission
NCT03653026,measures_secondary,Clinical Response
NCT03653026,has_criteria,Adapted Mayo score
NCT00868166,involves,Amyotrophic Lateral Sclerosis
NCT00868166,evaluates,TRO19622
NCT00868166,measures_primary,Overall Survival Rate
NCT00868166,measures_secondary,ALSFRS-R
NCT00868166,has_criteria,Month 1
NCT00838526,involves,erosive gastroesophageal reflux disease
NCT00838526,evaluates,Rabeprazole Extended-Release 50 mg
NCT00838526,evaluates,Ranitidine 150 mg
NCT00838526,measures_primary,Maintenance of complete healing
NCT00838526,measures_secondary,Sustained Resolution of Heartburn
NCT00838526,measures_secondary,Adverse Events
NCT00838526,has_criteria,Baseline to Week 26
NCT03759366,involves,Generalized Myasthenia Gravis
NCT03759366,evaluates,Eculizumab
NCT03759366,measures_primary,Change From Baseline
NCT03759366,measures_secondary,MG-ADL Total Score
NCT03759366,has_criteria,Pediatric Participants
NCT06132126,involves,Type 2 Diabetes Mellitus
NCT06132126,evaluates,LY3938577
NCT06132126,measures_primary,Incidence of Hypoglycemia
NCT06132126,measures_secondary,Number of Participants With Clinically Significant Changes in Vital Signs
NCT06132126,measures_secondary,Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters
NCT06132126,has_criteria,overtly healthy
NCT06132126,has_criteria,T2DM diagnosed
NCT06132126,has_criteria,body mass index
NCT06299826,involves,Chronic Heart Failure
NCT06299826,evaluates,AZD5462
NCT06299826,measures_primary,Echocardiography Parameters
NCT06299826,measures_secondary,Kansas City Cardiomyopathy Questionnaire
NCT06299826,measures_secondary,New York Heart Association Functional Class
NCT06299826,measures_secondary,cardiac biomarkers
NCT06299826,has_criteria,participants with HF
NCT01393626,involves,Crohn's Disease
NCT01393626,evaluates,CP-690
NCT01393626,measures_primary,Clinical Remission
NCT01393626,measures_secondary,Clinical Remission
NCT01393626,has_criteria,Moderate To Severe
NCT03393026,involves,Schizophrenia
NCT03393026,evaluates,Lurasidone HCl
NCT03393026,measures_primary,PANSS total scores
NCT03393026,measures_secondary,Clinical Global Impression-Improvement
NCT03393026,measures_secondary,Clinical Global Impression-Severity
NCT03393026,has_criteria,aged 20-75 years old
NCT05081557,involves,Atopic Dermatitis
NCT05081557,evaluates,Upadacitinib
NCT05081557,measures_primary,vIGA-AD 0/1
NCT05081557,measures_secondary,vIGA-AD 0/1
NCT05081557,has_criteria,>=12 Years Old
NCT01931566,involves,Mild Cognitive Impairment Due to Alzheimer's Disease
NCT01931566,evaluates,Pioglitazone
NCT01931566,measures_primary,Time to Diagnosis of MCI-AD
NCT01931566,measures_secondary,Change From Baseline for Cognitive Decline
NCT01931566,has_criteria,High-risk
NCT03880266,involves,Palmar Hyperhidrosis
NCT03880266,evaluates,Glycopyrronium Cloth
NCT03880266,measures_primary,Hand Sweating Severity Score
NCT03880266,measures_secondary,Gravimetrically-measured Sweat Production
NCT03880266,measures_secondary,Hyperhidrosis Disease Severity Scale
NCT03880266,has_criteria,Age ≥9 years
NCT03880266,has_criteria,Palmar hyperhidrosis 6 months
NCT03880266,has_criteria,Average sweat severity score ≥4
NCT03880266,has_criteria,HDSS 3 or 4
NCT04653766,evaluates,Ir-CPI
NCT04653766,measures_primary,Activated Partial Thromboplastin Time
NCT04653766,measures_secondary,Maximum Plasma Concentration
NCT04653766,measures_secondary,Time to Reach Maximum Plasma Concentration
NCT04653766,measures_secondary,Area Under the Plasma Concentration-time Curve
NCT04653766,has_criteria,Healthy Male Subjects
NCT03590366,involves,Rosacea
NCT03590366,evaluates,B244
NCT03590366,measures_primary,IGA Improvement
NCT03590366,measures_secondary,CEA Improvement
NCT03590366,measures_secondary,Skindex 16
NCT03590366,has_criteria,Baseline to Day 56
NCT01628926,involves,Parkinson's Disease
NCT01628926,evaluates,SPM 962
NCT01628926,measures_primary,UPDRS Part 3 Sum Score
NCT01628926,measures_secondary,UPDRS Part 2 Sum Score
NCT01628926,measures_secondary,Off Time
NCT01628926,measures_secondary,PDSS-2 sum score
NCT01628926,has_criteria,baseline
NCT02517866,involves,Essential Hypertension
NCT02517866,involves,Type 2 Diabetes
NCT02517866,evaluates,Azilsartan Medoxomil
NCT02517866,measures_primary,BP <140/85 mmHg
NCT02517866,measures_secondary,BP <130/80 mmHg
NCT02517866,has_criteria,Treatment-naïve
NCT04538066,involves,Alzheimer's Disease
NCT04538066,evaluates,Bryostatin
NCT04538066,measures_primary,Severe Impairment Battery Total Score
NCT04538066,measures_secondary,Changes From Baseline in SIB Total Scores
NCT04538066,has_criteria,moderate and severe AD
NCT05407766,involves,Crohn's disease
NCT05407766,evaluates,OSSM-001
NCT05407766,measures_primary,Fistula healing
NCT05407766,measures_secondary,Adverse events
NCT05407766,has_criteria,Refractory perianal
NCT05552326,involves,Severe Hypertriglyceridemia
NCT05552326,evaluates,Olezarsen
NCT05552326,measures_primary,Percent Change in Fasting TG
NCT05552326,measures_secondary,Proportion of Participants Achieving Fasting TG < 500 mg/dL
NCT05552326,has_criteria,Baseline TG ≥ 880 mg/dL
NCT04439526,involves,Psoriasis
NCT04439526,evaluates,Guselkumab
NCT04439526,measures_primary,sPGA Score Clear
NCT04439526,measures_secondary,sPGA Score Clear
NCT04439526,has_criteria,Naive or Bio-experienced
NCT06029426,involves,Major Depressive Disorder
NCT06029426,evaluates,Oral NMRA-335140
NCT06029426,measures_primary,Change from Baseline
NCT06029426,measures_secondary,Snaith-Hamilton Pleasure Scale
NCT06029426,has_criteria,DSM-5-TR diagnosis
NCT01448720,involves,Schizophrenia
NCT01448720,evaluates,Paliperidone Palmitate
NCT01448720,measures_primary,Change in PANSS
NCT01448720,measures_secondary,CGI-S scores
NCT01448720,measures_secondary,PSP
NCT01448720,has_criteria,DSM-IV diagnosis
NCT01448720,has_criteria,Schizophrenia diagnosis
NCT01448720,has_criteria,Physical examination
NCT01448720,has_criteria,Vital signs
NCT02756520,involves,chronic kidney disease
NCT02756520,evaluates,Ketosteril
NCT02756520,has_criteria,restricted protein diet
NCT00353574,involves,Resistant Hypertension
NCT00353574,evaluates,Darusentan
NCT00353574,measures_primary,Change in blood pressure
NCT00353574,measures_secondary,Ambulatory blood pressure
NCT00353574,has_criteria,Guideline-recommended antihypertensive drugs
NCT00353574,has_criteria,Diuretic
NCT00353574,has_criteria,Endothelin receptor antagonist
NCT01471574,involves,Hepatitis C Virus
NCT01471574,involves,HIV Virus
NCT01471574,evaluates,Daclatasvir
NCT01471574,evaluates,Pegylated Interferon-Alfa 2a
NCT01471574,evaluates,Ribavirin
NCT01471574,measures_primary,SVR12
NCT01471574,measures_secondary,HCV RNA levels
NCT01471574,has_criteria,HCV RNA <40
NCT00696774,involves,Depression
NCT00696774,evaluates,Duloxetine
NCT00696774,measures_primary,HAMD-17 Total Score
NCT00696774,measures_secondary,BPI-SF interference score
NCT00696774,has_criteria,Maier subscale score
NCT00609674,involves,Perennial Allergic Rhinitis
NCT00609674,evaluates,Fluticasone Furoate Nasal Spray
NCT00609674,measures_primary,rTNSS
NCT00609674,measures_secondary,iTNSS
NCT00609674,measures_secondary,rTOSS
NCT00609674,has_criteria,Baseline through End of Study
NCT05233774,involves,Alzheimer's disease
NCT05233774,evaluates,Lomecel-B
NCT05233774,measures_primary,Safety - SAEs
NCT05233774,measures_primary,Safety - AEs
NCT05233774,measures_secondary,Change in ADAS-cog-13
NCT05233774,measures_secondary,Change in MMSE
NCT05233774,has_criteria,written informed consent
NCT05233774,has_criteria,60 - 85 years of age
NCT05233774,has_criteria,mild Alzheimer's disease
NCT05233774,has_criteria,MMSE score 19 - 23
NCT05233774,has_criteria,Body weight 40 - 150 kg
NCT05233774,has_criteria,adult caregiver
NCT05233774,has_criteria,Brain MRI consistent with AD
NCT05233774,has_criteria,PET scan consistent with AD
NCT04087720,involves,Gout
NCT04087720,evaluates,Peglotcase
NCT04087720,measures_primary,sUA < 6 mg/dL responders
NCT04087720,measures_secondary,sUA < 5 mg/dL responders
NCT04087720,measures_secondary,Change From Baseline in HAQ-Pain VAS Score
NCT04087720,measures_secondary,Change From Baseline in HAQ-DI Score
NCT04087720,has_criteria,Kidney Transplant
NCT05188274,involves,Tourette Syndrome
NCT05188274,evaluates,T92
NCT05188274,measures_primary,TTS score
NCT05188274,measures_secondary,YGTSS-TRI score
NCT05188274,measures_secondary,TS-CGI severity
NCT05188274,has_criteria,≥ 30% reduction
NCT00412620,involves,Schizophrenia
NCT00412620,evaluates,ABT-925
NCT00412620,measures_primary,PANSS total score
NCT00412620,measures_secondary,Brief Psychiatric Rating Scale
NCT00412620,measures_secondary,Clinical Global Impression Severity score
NCT00412620,measures_secondary,Calgary Depression Scale for Schizophrenia Total score
NCT00412620,measures_secondary,Negative Symptom Assessment
NCT00412620,has_criteria,acute exacerbation
NCT00759720,involves,Type 2 Diabetes Mellitus
NCT00759720,evaluates,TAK-559
NCT00759720,evaluates,Glyburide
NCT00759720,measures_primary,Change from Baseline in Glycosylated hemoglobin level.
NCT00759720,measures_secondary,Change from baseline in Fasting plasma glucose.
NCT00759720,measures_secondary,Change from Baseline in Serum insulin.
NCT00759720,measures_secondary,Change from Baseline in C-peptide.
NCT00759720,measures_secondary,Change from Baseline in Lipids
NCT00759720,measures_secondary,Change from Baseline in Apolipoproteins
NCT00759720,measures_secondary,Change from Baseline in Free fatty acids.
NCT00759720,measures_secondary,Markers of thrombosis
NCT00759720,measures_secondary,Markers of inflammation
NCT00759720,measures_secondary,Urinary albumin/creatinine ratio.
NCT00759720,measures_secondary,Low-density lipoprotein fractionation
NCT00759720,has_criteria,glycosylated hemoglobin level
NCT00759720,has_criteria,fasting plasma glucose
NCT00759720,has_criteria,stable dose of glyburide
NCT00759720,has_criteria,stable or worsening self-monitoring blood glucose level
NCT00759720,has_criteria,low-density lipoprotein
NCT01928420,involves,Alzheimer's Disease
NCT01928420,evaluates,NIC5-15
NCT01928420,measures_primary,ADAS-Cog Score
NCT01928420,measures_secondary,ADCS-CCGIC Score
NCT01928420,measures_secondary,MMSE Score
NCT01928420,measures_secondary,ADCS-ADL Score
NCT01928420,has_criteria,Subjects With Alzheimer's Disease
NCT01473420,involves,Chronic Renal Failure
NCT01473420,evaluates,Epoetin Hospira
NCT01473420,evaluates,Epoetin Alfa
NCT01473420,measures_primary,Mean Weekly Hemoglobin
NCT01473420,measures_secondary,Total Dose of Study Medication
NCT01473420,measures_secondary,Percentage of Participants
NCT01473420,has_criteria,Hemodialysis
NCT01473420,has_criteria,Epoetin Maintenance Treatment
NCT01712074,involves,Alzheimer's Disease
NCT01712074,evaluates,PF-05212377
NCT01712074,measures_primary,Change From Baseline
NCT01712074,measures_secondary,Neuropsychiatric Inventory Total Score
NCT01712074,has_criteria,Clinical diagnosis of probable AD
NCT00488774,involves,Ulcerative Colitis
NCT00488774,evaluates,Golimumab
NCT00488774,measures_primary,Clinical Response
NCT00488774,measures_secondary,Clinical Remission
NCT00488774,has_criteria,Mayo score 6 to 12
NCT06592274,involves,Psoriasis
NCT06592274,evaluates,HB0017
NCT06592274,measures_primary,PASI 90 response
NCT06592274,measures_primary,sPGA 0/1
NCT06592274,measures_primary,PASI 75 response
NCT06592274,measures_primary,PASI 100 response
NCT06592274,measures_secondary,PASI 90 response maintainance
NCT06592274,measures_secondary,sPGA 0/1 response maintainance
NCT06592274,has_criteria,Longer Dose Interval
NCT01353274,involves,Hypertension
NCT01353274,evaluates,Micamlo® Combination Tablets AP
NCT01353274,measures_primary,Change From Baseline in SBP
NCT01353274,measures_secondary,Change From Baseline in DBP
NCT01353274,measures_secondary,Proportion of Patients Who Achieved the Target BP
NCT01353274,measures_secondary,Proportion of Patients Who Normalised Their BP
NCT01353274,has_criteria,Male and Female patients
NCT01353274,has_criteria,hypertension
NCT01353274,has_criteria,did not receive MICAMLO Combination Tablets AP
NCT01353274,has_criteria,history of hypersensitivity
NCT01353274,has_criteria,pregnant woman
NCT01353274,has_criteria,extremely poor bile secretion
NCT01353274,has_criteria,serious hepatic disorder
NCT00686920,involves,Hepatic Encephalopathy
NCT00686920,evaluates,Rifaximin
NCT00686920,measures_primary,Number Of Participants
NCT00686920,measures_secondary,Significant Mean Change
NCT00686920,has_criteria,Baseline up to Month 36
NCT00880620,involves,Parkinson's Disease
NCT00880620,evaluates,IPX066
NCT00880620,measures_primary,Change from Baseline
NCT00880620,measures_secondary,PDQ-39 Score
NCT00880620,has_criteria,Idiopathic PD
NCT02015520,involves,Rheumatoid Arthritis
NCT02015520,measures_primary,DAS28-CRP at Week 12
NCT02015520,measures_secondary,ACR20/50/70 Response Rates
NCT02015520,measures_secondary,CDAI Score at Week 12
NCT02015520,has_criteria,Change From Baseline
NCT06153420,involves,Irritable Bowel Syndrome With Predominant Diarrhea
NCT06153420,evaluates,CIN-103
NCT06153420,measures_primary,Study Composite Responder
NCT06153420,measures_secondary,Weekly Composite Responder
NCT06153420,has_criteria,Daily Composite Responder
NCT06492720,involves,Drug Resistant Epilepsy
NCT06492720,evaluates,NaviFUS™ System
NCT06492720,measures_primary,Changes seizure frequency
NCT06492720,measures_secondary,Responder rate
NCT06492720,measures_secondary,Seizure-free days
NCT06492720,measures_secondary,Subjective seizure strength
NCT06492720,measures_secondary,Quality of Life
NCT06492720,measures_secondary,Beck Anxiety Inventory
NCT06492720,measures_secondary,Beck Depression Inventory
NCT06492720,has_criteria,up to 33 weeks
NCT01900574,involves,Ulcerative Colitis
NCT01900574,evaluates,Golimumab
NCT01900574,measures_primary,Mayo score at Week 6
NCT01900574,measures_secondary,Pediatric Ulcerative Colitis Activity Index (PUCAI) score
NCT01900574,has_criteria,Pediatric patients
NCT03182374,involves,Knee Osteoarthritis
NCT03182374,evaluates,nSTRIDE APS
NCT03182374,evaluates,Hyaluronic Acid
NCT03182374,measures_primary,WOMAC LK3.1 Pain Score
NCT03182374,measures_secondary,NRS Pain Scale
NCT03182374,has_criteria,OMERACT-OARSI Responder Criteria
NCT04355520,involves,Advanced Breast Cancer
NCT04355520,evaluates,TQ-B3525 Tablets
NCT04355520,evaluates,Fulvestrant Injection
NCT04355520,measures_primary,Overall response rate
NCT04355520,measures_secondary,Disease control rate
NCT04355520,measures_secondary,Duration of Response
NCT04355520,measures_secondary,Progression-free survival
NCT04355520,measures_secondary,Overall survival
NCT04355520,has_criteria,Inclusion Criteria
NCT02357420,involves,Diabetic Gastroparesis
NCT02357420,evaluates,Relamorelin
NCT02357420,measures_primary,Weekly Vomiting Episodes
NCT02357420,measures_secondary,DGSSD 4-symptom Composite Score
NCT02357420,has_criteria,7 days prior to Day 1
NCT00848120,involves,Rheumatoid Arthritis
NCT00848120,evaluates,Tocilizumab
NCT00848120,measures_primary,ACR20 Response
NCT00848120,measures_secondary,ACR50 Response
NCT00848120,measures_secondary,ACR70 Response
NCT00848120,measures_secondary,HAQ-DI Score
NCT00848120,has_criteria,tender or swollen joint counts
NCT03978520,involves,Systemic Lupus Erythematosus
NCT03978520,evaluates,Elsubrutinib
NCT03978520,evaluates,Upadacitinib
NCT03978520,measures_primary,SLE Responder Index
NCT03978520,measures_secondary,Steroid Dose
NCT03978520,has_criteria,SLEDAI-2K score
NCT03978520,has_criteria,Physician's Global Assessment
NCT03978520,has_criteria,British Isles Lupus Assessment Group
NCT02149420,involves,Primary Sjögren's Syndrome
NCT02149420,evaluates,VAY736
NCT02149420,measures_primary,Change in ESSDAI
NCT02149420,measures_secondary,Change in ESSPRI
NCT02149420,measures_secondary,Change in SF-36
NCT02149420,measures_secondary,Change in MFI
NCT02149420,has_criteria,Baseline to Week 24
NCT00618774,involves,Hypertension
NCT00618774,evaluates,Telmisartan Plus Amlodipine
NCT00618774,measures_primary,Seated DBP at Week 8
NCT00618774,measures_primary,Seated SBP at Week 8
NCT00618774,measures_secondary,Seated DBP Control Rate
NCT00618774,measures_secondary,Seated SBP Control Rate
NCT00618774,has_criteria,Pseud-baseline
NCT01962974,involves,Rheumatoid Arthritis
NCT01962974,evaluates,Golimumab
NCT01962974,measures_primary,ACR20 Response
NCT01962974,measures_secondary,Antibodies to Infliximab
NCT01962974,has_criteria,Diminished Disease Control
NCT03942120,involves,Crohn's Disease
NCT03942120,evaluates,Stelara
NCT03942120,measures_primary,Change from Baseline in CDAI Score
NCT03942120,measures_secondary,Change from Baseline in C-reactive Protein Concentration
NCT03942120,measures_secondary,Change from Baseline in Harvey-Bradshaw Index Score
NCT03942120,has_criteria,Baseline up to 3 years
NCT04911374,involves,skin condition
NCT04911374,evaluates,Face Cream
NCT04911374,evaluates,Eye Cream
NCT04911374,measures_primary,Investigator Clinical Grading
NCT04911374,measures_primary,Investigator Tolerability Assessment
NCT04911374,measures_primary,Subject Tolerability Assessment
NCT04911374,measures_secondary,Erythema
NCT04911374,measures_secondary,Edema
NCT04911374,measures_secondary,Dryness
NCT04911374,measures_secondary,Burning
NCT04911374,measures_secondary,Itching
NCT04911374,measures_secondary,Stinging
NCT04911374,has_criteria,12 weeks
NCT04320173,involves,Adhesion
NCT04320173,evaluates,Lidocaine Topical System 1.8%
NCT04320173,evaluates,Lidocaine Patch 5%
NCT04320173,evaluates,Lidocaine Medicated Plaster 5%
NCT04320173,measures_primary,Mean Adhesion Score
NCT04320173,measures_secondary,Dermal Response Score
NCT04320173,has_criteria,Healthy
NCT06268873,involves,Chronic Kidney Disease
NCT06268873,involves,High Blood Pressure
NCT06268873,evaluates,Baxdrostat
NCT06268873,evaluates,Dapagliflozin
NCT06268873,measures_primary,change in eGFR
NCT06268873,measures_secondary,UACR
NCT06268873,measures_secondary,systolic BP
NCT06268873,measures_secondary,Kidney hierarchical composite endpoint
NCT06268873,has_criteria,≥ 18 years old
NCT06268873,has_criteria,eGFR 30 to 90 mL/min/1.73 m2
NCT06268873,has_criteria,UACR 200 to 5000 mg/g
NCT06173531,involves,Prader-Willi Syndrome
NCT06173531,evaluates,Carbetocin Nasal Spray
NCT06173531,measures_primary,Change from Baseline at Week 12
NCT06173531,measures_secondary,Clinical Global Impression-Severity (CGI-S) score
NCT06173531,measures_secondary,Clinical Global Impression-Change (CGI-C) score
NCT06173531,has_criteria,5 through 30 years of age
NCT06173531,has_criteria,Prader-Willi syndrome
NCT06173531,has_criteria,increased appetite
NCT06173531,has_criteria,HQ-CT total score ≥13
NCT06173531,has_criteria,CGI-S score ≥4
NCT02159131,evaluates,GSK1265744
NCT02159131,measures_primary,plasma pharmacokinetics
NCT02159131,measures_secondary,safety tolerability
NCT02159131,has_criteria,Healthy Adult Female Subjects
NCT05514782,involves,skin condition
NCT05514782,evaluates,Daily Anti-Aging Daily Serum
NCT05514782,measures_primary,Investigator Clinical Grading
NCT05514782,measures_secondary,Objective Tolerability
NCT05514782,has_criteria,Baseline timepoints
NCT01625182,involves,Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT01625182,evaluates,Fingolimod
NCT01625182,measures_primary,Time to First Confirmed Worsening
NCT01625182,measures_secondary,Change From Baseline for Grip Strength
NCT01625182,measures_secondary,Change From Baseline for Rasch-Built Linearly Weighted Overall Disability Scale
NCT01625182,has_criteria,Patients' perception of their ability to perform daily and social activities
NCT02364531,involves,Metastatic Prostate Cancer
NCT02364531,evaluates,ZYTIGA
NCT02364531,measures_primary,FACT-P Score
NCT02364531,measures_secondary,BFI Scale Score
NCT02364531,measures_secondary,BPI-SF Scale Score
NCT04998331,involves,CD30+ Malignancies
NCT04998331,evaluates,Brentuximab-vedotin
NCT04998331,measures_primary,Overall Response Rate
NCT04998331,measures_secondary,Duration of Response
NCT04998331,has_criteria,BV retreatment
NCT03568331,involves,atopic dermatitis
NCT03568331,evaluates,Tradipitant
NCT03568331,evaluates,Placebo
NCT03568331,measures_primary,Worst Itch NRS
NCT03568331,measures_secondary,SCORAD index
NCT03568331,measures_secondary,vIGA-AD
NCT03568331,has_criteria,Male and non-pregnant
NCT03568331,has_criteria,aged 18 - 70 years
NCT03568331,has_criteria,diagnosed with atopic dermatitis
NCT03568331,has_criteria,suffering from chronic pruritus
NCT03568331,has_criteria,BMI of ≥18 and ≤40 kg/m2
NCT04851873,involves,Spinal Muscular Atrophy
NCT04851873,evaluates,OAV101
NCT04851873,measures_primary,Change from baseline
NCT04851873,measures_secondary,Respiratory Rate
NCT04851873,has_criteria,Weight Bracket
NCT03316131,involves,Hyperuricemia
NCT03316131,evaluates,RDEA3170
NCT03316131,evaluates,Febuxostat
NCT03316131,evaluates,Dapagliflozin
NCT03316131,measures_primary,Peak UA excretion
NCT03316131,measures_secondary,Plasma Concentration (Cmax)
NCT03316131,measures_secondary,Area Under Plasma Concentration Time Curve
NCT03316131,measures_secondary,Area Under Plasma Concentration Time Curve Over a Dosing Interval (24 Hours)
NCT03316131,measures_secondary,Urinary Excretion of Serum UA (sUA)
NCT03316131,has_criteria,Baseline sUA levels
NCT01499082,involves,Type 2 Diabetes Mellitus
NCT01499082,evaluates,Insulin Glargine
NCT01499082,measures_primary,Change in HbA1c
NCT01499082,measures_secondary,Nocturnal hypoglycemia
NCT01499082,measures_secondary,Average Preinjection SMPG
NCT01499082,measures_secondary,Variability of Preinjection SMPG
NCT01499082,measures_secondary,Percentage HbA1c <7%
NCT01499082,measures_secondary,Change in Fasting Plasma Glucose
NCT01499082,measures_secondary,Percentage FPG <5.6 mmol/L
NCT01499082,measures_secondary,Change in 8-Point SMPG Profiles
NCT01499082,has_criteria,Basal Plus Mealtime Insulin
NCT03482882,involves,Parkinson's Disease
NCT03482882,involves,Depression
NCT03482882,evaluates,Pimavanserin
NCT03482882,measures_primary,Change From Baseline in HAMD-17 Total Score
NCT03482882,measures_secondary,Clinical Global Impression-Improvement (CGI-I)
NCT03482882,measures_secondary,Change From Baseline (CFB) in Clinical Global Impression-Severity (CGI-S)
NCT03482882,measures_secondary,Change From Baseline (CFB) in Scale of Outcomes in PD-Sleep Scale (SCOPA) Nighttime Sleep (NS)Score
NCT03482882,has_criteria,From baseline to Week 8
NCT03693131,involves,Hypertriglyceridemia
NCT03693131,evaluates,MND-2119
NCT03693131,measures_primary,Serum triglyceride level
NCT03693131,measures_secondary,Serum total cholesterol level
NCT03693131,measures_secondary,Serum LDL-C level
NCT03693131,measures_secondary,Serum LDL-C level
NCT03693131,measures_secondary,Serum HDL-C level
NCT03693131,measures_secondary,Serum non HDL-C level
NCT03693131,has_criteria,Fasting triglyceride level 150 mg/dL or higher
NCT03698331,involves,Withdrawal-emergent adverse events
NCT03698331,evaluates,Valbenazine
NCT03698331,measures_primary,Absolute Worst Total Score
NCT03698331,measures_secondary,Severity of Withdrawal Symptoms
NCT03698331,measures_secondary,Overall Improvement From Base
NCT01900431,involves,Non-Infectious Uveitis
NCT01900431,evaluates,Sarilumab
NCT01900431,measures_primary,Vitreous Haze reduction
NCT01900431,measures_secondary,Anterior Chamber Cell Score
NCT01900431,has_criteria,prednisone dose <10 mg/day
NCT04079231,involves,Diabetic Macular Edema
NCT04079231,evaluates,Brolucizumab
NCT04079231,evaluates,Aflibercept
NCT04079231,measures_primary,BCVA gain ≥15 letters
NCT04079231,measures_primary,BCVA change from baseline
NCT04079231,measures_secondary,BCVA gain ≥10 letters
NCT04079231,measures_secondary,BCVA loss ≥15 letters
NCT04079231,measures_secondary,BCVA loss ≥10 letters
NCT04079231,measures_secondary,maintained at q12w
NCT04079231,has_criteria,qualified for q12w
NCT02917031,involves,Heart Failure
NCT02917031,involves,Type 2 Diabetes Mellitus
NCT02917031,evaluates,saxagliptin
NCT02917031,evaluates,placebo
NCT02917031,measures_primary,LVEDV index
NCT02917031,measures_primary,LVESV index
NCT02917031,measures_primary,LVEF
NCT02917031,measures_primary,LVM
NCT02917031,measures_primary,NT-proBNP
NCT02917031,measures_secondary,Adverse Events
NCT02917031,has_criteria,T2DM and HF
NCT01715831,involves,Rheumatoid Arthritis
NCT01715831,evaluates,Tocilizumab
NCT01715831,measures_primary,DAS28-ESR
NCT01715831,measures_secondary,Serious Adverse Events
NCT01715831,measures_secondary,Non-Serious Adverse Events
NCT01715831,has_criteria,study drug
NCT05097131,involves,Alzheimer's Disease
NCT05097131,evaluates,Aducanumab-avwa
NCT05097131,measures_primary,Change from Baseline
NCT05097131,measures_secondary,Amsterdam Instrumental Activities of Daily Living Questionnaire Short Version Score
NCT05097131,measures_secondary,Functional Activities Questionnaire Score
NCT05097131,has_criteria,Up to 5 years
NCT02013531,involves,Major Depressive Disorder
NCT02013531,evaluates,Brexpiprazole
NCT02013531,measures_primary,MADRS Total Score
NCT02013531,measures_secondary,CGI-S Total Score
NCT02013531,measures_secondary,CGI-I Score
NCT02013531,has_criteria,Baseline
NCT02901431,involves,Autism Spectrum Disorder
NCT02901431,evaluates,Balovaptan
NCT02901431,measures_primary,Vineland™-II 2DC Score
NCT02901431,measures_secondary,Vineland™-II Composite Standard Score
NCT02901431,has_criteria,developmental disabilities
NCT06104631,involves,Crohn's Disease
NCT06104631,involves,Irritable Bowel Syndrome
NCT06104631,measures_primary,Subject's global assessment
NCT06104631,measures_secondary,Weekly change in mean 7-point Likert scale
NCT06104631,measures_secondary,Stool consistency
NCT06104631,measures_secondary,Stool number
NCT06104631,measures_secondary,IBS-related quality of life
NCT06104631,measures_secondary,Anxiety and depression
NCT06104631,measures_secondary,Serum CRP
NCT06104631,has_criteria,Patients with an SGA of relief score from 1 to 3
NCT03382431,involves,RSV
NCT03382431,evaluates,PC786
NCT03382431,measures_primary,RSV viral load
NCT03382431,measures_secondary,AUC 0-t RSV viral load
NCT03382431,measures_secondary,Number of participants reporting TEAE
NCT03382431,measures_secondary,Number of participants discontinuing due to AE
NCT03382431,measures_secondary,Number of participants meeting markedly abnormal criteria for 12-lead ECG
NCT03382431,measures_secondary,Number of participants meeting markedly abnormal criteria for vital signs
NCT03382431,measures_secondary,Number of participants meeting markedly abnormal criteria for safety laboratory assessments
NCT03382431,measures_secondary,Number of participants meeting markedly abnormal criteria for spirometry
NCT03382431,measures_secondary,Area under the plasma concentration versus time curve (AUC) of PC786
NCT03382431,measures_secondary,Maximum observed concentration (Cmax) of PC786
NCT03382431,measures_secondary,Time maximum concentration observed (Tmax) of PC786
NCT03382431,measures_secondary,Apparent terminal half life (T1/2) of PC786
NCT03382431,measures_secondary,Nasal concentrations of PC786
NCT03382431,measures_secondary,Mucus production following treatment with PC786 or placebo
NCT03382431,measures_secondary,RSV symptoms
NCT03382431,has_criteria,markedly abnormal criteria
NCT02174731,involves,Chronic Kidney Disease
NCT02174731,involves,Anemia
NCT02174731,evaluates,Roxadustat
NCT02174731,measures_primary,Change in Hb
NCT02174731,measures_secondary,Proportion of Hb
NCT02174731,has_criteria,Dialysis duration
NCT05825131,involves,Sanfilippo Syndrome Type IIIC
NCT05825131,measures_primary,Change From Baseline in DQ
NCT05825131,measures_secondary,Change From Baseline in VABS-II Development Quotient (DQ) Score
NCT01080131,involves,Acute Gout Flares
NCT01080131,evaluates,Canakinumab
NCT01080131,measures_primary,Time to First New Flare
NCT01080131,measures_secondary,Self-assessed Pain Intensity
NCT01080131,has_criteria,New gout flare
NCT05611931,involves,Endometrial Carcinoma
NCT05611931,evaluates,Selinexor
NCT05611931,measures_primary,Progression Free Survival
NCT05611931,measures_secondary,Overall Survival
NCT05611931,measures_secondary,Time to First Subsequent Therapy
NCT05611931,measures_secondary,Time to Second Subsequent Therapy
NCT05611931,measures_secondary,Progression-free Survival After Consecutive Treatment
NCT05611931,measures_secondary,European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
NCT05611931,has_criteria,P53 Wild-Type
NCT00488631,involves,Ulcerative Colitis
NCT00488631,evaluates,Golimumab
NCT00488631,measures_primary,Clinical response
NCT00488631,measures_secondary,Clinical remission
NCT00488631,measures_secondary,Mucosal healing
NCT00488631,has_criteria,Induction Baseline
NCT02854631,involves,Alcoholic Hepatitis
NCT02854631,evaluates,Selonsertib
NCT02854631,evaluates,Prednisolone
NCT02854631,measures_primary,Percentage of Deaths
NCT02854631,measures_secondary,Survival at Day 28
NCT02854631,measures_secondary,Survival at Week 8
NCT02854631,measures_secondary,Survival at Week 12
NCT02854631,measures_secondary,Survival at Week 24
NCT02854631,has_criteria,Day 28
NCT02854631,has_criteria,Week 8
NCT02854631,has_criteria,Week 12
NCT02854631,has_criteria,Week 24
NCT01959282,involves,Ulcerative Colitis
NCT01959282,evaluates,JNJ-54781532
NCT01959282,measures_primary,Mayo score at Week 8
NCT01959282,measures_secondary,clinical response at Week 8
NCT01959282,measures_secondary,clinical remission at Week 8
NCT01959282,measures_secondary,mucosal healing at Week 8
NCT01959282,has_criteria,moderately to severely active UC
NCT01959282,has_criteria,baseline Mayo score 6 to 12
NCT01959282,has_criteria,endoscopy sub score greater than or equal to 2
NCT04551066,involves,Myelofibrosis
NCT04551066,evaluates,Parsaclisib
NCT04551066,evaluates,Ruxolitinib
NCT04551066,measures_primary,Spleen Volume Reduction
NCT04551066,measures_secondary,Total Symptom Score
NCT04551066,measures_secondary,Change in TSS
NCT04551066,has_criteria,Baseline; Week 24
NCT05032066,involves,Idiopathic Pulmonary Fibrosis
NCT05032066,evaluates,HZN-825
NCT05032066,measures_primary,Change in FVC %
NCT05032066,measures_secondary,6MWT results
NCT05032066,measures_secondary,K-BILD scores
NCT05032066,has_criteria,Baseline to Week 52
NCT05108766,involves,Plaquetype Psoriasis
NCT05108766,evaluates,Tildrakizumab
NCT05108766,measures_primary,PASI 75 at Week 12
NCT05108766,measures_secondary,Physician's Global Assessment
NCT05108766,measures_secondary,Dermatology Life Quality Index
NCT05108766,has_criteria,Chinese Subjects
NCT03299166,involves,Obsessive Compulsive Disorder
NCT03299166,evaluates,Troriluzole
NCT03299166,measures_primary,Y-BOCS Total Score
NCT03299166,measures_secondary,Adverse Events
NCT03299166,has_criteria,untoward medical occurrence
NCT03576066,involves,Chronic Hepatitis B Infection
NCT03576066,evaluates,ABI-H0731
NCT03576066,measures_primary,Change in Mean log10 Serum HBsAg
NCT03576066,measures_primary,Change in Mean log10 Serum HBeAg
NCT03576066,measures_secondary,Number of Participants With One or More Adverse Events
NCT03576066,measures_secondary,Number of Participants With Premature Study Discontinuation
NCT03576066,measures_secondary,Number of Participants With One or More Abnormal Safety Laboratory Result
NCT03576066,measures_secondary,Number of Participants With a Clinically-significant Electrocardiogram Abnormality
NCT03576066,measures_secondary,Number of Participants With a Clinically-significant Change in Vital Signs
NCT03576066,measures_secondary,Number of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Have Normal ALT at Week 24
NCT03576066,measures_secondary,Trough Levels of ABI-H0731
NCT03576066,measures_secondary,Trough Levels of Entecavir (ETV)
NCT03576066,measures_secondary,Trough Levels of Tenofovir Alafenamide (TAF)
NCT03576066,measures_secondary,Trough Levels of Tenofovir Disoproxil Fumarate (TDF)
NCT03576066,measures_secondary,Trough to Peak Ratios of ABI-H0731
NCT02882126,involves,Pulmonary Arterial Hypertension
NCT02882126,evaluates,Subcutanous Remodulin
NCT02882126,measures_primary,Change in 6MWD
NCT02882126,measures_secondary,Borg Dyspnea Score
NCT02882126,has_criteria,Study Completion
NCT06059326,involves,T2DM
NCT06059326,evaluates,HSK7653
NCT06059326,measures_primary,DPP-4 inhibition rate
NCT06059326,measures_secondary,GLP-1
NCT06059326,measures_secondary,fasting plasma glucose
NCT06059326,measures_secondary,HbA1c
NCT06059326,has_criteria,Age ≥18 years
NCT06059326,has_criteria,Age ≤70 years
NCT06059326,has_criteria,BMI ≥19 kg/m2
NCT06059326,has_criteria,BMI ≤ 35 kg/m2
NCT06059326,has_criteria,HbA1c ≥7.0%
NCT06059326,has_criteria,HbA1c <10.0%
NCT06059326,has_criteria,FPG <13.9 mmol/L
NCT03591926,involves,Idiopathic Pulmonary Fibrosis
NCT03591926,evaluates,SM04646 Inhalation Solution
NCT03591926,measures_primary,Safety and tolerability
NCT03591926,measures_secondary,Plasma pharmacokinetics
NCT03591926,has_criteria,Clinically significant change
NCT03259074,involves,Ankylosing Spondylitis
NCT03259074,evaluates,Secukinumab
NCT03259074,evaluates,GP2017
NCT03259074,measures_primary,Radiographic progression
NCT03259074,measures_secondary,New syndesmophytes
NCT03259074,has_criteria,Syndesmophyte at baseline
NCT02611674,involves,ALS
NCT02611674,measures_primary,electrophysiological measures
NCT02611674,measures_secondary,muscle strength measures
NCT02611674,has_criteria,Investigator's discretion
NCT00936065,involves,Psoriasis
NCT00936065,evaluates,Etanercept
NCT00936065,evaluates,Acitretin
NCT00936065,measures_primary,PASI 75 score
NCT00936065,measures_secondary,PASI 50 score
NCT00936065,measures_secondary,PGA of Psoriasis
NCT00936065,has_criteria,Korean Patient
NCT01556165,involves,Parkinson's Disease
NCT01556165,evaluates,Rasagiline
NCT01556165,measures_primary,Change From Baseline
NCT01556165,measures_secondary,Time to Onset of Levodopa Therapy
NCT01556165,has_criteria,FAS patients
NCT00245765,involves,Chronic Plaque Psoriasis
NCT00245765,evaluates,CDP870
NCT00245765,measures_primary,PASI75 response
NCT00245765,measures_secondary,Time to PASI50
NCT00245765,measures_secondary,Time to PASI75
NCT00245765,measures_secondary,Time to Relapse
NCT00245765,has_criteria,Candidate for systemic therapy
NCT02859766,involves,Neovascular AMD
NCT02859766,evaluates,Abicipar Pegol
NCT02859766,measures_primary,Best Corrected Visual Acuity
NCT02859766,measures_secondary,Treatment Emergent Adverse Events
NCT02859766,has_criteria,Baseline to Week 20
NCT01224171,involves,Crohn's Disease
NCT01224171,evaluates,Vedolizumab
NCT01224171,measures_primary,Clinical Remission
NCT01224171,has_criteria,CDAI score ≤ 150 points
NCT01458171,involves,IgG Replacement Therapy
NCT01458171,evaluates,IgPro20
NCT01458171,measures_primary,Rate of Adverse Events
NCT01458171,measures_secondary,Number of Subjects With Newly Developing or Worsening AEs
NCT01458171,measures_secondary,Percentage of Infusions With Subject-assessed Tolerability of at Least 'Good
NCT01458171,has_criteria,24 weeks
NCT02555371,involves,Severe Eosinophilic Asthma
NCT02555371,evaluates,Mepolizumab
NCT02555371,measures_primary,Clinically significant exacerbation
NCT02555371,measures_secondary,Blood Eosinophil Count
NCT02555371,has_criteria,Maintenance systemic corticosteroids
NCT04186871,involves,Systemic Lupus Erythematosus
NCT04186871,involves,Primary Sjögren's Syndrome
NCT04186871,involves,Rheumatoid Arthritis
NCT04186871,evaluates,Branebrutinib
NCT04186871,evaluates,Abatacept
NCT04186871,measures_primary,mCLASI Response
NCT04186871,measures_primary,Corticosteroid < 10 mg/Day
NCT04186871,measures_secondary,Composite Response
NCT04186871,has_criteria,mCLASI activity score ≥ 10
NCT04186871,has_criteria,CS dose ≤ 10 mg
NCT06109311,involves,Type 2 Diabetes
NCT06109311,evaluates,Orforglipron
NCT06109311,measures_primary,Change from Baseline in HbA1c
NCT06109311,measures_secondary,Percentage of Participants Who Achieved HbA1c <7.0%
NCT06109311,measures_secondary,Percentage of Participants Who Achieved HbA1c ≤6.5%
NCT06109311,measures_secondary,Change from Baseline in Fasting Serum Glucose
NCT06109311,measures_secondary,Percentage Change from Baseline in Body Weight
NCT06109311,measures_secondary,Percentage Change from Baseline in non-HDL Cholesterol
NCT06109311,measures_secondary,Percentage Change from Baseline in Triglycerides
NCT06109311,measures_secondary,Change from Baseline in Systolic Blood Pressure
NCT06109311,measures_secondary,Change from Baseline in Daily Insulin Glargine Dose
NCT06109311,measures_secondary,Percentage of Participants Who Achieved Weight Loss of ≥5%
NCT06109311,measures_secondary,Percentage of Participants Who Achieved Weight Loss of ≥10%
NCT06109311,measures_secondary,Percentage of Participants Who Achieved Weight Loss of ≥15%
NCT06109311,measures_secondary,Change from Baseline in Short Form 36-Version 2 (SF-36v2) Acute Form Domain and Summary Scores
NCT04797611,involves,Parkinson's disease
NCT04797611,evaluates,STEM
NCT04797611,measures_primary,Change from baseline
NCT04797611,measures_secondary,Change from baseline
NCT04797611,measures_secondary,Change from baseline
NCT04797611,has_criteria,day 113 score
NCT06153693,involves,Uncontrolled Hypertension
NCT06153693,involves,Resistant Hypertension
NCT06153693,evaluates,Lorundrostat
NCT06153693,measures_primary,AOBP SBP at Week 6
NCT06153693,measures_secondary,Proportion of subjects
NCT06153693,has_criteria,2 prescribed AHT medications
NCT06153693,has_criteria,3 or more prescribed AHT medications
NCT01248793,involves,Ankylosing Spondylitis
NCT01248793,evaluates,Golimumab
NCT01248793,measures_primary,ASAS 20 at Week 14
NCT01248793,measures_secondary,Change From Baseline in BASFI at Week 14
NCT01248793,measures_secondary,Change From Baseline in BASMI at Week 14
NCT01248793,has_criteria,diagnosis of definite ankylosing spondylitis
NCT01248793,has_criteria,symptoms of active disease
NCT01248793,has_criteria,no active infections
NCT01248793,has_criteria,other inflammatory diseases
NCT01248793,has_criteria,complete ankylosis of the spine
NCT01248793,has_criteria,history of latent or active granulomatous infection
NCT01248793,has_criteria,serious infection within 2 months prior to first administration of study agent
NCT06073093,involves,Rheumatoid Arthritis
NCT06073093,evaluates,SAR441566
NCT06073093,measures_primary,ACR20 response
NCT06073093,measures_secondary,DAS28 CRP
NCT06073093,has_criteria,≥ 20% improvement
NCT04223193,involves,Parkinson's Disease
NCT04223193,evaluates,Flexible-Dose
NCT04223193,measures_primary,Change From Baseline in MDS-UPDRS Parts II and III Combined Score
NCT04223193,measures_secondary,Change From Baseline in MDS-UPDRS Parts II Score
NCT04223193,measures_secondary,"Percentage of Responders with ""Much Improved"" or ""Very Much Improved"" on Participant Global Impression of Change (PGIC )"
NCT04223193,has_criteria,27 Weeks
NCT04173793,involves,Heterozygous Familial Hypercholesterolemia
NCT04173793,evaluates,AK102
NCT04173793,measures_primary,Percent change LDL-C
NCT04173793,measures_secondary,High-density lipoprotein cholesterol
NCT04173793,measures_secondary,non-HDL cholesterol
NCT04173793,measures_secondary,Triglyceride cholesterol
NCT04173793,measures_secondary,Apolipoprotein B
NCT04173793,measures_secondary,Apolipoprotein A-I
NCT04173793,measures_secondary,Lipoprotein(a)
NCT04173793,measures_secondary,Total Cholesterol
NCT04173793,measures_secondary,Incidence adverse events
NCT04173793,measures_secondary,Serum concentrations AK102
NCT04173793,measures_secondary,anti-drug antibodies
NCT04173793,measures_secondary,proprotein convertase subtilisin/kexin type 9
NCT04173793,has_criteria,genetic confirmation
NCT04173793,has_criteria,clinical diagnosis
NCT04173793,has_criteria,lipid-lowering therapies
NCT04173793,has_criteria,statins
NCT04173793,has_criteria,ezetimibe
NCT04173793,has_criteria,Fasting LDL-C
NCT04173793,has_criteria,Atherosclerotic Cardiovascular Disease
NCT04810611,involves,Lower Risk MDS
NCT04810611,evaluates,Select Drug Combinations
NCT04810611,measures_primary,Reduction in RBC transfusions
NCT04810611,measures_secondary,Duration of transfusion independence
NCT04810611,measures_secondary,Change from baseline in hemoglobin
NCT04810611,measures_secondary,Change from baseline in platelet count
NCT04810611,measures_secondary,Change from baseline in ANC/WBC
NCT04810611,has_criteria,Transfusion dependent patients
NCT02187471,involves,Fibromyalgia
NCT02187471,evaluates,DS-5565
NCT02187471,evaluates,Pregabalin
NCT02187471,evaluates,Placebo
NCT02187471,measures_primary,Average Daily Pain Score
NCT02187471,measures_secondary,Patient Global Impression of Change
NCT02187471,measures_secondary,Fibromyalgia Index Questionnaire
NCT02187471,has_criteria,Baseline up to Week 13 postdose
NCT01590771,involves,Type 2 Diabetes Mellitus
NCT01590771,evaluates,Sitagliptin
NCT01590771,measures_primary,Change From Baseline in A1C
NCT01590771,measures_secondary,Change From Baseline in 2-hr PMG
NCT01590771,measures_secondary,Change From Baseline in FPG
NCT01590771,has_criteria,Up to 26 weeks
NCT01590771,has_criteria,Up to 24 weeks
NCT03622593,involves,Diabetic Macular Edema
NCT03622593,evaluates,Faricimab
NCT03622593,measures_primary,Change From Baseline BCVA
NCT03622593,measures_secondary,Percentage of Participants DRS Improvement
NCT03622593,has_criteria,Baseline BCVA
NCT00408993,involves,Diabetic Peripheral Neuropathic Pain
NCT00408993,evaluates,Duloxetine
NCT00408993,measures_primary,Change From Baseline
NCT00408993,measures_secondary,Clinical Global Impression of Severity
NCT00408993,measures_secondary,EuroQoL Questionnaire - 5 Dimensions
NCT00408993,has_criteria,Baseline and 12 weeks
NCT03198793,involves,Hypertension
NCT03198793,evaluates,QGC001
NCT03198793,measures_primary,Office systolic blood pressure
NCT03198793,measures_primary,Office diastolic blood pressure
NCT03198793,measures_secondary,Ambulatory systolic blood pressure
NCT03198793,measures_secondary,Ambulatory diastolic blood pressure
NCT03198793,measures_secondary,Mean office blood pressure
NCT03198793,measures_secondary,Percentage of responders
NCT03198793,has_criteria,Office blood pressure
NCT04176211,involves,Myasthenia Gravis
NCT04176211,measures_primary,Change in EQ-5D-5L score
NCT04176211,measures_secondary,Change in MG-ADL score
NCT04176211,measures_secondary,Change in MG-QoL15r score
NCT04176211,has_criteria,Monthly throughout 2 year study duration
NCT04176211,has_criteria,Four times per six months throughout 2 year study duration
NCT04050111,involves,Knee Joint Arthrosis
NCT04050111,evaluates,Autologous Stromal-Vascular Fraction of Adipose Tissue Cells
NCT04050111,measures_primary,Quality of life
NCT04050111,measures_secondary,Knee pain intensity
NCT04050111,has_criteria,Follow up to completion
NCT01318993,evaluates,GSK1605786A
NCT01318993,measures_primary,Change From Baseline
NCT01318993,measures_secondary,Heart Rate
NCT01318993,measures_secondary,Systolic Blood Pressure
NCT01318993,measures_secondary,Diastolic Blood Pressure
NCT01318993,has_criteria,>=1 dose
NCT04524611,involves,Crohn's Disease
NCT04524611,evaluates,Risankizumab
NCT04524611,evaluates,Ustekinumab
NCT04524611,measures_primary,CDAI<150 at Week 24
NCT04524611,measures_primary,CDAI<150 at Week 48
NCT04524611,measures_secondary,Endoscopic Remission at Week 24
NCT04524611,measures_secondary,Endoscopic Remission at Week 48
NCT04524611,measures_secondary,Endoscopic Response at Week 48
NCT04524611,has_criteria,Moderate to Severe Crohn's Disease
NCT04004611,involves,Ulcerative Colitis
NCT04004611,evaluates,Mirikizumab
NCT04004611,measures_primary,Clinical Remission
NCT04004611,measures_secondary,Clinical Response
NCT04004611,has_criteria,week 52
NCT06397911,involves,Atopic Dermatitis
NCT06397911,evaluates,FB825
NCT06397911,measures_primary,Eczema Area and Severity Index
NCT06397911,measures_secondary,Investigator Global Assessment
NCT06397911,measures_secondary,Severity Scoring of Atopic Dermatitis Index
NCT06397911,measures_secondary,pruritus numerical rating scale
NCT06397911,measures_secondary,Dermatology Life Quality Index
NCT06397911,measures_secondary,total IgE
NCT06397911,measures_secondary,allergen-specific IgE
NCT06397911,has_criteria,18-65 years of age
NCT06397911,has_criteria,Body weight ≥40 Kg
NCT06397911,has_criteria,moderate-to-severe atopic dermatitis
NCT01922011,involves,Acute Hematogenous Osteomyelitis
NCT01922011,evaluates,Daptomycin
NCT01922011,evaluates,Active Comparator
NCT01922011,measures_primary,Clinical Improvement
NCT01922011,measures_secondary,Composite End Point
NCT01922011,has_criteria,Pain
NCT01922011,has_criteria,Body temperature ≤ 38°C
NCT01922011,has_criteria,C-reactive Protein decreased
NCT01204593,involves,Type 1 Diabetes Mellitus
NCT01204593,evaluates,baSal BoluS Therapy
NCT01204593,measures_primary,Change in HbA1c
NCT01204593,measures_secondary,Percentage of patients with HbA1c < 7%
NCT01204593,measures_secondary,Fasting Blood Glucose
NCT01204593,measures_secondary,7-point SMBG
NCT01204593,measures_secondary,Daily dose for insulin glulisine
NCT01204593,measures_secondary,Daily dose for insulin glargine
NCT01204593,measures_secondary,Symptomatic hypoglycemias
NCT00879411,involves,hypertension
NCT00879411,evaluates,Telmisartan
NCT00879411,measures_primary,Change of Systolic BP
NCT00879411,measures_primary,Change of Diastolic BP
NCT00879411,has_criteria,recently diagnosed hypertension
NCT00879411,has_criteria,inadequate blood pressure treatment
NCT04871711,involves,Chronic hand eczema
NCT04871711,evaluates,Delgocitinib Cream
NCT04871711,measures_primary,IGA-CHE TS at Week 16
NCT04871711,measures_secondary,Reduction of HESD Itch Score
NCT04871711,measures_secondary,Reduction of HESD Score
NCT04871711,has_criteria,baseline HESD score
NCT00427011,involves,Parkinson's Disease
NCT00427011,evaluates,E2007
NCT00427011,measures_primary,Absolute OFF Time
NCT00427011,measures_secondary,UPDRS Part II
NCT00427011,measures_secondary,UPDRS Part III
NCT03681093,involves,Nasal Polyposis
NCT03681093,involves,Asthma
NCT03681093,evaluates,Fevipiprant
NCT03681093,measures_primary,Change From Baseline in Nasal Polyp Score
NCT03681093,measures_secondary,Change From Baseline in Nasal Congestion Score
NCT03681093,measures_secondary,Change From Baseline in Quality of Life
NCT03681093,measures_secondary,Change From Baseline in Sense of Smell
NCT03681093,has_criteria,Baseline
NCT01243671,involves,Intestinal Behçet's Disease
NCT01243671,evaluates,Adalimumab
NCT01243671,measures_primary,Marked improvement
NCT01243671,measures_secondary,Marked improvement
NCT01243671,has_criteria,Japanese Subjects
NCT03926793,involves,Pulmonary Arterial Hypertension
NCT03926793,evaluates,GB002
NCT03926793,measures_primary,6-Minute Walk Test
NCT03926793,measures_secondary,WHO Functional Class
NCT03926793,measures_secondary,NT-proBNP
NCT03926793,measures_secondary,PAH-SYMPACT
NCT03926793,measures_secondary,Right Ventricular function
NCT03926793,has_criteria,Up to 45 days
NCT03926793,has_criteria,Up to 200 days
NCT01134393,involves,Hypertension
NCT01134393,evaluates,Telmisartan
NCT01134393,evaluates,Amlodipine
NCT01134393,measures_primary,BP Control
NCT01134393,measures_secondary,Pulse Rate
NCT01134393,measures_secondary,Pulse Pressure
NCT01134393,has_criteria,Blood Pressure Control
NCT00687271,involves,Hypercholesterolemia
NCT00687271,evaluates,MK-6213
NCT00687271,measures_primary,LDL-C change
NCT00687271,measures_secondary,Adverse Event
NCT00687271,measures_secondary,Study drug discontinued
NCT00687271,has_criteria,up to 4 weeks
NCT03575871,involves,Atopic Dermatitis
NCT03575871,evaluates,PF-04965842
NCT03575871,measures_primary,IGA response at Week 12
NCT03575871,measures_secondary,EASI-75 response at Week 12
NCT03575871,has_criteria,Aged 12 years and older
NCT01910571,evaluates,P7435
NCT01910571,involves,overweight
NCT01910571,involves,obese
NCT01910571,measures_primary,AUC
NCT01910571,measures_primary,Cmax
NCT01910571,measures_primary,tmax
NCT01910571,measures_primary,tlag
NCT01910571,measures_primary,kel
NCT01910571,measures_primary,t½
NCT01910571,measures_secondary,Fasting serum lipids
NCT01910571,has_criteria,healthy subjects
NCT05070871,involves,Osteoarthritis
NCT05070871,evaluates,Salmon Bone Meal
NCT05070871,measures_primary,WOMAC composite score
NCT05070871,measures_secondary,Pain intensity
NCT05070871,measures_secondary,Global Assessment Scale
NCT05070871,measures_secondary,Numerical Rating Scale
NCT05070871,measures_secondary,Rescue medications
NCT05070871,measures_secondary,Quality of life
NCT05070871,has_criteria,Men and Women
NCT00216671,involves,Schizophrenia
NCT00216671,evaluates,Long-acting Injectable Risperidone
NCT00216671,measures_primary,PANSS Total Score
NCT00216671,measures_secondary,Clinical Global Impression - Severity
NCT00216671,measures_secondary,Global Assessment of Functioning
NCT00216671,has_criteria,acute episode
NCT06047171,involves,rapidly progressive glomerulonephritis
NCT06047171,evaluates,ALE.F02
NCT06047171,measures_primary,safety and tolerability
NCT06047171,measures_secondary,change in eGFR
NCT06047171,measures_secondary,change in UPCR AUC
NCT06047171,measures_secondary,time to stable proteinuria
NCT06047171,measures_secondary,time to stable hematuria
NCT06047171,measures_secondary,incidence of RRT
NCT06047171,measures_secondary,total glucocorticoid and immunosuppressive exposure
NCT06047171,has_criteria,AAV attributed
NCT03170193,evaluates,AMG 529
NCT03170193,measures_primary,Maximum Observed Concentration
NCT03170193,measures_secondary,Time to Maximum Observed Concentration
NCT03170193,measures_secondary,Area Under the Curve From Time 0 to the Last Quantifiable Concentration
NCT03170193,has_criteria,fatal
NCT03170193,has_criteria,life threatening
NCT03170193,has_criteria,hospitalization
NCT03170193,has_criteria,persistent disability
NCT03170193,has_criteria,congenital anomaly
NCT03682471,involves,Submental Fat
NCT03682471,evaluates,ATX-101
NCT03682471,measures_primary,% CR-SMFRS 1-Grade Responders
NCT03682471,measures_secondary,% SSRS Responders
NCT03682471,has_criteria,LTFU Baseline to Month 24
NCT00700271,involves,Hypertension
NCT00700271,evaluates,Amlodipine/Valsartan
NCT00700271,measures_primary,24-hour SBP
NCT00700271,measures_secondary,Nocturnal SBP
NCT00700271,measures_secondary,Diurnal SBP
NCT00700271,has_criteria,Screening period
NCT00675493,involves,Type 1 Diabetes
NCT00675493,involves,Type 2 Diabetes
NCT00675493,evaluates,NovoMix®30
NCT00675493,measures_primary,Change in HbA1c
NCT00675493,measures_secondary,Percentage of subjects achieving HbA1c below 7.0%
NCT00675493,measures_secondary,Change in FPG
NCT00675493,measures_secondary,Change in PPG
NCT00675493,measures_secondary,Change in insulin dose
NCT00675493,measures_secondary,Change in oral antidiabetic drug therapy
NCT00675493,measures_secondary,Change in body weight
NCT00675493,measures_secondary,Change in number of hypoglycaemic events
NCT00675493,measures_secondary,Number of adverse drug reactions
NCT00675493,has_criteria,Type 1 and type 2 diabetics
NCT00675493,has_criteria,treated with human premix insulin
NCT00675493,has_criteria,not currently being treated with biphasic insulin aspart 30
NCT00675493,has_criteria,not previously enrolled in this study
NCT00675493,has_criteria,no hypersensitivity to biphasic insulin aspart 30
NCT00675493,has_criteria,not pregnant or intending to become pregnant
NCT00675493,has_criteria,10 years of age or older
NCT01098071,involves,Adenoids Hypertrophy
NCT01098071,evaluates,Nasonex
NCT01098071,measures_primary,Nasal Obstruction Symptoms
NCT01098071,measures_secondary,Posterior Choana Obstruction
NCT01098071,measures_secondary,Number of Participants Referred
NCT01098071,measures_secondary,Severity of Rhinorrhea
NCT01098071,measures_secondary,Severity of Nasal Congestion
NCT01098071,measures_secondary,Severity of Nasal Itching
NCT01098071,has_criteria,Baseline to 12 weeks
NCT03595371,involves,Schnitzler's Syndrome
NCT03595371,evaluates,Dapansutrile Capsules
NCT03595371,measures_primary,SchS Symptom Index
NCT03595371,measures_secondary,Grade 0 or 1 symptoms
NCT03595371,has_criteria,Day 14
NCT02006628,involves,Schizophrenia
NCT02006628,involves,Psychotic Disorder
NCT02006628,evaluates,GWP42003
NCT02006628,measures_primary,PANSS Total Score
NCT02006628,measures_secondary,PANSS 'P' Score
NCT02006628,measures_secondary,PANSS 'N' Score
NCT02006628,has_criteria,Day 1 through Day 43
NCT03921528,involves,Spinal Muscular Atrophy
NCT03921528,evaluates,SRK-015
NCT03921528,measures_primary,change from baseline
NCT03921528,measures_secondary,Hammersmith Functional Motor Scale Expanded Total Score
NCT03921528,has_criteria,5-21 years of age
NCT06293261,involves,Hypertension
NCT06293261,involves,Hypercholesterolemia
NCT06293261,evaluates,Rosuampin
NCT06293261,measures_primary,MACCE
NCT06293261,measures_primary,SBP
NCT06293261,measures_primary,DBP
NCT06293261,measures_primary,Lipid Profile
NCT06293261,measures_primary,hs-CRP
NCT06293261,measures_primary,Fasting Blood Glucose
NCT06293261,measures_primary,HbA1c
NCT06293261,has_criteria,Aged ≥ 19 years
NCT06293261,has_criteria,Hypertension and hypercholesterolemia
NCT06293261,has_criteria,Rosuampin medication
NCT06293261,has_criteria,Written informed consent
NCT06293261,has_criteria,Hypersensitivity
NCT06293261,has_criteria,Pregnancy
NCT06293261,has_criteria,Liver failure
NCT06293261,has_criteria,Liver disease
NCT06293261,has_criteria,Aortic valvular stenosis
NCT06293261,has_criteria,Myopathy
NCT06293261,has_criteria,Cyclosporine
NCT06293261,has_criteria,Renal failure
NCT02105961,involves,Chronic Obstructive Pulmonary Disease
NCT02105961,evaluates,Mepolizumab
NCT02105961,measures_primary,Time to First Exacerbation
NCT02105961,measures_secondary,Rate of COPD Exacerbations
NCT02105961,measures_secondary,Change From Baseline in Mean SGRQ Score
NCT02105961,has_criteria,randomized participants
NCT05371028,involves,Short Bowel Syndrome
NCT05371028,evaluates,Teduglutide
NCT05371028,measures_primary,Change From Baseline
NCT05371028,measures_secondary,PN/IV Usage
NCT05371028,measures_secondary,Number of Participants Achieving Response
NCT05371028,measures_secondary,Percentage of Participants Achieving PN/IV Independence
NCT05371028,has_criteria,Up to 48 Months
NCT02116361,involves,Major Depressive Disorder
NCT02116361,evaluates,OnabotulinumtoxinA
NCT02116361,measures_primary,MADRS Total Score
NCT02116361,measures_secondary,CGI-S Score
NCT02116361,has_criteria,Adult Females
NCT04669028,involves,Alzheimer's Disease
NCT04669028,evaluates,NE3107
NCT04669028,measures_primary,CDR-SB
NCT04669028,measures_primary,ADAS-Cog12
NCT04669028,measures_secondary,ADCOMS
NCT04669028,measures_secondary,Activities of Daily Living Scale
NCT04669028,measures_secondary,Mini Mental State Exam
NCT04669028,measures_secondary,ADCS CGIC
NCT04669028,has_criteria,baseline and week 30
NCT01723228,involves,Parkinson's Disease
NCT01723228,evaluates,Rasagiline
NCT01723228,measures_primary,Change From Baseline
NCT01723228,measures_secondary,Montreal Cognitive Assessment
NCT01723228,measures_secondary,Penn Daily Activities Questionnaire
NCT01723228,measures_secondary,ADCS MCI-CGIC Score
NCT01723228,measures_secondary,Unified Parkinson's Disease Rating Scale
NCT01723228,has_criteria,Baseline to Week 24
NCT00770861,involves,hypertension
NCT00770861,evaluates,Nebivolol
NCT00770861,measures_primary,DBP at Week 8
NCT00770861,measures_secondary,SBP at Week 8
NCT00770861,has_criteria,Hispanic or Latino ethnicity
NCT00770861,has_criteria,18 to 80 years
NCT00770861,has_criteria,post-menopausal
NCT00770861,has_criteria,stage I or II hypertension
NCT00770861,has_criteria,no more than two anti-hypertensive medications
NCT00770861,has_criteria,uncontrolled diabetes mellitus
NCT01945593,involves,Hemophilia A
NCT01945593,evaluates,BAX 855
NCT01945593,measures_primary,Annualized Bleed Rate
NCT01945593,measures_secondary,Hemostatic Efficacy Rating
NCT01945593,has_criteria,Inhibitory antibodies to FVIII
NCT05220293,involves,Eosinophilic Chronic Rhinosinusitis
NCT05220293,evaluates,Betamethasone Dipropionate Nasal Cream
NCT05220293,measures_primary,Change in 4CSS
NCT05220293,measures_secondary,Change in VAS
NCT05220293,measures_secondary,Change in SNOT-22 Score
NCT05220293,measures_secondary,Change in Modified Lund Mackay Postoperative Endoscopy Score
NCT05220293,measures_secondary,Patient Global Impression of Change
NCT05220293,has_criteria,Adult patients with eCRS
NCT05220293,has_criteria,Undergoing maximal medical therapy
NCT05220293,has_criteria,Functional endoscopic sinus surgery
NCT05220293,has_criteria,Endoscopic bilateral nasal polyp score
NCT05310071,involves,Early Alzheimer's Disease
NCT05310071,evaluates,Aducanumab
NCT05310071,measures_primary,Change From Baseline
NCT05310071,measures_secondary,Integrated Alzheimer's Disease Rating Scale
NCT05310071,measures_secondary,ADCS-ADL-MCI Score
NCT05310071,measures_secondary,ADAS-Cog13 Score
NCT05310071,has_criteria,Baseline
NCT05310071,has_criteria,Baseline
NCT00603993,involves,Rheumatoid Arthritis
NCT00603993,evaluates,Adalimumab
NCT00603993,measures_primary,ACR20/50/70 Responders
NCT00603993,measures_secondary,Tender Joint Count
NCT00603993,measures_secondary,Swollen Joint Count
NCT00603993,measures_secondary,Physician's Global Assessment
NCT00603993,has_criteria,American College of Rheumatology
NCT04882293,involves,Type 2 Diabetes
NCT04882293,involves,Dyslipidemia
NCT04882293,evaluates,Atorvastatin/Fenofibrate
NCT04882293,evaluates,Atorvastatin
NCT04882293,measures_primary,Triglyceride levels
NCT04882293,measures_secondary,LDL cholesterol
NCT04882293,measures_secondary,Weight
NCT04882293,measures_secondary,BMI
NCT04882293,measures_secondary,Waist circumference
NCT04882293,measures_secondary,AST
NCT04882293,measures_secondary,ALT
NCT04882293,measures_secondary,HbA1c
NCT04882293,measures_secondary,Glucose levels
NCT04882293,has_criteria,Baseline measurement
NCT01439971,involves,Hemophilia
NCT01439971,evaluates,Recombinant Factor VIIa Variant (813d)
NCT01439971,measures_primary,Change From Baseline in SBP
NCT01439971,measures_primary,Change From Baseline in DBP
NCT01439971,measures_secondary,Change From Baseline in Body Weight
NCT01439971,measures_secondary,Change From Baseline in Body Temperature
NCT01439971,measures_secondary,Change From Baseline in Respiration Rate
NCT01439971,measures_secondary,Change From Baseline in Supine Pulse Rate
NCT01439971,has_criteria,Physical examinations
NCT03185793,involves,Hyperuricemia
NCT03185793,evaluates,SHR4640
NCT03185793,measures_primary,serum uric level
NCT03185793,measures_secondary,gout flares
NCT03185793,has_criteria,serum uric level
NCT02663193,involves,cancer
NCT02663193,evaluates,Enzalutamide
NCT02663193,evaluates,Abiraterone Acetate
NCT02663193,evaluates,Prednisone
NCT02663193,measures_primary,Change From Baseline
NCT02663193,measures_secondary,European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30
NCT02663193,measures_secondary,Functional Assessment of Chronic Illness Therapy Fatigue subscale (FACIT-Fatigue)
NCT02663193,measures_secondary,Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog)
NCT02663193,has_criteria,cancer participants
NCT00849693,involves,Major Depressive Disorder
NCT00849693,measures_primary,Change From Baseline
NCT06617793,involves,Relapsing Multiple Sclerosis
NCT06617793,evaluates,YTB323
NCT06617793,measures_primary,Expanded Disability Status Scale
NCT06617793,measures_secondary,Short Form Health Survey
NCT06617793,measures_secondary,Timed 25 Foot Walk
NCT06617793,measures_secondary,9 Hole Peg Test
NCT00956293,involves,Renal Transplant
NCT00956293,evaluates,Everolimus
NCT00956293,measures_primary,Renal Function
NCT00956293,measures_secondary,Acute Rejection
NCT00956293,has_criteria,de Novo Recipients
NCT02925793,involves,atopic dermatitis
NCT02925793,evaluates,DS107 Cream
NCT02925793,measures_primary,Change from baseline
NCT02925793,measures_secondary,Eczema Area and Severity Index
NCT02925793,has_criteria,Baseline and Week 8
NCT04115293,involves,Generalized Myasthenia Gravis
NCT04115293,evaluates,Zilucoplan
NCT04115293,measures_primary,Change From Baseline
NCT04115293,measures_secondary,Quantitative Myasthenia Gravis
NCT04115293,measures_secondary,Myasthenia Gravis Composite
NCT04115293,measures_secondary,Myasthenia Gravis-Activities of Daily Living
NCT04115293,measures_secondary,Myasthenia Gravis - Quality of Life Revised
NCT02580305,involves,Alzheimer's Disease
NCT02580305,evaluates,SUVN-502
NCT02580305,measures_primary,Change From Baseline
NCT02580305,measures_secondary,Clinical Dementia Rating Scale - Sum of Boxes
NCT02580305,measures_secondary,Alzheimer's Disease Cooperative Study Group-Activities of Daily Living
NCT02580305,measures_secondary,Neuropsychiatric Inventory
NCT02580305,has_criteria,Baseline to Week 26
NCT05013905,involves,Crohn's Disease
NCT05013905,evaluates,PRA023
NCT05013905,measures_primary,Endoscopic Improvement
NCT05013905,measures_secondary,Clinical Remission
NCT05013905,measures_secondary,Endoscopic and Clinical Improvement
NCT05013905,measures_secondary,Number of Participants Achieving a Composite Response
NCT05013905,measures_secondary,Normalization of C-reactive Protein
NCT05013905,measures_secondary,Normalization of Fecal Calprotectin
NCT05013905,measures_secondary,Clinical Response
NCT05013905,measures_secondary,Two Component Patient-reported Outcome (PRO-2) Remission
NCT05013905,has_criteria,Moderately to Severely Active
NCT00548405,involves,Multiple Sclerosis
NCT00548405,evaluates,Alemtuzumab
NCT00548405,evaluates,Rebif
NCT00548405,measures_primary,Sustained Accumulation of Disability
NCT00548405,measures_secondary,Annualized Relapse Rate
NCT00548405,measures_secondary,Relapse Free at Year 2
NCT00548405,has_criteria,Baseline score of 0
NCT00548405,has_criteria,Baseline score of 1.0 or more
NCT00548405,has_criteria,at least 48 hours
NCT00548405,has_criteria,at least 30 days of clinical stability
NCT02039505,involves,Ulcerative Colitis
NCT02039505,evaluates,MLN0002
NCT02039505,measures_primary,Clinical Response
NCT02039505,measures_primary,Clinical Remission
NCT02039505,measures_secondary,Treatment-Emergent Adverse Events
NCT02039505,has_criteria,complete Mayo score
NCT03622905,involves,Alzheimer's disease
NCT03622905,evaluates,DBS-f
NCT03622905,measures_primary,iADRS score
NCT03622905,measures_secondary,CDR-SB
NCT03622905,has_criteria,65 years old
NCT03622905,has_criteria,probable Alzheimer's disease
NCT03622905,has_criteria,CDR global rating 0.5 or 1
NCT03622905,has_criteria,ADAS-cog-11 score 10-24
NCT03622905,has_criteria,CSF biomarkers
NCT00988221,involves,Polyarticular Juvenile Idiopathic Arthritis
NCT00988221,evaluates,Tocilizumab
NCT00988221,measures_primary,ACR30 flare
NCT00988221,measures_secondary,ACR30/50/70/90 responses
NCT00988221,has_criteria,methotrexate and oral corticosteroids
NCT02784964,involves,Knee Osteoarthritis
NCT02784964,evaluates,Adipose-derived Stem Cells
NCT02784964,measures_primary,WOMAC pain score
NCT02784964,measures_secondary,Visual Analogue Scale
NCT02784964,measures_secondary,Knee Society Clinical Rating System Score
NCT02784964,measures_secondary,MRI examination results
NCT02784964,measures_secondary,WOMAC total score
NCT02784964,measures_secondary,acetaminophen consumption
NCT02784964,measures_secondary,NSAID consumption
NCT02784964,measures_secondary,time to acetaminophen consumption
NCT02784964,measures_secondary,time to NSAID consumption
NCT02784964,measures_secondary,clinically abnormal laboratory values
NCT02784964,measures_secondary,clinically abnormal vital signs
NCT02784964,measures_secondary,cartilage thickness
NCT02784964,has_criteria,aged 40-80 years
NCT02784964,has_criteria,Kellgren-Lawrence grading I-III
NCT02784964,has_criteria,WOMAC pain score 7-17
NCT06446921,involves,Digestive Complaints
NCT06446921,evaluates,Ginger Supplement
NCT06446921,measures_primary,Gastric emptying
NCT06446921,measures_secondary,Leuven Postprandial Distress scale
NCT06446921,measures_secondary,Short Form Nepean Dyspepsia Index
NCT06446921,measures_secondary,Overall Treatment Effect
NCT06446921,has_criteria,healthy adults
NCT00040664,involves,HIV-1
NCT00040664,evaluates,Amprenavir
NCT00040664,measures_primary,Number of Participants
NCT00040664,measures_secondary,Adverse Events
NCT00040664,has_criteria,Ages 2-18 Years
NCT05071664,involves,Psoriatic Arthritis
NCT05071664,evaluates,Guselkumab
NCT05071664,evaluates,Golimumab
NCT05071664,measures_primary,Minimal Disease Activity
NCT05071664,measures_secondary,ACR 50
NCT05071664,has_criteria,Week 24
NCT00505284,involves,Painful Diabetic Neuropathy
NCT00505284,evaluates,E2007
NCT00505284,measures_primary,Change in Pain Scores
NCT00505284,measures_secondary,Sleep Interference Scores
NCT00505284,has_criteria,Baseline to Week 15/EOT
NCT02287584,involves,Schizophrenia
NCT02287584,evaluates,DSP-5423P
NCT02287584,measures_primary,PANSS Total Score
NCT02287584,measures_secondary,Proportion of Subjects Who Achieve a Response
NCT02287584,has_criteria,20% or Greater Improvement
NCT05068284,involves,Crohn's Disease
NCT05068284,evaluates,ABBV-154
NCT05068284,measures_primary,Endoscopic Response
NCT05068284,measures_secondary,Clinical Remission
NCT05068284,measures_secondary,SF/AP
NCT05068284,has_criteria,18 to 75 Years
NCT02410902,involves,Autism
NCT02410902,evaluates,CM-AT
NCT02410902,measures_primary,ABC-I irritability
NCT02410902,measures_secondary,ABC-L lethargy
NCT02410902,has_criteria,3 through 6 years old
NCT04994002,involves,Complex Lymphatic Malformations
NCT04994002,evaluates,CERC-006
NCT04994002,measures_primary,incidence of adverse events
NCT04994002,measures_secondary,radiologic assessment
NCT04994002,measures_secondary,SF-36 score
NCT04994002,measures_secondary,Karnofsky Performance Status Score
NCT04994002,measures_secondary,Pain Scale Assessment
NCT04994002,has_criteria,Adults 18-31 Years
NCT02615002,involves,Alzheimer's Disease
NCT02615002,evaluates,Piromelatine
NCT02615002,measures_primary,cNTB Z-Scores
NCT02615002,measures_secondary,Global Impression of Change
NCT02615002,has_criteria,Mild Cognitive Impairment
NCT05349721,involves,Amyotrophic Lateral Sclerosis
NCT05349721,evaluates,PTC857
NCT05349721,measures_primary,ALSFRS-R Score
NCT05349721,measures_secondary,Slow Vital Capacity
NCT05349721,measures_secondary,Sniff Nasal Inspiratory Pressure
NCT05349721,measures_secondary,Modified Norris Scale
NCT05349721,measures_secondary,Rate of Death
NCT05349721,measures_secondary,Length of Time to Death
NCT05349721,measures_secondary,ALS Assessment Questionnaire
NCT05349721,measures_secondary,Neurofilament Light Chain
NCT05349721,has_criteria,decrease in ALSFRS-R score
NCT03817502,involves,Schizophrenia
NCT03817502,evaluates,Cariprazine
NCT03817502,measures_primary,PANSS total score
NCT03817502,measures_secondary,
NCT03817502,has_criteria,DSM-5 primary diagnosis of schizophrenia
NCT03817502,has_criteria,K-SADS-PL administered
NCT03817502,has_criteria,PANSS score ≥ 70
NCT03817502,has_criteria,CGI-S scale score of ≥ 4
NCT03817502,has_criteria,Current diagnosis of bipolar disorder
NCT03817502,has_criteria,Diagnosis of intellectual disability
NCT03817502,has_criteria,History of meeting DSM-5 diagnosis for any substance-related disorder
NCT01703702,involves,Alzheimer's Disease
NCT01703702,evaluates,Florbetapir (18F) PET Imaging
NCT01703702,measures_primary,Change in ADAS-Cog
NCT01703702,measures_secondary,Change in Patient Management
NCT01703702,measures_secondary,Change in Diagnostic Confidence
NCT01703702,has_criteria,mild impairment
NCT03619902,involves,Generalized Pustular Psoriasis
NCT03619902,evaluates,Imsidolimab
NCT03619902,measures_primary,Clinical Response
NCT03619902,measures_secondary,JDA-SI Total Score
NCT03619902,has_criteria,JDA-SI total score
NCT05861102,involves,Ankylosing Spondylitis
NCT05861102,evaluates,Jaktinib
NCT05861102,measures_primary,ASAS40 response
NCT05861102,measures_secondary,ASAS20 response
NCT05861102,has_criteria,Informed consent
NCT02054702,involves,Acute Schizophrenia
NCT02054702,evaluates,Brexpiprazole
NCT02054702,measures_primary,PANSS total score
NCT02054702,measures_secondary,Cognitive Test Battery Composite Score
NCT02054702,has_criteria,Baseline to Week 6
NCT04493502,involves,Hidradenitis Suppurativa
NCT04493502,evaluates,LY3041658
NCT04493502,measures_primary,HiSCR at Week 16
NCT04493502,measures_secondary,Mean Change in AN count
NCT04493502,has_criteria,HS diagnosis for at least 6 months
NCT04493502,has_criteria,HS lesions in at least 2 areas
NCT04493502,has_criteria,Inadequate response to oral antibiotics
NCT04493502,has_criteria,Total AN count >= 4
NCT04493502,has_criteria,Agree to use topical antiseptic
NCT04493502,has_criteria,Agree to stop topical antibiotics
NCT01552902,involves,Attention-deficit/Hyperactivity Disorder
NCT01552902,evaluates,Vyvanse
NCT01552902,evaluates,Concerta
NCT01552902,measures_primary,ADHD-RS-IV Total Score
NCT01552902,measures_secondary,Clinical Global Impression - Global Improvement
NCT01552902,has_criteria,13-17 years old
NCT01552902,has_criteria,>79.5lb
NCT01552902,has_criteria,available at 7:00AM
NCT01552902,has_criteria,female
NCT00778921,involves,Hypertension
NCT00778921,evaluates,Aliskiren/Amlodipine
NCT00778921,measures_primary,msDBP change
NCT00778921,measures_secondary,Adverse Events
NCT00778921,has_criteria,msDBP ≥ 90 mmHg
NCT00778921,has_criteria,msDBP < 110 mmHg
NCT00778921,has_criteria,Pregnant women exclusion
NCT00778921,has_criteria,Hypertension history exclusion
NCT04041284,involves,Migraine
NCT04041284,involves,Major Depressive Disorder
NCT04041284,evaluates,Fremanezumab
NCT04041284,measures_primary,Change in Migraine Days
NCT04041284,measures_secondary,HAM-D 17 Items Total Score
NCT04041284,has_criteria,Baseline to Week 12
NCT02391584,involves,Eustachian Tube Dysfunction
NCT02391584,evaluates,XprESS Eustachian Tube Dilation
NCT02391584,measures_primary,Mean Change in ETDQ-7 Score
NCT02391584,measures_secondary,Complication Rate
NCT02391584,measures_secondary,Technical Success Rate
NCT02391584,measures_secondary,Revision Rate
NCT02391584,has_criteria,6 weeks post procedure
NCT02391584,has_criteria,12 months
NCT01198002,involves,Rheumatoid Arthritis
NCT01198002,evaluates,Methotrexate
NCT01198002,measures_primary,ACR20 response
NCT01198002,measures_secondary,Van Der Heijde Modified Total Sharp Score
NCT01198002,has_criteria,≥20% improvement
NCT04909502,involves,Multiple Sclerosis
NCT04909502,evaluates,EHP-101
NCT04909502,measures_primary,Brain lesion activity
NCT04909502,measures_secondary,Disease progression
NCT04909502,measures_secondary,Disability status
NCT04909502,has_criteria,168 days (24 weeks)
NCT04895202,involves,Multiple Sclerosis
NCT04895202,evaluates,Mayzent
NCT04895202,measures_primary,6 month confirmed progression
NCT04895202,measures_secondary,SDMT score
NCT04895202,has_criteria,EDSS score ≤ 5
NCT04640584,involves,Mobility impairment
NCT04640584,evaluates,C-Brace
NCT04640584,measures_primary,Timed Walk Test
NCT04640584,measures_primary,Timed Up and Go Test
NCT04640584,measures_primary,Activities-specific Balance Confidence
NCT04640584,measures_secondary,Changes in mobility
NCT04640584,measures_secondary,Changes in balance
NCT04640584,measures_secondary,Risk of falling
NCT04640584,measures_secondary,Changes in walking ability
NCT04640584,has_criteria,Baseline measurements
NCT05029921,involves,Crohn's Disease
NCT05029921,evaluates,Ustekinumab
NCT05029921,measures_primary,Clinical Remission at Week 8
NCT05029921,measures_primary,Endoscopic Response at Week 16
NCT05029921,measures_secondary,Clinical Remission at Week 52
NCT05029921,measures_secondary,Patient-reported Outcome (PRO)-2 Remission at Week 8
NCT05029921,has_criteria,CDAI score less than 150
NCT05029921,has_criteria,SES-CD score less than or equal to 2
NCT05029921,has_criteria,AP mean daily score at or below 1
NCT05819021,involves,Major Depressive Disorder
NCT05819021,evaluates,SAINT® therapy
NCT05819021,measures_primary,CGI-I score change
NCT05819021,measures_secondary,MADRS score change
NCT05819021,measures_secondary,Cambridge Brain Science Tools
NCT05819021,measures_secondary,CGI-S score change
NCT05819021,has_criteria,Inclusion Criteria
NCT02028884,involves,Neuromyelitis Optica
NCT02028884,involves,Neuromyelitis Optica Spectrum Disorder
NCT02028884,evaluates,Satralizumab
NCT02028884,measures_primary,Time to First Relapse
NCT02028884,measures_secondary,Change From Baseline
NCT02028884,has_criteria,Protocol-defined relapse
NCT00454584,involves,Plaque Psoriasis
NCT00454584,evaluates,CNTO 1275
NCT00454584,evaluates,Etanercept
NCT00454584,measures_primary,PASI 75 score
NCT00454584,measures_secondary,PGA score
NCT00454584,measures_secondary,PASI 90 score
NCT00454584,measures_secondary,PASI difference
NCT00454584,has_criteria,Baseline visit
NCT02762084,involves,Gorlin Syndrome
NCT02762084,involves,Basal Cell Carcinomas
NCT02762084,evaluates,Patidegib Gel
NCT02762084,measures_primary,Percent Change in Tumor Size
NCT02762084,measures_secondary,GLI1 mRNA Levels
NCT02762084,has_criteria,clinically diagnosed BCC
NCT06383702,involves,Painful Diabetic Peripheral Neuropathy
NCT06383702,evaluates,Pregabalin
NCT06383702,measures_primary,NRS mean change
NCT06383702,measures_secondary,SF-MPQ score
NCT06383702,measures_secondary,MOS-SS score
NCT06383702,has_criteria,≥ 50% and ≥ 30% change
NCT05248802,involves,Functional Dyspepsia
NCT05248802,evaluates,DLBS2411
NCT05248802,measures_primary,SF-NDI score
NCT05248802,measures_secondary,VAS pain intensity
NCT05248802,measures_secondary,Symptom relief
NCT05248802,has_criteria,18-75 years old
NCT05248802,has_criteria,signed informed consent
NCT02191202,involves,HIV
NCT02191202,evaluates,NNRTI
NCT02191202,measures_primary,WHOQOL-HIV score
NCT02191202,measures_secondary,SF12 scores
NCT02191202,measures_secondary,symptom scale score
NCT02191202,measures_secondary,HADS
NCT02191202,measures_secondary,CD4 cell count
NCT02191202,measures_secondary,viral load
NCT02191202,measures_secondary,liver function tests
NCT02191202,measures_secondary,total cholesterol
NCT02191202,measures_secondary,triglycerides
NCT02191202,measures_secondary,fasting blood glucose
NCT02191202,measures_secondary,haemoglobin
NCT02191202,measures_secondary,plasma urea
NCT02191202,measures_secondary,creatinine
NCT02191202,has_criteria,NNRTI-naive patients
NCT02191202,has_criteria,positive HIV serology
NCT02191202,has_criteria,viral load < 500 copies/ml
NCT02191202,has_criteria,read and write French
NCT00424502,involves,Rheumatoid Arthritis
NCT00424502,evaluates,MabThera
NCT00424502,measures_primary,DAS28
NCT00424502,measures_secondary,HAQ-DI
NCT00424502,measures_secondary,Anti-CCP
NCT00424502,measures_secondary,VEGF
NCT00424502,measures_secondary,ESR
NCT00424502,measures_secondary,CRP
NCT00424502,has_criteria,adult patients
NCT00424502,has_criteria,>=18 years
NCT00424502,has_criteria,diagnosed RA
NCT00424502,has_criteria,>=3 months
NCT00424502,has_criteria,inadequate response
NCT00424502,has_criteria,anti-TNF therapies
NCT00424502,has_criteria,methotrexate
NCT05956002,evaluates,Etrasimod
NCT05956002,measures_primary,Area under the curve
NCT05956002,measures_secondary,Cmax
NCT05956002,measures_secondary,Number of participants
NCT05956002,measures_secondary,Treatment Emergent Treatment-Related Adverse Events
NCT05956002,measures_secondary,clinically significant clinical laboratory abnormalities
NCT05956002,measures_secondary,clinically significant vital signs change
NCT05956002,measures_secondary,clinically significant physical exam changes
NCT05956002,measures_secondary,clinically significant electrocardiogram changes
NCT05956002,measures_secondary,Mean degree of likeness of mouth feel
NCT05956002,measures_secondary,Mean degree of likeness of bitterness
NCT05956002,measures_secondary,Mean degree of likeness of tongue/mouth burn
NCT03774784,involves,ALECT2
NCT03774784,measures_primary,eGFR change
NCT03774784,measures_secondary,Time to ESRD
NCT03774784,has_criteria,Age 18 or older
NCT03774784,has_criteria,Renal biopsy-proven ALECT2
NCT00329602,involves,Restless Legs Syndrome
NCT00329602,evaluates,Ropinirole
NCT00329602,measures_primary,Change in IRLS score
NCT00329602,measures_secondary,Augmentation and EMR cases
NCT00329602,has_criteria,15-month study duration
NCT02581202,involves,HIV infection
NCT02581202,evaluates,Lopinavir/Ritonavir + Lamivudine
NCT02581202,measures_primary,Undetectable HIV-1 RNA
NCT02581202,measures_secondary,HIV-1 RNA viral load
NCT02581202,measures_secondary,CD4+ T-cell Counts
NCT02581202,measures_secondary,Resistance to NRTIs
NCT02581202,measures_secondary,Resistance to NNRTIs
NCT02581202,measures_secondary,Resistance to PIs
NCT02581202,measures_secondary,Anthropometric Measurements
NCT02581202,measures_secondary,Metabolic Parameters
NCT05224102,involves,Diabetic Macular Edema
NCT05224102,evaluates,Faricimab
NCT05224102,measures_primary,Best Corrected Visual Acuity
NCT05224102,measures_secondary,Ocular Adverse Events
NCT05224102,measures_secondary,Non-Ocular Adverse Events
NCT05224102,has_criteria,Treatment-Naive
NCT05224102,has_criteria,Underrepresented Patients
NCT02904902,involves,Hidradenitis Suppurativa
NCT02904902,evaluates,Adalimumab
NCT02904902,measures_primary,HiSCR at Week 12
NCT02904902,measures_secondary,AN Count of 0
NCT02904902,measures_secondary,Patient's Global Assessment of Skin Pain
NCT02904902,measures_secondary,Modified Sartorius Scale Score
NCT02904902,has_criteria,Baseline Numeric Rating Scale
NCT04944602,involves,Chronic Spontaneous Urticaria
NCT04944602,evaluates,SYN008
NCT04944602,evaluates,Xolair
NCT04944602,measures_primary,Weekly Itch Severity Score
NCT04944602,measures_primary,Urticaria Activity Score Over 7 Days
NCT04944602,measures_primary,Weekly Number of Hives Score
NCT04944602,measures_secondary,Hives Severity Score
NCT04944602,has_criteria,Refractory
NCT05051202,involves,Gastrointestinal symptoms
NCT05051202,evaluates,Sugars From Fiber
NCT05051202,measures_primary,Gastrointestinal symptoms
NCT05051202,measures_secondary,Bristol Stool Scale score
NCT05051202,has_criteria,Dietary fiber
NCT02955602,involves,Primary Biliary Cholangitis
NCT02955602,evaluates,Seladelpar
NCT02955602,measures_primary,Relative change from baseline in serum ALP levels at Week 8
NCT02955602,measures_secondary,Change in Aspartate Aminotransferase
NCT02955602,measures_secondary,Change in Alanine Aminotransferase
NCT02955602,measures_secondary,Change in Gamma-glutamyl Transferase
NCT02955602,measures_secondary,Change in Bilirubin - Total Bilirubin
NCT02955602,has_criteria,confirmed PBC
NCT02320721,involves,Type2 Diabetes
NCT02320721,evaluates,HOE901-U300
NCT02320721,evaluates,Lantus
NCT02320721,measures_primary,Change in HbA1c
NCT02320721,measures_secondary,Nocturnal Hypoglycemia
NCT02320721,measures_secondary,Hypoglycemia
NCT02320721,has_criteria,Older patients
NCT01181921,involves,Alzheimer-type dementia
NCT01181921,evaluates,Galantamine
NCT01181921,measures_primary,Sleep/Wake Patterns
NCT01181921,measures_secondary,
NCT01181921,has_criteria,Moderate dementia
NCT05455684,involves,Major Depressive Disorder
NCT05455684,evaluates,Aticaprant
NCT05455684,measures_primary,MADRS Total Score
NCT05455684,measures_secondary,DARS Total Score
NCT05455684,has_criteria,Inadequate Response to Current Antidepressant Therapy
NCT02981602,involves,Chronic HBV Infection
NCT02981602,evaluates,IONIS-HBVRx
NCT02981602,measures_primary,Number of SAEs
NCT02981602,measures_secondary,Change From Baseline
NCT02981602,has_criteria,Treatment-Naïve
NCT04193202,involves,Chronic Cough
NCT04193202,evaluates,Gefapixant
NCT04193202,measures_primary,LCQ total score
NCT04193202,measures_secondary,Cough Severity VAS
NCT04193202,measures_secondary,Adverse Events
NCT04193202,has_criteria,Up to approximately 14 weeks
NCT01896102,involves,Cerebral Adrenoleukodystrophy
NCT01896102,evaluates,Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector
NCT01896102,measures_primary,Month 24 MFD-Free survival
NCT01896102,measures_secondary,Acute Graft Versus Host Disease
NCT01896102,measures_secondary,Chronic Graft Versus Host Disease
NCT01896102,measures_secondary,Gadolinium Positivity on MRI
NCT01896102,has_criteria,alive at 24 months post-infusion
NCT01896102,has_criteria,had not developed any of the MFDs
NCT01896102,has_criteria,had not received rescue cell administration
NCT01896102,has_criteria,had not withdrawn from the study
NCT05976802,involves,Ulcerative Colitis
NCT05976802,evaluates,Budesonide Rectal Foam
NCT05976802,measures_primary,Clinical remission
NCT05976802,measures_secondary,Rectal bleeding subscore
NCT05976802,measures_secondary,Stool frequency subscore
NCT05976802,measures_secondary,Endoscopy subscore
NCT05976802,has_criteria,Age 5 to 17 years
NCT05976802,has_criteria,Established diagnosis UC
NCT05976802,has_criteria,Distal colon involvement
NCT05976802,has_criteria,Active mild to moderate UC
NCT05976802,has_criteria,mMCS 4 to 8
NCT05312021,involves,Heart Failure With Preserved Ejection Fraction
NCT05312021,evaluates,IMR-687
NCT05312021,measures_primary,NT-proBNP change
NCT05312021,measures_secondary,Kansas City Cardiomyopathy Questionnaire
NCT05312021,measures_secondary,NYHA Classification
NCT05312021,measures_secondary,Clinical Composite Score
NCT03548584,involves,Dementia of the Alzheimer's Type
NCT03548584,evaluates,Brexpiprazole
NCT03548584,measures_primary,Change From Baseline
NCT03548584,measures_secondary,Clinical Global Impression Severity
NCT03548584,has_criteria,Baseline and Week 12
NCT01087502,involves,Type-2-diabetes Mellitus
NCT01087502,evaluates,Linagliptin
NCT01087502,measures_primary,HbA1c Change From Baseline
NCT01087502,measures_secondary,Fasting Plasma Glucose Change From Baseline
NCT01087502,measures_secondary,Percentage of Patients With HbA1c <7.0%
NCT01087502,measures_secondary,Percentage of Patients With HbA1c <6.5%
NCT01087502,has_criteria,Moderate to Severe Renal Impairment
NCT01054443,involves,Immune Thrombocytopenia
NCT01054443,evaluates,Lusutrombopag
NCT01054443,measures_primary,Platelet count response
NCT01054443,measures_secondary,Duration of response
NCT01054443,measures_secondary,Bleeding severity
NCT01054443,has_criteria,Platelet count ≥ 50
NCT02307838,involves,Multiple Sclerosis
NCT02307838,evaluates,Fingolimod
NCT02307838,measures_primary,Disability Progression
NCT02307838,measures_secondary,EDSS <4 or <6
NCT02307838,measures_secondary,Not Using Wheelchair
NCT02307838,measures_secondary,Classified as SPMS
NCT02307838,has_criteria,Baseline EDSS score
NCT02384538,involves,Erosive Hand Osteoarthritis
NCT02384538,evaluates,ABT-981
NCT02384538,measures_primary,Pain Subdomain Score
NCT02384538,measures_secondary,Physical Function Subdomain Score
NCT02384538,has_criteria,Week 0 (Baseline)
NCT00785538,involves,Tumors
NCT00785538,evaluates,IMC-A12
NCT00785538,measures_primary,Number of AEs
NCT00785538,measures_secondary,Maximum Tolerated Dose
NCT00785538,has_criteria,Dose-limiting toxicity
NCT06015308,involves,Atopic Dermatitis
NCT06015308,evaluates,Amlitelimab
NCT06015308,measures_primary,Tetanus response
NCT06015308,measures_primary,Pneumococcal vaccine response
NCT06015308,measures_secondary,Treatment-emergent adverse events
NCT06015308,measures_secondary,Potentially clinically significant abnormalities
NCT06015308,measures_secondary,Discontinuation due to TEAEs
NCT06015308,measures_secondary,vIGA-AD
NCT06015308,measures_secondary,EASI score
NCT06015308,has_criteria,Aged 18 years and older
NCT05467943,involves,Follicular Lymphoma
NCT05467943,evaluates,Tazemetostat
NCT05467943,measures_primary,Objective response rate
NCT05467943,measures_secondary,Overall survival
NCT05467943,has_criteria,EZH2 (MT)
NCT05467943,has_criteria,EZH2 (WT)
NCT03452943,involves,Tourette Syndrome
NCT03452943,evaluates,TEV-50717
NCT03452943,measures_primary,Change From Baseline in TTS
NCT03452943,measures_secondary,TS-CGI Score
NCT03452943,has_criteria,age group at baseline
NCT01359943,involves,Rheumatoid Arthritis
NCT01359943,evaluates,Secukinumab
NCT01359943,measures_primary,ACR20 response
NCT01359943,measures_primary,ACR50 response
NCT01359943,measures_primary,ACR70 response
NCT01359943,measures_secondary,HAQ-DI Score
NCT01359943,has_criteria,Methotrexate use
NCT03459443,involves,C3G
NCT03459443,involves,IC-MPGN
NCT03459443,evaluates,ACH-0144471
NCT03459443,measures_primary,Change From Baseline
NCT03459443,measures_secondary,Proteinuria reduction
NCT03459443,measures_secondary,Slope Of eGFR
NCT03985943,involves,Atopic Dermatitis
NCT03985943,evaluates,Nemolizumab
NCT03985943,measures_primary,IGA success
NCT03985943,measures_secondary,EASI-75
NCT03985943,has_criteria,rescue therapy
NCT03810508,involves,Charcot-Marie-Tooth 4J
NCT03810508,evaluates,Magnetic Resonance Imaging
NCT03810508,measures_primary,Change from baseline
NCT03810508,measures_secondary,Pulmonary Function Test
NCT03810508,has_criteria,prior confirmed molecular diagnosis
NCT04205643,involves,Ulcerative Colitis
NCT04205643,evaluates,CT-P13
NCT04205643,measures_primary,Clinical Remission
NCT04205643,measures_secondary,Clinical Response
NCT04205643,measures_secondary,Endoscopic-Histologic Mucosal Improvement
NCT04205643,measures_secondary,Corticosteroid-Free Remission
NCT04205643,has_criteria,aged 18 to 75 years
NCT04476043,involves,Hidradenitis Suppurativa
NCT04476043,evaluates,INCB054707
NCT04476043,measures_primary,AN count at Week 16
NCT04476043,measures_secondary,HiSCR at Week 16
NCT04476043,measures_secondary,HiSCR at Weeks 2 Through 12
NCT04476043,measures_secondary,HiSCR75 From Weeks 2 to 16
NCT04476043,measures_secondary,IHS4 Score From Weeks 2 to 16
NCT04476043,has_criteria,disease severity
NCT04476043,has_criteria,geographical region
NCT02931838,involves,Psoriasis
NCT02931838,evaluates,BMS-986195
NCT02931838,measures_primary,PASI-75 Response Rate
NCT02931838,measures_secondary,PASI-50
NCT02931838,measures_secondary,PASI-90
NCT02931838,measures_secondary,PASI-100
NCT02931838,measures_secondary,sPGA0/1 Response Rate
NCT02931838,has_criteria,Moderate to Severe Psoriasis
NCT04677738,involves,Healthy Adults
NCT04677738,evaluates,Bifidobacterium breve
NCT04677738,measures_primary,Change in Fat loss
NCT04677738,measures_secondary,Body weight
NCT04677738,measures_secondary,BMI
NCT04677738,measures_secondary,Android/gynoid fat ratio
NCT04677738,measures_secondary,Muscle mass
NCT04677738,measures_secondary,Waist circumference
NCT04677738,measures_secondary,Hip circumference
NCT04677738,measures_secondary,Waist/hip circumference ratio
NCT04677738,measures_secondary,Microbiota composition analysis
NCT00902538,involves,Hypertension
NCT00902538,evaluates,Hydrochlorothiazide
NCT00902538,measures_primary,Change in SeDBP
NCT00902538,measures_primary,Change in SeSBP
NCT00902538,measures_secondary,24-hour DBP
NCT00902538,measures_secondary,24-hour SBP
NCT00902538,has_criteria,Seated blood pressure \<140/90 mm Hg
NCT00439738,involves,Hypertensive
NCT00439738,evaluates,Valsartan/Hydrochlorothiazide
NCT00439738,evaluates,Hydrochlorothiazide
NCT00439738,measures_primary,Change in MSSBP
NCT00439738,measures_secondary,Change in MSDBP
NCT00439738,measures_secondary,Blood Pressure Control
NCT00439738,measures_secondary,Postprandial Glucose
NCT00439738,measures_secondary,Postprandial Insulin
NCT00439738,measures_secondary,Postprandial Non-esterified Fatty Acids
NCT00439738,has_criteria,40 years of age
NCT00439738,has_criteria,Moderate or severe high blood pressure
NCT00439738,has_criteria,Central obesity
NCT00439738,has_criteria,Systolic blood pressure < 180 mmHg
NCT00439738,has_criteria,Diastolic blood pressure < 110 mmHg
NCT00439738,has_criteria,Not taking >3 blood pressure medications
NCT00439738,has_criteria,Able to stop blood pressure medications
NCT00439738,has_criteria,No history of Type 1 or Type 2 diabetes
NCT00439738,has_criteria,No history of stroke
NCT01336738,involves,Type 2 Diabetes Mellitus
NCT01336738,evaluates,PF-04991532
NCT01336738,measures_primary,Change From Baseline in HbA1c
NCT01336738,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT01336738,measures_secondary,Change From Baseline in Body Weight
NCT01336738,measures_secondary,Percentage of Participants Achieving Less Than (<) 6.5% or <7% Glycosylated Hemoglobin (HbA1c) Levels
NCT01336738,measures_secondary,Percentage of Participants With Greater Than or Equal to (>=) 1% or >= 2% Body Weight Gain From Baseline
NCT00773838,involves,Multiple Myeloma
NCT00773838,evaluates,Vorinostat
NCT00773838,evaluates,Bortezomib
NCT00773838,measures_primary,Objective Response Rate
NCT00773838,measures_secondary,Adverse Event
NCT00773838,has_criteria,Relapsed or Refractory
NCT03486938,involves,Mild Cognitive Impairment Due to Alzheimer's Disease
NCT03486938,evaluates,AGB101
NCT03486938,measures_primary,Change in CDR-SB Score
NCT03486938,measures_secondary,Change in MMSE Score
NCT03486938,measures_secondary,Change in FAQ Score
NCT03486938,has_criteria,good general health
NCT03486938,has_criteria,between 55 and 85 years old
NCT03486938,has_criteria,eighth-grade education
NCT03486938,has_criteria,proficient fluency
NCT00939003,involves,Axial Spondyloarthritis
NCT00939003,evaluates,Adalimumab
NCT00939003,measures_primary,ASAS40 response
NCT00939003,measures_secondary,ASAS20 response
NCT00939003,has_criteria,Baseline and Week 12
NCT00395343,involves,type 2 diabetes mellitus
NCT00395343,evaluates,Sitagliptin
NCT00395343,measures_primary,Change From Baseline in A1C
NCT00395343,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT00395343,measures_secondary,Change From Baseline in 2-hour Post-meal Glucose
NCT00395343,measures_secondary,Percent Change From Baseline in Index of Static Beta-Cell Sensitivity to Glucose
NCT00395343,measures_secondary,Percent of Patients With A1C < 7.0%
NCT00395343,measures_secondary,Percent of Patients With A1C < 6.5%
NCT00395343,has_criteria,Patient has type 2 diabetes mellitus
NCT00395343,has_criteria,Patient is poorly controlled while on insulin or insulin and metformin
NCT00395343,has_criteria,Patient has a history of type 1 diabetes mellitus or history of ketoacidosis
NCT00395343,has_criteria,Patient is taking oral antidiabetic agents other than metformin during the past 3 months
NCT00395343,has_criteria,Patient is currently on treatment with daily use of pre-prandial short-acting or rapid-acting insulin
NCT00040443,involves,Mild Cognitive Impairment
NCT00040443,evaluates,CX516
NCT00040443,measures_primary,Word List Delayed Recall
NCT00040443,has_criteria,Clinical diagnosis of mild cognitive impairment
NCT00040443,has_criteria,Good general health
NCT00040443,has_criteria,no additional diseases
NCT00040443,has_criteria,neurologic disease
NCT00040443,has_criteria,major depression
NCT00040443,has_criteria,psychiatric disorder
NCT00040443,has_criteria,schizophrenia
NCT00040443,has_criteria,substance abuse
NCT00040443,has_criteria,blackout
NCT00040443,has_criteria,epilepsy
NCT00040443,has_criteria,abnormal EEG
NCT00040443,has_criteria,hepatic illness
NCT00040443,has_criteria,renal illness
NCT00040443,has_criteria,cardiovascular illness
NCT00040443,has_criteria,pulmonary illness
NCT00040443,has_criteria,gastrointestinal illness
NCT00040443,has_criteria,hematological illness
NCT02425943,involves,injection site nodule
NCT02425943,involves,papule
NCT02425943,evaluates,Sculptra Aesthetic
NCT02425943,measures_primary,Change From Baseline
NCT02425943,measures_secondary,Percentage of Participants
NCT02425943,has_criteria,Up to 5 years
NCT00535938,involves,Cervical dystonia
NCT00535938,involves,Blepharospasm
NCT00535938,evaluates,Botox
NCT00535938,measures_primary,SF-6D Health Utility
NCT00535938,has_criteria,physician's discretion
NCT02138838,involves,Secondary Hyperparathyroidism
NCT02138838,involves,Chronic Kidney Disease
NCT02138838,evaluates,Cinacalcet
NCT02138838,measures_primary,iPTH reduction ≥ 30%
NCT02138838,measures_secondary,iPTH ≤ 300 pg/mL
NCT02138838,has_criteria,Age 6-18 years
NCT02138838,has_criteria,iPTH ≥ 300 pg/mL
NCT02138838,has_criteria,Corrected calcium ≥ 8.8 mg/dL
NCT02138838,has_criteria,CKD on dialysis ≥ 30 days
NCT01724138,involves,β-thalassemia major
NCT01724138,evaluates,Deferasirox
NCT01724138,measures_primary,PK profile
NCT01724138,measures_secondary,safety tolerability
NCT01724138,has_criteria,aged 2 to less than 6 years old
NCT00425438,involves,Lupus Nephritis
NCT00425438,evaluates,CellCept
NCT00425438,measures_primary,Complete Response
NCT00425438,measures_secondary,Treatment Response
NCT00425438,measures_secondary,Glomerular Filtration Rate
NCT00425438,has_criteria,urinary protein value
NCT00425438,has_criteria,serum creatinine value
NCT03633708,involves,Secondary Hyperparathyroidism
NCT03633708,involves,Chronic Kidney Disease
NCT03633708,involves,Hemodialysis
NCT03633708,evaluates,Etelcalcetide
NCT03633708,measures_primary,iPTH reduction
NCT03633708,measures_secondary,hypocalcemia
NCT03633708,measures_secondary,serum calcium
NCT03633708,measures_secondary,serum phosphorous
NCT03633708,measures_secondary,predialysis iPTH
NCT03633708,has_criteria,Pediatric Subjects
NCT01586338,involves,Symptomatic Osteoarthritis of the Knee(s)
NCT01586338,evaluates,Synvisc®
NCT01586338,measures_primary,Change From Baseline in WOMAC A1 Subscore
NCT01586338,measures_secondary,Change From Baseline in WOMAC A
NCT01586338,has_criteria,Chinese Subjects
NCT05726838,involves,Hypercholesterolemia
NCT05726838,evaluates,Inclisiran
NCT05726838,measures_primary,Percent change LDL-C
NCT05726838,measures_secondary,ASCVD-related events
NCT05726838,has_criteria,Up to 39 months
NCT04218838,involves,Sacroiliac Joint Dysfunction
NCT04218838,evaluates,CornerLoc SI Joint Stabilization
NCT04218838,evaluates,Steroid Injections
NCT04218838,measures_primary,Pain improvement
NCT04218838,measures_secondary,Quality of life
NCT04218838,has_criteria,50% pain reduction
NCT05643508,involves,Hypertension
NCT05643508,involves,Hyperlipidemia
NCT05643508,evaluates,DWC202206
NCT05643508,evaluates,DWC202207
NCT05643508,measures_primary,MSSBP change
NCT05643508,measures_secondary,LDL-C change
NCT05643508,has_criteria,Age 19 to 80
NCT05643508,has_criteria,Hypertension
NCT05643508,has_criteria,Hyperlipidemia
NCT05643508,has_criteria,Orthostatic hypotension
NCT05643508,has_criteria,Ventricular tachycardia
NCT05643508,has_criteria,Atrial fibrillation
NCT05643508,has_criteria,Uncontrolled diabetes
NCT02240108,involves,Crohn's Disease
NCT02240108,evaluates,Rifaximin Delayed Release
NCT02240108,measures_primary,Clinical Symptom Remission
NCT02240108,measures_secondary,Clinical Symptom Remission
NCT02240108,has_criteria,≤ 10 stools
NCT03547908,involves,HIV-1
NCT03547908,involves,Hepatitis B
NCT03547908,evaluates,Bictegravir/Emtricitabine/Tenofovir Alafenamide
NCT03547908,evaluates,Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate
NCT03547908,measures_primary,HIV-1 RNA < 50 copies/mL
NCT03547908,measures_primary,HBV DNA < 29 IU/mL
NCT03547908,measures_secondary,CD4 Cell Count
NCT03547908,measures_secondary,CD4 Percentage
NCT03547908,measures_secondary,ALT Normalization
NCT03547908,has_criteria,Missing = Failure
NCT02813408,involves,Metastatic Castration-resistant Prostate Cancer
NCT02813408,evaluates,Abiraterone Acetate
NCT02813408,evaluates,Enzalutamide
NCT02813408,measures_primary,Health Related Quality of Life
NCT02813408,measures_secondary,Fatigue
NCT02813408,measures_secondary,Pain
NCT02813408,measures_secondary,Cognitive Function
NCT02813408,has_criteria,12 months
NCT03875508,involves,Plaque Psoriasis
NCT03875508,evaluates,Risankizumab Autoinjector
NCT03875508,measures_primary,PASI 90 at Week 16
NCT03875508,measures_secondary,sPGA of Clear or Almost Clear
NCT03875508,has_criteria,Moderate to Severe
NCT01205438,involves,Systemic Lupus Erythematosus
NCT01205438,evaluates,LY2127399
NCT01205438,measures_primary,SLE Responder Index
NCT01205438,measures_secondary,SELENA SLEDAI score
NCT01205438,measures_secondary,PGA
NCT01205438,measures_secondary,BILAG
NCT01205438,has_criteria,concomitant medications
NCT01205438,has_criteria,prednisone dose
NCT01205438,has_criteria,BILAG C score
NCT01205438,has_criteria,BILAG A or B flares
NCT01205438,has_criteria,antimalarials
NCT01205438,has_criteria,immunosuppressants
NCT01205438,measures_secondary,Anti-dsDNA Level
NCT01205438,measures_secondary,SLEDAI2K Score
NCT01569438,involves,Interstitial Cystitis /Bladder Pain Syndrome
NCT01569438,evaluates,Gefapixant
NCT01569438,measures_primary,NPRS score at Week 4
NCT01569438,measures_secondary,PBIC-SD score at Week 4
NCT01569438,measures_secondary,ICSI score at Week 4
NCT01569438,has_criteria,Female participants
NCT06079190,involves,Early Alzheimer's Disease
NCT06079190,evaluates,GSK4527226
NCT06079190,measures_primary,CDR-SB Score
NCT06079190,measures_secondary,iADRS Score
NCT06079190,measures_secondary,ADAS-Cog14 Score
NCT06079190,has_criteria,Baseline
NCT05687890,involves,Chronic Kidney Disease
NCT05687890,evaluates,SC0062
NCT05687890,measures_primary,Change in UACR
NCT05687890,measures_secondary,Change in eGFR
NCT05687890,measures_secondary,Change in UAER
NCT05687890,measures_secondary,Change in UPER
NCT05687890,has_criteria,Cohort 1
NCT05687890,has_criteria,Cohort 2
NCT00548808,involves,Type 2 diabetes mellitus
NCT00548808,evaluates,insulin injection
NCT00548808,measures_primary,Change From Baseline
NCT00548808,measures_secondary,Percentage of Patients Achieving HbA1c
NCT00548808,measures_secondary,7-point Self-monitored Blood Glucose Profiles
NCT00548808,measures_secondary,Change From Baseline in Postprandial Blood Glucose
NCT00548808,measures_secondary,Daily Total Insulin Dose
NCT00548808,measures_secondary,Daily Total Insulin Dose Per Body Weight
NCT00548808,measures_secondary,Change From Baseline to 48 Week Endpoint in Lipid
NCT00548808,measures_secondary,Safety
NCT00548808,has_criteria,Type 2 diabetes mellitus
NCT00548808,has_criteria,oral antihyperglycemic medications
NCT00548808,has_criteria,Hemoglobin A1c (HbA1c)
NCT00548808,has_criteria,willing to receive insulin injection
NCT00548808,has_criteria,able to perform self monitoring of blood glucose
NCT00548808,has_criteria,taking any other glucose-lowering agents
NCT00548808,has_criteria,taken acarbose
NCT01177384,involves,Type 2 Diabetes Mellitus
NCT01177384,evaluates,Sitagliptin
NCT01177384,measures_primary,Change From Baseline in A1C
NCT01177384,measures_secondary,Change From Baseline in FPG
NCT01177384,has_criteria,T2DM on acarbose alone
NCT01177384,has_criteria,at least 18 years of age
NCT01177384,has_criteria,unlikely to conceive
NCT01177384,has_criteria,no history of type 1 diabetes mellitus
NCT01177384,has_criteria,no use of thiazolidinedione
NCT01177384,has_criteria,no use of DPP-4 inhibitors
NCT01177384,has_criteria,no use of GLP-1 receptor agonists
NCT01177384,has_criteria,no use of insulin
NCT01177384,has_criteria,no cardiovascular disorders
NCT01177384,has_criteria,no liver or kidney disease
NCT01177384,has_criteria,no cancer or clinically significant disease
NCT04575584,involves,COVID-19
NCT04575584,evaluates,Molnupiravir
NCT04575584,measures_primary,time to sustained recovery
NCT04575584,measures_secondary,All-cause Mortality
NCT04575584,measures_secondary,Adverse Event
NCT04575584,measures_secondary,Pulmonary Ordinal Outcome Score
NCT04575584,has_criteria,hospitalized adult
NCT03556202,involves,Psoriasis
NCT03556202,evaluates,LY3074828
NCT03556202,measures_primary,PASI 90 maintenance
NCT03556202,measures_secondary,PASI 100 achievement
NCT03556202,has_criteria,sPGA 0
NCT00632502,involves,Neutrophilic Asthma
NCT00632502,evaluates,Navarixin
NCT00632502,measures_primary,Mean Change in Sputum Neutrophil Count
NCT00632502,measures_secondary,Total Asthma Symptom Score
NCT00632502,measures_secondary,Change From Baseline in FEV1
NCT00632502,measures_secondary,Change From Baseline in AQLQ[S]
NCT00632502,has_criteria,Peripheral blood neutrophil count >=1500/µL
NCT02989402,involves,Alzheimer's Disease
NCT02989402,evaluates,Rivastigmine Patch 15cm2
NCT02989402,measures_primary,Change From Baseline in MMSE
NCT02989402,measures_secondary,Change From Baseline in ADCS-ADL SIV Score
NCT02989402,measures_secondary,Compliance by Caregiver Medication Questionnaire (CMQ) Score
NCT02989402,has_criteria,Skin Irritation
NCT03636984,involves,Rheumatoid Arthritis
NCT03636984,involves,Ankylosing Spondylitis
NCT03636984,evaluates,Anbainuo
NCT03636984,measures_primary,DAS28 ≥1.2
NCT03636984,measures_secondary,BASDAI 50 response
NCT03636984,measures_secondary,modified total Sharp score
NCT03636984,has_criteria,baseline and week 48
NCT02855684,involves,Type 2 Diabetes
NCT02855684,evaluates,Insulin Glargine
NCT02855684,evaluates,Lantus
NCT02855684,measures_primary,Change in HbA1c
NCT02855684,measures_secondary,Percentage of patients with hypoglycemia
NCT02855684,measures_secondary,Percentage of patients with HbA1c <7.0%
NCT02855684,measures_secondary,Percentage of patients with HbA1c ≤6.5%
NCT02855684,measures_secondary,Percentage of patients with FPG <100 mg/dL
NCT02855684,measures_secondary,Percentage of patients with FPG ≤120 mg/dL
NCT02855684,measures_secondary,Percentage of patients requiring rescue therapy
NCT02855684,measures_secondary,Change in fasting plasma glucose
NCT02855684,measures_secondary,Change in 8-point SMPG profiles
NCT02855684,measures_secondary,Change of mean 24-hour plasma glucose
NCT02855684,measures_secondary,Change in variability of plasma glucose profile
NCT02855684,measures_secondary,Change in daily basal insulin dose
NCT02855684,has_criteria,Adult patients with type 2 diabetes mellitus
NCT02855684,has_criteria,Signed written informed consent
NCT01419184,involves,complicated skin and skin structure infections
NCT01419184,evaluates,Daptomycin
NCT01419184,evaluates,Vancomycin
NCT01419184,measures_primary,Infection Related Hospital Length of Stay
NCT01419184,measures_secondary,Pain
NCT01419184,measures_secondary,Health-related Quality of Life
NCT01419184,has_criteria,Baseline (Day 0)
NCT01419184,has_criteria,End of Hospital Stay (up to Day 14)
NCT01003184,involves,Type 2 Diabetes
NCT01003184,evaluates,Exenatide
NCT01003184,evaluates,Insulin Detemir
NCT01003184,measures_primary,HbA1c ≤7.0% with weight loss
NCT01003184,measures_secondary,HbA1c ≤7.4% with weight loss
NCT01003184,measures_secondary,Change in HbA1c
NCT01003184,measures_secondary,Change in Body Weight
NCT01003184,measures_secondary,HbA1c ≤7.4% at endpoint
NCT01003184,measures_secondary,HbA1c ≤7.0% at endpoint
NCT01003184,measures_secondary,HbA1c ≤6.5% at endpoint
NCT01003184,measures_secondary,Change in Fasting Serum Glucose
NCT01003184,measures_secondary,Change in Systolic Blood Pressure
NCT01003184,measures_secondary,Change in Diastolic Blood Pressure
NCT01003184,has_criteria,missing baseline weight
NCT01003184,has_criteria,protocol violation
NCT01003184,has_criteria,missing post-baseline measurements
NCT02760602,involves,Prodromal Alzheimer's Disease
NCT02760602,evaluates,Solanezumab
NCT02760602,measures_primary,Change From Baseline in ADAS-Cog14 Score
NCT02760602,measures_secondary,Change From Baseline on ADCS-MCI-ADL
NCT02760602,measures_secondary,Change From Baseline on MMSE
NCT02760602,measures_secondary,Change From Baseline on MoCA
NCT02760602,measures_secondary,Change From Baseline on FAQ
NCT02760602,has_criteria,Baseline
NCT00659802,involves,Ulcerative Colitis
NCT00659802,evaluates,HMPL-004
NCT00659802,measures_primary,Clinical Response
NCT00659802,measures_secondary,Clinical Remission
NCT00659802,measures_secondary,Mucosal Healing
NCT00659802,has_criteria,active confirmed mild to moderate ulcerative colitis
NCT01078402,involves,Rheumatoid Arthritis
NCT01078402,involves,Psoriatic Arthritis
NCT01078402,involves,Ankylosing Spondylitis
NCT01078402,evaluates,HumIRA
NCT01078402,measures_primary,DAS28 decrease
NCT01078402,measures_secondary,BASDAI Decrease
NCT01078402,measures_secondary,HAQ-DI Score
NCT01078402,has_criteria,Disease Activity Score
NCT02479802,involves,Amyotrophic Lateral Sclerosis
NCT02479802,evaluates,Plasma Exchange With Albumin
NCT02479802,measures_primary,ALSFRS-R score
NCT02479802,measures_secondary,Percent Predicted FVC
NCT02479802,measures_secondary,ALS Cognitive Function
NCT02479802,has_criteria,Baseline
NCT02452190,involves,Asthma
NCT02452190,evaluates,Reslizumab
NCT02452190,measures_primary,Number of CAEs
NCT02452190,measures_secondary,Change in FEV1
NCT02452190,has_criteria,blood eosinophils
NCT02760264,involves,Duchenne Muscular Dystrophy
NCT02760264,evaluates,vamorolone
NCT02760264,measures_primary,Fasting Glucose
NCT02760264,measures_secondary,Insulin
NCT02760264,has_criteria,ambulant boys ages 4-<7 years
NCT04711603,involves,Pruritus
NCT04711603,evaluates,MR13A9
NCT04711603,measures_primary,Change from baseline in mean itch NRS score
NCT04711603,measures_secondary,Skindex-16 score
NCT04711603,measures_secondary,5-D itch scale score
NCT04711603,measures_secondary,Percentage of subjects with 3-point improvement in mean itch NRS score
NCT04711603,measures_secondary,Percentage of subjects with 4-point improvement in mean itch NRS score
NCT04711603,measures_secondary,Percentage of subjects with global symptoms in Patient Global Impression of Change (PGIC)
NCT04711603,has_criteria,Hemdialysis patients
NCT03402503,involves,Alzheimer's Disease
NCT03402503,evaluates,montelukast
NCT03402503,measures_primary,NTB composite score
NCT03402503,measures_secondary,MMSE
NCT03402503,has_criteria,cognitive function
NCT02470403,involves,Elevated Body Mass Index
NCT02470403,evaluates,LIK066
NCT02470403,measures_primary,Percent change in body weight
NCT02470403,measures_secondary,Adverse Events
NCT02470403,has_criteria,Baseline body weight
NCT01549964,involves,Type 2 diabetes mellitus
NCT01549964,evaluates,Fasiglifam
NCT01549964,evaluates,Placebo
NCT01549964,evaluates,Sitagliptin
NCT01549964,measures_primary,Change From Baseline in HbA1c
NCT01549964,measures_secondary,Incidence of HbA1c <7%
NCT01549964,measures_secondary,Change From Baseline in Fasting Plasma Glucose (FPG)
NCT01549964,has_criteria,HbA1c level ≥7.5 and <10.5%
NCT01549964,has_criteria,stable daily dose of ≥1500 mg of metformin
NCT01549964,has_criteria,stable daily dose of <1500 mg of metformin
NCT06465264,involves,Essential Hypertension
NCT06465264,evaluates,Allisartan Isoproxil/Amlodipine
NCT06465264,measures_primary,sitting systolic blood pressure
NCT06465264,measures_secondary,sitting diastolic blood pressure
NCT06465264,has_criteria,SBP/DBP<140/90 mmHg
NCT01370590,involves,High Cholesterol
NCT01370590,evaluates,Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet
NCT01370590,measures_primary,Percent Change LDL-C
NCT01370590,measures_secondary,Percent Change TC
NCT01370590,measures_secondary,Percent Change HDL-C
NCT01370590,measures_secondary,Percent Change Non-HDL-C
NCT01370590,measures_secondary,Percent Change Apo B
NCT01370590,measures_secondary,Percent Change Triglycerides
NCT01370590,has_criteria,cardiovascular risk
NCT01370590,has_criteria,statin-naïve
NCT01370590,has_criteria,LDL-C ≥130 mg/dL
NCT01370590,has_criteria,LDL-C ≥100 mg/dL
NCT05807490,evaluates,PF-07328948
NCT05807490,measures_primary,Number of Participants
NCT05807490,measures_secondary,Plasma Concentration
NCT05807490,has_criteria,Healthy Adults
NCT03561090,involves,Gastroesophageal Reflux Disease
NCT03561090,evaluates,IW-3718
NCT03561090,measures_primary,Change From Baseline in WHSS
NCT03561090,measures_secondary,Change From Baseline in WRFS
NCT03561090,measures_secondary,Percentage of Participants Who Were Overall Heartburn Responders
NCT03561090,has_criteria,4 of the 8 treatment weeks
NCT04657003,involves,Type 2 Diabetes
NCT04657003,evaluates,Tirzepatide
NCT04657003,measures_primary,Body Weight Reduction
NCT04657003,measures_secondary,Hemoglobin A1c
NCT04657003,has_criteria,Obesity or Overweight
NCT01052103,involves,Schizophrenia
NCT01052103,evaluates,LY2140023
NCT01052103,measures_primary,Change From Baseline
NCT01052103,measures_secondary,PANSS Total Score
NCT01052103,measures_secondary,Clinical Global Impression Severity
NCT01052103,has_criteria,baseline positive symptom stratum
NCT05053503,involves,Opioid Use Disorder
NCT05053503,evaluates,Transcutaneous Auricular Neurostimulation
NCT05053503,measures_primary,Relapse Prevention
NCT05053503,measures_secondary,Opiate Withdrawal Scale
NCT05053503,has_criteria,Opioid Use Disorder
NCT00647543,involves,Dyslipidemia
NCT00647543,evaluates,Atorvastatin
NCT00647543,measures_primary,LDL-C target
NCT00647543,measures_secondary,Adverse events
NCT00647543,measures_secondary,Laboratory test changes
NCT00647543,has_criteria,Lipid lowering therapy
NCT00647543,has_criteria,Study diet
NCT00647543,has_criteria,High blood pressure
NCT00647543,has_criteria,Liver function
NCT04456803,involves,Hyperphosphatemia
NCT04456803,involves,Chronic Kidney Disease
NCT04456803,evaluates,Ferric Citrate
NCT04456803,measures_primary,Change in serum phosphorus
NCT04456803,measures_secondary,Change in serum calcium
NCT04456803,measures_secondary,Intact-PTH level
NCT04456803,has_criteria,Age 18-75 years
NCT04456803,has_criteria,Hemodialysis 3x/week
NCT04456803,has_criteria,Serum phosphorus 1.97-3.23 mmol/L
NCT04456803,has_criteria,Kt/Vurea ≥1.2 or URR ≥65%
NCT04456803,has_criteria,Stable CKD-MBD drug treatment
NCT04456803,has_criteria,Expected survival >6 months
NCT01709903,involves,COPD
NCT01709903,evaluates,QVA149 110/50 μg o.d.
NCT01709903,measures_primary,Trough FEV1
NCT01709903,measures_secondary,FEV1 AUC
NCT01709903,has_criteria,moderate to severe COPD
NCT00525590,involves,Metastatic Brain Cancer
NCT00525590,evaluates,Surgery Plus GLIADEL® Wafer
NCT00525590,measures_primary,Rate of Deterioration
NCT00525590,measures_secondary,Number of Participants With Neurocognitive Domains Preserved
NCT00525590,has_criteria,Deterioration in NF
NCT03895203,involves,Psoriatic Arthritis
NCT03895203,evaluates,Bimekizumab
NCT03895203,measures_primary,ACR50 response
NCT03895203,measures_secondary,HAQ-DI score
NCT03895203,has_criteria,Active Psoriatic Arthritis
NCT02577003,involves,Type 2 Diabetes Mellitus
NCT02577003,evaluates,Ipragliflozin
NCT02577003,measures_primary,Change From Baseline in HbA1c
NCT02577003,measures_secondary,Percentage of Participants Who Experienced at Least One Adverse Event
NCT02577003,measures_secondary,Percentage of Participants Who Discontinued Study Drug Due to an AE
NCT02577003,measures_secondary,Change From Baseline in FPG
NCT02577003,measures_secondary,Change From Baseline in 2-hr PMG
NCT02577003,has_criteria,prior use of AHAs
NCT02577003,has_criteria,baseline eGFR value
NCT01076179,involves,hypertriglyceridemia
NCT01076179,involves,hypercholesterolemia
NCT01076179,involves,low HDL cholesterol
NCT01076179,involves,high LDL cholesterol
NCT01076179,involves,hyperglycemia
NCT01076179,involves,hyperbilirubinemia
NCT01076179,involves,elevated AST
NCT01076179,involves,elevated ALT
NCT01076179,involves,elevated γGT
NCT01076179,involves,elevated alkaline phosphatase
NCT01076179,involves,stomatitis
NCT01076179,involves,nausea
NCT01076179,involves,vomiting
NCT01076179,involves,diarrhea
NCT01076179,involves,abdominal pain
NCT01076179,involves,mood disorder
NCT01076179,involves,neurocerebellar disorder
NCT01076179,involves,headache
NCT01076179,involves,fatigue
NCT01076179,involves,fever
NCT01076179,involves,other
NCT01076179,evaluates,Kaletra
NCT01076179,measures_primary,Change From Baseline
NCT01076179,measures_secondary,Percentage of Participants
NCT01076179,has_criteria,Baseline (Week 0)
NCT02001584,involves,Obesity
NCT02001584,involves,Leanness
NCT02001584,evaluates,Baclofen
NCT02001584,evaluates,Memantine
NCT02001584,measures_primary,Safety and tolerability
NCT02001584,measures_secondary,Pharmacokinetic parameters
NCT02001584,has_criteria,Adult males or females aged 18 to 45 years inclusive
NCT02001584,has_criteria,BMI ≥18 kg/m² and ≤25 kg/m²
NCT02001584,has_criteria,BMI ≥33 kg/m² and ≤40 kg/m²
NCT02001584,has_criteria,Total body weight ≥50 kg
NCT02001584,has_criteria,Healthy as determined by Investigator
NCT05329584,involves,rotator cuff pathology
NCT05329584,evaluates,study intervention
NCT05329584,measures_primary,ASES MCID
NCT05329584,measures_primary,WORC Score
NCT05329584,measures_primary,Constant Score
NCT05329584,measures_secondary,ASES SCB
NCT05329584,has_criteria,Day 0 through Month 24
NCT02023879,involves,Hypercholesterolemia
NCT02023879,evaluates,Alirocumab
NCT02023879,measures_primary,Percent Change LDL-C
NCT02023879,measures_secondary,Percent Change LDL-C
NCT02023879,has_criteria,Statin untreated
NCT05097079,involves,sialorrhea
NCT05097079,evaluates,MYOBLOC
NCT05097079,measures_primary,change USFR
NCT05097079,measures_secondary,CGI-C score
NCT05097079,measures_secondary,PGI-C score
NCT05097079,has_criteria,pediatric subjects
NCT01155479,involves,Parkinson's Disease
NCT01155479,evaluates,Preladenant
NCT01155479,measures_primary,Change from baseline UPDRS2+3
NCT01155479,measures_secondary,Number of Participants With Adverse Events
NCT01155479,has_criteria,Untoward medical occurrence
NCT05016284,involves,Atopic Dermatitis
NCT05016284,evaluates,JW-100
NCT05016284,evaluates,EUCRISA
NCT05016284,measures_primary,ISGA score improvement
NCT05016284,measures_secondary,pruritus severity
NCT05016284,measures_secondary,AD signs
NCT05016284,has_criteria,≥18 years old
NCT05016284,has_criteria,stable AD
NCT05016284,has_criteria,pruritus
NCT05016284,has_criteria,typical morphology
NCT05016284,has_criteria,chronic dermatitis
NCT05016284,has_criteria,family history of atopy
NCT05016284,has_criteria,≥5% body surface area
NCT05016284,has_criteria,≤20% body surface area
NCT05016284,has_criteria,ISGA score 2 or 3
NCT01736579,involves,Alzheimer's Disease
NCT01736579,evaluates,IGIV
NCT01736579,measures_primary,ADAS-Cog Total Score
NCT01736579,measures_secondary,SIB Total Score
NCT01736579,measures_secondary,ADCS-ADL
NCT01736579,measures_secondary,MMSE
NCT01736579,has_criteria,6 months
NCT03713684,involves,Type 2 Diabetes Mellitus
NCT03713684,evaluates,Efpeglenatide
NCT03713684,measures_primary,Change From Baseline in HbA1c
NCT03713684,measures_secondary,Fasting Plasma Glucose
NCT03713684,measures_secondary,Body Weight
NCT03713684,measures_secondary,Hypoglycemic Events
NCT03713684,has_criteria,Inclusion criteria
NCT05030584,involves,Vasomotor Symptoms
NCT05030584,evaluates,Elinzanetant
NCT05030584,measures_primary,hot flash frequency
NCT05030584,measures_secondary,sleep disturbance
NCT05030584,measures_secondary,menopause quality of life
NCT05030584,has_criteria,Women Through Menopause
NCT03928184,involves,Knee Osteoarthritis
NCT03928184,evaluates,Lorecivivint
NCT03928184,measures_primary,OA pain
NCT03928184,measures_secondary,OA function
NCT03928184,measures_secondary,OA disease activity
NCT03928184,has_criteria,Moderately to Severely Symptomatic
NCT05148884,involves,L-dopa-induced Dyskinesia
NCT05148884,evaluates,NLX-112
NCT05148884,evaluates,Placebo
NCT05148884,measures_primary,Adverse Events
NCT05148884,measures_secondary,Electrocardiogram
NCT05148884,measures_secondary,Vital Signs
NCT05148884,has_criteria,clinically significant
NCT01512979,involves,Type 2 Diabetes
NCT01512979,evaluates,Linagliptin
NCT01512979,evaluates,Metformin
NCT01512979,measures_primary,Change From Baseline in HbA1c
NCT01512979,measures_secondary,Change From Baseline in FPG
NCT01512979,measures_secondary,Occurrence of Relative Efficacy Response
NCT01512979,measures_secondary,Occurrence of Treat to Target Efficacy Response
NCT01512979,has_criteria,Newly Diagnosed
NCT00306384,involves,Type 2 Diabetes Mellitus
NCT00306384,evaluates,Alogliptin
NCT00306384,measures_primary,Change From Baseline
NCT00306384,measures_secondary,Fasting Plasma Glucose
NCT00306384,measures_secondary,Percentage of Participants
NCT00306384,has_criteria,Randomization up to 4 years
NCT05242484,involves,Ulcerative Colitis
NCT05242484,evaluates,Guselkumab
NCT05242484,evaluates,Golimumab
NCT05242484,measures_primary,Clinical Remission at Week 48
NCT05242484,measures_primary,Endoscopic Improvement at Week 48
NCT05242484,measures_primary,Symptomatic Remission at Week 48
NCT05242484,measures_primary,Combination of Histological Remission and Endoscopic Improvement at Week 48
NCT05242484,measures_primary,Clinical Remission at Week 24
NCT05242484,measures_secondary,Adverse Events (AEs)
NCT05242484,measures_secondary,Serious Adverse Events (SAEs)
NCT05242484,has_criteria,Untoward medical occurrence
NCT00589979,involves,Osteoarthritis of the Knee
NCT00589979,evaluates,Lidoderm Patch
NCT00589979,measures_primary,Time-to-Exit
NCT00589979,measures_secondary,Exit Status
NCT00589979,has_criteria,2-category change in PRS
NCT01770379,involves,Rheumatoid Arthritis
NCT01770379,evaluates,Secukinumab
NCT01770379,measures_primary,ACR20 response
NCT01770379,measures_secondary,DAS28-CRP
NCT01770379,measures_secondary,HAQ-DI
NCT01770379,has_criteria,Anti-TNFα Agents
NCT00973479,involves,Rheumatoid Arthritis
NCT00973479,evaluates,Intravenous Golimumab
NCT00973479,measures_primary,ACR 20 response
NCT00973479,measures_secondary,DAS28 score
NCT00973479,has_criteria,Methotrexate Therapy
NCT00856284,involves,Type 2 Diabetes Mellitus
NCT00856284,evaluates,Alogliptin
NCT00856284,measures_primary,Change From Baseline in HbA1c
NCT00856284,measures_secondary,Fasting Plasma Glucose
NCT00856284,has_criteria,Baseline metformin dose
NCT03267784,involves,Diabetic Foot Ulcer
NCT03267784,evaluates,Allogeneic ABCB5-positive Stem Cells
NCT03267784,measures_primary,Percentage wound reduction
NCT03267784,measures_secondary,Wound infection
NCT03267784,has_criteria,Weeks 2
NCT00219284,involves,Parkinson's Disease
NCT00219284,evaluates,Carbidopa/Levodopa/Entacapone
NCT00219284,measures_primary,Change in UPDRS
NCT00219284,measures_primary,Change in PDQUALIF
NCT00219284,measures_secondary,Change in PDQUALIF
NCT00219284,has_criteria,Baseline to Week 4
NCT00219284,has_criteria,Baseline to Week 8
NCT00736879,involves,Type 2 Diabetes
NCT00736879,evaluates,Dapagliflozin
NCT00736879,measures_primary,HbA1c at Week 24
NCT00736879,measures_secondary,Total Body Weight at Week 24
NCT00736879,measures_secondary,Fasting Plasma Glucose at Week 24
NCT00736879,has_criteria,rescue medication (metformin)
NCT04016779,involves,Attention-Deficit/Hyperactivity Disorder
NCT04016779,evaluates,SPN-812
NCT04016779,measures_primary,AISRS Total score
NCT04016779,measures_secondary,CGI-S score
NCT04016779,has_criteria,Baseline and Week 6
NCT00848484,involves,Cognitive Impairment
NCT00848484,involves,Schizophrenia
NCT00848484,evaluates,MK5757
NCT00848484,measures_primary,Mean Change From Baseline
NCT00848484,measures_secondary,CogState Composite Score
NCT00848484,measures_secondary,Executive Functioning Composite Score
NCT00848484,has_criteria,Baseline and Week 2
NCT00890084,involves,Hypertension
NCT00890084,evaluates,telmisartan
NCT00890084,measures_primary,Blood Pressure < 140/90 mm Hg
NCT00890084,measures_secondary,Absolute Blood Pressure Decrease
NCT00890084,measures_secondary,BP Response Rate
NCT00890084,measures_secondary,Treatment Patterns
NCT00890084,measures_secondary,Change in Concomitant Antihypertensive Drugs Given
NCT00890084,measures_secondary,Percentage of Patients in Whom the Prescriber Decide to Further Lower the Blood Pressure to < 130/80 mm Hg
NCT00890084,measures_secondary,Percentage of Prescribers Who Adhered to European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines 2007
NCT00890084,has_criteria,Hypertensive patients with BP 140/90mmHg
NCT04642079,involves,Healthy Children
NCT04642079,evaluates,20vPnC
NCT04642079,measures_primary,Percentage of Participants
NCT04642079,measures_secondary,Systemic Events
NCT04642079,has_criteria,Age 15 Months
NCT00761579,involves,schizophrenia
NCT00761579,evaluates,Paliperidone Extended Release
NCT00761579,measures_primary,PANSS Total Score
NCT00761579,measures_secondary,PANSS Positive Subscale Score
NCT00761579,measures_secondary,PANSS Negative Subscale Score
NCT00761579,has_criteria,transition to Paliperidone ER
NCT01828879,involves,atopic dermatitis
NCT01828879,evaluates,Tacrolimus Ointment
NCT01828879,measures_primary,Physician's Global Evaluation of Clinical Response (PhGECR)
NCT01828879,measures_secondary,Eczema Area and Severity Index (EASI)
NCT01828879,measures_secondary,Participant's Assessment of Treatment Effects
NCT01828879,measures_secondary,Participant's Assessment of Itch
NCT01828879,has_criteria,Hanifin and Rajka Criteria
NCT00696384,involves,Essential Hypertension
NCT00696384,evaluates,Azilsartan Medoxomil
NCT00696384,measures_primary,Diastolic Blood Pressure
NCT00696384,measures_secondary,Systolic Blood Pressure
NCT00696384,has_criteria,first dose of study drug
NCT06365879,involves,Chronic Spontaneous Urticaria
NCT06365879,evaluates,CMAB007
NCT06365879,evaluates,Xolair
NCT06365879,measures_primary,Change From Baseline ISS7
NCT06365879,measures_primary,Change From Baseline UAS7
NCT06365879,measures_primary,Change From Baseline NHS7
NCT06365879,measures_secondary,Time to ISS7 MID Response
NCT06365879,has_criteria,Baseline ISS7
NCT02679079,involves,Tourette Syndrome
NCT02679079,evaluates,NBI-98854
NCT02679079,measures_primary,YGTSS Total Tic Score
NCT02679079,measures_secondary,CGI-TS-Improvement Score
NCT02679079,measures_secondary,YGTSS Impairment Score
NCT02679079,measures_secondary,YGTSS Global Tic Severity Score
NCT02679079,measures_secondary,Rush Video-based Tic Rating Scale Total Score
NCT02679079,has_criteria,TTS responder at Week 6
NCT06173284,involves,Atopic Dermatitis
NCT06173284,evaluates,611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody)
NCT06173284,measures_primary,EASI 75 Response
NCT06173284,measures_secondary,IGA Score
NCT06173284,measures_secondary,EASI-50
NCT06173284,measures_secondary,EASI-90
NCT06173284,has_criteria,Chinese Adults
NCT00704184,involves,Chronic Hepatitis C
NCT00704184,evaluates,Vaniprevir
NCT00704184,measures_primary,HCV RNA undetectable
NCT00704184,measures_secondary,Adverse Event
NCT00704184,has_criteria,Genotype 1 infection
NCT02175784,involves,Type 2 Diabetes Mellitus
NCT02175784,evaluates,Ipragliflozin
NCT02175784,measures_primary,Change in HbA1C
NCT02175784,measures_secondary,Fasting plasma glucose
NCT02175784,has_criteria,HbA1C value 7.5-10.0%
NCT02175784,has_criteria,BMI 20.0-45.0 kg/m2
NCT06493279,involves,Amyotrophic Lateral Sclerosis
NCT06493279,evaluates,RJK002
NCT06493279,measures_primary,ALSFRSr Score
NCT06493279,measures_secondary,incidence of adverse events
NCT06493279,measures_secondary,serious adverse events
NCT06493279,measures_secondary,Dose limiting toxicities
NCT06493279,has_criteria,≥ 18 years of age
NCT06493279,has_criteria,diagnosis consistent with ALS
NCT06493279,has_criteria,duration of disease < 2 years
NCT06493279,has_criteria,ALSFRS-R score ≥30
NCT06493279,has_criteria,respiratory scores ≥3
NCT06493279,has_criteria,FVC ≥70%
NCT06493279,has_criteria,BMI > 18 kg/m2
NCT05372679,involves,Hypertension
NCT05372679,evaluates,Renal Denervation
NCT05372679,measures_primary,Systolic BP reduction
NCT05372679,measures_secondary,Diastolic BP reduction
NCT05372679,has_criteria,Baseline BP measurement
NCT00918879,involves,Type 2 diabetes
NCT00918879,evaluates,saxagliptin
NCT00918879,measures_primary,HbA1c change
NCT00918879,measures_secondary,FPG change
NCT00918879,measures_secondary,Therapeutic Glycemic Response
NCT00918879,has_criteria,Drug naïve
NCT00918879,has_criteria,HbA1c ≥ 7.2%
NCT00918879,has_criteria,HbA1c ≤10.0%
NCT00918879,has_criteria,Insulin therapy within one year
NCT00918879,has_criteria,Type 1 diabetes
NCT05929079,involves,Type 2 Diabetes Mellitus
NCT05929079,evaluates,Retatrutide
NCT05929079,measures_primary,Percent Change from Baseline in Body Weight
NCT05929079,measures_secondary,Change from Baseline in Apnea-Hypopnea Index (AHI)
NCT05929079,has_criteria,body mass index (BMI)
NCT02460679,involves,Amyotrophic Lateral Sclerosis
NCT02460679,evaluates,EPI-589
NCT02460679,measures_primary,ALSFRS-R Total Score
NCT02460679,measures_secondary,Vital Capacity
NCT02460679,measures_secondary,MIP
NCT02460679,has_criteria,Baseline
NCT02002884,involves,Cerebral Palsy
NCT02002884,evaluates,Botulinum Toxin Type A
NCT02002884,measures_primary,Change From Baseline in Ashworth Scale
NCT02002884,measures_primary,Investigator's Global Impression of Change Scale
NCT02002884,measures_primary,Change From Baseline in AS Score
NCT02002884,has_criteria,spasticity of the arm(s) or of arm(s) and leg(s)
NCT06200207,involves,Heart Failure
NCT06200207,involves,Inflammation
NCT06200207,evaluates,Ziltivekimab
NCT06200207,evaluates,Placebo
NCT06200207,measures_primary,KCCQ CSS
NCT06200207,measures_secondary,6-minute walk distance
NCT06200207,measures_secondary,KCCQ-CSS change
NCT06200207,has_criteria,clinically meaningful change
NCT01466088,involves,Alzheimer's Disease
NCT01466088,evaluates,AZD3480
NCT01466088,measures_primary,ADAS-Cog
NCT01466088,measures_primary,CIBIC-(+)
NCT01466088,measures_secondary,ADCS-ADL
NCT01466088,measures_secondary,NPI
NCT01466088,measures_secondary,MMSE
NCT01466088,measures_secondary,ADRQL
NCT06004388,involves,Episodic Migraine
NCT06004388,evaluates,Digital Therapeutics
NCT06004388,measures_primary,Change in MMDs
NCT06004388,measures_secondary,Proportion of Patients with Decrease in MMDs
NCT06004388,has_criteria,Willing and able to provide written informed consent
NCT02032407,involves,Acne Vulgaris
NCT02032407,evaluates,Dapsone Gel
NCT02032407,measures_primary,Change From Baseline in GAAS
NCT02032407,measures_secondary,Percent Change From Baseline in Total Lesion Counts
NCT02032407,measures_secondary,Percent Change From Baseline in Inflammatory Lesion Counts
NCT02032407,has_criteria,Females With Skin of Color
NCT01593787,involves,Hypertensive patients
NCT01593787,evaluates,LCZ696
NCT01593787,measures_primary,Change in msSBP
NCT01593787,measures_secondary,Change in msDBP
NCT01593787,has_criteria,Renal dysfunction
NCT00651287,involves,Hypertension
NCT00651287,evaluates,Quinapril
NCT00651287,evaluates,Hydrochlorothiazide
NCT00651287,measures_primary,Response rate
NCT00651287,measures_secondary,Diastolic BP
NCT00651287,measures_secondary,Systolic BP
NCT00651287,measures_secondary,Heart rate
NCT00651287,has_criteria,Mild to moderate hypertension
NCT00651287,has_criteria,Diastolic blood pressure
NCT00651287,has_criteria,Systolic blood pressure
NCT00651287,has_criteria,Secondary hypertension
NCT00651287,has_criteria,Cardiac disease
NCT00651287,has_criteria,Antihypertensive treatment
NCT06353087,involves,Atopic Dermatitis
NCT06353087,evaluates,Abrocitinib
NCT06353087,measures_primary,EASI-75 Response
NCT06353087,measures_secondary,EASI-90 Response
NCT06353087,has_criteria,Percentage of Participants
NCT05582187,evaluates,Fosmanogepix
NCT05582187,measures_primary,Number of Participants
NCT05582187,measures_secondary,Clinically significant change
NCT05582187,has_criteria,BMI 17.5 to 40.0 kg/m2
NCT05582187,has_criteria,Total body weight > 50 kg
NCT05582187,has_criteria,Child Pugh Class A
NCT05582187,has_criteria,Stable hepatic impairment
NCT00071487,involves,Systemic Lupus Erythematosus
NCT00071487,evaluates,LymphoStat-B
NCT00071487,measures_primary,SELENA SLEDAI Score
NCT00071487,measures_secondary,SLE Flare Index
NCT00071487,measures_secondary,AUC of SELENA SLEDAI Score
NCT00071487,measures_secondary,BILAG Score
NCT00071487,has_criteria,Baseline
NCT00379756,involves,Erectile Dysfunction
NCT00379756,involves,Dyslipidemia
NCT00379756,evaluates,Vardenafil
NCT00379756,evaluates,Placebo
NCT00379756,measures_primary,success rate of insertion
NCT00379756,measures_secondary,success rate of maintenance
NCT00379756,has_criteria,valid attempts
NCT01683409,involves,Diabetic Kidney Disease
NCT01683409,evaluates,Baricitinib
NCT01683409,measures_primary,Change From Baseline in UACR
NCT01683409,measures_secondary,Change From Baseline in MCP-1/Creatinine Ratio
NCT01683409,measures_secondary,Change From Baseline in Creatinine Clearance
NCT01683409,measures_secondary,Change From Baseline in EQ-5D-5L
NCT01683409,has_criteria,baseline eGFR group
NCT06392009,involves,TSC
NCT06392009,involves,FCD Type II
NCT06392009,evaluates,Radiprodil
NCT06392009,measures_primary,Seizure frequency
NCT06392009,measures_secondary,Behavioral symptoms
NCT06392009,measures_secondary,Adverse events
NCT06392009,has_criteria,Abnormal laboratory tests
NCT06392009,has_criteria,Physical examination
NCT01153009,involves,Major Depressive Disorder
NCT01153009,evaluates,Vortioxetine
NCT01153009,measures_primary,Change From Baseline in MADRS Total Score
NCT01153009,measures_secondary,Percentage of Participants With a MADRS Response
NCT01153009,measures_secondary,Mean Clinical Global Impression Scale - Improvement (CGI-I) Score
NCT01153009,has_criteria,Baseline and Week 8
NCT01171807,involves,Ulcerative Colitis
NCT01171807,evaluates,Dexamethasone 21-Phosphate
NCT01171807,measures_primary,Disease remission
NCT01171807,measures_secondary,Cortisol Blood Level
NCT01171807,has_criteria,Steroid-dependent IBD
NCT00469456,involves,Alzheimer's Disease
NCT00469456,evaluates,Memantine
NCT00469456,measures_primary,Change From Baseline
NCT00469456,measures_secondary,ASHA FACS Total Score
NCT00469456,has_criteria,50 years or older
NCT00469456,has_criteria,native English speakers
NCT00469456,has_criteria,NINCDS-ADRDA criteria
NCT00469456,has_criteria,MMSE score 10 to 19
NCT01961609,involves,Psoriasis
NCT01961609,evaluates,Secukinumab
NCT01961609,measures_primary,PASI 75 at 16 weeks
NCT01961609,measures_secondary,PASI 75 at 16 weeks
NCT01961609,has_criteria,Inadequate Response
NCT01520909,involves,Childhood Chronic Immune Thrombocytopenia
NCT01520909,evaluates,eltrombopag
NCT01520909,measures_primary,Platelet count >=50 Gi/L
NCT01520909,measures_secondary,Weighted mean platelet count
NCT01520909,has_criteria,Platelet count >=50 Gi/L
NCT03247556,involves,Attention-Deficit/Hyperactivity Disorder
NCT03247556,evaluates,SPN-812
NCT03247556,measures_primary,ADHD-RS-5 Total score
NCT03247556,measures_secondary,CGI-I Scale
NCT03247556,measures_secondary,Conners 3 - Parent Short Form
NCT03247556,has_criteria,adolescents 6-18 years
NCT00041756,involves,Knee Osteoarthritis
NCT00041756,evaluates,PG-530742
NCT00041756,measures_primary,Minimum Joint Space Width
NCT00041756,measures_secondary,WOMAC Total Score
NCT00041756,has_criteria,radiographic technique
NCT02013609,involves,Major Depressive Disorder
NCT02013609,evaluates,Brexpiprazole
NCT02013609,measures_primary,MADRS Total Score
NCT02013609,measures_secondary,CGI-S Total Score
NCT02013609,measures_secondary,CGI-I Score
NCT02013609,has_criteria,18 to 35 Years Old
NCT00981409,involves,Pulmonary Thromboembolism
NCT00981409,involves,Venous Thromboembolism
NCT00981409,involves,Deep Vein Thromboembolism
NCT00981409,evaluates,GSK576428
NCT00981409,evaluates,Fondaparinux Sodium
NCT00981409,measures_primary,Recurrent VTE
NCT00981409,measures_secondary,Perfusion Lung Scan
NCT00981409,measures_secondary,Bleeding Event
NCT00981409,has_criteria,clinically overt bleeding
NCT00313209,involves,Chronic Obstructive Pulmonary Disease
NCT00313209,evaluates,Roflumilast
NCT00313209,measures_primary,FEV1 change
NCT00313209,measures_secondary,COPD Exacerbation Rate
NCT00313209,measures_secondary,Transition Dyspnea Index
NCT00313209,measures_secondary,Shortness of Breath Questionnaire
NCT00313209,has_criteria,24 weeks treatment period
NCT05956509,involves,Upper Limb Spasticity
NCT05956509,evaluates,ABBV-950
NCT05956509,measures_primary,Change in MAS-B
NCT05956509,measures_secondary,CGI-C Score
NCT05956509,measures_secondary,CGI-S Score
NCT05956509,measures_secondary,Percentage of Participants Achieving Wrist MAS-B Responder Status
NCT05956509,has_criteria,Adult Participants
NCT01109056,involves,Primary Pterygium
NCT01109056,evaluates,Cyclosporine Ophthalmic Emulsion
NCT01109056,measures_primary,Pterygium Hyperemia
NCT01109056,measures_secondary,Ocular Surface Disease Index©
NCT01109056,has_criteria,Baseline
NCT00641056,involves,Type 2 Diabetes
NCT00641056,evaluates,Exenatide Once Weekly
NCT00641056,evaluates,Insulin Glargine
NCT00641056,measures_primary,Change in HbA1c
NCT00641056,measures_secondary,Percentage of Patients Achieving HbA1c <=7.0% at Week 26
NCT00641056,measures_secondary,Percentage of Patients Achieving HbA1c <=6.5% at Week 26
NCT00641056,measures_secondary,Change in Fasting Serum Glucose
NCT00641056,measures_secondary,Change in Body Weight
NCT00641056,measures_secondary,Change in Total Cholesterol
NCT00641056,measures_secondary,Change in High-density Lipoprotein Cholesterol
NCT00641056,measures_secondary,Ratio of Triglycerides at Week 26 to Baseline
NCT00641056,measures_secondary,Change in Blood Pressure
NCT00641056,measures_secondary,Event Rate of Treatment-emergent Hypoglycemic Episodes
NCT00641056,has_criteria,Metformin Alone or in Combination With Sulfonylurea
NCT00752609,involves,Chronic Renal Failure
NCT00752609,involves,Anemia
NCT00752609,evaluates,Peginesatide Injection
NCT00752609,measures_primary,Mean change in Hemoglobin
NCT00752609,measures_secondary,Percentage of Participants
NCT00752609,measures_secondary,Red Blood Cell Transfusions
NCT00752609,has_criteria,Previously Treated With Darbepoetin Alfa
NCT01340209,involves,Asthma
NCT01340209,evaluates,Tiotropium
NCT01340209,measures_primary,drug-related adverse events
NCT01340209,measures_secondary,FEV1 Response
NCT01340209,measures_secondary,FVC Response
NCT01340209,measures_secondary,PEF Response
NCT01340209,measures_secondary,PEFam Response
NCT01340209,measures_secondary,PEFpm Response
NCT01340209,measures_secondary,PEF Variability Response
NCT01340209,measures_secondary,Rescue Medication
NCT01340209,measures_secondary,Asthma Symptoms
NCT01340209,has_criteria,moderate to severe persistent asthma
NCT05224609,involves,Liver Dysfunction
NCT05224609,evaluates,Lorlatinib
NCT05224609,measures_primary,AUC (inf) lorlatinib
NCT05224609,measures_primary,AUC (last) lorlatinib
NCT05224609,measures_primary,Cmax lorlatinib
NCT05224609,measures_secondary,treatment emergent adverse event
NCT05224609,measures_secondary,treatment related adverse event
NCT05224609,measures_secondary,serious adverse event
NCT05224609,measures_secondary,Clinically Significant Change
NCT05224609,has_criteria,Baseline up to Day 35
NCT01276509,involves,Crohn's Disease
NCT01276509,evaluates,PF-00547659
NCT01276509,measures_primary,CDAI-70 Response Rate
NCT01276509,measures_secondary,CDAI Remission
NCT01276509,measures_secondary,CDAI-100 Response Rate
NCT01276509,has_criteria,CDAI score of 150 or less
NCT01276509,has_criteria,CDAI score of 200 or greater
NCT00687609,involves,Attention Deficit Hyperactivity Disorder
NCT00687609,evaluates,Atomoxetine
NCT00687609,measures_primary,ADHD Symptoms
NCT00687609,measures_secondary,Global Impression
NCT00687609,has_criteria,Cannabis abuse
NCT00969709,involves,Major Depressive Disorder
NCT00969709,evaluates,Levomilnacipran ER
NCT00969709,measures_primary,Change in MADRS
NCT00969709,measures_secondary,Change in SDS
NCT00969709,has_criteria,18-65 years old
NCT00969709,has_criteria,DSM-IV-TR criteria
NCT00969709,has_criteria,8 weeks duration
NCT00969709,has_criteria,not pregnant
NCT00969709,has_criteria,not breastfeeding
NCT00969709,has_criteria,reliable birth control
NCT00969709,has_criteria,no manic episode
NCT00969709,has_criteria,no psychotic disorder
NCT00969709,has_criteria,no obsessive-compulsive disorder
NCT00969709,has_criteria,no suicide risk
NCT00524056,involves,Essential Tremor
NCT00524056,evaluates,Carisbamate
NCT00524056,measures_primary,TRS score
NCT00524056,measures_secondary,POMS
NCT00524056,measures_secondary,CES-D
NCT00524056,measures_secondary,QUEST
NCT00524056,has_criteria,baseline
NCT04041609,involves,Chronic Sinusitis
NCT04041609,evaluates,LYR-210 Depot
NCT04041609,measures_primary,CFBL in CS Symptom Scores
NCT04041609,measures_secondary,SNOT-22 Total Score
NCT04041609,has_criteria,Adult Subjects
NCT00388609,involves,Obesity
NCT00388609,evaluates,BMS-646256
NCT00388609,measures_primary,Percent change in body weight
NCT00388609,measures_secondary,BMI
NCT00388609,measures_secondary,waist circumference
NCT00388609,measures_secondary,hormonal measures
NCT00388609,measures_secondary,blood pressure
NCT00388609,measures_secondary,blood lipids
NCT00388609,measures_secondary,incidence of adverse events
NCT00388609,measures_secondary,QTc
NCT00388609,has_criteria,BMI ≥30 to ≤45 kg/m²
NCT00388609,has_criteria,BMI >27 to <30 kg/m²
NCT00388609,has_criteria,hypertension
NCT00388609,has_criteria,dyslipidemia
NCT00388609,has_criteria,hypertension defined as
NCT00388609,has_criteria,mean systolic blood pressure ≥140 and ≤160 mmHg
NCT00388609,has_criteria,diastolic blood pressure ≥ 90 and ≤ 105 mmHg
NCT00388609,has_criteria,stable dose treatment with a statin
NCT00388609,has_criteria,triglycerides ≥ 150 and ≤ 600 mg/dL
NCT00388609,has_criteria,LDL ≥ 130 and ≤ 300 mg/dL
NCT00388609,has_criteria,HDL < 40 mg/dL
NCT00388609,has_criteria,Type 1 or 2 diabetes mellitus
NCT00388609,has_criteria,history of MI
NCT00388609,has_criteria,history of heart failure
NCT00388609,has_criteria,history of symptomatic arrhythmia
NCT00388609,has_criteria,active hepatic disease
NCT00388609,has_criteria,any documented muscle disease
NCT00388609,has_criteria,history of neurological symptoms
NCT00388609,has_criteria,history of major psychiatric conditions
NCT00388609,has_criteria,history of depression
NCT00776009,involves,Attention-Deficit/Hyperactivity Disorder
NCT00776009,evaluates,Dex-Methylphenidate
NCT00776009,measures_primary,Change From Pre-dose
NCT00776009,measures_secondary,Change From Pre-dose
NCT00776009,measures_secondary,Change From Pre-dose
NCT00776009,has_criteria,Children (6-12 Years)
NCT00317356,involves,Ulcerative Colitis
NCT00317356,evaluates,OPC-6535
NCT00317356,measures_primary,Clinical Improvement Rate
NCT00317356,measures_secondary,Remission Rate
NCT00317356,measures_secondary,Mean Change DAI Score
NCT00317356,measures_secondary,Mean Change DAI Subscores
NCT00317356,measures_secondary,Mean Change CAI Score
NCT00317356,has_criteria,Baseline
NCT00293709,involves,Psoriatic Arthritis
NCT00293709,evaluates,Etanercept
NCT00293709,measures_primary,Percent BSA Affected
NCT00293709,measures_secondary,PASI
NCT00293709,measures_secondary,DAS 28
NCT00293709,has_criteria,Dermatologists treated
NCT02298556,involves,Hypertensive Patients
NCT02298556,involves,Type 2 Diabetes
NCT02298556,evaluates,Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination
NCT02298556,measures_primary,Absolute change in SBP
NCT02298556,measures_secondary,Absolute change in DBP
NCT02298556,measures_secondary,Ratio of patients achieving blood pressure ≤ 140 and/or 90 mmHg
NCT02298556,measures_secondary,Ratio of responder patients
NCT02298556,measures_secondary,Absolute change of heart rate
NCT02298556,measures_secondary,Correlation between absolute change in blood pressure and absolute change in heart rate
NCT02298556,measures_secondary,The absolute change in PR interval
NCT02298556,measures_secondary,The absolute change in HbA1c
NCT02298556,measures_secondary,The absolute change in microalbuminuria
NCT02298556,measures_secondary,Ratio of patients experiencing an adverse event
NCT02298556,measures_secondary,Correlation between physician's office and home blood pressure measurements
NCT02298556,measures_secondary,Blood pressure variability
NCT02298556,has_criteria,Elevated Heart Rate
NCT01011556,involves,Osteoporosis
NCT01011556,evaluates,Teriparatide
NCT01011556,measures_primary,Percent Change BMD
NCT01011556,measures_secondary,Procollagen Type 1 N-Terminal Propeptide
NCT01011556,measures_secondary,C-terminal telopeptide
NCT01011556,measures_secondary,Serum Procollagen Type 1 C-Propeptide
NCT01011556,has_criteria,Baseline
NCT01567956,involves,Ulcerative Colitis
NCT01567956,evaluates,Propionyl-L-Carnitine Hydrochloride
NCT01567956,measures_primary,Proportion of remission
NCT01567956,measures_secondary,Rectal bleeding
NCT01567956,measures_secondary,stool frequency
NCT01567956,measures_secondary,Histological response
NCT01567956,measures_secondary,C-reactive protein
NCT01567956,measures_secondary,Fibrinogen
NCT01567956,measures_secondary,Quality of life
NCT01567956,has_criteria,active ulcerative colitis
NCT03944109,involves,Hyperlipidemia
NCT03944109,evaluates,SHR-1209
NCT03944109,measures_primary,Percent change LDL-C
NCT03944109,measures_secondary,Number of adverse events
NCT03944109,measures_secondary,Absolute change LDL-C
NCT03944109,measures_secondary,Percent change LDL-C
NCT03944109,measures_secondary,Absolute change LDL-C
NCT03944109,measures_secondary,Percent change PCSK9
NCT03944109,measures_secondary,Absolute change PCSK9
NCT03439488,involves,Chronic Hepatitis B
NCT03439488,evaluates,JNJ-440
NCT03439488,measures_primary,Number of Adverse Events
NCT03439488,measures_secondary,Clinically Significant Changes
NCT03439488,measures_secondary,Vital Signs
NCT03439488,measures_secondary,ECG Abnormalities
NCT03439488,measures_secondary,Holter Monitoring Abnormalities
NCT03439488,measures_secondary,Clinical Laboratory Abnormalities
NCT03439488,has_criteria,Healthy Participants
NCT01929109,evaluates,LY2409021
NCT01929109,measures_primary,Maximum Concentration
NCT01929109,measures_secondary,Area Under the Concentration Curve
NCT01929109,has_criteria,Male participants
NCT01929109,has_criteria,Female participants
NCT01929109,has_criteria,body mass index
NCT01929109,has_criteria,renal function
NCT01929109,has_criteria,estimated creatinine clearance
NCT04724109,involves,Parkinson's Disease
NCT04724109,evaluates,Equfina
NCT04724109,measures_primary,Incidence Rate of ADRs
NCT04724109,measures_secondary,Change From Baseline in Symptoms of Parkinson's Disease
NCT04724109,has_criteria,duration of the disease
NCT04724109,has_criteria,severity of Parkinson's disease
NCT04724109,has_criteria,severity of hepatic impairment
NCT04724109,has_criteria,presence/absence of surgical treatment for Parkinson's disease
NCT04724109,has_criteria,presence/absence of comorbid retinal pathology
NCT04724109,has_criteria,history of drug allergy
NCT04724109,has_criteria,presence/absence of pregnancy/breast-feeding
NCT04724109,has_criteria,history of smoking
NCT01349907,involves,Pediatric Bipolar Disorder
NCT01349907,evaluates,Asenapine
NCT01349907,measures_primary,Y-MRS Total Score
NCT01349907,measures_secondary,Y-MRS Total Score Remitters
NCT01349907,measures_secondary,Y-MRS Total Score Responders
NCT01349907,has_criteria,Baseline Day 182 Day 350
NCT00848107,involves,Digital Ulcers
NCT00848107,evaluates,Oral Treprostinil
NCT00848107,measures_primary,Net ulcer burden
NCT00848107,measures_secondary,Total ulcer number
NCT00848107,measures_secondary,Formation of New Ulcers
NCT00848107,has_criteria,Baseline and Months 1
NCT01904409,involves,Liver Cirrhosis
NCT01904409,evaluates,Rifaximin Soluble Solid Dispersion (SSD) Tablets
NCT01904409,measures_primary,Time to all-cause mortality or hospitalization
NCT01904409,measures_secondary,Overall hospitalization rate
NCT01904409,measures_secondary,Pharmacokinetics of rifaximin
NCT01904409,measures_secondary,Incidence of treatment-emergent adverse events
NCT01904409,measures_secondary,Change in clinical laboratory parameters
NCT01904409,measures_secondary,Changes in electrocardiogram measurements
NCT01904409,measures_secondary,Changes in indices of health outcomes
NCT01904409,has_criteria,Diagnosis of liver cirrhosis and documented ascites
NCT02603809,involves,Essential Hypertension
NCT02603809,evaluates,ACT-132577
NCT02603809,measures_primary,Sitting Diastolic Blood Pressure
NCT02603809,measures_primary,Sitting Systolic Blood Pressure
NCT04599907,involves,Primary Axillary Hyperhidrosis
NCT04599907,evaluates,N-SWEAT Patch
NCT04599907,measures_primary,HDSS score at 4 weeks
NCT04599907,measures_secondary,Quality of Life
NCT04599907,has_criteria,HDSS 3 or 4 at baseline
NCT04481607,evaluates,TQB3454 Tablets
NCT04481607,measures_primary,Objective response rate
NCT04481607,measures_secondary,Progression-free survival
NCT04481607,has_criteria,up to 6 patients
NCT03305809,involves,Lewy Body Dementia
NCT03305809,involves,Idiopathic Parkinson's Disease
NCT03305809,involves,Dementia With Lewy Bodies
NCT03305809,evaluates,LY3154207
NCT03305809,measures_primary,Continuity of Attention
NCT03305809,measures_secondary,ADCS-CGIC Score
NCT03305809,has_criteria,Baseline
NCT05166109,involves,Becker Muscular Dystrophy
NCT05166109,evaluates,Vamorolone
NCT05166109,measures_primary,Sitting Blood Pressure
NCT05166109,measures_secondary,Heart Rate
NCT05166109,measures_secondary,Respiratory Rate
NCT05166109,measures_secondary,Body Temperature
NCT05166109,measures_secondary,Body Weight
NCT05166109,measures_secondary,Height
NCT05166109,has_criteria,24 weeks
NCT00798707,involves,Major Depressive Disorder
NCT00798707,evaluates,Desvenlafaxine Succinate Sustained Release
NCT00798707,measures_primary,Change From Baseline
NCT00798707,measures_secondary,CGI-Improvement
NCT00798707,measures_secondary,CGI-S
NCT00798707,measures_secondary,MADRS Total Score
NCT00798707,measures_secondary,HAM-D6 Total Score
NCT00798707,has_criteria,Baseline and Week 8
NCT06388707,involves,Drug-resistant Epilepsy
NCT06388707,evaluates,Low-intensity Focused Ultrasound Neuromodulation
NCT06388707,measures_primary,Change from baseline in seizure frequency
NCT06388707,measures_secondary,Change from baseline in electroencephalography epileptiform discharges
NCT06388707,measures_secondary,Days of seizure-free
NCT06388707,measures_secondary,Changes from baseline in Beck Anxiety Inventory
NCT06388707,measures_secondary,Changes from baseline in Beck Depression Inventory
NCT06388707,measures_secondary,Changes from baseline in Personal Impact of Epilepsy Scale
NCT06388707,has_criteria,up to 23 weeks
NCT02760407,involves,Rheumatoid Arthritis
NCT02760407,evaluates,Olokizumab
NCT02760407,evaluates,Placebo
NCT02760407,evaluates,Adalimumab
NCT02760407,measures_primary,ACR20 Response
NCT02760407,measures_secondary,Patient Global Assessment
NCT02760407,measures_secondary,Patient Assessment of Pain
NCT02760407,measures_secondary,HAQ-DI
NCT02760407,measures_secondary,Physician Global Assessment
NCT02760407,measures_secondary,CRP
NCT02760407,has_criteria,Methotrexate
NCT03430856,involves,Type 2 Diabetes Mellitus
NCT03430856,evaluates,Insulin Tregopil
NCT03430856,evaluates,Insulin Aspart
NCT03430856,measures_primary,Change From Baseline in HbA1c
NCT03430856,measures_secondary,Change From Baseline in HbA1c
NCT03430856,measures_secondary,Participants Achieving HbA1c < 7%
NCT03430856,measures_secondary,Percentage of Participants With Hypoglycemia Events
NCT03430856,measures_secondary,Weight (Kgs)
NCT03430856,measures_secondary,Lipid Profile
NCT03430856,measures_secondary,Post-prandial Glucose (PPG) Excursion
NCT03430856,measures_secondary,Number of Participants With Treatment-Emergent Adverse Events
NCT03430856,measures_secondary,Anti-drug Antibody Levels
NCT03430856,measures_secondary,CGM
NCT03186209,involves,Uncontrolled Asthma
NCT03186209,evaluates,Benralizumab
NCT03186209,measures_primary,Annual asthma exacerbation rate
NCT03186209,measures_secondary,Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L)
NCT03186209,measures_secondary,Change From Baseline at Week 48 in Total Asthma Symptom Score
NCT03186209,measures_secondary,Change From Baseline at Week 48 in Total Asthma Rescue Medication Use
NCT03186209,measures_secondary,Change From Baseline at Week 48 in Morning Peak Expiratory Flow (PEF)
NCT03186209,measures_secondary,Change From Baseline at Week 48 in Evening Peak Expiratory Flow (PEF)
NCT03186209,has_criteria,Baseline Eosinophils >=300/uL
NCT00644709,involves,High Cholesterol
NCT00644709,involves,Coronary Heart Disease
NCT00644709,evaluates,Atorvastatin
NCT00644709,measures_primary,LDL-C target
NCT00644709,measures_secondary,HDL-C
NCT00644709,measures_secondary,total cholesterol
NCT00644709,measures_secondary,triglyceride levels
NCT00644709,has_criteria,Dyslipidemia
NCT00644709,has_criteria,high risk CHD
NCT00644709,has_criteria,impaired liver function
NCT00644709,has_criteria,Gastrointestinal disease
NCT03593707,evaluates,PF-06865571
NCT03593707,measures_primary,Metformin Cmax
NCT03593707,measures_secondary,Metformin AUCinf
NCT03593707,has_criteria,Baseline up to 35 days after last dose of study medication
NCT05053607,involves,Multiple Myeloma
NCT05053607,evaluates,Isatuximab
NCT05053607,measures_primary,Change in PQAT-RW
NCT05053607,measures_secondary,Change in EORTC-QLQ-C30
NCT05053607,measures_secondary,Change in QLQ-MY20
NCT05053607,measures_secondary,Change in EQ5D
NCT05053607,measures_secondary,Change in CBI-B
NCT01606007,involves,Type 2 Diabetes
NCT01606007,evaluates,Saxagliptin & Dapagliflozin & Metformin
NCT01606007,measures_primary,HbA1c at Week 24
NCT01606007,measures_secondary,2-hour Post Prandial Glucose
NCT01606007,measures_secondary,Fasting Plasma Glucose
NCT01606007,measures_secondary,Body Weight
NCT01606007,measures_secondary,Therapeutic Glycemic Response
NCT01606007,has_criteria,last assessment prior to first dose
NCT01190007,involves,Hypertension
NCT01190007,evaluates,Caduet
NCT01190007,measures_primary,Systolic Blood Pressure
NCT01190007,measures_secondary,Diastolic Blood Pressure
NCT01190007,measures_secondary,LDL-C
NCT01190007,measures_secondary,Total Cholesterol
NCT01190007,measures_secondary,HDL-C
NCT01190007,has_criteria,Japanese Patients
NCT04891107,involves,Parkinson Disease
NCT04891107,evaluates,MR-005
NCT04891107,measures_primary,Change in Mobility Impact
NCT04891107,measures_secondary,Safety
NCT04891107,measures_secondary,Usability
NCT04891107,has_criteria,Walking Program Schedule
NCT02604407,involves,Attention-deficit/Hyperactivity Disorder
NCT02604407,evaluates,SHP465
NCT02604407,measures_primary,ADHD-RS Total Score
NCT02604407,measures_secondary,CGI-I Score
NCT02604407,has_criteria,18-55 years old
NCT00684307,involves,Atrial Fibrillation
NCT00684307,evaluates,AZD0837
NCT00684307,measures_primary,Bleeding Events
NCT00684307,measures_secondary,Creatinine
NCT00684307,measures_secondary,Alanine Aminotransferase
NCT00684307,measures_secondary,Bilirubin
NCT00684307,measures_secondary,D-Dimer
NCT00684307,measures_secondary,Activated Partial Thromboplastin Time
NCT00684307,measures_secondary,Ecarin Clotting Time
NCT00684307,measures_secondary,Plasma Concentration of AZD0837
NCT00684307,measures_secondary,Plasma Concentration of AR-H067637XX
NCT00684307,has_criteria,VKA naïve
NCT00694707,involves,Schizophrenia
NCT00694707,evaluates,Cariprazine
NCT00694707,measures_primary,PANSS Total Score
NCT00694707,measures_secondary,CGI-S Score
NCT00694707,has_criteria,Baseline to Week 6
NCT01278407,involves,Dementia With Lewy Bodies
NCT01278407,evaluates,E2020
NCT01278407,measures_primary,Change From Baseline in MMSE Score
NCT01278407,measures_secondary,Change From Baseline in NPI-2 Score
NCT01278407,has_criteria,Week 12 for Confirmatory Phase
NCT01706107,involves,Multiple Sclerosis
NCT01706107,evaluates,Tysabri
NCT01706107,measures_primary,Annualized Relapse Rate
NCT01706107,measures_primary,Multiple Sclerosis Impact Scale-29
NCT01706107,measures_secondary,Expanded Disability Status Scale
NCT01706107,measures_secondary,Work Productivity and Activity Impairment
NCT01706107,measures_secondary,EuroQol 5-Dimension
NCT01706107,has_criteria,Baseline
NCT01187407,involves,Major Depressive Disorder
NCT01187407,evaluates,LY2216684
NCT01187407,measures_primary,Change From Randomization
NCT01187407,measures_secondary,Sheehan Disability Scale
NCT01187407,has_criteria,Partial Response to SSRI
NCT01936688,involves,Chronic Plaque Psoriasis
NCT01936688,evaluates,MK-3222
NCT01936688,measures_primary,PASI-75 at Week 12
NCT01936688,measures_secondary,Physician's Global Assessment
NCT01936688,measures_secondary,DLQI at Week 12
NCT01936688,measures_secondary,PASI-90 Response
NCT01936688,measures_secondary,NAPSI at Week 12
NCT01936688,measures_secondary,Adverse Event
NCT01936688,has_criteria,Moderate-to-Severe
NCT01387607,involves,Fibromyalgia
NCT01387607,evaluates,Pregabalin
NCT01387607,measures_primary,Endpoint mean pain score
NCT01387607,measures_secondary,Fibromyalgia Impact Questionnaire (FIQ) Total Score
NCT01387607,has_criteria,last 7 pain diary entries
NCT01123707,involves,Major Depressive Disorder
NCT01123707,evaluates,Aripiprazole/Escitalopram
NCT01123707,measures_primary,CGI-S Score
NCT01123707,measures_secondary,PGI-S Score
NCT01123707,has_criteria,Treatment-Emergent Adverse Events
NCT00082407,involves,Type 2 Diabetes
NCT00082407,evaluates,Exenatide
NCT00082407,evaluates,Biphasic Insulin Aspart
NCT00082407,measures_primary,Change in HbA1c
NCT00082407,measures_secondary,Change in Body Weight
NCT00082407,measures_secondary,Change in Fasting Serum Glucose
NCT00082407,measures_secondary,Change in 7-point SMBG Profile
NCT00082407,measures_secondary,Percentage of Patients With Hypoglycemic Events
NCT00082407,measures_secondary,Change in Rate of Hypoglycemic Events
NCT00082407,has_criteria,stable dose of metformin
NCT00082407,has_criteria,optimally effective sulfonylurea
NCT00082407,has_criteria,HbA1c 7.0% to 11.0%
NCT00080288,involves,Chronic SWSD
NCT00080288,evaluates,Armodafinil
NCT00080288,measures_primary,MSLT sleep latency
NCT00080288,measures_secondary,CGI-C
NCT00080288,has_criteria,excessive sleepiness
NCT00080288,has_criteria,SWSD diagnosis
NCT00080288,has_criteria,night shift work
NCT02528188,involves,Osteoarthritis
NCT02528188,evaluates,Tanezumab
NCT02528188,measures_primary,Adjudicated Primary Composite Joint Safety Outcome
NCT02528188,measures_secondary,WOMAC Pain Subscale
NCT02528188,has_criteria,Baseline up to Week 80
NCT02020278,involves,Hyponatremia
NCT02020278,evaluates,Tolvaptan
NCT02020278,measures_primary,Change From Baseline
NCT02020278,measures_secondary,Percentage Of Participants
NCT02020278,measures_secondary,Percentage Of Participants
NCT02020278,measures_secondary,Percentage Of Participants
NCT02020278,measures_secondary,Change From Baseline
NCT02020278,has_criteria,Children and Adolescent
NCT04773678,involves,Asthma
NCT04773678,evaluates,CBP-201
NCT04773678,measures_primary,Absolute change FEV1
NCT04773678,measures_secondary,Percent change FEV1
NCT04773678,has_criteria,Adult 18-75 years
NCT06005688,evaluates,Carbamazepine
NCT06005688,evaluates,Vepdegestrant
NCT06005688,measures_primary,Cmax of Vepdegestrant
NCT06005688,measures_primary,AUCinf of Vepdegestrant
NCT06005688,measures_secondary,Number of Participants With Treatment-Emergent Adverse Events
NCT06005688,measures_secondary,Number of Participants With Clinical Laboratory Abnormalities
NCT06005688,measures_secondary,Number of Participants With Electrocardiogram Abnormalities
NCT06005688,measures_secondary,Number of Participants With Clinically Significant Change From Baseline in Vital Signs
NCT06005688,measures_secondary,Number of Participants With Abnormalities in Physical Examinations
NCT02793778,involves,Crohn's Disease
NCT02793778,evaluates,CROWN
NCT02793778,measures_primary,SES-CD score change
NCT02793778,measures_secondary,Plasma amino acid level
NCT02793778,measures_secondary,Quality of Life Score
NCT02793778,measures_secondary,Inflammatory biomarkers
NCT02793778,measures_secondary,Endoscopic response
NCT02793778,measures_secondary,Corticosteroid-free
NCT02793778,has_criteria,Adults 18-85 years
NCT02793778,has_criteria,Symptomatic CD
NCT02793778,has_criteria,CDAI score ≤ 350
NCT02793778,has_criteria,Active endoscopic disease
NCT02793778,has_criteria,Stable dose infliximab
NCT02793778,has_criteria,Able to consume oral nutrition
NCT01276288,involves,Type 2 Diabetes
NCT01276288,evaluates,Empagliflozin
NCT01276288,evaluates,Torasemide
NCT01276288,measures_primary,Change in clearance
NCT01276288,measures_secondary,Change in Urinary Excretion
NCT01276288,has_criteria,last 24-h collection
NCT03759288,involves,Crohn's Disease
NCT03759288,evaluates,Brazikumab
NCT03759288,measures_primary,CDAI remission
NCT03759288,measures_secondary,endoscopic response
NCT03759288,measures_secondary,clinical remission
NCT03759288,has_criteria,CDAI score below 150
NCT01423188,involves,Dyslipidemia
NCT01423188,evaluates,RVX000222
NCT01423188,measures_primary,percent change HDL-C
NCT01423188,measures_secondary,LDL-C
NCT01423188,measures_secondary,apoB
NCT01423188,measures_secondary,hsCRP
NCT01423188,has_criteria,2 weeks screening
NCT03678688,involves,Pulmonary Tuberculosis
NCT03678688,evaluates,OPC-167832
NCT03678688,measures_primary,Early Bactericidal Activity
NCT03678688,measures_secondary,Maximum Plasma Concentration
NCT03678688,has_criteria,Multiple Oral Doses
NCT03945188,involves,Ulcerative Colitis
NCT03945188,evaluates,Etrasimod
NCT03945188,evaluates,Placebo
NCT03945188,measures_primary,Clinical Remission
NCT03945188,measures_secondary,Endoscopic Improvement
NCT03945188,measures_secondary,Symptomatic Remission
NCT03945188,has_criteria,Week 12
NCT03945188,has_criteria,Week 52
NCT01865188,involves,Hypertension
NCT01865188,evaluates,LCZ696
NCT01865188,evaluates,Amlodipine
NCT01865188,measures_primary,Change from baseline
NCT01865188,measures_primary,msSBP
NCT01865188,measures_primary,msDBP
NCT01865188,has_criteria,baseline
NCT01580488,involves,Psoriasis Vulgaris
NCT01580488,evaluates,LEO 35299
NCT01580488,measures_primary,Total Clinical Score
NCT01580488,measures_secondary,Erythema
NCT01580488,measures_secondary,Infiltration
NCT01580488,measures_secondary,Scaling
NCT01580488,measures_secondary,Lesion Thickness
NCT01580488,measures_secondary,Skin Thickness
NCT01580488,has_criteria,Age 18 years or above
NCT01580488,has_criteria,Non-child bearing potential
NCT01580488,has_criteria,Stable psoriasis
NCT00125788,involves,Sickle Cell Anemia
NCT00125788,involves,Sickle ß0 Thalassemia
NCT00125788,evaluates,Oral L-glutamine
NCT00125788,measures_primary,mean number of painful crises
NCT00125788,measures_secondary,mean number of hospitalizations
NCT00125788,measures_secondary,mean number of emergency room visits
NCT00125788,measures_secondary,hemoglobin
NCT00125788,measures_secondary,hematocrit
NCT00125788,measures_secondary,reticulocyte count
NCT00125788,measures_secondary,narcotic usage
NCT00125788,measures_secondary,energy level
NCT00125788,measures_secondary,appetite level
NCT00125788,has_criteria,completed the study
NCT01644188,involves,Hypercholesterolemia
NCT01644188,involves,Cardiovascular disease
NCT01644188,evaluates,Alirocumab
NCT01644188,evaluates,Ezetimibe
NCT01644188,measures_primary,LDL-C at Week 24
NCT01644188,measures_secondary,Apo-B at Week 24
NCT01590888,involves,Huntington Disease
NCT01590888,evaluates,PBT2
NCT01590888,measures_primary,Change From Baseline in Cognitive Test Battery
NCT01590888,measures_secondary,Change From Baseline in Motor Function
NCT01590888,measures_secondary,Change From Baseline in Functional Abilities
NCT01590888,has_criteria,Baseline to 26 weeks
NCT03759678,involves,Ataxia-Telangiectasia
NCT03759678,evaluates,IB1001
NCT03759678,measures_primary,Clinical Impression of Change
NCT03759678,measures_secondary,Spinocerebellar Ataxia Functional Index
NCT03759678,has_criteria,Baseline (Day 1) to end of treatment with IB1001 (Approximately Day 42); End of treatment with IB1001 (Approximately Day 42) to the end of post-treatment washout (Approximately Day 84)
NCT06520878,involves,Mild to Moderate Cognitive Impairment
NCT06520878,evaluates,NANO-PSO
NCT06520878,measures_primary,Cognitive status
NCT06520878,measures_secondary,Fatigue Severity
NCT06520878,measures_secondary,Trail Making Test
NCT06520878,measures_secondary,Frailty
NCT06520878,has_criteria,Age 60 or older
NCT06520878,has_criteria,Cognitive impairment
NCT06520878,has_criteria,Probable dementia
NCT06520878,has_criteria,Typical variant Alzheimer's disease
NCT06520878,has_criteria,Progressive memory decline
NCT06520878,has_criteria,Hippocampal-type amnesic syndrome
NCT03452488,involves,COVID-19
NCT03452488,evaluates,Placebo
NCT03452488,measures_primary,Gait speed
NCT03452488,measures_secondary,Short Form-36
NCT03452488,measures_secondary,Handgrip Strength
NCT03452488,has_criteria,400 MW test
NCT03218488,involves,Plaque Psoriasis
NCT03218488,evaluates,Ustekinumab
NCT03218488,measures_primary,Growth: Height
NCT03218488,measures_primary,Growth: Weight
NCT03218488,measures_primary,Growth: BMI
NCT03218488,measures_secondary,Sexual Maturity
NCT03218488,has_criteria,6 years and older
NCT05021978,involves,Essential Tremor
NCT05021978,evaluates,PRAX-944
NCT05021978,measures_primary,TETRAS Upper Limb Score
NCT05021978,measures_secondary,Adverse Events
NCT05021978,measures_secondary,Vital Signs
NCT05021978,has_criteria,last non-missing value
NCT05098509,involves,Prader-Willi Syndrome
NCT05098509,evaluates,RAD011
NCT05098509,measures_primary,Change From Baseline
NCT05098509,measures_secondary,Clinician Global Impression
NCT05098509,has_criteria,Baseline
NCT04543409,involves,Eosinophilic Esophagitis
NCT04543409,evaluates,Benralizumab
NCT04543409,measures_primary,Histologic Response
NCT04543409,measures_secondary,Dysphagia Symptom Questionnaire
NCT04543409,measures_secondary,Tissue Eosinophils
NCT04543409,measures_secondary,EoE-HSS Grade
NCT04543409,has_criteria,peak esophageal intraepithelial eosinophil count
NCT03728309,involves,cheek skin smoothness
NCT03728309,evaluates,JUVÉDERM® VOLITE™ XC
NCT03728309,measures_primary,Cheek Smoothness Scale
NCT03728309,measures_secondary,Face-Q Satisfaction
NCT03728309,has_criteria,treatment emergent adverse event
NCT03066609,involves,Psoriasis
NCT03066609,evaluates,Secukinumab
NCT03066609,measures_primary,PASI 75
NCT03066609,measures_primary,PASI 90
NCT03066609,measures_secondary,Investigator's Global Assessment
NCT03066609,has_criteria,moderate to severe
NCT06488209,involves,Autoimmune Disease
NCT06488209,evaluates,LAD191
NCT06488209,measures_primary,Maximum Serum Concentration
NCT06488209,measures_secondary,Time to Reach Maximum Serum Concentration
NCT06488209,measures_secondary,Area Under the Serum Concentration-time Curve
NCT02971007,involves,Vulvovaginal Candidiasis
NCT02971007,evaluates,Oral Encochleated Amphotericin B
NCT02971007,measures_primary,Clinical Cure
NCT02971007,measures_secondary,Overall Response
NCT02971007,has_criteria,12 days
NCT05483907,involves,IPF
NCT05483907,evaluates,BBT-877
NCT05483907,measures_primary,Change from baseline in FVC
NCT05483907,measures_primary,Change from baseline in FVC (%)
NCT05483907,measures_primary,Change in overall respiratory health
NCT05483907,measures_primary,Change in overall IPF impacts
NCT05483907,measures_primary,Change in overall IPF symptoms
NCT05483907,measures_secondary,Change from baseline in DLCO
NCT05483907,measures_secondary,Change from baseline in functional exercise capacity
NCT05483907,measures_secondary,Pre-dose and 4 hr-post dose of plasma concentrations
NCT05483907,has_criteria,patients with IPF
NCT02337907,involves,Cognitive Impairment Due to Alzheimer's Disease
NCT02337907,evaluates,BI 409306
NCT02337907,measures_primary,Change From Baseline
NCT02337907,measures_secondary,Neuropsychological Test Battery response
NCT02337907,has_criteria,Baseline and 12 weeks
NCT02556307,involves,Hepatitis C
NCT02556307,evaluates,Peginterferon Alfa-2a
NCT02556307,evaluates,Ribavirin
NCT02556307,measures_primary,Sustained Virological Response
NCT02556307,measures_secondary,Undetectable HCV RNA
NCT02556307,measures_secondary,Thrombocyte Values
NCT02556307,measures_secondary,Leukocyte Values
NCT02556307,measures_secondary,Hemoglobin Values
NCT02556307,measures_secondary,Treatment Duration
NCT02556307,has_criteria,HCV genotype
NCT02556307,has_criteria,interleukin 28B genotype
NCT02556307,has_criteria,previous treatment
NCT01080807,involves,Shift Work Disorder
NCT01080807,evaluates,Armodafinil
NCT01080807,measures_primary,CGI-C rating
NCT01080807,measures_secondary,GAF score
NCT01080807,has_criteria,Late shift sleepiness
NCT00670007,involves,Emphysema
NCT00670007,evaluates,Zemaira® i.v.
NCT00670007,measures_primary,Rate of Change Lung Density
NCT00670007,measures_secondary,Absolute Change Lung Density
NCT00670007,measures_secondary,Percent Change Lung Density
NCT00670007,has_criteria,alpha1-proteinase Inhibitor Deficiency
NCT02336607,involves,Hypertension
NCT02336607,evaluates,Felodipine Sustained Release
NCT02336607,measures_primary,Blood Pressure Target
NCT02336607,measures_secondary,Blood Pressure Change
NCT02336607,has_criteria,Chinese Patients
NCT02720107,involves,Multiple Sclerosis
NCT02720107,evaluates,Fingolimod
NCT02720107,measures_primary,Disability Progression
NCT02720107,measures_secondary,Change in T Cells Status
NCT02720107,has_criteria,Baseline up to approximately 48 months
NCT03862807,involves,Hereditary Transthyretin-mediated Amyloidosis
NCT03862807,evaluates,Patisiran
NCT03862807,measures_primary,Serum TTR reduction
NCT03862807,measures_secondary,Neuropathy Impairment Score
NCT03862807,measures_secondary,Norfolk QoL-DN Score
NCT03862807,measures_secondary,Rasch-Built Overall Disability Scale
NCT03862807,measures_secondary,Composite Autonomic Symptom Score
NCT00677807,involves,Chronic Obstructive Pulmonary Disease
NCT00677807,evaluates,Indacaterol
NCT00677807,measures_primary,Clinically Notable Pulse Rate
NCT00677807,measures_secondary,Clinically Notable Systolic Blood Pressure
NCT00677807,measures_secondary,Clinically Notable Diastolic Blood Pressure
NCT00677807,has_criteria,Pulse Rate \<40 bpm
NCT00677807,has_criteria,Pulse Rate \<=50 bpm
NCT00677807,has_criteria,Decrease from baseline \>=15 bpm
NCT00677807,has_criteria,Systolic Blood Pressure \<75 mmHg
NCT00677807,has_criteria,Systolic Blood Pressure \<=90 mmHg
NCT00677807,has_criteria,Decrease from baseline \>=20 mmHg
NCT00677807,has_criteria,Systolic Blood Pressure \>200 mmHg
NCT00677807,has_criteria,Systolic Blood Pressure \>=180 mmHg
NCT00677807,has_criteria,Diastolic Blood Pressure \<40 mmHg
NCT00677807,has_criteria,Diastolic Blood Pressure \<=50 mmHg
NCT00677807,has_criteria,Decrease from baseline \>=15 mmHg
NCT00677807,has_criteria,Diastolic Blood Pressure \>115 mmHg
NCT00677807,has_criteria,Diastolic Blood Pressure \>=105 mmHg
NCT01812707,involves,Primary Hypercholesterolemia
NCT01812707,evaluates,Alirocumab
NCT01812707,measures_primary,Percent Change LDL-C
NCT01812707,measures_secondary,Total Cholesterol
NCT01812707,measures_secondary,HDL-C
NCT01812707,measures_secondary,Non-HDL-C
NCT01812707,measures_secondary,Apolipoprotein B
NCT01812707,measures_secondary,Fasting Triglycerides
NCT01812707,measures_secondary,Lipoprotein (a)
NCT01812707,has_criteria,Stable Atorvastatin
NCT04128007,involves,plaque psoriasis
NCT04128007,evaluates,ARQ-154 Foam
NCT04128007,measures_primary,S-IGA score
NCT04128007,measures_primary,B-IGA score
NCT04128007,measures_secondary,SI-NRS score
NCT04128007,measures_secondary,PSD score
NCT04128007,has_criteria,adolescent and adult subjects
NCT04882007,involves,Ulcerative Colitis
NCT04882007,evaluates,OSE-127
NCT04882007,measures_primary,Clinical Remission
NCT04882007,measures_secondary,Endoscopic Remission
NCT04882007,measures_secondary,Endoscopic improvement
NCT04882007,has_criteria,informed consent
NCT01297309,involves,Hypoparathyroidism
NCT01297309,evaluates,NPSP558
NCT01297309,measures_primary,Calcium Source
NCT01297309,measures_secondary,Serum calcium
NCT01297309,has_criteria,Calcium supplementation
NCT00389207,involves,Human Immunodeficiency Virus (HIV)-1
NCT00389207,evaluates,Nevirapine
NCT00389207,evaluates,Atazanavir/Ritonavir
NCT00389207,measures_primary,Proportion of Patients With VL < 50 Copies/ml
NCT00389207,measures_secondary,VL < 400 Copies/ml
NCT00389207,measures_secondary,Change in CD4+ Count From Baseline
NCT00389207,measures_secondary,Change in Framingham Score From Baseline
NCT00389207,has_criteria,Treatment Naive Adults
NCT01468207,involves,Hidradenitis Suppurativa
NCT01468207,evaluates,Adalimumab
NCT01468207,measures_primary,HiSCR at Week 12
NCT01468207,measures_secondary,Patient's Global Assessment of Skin Pain
NCT01468207,has_criteria,Hurley Stage
NCT06380907,involves,Chronic Plaque Psoriasis
NCT06380907,evaluates,ZL-1102
NCT06380907,measures_primary,mPASI 75 at Week 16
NCT06380907,measures_secondary,IGA treatment success
NCT06380907,measures_secondary,mPASI score change
NCT06380907,measures_secondary,mPASI 50/90/100
NCT06380907,measures_secondary,Time to achieve mPASI
NCT06380907,measures_secondary,Time to achieve IGA
NCT06380907,measures_secondary,Incidence of Adverse Events
NCT06380907,measures_secondary,Local tolerability scores
NCT06380907,measures_secondary,Serum concentration ZL-1102
NCT06380907,measures_secondary,Anti-drug antibody ZL-1102
NCT06380907,has_criteria,different doses
NCT00814307,involves,Rheumatoid Arthritis
NCT00814307,evaluates,CP-690
NCT00814307,evaluates,Placebo
NCT00814307,measures_primary,ACR20 response
NCT00814307,measures_secondary,HAQ-DI Score
NCT00814307,measures_secondary,DAS28-4 (ESR)
NCT00814307,has_criteria,Baseline
NCT04520607,involves,Osteoarthritis of the Knee
NCT04520607,evaluates,Lorecivivint
NCT04520607,measures_primary,medial joint space width
NCT04520607,measures_secondary,OA pain
NCT04520607,measures_secondary,OA function
NCT04520607,has_criteria,parent-study baseline
NCT01464307,involves,Spasticity
NCT01464307,evaluates,Botulinum Toxin Type A
NCT01464307,measures_primary,Ashworth Scale (AS)
NCT01464307,measures_primary,Investigator's Global Assessment of Efficacy
NCT01464307,measures_secondary,Response Rate
NCT01464307,has_criteria,Improvement (Reduction) of at Least 1 Point
NCT00755807,involves,Multiple Sclerosis Pain
NCT00755807,evaluates,Duloxetine
NCT00755807,measures_primary,Change From Baseline
NCT00755807,measures_secondary,Patient Global Impressions
NCT00755807,has_criteria,Baseline
NCT03358407,evaluates,GSK2983559
NCT03358407,measures_primary,Hematology Parameters
NCT03358407,measures_secondary,Adverse Events
NCT03358407,has_criteria,Potential Clinical Importance
NCT04213807,involves,Atrial Fibrillation
NCT04213807,evaluates,MAA868
NCT04213807,measures_primary,Factor XI Inhibition
NCT04213807,measures_secondary,Adverse Events
NCT04213807,measures_secondary,Bleeding Events
NCT04213807,measures_secondary,Immunogenicity
NCT04213807,has_criteria,Dose Levels
NCT03732807,involves,Alopecia Areata
NCT03732807,evaluates,PF-06651600
NCT03732807,measures_primary,SALT score <= 20
NCT03732807,measures_secondary,SALT score <= 10
NCT03732807,measures_secondary,PGI-C score
NCT03732807,has_criteria,Week 24
NCT05782907,involves,Ulcerative Colitis
NCT05782907,evaluates,Oral Upadacitinib
NCT05782907,measures_primary,AMS Clinical Remission
NCT05782907,measures_secondary,Endoscopic Improvement
NCT05782907,measures_secondary,Partial Mayo Score Clinical Remission
NCT05782907,measures_secondary,AMS Clinical Response
NCT05782907,has_criteria,Pediatric Participants
NCT02977507,involves,Facial Melasma
NCT02977507,evaluates,Topical Products
NCT02977507,measures_primary,Melasma Severity Rating Scale Score
NCT02977507,measures_secondary,Overall Hyperpigmentation Scale Score
NCT02977507,measures_secondary,Melasma Area and Severity Index (MASI) Score
NCT02977507,has_criteria,Baseline (Day 1) to Week 12
NCT04301609,involves,Chronic Fatigue Syndrome
NCT04301609,evaluates,ImmunoVita®
NCT04301609,measures_primary,Fatigue Impact Scale
NCT04301609,measures_secondary,Sleep Quality Index
NCT04301609,measures_secondary,Hospital Anxiety and Depression Scale
NCT04301609,has_criteria,9 months
NCT01313507,involves,Adverse Event
NCT01313507,evaluates,Immunoglobulin Intravenous (Human) 10% (NewGam)
NCT01313507,measures_primary,Change From Baseline
NCT01313507,measures_secondary,Quality of Life
NCT01313507,has_criteria,age \< 14 years
NCT01313507,has_criteria,age ≥ 14 years
NCT01473407,involves,Chronic Renal Failure
NCT01473407,evaluates,Intravenous Epoetin Hospira
NCT01473407,evaluates,Epoetin Alfa
NCT01473407,measures_primary,Mean Weekly Hemoglobin
NCT01473407,measures_secondary,Mean Weekly Dosage
NCT01473407,has_criteria,Hemodialysis
NCT02899988,involves,Plaque Psoriasis
NCT02899988,evaluates,Mirikizumab
NCT02899988,measures_primary,PASI 90
NCT02899988,measures_secondary,PASI 100
NCT02899988,has_criteria,moderate to severe
NCT00942188,involves,Type 2 Diabetes
NCT00942188,evaluates,LY2189102
NCT00942188,measures_primary,Change From Baseline in HbA1c
NCT00942188,measures_primary,Change From Baseline in Fasting Glucose
NCT00942188,measures_primary,Change From Baseline in Insulin Sensitivity
NCT00942188,measures_primary,Number of Participants With a Change From Baseline in Beta-Cell Function
NCT00942188,measures_secondary,Change From Baseline in HbA1c at Week 10 and Week 12
NCT00942188,has_criteria,Baseline
NCT01930188,involves,Type 2 Diabetes
NCT01930188,evaluates,Semaglutide
NCT01930188,evaluates,Sitagliptin
NCT01930188,measures_primary,Change in HbA1c
NCT01930188,measures_secondary,Change in Body Weight
NCT01930188,measures_secondary,Change in Fasting Plasma Glucose
NCT01930188,measures_secondary,Change in Systolic and Diastolic Blood Pressure
NCT01930188,measures_secondary,Change in Patient Reported Outcome
NCT01930188,has_criteria,randomised subjects
NCT03425188,involves,central sleep apnea
NCT03425188,evaluates,remedē System
NCT03425188,measures_primary,5-year survival rate
NCT03425188,measures_secondary,device-related SAEs
NCT03425188,measures_secondary,therapy-related SAEs
NCT03425188,measures_secondary,AHI Change
NCT03425188,measures_secondary,ESS Change
NCT03425188,has_criteria,moderate to severe
NCT03972488,involves,GEP-NET
NCT03972488,evaluates,Lutathera
NCT03972488,measures_primary,Progression Free Survival
NCT03972488,measures_secondary,Overall Response Rate
NCT03972488,measures_secondary,Time to Deteriration
NCT03972488,has_criteria,Grade 2 and Grade 3
NCT01886378,involves,Long-Chain Fatty Acid Oxidation Disorders
NCT01886378,evaluates,UX007
NCT01886378,measures_primary,AUC/Time for Workload
NCT01886378,measures_secondary,RER During Cycle Ergometry
NCT01886378,has_criteria,Change from Baseline
NCT01186588,involves,Impaired Hepatic Function
NCT01186588,evaluates,Canagliflozin
NCT01186588,measures_primary,Plasma concentrations
NCT01186588,measures_secondary,Adverse events
NCT01186588,has_criteria,Body mass index
NCT01186588,has_criteria,Blood pressure
NCT02736188,involves,Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy
NCT02736188,involves,Hereditary Inclusion Body Myopathy
NCT02736188,evaluates,Aceneuramic Acid Extended-Release
NCT02736188,measures_primary,Change From Baseline
NCT02736188,measures_secondary,Hand held dynamometry testing
NCT02736188,has_criteria,first dose of study drug
NCT02999178,involves,Progressive Fibrosing Interstitial Lung Disease
NCT02999178,evaluates,Nintedanib
NCT02999178,measures_primary,Annual Rate of Decline
NCT02999178,measures_secondary,King's Brief Interstitial Lung Disease Questionnaire
NCT02999178,has_criteria,HRCT fibrotic pattern
NCT01167088,involves,Non-alcoholic Fatty Liver Disease
NCT01167088,evaluates,MitoQ
NCT01167088,evaluates,Placebo
NCT01167088,measures_primary,Percentage change in ALT
NCT01167088,measures_secondary,Absolute change in ALT
NCT01167088,measures_secondary,Percentage of participants
NCT01167088,measures_secondary,Difference in percentage
NCT01167088,measures_secondary,Percentage and absolute change in AST
NCT01167088,measures_secondary,Change in HOMA-IR
NCT01167088,measures_secondary,Change in HbA1c
NCT01167088,measures_secondary,Percentage and absolute change in GGT
NCT01167088,measures_secondary,Areas under the ALT
NCT01167088,measures_secondary,Change in markers of liver inflammation
NCT01167088,measures_secondary,Change in biomarkers of mitochondrial function
NCT01167088,measures_secondary,Change in blood pressure
NCT01167088,measures_secondary,Change in blood lipid profile
NCT00575588,involves,Type 2 Diabetes
NCT00575588,evaluates,Saxagliptin
NCT00575588,measures_primary,HbA1c Change
NCT00575588,measures_secondary,Hypoglycaemic Event
NCT00575588,measures_secondary,Body Weight Change
NCT00575588,has_criteria,Baseline to Week 52
NCT00253188,involves,Alzheimer's Disease
NCT00253188,evaluates,Galantamine
NCT00253188,measures_primary,ADAS-cog/11 scores
NCT00253188,measures_primary,CIBIC-plus scores
NCT00253188,measures_secondary,ADAS-cog/13 scores
NCT00253188,measures_secondary,DAD scores
NCT00253188,measures_secondary,drug concentration
NCT00253188,measures_secondary,PGWB
NCT00253188,measures_secondary,Health/social care resource use
NCT00253188,measures_secondary,Incidence of adverse events
NCT00253188,measures_secondary,laboratory tests
NCT00253188,measures_secondary,ECGs
NCT00253188,measures_secondary,physical examinations
NCT00253188,has_criteria,diagnosis of Alzheimer's disease
NCT00253188,has_criteria,mild to moderate dementia
NCT00253188,has_criteria,Mini-Mental Status Examination score
NCT00253188,has_criteria,Alzheimer's Disease Assessment scale score
NCT00253188,has_criteria,gradual and progressive cognitive decline
NCT00253188,has_criteria,consistent informant
NCT05005507,involves,Chronic Hepatitis B Virus Infection
NCT05005507,evaluates,JNJ-73763989
NCT05005507,evaluates,Pegylated Interferon Alpha-2a
NCT05005507,evaluates,Nucleos(t)Ide Analogs
NCT05005507,measures_primary,HBsAg reduction
NCT05005507,measures_secondary,Adverse Events
NCT05005507,measures_secondary,Serious Adverse Events
NCT05005507,measures_secondary,Clinical Laboratory Tests
NCT05005507,measures_secondary,12-Lead Electrocardiograms
NCT05005507,measures_secondary,Vital Signs
NCT05005507,has_criteria,Up to 1 month 26 days
NCT03409107,involves,Chronic Kidney Disease
NCT03409107,involves,Anemia
NCT03409107,evaluates,Daprodustat
NCT03409107,measures_primary,Hemoglobin Increase
NCT03409107,measures_secondary,Quality of Life
NCT03409107,has_criteria,Baseline hemoglobin
NCT02600507,involves,Bipolar Depression
NCT02600507,evaluates,ITI-007
NCT02600507,measures_primary,MADRS Total Score
NCT02600507,measures_secondary,CGI-BP-S Depression Score
NCT02600507,has_criteria,Lithium or Valproate
NCT03034915,involves,Chronic Obstructive Pulmonary Disease
NCT03034915,evaluates,Umeclidinium/Vilanterol
NCT03034915,evaluates,UMEC
NCT03034915,evaluates,Salmeterol
NCT03034915,measures_primary,Change From Baseline in FEV1
NCT03034915,measures_secondary,Self Administered Computerized Transient Dyspnea Index Focal Score
NCT03034915,has_criteria,randomized participants
NCT02517385,involves,Gastrointestinal Symptoms
NCT02517385,involves,Liver Diseases
NCT02517385,evaluates,Essentiale® Paste
NCT02517385,measures_primary,Global overall symptoms
NCT02517385,measures_secondary,Gastrointestinal symptom score
NCT02517385,measures_secondary,Adverse events
NCT02517385,has_criteria,Number of patients
NCT00121485,involves,Heart Failure
NCT00121485,evaluates,Thoratec HeartMate II Left Ventricular Assist System
NCT00121485,measures_primary,Survival at two years
NCT00121485,measures_secondary,Minnesota Living With Heart Failure Questionnaire
NCT00121485,measures_secondary,Kansas City Cardiomyopathy Questionnaire
NCT00121485,measures_secondary,New York Heart Association Classification
NCT00121485,measures_secondary,Six Minute Walk Test
NCT00121485,has_criteria,Patients' status
NCT00423085,involves,Alzheimer's Disease
NCT00423085,evaluates,Rivastigmine Transdermal Patch
NCT00423085,measures_primary,ADAS-J Cog score
NCT00423085,measures_secondary,CIBIC Plus-J score
NCT00423085,measures_secondary,Disability Assessment for Dementia (DAD)
NCT00423085,measures_secondary,Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)
NCT00423085,has_criteria,activities of daily living
NCT03675685,involves,Edematous Fibrosclerotic Panniculopathy
NCT03675685,evaluates,Collagenase clostridium histolyticum
NCT03675685,measures_primary,Investigator CR-PCSS Rating
NCT03675685,measures_secondary,Investigator CR-PCSS Change From Baseline
NCT03675685,measures_secondary,Investigator CR-PCSS Responder Analysis at End of Study
NCT03675685,has_criteria,adult women
NCT00884585,involves,Atopic Keratoconjunctivitis
NCT00884585,evaluates,Cyclosporine 0.010%
NCT00884585,measures_primary,Treatment responders
NCT00884585,measures_secondary,Punctate corneal staining responders
NCT00884585,measures_secondary,Patients With Improvement
NCT00884585,has_criteria,≥ 1 grade improvement
NCT03283085,involves,Ulcerative Colitis
NCT03283085,involves,Crohn's Disease
NCT03283085,evaluates,Ontamalimab
NCT03283085,measures_primary,Number of Participants
NCT03283085,measures_secondary,Serious Infections
NCT03283085,measures_secondary,Clinical Laboratory Parameters
NCT03283085,measures_secondary,Electrocardiogram
NCT03283085,measures_secondary,Vital Signs
NCT03283085,has_criteria,first dose of study drug
NCT02144285,involves,Chronic Kidney Disease
NCT02144285,evaluates,LY3113593
NCT02144285,measures_primary,Iron Parameter Profile
NCT02144285,measures_secondary,TSat Parameter Profile
NCT02144285,measures_secondary,Hemoglobin (Hb) Parameter Profile
NCT05399485,involves,Migraine
NCT05399485,evaluates,Rimegepant
NCT05399485,measures_primary,migraine days per month
NCT05399485,measures_secondary,acute migraine medication
NCT05399485,has_criteria,Japanese Subjects
NCT02453256,involves,Systemic Sclerosis
NCT02453256,evaluates,Tocilizumab
NCT02453256,measures_primary,Change in mRSS
NCT02453256,measures_secondary,Percent Predicted FVC
NCT02453256,measures_secondary,Forced Vital Capacity
NCT02453256,measures_secondary,Health Assessment Questionnaire Disability Index Score
NCT02453256,has_criteria,Baseline to week 48
NCT00355056,involves,Migraine
NCT00355056,evaluates,device
NCT00355056,measures_primary,50% reduction migraine attacks
NCT00355056,measures_secondary,Migraine Disability Assessment
NCT00355056,measures_secondary,Procedural Success
NCT00355056,has_criteria,PFO Closure
NCT00642356,involves,Idiopathic Parkinson's Disease
NCT00642356,evaluates,Carbidopa/Levodopa/Entacapone
NCT00642356,evaluates,Immediate Release Carbidopa/Levodopa
NCT00642356,measures_primary,Change From Baseline
NCT00642356,measures_secondary,Change From Baseline
NCT00642356,has_criteria,aged 30 to 85 years
NCT00642356,has_criteria,male or female
NCT00642356,has_criteria,clinical diagnosis
NCT00642356,has_criteria,at least 2 of 3 symptoms
NCT00642356,has_criteria,non-motor symptoms
NCT05952856,involves,Hypercholesterolemia
NCT05952856,evaluates,Enlicitide Decanoate
NCT05952856,measures_primary,LDL-C percent change
NCT05952856,measures_secondary,non-HDL-C percent change
NCT05952856,measures_secondary,ApoB percent change
NCT05952856,measures_secondary,Lp(a) percent change
NCT05952856,has_criteria,Up to ~60 weeks
NCT05952856,has_criteria,Up to ~52 weeks
NCT05880056,involves,Essential Hypertension
NCT05880056,evaluates,Bisoprolol
NCT05880056,measures_primary,Blood pressure response
NCT05880056,measures_secondary,Bradycardia manifestation
NCT05880056,has_criteria,First dose hypotension
NCT00459537,involves,Onychomycosis
NCT00459537,evaluates,Topical 10% Terbinafine Hydrogen Chloride
NCT00459537,evaluates,5% Amorolfine Nail Lacquer
NCT00459537,measures_primary,Complete Cure
NCT00459537,measures_secondary,Clinical Effectiveness
NCT00459537,measures_secondary,Mycological Cure
NCT00459537,has_criteria,Mild to Moderate
NCT05502237,involves,Non-Small Cell Lung Cancer
NCT05502237,evaluates,Zimberelimab
NCT05502237,evaluates,Domvanalimab
NCT05502237,evaluates,Pembrolizumab
NCT05502237,measures_primary,Progression-free Survival
NCT05502237,measures_secondary,Overall Survival
NCT05502237,measures_secondary,Objective Response Rate
NCT05502237,measures_secondary,Duration of Response
NCT05502237,measures_secondary,Treatment-emergent Adverse Events
NCT05502237,measures_secondary,Clinical Laboratory Abnormalities
NCT05502237,measures_secondary,Time to First Symptom Deterioration
NCT05502237,has_criteria,Untreated Metastatic
NCT03664232,involves,Autism Spectrum Disorder
NCT03664232,evaluates,JNJ-42165279
NCT03664232,measures_primary,Change from Baseline
NCT03664232,measures_secondary,ABI Social Communication Domain Score
NCT03664232,measures_secondary,ABI Repetitive/Restrictive Behavior Domain Score
NCT03664232,measures_secondary,ABI Mood and Anxiety Domain Score
NCT02574637,involves,Crohn's Disease
NCT02574637,evaluates,Brazikumab
NCT02574637,measures_primary,CDAI Remission
NCT02574637,measures_secondary,Loose/Liquid Stool Frequency
NCT02574637,has_criteria,CDAI score \<150
NCT04796337,involves,Pulmonary Arterial Hypertension
NCT04796337,evaluates,Sotatercept
NCT04796337,measures_primary,Adverse Event
NCT04796337,measures_secondary,Discontinue Treatment
NCT04796337,measures_secondary,Anti-Drug Antibodies
NCT04796337,has_criteria,Detectable ADAs
NCT05550532,involves,Major Depressive Disorder
NCT05550532,evaluates,Aticaprant
NCT05550532,measures_primary,MADRS total score
NCT05550532,measures_secondary,DARS total score
NCT05550532,has_criteria,Inadequate Response to Current Antidepressant Therapy
NCT02292537,involves,Spinal Muscular Atrophy
NCT02292537,evaluates,Nusinersen
NCT02292537,measures_primary,Change From Baseline in HFMSE Score
NCT02292537,measures_secondary,Proportion of Participants Who Achieved a 3-Point Increase From Baseline in HFMSE Score
NCT02292537,has_criteria,Limited ambulation
NCT03153137,involves,Fontan-palliated Subjects
NCT03153137,evaluates,Macitentan
NCT03153137,measures_primary,Change From Baseline in Peak VO2
NCT03153137,measures_secondary,Mean Count Per Minute of Daily Physical Activity
NCT03153137,has_criteria,Up to 56 weeks
NCT04857437,evaluates,PF-07202954
NCT04857437,measures_primary,Number of Participants
NCT04857437,measures_secondary,Laboratory Abnormalities
NCT04857437,has_criteria,neutrophils/leukocytes
NCT04857437,has_criteria,monocytes/leukocytes
NCT04857437,has_criteria,low density lipoprotein
NCT04857437,has_criteria,creatine kinase
NCT04857437,has_criteria,specific gravity
NCT04857437,has_criteria,ketones
NCT04857437,has_criteria,urine protein
NCT04857437,has_criteria,urine hemoglobin
NCT04857437,has_criteria,nitrite
NCT04857437,has_criteria,urine erythrocytes
NCT04857437,has_criteria,red blood cells
NCT04857437,has_criteria,bacteria
NCT04857437,has_criteria,diastolic blood pressure
NCT04857437,has_criteria,systolic blood pressure
NCT04857437,has_criteria,pulse rate
NCT02150837,involves,Obesity
NCT02150837,evaluates,5 & 2 & 2 and 4 & 2 & 1 Plans
NCT02150837,measures_primary,change from baseline body weight
NCT02150837,measures_secondary,Percentage of Subjects Who Lose at Least 5% of Baseline Body Weight
NCT02150837,measures_secondary,Proportion of Subjects Who Lose at Least 10% of Baseline Body Weight
NCT02150837,measures_secondary,Lean Mass
NCT02150837,measures_secondary,Fat Mass
NCT02150837,measures_secondary,Abdominal Circumference
NCT02150837,measures_secondary,Waist Circumference
NCT02150837,measures_secondary,Hip Circumference
NCT02150837,measures_secondary,Blood Pressure
NCT02150837,measures_secondary,Pulse
NCT02150837,measures_secondary,Blood Pressure Categorical
NCT00524537,involves,Crohn's Disease
NCT00524537,evaluates,Humira
NCT00524537,measures_primary,SIBDQ Total Score
NCT00524537,measures_secondary,Adverse Events
NCT00524537,has_criteria,Moderately to Severely Active
NCT06015737,involves,Cutaneous Lupus Erythematosus
NCT06015737,evaluates,Anifrolumab
NCT06015737,measures_primary,CLA-IGA-R erythema score
NCT06015737,measures_primary,CLASI-A score
NCT06015737,measures_primary,CLA-IGA-R OMC score
NCT06015737,has_criteria,2-point reduction
NCT06015737,has_criteria,70% reduction
NCT06015737,has_criteria,1-point reduction
NCT06257537,involves,Osteoarthritis
NCT06257537,evaluates,Sustained Acoustic Medicine
NCT06257537,measures_primary,Change in Pain Units
NCT06257537,measures_secondary,WOMAC score
NCT06257537,measures_secondary,Global Rating of Change
NCT06257537,measures_secondary,Pain & Sleep Questionnaire
NCT06257537,measures_secondary,Depression Anxiety Stress Scale
NCT06257537,has_criteria,Have...
NCT00307437,involves,Psoriasis
NCT00307437,evaluates,Ustekinumab
NCT00307437,measures_primary,PASI 75 at Week 12
NCT00307437,measures_primary,PGA cleared or minimal at Week 12
NCT00307437,measures_secondary,Change in DLQI at Week 12
NCT00307437,has_criteria,randomized at Week 28
NCT02967237,involves,Type 2 Diabetes
NCT02967237,evaluates,Toujeo Insulin
NCT02967237,measures_primary,HbA1c change
NCT02967237,measures_secondary,fasting plasma glucose
NCT02967237,measures_secondary,HbA1c <7%
NCT02967237,measures_secondary,HbA1c <7.5%
NCT02967237,measures_secondary,HbA1c <8%
NCT02967237,measures_secondary,fasting plasma glucose
NCT02967237,measures_secondary,Diabetes Treatment Satisfaction Questionnaire
NCT02967237,has_criteria,Type 2 diabetic adult patients
NCT02967237,has_criteria,HbA1c >7.5%
NCT05714085,involves,Heart Failure Due to Left Ventricular Systolic Dysfunction
NCT05714085,evaluates,Vericiguat
NCT05714085,measures_primary,Change from baseline to Week 16 in NT-proBNP
NCT05714085,measures_secondary,Change from baseline to Week 16 in log-transformed NT-proBNP
NCT05714085,measures_secondary,Change from baseline to Week 52 in log-transformed NT-proBNP
NCT05714085,measures_secondary,Change from baseline to Week 52 in log-transformed NT-proBNP
NCT05714085,measures_secondary,First event of CV death
NCT05714085,measures_secondary,Time from randomization to the first event of CV death
NCT05714085,has_criteria,Participants with one or more adverse events (AE)
NCT05714085,has_criteria,Percentage of participants with one or more adverse events (AE)
NCT05714085,has_criteria,Participants who discontinued study drug due to an AE
NCT05714085,has_criteria,Percentage of participants who discontinued study drug due to an AE
NCT02880956,involves,Early Alzheimer's Disease
NCT02880956,evaluates,ABBV-8E12
NCT02880956,measures_primary,CDR-SB Score
NCT02880956,measures_secondary,Treatment Emergent Adverse Events
NCT02880956,has_criteria,study drug dose
NCT01451385,involves,Osteoarthritis
NCT01451385,involves,Chronic Low Back Pain
NCT01451385,evaluates,COV795
NCT01451385,measures_primary,Pain Intensity
NCT01451385,measures_secondary,Pain Relief From Medication
NCT01451385,measures_secondary,Pain Interference Scores
NCT01451385,measures_secondary,WOMAC Pain Score
NCT01451385,measures_secondary,WOMAC Stiffness Score
NCT01451385,has_criteria,Age ≥ 18 years
NCT02012985,involves,Primary Hyperoxaluria
NCT02012985,evaluates,Oxabact
NCT02012985,measures_primary,Change in urinary oxalate
NCT02012985,measures_secondary,Change in plasma oxalate
NCT02012985,has_criteria,baseline urinary oxalate level
NCT00282256,involves,Pediatric Liver Transplant
NCT00282256,evaluates,Modified-Release Tacrolimus
NCT00282256,measures_primary,Patient Survival
NCT00282256,measures_secondary,Graft Survival
NCT00282256,has_criteria,Stable Pediatric
NCT03774056,evaluates,HC-1119
NCT03774056,measures_primary,Maximal PSA Response Rate
NCT03774056,measures_secondary,Response rate of PSA
NCT03774056,has_criteria,
NCT04545385,involves,Asthma
NCT04545385,evaluates,TEV-48574
NCT04545385,measures_primary,Time to LoAC
NCT04545385,measures_secondary,ACQ-6 Score
NCT04545385,has_criteria,Loss of Asthma Control
NCT01734785,involves,Type 2 Diabetes
NCT01734785,evaluates,Empagliflozin
NCT01734785,evaluates,Linagliptin
NCT01734785,measures_primary,HbA1c Change
NCT01734785,measures_secondary,Fasting Plasma Glucose
NCT01734785,measures_secondary,Body Weight Change
NCT01734785,has_criteria,Baseline measurements
NCT03849456,involves,Autism Spectrum Disorder
NCT03849456,evaluates,GWP42006
NCT03849456,measures_primary,Change from Baseline
NCT03849456,measures_secondary,Change from Baseline
NCT03849456,has_criteria,Children 4 to 16 years
NCT03361956,involves,Chronic Hepatitis B Virus Infection
NCT03361956,evaluates,JNJ-56136379
NCT03361956,measures_primary,Change From Baseline in HBsAg Levels
NCT03361956,measures_secondary,Number of Participants With Treatment-Emergent Adverse Events
NCT03361956,has_criteria,didn't receive any hepatitis B virus treatment 6 months prior to baseline
NCT03361956,has_criteria,on entecavir or tenofovir disoproxil fumarate for at least 12 months prior to screening
NCT03361956,has_criteria,HBV deoxyribonucleic acid (DNA) <60 IU/mL
NCT01526785,involves,Pompe Disease
NCT01526785,evaluates,Alglucosidase Alfa
NCT01526785,measures_primary,Survival Rate
NCT01526785,measures_primary,Invasive Ventilator-Free Survival Rate
NCT01526785,measures_primary,Change From Baseline on LVM-Z
NCT01526785,measures_primary,Change From Baseline on GMFM-88
NCT01526785,measures_primary,Change From Baseline in FVC
NCT01526785,has_criteria,Week 52
NCT05531656,involves,Alzheimer's Disease
NCT05531656,evaluates,CT1812
NCT05531656,measures_primary,Change from baseline CDR-SB
NCT05531656,measures_secondary,ADAS-Cog 13
NCT05531656,measures_secondary,ADCS-ADL-MCI
NCT05531656,measures_secondary,CSF beta-amyloid
NCT05531656,measures_secondary,Plasma Aβ fragments
NCT05531656,measures_secondary,Plasma ptau
NCT05531656,measures_secondary,Plasma NfL
NCT05531656,measures_secondary,Volumetric MRI
NCT05531656,has_criteria,Early Alzheimer's Disease
NCT03571256,involves,Tourette Syndrome
NCT03571256,evaluates,TEV-50717
NCT03571256,measures_primary,Change From Baseline in TTS
NCT03571256,measures_secondary,Tourette Syndrome-Clinical Global Impression (TS-CGI) Score
NCT03571256,has_criteria,age group
NCT04684485,involves,Atopic Dermatitis
NCT04684485,evaluates,SCD-044
NCT04684485,measures_primary,Eczema Area and Severity Index (EASI) score
NCT04684485,measures_primary,Percent change in EASI score
NCT04684485,measures_secondary,Validated Investigator's Global Assessment (vlGA) scale
NCT04684485,measures_secondary,Peak Pruritus Numeric Rating Scale (PP-NRS)
NCT04684485,measures_secondary,SCORing Atopic Dermatitis (SCORAD) 50 and SCORAD 75 response
NCT04684485,measures_secondary,Dermatology Life Quality Index (DLQI)
NCT04684485,measures_secondary,Percent body surface area (BSA)
NCT04684485,measures_secondary,Patient Oriented Eczema Measure (POEM) score
NCT04684485,has_criteria,morphological findings
NCT03160885,involves,Atopic Dermatitis
NCT03160885,evaluates,Tralokinumab
NCT03160885,measures_primary,Eczema Area and Severity Index
NCT03160885,measures_secondary,Worst Daily Pruritus
NCT03160885,measures_secondary,SCORAD
NCT03160885,measures_secondary,DLQI
NCT03160885,has_criteria,Investigator's Global Assessment
NCT03403556,involves,Atherosclerotic Cardiovascular Disease
NCT03403556,involves,Type 2 Diabetes
NCT03403556,evaluates,Rosuvastatin
NCT03403556,evaluates,Ezetimibe
NCT03403556,measures_primary,LDL-C percent change
NCT03403556,measures_secondary,ASCVD risk
NCT03403556,measures_secondary,comprehensive lipid target
NCT03403556,measures_secondary,Hepatic Steatosis Index
NCT03403556,measures_secondary,Fatty Liver Index
NCT03403556,measures_secondary,NAFLD-LFS
NCT03403556,measures_secondary,HbA1c
NCT03403556,measures_secondary,fasting plasma glucose
NCT03403556,measures_secondary,sCD36
NCT03403556,measures_secondary,HOMA-IR
NCT03403556,measures_secondary,HOMA-B
NCT03403556,has_criteria,High Atherosclerotic Cardiovascular Disease Risk
NCT03403556,has_criteria,Type 2 Diabetes
NCT06185985,involves,Attention-Deficit/Hyperactivity Disorder
NCT06185985,evaluates,SPN-812
NCT06185985,measures_primary,Change from baseline
NCT06185985,measures_secondary,Inattention Subscale score
NCT06185985,measures_secondary,Hyperactivity/Impulsivity Subscale score
NCT06185985,has_criteria,Adults with ADHD
NCT01444456,involves,Chemotherapy-induced Anaemia
NCT01444456,evaluates,Darbepoetin Alfa
NCT01444456,measures_primary,Improvement in PPF
NCT01444456,measures_secondary,Increase in Hemoglobin
NCT01444456,has_criteria,Tumor Type
NCT01064856,involves,Peripheral Spondyloarthritis
NCT01064856,evaluates,Adalimumab
NCT01064856,measures_primary,PSpARC 40 response
NCT01064856,measures_secondary,Adverse Events
NCT01064856,has_criteria,Baseline through Week 156
NCT05271136,evaluates,Anti-Aging Serum
NCT05271136,measures_primary,Investigator Clinical Grading
NCT05271136,measures_secondary,Subject Tolerability Assessment
NCT05271136,has_criteria,Baseline
NCT02266836,involves,Stroke
NCT02266836,evaluates,MyndMove Therapy
NCT02266836,measures_primary,Change in UE-FMA
NCT02266836,measures_secondary,Change in Functional Independence Measure
NCT02266836,measures_secondary,Self-Care Functional Independence Measure
NCT02266836,measures_secondary,System Usability Scale
NCT02266836,has_criteria,Upper Extremity Fugl-Meyer Assessment
NCT00076336,involves,Chronic Hepatitis B
NCT00076336,involves,Cirrhosis
NCT00076336,evaluates,Telbivudine
NCT00076336,evaluates,Lamivudine
NCT00076336,measures_primary,Time to Clinical Response
NCT00076336,measures_primary,Duration of Clinical Response
NCT00076336,measures_secondary,Number of Participants With Improvement
NCT00076336,measures_secondary,Number of Participants With Stabilization
NCT00076336,measures_secondary,Number of Participants With Worsening
NCT00076336,has_criteria,Serum HBV DNA \< 4 log10 copies/mL
NCT00076336,has_criteria,Normal Alanine transaminase
NCT00076336,has_criteria,Child-Turcotte-Pugh score
NCT01061736,involves,Rheumatoid Arthritis
NCT01061736,evaluates,Sarilumab
NCT01061736,evaluates,Methotrexate
NCT01061736,measures_primary,ACR20 response
NCT01061736,measures_secondary,HAQ-DI
NCT01061736,measures_secondary,Van Der Heijde Modified Total Sharp Score
NCT01061736,has_criteria,Baseline to Week 12
NCT01061736,has_criteria,Baseline to Week 24
NCT01061736,has_criteria,Baseline
NCT01061736,has_criteria,Baseline
NCT00338936,involves,Essential Hypertension
NCT00338936,evaluates,VAH631
NCT00338936,measures_primary,Change in diastolic blood pressure
NCT00338936,measures_primary,Change in systolic blood pressure
NCT00338936,measures_secondary,Change in standing diastolic blood pressure
NCT00338936,measures_secondary,Change in standing systolic blood pressure
NCT00338936,measures_secondary,Laboratory abnormalities
NCT00338936,has_criteria,Successful completion of Protocol 1303
NCT00338936,has_criteria,Outpatients
NCT00338936,has_criteria,No crucial protocol violation in Protocol 1303
NCT00338936,has_criteria,No serious drug related adverse events in Protocol 1303
NCT00666536,involves,Hypertension
NCT00666536,evaluates,Valsartan + Amlodipine
NCT00666536,measures_primary,Change in MSSBP
NCT00666536,measures_secondary,Change in MSDBP
NCT00666536,has_criteria,Mean Sitting Systolic Blood Pressure greater than or equal to 150 mmHg and lower than 200 mmHg
NCT05111249,involves,Huntington's Disease
NCT05111249,evaluates,LMI070/Branaplam
NCT05111249,measures_primary,mHTT protein change
NCT05111249,measures_secondary,Ventricular Volume
NCT05111249,measures_secondary,Caudate Volume
NCT05111249,measures_secondary,Total Brain Volume
NCT05111249,measures_secondary,total HTT protein
NCT05111249,measures_secondary,mHTT protein
NCT05111249,measures_secondary,UHDRS Total Functional Capacity
NCT05111249,measures_secondary,UHDRS Total Motor Score
NCT05111249,has_criteria,Baseline up to approximately 2 years
NCT06305949,involves,Post-Stroke Dysphagia
NCT06305949,evaluates,Optimized Transcranial Direct Current Stimulation
NCT06305949,measures_primary,Functional Oral Intake Scale
NCT06305949,measures_secondary,Penetration-aspiration Scale
NCT06305949,has_criteria,Baseline
NCT03276936,involves,Papulopustular Rosacea
NCT03276936,evaluates,FMX103
NCT03276936,measures_primary,Inflammatory Lesion Count
NCT03276936,measures_secondary,Investigator's Global Assessments
NCT03276936,has_criteria,Baseline visit
NCT03369236,involves,C3 Glomerulopathy
NCT03369236,evaluates,Danicopan
NCT03369236,measures_primary,Change From Baseline In Composite Biopsy Score
NCT03369236,measures_primary,Change From Baseline In Proteinuria At Week 28
NCT03369236,measures_secondary,Slope Of Estimated Glomerular Filtration Rate (eGFR) From Baseline To 6 Months
NCT03369236,measures_secondary,Slope Of Estimated Glomerular Filtration Rate (eGFR) After Open-label Danicopan Treatment
NCT03369236,measures_secondary,Change From Baseline In eGFR At Week 28
NCT03369236,has_criteria,≥ 30% decrease from baseline
NCT03440736,involves,Psoriasis
NCT03440736,evaluates,Secukinumab
NCT03440736,measures_primary,PASI 90
NCT03440736,measures_secondary,PASI 75
NCT03440736,has_criteria,Metabolic Syndrome
NCT01451749,involves,Alzheimer's Disease
NCT01451749,evaluates,Shenwu Capsule
NCT01451749,measures_primary,Change in cognitive scores
NCT01451749,measures_secondary,Change in Memory Scores
NCT01451749,measures_secondary,Change in Functional Scores
NCT01451749,has_criteria,baseline and 24 weeks
NCT03119649,involves,Cystic Fibrosis
NCT03119649,evaluates,GLPG2222
NCT03119649,measures_primary,Sweat Chloride Concentration
NCT03119649,measures_secondary,Percent predicted FEV1
NCT03119649,measures_secondary,CFQ-R Respiratory Domain
NCT03119649,has_criteria,Prior to dosing
NCT02597049,involves,Type 2 Diabetes Mellitus
NCT02597049,evaluates,Dulaglutide
NCT02597049,measures_primary,Change From Baseline in HbA1c
NCT02597049,measures_secondary,Percentage of Participants With HbA1c <7%
NCT02597049,measures_secondary,Change From Baseline in Body Weight
NCT02597049,has_criteria,SGLT2 inhibitor dose
NCT03861936,involves,Masseter muscle prominence
NCT03861936,evaluates,BOTOX®
NCT03861936,measures_primary,MMPS Grade ≤ 3
NCT03861936,measures_secondary,Number of Participants With at Least One TEAE
NCT03861936,measures_secondary,Change From Baseline in Systolic Blood Pressure
NCT03861936,measures_secondary,Change From Baseline in Diastolic Blood Pressure
NCT03861936,measures_secondary,Change From Baseline in Respiratory Rate
NCT03861936,measures_secondary,Change From Baseline in Pulse Rate
NCT03861936,has_criteria,First dose (Day 1) to the End of Study (Up to Day 180)
NCT02365649,involves,Crohn's Disease
NCT02365649,evaluates,ABT-494
NCT02365649,measures_primary,Endoscopic Remission
NCT02365649,measures_secondary,Clinical Remission
NCT02365649,measures_secondary,CDAI < 150
NCT02365649,has_criteria,Immunomodulators or Anti-TNF Therapy
NCT02791256,involves,Chronic Hepatitis C
NCT02791256,evaluates,Peginterferon Alfa-2a
NCT02791256,evaluates,Ribavirin
NCT02791256,measures_primary,Virologic Response
NCT02791256,measures_secondary,Sustained Virologic Response
NCT02791256,measures_secondary,End-of-treatment Response
NCT02791256,measures_secondary,Hepatitis C Virus RNA
NCT02791256,has_criteria,Non-Responder Participants
NCT03325556,involves,Dementia-related Psychosis
NCT03325556,evaluates,Pimavanserin
NCT03325556,measures_primary,Time to Relapse
NCT03325556,measures_secondary,Discontinuation from DB Period
NCT03325556,has_criteria,≥30% increase in SAPS-H+D
NCT02120456,involves,Actinic Keratosis
NCT02120456,evaluates,LEO 43204
NCT02120456,measures_primary,Percent Reduction AK
NCT02120456,measures_secondary,Complete Clearance AK
NCT02120456,measures_secondary,Partial Clearance AK
NCT02120456,has_criteria,Dose Limiting Toxicity
NCT00156156,involves,Uterine Fibroids
NCT00156156,evaluates,Asoprisnil
NCT00156156,measures_primary,Change in bleeding score
NCT00156156,measures_secondary,Hemoglobin
NCT00156156,measures_secondary,Hematocrit
NCT00156156,measures_secondary,TIBC
NCT00156156,measures_secondary,Ferritin
NCT00156156,measures_secondary,Iron
NCT00156156,measures_secondary,Fibroid volume
NCT00156156,measures_secondary,Bloating
NCT00156156,measures_secondary,Pelvic pressure
NCT00156156,measures_secondary,Dysmenorrhea
NCT00156156,measures_secondary,Urinary symptoms
NCT00156156,measures_secondary,Symptom severity score
NCT00156156,measures_secondary,Quality of Life
NCT00156156,measures_secondary,SF-36 questionnaire
NCT00156156,measures_secondary,Work Limitations Questionnaire
NCT00156156,measures_secondary,Amenorrhea
NCT00156156,has_criteria,2 year treatment
NCT03280056,involves,Amyotrophic Lateral Sclerosis
NCT03280056,evaluates,NurOwn®
NCT03280056,measures_primary,ALSFRS-R Score
NCT03280056,measures_secondary,ALSFRS-R Score
NCT03280056,has_criteria,Intrathecal injection
NCT02738151,involves,Type 2 Diabetes Mellitus
NCT02738151,evaluates,Toujeo
NCT02738151,evaluates,Tresiba
NCT02738151,measures_primary,Change From Baseline in HbA1c
NCT02738151,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT02738151,measures_secondary,Change From Baseline in Fasting Self-Monitoring Plasma Glucose
NCT02738151,measures_secondary,Change From Baseline in 8 Point SMPG Profile
NCT02738151,measures_secondary,Change From Baseline in 4-point SMPG Profile
NCT02738151,has_criteria,Insulin-naive patients
NCT00938587,involves,Rheumatoid Arthritis
NCT00938587,evaluates,PF-04171327
NCT00938587,measures_primary,DAS28-4 (CRP)
NCT00938587,measures_secondary,Tender Joints Count
NCT00938587,measures_secondary,Swollen Joints Count
NCT00938587,measures_secondary,C-Reactive Protein
NCT00938587,has_criteria,CRP less than 10 mg/L
NCT02262754,involves,Chronic Low Back Pain
NCT02262754,evaluates,PF-06372865
NCT02262754,measures_primary,Daily LBPI Score
NCT02262754,measures_secondary,Treatment-Emergent Adverse Events
NCT02262754,measures_secondary,Laboratory Abnormalities
NCT02262754,has_criteria,Baseline
NCT02262754,has_criteria,up to 28 days after last dose
NCT04650854,involves,Generalized Myasthenia Gravis
NCT04650854,evaluates,Rozanolixizumab
NCT04650854,measures_primary,MG-ADL score
NCT04650854,measures_secondary,QMG score
NCT04650854,has_criteria,treatment cycle
NCT03839693,involves,Crow's Feet wrinkles
NCT03839693,evaluates,ET-01
NCT03839693,measures_primary,Change in IGA-C
NCT03839693,measures_secondary,Change in SSA-C
NCT03839693,has_criteria,females 25-65 years
NCT05324293,involves,androgenetic alopecia
NCT05324293,evaluates,HMI-115
NCT05324293,measures_primary,TAHC of non-vellus
NCT05324293,measures_secondary,Change in TAHC of non-vellus
NCT05324293,has_criteria,18 to 65 years old
NCT06413693,involves,healthy adults
NCT06413693,evaluates,PF-07293893
NCT06413693,measures_primary,skeletal muscle pACC/tACC ratio
NCT06413693,measures_secondary,Treatment Related Adverse Events
NCT06413693,measures_secondary,Laboratory Test Results
NCT06413693,measures_secondary,Vital Signs
NCT06413693,measures_secondary,12-lead Electrocardiograms
NCT06413693,measures_secondary,Physical Examinations
NCT06413693,measures_secondary,Plasma Concentration
NCT06413693,measures_secondary,Time to Reach Maximum Observed Plasma Concentration
NCT06413693,measures_secondary,Area under the serum concentration vs. time curve
NCT06413693,has_criteria,Males 18 to 65 years of age
NCT06413693,has_criteria,females of non-childbearing potential
NCT06413693,has_criteria,Body mass index (BMI) of 16 to 32 kg/m2
NCT06413693,has_criteria,total body weight >50 kg
NCT06413693,has_criteria,moderate-intensity aerobic physical activity
NCT06413693,has_criteria,vigorous-intensity aerobic physical activity
NCT06413693,has_criteria,clinically significant hematological
NCT06413693,has_criteria,clinically significant renal
NCT06413693,has_criteria,clinically significant endocrine
NCT06413693,has_criteria,clinically significant pulmonary
NCT06413693,has_criteria,clinically significant gastrointestinal
NCT06413693,has_criteria,clinically significant cardiovascular
NCT06413693,has_criteria,clinically significant hepatic
NCT06413693,has_criteria,clinically significant psychiatric
NCT06413693,has_criteria,clinically significant neurological
NCT06413693,has_criteria,clinically significant allergic disease
NCT06413693,has_criteria,history of human immunodeficiency virus (HIV) infection
NCT06413693,has_criteria,history of hepatitis B or hepatitis C
NCT06413693,has_criteria,Kidney impairment as defined by an estimated glomerular filtration rate (eGFR) <
NCT05238493,evaluates,VEL-101
NCT05238493,measures_primary,Number and Percentage of Participants with TEAEs
NCT05238493,measures_secondary,Number and Percentage of Participants with Serious TEAEs
NCT05238493,measures_secondary,Number and Percentage of Participants with Grade 3 or Higher TEAEs
NCT05238493,measures_secondary,Number and Percentage of Participants with TEAEs Leading to Withdrawal from the Study
NCT05238493,measures_secondary,Number and Percentage of Participants with TEAEs Leading to Death
NCT05238493,measures_secondary,Number and Percentage of Participants with Abnormal Chemistry Panel Results
NCT05238493,measures_secondary,Number and Percentage of Participants with Abnormal Hematology Panel Results
NCT04220996,involves,Depression
NCT04220996,involves,General Anxiety Disorder
NCT04220996,evaluates,Vortioxetine
NCT04220996,measures_primary,Change in MADRS
NCT04220996,measures_secondary,Change in HAM-A
NCT04220996,measures_secondary,Change in HADS
NCT04220996,measures_secondary,Change in FAST
NCT04220996,has_criteria,baseline to Week 8
NCT01710358,involves,Rheumatoid arthritis
NCT01710358,measures_primary,ACR20 Responder
NCT01710358,measures_secondary,HAQ-DI Score
NCT01710358,has_criteria,tender and swollen joint counts
NCT02997696,involves,Osteoarthritis of the knee
NCT02997696,evaluates,ONO-4474
NCT02997696,measures_primary,knee pain while walking
NCT02997696,measures_secondary,WOMAC pain
NCT02997696,measures_secondary,Patient Global Assessment
NCT02997696,measures_secondary,Clinical Global Impression
NCT02997696,has_criteria,Symptomatic OA of the knee
NCT03661996,involves,Knee OA
NCT03661996,evaluates,CNTX-4975-05
NCT03661996,measures_primary,procedure pain
NCT03661996,measures_secondary,participant satisfaction
NCT03661996,measures_secondary,investigator satisfaction
NCT03661996,has_criteria,subject type
NCT02335658,involves,Schizophrenia
NCT02335658,evaluates,DSP-5423P
NCT02335658,measures_primary,PANSS Total Score
NCT02335658,measures_secondary,Adverse Event
NCT02335658,has_criteria,Week 52
NCT03421496,involves,Infantile Spasms
NCT03421496,evaluates,Cannabidiol Oral Solution
NCT03421496,evaluates,Vigabatrin
NCT03421496,measures_primary,Complete Responders
NCT03421496,measures_primary,Resolution of Infantile Spasms
NCT03421496,measures_primary,Resolution of Hypsarrhythmia
NCT03421496,measures_secondary,Investigator Impression of Efficacy
NCT03421496,measures_secondary,Increase in Number of Spasm-Free Days
NCT03421496,measures_secondary,Percentage of Participants With Complete Response
NCT03421496,measures_secondary,Time to Relapse
NCT03421496,has_criteria,Parent(s)/caregiver(s) fully comprehends
NCT03421496,has_criteria,Clinical diagnosis of Infantile Spasms
NCT03992196,involves,Restless Legs Syndrome
NCT03992196,evaluates,Rotigotine Patch
NCT03992196,measures_primary,IRLS Sum Score
NCT03992196,measures_secondary,Treatment-emergent Adverse Events
NCT03992196,has_criteria,Adolescent Subjects
NCT00755196,involves,plaque psoriasis
NCT00755196,evaluates,Ointment
NCT00755196,measures_primary,OTPSS at Day 84
NCT00755196,measures_secondary,OTPSS at Day 7
NCT00755196,has_criteria,age >18 years
NCT00755196,has_criteria,stable plaque psoriasis
NCT00755196,has_criteria,two target plaques
NCT00755196,has_criteria,plaque size 5-100 cm2
NCT04167358,involves,Primary Biliary Cholangitis
NCT04167358,evaluates,Linerixibat
NCT04167358,measures_primary,Change in PBC-40
NCT04167358,measures_secondary,Change in EQ-5D-3L
NCT04167358,measures_secondary,Change in EQ VAS
NCT04167358,measures_secondary,Change in BDI-II
NCT04167358,has_criteria,Baseline and up to 65 months
NCT02100696,involves,Ulcerative Colitis
NCT02100696,evaluates,Etrolizumab
NCT02100696,measures_primary,Remission at Week 14
NCT02100696,measures_secondary,Clinical Response at Week 14
NCT02100696,has_criteria,Previously exposed to TNF Inhibitors
NCT00739596,involves,Stage 2 hypertension
NCT00739596,evaluates,aliskiren HCTZ
NCT00739596,evaluates,amlodipine
NCT00739596,measures_primary,Change in MSSBP
NCT00739596,measures_secondary,Change in MSDBP
NCT00739596,measures_secondary,Change in MSPP
NCT00739596,measures_secondary,Percentage of Responders
NCT00739596,measures_secondary,Percentage of Participants Achieving BP Control
NCT00739596,has_criteria,African American patients
NCT02919696,involves,Advanced Cancers
NCT02919696,involves,Metastatic Cancers
NCT02919696,evaluates,Abemaciclib
NCT02919696,evaluates,LY2835219
NCT02919696,measures_primary,Objective Response Rate
NCT02919696,measures_secondary,Number of participants
NCT03162796,involves,Psoriatic Arthritis
NCT03162796,evaluates,Guselkumab
NCT03162796,measures_primary,ACR 20 response
NCT03162796,measures_secondary,HAQ-DI Score
NCT03162796,has_criteria,Treatment Failure criteria
NCT00508365,involves,Hypertension
NCT00508365,evaluates,COREG CR
NCT00508365,evaluates,lisinopril
NCT00508365,measures_primary,orthostatic hypotension
NCT00508365,measures_secondary,plasma renin activity
NCT00508365,has_criteria,≥ 65 years of age
NCT00508365,has_criteria,BMI 24-37 kg/m2
NCT00508365,has_criteria,essential hypertension
NCT00508365,has_criteria,stable on treatment
NCT05142774,involves,atopic dermatitis
NCT05142774,evaluates,Tapinarof Cream
NCT05142774,measures_primary,Disease Clearance
NCT05142774,measures_secondary,Adverse Events
NCT05142774,has_criteria,vIGA-AD ≥ 1
NCT06307665,involves,Asthma
NCT06307665,evaluates,BDA MDI
NCT06307665,evaluates,AS MDI
NCT06307665,measures_primary,AAER
NCT06307665,measures_primary,TTF
NCT06307665,measures_secondary,Annualized SCS exposure
NCT06307665,measures_secondary,Number of AEs
NCT06307665,measures_secondary,Number of SAEs
NCT06307665,measures_secondary,Cmax
NCT06307665,measures_secondary,AUClast
NCT06307665,measures_secondary,AUCinf
NCT06307665,has_criteria,12 to < 18 Years
NCT02589665,involves,Ulcerative Colitis
NCT02589665,evaluates,Mirikizumab
NCT02589665,measures_primary,Clinical Remission
NCT02589665,measures_secondary,Clinical Response
NCT02589665,has_criteria,Week 12
NCT04640974,involves,Osteoarthritis of Ankle Joint
NCT04640974,evaluates,Cingal®
NCT04640974,measures_primary,Pain on Walking
NCT04640974,measures_secondary,AOFAS Score
NCT04640974,measures_secondary,Patient Global Assessment (PGA) Score
NCT04640974,measures_secondary,OMERACT-OARSI Responder Index
NCT04640974,has_criteria,6 Months
NCT01614665,involves,Organ Transplant
NCT01614665,evaluates,Tacrolimus
NCT01614665,measures_primary,AUC0-24h Tacrolimus
NCT01614665,measures_primary,Cmax Tacrolimus
NCT01614665,measures_secondary,Number of Participants with Adverse Events
NCT01614665,has_criteria,first dose of study drug
NCT01614665,has_criteria,last dose of study drug
NCT04360265,involves,MPS IIIA
NCT04360265,evaluates,ABO-102
NCT04360265,measures_primary,CSF HS
NCT04360265,measures_secondary,Cognitive Subtest
NCT04360265,measures_secondary,Language Subtest
NCT04360265,measures_secondary,Adaptive Behavior
NCT04360265,has_criteria,completed prior trial
NCT04360265,has_criteria,parent consent
NCT04360265,has_criteria,no other trials
NCT04360265,has_criteria,no medical contraindications
NCT00977665,involves,Multiple System Atrophy of the Parkinsonian Subtype
NCT00977665,evaluates,Rasagiline Mesylate 1 mg
NCT00977665,measures_primary,Change From Baseline to Week 48
NCT00977665,measures_secondary,Clinical Global Impression Improvement
NCT00977665,has_criteria,6 items or more missing
NCT02698865,involves,Hip Osteoarthritis
NCT02698865,measures_primary,Walking Pain Score
NCT02698865,has_criteria,BMI ≤ 35
NCT02698865,has_criteria,Kellgren-Lawrence grade 2 or 3
NCT02698865,has_criteria,Walking pain NRS ≥ 4 and ≤ 8
NCT02698865,has_criteria,≥ 30 years old
NCT02551874,involves,Type 2 Diabetes
NCT02551874,evaluates,Saxagliptin
NCT02551874,evaluates,Dapagliflozin
NCT02551874,evaluates,Insulin Glargine
NCT02551874,measures_primary,HbA1c at Week 24
NCT02551874,measures_secondary,Total Body Weight at Week 24
NCT02551874,measures_secondary,Confirmed Hypoglycaemia at Week 24
NCT02551874,measures_secondary,Therapeutic Glycemic Response at Week 24
NCT02551874,has_criteria,Glycemic Control on Metformin
NCT04526665,involves,Primary Biliary Cholangitis
NCT04526665,evaluates,Elafibranor
NCT04526665,measures_primary,Cholestasis Response
NCT04526665,measures_secondary,ALP Normalization
NCT04526665,measures_secondary,Pruritus
NCT04526665,has_criteria,Baseline PBC Worst Itch NRS Score ≥4
NCT01202565,involves,Plaque Psoriasis
NCT01202565,evaluates,Adalimumab
NCT01202565,measures_primary,Percent Change NAPSI
NCT01202565,measures_secondary,Percent Change PSSI
NCT01202565,has_criteria,Moderate to Severe
NCT00791765,involves,Plaque Psoriasis
NCT00791765,evaluates,Etanercept
NCT00791765,measures_primary,PSSI 75% Response
NCT00791765,measures_secondary,Percent Change From Baseline in PSSI
NCT00791765,has_criteria,Switching From Placebo
NCT04908865,involves,Systemic Lupus Erythematosus
NCT04908865,evaluates,Belimumab
NCT04908865,measures_primary,SELENA SLEDAI reduction
NCT04908865,measures_secondary,Physician Global Assessment
NCT04908865,measures_secondary,Parent Global Assessment
NCT04908865,has_criteria,Chinese Pediatric Participants
NCT01440374,involves,Thrombocytopenic Subjects
NCT01440374,involves,Myelodysplastic Syndromes
NCT01440374,involves,Acute Myeloid Leukemia
NCT01440374,evaluates,Eltrombopag
NCT01440374,measures_primary,Platelet Response
NCT01440374,measures_secondary,Clinically Relevant Thrombocytopenic Events
NCT01440374,has_criteria,Platelet count \<20 Gi/L
NCT01440374,has_criteria,Platelet count \>=20 Gi/L
NCT01440374,has_criteria,platelet transfusions
NCT01440374,has_criteria,Grade 3 hemorrhagic adverse events
NCT00603265,involves,Diabetic Peripheral Neuropathy
NCT00603265,evaluates,ADL5859
NCT00603265,measures_primary,Change From Baseline
NCT00603265,measures_secondary,Percentage of Responders
NCT00603265,measures_secondary,Patient Global Impression of Change
NCT00603265,measures_secondary,Change in Sleep Interference Scale
NCT00603265,has_criteria,Neuropathic Pain
NCT03762265,involves,Pemphigus Vulgaris
NCT03762265,evaluates,PRN1008
NCT03762265,measures_primary,Complete Remission
NCT03762265,has_criteria,corticosteroids dose
NCT00406965,involves,Allergic Asthma
NCT00406965,evaluates,HAE1
NCT00406965,measures_primary,asthma symptom score
NCT00406965,measures_secondary,beta2-agonist rescue medication
NCT00406965,has_criteria,FEV1 ≥ 40% to ≤ 80%
NCT05916365,involves,Atopic Dermatitis
NCT05916365,evaluates,Lebrikizumab
NCT05916365,measures_primary,EASI 50
NCT05916365,measures_secondary,EASI Score
NCT05916365,has_criteria,Baseline up to Week 108
NCT04669665,involves,Major Depressive Disorder
NCT04669665,evaluates,SLS-002
NCT04669665,measures_primary,MADRS Total Score
NCT04669665,measures_secondary,CGIS-SI/B Scale
NCT04669665,has_criteria,Imminent Risk of Suicide
NCT03391765,involves,Progressive Supranuclear Palsy
NCT03391765,evaluates,ABBV-8E12
NCT03391765,measures_primary,PSPRS Total Score
NCT03391765,measures_secondary,Unified Parkinson's Disease Rating Scale Part II
NCT03391765,measures_secondary,Clinical Global Impression of Severity
NCT03391765,measures_secondary,Schwab and England Activities of Daily Living Scale
NCT03391765,has_criteria,Baseline
NCT01432366,involves,Rheumatoid Arthritis
NCT01432366,evaluates,Beliefs About Medicines Questionnaire
NCT01432366,measures_primary,Disease Activity Score
NCT01432366,measures_secondary,Safety
NCT01432366,has_criteria,Beliefs about necessity
NCT04795466,involves,Mild Cognitive Impairment
NCT04795466,involves,Mild Alzheimer's Disease
NCT04795466,evaluates,Anti-inflammatory Agents
NCT04795466,measures_primary,Change from baseline in cognition
NCT04795466,measures_secondary,microglia activation
NCT04795466,measures_secondary,neuropsychiatric symptoms
NCT04795466,measures_secondary,function (activities of daily living)
NCT04795466,has_criteria,Baseline up to 30 days post last dose
NCT02647866,involves,Ulcerative Colitis
NCT02647866,evaluates,KHK4083
NCT02647866,measures_primary,Mucosal Healing
NCT02647866,measures_secondary,Clinical Improvement
NCT02647866,has_criteria,Anti-KHK4083 Antibodies
NCT06437626,involves,Stroke
NCT06437626,evaluates,Mexidol®
NCT06437626,measures_primary,Change from Baseline in mRS
NCT06437626,measures_secondary,Percentage of subjects having mRS scores >3
NCT06437626,measures_secondary,Percentage of subjects having mRS scores 0-1
NCT06437626,measures_secondary,Change from Baseline in NIHSS score
NCT06437626,has_criteria,Day 71
NCT02217566,involves,Metastatic Castration-Resistant Prostate Cancer
NCT02217566,evaluates,Abiraterone Acetate
NCT02217566,measures_primary,Time to PSA Progression
NCT02217566,measures_secondary,Overall Survival
NCT02217566,measures_secondary,Pain Progression
NCT02217566,has_criteria,PCWG2 criteria
NCT02217566,has_criteria,PSA Working Group 3 criteria
NCT00665366,involves,Bipolar I Disorder
NCT00665366,evaluates,Aripiprazole
NCT00665366,measures_primary,Change From Baseline
NCT00665366,measures_secondary,Change From Baseline
NCT00665366,has_criteria,Baseline to Week 12
NCT00847626,involves,Hypertension
NCT00847626,evaluates,Azilsartan Medoxomil
NCT00847626,evaluates,Chlorthalidone
NCT00847626,measures_primary,Trough Systolic Blood Pressure
NCT00847626,measures_secondary,Systolic Blood Pressure
NCT00847626,has_criteria,Baseline and Week 8
NCT01906866,involves,Neurodevelopmental Disabilities
NCT01906866,evaluates,Circadin®
NCT01906866,measures_primary,Total Sleep Time
NCT01906866,measures_secondary,Sleep Latency
NCT01906866,measures_secondary,Duration of Wake
NCT01906866,measures_secondary,Number of Awakenings
NCT01906866,measures_secondary,Longest Sleep Period
NCT01906866,measures_secondary,Social Functioning
NCT01906866,measures_secondary,Behavior at Home
NCT03739866,involves,Human Immunodeficiency Virus (HIV)
NCT03739866,evaluates,Lenacapavir
NCT03739866,measures_primary,Plasma HIV-1 RNA
NCT03739866,measures_secondary,Treatment Emergent Adverse Events
NCT03739866,measures_secondary,Treatment Emergent Laboratory Abnormalities
NCT03739866,has_criteria,Day 1 through 225 days
NCT02560766,involves,Restless Legs Syndrome
NCT02560766,evaluates,HORIZANT
NCT02560766,measures_primary,IRLS rating change
NCT02560766,measures_secondary,CGI-I scale
NCT02560766,measures_secondary,sleep parameters
NCT02560766,has_criteria,adolescent patients
NCT02560766,has_criteria,RLS diagnosis
NCT02560766,has_criteria,IRLS severity score
NCT02560766,has_criteria,RLS symptoms
NCT02560766,has_criteria,body weight
NCT02560766,has_criteria,pregnancy test
NCT00806026,involves,Idiopathic Restless Legs Syndrome
NCT00806026,evaluates,Pregabalin
NCT00806026,measures_primary,RLS Symptom Severity
NCT00806026,measures_secondary,Percentage of Participants
NCT00806026,has_criteria,Baseline|Change From Baseline
NCT01176266,involves,Hypophosphatasia
NCT01176266,evaluates,Asfotase Alfa
NCT01176266,measures_primary,rickets severity
NCT01176266,measures_secondary,adverse event
NCT01176266,has_criteria,treatment emergent
NCT02261974,involves,Female Sexual Function
NCT02261974,evaluates,VIveve Treatment
NCT02261974,measures_primary,FSFI total score
NCT02261974,measures_secondary,Vaginal Introitus Laxity Inventory
NCT02261974,has_criteria,6 months post-intervention
NCT02977065,involves,Dyslipidemia
NCT02977065,evaluates,CKD-519
NCT02977065,measures_primary,Percentage change LDL-C
NCT02977065,measures_secondary,Percentage change HDL-C
NCT02977065,measures_secondary,Change HDL-P size
NCT02977065,measures_secondary,Percentage change total cholesterol
NCT02977065,measures_secondary,Change concentration TG
NCT02977065,measures_secondary,Percentage change non-HDL-C
NCT02977065,has_criteria,Age 18 to 80 years
NCT02977065,has_criteria,LDL-C 100 to 190 mg/dL
NCT02977065,has_criteria,HDL-C <45 mg/dL
NCT02977065,has_criteria,Fasting TG <400 mg/dL
NCT02005666,involves,Acne vulgaris
NCT02005666,evaluates,Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel
NCT02005666,measures_primary,Percent change in lesions
NCT02005666,measures_secondary,Percent change in non-inflammatory lesions
NCT02005666,has_criteria,90% confidence interval
NCT05353166,involves,Heart Failure
NCT05353166,evaluates,REGN5381
NCT05353166,measures_primary,pulmonary capillary wedge pressure
NCT05353166,measures_secondary,right atrial pressure
NCT05353166,measures_secondary,cardiac output
NCT05353166,measures_secondary,systemic vascular resistance
NCT05353166,measures_secondary,mean pulmonary artery pressure
NCT05353166,measures_secondary,pulmonary vascular resistance
NCT05353166,measures_secondary,systolic blood pressure
NCT05353166,measures_secondary,diastolic blood pressure
NCT05353166,measures_secondary,mean arterial pressure
NCT05353166,measures_secondary,pulse rate
NCT05353166,measures_secondary,N-terminal pro-brain natriuretic peptide
NCT05353166,has_criteria,Elevated Pulmonary Capillary Wedge Pressure
NCT01831466,involves,plaque psoriasis
NCT01831466,evaluates,Tofacitinib Ointment
NCT01831466,measures_primary,PGA-C response
NCT01831466,measures_secondary,PGA-C response
NCT01831466,has_criteria,≥2 Grade/Point Improvement
NCT04506866,involves,Overactive Bladder
NCT04506866,evaluates,InterStim Micro
NCT04506866,measures_primary,Change From Baseline
NCT04506866,measures_secondary,CCIS Score
NCT04506866,measures_secondary,Number of CISC/Day
NCT04506866,has_criteria,diagnosis of OAB
NCT04506866,has_criteria,greater than or equal to 8 urgency frequency episodes per day
NCT04506866,has_criteria,minimum of 3 episodes of urinary urge incontinence in 72 hours
NCT04506866,has_criteria,18 years of age or older
NCT01486966,involves,Type 2 Diabetes
NCT01486966,evaluates,Insulin Detemir Plus Insulin Aspart
NCT01486966,evaluates,NPH Insulin Plus Human Soluble Insulin
NCT01486966,evaluates,Metformin
NCT01486966,measures_primary,Change From Baseline in Mean 8-point PG
NCT01486966,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT01486966,measures_secondary,Change From Baseline in Mean 2-hour Post Prandial Plasma Glucose
NCT01486966,measures_secondary,Change From Baseline in Mean Value of Pre-lunch
NCT01486966,measures_secondary,Percentage of Subjects Achieving FPG < 6.0 mmol / L
NCT01486966,measures_secondary,Percentage of Subjects Achieving Mean 2hPPG of 3 Meals < 8.0 mmol / L
NCT01486966,measures_secondary,Percentage of Subjects Achieving Both FPG and 2hPPG Targets
NCT01486966,measures_secondary,Percentage of Subjects Achieving FPG Target Without Nocturnal Hypoglycaemia
NCT01486966,measures_secondary,Change From Baseline in Fructosamine
NCT01486966,measures_secondary,Incidence of Hypoglycaemic Episodes
NCT01486966,has_criteria,Chinese Patients
NCT01914666,involves,Chronic Low Back Pain
NCT01914666,evaluates,Duloxetine
NCT01914666,measures_primary,Change From Baseline in BPI
NCT01914666,measures_secondary,Patient Global Impression of Improvement
NCT01914666,measures_secondary,Clinical Global Impression of Severity
NCT01914666,measures_secondary,Roland Morris Disability Questionnaire
NCT01914666,has_criteria,Baseline
NCT00257166,involves,Bipolar I Disorder
NCT00257166,evaluates,Ziprasidone
NCT00257166,measures_primary,Change From Baseline in YMRS Score
NCT00257166,measures_secondary,Clinical Global Impression - Severity (CGI-S) Score
NCT00257166,measures_secondary,Clinical Global Impression - Improvement (CGI-I) Score
NCT00257166,has_criteria,DSM-IV criteria for Bipolar I disorder
NCT00257166,has_criteria,age 10 - 17 years
NCT00257166,has_criteria,imminent risk of suicide or homicide
NCT00257166,has_criteria,serious or unstable medical illness
NCT01111565,involves,Major Depressive Disorder
NCT01111565,evaluates,Aripiprazole/Escitalopram Combination Therapy
NCT01111565,measures_primary,MADRS Total Score
NCT01111565,measures_secondary,CGI-I Score
NCT01111565,measures_secondary,Sheehan Disability Scale
NCT01111565,has_criteria,End of Phase B (Week 8)
NCT00718718,involves,Rheumatoid Arthritis
NCT00718718,evaluates,CNTO 136
NCT00718718,measures_primary,ACR 50 Response
NCT00718718,measures_secondary,DAS28
NCT00718718,has_criteria,Methotrexate Therapy
NCT00843518,involves,Alzheimer's dementia
NCT00843518,measures_primary,Mean Change From Baseline
NCT00843518,measures_secondary,Mean Change From Baseline
NCT00843518,measures_secondary,Mean Change From Baseline
NCT04088318,involves,VEGFR Inhibitor-Associated Hand-Foot Skin Reaction
NCT04088318,evaluates,OQL011
NCT04088318,measures_primary,PPE grade 0 or 1
NCT04088318,measures_primary,IGA-HFSR grade 0 or 1
NCT04088318,measures_secondary,IGA-HFSR grade 0 or 1
NCT04088318,measures_secondary,improvement in HFSR severity
NCT04088318,measures_secondary,HF-QoL Questionnaire total score
NCT04088318,has_criteria,Cancer Patients
NCT02758613,evaluates,Baricitinib
NCT02758613,evaluates,LY3009104
NCT02758613,measures_primary,Maximum Concentration
NCT02758613,measures_primary,Area Under the Concentration
NCT02758613,has_criteria,Healthy Chinese males
NCT02758613,has_criteria,Chinese females
NCT02758613,has_criteria,body mass index
NCT04776213,involves,Relapsing-remitting multiple sclerosis
NCT04776213,evaluates,Mavenclad
NCT04776213,measures_primary,Cognitive function decline
NCT04776213,measures_secondary,Health Related Quality of Life
NCT04776213,has_criteria,Baseline of parent study
NCT01808313,involves,Pulmonary Arterial Hypertension
NCT01808313,evaluates,Ambrisentan
NCT01808313,measures_primary,Change From Baseline in 6MWT
NCT01808313,measures_secondary,WHO Functional Classification
NCT01808313,has_criteria,pulmonary hypertension
NCT06058013,involves,Major Depressive Disorder
NCT06058013,evaluates,Oral NMRA-335140
NCT06058013,measures_primary,Change from Baseline
NCT06058013,measures_secondary,Snaith-Hamilton Pleasure Scale
NCT06058013,has_criteria,DSM-5-TR diagnosis
NCT03764618,involves,wAIHA
NCT03764618,evaluates,Fostamatinib Disodium
NCT03764618,measures_primary,Durable Hemoglobin Response
NCT03764618,measures_secondary,Hemoglobin Response by Week 24
NCT03764618,measures_secondary,Change From Baseline in Hemoglobin Level of 2 g/dL or Greater
NCT03764618,measures_secondary,Change in Hemoglobin From Baseline to End of Treatment
NCT03764618,measures_secondary,Use of Rescue Antibody Autoimmune Hemolytic Anemia (AIHA) Regimens
NCT03764618,measures_secondary,Change in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F)
NCT03282318,involves,Bladder Pain Syndrome/Interstitial Cystitis
NCT03282318,evaluates,ASP6294
NCT03282318,measures_primary,Change from Baseline in Average Mean Daily Pain Score at Week 12
NCT03282318,measures_primary,Change from Baseline in Average Worst Daily Pain Score at Week 12
NCT03282318,measures_primary,Change From Baseline in Mean Voiding Frequency per 24 hours at Week 12
NCT03282318,measures_primary,Change From Baseline in Mean Number of Level 3 or 4 Urgency Episodes per 24 hours at Week 12
NCT03282318,has_criteria,at least 5 recordings in that week
NCT03282318,has_criteria,at least 2 days recorded in that week
NCT06528613,involves,Benign Prostatic Hyperplasia
NCT06528613,evaluates,solifenacin/tamsulosin
NCT06528613,measures_primary,disease control score
NCT06528613,measures_secondary,quality-of-life score
NCT06528613,has_criteria,patient global impression
NCT00847613,involves,Rheumatoid Arthritis
NCT00847613,evaluates,CP-690
NCT00847613,measures_primary,ACR20 response
NCT00847613,measures_secondary,mTSS
NCT00847613,measures_secondary,HAQ-DI Score
NCT00847613,has_criteria,Methotrexate
NCT05606913,involves,Type 2 Diabetes
NCT05606913,evaluates,IBI362
NCT05606913,measures_primary,HbA1c change
NCT05606913,measures_secondary,body weigh percent change
NCT05606913,measures_secondary,HbA1c <7.0% and weight loss
NCT05606913,measures_secondary,HbA1c <7.0%
NCT05606913,has_criteria,T2D diagnosed according to WHO standards
NCT05606913,has_criteria,Age ≥ 18 years
NCT05606913,has_criteria,stable-dose metformin
NCT05606913,has_criteria,HbA1c 7.5%≤HbA1c≤11.0%
NCT05606913,has_criteria,BMI≥23 kg/m2
NCT02788513,involves,Cognitive Impairment Due to Alzheimer's Disease
NCT02788513,evaluates,BI 425809
NCT02788513,measures_primary,Change From Baseline
NCT02788513,measures_secondary,ADCS-ADL Score
NCT02788513,has_criteria,MMSE >=20
NCT01396213,involves,Celiac Disease
NCT01396213,evaluates,Larazotide Acetate
NCT01396213,measures_primary,CeD GSRS score
NCT01396213,measures_secondary,Gastrointestinal Symptoms Rating Scale
NCT01396213,measures_secondary,Bristol Stool Form Scale
NCT01396213,measures_secondary,Short Form 12 health survey Version 2
NCT01396213,has_criteria,gluten-free diet
NCT04928313,involves,Multiple Sclerosis
NCT04928313,evaluates,Cinnomer
NCT04928313,measures_primary,Annualized Relapse Rate
NCT04928313,measures_secondary,Expanded Disability Status Scale
NCT04928313,measures_secondary,T2 and Gd-enhancing lesions
NCT04928313,measures_secondary,Multiple Sclerosis International Quality of Life
NCT04928313,measures_secondary,Beck Depression Inventory II Total Score
NCT04928313,has_criteria,Patients with RRMS
NCT04928313,has_criteria,Patients diagnosed as SPMS with relapse
NCT04928313,has_criteria,Taking other DMTs
NCT04928313,has_criteria,0 ≤ EDSS ≤ 5
NCT03277313,involves,Primary Humoral Immunodeficiency
NCT03277313,evaluates,HYQVIA
NCT03277313,measures_primary,Mean ASBI per participant-year
NCT03277313,measures_secondary,Mean all infections per participant-year
NCT03277313,has_criteria,Age
NCT04707313,involves,Obesity
NCT04707313,evaluates,PF-06882961
NCT04707313,measures_primary,Percent Change in Body Weight
NCT04707313,measures_secondary,Number of Participants With TEAEs
NCT04707313,has_criteria,From first dose of study intervention
NCT03242018,involves,Type 2 Diabetes
NCT03242018,evaluates,Sotagliflozin
NCT03242018,measures_primary,Change From Baseline in HbA1c
NCT03242018,measures_secondary,Fasting Plasma Glucose
NCT03242018,measures_secondary,Body Weight
NCT03242018,measures_secondary,SBP
NCT03242018,measures_secondary,Urine Albumin: Creatinine Ratio
NCT03242018,measures_secondary,HbA1c
NCT03242018,has_criteria,Baseline UACR >30 mg/g
NCT05795218,involves,Essential Tremor
NCT05795218,evaluates,directSTIM™ Deep Brain Stimulation System
NCT05795218,measures_primary,percentage difference
NCT05795218,measures_secondary,total motor score
NCT05795218,has_criteria,target limb identified
NCT01999218,involves,Type 2 Diabetes Mellitus
NCT01999218,evaluates,Ertugliflozin
NCT01999218,evaluates,Glimepiride
NCT01999218,measures_primary,Change From Baseline in A1C
NCT01999218,measures_secondary,Percentage of Participants Experiencing AE
NCT01999218,measures_secondary,Percentage of Participants Discontinuing Study Treatment Due to an AE
NCT01999218,measures_secondary,Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia
NCT01999218,has_criteria,glycemic rescue criteria
NCT05018013,involves,Depression
NCT05018013,evaluates,Ammoxetine Hydrochloride Enteric-coated Tablets
NCT05018013,measures_primary,Change from baseline
NCT05018013,measures_secondary,Hamilton Depression Scale
NCT05018013,measures_secondary,Hamilton Anxiety Inventory
NCT05018013,measures_secondary,CGI-S score
NCT05018013,has_criteria,Baseline week 0 score
NCT03755518,involves,Primary Myelofibrosis
NCT03755518,evaluates,Fedratinib
NCT03755518,measures_primary,Spleen Volume Reduction
NCT03755518,measures_secondary,Adverse Events
NCT03755518,measures_secondary,Hemoglobin
NCT03755518,measures_secondary,Erythrocytes
NCT03755518,has_criteria,Previously Treated With Ruxolitinib
NCT00857818,involves,Schizophrenia
NCT00857818,involves,Bipolar I Disorder
NCT00857818,involves,Metabolic Syndrome
NCT00857818,evaluates,Aripiprazole
NCT00857818,evaluates,Standard of Care
NCT00857818,measures_primary,Non-HDL cholesterol
NCT00857818,measures_secondary,Fasting Triglyceride
NCT00857818,measures_secondary,Total Cholesterol
NCT00857818,measures_secondary,HDL Cholesterol
NCT00857818,measures_secondary,LDL Cholesterol
NCT00857818,measures_secondary,Fasting Glucose
NCT00857818,measures_secondary,Body Weight
NCT00857818,measures_secondary,CGI-S Scale
NCT00857818,has_criteria,Fasting Non-HDL
NCT03247517,involves,Attention-Deficit/Hyperactivity Disorder
NCT03247517,evaluates,SPN-812
NCT03247517,measures_primary,ADHD-RS-5 Total score
NCT03247517,measures_secondary,CGI-I Scale
NCT03247517,measures_secondary,Conners 3rd Edition
NCT04043234,evaluates,RESCU System
NCT04043234,measures_primary,prosthesis use duration
NCT04043234,measures_secondary,activity performance
NCT04043234,measures_secondary,functional status
NCT04043234,measures_secondary,psychosocial adjustment
NCT04043234,has_criteria,upper limb amputation
NCT01526434,involves,Rheumatoid Arthritis
NCT01526434,evaluates,Certolizumab Pegol
NCT01526434,measures_primary,HAQ-DI at Week 12
NCT01526434,measures_secondary,SF-36 PCS at Week 12
NCT01526434,has_criteria,Baseline (Week 0) to Week 16
NCT05101317,involves,Endometriosis
NCT05101317,evaluates,HMI-115
NCT05101317,measures_primary,Change of dysmenorrhea
NCT05101317,measures_secondary,Change in non-menstrual pelvic pain
NCT05101317,measures_secondary,Change in dyspareunia
NCT05101317,measures_secondary,Change from Baseline in the monthly mean Endometriosis Daily Impact Pain Scale
NCT05101317,measures_secondary,CFB by visit in permitted rescue medication use
NCT05101317,measures_secondary,Change in menstrual period heaviness
NCT05101317,has_criteria,Pre-menopausal female subjects
NCT05101317,has_criteria,clinical diagnosis of endometriosis
NCT05101317,has_criteria,Composite Pelvic Signs and Symptoms Score total score
NCT05504317,involves,Plaque Psoriasis
NCT05504317,evaluates,AK111
NCT05504317,measures_primary,PASI 75
NCT05504317,measures_secondary,PASI 90
NCT05504317,measures_secondary,PASI 100
NCT05504317,measures_secondary,sPGA 0/1
NCT05504317,has_criteria,Baseline till Week 20
NCT05323617,involves,Symptomatic Anemia
NCT05323617,evaluates,Romiplostim
NCT05323617,measures_primary,Hematologic response
NCT05323617,measures_secondary,Platelet transfusion
NCT05323617,measures_secondary,Red blood cell transfusion
NCT05323617,has_criteria,Previously untreated
NCT02000817,involves,Type 1 Diabetes Mellitus
NCT02000817,evaluates,Otelixizumab
NCT02000817,measures_primary,EBV Viral Load Detection
NCT02000817,measures_secondary,Abnormal Laboratory Results
NCT02000817,measures_secondary,Increase in QTc Interval
NCT02000817,measures_secondary,Abnormal Vital Sign Results
NCT02000817,has_criteria,At least one dose
NCT04221217,involves,Hypertriglyceridemia
NCT04221217,evaluates,MND-2119
NCT04221217,measures_primary,Triglyceride levels
NCT04221217,measures_secondary,Total Cholesterol
NCT04221217,measures_secondary,LDL-C
NCT04221217,measures_secondary,HDL-C
NCT04221217,measures_secondary,Non-HDL-C
NCT04221217,has_criteria,fasting triglyceride level 150 mg/dL
NCT04221217,has_criteria,triglyceride level < 500 mg/dL
NCT04221217,has_criteria,myocardial infarction
NCT04221217,has_criteria,angina pectoris
NCT04221217,has_criteria,aortic aneurysm
NCT04221217,has_criteria,pancreatitis
NCT04221217,has_criteria,hemorrhagic disease
NCT04221217,has_criteria,anti-coagulants
NCT04221217,has_criteria,anti-platelets
NCT04221217,has_criteria,dual antiplatelet therapy
NCT04221217,has_criteria,DOAC
NCT04221217,has_criteria,warfarin
NCT05107934,involves,Recurrent Pericarditis
NCT05107934,evaluates,RPH-104
NCT05107934,measures_primary,Time to recurrence
NCT05107934,measures_secondary,Clinical Response
NCT05107934,measures_secondary,Percentage of days with no or minimal pain
NCT05107934,has_criteria,Pericarditis recurrence
NCT02211417,involves,Atopic Dermatitis
NCT02211417,evaluates,Oral DS107
NCT02211417,measures_primary,IGA 0 or 1 at Week 8
NCT02211417,measures_secondary,Change From Baseline in EASI at Week 2
NCT02211417,has_criteria,Moderate to Severe AD
NCT02207634,involves,cognitive health
NCT02207634,evaluates,PCSK9 Binding antiBody
NCT02207634,measures_primary,Spatial Working Memory
NCT02207634,measures_secondary,Between-errors Z Score
NCT02207634,has_criteria,High cardiovascular risk
NCT04413617,involves,Rheumatoid Arthritis
NCT04413617,evaluates,PF-06650833
NCT04413617,evaluates,PF-06651600
NCT04413617,evaluates,TOFACITINIB
NCT04413617,measures_primary,DAS28-CRP Change
NCT04413617,measures_secondary,DAS28-CRP Remission
NCT04413617,has_criteria,inadequate response to methotrexate
NCT04983017,involves,inflammatory age
NCT04983017,evaluates,iAge® Intervention
NCT04983017,measures_primary,Change in iAge®
NCT04983017,measures_secondary,Eotaxin-1
NCT04983017,measures_secondary,Interferon-gamma
NCT04983017,measures_secondary,Growth Regulated Oncogene-alpha
NCT04983017,measures_secondary,Monokine Induced by Gamma Interferon
NCT04983017,measures_secondary,TNF-related Apoptosis Inducing Ligand
NCT04983017,measures_secondary,hemoglobin
NCT04983017,measures_secondary,A1C
NCT04983017,measures_secondary,hs-CRP
NCT04983017,measures_secondary,lipid panel
NCT04983017,measures_secondary,blood pressure
NCT04983017,measures_secondary,pulse wave velocity
NCT04983017,measures_secondary,heart rate variability
NCT04983017,measures_secondary,ankle bone density
NCT04983017,measures_secondary,hearing acuity
NCT04983017,has_criteria,Baseline
NCT01401517,involves,Peripheral Arterial Disease
NCT01401517,evaluates,Sodium Nitrite
NCT01401517,measures_primary,Brachial Artery FMD
NCT01401517,measures_secondary,Walking Distance
NCT01401517,measures_secondary,Quality of Life
NCT01401517,has_criteria,Twice daily 40mg 80mg
NCT01421134,involves,Major Depressive Disorder
NCT01421134,evaluates,Flexible Dose
NCT01421134,measures_primary,Mean Change MADRS
NCT01421134,measures_secondary,CGI-S Score
NCT01421134,measures_secondary,YMRS Total Score
NCT01421134,measures_secondary,Sheehan Disability Scale
NCT01421134,has_criteria,Baseline to Week 6
NCT04342117,involves,CLL/SLL
NCT04342117,involves,FL
NCT04342117,evaluates,PI3K-inhibitor
NCT04342117,measures_primary,Event-Free Survival
NCT04342117,measures_secondary,Quality of Life
NCT04342117,measures_secondary,Quality of Life
NCT04342117,has_criteria,2 years
NCT04342117,has_criteria,2 years
NCT04131517,evaluates,Padsevonil
NCT04131517,measures_primary,Ethinylestradiol Cmax
NCT04131517,measures_primary,Levonorgestrel Cmax
NCT04131517,measures_secondary,AUC[0-inf]
NCT04131517,has_criteria,Healthy Female Participants
NCT03259334,involves,Ulcerative Colitis
NCT03259334,evaluates,SHP647
NCT03259334,measures_primary,Remission at Week 12
NCT03259334,measures_secondary,Endoscopic Remission
NCT03259334,measures_secondary,Clinical Remission
NCT03259334,has_criteria,Moderate to Severe
NCT03845517,involves,Systemic Lupus Erythematosus
NCT03845517,evaluates,PF-06700841
NCT03845517,measures_primary,SRI-4 at Week 52
NCT03845517,measures_secondary,BICLA at Week 52
NCT03845517,has_criteria,SLEDAI-2K score reduction
NCT01049217,involves,HIV Neuropathy
NCT01049217,evaluates,Pregabalin
NCT01049217,measures_primary,Change From Baseline
NCT01049217,measures_secondary,Patient Global Impression
NCT01049217,has_criteria,Numeric Rating Scale
NCT02316717,involves,Non-alcoholic Steatohepatitis
NCT02316717,evaluates,IMM-124E
NCT02316717,measures_primary,Incidence of adverse events
NCT02316717,measures_secondary,Percentage Fat Content of Liver
NCT02316717,has_criteria,24 Weeks
NCT06332534,involves,Crohn's Disease
NCT06332534,evaluates,Upadacitinib
NCT06332534,measures_primary,Clinical response PCDAI
NCT06332534,measures_primary,Clinical remission PCDAI
NCT06332534,measures_secondary,Endoscopic response SES-CD
NCT06332534,measures_secondary,Adverse Events
NCT06332534,has_criteria,Pediatric subjects
NCT02341417,involves,Secondary Hyperparathyroidism
NCT02341417,involves,Chronic Kidney Disease
NCT02341417,evaluates,Cinacalcet
NCT02341417,measures_primary,iPTH reduction
NCT02341417,measures_secondary,iPTH reduction
NCT02341417,measures_secondary,Percent Change iPTH
NCT02341417,has_criteria,iPTH values
NCT02289417,involves,Ulcerative Colitis
NCT02289417,evaluates,Apremilast
NCT02289417,measures_primary,Clinical Remission
NCT02289417,measures_secondary,Rectal Bleeding Subscore
NCT02289417,has_criteria,Total Mayo Score
NCT01752634,involves,Psoriatic Arthritis
NCT01752634,evaluates,Secukinumab
NCT01752634,measures_primary,ACR20 response
NCT01752634,measures_secondary,PASI75 response
NCT01752634,has_criteria,≥3% Skin Involvement
NCT00968617,involves,Chronic Kidney Disease
NCT00968617,evaluates,MK2578
NCT00968617,measures_primary,Change From Baseline in Hemoglobin Level
NCT00968617,measures_secondary,Number of Participants With Composite Events of Death
NCT00968617,has_criteria,Hemoglobin Concentration After Treatment With MK2578
NCT01617434,involves,Type 2 Diabetes
NCT01617434,evaluates,Liraglutide
NCT01617434,evaluates,Placebo
NCT01617434,measures_primary,Change in HbA1c
NCT01617434,measures_secondary,Change in FPG
NCT01617434,measures_secondary,Change in SMPG
NCT01617434,measures_secondary,Change in Body Weight
NCT01617434,measures_secondary,Number of Subjects Achieving HbA1c Below 7.0%
NCT01617434,measures_secondary,Number of Subjects Achieving HbA1c Below or Equal to 6.5%
NCT01617434,measures_secondary,Number of Adverse Events
NCT01617434,has_criteria,randomised treatment
NCT06640517,involves,Plaque Psoriasis
NCT06640517,evaluates,Netakimab
NCT06640517,measures_primary,PASI75
NCT06640517,measures_secondary,sPGA0/1
NCT06640517,has_criteria,Children with moderate to severe
NCT02132117,involves,Rosacea
NCT02132117,evaluates,Oxymetazoline HCl Cream 1.0%
NCT02132117,measures_primary,2-Grade Improvement
NCT02132117,measures_secondary,Percent Change From Baseline
NCT02132117,has_criteria,Baseline
NCT00689117,involves,Acne
NCT00689117,evaluates,CT Gel
NCT00689117,measures_primary,Percent Change Lesion Counts
NCT00689117,measures_secondary,ISGA Score
NCT00689117,measures_secondary,Subjects Global Assessment
NCT00689117,has_criteria,Baseline
NCT03218917,involves,Non-Cystic Fibrosis Bronchiectasis
NCT03218917,evaluates,INS1007
NCT03218917,measures_primary,Time to first exacerbation
NCT03218917,measures_secondary,Quality of Life Questionnaire
NCT03218917,has_criteria,4 weeks between exacerbations
NCT04758117,involves,Oligo- or Poly-articular Psoriatic Arthritis
NCT04758117,evaluates,Oral Upadacitinib Tablets
NCT04758117,measures_primary,Minimal Disease Activity
NCT04758117,measures_secondary,Bath Ankylosing Spondylitis Disease Activity Index
NCT04758117,measures_secondary,Disease Activity in PSoriatic Arthritis score
NCT04758117,measures_secondary,Percentage of Participants with Dactylitis
NCT04758117,measures_secondary,Number of Fingernails Affected with Psoriasis
NCT04758117,measures_secondary,12-Item Short Form Health Survey
NCT04758117,has_criteria,Adult Participants
NCT06290934,involves,Ulcerative Colitis
NCT06290934,evaluates,GS-1427
NCT06290934,measures_primary,Clinical Response
NCT06290934,measures_secondary,Treatment-emerge...
NCT06290934,has_criteria,Moderately to Severely Active
NCT03504917,involves,Autism Spectrum Disorder
NCT03504917,evaluates,Balovaptan
NCT03504917,measures_primary,Vineland-II 2DC Score
NCT03504917,measures_secondary,Pediatric Quality of Life
NCT03504917,has_criteria,reliable study partner
NCT02585934,involves,Alzheimer's Disease
NCT02585934,evaluates,Intepirdine
NCT02585934,measures_primary,ADAS-Cog-11 Score Change
NCT02585934,measures_secondary,ADCS-ADL Score Change
NCT02585934,measures_secondary,CIBIC+ Score
NCT02585934,measures_secondary,Dependence Scale Score Change
NCT02585934,measures_secondary,Neuropsychiatric Inventory Score Change
NCT02585934,has_criteria,Baseline
NCT04675034,involves,Painful Osteoarthritis of the Knee
NCT04675034,evaluates,MEDI7352
NCT04675034,measures_primary,Change in NRS pain scores
NCT04675034,measures_secondary,WOMAC pain subscale
NCT04675034,measures_secondary,WOMAC physical function
NCT04675034,measures_secondary,Physician Global Assesment
NCT04675034,measures_secondary,ADA titre
NCT04675034,has_criteria,Adverse Events
NCT04732117,involves,Non-radiographic Axial Spondyloarthritis
NCT04732117,evaluates,Secukinumab
NCT04732117,measures_primary,ASAS40 response
NCT04732117,measures_secondary,BASDAI 50
NCT04732117,has_criteria,ASAS 5/6 response
NCT00492024,involves,Sinusitis
NCT00492024,evaluates,BAY12-8039
NCT00492024,measures_primary,Clinical response at TOC
NCT00492024,measures_secondary,Clinical improvement During Therapy
NCT00492024,measures_secondary,Continued Clinical Cure During Long-Term Follow-Up
NCT00492024,has_criteria,Day 3 or 4 of treatment
NCT00616434,involves,Ulcerative Colitis
NCT00616434,evaluates,Interferon Beta-1a
NCT00616434,measures_primary,Clinical Response
NCT00616434,measures_secondary,Adverse Events
NCT00616434,measures_secondary,SCCAI
NCT00616434,has_criteria,Decrease Mayo score
NCT06288217,involves,Stroke
NCT06288217,evaluates,Trigeminal Nerve Stimulation
NCT06288217,evaluates,Vagus Nerve Stimulation
NCT06288217,measures_primary,FMA-UE Average Change
NCT06288217,measures_secondary,ARAT Average Change
NCT06288217,measures_secondary,FMA-UE Response %
NCT06288217,has_criteria,completing all pre-specified treatment doses
NCT06288217,has_criteria,completing all pre-specified treatment sessions
NCT06288217,has_criteria,Within 7 days of completing 6 weeks of rehabilitation
NCT02728934,involves,Rheumatoid Arthritis
NCT02728934,evaluates,Golimumab IV
NCT02728934,evaluates,Infliximab
NCT02728934,measures_primary,Change from Baseline in CDAI Score
NCT02728934,measures_secondary,Proportion of Patients With an Infusion Reaction
NCT02728934,has_criteria,Bionaïve Patients
NCT06407934,involves,Atopic Dermatitis
NCT06407934,evaluates,Amlitelimab
NCT06407934,measures_primary,Proportion of responders
NCT06407934,measures_secondary,vIGA-AD 0 or 1
NCT06407934,has_criteria,Aged 12 years and older
NCT03235024,involves,atopic dermatitis
NCT03235024,evaluates,B244
NCT03235024,measures_primary,EASI score
NCT03235024,measures_secondary,Adverse events
NCT03235024,has_criteria,≥18 years of age
NCT00340834,involves,Relapsing-remitting Multiple Sclerosis
NCT00340834,evaluates,Fingolimod
NCT00340834,measures_primary,Annualized ARR
NCT00340834,measures_secondary,New or newly enlarged T2 lesions
NCT00340834,measures_secondary,Percentage of Participants Free of 3-month Disability Progression
NCT00340834,has_criteria,One point increase from baseline
NCT01008696,involves,Reflux Esophagitis
NCT01008696,evaluates,Rabeprazole
NCT01008696,evaluates,Lansoprazole
NCT01008696,measures_primary,Percentage Cured
NCT01008696,measures_secondary,Symptom Assessment Questionnaire
NCT01008696,measures_secondary,Investigator's overall assessment
NCT01008696,has_criteria,CYP2C19 genotyping
NCT01712516,involves,COPD
NCT01712516,evaluates,Indacaterol Maleate / Glycopyrronium Bromide
NCT01712516,measures_primary,FEV1 Area Under Curve
NCT01712516,measures_secondary,SGRQ Total Score
NCT01712516,has_criteria,Moderate to Severe Airflow Limitation
NCT03624816,involves,Chin Retrusion
NCT03624816,evaluates,Restylane Defyne
NCT03624816,measures_primary,Galderma Chin Retrusion Scale
NCT03624816,measures_secondary,FACE-Q Satisfaction
NCT03624816,has_criteria,at least 1-grade improvement
NCT00722917,involves,Type 2 Diabetes Mellitus
NCT00722917,evaluates,TAK-379
NCT00722917,measures_primary,Glycosylated Hemoglobin
NCT00722917,measures_secondary,fasting plasma glucose
NCT00722917,measures_secondary,body weight
NCT00722917,measures_secondary,alanine aminotransferase
NCT00722917,measures_secondary,TAK-379
NCT00722917,has_criteria,Adult Subjects
NCT02544217,evaluates,KH176
NCT02544217,measures_primary,Change From Baseline
NCT02544217,measures_secondary,Oxidative Phosphorylation
NCT02544217,measures_secondary,Red Blood Cell Count
NCT02544217,measures_secondary,Erythrocyte Sedimentation Rate
NCT02544217,measures_secondary,Hematocrit
NCT02618434,involves,Impulsive Aggression
NCT02618434,involves,ADHD
NCT02618434,evaluates,SPN-810
NCT02618434,measures_primary,percent change IA
NCT02618434,measures_secondary,CGI-S
NCT02618434,has_criteria,Baseline period
NCT00088634,involves,schizophrenia
NCT00088634,evaluates,New Medication
NCT00088634,measures_primary,Change From Baseline
NCT00088634,measures_secondary,PANSS Scores
NCT00088634,measures_secondary,CGI-S Scores
NCT00088634,measures_secondary,MADRS Scores
NCT00088634,has_criteria,DSM-IV criteria
NCT02323334,involves,Alzheimer's Disease
NCT02323334,evaluates,LY3202626
NCT02323334,measures_primary,Plasma Minimum A-beta 1-40
NCT02323334,measures_secondary,Cerebral Spinal Fluid (CSF) Minimum Amyloid-beta Peptide (A-beta) 1-40 Concentration
NCT02323334,has_criteria,Healthy Participants
NCT04568434,involves,Familial Chylomicronemia Syndrome
NCT04568434,evaluates,Olezarsen
NCT04568434,measures_primary,Percent Change in Fasting TG
NCT04568434,measures_secondary,Percent Change in Fasting apoC-III
NCT04568434,measures_secondary,Change from Baseline in Proportion of Participants
NCT04568434,measures_secondary,Change from Baseline in Fasting apoB-48
NCT04568434,measures_secondary,Percent Change in Fasting non-HDL-C
NCT04568434,measures_secondary,Adjudicated Acute Pancreatitis Event Rate
NCT04568434,measures_secondary,Change from Baseline in Proportion of Participants
NCT04568434,measures_secondary,Proportion of Participants Who Achieve Fasting TG
NCT04568434,measures_secondary,Adjudicated Acute Pancreatitis Event Rate
NCT04568434,measures_secondary,Proportion of Participants Who Achieve Fasting TG
NCT04568434,has_criteria,History of Pancreatitis
NCT04568434,has_criteria,≥ 2 Events of Adjudicated Acute Pancreatitis
NCT04677634,involves,Constipation
NCT04677634,evaluates,ISOThrive Prebiotic Nectar
NCT04677634,measures_primary,PAC-QOL score
NCT04677634,measures_secondary,PAC-SYM score
NCT04677634,has_criteria,Constipation symptoms
NCT02966834,involves,Primary Biliary Cholangitis
NCT02966834,evaluates,GSK2330672
NCT02966834,measures_primary,Mean Worst Daily Itch Score
NCT02966834,measures_secondary,PBC-40 Scale
NCT02966834,has_criteria,randomized medication
NCT00160524,involves,Crohn's Disease
NCT00160524,evaluates,CDP870
NCT00160524,measures_primary,HBI Remission
NCT00160524,measures_secondary,HBI Response
NCT00160524,has_criteria,Completed CDP870-031 or CDP870-032
NCT00400634,involves,Idiopathic Parkinson's Disease
NCT00400634,evaluates,CERE-120
NCT00400634,measures_primary,Change from Baseline
NCT00400634,measures_secondary,UPDRS Part III OFF
NCT00400634,has_criteria,12 hours off medication
NCT03761134,involves,Type 2 Diabetes Mellitus
NCT03761134,evaluates,Sotagliflozin
NCT03761134,measures_primary,Change in HbA1c
NCT03761134,measures_secondary,Change in 2-hour PPG
NCT03761134,measures_secondary,Change in fasting plasma glucose
NCT03761134,measures_secondary,Change in body weight
NCT03761134,measures_secondary,Change in systolic blood pressure
NCT03761134,measures_secondary,Adverse events
NCT03761134,has_criteria,Chinese patients with T2D
NCT03761134,has_criteria,Metformin alone
NCT03761134,has_criteria,Metformin with sulfonylurea
NCT03761134,has_criteria,Signed written informed consent
NCT00928434,involves,Prostate Cancer
NCT00928434,evaluates,Degarelix
NCT00928434,measures_primary,Serum PSA Levels
NCT00928434,measures_secondary,Quality of Life
NCT00928434,has_criteria,Phase A Visit 1-8
NCT00446524,involves,Essential Hypertension
NCT00446524,evaluates,Valsartan/amlodipine
NCT00446524,measures_primary,Diastolic blood pressure
NCT00446524,measures_primary,Systolic blood pressure
NCT00446524,measures_secondary,Weight
NCT00446524,measures_secondary,Pulse
NCT00446524,has_criteria,Abnormal vital signs
NCT03397134,involves,Schizophrenia
NCT03397134,evaluates,Roluperidone
NCT03397134,measures_primary,PANSS NSFS score
NCT03397134,measures_secondary,Personal and Social Performance
NCT03397134,measures_secondary,Clinical Global Impression of Severity
NCT04753034,involves,Atopic Dermatitis
NCT04753034,evaluates,TER-101 Topical Ointment
NCT04753034,measures_primary,Percent Change in EASI
NCT04753034,measures_secondary,Change in IGA
NCT04753034,measures_secondary,Itch
NCT04753034,has_criteria,12-65 years old
NCT04753034,has_criteria,IGA score 2 or 3
NCT06193434,involves,Atopic Dermatitis
NCT06193434,evaluates,IBI356
NCT06193434,measures_primary,Area under the concentration time curve
NCT06193434,measures_secondary,Maximum observed concentration
NCT06193434,measures_secondary,Systemic clearance
NCT06193434,measures_secondary,Volume of distribution
NCT06193434,measures_secondary,Elimination half-life
NCT06193434,has_criteria,Healthy Participants
NCT02392234,involves,Cystic Fibrosis
NCT02392234,evaluates,Ivacaftor
NCT02392234,evaluates,VX-661
NCT02392234,measures_primary,ppFEV1 at Week 4
NCT02392234,measures_primary,ppFEV1 at Week 8
NCT02392234,measures_secondary,CFQ-R Respiratory Domain Score
NCT02392234,measures_secondary,Treatment-Emergent Adverse Events
NCT02392234,measures_secondary,Serious Adverse Events
NCT02392234,measures_secondary,Sweat Chloride
NCT02392234,has_criteria,Heterozygous for F508del-CFTR
NCT02392234,has_criteria,second allele with CFTR mutation
NCT02392234,has_criteria,FEV1 greater than or equal to 40 percent
NCT04925934,involves,Systemic Lupus Erythematosus
NCT04925934,evaluates,VIB7734
NCT04925934,measures_primary,BICLA response
NCT04925934,measures_secondary,CLASI-A score
NCT04925934,has_criteria,OGC dose ≤ 7.5 mg/Day
NCT02211534,involves,Post-operative Pain
NCT02211534,evaluates,PEMF Therapy
NCT02211534,measures_primary,Change in Pain Intensity
NCT02211534,measures_secondary,Knee Injury and Osteoarthritis Outcome Score
NCT02211534,measures_secondary,Beck Depression Inventory
NCT02211534,has_criteria,Responders: Defined as subjects with a 5-point decrease in Beck Depression Inventory (BDI) score.
NCT05256134,involves,Alzheimer's Disease
NCT05256134,evaluates,Gantenerumab
NCT05256134,measures_primary,Change From Baseline
NCT05256134,measures_secondary,Time to Onset of Confirmed Clinical Progression
NCT05256134,has_criteria,Randomization to early termination
NCT02592434,involves,Juvenile Idiopathic Arthritis
NCT02592434,evaluates,Tofacitinib
NCT02592434,measures_primary,Disease Flare at Week 44
NCT02592434,measures_secondary,ACR50 Response at Week 44
NCT02592434,has_criteria,PRCSG/PRINTO criteria
NCT05228834,involves,Neurocognitive Function
NCT05228834,evaluates,Voxelotor
NCT05228834,measures_primary,Executive Abilities Composite Score
NCT05228834,measures_secondary,Pattern Comparison Processing Speed Test Scores
NCT05228834,measures_secondary,Nonexecutive Cognitive Abilities Composite Score
NCT05228834,has_criteria,Baseline (last assessment prior to first dose of study treatment)
NCT00706134,involves,Essential Hypertension
NCT00706134,evaluates,Aliskiren
NCT00706134,measures_primary,Change in msSBP
NCT00706134,measures_primary,Change in msDBP
NCT00706134,measures_secondary,Percentage of Patients Achieving Systolic Blood Pressure Response
NCT00706134,measures_secondary,Change in 24 Hour Ambulatory Systolic and Diastolic Blood Pressure
NCT00706134,measures_secondary,Change in the Smoothness Index of the Ambulatory Systolic Blood Pressure
NCT00706134,measures_secondary,Change in Morning Surge of Ambulatory Systolic Blood Pressure
NCT00706134,has_criteria,Light Meal
NCT01018134,involves,Psoriasis
NCT01018134,evaluates,Desoximetasone Spray
NCT01018134,measures_primary,Clinical Success
NCT01018134,measures_secondary,Total Lesion Severity Scale
NCT01018134,has_criteria,Physician Global Assessment
NCT06283524,involves,Multiple Sclerosis
NCT06283524,evaluates,eye-movement biomarkers
NCT06283524,measures_primary,MS severity
NCT06283524,measures_secondary,cognitive status
NCT06283524,has_criteria,neurologist examination
NCT05044234,involves,Psoriasis
NCT05044234,evaluates,Cedirogant (ABBV-157)
NCT05044234,measures_primary,PASI 75 at Week 16
NCT05044234,measures_secondary,sPGA Score at Week 16
NCT05044234,measures_secondary,PASI 50 at Week 16
NCT05044234,has_criteria,Adult Participants
NCT01422434,involves,Psoriasis
NCT01422434,evaluates,LEO 90105 Ointment
NCT01422434,measures_primary,Change From Baseline
NCT01422434,measures_secondary,Target Lesion Assessment
NCT01422434,measures_secondary,Physician's Global Assessment
NCT01422434,has_criteria,Baseline to Week 4
NCT04662619,involves,Atopic Dermatitis
NCT04662619,evaluates,EVC001
NCT04662619,measures_primary,Number of AD cases
NCT04662619,measures_secondary,Percentage of infants with AEs
NCT04662619,has_criteria,pruritus
NCT02861118,involves,Inflammatory Bowel Disease
NCT02861118,evaluates,Biological Therapy
NCT02861118,measures_primary,reduction HBI score
NCT02861118,measures_secondary,Partial Mayo score
NCT02861118,has_criteria,sociodemographic profile
NCT03001219,involves,Rheumatoid Arthritis
NCT03001219,evaluates,RO7123520
NCT03001219,measures_primary,ACR50 Response
NCT03001219,measures_secondary,Adverse Events
NCT03001219,measures_secondary,Anti-Drug Antibodies
NCT03001219,measures_secondary,Bone Mineral Density
NCT03001219,measures_secondary,CDAI Score
NCT03001219,has_criteria,Anti-TNF-Alpha Therapy
NCT04817618,involves,C3 Glomerulopathy
NCT04817618,evaluates,Iptacopan
NCT04817618,measures_primary,proteinuria reduction
NCT04817618,measures_secondary,eGFR improvement
NCT04817618,measures_secondary,fatigue
NCT04817618,has_criteria,stable or improved eGFR
NCT04817618,has_criteria,≥50% reduction in UPCR
NCT00618618,involves,Submental Fat
NCT00618618,evaluates,Deoxycholic Acid Injection
NCT00618618,measures_primary,Change From Baseline
NCT00618618,measures_secondary,Subject Satisfaction
NCT00618618,has_criteria,first dose of study drug
NCT02119819,involves,Type 2 Diabetes
NCT02119819,evaluates,New Drug
NCT02119819,measures_primary,Change From Baseline in HbA1c
NCT02119819,measures_secondary,Percent Change From Baseline in Body Weight
NCT02119819,measures_secondary,Change From Baseline in Fasting Blood Glucose
NCT02119819,measures_secondary,Change From Baseline in 7-point Self-Monitored Blood Glucose (SMBG) Values
NCT02119819,measures_secondary,Change From Baseline in Lipids
NCT02119819,has_criteria,metformin use
NCT02119819,has_criteria,baseline BMI category
NCT02119819,has_criteria,baseline HbA1c category
NCT02119819,has_criteria,country
NCT00827918,involves,Schizophrenia
NCT00827918,evaluates,MK-8998
NCT00827918,measures_primary,PANSS total score
NCT00827918,measures_secondary,Adverse Event
NCT00827918,measures_secondary,Discontinuation
NCT00827918,has_criteria,Acutely Psychotic
NCT00484718,involves,Osteoarthritis Of The Knee
NCT00484718,evaluates,Placebo
NCT00484718,evaluates,Oxycodone
NCT00484718,evaluates,Celecoxib
NCT00484718,measures_primary,Change From Baseline
NCT00484718,measures_secondary,Change From Baseline
NCT00484718,measures_secondary,Change From Baseline
NCT00484718,has_criteria,Baseline
NCT00522418,involves,Pharmacoresistant Partial Epilepsy
NCT00522418,evaluates,VNS Therapy
NCT00522418,measures_primary,Response Rate
NCT00522418,measures_secondary,Seizure Free Days
NCT00522418,measures_secondary,Change From Baseline in CES-D Score
NCT00522418,has_criteria,Baseline QOLIE Assessment
NCT01667419,involves,Cutaneous BRAF-Mutant Melanoma
NCT01667419,evaluates,Vemurafenib
NCT01667419,measures_primary,Disease-Free Survival
NCT01667419,measures_secondary,Distant Metastasis-Free Survival
NCT01667419,measures_secondary,Overall Survival
NCT01667419,measures_secondary,Percentage of Participants With Adverse Events
NCT01667419,measures_secondary,Change From Baseline in EORTC 30-Item Quality of Life Questionnaire (QLQ-C30) Score
NCT01667419,has_criteria,randomization
NCT03568318,involves,Atopic Dermatitis
NCT03568318,evaluates,Upadacitinib
NCT03568318,measures_primary,EASI 75 at Week 16
NCT03568318,measures_secondary,vIGA-AD at Week 16
NCT03568318,has_criteria,Adolescent and Adult Participants
NCT05323734,involves,TSC-related Epilepsy
NCT05323734,evaluates,GNX Treatment
NCT05323734,measures_primary,Percent change seizure frequency
NCT05323734,measures_secondary,Treatment responders
NCT05323734,measures_secondary,CGI-I
NCT05323734,measures_secondary,ADAMS
NCT05323734,has_criteria,Baseline (Day 1) through Week 16
NCT04968912,involves,Primary Sjogren's Syndrome
NCT04968912,evaluates,Nipocalimab
NCT04968912,measures_primary,clinESSDAI Score
NCT04968912,measures_secondary,ESSPRI Score
NCT04968912,has_criteria,Improvement >= 4 Points
NCT01786512,evaluates,Omecamtiv Mecarbil
NCT01786512,measures_primary,Change From Baseline in Systolic Ejection Time
NCT01786512,measures_secondary,Change From Baseline in Stroke Volume
NCT01786512,measures_secondary,Change From Baseline in Left Ventricular End Systolic Diameter
NCT02242812,involves,Hypertension
NCT02242812,evaluates,Telmisartan
NCT02242812,measures_primary,LVMI(H) change
NCT02242812,measures_secondary,LVMI(BSA) change
NCT02242812,measures_secondary,LVESV change
NCT02242812,measures_secondary,LVEDV change
NCT02242812,measures_secondary,LVEDVI(H) change
NCT02242812,measures_secondary,LVEDVI(BSA) change
NCT02242812,measures_secondary,EF change
NCT02242812,measures_secondary,ESWS change
NCT02242812,measures_secondary,24-hour SBP change
NCT02242812,measures_secondary,24-hour DBP change
NCT02242812,measures_secondary,seated SBP change
NCT02242812,measures_secondary,seated DBP change
NCT02242812,has_criteria,Untreated hypertension
NCT02242812,has_criteria,ABPM measurements
NCT00249912,involves,Hypercholesterolemia
NCT00249912,evaluates,Lapaquistat Acetate
NCT00249912,evaluates,Rosuvastatin
NCT00249912,measures_primary,Low Density Lipoprotein cholesterol
NCT00249912,measures_secondary,Adverse Events
NCT00249912,measures_secondary,Physical Examination
NCT00249912,measures_secondary,Safety Laboratory Tests
NCT00249912,measures_secondary,12- lead Electrocardiogram assessments
NCT00249912,measures_secondary,Best Corrected Visual Acuity results
NCT00249912,measures_secondary,Vital Signs
NCT00249912,measures_secondary,Triglycerides
NCT00249912,measures_secondary,Total Cholesterol
NCT00249912,measures_secondary,High Density Lipoprotein cholesterol
NCT00249912,measures_secondary,Very Low Density Lipoprotein cholesterol
NCT00249912,measures_secondary,apolipoprotein A1
NCT00249912,measures_secondary,apolipoprotein B
NCT00249912,measures_secondary,non- High Density Lipoprotein cholesterol
NCT00249912,measures_secondary,Low Density Lipoprotein cholesterol/High Density
NCT00249912,measures_secondary,Total Cholesterol/High Density Lipoprotein cholesterol
NCT00249912,measures_secondary,apolipoprotein A1/apolipoprotein B
NCT00249912,measures_secondary,high-sensitivity C-reactive protein
NCT00249912,measures_secondary,Low Density Lipoprotein cholesterol concentrations
NCT00249912,has_criteria,Woman of childbearing potential
NCT00807846,involves,Hypertension
NCT00807846,evaluates,Celecoxib
NCT00807846,evaluates,Naproxen
NCT00807846,measures_primary,Change From Baseline in SBP
NCT00807846,measures_secondary,Change From Baseline in DBP
NCT00807846,measures_secondary,Parent's Assessment of Overall Well-being
NCT00807846,measures_secondary,Participant's Assessment of Overall Well-being
NCT00807846,has_criteria,Pediatric Subjects
NCT04776746,involves,Rett Syndrome
NCT04776746,evaluates,Trofinetide
NCT04776746,measures_primary,Percentage of Patients
NCT04776746,measures_secondary,ECG changes
NCT04776746,measures_secondary,Vital Signs
NCT04776746,measures_secondary,Body Weight
NCT04776746,measures_secondary,Laboratory Parameters
NCT04776746,has_criteria,Baseline value
NCT01596712,involves,Atopic dermatitis
NCT01596712,evaluates,QGE031
NCT01596712,measures_primary,Serum QGE031 concentration
NCT01596712,measures_secondary,IgE serum concentrations
NCT01596712,measures_secondary,FcεRI expression
NCT01596712,measures_secondary,Immunogenicity
NCT01596712,has_criteria,Male Japanese subjects
NCT01596712,has_criteria,Serum IgE level ≥ 30 IU/mL
NCT01132612,involves,Psoriasis
NCT01132612,evaluates,secukinumab
NCT01132612,measures_primary,PASI
NCT01132612,measures_secondary,IGA Mod 2009
NCT01132612,has_criteria,completed core study
NCT03905512,involves,Gout
NCT03905512,evaluates,SEL-212
NCT03905512,evaluates,KRYSTEXXA
NCT03905512,measures_primary,SUA Reduction
NCT03905512,measures_secondary,Health Assessment Questionnaire-Disability Index
NCT03905512,measures_secondary,Provider Global Assessment of Disease Activity
NCT03905512,measures_secondary,Short Form Health Survey 36
NCT03905512,has_criteria,Refractory to Conventional Therapy
NCT00777946,involves,Hypertension
NCT00777946,evaluates,Aliskiren/Amlodipine
NCT00777946,measures_primary,msDBP change
NCT00777946,measures_primary,msSBP change
NCT00777946,measures_secondary,Serious Adverse Events
NCT00777946,measures_secondary,Adverse Events
NCT00777946,measures_secondary,Blood Pressure Control
NCT00777946,has_criteria,Not adequately responding
NCT03616912,involves,Systemic Lupus Erythematosus
NCT03616912,evaluates,Baricitinib
NCT03616912,evaluates,LY3009104
NCT03616912,measures_primary,SRI-4 response
NCT03616912,measures_secondary,SLEDAI-2K
NCT03616912,measures_secondary,BILAG
NCT03616912,measures_secondary,PGA
NCT03616912,has_criteria,SLEDAI-2K score
NCT03616912,has_criteria,BILAG A
NCT03616912,has_criteria,BILAG B
NCT03616912,has_criteria,PGA
NCT01377012,involves,Rheumatoid Arthritis
NCT01377012,evaluates,Secukinumab
NCT01377012,measures_primary,ACR20 at Week 24
NCT01377012,measures_secondary,ACR50
NCT01377012,has_criteria,Inadequate response to Anti-TNFα agents
NCT03254446,involves,Diabetes
NCT03254446,involves,Dyslipidemia
NCT03254446,involves,Hypertension
NCT03254446,evaluates,TRC150094
NCT03254446,measures_primary,Change in MAP
NCT03254446,measures_primary,Change in non-HDL cholesterol
NCT03254446,measures_primary,Change in HbA1c
NCT03254446,measures_secondary,Change in JBS3 risk score
NCT03254446,has_criteria,Age 30-70 years
NCT03254446,has_criteria,BMI 23-39 kg/m2
NCT03254446,has_criteria,HbA1C ≥7.5 %
NCT03254446,has_criteria,Stable therapy ≤2 oral hypoglycemic agents
NCT03254446,has_criteria,Non HDL-cholesterol ≥ 160 mg/dL
NCT03254446,has_criteria,Mean Arterial Pressure ≥100 mm Hg
NCT03254446,has_criteria,Uncontrolled hypertension SBP ≥ 180 mm Hg
NCT03254446,has_criteria,DBP ≥ 110 mmHg
NCT00968812,involves,type 2 diabetes
NCT00968812,evaluates,JNJ-28431754
NCT00968812,evaluates,glimepiride
NCT00968812,measures_primary,change in HbA1c
NCT00968812,measures_secondary,hypoglycemic event
NCT00968812,measures_secondary,body weight
NCT00968812,has_criteria,diagnosis of type 2 diabetes
NCT00968812,has_criteria,BMI 22 to 45 kg/m2
NCT00968812,has_criteria,stable metformin dosage
NCT00968812,has_criteria,HbA1c 7% to 9.5%
NCT00968812,has_criteria,fasting plasma glucose \<=270 mg/dL
NCT00243412,involves,Rheumatoid Arthritis
NCT00243412,evaluates,Rituximab
NCT00243412,measures_primary,DAS28-4(CRP)
NCT00243412,measures_secondary,ACR20
NCT00243412,has_criteria,Grade III or IV AE
NCT02323646,involves,Uterine Fibroids
NCT02323646,evaluates,Telapristone Acetate
NCT02323646,measures_primary,Amenorrhea at end
NCT02323646,measures_secondary,PBAC Scores
NCT02323646,has_criteria,18-weeks Treatment Course
NCT04983446,involves,COVID-19 pneumonia
NCT04983446,evaluates,intranasal foralumab
NCT04983446,measures_primary,chest CT severity score
NCT04983446,measures_secondary,resolution of severe COVID-19
NCT04983446,has_criteria,hospitalized with severe COVID-19
NCT04983446,has_criteria,SARS-CoV-2 infection
NCT04983446,has_criteria,≥ 18 years of age
NCT01544595,involves,Psoriasis
NCT01544595,evaluates,Secukinumab
NCT01544595,measures_primary,cumulative rate PASI 75
NCT01544595,measures_secondary,PASI 50
NCT01544595,has_criteria,PASI 75 responder
NCT01079195,involves,Hypertensive Patients
NCT01079195,evaluates,Tarka
NCT01079195,measures_primary,Systolic Blood Pressure
NCT01079195,measures_primary,Diastolic Blood Pressure
NCT01079195,measures_secondary,Target Blood Pressure
NCT01079195,has_criteria,Adult patients
NCT01167881,involves,Type 2 diabetes mellitus
NCT01167881,evaluates,Empagliflozin
NCT01167881,measures_primary,Change in HbA1c
NCT01167881,measures_secondary,Body Weight
NCT01167881,measures_secondary,Hypoglycaemic Events
NCT01167881,measures_secondary,Systolic Blood Pressure
NCT01167881,measures_secondary,Diastolic Blood Pressure
NCT01167881,has_criteria,HbA1c 7.0% to 10%
NCT01167881,has_criteria,BMI less than 45Kg/m2
NCT01167881,has_criteria,Metformin pre-treatment
NCT01167881,has_criteria,Age 18 years or more
NCT01167881,has_criteria,No other antidiabetic drugs
NCT00892281,involves,rosacea
NCT00892281,evaluates,Oracea
NCT00892281,measures_primary,IGA score change
NCT00892281,measures_secondary,CEA score change
NCT00892281,has_criteria,diagnosis of rosacea
NCT00892281,has_criteria,aged 18 and older
NCT02581995,involves,Diabetic Macular Edema
NCT02581995,evaluates,Aflibercept
NCT02581995,measures_primary,NEI VFQ-25 Total Score
NCT02581995,measures_secondary,NEI VFQ 25 Near Activities Subscale
NCT02581995,has_criteria,Baseline
NCT00048581,involves,Rheumatoid Arthritis
NCT00048581,evaluates,BMS-188667
NCT00048581,measures_primary,ACR 20 Response
NCT00048581,measures_secondary,Health Assessment Questionnaire
NCT00048581,has_criteria,Anti-TNF therapy failure
NCT00082381,involves,Type 2 Diabetes
NCT00082381,evaluates,AC2993
NCT00082381,measures_primary,Change in HbA1c
NCT00082381,measures_secondary,Change in Body Weight
NCT00082381,measures_secondary,Change in Fasting Serum Glucose
NCT00082381,measures_secondary,Change in 7-point SMBG Profile
NCT00082381,measures_secondary,Percentage of Patients With Hypoglycemic Events
NCT00082381,measures_secondary,Change in Rate of Hypoglycemic Events
NCT00082381,has_criteria,stable dose metformin
NCT00082381,has_criteria,sulfonylurea
NCT01294410,involves,Ulcerative Colitis
NCT01294410,evaluates,BMS-936557
NCT01294410,measures_primary,clinical remission
NCT01294410,measures_secondary,clinical response
NCT01294410,measures_secondary,mucosal healing
NCT01294410,measures_secondary,Adverse event
NCT01294410,measures_secondary,IBDQ
NCT01294410,has_criteria,moderate to severe UC
NCT01294410,has_criteria,endoscopic and histologic evidence
NCT01294410,has_criteria,Mayo score ≥6
NCT01294410,has_criteria,endoscopic subscore ≥2
NCT01294410,has_criteria,inadequate response
NCT01294410,has_criteria,conventional therapy
NCT01294410,has_criteria,Crohn's Disease
NCT01294410,has_criteria,Indeterminate Colitis
NCT01294410,has_criteria,limited to rectum
NCT01294410,has_criteria,fulminant colitis
NCT01294410,has_criteria,bowel perforation
NCT01294410,has_criteria,colostomy
NCT01294410,has_criteria,ileostomy
NCT01294410,has_criteria,total or subtotal colectomy
NCT04123795,involves,Chronic Plaque Psoriasis
NCT04123795,evaluates,Certolizumab Pegol
NCT04123795,measures_primary,PASI75 response
NCT04123795,measures_secondary,PGA Clear or Almost Clear
NCT04123795,measures_secondary,PASI90 response
NCT04123795,has_criteria,Moderate to Severe
NCT00286481,involves,Hypercholesterolemia
NCT00286481,evaluates,Lapaquistat Acetate
NCT00286481,evaluates,Simvastatin
NCT00286481,measures_primary,Low Density Lipoprotein cholesterol
NCT00286481,measures_secondary,Adverse Events
NCT00286481,measures_secondary,Physical Examination
NCT00286481,measures_secondary,Safety Laboratory Tests
NCT00286481,measures_secondary,12- lead Electrocardiogram assessments
NCT00286481,measures_secondary,Best Corrected Visual Acuity
NCT00286481,measures_secondary,Vital Signs
NCT00286481,measures_secondary,Triglycerides
NCT00286481,measures_secondary,Total Cholesterol
NCT00286481,measures_secondary,High Density Lipoprotein cholesterol
NCT00286481,measures_secondary,Very Low Density Lipoprotein cholesterol
NCT00286481,measures_secondary,apolipoprotein A1
NCT00286481,measures_secondary,apolipoprotein B
NCT00286481,measures_secondary,non- High Density Lipoprotein cholesterol
NCT00286481,measures_secondary,Low Density Lipoprotein cholesterol/High Density
NCT00286481,measures_secondary,Total Cholesterol/High Density Lipoprotein cholesterol
NCT00286481,measures_secondary,apolipoprotein A1/apolipoprotein B
NCT00286481,measures_secondary,high-sensitivity C-reactive protein
NCT00286481,measures_secondary,Low Density Lipoprotein cholesterol concentrations
NCT00286481,has_criteria,Woman of childbearing potential
NCT01280695,involves,Type 2 diabetes
NCT01280695,evaluates,MSDC-0602
NCT01280695,measures_primary,Change From Baseline in Fasting Plasma Glucose
NCT01280695,measures_secondary,Change From Baseline in HbA1c
NCT01280695,measures_secondary,Change From Baseline in Body Weight
NCT01280695,measures_secondary,Change From Baseline in Hematocrit
NCT01280695,measures_secondary,Change in Fasting Plasma Insulin
NCT01280695,measures_secondary,Change From Baseline in High Molecular Weight Adiponectin
NCT01280695,has_criteria,inclusion criteria
NCT00884481,involves,Relapsing-Remitting Multiple Sclerosis
NCT00884481,evaluates,Tysabri
NCT00884481,measures_primary,Fatigue scale
NCT00884481,measures_secondary,Capacity for Work
NCT00884481,measures_secondary,Health-related-quality of life
NCT00884481,measures_secondary,Sleepiness
NCT00884481,has_criteria,Age
NCT04153981,involves,Type 2 Diabetes
NCT04153981,evaluates,Insulin Glargine
NCT04153981,measures_primary,Change From Baseline in HbA1c
NCT04153981,measures_secondary,Change From Baseline in Body Weight
NCT04153981,measures_secondary,Change From Week 4 in Insulin Treatment Satisfaction Questionnaire
NCT04153981,measures_secondary,Number or Participants With Hypoglycemic Events
NCT04153981,has_criteria,Fasting blood glucose level ≤ 54 mg/dL
NCT01365481,involves,Chronic Kidney Disease
NCT01365481,evaluates,Valsartan
NCT01365481,measures_primary,Change in msSBP
NCT01365481,measures_primary,Change in MsDBP
NCT01365481,measures_secondary,Percentage UACR reduction
NCT01365481,measures_secondary,Percentage eGFR decrease
NCT02579681,involves,Relapsing Remitting Multiple Sclerosis
NCT02579681,evaluates,BG00012
NCT02579681,measures_primary,cognitive impairment index
NCT02579681,measures_secondary,annualized relapse rate
NCT02579681,measures_secondary,time to relapse
NCT02579681,has_criteria,EDSS>1.0
NCT02579681,has_criteria,EDSS=0
NCT02516410,involves,Cystic Fibrosis
NCT02516410,evaluates,VX-661
NCT02516410,evaluates,Ivacaftor
NCT02516410,measures_primary,FEV1
NCT02516410,measures_primary,CFQ-R Respiratory Domain Score
NCT02516410,measures_secondary,Pulmonary Exacerbation Events
NCT02516410,measures_secondary,Pulmonary Exacerbation Events Per Year
NCT02516410,has_criteria,F508del-CFTR Mutation
NCT01867710,involves,Prostate Cancer
NCT01867710,evaluates,Abiraterone
NCT01867710,measures_primary,Mineralocorticoid Excess Toxicity
NCT01867710,measures_secondary,PSA response rate
NCT01867710,has_criteria,mineralocorticoid excess
NCT02134210,involves,Chronic Plaque Psoriasis
NCT02134210,evaluates,CHS-0214
NCT02134210,evaluates,Enbrel
NCT02134210,measures_primary,PASI-75
NCT02134210,measures_secondary,PASI
NCT02134210,measures_secondary,PASI-50
NCT02134210,measures_secondary,PASI-90
NCT02134210,measures_secondary,PSGA
NCT02134210,has_criteria,Baseline
NCT00667810,involves,Alzheimer Disease
NCT00667810,evaluates,Bapineuzumab
NCT00667810,measures_primary,ADAS-Cog/11 Total Score
NCT00667810,measures_secondary,Disability Assessment for Demential (DAD) Total Score
NCT00667810,has_criteria,Week 78
NCT01838681,involves,Major Depressive Disorder
NCT01838681,evaluates,Brexpiprazole
NCT01838681,measures_primary,Full remission
NCT01838681,measures_secondary,Full functional remission
NCT01838681,measures_secondary,Full global score remission
NCT01838681,has_criteria,Inadequate response
NCT03435081,involves,Atopic Dermatitis
NCT03435081,evaluates,Baricitinib
NCT03435081,measures_primary,EASI75
NCT03435081,measures_secondary,Investigator's Global Assessment
NCT03435081,has_criteria,Adult Participants
NCT01023581,involves,Type 2 Diabetes Mellitus
NCT01023581,evaluates,Alogliptin
NCT01023581,measures_primary,Change From Baseline in HbA1c
NCT01023581,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT01023581,has_criteria,Glycosylated Hemoglobin concentration 7.5% to 10.0%  inclusive
NCT03325010,involves,Tourette Syndrome
NCT03325010,evaluates,NBI-98854
NCT03325010,measures_primary,Change From Baseline
NCT03325010,measures_secondary,Clinical Global Impression
NCT03325010,has_criteria,clinical diagnosis of TS
NCT04002310,involves,Age-related Macular Degeneration
NCT04002310,evaluates,BI 754132
NCT04002310,measures_primary,Number of DLEs
NCT04002310,measures_secondary,Drug-related Adverse Events
NCT04002310,has_criteria,drug administration
NCT02878681,involves,Diabetic Macular Edema
NCT02878681,evaluates,Ranibizumab
NCT02878681,evaluates,Aflibercept
NCT02878681,measures_primary,AUC of VEGF-A
NCT02878681,measures_secondary,Systemic VEGF-A levels
NCT02878681,has_criteria,Monthly intravitreal injections
NCT02448381,involves,Cutaneous T-Cell Lymphoma
NCT02448381,involves,Mycosis Fungoides
NCT02448381,evaluates,SGX301
NCT02448381,measures_primary,CAILS score improvement
NCT02448381,measures_secondary,treatment response
NCT02448381,has_criteria,≥50% CAILS improvement
NCT00648908,involves,Multiple Sclerosis
NCT00648908,evaluates,Fampridine-SR
NCT00648908,measures_primary,Timed 25 Foot Walk
NCT00648908,measures_secondary,Subject Global Impression
NCT00648908,measures_secondary,Clinician Global Impression of Change
NCT00648908,measures_secondary,Expanded Disability Status Scale
NCT00648908,has_criteria,baseline neurological exam
NCT01089023,involves,Rheumatoid Arthritis
NCT01089023,evaluates,Tocilizumab
NCT01089023,measures_primary,DAS28 response
NCT01089023,measures_secondary,Adverse Event
NCT01089023,has_criteria,Moderate to Severe Active
NCT02586623,involves,Neurogenic Orthostatic Hypotension
NCT02586623,evaluates,Droxidopa
NCT02586623,measures_primary,Time to intervention
NCT02586623,measures_secondary,Time to discontinuation
NCT02586623,has_criteria,OHSA Item #1 worsening
NCT03794323,involves,Healthy male subjects
NCT03794323,evaluates,BI 764122
NCT03794323,measures_primary,AUC0-inf
NCT03794323,measures_secondary,Cmax
NCT03794323,has_criteria,Healthy male subjects
NCT03794323,has_criteria,Age 18 to 50 years
NCT03794323,has_criteria,BMI 18.5 to 29.9 kg/m2
NCT03794323,has_criteria,Signed informed consent
NCT03794323,has_criteria,Adequate contraception
NCT03431623,involves,Chronic renal failure
NCT03431623,evaluates,test drug
NCT03431623,measures_primary,Ratio of subjects who achieve target level of hemoglobin
NCT03431623,measures_secondary,Days taken to reach target level of hemoglobin
NCT03431623,has_criteria,Patients with 19 years of age or older
NCT03431623,has_criteria,Patients with chronic renal failure of stage 3 or above
NCT03431623,has_criteria,Patients with Hb levels of 8 to 10g/dl
NCT00550550,involves,Allergic rhinoconjunctivitis
NCT00550550,evaluates,Grass Sublingual Tablet
NCT00550550,measures_primary,Total Symptom Score
NCT00550550,measures_secondary,Rhinoconjunctivitis Daily Symptom Score
NCT00550550,measures_secondary,Rhinoconjunctivitis Daily Medication Score
NCT00550550,has_criteria,Symptom score >=4
NCT06004050,involves,Chronic Hand Eczema
NCT06004050,evaluates,Delgocitinib Cream
NCT06004050,measures_primary,IGA-CHE TS at Week 16
NCT06004050,measures_secondary,HECSI-90 at Week 16
NCT06004050,measures_secondary,HECSI-75 at Week 16
NCT06004050,measures_secondary,Percentage Change in HECSI Score
NCT06004050,measures_secondary,Number of Participants With Reduction of HESD Itch Score
NCT06004050,measures_secondary,Number of Participants With Reduction of HESD Score
NCT06004050,measures_secondary,Number of Participants With Reduction of HESD Pain Score
NCT06004050,measures_secondary,Change in Dermatology Life Quality Index (DLQI) Score
NCT06004050,measures_secondary,Change in HESD Score
NCT06004050,measures_secondary,Change in HESD Itch Score
NCT06004050,measures_secondary,Change in HESD Pain Score
NCT06004050,measures_secondary,Change in Hand Eczema Impact Scale (HEIS) Score
NCT06004050,measures_secondary,Change in HEIS Proximal Daily Activity Limitations (PDAL) Score
NCT06004050,measures_secondary,Number of Participants With Reduction of DLQI Score
NCT06004050,measures_secondary,Number of Treatment-Emergent Adverse Events (AEs)
NCT01624350,involves,Anorectal Fistulas
NCT01624350,evaluates,Permacol™ Collagen Paste
NCT01624350,measures_primary,Fistula Healing
NCT01624350,measures_secondary,Quality of Life
NCT01624350,measures_secondary,Fecal Incontinence
NCT01624350,measures_secondary,Patient Satisfaction
NCT01624350,measures_secondary,Pain
NCT01624350,has_criteria,6 months
NCT01624350,has_criteria,3 months
NCT01624350,has_criteria,12 months
NCT00789750,involves,Type 2 diabetes mellitus
NCT00789750,evaluates,Colesevelam
NCT00789750,measures_primary,Change From Baseline in HbA1c
NCT00789750,measures_secondary,Fasting Plasma Glucose
NCT00789750,has_criteria,Diagnosis of Type 2 diabetes mellitus
NCT03783923,involves,Limb-Girdle Muscular Dystrophy 2I
NCT03783923,evaluates,Deflazacort
NCT03783923,measures_primary,Time to climb stairs
NCT03783923,measures_secondary,Forced Vital Capacity
NCT03783923,measures_secondary,2-Minute Walk Test
NCT03783923,measures_secondary,Time to up and go
NCT03783923,measures_secondary,Time to descend stairs
NCT03783923,measures_secondary,Time to run/walk 10 meters
NCT03783923,measures_secondary,Maximal Inspiratory Pressure
NCT03783923,measures_secondary,Maximal Expiratory Pressure
NCT03783923,measures_secondary,Hand-Held Myometry
NCT03783923,measures_secondary,Global T2 Relaxation Time
NCT03783923,has_criteria,Adverse Events
NCT00120523,involves,Atopic Dermatitis
NCT00120523,evaluates,Pimecrolimus Cream 1%
NCT00120523,measures_primary,Treatment Success Rate
NCT00120523,measures_secondary,Growth Velocity
NCT00120523,measures_secondary,Potential Effect on the Developing Immune System
NCT00120523,measures_secondary,Body Surface Area Involved With Atopic Dermatitis
NCT00120523,measures_secondary,Parent's Index of Quality of Life - Atopic Dermatitis
NCT00120523,has_criteria,Infants 3 - 12 Months of Age
NCT01545050,involves,Crohn's Disease
NCT01545050,evaluates,BMS-945429
NCT01545050,measures_primary,Clinical Remission
NCT01545050,measures_secondary,Clinical Response
NCT01545050,measures_secondary,IBDQ Score
NCT01545050,has_criteria,CDAI<150
NCT06216808,involves,Resistant Hypertension
NCT06216808,evaluates,HyperQureTM
NCT06216808,measures_primary,Change in ASBP
NCT06216808,measures_secondary,Change in ADBP
NCT06216808,measures_secondary,Change in Office SBP
NCT06216808,measures_secondary,Change in Office DBP
NCT06216808,measures_secondary,EQ-5D
NCT06216808,has_criteria,Target office SBP
NCT03675308,involves,Psoriatic Arthritis
NCT03675308,evaluates,Risankizumab
NCT03675308,evaluates,Placebo
NCT03675308,measures_primary,ACR20 response
NCT03675308,measures_secondary,HAQ-DI
NCT03675308,measures_secondary,PASI 90 response
NCT03675308,has_criteria,DMARD therapy
NCT05274750,involves,Chronic Rhinosinusitis With Nasal Polyps
NCT05274750,evaluates,Depemokimab
NCT05274750,measures_primary,Change from Baseline in total endoscopic Nasal polyps (NP) score at Week 52
NCT05274750,measures_secondary,Change from Baseline in mean nasal obstruction score
NCT05274750,measures_secondary,Change from Baseline in mean symptom score for rhinorrhea
NCT05274750,measures_secondary,Change from Baseline in mean symptom score for loss of smell
NCT05274750,measures_secondary,Change from Baseline in Lund Mackay (LMK) computed tomography (CT) score
NCT02674308,involves,Ulcerative Colitis
NCT02674308,involves,Crohn's Disease
NCT02674308,evaluates,Entyvio
NCT02674308,evaluates,Vedolizumab
NCT02674308,measures_primary,Disease Severity
NCT02674308,measures_secondary,Adverse Events
NCT02674308,has_criteria,Baseline and every 6 months
NCT02407223,involves,Nonradiographic Axial Spondyloarthritis
NCT02407223,evaluates,Ustekinumab
NCT02407223,measures_primary,ASAS 20 Response
NCT02407223,measures_secondary,ASAS 40 Response
NCT02407223,has_criteria,Treatment failure
NCT00917150,involves,Chronic Obstructive Pulmonary Disease
NCT00917150,evaluates,OPC-6535
NCT00917150,measures_primary,FEV1 Change From Baseline
NCT00917150,measures_secondary,Total Symptom Diary Score
NCT00917150,measures_secondary,St. George's Respiratory Questionnaire Total Score
NCT00917150,has_criteria,Age 40 to 75 years
NCT03847350,involves,essential hypertension
NCT03847350,evaluates,NEBILET
NCT03847350,measures_primary,Systolic Blood Pressure
NCT03847350,measures_primary,Diastolic Blood Pressure
NCT03847350,measures_secondary,Heart Rate
NCT03847350,measures_secondary,Heart Rate Variability
NCT03847350,has_criteria,aged 19 and older
NCT03847350,has_criteria,diagnosed with essential hypertension
NCT02575950,involves,Acne
NCT02575950,evaluates,LEO43204
NCT02575950,measures_primary,Total Lesion Count
NCT02575950,measures_secondary,Inflammatory Lesion Count
NCT02575950,measures_secondary,Non-inflammatory Lesion Count
NCT02575950,measures_secondary,Composite LSR Score
NCT02575950,has_criteria,Investigator's Global Assessment
NCT02720523,involves,Rheumatoid Arthritis
NCT02720523,evaluates,Upadacitinib
NCT02720523,measures_primary,ACR20 response
NCT02720523,measures_secondary,DAS28 (CRP)
NCT02720523,measures_secondary,HAQ-DI
NCT02720523,has_criteria,Stable dose csDMARDs
NCT02720523,has_criteria,Inadequate response
NCT05265923,involves,Atopic Dermatitis
NCT05265923,evaluates,CM310
NCT05265923,measures_primary,EASI-75 at week 16
NCT05265923,measures_secondary,IGA score 0 or 1
NCT05265923,measures_secondary,reduction IGA score
NCT05265923,measures_secondary,Incidence adverse events
NCT05265923,measures_secondary,Percent change EASI score
NCT05265923,measures_secondary,Percent change NRS score
NCT05265923,measures_secondary,Body surface area
NCT05265923,measures_secondary,Dermatology Life Quality Index
NCT05265923,has_criteria,moderate-to-severe AD
NCT05281523,involves,Chronic Rhinosinusitis With Nasal Polyps
NCT05281523,evaluates,Depemokimab
NCT05281523,measures_primary,Change from Baseline in total endoscopic nasal polyps score
NCT05281523,measures_secondary,Change from Baseline in mean nasal obstruction score
NCT05281523,measures_secondary,Change from Baseline in mean symptom score for rhinorrhea
NCT05281523,measures_secondary,Change from Baseline in mean symptom score for loss of smell
NCT05281523,measures_secondary,Change from Baseline in Lund Mackay CT score
NCT05281523,has_criteria,Baseline and at Week 52
NCT04239950,involves,Hypertriglyceridemia
NCT04239950,evaluates,Ethyl Icosapentate
NCT04239950,measures_primary,Triglyceride level
NCT04239950,measures_secondary,Total cholesterol level
NCT04239950,measures_secondary,LDL-C level
NCT04239950,measures_secondary,HDL-C level
NCT04239950,has_criteria,Serum Triglyceride level
NCT04239950,has_criteria,Lifestyle improvement
NCT04239950,has_criteria,Age 18 to <75 years
NCT04239950,has_criteria,Written consent
NCT04239950,has_criteria,Serum TG level
NCT04239950,has_criteria,HbA1c
NCT04239950,has_criteria,Alanine Aminotransferase
NCT04239950,has_criteria,Aspartate aminotransferase
NCT04239950,has_criteria,Angina pectoris
NCT04239950,has_criteria,Myocardial infarction
NCT02117050,involves,Multiple Sclerosis
NCT02117050,evaluates,Oral Dimethyl Fumarate
NCT02117050,measures_primary,Treatment Satisfaction Score
NCT02117050,measures_secondary,Patient-Determined Disease Steps Questionnaire Score
NCT02117050,measures_secondary,MSQoL-54 Score
NCT02117050,has_criteria,Baseline
NCT00573508,involves,Overactive Bladder
NCT00573508,evaluates,VESIcare
NCT00573508,measures_primary,Symptom Bother Score
NCT00573508,measures_secondary,HRQL Total Score
NCT00573508,has_criteria,Early discontinuation
NCT01362608,involves,Gout
NCT01362608,evaluates,Canakinumab
NCT01362608,measures_primary,Time to First New Flare
NCT01362608,measures_secondary,Gout Pain Intensity
NCT01362608,has_criteria,Postsurgical patients
NCT04583423,involves,Nonalcoholic Steatohepatitis (NASH)
NCT04583423,evaluates,MK-3655
NCT04583423,measures_primary,NASH resolution
NCT04583423,measures_secondary,Adverse Event (AE)
NCT04583423,measures_secondary,Discontinuing Study Medication
NCT04583423,has_criteria,Liver Fat Content (LFC)
NCT03793023,involves,type 2 diabetes mellitus
NCT03793023,evaluates,Teneligliptin
NCT03793023,measures_primary,Change in HbA1c
NCT03793023,measures_secondary,Change in FBG
NCT03793023,measures_secondary,Change in body weight
NCT03793023,measures_secondary,BMI
NCT03793023,measures_secondary,lipid profile
NCT03793023,measures_secondary,percentage of patients
NCT03793023,has_criteria,aged ≥19 years
NCT03793023,has_criteria,diagnosed type 2 diabetes
NCT03793023,has_criteria,treated with DPP4 inhibitor
NCT03793023,has_criteria,HbA1c≥7.0% at baseline
NCT04379050,involves,Parkinson's Disease
NCT04379050,evaluates,ABBV-951
NCT04379050,measures_primary,Percentage of Participants With AE
NCT04379050,measures_secondary,Numeric Grade on Infusion Site Evaluation Scale
NCT04379050,measures_secondary,Letter Grade on Infusion Site Evaluation Scale
NCT04379050,has_criteria,Adult Participants
NCT02100150,involves,Mild Traumatic Brain Injury
NCT02100150,evaluates,NNZ-2566
NCT02100150,measures_primary,Cognitive Function
NCT02100150,measures_secondary,Post-Concussion Symptoms
NCT02100150,measures_secondary,Postural Stability
NCT02100150,measures_secondary,Psychological Sequelae
NCT02100150,has_criteria,Day 28
NCT01008423,involves,Ulcerative Proctitis
NCT01008423,involves,Proctosigmoiditis
NCT01008423,evaluates,Budesonide Foam
NCT01008423,measures_primary,Remission at Week 6
NCT01008423,measures_secondary,Rectal Bleeding MMDAI Subscale Score
NCT01008423,has_criteria,Active disease
NCT01969123,involves,Alzheimer's Disease
NCT01969123,evaluates,EVP-6124
NCT01969123,measures_primary,ADAS-Cog-13 score
NCT01969123,measures_secondary,CDR-SB score
NCT01969123,measures_secondary,activities of daily living
NCT01969123,measures_secondary,psychiatric symptoms
NCT01969123,measures_secondary,MMSE score
NCT01969123,measures_secondary,COWAT score
NCT01969123,has_criteria,Ages 55-85 years
NCT01969123,has_criteria,Informed consent
NCT01969123,has_criteria,probable AD diagnosis
NCT01969123,has_criteria,Clinical decline within 12 months
NCT03060850,involves,CLL/SLL
NCT03060850,involves,MCL
NCT03060850,involves,DLBCL
NCT03060850,involves,Non-Hodgkin B-Cell lymphoma
NCT03060850,evaluates,AC0010
NCT03060850,measures_primary,Objective Response Rate
NCT03060850,measures_secondary,Tolerability
NCT03060850,measures_secondary,Maximum tolerated dose
NCT03060850,has_criteria,relapsed or refractory
NCT01060150,involves,Attention-Deficit/Hyperactivity Disorder
NCT01060150,evaluates,Osmotic Release Oral System (OROS) Methylphenidate
NCT01060150,measures_primary,Clinical Global Impression - Severity (CGI-S) Score
NCT01060150,measures_secondary,Clinical Global Impression - Improvement (CGI-I) Score
NCT01060150,measures_secondary,Learning Skill Test (LST) Total Score
NCT01060150,has_criteria,age 13-15 years
NCT01060150,has_criteria,age 16-18 years
NCT02608450,involves,Facial Acne Vulgaris
NCT02608450,evaluates,CB-03-01 Cream
NCT02608450,measures_primary,Percentage of Success
NCT02608450,measures_secondary,Change From Baseline in Lesion Counts
NCT02608450,has_criteria,age 9 years or older
NCT01985308,involves,Autism Spectrum Disorder
NCT01985308,evaluates,Magnetic Resonant Therapy
NCT01985308,measures_primary,CARS score change
NCT01985308,measures_secondary,CARS score at 5 weeks
NCT01985308,has_criteria,CARS score 36-47
NCT01985308,has_criteria,Age 4-12 years
NCT01985308,has_criteria,Disrupted sleep patterns
NCT03566823,involves,Crohn's Disease
NCT03566823,evaluates,Ontamalimab
NCT03566823,measures_primary,Clinical Remission
NCT03566823,measures_secondary,Endoscopic Response
NCT03566823,has_criteria,Moderate to Severe
NCT06431750,involves,Juvenile Enthesitis-related Arthritis
NCT06431750,involves,Psoriatic Arthritis
NCT06431750,evaluates,Secukinumab
NCT06431750,measures_primary,Drug survival rate
NCT06431750,measures_secondary,ACR Pedi 30/50/70/90 achievement rates
NCT06431750,measures_secondary,Clinical remission/inactive disease rates
NCT06431750,has_criteria,Absence of joints with active arthritis
NCT06431750,has_criteria,Absence of fever
NCT06431750,has_criteria,Absence of rash
NCT06431750,has_criteria,Absence of serositis
NCT06431750,has_criteria,Absence of splenomegaly
NCT06431750,has_criteria,Absence of generalized lymphadenopathy
NCT06431750,has_criteria,Absence of active uveitis
NCT06431750,has_criteria,Normal ESR
NCT06431750,has_criteria,Normal CRP
NCT06431750,has_criteria,Absence of disease activity according to the doctor's general assessment
NCT06431750,has_criteria,Morning stiffness less than 15 minutes
NCT00739908,involves,Major Depressive Disorder
NCT00739908,evaluates,CX157
NCT00739908,measures_primary,MADRS Response Rate
NCT00739908,measures_secondary,MADRS Remitter Rate
NCT00739908,has_criteria,Randomization and study end
NCT01247350,evaluates,LY3009104
NCT01247350,measures_primary,Maximum Concentration
NCT01247350,measures_secondary,Area Under the Curve
NCT01247350,measures_secondary,Half-Life
NCT01247350,measures_secondary,Apparent Volume of Distribution
NCT01247350,measures_secondary,Apparent Total Body Clearance
NCT00219050,involves,Severe Hypertension
NCT00219050,evaluates,Aliskiren-based Regimen
NCT00219050,evaluates,Lisinopril Based Regimen
NCT00219050,measures_primary,Diastolic blood pressure
NCT00219050,measures_primary,Systolic blood pressure
NCT00219050,measures_primary,Standing systolic blood pressure
NCT00219050,measures_primary,Standing diastolic blood pressure
NCT00219050,measures_secondary,Adverse events
NCT00219050,measures_secondary,Laboratory abnormalities
NCT00219050,has_criteria,Essential severe hypertension
NCT00219050,has_criteria,History of secondary hypertension
NCT00219050,has_criteria,History of hypertensive encephalopathy
NCT00219050,has_criteria,History of cerebrovascular accident
NCT00219050,has_criteria,Diabetic patients requiring insulin
NCT01618708,involves,Primary Osteoarthritis of the Hip
NCT01618708,evaluates,Synvisc-One®
NCT01618708,evaluates,Hylan G-F 20
NCT01618708,measures_primary,Change From Baseline
NCT01618708,measures_primary,WOMAC A1 Subscore
NCT01618708,measures_primary,WOMAC A Score
NCT01618708,measures_primary,Patient Global Self-Assessment
NCT01618708,measures_secondary,Percentage of WOMAC A1 Responder
NCT01618708,has_criteria,symptomatic osteoarthritis
NCT01618708,has_criteria,primary OA of the hip
NCT01618708,has_criteria,American College of Rheumatology Criteria
NCT04170023,involves,Paroxysmal Nocturnal Hemoglobinuria
NCT04170023,evaluates,ALXN2050
NCT04170023,measures_primary,Change From Baseline in Hgb
NCT04170023,measures_secondary,Number of Participants Who Had Transfusion Avoidance
NCT04170023,has_criteria,Baseline up to Week 12
NCT04292223,involves,Parkinson's Disease Psychosis
NCT04292223,evaluates,Pimavanserin
NCT04292223,measures_primary,mFSQ total score
NCT04292223,measures_secondary,Schwab and England ADL Scale
NCT04292223,measures_secondary,MDS-UPDRS Parts I and II
NCT04292223,measures_secondary,CGI-I score
NCT04292223,has_criteria,16 weeks
NCT03529123,involves,Type 2 diabetes mellitus
NCT03529123,evaluates,Insulin Glargine/Lixisenatide
NCT03529123,measures_primary,Change in HbA1c
NCT03529123,measures_secondary,Change in 2-hour PPG
NCT03529123,measures_secondary,Change in body weight
NCT03529123,has_criteria,Age ≥ 18 years
NCT03529123,has_criteria,Age < 65 years
NCT03529123,has_criteria,HbA1c ≥ 7.5%
NCT03529123,has_criteria,HbA1c ≤ 10%
NCT03529123,has_criteria,BMI ≥ 19 kg/m2
NCT03529123,has_criteria,BMI ≤ 40 kg/m2
NCT03529123,has_criteria,Basal insulin treatment
NCT03529123,has_criteria,Stable basal insulin
NCT00660023,involves,Chronic Renal Anemia
NCT00660023,evaluates,Intravenous Mircera
NCT00660023,measures_primary,Percentage Hb in target
NCT00660023,measures_secondary,Mean Change Hb
NCT00308750,involves,Non-Small Cell Lung Cancer
NCT00308750,evaluates,pemetrexed
NCT00308750,measures_primary,Time to Disease Progression
NCT00308750,measures_secondary,Adverse Events
NCT00308750,has_criteria,RECIST version 1.0
NCT02013050,involves,Head and Neck Cancer
NCT02013050,evaluates,SGX942
NCT02013050,measures_primary,Duration of SOM
NCT02013050,measures_secondary,Residual SOM
NCT02013050,measures_secondary,Incidence of Clinically Reported
NCT02013050,measures_secondary,"Percent of Patients With RECIST 1.1 Classification of ""Complete Response"
NCT02013050,has_criteria,WHO OM grading scale
NCT02568423,evaluates,Mirikizumab (LY3074828)
NCT02568423,measures_primary,Maximum Concentration (Cmax)
NCT02568423,measures_secondary,Area Under the Concentration (AUC) Curve
NCT02568423,has_criteria,overtly healthy males or females
NCT02568423,has_criteria,first generation Japanese or Caucasian
NCT02568423,has_criteria,body mass index (BMI) of 18.0 kg/m2 to 32.0 kg/m2
NCT02568423,has_criteria,body weight of 40.0 kg or higher
NCT02568423,has_criteria,body weight of 48.0 kg or higher
NCT02568423,has_criteria,had symptomatic herpes zoster
NCT02568423,has_criteria,evidence of active or latent tuberculosis
NCT06101823,involves,Atopic Dermatitis
NCT06101823,evaluates,OpSCF
NCT06101823,measures_primary,EASI score at Week 16
NCT06101823,measures_secondary,Incidence of AEs
NCT06101823,measures_secondary,Proportion of subjects achieving at least a 2-grade reduction from baseline to clear (0) or almost clear (1) in vIGA-AD
NCT06101823,measures_secondary,Change and percent change from baseline in weekly average of the daily Peak Pruritus Numerical Rating Scale (PP-NRS)
NCT06101823,has_criteria,clinically confirmed diagnosis of active AD
NCT06101823,has_criteria,at least a 6-month history of AD
NCT06101823,has_criteria,willing to use effective birth control
NCT06101823,has_criteria,not breastfeeding
NCT06101823,has_criteria,no clinically significant medical condition
NCT06101823,has_criteria,not used dupilumab within 26 weeks prior to Day 1
NCT06101823,has_criteria,not used tralokinumab within 12 weeks prior to Day 1
NCT01922050,involves,Actinic Keratosis
NCT01922050,evaluates,LEO 43204
NCT01922050,measures_primary,Percent Reduction AK
NCT01922050,measures_secondary,Complete Clearance AK
NCT01922050,has_criteria,Dose Limiting Toxicity
NCT02390050,involves,Type 2 Diabetes Mellitus
NCT02390050,evaluates,Bexagliflozin Tablets
NCT02390050,measures_primary,Change in HbA1c
NCT02390050,measures_secondary,Proportion of Subjects With HbA1c < 7%
NCT02390050,measures_secondary,Change in Body Weight Over Time
NCT02390050,measures_secondary,Change in Fasting Plasma Glucose Over Time
NCT02390050,measures_secondary,Change in Systolic and Diastolic Blood Pressure Over Time
NCT02390050,measures_secondary,Change in HbA1c Over Time
NCT02390050,has_criteria,Baseline to up to 12 weeks
NCT05549323,involves,Ulcerative Colitis
NCT05549323,evaluates,PF-07054894
NCT05549323,measures_primary,clinical remission
NCT05549323,measures_secondary,endoscopic appearance
NCT05549323,measures_secondary,clinical remission
NCT05549323,has_criteria,moderate to severe UC
NCT05549323,has_criteria,mild to moderate UC
NCT05549323,has_criteria,Total Mayo Score ≤2
NCT05549323,has_criteria,no individual subscore \>1
NCT03924323,involves,Generalized Anxiety Disorder
NCT03924323,evaluates,Escitalopram
NCT03924323,measures_primary,PARS severity score
NCT03924323,measures_secondary,Response Rate
NCT03924323,measures_secondary,Remission Rate
NCT03924323,measures_secondary,Change CGI-S
NCT03924323,measures_secondary,Change CGAS
NCT03924323,has_criteria,DSM-5 criteria
NCT05130450,involves,Familial Chylomicronemia Syndrome
NCT05130450,evaluates,Olezarsen
NCT05130450,measures_primary,Percent Change in Fasting TG
NCT05130450,measures_secondary,Adjudicated Acute Pancreatitis Event Rate
NCT05130450,has_criteria,≥ 2 Events of Adjudicated Acute Pancreatitis
NCT00601250,involves,Type 2 Diabetes
NCT00601250,evaluates,B I1356
NCT00601250,measures_primary,HbA1c Change
NCT00601250,measures_secondary,FPG Change
NCT00601250,has_criteria,previous anti-diabetic medication
NCT05272150,involves,Psoriasis
NCT05272150,evaluates,Guselkumab
NCT05272150,measures_primary,PASI 90 response
NCT05272150,measures_secondary,IGA Score
NCT05272150,measures_secondary,PSSI 90 response
NCT05272150,has_criteria,Skin of Color
NCT00325195,involves,Gout
NCT00325195,evaluates,PEG-uricase
NCT00325195,measures_primary,Plasma Uric Acid Responder
NCT00325195,measures_secondary,Tophus Burden
NCT00325195,measures_secondary,Gout Flare
NCT00325195,measures_secondary,Swollen Joints
NCT00325195,measures_secondary,Tender Joints
NCT00325195,measures_secondary,Patient Reported Outcomes
NCT00325195,has_criteria,plasma uric acid \< 6 mg/dL
NCT03055195,involves,Atopic Dermatitis
NCT03055195,evaluates,Mepolizumab
NCT03055195,measures_primary,IGA score improvement
NCT03055195,measures_secondary,EASI score change
NCT03055195,has_criteria,Baseline assessment
NCT04087395,evaluates,RHA® 4 With New Anesthetic Agent
NCT04087395,evaluates,RHA® 4-Lidocaine
NCT04087395,measures_primary,Injection pain
NCT04087395,measures_secondary,NLF WSRS Score
NCT04087395,measures_secondary,Percentage of Responders
NCT04087395,measures_secondary,Subject's Perception of Treatment Effectiveness
NCT04087395,involves,Nasolabial Folds
NCT04087395,has_criteria,Injection pain
NCT03328195,involves,Severe Dementia
NCT03328195,evaluates,Vielight Neuro RX Gamma
NCT03328195,measures_primary,Severe Impairment Battery score
NCT03328195,measures_secondary,Activities of Daily Living for Severe Alzheimer's Disease
NCT03328195,has_criteria,device-related adverse events
NCT00517881,involves,Chronic Renal Anemia
NCT00517881,evaluates,Subcutaneous C.E.R.A.
NCT00517881,measures_primary,Hemoglobin Concentration
NCT00517881,measures_secondary,Dose Adjustment
NCT00517881,has_criteria,Pre-Dialysis Participants
NCT01208181,involves,Rheumatoid Arthritis
NCT01208181,evaluates,Etoricoxib
NCT01208181,measures_primary,DAS28-CRP
NCT01208181,measures_secondary,Patient Global Assessment of Pain
NCT01208181,has_criteria,Adverse Event
NCT03324581,involves,Attention-deficit/Hyperactivity Disorder
NCT03324581,evaluates,OPC-64005
NCT03324581,measures_primary,Change From Baseline
NCT03324581,measures_secondary,CAARS-O:SV 18-item ADHD Symptoms Total Score
NCT03324581,has_criteria,DSM-5 diagnosis of ADHD
NCT03324581,has_criteria,Adult ADHD Clinical Diagnostic Scale (ACDS) v 1.2
NCT03324581,has_criteria,age 18 to 55 years
NCT03324581,has_criteria,willing to discontinue prohibited psychotropic medication
NCT03324581,has_criteria,no history of inadequate response to atomoxetine
NCT03324581,has_criteria,no allergies to stimulant or nonstimulant ADHD medications
NCT03324581,has_criteria,no other DSM-5 disorders including psychosis
NCT03324581,has_criteria,no bipolar disorder
NCT03324581,has_criteria,no major depressive disorder
NCT03324581,has_criteria,no panic disorder
NCT03260595,involves,Atopic Dermatitis
NCT03260595,evaluates,Crisaborole Ointment 2%
NCT03260595,measures_primary,Skin Irritation Index
NCT03260595,measures_secondary,Treatment-Emergent Adverse Events
NCT03260595,measures_secondary,Serious Adverse Events
NCT03260595,measures_secondary,Clinically Significant Vital Signs Abnormalities
NCT03260595,has_criteria,Skin irritation scores
NCT02349295,involves,Psoriatic Arthritis
NCT02349295,evaluates,Ixekizumab
NCT02349295,measures_primary,HAQ-DI Score
NCT02349295,measures_secondary,ACR20 response
NCT02349295,has_criteria,tender joint count
NCT01416181,involves,Secondary Progressive Multiple Sclerosis
NCT01416181,evaluates,Natalizumab
NCT01416181,measures_primary,Confirmed disability progression
NCT01416181,measures_secondary,Adverse Events
NCT01416181,has_criteria,≥1 point EDSS increase
NCT02769481,involves,Type 2 Diabetes
NCT02769481,evaluates,Bexagliflozin
NCT02769481,evaluates,Glimepiride
NCT02769481,measures_primary,HbA1c reduction
NCT02769481,measures_secondary,Body Weight
NCT02769481,measures_secondary,Systolic Blood Pressure
NCT02769481,measures_secondary,Hypoglycemia Events
NCT02769481,has_criteria,BMI ≥ 25 kg/m2
NCT02769481,has_criteria,SBP ≥ 140 mmHg
NCT00087581,involves,Kidney Transplantation
NCT00087581,evaluates,Mycophenolate Mofetil
NCT00087581,measures_primary,Treatment Failure
NCT00087581,measures_secondary,Acute Rejection
NCT00087581,has_criteria,Single organ recipient
NCT00087581,has_criteria,Immunosuppressive therapy
NCT00087581,has_criteria,History of malignancy
NCT02799381,involves,Parkinson's Disease
NCT02799381,evaluates,Levodopa-Carbidopa Intestinal Gel
NCT02799381,evaluates,Carbidopa-Levodopa Enteral Suspension
NCT02799381,measures_primary,Unified Dyskinesia Rating Scale
NCT02799381,measures_secondary,ON Time Without Troublesome Dyskinesia
NCT02799381,measures_secondary,Parkinson's Disease Questi...
NCT00846781,involves,Cystic Fibrosis Lung Disease
NCT00846781,evaluates,Denufosol Tetrasodium Inhalation Solution
NCT00846781,measures_primary,Rate of change in lung function
NCT00846781,measures_secondary,Change in FEV1
NCT00846781,has_criteria,Completed Study 08-110
NCT00846781,has_criteria,female patient of childbearing potential and is pregnant
NCT00846781,has_criteria,condition that might affect compliance with study procedures
NCT01816295,involves,Low Testosterone
NCT01816295,evaluates,Testosterone Solution
NCT01816295,measures_primary,Change in SAID Scale
NCT01816295,measures_secondary,Change in HED Scores
NCT01816295,has_criteria,Symptomatic hypogonadism
NCT05908695,involves,Alzheimer's Disease
NCT05908695,evaluates,Sodium Oligomannate
NCT05908695,measures_primary,Change from baseline in ADAS-cog/12 score
NCT05908695,measures_primary,Change from baseline in ADCS-ADL23 score
NCT05908695,measures_primary,Change from baseline in MMSE score
NCT05908695,measures_primary,Change from baseline in CIBIC-Plus score
NCT05908695,measures_primary,Change from baseline in NPI score
NCT05908695,measures_secondary,Change from baseline in ADCS-ADL23 score
NCT05908695,has_criteria,Mild to moderate AD
NCT05908695,has_criteria,History of cognitive decline
NCT05908695,has_criteria,MMSE scores 11-24
NCT05908695,has_criteria,Hachinski Ischemic Score ≤ 4
NCT05908695,has_criteria,Hamilton Rating Scale for Depression ≤ 10
NCT05908695,has_criteria,Brain MRI scan shows AD
NCT05908695,has_criteria,Reliable study partner
NCT04997395,involves,Long COVID
NCT04997395,evaluates,medicinal cannabis
NCT04997395,measures_primary,symptoms severity score
NCT04997395,measures_secondary,functional disability score
NCT04997395,measures_secondary,global health score
NCT04997395,measures_secondary,Fatigue
NCT04997395,has_criteria,diagnosed with long COVID
NCT00082095,involves,Metastatic Breast Cancer
NCT00082095,evaluates,Doxorubicin
NCT00082095,evaluates,Capecitabine
NCT00082095,measures_primary,Time to disease progression
NCT00082095,measures_secondary,Overall Response rate
NCT00082095,measures_secondary,Overall survival
NCT00082095,measures_secondary,Number of patients with adverse events
NCT00082095,measures_secondary,EORTC QLQ-C30
NCT00082095,measures_secondary,Subjective Significance Questionnaire
NCT00082095,has_criteria,Women 60 years and older
NCT04455581,involves,Familial Hypercholesterolemia
NCT04455581,evaluates,SHR-1209
NCT04455581,measures_primary,LDL-C at Week 12
NCT04455581,measures_secondary,Total Cholesterol at Week 12
NCT04455581,measures_secondary,HDL-C at Week 12
NCT04455581,measures_secondary,Non-HDL-C at Week 12
NCT04455581,measures_secondary,Triglycerides at Week 12
NCT04455581,measures_secondary,Apo B at Week 12
NCT04455581,measures_secondary,Apo A1 at Week 12
NCT04455581,measures_secondary,Lipo(a) at Week 12
NCT04455581,has_criteria,≥ 18 years of age
NCT04455581,has_criteria,homozygous familial hypercholesterolemia
NCT04455581,has_criteria,stable lipid-lowering therapies
NCT04455581,has_criteria,LDL cholesterol ≥ 130 mg/dl
NCT04455581,has_criteria,Triglyceride ≤ 400 mg/dL
NCT04455581,has_criteria,Bodyweight of ≥ 40 kg
NCT06427395,involves,Primary Biliary Cholangitis
NCT06427395,evaluates,Saroglitazar Magnesium
NCT06427395,measures_primary,Time to clinical outcome
NCT06427395,measures_secondary,Model for End Stage Liver Disease 3.0 score
NCT06427395,has_criteria,known Gilbert's syndrome
NCT01655381,involves,Rheumatoid Arthritis
NCT01655381,evaluates,Tocilizumab
NCT01655381,measures_primary,Percentage of Remission
NCT01655381,measures_secondary,Adverse Event
NCT01655381,has_criteria,Early Moderate to Severe
NCT06167681,involves,Parkinson's Disease
NCT06167681,evaluates,NouvNeu001
NCT06167681,measures_primary,MDS-UPDRS Part Ⅲ score
NCT06167681,measures_secondary,MDS-UPDRS Part I-IV
NCT06167681,measures_secondary,Hamilton Anxiety Rating Scale
NCT06167681,measures_secondary,Hamilton Depression Rating Scale
NCT06167681,measures_secondary,Pittsburgh Sleep Quality Index
NCT06167681,measures_secondary,Parkinson's Disease Quality of Life Questionnaire
NCT06167681,measures_secondary,Modified Hoehn Yahr Score
NCT06167681,measures_secondary,"Waking Hours in ""off"" State"
NCT06167681,measures_secondary,oral L-dopa Equivalent Dose
NCT06167681,has_criteria,Age 50-75 years old
NCT06167681,has_criteria,male or female
NCT06023095,involves,Obesity
NCT06023095,involves,Overweight
NCT06023095,evaluates,LY3502970
NCT06023095,measures_primary,Body Weight
NCT06023095,measures_secondary,Body Mass Index
NCT06023095,measures_secondary,Waist Circumference
NCT06023095,measures_secondary,Fasting Plasma Glucose
NCT06023095,has_criteria,Stable body weight
NCT06023095,has_criteria,Body mass index ≥ 30.0 kg/m²
NCT06023095,has_criteria,Hypertension
NCT06023095,has_criteria,Dyslipidemia
NCT06023095,has_criteria,Cardiovascular disease
NCT06023095,has_criteria,Obstructive sleep apnea
NCT01499095,involves,Type 2 Diabetes
NCT01499095,evaluates,Insulin Glargine
NCT01499095,measures_primary,Change in HbA1c
NCT01499095,measures_secondary,Nocturnal hypoglycemia
NCT01499095,measures_secondary,Average Preinjection SMPG
NCT01499095,measures_secondary,Variability of Preinjection SMPG
NCT01499095,has_criteria,rescue therapy
NCT03269695,involves,Ulcerative Colitis
NCT03269695,evaluates,PF-06687234
NCT03269695,measures_primary,Modified Clinical Remission
NCT03269695,measures_secondary,Modified Clinical Remission
NCT03269695,has_criteria,Not in Remission
NCT04998981,involves,Hypertriglyceridemia
NCT04998981,involves,Low HDL-C
NCT04998981,evaluates,K-877
NCT04998981,measures_primary,Percent change TG
NCT04998981,measures_secondary,TC
NCT04998981,measures_secondary,Apo A1
NCT04998981,has_criteria,Ability to understand and comply with study procedures
NCT04485481,involves,Healthy Adult Volunteers
NCT04485481,evaluates,ADX-914
NCT04485481,measures_primary,Maximum observed plasma concentration
NCT04485481,measures_primary,Time to reach maximum observed plasma concentration
NCT04485481,measures_primary,Area Under the plasma concentration time curve
NCT04485481,has_criteria,Healthy as determined by the Investigator
NCT04485481,has_criteria,Men and women age 18-50
NCT04485481,has_criteria,Alanine aminotransferase (ALT)
NCT04485481,has_criteria,QT-interval measurements corrected according to the Fridericia rule (QTcF \>450 msec) during controlled rest at Screening or family history of long QT syndrome
NCT04485481,has_criteria,Clinically significant abnormalities in rhythm
NCT00848081,involves,Benign Prostatic Hyperplasia
NCT00848081,evaluates,Tadalafil
NCT00848081,measures_primary,treatment-emergent dizziness
NCT00848081,measures_secondary,Orthostatic Vital Signs Test
NCT00848081,measures_secondary,International Prostate Symptom Score
NCT00848081,measures_secondary,Postvoid Residual Volume
NCT00848081,has_criteria,systolic blood pressure
NCT00848081,has_criteria,diastolic blood pressure
NCT00848081,has_criteria,heart rate
NCT02293681,involves,Ankylosing Spondylitis
NCT02293681,involves,Hip Involvement
NCT02293681,evaluates,Infliximab
NCT02293681,measures_primary,Harris Hip Score
NCT02293681,measures_secondary,BASDAI Score
NCT02293681,measures_secondary,BASFI Score
NCT02293681,has_criteria,Baseline and Week 30
NCT02293681,has_criteria,Baseline
NCT01561781,evaluates,Digoxin
NCT01561781,evaluates,Vandetanib
NCT01561781,measures_primary,AUC Digoxin
NCT01561781,measures_primary,Cmax Digoxin
NCT01561781,measures_secondary,Adverse events
NCT01561781,measures_secondary,ECG data
NCT01561781,measures_secondary,Laboratory data
NCT01561781,measures_secondary,Vital signs data
NCT01561781,measures_secondary,Other PK parameters
NCT01561781,has_criteria,Signed consent
NCT01561781,has_criteria,Age 18-45 years
NCT01561781,has_criteria,Weight ≥50 kg
NCT01561781,has_criteria,BMI 18-30 kg/m2
NCT01561781,has_criteria,Non-childbearing potential
NCT01561781,has_criteria,No clinically significant disease
NCT01561781,has_criteria,No severe allergy/hypersensitivity
NCT01561781,has_criteria,No current smoking
NCT01310114,involves,Ischemic Stroke
NCT01310114,evaluates,PDA001
NCT01310114,measures_primary,Modified Rankin Scale
NCT01310114,measures_secondary,Safety
NCT01310114,has_criteria,24 months
NCT05523895,involves,Autism Spectrum Disorder
NCT05523895,evaluates,Pimavanserin
NCT05523895,measures_primary,ABC-Irritability score
NCT05523895,measures_secondary,CGI-S of Irritability
NCT05523895,measures_secondary,CGI-I of irritability
NCT05523895,measures_secondary,RBS-R scores
NCT05523895,measures_secondary,VABS-Socialization score
NCT05523895,measures_secondary,Caregiver Strain Questionnaire
NCT05523895,has_criteria,Baseline score
NCT01468181,involves,Type 2 Diabetes Mellitus
NCT01468181,evaluates,LY2189265
NCT01468181,measures_primary,Change From Baseline in HbA1c
NCT01468181,measures_primary,Percentage of Participants Who Achieve HbA1c ≤6.5% or <7%
NCT01468181,measures_secondary,Change From Baseline in Fasting Blood Glucose
NCT01468181,measures_secondary,Change From Baseline in 7-Point Self-Monitored Blood Glucose
NCT01468181,has_criteria,Baseline through 52 Weeks
NCT03290781,involves,Ulcerative Colitis
NCT03290781,evaluates,Ontamalimab
NCT03290781,measures_primary,Composite score
NCT03290781,measures_secondary,Endoscopic remission
NCT03290781,measures_secondary,Clinical remission
NCT03290781,has_criteria,Induction study baseline
NCT04340895,involves,Ulcerative Colitis
NCT04340895,evaluates,Therapy Timely Adjustment Based on Self-monitoring
NCT04340895,measures_primary,Mayo Endoscopic Sub-score
NCT04340895,measures_secondary,Rectal Bleeding
NCT04340895,measures_secondary,Stool Frequency
NCT04340895,measures_secondary,Mayo Endoscopic Sub-score
NCT04340895,measures_secondary,Short Inflammatory Bowel Disease Questionnaire
NCT04340895,has_criteria,Self-monitoring
NCT01473381,involves,Major Depressive Disorder
NCT01473381,evaluates,Vilazodone
NCT01473381,measures_primary,Change From Baseline in MADRS Total Score
NCT01473381,measures_secondary,Change From Baseline in CGI-S Scale Score
NCT01473381,measures_secondary,Percentage of Participants With a MADRS Sustained Response
NCT01473381,has_criteria,Baseline to Week 10
NCT03717012,involves,Idiopathic Pulmonary Fibrosis
NCT03717012,evaluates,Pulmonary Rehabilitation
NCT03717012,measures_primary,6 Minute Walk Test
NCT03717012,measures_secondary,St George's Respiratory Questionnaire
NCT03717012,measures_secondary,King's Brief Interstitial Lung Disease
NCT03717012,has_criteria,Baseline (day 1)
NCT04513912,involves,Major Depressive Disorder With Insomnia Symptoms
NCT04513912,evaluates,Seltorexant
NCT04513912,evaluates,Quetiapine XR
NCT04513912,measures_primary,Response at Week 26
NCT04513912,measures_secondary,Change from baseline in Weight
NCT04513912,measures_secondary,Time to Study Drug Discontinuation
NCT04513912,has_criteria,Responded Inadequately to Antidepressant Therapy
NCT05148312,evaluates,AQ001S
NCT05148312,measures_primary,blood Cmax
NCT05148312,measures_primary,blood Tmax
NCT05148312,measures_primary,blood AUC
NCT05148312,measures_secondary,incidence Adverse Events
NCT05148312,measures_secondary,blood pressure
NCT05148312,measures_secondary,pulse rate
NCT05148312,measures_secondary,respiratory rate
NCT05148312,has_criteria,first study drug intake
NCT05111912,involves,Obesity
NCT05111912,evaluates,XW003
NCT05111912,evaluates,Liraglutide
NCT05111912,evaluates,Saxenda
NCT05111912,measures_primary,Percentage change in body weight
NCT05111912,measures_secondary,Body weight loss ≥5%
NCT05111912,measures_secondary,Body weight loss ≥10%
NCT05111912,measures_secondary,Body weight loss ≥15%
NCT05111912,measures_secondary,Waist circumference
NCT05111912,measures_secondary,Hip circumference
NCT05111912,measures_secondary,BMI
NCT05111912,measures_secondary,Fasting plasma glucose
NCT05111912,measures_secondary,Fasting serum insulin
NCT05111912,measures_secondary,HOMA-IR
NCT05111912,measures_secondary,Fasting lipids
NCT05111912,measures_secondary,Treatment-emergent adverse events
NCT05111912,has_criteria,Baseline body weight
NCT00628212,involves,Type 2 Diabetes
NCT00628212,evaluates,MP-513
NCT00628212,measures_primary,Change From Baseline in HbA1c
NCT00628212,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT00628212,measures_secondary,Change From Baseline in 2-hour Postprandial Plasma Glucose
NCT00628212,measures_secondary,Change From Baseline in AUC0-2h for Postprandial Plasma Glucose
NCT00628212,has_criteria,Patients 20-75 years old
NCT00628212,has_criteria,Dietary management and exercise for diabetes
NCT00628212,has_criteria,HbA1c 6.5-9.5%
NCT00628212,has_criteria,No prohibited drug use within 12 weeks
NCT04932512,involves,Non-alcoholic Fatty Liver Disease
NCT04932512,evaluates,ION224
NCT04932512,measures_primary,Percentage of Participants With at Least 2-point Reduction in NAS
NCT04932512,measures_secondary,NASH Resolution
NCT04932512,measures_secondary,Reduction of at Least 1 Stage in the Fibrosis Score
NCT04932512,measures_secondary,Absolute Change From Baseline in Liver-related Laboratory Test - ALT
NCT04932512,measures_secondary,Absolute Change From Baseline in Liver-related Laboratory Test - AST
NCT04932512,has_criteria,at least 1-point Improvement in Hepatocellular Ballooning or Lobular Inflammation
NCT02311881,involves,Osteoarthritis
NCT02311881,evaluates,Paracetamol 1000mg Sustained-release Tablets
NCT02311881,measures_primary,Time-weighted Mean Change
NCT02311881,measures_secondary,WOMAC Physical Function
NCT02311881,has_criteria,Baseline up to week 12
NCT03611010,involves,Hypercholesterolemia
NCT03611010,evaluates,Intravenous Atorvastatin
NCT03611010,measures_primary,Day 15 LDL-C
NCT03611010,measures_primary,Day 15 HDL-C
NCT03611010,has_criteria,steady-state
NCT06651281,involves,Crohn's Disease
NCT06651281,involves,Ulcerative Colitis
NCT06651281,evaluates,Tulisokibart
NCT06651281,measures_primary,Clinical Remission
NCT06651281,measures_secondary,Stool Frequency
NCT06651281,measures_secondary,Abdominal Pain
NCT06651281,measures_secondary,Endoscopic Remission
NCT06651281,has_criteria,CDAI score
NCT06651281,has_criteria,SF/APS
NCT06651281,has_criteria,SES-CD
NCT03835481,involves,Plaque Psoriasis
NCT03835481,evaluates,BI 730357
NCT03835481,measures_primary,PASI50/75/90/100 response
NCT03835481,measures_secondary,Static Physician Global Assessment
NCT03835481,has_criteria,Up to 117 days
NCT03835481,has_criteria,From week 13 onwards
NCT03835481,has_criteria,Up to 802 days
NCT01850381,involves,Parkinson Disease
NCT01850381,evaluates,GM 608
NCT01850381,measures_primary,Change in total UPDRS
NCT01850381,measures_secondary,Change in UPDRS sub-scores
NCT01850381,measures_secondary,Time to disability
NCT01850381,measures_secondary,Proportion of subjects requiring additional symptomatic treatment due to disability
NCT01850381,has_criteria,Baseline
NCT01832610,involves,Heart Failure
NCT01832610,evaluates,HeartWare HVAD®
NCT01832610,measures_primary,Overall Survival
NCT01832610,measures_secondary,Re-hospitalizations
NCT01832610,measures_secondary,Adverse Event
NCT01832610,measures_secondary,Health Status Change
NCT01832610,has_criteria,Intermacs definition
NCT05256810,involves,Gout
NCT05256810,evaluates,ALN-XDH
NCT05256810,measures_primary,Percent Change from Baseline in sUA
NCT05256810,measures_secondary,Plasma Concentrations of ALN-XDH
NCT05256810,has_criteria,serum uric acid level
NCT05256810,has_criteria,American College of Rheumatology criteria
NCT01018810,involves,Plaque Psoriasis
NCT01018810,evaluates,Study BDAD
NCT01018810,measures_primary,Percent Improvement PASI
NCT01018810,measures_secondary,Change From Baseline rPGA
NCT01018810,has_criteria,8 patients
NCT02998710,involves,Homocystinuria
NCT02998710,measures_primary,Met cycle metabolites levels
NCT02998710,measures_secondary,Quality of Life
NCT02998710,has_criteria,age 18+
NCT02998710,has_criteria,age 12-17
NCT05208281,involves,Mucopolysaccharidosis Type II
NCT05208281,evaluates,GNR-055
NCT05208281,measures_primary,Urine GAG excretion
NCT05208281,measures_secondary,Serum GAG level
NCT05208281,measures_secondary,Large joint range of motion
NCT05208281,measures_secondary,Liver and spleen volumes
NCT05208281,measures_secondary,6-minute walk test
NCT05208281,measures_secondary,Left ventricular mass
NCT05208281,measures_secondary,Lung Forced Vital Capacity
NCT05208281,has_criteria,Multiple-dose administration
NCT00998881,involves,Type 2 Diabetes
NCT00998881,evaluates,MP-513
NCT00998881,measures_primary,Change From Baseline in HbA1c
NCT00998881,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT00998881,measures_secondary,Change From Baseline in AUC0-2h for Postprandial Plasma Glucose
NCT00998881,measures_secondary,Change From Baseline in 2-hour Postprandial Plasma Glucose
NCT00998881,has_criteria,Patients 20-75 years old
NCT00998881,has_criteria,Dietary management and exercise
NCT00998881,has_criteria,HbA1c 6.5%-10.0%
NCT00998881,has_criteria,No diabetes drugs 12 weeks prior
NCT01662310,involves,Schizophrenia
NCT01662310,evaluates,Paliperidone
NCT01662310,measures_primary,Time to Relapse
NCT01662310,measures_secondary,PANSS Total Score
NCT01662310,has_criteria,Change From Baseline
NCT00659581,involves,Hypertension
NCT00659581,evaluates,Telmisartan
NCT00659581,measures_primary,Systolic Blood Pressure
NCT00659581,measures_secondary,Diastolic Blood Pressure
NCT00659581,has_criteria,Hypertension patients
NCT03325881,involves,Attention-Deficit/Hyperactivity Disorder
NCT03325881,evaluates,SHP465
NCT03325881,measures_primary,ADHD-RS-5 Total Score
NCT03325881,measures_secondary,Clinical Global Impression of Improvement
NCT03325881,has_criteria,DSM-5 criteria
NCT03338010,involves,Type 2 Diabetes Mellitus
NCT03338010,evaluates,LY2963016
NCT03338010,evaluates,Lantus
NCT03338010,measures_primary,Change From Baseline in HbA1c
NCT03338010,measures_secondary,7-Point Self-Monitored Blood Glucose
NCT03338010,measures_secondary,Percentage of Participants With HbA1c <7% at Week 24
NCT03338010,measures_secondary,Percentage of Participants With HbA1c ≤6.5% at Week 24
NCT03338010,measures_secondary,Change From Baseline in Glycemic Variability of Fasting Blood Glucose
NCT03338010,has_criteria,Adult Chinese Participants
NCT00153010,involves,Dementia of the Alzheimer's Type
NCT00153010,evaluates,NS 2330
NCT00153010,measures_primary,ADAS-Cog score
NCT00153010,measures_secondary,Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change
NCT00153010,measures_secondary,Alzheimer's Disease Cooperative Study-Activities of Daily Living
NCT00153010,measures_secondary,Neuropsychiatric Inventory
NCT00153010,measures_secondary,Mini-Mental State Examination
NCT00153010,measures_secondary,ADAS-Cog Extension
NCT00153010,measures_secondary,ADAS-Cog total score
NCT00153010,measures_secondary,types and frequencies of adverse events
NCT00153010,measures_secondary,proportion of patients discontinued
NCT00153010,measures_secondary,changes from baseline in vital signs
NCT00153010,measures_secondary,changes from baseline in laboratory measurements
NCT00153010,measures_secondary,changes from baseline in ECG readings
NCT00153010,measures_secondary,comparison of study groups for drug plasma concentrations
NCT00153010,measures_secondary,population PK parameters
NCT00153010,has_criteria,age 40-85 years
NCT00153010,has_criteria,diagnosis of probable Dementia of the Alzheimer's Type
NCT00153010,has_criteria,MMSE score 10-24
NCT00153010,has_criteria,ADAS-Cog score greater than 12
NCT00153010,has_criteria,Modified Hachinski Scale score no greater than 4
NCT00153010,has_criteria,central nervous system imaging compatible with Dementia of the Alzheimer's Type
NCT03325712,evaluates,BI 705564
NCT03325712,measures_primary,AUCτ
NCT03325712,measures_primary,Cmax
NCT03325712,measures_secondary,AUCτ
NCT03325712,has_criteria,Healthy Men
NCT02493712,involves,Ulcerative Colitis
NCT02493712,evaluates,IBD98-M
NCT02493712,measures_primary,Remission Rate
NCT02493712,measures_secondary,Improvement Rate
NCT02493712,has_criteria,age ≥18 and \<75 years
NCT01426412,involves,Elevated Low Density Lipoprotein Cholesterol
NCT01426412,evaluates,LY3015014
NCT01426412,measures_primary,Percent Change LDL-C
NCT01426412,measures_secondary,Number Participants With Detectable Levels
NCT01426412,has_criteria,Japanese descent; statin naive; LDL-C 100-180 mg/dL
NCT06259981,involves,Obesity
NCT06259981,evaluates,GLY-200
NCT06259981,measures_primary,weight change from baseline
NCT06259981,measures_secondary,body weight reduction
NCT06259981,has_criteria,BMI ≥ 32 and ≤ 40 kg/m²
NCT06259981,has_criteria,≥ 18 and ≤ 70 years old
NCT06259981,has_criteria,no diabetes mellitus
NCT06259981,has_criteria,no weight change >5% in last 3 months
NCT06259981,has_criteria,no weight loss/gain medication in last 6 months
NCT06259981,has_criteria,no gastric pH affecting drug
NCT06259981,has_criteria,no gastrointestinal motility affecting drug
NCT06259981,has_criteria,no GI tract abnormality or active disease in last 12 months
NCT06259981,has_criteria,no nausea
NCT01037881,involves,Atopic Dermatitis
NCT01037881,evaluates,LEO 29102 Cream
NCT01037881,measures_primary,EASI Score
NCT01037881,measures_secondary,Symptom Free Responders
NCT01037881,measures_secondary,Pruritus
NCT01037881,has_criteria,Symptom free responders
NCT05027581,involves,Knee Osteoarthritis
NCT05027581,evaluates,Chondrochymal®
NCT05027581,measures_primary,Change from baseline WOMAC pain score
NCT05027581,measures_secondary,Change from baseline WOMAC total score
NCT05027581,has_criteria,target knee
NCT01355081,involves,Major Depressive Disorder
NCT01355081,evaluates,Vortioxetine
NCT01355081,measures_primary,MADRS total score
NCT01355081,measures_secondary,HAM-D17 total score
NCT01355081,has_criteria,Baseline
NCT00410410,involves,Ulcerative Colitis
NCT00410410,evaluates,Abatacept
NCT00410410,measures_primary,Clinical Response
NCT00410410,measures_secondary,Adverse Events
NCT00410410,has_criteria,Clinical Response
NCT05528510,involves,Ulcerative Colitis
NCT05528510,evaluates,Guselkumab
NCT05528510,measures_primary,Clinical Remission
NCT05528510,measures_secondary,Symptomatic Remission
NCT05528510,measures_secondary,Endoscopic Improvement
NCT05528510,measures_secondary,Clinical Response
NCT05528510,measures_secondary,Clinical Remission
NCT05528510,measures_secondary,Histologic-Endoscopic Mucosal Improvement
NCT05528510,has_criteria,Moderately to severely active UC
NCT05528510,has_criteria,18 years of age or older
NCT05528510,has_criteria,Documented diagnosis of UC
NCT05528510,has_criteria,inadequate response to or intolerance of conventional therapy
NCT01120210,involves,Heart Failure
NCT01120210,evaluates,JNJ-39588146
NCT01120210,measures_primary,Least Squares mean change
NCT01120210,measures_secondary,Pulmonary Capillary Wedge Pressure
NCT01120210,has_criteria,Baseline up through 3 hours
NCT03287310,involves,Asthma
NCT03287310,evaluates,GSK3511294
NCT03287310,measures_primary,Number of Participants With Adverse Events
NCT03287310,measures_secondary,Change From Baseline in Neutrophil
NCT03287310,measures_secondary,Change From Baseline in Lymphocyte
NCT03287310,measures_secondary,Change From Baseline in Monocyte
NCT03287310,measures_secondary,Change From Baseline in Eosinophil
NCT03287310,measures_secondary,Change From Baseline in Basophil
NCT03287310,measures_secondary,Change From Baseline in Platelet Count
NCT03287310,measures_secondary,Change From Baseline in Red Blood Cell Count
NCT03287310,has_criteria,Mild to Moderate Asthma
NCT06499012,involves,Sarcopenia
NCT06499012,involves,Osteoarthritis
NCT06499012,evaluates,Nutrilite All-plant Protein Booster
NCT06499012,measures_primary,Change of SPPB Score
NCT06499012,measures_secondary,Change of WOMAC 3.1 index
NCT06499012,measures_secondary,Change of bone density
NCT06499012,measures_secondary,Improvement of Fat and Muscle Portions
NCT06499012,measures_secondary,Improvement of Quality of Life
NCT06499012,has_criteria,Middle-aged and Elderly People
NCT03815812,involves,Hypercholesterolemia
NCT03815812,evaluates,IBI306
NCT03815812,measures_primary,LDL-C change
NCT03815812,measures_secondary,non-HDL-C
NCT03815812,measures_secondary,ApoB
NCT03815812,measures_secondary,ApoB/ApoA1
NCT03815812,measures_secondary,Lp(a)
NCT03815812,has_criteria,age 18-70 years
NCT03815812,has_criteria,BMI 18-30 kg/m2
NCT04876781,involves,Rheumatoid arthritis
NCT04876781,evaluates,Xeljanz XR
NCT04876781,measures_primary,DAS28
NCT04876781,measures_secondary,EULAR Response
NCT04876781,measures_secondary,ACR20 response
NCT04876781,has_criteria,52 weeks treatment
NCT01753310,involves,Cervical Dystonia
NCT01753310,evaluates,Dysport®
NCT01753310,measures_primary,TWSTRS total score
NCT01753310,measures_secondary,Clinical Global Impression of Change
NCT01753310,has_criteria,single dose injection
NCT02547714,involves,Plaque Psoriasis
NCT02547714,evaluates,Subcutaneous Secukinumab
NCT02547714,measures_primary,PASI 75
NCT02547714,measures_secondary,Mean Percent Change
NCT02547714,has_criteria,Inadequate Response
NCT01857895,evaluates,Exenatide
NCT01857895,measures_primary,Number of participants
NCT01857895,measures_secondary,Adverse events
NCT01857895,has_criteria,Nausea/vomiting
NCT02041195,involves,Obesity
NCT02041195,evaluates,Setmelanotide
NCT02041195,measures_primary,Percent Change in Body Weight
NCT02041195,measures_secondary,Treatment-Emergent Adverse Events
NCT02041195,has_criteria,Obese Patients
NCT02717195,involves,Schizophrenia
NCT02717195,evaluates,Lu AF35700
NCT02717195,measures_primary,PANSS Total Score
NCT02717195,measures_secondary,PSP Total Score
NCT02717195,measures_secondary,CGI-S Score
NCT02717195,has_criteria,≥20% Reduction
NCT01617681,involves,Hypertension
NCT01617681,involves,CKD
NCT01617681,evaluates,Valsartan
NCT01617681,measures_primary,Change in MSBP
NCT01617681,measures_primary,Change in MDBP
NCT01617681,measures_secondary,UACR reduction
NCT01617681,has_criteria,Age
NCT02435914,involves,Dry Eye Disease
NCT02435914,evaluates,AGN-223575 Ophthalmic Suspension
NCT02435914,measures_primary,Change From Baseline in Conjunctival Redness Score
NCT02435914,measures_secondary,Change From Baseline in Ocular Surface Disease Index Total Score
NCT02435914,measures_secondary,Change From Baseline in Corneal Staining Score
NCT02435914,has_criteria,Baseline
NCT03345914,involves,Atopic Dermatitis
NCT03345914,evaluates,Dupilumab
NCT03345914,measures_primary,IGA 0 or 1
NCT03345914,measures_secondary,EASI-75
NCT03345914,measures_secondary,Percent Change EASI
NCT03345914,has_criteria,≥6 to <12 years
NCT04760314,involves,Atopic Dermatitis
NCT04760314,evaluates,Lebrikizumab
NCT04760314,evaluates,Topical Corticosteroids
NCT04760314,measures_primary,IGA Score 0 or 1
NCT04760314,measures_primary,EASI-75
NCT04760314,measures_secondary,Percent Change EASI
NCT04760314,has_criteria,Japanese Participants
NCT01116895,involves,Psoriasis Vulgaris
NCT01116895,evaluates,LEO 22811
NCT01116895,measures_primary,Percentage Change in PASI
NCT01116895,measures_secondary,PASI 75
NCT01116895,measures_secondary,PASI 50
NCT01116895,measures_secondary,IGA
NCT01116895,has_criteria,75% Reduction in PASI
NCT02893995,involves,Pulmonary Arterial Hypertension
NCT02893995,evaluates,Remodulin
NCT02893995,measures_primary,6-minute Walk Distance
NCT02893995,measures_secondary,Adverse Events
NCT02893995,measures_secondary,Subject Discontinuations
NCT02893995,has_criteria,16 Weeks
NCT03047395,involves,Plaque Type Psoriasis
NCT03047395,evaluates,Risankizumab
NCT03047395,measures_primary,sPGA Score of Clear
NCT03047395,measures_secondary,PASI 100
NCT03047395,measures_secondary,PASI 75
NCT03047395,measures_secondary,PASI 90
NCT03047395,has_criteria,first dose of study drug
NCT02106195,involves,Psoriasis Vulgaris
NCT02106195,evaluates,Belumosudil
NCT02106195,measures_primary,Change in PASI
NCT02106195,measures_secondary,Physician Global Assessment
NCT02106195,has_criteria,signed informed consent
NCT03762681,involves,Chronic Hepatitis B Virus Infection
NCT03762681,evaluates,RO7239958
NCT03762681,measures_primary,Number of Participants
NCT03762681,measures_secondary,Clinically Significant Changes
NCT03762681,has_criteria,Healthy Volunteers
NCT00874614,involves,Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
NCT00874614,evaluates,Ultratrace Iobenguane I131
NCT00874614,measures_primary,Reduction of Antihypertensive Medication
NCT00874614,measures_secondary,Overall Quality of Life
NCT00874614,has_criteria,Therapeutic Dose of AZEDRA®
NCT02001181,involves,atopic dermatitis
NCT02001181,evaluates,Tofacitinib Ointment
NCT02001181,measures_primary,Percent Change EASI
NCT02001181,measures_secondary,Physician's Global Assessment
NCT02001181,measures_secondary,Body Surface Area Efficacy
NCT02001181,has_criteria,Baseline (pre-dose)
NCT02279095,involves,Fibrodysplasia Ossificans Progressiva
NCT02279095,evaluates,Palovarotene
NCT02279095,measures_primary,Percentage of Flare-ups
NCT02279095,measures_secondary,Annualized Change in New HO Volume
NCT02279095,has_criteria,Flare-up screening
NCT00303381,involves,Ulcerative Colitis
NCT00303381,evaluates,Interferon-Beta-1a
NCT00303381,measures_primary,Endoscopically confirmed remission
NCT00303381,measures_secondary,Clinical remission
NCT00303381,has_criteria,Moderately active UC
NCT01064414,involves,Type 2 Diabetes Mellitus
NCT01064414,evaluates,Canagliflozin
NCT01064414,measures_primary,Change in HbA1c
NCT01064414,measures_secondary,Fasting Plasma Glucose
NCT01064414,has_criteria,reduced kidney function
NCT01064414,has_criteria,T2DM not on AHA
NCT01064414,has_criteria,history of diabetic ketoacidosis
NCT01064414,has_criteria,history of T1DM
NCT01064414,has_criteria,pancreas or beta cell transplantation
NCT01064414,has_criteria,diabetes secondary to pancreatitis
NCT01064414,has_criteria,proliferative diabetic retinopathy
NCT01064414,has_criteria,kidney disease requiring immunosuppressive therapy
NCT01064414,has_criteria,history of dialysis or kidney transplant
NCT01064414,has_criteria,nephrotic syndrome
NCT01064414,has_criteria,receiving anti hypertensive or anti-hyperlipidemic therapy
NCT01064414,has_criteria,history of a severe hypoglycemic episode
NCT00092014,involves,Postmenopausal Osteoporosis
NCT00092014,evaluates,Alendronate
NCT00092014,evaluates,Risedronate
NCT00092014,measures_primary,Bone Mineral Density
NCT00092014,measures_secondary,Biochemical markers
NCT00092014,has_criteria,Women with osteoporosis
NCT00092014,has_criteria,Bilateral hip replacements
NCT00092014,has_criteria,Esophageal abnormalities
NCT00092014,has_criteria,Metabolic bone disease
NCT00092014,has_criteria,Medications affecting bone turnover
NCT02068495,involves,hypertension
NCT02068495,evaluates,Candesartan Cilexetil/Amlodipine Besilate Combination Tablets
NCT02068495,measures_primary,Changes in SBP
NCT02068495,measures_secondary,Changes in DBP
NCT02068495,measures_secondary,Changes in Pulse Rate
NCT02068495,has_criteria,hypertension
NCT02068495,has_criteria,hypersensitivity
NCT02428595,involves,Fecal Incontinence
NCT02428595,evaluates,Eclipse™ System
NCT02428595,measures_primary,Count of Treatment Responders
NCT02428595,measures_secondary,St. Mark's Incontinence Severity Score
NCT02428595,measures_secondary,Fecal Incontinence Quality of Life (FIQoL) Score
NCT02428595,has_criteria,Intent to Treat (ITT) Cohort
NCT02428595,has_criteria,Per Protocol (PP) Population
NCT00747214,involves,Rheumatoid Arthritis
NCT00747214,evaluates,CRx-102
NCT00747214,measures_primary,Change in CRP
NCT00747214,measures_secondary,ACR 20 Scores
NCT00747214,measures_secondary,DAS28 Score
NCT00747214,measures_secondary,Fatigue (MAF Scale) Score
NCT00747214,has_criteria,Baseline and Day 42
NCT01533714,involves,Rheumatoid Arthritis
NCT01533714,evaluates,CDP6038
NCT01533714,measures_primary,DAS28(CRP)
NCT01533714,measures_secondary,PtGADA-VAS
NCT01533714,has_criteria,Treatment-emergent Adverse Events
NCT03440814,involves,Prader-Willi Syndrome
NCT03440814,evaluates,Diazoxide Choline
NCT03440814,measures_primary,HQ-CT Change
NCT03440814,measures_secondary,CGI-I
NCT03440814,measures_secondary,GI-C
NCT03440814,has_criteria,PWS condition
NCT01618695,involves,Refractory Partial-onset Seizures
NCT01618695,evaluates,Perampanel
NCT01618695,measures_primary,Percent Change in Seizure Frequency
NCT01618695,measures_secondary,Responder Rate
NCT01618695,has_criteria,50% reduction in seizure frequency
NCT04288895,involves,Major Depressive Disorder
NCT04288895,evaluates,Vortioxetine
NCT04288895,measures_primary,Change in PHQ-9
NCT04288895,measures_secondary,Change in CGI-S
NCT04288895,measures_secondary,Clinical Global Impression-improvement
NCT04288895,has_criteria,Major Depressive Disorder
NCT02185014,involves,Crohn's Disease
NCT02185014,evaluates,Repeated Dosing
NCT02185014,measures_primary,Endoscopic Improvement
NCT02185014,measures_secondary,
NCT02185014,has_criteria,Successfully completed M14-115
NCT02185014,has_criteria,Week 12 ileocolonoscopy
NCT02185014,has_criteria,prior and concomitant medication requirements
NCT02185014,has_criteria,latent tuberculosis (TB) prophylaxis
NCT05669014,involves,Dermatomyositis
NCT05669014,involves,Anti-synthetase Inflammatory Myositis
NCT05669014,evaluates,Daxdilimab
NCT05669014,measures_primary,TIS ≥ 40
NCT05669014,measures_primary,TIS ≥ 20
NCT05669014,measures_secondary,CDASI activity score
NCT05669014,has_criteria,2 consecutive visits
NCT01809314,involves,Cancer
NCT01809314,evaluates,Epoetin Beta
NCT01809314,measures_primary,Change in Hb Level
NCT01809314,measures_secondary,ECOG Performance Status
NCT01809314,has_criteria,Adults ≥ 18 years
NCT01809314,has_criteria,Solid tumors or lymphoproliferative disease
NCT01809314,has_criteria,Receiving chemotherapy
NCT01809314,has_criteria,Erythropoietin indicated
NCT01809314,has_criteria,Hb < 10 g/dL
NCT01896895,involves,Blepharospasm
NCT01896895,evaluates,Botulinum Toxin Type A
NCT01896895,measures_primary,JRS Severity Subscore
NCT01896895,measures_secondary,Blepharospasm Disability Index
NCT01896895,has_criteria,Baseline
NCT05327595,involves,Type 2 Diabetes Mellitus
NCT05327595,evaluates,LY3549492
NCT05327595,measures_primary,Fasting Glucose
NCT05327595,measures_secondary,Oral Glucose Tolerance 2 Hour Glucose
NCT05327595,has_criteria,T2DM for at least 6 months
NCT01772095,involves,Alzheimer Disease
NCT01772095,evaluates,Donepezil
NCT01772095,measures_primary,Change in MMSE
NCT01772095,measures_secondary,Clock Drawing Test
NCT01772095,measures_secondary,IADL
NCT01772095,has_criteria,Age 50 and older
NCT01772095,has_criteria,Diagnosis of dementia
NCT01772095,has_criteria,MMSE 15<24
NCT01772095,has_criteria,Reliable caregivers
NCT03562195,involves,Severe Asthma
NCT03562195,evaluates,Mepolizumab
NCT03562195,measures_primary,Exacerbations
NCT03562195,measures_secondary,SGRQ score
NCT03562195,has_criteria,Oral Corticosteroids
NCT02315755,involves,mRCC
NCT02315755,evaluates,Targeted Treatments
NCT02315755,measures_primary,Progression Free Survival
NCT02315755,measures_secondary,Overall Objective Response
NCT02315755,measures_secondary,FKSI-15 Score
NCT02315755,has_criteria,disease treatment
NCT06328712,involves,Charcot-Marie-Tooth Disease Type 1A
NCT06328712,evaluates,EN001
NCT06328712,measures_primary,CMTNSv2 score change
NCT06328712,measures_secondary,CMT examination score change
NCT06328712,measures_secondary,Rasch-modified CMTNSv2 score change
NCT06328712,measures_secondary,Rasch-modified CMTES score change
NCT06328712,measures_secondary,FDS score change
NCT06328712,measures_secondary,ONLS score change
NCT01474512,involves,Psoriasis
NCT01474512,evaluates,Ixekizumab
NCT01474512,measures_primary,sPGA of 0
NCT01474512,measures_secondary,PASI75
NCT01474512,has_criteria,Moderate to Severe Plaque Psoriasis
NCT01551446,involves,Chronic Kidney Disease
NCT01551446,involves,Type 2 Diabetes
NCT01551446,evaluates,Bardoxolone Methyl
NCT01551446,measures_primary,Change in renal perfusion
NCT01551446,measures_secondary,Change in cardiac function
NCT01551446,measures_secondary,Change in cerebral perfusion
NCT01551446,measures_secondary,Change in haemodynamic variables
NCT01551446,measures_secondary,Change in arterial stiffness
NCT01551446,measures_secondary,Change in body composition
NCT01551446,measures_secondary,Number of participants with adverse events
NCT01551446,measures_secondary,Plasma concentration of bardoxolone methyl
NCT01551446,measures_secondary,Change in cerebral white matter microstructure
NCT01551446,measures_secondary,Change in total body water
NCT01551446,has_criteria,eGFR ≥15.0 and ≤60.0 mL/min/1.73 m2
NCT01551446,has_criteria,History of type 2 diabetes
NCT01551446,has_criteria,Age ≥18 years
NCT01551446,has_criteria,Treatment with ACE inhibitor and/or ARB
NCT02620046,involves,Ulcerative Colitis
NCT02620046,involves,Crohn's Disease
NCT02620046,evaluates,Vedolizumab Subcutaneous
NCT02620046,measures_primary,Partial Mayo Score
NCT02620046,measures_primary,HBI score
NCT02620046,measures_secondary,Adverse Events
NCT02620046,measures_secondary,Serious Adverse Events
NCT02620046,has_criteria,Duration of Exposure
NCT02620046,has_criteria,Participant's Exposure
NCT03635112,involves,Crohn's Disease
NCT03635112,evaluates,TD-1473
NCT03635112,measures_primary,Change From Baseline
NCT03635112,measures_secondary,Clinical Response
NCT03635112,has_criteria,Baseline to Week 12
NCT01100112,involves,Ulcerative Colitis
NCT01100112,evaluates,Oral Budesonide-Multi-Matrix System
NCT01100112,measures_primary,Clinical Remission
NCT01100112,measures_secondary,Clinical Improvement
NCT01100112,has_criteria,UCDAI score
NCT06462612,involves,bipolar I disorder
NCT06462612,evaluates,Lumateperone
NCT06462612,measures_primary,YMRS total score
NCT06462612,measures_secondary,CGI-S
NCT06462612,has_criteria,DSM 5 criteria
NCT06217146,involves,Dementia
NCT06217146,involves,major neurocognitive disorder
NCT06217146,involves,Alzheimer's Disease
NCT06217146,evaluates,Medical Cannabis Oil
NCT06217146,measures_primary,Change in agitation
NCT06217146,measures_secondary,neuropsychiatric symptoms
NCT06217146,has_criteria,age ≥50 years
NCT06217146,has_criteria,diagnosis of major neurocognitive disorder
NCT06217146,has_criteria,diagnosis of probable AD
NCT06217146,has_criteria,NPI-12-agitation/aggression subdomain score of four or higher
NCT06217146,has_criteria,legal guardian
NCT06217146,has_criteria,stable SoC for treatment of agitation
NCT06217146,has_criteria,stable doses of Acetyl Choline Esterase inhibitors
NCT05173012,involves,Essential Tremor
NCT05173012,evaluates,SAGE-324
NCT05173012,measures_primary,Change From Baseline
NCT05173012,measures_secondary,TETRAS ADL Composite Score
NCT05173012,has_criteria,Diagnosis of ET
NCT02017912,involves,Amyotrophic Lateral Sclerosis
NCT02017912,evaluates,Autologous MSC-NTF Cells
NCT02017912,measures_primary,Change in ALSFRS-R Slopes
NCT02017912,measures_secondary,Change in SVC Slopes
NCT02017912,has_criteria,Up to 24 weeks
NCT01631812,involves,Parkinson's Disease
NCT01631812,evaluates,SPM 962
NCT01631812,measures_primary,UPDRS Part 3 Sum Score
NCT01631812,measures_secondary,UPDRS Part 2 Sum Score
NCT01631812,measures_secondary,"Absolute Time Spent ""Off"
NCT01631812,has_criteria,Skin Irritation Score
NCT02076412,involves,Immune Thrombocytopenic Purpura
NCT02076412,evaluates,Fostamatinib
NCT02076412,measures_primary,Platelet count ≥ 50
NCT02076412,measures_secondary,Bleeding According to IBLS
NCT02076412,has_criteria,baseline platelet count \< 15
NCT04607512,involves,Healthy Adult Subjects
NCT04607512,evaluates,Telaglenastat
NCT04607512,measures_primary,ΔΔQTcF
NCT04607512,measures_secondary,ΔHR
NCT04607512,measures_secondary,ΔPR
NCT04607512,measures_secondary,ΔQRS
NCT04607512,has_criteria,therapeutic dose
NCT06324812,involves,Atopic Dermatitis
NCT06324812,evaluates,611
NCT06324812,measures_primary,EASI - 75 Response
NCT06324812,measures_secondary,IGA Score 0 or 1
NCT06324812,measures_secondary,EASI - 50 Response
NCT06324812,has_criteria,Chinese Children and Adolescents
NCT00395512,involves,Type 2 Diabetes Mellitus
NCT00395512,evaluates,Alogliptin
NCT00395512,evaluates,Pioglitazone
NCT00395512,measures_primary,Change From Baseline in HbA1c
NCT00395512,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT00395512,measures_secondary,Percentage of Participants With Marked Hyperglycemia
NCT00395512,measures_secondary,Percentage of Participants Meeting Rescue Criteria
NCT00395512,has_criteria,fasting plasma glucose ≥200 mg/dL
NCT00395512,has_criteria,fasting plasma glucose ≥310 mg/dL
NCT00395512,has_criteria,fasting plasma glucose ≥275 mg/dL
NCT00395512,has_criteria,HbA1c ≥8.5% and ≤0.5% reduction in HbA1c
NCT03626012,involves,C9ORF72-Associated Amyotrophic Lateral Sclerosis
NCT03626012,evaluates,BIIB078
NCT03626012,measures_primary,ALSFRS-R Scores
NCT03626012,measures_secondary,Percent of Predicted Slow Vital Capacity
NCT03626012,measures_secondary,Muscle Strength
NCT03626012,has_criteria,Baseline through End of Study
NCT01614912,involves,Schizophrenia
NCT01614912,evaluates,SM-13496
NCT01614912,measures_primary,PANSS Total Score
NCT01614912,measures_secondary,CGI-S Score
NCT01614912,has_criteria,Week 6 prior study
NCT02640612,involves,Rheumatoid Arthritis
NCT02640612,evaluates,BI 695501
NCT02640612,measures_primary,DAS28 at Week 48
NCT02640612,measures_secondary,ACR20 response
NCT02640612,has_criteria,20% improvement
NCT01808612,involves,Major Depressive Disorder
NCT01808612,evaluates,Fluoxetine
NCT01808612,measures_primary,HAMD21 total score
NCT01808612,measures_secondary,HAMD17 total scores
NCT01808612,measures_secondary,Maier subscale
NCT01808612,measures_secondary,Anxiety/Somatization subscale
NCT01808612,measures_secondary,Retardation/Somatization subscale
NCT01808612,measures_secondary,Sleep subscale
NCT01808612,has_criteria,≥50% improvement
NCT03143712,evaluates,GLPG1690
NCT03143712,measures_primary,maximum plasma concentration
NCT03143712,measures_secondary,time to maximum concentration
NCT03143712,measures_secondary,last quantifiable concentration
NCT03143712,has_criteria,Male 18-50 years old
NCT03143712,has_criteria,BMI 18-30 kg/m2
NCT03143712,has_criteria,weight at least 50 kg
NCT06198712,involves,Sickle Cell Disease
NCT06198712,evaluates,Etavopivat
NCT06198712,measures_primary,Cmax
NCT06198712,measures_primary,Cmax
NCT06198712,measures_primary,Incidence of AEs
NCT06198712,measures_primary,Number of premature discontinuations
NCT06198712,measures_primary,Number of dose interruptions
NCT06198712,measures_primary,Number of dose reductions
NCT06198712,measures_secondary,Hemoglobin (Hb) response rate
NCT06198712,measures_secondary,Change in Hb from baseline
NCT06198712,measures_secondary,Change from baseline in VOCs
NCT06198712,measures_secondary,Change from baseline in Annualized Rate of VOC
NCT06198712,measures_secondary,Change from baseline in PROMIS Fatigue Scale
NCT06198712,has_criteria,Pediatric Patients
NCT01166646,involves,Plaque Psoriasis
NCT01166646,evaluates,Topical Investigational Lotion
NCT01166646,evaluates,Approved Cream
NCT01166646,measures_primary,Disease Severity Success
NCT01166646,measures_secondary,"Number of Subjects Whose Signs of Psoriasis Was Designated ""Success"
NCT01166646,has_criteria,Subjects are male or non-pregnant female
NCT01313312,involves,Upper Limb Spasticity
NCT01313312,evaluates,Dysport®
NCT01313312,measures_primary,Mean Change From Baseline
NCT01313312,measures_secondary,Heart Rate
NCT01313312,measures_secondary,Red Blood Cell Count
NCT01313312,measures_secondary,Haemoglobin
NCT01313312,measures_secondary,MCHC
NCT01313312,has_criteria,Treatment cycle
NCT02955212,involves,Rheumatoid Arthritis
NCT02955212,evaluates,Upadacitinib
NCT02955212,measures_primary,ACR20 response
NCT02955212,measures_secondary,DAS28 [CRP]
NCT02955212,measures_secondary,HAQ-DI
NCT02955212,has_criteria,csDMARDs inadequate response
NCT00785512,involves,hypertension
NCT00785512,evaluates,nebivolol
NCT00785512,measures_primary,diastolic blood pressure
NCT00785512,measures_primary,systolic blood pressure
NCT00785512,has_criteria,stage I or II hypertension
NCT00785512,has_criteria,18 to 79 years
NCT00785512,has_criteria,post-menopausal
NCT00785512,has_criteria,approved contraceptive
NCT00785512,has_criteria,no more than two anti-hypertensive medications
NCT00785512,has_criteria,not pregnant
NCT04857112,involves,Ulcerative Colitis
NCT04857112,evaluates,Amiselimod
NCT04857112,measures_primary,Change from Baseline
NCT04857112,measures_secondary,Endoscopic improvement
NCT04857112,measures_secondary,Clinical remission
NCT04857112,has_criteria,Baseline to Day 85
NCT06057012,involves,Postpartum Depression
NCT06057012,evaluates,BRII-296
NCT06057012,measures_primary,Change From Baseline
NCT06057012,measures_secondary,Adverse Events
NCT06057012,measures_secondary,Electrocardiogram Parameters
NCT06057012,measures_secondary,Clinical Laboratory Evaluations
NCT06057012,measures_secondary,Columbia-Suicide Severity Rating Scale Responses
NCT06057012,measures_secondary,Glasgow Coma Scale Score
NCT06057012,measures_secondary,Stanford Sleepiness Scale Score
NCT06057012,has_criteria,Baseline up to Day 45
NCT06625346,involves,Hypertension
NCT06625346,evaluates,EXTOR (Amlodipine/Valsartan)
NCT06625346,measures_primary,Systolic Blood Pressure
NCT06625346,measures_primary,Diastolic Blood Pressure
NCT06625346,measures_secondary,Health-Related Quality of Life
NCT06625346,has_criteria,newly diagnosed hypertensive patients
NCT03943446,involves,Crohn's Disease
NCT03943446,evaluates,TAK-018
NCT03943446,measures_primary,Endoscopic Recurrence
NCT03943446,measures_secondary,Fecal Calprotectin
NCT03943446,has_criteria,Documented diagnosis of CD
NCT01227512,involves,Dilutional Hyponatremia
NCT01227512,evaluates,Tolvaptan
NCT01227512,evaluates,Fluid Restriction
NCT01227512,measures_primary,Length of Hospital Stay
NCT01227512,measures_secondary,Change From Baseline to 48 Hour Post Dose in Clinical Global Impression-Severity (CGI-S) of Hyponatremia Symptoms.
NCT01227512,measures_secondary,Change From Baseline to 24 and 72 Hours Post Dose in CGI-S of Hyponatremia Symptoms.
NCT01227512,measures_secondary,Change From Baseline to 48 Hours Post Dose in Clinical Global Impression - Improvement (CGI-I) Score of Hyponatremia Symptoms.
NCT02670746,involves,Pancreatic Cancer
NCT02670746,evaluates,Nab-paclitaxel
NCT02670746,evaluates,Gemcitabine
NCT02670746,measures_primary,Overall survival
NCT02670746,measures_secondary,Change from baseline
NCT02670746,measures_secondary,Change from baseline
NCT02670746,measures_secondary,Change from baseline
NCT02670746,has_criteria,Grade 1-5 neuropathy
NCT01728246,involves,Chronic Osteoarthritis
NCT01728246,evaluates,Tramadol/Paracetamol
NCT01728246,measures_primary,VAS-pain Score
NCT01728246,measures_secondary,ODI Score
NCT01728246,has_criteria,Change From Baseline
NCT03258814,involves,Axial Spondyloarthritis
NCT03258814,evaluates,Combined Adalimumab Treatment
NCT03258814,evaluates,Active Supervised Training
NCT03258814,measures_primary,Change Form Baseline
NCT03258814,measures_secondary,Bath Ankylosing Spondylitis Metrology Index
NCT03258814,measures_secondary,Bath Ankylosing Spondylitis Functional Index
NCT03258814,has_criteria,Patients With AS
NCT01472614,involves,Type-2 Diabetes Mellitus
NCT01472614,evaluates,DLBS3233
NCT01472614,measures_primary,Reduction of A1c
NCT01472614,measures_secondary,Reduction of venous A1c
NCT01472614,measures_secondary,Reduction of venous FPG
NCT01472614,measures_secondary,Reduction of venous 1h-PG
NCT01472614,measures_secondary,Change in fasting insulin level
NCT01472614,measures_secondary,Change in HOMA-R
NCT01472614,measures_secondary,Change in HOMA-B
NCT01472614,measures_secondary,Change in adiponectin level
NCT01472614,measures_secondary,Change in lipid profile
NCT01472614,measures_secondary,Change in body weight
NCT01472614,measures_secondary,Hematology parameters
NCT01472614,measures_secondary,Liver function parameters
NCT01472614,measures_secondary,Renal function parameter
NCT01472614,has_criteria,n... [TRUNCATED]
NCT01493414,involves,Primary Myelofibrosis
NCT01493414,involves,Post Polycythemia Myelofibrosis
NCT01493414,involves,Post-essential Thrombocythemia Myelofibrosis
NCT01493414,evaluates,INC424
NCT01493414,measures_primary,Spleen Length Reduction
NCT01493414,measures_secondary,Best Overall Response
NCT01493414,has_criteria,Spleen length 5-10 cm
NCT01493414,has_criteria,Spleen length >10 cm
NCT04863014,involves,Severe Hypertriglyceridemia
NCT04863014,evaluates,Evinacumab
NCT04863014,measures_primary,Acute Pancreatitis episodes
NCT04863014,measures_secondary,Percent Change in ApoC3
NCT04863014,measures_secondary,Percent Change in Fasting Triglycerides
NCT04863014,measures_secondary,Percent Change in Total Cholesterol
NCT04863014,measures_secondary,Percent Change in Non-HDL-C
NCT04863014,measures_secondary,Percent Change in Apolipoprotein B48
NCT04863014,measures_secondary,Percent Change in Apolipoprotein B100
NCT04863014,measures_secondary,Nuclear Magnetic Resonance Particle Size
NCT04863014,measures_secondary,Number of TEAEs
NCT04863014,has_criteria,Treatment-emergent Adverse Events
NCT03017014,involves,Crohn's Disease
NCT03017014,evaluates,Adalimumab
NCT03017014,measures_primary,Time to loss of benefit
NCT03017014,measures_secondary,C-reactive protein
NCT03017014,measures_secondary,calprotectin
NCT03017014,measures_secondary,wPCDAI
NCT03017014,has_criteria,dose escalation
NCT03017014,has_criteria,hospitalization
NCT04976595,involves,Hypogonadism
NCT04976595,evaluates,Nasal Testosterone Gel
NCT04976595,measures_primary,Change From Baseline in 24-hour Systolic Blood Pressure
NCT04976595,measures_secondary,Change From Baseline in 24-hour Average Mean Arterial Pressure
NCT04976595,measures_secondary,Change From Baseline in 24-hour Average Systolic Blood Pressure
NCT04976595,measures_secondary,Change From Baseline in 24-hour Average Diastolic Blood Pressure
NCT04976595,measures_secondary,Change From Baseline in 24-hour Average Pulse Pressure
NCT04976595,measures_secondary,Change From Baseline in 24-hour Average Heart Rate
NCT04976595,measures_secondary,Change From Baseline in Hourly Average Mean Arterial Pressure
NCT04976595,measures_secondary,Change From Baseline in Hourly Average Systolic Blood Pressure
NCT04976595,measures_secondary,Change From Baseline in Hourly Average Diastolic Blood Pressure
NCT04976595,measures_secondary,Change From Baseline in Hourly Average Pulse Pressure
NCT04976595,measures_secondary,Change From Baseline in Hourly Average Heart Rate
NCT04976595,measures_secondary,Percentage of Participants With New Anti-hypertensive Medications
NCT04976595,measures_secondary,Percentage of Participants With Dose Increases in Anti-hypertensive Medications
NCT04976595,has_criteria,Male between 18 and 80 years of age
NCT06546995,involves,Alzheimer's Disease
NCT06546995,evaluates,NMRA-323511
NCT06546995,measures_primary,CMAI Total Score
NCT06546995,measures_secondary,C-SSRS scores
NCT06546995,has_criteria,Agitation Associated With Dementia
NCT04749914,involves,Healthy Volunteers
NCT04749914,evaluates,Lasmiditan
NCT04749914,measures_primary,Cmax of Dabigatran
NCT04749914,measures_primary,AUC[0-∞] of Dabigatran
NCT04749914,measures_secondary,Cmax of Rosuvastatin
NCT04749914,measures_secondary,AUC[0-∞] of Rosuvastatin
NCT04749914,has_criteria,Body mass index (BMI)
NCT04749914,has_criteria,known allergies
NCT04749914,has_criteria,abnormal blood pressure
NCT06134414,involves,Paroxysmal Nocturnal Hemoglobinuria
NCT06134414,evaluates,MY008211A
NCT06134414,measures_primary,hemoglobin increase
NCT06134414,measures_secondary,LDH level
NCT06134414,measures_secondary,reticulocyte count
NCT06134414,has_criteria,RBC transfusion
NCT03127514,involves,Amyotrophic Lateral Sclerosis
NCT03127514,evaluates,AMX0035
NCT03127514,measures_primary,ALSFRS-R Slope Change
NCT03127514,measures_secondary,Number of Participants With Adverse Events
NCT03127514,measures_secondary,Number of Participants in Each Group
NCT03127514,measures_secondary,ATLIS Total Score Change
NCT03127514,measures_secondary,Change in Plasma Levels of pNF-H
NCT03127514,measures_secondary,Rate of Decline in SVC
NCT03127514,has_criteria,24 Weeks
NCT01904214,involves,Renal Impairment
NCT01904214,evaluates,BAF312
NCT01904214,measures_primary,Adverse Events
NCT01904214,measures_secondary,Safety Tolerability
NCT01904214,has_criteria,BMI 18-38 kg/m2
NCT01642914,involves,Chronic Constipation
NCT01642914,involves,Abdominal Bloating
NCT01642914,evaluates,Linaclotide
NCT01642914,measures_primary,9/12 Week CSBM 3+1 Responder
NCT01642914,measures_secondary,Change From Baseline in 12-Week Abdominal Bloating
NCT01642914,measures_secondary,Percent Change From Baseline in 12-week Abdominal Bloating
NCT01642914,has_criteria,14 days before randomization
NCT01408095,involves,Type 2 diabetes mellitus
NCT01408095,evaluates,LY2608204
NCT01408095,measures_primary,Change from baseline
NCT01408095,measures_secondary,Incidence of Hypoglycemic Episodes
NCT01408095,has_criteria,stable dose of metformin
NCT01408095,has_criteria,stable dose of sulfonylurea
NCT01408095,has_criteria,stable dose of meglitinide
NCT05504395,involves,Prader-Willi Syndrome
NCT05504395,evaluates,CSTI-500
NCT05504395,measures_primary,Cmax
NCT05504395,measures_primary,AUC0-72
NCT05504395,measures_primary,AUC0-inf
NCT05504395,measures_secondary,Incidence of TEAEs
NCT05504395,measures_secondary,Clinically significant findings in physical examinations
NCT05504395,measures_secondary,Clinically significant findings in vital signs
NCT05504395,has_criteria,Clinically significant changes in vital parameters
NCT02650895,involves,Healthy adult subjects
NCT02650895,evaluates,Efprezimod Alfa
NCT02650895,measures_primary,Adverse Events
NCT02650895,measures_secondary,Serum CD24Fc concentration
NCT02650895,has_criteria,Healthy male and female volunteers
NCT01734395,involves,Alzheimer's disease
NCT01734395,evaluates,Galantamine
NCT01734395,measures_primary,Attention Questionnaire Scores
NCT01734395,measures_secondary,Burden Interview Scores
NCT01734395,measures_secondary,Mini Mental State Exam Scores
NCT01734395,has_criteria,DSM-IV criteria
NCT01450514,involves,Schizophrenia
NCT01450514,involves,Schizoaffective disorder
NCT01450514,evaluates,Pipamperone
NCT01450514,measures_primary,Change from baseline
NCT01450514,measures_secondary,Residual PANSS item(s)
NCT01450514,measures_secondary,SWN score
NCT01450514,measures_secondary,IMI-SR score
NCT01450514,measures_secondary,CGI-I score
NCT01450514,measures_secondary,BARS total
NCT01450514,measures_secondary,BACS score
NCT01450514,has_criteria,Informed consent
NCT01450514,has_criteria,Age 18-65 years
NCT01450514,has_criteria,Stable risperidone or paliperidone treatment
NCT01450514,has_criteria,DSM-IV-R criteria
NCT01450514,has_criteria,Mini International Neuropsychiatric Interview
NCT02708095,involves,Systemic Lupus Erythematosus
NCT02708095,evaluates,Baricitinib
NCT02708095,measures_primary,Arthritis and/or Rash
NCT02708095,measures_secondary,SLE Responder Index 4
NCT02708095,has_criteria,SLEDAI-2K definitions
NCT04352595,involves,Atopic Dermatitis
NCT04352595,evaluates,Hemay808
NCT04352595,measures_primary,EASI score change
NCT04352595,measures_secondary,IGA response
NCT04352595,measures_secondary,EASI90
NCT04352595,measures_secondary,EASI75
NCT04352595,measures_secondary,EASI50
NCT04352595,measures_secondary,Pruritus NRS
NCT04352595,measures_secondary,DLQI Total Score
NCT04352595,has_criteria,Baseline EASI score
NCT02584855,involves,Psoriatic Arthritis
NCT02584855,evaluates,Ixekizumab
NCT02584855,measures_primary,Time to Relapse
NCT02584855,measures_secondary,Percentage of Participants Who Relapse
NCT02584855,has_criteria,MDA for 3 consecutive months
NCT05560555,involves,Hereditary Transthyretin Amyloidosis
NCT05560555,measures_primary,Change in NIS
NCT05560555,measures_secondary,Norfolk QOL-DN
NCT01188655,involves,Ankylosing Spondylitis
NCT01188655,evaluates,Enbrel
NCT01188655,measures_primary,BASDAI 40 Response
NCT01188655,measures_secondary,Change From Baseline in BASDAI
NCT01188655,measures_secondary,Change From Baseline in BASFI
NCT01188655,measures_secondary,Participant's Global Assessment
NCT01188655,measures_secondary,Physician's Global Assessment
NCT01188655,has_criteria,Decrease of 40 percent
NCT02953314,involves,Cystic Fibrosis
NCT02953314,evaluates,VX-661/Ivacaftor
NCT02953314,measures_primary,ppFEV1
NCT02953314,measures_secondary,Weight
NCT02953314,measures_secondary,Weight-for-age Z-Score
NCT02953314,measures_secondary,Height
NCT02953314,measures_secondary,Height-for-age z-Score
NCT02953314,has_criteria,Pediatric Subjects
NCT00394914,involves,Common cold
NCT00394914,involves,Asthma exacerbation
NCT00394914,evaluates,Pleconaril Nasal Spray
NCT00394914,measures_primary,Asthma Control Questionnaire
NCT00394914,measures_secondary,Rhinovirus PCR-Positive Colds
NCT00394914,has_criteria,Rhinovirus exposure
NCT02603614,involves,Chronic Stable Heart Failure
NCT02603614,involves,Moderate Renal Impairment
NCT02603614,evaluates,Cenderitide
NCT02603614,measures_primary,Safety and tolerability
NCT02603614,measures_secondary,Pharmacokinetics
NCT02603614,measures_secondary,Pharmacodynamics
NCT02603614,has_criteria,Subject's participation
NCT05349214,involves,Sjogren's Syndrome
NCT05349214,evaluates,Ianalumab
NCT05349214,measures_primary,ESSDAI score at Week 48
NCT05349214,measures_secondary,ESSDAI<5 at Week 48
NCT05349214,measures_secondary,SSSD score at Week 48
NCT05349214,has_criteria,≥3 points reduction from baseline
NCT06639295,involves,Chronic Rhinosinusitis with Nasal Polyps
NCT06639295,evaluates,611
NCT06639295,measures_primary,Bilateral NPS
NCT06639295,measures_secondary,Nasal Congestion Symptom Severity Score
NCT06639295,measures_secondary,Lund Mackay Score
NCT06639295,measures_secondary,Total Nasal Symptom Score
NCT06639295,measures_secondary,University of Pennsylvania Smell Identification Test Score
NCT06639295,has_criteria,Change From Baseline
NCT06542614,involves,Plaque Psoriasis
NCT06542614,measures_primary,PASI 75 at week 12
NCT06542614,measures_secondary,sPGA 0/1 at week 12
NCT06542614,measures_secondary,PASI 50 at week 12
NCT06542614,measures_secondary,PASI 90 at week 12
NCT06542614,measures_secondary,PASI 100 at week 12
NCT06542614,measures_secondary,Body Surface Area (BSA) score
NCT06542614,measures_secondary,Dermatology Life Quality Index (DLQI) score
NCT06542614,measures_secondary,incidence of abnormal laboratory test markers
NCT06542614,measures_secondary,Adverse event (AE)
NCT06542614,measures_secondary,Serious Adverse Events (SAEs)
NCT00253214,involves,Alzheimer's disease
NCT00253214,evaluates,Galantamine
NCT00253214,measures_primary,ADAS-cog/11 score
NCT00253214,measures_secondary,CIBIC-plus score
NCT00253214,has_criteria,Mini-Mental Status Examination score
NCT00253214,has_criteria,Alzheimer's Disease Assessment scale score
NCT00253214,has_criteria,gradual cognitive decline
NCT00253214,has_criteria,consistent informant
NCT00420095,involves,Diabetes Mellitus
NCT00420095,evaluates,Insulin lispro low mix
NCT00420095,evaluates,Human insulin mix 30/70
NCT00420095,measures_primary,Change in HbA1c
NCT00420095,measures_secondary,Change in Fasting Blood Glucose
NCT00420095,measures_secondary,Change in Total Daily Insulin Dose
NCT00420095,measures_secondary,Number of Participants Achieving Target HbA1c Values
NCT00420095,measures_secondary,Number of Participants With Laboratory Parameters Significantly Different From Baseline
NCT00420095,measures_secondary,Hypoglycemia Rate Per Participant Per 30 Days
NCT00420095,has_criteria,Target HbA1c value
NCT00420095,has_criteria,Laboratory parameters
NCT05813795,involves,Overweight or Obesity
NCT05813795,evaluates,XW003
NCT05813795,measures_primary,Percent change in body weight
NCT05813795,measures_secondary,Proportion of subjects with weight loss
NCT05813795,has_criteria,BMI between 24.0 to 28.0 kg/m2
NCT05813795,has_criteria,BMI ≥ 28 kg/m2
NCT05813795,has_criteria,Weight change of no more than 5%
NCT05813795,has_criteria,Willing and able to maintain stable diet
NCT01620255,involves,Ulcerative Colitis
NCT01620255,evaluates,PF-00547659
NCT01620255,measures_primary,Clinical Remission
NCT01620255,measures_secondary,Clinical Response
NCT01620255,measures_secondary,Mucosal Healing
NCT01620255,has_criteria,Total Mayo Score
NCT01370655,involves,Hypertension
NCT01370655,evaluates,MK-7145
NCT01370655,evaluates,Placebo
NCT01370655,evaluates,Hydrochlorothiazide
NCT01370655,measures_primary,Change in Systolic BP
NCT01370655,measures_primary,Change in Diastolic BP
NCT01370655,measures_secondary,Urine Sodium
NCT01370655,measures_secondary,Adverse Events
NCT01370655,has_criteria,Male Participants
NCT03860155,involves,Acute-on-Chronic Liver Failure
NCT03860155,evaluates,Allogeneic ABCB5-positive Stem Cells
NCT03860155,measures_primary,Change of MELD score
NCT03860155,measures_secondary,Child-Pugh-Score
NCT03860155,measures_secondary,CLIF-C ACLF score
NCT03860155,measures_secondary,Overall survival time
NCT03860155,has_criteria,Between Screening and Week 24
NCT06254014,involves,type 2 diabetes mellitus
NCT06254014,evaluates,JY09
NCT06254014,measures_primary,HbA1c <6.5%
NCT06254014,measures_secondary,HbA1c <7%
NCT06254014,has_criteria,≥18 years of age
NCT06254014,has_criteria,≤75 years of age
NCT06254014,has_criteria,T2DM diagnosis
NCT06254014,has_criteria,≥12 weeks T2DM
NCT06254014,has_criteria,dietary and exercise interventions
NCT06254014,has_criteria,no antidiabetic medications
NCT06254014,has_criteria,HbA1c ≥7.5%
NCT06254014,has_criteria,HbA1c ≤11.0%
NCT06254014,has_criteria,HbA1c ≥7.0%
NCT06254014,has_criteria,HbA1c ≤10.5%
NCT06254014,has_criteria,FPG 13.9 mmol/L
NCT02965846,involves,Evaporative Dry Eye
NCT02965846,evaluates,Topical Ophthalmic AGN-195263
NCT02965846,measures_primary,Change From Baseline in TBUT
NCT02965846,measures_secondary,Overall Ocular Discomfort Score
NCT02965846,has_criteria,Tear film break-up time ≥ 2 seconds and ≤ 7 seconds
NCT02965846,has_criteria,Corneal sodium fluorescein staining score ≥ 1 and ≤ 4
NCT02965846,has_criteria,Anesthetized Schirmer's tear test score ≥ 10 mm after 5 minutes
NCT02965846,has_criteria,OSDI score > 12
NCT02965846,has_criteria,Overall ocular discomfort score ≥ 1 and < 4
NCT02965846,has_criteria,Ocular burning score ≥ 1 and < 4
NCT02965846,has_criteria,Blurred vision score ≥ 1 and < 4
NCT02965846,has_criteria,lower lid margin meibum quality global assessment score ≥ 1
NCT03703869,involves,Type 2 Diabetes Mellitus
NCT03703869,evaluates,Toujeo
NCT03703869,measures_primary,Change in HbA1c
NCT03703869,measures_secondary,Fasting Plasma Glucose
NCT03703869,measures_secondary,Self-Monitored Plasma Glucose
NCT03703869,measures_secondary,Hypoglycemia
NCT03703869,measures_secondary,Adverse events
NCT03703869,measures_secondary,Serious adverse events
NCT03703869,measures_secondary,Body weight
NCT03703869,has_criteria,Insulin-naïve patients
NCT03446846,involves,Major Depressive Disorder
NCT03446846,evaluates,MIN-117
NCT03446846,measures_primary,Change in MADRS
NCT03446846,measures_secondary,Change in HAM-A
NCT03446846,measures_secondary,Change in CGI-S
NCT03446846,has_criteria,Adult Patients
NCT06373146,involves,Obesity
NCT06373146,evaluates,Tirzepatide
NCT06373146,evaluates,Mibavademab
NCT06373146,measures_primary,Body Weight Change
NCT06373146,measures_secondary,CoEQ Scores
NCT06373146,measures_secondary,FCQ-T-r Scores
NCT06373146,has_criteria,BMI ≥30 kg/m2
NCT06373146,has_criteria,BMI ≤40 kg/m2
NCT06373146,has_criteria,self-injection training
NCT06373146,has_criteria,contraceptive use
NCT02730169,involves,Hypogonadotropic Hypogonadism
NCT02730169,evaluates,BGS649
NCT02730169,measures_primary,Normalised testosterone
NCT02730169,measures_secondary,LH change
NCT02730169,has_criteria,Male Obese Subjects
NCT04442269,involves,Allergic Bronchopulmonary Aspergillosis
NCT04442269,evaluates,Dupilumab
NCT04442269,measures_primary,Change in FEV1
NCT04442269,measures_secondary,Annualized Rate of Exacerbations
NCT04442269,measures_secondary,Annualized Rate of Severe Respiratory Exacerbations
NCT04442269,measures_secondary,Annualized Rate of Severe Respiratory Exacerbations Requiring Hospitalization or Observation
NCT04442269,measures_secondary,Change From Baseline in ACQ-5 Score
NCT04442269,has_criteria,severe respiratory exacerbations
NCT01575769,involves,Polyarticular-Course Juvenile Idiopathic Arthritis
NCT01575769,evaluates,study medication
NCT01575769,measures_primary,JIA ACR 30 Response
NCT01575769,measures_secondary,Percentage of Participants With Adverse Events
NCT01575769,has_criteria,Baseline to 12 weeks after last actual study medication
NCT00542269,involves,Metabolic Syndrome
NCT00542269,evaluates,Aliskiren/Ramipril/Amlodipine
NCT00542269,evaluates,Ramipril/Amlodipine
NCT00542269,evaluates,Aliskiren/Amlodipine
NCT00542269,measures_primary,Change in msSBP
NCT00542269,measures_primary,Change in msDBP
NCT05692869,involves,Healthy Participants
NCT05692869,evaluates,Continuous Blood Pressure Monitoring
NCT05692869,measures_primary,Mean Change in SBP
NCT05692869,measures_secondary,Mean Change in DBP
NCT05692869,has_criteria,BMI 18.0 to 35 kg/m2
NCT05692869,has_criteria,blood pressure
NCT05692869,has_criteria,written informed consent
NCT05692869,has_criteria,no health problems
NCT05692869,has_criteria,no history of sensitive skin
NCT05692869,has_criteria,no drug abuse
NCT05692869,has_criteria,not pregnant or lactating
NCT05692869,has_criteria,no known allergies
NCT05183646,involves,FSGS
NCT05183646,evaluates,DMX-200
NCT05183646,measures_primary,eGFR slope
NCT05183646,measures_primary,urine PCR
NCT05183646,measures_secondary,Incidence AEs
NCT05183646,has_criteria,12 to 80 years old
NCT03317769,involves,schizophrenia
NCT03317769,measures_primary,social functioning
NCT03317769,measures_secondary,negative symptoms
NCT03317769,measures_secondary,quality of life
NCT02277769,involves,Atopic Dermatitis
NCT02277769,evaluates,Dupilumab
NCT02277769,measures_primary,IGA score 0 or 1
NCT02277769,measures_primary,EASI-75
NCT02277769,measures_primary,Pruritus NRS
NCT02277769,measures_secondary,EASI score
NCT02277769,has_criteria,Moderate-to-Severe AD
NCT00760669,involves,Ankylosing Spondylitis
NCT00760669,involves,Rheumatoid Arthritis
NCT00760669,involves,Psoriatic Arthritis
NCT00760669,involves,Psoriasis
NCT00760669,evaluates,Infliximab Injection
NCT00760669,measures_primary,Change From Baseline in BASDAI
NCT00760669,measures_secondary,Erythrocytic Sedimentation Rate
NCT00760669,measures_secondary,C-Reactive Protein
NCT00760669,measures_secondary,Number of Swollen Joints
NCT03766269,involves,Pain
NCT03766269,evaluates,Dronabinol
NCT03766269,measures_primary,Pain intensity
NCT03766269,measures_secondary,Opioid dose
NCT03766269,measures_secondary,Opioid use frequency
NCT03766269,has_criteria,Baseline pain
NCT00445146,involves,HIV-1 Infection
NCT00445146,evaluates,EVG+RTV
NCT00445146,measures_primary,Any Treatment-Emergent
NCT00445146,measures_secondary,Laboratory Abnormality
NCT00445146,measures_secondary,Marked Treatment-Emergent
NCT00445146,has_criteria,qualifying event
NCT03948646,involves,Axillary Hyperhidrosis
NCT03948646,evaluates,Sofpironium Bromide Gel
NCT03948646,measures_primary,Hyperhidrosis Disease Severity
NCT03948646,measures_secondary,Gravimetric Sweat Production
NCT03948646,has_criteria,15% Sofpironium Bromide
NCT01017146,involves,Common Facial Acne
NCT01017146,evaluates,Tazarotene Foam
NCT01017146,measures_primary,Absolute Change in Lesion Counts
NCT01017146,measures_secondary,ISGA Score
NCT01017146,has_criteria,Minimum 2-grade Improvement
NCT01944969,involves,Major Depressive Disorder
NCT01944969,evaluates,Brexpiprazole
NCT01944969,measures_primary,Change in Depressive Symptoms
NCT01944969,measures_secondary,Proportion of Patients in Remission
NCT01944969,measures_secondary,Change in Clinical Global Impression
NCT01944969,measures_secondary,Change in Health-related Quality of Life
NCT01944969,has_criteria,From baseline to Week 52
NCT05413369,involves,Type 2 Diabetes Mellitus
NCT05413369,evaluates,iGlarLixi
NCT05413369,evaluates,IDegAsp
NCT05413369,measures_primary,Change in HbA1c
NCT05413369,measures_secondary,Change in body weight
NCT05413369,measures_secondary,Proportion of participants to reach HbA1c<7%
NCT05413369,measures_secondary,Proportion of participants reaching HbA1c targets <7% without body weight gain
NCT05413369,measures_secondary,Proportion of participants reaching HbA1c < 7% with no body weight gain and no hypoglycemia
NCT05413369,measures_secondary,Change in Fasting plasma glucose
NCT05413369,measures_secondary,Change in 7-point self-monitored plasma glucose profile
NCT05413369,measures_secondary,Proportion of participants reaching HbA1c target <7% with no hypoglycemia
NCT05413369,measures_secondary,Proportions of participants reaching HbA1c target < 7% with no clinically relevant hypoglycaemia
NCT05413369,measures_secondary,Total insulin dose
NCT05413369,measures_secondary,Percentage of participants requiring rescue therapy
NCT05413369,measures_secondary,Incidence and Event rates of hypoglycemia
NCT05413369,measures_secondary,Adverse events
NCT05413369,measures_secondary,Change in fasting C-peptide
NCT05413369,has_criteria,at least 18 years of age
NCT05413369,has_criteria,diagnosed with T2DM
NCT05413369,has_criteria,treated with metformin
NCT06534346,evaluates,DA-302168S
NCT06534346,measures_primary,Number of adverse events
NCT06534346,measures_secondary,Concentration of blood glucose
NCT06534346,has_criteria,Fasting and postprandial blood glucose
NCT02763046,involves,Ankylosing Spondylitis
NCT02763046,evaluates,Secukinumab
NCT02763046,measures_primary,ASAS20 Response
NCT02763046,measures_secondary,ASAS-NSAID Score
NCT02763046,has_criteria,ASAS criteria
NCT06603246,involves,Muco-Obstructive Disease
NCT06603246,evaluates,Inhaled GDC-6988
NCT06603246,measures_primary,Spirometry Abnormalities
NCT06603246,measures_secondary,Plasma concentration GDC-6988
NCT06603246,measures_secondary,Sputum Percent Solids
NCT06603246,measures_secondary,Whole-Lung MCC Scintigraphy
NCT06603246,has_criteria,Baseline up to 6 Weeks
NCT02136069,involves,Ulcerative Colitis
NCT02136069,evaluates,Etrolizumab
NCT02136069,evaluates,Infliximab
NCT02136069,measures_primary,Clinical Remission
NCT02136069,measures_secondary,Clinical Response
NCT02136069,has_criteria,TNF Inhibitors
NCT00267969,involves,Psoriasis
NCT00267969,evaluates,Ustekinumab
NCT00267969,measures_primary,PASI 75% Improvement
NCT00267969,measures_secondary,Physician Global Assessment
NCT00267969,measures_secondary,Dermatology Life Quality Index
NCT00267969,has_criteria,randomly assigned
NCT04547946,involves,Melanoma
NCT04547946,evaluates,Tafinlar® + Mekinist®
NCT04547946,measures_primary,Change from baseline
NCT04547946,measures_secondary,EQ-5D-3L score
NCT04547946,has_criteria,adjuvant treatment
NCT02224846,involves,Erectile Dysfunction
NCT02224846,evaluates,Tadalafil
NCT02224846,measures_primary,Change From Baseline
NCT02224846,measures_secondary,Adverse Event
NCT02224846,has_criteria,Baseline through Month 12
NCT00468546,involves,Rheumatoid Arthritis
NCT00468546,evaluates,MabThera
NCT00468546,evaluates,Methotrexate
NCT00468546,measures_primary,ACR 20 response
NCT00468546,measures_secondary,ACR 50 response
NCT00468546,has_criteria,Anti-Tumor Necrosis Factor Alpha Therapy
NCT01532869,involves,Systemic Sclerosis
NCT01532869,evaluates,RoActemra
NCT01532869,evaluates,Placebo
NCT01532869,measures_primary,mRSS at Week 24
NCT01532869,measures_secondary,Treatment-Emergent Adverse Events
NCT01532869,measures_secondary,Serious Adverse Events
NCT01532869,measures_secondary,SHAQ-DI
NCT01532869,has_criteria,first dose of study drug
NCT04846881,involves,Schizophrenia
NCT04846881,evaluates,Iclepertin
NCT04846881,measures_primary,Change from baseline
NCT04846881,measures_secondary,Virtual Reality Functional Capacity Assessment Tool
NCT04846881,measures_secondary,Tower of London
NCT04846881,has_criteria,Cognitive Impairment Associated with Schizophrenia
NCT06227910,involves,Crohn's Disease
NCT06227910,evaluates,Vedolizumab
NCT06227910,evaluates,Upadacitinib
NCT06227910,measures_primary,Clinical Remission
NCT06227910,measures_secondary,Endoscopic Response
NCT06227910,measures_secondary,PRO2 Remission
NCT06227910,has_criteria,CDAI score < 150
NCT04586010,involves,Relapsing Multiple Sclerosis
NCT04586010,evaluates,Fenebrutinib
NCT04586010,evaluates,Teriflunomide
NCT04586010,measures_primary,Annualized Relapse Rate
NCT04586010,measures_primary,Time to Onset of cCDP12
NCT04586010,measures_primary,Time to Onset of cCDP24
NCT04586010,measures_primary,Time to Onset of CDP12
NCT04586010,measures_primary,Time to Onset of CDP24
NCT04586010,measures_primary,Total Number of Gd+ Lesions
NCT04586010,measures_primary,Percentage Change in Total Brain Volume
NCT04586010,measures_primary,Change in MSIS-29 Physical Scale
NCT04586010,measures_primary,Time to Onset of 12-week Confirmed 4-point worsening in SDMT Score
NCT04586010,measures_secondary,Total Number of Gd+ Lesions
NCT04586010,measures_secondary,Percentage Change in Total Brain Volume
NCT04586010,measures_secondary,Change in MSIS-29 Physical Scale
NCT04586010,measures_secondary,Time to Onset of 12-week Confirmed 4-point worsening in SDMT Score
NCT04586010,has_criteria,Minimum of 96 weeks
NCT04521023,involves,Hypertension
NCT04521023,evaluates,Candemore Plus Tab
NCT04521023,evaluates,Cantabell Tab
NCT04521023,measures_primary,cSBP change after 8 weeks
NCT04521023,measures_primary,cDBP change after 8 weeks
NCT04521023,measures_secondary,sitSBP change after 8 weeks
NCT04521023,measures_secondary,sitDBP change after 8 weeks
NCT04521023,has_criteria,over 19 years old
NCT04521023,has_criteria,informed consent
NCT04521023,has_criteria,Hypertensive Patients
NCT04521023,has_criteria,secondary hypertension
NCT04521023,has_criteria,other trial within 30 days
NCT02016885,involves,Axillary Hyperhidrosis
NCT02016885,evaluates,Glycopyrrolate
NCT02016885,measures_primary,HDSS improvement
NCT02016885,measures_secondary,Gravimetric Sweat Production
NCT02016885,measures_secondary,DLQI
NCT02016885,has_criteria,Minimum 2-grade improvement
NCT02016885,has_criteria,Minimum 1-grade improvement
NCT00806585,involves,Type 2 Diabetes Mellitus
NCT00806585,involves,Hypertension
NCT00806585,evaluates,MK0736
NCT00806585,measures_primary,Change From Baseline in SiDBP
NCT00806585,measures_primary,Change From Baseline in SiSBP
NCT00806585,measures_secondary,Percent Change From Baseline in LDL-C
NCT00806585,measures_secondary,Change From Baseline in Body Weight
NCT00806585,measures_secondary,Change From Baseline in HbA1c
NCT00806585,has_criteria,Fasting weight
NCT02241785,involves,Relapsing Multiple Sclerosis
NCT02241785,evaluates,Natalizumab
NCT02241785,measures_primary,Proportion of NEDA
NCT02241785,measures_secondary,Change in lesion volume
NCT02241785,has_criteria,EDSS progression
NCT03952156,involves,Phenylketonuria
NCT03952156,evaluates,HMI-102
NCT03952156,measures_primary,Plasma Phe Concentration
NCT03952156,measures_secondary,Total protein intake
NCT03952156,has_criteria,Subjects with PKU
NCT00559585,involves,rheumatoid arthritis
NCT00559585,evaluates,Methotrexate
NCT00559585,measures_primary,ACR 20 Response
NCT00559585,measures_primary,ACR 50 Response
NCT00559585,measures_primary,ACR 70 Response
NCT00559585,measures_secondary,Health Assessment Questionnaire Disability Index (HAQ-DI)
NCT00559585,has_criteria,active rheumatoid arthritis
NCT05155085,involves,Atopic Dermatitis
NCT05155085,evaluates,Lirentelimab
NCT05155085,measures_primary,EASI-75 at Week 14
NCT05155085,measures_secondary,IGA Score
NCT05155085,has_criteria,≥18 and ≤80 years
NCT05155085,has_criteria,Chronic AD
NCT05155085,has_criteria,present for at least 3 years
NCT06134115,involves,Primary Knee Osteoarthritis
NCT06134115,evaluates,Lipocet
NCT06134115,measures_primary,Change From Baseline in Pain
NCT06134115,measures_secondary,Change From Baseline in ROM
NCT06134115,measures_secondary,Change From Baseline in WOMAC Total score
NCT06134115,has_criteria,ACR/EULAR criteria
NCT06134115,has_criteria,aged ≥ 40 and ≤80 years
NCT06134115,has_criteria,Kellgren-Lawrence grade 3 or 4
NCT04995315,involves,Pyruvate Kinase Deficiency
NCT04995315,evaluates,Cogstate Brief Battery
NCT04995315,measures_primary,CBB Scores
NCT04995315,measures_secondary,Blood Transfusions
NCT04995315,has_criteria,≥18 years of age
NCT04995315,has_criteria,enrolled in AG348-C-008
NCT03158285,involves,Psoriatic Arthritis
NCT03158285,evaluates,Guselkumab
NCT03158285,measures_primary,ACR 20 response
NCT03158285,measures_secondary,HAQ-DI Score
NCT03158285,has_criteria,Treatment Failure criteria
NCT03998137,involves,Bone Graft
NCT03998137,evaluates,AUGMENT® Injectable Bone Graft
NCT03998137,evaluates,Autologous Bone Graft
NCT03998137,measures_primary,% Bone Bridging
NCT03998137,measures_secondary,AOFAS Hindfoot and Ankle Score
NCT03998137,measures_secondary,Foot Function Index
NCT03998137,has_criteria,Informed consent
NCT01244815,involves,Pediatric Bipolar Disorder
NCT01244815,evaluates,Asenapine
NCT01244815,measures_primary,Change From Baseline in Y-MRS Total Score at Day 21
NCT01244815,measures_secondary,Change from baseline in CGI-BP overall score at Day 21
NCT01244815,has_criteria,Total Y-MRS 50% Responders
NCT02336685,involves,osteoarthritis
NCT02336685,evaluates,Fulranumab
NCT02336685,measures_primary,WOMAC pain score
NCT02336685,measures_primary,WOMAC physical function score
NCT02336685,measures_primary,PGA score
NCT02336685,measures_secondary,WOMAC stiffness score
NCT02336685,measures_secondary,daily NRS score
NCT02336685,measures_secondary,MOS Sleep subscale scores
NCT02336685,has_criteria,hip or knee OA
NCT04867785,involves,Type 2 Diabetes
NCT04867785,evaluates,LY3437943
NCT04867785,measures_primary,Change in HbA1c
NCT04867785,measures_secondary,Percentage of Participants Reaching HbA1c <7.0%
NCT04867785,has_criteria,Baseline HbA1c Group
NCT06497985,involves,MSS/pMMR Colorectal Cancer
NCT06497985,evaluates,Tucidinostat
NCT06497985,measures_primary,Overall Survival
NCT06497985,measures_secondary,Progression Free Survival
NCT06497985,measures_secondary,Overall response rate
NCT06497985,measures_secondary,Duration of response
NCT06497985,measures_secondary,Disease control rate
NCT06497985,measures_secondary,Change From Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life Scale Score
NCT06497985,measures_secondary,Change From Baseline in EuroQoL 5 Dimension 5 Level Health Utility Index Scores
NCT06497985,has_criteria,Up to approximately 2 years
NCT03589885,involves,Plaque Psoriasis
NCT03589885,evaluates,Secukinumab 2 mL Auto-injector
NCT03589885,measures_primary,PASI 75 Response
NCT03589885,measures_secondary,IGA Mod 2011 Response
NCT03589885,measures_secondary,PASI 90 Response
NCT03589885,measures_secondary,PASI 50
NCT03589885,measures_secondary,Successful Self-injection
NCT03589885,measures_secondary,Dermatology Life Quality Index
NCT03589885,has_criteria,moderate to severe
NCT02465437,involves,Systemic Sclerosis
NCT02465437,evaluates,JBT-101
NCT02465437,measures_primary,CRISS score
NCT02465437,measures_secondary,mRSS total score
NCT02465437,has_criteria,renal crisis
NCT01387815,involves,Psoriasis
NCT01387815,evaluates,Humira
NCT01387815,measures_primary,PGA Score ≤1
NCT01387815,measures_secondary,Time to PGA ≤1
NCT01387815,has_criteria,intent to treat
NCT01663415,involves,Metastatic Castration-Resistant Prostate Cancer
NCT01663415,evaluates,Enzalutamide
NCT01663415,measures_primary,Radiographic PFS
NCT01663415,measures_secondary,Overall survival
NCT01663415,measures_secondary,Time to PSA progression
NCT01663415,measures_secondary,Quality of life score
NCT01663415,measures_secondary,Quality of Life score
NCT01663415,measures_secondary,Pain Assessments
NCT01663415,has_criteria,Chemotherapy-Naïve
NCT01847885,involves,Chronic Post-Stroke Shoulder Pain
NCT01847885,evaluates,Electrical Stimulation
NCT01847885,measures_primary,Change From Baseline Shoulder Pain Intensity
NCT01847885,measures_secondary,Shoulder Pain Interference
NCT01847885,has_criteria,Adverse Event Rates
NCT04888585,involves,Rheumatoid Arthritis
NCT04888585,evaluates,ABBV-154
NCT04888585,measures_primary,ACR50 at Week 12
NCT04888585,measures_secondary,Change in DAS28 (CRP)
NCT04888585,measures_secondary,Change in CDAI
NCT04888585,has_criteria,18 to 75 Years of Age
NCT05525715,involves,Atopic Dermatitis
NCT05525715,evaluates,QY201 Tablet
NCT05525715,measures_primary,EASI75 Response
NCT05525715,measures_secondary,vital signs
NCT05525715,has_criteria,treatment emergent adverse events
NCT01814085,involves,Severe Depression
NCT01814085,evaluates,Escitalopram
NCT01814085,measures_primary,Remission at Week 8
NCT01814085,measures_secondary,Clinical Response at Week 8
NCT01814085,measures_secondary,Clinical Onset at Week 8
NCT01814085,measures_secondary,Change from Baseline in MADRS Total Score
NCT01611415,evaluates,Ipragliflozin
NCT01611415,evaluates,Furosemide
NCT01611415,measures_primary,urine sodium excretion
NCT01611415,measures_secondary,pharmacodynamic parameters
NCT01611415,measures_secondary,pharmacokinetics
NCT01611415,has_criteria,Body Mass Index
NCT01611415,has_criteria,liver function tests
NCT01611415,has_criteria,pulse
NCT01611415,has_criteria,blood pressure
NCT01541215,involves,Type 2 Diabetes
NCT01541215,evaluates,Liraglutide
NCT01541215,measures_primary,Change in HbA1c
NCT01541215,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT01541215,measures_secondary,Change From Baseline in Body Mass Index
NCT01541215,has_criteria,All available data
NCT02064985,involves,stable coronary heart disease
NCT02064985,evaluates,ticagrelor
NCT02064985,measures_primary,IPA (final extent)
NCT02064985,measures_secondary,Percent Change From Baseline in PRU
NCT02064985,has_criteria,Chinese patients
NCT03944785,involves,Parkinson's Disease
NCT03944785,evaluates,XADAGO
NCT03944785,measures_primary,Change From Baseline
NCT03944785,measures_secondary,Parkinson's Disease Questionnaire
NCT03944785,measures_secondary,Montreal Cognitive Assessment
NCT03944785,measures_secondary,Treatment Satisfaction Questionnaire
NCT03944785,has_criteria,Baseline to Study Day 60
NCT02245737,involves,Early Alzheimer's Disease
NCT02245737,evaluates,Lanabecestat
NCT02245737,measures_primary,ADAS-Cog13
NCT02245737,measures_secondary,ADCS-iADL
NCT02245737,measures_secondary,FAQ Score
NCT02245737,has_criteria,Baseline
NCT04388215,evaluates,CKD-348
NCT04388215,measures_primary,Change rate in LDL-C
NCT04388215,measures_secondary,Systolic Blood Pressure
NCT04388215,measures_secondary,Diastolic Blood Pressure
NCT04388215,measures_secondary,Total Cholesterol
NCT04388215,measures_secondary,Triglyceride
NCT04388215,measures_secondary,HDL-C
NCT04388215,has_criteria,Blood Pressure < 140/90 mmHg
NCT01278485,involves,Diabetes
NCT01278485,evaluates,MK-0431-402
NCT01278485,measures_primary,Hypoglycemic Episodes
NCT01278485,measures_secondary,Hemoglobin A1c
NCT01278485,measures_secondary,EQ-5D Quality-of-Life
NCT01278485,has_criteria,Hemoglobin A1c <7.0%
NCT05250115,involves,Atopic Dermatitis
NCT05250115,evaluates,Abrocitinib
NCT05250115,measures_primary,IGA of clear
NCT05250115,measures_primary,EASI-75
NCT05250115,measures_secondary,EASI-90
NCT05250115,has_criteria,≥2 points reduction
NCT06489015,involves,Alzheimer's Disease
NCT06489015,evaluates,Recombinant Human Serum Albumin
NCT06489015,measures_primary,ADAS-Cog score
NCT06489015,measures_secondary,CDR-GS
NCT06489015,has_criteria,baseline at Weeks 7
NCT05039515,involves,Fibrodysplasia Ossificans Progressiva
NCT05039515,evaluates,Fidrisertib
NCT05039515,measures_primary,Annualized change in HO volume
NCT05039515,measures_secondary,Incidence of Adverse Events
NCT05039515,has_criteria,Dosage Regimens
NCT03099785,involves,Irritable Bowel Syndrome
NCT03099785,evaluates,Rifamycin SV-MMX®
NCT03099785,measures_primary,relief of abdominal pain
NCT03099785,measures_secondary,relief of global IBS symptoms
NCT03099785,measures_secondary,relief of IBS-related bloating
NCT03099785,has_criteria,daily assessments
NCT05353985,involves,Celiac Disease
NCT05353985,evaluates,TAK-062
NCT05353985,measures_primary,CDSD GI symptom severity
NCT05353985,measures_secondary,Villous Height to Crypt Depth Ratio
NCT05353985,measures_secondary,Treatment-Emergent Adverse Event
NCT05353985,has_criteria,Gluten-Free Diet
NCT02410837,involves,Pneumothorax
NCT02410837,involves,Bronchopulmonary hemorrhage
NCT02410837,involves,Respiratory Failure
NCT02410837,evaluates,superDimension™ Navigation System
NCT02410837,measures_primary,incidence of pneumothorax
NCT02410837,measures_secondary,incidence of bronchopulmonary hemorrhage
NCT02410837,measures_secondary,incidence of respiratory failure
NCT02410837,has_criteria,Grade 2 or higher
NCT00954915,involves,Psoriasis
NCT00954915,evaluates,Teplizumab
NCT00954915,measures_primary,LS-PGA score
NCT00954915,measures_secondary,PASI score
NCT00954915,measures_secondary,Physician's Global Assessment
NCT00954915,has_criteria,Moderate or Severe
NCT06370715,involves,Type 2 Diabetes Mellitus
NCT06370715,evaluates,LY900014
NCT06370715,measures_primary,Percentage of Hypoglycemia
NCT06370715,measures_secondary,Severe Hypoglycemic Events
NCT06370715,measures_secondary,Nocturnal Hypoglycemia Events
NCT06370715,measures_secondary,Nocturnal and Documented Hypoglycemic Events
NCT06370715,measures_secondary,Change from Baseline to Week 26 in Body Weight
NCT06370715,measures_secondary,Change from Baseline to Week 26 in Insulin Treatment Satisfaction Questionnaire (ITSQ) Score
NCT06370715,measures_secondary,Change from Baseline to Week 26 in Hemoglobin A1c (HbA1c)
NCT06370715,measures_secondary,Percentage of Participants Achieving HbA1c Less Than (<) 7%
NCT06370715,has_criteria,Adult Participants
NCT00171015,involves,essential hypertension
NCT00171015,evaluates,Valsartan/Hydrochlorizide
NCT00171015,measures_primary,Change in diastolic BP
NCT00171015,measures_secondary,Change in systolic BP
NCT00171015,has_criteria,MSDBP >100 mmHg and <110 mmHg
NCT00171015,has_criteria,MSDBP >90 mmHg
NCT00171015,has_criteria,MSDBP <110 mmHg
NCT00171015,has_criteria,MSSBP <180 mmHg
NCT00171015,has_criteria,not pregnant or nursing
NCT00171015,has_criteria,able to discontinue antihypertensive medications
NCT02165215,involves,Ulcerative Colitis
NCT02165215,evaluates,Etrolizumab
NCT02165215,measures_primary,Remission at Week 62
NCT02165215,measures_secondary,Improvement From Baseline in Endoscopic Appearance of the Mucosa
NCT02165215,has_criteria,Naive to TNF Inhibitors
NCT04168385,involves,Cholestatic Liver Disease
NCT04168385,evaluates,Maralixibat
NCT04168385,measures_primary,ItchRO(Obs) severity
NCT04168385,measures_primary,ItchRO(Obs) frequency
NCT04168385,measures_secondary,Clinician Scratch Scale
NCT04168385,measures_secondary,serum bile acid levels
NCT04168385,measures_secondary,time to liver-associated outcomes
NCT04168385,measures_secondary,growth
NCT04168385,has_criteria,previously participated
NCT02083185,involves,Prostate Cancer
NCT02083185,evaluates,TAK-385
NCT02083185,measures_primary,Effective Castration Rate
NCT02083185,measures_secondary,Treatment-Emergent Adverse Events
NCT02083185,has_criteria,testosterone concentrations
NCT00323037,involves,Stable Chronic Heart Failure
NCT00323037,evaluates,Coreg CR
NCT00323037,evaluates,Coreg IR
NCT00323037,measures_primary,Change From Baseline in LVESVI
NCT00323037,measures_secondary,Change From Baseline in LVEF
NCT00323037,measures_secondary,Change From Baseline in LVEDV
NCT00323037,measures_secondary,Change From Baseline in LVESV
NCT00323037,measures_secondary,Change From Baseline in LVEDVI
NCT00323037,measures_secondary,Change From Baseline in IVST
NCT00323037,measures_secondary,Change From Baseline in PWT
NCT00323037,measures_secondary,Change From Baseline in LVM
NCT00323037,measures_secondary,Change From Baseline in EDD
NCT00323037,measures_secondary,Change From Baseline in ESD
NCT00323037,measures_secondary,Change From Baseline in Deceleration Time
NCT00323037,measures_secondary,Change From Baseline in E:A Ratio
NCT00323037,measures_secondary,Change From Baseline in BNP Levels
NCT00323037,measures_secondary,Incidence of Hospitalizations
NCT00323037,measures_secondary,Drug Dose Tolerability
NCT00323037,measures_secondary,Treatment Compliance
NCT03933215,involves,Relapsing-remitting multiple sclerosis
NCT03933215,evaluates,cladribine tablets
NCT03933215,measures_primary,Annualized Relapse Rate
NCT03933215,measures_secondary,Treatment Satisfaction Questionnaire
NCT03933215,measures_secondary,Short Form Health Survey
NCT03933215,measures_secondary,Modified Fatigue Impact Scale
NCT03933215,measures_secondary,Beck-Depression Inventory
NCT03933215,measures_secondary,Work Productivity Activity Impairment
NCT03933215,measures_secondary,Patient Determined Disease Steps
NCT03933215,has_criteria,Suboptimally Controlled
NCT05789537,involves,Hemophilia B
NCT05789537,evaluates,SerpinPC
NCT05789537,measures_primary,Annualized Bleeding Rate
NCT05789537,measures_secondary,Haemophilia Quality-of-Life Questionnaire
NCT05789537,has_criteria,Male participants 12-65 years
NCT04247815,involves,Rheumatoid Arthritis
NCT04247815,evaluates,ATI-450 Plus Methotrexate
NCT04247815,evaluates,Methotrexate
NCT04247815,measures_primary,Safety and Tolerability
NCT04247815,measures_secondary,Percent Change in hsCRP
NCT04247815,measures_secondary,Change From Baseline in DAS28
NCT04247815,measures_secondary,Number and Percent of Patients Achieving DAS28-CRP <2.6
NCT04247815,has_criteria,Moderate to Severe Rheumatoid Arthritis
NCT00327015,involves,Type 2 Diabetes
NCT00327015,evaluates,BMS-477118
NCT00327015,evaluates,Metformin
NCT00327015,measures_primary,Change From Baseline in A1C
NCT00327015,measures_primary,Change From Baseline in FPG
NCT00327015,measures_secondary,Percentage of Participants Achieving A1C < 7%
NCT00327015,measures_secondary,Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC)
NCT00327015,has_criteria,Diet and Exercise
NCT03835715,involves,Depression
NCT03835715,evaluates,Vortioxetine
NCT03835715,measures_primary,Oxford Depression Questionnaire
NCT03835715,measures_secondary,Motivation and Energy Inventory
NCT03835715,measures_secondary,Digit-Symbol Substitution Test
NCT03835715,has_criteria,Change from baseline
NCT00653185,involves,Type 2 Diabetes Mellitus
NCT00653185,evaluates,SYR-472
NCT00653185,measures_primary,glycosylated hemoglobin
NCT00653185,measures_secondary,fasting plasma glucose
NCT00653185,measures_secondary,1
NCT00653185,measures_secondary,Proinsulin
NCT00653185,measures_secondary,Proinsulin/insulin ratio
NCT00653185,measures_secondary,C-peptide
NCT00653185,measures_secondary,insulin
NCT00653185,measures_secondary,Homeostasis model assessment of beta cell function
NCT00653185,measures_secondary,Homeostasis model assessment of insulin resistance
NCT00653185,measures_secondary,rescue
NCT00653185,measures_secondary,glycosylated hemoglobin
NCT00653185,measures_secondary,glycosylated hemoglobin
NCT00653185,measures_secondary,Fasting lipids
NCT00653185,measures_secondary,Body weight
NCT00653185,has_criteria,
NCT01873885,involves,Essential Hypertension
NCT01873885,evaluates,Vasomera
NCT01873885,measures_primary,Hemodynamic Parameters
NCT01873885,measures_secondary,Pharmacokinetic Profile
NCT01873885,measures_secondary,Safety and Tolerability
NCT01873885,has_criteria,stage 1 or stage 2
NCT05370885,involves,Ulcerative Colitis
NCT05370885,evaluates,VE202
NCT05370885,measures_primary,Endoscopic response
NCT05370885,measures_secondary,Treatment-Emergent Adverse Events
NCT05370885,has_criteria,8 weeks of treatment
NCT05607056,involves,Antibiotic-associated Diarrhea
NCT05607056,evaluates,Sinquanon
NCT05607056,measures_primary,Incidence of AAD
NCT05607056,measures_secondary,Severity of AAD
NCT05607056,measures_secondary,Duration of diarrhea
NCT05607056,measures_secondary,Antibiotic-associated adverse experiences
NCT05607056,measures_secondary,Visual-analogue scale for the gastrointestinal quality of life
NCT05607056,has_criteria,21+2 days after completion of antibiotic dosing
NCT06458556,involves,urge predominate urinary incontinence
NCT06458556,evaluates,radiofrequency (RF) ablation
NCT06458556,measures_primary,incontinence-related quality of life
NCT06458556,measures_secondary,UDI-6
NCT06458556,has_criteria,subject-reported
NCT00904215,involves,Hypertension
NCT00904215,evaluates,Telmisartan
NCT00904215,evaluates,Telmisartan With HCTZ
NCT00904215,measures_primary,Change in SBP
NCT00904215,measures_primary,Change in DBP
NCT00904215,measures_primary,Change in WHO-QOL
NCT00904215,measures_secondary,Change in VAS
NCT00904215,has_criteria,baseline (visit 1)
NCT00904215,has_criteria,after 12 weeks (visit 3)
NCT04128085,involves,Advanced Malignant Tumors
NCT04128085,evaluates,TQB3804
NCT04128085,measures_primary,Progression Free Survival
NCT04128085,measures_secondary,Objective Response Rate
NCT04128085,measures_secondary,Disease Control Rate
NCT04128085,has_criteria,Baseline up to 52 weeks
NCT00853385,involves,Rheumatoid Arthritis
NCT00853385,evaluates,CP-690
NCT00853385,evaluates,Humira
NCT00853385,evaluates,Placebo
NCT00853385,measures_primary,ACR20 response
NCT00853385,measures_secondary,HAQ-DI
NCT00853385,measures_secondary,DAS28-4 (ESR)
NCT00853385,has_criteria,28-joint count
NCT00730015,involves,Chronic Constipation
NCT00730015,evaluates,Linaclotide
NCT00730015,measures_primary,12-Week CSBM Frequency
NCT00730015,measures_secondary,Stool Consistency
NCT00730015,measures_secondary,Severity of Straining
NCT00730015,measures_secondary,Abdominal Discomfort
NCT00730015,measures_secondary,Bloating
NCT00730015,measures_secondary,Constipation Severity
NCT00730015,has_criteria,baseline frequency
NCT03825315,involves,Plantar Fasciitis
NCT03825315,evaluates,DaxibotulinumtoxinA
NCT03825315,measures_primary,NPRS score at Week 8
NCT03825315,measures_secondary,Foot Function Index
NCT03825315,has_criteria,Change from baseline
NCT02872285,involves,chronic plaque-type psoriasis
NCT02872285,evaluates,LYC-30937-EC
NCT02872285,measures_primary,Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI)
NCT02872285,measures_secondary,Number of Subjects Who Achieve a ≥ 75% Reduction From Baseline in PASI at Week 12
NCT02872285,measures_secondary,Mean Percent Change From Baseline to Week 12 in Percent Body Surface Area (BSA)
NCT02872285,has_criteria,Baseline to Week 12
NCT02263885,involves,Parkinson's Disease
NCT02263885,evaluates,ExAblate Transcranial MRgFUS of the Globus Pallidum
NCT02263885,measures_primary,safety
NCT02263885,measures_secondary,Unified Dyskinesia Rating Scale Total Score
NCT02263885,measures_secondary,Unified Dyskinesia Rating Scale (UDysRS) Part III
NCT02263885,measures_secondary,Movement Disorders Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Motor Exam
NCT02263885,measures_secondary,Mood Disorders Society - Unified Parkinson's Disease Rating Scale Part II
NCT02263885,has_criteria,Screening
NCT02263885,has_criteria,Month 3
NCT02263885,has_criteria,Month 6
NCT02263885,has_criteria,Month 12
NCT02263885,has_criteria,Month 24
NCT06317285,involves,Idiopathic Pulmonary Fibrosis
NCT06317285,evaluates,GSK3915393
NCT06317285,measures_primary,Absolute Change FVC
NCT06317285,measures_secondary,Percent Predicted FVC
NCT06317285,measures_secondary,Relative Decline FVC
NCT06317285,measures_secondary,Adverse Events
NCT06317285,measures_secondary,Clinically Important Findings
NCT06317285,has_criteria,IPF Participants
NCT00790985,involves,Osteoarthritis of the Knee
NCT00790985,evaluates,Flavocoxid
NCT00790985,evaluates,Naproxen
NCT00790985,measures_primary,WOMAC Composite Score
NCT00790985,measures_secondary,Pain
NCT00790985,measures_secondary,Stiffness
NCT00790985,measures_secondary,Physical Function
NCT00790985,has_criteria,Baseline and Week 12
NCT01023256,involves,Rheumatoid Arthritis
NCT01023256,evaluates,MOR103
NCT01023256,measures_primary,Change from baseline DAS28
NCT01023256,measures_secondary,ACR20 response
NCT01023256,has_criteria,ACR improvement criteria
NCT03818256,involves,Obesity
NCT03818256,involves,Schizophrenia
NCT03818256,involves,Bipolar Disorder
NCT03818256,evaluates,Miricorilant
NCT03818256,evaluates,Placebo
NCT03818256,measures_primary,Weight Loss
NCT03818256,measures_secondary,HOMA-IR
NCT03818256,measures_secondary,Waist-to-hip Ratio
NCT03818256,has_criteria,Antipsychotic Medications
NCT01671956,involves,Ulcerative Colitis
NCT01671956,evaluates,Bertilimumab
NCT01671956,measures_primary,Clinical response
NCT01671956,measures_secondary,UCEIS score
NCT01671956,measures_secondary,Clinical remission
NCT01671956,measures_secondary,Mucosal healing
NCT01671956,has_criteria,Age 18-70 years
NCT01671956,has_criteria,Active moderate to severe UC
NCT01671956,has_criteria,Mayo score 6-12
NCT01671956,has_criteria,Endoscopic Finding Sub-score ≥2
NCT01671956,has_criteria,Rectal Bleeding Sub-score ≥1
NCT01671956,has_criteria,PGA Sub-score ≥2
NCT01671956,has_criteria,Eotaxin-1 ≥100 pg/mg
NCT01671956,has_criteria,Adequate cardiac
NCT01671956,has_criteria,No history of colonic surgery
NCT01671956,has_criteria,Not receiving TPN
NCT01671956,has_criteria,Negative Clostridium difficile toxin assay
NCT01671956,has_criteria,Negative TB infection
NCT01671956,has_criteria,Not pregnant or breastfeeding
NCT06323356,involves,Generalized Pustular Psoriasis
NCT06323356,involves,Erythrodermic Psoriasis
NCT06323356,evaluates,TAK-279
NCT06323356,measures_primary,sPGA score at Week 16
NCT06323356,measures_secondary,PASI score at Week 16
NCT06323356,has_criteria,≥2-Point Decrease from Baseline
NCT06323356,measures_primary,sPGA score at Week 52
NCT05382156,involves,Endogenous Cushing's Syndrome
NCT05382156,evaluates,Osilodrostat
NCT05382156,measures_primary,Complete response rate
NCT05382156,measures_primary,Partial response rate
NCT05382156,measures_primary,Overall response rate
NCT05382156,measures_secondary,Pituitary tumour size
NCT05382156,measures_secondary,Adverse Events
NCT05382156,has_criteria,National Cancer Institute-Common Toxicology Criteria
NCT01925209,involves,Sporadic Inclusion Body Myositis
NCT01925209,evaluates,Bimagrumab/BYM338
NCT01925209,measures_primary,6 Minute Walking Distance
NCT01925209,measures_secondary,Quadriceps Quantitative Muscle Testing
NCT01925209,measures_secondary,Sporadic Inclusion Body Myositis Functional Assessment
NCT01925209,measures_secondary,Estimated Annual Number of Falls
NCT01925209,measures_secondary,Short Physical Performance Battery
NCT01254656,involves,HIV-1 Infection
NCT01254656,evaluates,Lersivirine
NCT01254656,measures_primary,HIV-1 RNA level
NCT01254656,measures_secondary,CD4+ Lymphocyte Counts
NCT01254656,has_criteria,Completed Treatment
NCT01755156,involves,Type 2 Diabetes Mellitus
NCT01755156,evaluates,Omarigliptin
NCT01755156,measures_primary,Change From Baseline in A1C
NCT01755156,measures_secondary,Percentage of Participants Who Experienced at Least One Adverse Event
NCT01755156,measures_secondary,Percentage of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT01755156,measures_secondary,Percentage of Participants Who Experienced an Adverse Event Which Were Included Under the System Order Class of Investigations
NCT01755156,has_criteria,Inadequate Glycemic Control
NCT04620356,involves,Nocturnal Enuresis
NCT04620356,evaluates,DryNites Absorbent Pants
NCT04620356,measures_primary,Wet nights
NCT04620356,measures_secondary,Emotional wellbeing
NCT04620356,measures_secondary,Parent/carer quality of life
NCT04620356,has_criteria,Child daytime sleepiness
NCT02351856,involves,LMNA-Related Dilated Cardiomyopathy
NCT02351856,evaluates,ARRY-371797
NCT02351856,measures_primary,Change From Baseline
NCT02351856,measures_secondary,Laboratory Hematology Test Results
NCT02351856,has_criteria,Baseline up to 30 days
NCT03697109,involves,Endogenous Cushing Syndrome
NCT03697109,evaluates,Relacorilant
NCT03697109,measures_primary,change in HbA1c
NCT03697109,measures_secondary,change in glucose
NCT03697109,has_criteria,HbA1c at Baseline >6.5%
NCT04678856,involves,Chronic Rhinosinusitis with Nasal Polyps
NCT04678856,evaluates,Dupilumab
NCT04678856,measures_primary,Sinus opacification
NCT04678856,measures_secondary,sTSS
NCT04678856,measures_secondary,Adverse events
NCT04678856,has_criteria,Age ≥18 years
NCT04678856,has_criteria,Bilateral sinus inflammation
NCT04678856,has_criteria,LMK ≥8
NCT04678856,has_criteria,Ethmoid opacification
NCT04678856,has_criteria,Loss of smell
NCT04678856,has_criteria,Rhinorrhea
NCT01541956,involves,Type 2 Diabetes
NCT01541956,evaluates,Vildagliptin
NCT01541956,measures_primary,Change from baseline HbA1c
NCT01541956,measures_secondary,Percentage of patients achieving target HbA1c
NCT01541956,measures_secondary,Mean change from baseline FPG
NCT01541956,measures_secondary,Mean change from baseline PPG
NCT01541956,measures_secondary,Number of patients with adverse events
NCT01541956,has_criteria,Body Mass Index (BMI)
NCT01541956,has_criteria,Age
NCT02275156,involves,Severe Renal Impairment
NCT02275156,involves,End-stage Renal Disease
NCT02275156,evaluates,Evolocumab
NCT02275156,measures_primary,Maximum Observed Serum Concentration
NCT02275156,measures_primary,Area Under the Concentration-time Curve
NCT02275156,measures_secondary,Number of Participants With Adverse Events
NCT02275156,measures_secondary,Number of Participants With Clinically Relevant Vital Sign or Clinical Laboratory Changes
NCT02275156,measures_secondary,Number of Participants With Anti-evolocumab Antibodies
NCT02275156,has_criteria,life threatening
NCT02275156,has_criteria,requires in patient hospitalization
NCT02275156,has_criteria,persistent or significant disability/incapacity
NCT01288209,involves,Hepatitis C
NCT01288209,evaluates,TMC435
NCT01288209,measures_primary,SVR12
NCT01288209,measures_secondary,SVR24
NCT01288209,measures_secondary,HCV RNA drop
NCT01288209,measures_secondary,Undetectable HCV RNA
NCT00348309,involves,Alzheimer's Disease
NCT00348309,evaluates,Rosiglitazone
NCT00348309,measures_primary,Change From Baseline in ADAS-Cog Total Score
NCT00348309,measures_secondary,Change From Baseline in CDR-SB
NCT00348309,measures_secondary,Change From Baseline in DAD Total Score
NCT00348309,has_criteria,APOE4 negative
NCT02531009,involves,Systemic Sclerosis
NCT02531009,evaluates,
NCT02531009,measures_primary,UCLA-SCTC GIT score
NCT02531009,measures_secondary,
NCT02531009,has_criteria,
NCT01688037,involves,Tardive Dyskinesia
NCT01688037,involves,Schizophrenia
NCT01688037,involves,Schizoaffective Disorder
NCT01688037,evaluates,NBI-98854
NCT01688037,measures_primary,AIMS Dyskinesia Total Score Change
NCT01688037,measures_secondary,CGI-TD
NCT01688037,has_criteria,Baseline and Week 6
NCT03806452,involves,Sickle cell disease
NCT03806452,evaluates,Siklos
NCT03806452,measures_primary,ACR decrease 30%
NCT03806452,measures_secondary,eGFR change
NCT03806452,measures_secondary,ACR change
NCT03806452,measures_secondary,Albuminuria shift
NCT03806452,measures_secondary,ACR evolution curve
NCT03806452,measures_secondary,eGFR evolution curve
NCT03806452,measures_secondary,Clinical markers
NCT03806452,measures_secondary,Biological markers
NCT03806452,has_criteria,Sickle cell disease related organopathy
NCT01071252,involves,Chronic Plaque-type Psoriasis
NCT01071252,evaluates,AIN457
NCT01071252,measures_primary,PASI 75 Achievement
NCT01071252,measures_secondary,Investigator's Global Assessment
NCT01071252,measures_secondary,PASI 50
NCT01071252,measures_secondary,PASI 75
NCT01071252,measures_secondary,PASI 90
NCT01071252,measures_secondary,Time to Relapse
NCT01071252,has_criteria,maximum PASI change
NCT04444752,involves,atopic dermatitis
NCT04444752,evaluates,CBP-201
NCT04444752,measures_primary,Percent Reduction in EASI
NCT04444752,measures_secondary,vIGA of 0/1
NCT04444752,measures_secondary,Response Rate
NCT04444752,has_criteria,adult ≥18 and ≤ 75 years
NCT04218552,involves,Essential Hypertension
NCT04218552,evaluates,AD-209
NCT04218552,measures_primary,Change rate of MSSBP
NCT04218552,measures_secondary,Proportion of BP normalization
NCT04218552,measures_secondary,Reaction rate of BP
NCT04218552,has_criteria,MSSBP/MSDBP < 140/90 mmHg
NCT04218552,has_criteria,MSSBP/MSDBP < 130/80 mmHg
NCT00546052,involves,Metabolic Syndrome
NCT00546052,involves,Hypertension
NCT00546052,evaluates,Losartan
NCT00546052,evaluates,HCTZ
NCT00546052,measures_primary,Change in Hemoglobin A1c
NCT00546052,measures_secondary,Change in Fasting Blood Glucose
NCT00546052,measures_secondary,Target Blood Pressure
NCT00546052,measures_secondary,Change in Systolic Blood Pressure
NCT00546052,measures_secondary,Change in Diastolic Blood Pressure
NCT00546052,has_criteria,Adult Patient
NCT00546052,has_criteria,Waist circumference
NCT00546052,has_criteria,BMI
NCT00546052,has_criteria,Untreated hypertension
NCT00546052,has_criteria,Controlled hypertension
NCT03896152,involves,Paroxysmal nocturnal hemoglobinuria
NCT03896152,evaluates,iptacopan
NCT03896152,measures_primary,LDH reduction
NCT03896152,measures_secondary,Hemoglobin
NCT03896152,measures_secondary,Free Hemoglobin
NCT03896152,measures_secondary,Carboxyhemoglobin
NCT03896152,measures_secondary,Absolute Reticulocyte Count
NCT03896152,has_criteria,LDH ≥ 1.5x ULN
NCT05536752,involves,Dry AMD
NCT05536752,measures_primary,Change from baseline in BCVA
NCT05536752,measures_secondary,Change from baseline in drusen volume
NCT03460652,involves,ADHD
NCT03460652,evaluates,KP415
NCT03460652,measures_primary,Change From Baseline
NCT03460652,measures_secondary,CGI-S
NCT03460652,measures_secondary,Children's Sleep Habits Questionnaire
NCT03460652,has_criteria,DSM-5 criteria for ADHD
NCT06037252,involves,Type 2 Diabetes
NCT06037252,involves,Obesity
NCT06037252,evaluates,Tirzepatide
NCT06037252,evaluates,LY3298176
NCT06037252,measures_primary,Percent Change Body Weight
NCT06037252,measures_secondary,Change from Baseline HbA1c
NCT06037252,measures_secondary,Body Mass Index
NCT06037252,measures_secondary,Waist Circumference
NCT06037252,has_criteria,Body Mass Index ≥35 kg/m²
NCT06037252,has_criteria,Stable body weight (±5%)
NCT06037252,has_criteria,Type 2 Diabetes
NCT06037252,has_criteria,Stable metformin treatment ≥1500 mg/day
NCT06037252,has_criteria,No Type 1 Diabetes
NCT06037252,has_criteria,No history of ketoacidosis
NCT06037252,has_criteria,No severe hypoglycemia within 6 months
NCT00531752,involves,Attention Deficit Hyperactivity Disorder
NCT00531752,evaluates,PF-03654746
NCT00531752,measures_primary,Change From Baseline
NCT00531752,measures_secondary,Percentage of Participants
NCT00531752,has_criteria,Adult
NCT01741532,involves,Pantothenate Kinase-associated Neurodegeneration
NCT01741532,evaluates,Deferiprone
NCT01741532,measures_primary,Change in BAD total score
NCT01741532,measures_primary,Change in UPDRS
NCT01741532,measures_secondary,Change in FIM
NCT01741532,measures_secondary,Patient Global Impression of Improvement
NCT01741532,has_criteria,Baseline to 18 Months
NCT02477332,involves,CSU
NCT02477332,evaluates,ligelizumab
NCT02477332,measures_primary,Complete Hives Response
NCT02477332,measures_secondary,Change From Baseline in Hives Severity Score
NCT02477332,has_criteria,Week 12
NCT00857532,involves,Parkinson's Disease
NCT00857532,evaluates,Florbetapir F 18 PET Imaging
NCT00857532,measures_primary,global amyloid burden
NCT00857532,measures_secondary,cognitive decline
NCT00857532,has_criteria,age and education adjusted DRS-2
NCT03954132,involves,Chronic Obstructive Pulmonary Disease
NCT03954132,evaluates,Spiolto® Respimat®
NCT03954132,evaluates,Triple Combination Therapy
NCT03954132,measures_primary,Change in mMRC Score
NCT03954132,measures_secondary,Change in CATᵀᴹ Score
NCT03954132,has_criteria,Minimum Clinically Important Difference
NCT03467152,involves,Dementia With Lewy Bodies
NCT03467152,evaluates,Irsenontrine
NCT03467152,measures_primary,Change From Baseline in MoCA Total Score
NCT03467152,measures_secondary,CIBIC-Plus Scale
NCT03467152,measures_secondary,CGIC-DLB Scale
NCT03467152,has_criteria,Clinician's Interview Based Impression
NCT00661700,involves,Erectile Dysfunction
NCT00661700,evaluates,vardenafil
NCT00661700,measures_primary,IIEF EF domain
NCT00661700,measures_secondary,Global Assessment Question
NCT00661700,has_criteria,premature termination
NCT01644500,involves,Type 2 Diabetes Mellitus
NCT01644500,evaluates,Dulaglutide
NCT01644500,evaluates,Glimepiride
NCT01644500,measures_primary,Change From Baseline in HbA1c
NCT01644500,measures_secondary,Percentage of Participants Attaining HbA1c of <7% or ≤6.5%
NCT01644500,measures_secondary,Change From Baseline in Fasting Blood Glucose
NCT01644500,measures_secondary,Change From Baseline in 7-point Self-monitored Blood Glucose Profiles
NCT01644500,has_criteria,pre-study therapy stratum
NCT00400400,involves,Renal Transplant
NCT00400400,evaluates,Enteric-coated Mycophenolate Sodium
NCT00400400,evaluates,Mycophenolate Mofetil
NCT00400400,measures_primary,Change From Baseline to Day 30
NCT00400400,measures_secondary,Number of Participants With Biopsy-proven Acute Rejection
NCT00400400,measures_secondary,Number of Participants With Treated Acute Rejection
NCT00400400,has_criteria,Gastrointestinal Intolerance
NCT00689052,involves,Fibromyalgia
NCT00689052,evaluates,Pramipexole ER
NCT00689052,evaluates,Placebo
NCT00689052,measures_primary,24-hour Average Pain Score
NCT00689052,measures_secondary,Patient's Global Impression of Improvement
NCT00689052,measures_secondary,Short Form 36
NCT00689052,has_criteria,Baseline and Week 29
NCT00689052,has_criteria,30% or 50% Improvement
NCT01903252,involves,Ulcerative Colitis
NCT01903252,evaluates,TP05
NCT01903252,measures_primary,Clinical Remission
NCT01903252,measures_secondary,Clinical Response
NCT01903252,has_criteria,Decrease in PMCS
NCT06398652,involves,Plaque Psoriasis
NCT06398652,evaluates,CMAB015
NCT06398652,evaluates,Secukinumab
NCT06398652,measures_primary,PASI 75 at week 12
NCT06398652,measures_secondary,IGA (mod 2011) 0/1 at week 12
NCT06398652,measures_secondary,IGA (mod 2011) 0/1 at week 52
NCT06398652,has_criteria,moderate to severe
NCT02666352,involves,Hepatic Insufficiency
NCT02666352,evaluates,Uprifosbuvir
NCT02666352,evaluates,Ruzasvir
NCT02666352,measures_primary,AUC0-last
NCT02666352,measures_primary,AUC0-inf
NCT02666352,measures_primary,AUC0-24hr
NCT02666352,measures_primary,Cmax
NCT02666352,measures_primary,C24hr
NCT05312632,involves,Parkinson's Disease
NCT05312632,evaluates,Safinamide Mesilate
NCT05312632,measures_primary,"Change From Baseline in Daily ""OFF"" Time"
NCT05312632,measures_secondary,Change From Baseline in PDQ-39 Score
NCT05312632,measures_secondary,Change From Baseline in MDS-UPDRS Part 3
NCT05312632,has_criteria,Motor Fluctuation
NCT05094700,involves,sensitive skin
NCT05094700,evaluates,Polymeric Surfactant Technology Cleanser
NCT05094700,measures_primary,skin tolerability
NCT05094700,measures_secondary,skin efficacy
NCT05094700,has_criteria,eczema/atopic dermatitis
NCT04214652,involves,Acne Vulgaris
NCT04214652,evaluates,IDP-126 Gel
NCT04214652,measures_primary,Inflammatory Lesion Count
NCT04214652,measures_secondary,Noninflammatory Lesion Count
NCT04214652,has_criteria,9 years of age
NCT04214652,has_criteria,Informed consent
NCT04214652,has_criteria,EGSS 3 or 4
NCT04214652,has_criteria,30 to 100 inflammatory lesions
NCT04214652,has_criteria,35 to 150 non-inflammatory lesions
NCT04214652,has_criteria,2 or fewer nodules
NCT03697252,involves,Schizophrenia
NCT03697252,evaluates,KarXT
NCT03697252,measures_primary,PANSS total score
NCT03697252,measures_secondary,PANSS positive score
NCT03697252,measures_secondary,PANSS negative score
NCT03697252,measures_secondary,CGI-S score
NCT03697252,has_criteria,Adult patients
NCT03981900,involves,Rheumatoid Arthritis
NCT03981900,evaluates,Tofacitinib
NCT03981900,measures_primary,Drug survival duration
NCT03981900,measures_secondary,Total Pain Catastrophising Scale
NCT03981900,measures_secondary,Coping Strategies Questionnaire
NCT03981900,has_criteria,Permanent drug discontinuation
NCT01569152,involves,Rheumatoid Arthritis
NCT01569152,evaluates,MK-8457
NCT01569152,evaluates,Methotrexate
NCT01569152,measures_primary,ACR20 response
NCT01569152,measures_secondary,DAS28-ESR
NCT01569152,has_criteria,Active Rheumatoid Arthritis
NCT03395132,involves,Atopic Dermatitis
NCT03395132,evaluates,Fucicort® Lipid Cream
NCT03395132,measures_primary,m-EASI at Day 15
NCT03395132,measures_secondary,Investigator's Global Assessment
NCT03395132,has_criteria,moderate' disease at baseline
NCT04092452,involves,Hidradenitis Suppurativa
NCT04092452,evaluates,PF-06650833
NCT04092452,evaluates,PF-06700841
NCT04092452,evaluates,PF 06826647
NCT04092452,measures_primary,HiSCR response
NCT04092452,measures_secondary,AN count
NCT04092452,measures_secondary,IHS4 score
NCT04092452,has_criteria,Minimum Risk
NCT06141200,involves,Essential Hypertension
NCT06141200,evaluates,NW Roselle
NCT06141200,measures_primary,Systolic Blood Pressure Paired Change
NCT06141200,measures_primary,Diastolic Blood Pressure Paired Change
NCT06141200,measures_secondary,Rate of achieving blood pressure levels
NCT06141200,measures_secondary,Rate of achieving systolic blood pressure range
NCT06141200,measures_secondary,Rate of achieving diastolic blood pressure range
NCT06141200,measures_secondary,Compliance Rate
NCT06141200,measures_secondary,Adverse events rate
NCT06141200,has_criteria,Grade 1 essential hypertension
NCT01709500,involves,Heterozygous Familial Hypercholesterolemia
NCT01709500,evaluates,Alirocumab
NCT01709500,measures_primary,Percent Change LDL-C
NCT01709500,measures_secondary,Apolipoprotein B
NCT01709500,has_criteria,Lipid-Modifying Therapy
NCT05933200,involves,LC-FAOD
NCT05933200,evaluates,Triheptanoin
NCT05933200,evaluates,Even-chain
NCT05933200,measures_primary,Annualized Event Rate
NCT05933200,measures_primary,Annualized Duration
NCT05933200,measures_secondary,Hypoglycemic Event-rate
NCT05933200,measures_secondary,Clinician-reported Change
NCT05933200,measures_secondary,Left Ventricular Ejection Fraction
NCT05933200,measures_secondary,Left Ventricular Systolic Volume
NCT05933200,measures_secondary,Left Ventricular Wall Mass
NCT05933200,measures_secondary,Hepatic Proton Density Fat Fraction
NCT05933200,measures_secondary,Creatine Kinase/Alanine Aminotransferase
NCT05933200,measures_secondary,Alanine Aminotransferase
NCT05933200,measures_secondary,Aspartate Aminotransferase
NCT05933200,measures_secondary,Annualized Frequency of Rhabdomyolysis
NCT05933200,measures_secondary,Annualized Duration of Rhabdomyolysis
NCT05933200,measures_secondary,Caregiver-reported Pediatric Quality of Life Inventory
NCT05933200,measures_secondary,PedsQL Infant Scale Score
NCT05933200,has_criteria,Pediatric Patients
NCT00663052,involves,Psoriasis
NCT00663052,evaluates,Etanercept
NCT00663052,measures_primary,PASI 75% improvement
NCT00663052,measures_secondary,PASI 50% improvement
NCT00663052,has_criteria,Moderate to Severe Psoriasis
NCT00839852,involves,Chronic Stable Schizophrenia
NCT00839852,evaluates,Cariprazine
NCT00839852,measures_primary,PANSS Total Score
NCT00839852,measures_secondary,CGI-S Score
NCT00839852,has_criteria,Baseline to Week 48
NCT04166552,involves,Diffuse Cutaneous Systemic Sclerosis
NCT04166552,evaluates,EHP-101
NCT04166552,measures_primary,ACR CRISS score
NCT04166552,measures_secondary,modified Rodnan Skin Score
NCT04166552,has_criteria,renal crisis
NCT06152237,involves,Rett Syndrome
NCT06152237,evaluates,TSHA-102
NCT06152237,measures_primary,incidence of AEs
NCT06152237,measures_secondary,Change from baseline
NCT06152237,has_criteria,Pediatric Females
NCT01589237,involves,Familial Chylomicronemia Syndrome
NCT01589237,evaluates,LCQ908
NCT01589237,measures_primary,Triglyceride Levels
NCT01589237,measures_secondary,Cholesterol Levels
NCT01589237,measures_secondary,HDL Cholesterol Levels
NCT01589237,measures_secondary,Non HDL Cholesterol Levels
NCT01589237,has_criteria,Fasting lipid panel
NCT01529515,involves,Schizophrenia
NCT01529515,evaluates,Paliperidone Palmitate
NCT01529515,measures_primary,Time to relapse
NCT01529515,measures_secondary,PANSS Total Score
NCT01529515,measures_secondary,CGI-S Scale
NCT01529515,measures_secondary,PSP Scale
NCT01529515,has_criteria,Baseline (Day 1)
NCT01529515,has_criteria,Endpoint (Approximately Week 60)
NCT01012037,involves,Type 2 Diabetes
NCT01012037,evaluates,Linagliptin
NCT01012037,measures_primary,HbA1c Change
NCT01012037,measures_secondary,FPG Change
NCT01012037,has_criteria,prior oral antidiabetics
NCT03028415,involves,Ankle Fusion
NCT03028415,evaluates,AMPLEX
NCT03028415,measures_primary,Radiographic Fusion Success
NCT03028415,measures_secondary,Pain on weight-bearing
NCT03028415,has_criteria,≥50% bone bridging
NCT04800315,involves,Atopic Dermatitis
NCT04800315,evaluates,Cendakimab
NCT04800315,measures_primary,EASI at Week 16
NCT04800315,measures_secondary,vIGA-AD Score
NCT04800315,has_criteria,vIGA-AD response
NCT06603285,involves,pulmonary hypertension
NCT06603285,evaluates,Remodulin
NCT06603285,measures_primary,NT-proBNP change
NCT06603285,measures_secondary,WHO functional class
NCT06603285,measures_secondary,6-minute walk distance
NCT06603285,has_criteria,daily doses administered
NCT04830215,involves,Major Depressive Disorder
NCT04830215,evaluates,Brexpiprazole
NCT04830215,measures_primary,Change From Baseline
NCT04830215,measures_secondary,IDS-SR Total Score
NCT04830215,has_criteria,Baseline to Week 8
NCT01520285,involves,Hypertension
NCT01520285,evaluates,Lercanidipine Hydrochloride Tablet
NCT01520285,evaluates,Felodipine Sustained-Release Tablet
NCT01520285,measures_primary,Change in diastolic blood pressure
NCT01520285,measures_primary,Change in systolic blood pressure
NCT01520285,measures_secondary,Normalization rate
NCT01520285,has_criteria,SBP<140mmHg
NCT01520285,has_criteria,DBP<90mmHg
NCT01520285,has_criteria,mean BP<130/80 mm Hg
NCT01520285,has_criteria,mean BP<135/85 mm Hg
NCT04766385,involves,Hyperphosphatemia
NCT04766385,evaluates,KHK7791
NCT04766385,measures_primary,serum phosphorous levels
NCT04766385,measures_secondary,Ca × P product levels
NCT04766385,has_criteria,target serum phosphorus level
NCT01104415,involves,Carcinoid Syndrome
NCT01104415,evaluates,Telotristat Etiprate
NCT01104415,measures_primary,Bowel Movements
NCT01104415,measures_secondary,Stool Form/Consistency
NCT01104415,has_criteria,non-missing assessment
NCT02413515,involves,Hypertension
NCT02413515,evaluates,Nifedipine GITs 60mg
NCT02413515,measures_primary,Mean Sitting SBP
NCT02413515,measures_secondary,Mean Sitting DBP
NCT02413515,has_criteria,Aged 18-65 years
NCT01594515,involves,Healthy Male Volunteers
NCT01594515,evaluates,BI 1015550
NCT01594515,measures_primary,Number (%) of Subjects
NCT01594515,measures_secondary,Percentage of subjects
NCT01594515,has_criteria,Informed consent
NCT04311515,involves,Mild AD Dementia
NCT04311515,evaluates,PU AD
NCT04311515,measures_primary,Change from baseline
NCT04311515,measures_secondary,Incidence of Adverse Events
NCT04311515,measures_secondary,Serious adverse events
NCT04311515,has_criteria,Pharmacologic parameters
NCT00363415,involves,Extensive-Stage Small Cell Lung Cancer
NCT00363415,evaluates,Pemetrexed and Carboplatin
NCT00363415,evaluates,Etoposide Carboplatin
NCT00363415,measures_primary,Overall Survival
NCT00363415,measures_secondary,Progression Free Survival
NCT00363415,measures_secondary,Change From Baseline to Each Cycle in Functional Assessment of Cancer Therapy - Lung (FACT-L)
NCT00363415,has_criteria,baseline to date of death from any cause (up to 19.6 months)
NCT00363415,has_criteria,baseline to measured progressive disease (up to 14.7 months)
NCT00363415,has_criteria,baseline and 6 cycles (21-day cycles)
NCT05073315,involves,Plaque Psoriasis
NCT05073315,evaluates,ABP 501
NCT05073315,evaluates,Humira
NCT05073315,measures_primary,PASI Percent Improvement
NCT05073315,measures_secondary,Number of Participants Achieving PASI 75 Response
NCT05073315,has_criteria,Moderate to Severe
NCT03738215,involves,Major Depressive Disorder
NCT03738215,evaluates,Cariprazine
NCT03738215,measures_primary,MADRS total score
NCT03738215,measures_secondary,CGI-S Score
NCT03738215,has_criteria,randomized participants
NCT05935215,involves,Atypical Hemolytic Uremic Syndrome
NCT05935215,evaluates,Iptacopan
NCT05935215,measures_primary,TMA manifestation
NCT05935215,measures_secondary,Platelets
NCT05935215,measures_secondary,LDH
NCT05935215,measures_secondary,hemoglobin
NCT05935215,measures_secondary,serum creatinine
NCT05935215,measures_secondary,UPCR
NCT05935215,has_criteria,functionally significant mutations
NCT05985915,involves,Sjogrens Syndrome
NCT05985915,evaluates,Ianalumab
NCT05985915,measures_primary,ESSDAI change
NCT05985915,measures_secondary,ESSPRI
NCT05985915,measures_secondary,SSSD
NCT05985915,has_criteria,active Sjogrens syndrome
NCT01706315,evaluates,GSK2140944
NCT01706315,measures_primary,change from baseline
NCT01706315,measures_secondary,adverse events
NCT01706315,has_criteria,Healthy Adult Subjects
NCT03359837,involves,Type 2 Diabetes
NCT03359837,evaluates,Two Treatment Regimens
NCT03359837,measures_primary,Change in HbA1c
NCT03359837,measures_secondary,Change in FPG from baseline
NCT03359837,has_criteria,FPG <6.1 mmol/L
NCT03359837,has_criteria,FPG <7 mmol/L
NCT03359837,has_criteria,HbA1c <7%
NCT00605215,involves,Relapsing-Remitting Multiple Sclerosis
NCT00605215,evaluates,Laquinimod
NCT00605215,measures_primary,Annualized Relapse Rate
NCT00605215,measures_secondary,Change From Baseline in Disability
NCT00605215,has_criteria,Baseline up to Month 24
NCT01582815,involves,Depression
NCT01582815,involves,Anxiety Symptoms
NCT01582815,evaluates,JNJ-40411813
NCT01582815,measures_primary,HAM-A6 score
NCT01582815,measures_primary,HDRS17 total score
NCT01582815,measures_primary,SIGH-A total score
NCT01582815,measures_primary,CGI-I scale
NCT01582815,measures_secondary,HDRS17 anxiety/somatization factor
NCT01582815,has_criteria,Baseline
NCT02657915,involves,Multiple Sclerosis
NCT02657915,evaluates,Remyelinating Therapy
NCT02657915,measures_primary,Time to CDMS
NCT02657915,measures_secondary,EDSS score
NCT02657915,has_criteria,neurologic events
NCT05225415,involves,Dementia With Lewy Bodies
NCT05225415,evaluates,CT1812
NCT05225415,measures_primary,Montreal Cognitive Assessment Scale
NCT05225415,measures_secondary,Epworth Sleepiness Scale
NCT05225415,measures_secondary,Clinician Assessment of Fluctuation
NCT05225415,measures_secondary,ADCS-Clinical Global Impression of Change
NCT05225415,measures_secondary,ADCS - Activities of Daily Living
NCT05225415,measures_secondary,Movement Disorder Society - United Parkinson's Disease Rating Scale Part III
NCT05225415,measures_secondary,Cognitive Drug Research Battery
NCT05225415,has_criteria,Mild to Moderate
NCT06512337,involves,Moderate Plaque Psoriasis
NCT06512337,evaluates,Deucravacitinib
NCT06512337,measures_primary,sPGA 0/1 score
NCT06512337,measures_secondary,PASI score
NCT06512337,measures_secondary,Psoriasis BSA involvement
NCT06512337,has_criteria,Participant psoriasis BSA
NCT03333915,involves,Advanced Solid Tumors
NCT03333915,evaluates,Pamiparib
NCT03333915,measures_primary,Objective Response Rate
NCT03333915,measures_secondary,Treatment-Emergent Adverse Events
NCT03333915,has_criteria,High Grade Ovarian Cancer
NCT02193815,involves,plaque psoriasis
NCT02193815,evaluates,PF-06263276 4% Solution
NCT02193815,measures_primary,Psoriatic skin thickness
NCT02193815,measures_secondary,Area Under the Curve
NCT02193815,has_criteria,Healthy male and/or female
NCT01623115,involves,Heterozygous Familial Hypercholesterolemia
NCT01623115,evaluates,Alirocumab
NCT01623115,measures_primary,LDL-C at Week 24
NCT01623115,measures_secondary,Apolipoprotein B (Apo B) at Week 24
NCT01623115,has_criteria,Lipid-Modifying Therapy
NCT02446015,involves,Dry Eye
NCT02446015,evaluates,SYSTANE® ULTRA
NCT02446015,measures_primary,Change From Baseline in TOSS Score
NCT02446015,measures_secondary,Change From Baseline in IDEEL SB Score
NCT02446015,measures_secondary,Change From Baseline in IDEEL Treatment Satisfaction Scores
NCT02446015,has_criteria,One eye per subject
NCT01032915,involves,Quiescent Non-infectious Uveitis
NCT01032915,evaluates,AIN457
NCT01032915,measures_primary,Time to Recurrence
NCT01032915,measures_secondary,Composite Immunosuppressive Medication Score
NCT01032915,has_criteria,Immunosuppressive agents
NCT00358215,involves,Heart Failure
NCT00358215,evaluates,Darbepoetin Alfa
NCT00358215,measures_primary,Time to death or hospitalization
NCT00358215,measures_secondary,Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score
NCT00358215,has_criteria,From randomization to end of study
NCT01240915,involves,Ulcerative Colitis
NCT01240915,evaluates,Multistem(r)
NCT01240915,measures_primary,Change From Baseline in Endoscopic Score
NCT01240915,measures_secondary,Change From Baseline in Rectal Bleeding Mayo Subscore
NCT01240915,measures_secondary,Number of Participants With Treatment-Emergent Adverse Events
NCT01240915,has_criteria,Baseline up to Week 52
NCT01952015,involves,Generalized Pustular Psoriasis
NCT01952015,evaluates,Secukinumab
NCT01952015,measures_primary,Clinical global impression
NCT01952015,measures_secondary,JDA Total Score
NCT01952015,has_criteria,Japanese Subjects
NCT04306315,involves,Plaque Psoriasis
NCT04306315,evaluates,Brodalumab
NCT04306315,measures_primary,PASI 90 response
NCT04306315,measures_secondary,sPGA score
NCT04306315,has_criteria,≥120 Kg Body Weight
NCT05758415,involves,Rotator Cuff Tendinopathy
NCT05758415,evaluates,Secukinumab
NCT05758415,measures_primary,WORC PSD score
NCT05758415,measures_secondary,PROMIS-SF Upper Extremity score
NCT05758415,has_criteria,moderate to severe RCT
NCT05688852,involves,Crohn's Disease
NCT05688852,evaluates,VTX958
NCT05688852,measures_primary,Change in CDAI
NCT05688852,measures_secondary,Endoscopic response
NCT05688852,measures_secondary,Simple endoscopic score
NCT05688852,has_criteria,Screening to week 12
NCT01641952,involves,Rheumatoid Arthritis
NCT01641952,evaluates,MabThera/Rituxan
NCT01641952,measures_primary,DAS28 response
NCT01641952,measures_secondary,DAS28 score
NCT01641952,has_criteria,Anti-TNF agent intolerance
NCT00624052,involves,Hypertension
NCT00624052,evaluates,telmisartan40mg+amlodipine10mg
NCT00624052,evaluates,telmisartan80mg+amlodipine10 mg
NCT00624052,measures_primary,DBP Control
NCT00624052,measures_primary,SBP Control
NCT00624052,measures_secondary,Change From Baseline to End of Study in Trough Seated Diastolic Blood Pressure
NCT00624052,measures_secondary,Change From Baseline to End of Study in Trough Seated Systolic Blood Pressure
NCT00624052,measures_secondary,Change in DBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052
NCT00624052,measures_secondary,Change in SBP From Last Available Trough in NCT00553267 to Last Available Trough in NCT00624052
NCT00624052,measures_secondary,Trough Seated DBP Response
NCT00624052,measures_secondary,Trough Seated SBP Response
NCT00624052,has_criteria,visit 3 of trial 1235.6
NCT00624052,has_criteria,visit 3 of study NCT00553267
NCT00624052,has_criteria,34 weeks or last value on treatment
NCT00819052,involves,Human Immunodeficiency Virus One
NCT00819052,evaluates,Nevirapine Extended Release
NCT00819052,measures_primary,sustained virologic response
NCT00819052,measures_secondary,CD4 Count
NCT00819052,has_criteria,Full Analysis Set Population
NCT01990300,involves,Type 2 Diabetes Mellitus
NCT01990300,evaluates,Alogliptin/Pioglitazone
NCT01990300,measures_primary,Glycosylated Hemoglobin
NCT01990300,measures_secondary,Fasting Blood Glucose
NCT01990300,has_criteria,type 2 diabetes mellitus
NCT01990300,has_criteria,cardiac failure
NCT01990300,has_criteria,severe ketosis
NCT01990300,has_criteria,diabetic coma
NCT01990300,has_criteria,type 1 diabetes mellitus
NCT01990300,has_criteria,hepatic dysfunction
NCT01990300,has_criteria,renal dysfunction
NCT01990300,has_criteria,severe infection
NCT01990300,has_criteria,traumatic injury
NCT01990300,has_criteria,hypersensitivity
NCT01990300,has_criteria,pregnancy
NCT01625000,involves,Schizophrenia
NCT01625000,evaluates,MP-214
NCT01625000,measures_primary,PANSS Total Score
NCT01625000,measures_secondary,CGI-S Score
NCT01625000,has_criteria,DSM-IV-TR criteria
NCT03692052,involves,Non-transfusion-dependent Thalassemia
NCT03692052,evaluates,AG-348
NCT03692052,measures_primary,Hemoglobin Response
NCT03692052,measures_secondary,Sustained Hb Response
NCT03692052,measures_secondary,Delayed Hb Response
NCT03692052,measures_secondary,Change From Baseline
NCT03692052,has_criteria,Baseline Hb concentration
NCT00708552,involves,Alzheimer's Disease
NCT00708552,evaluates,SB-742457
NCT00708552,evaluates,Donepezil
NCT00708552,evaluates,Placebo
NCT00708552,measures_primary,Change From Baseline
NCT00708552,measures_secondary,CIBIC+ Score
NCT00708552,measures_secondary,RBANS Total Score
NCT00708552,has_criteria,Week 0
NCT02496000,involves,Type 2 Diabetes Mellitus
NCT02496000,evaluates,ORMD-0801
NCT02496000,measures_primary,Mean Night Time Glucose
NCT02496000,measures_secondary,Mean 24-hour Glucose
NCT02496000,has_criteria,Baseline-Study day -7 (± 1 day)
NCT00365352,involves,Restless Legs Syndrome
NCT00365352,evaluates,XP13512
NCT00365352,measures_primary,IRLS Rating Scale
NCT00365352,measures_secondary,CGI-I Scale
NCT00365352,has_criteria,"Much Improved"" or ""Very Much Improved"
NCT06423352,involves,Hypertension
NCT06423352,evaluates,Zilebesiran
NCT06423352,measures_primary,Change from Baseline in SBP
NCT06423352,measures_primary,Change from Baseline in DBP
NCT06423352,measures_secondary,Percent Change from Baseline in Serum Angiotensinogen
NCT06423352,measures_secondary,Pharmacokinetics of Zilebesiran
NCT06423352,has_criteria,Born in Japan
NCT06423352,has_criteria,Japanese ancestry
NCT06423352,has_criteria,Mean systolic office blood pressure
NCT06423352,has_criteria,24-hour mean SBP
NCT06423352,has_criteria,No antihypertensive medication
NCT06423352,has_criteria,Secondary hypertension
NCT06423352,has_criteria,Symptomatic orthostatic hypotension
NCT06423352,has_criteria,Elevated serum potassium
NCT06423352,has_criteria,Estimated glomerular filtration rate
NCT06423352,has_criteria,Received investigational agent
NCT06423352,has_criteria,Type 1 diabetes mellitus
NCT06423352,has_criteria,Type 2 diabetes mellitus
NCT06423352,has_criteria,History of intolerance to SC injection
NCT01300052,involves,Plaque-Type Psoriasis
NCT01300052,evaluates,AN2728 Topical Ointment
NCT01300052,measures_primary,PGA success at Day 84
NCT01300052,measures_secondary,Change From Baseline in %BSA
NCT01300052,has_criteria,Baseline to Day 84
NCT06176352,involves,Choroidal Neovascularization
NCT06176352,evaluates,Faricimab
NCT06176352,measures_primary,Change from Baseline in BCVA
NCT06176352,measures_secondary,Percentage of Participants Gaining ≥15 Letters in BCVA
NCT06176352,has_criteria,Pathologic Myopia
NCT02876900,involves,Schizophrenia
NCT02876900,evaluates,HP-3070
NCT02876900,evaluates,Placebo
NCT02876900,measures_primary,PANSS total score
NCT02876900,measures_secondary,Clinical Global Impression - Severity of Illness Scale
NCT02876900,has_criteria,Current diagnosis of schizophrenia
NCT02876900,has_criteria,PANSS total score ≥80
NCT02899000,involves,Severe Inflammatory Acne
NCT02899000,evaluates,Oral Isotretinoin
NCT02899000,measures_primary,Number of Inflammatory Lesions
NCT02899000,measures_secondary,Subject Assessment of Acne Improvement
NCT02899000,has_criteria,12 years of age or older
NCT01159600,involves,Type 2 Diabetes
NCT01159600,evaluates,Empagliflozin
NCT01159600,measures_primary,HbA1c Change
NCT01159600,measures_secondary,Body Weight Change
NCT01159600,measures_secondary,Mean Daily Plasma Glucose Change
NCT01159600,has_criteria,metformin alone
NCT01159600,has_criteria,metformin plus sulphonylurea
NCT02546700,involves,Chronic Obstructive Pulmonary Disease
NCT02546700,evaluates,Lebrikizumab
NCT02546700,measures_primary,FEV1 at Week 12
NCT02546700,measures_secondary,COPD Exacerbation
NCT02546700,has_criteria,Baseline up to Week 36
NCT06250400,involves,Chronic Spontaneous Urticaria
NCT06250400,evaluates,Histamine Human Immunoglobulin
NCT06250400,measures_primary,disease control rate
NCT06250400,measures_secondary,Changes in UAS7 scores
NCT06250400,has_criteria,minimum of 4 out of 7
NCT04577352,involves,Friedreich Ataxia
NCT04577352,evaluates,Vatiquinone
NCT04577352,measures_primary,Change From Baseline in mFARS Score at Week 72
NCT04577352,measures_secondary,Change From Baseline in FARS-ADL Score at Week 72
NCT04577352,measures_secondary,Change From Baseline in 1-Minute Walk Test at Week 72
NCT04577352,measures_secondary,Number of Falls Through Week 72
NCT04577352,has_criteria,Baseline
NCT04483700,involves,Ankylosing Spondylitis
NCT04483700,evaluates,Filgotinib
NCT04483700,measures_primary,ASAS40 Response
NCT04483700,measures_secondary,ASAS20 Response
NCT04483700,has_criteria,Naive to biologic DMARD therapy
NCT00771199,involves,Cancer Pain
NCT00771199,evaluates,Transdermal Therapeutic System (TTS)-Fentanyl
NCT00771199,measures_primary,Pain severity
NCT00771199,measures_secondary,Quality of Life
NCT00771199,has_criteria,Analgesic requirements
NCT04524442,involves,Gastroenteropancreatic Neuroendocrine Tumor
NCT04524442,evaluates,LysaKare
NCT04524442,measures_primary,Serum potassium levels
NCT04524442,measures_secondary,Treatment emergent adverse events
NCT04524442,measures_secondary,Notable changes in vital signs
NCT04524442,measures_secondary,Notable changes in ECG
NCT04524442,measures_secondary,Notable changes in Hematology parameters
NCT04524442,measures_secondary,Notable changes in Chemistry parameters
NCT04524442,measures_secondary,Notable changes in Electrolyte parameters
NCT04524442,has_criteria,Adult
NCT03390842,involves,Metabolic acidosis
NCT03390842,evaluates,TRC101
NCT03390842,measures_primary,Change from baseline
NCT03390842,measures_secondary,Kidney Disease Quality of Life
NCT03390842,has_criteria,Change from baseline
NCT02515942,involves,Geographic Atrophy
NCT02515942,evaluates,CLG561
NCT02515942,measures_primary,Change in GA Lesion Size
NCT02515942,measures_secondary,Intraocular Pressure
NCT02515942,has_criteria,Baseline prior to first dose
NCT01812642,involves,Schizophrenia
NCT01812642,evaluates,JNJ-37822681
NCT01812642,measures_primary,Change From Baseline
NCT01812642,measures_secondary,Barnes Akathisia Rating Scale
NCT01812642,measures_secondary,Simpson Angus Rating Scale
NCT01812642,has_criteria,Stable Schizophrenia
NCT01960842,involves,Parkinson's Disease
NCT01960842,evaluates,ABT-SLV187
NCT01960842,measures_primary,"Average Daily ""Off"" Time"
NCT01960842,measures_secondary,"Average Daily ""On"" Time"
NCT01960842,measures_secondary,Parkinson's Disease Questionnaire
NCT01960842,has_criteria,Optimized Treatment
NCT04675242,involves,blepharitis
NCT04675242,evaluates,NCX 4251 Ophthalmic Suspension
NCT04675242,measures_primary,Complete Cure Blepharitis
NCT04675242,measures_secondary,Eyelid Margin Redness
NCT04675242,measures_secondary,Eyelid Debris
NCT04675242,measures_secondary,Eyelid Discomfort
NCT04675242,measures_secondary,Eye Dryness Symptoms
NCT04675242,measures_secondary,Eye Dryness Sign
NCT04675242,has_criteria,documented history blepharitis
NCT04675242,has_criteria,qualifying criteria blepharitis exacerbation
NCT04675242,has_criteria,best-corrected visual acuity
NCT04675242,has_criteria,abnormality eyelids lashes
NCT04675242,has_criteria,previous eyelid surgery
NCT04675242,has_criteria,IOP > 21 mmHg
NCT04675242,has_criteria,use steroids past 30 days
NCT04675242,has_criteria,use retinoids past 12 months
NCT04675242,has_criteria,uncontrolled systemic disease
NCT02505542,involves,Ankylosing spondylitis
NCT02505542,evaluates,certolizumab pegol
NCT02505542,measures_primary,Percentage of Participants
NCT02505542,measures_secondary,ASDAS
NCT02505542,has_criteria,Sustained remission
NCT03464136,involves,Crohn's Disease
NCT03464136,evaluates,Adalimumab
NCT03464136,evaluates,Ustekinumab
NCT03464136,measures_primary,Clinical Remission
NCT03464136,measures_primary,Corticosteroid-free Remission
NCT03464136,measures_primary,Clinical Response
NCT03464136,measures_secondary,Patient Reported Outcome
NCT03464136,has_criteria,CDAI score \<150
NCT03414736,involves,Overweight to obese subjects
NCT03414736,involves,Type 2 Diabetes Mellitus
NCT03414736,evaluates,SAR425899
NCT03414736,measures_primary,Change in body weight
NCT03414736,measures_secondary,Change in fasting plasma glucose
NCT03414736,measures_secondary,Change in hemoglobin A1c
NCT03414736,measures_secondary,Adverse events
NCT03414736,has_criteria,Overweight to obese subjects
NCT03414736,has_criteria,Type 2 Diabetes Mellitus
NCT03414736,has_criteria,Not requiring anti-diabetic pharmacotherapy
NCT03414736,has_criteria,Motivated to lose weight
NCT02321436,involves,Stroke
NCT02321436,evaluates,Dysport Injections
NCT02321436,measures_primary,MAS score
NCT02321436,measures_secondary,Fugl-Meyer Assessment
NCT02321436,has_criteria,Increased muscle tone
NCT04544449,involves,Primary Progressive Multiple Sclerosis
NCT04544449,evaluates,Fenebrutinib
NCT04544449,evaluates,Ocrelizumab
NCT04544449,measures_primary,Time to Onset of cCDP12
NCT04544449,measures_primary,Time to Onset of cCDP24
NCT04544449,measures_secondary,Percentage Change in Total Brain Volume
NCT04544449,measures_secondary,Change from Baseline in MSIS-29 Physical Scale
NCT04544449,measures_secondary,Time to Onset of 12-week Confirmed 4-point Worsening in SDMT Score
NCT04544449,has_criteria,Adult Participants
NCT00467649,involves,Type 2 Diabetes
NCT00467649,evaluates,Basal Insulin
NCT00467649,measures_primary,HbA1c <=7% at Week 24
NCT00467649,measures_primary,no Weight Gain at Week 24
NCT00467649,measures_primary,no Severe Hypoglycemia
NCT00467649,measures_secondary,Change in HbA1c From Baseline at Week 24
NCT00467649,measures_secondary,Change in Body Weight From Baseline at Week 24
NCT00467649,measures_secondary,Change in Waist Circumference From Baseline at Week 24
NCT00467649,measures_secondary,Change in Fasting Plasma Glucose From Baseline at Week 24
NCT00467649,measures_secondary,Fasting Serum Lipids Change From Baseline to Week 24
NCT00467649,measures_secondary,Phase 2: Change in HbA1c at Week 36
NCT00467649,measures_secondary,Phase 2: Change in Body Weight at Week 36
NCT00467649,has_criteria,24 Weeks
NCT05348642,involves,Irritable Bowel Syndrome
NCT05348642,evaluates,Pasteurized Akkermansia Muciniphila
NCT05348642,measures_primary,IBS-SSS score
NCT05348642,measures_secondary,IBS-GIS score
NCT05348642,measures_secondary,stool frequency
NCT05348642,measures_secondary,stool consistency
NCT05348642,measures_secondary,HADS score
NCT05348642,has_criteria,Patients were defined
NCT00640042,involves,Chronic Pain
NCT00640042,evaluates,Avinza
NCT00640042,measures_primary,Average Pain Score
NCT00640042,measures_secondary,Adverse Events
NCT00640042,has_criteria,SOAPP-R score
NCT00502242,involves,Renal Transplant
NCT00502242,evaluates,Ramipril
NCT00502242,measures_primary,U p/c <0.5
NCT00502242,measures_primary,U Alb/c <0.5
NCT00502242,has_criteria,SRL conversion
NCT02564042,involves,Plaque Psoriasis
NCT02564042,evaluates,GSK2894512 Cream
NCT02564042,measures_primary,PGA score 0 or 1
NCT02564042,measures_secondary,PASI improvement
NCT02564042,has_criteria,randomized participants
NCT06603142,involves,Primary Gout
NCT06603142,involves,Hyperuricemia
NCT06603142,evaluates,AR882 Capsules
NCT06603142,evaluates,Febuxostat Tablets
NCT06603142,measures_primary,serum uric acid levels
NCT06603142,measures_secondary,Adverse events
NCT06566170,involves,Alzheimer's Disease
NCT06566170,evaluates,Donanemab
NCT06566170,measures_primary,Time to First Increase
NCT06566170,measures_primary,Dependence Level
NCT06566170,measures_secondary,Time to Loss of Independence
NCT06566170,measures_secondary,Time to Institutionalization
NCT06566170,measures_secondary,Change from Baseline
NCT06566170,measures_secondary,Functional Assessment Questionnaire
NCT06566170,measures_secondary,Neuropsychiatric Inventory
NCT06566170,has_criteria,Dependence Level <3
NCT05685732,involves,ADHD
NCT05685732,evaluates,Azstarys
NCT05685732,measures_primary,ADHD-RS change
NCT05685732,measures_secondary,CGI-S
NCT05685732,measures_secondary,CGI-I
NCT05685732,has_criteria,at least 4 years old
NCT05685732,has_criteria,less than 5 years 10 months
NCT05685732,has_criteria,body weight 5th-95th percentile
NCT03092232,evaluates,PF-06865571
NCT03092232,measures_primary,AUClast for PF-06865571
NCT03092232,measures_primary,AUC (0-infinity)
NCT03092232,measures_primary,Dose normalized AUClast
NCT03092232,measures_primary,Dose normalized AUCinf
NCT03092232,has_criteria,Screening up to 35 days
NCT02079532,involves,Rheumatoid Arthritis
NCT02079532,evaluates,MabThera
NCT02079532,measures_primary,DAS28 Score
NCT02079532,measures_secondary,EULAR Response
NCT02079532,has_criteria,Inadequate response
NCT04179032,involves,Systemic Lupus Erythematosus
NCT04179032,evaluates,Belimumab
NCT04179032,measures_primary,Number of Participants
NCT04179032,measures_secondary,Adverse Events
NCT04179032,has_criteria,Untoward medical occurrence
NCT01749137,involves,Obesity
NCT01749137,evaluates,RM-493
NCT01749137,measures_primary,Percent Change in Body Weight
NCT01749137,measures_secondary,Percentage of Participants Who Lost ≥ 5% of Their Baseline Body Weight
NCT01749137,measures_secondary,Number of Participants Who Consistently Achieved Targeted Plasma Concentration of ~6 ng/mL
NCT01749137,measures_secondary,Percentage of Participants With Treatment Emergent Adverse Events
NCT01749137,measures_secondary,Change From Baseline in Ambulatory Blood Pressure Monitoring Parameter (ABPM) - Systolic Blood Pressure
NCT01749137,measures_secondary,Change From Baseline in ABPM - Diastolic Blood Pressure
NCT01749137,measures_secondary,Change From Baseline in ABPM - Mean Arterial Blood Pressure
NCT01749137,has_criteria,Baseline up to Day 90
NCT00641537,involves,Hematologic and Hepatic Toxicity
NCT00641537,evaluates,Investigational Medicinal Product
NCT00641537,measures_primary,Mean Change From Baseline
NCT00641537,measures_secondary,Number of Participants
NCT00641537,has_criteria,Treatment Emergent Adverse Events
NCT01313637,involves,COPD
NCT01313637,evaluates,GSK573719/Vilanterol
NCT01313637,measures_primary,Change From Baseline FEV1
NCT01313637,measures_secondary,Transition Dyspnea Index
NCT01313637,has_criteria,Baseline dyspnea index
NCT06073132,involves,Generalized Epidermolysis Bullosa Simplex
NCT06073132,evaluates,Diacerein 1% Ointment
NCT06073132,measures_primary,Proportion of patients achieving treatment success
NCT06073132,measures_secondary,Change in % BSA of EBS lesions
NCT06073132,measures_secondary,Change in pain intensity score
NCT06073132,measures_secondary,Change in pruritus intensity score
NCT06073132,measures_secondary,Change in EBDASI score
NCT06073132,measures_secondary,Change in QOLEB score
NCT06073132,has_criteria,patients 3 years and older
NCT06073132,has_criteria,patients aged 6 years and older
NCT00552032,involves,Adenoid Hypertrophy
NCT00552032,evaluates,Mometasone Furoate Nasal Spray
NCT00552032,measures_primary,Adenoid/Choana Index
NCT00552032,measures_secondary,Total Severity Symptom Scores
NCT00552032,measures_secondary,Total Frequency Symptom Scores
NCT00552032,has_criteria,Nasopharyngoscopic examination
NCT03844932,involves,Ulcerative Colitis
NCT03844932,evaluates,ST-0529
NCT03844932,measures_primary,Clinical Remission at Week 12
NCT03844932,measures_secondary,Clinical Response at Week 12
NCT03844932,measures_secondary,Endoscopic Healing at Week 12
NCT03844932,measures_secondary,Corticosteroid-free clinical response at Week 12
NCT03844932,measures_secondary,Corticosteroid-free clinical remission at Week 12
NCT03844932,has_criteria,oral corticosteroids
NCT04724837,involves,Chronic Kidney Disease
NCT04724837,evaluates,Zibotentan
NCT04724837,evaluates,Dapagliflozin
NCT04724837,measures_primary,Change in UACR
NCT04724837,measures_secondary,Office Systolic Blood Pressure
NCT04724837,measures_secondary,Office Diastolic Blood Pressure
NCT04724837,measures_secondary,eGFR
NCT04724837,measures_secondary,Adverse Events
NCT04724837,has_criteria,Screening to Follow-up visit
NCT05162937,involves,Axial Spondyloarthritis
NCT05162937,evaluates,GR1501 Injection
NCT05162937,measures_primary,ASAS 20 responder
NCT05162937,measures_secondary,ASAS 40 responder
NCT05162937,measures_secondary,ASAS 5/6 responder
NCT05162937,has_criteria,Improvement of 20%
NCT05593432,involves,Cutaneous Lichen Planus
NCT05593432,evaluates,Ruxolitinib Cream
NCT05593432,measures_primary,IGA-TS at Week 16
NCT05593432,measures_secondary,IGA at Week 16
NCT05593432,has_criteria,Baseline; Week 16
NCT05593432,has_criteria,Baseline; Weeks 2
NCT05593432,has_criteria,Baseline; Open-label Extension Period
NCT03822832,involves,Atopic Eczema
NCT03822832,evaluates,BI 655130
NCT03822832,measures_primary,EASI Score at Week 16
NCT03822832,measures_secondary,EASI Score at Week 16
NCT03822832,has_criteria,Baseline endpoint
NCT01044537,involves,Type 2 Diabetes Mellitus
NCT01044537,evaluates,PF-04937319
NCT01044537,measures_primary,AUClast
NCT01044537,measures_secondary,Cmax
NCT01044537,measures_secondary,Tmax
NCT01044537,measures_secondary,CL/F
NCT01044537,measures_secondary,Vz/F
NCT01044537,measures_secondary,t1/2
NCT01044537,has_criteria,first dose of study medication
NCT03978637,involves,Bronchiolitis Obliterans Syndrome
NCT03978637,evaluates,Itacitinib
NCT03978637,measures_primary,Change from baseline in FEV1
NCT03978637,measures_secondary,Duration of FEV1 response
NCT03978637,measures_secondary,Time to progression
NCT03978637,measures_secondary,Change from baseline in SGRQ total score
NCT03978637,measures_secondary,Change from baseline in QOL-SF-12 questionnaire
NCT03978637,measures_secondary,Categorical summary or change from baseline in EQ-5D-3L questionnaire
NCT03978637,measures_secondary,Overall Survival
NCT03978637,has_criteria,treatment-emergent adverse events
NCT02992132,involves,Alzheimer's Disease
NCT02992132,evaluates,Pimavanserin
NCT02992132,measures_primary,Agitation
NCT02992132,measures_secondary,Caregiver burden
NCT02992132,has_criteria,Baseline to 12 weeks
NCT01663532,involves,Schizophrenia
NCT01663532,evaluates,Aripiprazole Intramuscular Depot
NCT01663532,measures_primary,PANSS Total Score
NCT01663532,measures_secondary,CGI-S Score
NCT01663532,measures_secondary,PANSS Positive Subscale Score
NCT01663532,has_criteria,Baseline to Week 10
NCT03895437,involves,Diabetes Autoimmunity
NCT03895437,evaluates,TOL-3021
NCT03895437,measures_primary,log-transformed MMTT C-peptide AUC
NCT03895437,measures_secondary,clinically important hypoglycemia
NCT03895437,measures_secondary,daily Insulin requirements
NCT03895437,measures_secondary,HbA1c
NCT03895437,measures_secondary,GCM measurement of glucose levels
NCT03895437,measures_secondary,Clinical responder analysis
NCT03895437,measures_secondary,non-fasting or fasting C-peptide single test
NCT03895437,measures_secondary,HbA1c
NCT06075537,involves,Mucopolysaccharidosis Type II
NCT06075537,evaluates,Tividenofusp Alfa
NCT06075537,measures_primary,urine GAG concentrations
NCT06075537,measures_secondary,Vineland-3 Adaptive Behavior Scale
NCT06075537,measures_secondary,Bayley Scales of Infant and Toddler Development
NCT06075537,measures_secondary,distance walked
NCT06075537,measures_secondary,urine HS and dermatan sulfate
NCT06075537,measures_secondary,Liver volume
NCT06075537,measures_secondary,Spleen volume
NCT06075537,measures_secondary,Parent/Caregiver Global Impression of Change
NCT06075537,has_criteria,5 years
NCT04442737,evaluates,Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
NCT04442737,measures_primary,Percent Change From Baseline in Body Weight at Week 24
NCT04442737,measures_secondary,Percentage of Participants With Change From Baseline Greater Than or Equal to (>=) 3% to <= 5% in Body Weight Over Time
NCT04442737,has_criteria,BMI >=30 Kilograms Per Square Meter (kg/m^2)
NCT06372470,involves,Hypertension
NCT06372470,evaluates,Zestril
NCT06372470,measures_primary,Home Blood Pressure
NCT06372470,measures_secondary,systolic blood pressure
NCT06372470,measures_secondary,diastolic blood pressure
NCT06372470,measures_secondary,time to BP Control
NCT06372470,measures_secondary,patient adherence
NCT06372470,measures_secondary,data collection adherence
NCT06372470,measures_secondary,patient thoughts
NCT06372470,measures_secondary,discontinuation due to side effects
NCT06372470,measures_secondary,spontaneous side effects
NCT06372470,has_criteria,target Home Blood Pressure
NCT02200770,involves,Neuromyelitis Optica Spectrum Disorders
NCT02200770,evaluates,Inebilizumab
NCT02200770,measures_primary,Time to NMOSD Attack
NCT02200770,measures_secondary,Worsening in EDSS Score
NCT02200770,has_criteria,protocol-defined attack criteria
NCT03562637,involves,Glob H positive TNBC
NCT03562637,evaluates,adagloxad simolenin
NCT03562637,measures_primary,invasive disease free survival
NCT03562637,measures_secondary,Overall Survival
NCT03562637,measures_secondary,Quality of Life
NCT03562637,has_criteria,5 years
NCT03562637,has_criteria,7 years
NCT03562637,has_criteria,7 years
NCT01182337,involves,Lumbar Disc Degeneration
NCT01182337,evaluates,rhGDF-5
NCT01182337,measures_primary,Clinically Significant Abnormal results
NCT01182337,measures_secondary,Treatment Emergent Adverse Events
NCT01182337,measures_secondary,Oswestry Disability Index Change
NCT01182337,has_criteria,12 months
NCT02236637,involves,prostate cancer
NCT02236637,evaluates,systemic mCRPC therapies
NCT02236637,measures_primary,ECOG performance status
NCT02236637,measures_secondary,Medical Resource Utilization
NCT02236637,measures_secondary,European Quality of Life-5 Dimensions
NCT02236637,has_criteria,treatment initiation/termination
NCT02094937,involves,Asthma
NCT02094937,evaluates,Fluticasone Furoate
NCT02094937,evaluates,Fluticasone Propionate
NCT02094937,measures_primary,Well-controlled Asthma
NCT02094937,measures_secondary,Asthma symptom scores
NCT02094937,has_criteria,poorly-controlled asthma
NCT01411137,involves,Parkinson's Disease
NCT01411137,evaluates,IPX066
NCT01411137,measures_primary,Patient Global Impression
NCT01411137,measures_secondary,Clinical Global Impression
NCT01411137,measures_secondary,Parkinson's disease Questionnaire-8
NCT01411137,has_criteria,Diagnosed with idiopathic PD
NCT01411137,has_criteria,At least 30 years old
NCT01411137,has_criteria,Stable LD regimen
NCT02906579,involves,Type 2 Diabetes
NCT02906579,involves,Hypertension
NCT02906579,evaluates,IW-1973
NCT02906579,measures_primary,Cholesterol
NCT02906579,measures_secondary,GGT
NCT02906579,measures_secondary,Hemoglobin A1c
NCT02906579,has_criteria,Stable Type 2 Diabetes
NCT02985879,involves,Progressive Supranuclear Palsy
NCT02985879,evaluates,ABBV-8E12
NCT02985879,measures_primary,PSPRS Total Score
NCT02985879,measures_secondary,UPDRS Part II
NCT02985879,has_criteria,up to 80 weeks
NCT02853084,involves,CAPS
NCT02853084,evaluates,anakinra
NCT02853084,measures_primary,Diary Symptom Sum Score
NCT02853084,measures_secondary,SAA
NCT02853084,measures_secondary,physician's global assessment
NCT02853084,measures_secondary,patient's global assessment
NCT02853084,has_criteria,NALP3 mutation
NCT02853084,has_criteria,CAPS diagnosis
NCT02853084,has_criteria,stable doses anakinra
NCT02853084,has_criteria,current stable doses methotrexate
NCT02853084,has_criteria,current stable doses corticosteroids
NCT02853084,has_criteria,hereditary periodic fever syndrome
NCT02853084,has_criteria,autoinflammatory disease other than CAPS
NCT02853084,has_criteria,disease inadequately controlled
NCT02414984,involves,Rheumatoid Arthritis
NCT02414984,evaluates,Golimumab
NCT02414984,measures_primary,DAS28 at Month
NCT02414984,measures_secondary,PtGA at Month
NCT02414984,measures_secondary,MDGA at Month
NCT02414984,has_criteria,treatment gap
NCT01001702,involves,Mental Illness
NCT01001702,evaluates,Oral Aripiprazole
NCT01001702,measures_primary,CGI-S Score
NCT01001702,measures_secondary,Clinical Significant Laboratory Tests
NCT01001702,has_criteria,Fasting clinical laboratory tests
NCT05350202,involves,Heart Failure
NCT05350202,evaluates,empagliflozin
NCT05350202,measures_primary,KCCQ Clinical summary score
NCT05350202,measures_secondary,KCCQ total symptom score
NCT05350202,measures_secondary,KCCQ overall summary score
NCT05350202,measures_secondary,NYHA Class
NCT05350202,has_criteria,chronic Heart Failure
NCT02118584,involves,Ulcerative Colitis
NCT02118584,evaluates,Etrolizumab
NCT02118584,measures_primary,Clinical Remission
NCT02118584,measures_secondary,Endoscopic Remission
NCT02118584,has_criteria,Previously enrolled
NCT00710684,involves,Alzheimer's Disease
NCT00710684,evaluates,SB-742457
NCT00710684,evaluates,Donepezil
NCT00710684,measures_primary,ADAS-Cog Total Score
NCT00710684,measures_secondary,CDR-SB Score
NCT00710684,has_criteria,Baseline(Week 0)
NCT03759379,involves,Hereditary Transthyretin Amyloidosis
NCT03759379,evaluates,Vutrisiran
NCT03759379,measures_primary,mNIS+7 score
NCT03759379,measures_secondary,Norfolk QoL-DN
NCT03759379,measures_secondary,10-MWT
NCT03759379,has_criteria,Baseline
NCT06174779,involves,Adult Obesity
NCT06174779,evaluates,HM11260C
NCT06174779,measures_primary,Percent change body weight
NCT06174779,measures_secondary,Body weight loss ≥ 5%
NCT06174779,has_criteria,BMI ≥ 30 kg/m2
NCT06174779,has_criteria,BMI 27 kg/m2 ≤ BMI < 30 kg/m2
NCT06174779,has_criteria,Risk factors or comorbidities
NCT06174779,has_criteria,Failed weight control
NCT01865084,involves,Duchenne muscular dystrophy
NCT01865084,evaluates,Tadalafil
NCT01865084,measures_primary,6MWD change
NCT01865084,measures_secondary,NSAA Global Score
NCT01865084,measures_secondary,Timed function tests
NCT01865084,has_criteria,boys with DMD
NCT05209984,involves,Overweight
NCT05209984,evaluates,Sibutramine/Topiramate XR
NCT05209984,measures_primary,Percent body weight loss
NCT05209984,measures_secondary,Weight reduction
NCT05209984,has_criteria,BMI ≥ 27kg/m2 and \< 45kg/m2
NCT00410384,involves,Systemic Lupus Erythematosus
NCT00410384,evaluates,Belimumab
NCT00410384,measures_primary,SRI Response Rate
NCT00410384,measures_secondary,SELENA SLEDAI score
NCT00410384,measures_secondary,PGA
NCT00410384,measures_secondary,BILAG A organ domain score
NCT00410384,measures_secondary,BILAG B organ domain score
NCT00410384,has_criteria,≥ 4 point reduction
NCT00410384,has_criteria,no worsening
NCT03413384,involves,Parkinson's Disease Dementia
NCT03413384,evaluates,Ceftriaxone
NCT03413384,measures_primary,ADAS-Cog score
NCT03413384,measures_secondary,UPDRS score
NCT03413384,measures_secondary,Judgment of Line Orientation score
NCT03413384,measures_secondary,Mini-Mental State Examination score
NCT03413384,measures_secondary,Clinical Dementia Rating Scale score
NCT03413384,measures_secondary,Color Trail Test score
NCT03413384,has_criteria,Mild to Moderate
NCT02318602,involves,Seizure Disorder
NCT02318602,evaluates,Cannabidiol Oral Solution
NCT02318602,measures_primary,Percentage of Participants With Adverse Events
NCT02318602,measures_secondary,Clinically Significant Change From Baseline in Laboratory Values
NCT02318602,measures_secondary,Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings
NCT02318602,measures_secondary,Clinically Significant Change From Baseline in Vital Signs
NCT02318602,measures_secondary,Change From Baseline in Trough Plasma Levels of Cannabidiol and Its 7-OH Metabolite
NCT02318602,has_criteria,Up to Week 50
NCT02318602,has_criteria,Up to Week 48
NCT02318602,has_criteria,Up to Week 50
NCT00216502,involves,Alzheimer's Disease
NCT00216502,evaluates,Galantamine
NCT00216502,measures_primary,Time to worsening of symptoms
NCT00216502,measures_secondary,Change in ADAS-cog
NCT00216502,measures_secondary,CIBIC-plus
NCT00216502,measures_secondary,DAD scores
NCT00216502,has_criteria,Diagnosis of probable Alzheimer's disease
NCT00216502,has_criteria,Mild to moderate impairment
NCT00216502,has_criteria,Score from 11-24 on MMSE
NCT00216502,has_criteria,Post-menopausal
NCT00216502,has_criteria,Signed informed consent
NCT00216502,has_criteria,Exclusion: Parkinson's Disease
NCT00216502,has_criteria,Exclusion: Pick's Disease
NCT00216502,has_criteria,Exclusion: Huntington's Chorea
NCT00216502,has_criteria,Exclusion: Creutzfeld-Jacob disease
NCT00216502,has_criteria,Exclusion: Down's syndrome
NCT00216502,has_criteria,Exclusion: brain cancer
NCT00216502,has_criteria,Exclusion: mental retardation
NCT00216502,has_criteria,Exclusion: epilepsy
NCT00216502,has_criteria,Exclusion: psychiatric disease
NCT00216502,has_criteria,Exclusion: liver failure
NCT00216502,has_criteria,Exclusion: kidney failure
NCT00216502,has_criteria,Exclusion: heart failure
NCT00216502,has_criteria,Exclusion: significant heart disease
NCT00216502,has_criteria,Exclusion: significant lung disease
NCT00216502,has_criteria,Exclusion: significant digestive disease
NCT00216502,has_criteria,Exclusion: significant hormone disease
NCT00216502,has_criteria,Exclusion: significant mental disease
NCT00216502,has_criteria,Exclusion: Vitamin B deficiency
NCT00216502,has_criteria,Exclusion: severe head injury
NCT00216502,has_criteria,Exclusion: blood clot in brain
NCT00216502,has_criteria,Exclusion: hospitalized
NCT00216502,has_criteria,Exclusion: nursing homes
NCT00216502,has_criteria,Exclusion: residential care facilities
NCT00216502,has_criteria,Exclusion: brain infections
NCT00216502,has_criteria,Exclusion: drug or alcohol abuse
NCT05121402,involves,Ulcerative Colitis
NCT05121402,evaluates,TLL018
NCT05121402,measures_primary,clinical remission
NCT05121402,measures_secondary,Adverse Events
NCT05121402,has_criteria,Up to 8 weeks
NCT02873702,involves,Erosive Esophagitis
NCT02873702,evaluates,Dexlansoprazole
NCT02873702,measures_primary,Healing at Week 8
NCT02873702,measures_secondary,Healing at Month 6
NCT02873702,has_criteria,Endoscopically confirmed EE
NCT00616902,involves,Chronic Kidney Disease
NCT00616902,involves,Renal Failure
NCT00616902,involves,Cardiac Morbidity
NCT00616902,evaluates,Paricalcitol Injection
NCT00616902,measures_primary,Change from Baseline in LVMI
NCT00616902,measures_secondary,Diastolic Mitral Annular Relaxation Velocity (E')
NCT00616902,measures_secondary,Isovolumetric Relaxation Time (IVRT)
NCT00616902,measures_secondary,Peak E-wave Velocity to Lateral E-wave Velocity (E/E')
NCT00616902,measures_secondary,E-wave Deceleration Time (DT)
NCT00616902,has_criteria,Stage 5 chronic kidney disease
NCT00616902,has_criteria,Hemodialysis
NCT02293902,involves,Rheumatoid Arthritis
NCT02293902,evaluates,Sarilumab
NCT02293902,measures_primary,ACR20 response
NCT02293902,measures_secondary,Adverse Events
NCT02293902,has_criteria,Japanese Patients
NCT01100879,involves,Multiple Myeloma
NCT01100879,evaluates,Ferric Carboxymaltose
NCT01100879,measures_primary,Change in Hb
NCT01100879,measures_secondary,Time to Hb response
NCT01100879,has_criteria,red blood cell transfusions
NCT05048784,evaluates,Sotorasib
NCT05048784,measures_primary,Maximum Observed Plasma Concentration
NCT05048784,measures_primary,Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration
NCT05048784,measures_primary,Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity
NCT05048784,has_criteria,Treatment-emergent AE
NCT01669902,involves,Rheumatoid Arthritis
NCT01669902,evaluates,Tocilizumab
NCT01669902,measures_primary,Swollen Joint Count
NCT01669902,measures_secondary,Tender Joint Count
NCT01669902,measures_secondary,Disease Activity Score
NCT01669902,has_criteria,Dose modification
NCT03867084,involves,Hepatocellular Carcinoma
NCT03867084,evaluates,Pembrolizumab
NCT03867084,measures_primary,Recurrence-Free Survival
NCT03867084,measures_secondary,Overall Survival
NCT03867084,measures_secondary,Percentage of Participants
NCT03867084,has_criteria,Complete Radiological Response
NCT01325402,involves,Alzheimer's Disease
NCT01325402,evaluates,[18F]AZD4694
NCT01325402,measures_primary,Maximum Diagnostic Mass
NCT01325402,measures_secondary,Number of Adverse Events
NCT01325402,measures_secondary,Correlation between early uptake
NCT01325402,measures_secondary,Correlation between β-amyloid load
NCT01325402,has_criteria,Body Mass Index 18-30 kg/m2
NCT01325402,has_criteria,weigh at least 50kg
NCT01325402,has_criteria,Mini Mental State Examination score
NCT01325402,has_criteria,Hachinski Ischemic Score =4
NCT01325402,has_criteria,Clinical diagnosis of probable Alzheimer's Disease
NCT02073279,involves,Neuromyelitis Optica
NCT02073279,involves,Neuromyelitis Optica Spectrum Disorder
NCT02073279,evaluates,Satralizumab
NCT02073279,measures_primary,Time to First Relapse
NCT02073279,measures_secondary,Change From Baseline to Week 24 in Visual Analogue Scale for Pain
NCT02073279,measures_secondary,Change From Baseline to Week 24 in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale
NCT02073279,has_criteria,protocol-defined relapse
NCT00762684,involves,Type 2 Diabetes Mellitus
NCT00762684,evaluates,TAK-559
NCT00762684,measures_primary,Change from baseline in glycosylated hemoglobin
NCT00762684,measures_secondary,Change from baseline in fasting plasma glucose
NCT00762684,measures_secondary,Change from baseline in serum insulin
NCT00762684,measures_secondary,Change from baseline in C-peptide
NCT00762684,measures_secondary,Change from baseline in triglycerides
NCT00762684,measures_secondary,Change from baseline in total cholesterol
NCT00762684,measures_secondary,Change from baseline in high-density lipoprotein
NCT00762684,measures_secondary,Change from baseline in low-density lipoprotein
NCT00762684,measures_secondary,Change from baseline in very-low-density lipoprotein
NCT00762684,measures_secondary,Change from base line in apolipoproteins A1 and B 100
NCT00762684,measures_secondary,Change from baseline in free fatty acids
NCT00762684,measures_secondary,Change from baseline in thrombosis marker (plasminogen activator inhibitor-1)
NCT00762684,measures_secondary,Change from baseline in thrombosis marker (fibrinogen)
NCT00762684,measures_secondary,Change from baseline in inflammation marker (Interleukin-6)
NCT00762684,measures_secondary,Change from baseline in inflammation marker (C-reactive protein)
NCT00762684,measures_secondary,Change from baseline in urinary albumin to creatinine ratio
NCT00762684,has_criteria,diagnosed with type 2 diabetes mellitus
NCT00762684,has_criteria,stable dose of an oral anti-diabetic monotherapy
NCT00762684,has_criteria,glycosylated hemoglobin level
NCT00762684,has_criteria,fasting plasma glucose
NCT04944784,involves,Amyotrophic Lateral Sclerosis
NCT04944784,evaluates,reldesemtiv
NCT04944784,measures_primary,ALSFRS-R total score
NCT04944784,measures_secondary,respiratory insufficiency
NCT04944784,measures_secondary,survival time
NCT04944784,has_criteria,age 18-80 years
NCT04944784,has_criteria,ALS diagnosis
NCT04947579,involves,Ankylosing Spondylitis
NCT04947579,evaluates,CC-99677
NCT04947579,measures_primary,ASAS 20 at Week 12
NCT04947579,measures_primary,ASAS 40 at Week 12
NCT04947579,measures_secondary,Change From Baseline in ASDAS-CRP at Week 12
NCT04947579,has_criteria,last non-missing value
NCT00831779,involves,Type 2 Diabetes
NCT00831779,evaluates,Dapagliflozin
NCT00831779,measures_primary,Insulin Sensitivity
NCT00831779,measures_secondary,Insulin Secretion
NCT00831779,has_criteria,A1C ≥ 7.0 and ≤ 10.0%
NCT00831779,has_criteria,metformin therapy
NCT00831779,has_criteria,insulin secretagogue
NCT00831779,has_criteria,C-peptide ≥ 1.0 ng/ml
NCT00831779,has_criteria,BMI ≤ 45.0 kg/m2
NCT00831779,has_criteria,UACR \> 1
NCT00831779,has_criteria,AST \> 3X ULN
NCT00831779,has_criteria,ALT \> 3X ULN
NCT00831779,has_criteria,Serum Total Bilirubin \> 2 mg/dL
NCT00831779,has_criteria,Serum Creatinine ≥ 1.50 mg/dL
NCT00831779,has_criteria,Serum Creatinine ≥ 1.40 mg/dL
NCT02655679,involves,Atopic Dermatitis
NCT02655679,evaluates,VTP-38543
NCT02655679,measures_primary,Number of Participants
NCT02655679,measures_secondary,Clinically Significant Changes
NCT02655679,has_criteria,Adult Participants
NCT04677179,involves,Ulcerative Colitis
NCT04677179,evaluates,LY3471851
NCT04677179,measures_primary,Clinical Remission
NCT04677179,measures_secondary,Clinical Response
NCT04677179,measures_secondary,Endoscopic Remission
NCT04677179,has_criteria,Adult Participants
NCT03531684,involves,Alzheimer's Disease
NCT03531684,evaluates,MMFS
NCT03531684,measures_primary,NTB composite score
NCT03531684,measures_secondary,CDR-SB score
NCT03531684,measures_secondary,mMMSE total score
NCT03531684,measures_secondary,ADCS-ADL-MCI24
NCT03531684,measures_secondary,ADCS-MCI-CGIC score
NCT03531684,has_criteria,Early AD
NCT04136184,involves,Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
NCT04136184,evaluates,Eplontersen
NCT04136184,measures_primary,Change from baseline in mNIS+7
NCT04136184,measures_secondary,Norfolk Quality of Life Diabetic Neuropathy
NCT04136184,measures_secondary,Percent change from baseline in serum TTR concentration
NCT04136184,measures_secondary,Percent change from baseline in serum transthyretin (TTR) concentration
NCT04136184,measures_secondary,Change from baseline in modified neuropathy impairment score plus 7 (mNIS+7)
NCT04136184,measures_secondary,Change from baseline in Norfolk QOL-DN
NCT04136184,has_criteria,Baseline
NCT04136184,has_criteria,Baseline
NCT00212784,involves,Schizophrenia
NCT00212784,involves,Schizoaffective Disorder
NCT00212784,evaluates,Asenapine
NCT00212784,measures_primary,Change in PANSS score
NCT00212784,measures_secondary,PANSS subscale scores
NCT00212784,measures_secondary,Marder factor scores
NCT00212784,measures_secondary,CGI-S
NCT00212784,measures_secondary,LOF
NCT00212784,measures_secondary,SF-12
NCT00212784,measures_secondary,SWN
NCT00212784,measures_secondary,Calgary Depression Scale for Schizophrenia
NCT00212784,measures_secondary,Resource utilization
NCT00212784,measures_secondary,Satisfaction with treatment
NCT00212784,has_criteria,uncontrolled medical condition
NCT00212784,has_criteria,psychiatric disorder
NCT06038279,involves,Allergic Rhinitis
NCT06038279,evaluates,INI-2004
NCT06038279,measures_primary,Change from baseline
NCT06038279,measures_secondary,Vital signs measurements
NCT06038279,has_criteria,Single ascending Dose
NCT03421379,involves,Diabetes Mellitus
NCT03421379,evaluates,LY900018
NCT03421379,measures_primary,Plasma glucose increase
NCT03421379,measures_secondary,Change From Baseline in Maximal Blood Glucose
NCT03421379,measures_secondary,Time to Maximal Concentration
NCT03421379,has_criteria,Pre-dose up to 30 minutes post each glucagon administration
NCT00483379,involves,Respiratory Decline
NCT00483379,evaluates,Alglucosidase Alfa
NCT00483379,measures_primary,ventilator use
NCT00483379,measures_secondary,motor function decline
NCT00483379,has_criteria,clinical decline
NCT02520284,involves,Ulcerative Colitis
NCT02520284,evaluates,Andecaliximab
NCT02520284,measures_primary,EBS Clinical Remission
NCT02520284,measures_secondary,MCS Remission
NCT02520284,measures_secondary,MCS Response
NCT02520284,has_criteria,Moderately to Severely Active
NCT06079879,involves,Essential Thrombocythemia
NCT06079879,evaluates,Bomedemstat
NCT06079879,measures_primary,Durable Clinicohematologic Response Rate
NCT06079879,measures_secondary,Change From Baseline in MFSAF v4.0 Individual Fatigue Symptom Item Score
NCT06079879,measures_secondary,Change From Baseline in PROMIS Fatigue SF-7a Total Fatigue Score
NCT06079879,measures_secondary,Change From Baseline in Total Symptom Score as Measured on the MFSAF v4.0
NCT06079879,has_criteria,Inadequate Response or Intolerance of Hydroxyurea
NCT01049984,involves,Parkinson's Disease
NCT01049984,evaluates,Rasagiline
NCT01049984,measures_primary,UPDRS Total Score
NCT01049984,measures_secondary,UPDRS Part II
NCT01049984,has_criteria,site rater training
NCT04104321,involves,NASH
NCT04104321,evaluates,Aramchol
NCT04104321,measures_primary,Resolution of NASH
NCT04104321,measures_primary,Improvement in Fibrosis
NCT04104321,measures_secondary,All-cause mortality
NCT04104321,measures_secondary,Liver transplant
NCT04104321,measures_secondary,Histological progression to cirrhosis
NCT04104321,measures_secondary,MELD score >15
NCT04104321,measures_secondary,Hospitalization due to hepatic decompensation
NCT04104321,has_criteria,Age 18 to 75 years
NCT04104321,has_criteria,Histological confirmation of NASH
NCT06203002,involves,Diabetic Peripheral Neuropathic Pain
NCT06203002,measures_primary,Change from Baseline to Week 8 in Average Daily Pain Score
NCT06203002,measures_secondary,Burning Pain
NCT06203002,measures_secondary,Pain Interference on Sleep
NCT06203002,measures_secondary,Patient Global Impression of Change Score
NCT06203002,measures_secondary,Total Neuropathic Pain Symptom Inventory Score
NCT06203002,has_criteria,Adult ≥18 years of age
NCT06203002,has_criteria,Body mass index 18.0 to 40.0 kg/m^2
NCT06203002,has_criteria,Type 1 or Type 2 Diabetes Mellitus
NCT06203002,has_criteria,Chronic DPNP for ≥6 months
NCT06203002,has_criteria,Glycosylated hemoglobin ≤11%
NCT06203002,has_criteria,Stable diabetes regimen for ≥3 months
NCT01369602,involves,Renal Impairment
NCT01369602,evaluates,PF-04991532
NCT01369602,measures_primary,AUClast
NCT01369602,measures_primary,Cmax
NCT01369602,measures_primary,Tmax
NCT01369602,measures_primary,Renal Clearance
NCT01369602,measures_primary,Amount of drug excreted
NCT01369602,has_criteria,Stable renal function
NCT01369602,has_criteria,Body Mass Index
NCT01369602,has_criteria,Total body weight
NCT01369602,has_criteria,Contraception
NCT01369602,has_criteria,Myocardial infarction
NCT01369602,has_criteria,Heart failure
NCT01369602,has_criteria,Acute renal disease
NCT01846702,evaluates,LY3084077
NCT01846702,measures_primary,Percent Change Fasting Triglycerides
NCT01846702,measures_secondary,Change From Baseline in Fasting Insulin
NCT01846702,measures_secondary,Change From Baseline in Weight
NCT01846702,measures_secondary,Change From Baseline Up to Day 2 in Level of C-peptide AUC
NCT01162421,involves,Rheumatoid Arthritis
NCT01162421,evaluates,Adalimumab
NCT01162421,measures_primary,Radiographic progression
NCT01162421,measures_secondary,Change From Baseline in mTSS
NCT01162421,has_criteria,Methotrexate failure
NCT06443502,involves,Chronic Pouchitis
NCT06443502,evaluates,Vedolizumab
NCT06443502,measures_primary,mPDAI Remission
NCT06443502,measures_secondary,mPDAI Remission
NCT06443502,has_criteria,Children and Teenagers
NCT03933202,involves,Multiple Sclerosis
NCT03933202,evaluates,cladribine tablets
NCT03933202,measures_primary,Annualized Relapse Rate
NCT03933202,measures_secondary,Treatment Satisfaction Questionnaire
NCT03933202,has_criteria,Suboptimally Controlled Participants
NCT03797521,involves,Trichotillomania
NCT03797521,measures_primary,hairpulling frequency
NCT03797521,measures_secondary,severity
NCT03797521,has_criteria,Adult
NCT03670121,involves,Homogeneous Emphysema
NCT03670121,evaluates,Sequential Segmental Bronchoscopic Thermal Vapor Ablation
NCT03670121,measures_primary,Change in FEV1
NCT03670121,measures_secondary,Change in St Georges Respiratory Questionnaire for COPD Patients score
NCT03670121,measures_secondary,Change in FVC
NCT03670121,measures_secondary,Change in Forced Vital Capacity
NCT03670121,measures_secondary,Change in FRC
NCT03670121,measures_secondary,Change in Forced Residual Capacity
NCT03670121,measures_secondary,Change in RV
NCT03670121,measures_secondary,Change in Residual Volume
NCT03670121,measures_secondary,Change in TLC
NCT03670121,measures_secondary,Change in Total Lung Capacity
NCT03670121,measures_secondary,Change in RV/TLC
NCT03670121,measures_secondary,Change in Residual Volume/Total Lung Capacity
NCT03670121,measures_secondary,Change in DLCO
NCT03670121,measures_secondary,Change in Diffusing capacity of the lung for carbon monoxide
NCT05174221,involves,Primary Immunoglobulin A Nephropathy
NCT05174221,evaluates,Mezagitamab
NCT05174221,measures_primary,Percent Change From Baseline in Proteinuria
NCT05174221,measures_secondary,Percentage of Participants With TEAEs
NCT05174221,has_criteria,Stable Background Therapy
NCT00795821,involves,Major Depressive Disorder
NCT00795821,measures_primary,MADRS at Week 10
NCT00795821,measures_secondary,Sheehan Disability Scale (SDS) Global Functional Impairment
NCT01352221,involves,Iron Deficiency Anaemia
NCT01352221,involves,Crohn's Disease
NCT01352221,evaluates,Oral Ferric Iron
NCT01352221,measures_primary,Change in Hb Concentration
NCT01352221,measures_secondary,Proportion of Subjects That Achieved ≥1 g/dL Change From Baseline in Hb Concentration at Week 12
NCT01352221,measures_secondary,Proportion of Subjects That Achieved ≥2 g/dL Change From Baseline in Hb Concentration at Week 12
NCT01352221,measures_secondary,Proportion of Subjects That Achieved Hb Concentration Within Normal Range at Week 12
NCT01352221,has_criteria,Randomisation Visit (Week 0)
NCT04986202,involves,Heart Failure
NCT04986202,evaluates,AZD4831
NCT04986202,measures_primary,Kansas City Cardiomyopathy Questionnaire-Total Symptom Score
NCT04986202,measures_secondary,Six Minute Walk Distance
NCT04986202,measures_secondary,N-terminal pro-brain natriuretic peptide (NT-proBNP)
NCT04986202,measures_secondary,Left ventricular global longitudinal strain (LV-GLS)
NCT04986202,measures_secondary,Left atrial volume index (LAVI)
NCT04986202,measures_secondary,Left ventricular mass index (LVMI)
NCT01227902,involves,Partial-onset Seizures
NCT01227902,evaluates,Retigabine
NCT01227902,measures_primary,POS frequency reduction
NCT01227902,measures_secondary,Seizure frequency change
NCT01227902,has_criteria,>=50% reduction
NCT03505021,involves,Amyotrophic Lateral Sclerosis
NCT03505021,evaluates,Oral Levosimendan
NCT03505021,measures_primary,Supine Slow Vital Capacity
NCT03505021,measures_secondary,ALS Functional Rating Scale-Revised
NCT03505021,has_criteria,Slow vital capacity decline
NCT00498602,involves,Alzheimer's Disease
NCT00498602,evaluates,ACC-001
NCT00498602,measures_primary,Geometric Mean Titers
NCT00498602,measures_secondary,Change From Baseline GMTs
NCT00498602,has_criteria,6-week screening
NCT06357221,involves,Psoriasis
NCT06357221,evaluates,Topical Skincare Products
NCT06357221,measures_primary,Change in psoriatic BSA
NCT06357221,measures_secondary,Target lesion severity
NCT06357221,measures_secondary,Physician Global Assessment
NCT06357221,measures_secondary,Skin quality
NCT06357221,has_criteria,Baseline
NCT02447302,involves,Ulcerative Colitis
NCT02447302,evaluates,Etrasimod
NCT02447302,measures_primary,Change From Baseline in Adapted Mayo Score
NCT02447302,measures_secondary,Percentage of Participants Who Achieved Endoscopic Improvement
NCT02447302,measures_secondary,Change From Baseline in 2-component MCS
NCT02447302,measures_secondary,Change From Baseline in Total Mayo Score
NCT02447302,has_criteria,flexible proctosigmoidoscopy
NCT04338321,involves,Treatment Resistant Major Depressive Disorder
NCT04338321,evaluates,Esketamine Nasal Spray
NCT04338321,evaluates,Quetiapine Extended Release
NCT04338321,measures_primary,Remission at Week 8
NCT04338321,measures_secondary,Relapse-free Until Week 32
NCT04338321,has_criteria,MADRS total score <=10
NCT01724021,involves,Diffuse Large B-Cell Lymphoma
NCT01724021,involves,Follicular Non-Hodgkin's Lymphoma
NCT01724021,evaluates,Rituximab
NCT01724021,measures_primary,Participant preference
NCT01724021,measures_secondary,Adverse Events
NCT01724021,measures_secondary,Time for Rituximab Administration
NCT01724021,has_criteria,CD20+
NCT05803421,involves,Type 2 Diabetes
NCT05803421,involves,Obesity
NCT05803421,involves,Overweight
NCT05803421,evaluates,Orforglipron
NCT05803421,evaluates,Insulin Glargine
NCT05803421,measures_primary,Time to MACE-4
NCT05803421,measures_primary,Time to MACE-3
NCT05803421,measures_secondary,Change from Baseline HbA1c
NCT05803421,measures_secondary,Change from Baseline Fasting Serum Glucose
NCT05803421,measures_secondary,Change from Baseline SMBG
NCT05803421,measures_secondary,Percentage of Participants with HbA1c Target Values
NCT05803421,measures_secondary,Change from Baseline Body Weight
NCT05803421,measures_secondary,Percent Change from Baseline Body Weight
NCT05803421,measures_secondary,Change from Baseline SF-36v2 Acute Form Domain Score
NCT05803421,has_criteria,Cardiovascular Risk
NCT01674621,involves,Osteoporosis
NCT01674621,evaluates,BA058
NCT01674621,measures_primary,Percent Change BMD
NCT01674621,measures_secondary,Serum BSAP
NCT01674621,measures_secondary,Serum PICP
NCT01674621,measures_secondary,Serum Osteocalcin
NCT01674621,measures_secondary,Serum PINP
NCT01674621,measures_secondary,Serum CTXI
NCT01674621,has_criteria,Abnormal Physical Examinations
NCT03126721,evaluates,PF-06751979
NCT03126721,measures_primary,midazolam AUClast
NCT03126721,measures_secondary,midazolam Cmax
NCT03126721,measures_secondary,midazolam AUCinf
NCT03126721,has_criteria,Healthy adults
NCT03126721,has_criteria,18-55 years
NCT06045221,involves,Type 2 Diabetes
NCT06045221,evaluates,Orforglipron
NCT06045221,evaluates,Semaglutide
NCT06045221,measures_primary,Change from Baseline in HbA1c
NCT06045221,measures_secondary,Percentage of Participants Who Achieved HbA1c <7.0% 53 millimole/mole (mmol/mol)
NCT06045221,measures_secondary,Percentage of Participants Who Achieved HbA1c ≤6.5% (48 mmol/mol)
NCT06045221,measures_secondary,Percentage Change from Baseline in Body Weight
NCT06045221,measures_secondary,Percentage of Participants Who Achieved HbA1c <5.7% (39 mmol/mol)
NCT06045221,measures_secondary,Change from Baseline in Fasting Serum Glucose
NCT06045221,measures_secondary,Change from Baseline in Daily Average 7-point Self-monitored Blood Glucose (SMBG)
NCT06045221,measures_secondary,Percentage of Participants Who Achieved Weight Loss of ≥5%
NCT06045221,measures_secondary,Percentage of Participants Who Achieved Weight Loss of ≥10%
NCT06045221,measures_secondary,Percentage of Participants Who Achieved Weight Loss of ≥15%
NCT06045221,measures_secondary,Change from Baseline in Systolic Blood Pressure (SBP)
NCT06045221,measures_secondary,Change from Baseline in Diastolic Blood Pressure (DBP)
NCT06045221,measures_secondary,Percentage Change from Baseline in Total Cholesterol
NCT06045221,measures_secondary,Percentage Change from Baseline in High Density Lipoprotein (HDL)-Cholesterol
NCT06045221,measures_secondary,Percentage Change from Baseline in Low Density Lipoprotein (LDL)-Cholesterol
NCT06045221,measures_secondary,Percentage Change from Baseline in Very Low Density Lipoprotein (VLDL)-Cholesterol
NCT06045221,measures_secondary,Percentage Change from Baseline in Non-HDL-Cholesterol
NCT06045221,measures_secondary,Percentage Change from Baseline in Triglycerides
NCT06045221,measures_secondary,Change from Baseline in Short Form 36 Version 2 (SF-36-v2) Acute Form Domain Summary Scores
NCT05986721,involves,Mild Cognitive Impairment
NCT05986721,evaluates,AGB101
NCT05986721,measures_primary,Change in EC Volume
NCT05986721,measures_secondary,Change in CDR-SB Score
NCT05986721,measures_secondary,Change in CDR-Memory Box Score
NCT05986721,has_criteria,8th grade education
NCT05986721,has_criteria,good general health
NCT05986721,has_criteria,willing to consent
NCT03105102,involves,Crohn's Disease
NCT03105102,evaluates,Risankizumab
NCT03105102,measures_primary,CDAI clinical remission
NCT03105102,measures_secondary,Endoscopic response
NCT03105102,has_criteria,CDAI score < 150
NCT04663321,involves,Treatment-Resistant Depression
NCT04663321,evaluates,MK-1942
NCT04663321,measures_primary,Change From Baseline
NCT04663321,measures_secondary,Adverse Event
NCT04663321,has_criteria,Up to approximately 6 Weeks
NCT00390221,involves,Relapsing-Remitting Multiple Sclerosis
NCT00390221,evaluates,Daclizumab High Yield Process (DAC HYP)
NCT00390221,measures_primary,Adjusted Annualized Relapse Rate
NCT00390221,measures_secondary,Gd-Enhancing Lesions
NCT00390221,measures_secondary,T2 Hyperintense Lesions
NCT00390221,measures_secondary,Proportion of Participants Who Relapsed
NCT00390221,measures_secondary,Mean Change From Baseline in MSIS-29 Physical Impact Score
NCT00390221,has_criteria,Baseline through Week 52
NCT04721821,involves,Rheumatoid Arthritis
NCT04721821,evaluates,Tofacitinib
NCT04721821,evaluates,Tumor Necrosis Factor Inhibitors
NCT04721821,measures_primary,Low Disease Activity
NCT04721821,measures_secondary,Clinical Disease Activity Index
NCT04721821,has_criteria,Moderate or high disease activity
NCT05137002,involves,Uncontrolled Hypertension
NCT05137002,evaluates,CIN-107
NCT05137002,measures_primary,Change From Baseline in Mean Seated SBP
NCT05137002,measures_secondary,Change From Baseline in Mean Seated DBP
NCT05137002,measures_secondary,Change From Baseline in 24-hour Urine Aldosterone
NCT05137002,measures_secondary,Change From Baseline in 24-hour Serum Aldosterone
NCT05137002,measures_secondary,Percentage of Patients Achieving a Mean Seated SBP <130 mmHg
NCT05137002,measures_secondary,Change From Baseline in 24-hour Urine Renin
NCT05137002,measures_secondary,Change From Baseline in 24-hour Serum Renin
NCT05137002,has_criteria,stable regimen of background antihypertensive agent(s)
NCT05137002,has_criteria,mean seated systolic blood pressure ≥ 140 mmHg
NCT05137002,has_criteria,ability to be adherent to the study drug
NCT05137002,has_criteria,stable regimen of SGLT2 inhibitor
NCT04388202,involves,Major Depressive Disorder
NCT04388202,evaluates,sertraline
NCT04388202,evaluates,escitalopram
NCT04388202,measures_primary,QIDS-SR response rate
NCT04388202,measures_secondary,QIDS-SR score decrease
NCT04388202,has_criteria,age 22 or older
NCT04388202,has_criteria,DSM-5 depression diagnosis
NCT04388202,has_criteria,PHQ-9 score 10 or more
NCT04388202,has_criteria,no prior study medication
NCT04388202,has_criteria,no prior ECT/TMS/esketamine
NCT02192164,involves,Psoriasis
NCT02192164,evaluates,Etanercept
NCT02192164,measures_primary,PASI score at Week 24
NCT02192164,measures_primary,PASI score at Week 12
NCT02192164,measures_secondary,Percentage of Part...
NCT02192164,has_criteria,Smoking Status
NCT01482884,involves,Ulcerative Colitis
NCT01482884,evaluates,Tralokinumab
NCT01482884,measures_primary,Change in Mayo Score
NCT01482884,measures_secondary,Mucosal Healing
NCT01482884,measures_secondary,Clinical Remission
NCT01482884,has_criteria,Mayo score ≤2
NCT06515002,involves,Cystic Fibrosis
NCT06515002,evaluates,BI 3720931
NCT06515002,measures_primary,FEV1pp at Week 8
NCT06515002,measures_secondary,FEV1pp at Week 24
NCT06515002,has_criteria,drug-related adverse events
NCT02431702,involves,Schizophrenia
NCT02431702,involves,Schizophreniform
NCT02431702,evaluates,Paliperidone Palmitate Long-Acting Injection
NCT02431702,evaluates,Oral Antipsychotics
NCT02431702,measures_primary,Time to First Treatment Failure
NCT02431702,measures_secondary,Change From Baseline in Cognition
NCT02431702,has_criteria,Recent-onset
NCT01910402,involves,Human Immunodeficiency Virus (HIV)-1
NCT01910402,evaluates,Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC)
NCT01910402,measures_primary,Plasma HIV-1 RNA <50 c/mL at Week 48
NCT01910402,measures_secondary,Change From Baseline in Plasma HIV-1 RNA
NCT01910402,has_criteria,ART Naïve Women
NCT00787202,involves,Ulcerative Colitis
NCT00787202,evaluates,CP-690
NCT00787202,measures_primary,Clinical Response
NCT00787202,measures_secondary,Clinical Remission
NCT00787202,measures_secondary,Endoscopic Response
NCT00787202,measures_secondary,Endoscopic Remission
NCT00787202,has_criteria,Moderate and Severe
NCT01708902,involves,Type 2 Diabetes
NCT01708902,evaluates,Linagliptin Plus Metformin
NCT01708902,measures_primary,Change From Baseline HbA1c
NCT01708902,measures_secondary,Treat to Target Efficacy Response
NCT01708902,has_criteria,Drug naïve
NCT03397121,involves,Heterozygous Familial Hypercholesterolemia
NCT03397121,evaluates,Inclisiran
NCT03397121,measures_primary,Percent Change in LDL-C
NCT03397121,measures_secondary,PCSK9
NCT03397121,measures_secondary,Total Cholesterol
NCT03397121,measures_secondary,Apolipoprotein B
NCT03397121,measures_secondary,Non-HDL-C
NCT03397121,has_criteria,≥18 years of age
NCT03397121,has_criteria,LDL-C ≥2.6 mmol/L
NCT03397121,has_criteria,fasting triglyceride \<4.52 mmol/L
NCT03397121,has_criteria,maximally tolerated dose
NCT03397121,has_criteria,documented intolerance to statins
NCT03397121,has_criteria,stable dose for ≥30 days
NCT03645421,involves,Type 2 Diabetes
NCT03645421,evaluates,MEDI0382
NCT03645421,measures_primary,24-hour heart rate
NCT03645421,measures_secondary,Glucose AUC[0-4h]
NCT03645421,measures_secondary,Body weight
NCT03645421,has_criteria,Japanese Preobese or Obese
NCT03462121,involves,Alzheimer's Disease
NCT03462121,involves,Cerebrovascular Disease
NCT03462121,evaluates,RPh201
NCT03462121,measures_primary,ADAS-Cog score
NCT03462121,measures_secondary,CDR-SB score
NCT03462121,measures_secondary,AEs
NCT03462121,has_criteria,Month 6
NCT01961921,involves,Transthyretin (TTR)-Mediated Amyloidosis
NCT01961921,evaluates,Patisiran
NCT01961921,measures_primary,Percentage Change in TTR
NCT01961921,measures_secondary,Change From Baseline in mNIS+7
NCT01961921,measures_secondary,Change From Baseline in Quality of Life
NCT01961921,measures_secondary,Change in Gait Speed With 10-meter Walk Test
NCT01961921,has_criteria,Patients Who Have Already Been Treated With ALN-TTR02
NCT02002221,involves,Type 2 Diabetes Mellitus
NCT02002221,evaluates,Vildagliptin
NCT02002221,measures_primary,Change in HbA1c
NCT02002221,measures_secondary,Fasting Plasma Glucose
NCT02002221,measures_secondary,Hypoglycemia
NCT02002221,measures_secondary,Adverse Events
NCT02002221,has_criteria,Baseline HbA1c ≥ 7%
NCT00658021,involves,Type 2 Diabetes
NCT00658021,evaluates,Exenatide
NCT00658021,measures_primary,HbA1c at Week 28
NCT00658021,measures_secondary,Body Weight
NCT00658021,has_criteria,last non-missing assessment
NCT00105521,involves,Parkinson's Disease
NCT00105521,evaluates,Sarizotan
NCT00105521,measures_primary,On-time without dyskinesia
NCT00105521,measures_secondary,Modified AIMS Score
NCT00105521,measures_secondary,UPDRS Items 32 and 33 Composite Score
NCT00105521,measures_secondary,UPDRS Part III Total Score
NCT00105521,has_criteria,Treatment Associated Dyskinesia
NCT00460564,involves,Post-Stroke Upper Limb Spasticity
NCT00460564,evaluates,GSK1358820
NCT00460564,measures_primary,AUC MAS wrist score
NCT00460564,measures_secondary,Mean Change MAS wrist score
NCT00460564,has_criteria,Baseline
NCT02146664,involves,Acute NSTEMI
NCT02146664,evaluates,DLBS1033
NCT02146664,measures_primary,Infarct size
NCT02146664,measures_secondary,LV function
NCT02146664,measures_secondary,Composite endpoints
NCT02146664,measures_secondary,Individual event of MACE
NCT02146664,measures_secondary,Nitroglycerin amount
NCT02146664,measures_secondary,Plasma fibrinogen level
NCT02146664,measures_secondary,Plasma d-dimer level
NCT02146664,measures_secondary,hs-CRP
NCT02146664,measures_secondary,Routine hematology
NCT02146664,measures_secondary,Liver function
NCT02146664,measures_secondary,Renal function
NCT00723190,involves,Attention Deficit Hyperactivity Disorder
NCT00723190,evaluates,CLONICEL
NCT00723190,measures_primary,Change From Baseline in 12-lead Electrocardiogram
NCT00723190,measures_secondary,Change From Baseline in Body Weight
NCT00723190,measures_secondary,Change From Baseline in Diastolic Blood Pressure
NCT00723190,measures_secondary,Change From Baseline in Systolic Blood Pressure
NCT00723190,measures_secondary,Change From Baseline in Body Temperature
NCT00723190,measures_secondary,Change From Baseline in Heart Rate
NCT00723190,has_criteria,1 year
NCT03179202,involves,Back Pain
NCT03179202,evaluates,Electrical Stimulation
NCT03179202,measures_primary,Pain reduction
NCT03179202,measures_secondary,Adverse Event
NCT03179202,has_criteria,Up to 15 months
NCT03160521,involves,Acute Schizophrenia
NCT03160521,evaluates,Risperidone in Situ Microparticle (ISM)®
NCT03160521,measures_primary,PANSS Total Score
NCT03160521,measures_secondary,CGI-S Total Score
NCT03160521,measures_secondary,CGI-I Score
NCT03160521,has_criteria,study day 85
NCT04120402,involves,Osteoarthritis of the Knee
NCT04120402,evaluates,EP-104IAR
NCT04120402,measures_primary,Change From Baseline
NCT04120402,measures_secondary,Area Under the Curve
NCT04120402,has_criteria,12 weeks
NCT01603602,involves,Upper Limb Spasticity
NCT01603602,evaluates,BOTOX®
NCT01603602,measures_primary,MAS-B Score
NCT01603602,measures_secondary,CGI of Overall Change
NCT01603602,has_criteria,Baseline (Day 1)
NCT00195702,involves,Rheumatoid Arthritis
NCT00195702,evaluates,Adalimumab
NCT00195702,measures_primary,ACR20 Response
NCT00195702,measures_secondary,Modified Total Sharp X-ray Score
NCT00195702,has_criteria,American College of Rheumatology 20%
NCT00457821,involves,Cystic Fibrosis
NCT00457821,evaluates,Ivacaftor
NCT00457821,measures_primary,Nasal Potential Difference
NCT00457821,measures_secondary,Percent Predicted FEV1
NCT00457821,measures_secondary,Cystic Fibrosis Questionnaire-Revised
NCT00457821,has_criteria,Baseline to Follow-up
NCT05763121,involves,Severe Eosinophilic Asthma
NCT05763121,evaluates,Dexpramipexole
NCT05763121,measures_primary,Annualized rate exacerbations
NCT05763121,measures_secondary,Asthma Control Questionnaire-6
NCT05763121,measures_secondary,Asthma Quality of Life Questionnaire
NCT05763121,has_criteria,Age 12 years and older
NCT01915264,involves,Type 2 Diabetes
NCT01915264,evaluates,acarbose/metformin fixed dose combination
NCT01915264,measures_primary,Incidence of hypoglycemia
NCT01915264,measures_secondary,Mean change in HbA1c
NCT01915264,has_criteria,Best clinical practice
NCT01915264,has_criteria,Informed consent
NCT01915264,has_criteria,Acarbose or metformin monotherapy
NCT01915264,has_criteria,No acarbose/metformin 3 months prior
NCT04707664,involves,COVID-19
NCT04707664,evaluates,Sargramostim
NCT04707664,measures_primary,Number of ER visits/hospitalizations/death
NCT04707664,measures_secondary,Disease Progression Based on NIAID Score
NCT04707664,measures_secondary,Time to Disease Progression Based on NIAID Score
NCT04707664,measures_secondary,Change From Baseline in Overall Symptom Scores
NCT04707664,measures_secondary,Number of Participants With Adverse Events
NCT04707664,has_criteria,positive laboratory diagnosis
NCT01486264,involves,Cervical Dystonia
NCT01486264,evaluates,Xeomin
NCT01486264,measures_primary,TWSTRS Severity
NCT01486264,measures_secondary,TWSTRS Total
NCT01486264,has_criteria,Injection Schedule
NCT06538064,involves,Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT06538064,evaluates,HyQvia
NCT06538064,measures_primary,Treatment Satisfaction
NCT06538064,measures_secondary,Health-Related Quality of Life
NCT06538064,has_criteria,subcutaneous immunoglobulin/intravenous immunoglobulin
NCT00558064,involves,Hypertension
NCT00558064,evaluates,Amlodipine
NCT00558064,measures_primary,Diastolic Blood Pressure
NCT00558064,measures_secondary,Systolic Blood Pressure
NCT00558064,has_criteria,Seated trough blood pressure
NCT01635764,involves,Hidradenitis Suppurativa
NCT01635764,evaluates,Adalimumab
NCT01635764,measures_primary,Clinical Response
NCT01635764,measures_secondary,Clinical Response
NCT01635764,has_criteria,Prior phase 3 study
NCT01396421,involves,Acute Schizophrenia
NCT01396421,evaluates,OPC-34712
NCT01396421,measures_primary,PANSS Total Score
NCT01396421,measures_secondary,CGI-S Score
NCT01396421,has_criteria,Adults
NCT01439321,involves,Chronic Immune Thrombocytopenic Purpura
NCT01439321,evaluates,Eltrombopag
NCT01439321,evaluates,Romiplostim
NCT01439321,measures_primary,Treatment satisfaction
NCT01439321,measures_secondary,SF-36 score
NCT01439321,has_criteria,Adults 18 years and older
NCT01439321,has_criteria,Diagnosed with chronic ITP
NCT01439321,has_criteria,Switched to eltrombopag or romiplostim
NCT01439321,has_criteria,Received corticosteroids
NCT01439321,has_criteria,Medical history available
NCT02316821,involves,Chronic Kidney Disease
NCT02316821,involves,Type 2 Diabetes
NCT02316821,evaluates,Bardoxolone Methyl
NCT02316821,measures_primary,glomerular filtration rate
NCT02316821,measures_secondary,estimated GFR
NCT02316821,has_criteria,CKD patients
NCT02316821,has_criteria,type 2 diabetes mellitus
NCT02316821,has_criteria,stable dose ACE inhibitors
NCT02316821,has_criteria,stable dose ARBs
NCT02316821,has_criteria,estimated GFR levels
NCT02316821,has_criteria,mean systolic blood pressure
NCT01733121,involves,Tardive Dyskinesia
NCT01733121,evaluates,NBI-98854
NCT01733121,measures_primary,AIMS Dyskinesia Total Score Change
NCT01733121,measures_secondary,CGI-TD
NCT01733121,has_criteria,neuroleptic-induced tardive dyskinesia
NCT01733121,has_criteria,schizophrenia
NCT01733121,has_criteria,schizoaffective disorder
NCT01733121,has_criteria,mood disorder
NCT01733121,has_criteria,gastrointestinal disorder
NCT01733121,has_criteria,antipsychotic medication
NCT04032964,involves,Soft Tissue Sarcoma
NCT04032964,evaluates,L19TNF
NCT04032964,evaluates,Doxorubicin
NCT04032964,measures_primary,Progression-free survival
NCT04032964,measures_secondary,Overall response rate
NCT04032964,measures_secondary,Disease Control Rate
NCT04032964,has_criteria,Human anti-fusion protein antibodies
NCT01287364,involves,Allergic Rhinitis
NCT01287364,evaluates,Intranasal Corticosteroids
NCT01287364,measures_primary,Treatment Satisfaction
NCT01287364,measures_secondary,Nasal Symptom Score
NCT01287364,has_criteria,Baseline rTNSS
NCT00701090,involves,Type 2 Diabetes
NCT00701090,evaluates,Sitagliptin
NCT00701090,evaluates,Glimepiride
NCT00701090,measures_primary,Change From Baseline in HbA1c
NCT00701090,measures_secondary,Change From Baseline in FPG
NCT00701090,measures_secondary,Percent of Patients With Hypoglycemia
NCT00701090,measures_secondary,Change From Baseline in Body Weight
NCT00701090,measures_secondary,Percent of Patients With A1C <7.0%
NCT00701090,measures_secondary,Percent of Patients With A1C <6.5%
NCT04426890,involves,Chronic Spontaneous Urticaria
NCT04426890,evaluates,CT-P39
NCT04426890,evaluates,Xolair
NCT04426890,measures_primary,Change from baseline
NCT04426890,measures_secondary,Weekly Itch Severity Score
NCT04426890,measures_secondary,Urticaria Activity Score
NCT04426890,measures_secondary,Hives Severity Score
NCT04426890,measures_secondary,Angioedema-free days
NCT04426890,measures_secondary,Dermatology Life Quality Index
NCT04426890,has_criteria,dose levels
NCT04612790,involves,Bullous Pemphigoid
NCT04612790,evaluates,Benralizumab
NCT04612790,measures_primary,complete remission
NCT04612790,measures_secondary,relapse-free
NCT04612790,measures_secondary,OCS exposure
NCT04612790,measures_secondary,BPDAI activity
NCT04612790,measures_secondary,BPDAI-Pruritus score
NCT04612790,has_criteria,≥ 2 months
NCT01708590,involves,plaque psoriasis
NCT01708590,evaluates,brodalumab
NCT01708590,measures_primary,PASI75 at week 12
NCT01708590,measures_secondary,sPGA Score Success
NCT01708590,has_criteria,stable moderate to severe plaque psoriasis
NCT01708590,has_criteria,involved body surface area (BSA) ≥ 10%
NCT01708590,has_criteria,PASI ≥ 12
NCT01708590,has_criteria,sPGA ≥ 3
NCT01708590,has_criteria,known history of Crohn's disease
NCT05442190,involves,Psoriasis
NCT05442190,evaluates,Topical SGX302
NCT05442190,measures_primary,PASI 75
NCT05442190,measures_secondary,PASI 90
NCT05442190,has_criteria,18 weeks
NCT03806790,involves,Psoriasis Vulgaris
NCT03806790,evaluates,LEO 90100 Foam
NCT03806790,measures_primary,Overall Improvement Rate
NCT03806790,measures_secondary,Change in Total Sign Score
NCT03806790,measures_secondary,Number of Adverse Events
NCT03806790,has_criteria,Japanese Subjects
NCT00669864,involves,Type 2 diabetes
NCT00669864,evaluates,Biphasic Insulin Aspart 30 Combined With Metformin
NCT00669864,measures_primary,Change in HbA1c
NCT00669864,measures_secondary,Change in 8-point Plasma Glucose Profile
NCT00669864,has_criteria,Type 2 diabetes
NCT00669864,has_criteria,basal insulin
NCT01442064,involves,Macular Edema
NCT01442064,evaluates,Ranibizumab
NCT01442064,measures_primary,Best Corrected Visual Acuity
NCT01442064,measures_secondary,Central Foveal Thickness
NCT01442064,has_criteria,Retinal Vein Occlusion
NCT05573464,involves,Chronic Obstructive Pulmonary Disease
NCT05573464,evaluates,Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant
NCT05573464,measures_primary,Adverse Events
NCT05573464,measures_secondary,Digital 12-lead Holter electrocardiogram
NCT05573464,measures_secondary,12-lead ECG
NCT05573464,measures_secondary,laboratory values
NCT05573464,measures_secondary,Blood Pressure
NCT05573464,measures_secondary,pulse rate
NCT05573464,measures_secondary,respiratory rate
NCT04647890,involves,Systemic Sclerosis
NCT04647890,evaluates,FT011
NCT04647890,measures_primary,mRSS Change
NCT04647890,measures_secondary,%FVC Change
NCT04647890,has_criteria,Baseline to Week 16
NCT02978690,involves,Generalized Pustular Psoriasis
NCT02978690,evaluates,Spesolimab
NCT02978690,measures_primary,% GPPASI change
NCT02978690,measures_secondary,GPPGA Total Score
NCT02978690,has_criteria,Baseline and Week 2
NCT03598790,involves,Chronic Plaque Psoriasis
NCT03598790,evaluates,Bimekizumab
NCT03598790,measures_primary,PASI90 response
NCT03598790,measures_secondary,Investigator's Global Assessment
NCT03598790,has_criteria,Adult Subjects
NCT02053103,involves,Type 2 Diabetes Mellitus
NCT02053103,evaluates,PF-05175157
NCT02053103,measures_primary,Change from baseline in WMDG
NCT02053103,measures_secondary,Fasting plasma glucose
NCT02053103,has_criteria,Metformin dose ≥1000 mg
NCT02053103,has_criteria,Hemoglobin A1c 7-10%
NCT02053103,has_criteria,Body Mass Index ≥25 kg/m2
NCT03760003,involves,Ulcerative Colitis
NCT03760003,evaluates,ABX464
NCT03760003,evaluates,ABX464-N-Glu
NCT03760003,measures_primary,Modified Mayo Score
NCT03760003,measures_secondary,Clinical remission
NCT03760003,measures_secondary,Clinical response
NCT03760003,measures_secondary,Endoscopic Improvement
NCT03760003,measures_secondary,Mucosal healing
NCT03760003,measures_secondary,Stool and rectal bleeding frequency
NCT03760003,measures_secondary,Partial Modified Mayo Score
NCT03760003,measures_secondary,Fecal calprotectin
NCT03760003,measures_secondary,C Reactive Protein
NCT03760003,measures_secondary,miR-124 expression
NCT03760003,measures_secondary,IBDQ
NCT03760003,measures_secondary,Inflammatory Infiltrate
NCT03760003,measures_secondary,IL-6
NCT03760003,measures_secondary,TNFα
NCT03760003,measures_secondary,IL-1b
NCT03760003,measures_secondary,IL-10
NCT03760003,has_criteria,Moderate to Severe
NCT04173403,involves,Hypercholesterolemia
NCT04173403,evaluates,AK102
NCT04173403,measures_primary,Percent Change LDL-C
NCT04173403,measures_secondary,Incidence adverse events
NCT04173403,measures_secondary,Percent Change HDL cholesterol
NCT04173403,measures_secondary,Percent Change non-HDL cholesterol
NCT04173403,measures_secondary,Percent Change Triglyceride
NCT04173403,measures_secondary,Percent Change Apo B
NCT04173403,measures_secondary,Percent Change Apo A-I
NCT04173403,measures_secondary,Percent Change Total Cholesterol
NCT04173403,measures_secondary,Change From Baseline PCSK9
NCT04173403,measures_secondary,Concentrations AK102
NCT04173403,measures_secondary,Number subjects develop ADAs
NCT04173403,has_criteria,Body weight ≥ 40 kg
NCT04173403,has_criteria,Completed AK102-202 study
NCT04173403,has_criteria,Poor compliance AK102-202
NCT04173403,has_criteria,AE led to permanent discontinuation AK102
NCT04173403,has_criteria,Prior use PCSK9 inhibitors
NCT01559103,involves,Rheumatoid Arthritis
NCT01559103,evaluates,MEDI5117
NCT01559103,measures_primary,Safety profile
NCT01559103,measures_secondary,Pharmacokinetics
NCT01559103,has_criteria,Baseline day -1
NCT01634243,involves,Parkinson's Disease
NCT01634243,evaluates,SPM 962
NCT01634243,measures_primary,UPDRS Part 2 sum score
NCT01634243,measures_primary,UPDRS Part 3 sum score
NCT01634243,measures_secondary,Incidence of adverse events
NCT01634243,measures_secondary,Vital signs
NCT01634243,measures_secondary,Laboratory parameters
NCT01634243,has_criteria,Maintenance dose
NCT00446043,involves,Acne Vulgaris
NCT00446043,evaluates,Adapalene/Benzoyl Peroxide Topical Gel
NCT00446043,measures_primary,Lesion Count at Month 12
NCT00446043,measures_secondary,Participant's Assessment Scale of Acne
NCT00446043,has_criteria,Local Tolerability Assessment For Erythema
NCT03425643,involves,Non-small Cell Lung Cancer
NCT03425643,evaluates,Pembrolizumab
NCT03425643,measures_primary,Event Free Survival
NCT03425643,measures_primary,Overall Survival
NCT03425643,measures_secondary,Major Pathological Response
NCT03425643,measures_secondary,Pathological Complete Response
NCT03425643,measures_secondary,Change From Baseline in Neoadjuvant Phase in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) Score
NCT03425643,has_criteria,Resectable Stage II
NCT05082090,involves,Spine Devices
NCT05082090,evaluates,Orthofix Spine Devices
NCT05082090,measures_primary,Fusion status
NCT05082090,measures_primary,Pain intensity
NCT05082090,measures_primary,Function
NCT05082090,measures_secondary,Neck Disability Index
NCT05082090,measures_secondary,Oswestry Disability Index
NCT05082090,has_criteria,Pre-Operative to 10-years Post-Operative
NCT04044690,involves,Dermatomyositis
NCT04044690,evaluates,IgPro20
NCT04044690,measures_primary,Responder Rate
NCT04044690,measures_secondary,Mean Total Improvement Score
NCT04044690,measures_secondary,Mean difference (IgPro20 minus placebo) in TIS
NCT04044690,measures_secondary,Mean changes from Baseline in Manual Muscle Testing (MMT-8)
NCT04044690,measures_secondary,Mean change difference (IgPro20 minus placebo) in MMT-8
NCT04044690,has_criteria,24 weeks of randomized treatment
NCT00954590,involves,Alzheimer's Disease
NCT00954590,evaluates,Dimebon
NCT00954590,measures_primary,Neuropsychiatric Inventory
NCT00954590,measures_secondary,Activities of Daily Living
NCT00954590,has_criteria,Moderate-to-Severe Alzheimer's disease
NCT00954590,has_criteria,Mini-Mental State Examination Score
NCT00954590,has_criteria,donepezil
NCT00954590,has_criteria,Other causes of dementia
NCT00954590,has_criteria,Major structural brain disease
NCT00954590,has_criteria,Unstable medical condition
NCT00762190,involves,Type 2 Diabetes Mellitus
NCT00762190,evaluates,TAK-559
NCT00762190,measures_primary,Change from Baseline in
NCT00762190,measures_secondary,Incidence of Adverse events
NCT00762190,measures_secondary,Clinical safety lab tests
NCT00762190,measures_secondary,12-lead electrocardiogram
NCT00762190,measures_secondary,Urinalysis
NCT00762190,measures_secondary,Change from Baseline in Blood pressure and pulse
NCT00762190,measures_secondary,Change from Baseline in Body weight
NCT00762190,measures_secondary,Left ventricular mass index by body surface area measured by echocardiogram
NCT00762190,measures_secondary,Change from Baseline in total daily dose of insulin
NCT00762190,measures_secondary,Change from Baseline in triglycerides
NCT00762190,measures_secondary,Change from Baseline in cholesterol
NCT00762190,measures_secondary,Change from Baseline in total
NCT00762190,measures_secondary,Change from Baseline in low-density lipoproteins
NCT00762190,measures_secondary,Change from Baseline in low-density lipoprotein fractionation
NCT00762190,measures_secondary,Change from Baseline in very low-density lipoprotein
NCT00762190,measures_secondary,Change from Baseline in free fatty acids
NCT00762190,measures_secondary,Change from Baseline in apolipoproteins (AI
NCT00762190,has_criteria,American Diabetes Association diagnostic criteria
NCT00762190,has_criteria,insulin therapy
NCT00762190,has_criteria,glycosylated hemoglobin less than or equal to 8.0%
NCT00762190,has_criteria,fasting plasma glucose less than or equal to 200 mg/dL (11.1 mmol/L)
NCT00762190,has_criteria,low density lipoprotein less than or equal to 160 mg/dL (4.1 mmol/L)
NCT00762190,has_criteria,thyroid stimulating hormone level less than or equal to 5.5 μU/mL (5.5 μU/L) and greater than or equal to 0.35 μU/mL (0.35 μU/L)
NCT00762190,has_criteria,dietary counseling during study
NCT00762190,has_criteria,dietary advice greater than or equal to 2.5 months prior to Screening
NCT00762190,has_criteria,ejection fraction greater than or equal to 40% from echoca...
NCT03211403,involves,High Serum Uric Acid Level
NCT03211403,evaluates,SHR4640
NCT03211403,measures_primary,Peak Plasma Concentration
NCT03211403,measures_primary,Area under the plasma concentration
NCT03211403,measures_primary,Half-time
NCT03211403,measures_primary,Time to the peak plasma concentration
NCT03211403,has_criteria,Male Subjects
NCT00623103,involves,Parkinson's Disease
NCT00623103,involves,Dementia
NCT00623103,evaluates,Rivastigmine
NCT00623103,measures_primary,Change in UPDRS
NCT00623103,measures_secondary,Change in Mattis DRS-2
NCT00623103,has_criteria,PD Motor Symptoms
NCT04042103,involves,Plaque Psoriasis
NCT04042103,evaluates,Tapinarof Cream
NCT04042103,measures_primary,Clinically Significant Changes
NCT04042103,measures_secondary,Irritation
NCT04042103,has_criteria,Application sites
NCT00775203,involves,Unipolar Major Depressive Disorder
NCT00775203,evaluates,Trazodone Contramid® OAD
NCT00775203,evaluates,Placebo
NCT00775203,measures_primary,Change in HAMD-17
NCT00775203,measures_secondary,HAMD-17 Responders
NCT00775203,measures_secondary,HAMD-17 Remitters
NCT00775203,measures_secondary,Change in HAMD-17 Depressed Mood Item
NCT00775203,measures_secondary,Change in MADRS Total Score
NCT03739203,involves,Major Depressive Disorder
NCT03739203,evaluates,Cariprazine
NCT03739203,measures_primary,Change From Baseline
NCT03739203,measures_secondary,Change From Baseline
NCT03739203,has_criteria,Written informed consent
NCT05818943,involves,GRIN-related Disorder
NCT05818943,evaluates,Radiprodil
NCT05818943,measures_primary,V-EEG seizure burden
NCT05818943,measures_secondary,seizure frequency
NCT05818943,measures_secondary,Aberrant Behavior Checklist-Community
NCT05818943,has_criteria,Baseline (week 5)
NCT01562743,involves,Restless Legs Syndrome
NCT01562743,evaluates,SPM 962
NCT01562743,measures_primary,Change of PSQI
NCT01562743,measures_secondary,Change of IRLS Sum Score
NCT01562743,has_criteria,Augmentation
NCT04647721,involves,Nasolabial Folds
NCT04647721,evaluates,Radiesse
NCT04647721,measures_primary,Wrinkle Severity Rating Scale
NCT04647721,measures_secondary,Investigator Global Aesthetic Improvement Scale
NCT04647721,measures_secondary,Subject Global Aesthetic Improvement Scale
NCT04647721,has_criteria,Baseline and Week 24
NCT06582264,involves,Ulcerative Colitis
NCT06582264,evaluates,MB310
NCT06582264,measures_primary,Clinical remission Day 91
NCT06582264,measures_secondary,Steroid-free remission Day 91
NCT06582264,measures_secondary,Persistent steroid-free remission Day 91
NCT06582264,measures_secondary,Clinical response Day 91
NCT06582264,measures_secondary,Endoscopic improvement Day 91
NCT06582264,measures_secondary,Clinical improvement Day 91
NCT06582264,has_criteria,Active mild-to-moderate
NCT03191864,involves,Eosinophilic Esophagitis
NCT03191864,evaluates,APT-1011
NCT03191864,measures_primary,histology
NCT03191864,measures_secondary,EREFs
NCT03191864,has_criteria,Part 1 Induction
NCT01681121,involves,Narcolepsy
NCT01681121,evaluates,ADX-N05
NCT01681121,measures_primary,Average sleep latency time
NCT01681121,measures_secondary,CGI-C Scores
NCT01681121,has_criteria,Baseline up to Week 12
NCT04296864,involves,Atopic Keratoconjunctivitis
NCT04296864,evaluates,Dupilumab
NCT04296864,measures_primary,treatment responders
NCT04296864,measures_secondary,composite symptom score
NCT04296864,has_criteria,at least 18 years of age
NCT01340664,involves,Type 2 Diabetes Mellitus
NCT01340664,evaluates,Canagliflozin
NCT01340664,measures_primary,Change in HbA1c
NCT01340664,measures_secondary,Change in Fasting Plasma Glucose
NCT01340664,measures_secondary,Percent Change in Body Weight
NCT01340664,measures_secondary,Percentage of Patients With HbA1c <7%
NCT01340664,has_criteria,Diagnosis of T2DM
NCT01340664,has_criteria,Metformin treatment
NCT01340664,has_criteria,HbA1c 7 to 10.5%
NCT01340664,has_criteria,Fasting plasma glucose <270 mg/dL
NCT01759264,involves,Crohn's Disease
NCT01759264,evaluates,Adalimumab
NCT01759264,measures_primary,Percentage of Remission
NCT01759264,measures_secondary,Clinical Response
NCT01759264,has_criteria,Active luminal moderate-to-severe
NCT05954390,involves,stage IV metastatic colorectal cancer
NCT05954390,evaluates,LentinexHP
NCT05954390,measures_primary,Quality of Life
NCT05954390,measures_secondary,self-perception of health
NCT05954390,has_criteria,age 18 years or older
NCT05954390,has_criteria,stage IV metastatic colorectal cancer
NCT05954390,has_criteria,ECOG performance status 0-1
NCT05954390,has_criteria,1st or 2nd line chemotherapy
NCT05954390,has_criteria,5-fluorouracil based regimen
NCT00428090,involves,Alzheimer's Disease
NCT00428090,evaluates,Rosiglitazone
NCT00428090,measures_primary,Change From Baseline
NCT00428090,measures_secondary,ADAS-Cog Total Score
NCT00428090,has_criteria,APOE e4 Status
NCT04442490,involves,Major Depressive Disorder
NCT04442490,evaluates,Sage-217
NCT04442490,measures_primary,Change From Baseline
NCT04442490,measures_secondary,CGI-S Score
NCT04442490,has_criteria,Adult Participants
NCT04117490,involves,Knee Osteoarthritis
NCT04117490,evaluates,IP
NCT04117490,measures_primary,Knee joint pain
NCT04117490,measures_secondary,Knee joint stiffness
NCT04117490,measures_secondary,Knee joint function
NCT04117490,has_criteria,≥ 40 to ≤ 65 years
NCT04117490,has_criteria,BMI ≥ 18 and ≤ 29.9 kg/m2
NCT04117490,has_criteria,Fasting blood sugar ≤ 126 mg/dl
NCT04117490,has_criteria,SGOT & <2X UNL
NCT04117490,has_criteria,SGPT & <2X UNL
NCT04117490,has_criteria,Serum Creatinine & <1.5X UNL
NCT04117490,has_criteria,Knee joint pain rated ≥ 60
NCT04117490,has_criteria,Osteoarthritis grade II/ III
NCT00877890,involves,Type 2 Diabetes Mellitus
NCT00877890,evaluates,Exenatide Once Weekly
NCT00877890,measures_primary,Change in HbA1c
NCT00877890,measures_secondary,Fasting Plasma Glucose
NCT00877890,has_criteria,Baseline (Day 1)
NCT02262364,involves,Knee Osteoarthritis
NCT02262364,evaluates,NStride Autologous Protein Solution
NCT02262364,measures_primary,Change From Baseline
NCT02262364,measures_secondary,Pain as Measured
NCT02262364,has_criteria,12 months
NCT03483090,involves,Osteoarthritis of the Knee
NCT03483090,evaluates,Deep Sea Krill Oil Supplementation
NCT03483090,measures_primary,WOMAC Pain subscale
NCT03483090,measures_secondary,WOMAC Stiffness subscale
NCT03483090,measures_secondary,WOMAC Physical Function subscale
NCT03483090,measures_secondary,Serum lipid concentrations
NCT03483090,has_criteria,Venous blood
NCT00571064,involves,Alzheimer's Disease
NCT00571064,evaluates,Donepezil Hydrochloride
NCT00571064,measures_primary,Change from Baseline in MMSE Total Score
NCT00571064,measures_secondary,MMSE Total Scores
NCT03380390,involves,Rosacea
NCT03380390,evaluates,Oxymetazoline
NCT03380390,evaluates,Energy-Based Therapy
NCT03380390,measures_primary,Erythema Assessment Scale
NCT03380390,measures_secondary,Clinician's Telangiectasia Assessment
NCT03380390,has_criteria,Baseline (Day 1) to Day 56
NCT02480764,involves,Hypertension
NCT02480764,evaluates,Azilsartan Medoxomil
NCT02480764,evaluates,Valsartan
NCT02480764,measures_primary,Change in SBP
NCT02480764,measures_secondary,Change in DBP
NCT02480764,measures_secondary,Clinic SBP Response
NCT02480764,measures_secondary,Clinic DBP Response
NCT02480764,measures_secondary,Both Clinic SBP and DBP Response
NCT00828464,involves,Chronic Hand Dermatitis
NCT00828464,evaluates,Clobetasol Propionate
NCT00828464,measures_primary,ISGA improvement (%)
NCT00828464,measures_secondary,Visual Analogue Assessment Scale
NCT00828464,measures_secondary,Hand Eczema Severity Index Score
NCT00828464,has_criteria,At least 1-grade improvement
NCT02874664,involves,Small Cell Lung Cancer
NCT02874664,evaluates,rovalpituzumab teserine
NCT02874664,measures_primary,Change in QTcF interval
NCT02874664,measures_secondary,RR interval
NCT02874664,measures_secondary,PR interval
NCT02874664,measures_secondary,QRS duration interval
NCT02874664,measures_secondary,waveform composition interval
NCT02874664,has_criteria,From first dose through 30 days post-last-dose
NCT02960490,involves,Rheumatoid Arthritis
NCT02960490,evaluates,E6011
NCT02960490,measures_primary,ACR20 Response
NCT02960490,measures_secondary,Tender joint count
NCT02960490,measures_secondary,Swollen joint count
NCT02960490,has_criteria,20% reduction from baseline
NCT06433921,involves,Asthma
NCT06433921,evaluates,Salbutamol
NCT06433921,measures_primary,PC20 methacholine
NCT06433921,measures_secondary,Peak QTc Interval
NCT06433921,measures_secondary,Peak Heart Rate
NCT06433921,measures_secondary,Minimum Serum Potassium
NCT06433921,measures_secondary,Maximum Observed Plasma Concentration
NCT06433921,measures_secondary,Time to Reach Cmax
NCT06433921,measures_secondary,Area Under the Plasma Concentration-time Curve
NCT06433921,measures_secondary,Incidence of Adverse Events
NCT06433921,measures_secondary,Absolute Values for 12-lead Electrocardiogram
NCT06433921,measures_secondary,Absolute Values for 12-lead ECGs Recording
NCT06433921,measures_secondary,Change from Baseline for Post-dose 12-lead ECGs Recording
NCT06433921,measures_secondary,Number of Participants with Clinically Significant Changes
NCT06433921,measures_secondary,Absolute Values of Vital Signs
NCT06433921,has_criteria,Male or female
NCT06433921,has_criteria,18 to 65 years of age
NCT06433921,has_criteria,≥50 kg
NCT06433921,has_criteria,Documented history of asthma
NCT06433921,has_criteria,Receiving asthma treatments
NCT00998764,involves,Alzheimer Disease
NCT00998764,evaluates,Bapineuzumab
NCT00998764,measures_primary,ADAS-Cog/11 score
NCT00998764,measures_secondary,Safety
NCT00998764,has_criteria,Serious Adverse Event
NCT00924664,involves,Chronic Low Back Pain
NCT00924664,evaluates,Tanezumab
NCT00924664,measures_primary,Neuropathy Impairment Score
NCT03943264,involves,Alzheimer's
NCT03943264,evaluates,XPro1595
NCT03943264,measures_primary,cognitive function
NCT03943264,measures_secondary,FreeWater content
NCT03943264,measures_secondary,amyloid beta
NCT03943264,measures_secondary,tau
NCT03943264,has_criteria,cognitive impairment
NCT01482390,involves,Chronic hepatitis C
NCT01482390,evaluates,Mericitabine
NCT01482390,measures_primary,SVR12
NCT01482390,measures_secondary,SVR-4
NCT01482390,measures_secondary,SVR-24
NCT01482390,measures_secondary,Virological Response
NCT01482390,measures_secondary,Treatment-Resistant Mutations
NCT01482390,measures_secondary,HCV RNA Levels
NCT01482390,measures_secondary,Adverse Event
NCT01482390,has_criteria,Chronic hepatitis C infection
NCT01482390,has_criteria,Hepatitis C genotype 1a or 1b
NCT01482390,has_criteria,Prior hepatitis C treatment
NCT02688764,involves,Chronic Kidney Disease
NCT02688764,involves,Hyperphosphataemia
NCT02688764,evaluates,PA21
NCT02688764,evaluates,Calcium Acetate
NCT02688764,measures_primary,Change in Serum Phosphorus
NCT02688764,measures_secondary,Adverse Events
NCT02688764,measures_secondary,Serum Phosphorus Levels
NCT02688764,has_criteria,Age-dependent Target Range
NCT01323790,involves,Non-cancer-related Pain
NCT01323790,involves,Opioid-induced Constipation
NCT01323790,evaluates,Study Drug
NCT01323790,measures_primary,Responder/Non-responder
NCT01323790,measures_secondary,Time to First Post-dose Laxation
NCT01323790,measures_secondary,Change From Baseline in Mean Number of Days
NCT01323790,measures_secondary,Change From Baseline in Degree of Straining
NCT01323790,measures_secondary,Change From Baseline in Stool Consistency
NCT01323790,has_criteria,spontaneous bowel movements
NCT01323790,has_criteria,rescue medication
NCT04851964,involves,Chronic Rhinosinusitis With Nasal Polyposis
NCT04851964,evaluates,Tezepelumab
NCT04851964,measures_primary,Nasal Polyp Score
NCT04851964,measures_secondary,Nasal Congestion
NCT04851964,measures_secondary,Loss of Smell
NCT04851964,measures_secondary,Nasal Polyp-Quality of Life
NCT04851964,measures_secondary,Nasal Polyposis Surgery
NCT04851964,measures_secondary,Sinus Opacification
NCT04851964,has_criteria,Nasal Polyposis
NCT05219864,involves,Chronic Hand Eczema
NCT05219864,evaluates,Topical Ruxolitinib
NCT05219864,measures_primary,IGA-CHE-TS
NCT05219864,measures_secondary,Itch NRS score
NCT05219864,measures_secondary,Pain NRS score
NCT05219864,measures_secondary,mTLSS
NCT05219864,has_criteria,≥ 4-point improvement
NCT05219864,has_criteria,≥ 2-point improvement
NCT04044664,involves,Post-Traumatic Stress Disorder
NCT04044664,evaluates,NYX-783
NCT04044664,measures_primary,Change from baseline
NCT04044664,measures_secondary,PCL-5 Global Score
NCT04044664,measures_secondary,PSQI Global Score
NCT04044664,has_criteria,Change from baseline
NCT03588390,involves,Healthy male subjects
NCT03588390,evaluates,BI 1323495
NCT03588390,measures_primary,AUC0-∞
NCT03588390,measures_primary,Cmax
NCT03588390,has_criteria,Age 18-45 years
NCT03588390,has_criteria,BMI 18.5-29.9 kg/m2
NCT03588390,has_criteria,Signed consent
NCT06502990,involves,Generalised Lipodystrophy
NCT06502990,involves,diabetes mellitus
NCT06502990,involves,hypertriglyceridaemia
NCT06502990,evaluates,metreleptin
NCT06502990,measures_primary,fasting serum TG levels
NCT06502990,measures_secondary,glycated haemoglobin (HbA1c)
NCT06502990,measures_secondary,liver volume
NCT06502990,measures_secondary,liver span
NCT06502990,has_criteria,fasting TG levels ≥2.3 mmol/L
NCT06502990,has_criteria,HbA1c ≥6.5%
NCT06502990,has_criteria,Baseline HbA1c ≥6.5%
NCT06502990,has_criteria,Baseline HbA1c ≥5.7%
NCT06502990,has_criteria,fasting serum TG ≥ 1.7 mmol/L
NCT06502990,has_criteria,fasting serum TG ≥ 2.3 mmol/L
NCT02240121,involves,Crohn's Disease
NCT02240121,evaluates,Rifaximin Delayed Release DR Tablets
NCT02240121,measures_primary,Clinical Symptom Remission
NCT02240121,measures_secondary,Clinical Symptom Remission
NCT02240121,has_criteria,≤ 10 liquid/very soft stools
NCT01231464,involves,Allergic Rhinitis
NCT01231464,evaluates,Fluticasone Furoate Nasal Spray
NCT01231464,measures_primary,rTNSS change from baseline
NCT01231464,measures_secondary,Nasal Finding Score
NCT01231464,measures_secondary,Severity of Overall Interference
NCT01231464,has_criteria,Baseline through Day 14
NCT01856764,involves,atopic dermatitis
NCT01856764,evaluates,Topical Roflumilast
NCT01856764,measures_primary,Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD)
NCT01856764,measures_secondary,Change From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values
NCT01856764,measures_secondary,Change From Baseline to Day 15 in Participants' Assessment of Pruritus
NCT01856764,has_criteria,Is male or female between 18 to 65 years of age
NCT01856764,has_criteria,Has lesional skin areas of moderate severity characterized by modified local SCORing Atopic Dermatitis (SCORAD) of at least 4
NCT01856764,has_criteria,Has an index/target lesion of moderate severity approximately 20 cm\^2
NCT01856764,has_criteria,Is willing to wash out from AD current active therapy prior to entry in the study
NCT01856764,has_criteria,Is willing and able to apply the study medication as directed
NCT01856764,has_criteria,If a male who is nonsterilized and sexually active with a female partner of childbearing potential
NCT06619990,involves,Ulcerative Colitis
NCT06619990,evaluates,XmAb942
NCT06619990,measures_primary,Modified Mayo Score
NCT06619990,measures_secondary,Histologic-endoscopic remission
NCT06619990,measures_secondary,Endoscopic remission
NCT06619990,has_criteria,Geboes score
NCT03401190,involves,Acute Pancreatitis
NCT03401190,involves,Systemic Inflammatory Response Syndrome
NCT03401190,evaluates,CM4620 Injectable Emulsion
NCT03401190,measures_primary,Change in CTSI Score
NCT03401190,measures_secondary,Tolerating Solid Food
NCT03401190,measures_secondary,Persistent SIRS
NCT03401190,has_criteria,Temperature \< 36°C or \> 38°C
NCT03401190,has_criteria,Heart rate \> 90 beats/minute
NCT03401190,has_criteria,Respiratory rate \> 20 breaths/minute
NCT03401190,has_criteria,White blood cell count \> 12
NCT03401190,has_criteria,White blood cell count \< 4
NCT03401190,has_criteria,White blood cell count \> 10% immature (band) forms
NCT03536390,involves,Attention Deficit Hyperactivity Disorder
NCT03536390,evaluates,Methylphenidate HCl ERCT
NCT03536390,measures_primary,ADHD RS-IV Preschool-Home Version
NCT03536390,measures_secondary,Clinical Global Impression - Severity
NCT03536390,measures_secondary,Clinical Global Impression of Improvement
NCT03536390,has_criteria,4-5 Year Old Children
NCT00267943,involves,Essential hypertension
NCT00267943,evaluates,Telmisartan + Hydrochlorothiazide
NCT00267943,measures_primary,DBP control 24 hours
NCT00267943,measures_secondary,Change from baseline in trough seated DBP
NCT00267943,measures_secondary,Change from baseline in trough seated SBP
NCT00267943,measures_secondary,Proportion of patients achieving DBP response
NCT00267943,measures_secondary,Proportion of patients achieving SBP response
NCT00267943,measures_secondary,Proportion of patients achieving SBP response
NCT00267943,measures_secondary,Proportion of patients in the trough seated BP category optimal
NCT00267943,measures_secondary,Proportion of patients in the trough seated BP category normal
NCT00267943,measures_secondary,Proportion of patients in the trough seated BP category high-normal
NCT00267943,measures_secondary,Proportion of patients in the trough seated BP category high
NCT00267943,measures_secondary,Proportion of patients requiring additional antihypertensive therapy
NCT00267943,measures_secondary,Additional reduction in BP by the use of additional antihypertensive therapy
NCT00267943,measures_secondary,Time to starting additional antihypertensive therapy
NCT00267943,measures_secondary,Incidence and intensity of Adverse events
NCT00267943,measures_secondary,Physical examinations
NCT00267943,measures_secondary,Change in laboratory parameters
NCT00267943,measures_secondary,12-Lead Electrocardiogramm ECG
NCT00267943,measures_secondary,Vital Signs (pulse rate
NCT00267943,has_criteria,Essential hypertension
NCT00267943,has_criteria,Currently taking between one and three antihypertensive medications
NCT00267943,has_criteria,Blood pressure not adequately controlled
NCT04126343,involves,Cardiac Effects
NCT04126343,evaluates,Padsevonil
NCT04126343,measures_primary,QTcF on Day 8
NCT04126343,measures_secondary,Heart Rate
NCT04126343,measures_secondary,PR Interval
NCT03540043,involves,Atopic Dermatitis
NCT03540043,evaluates,Thykamine
NCT03540043,measures_primary,Change from baseline in AD score
NCT03540043,measures_secondary,Change from baseline in pruritus
NCT03540043,measures_secondary,Proportion of patients with change in IGA
NCT03540043,measures_secondary,Change in Eczema Area and Severity Index (EASI)
NCT03540043,has_criteria,Baseline and 4 weeks
NCT04043338,involves,Healthy Adult Subjects
NCT04043338,evaluates,XC130-A10H
NCT04043338,measures_primary,Cmax of XC130-A10H
NCT04043338,measures_secondary,AUC of XC130-A10H
NCT04043338,measures_secondary,Tmax of XC130-A10H
NCT04043338,has_criteria,Healthy
NCT04043338,has_criteria,18-75 years of age
NCT04043338,has_criteria,BMI ≥ 18 and ≤ 32.0 kg/m2
NCT04043338,has_criteria,Medically healthy
NCT04043338,has_criteria,Understand study procedures
NCT00465738,involves,Upper Limb Spasticity
NCT00465738,evaluates,IncobotulinumtoxinA
NCT00465738,measures_primary,Responder at Week 4
NCT00465738,measures_secondary,Frenchay Arm Test
NCT00465738,has_criteria,primary therapeutic target
NCT00676338,involves,Type 2 Diabetes
NCT00676338,evaluates,Exenatide
NCT00676338,measures_primary,Change in HbA1c
NCT00676338,measures_secondary,Change in Fasting Serum Glucose
NCT00676338,measures_secondary,Change in Body Weight
NCT00676338,measures_secondary,Change in Fasting Total Cholesterol
NCT00676338,measures_secondary,Change in Fasting High-Density Lipoprotein
NCT00676338,measures_secondary,Ratio of Fasting Triglycerides
NCT00676338,measures_secondary,Event Rate of Hypoglycemic Events
NCT00676338,has_criteria,Drug-Naive Patients
NCT01374438,involves,Alzheimer's Disease
NCT01374438,evaluates,MSDC-0160
NCT01374438,measures_primary,Global Cognitive Function
NCT01374438,measures_secondary,ADAS-Cog Subscale
NCT01374438,measures_secondary,Executive Function Scale
NCT01374438,has_criteria,3 months treatment
NCT02579603,involves,Idiopathic Pulmonary Fibrosis
NCT02579603,evaluates,Nintedanib
NCT02579603,evaluates,Pirfenidone
NCT02579603,measures_primary,Gastrointestinal AEs
NCT02579603,measures_secondary,Plasma Concentrations
NCT02579603,has_criteria,On-treatment AEs
NCT04828343,evaluates,Rozanolixizumab
NCT04828343,measures_primary,Maximum Plasma Concentration
NCT04828343,measures_primary,Time to Maximum Plasma Concentration
NCT04828343,measures_primary,Area Under the Plasma Concentration-time Curve
NCT04828343,measures_primary,Baseline-corrected Area Under the Total Immunglobulin IgG-time Curve
NCT01582243,involves,Type 2 Diabetes Mellitus
NCT01582243,evaluates,Vildagliptin Plus Metformin
NCT01582243,measures_primary,Mean Change HbA1c
NCT01582243,measures_secondary,Fasting Plasma Glucose
NCT01582243,measures_secondary,Postprandial Plasma Glucose
NCT01582243,measures_secondary,Mean Amplitude of Glycemic Excursions
NCT01582243,has_criteria,age 20 years
NCT01582243,has_criteria,T2DM diagnosis
NCT01582243,has_criteria,metformin monotherapy
NCT01582243,has_criteria,HbA1c ≤ 6.5%
NCT00464438,involves,bacterial conjunctivitis
NCT00464438,evaluates,Gatifloxacin
NCT00464438,measures_primary,Clinical Success
NCT00464438,measures_secondary,Microbiological Improvement
NCT00464438,measures_secondary,Improvement in Ocular Signs
NCT00464438,has_criteria,diagnosed with bacterial conjunctivitis
NCT03055338,involves,Schizophrenia
NCT03055338,evaluates,MK-8189
NCT03055338,measures_primary,PANSS total score
NCT03055338,measures_secondary,Adverse Event
NCT03055338,measures_secondary,Discontinuing study treatment
NCT03055338,has_criteria,Up to 6 weeks
NCT04975438,involves,Atopic Dermatitis
NCT04975438,evaluates,GSK1070806
NCT04975438,measures_primary,EASI score change
NCT04975438,measures_secondary,Safety
NCT03455543,involves,Diabetic Distal Symmetric Peripheral Neuropathy
NCT03455543,evaluates,Dual Field PEMF Therapy
NCT03455543,measures_primary,Change in Pain Intensity
NCT03455543,measures_secondary,Patient Global Impression
NCT03455543,measures_secondary,Time to 30% or 2-point Reduction in NPRS
NCT03455543,measures_secondary,Change in Neuropathy Related Quality of Life
NCT03455543,has_criteria,2 Point or 30% Reduction in Pain
NCT06598943,involves,Ulcerative Colitis
NCT06598943,evaluates,Eltrekibart
NCT06598943,evaluates,Mirikizumab
NCT06598943,measures_primary,Clinical Remission
NCT06598943,measures_primary,Clinical Response
NCT06598943,measures_primary,Endoscopic Improvement
NCT06598943,measures_primary,Endoscopic Remission
NCT06598943,measures_primary,Clinical Remission
NCT06598943,measures_primary,Histologic-Endoscopic Mucosal Improvement
NCT06598943,measures_primary,IBDQ Total Score
NCT06598943,measures_secondary,Change From Baseline to Week 12 in IBDQ Total Score
NCT06598943,measures_secondary,Ctrough ss of Eltrekibart
NCT06598943,measures_secondary,Ctrough ss of Mirikizumab
NCT03247543,involves,Attention-Deficit/Hyperactivity Disorder
NCT03247543,evaluates,SPN-812
NCT03247543,measures_primary,ADHD-RS-5 Total score
NCT03247543,measures_secondary,CGI-I Scale score
NCT03247543,measures_secondary,Conners 3 - Parent Short Form
NCT03247543,has_criteria,children 6 to 18 years
NCT00876343,involves,Major Depressive Disorder
NCT00876343,evaluates,Aripiprazole
NCT00876343,measures_primary,MADRS total score
NCT00876343,measures_secondary,Sheehan Disability Scale
NCT00876343,has_criteria,Patients who are either in...
NCT05588843,involves,Ulcerative Colitis
NCT05588843,evaluates,SAR443122
NCT05588843,measures_primary,clinical remission at Week 12
NCT05588843,measures_secondary,endoscopic improvement at Week 12
NCT05588843,measures_secondary,clinical response at Week 12
NCT05588843,measures_secondary,clinical remission at Week 12
NCT05588843,measures_secondary,Change from baseline on PRO2 total score
NCT05588843,measures_secondary,histological improvement at Week 12
NCT05588843,measures_secondary,Histologic-endoscopic mucosal improvement at Week 12
NCT05588843,measures_secondary,Change from baseline in IBDQ total score at Week 12
NCT05588843,measures_secondary,Change from baseline in bowel signs and symptoms
NCT05588843,measures_secondary,Change from baseline in abdominal signs and symptoms
NCT05588843,measures_secondary,maximum concentration [Cmax]
NCT05588843,measures_secondary,time to Cmax [tmax]
NCT05588843,measures_secondary,area under the curve over the dosing interval [AUC0-tau]
NCT05588843,measures_secondary,elimination half-life [t1/2z]
NCT01128738,involves,Axillary Hyperhidrosis
NCT01128738,evaluates,GSK1358820
NCT01128738,measures_primary,Percentage of Responders
NCT01128738,measures_secondary,Mean Weight of Axillary Sweating
NCT01128738,has_criteria,Baseline in mean weight
NCT03830203,involves,Rheumatoid Arthritis
NCT03830203,evaluates,BAT1806
NCT03830203,evaluates,RoActemra
NCT03830203,measures_primary,ACR20 response
NCT03830203,measures_secondary,tender joint count
NCT03830203,measures_secondary,swollen joint count
NCT03830203,measures_secondary,ACR core measures
NCT03830203,has_criteria,age 18 years or older
NCT03830203,has_criteria,ACR/EULAR 2010 criteria
NCT03830203,has_criteria,active RA
NCT03830203,has_criteria,≥ 6 tender joints
NCT03830203,has_criteria,≥ 6 swollen joints
NCT03830203,has_criteria,CRP > ULN or ESR ≥ 28 mm/hour
NCT03756103,involves,Essential Hypertension
NCT03756103,evaluates,SPH3127
NCT03756103,measures_primary,Changes in SBP
NCT03756103,measures_primary,Changes in DBP
NCT03756103,measures_secondary,Ambulatory Blood Pressure
NCT03756103,measures_secondary,Plasma Renin Activity
NCT03756103,has_criteria,Baseline to 54-58 days
NCT03756103,has_criteria,Baseline to 14±2
NCT03756103,has_criteria,Baseline to 28±2 and 56±2 days
NCT03756103,has_criteria,Baseline to 14±2
NCT03586843,evaluates,JNJ-64565111
NCT03586843,measures_primary,Gastrointestinal Adverse Events
NCT03586843,has_criteria,Otherwise Healthy
NCT03962543,involves,Neurofibromatosis Type 1
NCT03962543,evaluates,Mirdametinib
NCT03962543,measures_primary,Response rate
NCT03962543,measures_secondary,Adverse events
NCT03962543,measures_secondary,Duration of response
NCT03962543,measures_secondary,Quality of life
NCT03962543,measures_secondary,Pain
NCT03962543,has_criteria,≥ 5 years of age
NCT03962543,has_criteria,≥ 8 years of age
NCT03962543,has_criteria,≥ 6 years of age
NCT00282243,involves,Liver Transplant
NCT00282243,evaluates,Tacrolimus
NCT00282243,measures_primary,Patient Survival
NCT00282243,measures_secondary,Graft Survival
NCT00282243,has_criteria,Stable Liver Transplant
NCT01010503,involves,Rheumatoid Arthritis
NCT01010503,evaluates,Tocilizumab
NCT01010503,evaluates,Methotrexate
NCT01010503,measures_primary,Disease Activity Score
NCT01010503,measures_secondary,Patient Global Assessment of Pain
NCT01010503,has_criteria,Week 8
NCT02010203,involves,Non-Muscle Invasive Bladder Cancer
NCT02010203,evaluates,vesigenurtacel-L
NCT02010203,measures_primary,1-year Disease-Free Survival
NCT02010203,measures_secondary,Proportion of Patients With Recurrence
NCT02010203,measures_secondary,Proportion of Patients With Progressive Disease
NCT02010203,measures_secondary,Disease-free Survival
NCT02010203,measures_secondary,Overall Disease-free Survival
NCT02010203,measures_secondary,Overall Survival
NCT02010203,measures_secondary,Proportion of Patients Undergoing Repeat TURBT
NCT02010203,measures_secondary,Proportion of Patients Undergoing Cystectomy
NCT02010203,measures_secondary,Immunologic Response of PBMCs
NCT04385303,involves,Knee Osteoarthritis
NCT04385303,evaluates,Lorecivivint
NCT04385303,measures_primary,Pain numeric rating scale
NCT04385303,measures_secondary,WOMAC Function
NCT04385303,has_criteria,Baseline and Week 12
NCT06422143,involves,Metastatic Squamous Non-small Cell Lung Cancer
NCT06422143,evaluates,Pembrolizumab
NCT06422143,evaluates,Sacituzumab Tirumotecan
NCT06422143,measures_primary,Overall survival
NCT06422143,measures_secondary,Progression-Free Survival
NCT06422143,measures_secondary,Number of participants
NCT06422143,measures_secondary,Number of participants discontinuing
NCT06422143,measures_secondary,Change in Score
NCT06422143,has_criteria,randomization to death
NCT04624243,involves,Schizophrenia
NCT04624243,evaluates,MK-8189
NCT04624243,measures_primary,PANSS total score
NCT04624243,measures_secondary,PANSS positive subscale
NCT04624243,measures_secondary,CGI-S score
NCT04624243,has_criteria,Adverse events
NCT04624243,has_criteria,Discontinue treatment
NCT03289143,involves,Prodromal to Mild Alzheimer's Disease
NCT03289143,evaluates,Semorinemab
NCT03289143,measures_primary,Change From Baseline
NCT03289143,measures_secondary,Percentage of Participants With Adverse Events
NCT03289143,has_criteria,Baseline and 73 Weeks
NCT01485003,involves,Multiple Sclerosis
NCT01485003,evaluates,Tysabri
NCT01485003,measures_primary,disease activity-free
NCT01485003,measures_secondary,clinical disease activity-free
NCT01485003,has_criteria,Anti-JC Virus Antibody negative
NCT03767543,involves,Type 2 Diabetes Mellitus
NCT03767543,evaluates,Insulin Glargine/Lixisenatide
NCT03767543,measures_primary,Change in HbA1c
NCT03767543,measures_secondary,Change in fasting plasma glucose
NCT03767543,measures_secondary,Change in fasting SMPG
NCT03767543,measures_secondary,Change in 7-point SMPG profile
NCT03767543,measures_secondary,Change in body weight
NCT03767543,has_criteria,A1c ≤7%
NCT01604343,involves,Rheumatoid Arthritis
NCT01604343,evaluates,CNTO 136
NCT01604343,measures_primary,ACR 20 response
NCT01604343,measures_secondary,vdH-S Score
NCT01604343,has_criteria,DMARD Therapy
NCT00420238,involves,Axial Ankylosing Spondylitis
NCT00420238,evaluates,Etanercept
NCT00420238,measures_primary,BASDAI normalized AUC
NCT00420238,measures_secondary,BASDAI 50 Response
NCT00420238,measures_secondary,ASAS 20
NCT00420238,has_criteria,Baseline
NCT01035138,involves,Alzheimer's Disease
NCT01035138,evaluates,Semagacestat
NCT01035138,measures_primary,Change From Baseline ADAS-Cog11
NCT01035138,measures_primary,Change From Baseline ADCS-ADL
NCT01035138,measures_primary,Percent Change From Baseline Aβ 1-42
NCT01035138,measures_primary,Change From Baseline Hippocampal Volume
NCT01035138,measures_primary,Change From Baseline AV-45-PET
NCT01035138,has_criteria,Baseline (LFAN randomization)
NCT01652703,involves,Hyperlipidemia
NCT01652703,evaluates,Evolocumab
NCT01652703,measures_primary,LDL-C change at Week 12
NCT01652703,measures_secondary,Non-HDL-C change
NCT01652703,measures_secondary,Apolipoprotein B change
NCT01652703,measures_secondary,VLDL-C change
NCT01652703,measures_secondary,Total Cholesterol/HDL-C Ratio change
NCT01652703,measures_secondary,Apolipoprotein B/Apolipoprotein A-1 Ratio change
NCT01652703,has_criteria,Japanese adult
NCT01652703,has_criteria,statin therapy
NCT01652703,has_criteria,fasting LDL-C ≥ 115 mg/dL
NCT01652703,has_criteria,fasting triglycerides ≤ 400 mg/dL
NCT01652703,has_criteria,NYHA class I or II
NCT01652703,has_criteria,controlled hypertension
NCT01652703,has_criteria,controlled type 2 diabetes
NCT01652703,has_criteria,left ventricular ejection fraction ≥ 30%
NCT01370603,involves,High Cholesterol
NCT01370603,evaluates,Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet
NCT01370603,measures_primary,Percent Change LDL-C
NCT01370603,measures_secondary,Percent Change TC
NCT01370603,measures_secondary,Percent Change HDL-C
NCT01370603,measures_secondary,Percent Change Non-HDL-C
NCT01370603,measures_secondary,Percent Change Apo B
NCT01370603,measures_secondary,Percent Change Triglycerides
NCT01370603,has_criteria,cardiovascular risk
NCT01370603,has_criteria,statin-naïve
NCT01370603,has_criteria,LDL-C ≥130 mg/dL
NCT01370603,has_criteria,LDL-C ≥100 mg/dL
NCT00889603,involves,Alzheimer's Disease
NCT00889603,evaluates,Aricept
NCT00889603,measures_primary,Change From Baseline in MMSE Total
NCT00889603,measures_secondary,Change From Baseline in Functional Activity Questionnaire
NCT00889603,has_criteria,Baseline and Week 24
NCT06185543,involves,Alzheimer's Disease
NCT06185543,evaluates,PrimeC
NCT06185543,measures_primary,Clinical Dementia Rating Scale
NCT06185543,measures_secondary,ADAS-Cog 14
NCT06185543,measures_secondary,ADCS-iADL
NCT06185543,measures_secondary,Mini-Mental State Examination
NCT06185543,has_criteria,informed consent form
NCT02277743,involves,Atopic Dermatitis
NCT02277743,evaluates,Dupilumab
NCT02277743,measures_primary,IGA score 0 or 1
NCT02277743,measures_secondary,EASI-75
NCT02277743,measures_secondary,Pruritus NRS
NCT01870843,involves,Major Depressive Disorder With Anxiety Symptom
NCT01870843,evaluates,Escitalopram
NCT01870843,measures_primary,Change in Q-LES-Q-SF
NCT01870843,measures_secondary,Change in Sheehan Disability Scale
NCT01870843,has_criteria,Remission Rate Based on MADRS
NCT00524043,involves,Schizophrenia
NCT00524043,evaluates,Paliperidone Extended Release
NCT00524043,measures_primary,Change From Baseline
NCT00524043,measures_secondary,CGI-S
NCT00524043,measures_secondary,PSP Score
NCT00524043,has_criteria,Baseline
NCT03697603,involves,Major Depressive Disorder
NCT03697603,evaluates,Brexpiprazole
NCT03697603,measures_primary,MADRS Total Scores
NCT03697603,measures_secondary,CGI-I Improvement Rate
NCT03697603,has_criteria,Baseline (the end of Phase A)
NCT01288443,involves,Primary Hypercholesterolemia
NCT01288443,evaluates,Alirocumab
NCT01288443,measures_primary,Percent Change LDL-C
NCT01288443,measures_secondary,Absolute Change LDL-C
NCT01288443,measures_secondary,Percentage of Participants
NCT01288443,measures_secondary,Total Cholesterol
NCT01288443,measures_secondary,HDL-C
NCT01288443,measures_secondary,Non-HDL-C
NCT01288443,measures_secondary,Apolipoprotein B
NCT01288443,measures_secondary,Fasting Triglycerides
NCT01288443,measures_secondary,Lipoprotein(a)
NCT02087943,involves,Atopic Dermatitis
NCT02087943,evaluates,Apremilast
NCT02087943,measures_primary,EASI 50 at Week 12
NCT02087943,measures_secondary,Percentage Change in EASI Score at Week 12
NCT02087943,measures_secondary,Percentage of Participants Who Achieved a Score of 0 (Cleared) or 1 (Almost Cleared) and at Least a 2-point Reduction From Baseline in a Static Physician's Global Assessment of Acute Signs (sPGA-A) at Week 12
NCT02087943,measures_secondary,The Percentage Change From Baseline in the Average Weekly Pruritus Numerical Rating Scale (NRS) Score at Week 4
NCT02087943,has_criteria,Moderate to Severe AD
NCT06347003,involves,Severe Hypertriglyceridemia
NCT06347003,evaluates,Plozasiran
NCT06347003,measures_primary,Percent Change in Fasting Serum Triglyceride
NCT06347003,measures_secondary,Proportion of Participants Who Achieve Fasting TG Levels of <500 mg/dL
NCT06347003,measures_secondary,Adjudicated Abdominal Clinical Event Rate
NCT06347003,measures_secondary,Proportion of Participants Who Achieve Fasting TG Levels of <150 mg/dL
NCT06347003,measures_secondary,Number of Participants with Adverse Events
NCT06347003,measures_secondary,Incidence Rates of New-Onset Diabetes Mellitus
NCT06347003,measures_secondary,Incidence Rates of Impaired Glucose Tolerance
NCT06347003,measures_secondary,Incidence Rates of Worsening of Existing Diabetes
NCT06347003,measures_secondary,Change from Baseline in Hemoglobin A1c
NCT06347003,measures_secondary,Change from Baseline in Fasting Blood Glucose
NCT06347003,measures_secondary,Change from Baseline in C-peptide
NCT06347003,measures_secondary,Change from Baseline in Homeostatic Model Assessment for Insulin Resistance
NCT00850343,involves,Rheumatoid Arthritis
NCT00850343,evaluates,Certolizumab Pegol
NCT00850343,measures_primary,ACR20 Response
NCT00850343,measures_secondary,arthirtis pain
NCT00850343,measures_secondary,disease activity
NCT00850343,has_criteria,tender joint count
NCT03616821,involves,Ulcerative Colitis
NCT03616821,evaluates,Brazikumab
NCT03616821,measures_primary,Clinical remission
NCT03616821,measures_secondary,Sustained remission
NCT03616821,measures_secondary,CS-free remission
NCT03616821,measures_secondary,Clinical response
NCT03616821,measures_secondary,Endoscopic improvement
NCT03616821,has_criteria,Moderately to severely active
NCT05517421,involves,Thyroid Eye Disease
NCT05517421,evaluates,Batoclimab
NCT05517421,measures_primary,proptosis responder
NCT05517421,measures_secondary,Clinical Activity Score
NCT05517421,measures_secondary,Gorman score for diplopia
NCT05517421,has_criteria,TSHR antibody
NCT05136521,evaluates,300 mg Trazodone Hydrochloride (New Polymer)
NCT05136521,evaluates,300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets)
NCT05136521,measures_primary,Cmax of plasma trazodone
NCT05136521,measures_primary,AUC(0-t) of plasma trazodone
NCT05136521,measures_primary,AUC(0-∞) of plasma trazodone
NCT05136521,measures_secondary,Residual area of plasma trazodone
NCT05136521,has_criteria,Treatment emergent adverse events
NCT01088464,involves,Advanced Solid Tumors
NCT01088464,evaluates,IMC-11F8
NCT01088464,measures_primary,Not Available
NCT01088464,measures_secondary,Not Available
NCT01088464,has_criteria,Not Available
NCT05382364,involves,Cancer
NCT05382364,evaluates,Tucatinib
NCT05382364,measures_primary,Percentage of AE
NCT05382364,measures_secondary,Discontinuation due to AE
NCT05382364,has_criteria,Up to approximately 2.5 years
NCT00749190,involves,Type 2 Diabetes
NCT00749190,evaluates,BI 10773
NCT00749190,measures_primary,Change From Baseline in HbA1c
NCT00749190,measures_secondary,Change of FPG From Baseline
NCT00749190,measures_secondary,Change of HbA1c From Baseline
NCT00749190,measures_secondary,Proportion of Patients Who Achieve an HbA1c
NCT00749190,measures_secondary,Proportion of Patients Who Achieve an HbA1c Lowering
NCT00749190,measures_secondary,Change From Baseline to Week 12 in Fasting Plasma Insulin
NCT00749190,measures_secondary,Change in Homeostasis Model Assessment Index for Insulin Resistance
NCT04086121,evaluates,BI 655130
NCT04086121,involves,Atopic Eczema
NCT04086121,measures_primary,EASI score at Week 48
NCT04086121,measures_secondary,EASI50 at Week 48
NCT02080364,involves,Mild Alzheimer's Disease
NCT02080364,evaluates,Azeliragon
NCT02080364,measures_primary,Change From Baseline in ADAS-cog
NCT02080364,measures_primary,Change From Baseline in CDR-sb
NCT02080364,measures_primary,Change From Baseline in MRI Brain Volumetric Measures
NCT02080364,measures_secondary,Change From Baseline in the Normalized Mean Composite SUVR of the 5 Regions
NCT02080364,has_criteria,Baseline and 18 months
NCT02242864,involves,Hypertension
NCT02242864,involves,Diabetes mellitus
NCT02242864,evaluates,Micardis®
NCT02242864,evaluates,MicardisPlus®
NCT02242864,measures_primary,Change in SBP
NCT02242864,measures_primary,Change in DBP
NCT02242864,measures_secondary,Metabolic parameters
NCT02242864,measures_secondary,Tolerability
NCT02242864,has_criteria,Age > 18 years
NCT02242864,has_criteria,Hypertension
NCT02242864,has_criteria,Diabetes mellitus
NCT01782690,involves,Metastatic Pancreatic Cancer
NCT01782690,evaluates,Erlotinib
NCT01782690,evaluates,Gemcitabine
NCT01782690,measures_primary,Overall Survival
NCT01782690,measures_secondary,Rash
NCT01782690,has_criteria,Up to 12 months
NCT00158821,involves,HIV-1 infection
NCT00158821,evaluates,Tenofovir Disoproxil Fumarate
NCT00158821,evaluates,Stavudine
NCT00158821,measures_primary,HIV-1 RNA levels
NCT00158821,measures_secondary,safety
NCT00158821,measures_secondary,efficacy
NCT00158821,measures_secondary,tolerability
NCT00158821,has_criteria,completed 96 weeks
NCT00158821,has_criteria,effective contraception
NCT00158821,has_criteria,informed consent
NCT03597464,involves,Lupus Nephritis
NCT03597464,evaluates,voclosporin
NCT03597464,evaluates,placebo
NCT03597464,measures_primary,Renal Response
NCT03597464,measures_secondary,Partial Renal Response
NCT03597464,measures_secondary,Renal Flare
NCT03597464,has_criteria,urine protein creatinine ratio
NCT03597464,has_criteria,estimated glomerular filtration rate
NCT03597464,has_criteria,rescue medication
NCT03597464,has_criteria,prednisone
NCT06056921,involves,Refractory systemic lupus erythematosus
NCT06056921,involves,Refractory Systemic scleroderma
NCT06056921,involves,Refractory Sjogren's syndrome
NCT06056921,evaluates,CD19 CAR-T cells
NCT06056921,measures_primary,SRI-4 response rate
NCT06056921,measures_primary,Change value of ESSDAI score
NCT06056921,measures_primary,Change value of mRSS score
NCT06056921,has_criteria,SLEDAI-2K rating
NCT05795621,involves,Thyroid Eye Disease
NCT05795621,evaluates,IBI311
NCT05795621,measures_primary,proptosis responder rate
NCT05795621,measures_secondary,clinical activity score
NCT05795621,has_criteria,CAS value 0 or 1
NCT03368664,involves,RRMS
NCT03368664,evaluates,Alemtuzumab
NCT03368664,measures_primary,Change From Baseline EDSS
NCT03368664,measures_secondary,Number of New T2 Lesions
NCT03368664,measures_secondary,Number Participants with TEAE
NCT03368664,measures_secondary,Annualized Relapse Rate
NCT03368664,has_criteria,Disease Activity on Prior DMT
NCT02417064,involves,Treatment-resistant Depression
NCT02417064,evaluates,Intranasal Esketamine
NCT02417064,measures_primary,Change From Baseline
NCT02417064,measures_secondary,Percentage of Participants
NCT02417064,has_criteria,Onset of Clinical Response
NCT01902290,involves,Asthma
NCT01902290,evaluates,Brodalumab
NCT01902290,measures_primary,Change From Baseline in ACQ Composite Score
NCT01902290,measures_secondary,Asthma Exacerbation Rate
NCT01902290,has_criteria,Inadequately Controlled Asthma
NCT00383721,involves,Chronic Obstructive Pulmonary Disease
NCT00383721,evaluates,Mometasone Furoate/Formoterol Combination
NCT00383721,measures_primary,FEV1 AUC
NCT00383721,measures_secondary,SGRQ Total Score
NCT00383721,has_criteria,COPD symptom-free nights
NCT01098721,involves,Psoriasis
NCT01098721,evaluates,1.0% WBI-1001
NCT01098721,measures_primary,PGA score change
NCT01098721,measures_secondary,PASI score change
NCT01098721,measures_secondary,BSA change
NCT01098721,has_criteria,Baseline (Day 0)
NCT03616964,involves,Systemic Lupus Erythematosus
NCT03616964,evaluates,Baricitinib
NCT03616964,measures_primary,SRI-4 Response
NCT03616964,has_criteria,SLEDAI-2K score
NCT01122264,involves,Erectile Dysfunction
NCT01122264,evaluates,tadalafil
NCT01122264,evaluates,sildenafil citrate
NCT01122264,measures_primary,Time to discontinuation
NCT01122264,measures_secondary,International Index of Erectile Function
NCT01122264,measures_secondary,International Index of Erectile Function Orgasmic Function Domain
NCT01122264,has_criteria,Baseline up to 334 days
NCT00760864,involves,Rheumatoid arthritis
NCT00760864,evaluates,TAK-715
NCT00760864,measures_primary,ACR 20% improvement
NCT00760864,measures_secondary,ACR 50% improvement
NCT00760864,measures_secondary,ACR 70% improvement
NCT00760864,measures_secondary,Swollen-tender joint counts
NCT00760864,measures_secondary,Pain assessment
NCT00760864,measures_secondary,Disease activity
NCT00760864,measures_secondary,Physical function
NCT00760864,measures_secondary,C-reactive protein
NCT00760864,measures_secondary,Erythrocyte sedimentation rate
NCT00760864,has_criteria,American College of Rheumatology criteria
NCT01455090,involves,Hepatitis C Virus
NCT01455090,evaluates,BMS-650032
NCT01455090,evaluates,BMS-790052
NCT01455090,evaluates,BMS 791325
NCT01455090,evaluates,BMS-794712
NCT01455090,measures_primary,SVR12
NCT01455090,measures_secondary,viral breakthrough
NCT01455090,measures_secondary,viral relapse
NCT01455090,has_criteria,Previously Treated
NCT02973321,involves,Type 2 Diabetes Mellitus
NCT02973321,evaluates,SAR425899
NCT02973321,measures_primary,Change From Baseline in HbA1c
NCT02973321,measures_secondary,Percentage of Participants Reached HbA1c Target
NCT02973321,measures_secondary,Percentage of Participants Achieving >=5% or >=10% Body Weight Loss
NCT02973321,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT02973321,measures_secondary,Change From Baseline in Average 7 Point Self-Monitoring Plasma Glucose
NCT02973321,has_criteria,Baseline
NCT00530621,involves,Lung Cancer
NCT00530621,evaluates,Enzastaurin
NCT00530621,evaluates,Placebo
NCT00530621,measures_primary,Progression-Free Survival
NCT00530621,measures_secondary,Overall Survival
NCT00530621,measures_secondary,Time-to-Worsening
NCT00530621,measures_secondary,Lung Cancer Symptom Scale
NCT00530621,has_criteria,Response Evaluation Criteria In Solid Tumors
NCT02260921,involves,Knee Pain
NCT02260921,evaluates,Iovera° Device
NCT02260921,measures_primary,WOMAC Pain Subscale
NCT02260921,measures_secondary,VAS pain
NCT02260921,measures_secondary,Total WOMAC Score
NCT02260921,has_criteria,Baseline to Day 30
NCT03230864,involves,Schizophrenia
NCT03230864,evaluates,Lu AF35700
NCT03230864,measures_primary,Change From Randomization to Week 8 in PANSS Total Score
NCT03230864,measures_secondary,Change From Randomization to Week 8 in CGI-S Score
NCT03230864,measures_secondary,Change From Randomization to Week 8 in 16-item Negative Symptom Assessment (NSA-16 Total) Score
NCT03230864,has_criteria,Treatment-resistant
NCT03100864,involves,Ulcerative Colitis
NCT03100864,evaluates,BI 655130
NCT03100864,measures_primary,Percent Change CRP
NCT03100864,measures_secondary,Percent Change Faecal Calprotectin
NCT03100864,measures_secondary,Percent Change Faecal Lactoferrin
NCT03100864,measures_secondary,Clinical Remission
NCT03100864,has_criteria,Mayo Score ≤2 Points
NCT02431806,involves,Major Depressive Disorder
NCT02431806,evaluates,Levomilnacipran ER
NCT02431806,measures_primary,Change From Baseline
NCT02431806,measures_secondary,Clinical Global Impression-Severity Scale
NCT02431806,has_criteria,Age 12-17 years
NCT02431806,has_criteria,DSM-IV-TR criteria for MDD
NCT02431806,has_criteria,CDRS-R score ≥ 40
NCT02431806,has_criteria,CGI-S score ≥ 4
NCT00950599,involves,Type 2 Diabetes
NCT00950599,evaluates,Saxagliptin
NCT00950599,measures_primary,Change From Baseline in A1C
NCT00950599,measures_secondary,Fasting Serum Glucose
NCT00950599,measures_secondary,Fructosamine
NCT00950599,measures_secondary,Insulin
NCT00950599,has_criteria,0-40 mg cohort
NCT02485899,involves,CLN2 Disease
NCT02485899,evaluates,BMN 190
NCT02485899,measures_primary,Unreversed ML decline
NCT02485899,measures_secondary,Probability of Unreversed ML Score of Zero
NCT02485899,has_criteria,Not specified
NCT00521742,involves,Type 2 Diabetes Mellitus
NCT00521742,involves,Cardiac Disease
NCT00521742,evaluates,Pioglitazone
NCT00521742,evaluates,Glyburide
NCT00521742,measures_primary,walking distance
NCT00521742,measures_secondary,Morbidity and Mortality
NCT00521742,measures_secondary,Cardiovascular Treatment Program
NCT00521742,measures_secondary,Electrocardiogram Parameter
NCT00521742,measures_secondary,Ventricular Heart Rate
NCT00521742,measures_secondary,Left Ventricular Mass
NCT00521742,measures_secondary,Left Ventricular Ejection Fraction
NCT00521742,measures_secondary,Cardiac Index
NCT00521742,measures_secondary,Fractional Shortening
NCT00521742,measures_secondary,Blood Pressure
NCT00521742,measures_secondary,Heart Rate
NCT00521742,measures_secondary,Body Weight
NCT00521742,has_criteria,Females of childbearing potential
NCT00521742,has_criteria,Sexually active
NCT00521742,has_criteria,Type 2 diabetes mellitus
NCT00521742,has_criteria,Sulfonylurea monotherapy
NCT00521742,has_criteria,Sulfonylurea/metformin combination therapy
NCT00521742,has_criteria,Metformin monotherapy
NCT00521742,has_criteria,New York Heart Association functional Class I
NCT00521742,has_criteria,Dietary counseling
NCT00521742,has_criteria,Glycosylated hemoglobin 7.5% to 12%
NCT00868699,involves,Bipolar I Depression
NCT00868699,evaluates,Lurasidone
NCT00868699,measures_primary,MADRS Total Score
NCT00868699,measures_secondary,CGI-BP-S Score
NCT00868699,measures_secondary,Sheehan Disability Scale
NCT00967499,involves,Postoperative Nausea and Vomiting
NCT00967499,evaluates,Palonosetron
NCT00967499,evaluates,Ondansetron
NCT00967499,measures_primary,Complete Control
NCT00967499,measures_secondary,Complete Response
NCT00967499,measures_secondary,Emesis Episode
NCT00967499,measures_secondary,Rescue Medication
NCT00967499,measures_secondary,Nausea Severity Score
NCT00967499,measures_secondary,Modified Osoba Nausea and Emesis Module Questionnaire Score
NCT00967499,has_criteria,Postanesthesia Care Unit
NCT00381342,involves,type 2 diabetes
NCT00381342,evaluates,Exenatide
NCT00381342,measures_primary,Change in HbA1c
NCT00381342,measures_secondary,Change in fasting serum glucose
NCT00381342,measures_secondary,Change in body weight
NCT00381342,measures_secondary,Changes in beta-cell function
NCT00381342,measures_secondary,Changes in fasting glucose
NCT00381342,has_criteria,HbA1c between 6.5% and 10.0%
NCT00381342,has_criteria,Body Mass Index (BMI) between 25 kg/m\^2 and 45 kg/m\^2
NCT06625242,involves,Rheumatoid Arthritis
NCT06625242,evaluates,Filgotinib
NCT06625242,measures_primary,ACR20 Response
NCT06625242,measures_secondary,DAS28 (CRP)
NCT06625242,has_criteria,Prior Treatment Therapy
NCT03226899,involves,Gout
NCT03226899,involves,Renal Impairment
NCT03226899,evaluates,Lesinurad
NCT03226899,measures_primary,Serum Urate < 6.0 mg/dL
NCT03226899,measures_secondary,Estimated Creatinine Clearance
NCT03226899,measures_secondary,Serum Creatinine Elevations
NCT03226899,has_criteria,sCr or eCrCl Criteria
NCT03472742,involves,Liver Cirrhosis
NCT03472742,evaluates,study medication
NCT03472742,measures_primary,Change of Child-Pugh Score
NCT03472742,measures_secondary,Improvement rate of Child-Pugh score
NCT03472742,measures_secondary,Improvement rate of Child-Pugh grade
NCT03472742,has_criteria,abnormal systolic blood pressure
NCT03472742,has_criteria,abnormal diastolic blood pressure
NCT03472742,has_criteria,abnormal pulse rate
NCT03472742,has_criteria,abnormal body temperature
NCT03472742,has_criteria,abnormal electrocardiogram
NCT03472742,has_criteria,abnormal clinical chemistry parameters
NCT01430442,involves,Migraine
NCT01430442,evaluates,Rimegepant
NCT01430442,measures_primary,Pain Freedom at 2 hours
NCT01430442,measures_secondary,Total Migraine Freedom at 2 hours
NCT01430442,has_criteria,baseline moderate pain or severe pain
NCT04949399,involves,Platysma Prominence
NCT04949399,evaluates,OnabotulinumtoxinA
NCT04949399,measures_primary,Composite Achievement
NCT04949399,measures_secondary,Percentage of Participants
NCT04949399,has_criteria,Grade 1 or 2
NCT03351699,involves,Human Immunodeficiency Virus (HIV)-1 infection
NCT03351699,evaluates,MK-4250
NCT03351699,measures_primary,Change from Baseline in plasma HIV-1 RNA
NCT03351699,measures_secondary,Percentage of Participants Experiencing ≥1 Adverse Events
NCT03351699,measures_secondary,Percentage of Participants Who Discontinued
NCT03351699,has_criteria,Anti-Retroviral Therapy-naive
NCT02372799,involves,Major Depressive Disorder
NCT02372799,evaluates,Vilazodone
NCT02372799,measures_primary,CDRS-R Total Score
NCT02372799,measures_secondary,CGI-S Score
NCT02372799,has_criteria,Age 7-17 years
NCT02372799,has_criteria,MDD diagnosis
NCT02372799,has_criteria,CDRS-R score 40 or greater
NCT02372799,has_criteria,CGI-S score 4 or greater
NCT03092999,involves,Hepatic Impairment
NCT03092999,evaluates,BAY1002670
NCT03092999,measures_primary,AUCu
NCT03092999,measures_primary,Cmax
NCT03092999,measures_secondary,Treatment Emergent Adverse Events
NCT03092999,measures_secondary,Severity of Treatment Emergent Adverse Events
NCT03092999,measures_secondary,blood laboratory parameters
NCT03092999,measures_secondary,urine laboratory parameters
NCT03092999,measures_secondary,Vital Signs
NCT03092999,measures_secondary,Electrocardiogram (ECG)
NCT03092999,has_criteria,informed consent
NCT03092999,has_criteria,age 18-79 years
NCT03092999,has_criteria,BMI 18-34 kg/m2
NCT03092999,has_criteria,contraception
NCT02792842,involves,Postoperative Stage II / III Colon Cancer
NCT02792842,evaluates,ART-123
NCT02792842,measures_primary,FACT/GOG-Ntx-12 Score
NCT02792842,measures_secondary,Peripheral Sensory Neuropathy
NCT02792842,has_criteria,NCI-CTCAE Grade 2 or Higher
NCT00127842,involves,Psoriatic Arthritis
NCT00127842,evaluates,Etanercept
NCT00127842,measures_primary,HAQ DI score
NCT00127842,measures_secondary,HLQ Absence From Work
NCT00127842,measures_secondary,HLQ Reduced Productivity
NCT00127842,has_criteria,≥ 0.50 units improvement
NCT05868499,involves,Adverse events
NCT05868499,evaluates,Not specified
NCT05868499,measures_primary,Systolic Blood Pressure
NCT05868499,measures_secondary,Not specified
NCT05868499,has_criteria,Signed IRB approved consent
NCT05851599,involves,Obesity
NCT05851599,evaluates,SKF7®
NCT05851599,measures_primary,Weight loss
NCT05851599,measures_secondary,Waist circumference
NCT05851599,measures_secondary,BMI
NCT05851599,measures_secondary,Blood lipid concentrations
NCT05851599,measures_secondary,Adverse events
NCT05851599,has_criteria,BMI 30-37 kg/m2
NCT05851599,has_criteria,Waist circumference ≥ 60% height
NCT05851599,has_criteria,Hypertension
NCT05851599,has_criteria,Diabetes
NCT05851599,has_criteria,Hyperlipidaemia
NCT02727699,involves,Mild Dementia Due to AD
NCT02727699,evaluates,Xanamem
NCT02727699,measures_primary,ADAS-Cog v14
NCT02727699,measures_secondary,ADCOMs
NCT02727699,measures_secondary,RAVLT
NCT02727699,has_criteria,Baseline
NCT00076999,involves,Human Immunodeficiency Virus
NCT00076999,evaluates,Tipranavir
NCT00076999,measures_primary,Viral Load Reduction
NCT00076999,measures_secondary,HIV RNA <400 Copies/mL
NCT00076999,measures_secondary,HIV RNA <50 Copies/mL
NCT05019742,involves,Ulcerative Colitis
NCT05019742,evaluates,SPH3127
NCT05019742,measures_primary,Change from baseline
NCT05019742,measures_secondary,Robarts Histopathology Index
NCT05019742,measures_secondary,UC-100 score
NCT05019742,has_criteria,Screening (baseline)
NCT02872142,involves,Amyotrophic Lateral Sclerosis
NCT02872142,evaluates,Plasma Exchange With Albutein® 5%
NCT02872142,measures_primary,Change From Baseline in ALSFRS-R Score
NCT02872142,measures_secondary,Percent Predicted Forced Vital Capacity
NCT02872142,measures_secondary,Behaviour Status Sub-scale Score of the ALS-CBS Test
NCT02872142,measures_secondary,Symptom Status Sub-scale Score of the ALS-CBS Test
NCT04391842,involves,knee osteoarthritis
NCT04391842,evaluates,Sustained Acoustic Medicine
NCT04391842,measures_primary,Change in Pain Units
NCT04391842,measures_secondary,WOMAC Scores
NCT04391842,has_criteria,Physician-diagnosed knee OA
NCT05375942,involves,Rheumatoid Arthritis
NCT05375942,evaluates,Inflectra
NCT05375942,measures_primary,LDA at 6 Months
NCT05375942,measures_primary,Clinical Remission at 6 Months
NCT05375942,measures_secondary,Change From Baseline in CDAI
NCT05375942,has_criteria,Disease activity (CDAI)
NCT00420342,involves,Prehypertension
NCT00420342,evaluates,Angeliq
NCT00420342,evaluates,Prempro
NCT00420342,measures_primary,Change in SBP
NCT00420342,measures_secondary,Change in DBP
NCT00420342,has_criteria,Sodium sensitive
NCT06411899,involves,Hidradenitis Suppurativa
NCT06411899,evaluates,Sonelokimab
NCT06411899,measures_primary,Hidradenitis Suppurativa Clinical Response 75
NCT06411899,measures_secondary,Hidradenitis Suppurativa Clinical Response 50
NCT06411899,measures_secondary,International Hidradenitis Suppurativa Severity Score System
NCT06411899,measures_secondary,Dermatology Life Quality Index
NCT06411899,measures_secondary,Reduction from Numerical Rating Scale
NCT06411899,measures_secondary,Patient Global Impression-Severity of Illness-Hidradenitis Suppurativa
NCT06411899,has_criteria,adult participants
NCT04641299,involves,Dyslipidemia
NCT04641299,evaluates,AZD8233
NCT04641299,measures_primary,Change in LDL-C
NCT04641299,measures_secondary,PCSK9 Concentration
NCT04641299,measures_secondary,TC
NCT04641299,has_criteria,18 to 75 years of age
NCT04641299,has_criteria,fasting LDL-C ≥ 70 mg/dL
NCT04641299,has_criteria,fasting triglycerides \< 400 mg/dL
NCT04641299,has_criteria,moderate- or high-intensity statin therapy
NCT01460342,involves,Benign Prostatic Hyperplasia
NCT01460342,evaluates,Tadalafil
NCT01460342,measures_primary,IPSS Total Score
NCT01460342,measures_secondary,IPSS Storage Subscore
NCT01460342,has_criteria,Asian Men
NCT01664949,involves,Dry Eye Disease
NCT01664949,evaluates,A New Eye Drop Formulation
NCT01664949,measures_primary,Change From Baseline
NCT01664949,measures_secondary,Tear Break-up Time
NCT01664949,measures_secondary,Corneal Staining
NCT01664949,measures_secondary,Conjunctival Staining
NCT01664949,has_criteria,Baseline
NCT04228406,evaluates,GST-HG161
NCT04228406,measures_primary,Objective response rate
NCT04228406,measures_secondary,Area Under Curve
NCT04228406,measures_secondary,Peak Plasma Concentration
NCT04228406,measures_secondary,Cl/F
NCT04228406,measures_secondary,T1/2
NCT04228406,has_criteria,Dose-Limiting Toxicity
NCT04228406,has_criteria,Maximum Tolerated Dose
NCT02157506,involves,Heart Failure
NCT02157506,evaluates,CXL-1427
NCT02157506,measures_primary,PCWP change
NCT02157506,measures_secondary,PAD change
NCT02157506,measures_secondary,Cardiac Index
NCT00810199,involves,Rheumatoid Arthritis
NCT00810199,evaluates,Tocilizumab
NCT00810199,evaluates,Methotrexate
NCT00810199,measures_primary,DAS28 Remission
NCT00810199,measures_secondary,ACR20 Response
NCT00810199,measures_secondary,ACR50 Response
NCT00810199,has_criteria,Inadequate Response
NCT01499199,involves,HIV-1 infection
NCT01499199,evaluates,Dolutegravir
NCT01499199,measures_primary,HIV-1 RNA response
NCT01499199,measures_secondary,Plasma DTG concentrations
NCT01499199,has_criteria,ART-naive Subjects
NCT02059642,involves,Attention Deficit/Hyperactivity
NCT02059642,evaluates,MG01CI
NCT02059642,evaluates,Placebo
NCT02059642,measures_primary,change in ADHD symptom score
NCT02059642,measures_secondary,Treatment Emergent Adverse Events
NCT02059642,has_criteria,age 18 to 55 years
NCT02059642,has_criteria,DSM-IV diagnosis
NCT02059642,has_criteria,DSM5 diagnosis
NCT02059642,has_criteria,moderate clinical severity
NCT03570970,evaluates,Benapenem
NCT03570970,measures_primary,Number of subjects
NCT03570970,measures_secondary,Number of subjects
NCT03570970,measures_secondary,Number of subjects
NCT03570970,measures_secondary,Number of subjects
NCT03570970,has_criteria,Male or female healthy subjects
NCT03570970,has_criteria,aged 18-45
NCT03570970,has_criteria,Body weight ≥ 50 kg
NCT03570970,has_criteria,body mass index 19.0-24.0 kg/m2
NCT00145470,involves,Bipolar Disorder
NCT00145470,evaluates,Asenapine
NCT00145470,measures_primary,Y-MRS score
NCT00145470,measures_secondary,Adverse Event
NCT00145470,measures_secondary,Discontinuing study treatment
NCT00145470,has_criteria,Up to Day 114
NCT00145470,has_criteria,Up to Day 84
NCT03444870,involves,Early Alzheimer's Disease
NCT03444870,evaluates,Gantenerumab
NCT03444870,measures_primary,Global Outcome
NCT03444870,measures_secondary,ADAS-Cog13 Score
NCT03444870,has_criteria,Baseline
NCT01076075,involves,Type 2 diabetes mellitus
NCT01076075,evaluates,Sitagliptin
NCT01076075,measures_primary,Change From Baseline in Hemoglobin A1C (%)
NCT01076075,measures_secondary,Number of Participants With One or More Adverse Events
NCT01076075,measures_secondary,Number of Participants Discontinuing Study Drug Due to An Adverse Event
NCT01076075,measures_secondary,Change From Baseline in 2-hour Post-Meal Glucose at Week 24
NCT01076075,measures_secondary,Change From Baseline in Fasting Plasma Glucose at Week 24
NCT01076075,has_criteria,Type 2 diabetes mellitus
NCT01076075,has_criteria,Hemoglobin A1C of ≥7.5% and ≤10.5%
NCT01076075,has_criteria,metformin
NCT01076075,has_criteria,glimepiride
NCT01076075,has_criteria,gliclazide
NCT01076075,has_criteria,Male
NCT01076075,has_criteria,female
NCT01076075,has_criteria,Type 1 diabetes mellitus
NCT01076075,has_criteria,ketoacidosis
NCT01076075,has_criteria,dipeptidyl peptidase-4 inhibitor
NCT01076075,has_criteria,glucagon-like peptide-1 mimetic
NCT01076075,has_criteria,insulin therapy
NCT01076075,has_criteria,weight loss program
NCT01076075,has_criteria,liver disease
NCT01076075,has_criteria,heart failure
NCT01076075,has_criteria,heart disease
NCT01076075,has_criteria,stroke
NCT01076075,has_criteria,high blood pressure
NCT01076075,has_criteria,blood disorders
NCT01076075,has_criteria,cancer
NCT01076075,has_criteria,HIV positive
NCT01076075,has_criteria,Pregnant
NCT00151775,involves,High Blood Pressure
NCT00151775,evaluates,Olmesartan Medoxomil
NCT00151775,measures_primary,Systolic Blood Pressure
NCT00151775,measures_secondary,Diastolic Blood Pressure
NCT00151775,has_criteria,Children and Adolescent
NCT06617975,involves,Knee Osteoarthritis
NCT06617975,evaluates,Spa Therapy
NCT06617975,measures_primary,MCII at 6 months
NCT06617975,measures_secondary,WOMAC function subscale
NCT06617975,has_criteria,absence of knee surgery
NCT04270370,evaluates,LY3478045
NCT04270370,measures_primary,AUC[0-inf]
NCT04270370,measures_primary,Cmax
NCT04270370,has_criteria,overtly healthy
NCT04270370,has_criteria,body mass index
NCT04270370,has_criteria,stable weight
NCT04270370,has_criteria,safety laboratory tests
NCT04270370,has_criteria,fructosuria
NCT04270370,has_criteria,abnormality ECG
NCT03720470,involves,Atopic Dermatitis
NCT03720470,evaluates,PF-04965842
NCT03720470,evaluates,Dupilumab
NCT03720470,measures_primary,IGA Response
NCT03720470,measures_primary,EASI Response
NCT03720470,measures_secondary,EASI Improvement
NCT03720470,has_criteria,Moderate to Severe AD
NCT01414075,involves,Anemia
NCT01414075,evaluates,Roxadustat
NCT01414075,measures_primary,Maximum Change Hb
NCT01414075,measures_secondary,Number of Participants
NCT01414075,has_criteria,Newly Initiated Dialysis
NCT05930275,involves,Crohn's Disease
NCT05930275,evaluates,Upadacitinib
NCT05930275,measures_primary,Time to CR
NCT05930275,measures_secondary,Percentage of Participants Achieving Clinical Remission
NCT05930275,has_criteria,moderate-to-severe crohn's disease
NCT05779475,involves,Parkinson's disease
NCT05779475,evaluates,cell therapy transplantation
NCT05779475,measures_primary,Change in MDS-UPDRS
NCT05779475,measures_secondary,count of participants
NCT05779475,has_criteria,aged 50-68 years
NCT05779475,has_criteria,diagnosed with Parkinson's disease
NCT05779475,has_criteria,moderate Parkinson's disease
NCT05779475,has_criteria,symptoms not controlled by medications
NCT02688075,involves,Type 2 Diabetes Mellitus
NCT02688075,evaluates,Canagliflozin Treatment
NCT02688075,measures_primary,Change From Baseline in Mean HbA1c
NCT02688075,measures_secondary,Percentage of Participants Achieving HbA1c Less Than 7.0 Percent
NCT02688075,measures_secondary,Percentage of Participants Achieving HbA1c Less Than 6.5 Percent
NCT02688075,measures_secondary,Change From Baseline in Mean Weight
NCT02688075,measures_secondary,Change From Baseline in BMI
NCT02688075,measures_secondary,Change From Baseline in Waist Circumference
NCT02688075,measures_secondary,Percentage of Participants With Weight Loss From Baseline
NCT02688075,measures_secondary,Percentage of Participants With Greater Than or Equal to 0.5% Reduction in HbA1c Plus Weight Loss >=3%
NCT02688075,measures_secondary,Current Health Satisfaction Questionnaire (CHES-Q)
NCT02688075,measures_secondary,Canagliflozin Treatment Adherence
NCT02688075,has_criteria,Up to Month 12
NCT04665570,involves,Type 2 Diabetes
NCT04665570,evaluates,Acarbose
NCT04665570,evaluates,Metformin
NCT04665570,measures_primary,Mean change in HbA1c
NCT04665570,measures_secondary,Change in fasting blood glucose
NCT04665570,measures_secondary,Change in postprandial glucose level
NCT04665570,measures_secondary,Occurrence of Hypoglycemic events
NCT04665570,measures_secondary,Severity of Hypoglycemic events
NCT04665570,measures_secondary,Occurrence of Gastrointestinal intolerance
NCT04665570,measures_secondary,Occurrence of other AEs
NCT04665570,measures_secondary,Change in patient tolerability to therapy
NCT04665570,measures_secondary,Mean change in body weight
NCT04665570,measures_secondary,Mean change in lipid profile
NCT04665570,has_criteria,Recently Diagnosed
NCT01835470,involves,Juvenile Idiopathic Arthritis
NCT01835470,evaluates,Abatacept
NCT01835470,measures_primary,ACR Pediatric 30 Response
NCT01835470,measures_secondary,ACR Pediatric 50
NCT01835470,measures_secondary,Inactive Disease
NCT01835470,has_criteria,active joints
NCT03020199,involves,Plaque Psoriasis
NCT03020199,evaluates,Secukinumab
NCT03020199,evaluates,Narrow-band UVB
NCT03020199,measures_primary,PASI 90
NCT03020199,measures_secondary,PASI 90
NCT03020199,has_criteria,New-onset moderate
NCT03724942,involves,Alzheimer's Disease
NCT03724942,evaluates,brexpiprazole
NCT03724942,measures_primary,Mean Change CMAI Score
NCT03724942,measures_secondary,Clinical Global Impression of Severity Score
NCT03724942,measures_secondary,Clinical Global Impression of Improvement Score
NCT03724942,has_criteria,completed double-blind treatment
NCT03635099,involves,Plaque Psoriasis
NCT03635099,evaluates,BI 730357
NCT03635099,measures_primary,PASI 75 at Week 12
NCT03635099,measures_secondary,sPGA 0/1 at Week 12
NCT03635099,measures_secondary,PASI 50 at Week 12
NCT03635099,has_criteria,Week 12 treatment
NCT01930799,involves,Multiple Sclerosis
NCT01930799,evaluates,video
NCT01930799,measures_primary,KHQ domain scores
NCT01930799,measures_secondary,Patient Post-Video Questionnaire
NCT01930799,has_criteria,relapsing-remitting multiple sclerosis
NCT05335499,involves,Chronic Spontaneous Urticaria
NCT05335499,evaluates,TAS5315
NCT05335499,measures_primary,UAS7 at week 12
NCT05335499,measures_secondary,Angioedema Activity Score
NCT05335499,measures_secondary,Dermatology life quality index
NCT05335499,measures_secondary,Urticaria control test
NCT05335499,measures_secondary,pharmacodynamics marker
NCT05335499,has_criteria,Aged 18 to 75 years
NCT05335499,has_criteria,Diagnosis of CSU
NCT05335499,has_criteria,Itch and hives for at least 6 consecutive weeks
NCT05335499,has_criteria,UAS7 score ≥ 16 and HSS7 score ≥ 8
NCT05335499,has_criteria,In-clinic UAS ≥ 4
NCT02181842,involves,Type 2 Diabetes
NCT02181842,involves,Cerebral Infarction
NCT02181842,evaluates,Pioglitazone Tablets
NCT02181842,measures_primary,Good Glycemic Control
NCT02181842,measures_secondary,Systolic Blood Pressure
NCT02181842,measures_secondary,Diastolic Blood Pressure
NCT02181842,measures_secondary,HDL-Cholesterol
NCT02181842,measures_secondary,LDL-Cholesterol
NCT02181842,measures_secondary,HbA1c
NCT02181842,has_criteria,Fasting Blood Glucose
NCT01020799,involves,Depression
NCT01020799,evaluates,AZD7268
NCT01020799,measures_primary,MADRS total score change
NCT01020799,measures_secondary,MADRS response
NCT01020799,measures_secondary,MADRS remission
NCT01020799,measures_secondary,HAM-D total score change
NCT01020799,has_criteria,Full Analysis Set
NCT01088399,involves,Growth Hormone Deficiency
NCT01088399,evaluates,Somatropin
NCT01088399,measures_primary,Fracture Incidence
NCT01088399,measures_secondary,Change in BMI
NCT01088399,measures_secondary,Change in SBP
NCT01088399,measures_secondary,Change in DBP
NCT01088399,measures_secondary,Change in Cholesterol
NCT01088399,measures_secondary,Change in Triglycerides
NCT01088399,measures_secondary,Change in Waist Circumference
NCT01088399,measures_secondary,Change in QLS-H Z-score
NCT01088399,has_criteria,Baseline
NCT02761642,involves,Breast Cancer
NCT02761642,evaluates,Epoetin Beta
NCT02761642,measures_primary,Change From Baseline
NCT02761642,measures_secondary,Percentage of Response
NCT02761642,has_criteria,Hemoglobin Level
NCT06605599,involves,Bipolar I Disorder
NCT06605599,involves,Bipolar II Disorder
NCT06605599,evaluates,ABBV-932
NCT06605599,measures_primary,Change From Baseline
NCT06605599,measures_secondary,Change From Baseline
NCT06605599,measures_secondary,Change From Baseline
NCT06605599,measures_secondary,Change From Baseline
NCT06605599,has_criteria,Up to Week 6
NCT04801199,involves,Type 2 Diabetes Mellitus
NCT04801199,evaluates,CPL-2009-0031
NCT04801199,measures_primary,HbA1c level
NCT04801199,measures_secondary,Fasting Blood Sugar
NCT04801199,measures_secondary,Postprandial Blood Sugar
NCT04801199,measures_secondary,Serious Adverse Events
NCT04801199,measures_secondary,hypoglycemic events
NCT04801199,measures_secondary,adverse events
NCT04801199,has_criteria,adult patient 18-65 years
NCT04801199,has_criteria,HbA1c ≥ 7 to 10
NCT04801199,has_criteria,oral hypoglycemic agents ≤ 2
NCT04801199,has_criteria,BMI 18.5 - 35 kg/m2
NCT02864342,involves,COPD
NCT02864342,evaluates,Symbicort
NCT02864342,measures_primary,Mean CCQ Scores
NCT02864342,measures_secondary,Mean Change in Score
NCT02864342,has_criteria,2 sets of 2 puffs
NCT05817942,involves,Ulcerative Colitis
NCT05817942,evaluates,Filgotinib
NCT05817942,measures_primary,Treatment Persistence Rate
NCT05817942,measures_secondary,Clinical Response Rate
NCT05817942,measures_secondary,Clinical Remission Rate
NCT05817942,measures_secondary,Change from Baseline in HRQoL
NCT05817942,measures_secondary,Change from Baseline in Urgency NRS
NCT05817942,measures_secondary,Change from Baseline in FACIT-F
NCT05817942,measures_secondary,Number of Participants with AEs
NCT05817942,measures_secondary,Number of Participants with SAEs
NCT05817942,has_criteria,Moderately or severely active UC
NCT05817942,has_criteria,Filgotinib-naïve
NCT05642442,involves,Parkinson's Disease
NCT05642442,evaluates,Suvecaltamide
NCT05642442,measures_primary,TETRAS composite score
NCT05642442,measures_secondary,Clinical Global Impression of Severity
NCT05642442,has_criteria,Baseline to Week 17 post-dose
NCT04118842,evaluates,Savolitinib
NCT04118842,evaluates,Rifampicin
NCT04118842,measures_primary,Cmax ratios
NCT04118842,measures_primary,AUC ratios
NCT04118842,measures_secondary,Adverse events
NCT04118842,measures_secondary,Systolic BP
NCT04118842,measures_secondary,Diastolic BP
NCT04118842,measures_secondary,Pulse rate
NCT04118842,measures_secondary,Electrocardiograms
NCT01537042,involves,Restless Legs Syndrome
NCT01537042,involves,End-Stage Renal Disease
NCT01537042,evaluates,Rotigotine Skin Patch
NCT01537042,measures_primary,PLMI Ratio
NCT01537042,measures_secondary,IRLS Sum Score
NCT01537042,has_criteria,Hemodialysis
NCT04252742,involves,Episodic Migraine
NCT04252742,evaluates,Erenumab
NCT04252742,measures_primary,Headache pain intensity
NCT04252742,measures_secondary,Physical Function Domain Score
NCT04252742,has_criteria,at least moderate headache pain intensity
NCT01010542,involves,Psoriasis
NCT01010542,evaluates,ILV-095
NCT01010542,measures_primary,PASI score improvement
NCT01010542,measures_secondary,PASI score
NCT01010542,has_criteria,Baseline
NCT00827242,involves,Benign Prostatic Hyperplasia
NCT00827242,evaluates,Tadalafil
NCT00827242,measures_primary,Change From Baseline
NCT00827242,measures_secondary,Benign Prostatic Hyperplasia Impact Index
NCT00827242,has_criteria,Baseline
NCT00827242,has_criteria,Baseline
NCT05811442,involves,Alzheimer's Disease
NCT05811442,measures_primary,Change from baseline in ADAS-Cog 13
NCT05811442,measures_secondary,Change from baseline in CDR-SB
NCT05811442,measures_secondary,Change from baseline in MMSE
NCT05811442,measures_secondary,Change from baseline in ADCS-ADL
NCT05811442,measures_secondary,Change from baseline in NPI 12-item behavioral domain scores
NCT05811442,measures_secondary,Change from baseline in NPI caregiver stress scores
NCT00375713,involves,atopic dermatitis
NCT00375713,involves,contact dermatitis
NCT00375713,involves,prurigo
NCT00375713,involves,pruritus
NCT00375713,evaluates,Xyzal
NCT00375713,evaluates,Zyrtec
NCT00375713,measures_primary,Pruritus Severity Score
NCT00375713,measures_secondary,Duration of Pruritus
NCT00375713,measures_secondary,Global Improvement
NCT00375713,has_criteria,diagnosed dermatitis
NCT00375713,has_criteria,require topical steroid
NCT00375713,has_criteria,minimum pruritus
NCT02817906,involves,Alzheimer's disease
NCT02817906,involves,agitation
NCT02817906,evaluates,ITI-007
NCT02817906,measures_primary,Change From Baseline CMAI-C
NCT02817906,measures_secondary,Change From Baseline CGI-S
NCT02817906,has_criteria,Clinical diagnosis probable Alzheimer's disease
NCT02817906,has_criteria,Clinically significant agitation
NCT02817906,has_criteria,Able attend outpatient clinic visits
NCT02817906,has_criteria,primary caregiver
NCT02817906,has_criteria,Unable comply study procedures
NCT02817906,has_criteria,Medically inappropriate study participation
NCT06559306,involves,Major Depressive Disorder
NCT06559306,involves,Insomnia
NCT06559306,evaluates,Seltorexant
NCT06559306,measures_primary,MADRS Total Score
NCT06559306,measures_secondary,MADRS-WOSI Total Score
NCT06559306,measures_secondary,PROMIS-SD T-score
NCT06559306,has_criteria,Stable Response
NCT03016013,involves,Rheumatoid Arthritis
NCT03016013,evaluates,TACI-antibody Fusion Protein Injection
NCT03016013,measures_primary,ACR20 response
NCT03016013,measures_secondary,DAS28 score
NCT03016013,has_criteria,MTX inadequate response
NCT01187836,involves,Heart Failure
NCT01187836,evaluates,TRV120027
NCT01187836,measures_primary,Pulmonary Capillary Wedge Pressure
NCT01187836,measures_secondary,Safety and Tolerability
NCT01187836,measures_secondary,Pharmacokinetics
NCT01187836,measures_secondary,Hemodynamics
NCT01187836,measures_secondary,Laboratory Evaluations
NCT01187836,has_criteria,Diagnosis of congestive heart failure
NCT03449199,involves,Type 2 Diabetes
NCT03449199,involves,Albuminuria
NCT03449199,evaluates,TMX-049
NCT03449199,measures_primary,log-transformed UACR
NCT03449199,measures_secondary,Estimated Glomerular Filtration Rate
NCT03449199,measures_secondary,Serum Uric Acid
NCT03449199,measures_secondary,Urinary Albumin-to-Creatinine Ratio
NCT03449199,measures_secondary,Proportion of Subjects
NCT03449199,has_criteria,Baseline and Week 12
NCT06627699,involves,Total Knee Arthroplasty
NCT06627699,evaluates,Freedom Total Knee® System
NCT06627699,measures_primary,Revision of any component
NCT06627699,measures_secondary,Knee Society Score
NCT06627699,measures_secondary,KOOS-JR
NCT06627699,has_criteria,device / device composite failure
NCT06447506,involves,Atopic Dermatitis
NCT06447506,evaluates,GSK1070806
NCT06447506,measures_primary,IGA score 0 or 1
NCT06447506,measures_secondary,EASI reduction 75%
NCT05494606,involves,Ulcerative colitis
NCT05494606,evaluates,Upadacitinib
NCT05494606,measures_primary,Median Time to CR
NCT05494606,measures_secondary,Percentage of Participants Achieving CR
NCT05494606,has_criteria,Moderate to severe UC
NCT05494606,has_criteria,Initiating upadacitinib
NCT05494606,has_criteria,Prescribed upadacitinib
NCT05494606,has_criteria,Able to understand
NCT05494606,has_criteria,Willing to continue documentation
NCT05494606,has_criteria,Willing to participate in data collection
NCT02990806,involves,Rheumatoid Arthritis
NCT02990806,evaluates,NI-071
NCT02990806,measures_primary,ACR20-CRP response
NCT02990806,measures_secondary,AUCtau
NCT02990806,has_criteria,20% improvement
NCT04491006,involves,Alzheimer's Disease
NCT04491006,evaluates,ATH-1017
NCT04491006,measures_primary,ERP P300 latency
NCT04491006,measures_secondary,ADAS-Cog11 score
NCT04491006,has_criteria,Age 55 to 85 years
NCT04491006,has_criteria,MMSE 14-24
NCT04491006,has_criteria,CDR 1 or 2
NCT04491006,has_criteria,diagnosis of dementia
NCT01047306,involves,Sanfilippo Syndrome Type A (MPS IIIA)
NCT01047306,evaluates,BSID-III/KABC-II
NCT01047306,measures_primary,Change From Baseline
NCT01047306,measures_secondary,Developmental Quotient (DQ) Scores
NCT01047306,has_criteria,calendar age and VABS-II age -equivalent score
NCT05730699,involves,Neuromyelitis Optica Spectrum Disorders
NCT05730699,evaluates,Divozilimab
NCT05730699,measures_primary,Time to relapse
NCT05730699,measures_secondary,Annualized relapse rate
NCT05730699,measures_secondary,Proportion of subjects without relapse
NCT05730699,measures_secondary,Change in EDSS score
NCT05730699,measures_secondary,Proportion of subjects with confirmed increase in disability
NCT05730699,measures_secondary,Vision acuity change
NCT05730699,measures_secondary,Change in T25-FW test
NCT05730699,has_criteria,Week 24
NCT00853099,involves,Ulcerative Colitis
NCT00853099,evaluates,Adalimumab
NCT00853099,measures_primary,Clinical Remission
NCT00853099,measures_secondary,Mayo score
NCT00853099,has_criteria,Japanese Subjects
NCT02153099,involves,Healthy Participants
NCT02153099,evaluates,ENV8058
NCT02153099,measures_primary,Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
NCT02153099,measures_secondary,Percentage of Participants With Markedly Abnormal Safety Laboratory Tests
NCT02153099,measures_secondary,Percentage of Participants With Markedly Abnormal Vital Sign Measurements
NCT02153099,has_criteria,Baseline up to Day 30
NCT02153099,has_criteria,Baseline up to Day 14
NCT02153099,has_criteria,Baseline up to Day 14
NCT03323749,involves,Primary Mitochondrial Myopathy
NCT03323749,evaluates,Elamipretide
NCT03323749,measures_primary,Change From Baseline in Distance Walked
NCT03323749,measures_secondary,Total Fatigue Score
NCT03323749,measures_secondary,Fatigue During Activities Score
NCT03323749,measures_secondary,Neuro-QoL Fatigue Activities of Daily Living
NCT03323749,measures_secondary,Change From Baseline in the Most Bothersome Symptom Score
NCT02284906,involves,Alzheimer Disease
NCT02284906,involves,Mild Cognitive Impairment
NCT02284906,evaluates,Pioglitazone
NCT02284906,measures_primary,Change From Baseline
NCT02284906,measures_secondary,Time to Diagnosis
NCT02284906,has_criteria,Completed AD-4833/TOMM40_301 study
NCT02284906,has_criteria,Age 65 years or older
NCT02284906,has_criteria,Capable of understanding protocol
NCT02284906,has_criteria,Informed consent
NCT05570006,involves,Ulcerative Colitis
NCT05570006,evaluates,ABBV-668 Oral Capsules
NCT05570006,measures_primary,Endoscopic Improvement
NCT05570006,measures_secondary,Clinical Remission
NCT05570006,measures_secondary,Clinical Response
NCT05570006,has_criteria,Moderate to Severe
NCT03919799,involves,Diffuse Cutaneous Systemic Sclerosis
NCT03919799,evaluates,KD025
NCT03919799,measures_primary,CRISS score >= 60%
NCT03919799,measures_secondary,mRSS
NCT03919799,measures_secondary,FVC percent predicted
NCT03919799,measures_secondary,physician global assessment
NCT03919799,measures_secondary,patient global assessment
NCT03919799,measures_secondary,SHAQ-DI
NCT03919799,has_criteria,new onset renal crisis
NCT03919799,has_criteria,new onset lung fibrosis
NCT03919799,has_criteria,pulmonary arterial hypertension
NCT03919799,has_criteria,left ventricular failure
NCT01631513,involves,Chronic Pain
NCT01631513,evaluates,Tapentadol Extended Release
NCT01631513,measures_primary,Pain intensity
NCT01631513,measures_secondary,Quality of life
NCT01631513,measures_secondary,Pain interference
NCT01631513,measures_secondary,Sleep quality
NCT01631513,has_criteria,Conversion From Hydrocodone
NCT04088149,involves,Chronic Stroke
NCT04088149,evaluates,GXNPC-1
NCT04088149,measures_primary,Net Change NIHSS
NCT04088149,measures_secondary,Net Change FMA
NCT04088149,measures_secondary,Net Change BI
NCT04088149,has_criteria,Baseline (0 week)
NCT02897349,involves,Type 2 Diabetes
NCT02897349,evaluates,Linagliptin
NCT02897349,measures_primary,Percentage Change HbA1c
NCT02897349,measures_secondary,Change From Baseline FPG
NCT02897349,measures_secondary,Change From Baseline PPG
NCT02897349,has_criteria,HbA1c <7.0% excluded
NCT02897349,has_criteria,HbA1c <6.5% excluded
NCT03339999,involves,Plaque Psoriasis
NCT03339999,evaluates,AGN-242428
NCT03339999,measures_primary,PASI score ≥ 75%
NCT03339999,measures_secondary,PGA score ≥ 2-point reduction
NCT03339999,measures_secondary,PGA score 0 or 1
NCT03339999,measures_secondary,PASI score ≥ 50%
NCT03339999,measures_secondary,PASI score ≥ 90%
NCT03339999,has_criteria,Treatment-emergent Adverse Events
NCT01350999,involves,Hypertriglyceridemia
NCT01350999,evaluates,TAK-085
NCT01350999,measures_primary,Triglyceride Level
NCT01350999,measures_secondary,LDL-C
NCT01350999,measures_secondary,Total Cholesterol
NCT01350999,measures_secondary,HDL-C
NCT01350999,measures_secondary,Non-HDL-C
NCT01350999,has_criteria,Triglyceride level 150 mg/dL
NCT01350999,has_criteria,Aged 20 to less than 75 years
NCT01350999,has_criteria,Outpatient
NCT03526549,involves,Edematous Fibrosclerotic Panniculopathy
NCT03526549,evaluates,EN3835
NCT03526549,measures_primary,Time to 2-Level Reduction
NCT03526549,measures_secondary,Time to 1-Level Reduction
NCT03526549,has_criteria,Screening assessment
NCT00829049,involves,Acne Vulgaris
NCT00829049,evaluates,Tazarotene Cream 0.1%
NCT00829049,evaluates,Adapalene Gel 0.3%
NCT00829049,measures_primary,Percent Change Lesion Counts
NCT00829049,measures_secondary,Investigator Global Assessment
NCT00829049,measures_secondary,Overall Disease Severity Score
NCT00829049,has_criteria,Moderate to Severe
NCT00446849,involves,Ulcerative Colitis
NCT00446849,evaluates,MMX Mesalamine
NCT00446849,measures_primary,Clinical Recurrence
NCT00446849,measures_secondary,Subject Compliance
NCT00446849,has_criteria,4 or more bowel movements per day
NCT05567406,involves,Chronic Graft Versus Host Disease
NCT05567406,evaluates,Oral Belumosudil
NCT05567406,measures_primary,Overall Response Rate
NCT05567406,measures_secondary,Duration of Response
NCT05567406,measures_secondary,Lee Symptom Scale Score
NCT05567406,has_criteria,At Least 2 Prior Lines of Systemic Therapy
NCT02318706,involves,Diabetic Peripheral Neuropathic Pain
NCT02318706,evaluates,DS-5565
NCT02318706,measures_primary,Change in ADPS
NCT02318706,measures_secondary,Change in VAS pain
NCT02318706,has_criteria,Type 1 or type 2 diabetes mellitus
NCT02318706,has_criteria,Painful distal symmetric polyneuropathy
NCT02318706,has_criteria,Pain scale ≥ 40 mm
NCT02963506,involves,Ankylosing Spondylitis
NCT02963506,evaluates,Bimekizumab
NCT02963506,measures_primary,ASAS40 response
NCT02963506,measures_secondary,ASDAS [CRP]
NCT02963506,has_criteria,Active Ankylosing Spondylitis
NCT00078806,involves,Systemic Onset Juvenile Rheumatoid Arthritis
NCT00078806,evaluates,Etanercept
NCT00078806,measures_primary,Time to flare
NCT00078806,measures_secondary,Change From Baseline
NCT00078806,has_criteria,Disease flare
NCT05999799,involves,Atopic Dermatitis
NCT05999799,evaluates,GSK1070806
NCT05999799,measures_primary,EASI score percent changes
NCT05999799,measures_secondary,Number of Participants Achieving EASI Reduction
NCT05999799,measures_secondary,Investigator's Global Assessment score
NCT05999799,has_criteria,Baseline and Week 16
NCT02499900,involves,Relapsing Remitting Multiple Sclerosis
NCT02499900,evaluates,Copaxone
NCT02499900,measures_primary,Change From Baseline MSQ
NCT02499900,measures_secondary,Change From Baseline TSQM-9 Convenience Score
NCT02499900,has_criteria,Baseline Month 0 Months 1 3 and 6
NCT02601300,involves,Ulcerative Colitis
NCT02601300,evaluates,Mongersen
NCT02601300,measures_primary,Clinical Remission
NCT02601300,measures_secondary,Modified Mayo Score
NCT02601300,has_criteria,Week 8
NCT03406000,involves,Type 2 Diabetes
NCT03406000,evaluates,Insulin Glargine 300 U/mL
NCT03406000,measures_primary,HbA1c change
NCT03406000,measures_secondary,fasting plasma glucose
NCT03406000,measures_secondary,fasting SMBG
NCT03406000,measures_secondary,8-point SMBG
NCT03406000,has_criteria,HbA1c target
NCT03100500,involves,Asthma
NCT03100500,evaluates,QMF149
NCT03100500,measures_primary,Change From Baseline FEV1
NCT03100500,measures_secondary,Change From Baseline PEF
NCT03100500,measures_secondary,Change From Baseline ACQ-7
NCT03100500,has_criteria,Japanese Participants
NCT04391959,involves,Meibomian Gland Dysfunction
NCT04391959,evaluates,AZR-MD-001
NCT04391959,measures_primary,Change from Baseline in MGS
NCT04391959,measures_secondary,Total OSDI
NCT04391959,has_criteria,18 years of age or older
NCT04391959,has_criteria,Best-corrected visual acuity 20/40 or better
NCT04391959,has_criteria,Evidence of meibomian gland obstruction
NCT04391959,has_criteria,Reported dry eye signs and symptoms
NCT01711359,involves,Rheumatoid arthritis
NCT01711359,measures_primary,ACR20 Responder Index
NCT01711359,measures_secondary,Change From Baseline in HAQ-DI Score
NCT01711359,has_criteria,tender and swollen joint counts
NCT05811000,involves,Alzheimer's Disease
NCT05811000,evaluates,PM012 Tablet
NCT05811000,measures_primary,ADAS-cog score
NCT05811000,measures_secondary,ADCS-MCI-ADLI score
NCT05811000,measures_secondary,CDR score
NCT05811000,has_criteria,12 weeks post-dose
NCT05811000,has_criteria,8 weeks post-dose
NCT00979459,involves,type 2 diabetes
NCT00979459,evaluates,MK-1006
NCT00979459,measures_primary,AUC(0-infinity)
NCT00979459,measures_primary,Cmax
NCT00979459,measures_secondary,Adverse Event
NCT00979459,measures_secondary,Discontinuation
NCT00979459,has_criteria,non-child bearing potential
NCT00979459,has_criteria,T2D
NCT00979459,has_criteria,diet and exercise
NCT00979459,has_criteria,oral anti-hyperglycemic agent
NCT00979459,has_criteria,nonsmoker
NCT00979459,has_criteria,stroke
NCT00979459,has_criteria,seizures
NCT00979459,has_criteria,neurological disorder
NCT00979459,has_criteria,endocrine abnormalities
NCT00979459,has_criteria,gastrointestinal abnormalities
NCT00979459,has_criteria,cardiovascular abnormalities
NCT00979459,has_criteria,blood abnormalities
NCT00979459,has_criteria,liver abnormalities
NCT00979459,has_criteria,immune abnormalities
NCT00979459,has_criteria,kidney abnormalities
NCT00979459,has_criteria,respiratory abnormalities
NCT00979459,has_criteria,genitourinary abnormalities
NCT00979459,has_criteria,cancer
NCT00979459,has_criteria,diabetic retinopathy
NCT00979459,has_criteria,neuropathy
NCT00979459,has_criteria,eye infection
NCT00979459,has_criteria,glaucoma
NCT00979459,has_criteria,eye surgery
NCT00979459,has_criteria,type 1 diabetes
NCT00979459,has_criteria,coronary artery disease
NCT00979459,has_criteria,alcohol consumption
NCT00979459,has_criteria,caffeine consumption
NCT03672175,involves,Major Depressive Disorder
NCT03672175,evaluates,SAGE-217
NCT03672175,measures_primary,Change From Baseline
NCT03672175,measures_secondary,Clinical Global Impression - Severity
NCT03672175,has_criteria,Adult Participants
NCT00767000,involves,Type 2 Diabetes Mellitus
NCT00767000,evaluates,MK-0941
NCT00767000,measures_primary,Change in HbA1c
NCT00767000,measures_secondary,Change in 2-hour Post Meal Glucose Level
NCT00767000,measures_secondary,Change in Fasting Plasma Glucose Level
NCT00767000,measures_secondary,Percentage of Participants Who Achieve an HbA1c of <7.0%
NCT00767000,measures_secondary,Percentage of Participants Achieving an HbA1c of <7.0% at Week 54 Who Maintain an HbA1c of <7.0%
NCT00767000,has_criteria,has type 2 diabetes mellitus
NCT00767000,has_criteria,has body mass index >20 and <43 kg/m^2
NCT00767000,has_criteria,is a male
NCT00767000,has_criteria,currently on a stable dose of insulin with or without metformin for Type 2 diabetes mellitus
NCT00767000,has_criteria,completed the base study either on double-blind study medication or as part of the post-treatment follow up population
NCT00767000,has_criteria,had ≥85% compliance with double-blind and open-label medication during the base study double-blind treatment period
NCT01393600,involves,Tardive Dyskinesia
NCT01393600,involves,Schizophrenia
NCT01393600,involves,Schizoaffective Disorder
NCT01393600,evaluates,NBI-98854
NCT01393600,measures_primary,AIMS dyskinesia total score
NCT01393600,measures_secondary,CGI-TD
NCT01393600,has_criteria,schizophrenia
NCT01393600,has_criteria,schizoaffective disorder
NCT01393600,has_criteria,neuroleptic-induced tardive dyskinesia
NCT01393600,has_criteria,stable antipsychotic medication
NCT01393600,has_criteria,stable concurrent medications
NCT01393600,has_criteria,hormonal or two forms of nonhormonal birth control
NCT01393600,has_criteria,not pregnant
NCT01393600,has_criteria,good general health
NCT01393600,has_criteria,BMI 18 to 38 kg/m2
NCT04873700,involves,Inflammatory Bowel Disease
NCT04873700,involves,Ulcerative Colitis
NCT04873700,involves,Crohn's Disease
NCT04873700,measures_primary,Percentage of Participants
NCT04873700,has_criteria,Harvey Bradshaw index
NCT04873700,has_criteria,Crohn's disease active index
NCT04873700,has_criteria,Partial Mayo Score
NCT02762500,involves,Ulcerative Colitis
NCT02762500,evaluates,LYC-30937-EC
NCT02762500,measures_primary,Clinical Remission
NCT02762500,measures_secondary,Clinical Response
NCT02762500,has_criteria,Modified Mayo Score
NCT04857359,involves,Parkinson's Disease
NCT04857359,evaluates,Dipraglurant
NCT04857359,measures_primary,Change from baseline
NCT04857359,measures_secondary,ON time without troublesome dyskinesia
NCT04857359,measures_secondary,OFF time
NCT04857359,has_criteria,stable regimen of antiparkinson's medications
NCT04857359,has_criteria,moderate to severe dyskinesia
NCT04857359,has_criteria,ON time with troublesome dyskinesia
NCT04235959,involves,Type 2 Diabetes Mellitus
NCT04235959,evaluates,Tirzepatide
NCT04235959,measures_primary,Number of SAEs
NCT04235959,measures_secondary,Pharmacokinetics
NCT04235959,has_criteria,type 2 diabetes mellitus
NCT00762359,involves,Aspirin-Induced Gastric Ulcer
NCT00762359,involves,Aspirin-Induced Duodenal Ulcer
NCT00762359,evaluates,Lansoprazole
NCT00762359,measures_primary,Number of ulcers
NCT00762359,measures_secondary,Lanza Score
NCT00762359,has_criteria,mucosal defect
NCT01624259,involves,Type 2 Diabetes
NCT01624259,evaluates,Dulaglutide
NCT01624259,evaluates,Liraglutide
NCT01624259,measures_primary,Glycosylated Hemoglobin
NCT01624259,measures_secondary,Body Weight
NCT01624259,measures_secondary,Body Mass Index
NCT01624259,measures_secondary,Fasting Plasma Glucose
NCT01624259,measures_secondary,7-Point Self Monitored Plasma Glucose
NCT01624259,has_criteria,Baseline HbA1c
NCT06058000,involves,Atopic Dermatitis
NCT06058000,evaluates,QLM3003 Ointment
NCT06058000,measures_primary,EASI-75 at Week 8
NCT06058000,measures_secondary,IGA Score at Week 8
NCT06058000,has_criteria,Mild or Moderate AD
NCT00738400,involves,Erectile Dysfunction
NCT00738400,involves,Metabolic Syndrome
NCT00738400,evaluates,Vardenafil
NCT00738400,measures_primary,IIEF-EF domain score
NCT00738400,measures_secondary,Success of Penetration
NCT00738400,measures_secondary,Success of Erection Maintenance
NCT00738400,measures_secondary,"Back to Normal"" Erectile Function"
NCT00738400,has_criteria,Baseline and 8 weeks
NCT01381900,involves,Type 2 Diabetes Mellitus
NCT01381900,evaluates,Canagliflozin
NCT01381900,measures_primary,Change in HbA1c
NCT01381900,measures_secondary,Change in FPG
NCT01381900,measures_secondary,Percent Change in Body Weight
NCT01381900,measures_secondary,Percentage of Patients With HbA1c <7% at Week 18
NCT01381900,measures_secondary,Percentage of Patients With HbA1c <6.5% at Week 18
NCT01381900,has_criteria,inadequate glycemic control
NCT00754559,involves,Rheumatoid Arthritis
NCT00754559,evaluates,Tocilizumab
NCT00754559,measures_primary,Low Disease Activity Score
NCT00754559,measures_secondary,DAS28 Response
NCT00754559,has_criteria,Disease Activity score
NCT00950859,involves,HIV-1
NCT00950859,evaluates,GSK1349572
NCT00950859,measures_primary,HIV-1 RNA <400 c/mL
NCT00950859,measures_secondary,TLOVR
NCT00950859,has_criteria,Raltegravir resistant
NCT02289300,involves,Liver Cancer
NCT02289300,evaluates,DCB-BO1202
NCT02289300,measures_primary,Liver stiffness measurement
NCT02289300,measures_secondary,HBV DNA
NCT02289300,has_criteria,Aged 20-65 years
NCT01727700,involves,Tourette's Disorder
NCT01727700,evaluates,Aripiprazole
NCT01727700,measures_primary,YGTSS Total Tic Score
NCT01727700,measures_secondary,CGI-TS Score
NCT01727700,has_criteria,Children and Adolescents
NCT01899300,involves,Caustic Strictures
NCT01899300,evaluates,Esophageal Fully Covered Metal Stents
NCT01899300,measures_primary,Stent Placement Success
NCT01899300,measures_secondary,Stent Removal Success
NCT01899300,measures_secondary,Change in Patient's Report on Pain
NCT01899300,measures_secondary,Change of Pain Medication Intake
NCT01899300,measures_secondary,Change in Dysphagia Score
NCT01899300,has_criteria,Stent tolerability
NCT01899300,has_criteria,adequate ability to sustain nutrition
NCT05295459,involves,Chronic Rhinosinusitis
NCT05295459,evaluates,LYR-210
NCT05295459,measures_primary,CFBL 3CS Week 24
NCT05295459,measures_secondary,SNOT-22 total score
NCT05295459,measures_secondary,percent opacification
NCT05295459,has_criteria,nasal polyps
NCT03952559,involves,Atopic Dermatitis
NCT03952559,evaluates,Baricitinib
NCT03952559,measures_primary,IGA 0 or 1
NCT03952559,measures_secondary,EASI75
NCT03952559,has_criteria,Age
NCT00664859,involves,Dyslipidemia
NCT00664859,evaluates,LCP-AtorFen
NCT00664859,measures_primary,Change in Non-HDL Cholesterol
NCT00664859,measures_secondary,Change in LDL Cholesterol
NCT00664859,has_criteria,Study drug compliance
NCT00664859,has_criteria,Resting blood pressure
NCT00664859,has_criteria,Symptoms of unexplained muscle pain
NCT00664859,has_criteria,Diagnosis of myopathy
NCT00664859,has_criteria,Clinically significant change in physical exam
NCT00664859,has_criteria,Clinically significant change in medical history
NCT01500200,involves,Major Depressive Disorder
NCT01500200,evaluates,ALKS 5461
NCT01500200,measures_primary,HAM-D17 Total Score
NCT01500200,measures_secondary,MADRS Total Score
NCT01500200,has_criteria,Baseline and 4 weeks
NCT02320149,involves,Acne
NCT02320149,evaluates,Sarecycline
NCT02320149,measures_primary,Facial lesion counts
NCT02320149,measures_secondary,Investigator Global Assement
NCT02320149,has_criteria,Baseline to Week 12
NCT04054206,involves,Healthy Volunteers
NCT04054206,evaluates,MN-166 (ibudilast)
NCT04054206,measures_primary,Cmax of MN-166
NCT04054206,measures_secondary,Adverse events
NCT04054206,measures_secondary,Physical exam results
NCT04054206,has_criteria,Single-dose regimen
NCT06597006,involves,Homozygous Familial Hypercholesterolemia
NCT06597006,evaluates,Inclisiran
NCT06597006,measures_primary,Percent change in LDL-C
NCT06597006,measures_secondary,total cholesterol
NCT06597006,measures_secondary,non-HDL-C
NCT06597006,measures_secondary,triglycerides
NCT06597006,measures_secondary,HDL-C
NCT06597006,measures_secondary,VLDL-C
NCT06597006,measures_secondary,PCSK9
NCT06597006,measures_secondary,Apo B
NCT06597006,measures_secondary,Apo A1
NCT02884206,involves,Chronic Heart Failure
NCT02884206,involves,Preserved Ejection Fraction
NCT02884206,evaluates,LCZ696
NCT02884206,evaluates,Valsartan
NCT02884206,measures_primary,CogState GCCS
NCT02884206,measures_secondary,Cortical Composite SUVr
NCT02884206,has_criteria,Apolipoprotein E ε4 allele
NCT00160706,involves,Crohn's Disease
NCT00160706,evaluates,CDP870-034
NCT00160706,measures_primary,HBI Remission
NCT00160706,measures_secondary,HBI Response
NCT00160706,has_criteria,Exacerbation of Crohn's Disease
NCT04221906,involves,Psoriasis Plaque
NCT04221906,evaluates,BOS-475
NCT04221906,measures_primary,psoriatic infiltrate thickness
NCT04221906,measures_secondary,psoriatic infiltrate thickness
NCT04221906,has_criteria,chronic stable plaque psoriasis
NCT04221906,has_criteria,aged 18-69 years
NCT04221906,has_criteria,willing to follow procedures
NCT04948606,involves,Multiple sclerosis
NCT04948606,evaluates,Diroximel Fumarate
NCT04948606,measures_primary,Annualized Relapse Rate
NCT04948606,measures_secondary,Change in CPST Score
NCT04948606,measures_secondary,Change in Neuro-QoL™
NCT04948606,measures_secondary,Change in EDSS
NCT04948606,has_criteria,Days on DRF treatment
NCT02941549,involves,NAFLD
NCT02941549,evaluates,Epeleuton
NCT02941549,measures_primary,Change in ALT
NCT02941549,measures_secondary,Liver Stiffness
NCT02941549,has_criteria,Treatment Emergent Adverse Events
NCT01163149,involves,Hypophosphatasia
NCT01163149,evaluates,asfotase alfa
NCT01163149,measures_primary,distance walked
NCT01163149,measures_secondary,HPP-related Osteomalacia
NCT01163149,has_criteria,up to 288 weeks exposure
NCT01609049,involves,Chronic Hepatitis C
NCT01609049,involves,Liver Cirrhosis
NCT01609049,evaluates,Peginterferon Alfa-2a
NCT01609049,evaluates,Ribavirin
NCT01609049,measures_primary,Undetectable HCV RNA
NCT01609049,measures_secondary,Sustained Virological Response
NCT01609049,measures_secondary,Decrease in HCV RNA
NCT01609049,has_criteria,Serologically confirmed CHC
NCT01609049,has_criteria,HCV RNA detectable
NCT01609049,has_criteria,Compensated liver cirrhosis
NCT01609049,has_criteria,Child-Pugh Class A
NCT01609049,has_criteria,Initiating combined therapy
NCT01609049,has_criteria,Human immunodeficiency virus
NCT01609049,has_criteria,Contraindications
NCT02321306,involves,Primary Biliary Cirrhosis
NCT02321306,evaluates,LUM001
NCT02321306,measures_primary,Number of Adverse Events
NCT02321306,measures_secondary,Liver enzymes
NCT02321306,has_criteria,Completed core treatment protocol
NCT02321306,has_criteria,Ability to understand consent
NCT02321306,has_criteria,History of non-adherence
NCT03591406,involves,Iron Deficiency Anaemia
NCT03591406,evaluates,Ferric Carboxymaltose
NCT03591406,evaluates,Iron Sucrose
NCT03591406,measures_primary,Haemoglobin (Hb)
NCT03591406,measures_secondary,Change in Hb
NCT03591406,measures_secondary,TSAT
NCT03591406,measures_secondary,Serum ferritin
NCT03591406,measures_secondary,Serum Iron
NCT03591406,has_criteria,Hb \<11 g/dL
NCT03591406,has_criteria,Hb \<12 g/dL
NCT04350606,evaluates,PF-06462700
NCT04350606,involves,Aplastic Anemia
NCT04350606,measures_primary,Hematologic response
NCT04350606,measures_secondary,Number of Participants Survived
NCT04350606,has_criteria,absolute neutrophil count
NCT02975206,involves,atopic dermatitis
NCT02975206,evaluates,Serlopitant
NCT02975206,measures_primary,change in WI-NRS
NCT02975206,measures_secondary,Quality of Life
NCT02975206,has_criteria,age 13 years or older
NCT02975206,has_criteria,pruritus prior to screening
NCT02975206,has_criteria,diagnosis of atopic dermatitis
NCT02975206,has_criteria,good health
NCT03429049,involves,Osteoarthritis
NCT03429049,evaluates,CNTX-4975-05
NCT03429049,evaluates,Placebo
NCT03429049,measures_primary,Pain With Walking
NCT03429049,measures_secondary,WOMAC A
NCT03429049,measures_secondary,WOMAC B
NCT03429049,has_criteria,Baseline
NCT03769506,involves,Recurrent Head/Neck Cancer
NCT03769506,evaluates,ASP-1929 Photoimmunotherapy
NCT03769506,measures_primary,Progression-Free Survival
NCT03769506,measures_secondary,Objective Response Rate
NCT03769506,measures_secondary,Duration of Response
NCT03769506,measures_secondary,Event-Free Survival
NCT03769506,measures_secondary,Eastern Cooperative Oncology Group performance status
NCT03769506,measures_secondary,Quality of Life
NCT03769506,has_criteria,two lines of therapy
NCT00839306,involves,erosive gastroesophageal reflux disease
NCT00839306,evaluates,Rabeprazole Extended Release 50 mg
NCT00839306,evaluates,Ranitidine 150 mg
NCT00839306,measures_primary,Healing of eGERD
NCT00839306,measures_secondary,Heartburn resolution
NCT00839306,has_criteria,Healed erosive esophagitis
NCT02006706,involves,Rheumatoid Arthritis
NCT02006706,evaluates,Rituximab
NCT02006706,evaluates,Methotrexate
NCT02006706,measures_primary,DAS28 at Week 24
NCT02006706,measures_secondary,HAQ-DI
NCT02006706,has_criteria,adult patients
NCT02006706,has_criteria,rheumatoid arthritis after inadequate response to >=1 DMARD treatment
NCT02006706,has_criteria,active disease
NCT02006706,has_criteria,DMARDs other than methotrexate withdrawn for at least 4 weeks prior to start of study treatment
NCT02006706,has_criteria,autoimmune disease other than rheumatoid arthritis
NCT02006706,has_criteria,bone/joint surgery within 8 weeks prior to screening
NCT02006706,has_criteria,concurrent treatment with any DMARD or antiTNF-alfa
NCT02006706,has_criteria,intra-articular or parenteral corticosteroids within 4 weeks prior to screening
NCT00866606,involves,Hemophilia
NCT00866606,evaluates,BeneFIX
NCT00866606,measures_primary,Hemostatic Efficacy
NCT00866606,measures_secondary,FIX Inhibitor Development
NCT00866606,has_criteria,Exposure History
NCT06606106,evaluates,LY3537031
NCT06606106,measures_primary,Change from Baseline in Body Weight
NCT06606106,measures_secondary,Change from Baseline in Fasting Glucose
NCT06606106,measures_secondary,Change from Baseline in Oral Glucose Tolerance Test Results
NCT06606106,measures_secondary,Change from Baseline in AUC of Glucose
NCT06606106,measures_secondary,Change from Baseline in Insulin Levels
NCT06606106,measures_secondary,Change from Baseline in Connecting Peptide (C-peptide) Levels
NCT06606106,measures_secondary,Change from Baseline in Cmax of Acetaminophen to Assess the Delay in Gastric Emptying
NCT06606106,measures_secondary,Change from Baseline in AUC of Acetaminophen to Assess the Delay in Gastric Emptying
NCT06606106,measures_secondary,Change from Baseline in Time to Peak Drug Concentration (Tmax) of Acetaminophen to Assess the Delay in Gastric Emptying
NCT04153149,involves,Transthyretin Amyloidosis with Cardiomyopathy
NCT04153149,evaluates,Vutrisiran
NCT04153149,measures_primary,All-cause mortality
NCT04153149,measures_primary,Recurrent CV events
NCT04153149,measures_secondary,6-Minute Walk Test
NCT04153149,measures_secondary,Kansas City Cardiomyopathy Questionnaire
NCT04153149,has_criteria,documented diagnosis of ATTR amyloidosis
NCT03952806,involves,Multiple System Atrophy
NCT03952806,evaluates,BHV-3241
NCT03952806,measures_primary,Modified UMSARS Score
NCT03952806,measures_secondary,Clinical Global Impression of Improvement Score
NCT03952806,has_criteria,Treatment-Emergent Adverse Events
NCT00857506,involves,Mild Cognitive Impairment
NCT00857506,involves,Alzheimer's Disease
NCT00857506,evaluates,Florbetapir F 18 (18F-AV-45)
NCT00857506,measures_primary,Change in ADAS-Cog
NCT00857506,measures_secondary,ADAS-Cog deterioration
NCT00857506,measures_secondary,CDR global score
NCT00857506,has_criteria,Aβ+ and Aβ- subjects
NCT02178306,involves,Hypertension
NCT02178306,involves,Renal Impairment
NCT02178306,evaluates,Telmisartan
NCT02178306,measures_primary,Diastolic blood pressure
NCT02178306,measures_secondary,Systolic blood pressure
NCT02178306,measures_secondary,Proteinuria
NCT02178306,measures_secondary,Electrolyte excretion
NCT02178306,measures_secondary,Telmisartan plasma concentration
NCT02178306,has_criteria,Serum creatinine
NCT02178306,has_criteria,Proteinuria
NCT02178306,has_criteria,Hemodialysis
NCT02178306,has_criteria,Age
NCT02178306,has_criteria,Informed consent
NCT02178306,has_criteria,Antihypertensive therapy
NCT04667949,involves,Relapsing Multiple Sclerosis
NCT04667949,evaluates,Fingolimod
NCT04667949,measures_primary,Annualized relapse rate
NCT04667949,measures_secondary,Adverse events
NCT04667949,measures_secondary,Serious adverse events
NCT04667949,measures_secondary,T1 hypo-intense lesion volume
NCT04667949,measures_secondary,T2 lesion-new/newly enhancing lesion volume
NCT04667949,measures_secondary,Gd-enhancing T1 lesion volume
NCT04667949,has_criteria,Baseline to Month 24
NCT01263106,evaluates,LY2216684
NCT01263106,evaluates,Theophylline
NCT01263106,measures_primary,Mean Change From Baseline in Heart Rate
NCT01263106,measures_secondary,AUC0-∞
NCT01263106,measures_secondary,Cmax
NCT01263106,measures_secondary,Tmax
NCT01263106,has_criteria,overtly healthy males or females
NCT01263106,has_criteria,reliable method of birth control
NCT01263106,has_criteria,women of child-bearing potential
NCT04532749,involves,Major Depressive Disorder
NCT04532749,evaluates,Seltorexant
NCT04532749,measures_primary,Change from Baseline
NCT04532749,measures_secondary,Sleep Disturbance
NCT04532749,has_criteria,Responded Inadequately
NCT00977106,involves,Rheumatoid Arthritis
NCT00977106,evaluates,Tocilizumab
NCT00977106,measures_primary,HAQ-DI at Week 4
NCT00977106,measures_secondary,Patient Global Assessment of Disease Activity
NCT00977106,has_criteria,Inadequate response to DMARDs or Anti-TNF
NCT03402659,involves,Mild Alzheimer's Disease
NCT03402659,evaluates,Neflamapimod
NCT03402659,measures_primary,change in recall
NCT03402659,measures_secondary,WMS immediate recall
NCT03402659,measures_secondary,WMS delayed recall
NCT03402659,has_criteria,CDR-Global Score
NCT01240759,involves,Type 2 Diabetes Mellitus
NCT01240759,evaluates,S-707106
NCT01240759,measures_primary,Hemoglobin A1c < 7.0%
NCT01240759,measures_secondary,Fasting plasma glucose
NCT01240759,measures_secondary,1
NCT01240759,measures_secondary,Fructosamine
NCT01240759,measures_secondary,Glycoalbumin
NCT01240759,measures_secondary,C-peptide
NCT01240759,measures_secondary,Beta-cell function
NCT01240759,measures_secondary,insulin resistance
NCT01240759,has_criteria,type 2 diabetes mellitus
NCT01240759,has_criteria,metformin therapy
NCT01240759,has_criteria,BMI ≥25.0 and \<45.0
NCT02843659,involves,Primary Sjögren's Syndrome
NCT02843659,evaluates,BMS-931699
NCT02843659,evaluates,BMS-986142
NCT02843659,measures_primary,ESSDAI Scores
NCT02843659,measures_secondary,ESSPRI Score
NCT02843659,has_criteria,disease activity
NCT03569475,involves,Major Depressive Disorder
NCT03569475,evaluates,Levomilnacipran ER
NCT03569475,measures_primary,Change From Baseline
NCT03569475,measures_secondary,Clinical Global Impression-Severity
NCT03569475,has_criteria,DSM-5 criteria for MDD
NCT01119859,involves,Rheumatoid Arthritis
NCT01119859,evaluates,Tocilizumab
NCT01119859,evaluates,Adalimumab
NCT01119859,measures_primary,DAS28 < 2.6
NCT01119859,measures_secondary,DAS28 ≤ 3.2
NCT01119859,measures_secondary,ACR20/50/70
NCT01119859,has_criteria,duration of RA
NCT02210000,involves,Gastroparesis
NCT02210000,involves,Type 1 Diabetes
NCT02210000,involves,Type 2 Diabetes
NCT02210000,evaluates,Camicinal
NCT02210000,measures_primary,Percentage of Responders
NCT02210000,measures_secondary,Change From Baseline
NCT02210000,has_criteria,Gastroparesis Symptoms
NCT01307800,involves,Schizophrenia
NCT01307800,evaluates,LY2140023
NCT01307800,measures_primary,PANSS Total Score
NCT01307800,measures_secondary,PSP Score
NCT01307800,has_criteria,Baseline
NCT02914600,involves,Crohn's Disease
NCT02914600,evaluates,Filgotinib
NCT02914600,measures_primary,liquid or soft stools
NCT02914600,measures_secondary,abdominal pain
NCT02914600,has_criteria,study drug start date
NCT01082159,involves,back pain
NCT01082159,evaluates,Vertos Mild
NCT01082159,measures_primary,VAS pain
NCT01082159,measures_secondary,Oswestry Disability Index
NCT01082159,measures_secondary,Short Form 12
NCT01082159,has_criteria,chronic back pain
NCT03073200,involves,Plaque Psoriasis
NCT03073200,evaluates,Ixekizumab
NCT03073200,measures_primary,PASI 75
NCT03073200,measures_primary,sPGA 0 or 1
NCT03073200,measures_secondary,PASI 90
NCT03073200,has_criteria,Children 6 to 18 years
NCT01557400,involves,Nonsense Mutation Duchenne/Becker Muscular Dystrophy
NCT01557400,evaluates,Ataluren
NCT01557400,measures_primary,6MWD
NCT01557400,measures_secondary,Physical Function
NCT01557400,has_criteria,ambulatory
NCT03747575,involves,Atopic Dermatitis
NCT03747575,evaluates,MSTT1041A
NCT03747575,measures_primary,Percent Change EASI Score
NCT03747575,measures_secondary,Investigator's Global Assessment
NCT03747575,measures_secondary,Eczema Area and Severity Index (EASI-75) Score
NCT03747575,measures_secondary,Percent Change Pruritus
NCT03747575,measures_secondary,Percent Change Body Surface Area
NCT03747575,measures_secondary,Percent Change Disease Severity
NCT03747575,measures_secondary,Percentage of Participants Adverse Events
NCT03747575,has_criteria,Baseline
NCT02187159,involves,Fibromyalgia
NCT02187159,evaluates,DS-5565
NCT02187159,evaluates,Pregabalin
NCT02187159,evaluates,Placebo
NCT02187159,measures_primary,Change in ADPS
NCT02187159,measures_secondary,Patient Global Impression
NCT02187159,measures_secondary,Fibromyalgia Index Questionnaire
NCT02187159,has_criteria,Baseline up to Week 13
NCT04130659,involves,GERD
NCT04130659,evaluates,MARIAL®
NCT04130659,measures_primary,Reflux Symptoms Index
NCT04130659,measures_secondary,GERD Impact Scale
NCT04130659,measures_secondary,GERD Health-Related Quality of Life
NCT04130659,has_criteria,180 days
NCT00386100,involves,Type 2 Diabetes
NCT00386100,evaluates,AVANDAMET
NCT00386100,evaluates,Metformin
NCT00386100,measures_primary,Change From Baseline in HbA1c
NCT00386100,measures_secondary,Number of Participants Achieving HbA1c <=6.5% and <7% at Week 80
NCT00386100,measures_secondary,Change in Fasting Plasma Glucose (FPG) From Baseline at Week 80
NCT00386100,measures_secondary,Change From Baseline in FPG at Week 80
NCT00386100,measures_secondary,Number of Participants Achieving FPG <=6 mmol/L (110 mg/dL) and <=7 mmol/L (126 mg/dL) at Week 80
NCT00386100,measures_secondary,Number of Participants Achieving Treatment Failure
NCT00386100,has_criteria,HbA1c level >= 7% after Week 32 or withdrawal due to insufficient therapeutic effect (ITE) at any time
NCT05748600,involves,Eosinophilic Asthma
NCT05748600,evaluates,Dexpramipexole
NCT05748600,measures_primary,Change in pre-BD FEV₁
NCT05748600,measures_secondary,Asthma Control Questionnaire-6
NCT05748600,has_criteria,≥12 years of age
NCT06282159,involves,Generalized Myasthenia Gravis
NCT06282159,evaluates,DNTH103
NCT06282159,measures_primary,MG-ADL scale score
NCT06282159,measures_secondary,ECG parameters
NCT06282159,measures_secondary,clinical laboratory values
NCT06282159,has_criteria,Baseline (Day 1) to Safety Follow-Up Visit (up to Week 40)
NCT03583359,involves,jawline contour
NCT03583359,evaluates,Radiesse
NCT03583359,measures_primary,Responder Rate
NCT03583359,measures_secondary,Face-Q Satisfaction
NCT03583359,measures_secondary,GAIS Scores
NCT03583359,has_criteria,moderate or severe jawline ratings
NCT03583359,has_criteria,22 to 65 years of age
NCT03583359,has_criteria,symmetrical jawlines
NCT05819359,involves,GBA-PD
NCT05819359,evaluates,BIA 28-6156
NCT05819359,measures_primary,Time to progression
NCT05819359,measures_secondary,CGI-C worsening
NCT05819359,has_criteria,From Baseline up to Week 78
NCT01421459,involves,Type 2 Diabetes
NCT01421459,measures_primary,Change From Baseline HbA1c
NCT01421459,measures_secondary,Insulin Antibody Levels
NCT01421459,measures_secondary,7-Point SMBG Profiles
NCT01421459,measures_secondary,Glycemic Variability Fasting Blood Glucose
NCT01421459,has_criteria,Baseline HbA1c
NCT03597100,involves,Essential Tremor
NCT03597100,evaluates,Cala Therapy
NCT03597100,measures_primary,Tremor power change
NCT03597100,measures_secondary,Activities of Daily Living
NCT03597100,has_criteria,≥22 years of age
NCT03597100,has_criteria,Competent consent
NCT03597100,has_criteria,Essential tremor diagnosis
NCT03597100,has_criteria,TETRAS score ≥2
NCT03597100,has_criteria,TETRAS subset score ≥6
NCT00647400,involves,Psoriasis
NCT00647400,evaluates,adalimumab
NCT00647400,measures_primary,PASI50 Response
NCT00647400,measures_secondary,PASI75 Response
NCT00647400,measures_secondary,PASI90 Response
NCT00647400,has_criteria,completed Study M04-688
NCT00647400,has_criteria,unsuitable candidate
NCT03912259,involves,Atopic Dermatitis
NCT03912259,evaluates,Dupilumab
NCT03912259,measures_primary,IGA score 0 or 1
NCT03912259,measures_secondary,EASI-75 response
NCT03912259,measures_secondary,Pruritus NRS score
NCT03912259,has_criteria,Chinese Adult Patients
NCT00776659,involves,Breast Cancer
NCT00776659,evaluates,Aromasin
NCT00776659,measures_primary,Locoregional recurrence
NCT00776659,measures_secondary,Second Primary Cancer
NCT00776659,measures_secondary,Death
NCT00776659,measures_secondary,Aromasin discontinuation
NCT00776659,measures_secondary,Adverse Events
NCT00776659,measures_secondary,HDL-C
NCT00776659,measures_secondary,LDL-C
NCT00776659,measures_secondary,Total Cholesterol
NCT00776659,measures_secondary,Triglycerides
NCT00776659,measures_secondary,Bone Mineral Density
NCT00776659,has_criteria,Adjuvant therapy
NCT00333359,involves,Restless Legs Syndrome
NCT00333359,evaluates,Gabapentin Enacarbil
NCT00333359,measures_primary,IRLS Rating Scale Score
NCT00333359,measures_secondary,CGI-I
NCT00333359,has_criteria,Responders to Treatment
NCT03968159,involves,Major Depressive Disorder
NCT03968159,evaluates,Pimavanserin
NCT03968159,measures_primary,Change From Baseline
NCT03968159,measures_secondary,Clinical Global Impression-Severity Score
NCT03968159,measures_secondary,Sheehan Disability Scale Score
NCT03968159,measures_secondary,Changes in Sexual Functioning Questionnaire Short Form
NCT03968159,measures_secondary,Karolinska Sleepiness Scale Score
NCT03968159,has_criteria,Inadequate Response to Antidepressant Treatment
NCT03602859,involves,Nonmucinous epithelial ovarian cancer
NCT03602859,evaluates,TSR-042
NCT03602859,evaluates,Niraparib
NCT03602859,measures_primary,Progression Free Survival
NCT03602859,measures_secondary,Overall Survival
NCT03602859,measures_secondary,Change from Baseline in EQ-5D-5L
NCT03602859,measures_secondary,Change from Baseline in EORTC-QLQ-C30
NCT03602859,has_criteria,Stage III or IV
NCT05876559,involves,Postpartum Care
NCT05876559,evaluates,Joyuus
NCT05876559,measures_primary,Change between baseline
NCT05876559,measures_secondary,Edinburgh Postnatal Depression Scale
NCT05876559,measures_secondary,State-Trait Anxiety Inventory
NCT05876559,measures_secondary,Connor-Davidson Resilience Scale
NCT00477659,involves,Alzheimer's Disease
NCT00477659,measures_primary,Change From Baseline
NCT00477659,measures_secondary,ADAS-Cog Score
NCT00477659,measures_secondary,MMSE Score
NCT00477659,has_criteria,Baseline and Week 12
NCT01590459,involves,Rheumatoid Arthritis
NCT01590459,evaluates,VX-509
NCT01590459,measures_primary,ACR20-CRP response
NCT01590459,measures_secondary,DAS28-CRP
NCT01590459,has_criteria,stable MTX
NCT01590459,has_criteria,CRP level above normal
NCT01590459,has_criteria,swollen joint count ≥6
NCT01590459,has_criteria,tender joint count ≥6
NCT01590459,has_criteria,age 18-80 years
NCT05032859,involves,Atopic Dermatitis
NCT05032859,evaluates,Tapinarof
NCT05032859,measures_primary,vIGA-AD clear/almost clear
NCT05032859,measures_secondary,EASI improvement
NCT05032859,measures_secondary,%BSA affected
NCT01756300,involves,Resistant Hypertension
NCT01756300,evaluates,Catheter Based Renal Denervation
NCT01756300,measures_primary,Major adverse events
NCT01756300,measures_secondary,Office systolic blood pressure
NCT01756300,measures_secondary,Diastolic blood pressure
NCT01756300,measures_secondary,24-hour ABPM systolic blood pressure
NCT01756300,measures_secondary,24-hour ABPM diastolic blood pressure
NCT01756300,has_criteria,renal artery stenosis
NCT02477800,involves,Early Alzheimer's Disease
NCT02477800,evaluates,Aducanumab
NCT02477800,measures_primary,CDR-SB Score
NCT02477800,measures_secondary,MMSE Score
NCT02477800,measures_secondary,ADAS-Cog 13 Score
NCT02477800,has_criteria,Baseline
NCT01930175,involves,Pemphigus Vulgaris
NCT01930175,evaluates,VAY736
NCT01930175,measures_primary,PDAI at Week 12
NCT01930175,measures_secondary,ABSIS at Baseline
NCT01930175,measures_secondary,ABSIS at Week 12
NCT01930175,measures_secondary,Change From Baseline in IGA at Week 12
NCT01930175,measures_secondary,VAY736 Serum Concentration - AUCinf
NCT01930175,has_criteria,Baseline
NCT01930175,has_criteria,Week 12
NCT01436500,involves,Hepatorenal Syndrome
NCT01436500,evaluates,Ifetroban
NCT01436500,measures_primary,Serum Creatinine Reduction
NCT01436500,measures_secondary,Creatinine Clearance
NCT01436500,has_criteria,Chronic liver disease
NCT04763252,involves,Chronic Pain
NCT04763252,evaluates,Spectrum Therapeutics
NCT04763252,measures_primary,pain relief
NCT04763252,measures_secondary,sleep
NCT04763252,measures_secondary,daily functioning
NCT04763252,measures_secondary,quality of life
NCT04763252,has_criteria,physician-verified
NCT02202837,involves,rheumatoid arthritis
NCT02202837,evaluates,Etanercept
NCT02202837,measures_primary,DAS28 less than 2.6
NCT02202837,measures_secondary,SDAI less than or equal to 3.3
NCT02202837,measures_secondary,CDAI less than or equal to 2.8
NCT02202837,has_criteria,DAS28 score
NCT02202837,has_criteria,SDAI score
NCT02202837,has_criteria,CDAI score
NCT03292952,involves,ADHD
NCT03292952,evaluates,KP415
NCT03292952,measures_primary,SKAMP Combined Scores
NCT03292952,measures_secondary,PERMP Rating Scale
NCT03292952,has_criteria,DSM-5 criteria
NCT02379052,involves,Eosinophilic Esophagitis
NCT02379052,evaluates,Dupilumab
NCT02379052,measures_primary,Absolute Change SDI
NCT02379052,measures_secondary,Percent Change SDI
NCT02379052,has_criteria,Adult Participants
NCT00935532,involves,Type 2 Diabetes Mellitus
NCT00935532,evaluates,Exenatide Once-Weekly Injection
NCT00935532,evaluates,Once-Daily Insulin
NCT00935532,measures_primary,Change in HbA1c
NCT00935532,measures_secondary,Percentage of Subjects Achieving HbA1c<=7%
NCT00935532,measures_secondary,Percentage of Subjects Achieving HbA1c<=6.5%
NCT00935532,measures_secondary,Change in Fasting Serum Glucose
NCT00935532,measures_secondary,Change in Body Weight
NCT00935532,measures_secondary,Change in Total Cholesterol
NCT00935532,measures_secondary,Change in High-density Lipoprotein Cholesterol
NCT00935532,measures_secondary,Ratio of Fasting Triglycerides at Endpoint to Baseline
NCT00935532,measures_secondary,Change in Blood Pressure
NCT00810732,involves,Chronic Kidney Disease
NCT00810732,evaluates,Sitaxsentan
NCT00810732,measures_primary,Urine total protein
NCT00810732,measures_secondary,Systemic Arterial Blood Pressure
NCT00810732,measures_secondary,Carotid-Femoral PWV
NCT00810732,has_criteria,stage 1-5 CKD
NCT01309737,involves,Chronic Plaque Psoriasis
NCT01309737,evaluates,CP-690
NCT01309737,measures_primary,PGA response at Week 16
NCT01309737,measures_secondary,PASI 75 response at Week 16
NCT01309737,measures_secondary,Percent Change From Baseline in BSA at Week 16
NCT01309737,has_criteria,Moderate to Severe Psoriasis
NCT01418352,involves,Tourette's Disorder
NCT01418352,evaluates,Oral Aripiprazole
NCT01418352,measures_primary,YGTSS Total Tic Score
NCT01418352,measures_secondary,CGI-TS Score
NCT01418352,measures_secondary,GTS-QOL Overall Score
NCT01418352,has_criteria,Baseline and Week 8
NCT06568237,involves,Multiple System Atrophy
NCT06568237,evaluates,TEV-56286
NCT06568237,measures_primary,Change From Baseline in the Modified UMSARS Part I Score
NCT06568237,measures_secondary,Change From Baseline in the Total UMSARS Score
NCT06568237,measures_secondary,Change From Baseline in the UMSARS Part 1 Score
NCT06568237,measures_secondary,Change in the Multiple System Atrophy - Quality of Life (MSA-QoL) Score
NCT06568237,measures_secondary,Change From Baseline in the Clinical Global Impression Scale - Severity (CGI-S)
NCT06568237,has_criteria,Baseline to Week 48
NCT01496352,involves,Colorectal Surgery
NCT01496352,evaluates,DFA-02
NCT01496352,measures_primary,Adverse Events
NCT01496352,measures_secondary,AUC
NCT01496352,measures_secondary,Cmax
NCT01496352,measures_secondary,Renal Function
NCT01496352,measures_secondary,Antibiotic Resistance
NCT01496352,measures_secondary,Surgical Site Infection
NCT01496352,has_criteria,Baseline up to Day 30
NCT01496352,has_criteria,Baseline up to Day 14
NCT01496352,has_criteria,Baseline up to Day 5
NCT01496352,has_criteria,Up to 30 Days After Surgery
NCT01029652,involves,Acute Gout Flares
NCT01029652,evaluates,Canakinumab
NCT01029652,measures_primary,Time to First New Flare
NCT01029652,measures_secondary,Self-assessed Pain Intensity
NCT01029652,has_criteria,Flare in joint
NCT03170232,involves,Chronic Obstructive Pulmonary Disease
NCT03170232,evaluates,Danirixin
NCT03170232,measures_primary,rate of decline FEV1
NCT03170232,measures_secondary,SGRQ total score
NCT03170232,has_criteria,Baseline (Day 1)
NCT03181932,involves,Methicillin-resistant Staphylococcus Aureus Infection
NCT03181932,involves,Cystic Fibrosis
NCT03181932,evaluates,AeroVanc
NCT03181932,measures_primary,FEV1 percent predicted
NCT03181932,measures_secondary,Pulmonary Exacerbations
NCT03181932,measures_secondary,Time to First Pulmonary Exacerbation
NCT03181932,measures_secondary,CFQ-R Scores
NCT03181932,measures_secondary,CFRSD-CRISS Scores
NCT03181932,measures_secondary,Relative Change in FEV1
NCT03181932,measures_secondary,Number of Successful Response Cycles
NCT03181932,has_criteria,Baseline and Week 4
NCT01156532,involves,Psoriasis
NCT01156532,evaluates,Adalimumab
NCT01156532,measures_primary,PASI-75 Response
NCT01156532,measures_secondary,DLQI Score
NCT01156532,measures_secondary,EQ-5D Index Score
NCT01156532,has_criteria,Baseline to Week 16
NCT02452632,involves,Type 2 Diabetes Mellitus
NCT02452632,evaluates,ASP1941
NCT02452632,measures_primary,Change from baseline HbA1c
NCT02452632,measures_secondary,Fasting plasma glucose
NCT02452632,measures_secondary,Fasting serum insulin
NCT02452632,measures_secondary,Body weight
NCT02452632,measures_secondary,Waist circumference
NCT02452632,has_criteria,Inadequate Glycemic Control
NCT02348632,involves,Narcolepsy
NCT02348632,involves,OSA
NCT02348632,evaluates,JZP-110
NCT02348632,measures_primary,Change in ESS Score
NCT02348632,measures_secondary,Patient Global Impression of Change
NCT02348632,measures_secondary,Clinical Global Impression of Change
NCT02348632,has_criteria,Excessive Sleepiness
NCT00332332,involves,Psoriasis
NCT00332332,evaluates,Etanercept
NCT00332332,measures_primary,Physician Global Assessment
NCT00332332,measures_secondary,Body Surface Area Affected
NCT00332332,measures_secondary,Dermatology Life Quality Index Total Score
NCT00332332,has_criteria,18 years of age or older
NCT00332332,has_criteria,Moderate to severe plaque psoriasis
NCT00332332,has_criteria,Active infections
NCT00332332,has_criteria,skin conditions other than psoriasis
NCT03235752,involves,Ulcerative Colitis
NCT03235752,evaluates,TJ301 IV
NCT03235752,measures_primary,Clinical and endoscopy response
NCT03235752,measures_secondary,Clinical and endoscopy remission
NCT03235752,has_criteria,Active UC of more than 3 months
NCT01262352,involves,Cystic Fibrosis
NCT01262352,evaluates,Ivacaftor
NCT01262352,measures_primary,Lung Clearance Index
NCT01262352,measures_secondary,Percent Predicted FEV1
NCT01262352,measures_secondary,Sweat Chloride
NCT01262352,measures_secondary,CF Questionnaire-Revised Score
NCT01262352,has_criteria,G551D-CFTR mutation
NCT01262352,has_criteria,FEV1 >90% predicted
NCT00297232,involves,Multiple Sclerosis
NCT00297232,evaluates,Natalizumab
NCT00297232,measures_primary,Time to EDSS progression
NCT00297232,measures_secondary,Time to EDSS improvement
NCT00297232,has_criteria,Completed Study C-1801
NCT03328052,involves,depression
NCT03328052,evaluates,PEER recommended therapy
NCT03328052,measures_primary,50% reduction
NCT03328052,measures_secondary,physician access
NCT03328052,has_criteria,clinical diagnosis depression
NCT04719832,involves,Severe Asthma
NCT04719832,evaluates,GSK3511294
NCT04719832,measures_primary,Annualized exacerbations
NCT04719832,measures_secondary,SGRQ total score
NCT04719832,measures_secondary,ACQ-5 score
NCT04719832,measures_secondary,FEV1
NCT04719832,has_criteria,Eosinophilic Phenotype
NCT03139032,involves,Inflammatory Bowel Disease
NCT03139032,evaluates,Etrasimod
NCT03139032,measures_primary,Endoscopic Improvement
NCT03139032,measures_secondary,Fecal Calprotectin
NCT03139032,has_criteria,Active Skin EIM
NCT01689532,involves,Rheumatoid Arthritis
NCT01689532,evaluates,CNTO 136
NCT01689532,measures_primary,ACR 20 Response
NCT01689532,measures_secondary,ACR 50 Response
NCT01689532,has_criteria,Unresponsive to Methotrexate
NCT03558152,involves,Ulcerative Colitis
NCT03558152,evaluates,UTTR1147A
NCT03558152,evaluates,Placebo
NCT03558152,evaluates,Vedolizumab
NCT03558152,measures_primary,Clinical Remission
NCT03558152,measures_secondary,Sustained Remission
NCT03558152,measures_secondary,Clinical Response
NCT03558152,measures_secondary,Maximum Serum Concentration
NCT03558152,measures_secondary,Minimum Serum Concentration
NCT03558152,has_criteria,Week 8 assessments
NCT03558152,has_criteria,Rescue Therapy
NCT03558152,has_criteria,Week 30 assessments
NCT01915732,involves,Acne Vulgaris
NCT01915732,evaluates,Duac
NCT01915732,evaluates,Clindamycin Phosphate Gel
NCT01915732,measures_primary,Absolute Change in Total Lesion Count
NCT01915732,measures_secondary,Improvement in ISGA Score
NCT01915732,has_criteria,Improvement of 2 grades
NCT02002832,involves,Schizophrenia
NCT02002832,evaluates,Lurasidone
NCT02002832,measures_primary,PANSS total score
NCT02002832,measures_secondary,CGI-I Score
NCT02002832,has_criteria,aged 18-65 years
NCT02002832,has_criteria,DSM-IV-TR schizophrenia
NCT02002832,has_criteria,PANSS total score 70-120
NCT02002832,has_criteria,CGI-S score ≥ 4
NCT02002832,has_criteria,not pregnant
NCT02002832,has_criteria,reliable contraception
NCT02002832,has_criteria,off antipsychotic medication
NCT02002832,has_criteria,comply with protocol
NCT00412932,involves,Hypertension
NCT00412932,evaluates,Olmesartan medoxomil
NCT00412932,measures_primary,Change From Baseline
NCT00412932,measures_primary,Mean 24-hour Ambulatory Systolic Blood Pressure
NCT00412932,measures_secondary,Mean 24-hour Ambulatory Diastolic Blood Pressure
NCT00412932,measures_secondary,Mean Daytime Systolic Blood Pressure
NCT00412932,measures_secondary,Mean Nighttime Systolic Blood Pressure
NCT00412932,has_criteria,Baseline and 12-week measurements
NCT02388737,involves,Erosive Esophagitis
NCT02388737,evaluates,Vonoprazan
NCT02388737,evaluates,Lansoprazole
NCT02388737,measures_primary,Recurrence of Erosive Esophagitis
NCT02388737,measures_secondary,Adverse Events
NCT02388737,has_criteria,Endoscopically confirmed
NCT02832037,involves,Schizophrenia
NCT02832037,evaluates,BI 425809
NCT02832037,measures_primary,Cognitive Function
NCT02832037,measures_secondary,Everyday Functional Capacity
NCT02832037,has_criteria,missing
NCT04680637,involves,Systemic Lupus Erythematosus
NCT04680637,evaluates,Efavaleukin Alfa
NCT04680637,measures_primary,SRI-4 response
NCT04680637,measures_secondary,BICLA response
NCT04680637,has_criteria,protocol-permitted therapies
NCT03848832,involves,Rett Syndrome
NCT03848832,evaluates,GWP42003-P
NCT03848832,measures_primary,Change From Baseline
NCT03848832,measures_secondary,CGI-I Score
NCT03848832,has_criteria,Baseline; Week 24
NCT01130532,involves,Erectile Dysfunction
NCT01130532,measures_primary,IIEF-EF domain score
NCT01130532,measures_secondary,IIEF-IS domain score
NCT02591537,involves,Abdominoplasty
NCT02591537,evaluates,OxyGenesys Dissolved Oxygen Dressing
NCT02591537,measures_primary,Mean time to healing
NCT02591537,measures_secondary,Wound degree of epithelialization percent change
NCT02591537,measures_secondary,Pain on Test Versus Control Side
NCT02591537,measures_secondary,Scar Quality Analysis
NCT02591537,has_criteria,14 days
NCT02591537,has_criteria,Day 28
NCT02591537,has_criteria,Day 42
NCT03398837,involves,Diffuse Cutaneous Systemic Sclerosis
NCT03398837,evaluates,Lenabasum
NCT03398837,measures_primary,ACR CRISS score
NCT03398837,measures_secondary,modified Rodnan skin score
NCT03398837,measures_secondary,Health Assessment Questionnaire - Disability Index
NCT03398837,measures_secondary,forced vital capacity
NCT03398837,has_criteria,≥ 18 years of age
NCT01748552,involves,Diabetes
NCT01748552,evaluates,LY2922083
NCT01748552,measures_primary,Blood Glucose AUEC
NCT01748552,measures_secondary,C-Peptide AUEC
NCT01748552,has_criteria,type 2 diabetes
NCT02507752,involves,Rheumatoid Arthritis
NCT02507752,evaluates,Rituximab
NCT02507752,measures_primary,HAQ at Week 24
NCT02507752,measures_secondary,SF-36 Physical Component Score
NCT02507752,measures_secondary,SF-36 Mental Component Score
NCT02507752,has_criteria,clinically important reduction
NCT06376032,involves,attention-deficit/hyperactivity disorder
NCT06376032,evaluates,Computerized Adaptive Test
NCT06376032,measures_primary,ADHD severity
NCT06376032,measures_secondary,Cognitive Function
NCT06376032,measures_secondary,Satisfaction with Participation
NCT06376032,measures_secondary,Academic Self-Efficacy
NCT06376032,has_criteria,adults 18 and over
NCT05645432,involves,Tinnitus
NCT05645432,evaluates,Brexanolone
NCT05645432,measures_primary,VAS-L Ratings
NCT05645432,measures_secondary,VAS-A Ratings
NCT05645432,has_criteria,Baseline
NCT01111552,involves,Major Depressive Disorder
NCT01111552,evaluates,Aripiprazole/Escitalopram
NCT01111552,measures_primary,MADRS Total Score
NCT01111552,measures_secondary,CGI-I Score
NCT01111552,measures_secondary,Sheehan Disability Scale
NCT01111552,has_criteria,End of Phase B (Week 8)
NCT05117632,involves,Major Depressive Disorder
NCT05117632,involves,Posttraumatic Stress Disorder
NCT05117632,evaluates,ALTO-100
NCT05117632,measures_primary,change from baseline
NCT05117632,measures_primary,change from baseline
NCT05117632,measures_primary,change from baseline
NCT05117632,has_criteria,Adverse Events
NCT01309932,involves,Hepatitis C
NCT01309932,evaluates,Pegylated Interferon Lambda
NCT01309932,measures_primary,SVR24
NCT01309932,measures_secondary,HCV RNA levels
NCT01309932,has_criteria,HCV genotype 1
NCT00519532,involves,Idiopathic Parkinson's Disease
NCT00519532,evaluates,Rotigotine
NCT00519532,measures_primary,Change From Baseline in UPDRS III Score
NCT00519532,measures_secondary,Parkinson Disease Sleep Scale
NCT00519532,measures_secondary,Nocturnal Akinesia
NCT00519532,measures_secondary,Number of Nocturias
NCT00519532,has_criteria,Visit 2 of previous double- blind trial SP889
NCT04752332,involves,Early Breast Cancer
NCT04752332,evaluates,Abemaciclib
NCT04752332,evaluates,Hormone Therapy
NCT04752332,measures_primary,Invasive Disease Free Survival
NCT04752332,measures_secondary,Overall Survival
NCT04752332,measures_secondary,Distant Relapse-Free Survival
NCT04752332,measures_secondary,Percentage of Participants with CNS Metastases
NCT04752332,measures_secondary,Change from Baseline in EORTC QLQ-C30 Scale Score
NCT04752332,measures_secondary,Change from Baseline in EQ-5D 5L Index Score
NCT04752332,has_criteria,Cycle 1 up to end of Year 4
NCT02195700,involves,Tardive Dyskinesia
NCT02195700,evaluates,Treatment
NCT02195700,measures_primary,AIMS score change
NCT02195700,measures_secondary,Treatment success
NCT02195700,has_criteria,Week 12 visit
NCT01467700,involves,Bipolar I Disorder
NCT01467700,involves,Acute Depressive Episodes
NCT01467700,evaluates,Ramelteon Sublingual
NCT01467700,measures_primary,MADRS Total Score
NCT01467700,measures_secondary,Q-LES-Q-SF Short Form Total Score
NCT01467700,has_criteria,Adult Patients
NCT00783432,involves,Chronic Allergic Rhinitis
NCT00783432,involves,Nonallergic Rhinitis
NCT00783432,evaluates,Nasal Spray
NCT00783432,measures_primary,RQLQ Score Change
NCT00783432,measures_secondary,Head and Neck Examination
NCT00783432,has_criteria,Adult
NCT02068352,involves,Atopic Dermatitis
NCT02068352,evaluates,Topical OPA-15406 Ointment
NCT02068352,measures_primary,IGA Score at Week 4
NCT02068352,measures_secondary,Change From Baseline in IGA Score
NCT02068352,has_criteria,Baseline IGA score
NCT02402452,involves,Renal Impairment
NCT02402452,evaluates,Voxilaprevir
NCT02402452,measures_primary,Treatment-Emergent Adverse Events
NCT02402452,measures_secondary,Laboratory Abnormalities
NCT02402452,has_criteria,Stable chronic kidney disease
NCT02402452,has_criteria,Creatinine clearance \< 30 mL/min
NCT02402452,has_criteria,Screening laboratory values
NCT02402452,has_criteria,Two effective contraception methods
NCT04002752,evaluates,JNJ-73763989
NCT04002752,measures_primary,AUC[0-last]
NCT04002752,measures_secondary,Number of Participants with Adverse Events
NCT04002752,has_criteria,Healthy Japanese Adult Participants
NCT00698932,involves,Type 2 Diabetes
NCT00698932,evaluates,saxagliptin
NCT00698932,measures_primary,HbA1c change
NCT00698932,measures_secondary,Fasting Plasma Glucose
NCT00698932,measures_secondary,Area Under the Curve
NCT00698932,has_criteria,Inadequate Glycemic Control
NCT03950232,involves,Ulcerative Colitis
NCT03950232,measures_primary,Clinical Remission
NCT03950232,measures_secondary,Endoscopic Improvement
NCT03950232,has_criteria,previously enrolled
NCT04080752,involves,Depression
NCT04080752,evaluates,JNJ-61393215
NCT04080752,measures_primary,Change From Baseline in HDRS-17 Total Score at Week 6
NCT04080752,measures_secondary,Change From Baseline in HAM-A Total Score at Week 6
NCT04080752,has_criteria,Baseline and Week 6
NCT04080752,measures_secondary,Change From Baseline in HAM-A Total Score at Weeks 2 and 4
NCT02219932,involves,Multiple Sclerosis
NCT02219932,evaluates,Prolonged-Release Fampridine
NCT02219932,measures_primary,MSWS-12 improvement
NCT02219932,measures_secondary,TUG speed
NCT02219932,has_criteria,mean MSWS-12 score
NCT02430532,involves,Secondary Progressive Multiple Sclerosis
NCT02430532,evaluates,Delay of Disability Progression
NCT02430532,measures_primary,Time to Disability Progression
NCT02430532,measures_secondary,Change From Baseline to 2 Years on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12)
NCT02430532,has_criteria,1 or more of the following criteria
NCT04025632,involves,Immune-Mediated Necrotizing Myopathy
NCT04025632,evaluates,Zilucoplan
NCT04025632,measures_primary,Percentage Change CK
NCT04025632,measures_secondary,Treatment-Emergent Adverse Event
NCT04025632,measures_secondary,Minimal Response
NCT04025632,has_criteria,ACR/EULAR Response Criteria
NCT03376932,involves,Asthma
NCT03376932,evaluates,Fluticasone Furoate/ Umeclidinium/ Vilanterol
NCT03376932,measures_primary,ACT total score
NCT03376932,measures_secondary,Asthma exacerbations
NCT03376932,has_criteria,Baseline and up to 24 weeks
NCT02972632,involves,Major Depressive Disorder
NCT02972632,evaluates,Vortioxetine
NCT02972632,measures_primary,Goal Attainment Scale Score
NCT02972632,measures_secondary,Patient Health Questionnaire (PHQ-9) Score
NCT02972632,has_criteria,individualized goals
NCT04250337,involves,Atopic Dermatitis
NCT04250337,evaluates,Lebrikizumab
NCT04250337,measures_primary,IGA score 0 or 1
NCT04250337,measures_secondary,EASI-75
NCT04250337,measures_secondary,EASI-90
NCT04250337,has_criteria,Baseline to Week 16
NCT02215252,involves,Diabetic Peripheral Neuropathy
NCT02215252,evaluates,PF-05089771
NCT02215252,measures_primary,Pain Numeric Rating Scale
NCT02215252,measures_secondary,Responder Rate
NCT02215252,measures_secondary,Neuropathic Pain Symptom Inventory
NCT02215252,has_criteria,Daily pain diaries
NCT01645332,involves,Type 2 Diabetes Mellitus
NCT01645332,evaluates,DLBS3233
NCT01645332,measures_primary,Reduction of A1c
NCT01645332,measures_secondary,Reduction of venous FPG
NCT01645332,measures_secondary,Reduction of venous 2h-PG
NCT01645332,measures_secondary,Response rate
NCT01645332,measures_secondary,Change in fasting insulin level
NCT01645332,measures_secondary,Change in HOMA-IR
NCT01645332,measures_secondary,Change in HOMA-B
NCT01645332,measures_secondary,Change in adiponectin level
NCT01645332,measures_secondary,Change in lipid profile
NCT01645332,measures_secondary,Change in body weight
NCT01645332,measures_secondary,Vital signs
NCT01645332,measures_secondary,Liver function
NCT01645332,measures_secondary,Renal function
NCT01645332,measures_secondary,Electrocardiography
NCT01645332,measures_secondary,Adverse events
NCT01645332,has_criteria,Male or female s...
NCT01487200,involves,Osteoarthritis of the knee
NCT01487200,evaluates,FX006
NCT01487200,measures_primary,Change from baseline
NCT01487200,measures_secondary,Urinary Free Cortisol Excretion
NCT01487200,has_criteria,BMI ≤ 40 kg/m2
NCT01487200,has_criteria,Diagnosis of OA of the knee
NCT01487200,has_criteria,Age ≥35 years
NCT03242252,involves,Type 2 Diabetes
NCT03242252,involves,moderate renal insufficiency
NCT03242252,evaluates,Sotagliflozin
NCT03242252,measures_primary,Change From Baseline in HbA1c
NCT03242252,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT03242252,measures_secondary,Change From Baseline in SBP
NCT03242252,measures_secondary,Change From Baseline in Body Weight
NCT03242252,measures_secondary,Percentage Change From Baseline in the Urine Albumin: Creatinine Ratio
NCT03242252,measures_secondary,Percentage of Participants With HbA1c <6.5%
NCT03242252,measures_secondary,Percentage of Participants With HbA1c <7.0%
NCT03242252,measures_secondary,Percentage of Participants With Treatment-emergent Adverse Events
NCT03242252,has_criteria,Type 2 Diabetes
NCT03242252,has_criteria,moderate renal insufficiency
NCT03242252,has_criteria,eGFR 30-60 mL/min/1.73 m^2
NCT03242252,has_criteria,written informed consent
NCT03242252,has_criteria,HbA1c 7.0-11.0%
NCT06298032,evaluates,Olamkicept
NCT06298032,measures_primary,Change in vital signs
NCT06298032,measures_secondary,Clinically significant abnormal findings
NCT06298032,has_criteria,Healthy Persons
NCT02024932,involves,Spinal and Bulbar Muscular Atrophy
NCT02024932,evaluates,BVS857
NCT02024932,measures_primary,Thigh Muscle Volume
NCT02024932,measures_secondary,Adult Myopathy Assessment Tool
NCT02024932,measures_secondary,Total Lean Body Mass
NCT02024932,has_criteria,Cohort 5
NCT02412852,involves,Diabetic Pain
NCT02412852,evaluates,Sustained Release Sodium Nitrite
NCT02412852,measures_primary,Safety & tolerability
NCT02412852,measures_secondary,Pharmacokinetics
NCT02412852,has_criteria,Multiple doses
NCT01456052,involves,Ulcerative Colitis
NCT01456052,evaluates,Telotristat Etiprate
NCT01456052,measures_primary,Clinical Response
NCT01456052,measures_secondary,Clinical Remission
NCT01456052,has_criteria,Modified Mayo score
NCT02548052,involves,plaque psoriasis
NCT02548052,evaluates,Topical GSK2981278 Ointment
NCT02548052,measures_primary,infiltrate thickness
NCT02548052,measures_secondary,clinical assessment score
NCT02548052,has_criteria,18 years of age
NCT06214052,involves,HIV-1
NCT06214052,evaluates,VH4524184
NCT06214052,measures_primary,Plasma HIV-1 RNA
NCT06214052,measures_secondary,Adverse Events
NCT06214052,measures_secondary,Liver Panel Laboratory Parameters
NCT06214052,has_criteria,treatment-naïve
NCT02672852,involves,Plaque Psoriasis
NCT02672852,evaluates,Risankizumab
NCT02672852,measures_primary,PASI90 at Week 16
NCT02672852,measures_secondary,sPGA Score at Week 16
NCT02672852,measures_secondary,sPGA Score at Week 52
NCT02672852,has_criteria,Moderate to Severe
NCT00673452,involves,Fibromyalgia
NCT00673452,evaluates,Duloxetine
NCT00673452,evaluates,Placebo
NCT00673452,measures_primary,PGI-I at Week 12
NCT00673452,measures_secondary,Change From Baseline in BPI
NCT00673452,measures_secondary,Change From Baseline in MFI
NCT00673452,measures_secondary,Change From Baseline in BDI-II
NCT04842032,involves,XLH
NCT04842032,evaluates,KRN23
NCT04842032,measures_primary,Change in mean serum phosphorus
NCT04842032,measures_secondary,Change in rickets
NCT04842032,measures_secondary,Rickets Severity Score
NCT04842032,has_criteria,Pediatric Chinese Patients
NCT02672332,involves,Acne
NCT02672332,evaluates,SB204
NCT02672332,measures_primary,Inflammatory Lesion Counts
NCT02672332,measures_secondary,Non-inflammatory Lesion Counts
NCT02672332,measures_secondary,Investigator Global Assessment
NCT02672332,measures_secondary,Percent Change
NCT02672332,measures_secondary,Time to Reduction
NCT02672332,has_criteria,Baseline and Week 12
NCT04735432,involves,Generalized Myasthenia Gravis
NCT04735432,evaluates,Efgartigimod PH20 SC
NCT04735432,evaluates,Efgartigimod
NCT04735432,measures_primary,Percent Change From Baseline
NCT04735432,measures_secondary,Percent Change From Baseline
NCT04735432,measures_secondary,Percent Change From Baseline
NCT04735432,measures_secondary,Percent Change From Baseline
NCT04735432,measures_secondary,AUEC of the Percent Change
NCT04735432,has_criteria,mITT Analysis Set
NCT04365400,involves,Hypertriglyceridemia
NCT04365400,involves,Type 2 Diabetes
NCT04365400,evaluates,Epeleuton
NCT04365400,measures_primary,% Change in Triglycerides
NCT04365400,measures_secondary,Change in HbA1c
NCT04365400,has_criteria,HbA1C 7.0-10.0%
NCT04365400,has_criteria,fasting triglyceride ≥200 mg/dL
NCT04365400,has_criteria,fasting triglyceride <750 mg/dL
NCT04365400,has_criteria,stable statin therapy
NCT02728752,involves,Dermatomyositis
NCT02728752,evaluates,Octagam 10%
NCT02728752,measures_primary,Total response rate
NCT02728752,measures_secondary,Mean Change
NCT02728752,has_criteria,≥20 points TIS
NCT03319732,involves,Multiple Sclerosis
NCT03319732,evaluates,Arbaclofen Extended-Release Tablets
NCT03319732,measures_primary,TNmAS-MAL
NCT03319732,measures_secondary,Expanded Disability Status Scale
NCT03319732,has_criteria,18 to 65 years old
NCT06327815,involves,Type 2 Diabetes Mellitus
NCT06327815,evaluates,Dapagliflozin/Metformin
NCT06327815,measures_primary,Change in HbA1c
NCT06327815,measures_secondary,Fasting Plasma Glucose
NCT06327815,measures_secondary,Postprandial Glucose
NCT06327815,measures_secondary,Diabetes Treatment Satisfaction Questionnaire
NCT06327815,measures_secondary,Diabetes Quality of Life
NCT06327815,has_criteria,Chinese patients
NCT02616315,involves,Weight Regain
NCT02616315,evaluates,Naltrexone HCl/Bupropion HCl Extended Release
NCT02616315,measures_primary,Percent Change in Body Weight
NCT02616315,measures_secondary,Percentage of Participants Achieving a Loss
NCT02616315,has_criteria,Post Bariatric Surgery
NCT00506415,involves,Alzheimer's Disease
NCT00506415,evaluates,Rivastigmine
NCT00506415,measures_primary,Change in ADAS-Cog
NCT00506415,measures_secondary,Change in ADCS-IADL
NCT00506415,has_criteria,Functional decline
NCT05690685,involves,Chronic Wounds
NCT05690685,evaluates,Silver I Alginate Non-Woven Dressing
NCT05690685,measures_primary,Wound progression
NCT05690685,measures_secondary,Pain assessment
NCT05690685,measures_secondary,Change in wound odour
NCT05690685,measures_secondary,Ease of use assessment
NCT05690685,has_criteria,Reduction or no signs
NCT02418585,involves,Treatment-resistant Depression
NCT02418585,evaluates,Intranasal Esketamine
NCT02418585,measures_primary,Change From Baseline in MADRS Total Score
NCT02418585,measures_secondary,Percentage of Participants With Onset of Clinical Response
NCT02418585,has_criteria,at least 50 percent
NCT04877756,involves,Hypertrophic Scarring
NCT04877756,evaluates,OLX10010
NCT04877756,measures_primary,Recurrence of scar
NCT04877756,measures_secondary,Scar severity
NCT04877756,has_criteria,Scar revision surgery
NCT05006885,involves,Non-alcoholic Fatty Liver Disease
NCT05006885,evaluates,ALT-801
NCT05006885,measures_primary,liver fat fraction
NCT05006885,measures_secondary,body weight
NCT05006885,measures_secondary,lipid metabolism
NCT05006885,measures_secondary,hemoglobin A1c
NCT05006885,measures_secondary,fibrosis markers
NCT05006885,has_criteria,Overweight and Obese
NCT05348785,involves,Parkinson's Disease
NCT05348785,evaluates,BIIB122 Tablets
NCT05348785,measures_primary,Time to confirmed worsening
NCT05348785,measures_secondary,Number of Participants With TEAEs
NCT05348785,measures_secondary,Number of Participants With SAEs
NCT05348785,has_criteria,Ages 30 to 80
NCT05205785,involves,Irritable Bowel Syndrome
NCT05205785,evaluates,Human Milk Oligosaccharides
NCT05205785,measures_primary,stool consistency
NCT05205785,measures_secondary,pain severity score
NCT05205785,measures_secondary,total IBS severity score
NCT05205785,measures_secondary,IBS Quality of Life score
NCT05205785,has_criteria,2 week run in period
NCT01793285,involves,Ankylosing Spondylitis
NCT01793285,evaluates,Etanercept
NCT01793285,measures_primary,Time to Diagnosis
NCT01793285,measures_secondary,Patient Global Assessment
NCT01793285,has_criteria,Baseline up to Year 3
NCT01649856,involves,Diffuse Large B-Cell Lymphoma
NCT01649856,evaluates,Rituximab
NCT01649856,measures_primary,Complete Response
NCT01649856,measures_secondary,Cancer Treatment Satisfaction
NCT01649856,has_criteria,CD20-Positive
NCT02696785,involves,Radiographic Axial Spondyloarthritis
NCT02696785,evaluates,Ixekizumab
NCT02696785,measures_primary,ASAS40 Response
NCT02696785,measures_secondary,ASAS20 Response
NCT02696785,has_criteria,bDMARD-Naive
NCT01368185,involves,Hypertension
NCT01368185,evaluates,MK-0954A
NCT01368185,measures_primary,Serum Uric Acid
NCT01368185,measures_secondary,Diastolic Blood Pressure
NCT01368185,measures_secondary,Systolic Blood Pressure
NCT01368185,has_criteria,Hyperuricemia
NCT05590585,involves,Atopic Dermatitis
NCT05590585,evaluates,Dupilumab
NCT05590585,measures_primary,EASI-75
NCT05590585,measures_secondary,Investigator's Global Assessment
NCT05590585,measures_secondary,Percent change from baseline in EASI
NCT05590585,measures_secondary,Absolute change from baseline in EASI
NCT05590585,measures_secondary,Proportion of participants with EASI-50
NCT05590585,has_criteria,Adolescent and Adult Skin of Color
NCT01037985,involves,Scar appearance
NCT01037985,evaluates,EXC 001
NCT01037985,measures_primary,Scar assessment score
NCT01037985,measures_secondary,Physician observer score
NCT01037985,measures_secondary,Participant observer score
NCT01037985,has_criteria,Elective abdominoplasty
NCT04406415,involves,Healthy Volunteers
NCT04406415,evaluates,Oral Nafamostat
NCT04406415,measures_primary,Adverse events
NCT04406415,measures_secondary,Pharmacokinetics
NCT04406415,has_criteria,Age 18-70 years old
NCT02565615,involves,Cardiovascular Disease
NCT02565615,evaluates,Atorvastatin
NCT02565615,measures_primary,Achievement Rate for LDL-C
NCT02565615,measures_secondary,Change From Baseline
NCT02565615,has_criteria,CVD risk stratification
NCT05368285,involves,Chronic spontaneous urticaria
NCT05368285,evaluates,barzolvolimab
NCT05368285,measures_primary,UAS7 (Urticaria Activity Score)
NCT05368285,measures_secondary,ISS7
NCT05368285,measures_secondary,HSS7
NCT05368285,measures_secondary,AAS7
NCT05368285,has_criteria,Males and females
NCT05368285,has_criteria,>= 18 years of age
NCT05368285,has_criteria,CSU diagnosis
NCT05368285,has_criteria,>= 6 months
NCT05368285,has_criteria,Hives for >= 6 weeks
NCT05368285,has_criteria,Stable H1-antihistamine
NCT01563185,involves,Juvenile Idiopathic Arthritis
NCT01563185,evaluates,DUEXIS
NCT01563185,measures_primary,CHQ-PF50 Scores
NCT01563185,measures_secondary,ACR Pediatric Core Measures
NCT01563185,has_criteria,Baseline to Endpoint
NCT01530256,involves,Steroid-refractory Acute Graft Versus Host Disease
NCT01530256,evaluates,ALD518
NCT01530256,measures_primary,Acute GVHD Response
NCT01530256,measures_secondary,Relapse of Underlying Malignant Disease
NCT01530256,measures_secondary,Overall Survival
NCT01530256,measures_secondary,Change in FACT-BMT
NCT01530256,has_criteria,Week 24
NCT01144715,involves,Stroke
NCT01144715,measures_primary,Arm-hand function
NCT01144715,measures_secondary,Quality of Life
NCT01144715,has_criteria,8 weeks post enrolment
NCT00465985,involves,Muckle-Wells Syndrome
NCT00465985,evaluates,ACZ885
NCT00465985,measures_primary,Disease Flare Percent
NCT00465985,measures_secondary,Treatment Response
NCT00465985,has_criteria,CRP and/or SAA > 30 mg/L
NCT01942785,involves,Major Depressive Disorder
NCT01942785,evaluates,Brexpiprazole
NCT01942785,measures_primary,Change From Baseline
NCT01942785,measures_secondary,Delay Discounting
NCT01942785,has_criteria,Inadequate Response
NCT06574685,involves,Ocular Surface Disease
NCT06574685,evaluates,Twinkle Eyez Supplementation
NCT06574685,measures_primary,Ocular Health
NCT06574685,measures_secondary,Immunity
NCT06574685,has_criteria,Lutein and zeaxanthin intakes
NCT06031415,involves,Rheumatoid Arthritis
NCT06031415,evaluates,GS-0272
NCT06031415,measures_primary,DAS28 (CRP)
NCT06031415,measures_secondary,Antidrug Antibodies
NCT06031415,has_criteria,Diagnosis of RA
NCT00457015,involves,Hereditary Angioedema
NCT00457015,evaluates,DX-88
NCT00457015,measures_primary,MSCS score
NCT00457015,measures_secondary,Treatment Outcome Score
NCT00457015,has_criteria,Change From Baseline
NCT03350815,involves,Ankylosing Spondylitis
NCT03350815,evaluates,Secukinumab
NCT03350815,measures_primary,Inactive Disease
NCT03350815,measures_secondary,ASDAS score
NCT03350815,has_criteria,Dose Escalation
NCT06613685,involves,HIV-1
NCT06613685,evaluates,GS-1720
NCT06613685,evaluates,GS-4182
NCT06613685,evaluates,Biktarvy
NCT06613685,measures_primary,HIV-1 RNA < 50 Copies/mL
NCT06613685,measures_primary,HIV-1 RNA < 50 Copies/mL
NCT06613685,measures_primary,HIV-1 RNA < 50 Copies/mL
NCT06613685,measures_secondary,Change From Baseline in log10 HIV-1 RNA
NCT06613685,measures_secondary,Change From Baseline in CD4 Cell Count
NCT06613685,measures_secondary,Percentage of Participants Experiencing TEAEs
NCT06613685,measures_secondary,Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities
NCT02808585,involves,HFrEF
NCT02808585,evaluates,PB1046
NCT02808585,measures_primary,Rhythm abnormalities
NCT02808585,measures_secondary,12-Lead ECG
NCT02808585,has_criteria,Stable HFrEF
NCT01694485,involves,Ulcerative Colitis
NCT01694485,evaluates,Abrilumab
NCT01694485,measures_primary,Remission at Week 8
NCT01694485,measures_secondary,Response at Week 8
NCT01694485,has_criteria,Mayo Score ≤ 2 points
NCT03695185,involves,Ulcerative Colitis
NCT03695185,evaluates,Ravagalimab
NCT03695185,measures_primary,Endoscopic Improvement
NCT03695185,measures_secondary,Clinical Remission
NCT03695185,measures_secondary,Clinical Response
NCT03695185,has_criteria,Prior Therapy
NCT04770285,involves,Major Depressive Disorder
NCT04770285,evaluates,Digital Therapeutics
NCT04770285,measures_primary,Change From Baseline
NCT04770285,measures_secondary,Change From Baseline
NCT04770285,has_criteria,Baseline (Day 1)
NCT00781885,involves,Pulmonary Arterial Hypertension
NCT00781885,evaluates,Beraprost Sodium Modified Release
NCT00781885,measures_primary,Change in BMI
NCT00781885,measures_secondary,Change in Weight
NCT00781885,measures_secondary,Change in Heart Rate
NCT00781885,has_criteria,Twice-daily Administration
NCT01014585,involves,Fibromyalgia
NCT01014585,evaluates,Milnacipran
NCT01014585,measures_primary,Time to LTR
NCT01014585,measures_secondary,Time to Worsening PGIC
NCT01014585,measures_secondary,Time to Worsening MAF
NCT01014585,has_criteria,\< 30% reduction
NCT05777785,involves,ADHD
NCT05777785,evaluates,Novel Device
NCT05777785,measures_primary,ASRS Total Score
NCT05777785,measures_secondary,CGI-I
NCT05777785,measures_secondary,CPT-3 d
NCT05777785,measures_secondary,BRIEF-A
NCT05777785,has_criteria,DSM-V-TR criteria
NCT05777317,involves,Painful Diabetic Neuropathy
NCT05777317,evaluates,10 kHz Spinal Cord Stimulation
NCT05777317,measures_primary,Lower limb pain responder rate
NCT05777317,measures_secondary,Neurological improvement responder rate
NCT05777317,has_criteria,at least 50% reduction
NCT00296504,involves,HIV-1 infection
NCT00296504,evaluates,GW433908
NCT00296504,evaluates,Fosamprenavir
NCT00296504,measures_primary,Change From Baseline
NCT00296504,measures_secondary,Total Cholesterol/HDL Ratio
NCT00296504,has_criteria,Fasting blood samples
NCT05297201,involves,Levodopa Induced Dyskinesia
NCT05297201,evaluates,CPL500036
NCT05297201,measures_primary,Change from baseline
NCT05297201,measures_secondary,Change from baseline
NCT05297201,has_criteria,Day -1
NCT01683604,involves,Rheumatoid Arthritis
NCT01683604,evaluates,Tocilizumab
NCT01683604,measures_primary,Percentage of participants
NCT01683604,measures_secondary,Patient Assessment of Pain
NCT01683604,has_criteria,Baseline
NCT00256204,involves,Parkinson's Disease
NCT00256204,evaluates,Rasagiline
NCT00256204,measures_primary,Change in UPDRS
NCT00256204,measures_secondary,Change in UPDRS
NCT00256204,has_criteria,idiopathic PD
NCT03075904,involves,Pemphigus
NCT03075904,evaluates,SYNT001
NCT03075904,measures_primary,Percent Reduction IgG
NCT03075904,measures_secondary,Pemphigus Disease Area Index
NCT03075904,has_criteria,Treatment Period
NCT05382104,evaluates,Maribavir
NCT05382104,measures_primary,Number of Participants
NCT05382104,measures_secondary,Severity of TEAEs
NCT05382104,has_criteria,start of study drug administration
NCT06403501,involves,facial acne vulgaris
NCT06403501,evaluates,Clascoterone Cream 1%
NCT06403501,measures_primary,IGA score 0 or 1
NCT06403501,measures_secondary,Non-inflammatory Lesion Counts
NCT06403501,measures_secondary,Inflammatory Lesion Counts
NCT06403501,measures_secondary,Total Lesion Counts
NCT06403501,has_criteria,moderate to severe acne
NCT06403501,has_criteria,Investigator's Global Assessment 3 or 4
NCT06403501,has_criteria,30 to 75 inflammatory lesions
NCT06403501,has_criteria,30 to 100 non-inflammatory lesions
NCT06403501,has_criteria,12 years of age or older
NCT03127267,involves,Amyotrophic Lateral Sclerosis
NCT03127267,evaluates,Masitinib
NCT03127267,measures_primary,ALSFRS-R score
NCT03127267,measures_secondary,ALS quality of life
NCT03127267,measures_secondary,Progression free survival
NCT03127267,measures_secondary,Forced Vital Capacity
NCT03127267,measures_secondary,Hand-held dynamometry
NCT03127267,measures_secondary,Combined Assessment of Function and Survival
NCT03127267,has_criteria,laboratory supported probable ALS
NCT03127267,has_criteria,clinically probable ALS
NCT03127267,has_criteria,definite ALS
NCT03127267,has_criteria,familial or sporadic ALS
NCT03127267,has_criteria,ALS disease duration
NCT03127267,has_criteria,riluzole treatment
NCT03127267,has_criteria,ALSFRS-R score progression
NCT04099667,involves,Lower Limb Spasticity
NCT04099667,evaluates,MYOBLOC
NCT04099667,measures_primary,Change in MAS score
NCT04099667,measures_primary,Clinical Global Impression of Change
NCT04099667,measures_secondary,Patient Global Impression of Change
NCT04099667,has_criteria,Week 4 post-injection
NCT03605667,involves,Alzheimer's Disease
NCT03605667,evaluates,BHV-4157
NCT03605667,measures_primary,ADAS-Cog Total Score
NCT03605667,measures_secondary,CDR-Sum of Boxes Total Score
NCT03605667,measures_secondary,MRI Hippocampal Volume
NCT03605667,has_criteria,Baseline (Day 1)
NCT02668640,involves,Rheumatoid Arthritis
NCT02668640,evaluates,Adalimumab
NCT02668640,measures_primary,HAQ-DI Score
NCT02668640,measures_secondary,SF-36 PCS Score
NCT02668640,measures_secondary,SF-36 MCS Score
NCT02409667,involves,Plaque Psoriasis
NCT02409667,evaluates,Secukinumab
NCT02409667,measures_primary,PASI 90 Response Rate
NCT02409667,measures_secondary,PASI 50
NCT02409667,has_criteria,PASI 90 Response at Week 24
NCT05677867,evaluates,PF-07081532
NCT05677867,measures_primary,AUCinf
NCT05677867,measures_primary,AUClast
NCT05677867,measures_primary,Cmax
NCT05677867,has_criteria,treatment-emergent adverse events
NCT00405067,involves,Moderate Hypercholesterolemia
NCT00405067,evaluates,BMS-201038
NCT00405067,evaluates,Ezetimibe
NCT00405067,measures_primary,Percent Change in LDL-C
NCT00405067,measures_secondary,Total Cholesterol
NCT00405067,measures_secondary,Non-HDL-C
NCT00405067,measures_secondary,Tryglycerides
NCT00405067,measures_secondary,HDL-C
NCT00405067,measures_secondary,Lipoprotein(a)
NCT00405067,measures_secondary,Apolipoprotein A1
NCT00405067,measures_secondary,Apolipoprotein B
NCT00405067,measures_secondary,High-sensitivity C-reactive Protein
NCT00405067,measures_secondary,Body Weight
NCT00405067,has_criteria,18 to 70 years
NCT00405067,has_criteria,LDL-C >160 mg/dl
NCT00405067,has_criteria,LDL-C <250 mg/dl
NCT00405067,has_criteria,Fasting TGs <400 mg/dl
NCT05971940,involves,Type 2 Diabetes
NCT05971940,evaluates,Orforglipron
NCT05971940,measures_primary,Change from Baseline HbA1c
NCT05971940,measures_secondary,Fasting Serum Glucose
NCT05971940,measures_secondary,Body Weight
NCT05971940,measures_secondary,Daily Average 7-point SMBG
NCT05971940,measures_secondary,Systolic Blood Pressure
NCT05971940,measures_secondary,Non-HDL Cholesterol
NCT05971940,measures_secondary,Triglycerides
NCT05971940,measures_secondary,Weight Loss
NCT05971940,measures_secondary,SF-36v2 Acute Form
NCT05971940,has_criteria,Adult Participants
NCT04419467,involves,Diabetic Kidney Disease
NCT04419467,evaluates,CSL346
NCT04419467,measures_primary,Urinary Albumin-to-creatinine Ratio
NCT04419467,measures_secondary,Serum Creatinine
NCT04419467,measures_secondary,Estimated Glomerular Filtration Rate
NCT04419467,measures_secondary,Systolic Blood Pressure
NCT04419467,measures_secondary,Diastolic Blood Pressure
NCT04419467,has_criteria,Treatment with CSL346
NCT03343067,involves,Endometriosis
NCT03343067,evaluates,Elagolix
NCT03343067,measures_primary,Proportion of Responders
NCT03343067,measures_secondary,Change From Baseline
NCT03343067,has_criteria,Moderate to Severe Pain
NCT04676867,involves,COVID-19
NCT04676867,evaluates,Dalcetrapib
NCT04676867,measures_primary,Time to resolution
NCT04676867,measures_secondary,Change From Baseline in log10 Viral Load
NCT04676867,has_criteria,Confirmed
NCT04672967,involves,Autism Spectrum Disorder
NCT04672967,evaluates,Vineland Adaptive Behavior Scale
NCT04672967,measures_primary,adaptive function
NCT04672967,measures_secondary,cognitive functioning
NCT04672967,has_criteria,age 68 months
NCT06052267,involves,Asthma
NCT06052267,evaluates,Fluticasone Propionate/Albuterol Sulfate
NCT06052267,measures_primary,Time to First CAE
NCT06052267,measures_secondary,Annualized CAE Rate
NCT06052267,measures_secondary,Asthma Control Questionnaire-5 Response
NCT06052267,measures_secondary,Composite Responders
NCT06052267,has_criteria,≥6 years
NCT06052267,has_criteria,≥7 years
NCT00830167,involves,Fibromyalgia
NCT00830167,evaluates,Pregabalin
NCT00830167,measures_primary,NRS-Pain scores
NCT00830167,measures_secondary,PGIC
NCT00830167,measures_secondary,MOS Sleep Scale
NCT00830167,has_criteria,Baseline
NCT02667067,involves,Cervical spondylosis
NCT02667067,evaluates,Simplify® Cervical Artificial Disc
NCT02667067,measures_primary,NDI improvement
NCT02667067,measures_secondary,VAS Neck and Arm Pain
NCT02667067,measures_secondary,Neurological status
NCT02667067,has_criteria,15 point NDI improvement
NCT05797740,involves,Multiple Sclerosis
NCT05797740,evaluates,Cladribine tablets
NCT05797740,measures_primary,Time to Discontinuation
NCT05797740,measures_secondary,Cumulative Cladribine Dose
NCT05797740,measures_secondary,Number of Relapses
NCT05797740,measures_secondary,Proportion of Severe Relapses
NCT05797740,measures_secondary,Percentage of Participants Free From Relapse
NCT05797740,measures_secondary,Time From Onset of Relapse to Recovery
NCT05797740,measures_secondary,Annualized Relapse Rate
NCT05797740,measures_secondary,Percentage of Participants Free From MRI Activity
NCT05797740,measures_secondary,Percentage of Participants with Minimal MRI Activity
NCT05797740,measures_secondary,Timed 25-Foot Walk Score
NCT05797740,measures_secondary,Percentage of Participants with Increase/Decrease in T25FW Score
NCT05797740,measures_secondary,9-Hole Peg Test Score
NCT05797740,measures_secondary,Percentage of Participants with Increase/Decrease in 9HPT Score
NCT05797740,measures_secondary,Percentage of Participants With Progressed
NCT05797740,measures_secondary,Percentage of Participants With Sustained Disability Progression
NCT01648140,involves,Chronic Hepatitis C
NCT01648140,evaluates,GSK2336805
NCT01648140,measures_primary,Number of Participants Achieving eRVR
NCT01648140,measures_secondary,Adverse Events
NCT01648140,measures_secondary,Serious Adverse Events
NCT01648140,measures_secondary,Systolic Blood Pressure
NCT01648140,measures_secondary,Diastolic Blood Pressure
NCT01648140,has_criteria,Plasma HCV RNA \<LLOQ
NCT05680740,involves,plaque psoriasis
NCT05680740,evaluates,VTAMA (Tapinarof) Cream
NCT05680740,measures_primary,iPGA score 0 or 1
NCT05680740,measures_secondary,iPGA score 0 or 1
NCT05680740,has_criteria,18 years or older
NCT05680740,has_criteria,plaque psoriasis
NCT05680740,has_criteria,stable disease
NCT05680740,has_criteria,iPGA score 2
NCT05680740,has_criteria,female of childbearing potential
NCT05680740,has_criteria,negative pregnancy test
NCT02780167,involves,Atopic Dermatitis
NCT02780167,evaluates,Pf-04965842
NCT02780167,measures_primary,IGA for Clear
NCT02780167,measures_secondary,EASI
NCT02780167,has_criteria,Moderate to Severe
NCT02342067,involves,Nonalcoholic steatohepatitis
NCT02342067,evaluates,Cenicriviroc
NCT02342067,evaluates,Pioglitazone
NCT02342067,measures_primary,Pharmacokinetic Assessment
NCT02342067,measures_secondary,Adverse Events
NCT02342067,measures_secondary,Changes from Baseline
NCT02342067,has_criteria,BMI ≥ 18 and ≤ 35 kg/m2
NCT02342067,has_criteria,No clinically relevant abnormalities
NCT02342067,has_criteria,Agree to comply
NCT01924767,involves,Cardiac disorders
NCT01924767,evaluates,BI 10773 Tablets
NCT01924767,measures_primary,Percentage of Participants
NCT01924767,measures_secondary,Micturition Frequency
NCT01924767,has_criteria,Clinically relevant findings
NCT04267640,involves,Peripheral Ischemic Ulcers
NCT04267640,evaluates,AMG0001
NCT04267640,measures_primary,Complete ulcer healing
NCT04267640,measures_secondary,Ulcer size reduction
NCT04267640,has_criteria,PAD and mild/moderate foot ischemia
NCT02573467,involves,Sporadic Inclusion Body Myositis
NCT02573467,evaluates,BYM338
NCT02573467,measures_primary,6 Minute Walking Distance
NCT02573467,measures_primary,Quadriceps Quantitative Muscle Testing
NCT02573467,measures_primary,Sporadic Inclusion Body Myositis (sIBM) Functional Assessment (sIFA) Score
NCT00219167,involves,High Blood Pressure
NCT00219167,evaluates,Aliskiren
NCT00219167,measures_primary,Change in systolic blood pressure
NCT00219167,measures_secondary,Change in diastolic blood pressure
NCT00219167,has_criteria,Patients 65 years old
NCT00219167,has_criteria,Essential hypertension
NCT00219167,has_criteria,Severe hypertension
NCT00219167,has_criteria,Secondary hypertension
NCT00219167,has_criteria,Hypertensive encephalopathy
NCT00219167,has_criteria,Cerebrovascular accident
NCT00406367,involves,Blepharospasm
NCT00406367,evaluates,IncobotulinumtoxinA
NCT00406367,measures_primary,JRS Severity Subscore
NCT00406367,measures_secondary,Blepharospasm Disability Index
NCT00406367,has_criteria,Baseline
NCT00805467,involves,rheumatoid arthritis
NCT00805467,evaluates,R935788
NCT00805467,measures_primary,DAS28-CRP Score
NCT00805467,measures_secondary,HAQ-DI Score
NCT00805467,has_criteria,not applicable
NCT05842967,involves,Severe RSV Disease
NCT05842967,evaluates,RSVpreF
NCT05842967,measures_primary,proportion of participants reporting
NCT05842967,measures_secondary,systemic reactions
NCT05842967,measures_secondary,local reactions
NCT05842967,has_criteria,study administration intervention
NCT04783389,involves,Chronic Rhinosinusitis With Nasal Polyps
NCT04783389,evaluates,CBP-201
NCT04783389,evaluates,Rademikibart
NCT04783389,measures_primary,Endoscopic Nasal Polyp Score
NCT04783389,measures_secondary,Nasal Congestion Score
NCT04783389,measures_secondary,Maxillary Sinus Volume
NCT04783389,has_criteria,Adult Patients
NCT02777489,involves,Obesity
NCT02777489,evaluates,Perindopril
NCT02777489,measures_primary,Body weight loss
NCT02777489,measures_secondary,Fat mass loss
NCT02777489,has_criteria,BMI 30.0 to 40.0 kg/m2
NCT06483789,involves,Panic Disorder
NCT06483789,evaluates,HB-1
NCT06483789,measures_primary,Change in CGI-S
NCT06483789,measures_secondary,Change in PDSS
NCT06483789,has_criteria,Screening
NCT01587989,involves,Rheumatoid Arthritis
NCT01587989,evaluates,RoActemra
NCT01587989,evaluates,Methotrexate
NCT01587989,measures_primary,DAS28 remission
NCT01587989,measures_secondary,CDAI remission
NCT01587989,has_criteria,Inadequate response
NCT03524092,involves,Ulcerative Colitis
NCT03524092,evaluates,Mirikizumab
NCT03524092,measures_primary,Clinical remission at Week 40
NCT03524092,measures_secondary,Endoscopic remission at Week 40
NCT03524092,measures_secondary,Histologic remission at Week 40
NCT03524092,measures_secondary,Symptomatic remission at Week 40
NCT03524092,has_criteria,Moderately to severely active
NCT03943589,involves,Guillain-Barré Syndrome
NCT03943589,evaluates,Imlifidase
NCT03943589,measures_primary,GBS DS grade
NCT03943589,measures_secondary,Ability to walk
NCT03943589,has_criteria,Screening up to Day 360
NCT01387789,involves,Rheumatoid Arthritis
NCT01387789,evaluates,Adalimumab
NCT01387789,measures_primary,HAQ-DI Scores
NCT01387789,measures_secondary,HAQ-VAS Scores
NCT01387789,measures_secondary,SF-36 Scores
NCT01387789,has_criteria,Baseline and 6 months
NCT05307692,involves,Probable Alzheimer's Disease
NCT05307692,evaluates,Seltorexant
NCT05307692,measures_primary,Change from Baseline in NPI-C A plus A Scores
NCT05307692,measures_secondary,Change From Baseline on CMAI-C Score
NCT05307692,measures_secondary,Change from Baseline in SDI Total Score
NCT05307692,has_criteria,Baseline up to Day 43
NCT00649792,involves,Multiple Sclerosis
NCT00649792,evaluates,Fampridine-SR
NCT00649792,measures_primary,Timed 25-Foot Walk
NCT00649792,measures_secondary,Subject Global Impression
NCT00649792,measures_secondary,Clinician's Global Impression
NCT00649792,measures_secondary,Expanded Disability Status Scale
NCT00649792,has_criteria,previously enrolled in MS-F204
NCT00649792,has_criteria,clinically defined multiple sclerosis
NCT05365789,involves,Common Cold
NCT05365789,evaluates,Nasal Spray
NCT05365789,measures_primary,Change of nasal congestion
NCT05365789,measures_secondary,Change of other cold symptoms
NCT05365789,has_criteria,Aged 3 - 48 months
NCT04040192,involves,Atopic Dermatitis
NCT04040192,evaluates,Crisaborole Ointment 2%
NCT04040192,measures_primary,Duration of flare-free maintenance
NCT04040192,measures_secondary,Number of Participants With TEAEs
NCT04040192,measures_secondary,Number of Flare-Free Days
NCT04040192,measures_secondary,Number of Flares
NCT04040192,has_criteria,Randomization to first flare
NCT02699892,involves,Rheumatoid Arthritis
NCT02699892,evaluates,Rituximab
NCT02699892,measures_primary,DAS28 reduction
NCT02699892,measures_secondary,EULAR Good Response
NCT02699892,has_criteria,DAS28 score
NCT01994889,involves,Transthyretin Cardiomyopathy
NCT01994889,evaluates,Tafamidis
NCT01994889,measures_primary,All-Cause Mortality
NCT01994889,measures_secondary,Cardiovascular-Related Hospitalizations
NCT01994889,has_criteria,Baseline up to Month 30
NCT01610492,involves,Idiopathic Membranous Glomerulonephropathy
NCT01610492,evaluates,Belimumab
NCT01610492,measures_primary,Change From Baseline
NCT01610492,measures_secondary,Anti-PLA2R Autoantibody Titers
NCT01610492,has_criteria,eligible participants
NCT00731692,involves,PPMS
NCT00731692,measures_primary,3-month Confirmed Disability Progression
NCT00731692,measures_secondary,Percent Change From Baseline in Brain Volume at Month 36
NCT00731692,has_criteria,36 months after last patient was randomized
NCT01163292,involves,Rheumatoid Arthritis
NCT01163292,evaluates,Adalimumab
NCT01163292,measures_primary,mTSS Change
NCT01163292,measures_secondary,HAQ-DI
NCT01163292,has_criteria,DAS28 score
NCT01299389,involves,Schizophrenia
NCT01299389,evaluates,Paliperidone Palmitate
NCT01299389,measures_primary,Change From Baseline in PANSS Total Score
NCT01299389,measures_secondary,Change From Baseline in CGI-S Score
NCT01299389,measures_secondary,Change From Baseline in PANSS Marder Subscale Scores
NCT01299389,has_criteria,up to Week 13 or early discontinuation
NCT06274489,involves,Alport Syndrome
NCT06274489,evaluates,Setanaxib
NCT06274489,measures_primary,UPCR reduction
NCT06274489,measures_secondary,Serious Adverse Events
NCT06274489,measures_secondary,Adverse Events of Special Interest
NCT06274489,has_criteria,aged 12 to 50 years
NCT02970292,involves,Schizophrenia
NCT02970292,evaluates,Pimavanserin
NCT02970292,measures_primary,PANSS Total Score
NCT02970292,measures_secondary,CGI-S Score
NCT02970292,measures_secondary,PANSS Positive Subscale Score
NCT02970292,measures_secondary,PANSS Negative Subscale Score
NCT02970292,measures_secondary,PANSS General Psychopathological Scale Score
NCT02970292,has_criteria,From baseline to Week 6
NCT03531892,involves,Ulcerative Colitis
NCT03531892,evaluates,AJM300
NCT03531892,measures_primary,Clinical Response Rate
NCT03531892,measures_primary,Clinical Remission Rate
NCT03531892,measures_primary,Mucosal Healing Rate
NCT03531892,measures_primary,Complete Mucosal Healing Rate
NCT03531892,measures_secondary,Clinical Response Rate
NCT03531892,measures_secondary,Clinical Remission Rate
NCT03531892,has_criteria,Active Ulcerative Colitis
NCT03410992,involves,Chronic Plaque Psoriasis
NCT03410992,evaluates,Bimekizumab
NCT03410992,measures_primary,PASI90 Response
NCT03410992,measures_secondary,Investigator's Global Assessment
NCT03410992,has_criteria,Moderate to Severe
NCT01104792,involves,Schizophrenia
NCT01104792,evaluates,Cariprazine
NCT01104792,measures_primary,PANSS Total Score
NCT01104792,measures_secondary,CGI-S Score
NCT01104792,has_criteria,informed consent
NCT02118792,involves,Atopic Dermatitis
NCT02118792,evaluates,AN2728 Topical Ointment
NCT02118792,measures_primary,ISGA score improvement
NCT02118792,measures_secondary,Treatment-Emergent Adverse Events
NCT02118792,measures_secondary,Serious Adverse Events
NCT02118792,has_criteria,2 years and older
NCT02498392,involves,Major Depressive Disorder With Anxious Distress
NCT02498392,evaluates,JNJ-42165279
NCT02498392,measures_primary,HDRS17 Total Score
NCT02498392,measures_secondary,HAM-A6 Score
NCT02498392,has_criteria,eITT Population
NCT05471492,involves,Crohn's Disease
NCT05471492,evaluates,PF-06480605
NCT05471492,measures_primary,SES-CD50 response
NCT05471492,measures_secondary,CDAI clinical remission
NCT05471492,measures_secondary,endoscopic remission
NCT05471492,measures_secondary,endoscopic mucosal healing
NCT05471492,measures_secondary,IBDQ total score
NCT05471492,has_criteria,adult participants
NCT02260089,involves,Hypertensive Patients
NCT02260089,evaluates,Telmisartan
NCT02260089,measures_primary,Blood pressure changes
NCT02260089,measures_secondary,Adverse events
NCT02260089,measures_secondary,Laboratory values
NCT02260089,measures_secondary,ECG changes
NCT02260089,has_criteria,Blood pressure 140/90 mm Hg or higher
NCT02260089,has_criteria,18 years old or older
NCT02260089,has_criteria,Not pregnant or breast-feeding
NCT02260089,has_criteria,No secondary cause hypertension
NCT02260089,has_criteria,Systolic blood pressure ≤ 200 mm Hg
NCT02260089,has_criteria,Diastolic blood pressure ≤ 115 mm Hg
NCT02260089,has_criteria,Laboratory values ≤ 2x upper normal limit
NCT02260089,has_criteria,No prior ACE inhibitor or AIIAR intolerance
NCT02260089,has_criteria,New York Heart Association class I or II heart failure
NCT02260089,has_criteria,No stroke in 6 months prior
NCT02260089,has_criteria,Controlled type 2 diabetes mellitus
NCT02192489,involves,Skin Sarcoidosis
NCT02192489,evaluates,CC-220
NCT02192489,measures_primary,modified Sarcoidosis Activity and Severity Index
NCT02192489,measures_secondary,lesion induration
NCT02192489,measures_secondary,sarcoidosis disease markers
NCT02192489,has_criteria,Up to 12 weeks
NCT01700192,involves,House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis
NCT01700192,evaluates,SCH 900237/MK-8237
NCT01700192,measures_primary,Average Total Combined Rhinitis Score
NCT01700192,measures_secondary,Rhinitis Daily Symptom Score
NCT01700192,measures_secondary,Rhinitis Daily Medication Score
NCT01700192,measures_secondary,Total Combined Rhinoconjunctivitis Score
NCT01700192,has_criteria,Up to 54 weeks
NCT01700192,has_criteria,Up to 52 weeks
NCT01414192,involves,Dyslipidemia
NCT01414192,evaluates,MK-0653A
NCT01414192,measures_primary,Rate of CV events
NCT01414192,measures_secondary,Percentage Change LDL-C
NCT01414192,has_criteria,CV risk factors
NCT05619692,involves,Alzheimer's Disease
NCT05619692,involves,Mild Cognitive Impairment
NCT05619692,evaluates,SAGE-718
NCT05619692,measures_primary,WAIS-IV Coding Test
NCT05619692,measures_secondary,Treatment-emergent Adverse Events
NCT05619692,measures_secondary,Number of Participants Who Withdraw
NCT05619692,has_criteria,Memory complaint
NCT05619692,has_criteria,Clinical Dementia Rating
NCT05619692,has_criteria,Activities of daily living
NCT05619692,has_criteria,Brain Magnetic Resonance Imaging
NCT03039192,involves,Major Depressive Disorder
NCT03039192,evaluates,Intranasal Esketamine
NCT03039192,measures_primary,Change From Baseline in MADRS Total Score
NCT03039192,measures_secondary,Change From Baseline in CGI-SS-R Score
NCT03039192,has_criteria,At Imminent Risk for Suicide
NCT01668667,involves,Restless Leg Syndrome
NCT01668667,evaluates,Gabapentin Enacarbil
NCT01668667,measures_primary,IRLS Rating Scale Score
NCT01668667,measures_secondary,CGI-I Responders
NCT01668667,has_criteria,Baseline
NCT00592904,involves,Painful Diabetic Neuropathy
NCT00592904,involves,Post-Herpetic Neuralgia
NCT00592904,evaluates,Perampanel
NCT00592904,measures_primary,SF-MPQ scores
NCT00592904,measures_secondary,PGIC
NCT00592904,has_criteria,Baseline and Week 48
NCT01986101,involves,Bipolar I Depression
NCT01986101,evaluates,SM-13496
NCT01986101,measures_primary,Change From Baseline in MADRS Total Score at Week 6
NCT01986101,measures_secondary,Change From Baseline in CGI-BP-S (Depression) Score at Week 6
NCT01986101,measures_secondary,Change From Baseline in SDS Total Score at Week 6 (LOCF)
NCT01986101,has_criteria,Baseline to 6 weeks
NCT01104701,involves,Type 2 Diabetes
NCT01104701,evaluates,Exenatide
NCT01104701,measures_primary,HbA1c change
NCT01104701,measures_secondary,Body weight
NCT01104701,measures_secondary,Fasting glucose
NCT01104701,has_criteria,completed protocol
NCT01174004,involves,Parkinson's Disease Psychosis
NCT01174004,evaluates,Pimavanserin
NCT01174004,measures_primary,SAPS-PD score change
NCT01174004,measures_secondary,UPDRS Parts II+III score change
NCT01174004,has_criteria,stable anti-Parkinson's medication
NCT02738801,involves,Idiopathic Pulmonary Fibrosis
NCT02738801,evaluates,GLPG1690
NCT02738801,measures_primary,Mean Maximum Observed Plasma Concentration
NCT02738801,measures_secondary,Median Time to Occurrence of GLPG1690 Cmax
NCT02738801,measures_secondary,Mean Area Under the Plasma Concentration-Time Curve
NCT02738801,measures_secondary,Mean GLPG1690 Plasma Concentration Observed at Predose
NCT02738801,measures_secondary,Mean Peak Area Ratio of Lysophosphatidic Acid C18:2 Species in Blood
NCT02738801,measures_secondary,Mean Peak Area Ratio of LPA C18:2 Species in Bronchoalveolar Lavage Fluid
NCT02738801,has_criteria,Subjects able and willing to sign the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved Informed Consent Form (ICF)
NCT03099304,involves,Vitiligo
NCT03099304,evaluates,INCB018424 Phosphate Cream
NCT03099304,measures_primary,F-VASI50 responder
NCT03099304,measures_secondary,F-PhGVA
NCT03099304,measures_secondary,T-VASI
NCT03099304,has_criteria,≥ 50% improvement
NCT05212701,involves,Fatigue
NCT05212701,involves,Breast Cancer
NCT05212701,evaluates,Oral Reparixin
NCT05212701,measures_primary,Change from baseline
NCT05212701,measures_secondary,EQ-5D-5L score
NCT05212701,has_criteria,Locally Advanced
NCT03281304,involves,Ulcerative Colitis
NCT03281304,evaluates,Tofacitinib
NCT03281304,measures_primary,Remission at Month 6
NCT03281304,measures_secondary,Time to Loss of Remission
NCT03281304,has_criteria,Modified Mayo Score
NCT01249404,involves,Lower Limb Spasticity
NCT01249404,evaluates,Dysport
NCT01249404,measures_primary,MAS Score
NCT01249404,measures_secondary,Comfortable Walking Speed
NCT01249404,has_criteria,Baseline and Week 4
NCT01548404,involves,Extrinsic Atopic Dermatitis
NCT01548404,evaluates,Dupilumab
NCT01548404,measures_primary,EASI score at Week 12
NCT01548404,measures_secondary,IGA score at Week 12
NCT01548404,measures_secondary,EASI-50 at Week 12
NCT01548404,has_criteria,rescue medication
NCT01649804,involves,Rheumatoid Arthritis
NCT01649804,evaluates,WA19926
NCT01649804,measures_primary,Disease Activity
NCT01649804,measures_secondary,Remission
NCT01649804,has_criteria,End of Study
NCT03911401,involves,Atopic Dermatitis
NCT03911401,evaluates,OPA-15406 Ointment
NCT03911401,measures_primary,Responder Rate IGA
NCT03911401,measures_secondary,EASI Score
NCT03911401,measures_secondary,VRS for Pruritus
NCT03911401,has_criteria,aged 7 to 14 years
NCT02002767,evaluates,Velpatasvir
NCT02002767,measures_primary,Percentage Protein Binding
NCT02002767,measures_secondary,Treatment-Emergent Adverse Events
NCT02002767,measures_secondary,Treatment-Emergent Laboratory Abnormalities
NCT02002767,has_criteria,Renal Function
NCT04815967,involves,Upper Limb Spasticity
NCT04815967,evaluates,MYOBLOC
NCT04815967,measures_primary,Change in MAS score
NCT04815967,measures_primary,Clinical Global Impression of Change
NCT04815967,measures_secondary,Change in MAS score
NCT04815967,has_criteria,Week 4 post-injection
NCT04007367,involves,Major Depressive Disorder
NCT04007367,evaluates,SAGE-217
NCT04007367,measures_primary,Time to Relapse
NCT04007367,measures_secondary,Percentage of Relapse
NCT04007367,has_criteria,2 consecutive HAM-D scores ≥ 18
NCT03833167,involves,Locally Advanced Cutaneous Squamous Cell Carcinoma
NCT03833167,evaluates,Pembrolizumab
NCT03833167,measures_primary,Recurrence-Free Survival
NCT03833167,measures_secondary,Overall Survival
NCT03833167,measures_secondary,Change From Baseline in EORTC QLQ-C30 Score
NCT03833167,measures_secondary,Change From Baseline in Physical Functioning Using EORTC QLQ-C30 Items 1-5 Score
NCT03833167,has_criteria,Up to approximately 60 months
NCT02873767,evaluates,UCB4019
NCT02873767,measures_primary,Change from Baseline in total Immunoglobulin G (IgG) concentration at day 7
NCT02873767,measures_secondary,Change from Baseline in total Immunoglobulin G (IgG) concentration at day 10
NCT02873767,measures_secondary,Change from Baseline in total Immunoglobulin G (IgG) concentration at day 13
NCT02873767,has_criteria,Healthy Volunteers
NCT01681004,involves,SI Joint Pain
NCT01681004,evaluates,Sacroiliac Fusion
NCT01681004,measures_primary,Subject Success
NCT01681004,measures_secondary,Improvement in SI Joint Pain VAS Score
NCT01681004,has_criteria,VAS back pain score
NCT00640601,involves,Schizophrenia
NCT00640601,evaluates,SEROQUEL XR
NCT00640601,measures_primary,Change in CGI-CB Score
NCT00640601,measures_secondary,Change in PANSS Total Score
NCT00640601,has_criteria,Baseline to 24 weeks
NCT04266301,involves,Myelodysplastic Syndrome
NCT04266301,involves,Chronic Myelomonocytic Leukemia-2
NCT04266301,evaluates,MBG453
NCT04266301,evaluates,Azacitidine
NCT04266301,measures_primary,Overall Survival
NCT04266301,measures_secondary,Time to definitive deterioration of fatigue
NCT04266301,measures_secondary,Red Blood Cell transfusion-free intervals
NCT04266301,measures_secondary,Percent of subjects with at least 3 point confirmed improvement from baseline in FACIT-fatigue scoresscore
NCT04266301,measures_secondary,Percent of subjects with at least 10 point confirmed improvement from baseline in physical functioning using European Or ganization for Research and Treatment of Cancer's Core Quality of Life Questionnaire
NCT04266301,has_criteria,IPSS-R
NCT05401201,involves,Oral Lichen Planus
NCT05401201,evaluates,Dual-light Antibacterial Photodynamic Therapy
NCT05401201,measures_primary,Pain score improvement
NCT05401201,measures_secondary,aMMP-8 reduction
NCT05401201,has_criteria,VAS score 0-10
NCT04212169,involves,Atopic Dermatitis
NCT04212169,evaluates,MEDI3506
NCT04212169,measures_primary,EASI Score change
NCT04212169,measures_secondary,IGA score
NCT04212169,measures_secondary,Weekly Mean of Daily ...
NCT04212169,has_criteria,moderate-to-severe AD
NCT04507269,involves,Chronic Hepatitis B
NCT04507269,evaluates,VIR-2218
NCT04507269,measures_primary,Treatment-emergent Adverse Events
NCT04507269,measures_secondary,hematology
NCT04507269,has_criteria,study drug start date
NCT01877668,involves,Psoriatic Arthritis
NCT01877668,evaluates,Tofacitinib
NCT01877668,measures_primary,ACR20 at Month 3
NCT01877668,measures_secondary,Change From Baseline in HAQ-DI Score
NCT01877668,measures_secondary,Change From Baseline in mTSS
NCT01877668,has_criteria,American College of Rheumatology
NCT00678210,involves,Psoriasis
NCT00678210,evaluates,CP-690
NCT00678210,measures_primary,PASI 75 Score
NCT00678210,measures_secondary,Physician's Global Assessment
NCT00678210,has_criteria,Moderate to Severe
NCT01470612,involves,Ulcerative Colitis
NCT01470612,evaluates,Tofacitinib
NCT01470612,measures_primary,Number of TEAEs
NCT01470612,measures_secondary,Serious Infections
NCT01470612,has_criteria,Treatment Emergent Adverse Events
NCT00875810,involves,cervical disc surgery
NCT00875810,evaluates,PRESTIGE® Cervical Disc System
NCT00875810,measures_primary,quality of life
NCT00875810,measures_secondary,Neck Disability Index Score
NCT00875810,has_criteria,Patient must...
NCT01456169,involves,High Blood Pressure
NCT01456169,evaluates,Azilsartan Medoxomil and Chlorthalidone
NCT01456169,measures_primary,Change From Baseline to Week 8
NCT01456169,measures_secondary,Change From Baseline to Week 8
NCT01456169,has_criteria,Patients With High Blood Pressure
NCT01074268,involves,Type 1 Diabetes
NCT01074268,evaluates,NN1250 Plus Insulin Aspart
NCT01074268,evaluates,Insulin Detemir Plus Insulin Aspart
NCT01074268,measures_primary,Change in HbA1c
NCT01074268,measures_primary,Rate of Treatment Emergent Adverse Events
NCT01074268,measures_secondary,Change in HbA1c
NCT01074268,measures_secondary,Mean of 9-point Self Measured Plasma Glucose Profile
NCT01074268,has_criteria,Week 0
NCT01074268,has_criteria,Week 26
NCT01074268,has_criteria,Week 52
NCT03644069,involves,Celiac Disease
NCT03644069,evaluates,Nexvax-2
NCT03644069,measures_primary,CeD PRO score
NCT03644069,measures_secondary,GI symptom sub-domains
NCT03644069,measures_secondary,individual GI item scores
NCT03644069,has_criteria,gluten exposure
NCT04364269,involves,β-thalassaemia
NCT04364269,evaluates,VIT-2763
NCT04364269,measures_primary,Changes in Systolic Blood Pressure
NCT04364269,measures_primary,Changes in Diastolic Blood Pressure
NCT04364269,measures_primary,Changes in Heart Rate
NCT04364269,measures_primary,Changes in 12-lead ECG Parameters
NCT04364269,measures_primary,Change From Baseline in Total Serum Iron
NCT04364269,measures_primary,Change From Baseline in Serum Ferritin
NCT04364269,has_criteria,screening period
NCT00883168,involves,Seasonal Allergies
NCT00883168,evaluates,Nasal Spray
NCT00883168,measures_primary,Change From Baseline in 12 Hour rTNSS
NCT00883168,measures_primary,Change From Baseline in 12 Hour iTNSS
NCT00883168,measures_primary,Change From Baseline in Adult RQLQ
NCT00883168,measures_secondary,Change From Baseline in 12 Hour rTNSS
NCT00883168,measures_secondary,Change From Baseline in 12 Hour iTNSS
NCT00883168,measures_secondary,Change From Baseline in Adult RQLQ
NCT00883168,has_criteria,12 years of age and older
NCT00883168,has_criteria,Moderate-to-severe rhinitis
NCT00883168,has_criteria,Sleep disturbance
NCT00883168,has_criteria,Impairment of daily activities
NCT00883168,has_criteria,Impairment of school or work
NCT00883168,has_criteria,Troublesome symptoms
NCT00883168,has_criteria,12-hour reflective TNSS of at least 8
NCT00883168,has_criteria,congestion score of 2 or 3
NCT04993768,involves,Progressive Supranuclear Palsy
NCT04993768,evaluates,TPN-101
NCT04993768,measures_primary,PSPRS score
NCT04993768,measures_secondary,neurofilament light
NCT04993768,has_criteria,reliable caregiver
NCT04993768,has_criteria,PSP symptoms less than 5 years
NCT04993768,has_criteria,MMSE score ≥ 18
NCT05869669,involves,Dementia With Lewy Bodies
NCT05869669,evaluates,Neflamapimod
NCT05869669,measures_primary,CDR-SB score
NCT05869669,measures_secondary,TUG score
NCT05869669,measures_secondary,NTB composite score
NCT05869669,measures_secondary,ADCS-GCIC score
NCT05869669,has_criteria,16 weeks
NCT01243268,involves,Hypertension
NCT01243268,evaluates,Twynsta
NCT01243268,measures_primary,Blood Pressure
NCT01243268,measures_secondary,DBP Response
NCT01243268,measures_secondary,SBP Response
NCT01243268,has_criteria,Exploratory character
NCT01556568,involves,Noonan Syndrome Hypertrophic Cardiomyopathy
NCT01556568,evaluates,MEK162
NCT01556568,measures_primary,Change from baseline in LVM
NCT01556568,measures_secondary,Cardiac energetics state
NCT01556568,has_criteria,Baseline to 3 months and 6 months
NCT00404768,involves,Pre-Term Labor
NCT00404768,evaluates,GSK221149A
NCT00404768,measures_primary,Number of Participants
NCT00404768,measures_secondary,Electrocardiogram Values
NCT00404768,measures_secondary,Clinical Chemistry and Hematology Parameter Values
NCT00404768,has_criteria,Pregnant Women (30-36 Weeks)
NCT01496469,involves,hypertension
NCT01496469,evaluates,Febuxostat
NCT01496469,measures_primary,Change in SBP
NCT01496469,measures_secondary,Change in DBP
NCT01496469,has_criteria,serum uric acid ≥7.0 mg/dL
NCT01496469,has_criteria,average clinic SBP ≥145 mm Hg
NCT01496469,has_criteria,average clinic DBP ≥90 mm Hg
NCT01496469,has_criteria,24-hour mean ambulatory SBP ≥130 mm Hg
NCT01496469,has_criteria,maximum antihypertensive medications ≤ 2
NCT02969369,involves,Parkinson's Disease Psychosis
NCT02969369,evaluates,SEP-363856
NCT02969369,measures_primary,Change From Double Blind Baseline in SAPS-PD Score at Week 6
NCT02969369,measures_secondary,Change From Double Blind Baseline in CGI-S at Week 6
NCT02969369,measures_secondary,Change From Double Blind Baseline in NPI at Week 6
NCT02969369,has_criteria,Double Blind treatment period
NCT06447168,involves,Primary Biliary Cholangitis
NCT06447168,evaluates,Elafibranor
NCT06447168,measures_primary,ALP response
NCT06447168,measures_secondary,ALP normalization
NCT06447168,measures_secondary,ALT
NCT06447168,measures_secondary,AST
NCT06447168,measures_secondary,GGT
NCT06447168,measures_secondary,TB
NCT06447168,measures_secondary,conjugated bilirubin
NCT06447168,measures_secondary,creatinine
NCT06447168,measures_secondary,albumin
NCT06447168,measures_secondary,pruritus
NCT06447168,measures_secondary,fatigue
NCT06447168,has_criteria,ongoing treatment
NCT04574869,involves,Acute Lung Injury
NCT04574869,involves,COVID-19 Pneumonia
NCT04574869,involves,Respiratory Failure
NCT04574869,evaluates,RLS-0071
NCT04574869,measures_primary,Adverse Events
NCT04574869,measures_secondary,ADA titers
NCT04574869,measures_secondary,plasma concentration
NCT04574869,has_criteria,single dose
NCT04574869,has_criteria,multiple doses
NCT05359068,involves,Essential Hypertension
NCT05359068,evaluates,SPH3127
NCT05359068,measures_primary,msDBP at week 12
NCT05359068,measures_secondary,msSBP at week 12
NCT05359068,measures_secondary,Total effective rate
NCT05359068,measures_secondary,Rate of reaching target blood pressure
NCT05359068,measures_secondary,Number of subjects with adverse event
NCT05359068,has_criteria,Age ≥18 years
NCT05359068,has_criteria,Diagnosed with mild-moderate essential hypertension
NCT05359068,has_criteria,Understood study procedures
NCT05359068,has_criteria,Signed informed consent
NCT05359068,has_criteria,No secondary hypertension
NCT05359068,has_criteria,No acute hypertension
NCT05359068,has_criteria,No severe heart disease
NCT05359068,has_criteria,No severe cerebrovascular disease
NCT05359068,has_criteria,No severe retinopathy
NCT05359068,has_criteria,Controlled diabetes
NCT05359068,has_criteria,No malignant tumor
NCT05359068,has_criteria,No mental disorder
NCT05359068,has_criteria,No other antihypertensive drugs
NCT05359068,has_criteria,No alcohol or drug abuse
NCT05359068,has_criteria,Not pregnant or lactating
NCT05359068,has_criteria,Not planning pregnancy
NCT02773368,involves,Type 2 Diabetes Mellitus
NCT02773368,evaluates,Insulin Degludec/Liraglutide
NCT02773368,evaluates,Insulin Glargine
NCT02773368,measures_primary,Change in HbA1c
NCT02773368,measures_secondary,Change in Body Weight
NCT02773368,measures_secondary,Number of Hypoglycaemic Episodes
NCT02773368,measures_secondary,Insulin Dose
NCT02773368,measures_secondary,Change in Fasting Plasma Glucose
NCT02773368,measures_secondary,Number of Adverse Events
NCT02773368,measures_secondary,Responder HbA1c Below 7.0%
NCT02773368,has_criteria,randomised treatment
NCT01288469,involves,Primary Hypercholesterolemia
NCT01288469,evaluates,Alirocumab
NCT01288469,measures_primary,Percent Change LDL-C
NCT01288469,measures_secondary,Total Cholesterol
NCT01288469,measures_secondary,Triglycerides
NCT01288469,measures_secondary,Non-HDL-C
NCT01288469,measures_secondary,Apo-B
NCT01288469,measures_secondary,Lipoprotein(a)
NCT01288469,measures_secondary,HDL-C
NCT00905268,involves,Friedreich's Ataxia
NCT00905268,evaluates,Idebenone
NCT00905268,measures_primary,Absolute Change ICARS
NCT00905268,measures_secondary,Proportion of Patients Improving
NCT00905268,measures_secondary,Change in Peak Systolic Strain Rate
NCT00905268,has_criteria,FRDA cardiomyopathy criteria
NCT03068468,involves,Progressive Supranuclear Palsy
NCT03068468,evaluates,BIIB092
NCT03068468,measures_primary,PSPRS at Week 52
NCT03068468,measures_secondary,MDS-UPDRS Part II at Week 52
NCT03068468,has_criteria,up to 52 weeks
NCT02970162,involves,Lambert-Eaton Myasthenic Syndrome
NCT02970162,evaluates,Amifampridine Phosphate
NCT02970162,measures_primary,change from baseline in QMG score
NCT02970162,measures_secondary,change from baseline in SGI score
NCT02970162,measures_secondary,change from baseline in CGI-I score
NCT02970162,has_criteria,≥18 years of age
NCT02970162,has_criteria,LEMS diagnosis
NCT02970162,has_criteria,stable dose of cholineste...
NCT04680962,involves,Rheumatoid Arthritis
NCT04680962,evaluates,MabionCD20
NCT04680962,measures_primary,DAS28-ESR score
NCT04680962,measures_secondary,DAS28-CRP score
NCT04680962,has_criteria,Baseline to Week 48
NCT04004429,involves,Rheumatoid Arthritis
NCT04004429,evaluates,AP1189
NCT04004429,measures_primary,Change in CDAI
NCT04004429,measures_secondary,ACR20
NCT04004429,has_criteria,Active joint disease
NCT05784129,involves,Crohn's Disease
NCT05784129,evaluates,Guselkumab
NCT05784129,measures_primary,Clinical Remission
NCT05784129,measures_secondary,Endoscopic Recurrence
NCT05784129,has_criteria,Surgical Resection
NCT03622580,involves,Diabetic Macular Edema
NCT03622580,evaluates,Faricimab
NCT03622580,measures_primary,Change From Baseline in BCVA
NCT03622580,measures_secondary,Percentage of Participants With a ≥2-Step Diabetic Retinopathy Severity Improvement From Baseline on the ETDRS Diabetic Retinopathy Severity Scale at Week 52
NCT03622580,has_criteria,baseline BCVA (≥64 vs. \<64 letters)
NCT03622580,has_criteria,prior intravitreal anti-VEGF therapy (yes vs. no)
NCT03622580,has_criteria,region of enrollment
NCT00297362,involves,Alzheimer's Disease
NCT00297362,evaluates,Galantamine Hydrobromide
NCT00297362,measures_primary,Changes from baseline
NCT00297362,measures_secondary,Disability Assessment for Dementia
NCT00297362,measures_secondary,Neuropsychiatric Inventory
NCT00297362,measures_secondary,Clinical Global Impression
NCT00297362,measures_secondary,Cornell Scale
NCT05802862,involves,Type 2 Diabetes
NCT05802862,evaluates,Insulin Degludec/Insulin Aspart Biosimilar
NCT05802862,measures_primary,Change From Baseline in HbA1c
NCT05802862,measures_secondary,Percentage of Participant Who Achieved HbA1c<7% and ≤6.5%
NCT05802862,measures_secondary,Change From Baseline in Fasting Plasma Glucose(FPG)
NCT05802862,measures_secondary,Change From Baseline in 7-Point Self-Monitoring Blood Glucose (SMBG) Values
NCT05802862,measures_secondary,Change From Baseline in Body weight
NCT05802862,measures_secondary,Number of Treatment-emergent Adverse Events (TEAE) and Serious Adverse Events(SAE)
NCT05802862,has_criteria,Informed consent
NCT05962762,involves,Ankylosing Spondylitis
NCT05962762,evaluates,Umbilical Cord Mesenchymal Stem Cells
NCT05962762,measures_primary,ASAS20 Response
NCT05962762,measures_secondary,ASAS50 Response
NCT05962762,measures_secondary,BASDAI
NCT05962762,measures_secondary,BASFI
NCT05962762,has_criteria,Maximum tolerated dose
NCT02714062,involves,Obesity
NCT02714062,evaluates,VI-0521
NCT02714062,evaluates,Placebo
NCT02714062,measures_primary,Weight Loss
NCT02714062,measures_secondary,Change in Waist Circumference
NCT02714062,measures_secondary,Change in Blood Pressure
NCT02714062,measures_secondary,Change in OGTT of Fasting and 2-hour Glucose
NCT02714062,measures_secondary,Change in Lipid Parameters
NCT02714062,measures_secondary,Change in Visual Analog Scale (VAS) Hunger Scores
NCT02714062,has_criteria,Obese Adolescents
NCT00931762,involves,Primary Myelofibrosis
NCT00931762,evaluates,Panobinostat
NCT00931762,measures_primary,Overall Response Rate
NCT00931762,measures_secondary,Change From Baseline
NCT00931762,has_criteria,IWG-MRT Criteria
NCT01083680,involves,Crohn's Disease
NCT01083680,measures_primary,CDAI score change
NCT01083680,measures_secondary,CDAI disease classification
NCT00614380,involves,Hypertension
NCT00614380,evaluates,Telmisartan
NCT00614380,evaluates,Amlodipine
NCT00614380,measures_primary,Trough Seated DBP Control
NCT00614380,measures_primary,Trough Seated SBP Control
NCT00614380,measures_secondary,Change From Baseline in Trough Seated Diastolic Blood Pressure
NCT00614380,measures_secondary,Change in DBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7
NCT00614380,measures_secondary,Change From Baseline in Trough Seated Systolic Blood Pressure
NCT00614380,measures_secondary,Change in SBP From Last Available Trough in 1235.5 to Last Available Trough in 1235.7
NCT00614380,measures_secondary,Trough Seated DBP Response
NCT00614380,measures_secondary,Trough Seated SBP Response
NCT00614380,measures_secondary,Trough Blood Pressure (BP) Normality Classes
NCT00614380,has_criteria,End of study (34 weeks or last value on treatment)
NCT02283762,involves,Systemic Sclerosis
NCT02283762,evaluates,Riociguat
NCT02283762,measures_primary,mRSS change
NCT02283762,measures_secondary,CRISS probability
NCT02283762,measures_secondary,HAQ-DI score
NCT02283762,has_criteria,Baseline to week 52
NCT04632862,involves,Type 2 Diabetes Mellitus
NCT04632862,evaluates,DWP16001
NCT04632862,measures_primary,HbA1c level
NCT04632862,measures_secondary,FPG level
NCT04632862,has_criteria,Adults aged 19 to 80 years
NCT04632862,has_criteria,HbA1c 7% to 10%
NCT04632862,has_criteria,BMI 20-45 kg/m2
NCT04632862,has_criteria,Stable diet and exercise
NCT04632862,has_criteria,Voluntary participation
NCT04632862,has_criteria,Not type 1 diabetes
NCT04632862,has_criteria,No stress urinary incontinence
NCT04632862,has_criteria,No severe diabetes complications
NCT04632862,has_criteria,eGFR >= 60 mL/min/1.73 m2
NCT03711162,involves,Idiopathic Pulmonary Fibrosis
NCT03711162,evaluates,GLPG1690
NCT03711162,measures_primary,Annual Rate of Decline in FVC
NCT03711162,measures_secondary,Percentage of Participants With Disease Progression
NCT03711162,measures_secondary,Percentage of Participants With Respiratory-Related Hospitalization
NCT03711162,measures_secondary,Change From Baseline in St.George's Respiratory Questionnaire Total Score
NCT03711162,has_criteria,Baseline up to week 52
NCT00860262,involves,Severe Hypertension
NCT00860262,evaluates,Telmisartan and Amlodipine Fixed Dose Combination
NCT00860262,measures_primary,Change From Baseline in SBP
NCT00860262,measures_secondary,Change From Baseline in DBP
NCT00860262,has_criteria,DBP \< 90mmHg
NCT00860262,has_criteria,SBP\< 140 mmHg
NCT04727580,involves,Impaired glucose tolerance
NCT04727580,evaluates,HSK7653
NCT04727580,measures_primary,Change From Baseline in Plasma Glucose AUC 0-3h
NCT04727580,measures_secondary,Change From Baseline in Insulin AUC 0-3h
NCT04727580,measures_secondary,Change From Baseline in C-peptide AUC 0-3h
NCT04727580,measures_secondary,Change From Baseline in Fasting Glucose
NCT04727580,measures_secondary,Change From Baseline in Fasting Insulin
NCT04727580,measures_secondary,Change From Baseline in Fasting C-peptide
NCT04727580,measures_secondary,Change From Baseline in HOMA-IS
NCT04727580,measures_secondary,Change From Baseline in HOMA-β
NCT04727580,measures_secondary,Change From Baseline in Hemoglobin A1c (HbA1c)
NCT04727580,measures_secondary,Change From Baseline in Plasma Glucose Area Under the Curve 0 to 3 Hours (AUC 0-3 Hrs) for Oral Glucose Tolerance Test (OGTT)
NCT04727580,measures_secondary,Incidence of Treatment-Emergent Adverse Events
NCT04727580,has_criteria,BMI in the range of ≥ 18.0 kg/m2 to ≤ 35.0 kg/m2
NCT04727580,has_criteria,Impaired glucose tolerance
NCT01016262,involves,Ulcerative Proctitis
NCT01016262,evaluates,MAX-002 Suppository
NCT01016262,measures_primary,Responders at Week 6
NCT01016262,measures_secondary,Time to Relief of Rectal Bleeding
NCT01016262,measures_secondary,Change From Baseline in IBDQ Score at Week 6
NCT01016262,has_criteria,Mayo DAI score less than 3
NCT01077362,involves,Psoriatic Arthritis
NCT01077362,evaluates,Ustekinumab
NCT01077362,measures_primary,ACR 20 Response
NCT01077362,measures_secondary,Disability Index Score
NCT01077362,has_criteria,Baseline Body Surface Area
NCT05100862,involves,Follicular Lymphoma
NCT05100862,involves,Marginal Zone Lymphoma
NCT05100862,evaluates,Zanubrutinib
NCT05100862,evaluates,Anti-CD20
NCT05100862,evaluates,Lenalidomide
NCT05100862,evaluates,Rituximab
NCT05100862,measures_primary,Progression-free Survival
NCT05100862,measures_secondary,Duration Of Response
NCT05100862,measures_secondary,Overall Response Rate
NCT05100862,measures_secondary,Complete Response Rate
NCT05100862,measures_secondary,Time To Response
NCT05100862,measures_secondary,Time to Next Ant-Lymphoma Treatment
NCT05100862,measures_secondary,Overall Survival
NCT05100862,measures_secondary,Health-related Quality Of Life
NCT05100862,has_criteria,Relapsed/Refractory
NCT00834262,involves,Type 2 Diabetes
NCT00834262,evaluates,Biphasic Insulin Aspart
NCT00834262,measures_primary,HbA1c change
NCT00834262,measures_secondary,Weight (BMI) change
NCT00834262,has_criteria,HbA1c greater than 7%
NCT00834262,has_criteria,insulin with or without OAD
NCT00834262,has_criteria,hypersensitivity to biphasic insulin aspart
NCT00834262,has_criteria,pregnancy or breastfeeding
NCT03976362,involves,Metastatic Squamous Non-small Cell Lung Cancer
NCT03976362,evaluates,Pembrolizumab
NCT03976362,evaluates,Olaparib
NCT03976362,measures_primary,Progression-free Survival
NCT03976362,measures_secondary,Overall Survival
NCT03976362,measures_secondary,Number of Adverse Events
NCT03976362,measures_secondary,Number of participants discontinuing study intervention
NCT03976362,measures_secondary,Change from Baseline in EORTC QLQ-C30 Global Health Status / Quality of Life
NCT03976362,has_criteria,Up to approximately 3 years
NCT03976362,has_criteria,Up to approximately 4 years
NCT03976362,has_criteria,Up to approximately 5 years
NCT04607980,involves,Plaque Psoriasis
NCT04607980,evaluates,ABP 654
NCT04607980,measures_primary,PASI Percent Change
NCT04607980,measures_secondary,PASI 75 Response
NCT04607980,has_criteria,Moderate to Severe
NCT03324880,involves,Hypoparathyroidism
NCT03324880,evaluates,rhPTH(1-84)
NCT03324880,measures_primary,Symptom Subscale Score
NCT03324880,measures_secondary,FACIT-Fatigue Score
NCT03324880,measures_secondary,Physical Component Summary
NCT01867762,involves,Chronic Obstructive Pulmonary Disease
NCT01867762,evaluates,JNJ 49095397
NCT01867762,measures_primary,Change From Baseline in FEV1
NCT01867762,measures_secondary,Rescue Medication Use
NCT01867762,measures_secondary,E-RS
NCT01867762,measures_secondary,SGRQ-C
NCT01867762,has_criteria,Baseline (Week 0) to Week 12
NCT03232281,involves,Endometriosis
NCT03232281,evaluates,Triptorelin Pamoate PR 3-month
NCT03232281,evaluates,Triptorelin Acetate PR 1-month
NCT03232281,measures_primary,Percentage of Subjects Castrated
NCT03232281,measures_secondary,Endometriosis-associated Pelvic Pain
NCT03232281,has_criteria,serum oestradiol (E2) ≤184 pmol/L or 50 pg/mL
NCT03819881,involves,Multi-Sensitized Allergic Subjects
NCT03819881,evaluates,STMC-103H
NCT03819881,measures_primary,Incidence of abnormal laboratory test results
NCT03819881,measures_secondary,Change in blood pressure
NCT03819881,measures_secondary,Change in respiration rate
NCT03819881,measures_secondary,Change in heart rate
NCT03819881,has_criteria,Voluntary informed consent
NCT03896581,involves,Psoriatic Arthritis
NCT03896581,evaluates,Bimekizumab
NCT03896581,measures_primary,Change From Baseline in HAQ-DI
NCT03896581,measures_secondary,ACR50 response rate
NCT03896581,has_criteria,≥ 50% improvement
NCT03441581,involves,Bile Acid Malabsorption
NCT03441581,evaluates,Eluxadoline
NCT03441581,measures_primary,Change in BSFS Score
NCT03441581,measures_secondary,Treatment-Emergent Adverse Events
NCT03441581,measures_secondary,Potentially Clinically Significant Change in Laboratory Tests
NCT03441581,measures_secondary,Potentially Clinically Significant Change in Vital Signs
NCT03441581,measures_secondary,Clinically Significant Change in General Physical Condition
NCT03441581,has_criteria,Baseline (Day 1) to Week 4
NCT06599710,involves,Colorectal Cancer
NCT06599710,evaluates,AndoSanTM
NCT06599710,measures_primary,cancer-related fatigue
NCT06599710,measures_secondary,Health-related QoL
NCT06599710,has_criteria,6 weeks IP intake
NCT01090310,involves,Quiescent Non-infectious Uveitis
NCT01090310,evaluates,AIN457
NCT01090310,measures_primary,Time to first recurrence
NCT01090310,measures_secondary,Change in Vitreous Haze Score
NCT01090310,measures_secondary,Mean Change in BCVA
NCT01090310,has_criteria,≥ 2 step increase in vitreous haze
NCT04577781,involves,Rheumatoid Arthritis
NCT04577781,evaluates,GLPG3970
NCT04577781,measures_primary,DAS28 (CRP)
NCT04577781,measures_secondary,Treatment Emergent Adverse Events
NCT04577781,has_criteria,Inadequate Response to Methotrexate
NCT01009281,involves,Crohn's Disease
NCT01009281,evaluates,AIN457
NCT01009281,measures_primary,Change From Baseline
NCT01009281,measures_secondary,Interleukin 17
NCT01009281,measures_secondary,Fecal Calprotectin
NCT01009281,measures_secondary,Lactoferrin
NCT01009281,measures_secondary,C-Reactive Protein
NCT01009281,has_criteria,Patients who participate
NCT01009281,has_criteria,treating physician
NCT01009281,has_criteria,protocol violation
NCT01009281,has_criteria,discontinued before Visit 8
NCT05203510,involves,Pulmonary Arterial Hypertension
NCT05203510,evaluates,Treprostinil
NCT05203510,measures_primary,RVEF at Month 12
NCT05203510,measures_secondary,mPAP at Month 12
NCT05203510,measures_secondary,Clinical Improvement
NCT05203510,has_criteria,6MWD increase
NCT05203510,has_criteria,WHO FC
NCT05203510,has_criteria,NT-proBNP decrease
NCT03933410,involves,Urea Cycle Disorder
NCT03933410,evaluates,KB195
NCT03933410,measures_primary,fasting plasma ammonia reduction
NCT03933410,measures_secondary,adverse events
NCT03933410,measures_secondary,severe adverse events
NCT03933410,measures_secondary,Gastrointestinal Tolerability Questionnaire
NCT03933410,measures_secondary,Bristol Stool Scale
NCT03933410,has_criteria,signed informed consent
NCT03933410,has_criteria,confirmed UCD
NCT03933410,has_criteria,age 12 to 70 years
NCT03933410,has_criteria,BMI 20.0 to 40.0 kg/m2
NCT03933410,has_criteria,poorly controlled disease
NCT04929210,involves,Ankylosing Spondylitis
NCT04929210,evaluates,Guselkumab
NCT04929210,measures_primary,BASDAI Score at Week 24
NCT04929210,measures_primary,ASDAS-CRP at Week 24
NCT04929210,measures_primary,DAPSA at Week 24
NCT04929210,has_criteria,Bio-naive Participants
NCT04291781,involves,IgA nephropathy
NCT04291781,evaluates,RC18
NCT04291781,measures_primary,urine protein excretion
NCT04291781,measures_secondary,eGFR
NCT04291781,measures_secondary,urine protein/creatine ratio
NCT04291781,measures_secondary,urine albumin/creatine ratio
NCT04291781,measures_secondary,Immunoglobulin G
NCT04291781,measures_secondary,Immunoglobulin M
NCT04291781,measures_secondary,Immunoglobulin A
NCT04291781,measures_secondary,urine red blood cells
NCT04291781,measures_secondary,B-lymphocytes
NCT04291781,measures_secondary,complement 3
NCT04291781,measures_secondary,complement 4
NCT04291781,has_criteria,24-hour urine protein excretion
NCT04291781,has_criteria,eGFR
NCT04291781,has_criteria,age 18-70 years
NCT04291781,has_criteria,ACEI/ARB treatment
NCT06264310,involves,Worsening Heart Failure
NCT06264310,evaluates,R2R01
NCT06264310,measures_primary,Change from Baseline on NT-pro-BNP
NCT06264310,measures_secondary,Cystatin C
NCT06264310,measures_secondary,Creatinine clearance
NCT06264310,measures_secondary,Number of patients requiring dose adjustment of oral diuretics
NCT06264310,measures_secondary,Number of patients with an event of: WHF-induced SDAC or other outpatient clinic visits requiring additional intensification of the therapy/IV loop diuretics
NCT06264310,measures_secondary,Number of cardiovascular hospitalizations
NCT06264310,has_criteria,Dose levels of R2R01
NCT01000610,involves,Rheumatoid Arthritis
NCT01000610,evaluates,MabThera
NCT01000610,measures_primary,DAS28 improvement
NCT01000610,measures_secondary,Bone Density
NCT01000610,has_criteria,Inadequate response to Methotrexate
NCT05233410,involves,Chronic Hand Eczema
NCT05233410,evaluates,Topical Ruxolitinib
NCT05233410,measures_primary,IGA-CHE-TS
NCT05233410,measures_secondary,Itch NRS score
NCT05233410,measures_secondary,Skin Pain NRS score
NCT05233410,measures_secondary,mTLSS
NCT05233410,has_criteria,Baseline to Week 32
NCT01852110,involves,Alzheimer's Disease
NCT01852110,evaluates,MK-7622
NCT01852110,measures_primary,Change From Baseline
NCT01852110,measures_secondary,Number of Participants
NCT01852110,has_criteria,Baseline and week 12
NCT02421510,involves,Type 1 Diabetes Mellitus
NCT02421510,evaluates,Sotagliflozin
NCT02421510,measures_primary,Change From Baseline in A1C
NCT02421510,measures_secondary,Percentage of Participants With A1C <7.0%
NCT02421510,measures_secondary,Change From Baseline in Body Weight
NCT02421510,measures_secondary,Change From Baseline in Mean Daily Bolus Insulin Dose
NCT02421510,has_criteria,Inadequate Glycemic Control
NCT04530344,involves,Vitiligo
NCT04530344,evaluates,Ruxolitinib Cream
NCT04530344,measures_primary,Time to Relapse
NCT04530344,measures_secondary,Loss of Adequate Response
NCT04530344,measures_secondary,Percentage of Participants Achieving a ≥50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score During the Extension Treatment Period
NCT04530344,has_criteria,<75% improvement from Baseline in the Face Vitiligo Area Scoring Index score (F-VASI75) response
NCT00760344,involves,Type 2 Diabetes Mellitus
NCT00760344,evaluates,SYR-472
NCT00760344,measures_primary,Change in glycosylated hemoglobin
NCT00760344,measures_secondary,Fasting plasma glucose
NCT00760344,measures_secondary,1
NCT00760344,measures_secondary,Proinsulin
NCT00760344,measures_secondary,Insulin
NCT00760344,measures_secondary,Proinsulin/insulin ratio
NCT00760344,measures_secondary,C-peptide
NCT00760344,measures_secondary,Homeostasis model assessment of insulin resistance
NCT00760344,measures_secondary,Homeostasis model assessment of beta-cell function
NCT00760344,measures_secondary,Incidence of marked hyperglycemia
NCT00760344,measures_secondary,Incidence of rescue
NCT00760344,measures_secondary,Glycosylated hemoglobin less than or equal to 6.5%
NCT00760344,measures_secondary,Glycosylated hemoglobin less than or equal to 7.0%
NCT00760344,measures_secondary,Fasting lipids
NCT00760344,measures_secondary,Body weight
NCT00760344,has_criteria,historical diagnosis of type 2 diabetes mellitus
NCT00760344,has_criteria,less than 7 days of antidiabetic therapy
NCT00760344,has_criteria,metformin monotherapy for at least 8 weeks
NCT00760344,has_criteria,stable daily dose of metformin for at least 12 weeks
NCT01294644,involves,Submental Fat
NCT01294644,evaluates,Deoxycholic Acid Injection
NCT01294644,measures_primary,CR-SMFRS 1-grade Response
NCT01294644,measures_secondary,CR-SMFRS 2-grade Response
NCT01294644,measures_secondary,SSRS Response
NCT01294644,measures_secondary,Change From Baseline in CR-SMFRS Score
NCT01294644,has_criteria,Baseline and 12 weeks after last treatment
NCT02952092,involves,Chronic Kidney Disease
NCT02952092,involves,Anemia
NCT02952092,evaluates,ASP1517
NCT02952092,measures_primary,Change from baseline Hb
NCT02952092,measures_secondary,Proportion of participants with target Hb level
NCT02952092,measures_secondary,Rate of rise in Hb levels
NCT02952092,has_criteria,Hemodialysis patients
NCT02735044,involves,Type 1 Diabetes Mellitus
NCT02735044,evaluates,HOE901-U300
NCT02735044,evaluates,Lantus
NCT02735044,measures_primary,Change From Baseline in HbA1c
NCT02735044,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT02735044,measures_secondary,Percentage of Participants With HbA1c Values of <7.5% at Month 6
NCT02735044,measures_secondary,Percentage of Participants With HbA1c Values of <7.5% Without Any Episode of Severe and/or Documented Self-Monitored Plasma Glucose ([SMPG] <54 mg/dL [3.0 mmol/L]) Symptomatic Hypoglycemia During the Last 3 Months of the Main 6-month Randomized Period
NCT02735044,has_criteria,premature study discontinuation
NCT02833844,involves,Human Immunodeficiency Virus
NCT02833844,involves,Hyperlipidemia
NCT02833844,involves,Mixed Dyslipidemia
NCT02833844,evaluates,Evolocumab
NCT02833844,measures_primary,Change From Baseline in LDL-C
NCT02833844,measures_secondary,Percentage of Participants Acheiving LDL-C < 70 mg/dL
NCT02833844,measures_secondary,Percentage of Participants With an LDL-C Response
NCT02833844,measures_secondary,Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol
NCT02833844,measures_secondary,Percent Change From Baseline in Apolipoprotein B
NCT02833844,measures_secondary,Percent Change From Baseline in Total Cholesterol
NCT03882892,involves,Hypercholesterolemia
NCT03882892,evaluates,Ezetimibe
NCT03882892,evaluates,Atovastatin
NCT03882892,measures_primary,Percentage of Adverse Events
NCT03882892,measures_secondary,Percent Change in LDL-C
NCT03882892,measures_secondary,Percent Change in HDL-C
NCT03882892,measures_secondary,Percent Change in Triglyceride Levels
NCT03882892,measures_secondary,Percent Change in Total Cholesterol
NCT03882892,has_criteria,Successfully completed parent study
NCT03882892,has_criteria,Negative pregnancy test
NCT03882892,has_criteria,Effective birth control
NCT03882892,has_criteria,Stable hormone therapy
NCT03882892,has_criteria,Follow NCEP Step 1 diet
NCT03882892,has_criteria,Not discontinued from parent study
NCT03882892,has_criteria,No interfering conditions
NCT03882892,has_criteria,Not pregnant or lactating
NCT03882892,has_criteria,Not HIV positive
NCT05621044,involves,Obesity
NCT05621044,evaluates,Physical Activity Smartphone App
NCT05621044,measures_primary,Change from Baseline
NCT05621044,measures_secondary,Weight
NCT05621044,measures_secondary,Blood Pressure
NCT05621044,measures_secondary,Quality of Life
NCT05621044,measures_secondary,Dietary Habits
NCT05621044,has_criteria,African American Men
NCT06108544,involves,Plaque Psoriasis
NCT06108544,evaluates,TAK-279
NCT06108544,measures_primary,sPGA Clear/Almost Clear
NCT06108544,measures_secondary,PASI 75% Improvement
NCT06108544,measures_secondary,PASI-90 90% Improvement
NCT06108544,has_criteria,Moderate-to-severe
NCT01665144,involves,Secondary Progressive Multiple Sclerosis
NCT01665144,evaluates,Siponimod
NCT01665144,measures_primary,3-month Confirmed Disability Progression
NCT01665144,measures_secondary,T25W Worsening
NCT01665144,measures_secondary,Change From Baseline in T2 Lesion Volume
NCT01665144,has_criteria,Baseline
NCT00561392,involves,Alzheimer's Disease
NCT00561392,evaluates,Rivastigmine 10 cm^2 Patch
NCT00561392,measures_primary,MMSE Score at Week 24
NCT00561392,measures_secondary,Trail-making Test Part A Score at Week 24
NCT00561392,has_criteria,Baseline to Week 24
NCT00626392,involves,Dyslipidemia
NCT00626392,evaluates,Acetylsalicylic Acid
NCT00626392,measures_primary,Maximum Flushing Severity
NCT00626392,measures_secondary,Mean Flushing Severity
NCT00626392,has_criteria,18 years of age
NCT02057692,involves,Alagille Syndrome
NCT02057692,evaluates,LUM001
NCT02057692,measures_primary,Pruritus
NCT02057692,measures_secondary,Fasting Serum Bile Acid
NCT02057692,measures_secondary,Liver Enzyme Levels
NCT02057692,measures_secondary,Total and Direct Bilirubin Concentrations
NCT02057692,has_criteria,Diagnosis of Alagille Syndrome
NCT02057692,has_criteria,Evidence of cholestasis
NCT02057692,has_criteria,Moderate to severe pruritus
NCT02057692,has_criteria,Ability to understand and willingness to sign informed consent/assent prior to initiation of any study procedures
NCT02057692,has_criteria,Surgical disruption of the enterohepatic circulation
NCT02057692,has_criteria,Liver transplant
NCT02057692,has_criteria,History or presence of other concomitant liver disease
NCT02057692,has_criteria,Females who are pregnant or lactating
NCT02057692,has_criteria,Known HIV infection
NCT01172444,involves,Ulcerative Proctitis
NCT01172444,evaluates,Mesalamine
NCT01172444,measures_primary,DAI score difference
NCT01172444,measures_secondary,Improvement
NCT01172444,has_criteria,Adults 18-65 years
NCT02549092,involves,Parkinson's Disease
NCT02549092,evaluates,Levodopa-Carbidopa Intestinal Gel
NCT02549092,evaluates,Optimized Medical Treatment
NCT02549092,measures_primary,NMSS Total Score
NCT02549092,measures_primary,Modified PDSS-2 Total Score
NCT02549092,measures_primary,PDQ-8 Summary Index Score
NCT02549092,has_criteria,Advanced Parkinson's Disease
NCT05761444,involves,very high-risk patients
NCT05761444,evaluates,ezetimibe with atorvastatin
NCT05761444,measures_primary,LDL-C change from baseline
NCT05761444,measures_secondary,LDL-C goal achievement
NCT05761444,measures_secondary,HDL-C change
NCT05761444,measures_secondary,non-HDL-C change
NCT05761444,measures_secondary,triglycerides change
NCT05761444,measures_secondary,total cholesterol change
NCT05761444,measures_secondary,TEAEs
NCT05761444,has_criteria,6 weeks
NCT05761444,has_criteria,12 weeks
NCT01550744,involves,Plaque Psoriasis
NCT01550744,evaluates,Ustekinumab
NCT01550744,measures_primary,Static PGA score
NCT01550744,measures_secondary,PASI 75 Response
NCT01550744,has_criteria,Moderate-to-Severe
NCT04675944,evaluates,BIA 5-1058
NCT04675944,measures_primary,Cmax
NCT04675944,measures_primary,AUC0-t
NCT04675944,measures_primary,AUC0-inf
NCT04675944,measures_primary,Cmax
NCT04675944,measures_primary,AUC0-τ
NCT04675944,has_criteria,Informed consent
NCT04675944,has_criteria,Age 18-45 years
NCT04675944,has_criteria,Healthy status
NCT02667444,involves,Acne
NCT02667444,evaluates,SB204
NCT02667444,evaluates,Vehicle Gel
NCT02667444,measures_primary,Inflammatory Lesion Count
NCT02667444,measures_secondary,Non-inflammatory Lesion Count
NCT02667444,measures_secondary,Investigator Global Assessment
NCT02667444,measures_secondary,Time to Reduction in Inflammatory Lesion Count
NCT02667444,has_criteria,Baseline and Week 12
NCT02471144,involves,Plaque Psoriasis
NCT02471144,measures_primary,PASI 75
NCT02471144,measures_secondary,IGA Mod 2011 Response
NCT01483144,involves,Familial Adenomatous Polyposis
NCT01483144,evaluates,Eflornithine Plus Sulindac
NCT01483144,measures_primary,Improvement in Investigator Upper GI Assessment
NCT01483144,measures_primary,Global assessment of change in upper GI polyp burden
NCT01483144,measures_secondary,Improvement in Investigator Lower GI Assessment
NCT01483144,measures_secondary,Global assessment of change in lower GI polyp burden
NCT01483144,has_criteria,Diagnosis of phenotypic classical FAP
NCT01483144,has_criteria,Adenomatous polyposis coli (APC) mutation
NCT01483144,has_criteria,100's to 1
NCT03100344,involves,Atopic Dermatitis
NCT03100344,evaluates,Nemolizumab
NCT03100344,measures_primary,EASI at Week 24
NCT03100344,measures_secondary,Pruritus Categorical Scale Success
NCT03100344,measures_secondary,Peak Pruritus Numeric Rating Scale
NCT03100344,measures_secondary,SCORAD at Week 24
NCT03100344,has_criteria,Baseline to Week 24
NCT02239692,involves,Colon Cleansing
NCT02239692,evaluates,PICOPREP Tailored Dosing Schedule
NCT02239692,evaluates,PICOPREP Day-before Dosing Schedule
NCT02239692,measures_primary,Total Ottawa Scale
NCT02239692,measures_secondary,Ascending Colon Cleansing Responder Status
NCT02239692,measures_secondary,Frequency and Intensity of Adverse Events
NCT02239692,measures_secondary,Clinically Significant Changes in Vital Signs
NCT02239692,measures_secondary,Clinically Significant Changes in Laboratory Values
NCT02239692,has_criteria,Day 1 (day of colonoscopy)
NCT01975246,involves,Essential hypertension
NCT01975246,evaluates,Micamlo
NCT01975246,measures_primary,Change in DBP
NCT01975246,measures_primary,Change in SBP
NCT01975246,measures_secondary,Proportion of patients
NCT01975246,has_criteria,Mean seated DBP >=90 mmHg
NCT01975246,has_criteria,Mean seated DBP <=114 mmHg
NCT01975246,has_criteria,Mean seated SBP <=200 mmHg
NCT01975246,has_criteria,Age 20 years or older
NCT03627468,involves,Axillary Hyperhidrosis
NCT03627468,evaluates,BBI-4000 Gel
NCT03627468,measures_primary,HDSM-Ax-11 score
NCT03627468,measures_secondary,Local tolerability
NCT03627468,has_criteria,Safety subjects
NCT00085969,involves,Type 2 Diabetes Mellitus
NCT00085969,evaluates,Exenatide
NCT00085969,measures_primary,Change in HbA1c
NCT00085969,measures_secondary,Change in serum fructosamine concentration
NCT00085969,measures_secondary,Change in body weight
NCT00085969,measures_secondary,Change in fasting plasma glucose concentration
NCT00085969,measures_secondary,Change in postprandial blood glucose concentrations
NCT00085969,has_criteria,type 2 diabetes mellitus treated
NCT03897868,involves,Essential Hypertension
NCT03897868,evaluates,HCP1803
NCT03897868,measures_primary,Change in systolic blood pressure
NCT03897868,measures_secondary,Change in diastolic blood pressure
NCT03897868,measures_secondary,Blood pressure control
NCT03897868,measures_secondary,Proportion of responders
NCT03897868,has_criteria,Mean sitSBP 140 mmHg ≤ \< 180 mmHg
NCT03897868,has_criteria,Mean sitDBP \< 110 mmHg
NCT03897868,has_criteria,Difference in sitSBP > 20 mmHg
NCT03897868,has_criteria,Difference in sitDBP > 10 mmHg
NCT03897868,has_criteria,Difference in sitSBP ≥ 15 mmHg
NCT03897868,has_criteria,Mean sitSBP ≥ 180 mmHg
NCT03897868,has_criteria,Mean sitDBP ≥ 110 mmHg
NCT00824369,involves,HIV-1
NCT00824369,evaluates,UK-453
NCT00824369,measures_primary,HIV-1 RNA level
NCT00824369,measures_secondary,CD4+ Cell Count
NCT00824369,has_criteria,Previous study participation
NCT00824369,has_criteria,At least 18 years old
NCT00824369,has_criteria,Follow-up for 96 weeks
NCT00824369,has_criteria,Not in another trial
NCT00824369,has_criteria,Willing to be followed 12 months
NCT01724268,involves,Rheumatoid Arthritis
NCT01724268,evaluates,Corticosteroids
NCT01724268,evaluates,Anti TNF
NCT01724268,measures_primary,Disease activity score
NCT01724268,measures_secondary,HAQ Score
NCT01724268,has_criteria,Males or females aged 18 years or older
NCT01724268,has_criteria,2010 American College of Rheumatology/European League Against Rheumatism Criteria for Rheumatoid Arthritis
NCT01724268,has_criteria,Rheumatoid arthritis of < 2 years duration
NCT01724268,has_criteria,Active disease at the time of enrollment
NCT01724268,has_criteria,Modified Disease Activity Score ≥ 3.2
NCT01724268,has_criteria,Functional status of class I
NCT01724268,has_criteria,Methotrexate 25 mg weekly
NCT01724268,has_criteria,PPD negative or completed ≥1 month of latent TB treatment
NCT01724268,has_criteria,Normal Chest X-Ray
NCT01724268,has_criteria,Hepatitis B Negative
NCT01724268,has_criteria,Not on NSAID
NCT01498068,involves,Chronic Hepatitis C
NCT01498068,evaluates,Telaprevir
NCT01498068,measures_primary,HCV RNA levels
NCT01498068,measures_secondary,Virologic Failure
NCT01498068,has_criteria,Treatment-naive patients
NCT05419869,involves,Major Depressive Disorder
NCT05419869,evaluates,ALTO-100
NCT05419869,measures_primary,MADRS score change
NCT05419869,measures_secondary,CGI-S score change
NCT05419869,has_criteria,moderate to severe depression
NCT03760068,involves,type 1 diabetes mellitus
NCT03760068,evaluates,Mylan Insulin Aspart
NCT03760068,measures_primary,TEAR positive
NCT03760068,measures_secondary,Change in HbA1c
NCT03760068,measures_secondary,Change in Fasting Plasma Glucose
NCT03760068,measures_secondary,Change in Prandial Insulin Dose
NCT03760068,measures_secondary,Change in Basal Insulin Dose
NCT03760068,measures_secondary,Change in Total Daily Insulin Dose
NCT03760068,measures_secondary,Change in 7-point SMBG Profile
NCT03760068,has_criteria,written informed consent
NCT03760068,has_criteria,diagnosis of type 1 diabetes mellitus
NCT03760068,has_criteria,able and willing to comply
NCT03565068,involves,Schizophrenia
NCT03565068,evaluates,MK-8189
NCT03565068,measures_primary,AUC0-24hr
NCT03565068,measures_secondary,Adverse Events
NCT03565068,measures_secondary,Discontinuation
NCT02763969,involves,Psoriasis
NCT02763969,evaluates,BMS-986202
NCT02763969,measures_primary,psoriasis area
NCT02763969,measures_secondary,Severity index (PASI) score
NCT02763969,has_criteria,moderate to severe psoriasis
NCT03612869,involves,Mucopolysaccharidosis Type IIIA
NCT03612869,evaluates,AAVrh10-h.SGSH Gene Therapy
NCT03612869,measures_primary,Change in DQ
NCT03612869,measures_secondary,Adaptive behavior
NCT03612869,measures_secondary,Sleep pattern
NCT03612869,has_criteria,Age and ability
NCT01876368,involves,Essential Hypertension
NCT01876368,evaluates,LCZ696
NCT01876368,evaluates,Olmesartan
NCT01876368,measures_primary,Change From Baseline in maSBP
NCT01876368,measures_primary,Change From Baseline in maDBP
NCT01876368,measures_secondary,Change From Baseline in msSBP
NCT01876368,measures_secondary,Change From Baseline in msDBP
NCT01876368,measures_secondary,Change From Baseline in Office Pulse Pressure
NCT01876368,has_criteria,Successful overall blood pressure control
NCT02627768,involves,Psoriatic Arthritis
NCT02627768,evaluates,STELARA
NCT02627768,evaluates,Tumor Necrosis Factor Alpha Inhibitor Therapies
NCT02627768,measures_primary,Time to Drug Stop
NCT02627768,measures_secondary,Change From Baseline in DAS28
NCT02627768,measures_secondary,Change From Baseline in DAPSA Scores
NCT02627768,has_criteria,Baseline and Month 36
NCT05218668,involves,Amyotrophic Lateral Sclerosis
NCT05218668,evaluates,Rho Kinase Inhibitor
NCT05218668,measures_primary,ALSFRS-R slope
NCT05218668,measures_secondary,Slow Vital Capacity
NCT05218668,has_criteria,predicted SVC
NCT01782469,involves,Rheumatoid Arthritis
NCT01782469,evaluates,Adalimumab
NCT01782469,measures_primary,Mean Change in Synovitis
NCT01782469,measures_secondary,Number of Joints With Detected Erosions
NCT01782469,measures_secondary,Percentage of Participants Who Achieved ≥ 20% Improvement in Both Tender Joint Count (TJC) and Swollen Joint Count (SJC)
NCT01782469,measures_secondary,Mean Change in Health Assessment Questionnaire (HAQ) Score
NCT01782469,has_criteria,Baseline (Visit 1) to 13 weeks
NCT00881868,involves,Plaque Psoriasis
NCT00881868,evaluates,Clobetasol Propionate Spray
NCT00881868,evaluates,Vehicle Spray
NCT00881868,measures_primary,Global Severity Score
NCT00881868,measures_secondary,Scalp Psoriasis Individual Sign Scores
NCT00881868,measures_secondary,Extent of Scalp Involvement Index
NCT00881868,measures_secondary,Pruritus
NCT00881868,has_criteria,GSS is Clear
NCT02505568,involves,Intestinal Behcet's Disease
NCT02505568,evaluates,Infliximab
NCT02505568,measures_primary,DAIBD Score at Week 8
NCT02505568,measures_secondary,Clinical Response by DAIBD
NCT02505568,measures_secondary,Crohn's Disease Activity Index (CDAI) 70 Response
NCT02505568,has_criteria,Participant With Moderate-to-Severe Refractory
NCT05343468,involves,Down syndrome
NCT05343468,evaluates,Assistive Technology
NCT05343468,measures_primary,Adaptive Behavior
NCT05343468,measures_secondary,Quality of Life
NCT05343468,has_criteria,Age 7-17
NCT03178669,involves,Ulcerative Colitis
NCT03178669,evaluates,Cobitolimod
NCT03178669,measures_primary,Clinical Remission
NCT03178669,measures_secondary,Modified Clinical Remission
NCT03178669,has_criteria,Age ≥ 18 years old
NCT03178669,has_criteria,Established diagnosis of Ulcerative Colitis
NCT03178669,has_criteria,Moderately to severely active left sided UC
NCT03178669,has_criteria,Current oral 5-Aminosalicylic Acid (5-ASA)/ Sulphasalazine (SP) use
NCT02474069,involves,Plaque-type Psoriasis
NCT02474069,evaluates,Secukinumab
NCT02474069,measures_primary,PASI 90 Response
NCT02474069,measures_secondary,improvement from baseline
NCT02474069,has_criteria,PASI 50
NCT03358329,involves,Chronic Sinusitis
NCT03358329,involves,Nasal Polyps
NCT03358329,evaluates,S8 Sinus Implant
NCT03358329,measures_primary,SNOT-22 Total Score
NCT03358329,measures_secondary,Nasal Obstruction/Congestion Score
NCT03358329,has_criteria,365 days
NCT00087529,involves,Primary Progressive Multiple Sclerosis
NCT00087529,evaluates,Rituximab
NCT00087529,measures_primary,Time to CDP
NCT00087529,measures_secondary,Percentage of Participants With CDP
NCT00087529,has_criteria,Disease progression
NCT03315780,involves,Type 2 Diabetes
NCT03315780,evaluates,Dulaglutide
NCT03315780,measures_primary,Glucose AUC 0-4h change
NCT03315780,measures_secondary,Fasting Blood Glucose
NCT03315780,measures_secondary,Postprandial Blood Glucose
NCT03315780,measures_secondary,Insulin AUC 0-4h change
NCT03315780,measures_secondary,C-Peptide AUC 0-4h change
NCT03315780,measures_secondary,Glucagon AUC 0-4h change
NCT03315780,has_criteria,Baseline
NCT05807529,involves,Knee Osteoarthritis
NCT05807529,evaluates,2ccPA
NCT05807529,measures_primary,WOMAC score
NCT05807529,measures_secondary,Pain NRS
NCT05807529,has_criteria,single ascending dose
NCT00408629,involves,Ulcerative Colitis
NCT00408629,evaluates,Adalimumab
NCT00408629,measures_primary,Clinical Remission
NCT00408629,measures_secondary,Clinical Response
NCT00408629,has_criteria,Mayo Score
NCT03461380,involves,menopausal female climacteric states
NCT03461380,evaluates,Menopause Relief EP-40
NCT03461380,measures_primary,change in KMI
NCT03461380,measures_primary,change in MRS
NCT03461380,has_criteria,menopausal syndrome
NCT05417880,involves,Type Two Diabetes Mellitus
NCT05417880,evaluates,Vitamin D
NCT05417880,measures_primary,Mean change in HbA1c
NCT05417880,measures_secondary,Fasting Blood Sugar
NCT05417880,measures_secondary,Random Blood Sugar
NCT05417880,measures_secondary,Hypotension
NCT05417880,measures_secondary,Dehydration
NCT05417880,measures_secondary,Urinary Tract Infection
NCT05417880,measures_secondary,Diabetic Ketoacidosis
NCT05417880,measures_secondary,Fungal infections
NCT05417880,measures_secondary,Mean change on body weight
NCT05417880,measures_secondary,Blood Pressure change
NCT05417880,measures_secondary,Total Cholesterol
NCT05417880,measures_secondary,High Density Lipoprotein
NCT05417880,measures_secondary,Low Density Lipoprotein
NCT05417880,measures_secondary,Triglycerides
NCT00395629,involves,Hereditary Hemochromatosis
NCT00395629,evaluates,Deferasirox
NCT00395629,measures_primary,Serum Ferritin Change
NCT00395629,measures_secondary,Deferasirox Trough Concentrations
NCT00395629,has_criteria,0 to 48 weeks
NCT05139680,involves,Mixed Phenotype Hereditary Transthyretin Amyloidosis
NCT05139680,evaluates,Tafamidis
NCT05139680,measures_primary,Neurologic Disease Progression
NCT05139680,measures_secondary,Walking Capacity
NCT05139680,has_criteria,at least 6 months
NCT02522780,involves,Ulcerative Colitis
NCT02522780,evaluates,Mesalamine
NCT02522780,measures_primary,Proportion of Remission
NCT02522780,measures_secondary,Time to Relapse
NCT02522780,has_criteria,escalation of therapy
NCT06396429,involves,Overweight
NCT06396429,involves,Obese
NCT06396429,evaluates,HRS9531
NCT06396429,evaluates,Placebo
NCT06396429,measures_primary,Weight change after 48 weeks
NCT06396429,measures_secondary,Weight loss ≥5%
NCT06396429,measures_secondary,Weight loss ≥10%
NCT06396429,measures_secondary,Weight loss ≥15%
NCT06396429,measures_secondary,Waist circumference change
NCT06396429,measures_secondary,BMI change
NCT06396429,measures_secondary,Systolic blood pressure change
NCT06396429,measures_secondary,Diastolic blood pressure change
NCT06396429,measures_secondary,Total Cholesterol change
NCT06396429,measures_secondary,LDL Cholesterol change
NCT06396429,measures_secondary,Triglycerides change
NCT06396429,measures_secondary,HDL Cholesterol change
NCT06396429,measures_secondary,Fasting plasma glucose change
NCT06396429,measures_secondary,Glycosylated haemoglobin change
NCT06396429,measures_secondary,Fasting serum insulin change
NCT06396429,measures_secondary,SF-36 V2 scores change
NCT06396429,measures_secondary,Number of AEs
NCT06396429,has_criteria,BMI≥28.0 Kg/m2
NCT06396429,has_criteria,≥18 years of age
NCT06396429,has_criteria,weight-related comorbidity
NCT01054729,involves,Hepatitis C
NCT01054729,evaluates,Sofosbuvir
NCT01054729,measures_primary,HCV RNA at Week 4
NCT01054729,measures_secondary,Rapid virologic response
NCT01054729,measures_secondary,Sustained Virologic Response
NCT01054729,has_criteria,Treatment Naïve GT 1 HCV
NCT01072929,involves,Major Depression
NCT01072929,involves,Bipolar I Disorder
NCT01072929,evaluates,Armodafinil
NCT01072929,measures_primary,Change from baseline
NCT01072929,measures_secondary,Percentage of Responders
NCT01072929,measures_secondary,Percentage in Remission
NCT01072929,has_criteria,Adults
NCT04072380,involves,Narcolepsy With or Without Cataplexy
NCT04072380,evaluates,SUVN-G3031 (Samelisant)
NCT04072380,measures_primary,Change from baseline in the mean total ESS score at Day 14
NCT04072380,measures_secondary,Change from baseline in the mean CGI-S score at Day 14
NCT04072380,measures_secondary,Change from baseline in the mean MWT score at Day 14
NCT04072380,has_criteria,Ages 18 to 65 years
NCT04072380,has_criteria,Narcolepsy with or without cataplexy
NCT04072380,has_criteria,MSLT of ≤ 8 minutes
NCT04072380,has_criteria,ESS score of ≥ 12
NCT04072380,has_criteria,mean MWT time of \< 12 min
NCT04072380,has_criteria,Body mass index 18 to \< 45 kg/m2
NCT04072380,has_criteria,Negative urine drug screen
NCT04072380,has_criteria,Not of childbearing potential or highly effective birth control
NCT02577029,involves,Chronic Hepatitis B Virus
NCT02577029,evaluates,ARC-520 Injection
NCT02577029,measures_primary,HBsAg reduction at Week 60
NCT02577029,measures_secondary,HBsAg loss
NCT02577029,measures_secondary,Anti-HBs seroconversion
NCT02577029,has_criteria,first dose of study drug
NCT03711929,involves,Uveitis
NCT03711929,evaluates,DE-109 Sirolimus
NCT03711929,measures_primary,Vitreous Haze 0 response
NCT03711929,measures_secondary,Composite Score
NCT03711929,has_criteria,rescue therapies
NCT02612129,involves,Niemann-Pick Disease Type C
NCT02612129,evaluates,Arimoclomol
NCT02612129,measures_primary,Percentage of Responders
NCT02612129,measures_secondary,5-domain NPCCSS
NCT02612129,has_criteria,Baseline to Month 12
NCT01767129,involves,Parkinson's Disease
NCT01767129,involves,Levodopa-induced Dyskinesia
NCT01767129,evaluates,AVP-923
NCT01767129,measures_primary,Dyskinesia Severity AUC
NCT01767129,measures_secondary,Disability AUC
NCT01767129,has_criteria,Levodopa infusion
NCT03760029,involves,Duchenne Muscular Dystrophy
NCT03760029,evaluates,Northstar Ambulatory Assessment (NSAA)
NCT03760029,measures_primary,Age at failure to walk
NCT03760029,measures_primary,Age at failure to stand
NCT03760029,measures_primary,Age at failure to self-feed
NCT03760029,measures_secondary,Change From Baseline in Northstar Ambulatory Assessment (NSAA) Total Score at Month 6
NCT03760029,has_criteria,Ambulatory Participants Aged >=3 Years
NCT03623529,involves,Hypotension Associated With Distributive or Vasodilatory Shock
NCT03623529,evaluates,LJPC-501
NCT03623529,measures_primary,norepinephrine equivalent doses
NCT03623529,measures_secondary,PELOD-2 score
NCT03623529,measures_secondary,catecholamine doses
NCT03623529,measures_secondary,mean arterial pressure
NCT03623529,measures_secondary,heart rate
NCT03623529,has_criteria,catecholamine-resistant hypotension
NCT03623529,has_criteria,> 2 years of age
NCT03623529,has_criteria,< 18 years of age
NCT02927080,involves,Facioscapulohumeral Muscular Dystrophy
NCT02927080,evaluates,ACE-083
NCT02927080,measures_primary,Total Muscle Volume
NCT02927080,measures_secondary,Percent Change of TMV
NCT02927080,has_criteria,Patients With FSHD
NCT04923204,involves,Bipolar Depression
NCT04923204,evaluates,NEUROPHARMAGEN
NCT04923204,measures_primary,Clinical Global Impression
NCT04923204,measures_secondary,Hamilton Rating Scale
NCT04923204,measures_secondary,Functioning Assessment Short Test
NCT04923204,has_criteria,current status after end of index episode
NCT02087904,involves,Knee Osteoarthritis
NCT02087904,evaluates,ABT-981
NCT02087904,measures_primary,Change From Baseline
NCT02087904,measures_secondary,Quantitative Synovitis
NCT02087904,measures_secondary,Effusion Volume
NCT02087904,measures_secondary,WORMS Semi-Quantitative
NCT02087904,has_criteria,Baseline
NCT02087904,has_criteria,Baseline
NCT02087904,has_criteria,Baseline
NCT02087904,has_criteria,Baseline
NCT02087904,has_criteria,Baseline
NCT02133001,involves,Major Depressive Disorder
NCT02133001,evaluates,Intranasal Esketamine
NCT02133001,measures_primary,Change From Baseline
NCT02133001,measures_secondary,Percentage of Participants
NCT02133001,has_criteria,Imminent Risk for Suicide
NCT04872101,involves,Chronic hand eczema
NCT04872101,evaluates,Delgocitinib Cream
NCT04872101,measures_primary,IGA-CHE TS at Week 16
NCT04872101,measures_primary,IGA-CHE TS at Week 8
NCT04872101,measures_primary,IGA-CHE TS at Week 4
NCT04872101,measures_secondary,Reduction of HESD Itch Score
NCT00814801,involves,Alzheimer's Disease
NCT00814801,evaluates,Galantamine
NCT00814801,measures_primary,Change From Baseline
NCT00814801,measures_secondary,Change From Baseline
NCT00814801,measures_secondary,Change From Baseline
NCT00814801,measures_secondary,Change From Baseline
NCT00814801,has_criteria,Baseline and 24 weeks
NCT06344104,involves,Hypertension
NCT06344104,evaluates,Baxdrostat
NCT06344104,measures_primary,seated SBP at Week 12
NCT06344104,measures_secondary,ambulatory 24-hour SBP
NCT06344104,has_criteria,Inclusion Criter...
NCT00441701,involves,Chronic Obstructive Pulmonary Disease
NCT00441701,evaluates,Navarixin
NCT00441701,measures_primary,Change from Baseline
NCT00441701,measures_secondary,Pre-bronchodilator FEV1
NCT00441701,has_criteria,Moderate to Severe
NCT00985504,involves,Major Depressive Disorder
NCT00985504,involves,Apathy
NCT00985504,measures_primary,Change From Baseline in AES-C Total Score
NCT00985504,measures_secondary,Change From Baseline in AES-C Subscale Scores
NCT00985504,measures_secondary,Change From Baseline in RSAT Total and Individual Item Scores
NCT02902601,involves,Major Depressive Disorder
NCT02902601,evaluates,JNJ-54175446
NCT02902601,measures_primary,Depressive Symptoms
NCT02902601,measures_secondary,Biomarker Profiles
NCT02902601,has_criteria,2 to 8 hours post dose
NCT02528201,involves,Ankylosing Spondylitis
NCT02528201,evaluates,Celecoxib
NCT02528201,evaluates,Diclofenac
NCT02528201,measures_primary,Patient Global Assessment of Pain Intensity (VAS)
NCT02528201,measures_secondary,Bath Ankylosing Spondylitis Functional Index (BASFI)
NCT02528201,measures_secondary,Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
NCT02528201,measures_secondary,Participants and Physicians Global Assessment of Disease Activity
NCT02528201,measures_secondary,Participants and Physicians Global Assessment of Treatment
NCT02528201,has_criteria,Baseline
NCT02528201,has_criteria,Weeks 2
NCT02183701,involves,Essential Hypertension
NCT02183701,evaluates,Telmisartan
NCT02183701,evaluates,Losartan
NCT02183701,evaluates,Hydrochlorothiazide
NCT02183701,measures_primary,Diastolic blood pressure
NCT02183701,measures_primary,Systolic blood pressure
NCT02183701,measures_secondary,Pulse rate
NCT02183701,measures_secondary,Adverse events
NCT02183701,measures_secondary,Physical examination
NCT02183701,measures_secondary,Laboratory parameters
NCT02183701,measures_secondary,Electrocardiogram
NCT02183701,has_criteria,Diastolic blood pressure
NCT02183701,has_criteria,Systolic blood pressure
NCT02183701,has_criteria,Age 18 or older
NCT02183701,has_criteria,Informed consent
NCT02183701,has_criteria,Pre-menopausal women
NCT02183701,has_criteria,Surgical sterilization
NCT02183701,has_criteria,Birth control
NCT03202004,involves,Plaque Psoriasis
NCT03202004,evaluates,GSK2894512
NCT03202004,measures_primary,PGA score clear or almost clear
NCT03202004,measures_secondary,PASI improvement
NCT03202004,measures_secondary,itch/pruritus reduction
NCT03202004,has_criteria,>=3-point reduction
NCT00288704,involves,Familial Cold Auto-inflammatory Syndrome
NCT00288704,involves,Muckle-Wells Syndrome
NCT00288704,evaluates,rilonacept
NCT00288704,measures_primary,Key Symptom Score
NCT00288704,measures_secondary,Key Symptom Score
NCT00288704,has_criteria,adults age 18 and above
NCT00288704,has_criteria,diagnosed with FCAS or MWS
NCT00288704,has_criteria,documented NLRP-3 mutation
NCT01001104,involves,Type 2 Diabetes
NCT01001104,evaluates,LY2189265
NCT01001104,measures_primary,Change in HbA1c
NCT01001104,measures_secondary,Percentage of Participants Achieving HbA1c<7%
NCT01001104,measures_secondary,Percentage of Participants Achieving HbA1c<6.5%
NCT01001104,measures_secondary,Change From Baseline in Fasting Blood Glucose
NCT01001104,measures_secondary,Change From Baseline in the Mean Daily Blood Glucose
NCT01001104,measures_secondary,Change From Baseline in Total Body Weight
NCT01723904,involves,Parkinson's Disease
NCT01723904,evaluates,Rotigotine
NCT01723904,measures_primary,Change from Baseline
NCT01723904,measures_secondary,Activities in Daily Living
NCT01723904,has_criteria,Low doses Pramipexole
NCT01154101,involves,Plaque-Type Psoriasis
NCT01154101,evaluates,SRT2104
NCT01154101,measures_primary,Improvement Score
NCT01154101,measures_secondary,Adverse Events
NCT01154101,has_criteria,Krueger criteria
NCT00040404,involves,Parkinson's Disease
NCT00040404,evaluates,CEP-1347
NCT00040404,measures_primary,([123I]β-CIT) Uptake
NCT00040404,measures_secondary,Safety and Tolerability
NCT00040404,has_criteria,Age 30 years or older
NCT03625401,involves,Alzheimer's Disease
NCT03625401,evaluates,AD-35
NCT03625401,measures_primary,ADAS-cog 11 score
NCT03625401,measures_secondary,NPI score
NCT03625401,measures_secondary,ADCS-ADL score
NCT03625401,measures_secondary,CIBIC+ score
NCT03625401,measures_secondary,ADAS-cog 11 score
NCT03625401,has_criteria,probable AD
NCT03625401,has_criteria,Mini-Mental State Examination
NCT03625401,has_criteria,brain magnetic resonance imaging
NCT03625401,has_criteria,Aβ-based treatment
NCT03625401,has_criteria,tau-based treatment
NCT03625401,has_criteria,Acetyl cholinesterase inhibito...
NCT01523301,involves,Idiopathic Parkinson's Disease
NCT01523301,evaluates,Rotigotine
NCT01523301,measures_primary,Change From Baseline
NCT01523301,measures_secondary,Beck Depression Inventory
NCT01523301,measures_secondary,Unified Parkinson's Disease Rating Scale
NCT01523301,has_criteria,Maintenance Period
NCT00549601,involves,Alzheimer's Disease
NCT00549601,evaluates,Rivastigmine
NCT00549601,measures_primary,Percentage of Patients
NCT00549601,measures_secondary,Gastrointestinal Adverse Event
NCT00549601,measures_secondary,Skin Adverse Event
NCT00549601,measures_secondary,Overall Caregiver Satisfaction
NCT00549601,measures_secondary,Overall Patient Satisfaction
NCT00549601,has_criteria,Mild to Moderate
NCT01350804,involves,Rheumatoid Arthritis
NCT01350804,evaluates,Secukinumab
NCT01350804,measures_primary,ACR20 response
NCT01350804,measures_secondary,DAS28-CRP
NCT01350804,measures_secondary,HAQ-DI
NCT01350804,has_criteria,Inadequate response to Anti-TNFα agents
NCT01599104,involves,Essential Hypertension
NCT01599104,evaluates,LCZ696
NCT01599104,evaluates,Olmesartan
NCT01599104,measures_primary,Change From Baseline in msSBP
NCT01599104,measures_primary,Change From Baseline in maSBP
NCT01599104,measures_primary,Change From Baseline in maDBP
NCT01599104,measures_secondary,Percentage of Participants Achieving a Successful Response
NCT01599104,measures_secondary,Percentage of Participants Achieving a Successful msSBP Response
NCT01599104,measures_secondary,Percentage of Participants Achieving a Successful msDBP Response
NCT01599104,measures_secondary,Change From Baseline in maSBP and maDBP for Daytime/Nighttime
NCT01599104,has_criteria,Baseline
NCT02787304,involves,Nonalcoholic Steatohepatitis
NCT02787304,evaluates,Volixibat
NCT02787304,measures_primary,Binary response
NCT02787304,measures_secondary,Liver Histology
NCT02787304,measures_secondary,Hepatic Steatosis
NCT02787304,measures_secondary,Fibrosis stage
NCT02787304,has_criteria,Baseline
NCT02237001,involves,Torn Meniscus
NCT02237001,evaluates,Suture Repair
NCT02237001,measures_primary,Freedom From Re-operation
NCT02237001,measures_secondary,Change in Knee Pain
NCT02237001,has_criteria,Baseline
NCT00044668,involves,Type 2 Diabetes
NCT00044668,evaluates,AC2993
NCT00044668,measures_primary,Change in HbA1c
NCT00044668,measures_secondary,fasting plasma glucose
NCT00044668,measures_secondary,lipids
NCT00044668,has_criteria,metformin
NCT00044668,has_criteria,sulfonylurea
NCT00044668,has_criteria,BMI 25-45 kg/m\^2
NCT00044668,has_criteria,HbA1c 7.5 % - 12.0 %
NCT00764868,involves,Attention-Deficit/Hyperactivity Disorder
NCT00764868,evaluates,Vyvanse
NCT00764868,measures_primary,ADHD-RS-IV Total Score
NCT00764868,measures_secondary,Youth Quality of Life Instrument
NCT00764868,has_criteria,aged 13-17 years
NCT00411801,involves,Thrombotic Thrombocytopenic Purpura
NCT00411801,evaluates,Uniplas
NCT00411801,evaluates,Cryosupernatant Plasma
NCT00411801,measures_primary,Change in platelet count
NCT00411801,measures_secondary,Percentage of deaths
NCT00411801,measures_secondary,Complete response
NCT00411801,measures_secondary,Partial response
NCT00411801,measures_secondary,Non-response
NCT00411801,measures_secondary,Transient response
NCT00411801,measures_secondary,Plasma volume
NCT00411801,measures_secondary,Time to max platelet count
NCT00411801,has_criteria,Baseline to Month 1
NCT00411801,has_criteria,Baseline to Month 3
NCT00411801,has_criteria,Baseline to the end of the study
NCT01185340,involves,Major Depressive Disorder
NCT01185340,evaluates,Selective Serotonin Reuptake Inhibitor
NCT01185340,measures_primary,Change From Randomization to Week 8 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
NCT01185340,measures_secondary,Sheehan Disability Scale (SDS) Global Functional Impairment Score
NCT01185340,measures_secondary,Fatigue Associated With Depression (FAsD) Impact Subscale Score
NCT01185340,has_criteria,Partial Responders
NCT03014544,involves,Major Depressive Disorder
NCT03014544,evaluates,Computer-Administered Cognitive Test Battery
NCT03014544,measures_primary,Performance Score
NCT03014544,measures_secondary,Digit Span Forward
NCT03014544,measures_secondary,Digit Span Backward
NCT03014544,has_criteria,Up to Test Day 4
NCT04990440,involves,Atopic Dermatitis
NCT04990440,evaluates,Bermekimab
NCT04990440,measures_primary,EASI-75 response
NCT04990440,measures_secondary,Serum Bermekimab
NCT04990440,has_criteria,Adult participants
NCT02061540,involves,Primary Sclerosing Cholangitis
NCT02061540,evaluates,LUM001
NCT02061540,measures_primary,Fasting Serum Bile Acid Level
NCT02061540,measures_secondary,Liver Enzyme Levels in Serum
NCT02061540,measures_secondary,Bilirubin Levels
NCT02061540,measures_secondary,Pruritus as Measured by Adult Itch Reported Outcome (ItchRO) Weekly Sum Score
NCT02061540,has_criteria,treatment-emergent adverse events
NCT01544140,evaluates,Midazolam
NCT01544140,evaluates,Vandetanib
NCT01544140,measures_primary,AUC for midazolam
NCT01544140,measures_primary,Cmax for midazolam
NCT01544140,measures_secondary,Frequency and severity of adverse events
NCT01544140,measures_secondary,ECG data
NCT01544140,measures_secondary,Laboratory data
NCT01544140,measures_secondary,Vital signs data
NCT01544140,has_criteria,males or females aged 18 to 50 years
NCT01544140,has_criteria,weight of at least 50 kg
NCT01544140,has_criteria,BMI between 18 and 30 kg/m2
NCT01544140,has_criteria,negative pregnancy test
NCT01544140,has_criteria,non-childbearing potential
NCT01544140,has_criteria,no clinically significant disease
NCT01544140,has_criteria,no severe allergy/hypersensitivity
NCT01544140,has_criteria,no smoking more than 5 cigarettes per day
NCT01544140,has_criteria,screening blood pressure less than 140/90 mmHg
NCT05377944,involves,plaque-type psoriasis
NCT05377944,evaluates,BAT2306
NCT05377944,evaluates,Cosentyx
NCT05377944,measures_primary,Percent change PASI
NCT05377944,measures_secondary,PASI-50/75/90/100
NCT05377944,measures_secondary,Investigator's Global Assessment
NCT05377944,has_criteria,≥ 18 years old
NCT05377944,has_criteria,plaque-type psoriasis
NCT05377944,has_criteria,PASI ≥ 12
NCT05377944,has_criteria,IGA ≥ 3
NCT05377944,has_criteria,BSA ≥ 10%
NCT05377944,has_criteria,topical treatment
NCT05377944,has_criteria,phototherapy
NCT05377944,has_criteria,previous systemic therapy
NCT06649344,involves,Type 2 Diabetes
NCT06649344,evaluates,HRS9531
NCT06649344,evaluates,Semaglutide
NCT06649344,measures_primary,Change in HbA1c
NCT06649344,measures_secondary,Change in body weight
NCT06649344,measures_secondary,Proportion of Subjects with HbA1c≤6.5%
NCT06649344,measures_secondary,Proportion of Subjects with HbA1c<7%
NCT06649344,measures_secondary,Change in FPG
NCT06649344,measures_secondary,Incidence and severity of adverse events
NCT06649344,has_criteria,Week 0 to Week 32
NCT01412944,involves,Psoriasis
NCT01412944,evaluates,Secukinumab
NCT01412944,measures_primary,PASI 75 improvement
NCT01412944,measures_secondary,IGA Mod 2011 0 or 1
NCT01412944,has_criteria,Partial Response
NCT04804540,involves,Ulcerative Colitis
NCT04804540,involves,Crohn's Disease
NCT04804540,evaluates,Vedolizumab
NCT04804540,measures_primary,Clinical Response
NCT04804540,measures_secondary,Adverse Events
NCT04804540,measures_secondary,Serious Adverse Events
NCT04804540,measures_secondary,Adverse Events of Special Interest
NCT04804540,measures_secondary,Adverse Drug Reactions
NCT04804540,measures_secondary,Unexpected ADRs
NCT04804540,has_criteria,6 months after last dose
NCT01862640,involves,Alzheimer's agitation
NCT01862640,evaluates,Brexpiprazole
NCT01862640,measures_primary,CMAI total score
NCT01862640,measures_secondary,CGI-S score
NCT01862640,has_criteria,agitation associated with dementia
NCT05151744,involves,Diabetic Macular Edema
NCT05151744,evaluates,Vamikibart
NCT05151744,evaluates,Ranibizumab
NCT05151744,measures_primary,BCVA change
NCT05151744,measures_secondary,Systemic AEs
NCT05151744,measures_secondary,Ocular AEs
NCT05151744,measures_secondary,Abnormal lab findings
NCT05151744,measures_secondary,Abnormal vital signs
NCT05151744,measures_secondary,Abnormal ECG
NCT05151744,has_criteria,Treatment-naïve
NCT02265744,involves,Systemic Lupus Erythematosus
NCT02265744,evaluates,Biologic
NCT02265744,measures_primary,BICLA Response Rate
NCT02265744,measures_secondary,SLE Responder Index
NCT02265744,has_criteria,SLEDAI-2K score
NCT02534844,involves,Niemann-Pick Type C1 disease
NCT02534844,evaluates,VTS-270
NCT02534844,measures_primary,NPC-SS Total Score
NCT02534844,measures_secondary,Clinician Global Impression of Change
NCT02534844,has_criteria,Baseline
NCT01355367,involves,Hypertension
NCT01355367,evaluates,BAYA1040
NCT01355367,measures_primary,Diastolic blood pressure
NCT01355367,measures_secondary,Systolic blood pressure
NCT01355367,has_criteria,Tolerable test drug
NCT02387801,involves,Psoriasis
NCT02387801,evaluates,Ixekizumab
NCT02387801,measures_primary,PatGA Score
NCT02387801,measures_secondary,Itch NRS Score
NCT02387801,measures_secondary,DLQI
NCT02387801,measures_secondary,%BSA
NCT02387801,has_criteria,Moderate-to-Severe
NCT01005901,involves,Chronic Obstructive Pulmonary Disease
NCT01005901,evaluates,NVA237
NCT01005901,measures_primary,FEV1 at 12 weeks
NCT01005901,measures_secondary,Transition Dyspnea Index
NCT01005901,measures_secondary,Quality of Life Assessment
NCT01005901,measures_secondary,Time to COPD exacerbation
NCT01005901,has_criteria,baseline inhaled corticosteroid use
NCT04998201,involves,Mixed Dyslipidemia
NCT04998201,evaluates,ARO-APOC3
NCT04998201,measures_primary,Percent Change TG
NCT04998201,measures_secondary,Apolipoprotein C-III
NCT04998201,measures_secondary,Non-HDL-C
NCT04998201,measures_secondary,HDL-C
NCT04998201,measures_secondary,ApoB
NCT04998201,measures_secondary,LDL-C
NCT04998201,measures_secondary,Adverse Events
NCT04998201,has_criteria,TG ≥ 150 mg/dL
NCT05251701,involves,Parkinson's disease
NCT05251701,evaluates,PKG assessments
NCT05251701,measures_primary,Gait/walking
NCT05251701,measures_primary,Device Assisted Therapy readiness
NCT05251701,measures_primary,Percent Time Bradykinesia
NCT05251701,measures_secondary,MDS-UPDRS
NCT05251701,measures_secondary,PDQ-39
NCT05251701,has_criteria,DAT criteria
NCT01064401,involves,Relapsing-Remitting Multiple Sclerosis
NCT01064401,evaluates,BIIB019
NCT01064401,evaluates,Interferon β 1a
NCT01064401,measures_primary,Adjusted ARR
NCT01064401,measures_secondary,New or Newly Enlarging T2 Hyperintense Lesions
NCT01064401,measures_secondary,Proportion of Participants With Sustained Disability Progression
NCT01064401,has_criteria,Baseline EDSS score
NCT01953601,involves,Prodromal Alzheimer's Disease
NCT01953601,evaluates,Verubecestat
NCT01953601,measures_primary,CDR-SB score
NCT01953601,measures_secondary,CDR-SB score
NCT01953601,has_criteria,Baseline measurement
NCT02655601,involves,High Grade Glioma
NCT02655601,evaluates,BMX-001
NCT02655601,measures_primary,Overall survival
NCT02655601,measures_secondary,Progression-free survival
NCT02655601,measures_secondary,Protection/improvement of cognition
NCT02655601,has_criteria,newly diagnosed
NCT03452501,involves,Inflammatory Bowel Diseases
NCT03452501,evaluates,Remsima
NCT03452501,measures_primary,Clinical response or remission
NCT03452501,measures_secondary,Disease control
NCT03452501,has_criteria,naïve patients with CD
NCT05533801,evaluates,Lecanemab
NCT05533801,measures_primary,AUC(0-t)
NCT05533801,measures_primary,AUC(0-inf)
NCT05533801,measures_primary,Cmax
NCT05533801,measures_primary,Tmax
NCT05533801,measures_primary,t1/2
NCT05533801,measures_secondary,Number of Participants With TEAEs
NCT05533801,measures_secondary,Number of Participants With Abnormal Laboratory Values
NCT05533801,measures_secondary,Number of Participants With Abnormal Vital Signs Values
NCT05533801,measures_secondary,Number of Participants With Anti-drug Antibodies
NCT05533801,has_criteria,Baseline up to Day 50
NCT05533801,has_criteria,Baseline up to Day 22
NCT01346501,involves,Rheumatoid Arthritis
NCT01346501,evaluates,Adalimumab
NCT01346501,measures_primary,DAS28-CRP score
NCT01346501,measures_secondary,MMP-3 serum level
NCT01346501,has_criteria,DAS28-CRP score < 3.2
NCT05450601,involves,Essential Hypertension
NCT05450601,evaluates,HCP2102
NCT05450601,measures_primary,Change in systolic BP
NCT05450601,measures_secondary,Change in diastolic BP
NCT05450601,measures_secondary,Change in pulse BP
NCT05450601,measures_secondary,Target blood pressure
NCT05450601,measures_secondary,Blood pressure responder rate
NCT05450601,has_criteria,Patients
NCT03895801,involves,Granulomatosis With Polyangiitis
NCT03895801,involves,Microscopic Polyangiitis
NCT03895801,evaluates,IFX-1
NCT03895801,measures_primary,Percentage of subjects achieving clinical response
NCT03895801,measures_primary,Percentage of subjects with clinical remission
NCT03895801,measures_secondary,Change From Baseline in BVASv3 Total Score
NCT03895801,measures_secondary,Vasculitis Damage Index (VDI)
NCT03895801,measures_secondary,Physician Global Assessment (PGA)
NCT03895801,measures_secondary,Estimated Glomerular Filtration Rate
NCT03895801,has_criteria,rescue therapy
NCT02496767,involves,Amyotrophic Lateral Sclerosis
NCT02496767,evaluates,Tirasemtiv
NCT02496767,measures_primary,Change From Baseline
NCT02496767,measures_secondary,ALSFRS-R Respiratory Domain Score
NCT02496767,has_criteria,3 to 5 breaths at rest
NCT01623310,involves,chronic sinusitis
NCT01623310,involves,nasal polyps
NCT01623310,evaluates,Intranasal Fluticasone Propionate
NCT01623310,measures_primary,SNOT-22 Total Score
NCT01623310,measures_secondary,Lund-Mackay Total Score
NCT01623310,measures_secondary,Patient Global Impression of Change
NCT01623310,measures_secondary,Summed Bilateral Nasal Polyp Grading Scale Score
NCT01623310,has_criteria,nasal polyps
NCT00834210,involves,Facial Acne Vulgaris
NCT00834210,evaluates,Dapsone Gel 5% and Tazarotene Cream 0.1%
NCT00834210,evaluates,Tazarotene Cream 0.1%
NCT00834210,measures_primary,Change From Baseline
NCT00834210,measures_primary,Inflammatory Lesion Counts
NCT00834210,measures_secondary,Investigator Global Assessment
NCT00834210,measures_secondary,Overall Disease Severity
NCT00834210,measures_secondary,Non-Inflammatory Lesion Counts
NCT00834210,has_criteria,Baseline
NCT01285310,involves,Rheumatoid Arthritis
NCT01285310,evaluates,Apremilast
NCT01285310,measures_primary,ACR 20 response
NCT01285310,measures_secondary,HAQ-DI score
NCT01285310,has_criteria,≥ 20% improvement
NCT00927810,involves,Gout
NCT00927810,evaluates,Canakinumab
NCT00927810,measures_primary,Gout pain
NCT00927810,measures_secondary,Patient's global assessment
NCT00927810,measures_secondary,Physician's global assessment
NCT00927810,has_criteria,Adverse events
NCT03737110,involves,Recurrent Pericarditis
NCT03737110,evaluates,Rilonacept
NCT03737110,measures_primary,Time to recurrence
NCT03737110,measures_secondary,Percentage of Participants Who Maintained Clinical Response at Week 16 of the RW Period
NCT03737110,has_criteria,Pericarditis pain with supportive objective evidence
NCT03654755,involves,Atopic Dermatitis
NCT03654755,evaluates,ASN002
NCT03654755,measures_primary,Change From Baseline in EASI Score
NCT03654755,measures_secondary,5-D Pruritus Scale
NCT03654755,measures_secondary,Pruritus (Itch) NRS
NCT03654755,has_criteria,Moderate to Severe
NCT03364114,involves,Barrett's esophagus
NCT03364114,evaluates,EndoRotor
NCT03364114,measures_primary,complete removal
NCT03364114,measures_primary,serious adverse events
NCT03364114,measures_secondary,activated fibroblasts
NCT03364114,measures_secondary,Barrett's esophagus
NCT03364114,measures_secondary,post procedure pain
NCT03364114,has_criteria,greater than 30 years
NCT03364114,has_criteria,less than 90 years
NCT03364114,has_criteria,confirmed Barrett's esophagus
NCT03364114,has_criteria,dysplasia
NCT03214081,involves,Reflux Esophagitis
NCT03214081,evaluates,Vonoprazan
NCT03214081,measures_primary,Endoscopic Relapse Rate
NCT03214081,measures_secondary,Heartburn Severity
NCT03214081,measures_secondary,Acid Reflux Severity
NCT03214081,has_criteria,Grade A to D
NCT05189210,involves,Alzheimer's Disease
NCT05189210,evaluates,GV1001
NCT05189210,measures_primary,ADAS-cog11 score
NCT05189210,measures_secondary,A-IADL-Q score
NCT05189210,measures_secondary,CDR-SB score
NCT05189210,has_criteria,cognitive decline
NCT02932410,involves,Pulmonary Arterial Hypertension
NCT02932410,evaluates,Macitentan
NCT02932410,measures_primary,Time to first CEC-confirmed Disease Progression Event
NCT02932410,measures_secondary,Time to First CEC-confirmed Hospitalization for PAH
NCT02932410,measures_secondary,Time to CEC-confirmed death due to PAH
NCT02932410,measures_secondary,Time to death (all causes)
NCT02932410,measures_secondary,The Percentage of Participants with World Health Organization (WHO) Functional Class (FC) I or II versus III or IV
NCT02932410,measures_secondary,Change from Baseline to Week 24 in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
NCT02932410,has_criteria,Greater than or Equal to 2 Years
NCT02932410,has_criteria,Less than 2 Years
NCT02693210,involves,Rheumatoid Arthritis
NCT02693210,evaluates,Mabthera
NCT02693210,evaluates,Cyclophosphamide
NCT02693210,evaluates,Methotrexate
NCT02693210,measures_primary,ACR 50 response
NCT02693210,measures_secondary,ACR 20 response
NCT02693210,measures_secondary,ACR 70 response
NCT02693210,measures_secondary,AUC ACRn
NCT02693210,measures_secondary,AUC DAS
NCT02693210,measures_secondary,Swollen Joint Count
NCT02693210,measures_secondary,Tender Joint Count
NCT02693210,measures_secondary,VAS global assessment
NCT02693210,measures_secondary,Physician global assessment
NCT02693210,measures_secondary,HAQ-DI scores
NCT02693210,measures_secondary,Participant pain
NCT02693210,measures_secondary,CRP Levels
NCT02693210,measures_secondary,ESR
NCT02693210,measures_secondary,Rheumatoid factor
NCT02693210,has_criteria,moderate to severe RA
NCT02693210,has_criteria,failed 1-5 DMARDS
NCT02693210,has_criteria,partial methotrexate response
NCT02693210,has_criteria,methotrexate 16 weeks
NCT02693210,has_criteria,>=21 years old
NCT03958955,involves,Discoid Lupus Erythematosus
NCT03958955,evaluates,Delgocitinib Cream
NCT03958955,measures_primary,IGA score reduction
NCT03958955,measures_secondary,Erythema score
NCT03958955,has_criteria,Target lesions IGA 0 or 1
NCT01103414,involves,Type 2 diabetes
NCT01103414,evaluates,Mitoglitazone
NCT01103414,measures_primary,Change From Baseline in Fasting Plasma Glucose
NCT01103414,measures_secondary,Change from baseline in HbA1c
NCT01103414,measures_secondary,Percent Change From Baseline to Week 12 Endpoint in HMW Adiponectin
NCT01103414,measures_secondary,Change From Baseline to Week 12 Endpoint in Hematocrit
NCT01103414,measures_secondary,Change From Baseline in Hemoglobin
NCT01103414,measures_secondary,Change From Baseline in RBC
NCT01103414,measures_secondary,Change in Body Weight From Baseline to Week 12 Endpoint
NCT01103414,measures_secondary,Change From Baseline in Waist Circumference at Week 12 Endpoint
NCT01103414,measures_secondary,Presence of Edema Post Baseline During 12 Weeks Active Treatment
NCT01103414,has_criteria,once-daily dosing
NCT00460655,involves,Post-Stroke Lower Limb Spasticity
NCT00460655,evaluates,GSK1358820
NCT00460655,measures_primary,AUC MAS ankle score
NCT00460655,measures_secondary,Physician's Rating Score
NCT00460655,measures_secondary,Time to walk 10 meters
NCT00460655,has_criteria,Baseline
NCT01518855,involves,Essential Hypertension
NCT01518855,evaluates,Controlled Release Nifedipine and Valsartan Combination Therapy
NCT01518855,measures_primary,Proportion achieving target blood pressure
NCT01518855,measures_secondary,Change in blood pressure
NCT01518855,measures_secondary,Incidence of treatment-emergent drug-related adverse events
NCT01518855,has_criteria,SBP\>/=160mmHg or DBP\>/=100mmHg
NCT01518855,has_criteria,SBP\>/=150mmHg or DBP\>/=95mmHg
NCT01518855,has_criteria,SBP \> 200mmHg or DBP \> 120mmHg
NCT02709655,involves,Major Depressive Disorder
NCT02709655,evaluates,Vortioxetine
NCT02709655,measures_primary,CDRS-R Total Score
NCT02709655,measures_secondary,CDRS-R Subscores
NCT02709655,has_criteria,Paediatric Participants
NCT06053814,involves,Duchenne muscular dystrophy
NCT06053814,evaluates,NS-050/NCNP-03
NCT06053814,measures_primary,dystrophin protein
NCT06053814,measures_secondary,North Star Ambulatory Assessment
NCT06053814,has_criteria,exon 50-skipped mRNA
NCT00581555,involves,Plaque Psoriasis
NCT00581555,evaluates,Etanercept
NCT00581555,measures_primary,Change From Randomization in PASI Score
NCT00581555,measures_secondary,PASI Area Under the Curve
NCT00581555,measures_secondary,Change From Randomization in PGA Score
NCT00581555,measures_secondary,Relapse (Loss of 50% Improvement in PASI)
NCT00581555,measures_secondary,Probability of Being Relapse Free
NCT00581555,measures_secondary,Percent (%) Change of PASI Score
NCT00581555,has_criteria,Randomization to Week 24
NCT03877510,involves,Parkinson's Disease
NCT03877510,evaluates,IPX203
NCT03877510,measures_primary,MDS-UPDRS Total Score
NCT03877510,measures_secondary,Change From Baseline in MDS-UPDRS Total Score
NCT03877510,has_criteria,Motor Fluctuations
NCT00929110,involves,Chronic Obstructive Pulmonary Disease
NCT00929110,evaluates,Glycopyrronium Bromide
NCT00929110,measures_primary,Trough FEV1 at Week 12
NCT00929110,measures_secondary,Transition Dyspnea Index
NCT00929110,measures_secondary,Health-related Quality of Life
NCT00929110,has_criteria,Baseline FEV1 measurement
NCT00929110,has_criteria,baseline inhaled corticosteroid use
NCT00929110,has_criteria,FEV1 prior to inhalation of SABA
NCT00929110,has_criteria,FEV1 45 min post-inhalation of SABA
NCT04263610,involves,Chronic Plaque Psoriasis
NCT04263610,evaluates,Tildrakizumab
NCT04263610,measures_primary,PASI 75 at Week 40
NCT04263610,measures_secondary,PASI 50
NCT04263610,has_criteria,Non-Responders to DMF
NCT00931710,involves,Stage 2 systolic hypertension
NCT00931710,evaluates,valsartan/amlodipine
NCT00931710,measures_primary,Change in MSSBP
NCT00931710,measures_secondary,Change in MSDBP
NCT00931710,measures_secondary,Cumulative Percentage of Patients Achieving Blood Pressure Control
NCT00931710,measures_secondary,Cumulative Percentage of Treatment Responders
NCT00931710,has_criteria,Male or female
NCT06333210,involves,Axial Spondyloarthritis
NCT06333210,evaluates,BCD-180
NCT06333210,measures_primary,ASAS40 response
NCT06333210,measures_secondary,ASDAS-CRP score
NCT06333210,has_criteria,bDMARDs
NCT05169710,involves,Bipolar I Disorder
NCT05169710,involves,Major Depressive Episode
NCT05169710,evaluates,Investigational Drug
NCT05169710,measures_primary,Change From Baseline
NCT05169710,measures_secondary,Global Severity Assessed
NCT05169710,has_criteria,DSM-5 criteria
NCT05169710,has_criteria,18 to 65 years
NCT05169710,has_criteria,MADRS total score ≥ 22
NCT05344469,involves,Relapsing Multiple Sclerosis
NCT05344469,evaluates,Injectable Treatments
NCT05344469,measures_primary,Proportion of patients
NCT05344469,measures_secondary,Health economy impact
NCT05344469,has_criteria,Baseline
NCT01404169,involves,Alzheimer's Disease
NCT01404169,evaluates,Donepezil Hydrochloride
NCT01404169,measures_primary,SIB score change
NCT01404169,measures_secondary,CIBIC+ overall score
NCT01404169,has_criteria,age 50 to 90 years
NCT01404169,has_criteria,DSM-IV-TR criteria
NCT01404169,has_criteria,NINCDS-ADRDA criteria
NCT01404169,has_criteria,MMSE 1 to 12
NCT01404169,has_criteria,SIB 10 to 90
NCT00644969,involves,Schizophrenia
NCT00644969,involves,Schizoaffective Disorder
NCT00644969,evaluates,study treatment
NCT00644969,measures_primary,PANSS Total Score
NCT00644969,measures_secondary,PANSS Total Score
NCT00644969,has_criteria,Baseline to Week 12
NCT04892069,involves,Type 2 Diabetes Mellitus
NCT04892069,evaluates,Ryzodeg
NCT04892069,measures_primary,HbA1c less than 7%
NCT04892069,measures_secondary,Change in fasting plasma glucose
NCT04892069,measures_secondary,Change in insulin dose
NCT04892069,measures_secondary,Change in body weight
NCT04892069,measures_secondary,Change in the occurrence of severe hypoglycaemic events
NCT04892069,has_criteria,Informed consent obtained
NCT04892069,has_criteria,Age above or equal to 18 years
NCT04892069,has_criteria,Diagnosed with Type 2 Diabetes Mellitus
NCT00137969,involves,Systemic Lupus Erythematosus
NCT00137969,evaluates,Rituximab
NCT00137969,measures_primary,AUCMB of BILAG Score
NCT00137969,measures_secondary,Major Clinical Response
NCT00137969,has_criteria,BILAG Score
NCT03190369,involves,Osteoarthritis
NCT03190369,evaluates,Synvisc-One
NCT03190369,measures_primary,WOMAC A1 Pain
NCT03190369,measures_secondary,WOMAC A Score
NCT03190369,has_criteria,Chinese Patients
NCT04162769,involves,Atopic Dermatitis
NCT04162769,evaluates,Etrasimod
NCT04162769,measures_primary,Percent Change EASI
NCT04162769,measures_secondary,vIGA 0 or 1 Score
NCT04162769,has_criteria,Baseline Day 1
NCT04134169,involves,Rheumatoid Arthritis
NCT04134169,evaluates,FURESTEM-RA Inj(K0202)
NCT04134169,measures_primary,ACR reaction rate
NCT04134169,measures_secondary,EULAR reaction rate
NCT04134169,measures_secondary,DAS28-ESR change
NCT04134169,measures_secondary,KHAQ change
NCT04134169,measures_secondary,CDAI change
NCT04134169,measures_secondary,Pain VAS change
NCT04134169,measures_secondary,Modified Sharp/Van der Heijde Socre change
NCT04134169,has_criteria,more than one medication
NCT04134169,has_criteria,informed consent
NCT02046369,involves,Pediatric Bipolar Disorder
NCT02046369,evaluates,Lurasidone
NCT02046369,measures_primary,Change in CDRS-R
NCT02046369,measures_secondary,Change in PARS score
NCT02046369,measures_secondary,Change in PQ-LES-Q score
NCT02046369,has_criteria,ages 6-17 years
NCT02182869,involves,Chronic Obstructive Pulmonary Disease
NCT02182869,evaluates,Combivent® HFA
NCT02182869,measures_primary,Change in FEV1
NCT02182869,measures_secondary,Change in FVC
NCT02182869,has_criteria,clinically significant changes
NCT04639310,involves,KCNQ2 Developmental and Epileptic Encephalopathy
NCT04639310,evaluates,XEN496
NCT04639310,measures_primary,Percent Change in Seizure Frequency
NCT04639310,measures_secondary,Caregiver Global Impression of Change
NCT04639310,has_criteria,at least minimally improved
NCT04378569,involves,Chronic Hand Eczema
NCT04378569,evaluates,ARQ-252 Cream
NCT04378569,measures_primary,IGA score
NCT04378569,measures_secondary,Adverse Event
NCT04378569,measures_secondary,Serious Adverse Event
NCT04378569,has_criteria,Up to 3 weeks
NCT02323269,involves,RRMS
NCT02323269,evaluates,DMF
NCT02323269,measures_primary,Annualized Relapse Rate
NCT02323269,measures_secondary,Treatment Satisfaction Questionnaire
NCT02323269,measures_secondary,Short-Form 36
NCT02323269,measures_secondary,Modified Fatigue Impact Scale
NCT02323269,measures_secondary,Beck Depression Inventory
NCT02323269,measures_secondary,Work Productivity and Impairment Questionnaire
NCT03926169,involves,Hidradenitis Suppurativa
NCT03926169,evaluates,Risankizumab
NCT03926169,evaluates,Placebo
NCT03926169,measures_primary,HiSCR at Week 16
NCT03926169,measures_secondary,PGA of Skin Pain NRS30
NCT03926169,measures_secondary,DLQI Score
NCT03926169,has_criteria,Baseline NRS ≥ 3
NCT02336503,involves,Axillary Hyperhidrosis
NCT02336503,evaluates,BBI-4000
NCT02336503,measures_primary,HDSS decrease
NCT02336503,measures_secondary,Sweat Production Change
NCT02336503,has_criteria,Hyperhidrosis severity 3 or 4
NCT02336503,has_criteria,6 months duration
NCT02336503,has_criteria,50 mg sweat production
NCT03733301,involves,Atopic Dermatitis
NCT03733301,evaluates,Baricitinib
NCT03733301,evaluates,Topical Corticosteroids
NCT03733301,measures_primary,IGA 0 or 1
NCT03733301,measures_primary,EASI75
NCT03733301,measures_primary,EASI90
NCT03733301,has_criteria,Adults
NCT04233801,involves,Type 2 Diabetes
NCT04233801,evaluates,Empagliflozin
NCT04233801,measures_primary,Change in HbA1c
NCT04233801,measures_secondary,Percentage of Participants HbA1c<7.0%
NCT04233801,measures_secondary,Change in Body Weight
NCT04233801,measures_secondary,Change in Systolic Blood Pressure
NCT04233801,measures_secondary,Change in Diastolic Blood Pressure
NCT04233801,measures_secondary,Change in Fasting Plasma Glucose
NCT04233801,measures_secondary,Change in 2-hour Post-prandial Glucose
NCT04233801,has_criteria,Chinese Patients Insulin
NCT00658567,involves,Parkinson's Disease Psychosis
NCT00658567,evaluates,Pimavanserin
NCT00658567,measures_primary,SAPS-H+D score
NCT00658567,measures_secondary,UPDRS Parts II+III score
NCT00658567,has_criteria,Parkinson's disease duration 1 year
NCT01592201,involves,schizophrenia
NCT01592201,evaluates,Paliperidone ER
NCT01592201,measures_primary,medication satisfaction
NCT01592201,measures_secondary,PANSS score
NCT01592201,measures_secondary,DAI-10 Score
NCT01592201,measures_secondary,CGI-S Score
NCT01592201,measures_secondary,PSP
NCT01592201,has_criteria,Non-satisfied patients
NCT01753167,involves,Cytomegalovirus Disease
NCT01753167,evaluates,MCMV5322A/MCMV3068A
NCT01753167,measures_primary,Time to Detectable CMV Viral Load
NCT01753167,measures_secondary,Percentage of Participants With Adverse Events
NCT01753167,has_criteria,High-Risk Kidney Allograft Recipients
NCT00878501,involves,Osteoarthritis
NCT00878501,evaluates,AZD1386
NCT00878501,measures_primary,WOMAC Pain Subscale
NCT00878501,measures_secondary,WOMAC Function Subscale
NCT00878501,measures_secondary,WOMAC Stiffness Subscale
NCT00878501,has_criteria,Baseline
NCT03627767,involves,Atopic Dermatitis
NCT03627767,evaluates,PF-04965842
NCT03627767,measures_primary,Loss of Response
NCT03627767,measures_secondary,Time to Loss of Response
NCT03627767,has_criteria,Aged 12 Years and Over
NCT00253201,involves,Alzheimer's Disease
NCT00253201,evaluates,Galantamine
NCT00253201,measures_primary,ADAS-cog/11 scores
NCT00253201,measures_primary,CIBIC-plus scores
NCT00253201,measures_secondary,ADAS-cog/13 scores
NCT00253201,measures_secondary,DAD scores
NCT00253201,measures_secondary,Drug concentration
NCT00253201,measures_secondary,PGWB
NCT00253201,measures_secondary,Health/social care
NCT00253201,measures_secondary,Adverse events
NCT00253201,measures_secondary,Laboratory tests
NCT00253201,measures_secondary,ECGs
NCT00253201,measures_secondary,Physical examinations
NCT00253201,has_criteria,Diagnosis of Alzheimer's Disease
NCT00253201,has_criteria,MMSE score 11-24
NCT00253201,has_criteria,ADAS-cog score at least 12
NCT00253201,has_criteria,Gradual cognitive decline
NCT00253201,has_criteria,Consistent informant
NCT00253201,has_criteria,No Neurogenerative disorders
NCT00253201,has_criteria,No dementia from strokes
NCT00253201,has_criteria,No acute cerebral trauma
NCT00253201,has_criteria,No endocrine or metabolic disease
NCT00253201,has_criteria,No mental retardation
NCT00253201,has_criteria,No brain tumor
NCT00253201,has_criteria,No epilepsy
NCT00253201,has_criteria,No psychiatric disease
NCT00253201,has_criteria,No peptic ulcer
NCT00253201,has_criteria,No liver
NCT00253201,has_criteria,No heart disease
NCT00253201,has_criteria,No females of child bearing potential without contraception
NCT02173301,involves,Chronic Plaque-Type Psoriasis
NCT02173301,evaluates,XP23829
NCT02173301,measures_primary,PASI 75
NCT02173301,measures_secondary,PASI score
NCT02173301,measures_secondary,sPGA score
NCT02173301,has_criteria,Baseline PASI
NCT00849901,involves,Major Depressive Disorder
NCT00849901,measures_primary,Change From Baseline
NCT00849901,measures_secondary,CDRS-R Subscale Score
NCT00849901,has_criteria,age category
NCT04373967,involves,Type 2 Diabetes
NCT04373967,evaluates,Liraglutide
NCT04373967,measures_primary,HbA1c reduction
NCT04373967,measures_secondary,Body weight
NCT04373967,has_criteria,Stably daily dose of metformin
NCT04373967,has_criteria,HbA1c 7-11%
NCT02522767,involves,Ulcerative Colitis
NCT02522767,evaluates,Mesalamine
NCT02522767,measures_primary,Proportion of Remission
NCT02522767,measures_secondary,Endoscopic Improvement
NCT02522767,has_criteria,Rectal Bleeding Score
NCT00756938,involves,Hypertension
NCT00756938,evaluates,Losartan
NCT00756938,measures_primary,Systolic Blood Pressure
NCT00756938,measures_secondary,Adverse Event
NCT00756938,has_criteria,Pediatric Patients
NCT02994238,involves,Asthma
NCT02994238,measures_primary,Asthma Control Test
NCT02994238,measures_secondary,Pediatric Asthma Caregiver Quality of Life
NCT02994238,has_criteria,English-speaking parents
NCT02994238,has_criteria,Children 4-17 years old
NCT00195338,involves,Rheumatoid arthritis
NCT00195338,evaluates,Enbrel
NCT00195338,measures_primary,Change in synovitis
NCT00195338,measures_secondary,HAQ score
NCT00195338,measures_secondary,Methotrexate dose
NCT00195338,has_criteria,moderate to severe active rheumatoid arthritis
NCT00195338,has_criteria,aged 17 years or more
NCT00195338,has_criteria,inadequate response to DMards
NCT00195338,has_criteria,written informed consent
NCT03095508,involves,Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx
NCT03095508,evaluates,Angal S
NCT03095508,evaluates,ANTI-ANGIN® FORMULA
NCT03095508,measures_primary,Percentage of Patients Without Sore Throat
NCT03095508,measures_primary,TSS Total Score Reduction
NCT03095508,measures_secondary,Change From Baseline in TSS Total Score
NCT03095508,measures_secondary,Number of Participants Who Fully Recovered
NCT03095508,measures_secondary,Change in the Sore Throat Intensity by 100 mm VAS
NCT03095508,has_criteria,TSS questionnaire ≤ 2
NCT05588908,involves,Acute Gout
NCT05588908,evaluates,Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
NCT05588908,measures_primary,Pain Intensity
NCT05588908,measures_secondary,Adverse Events
NCT05588908,has_criteria,Chinese Participants
NCT01139008,involves,healthy skin
NCT01139008,evaluates,MetroGel 1%
NCT01139008,evaluates,Finacea 15%
NCT01139008,measures_primary,tolerability score
NCT01139008,measures_secondary,subject preference
NCT01139008,has_criteria,healthy adults
NCT01139008,has_criteria,healthy skin
NCT01139008,has_criteria,no skin pigmentation
NCT01139008,has_criteria,no allergy to study drugs
NCT01582308,involves,Type 2 Diabetes Mellitus
NCT01582308,evaluates,Sitagliptin
NCT01582308,evaluates,Saxagliptin
NCT01582308,evaluates,Vildagliptin
NCT01582308,measures_primary,Percent Inhibition of DPP-4
NCT01582308,measures_secondary,AUC 0-24hr
NCT01582308,measures_secondary,AUC 0-12hr
NCT01582308,measures_secondary,Cmax
NCT01582308,measures_secondary,Tmax
NCT01582308,has_criteria,female participants
NCT02343003,involves,Knee Pain
NCT02343003,evaluates,Cooled Radiofrequency
NCT02343003,evaluates,Corticosteroid Injection
NCT02343003,measures_primary,Knee pain reduction
NCT02343003,measures_secondary,Adverse Events
NCT02343003,has_criteria,Age ≥ 21 years
NCT02343003,has_criteria,Chronic knee pain
NCT02343003,has_criteria,Positive response to nerve block
NCT02343003,has_criteria,NRS ≥ 6
NCT02343003,has_criteria,Osteoarthritis grade 2-4
NCT02826603,involves,Plaque Psoriasis
NCT02826603,evaluates,Secukinumab
NCT02826603,evaluates,Ustekinumab
NCT02826603,measures_primary,PASI 90 response
NCT02826603,measures_secondary,PASI 75 response
NCT02826603,measures_secondary,PASI 100 response
NCT02826603,has_criteria,IGA Mod 2011
NCT04663308,involves,Primary Sclerosing Cholangitis
NCT04663308,evaluates,Volixibat
NCT04663308,measures_primary,daily itch scores
NCT04663308,measures_secondary,itch response
NCT04663308,measures_secondary,adverse events
NCT04663308,measures_secondary,serum bile acid levels
NCT04663308,measures_secondary,alkaline phosphatase
NCT04663308,measures_secondary,total bilirubin levels
NCT04663308,measures_secondary,Primary Sclerosing Cholangitis-Specific Patient-Reported Outcome
NCT04663308,measures_secondary,PROMIS® fatigue questionnaire
NCT04663308,measures_secondary,PROMIS® sleep disturbance questionnaire
NCT04663308,has_criteria,informed consent
NCT04663308,has_criteria,age ≥12 years
NCT01654250,involves,Attention deficit hyperactivity disorder
NCT01654250,evaluates,NWP09
NCT01654250,measures_primary,SKAMP combined score
NCT01654250,measures_secondary,Onset and duration
NCT01654250,has_criteria,Post-dose time-points
NCT02804750,involves,Cushing's syndrome
NCT02804750,evaluates,CORT125134
NCT02804750,measures_primary,Improvement in blood pressure
NCT02804750,measures_secondary,Reduction in AUCglucose
NCT02804750,has_criteria,confirmed diagnosis of endogenous Cushing's syndrome
NCT02804750,has_criteria,requires medical treatment of hypercortisolemia
NCT02804750,has_criteria,type 2 diabetes mellitus
NCT02804750,has_criteria,impaired glucose tolerance
NCT02804750,has_criteria,hypertension
NCT00541450,involves,Type 2 Diabetes
NCT00541450,evaluates,Sitagliptin
NCT00541450,evaluates,MK0431A
NCT00541450,evaluates,Pioglitazone
NCT00541450,measures_primary,Change in A1C
NCT00541450,measures_secondary,2-hour Postprandial Glucose
NCT00541450,measures_secondary,Fasting Plasma Glucose
NCT00541450,has_criteria,Baseline to 40 weeks
NCT00541450,has_criteria,Baseline to 12 weeks
NCT05754450,involves,Leukocyte Adhesion Deficiency Type II
NCT05754450,evaluates,AVTX-803
NCT05754450,measures_primary,Change from Baseline in the composite Nijmegen Pediatric Congenital Disorders of Glycosylation (CDG) Rating Scale (NPCRS)
NCT05754450,measures_secondary,Change from Baseline in the individual parameters of the Nijmegen Pediatric Congenital Disorders of Glycosylation (CDG) Rating Scale (NPCRS)
NCT05754450,measures_secondary,Goal Attainment Score (GAS)
NCT05754450,measures_secondary,Clinician Global Impression of Severity (CGI-S)
NCT02187055,involves,Rheumatoid Arthritis
NCT02187055,evaluates,Tofacitinib
NCT02187055,evaluates,Methotrexate
NCT02187055,evaluates,Adalimumab
NCT02187055,measures_primary,ACR50 Response
NCT02187055,measures_secondary,SDAI Value
NCT02187055,measures_secondary,CDAI Value
NCT02187055,measures_secondary,DAS28-4
NCT01928914,involves,QTc
NCT01928914,evaluates,tafenoquine
NCT01928914,measures_primary,change from baseline
NCT01928914,measures_secondary,plasma concentrations
NCT01928914,has_criteria,1200mg dose of tafenoquine
NCT00430950,involves,Essential Hypertension
NCT00430950,evaluates,Olmesartan/Hydrochlorothiazide
NCT00430950,measures_primary,Change in Diastolic Blood Pressure
NCT00430950,measures_secondary,Systolic Blood Pressure
NCT00430950,measures_secondary,Ambulatory Blood Pressure
NCT00430950,has_criteria,Moderate to severe HTN
NCT00430950,has_criteria,Age 18 years or older
NCT00430950,has_criteria,No pregnancy
NCT00430950,has_criteria,No recent MI
NCT00430950,has_criteria,No recent unstable angina
NCT00430950,has_criteria,No recent percutaneous coronary intervention
NCT00430950,has_criteria,No recent severe heart failure
NCT00430950,has_criteria,No recent hypertensive encephalopathy
NCT00430950,has_criteria,No recent cerebrovascular accident
NCT00430950,has_criteria,No recent transient ischaemic attack
NCT00430950,has_criteria,No clinically significant abnormal laboratory values
NCT00430950,has_criteria,No secondary HTN
NCT02404350,involves,Psoriatic Arthritis
NCT02404350,evaluates,Secukinumab
NCT02404350,measures_primary,ACR20 response
NCT02404350,measures_secondary,Joint/Bone Structural Damage
NCT02404350,has_criteria,Active Psoriatic Arthritis
NCT04555655,involves,Cognitive Decline
NCT04555655,evaluates,Chicken Extract
NCT04555655,evaluates,Peptide Supplement
NCT04555655,measures_primary,Change from baseline in ADCOMS
NCT04555655,measures_secondary,Change from baseline in Florbetaben (18F) PET scan
NCT04555655,measures_secondary,Change from baseline in handgrip strength
NCT04555655,measures_secondary,Change from baseline in plasma tau protein & amyloid-beta 42 ratio
NCT04555655,measures_secondary,Change from baseline in Alzheimer's Disease Composite Score (ADCOMS)
NCT04555655,measures_secondary,Change from baseline in blood myeloperoxidase (MPO)
NCT04555655,measures_secondary,Change from baseline in inflammation
NCT04555655,measures_secondary,Change from baseline in fasting blood glucose level
NCT04555655,measures_secondary,Change from baseline in Taiwanese Depression Questionnaire (TQD) scores
NCT04555655,has_criteria,Non-demented Elderly Adults
NCT02565914,involves,Cystic Fibrosis
NCT02565914,evaluates,VX-661
NCT02565914,evaluates,Ivacaftor
NCT02565914,measures_primary,ppFEV1
NCT02565914,measures_secondary,Adverse Events
NCT02565914,measures_secondary,Serious Adverse Events
NCT02565914,has_criteria,F508del-CFTR Mutation
NCT04267614,involves,Rheumatoid Arthritis
NCT04267614,evaluates,Etanercept
NCT04267614,measures_primary,DAS28 at Month 12
NCT04267614,measures_secondary,CDAI Score at Month 12
NCT04267614,has_criteria,referral to management of RA
NCT00717769,involves,Atopic Dermatitis
NCT00717769,evaluates,SUN13834
NCT00717769,measures_primary,Eczema Area and Severity Index (EASI) Score
NCT00717769,measures_secondary,Investigator's Global Assessment (IGA) score
NCT00717769,measures_secondary,Pruritus score
NCT00717769,measures_secondary,Insomnia score
NCT00717769,has_criteria,Adult Subjects
NCT04697069,involves,Acneiform Rash
NCT04697069,evaluates,Imsidolimab
NCT04697069,measures_primary,Facial lesion count
NCT04697069,measures_secondary,Acneiform Rash CTCAE
NCT04697069,has_criteria,Baseline
NCT03996369,involves,Ulcerative Colitis
NCT03996369,evaluates,Etrasimod
NCT03996369,evaluates,Placebo
NCT03996369,measures_primary,Clinical Remission
NCT03996369,measures_secondary,Endoscopic Improvement
NCT03996369,measures_secondary,Symptomatic Remission
NCT03996369,measures_secondary,Mucosal Healing
NCT03996369,has_criteria,Week 12
NCT01453569,involves,Alzheimer's Disease
NCT01453569,evaluates,Sodium Oligo-mannurarate Capsule
NCT01453569,measures_primary,Change ADAS-cog/12
NCT01453569,measures_secondary,Change CIBIC-plus
NCT01453569,measures_secondary,Change ADCS-ADL
NCT01453569,has_criteria,24 weeks
NCT04846868,involves,Schizophrenia
NCT04846868,evaluates,Iclepertin
NCT04846868,measures_primary,Change from baseline
NCT04846868,measures_secondary,Change from baseline
NCT04846868,has_criteria,Cognitive Impairment Associated with Schizophrenia
NCT02053168,involves,Ventral Hernia
NCT02053168,involves,Incisional Hernia
NCT02053168,evaluates,Phasix Mesh
NCT02053168,measures_primary,Hernia Recurrence
NCT02053168,measures_secondary,Device Related Adverse Events
NCT02053168,measures_secondary,Carolinas Comfort Scale
NCT02053168,measures_secondary,Short Form (SF)-12 Version 2
NCT02053168,has_criteria,study procedure
NCT02053168,has_criteria,abdominal space
NCT02053168,has_criteria,lower abdominal
NCT02053168,has_criteria,inguinal
NCT02053168,has_criteria,pubic regions
NCT00326768,involves,Hypertension
NCT00326768,evaluates,Telmisartan 80 mg/HCTZ 12.5 mg
NCT00326768,evaluates,Telmisartan 40 mg/HCTZ 12.5 mg
NCT00326768,measures_primary,Seated DBP control rate
NCT00326768,measures_primary,Seated SBP control rate
NCT00326768,measures_secondary,Seated DBP response rate
NCT00326768,measures_secondary,Seated SBP response rate
NCT00326768,measures_secondary,Seated blood pressure normality criteria
NCT00326768,measures_secondary,Changes in seated DBP
NCT00326768,measures_secondary,Changes in seated SBP
NCT00326768,has_criteria,mean seated DBP over 90 mmHg
NCT00326768,has_criteria,mean seated DBP under 114 mmHg
NCT00326768,has_criteria,Age over 20 years
NCT00326768,has_criteria,Age under 80 years
NCT00326768,has_criteria,Outpatient
NCT00326768,has_criteria,able to stop anti-hypertensive therapy
NCT00326768,has_criteria,written informed consent
NCT00326768,has_criteria,taking four or more anti-hypertensive medications
NCT00326768,has_criteria,known or suspected secondary hypertension
NCT00326768,has_criteria,mean seated DBP over 114 mmHg
NCT00326768,has_criteria,mean seated SBP over 200 mmHg
NCT00326768,has_criteria,sustained ventricular tachycardia
NCT06427668,involves,Alzheimer's Disease
NCT06427668,evaluates,SPG302
NCT06427668,measures_primary,Change in ADAS-COG
NCT06427668,measures_secondary,Change in MMSE
NCT06427668,measures_secondary,C-SSRS
NCT06427668,measures_secondary,Change in ADCS - CGIC
NCT06427668,has_criteria,Prospective suicidality
NCT00048568,involves,Rheumatoid Arthritis
NCT00048568,evaluates,Abatacept
NCT00048568,measures_primary,ACR 20 responders
NCT00048568,measures_secondary,Health Assessment Questionnaire
NCT00048568,has_criteria,Methotrexate inadequate response
NCT01169701,involves,Renal Transplant
NCT01169701,evaluates,Everolimus + Mycophenolic Acid
NCT01169701,evaluates,CNI+MPA
NCT01169701,measures_primary,Change From Baseline in LVMI
NCT01169701,measures_secondary,Mean 24 Hour Systolic and Diastolic Blood Pressure
NCT01169701,measures_secondary,Pulse Wave Velocity
NCT01169701,measures_secondary,Percentage of Participants With Major Cardiovascular Events
NCT01169701,measures_secondary,Renal Function Measured by Serum Creatinine
NCT01169701,measures_secondary,Renal Function as Measured by Creatinine Clearance
NCT01169701,measures_secondary,Renal Function as Measured by Estimated Glomerular Filtration Rate
NCT01169701,has_criteria,Maintenance Renal Transplant Recipients
NCT01440101,involves,Relapsing-Remitting Multiple Sclerosis
NCT01440101,evaluates,Natalizumab
NCT01440101,measures_primary,New active lesions
NCT01440101,measures_secondary,Annualized relapse rate
NCT01440101,has_criteria,Baseline (Week 0) to Week 24
NCT03298867,involves,Graves' Orbitopathy
NCT03298867,evaluates,Teprotumumab Infusions
NCT03298867,measures_primary,Proptosis responders
NCT03298867,measures_secondary,Clinical Activity Score
NCT03298867,has_criteria,Proptosis reduction
NCT04566601,involves,Borderline Personality Disorder
NCT04566601,evaluates,BI 1358894
NCT04566601,measures_primary,Change from baseline
NCT04566601,measures_secondary,ZAN-BPD Response
NCT04566601,has_criteria,ZAN-BPD Reduction
NCT03766867,involves,Depression
NCT03766867,evaluates,Vortioxetine
NCT03766867,measures_primary,MADRS-6 subscale score
NCT03766867,measures_secondary,MADRS-6 subscale score
NCT03766867,has_criteria,24 h post-infusion
NCT01477567,evaluates,LY3009385
NCT01477567,measures_primary,Change in blood glucose
NCT01477567,measures_secondary,Change in C-peptide
NCT01477567,measures_secondary,Change in Glucagon
NCT01477567,has_criteria,Healthy Participants
NCT06075667,involves,Obesity
NCT06075667,involves,Overweight
NCT06075667,involves,Weight-Related Comorbidities
NCT06075667,evaluates,Tirzepatide
NCT06075667,measures_primary,Percent Change BMI
NCT06075667,measures_secondary,Percentage of Participants with ≥5% BMI Reduction
NCT06075667,measures_secondary,Change from Baseline in Body Weight
NCT06075667,measures_secondary,Change from Baseline in Waist Circumference
NCT06075667,measures_secondary,Change in Impact of Weight on Quality of Life (IWQOL)-Kids Physical Comfort Domain Score
NCT06075667,measures_secondary,Change from Baseline in Body Weight Percentile
NCT06075667,measures_secondary,Change from Baseline in Systolic Blood Pressure
NCT06075667,measures_secondary,Change from Baseline in Diastolic Blood Pressure
NCT06075667,measures_secondary,Percent Change from Baseline in Total Cholesterol
NCT06075667,measures_secondary,Change from Baseline in Fasting Glucose
NCT06075667,measures_secondary,Change from Baseline in Fasting Insulin
NCT06075667,has_criteria,Adolescent Participants
NCT05442567,involves,Ulcerative Colitis
NCT05442567,involves,Crohn's Disease
NCT05442567,evaluates,Vedolizumab
NCT05442567,measures_primary,IMPACT-III Total Score
NCT05442567,measures_secondary,Adverse Event
NCT05442567,measures_secondary,Serious infections
NCT05442567,measures_secondary,Malignancies
NCT05442567,measures_secondary,Progressive multifocal leukoencephalopathy
NCT05442567,measures_secondary,Growth concerns
NCT05442567,measures_secondary,Pubertal development concerns
NCT05442567,measures_secondary,Bowel surgery
NCT05442567,has_criteria,Aged 9 to 17 years
NCT01972568,involves,Systemic Lupus Erythematosus
NCT01972568,evaluates,Atacicept
NCT01972568,measures_primary,SLEDAI-2K reduction
NCT01972568,measures_secondary,Prednisone-Equivalent Corticosteroid
NCT01972568,has_criteria,>=25% Prednisone reduction
NCT01856569,involves,Ankylosing Spondylitis
NCT01856569,evaluates,Anti Tnf Treatment
NCT01856569,measures_primary,Percentage of Participants
NCT01856569,measures_secondary,BASDAI Total Score
NCT01856569,has_criteria,Low disease activity
NCT00810069,involves,Major Depressive Disorder
NCT00810069,evaluates,Switch in Medication
NCT00810069,measures_primary,Time to Confirmed Response
NCT00810069,measures_secondary,Time to Confirmed Remission
NCT00810069,has_criteria,Week 4 through Week 16
NCT02101268,involves,Primary Myelofibrosis
NCT02101268,involves,Post-polycythemia Vera MF
NCT02101268,involves,Post-essential Thrombocythemia MF
NCT02101268,evaluates,Momelotinib
NCT02101268,measures_primary,Splenic Response Rate
NCT02101268,measures_secondary,Total Symptom Score Response Rate
NCT02101268,measures_secondary,Rate of Red Blood Cell Transfusion
NCT02101268,measures_secondary,RBC Transfusion Independence Rate
NCT02101268,has_criteria,≥35% spleen volume reduction
NCT02101268,has_criteria,≥50% TSS reduction
NCT02101268,has_criteria,≥20 daily TSS available
NCT02101268,has_criteria,Hemoglobin Level Below 8 g/dL
NCT01058668,involves,Bipolar I Disorder
NCT01058668,evaluates,Cariprazine
NCT01058668,measures_primary,Change From Baseline in YMRS Total Score
NCT01058668,measures_secondary,Change From Baseline in CGI-S Total Score
NCT01058668,has_criteria,Patients who have provided informed consent
NCT03924817,involves,Obstructive Sleep Apnea
NCT03924817,evaluates,Mandibular Advancement Devices
NCT03924817,measures_primary,AHI at 3 months
NCT03924817,measures_primary,Sleep quality
NCT03924817,measures_secondary,Daytime sleepiness
NCT03924817,has_criteria,Baseline compared
NCT03777917,involves,Infraorbital Hollow
NCT03777917,evaluates,Belotero Balance Injection
NCT03777917,measures_primary,Responder Rate
NCT03777917,measures_secondary,Face-Q Satisfaction
NCT03777917,has_criteria,Baseline up to Month 2
NCT03633617,involves,Eosinophilic Esophagitis
NCT03633617,evaluates,Dupilumab
NCT03633617,measures_primary,Peak Esophageal Eosinophil Count
NCT03633617,measures_secondary,Dysphagia Symptom Questionnaire
NCT03633617,measures_secondary,EoEHSS Mean Grade Score
NCT03633617,has_criteria,Adult and Adolescent Patients
NCT06583941,involves,Generalized Anxiety Disorder
NCT06583941,evaluates,Virtiva® Plus Ginkgo Biloba Extract
NCT06583941,measures_primary,Perceived Stress
NCT06583941,measures_secondary,Generalized Anxiety
NCT06583941,measures_secondary,Quality of Life
NCT06583941,has_criteria,Pre-Event
NCT04949841,involves,chronic hand eczema
NCT04949841,measures_primary,IGA-CHE score
NCT04949841,measures_secondary,HECSI score
NCT04949841,measures_secondary,HECSI-75
NCT04949841,has_criteria,completed DELTA 1 or DELTA 2
NCT00409617,involves,Crohn's Disease
NCT00409617,evaluates,Adalimumab
NCT00409617,measures_primary,HBI less than 5
NCT00409617,measures_secondary,Draining Fistulas
NCT00409617,has_criteria,Baseline HBI score
NCT02006641,involves,Mild-moderate Alzheimer's Disease
NCT02006641,evaluates,Idalopirdine
NCT02006641,measures_primary,Change in Cognition
NCT02006641,measures_secondary,Change in Daily Functioning
NCT02006641,measures_secondary,Change in Global Impression
NCT02006641,measures_secondary,Change in Behavioural Disturbance
NCT02006641,has_criteria,Baseline and Week 24
NCT01668641,involves,Rheumatoid Arthritis
NCT01668641,evaluates,GLPG0634
NCT01668641,measures_primary,ACR20 response
NCT01668641,measures_secondary,ACR50/70 response
NCT01668641,measures_secondary,time to response
NCT01668641,measures_secondary,DAS28 score
NCT01668641,has_criteria,swollen joints
NCT01668641,has_criteria,tender joints
NCT01668641,has_criteria,CRP ≥1.0 mg/dL
NCT01452919,involves,Schizophrenia
NCT01452919,evaluates,study drug
NCT01452919,measures_primary,Discontinuation Symptom Checklist-Modified Rickels Total Score
NCT01452919,measures_secondary,CIWA-Ar Total Score
NCT01452919,has_criteria,randomization treatment
NCT02047019,involves,Essential Hypertension
NCT02047019,evaluates,Nifedipine Gastrointestinal Therapeutic System
NCT02047019,evaluates,Candesartan Cilexetil
NCT02047019,measures_primary,Change in MSSBP
NCT02047019,measures_secondary,Change in MSDBP
NCT02047019,measures_secondary,Blood pressure Response Rate
NCT02047019,measures_secondary,Blood pressure Control Rate
NCT02047019,measures_secondary,Mean change in ambulatory blood pressure
NCT02047019,measures_secondary,Number of participants with adverse events
NCT02047019,has_criteria,Inadequately Controlled on Candesartan Cilexetil
NCT01161641,involves,Protein Losing Enteropathy
NCT01161641,evaluates,ODSH
NCT01161641,measures_primary,Decrease Fecal alpha 1 antitrypsin
NCT01161641,measures_secondary,Serum albumin levels
NCT01161641,has_criteria,Single ventricle palliative surgery
NCT02069119,involves,Paroxysmal Atrial Fibrillation
NCT02069119,involves,Persistent Atrial Fibrillation
NCT02069119,evaluates,OPC-108459
NCT02069119,measures_primary,NSR within 90 minutes
NCT02069119,measures_secondary,Cmax of Plasma OPC-108459
NCT02069119,has_criteria,recent or new onset
NCT00776919,involves,Acne
NCT00776919,evaluates,Clindamycin / Benzoyl Peroxide Gel
NCT00776919,measures_primary,Inflammatory Lesion Counts
NCT00776919,measures_secondary,Non-inflammatory Lesion Counts
NCT00776919,measures_secondary,Total Lesion Counts
NCT00776919,has_criteria,Trained study personnel
NCT00554619,evaluates,GSK1325760A
NCT00554619,measures_primary,Six Minutes Walk Distance
NCT00554619,measures_secondary,Borg Dyspnea Index
NCT03691818,involves,Knee Osteoarthritis
NCT03691818,evaluates,X0002 Spray
NCT03691818,measures_primary,Relief of Knee Pain
NCT03691818,measures_secondary,WOMAC subscale scores
NCT03691818,has_criteria,Osteoarthritis of the Knee
NCT02740218,involves,Psoriasis
NCT02740218,evaluates,Apremilast
NCT02740218,measures_primary,PASI75 response
NCT02740218,measures_secondary,PASI50
NCT02740218,measures_secondary,DLQI
NCT02740218,has_criteria,Up to approximately 7 months
NCT01579318,involves,Cutaneous Lymphoma
NCT01579318,evaluates,IL12 Plasmid Electroporation
NCT01579318,measures_primary,Objective Response Rate
NCT01579318,measures_secondary,Composite Global Score
NCT01579318,has_criteria,skin
NCT02739217,involves,Alström Syndrome
NCT02739217,evaluates,PBI-4050
NCT02739217,measures_primary,Change from baseline
NCT02739217,measures_secondary,biomarkers in blood
NCT02739217,measures_secondary,NT-proBNP
NCT02739217,measures_secondary,antidiabetic treatment
NCT02739217,has_criteria,24 weeks
NCT02739217,has_criteria,Extension Period
NCT02772419,involves,Eosinophilic Chronic Rhinosinusitis
NCT02772419,evaluates,Benralizumab
NCT02772419,measures_primary,nasal polyp score
NCT02772419,measures_secondary,Computed tomography score
NCT02772419,measures_secondary,Blood eosinophil count
NCT02772419,measures_secondary,Nasal Airway Resistance
NCT02772419,measures_secondary,Olfactory thresholds
NCT02772419,measures_secondary,improvement of olfactory dysfunction
NCT02772419,measures_secondary,Sino-Nasal Outcome Test-2
NCT02772419,measures_secondary,Symptom score by Visual Analog Scale
NCT02772419,has_criteria,Patien...
NCT04130919,involves,Ulcerative Colitis
NCT04130919,evaluates,Tilpisertib
NCT04130919,measures_primary,Clinical Remission
NCT04130919,measures_secondary,Endoscopic Response
NCT04130919,measures_secondary,MCS Response
NCT04130919,has_criteria,Adults with UC
NCT04664153,involves,Atopic Dermatitis
NCT04664153,involves,Plaque Psoriasis
NCT04664153,evaluates,PF-07038124 Ointment
NCT04664153,measures_primary,EASI Total Score
NCT04664153,measures_secondary,PASI Score
NCT04664153,has_criteria,Percent BSA affected
NCT06052254,involves,Alzheimer's Disease
NCT06052254,evaluates,Dexmedetomidine Transdermal Systems
NCT06052254,measures_primary,Change from baseline
NCT06052254,measures_secondary,CGI-I score
NCT06052254,has_criteria,positive response to screening question
NCT02612454,involves,Atopic Dermatitis
NCT02612454,evaluates,Dupilumab
NCT02612454,measures_primary,EASI-75 response
NCT02612454,measures_secondary,IGA score
NCT02612454,measures_secondary,Change from baseline EASI
NCT02612454,measures_secondary,Percent change from baseline EASI
NCT02612454,measures_secondary,Change from baseline BSA
NCT02612454,has_criteria,≥6 Months to <18 Years of Age
NCT02898454,involves,Nasal Polyps
NCT02898454,evaluates,Dupilumab
NCT02898454,measures_primary,Nasal Congestion
NCT02898454,measures_secondary,Nasal Polyp Score
NCT02898454,measures_secondary,Opacification of Sinuses
NCT02898454,has_criteria,300 mg q2w regimen
NCT03798054,involves,Type 2 Diabetes
NCT03798054,evaluates,Insulin Glargine/Lixisenatide
NCT03798054,measures_primary,Change in HbA1c
NCT03798054,measures_secondary,Change in PPG
NCT03798054,measures_secondary,Change in FPG
NCT03798054,measures_secondary,Change in SMPG profile
NCT03798054,has_criteria,HbA1c <7.0%
NCT01955733,involves,Rheumatoid Arthritis
NCT01955733,evaluates,BI 695500
NCT01955733,measures_primary,DAS28 (ESR) score
NCT01955733,measures_secondary,ACR20 response
NCT01955733,has_criteria,Improvement Since Baseline
NCT02669433,involves,Dementia With Lewy Bodies
NCT02669433,evaluates,intepirdine
NCT02669433,measures_primary,UPDRS Part III Change
NCT02669433,measures_secondary,ADAS-Cog-11 Change
NCT02669433,measures_secondary,CIBIC+ Change
NCT02669433,has_criteria,MMSE score 14-26
NCT02669433,has_criteria,reliable caregiver
NCT02098733,involves,Type 2 Diabetes Mellitus
NCT02098733,evaluates,Sonias Combination Tablets
NCT02098733,measures_primary,Change From Baseline in Glycosylated Hemoglobin (HbA1c)
NCT02098733,measures_secondary,Fasting Blood Glucose Level
NCT02098733,measures_secondary,Fasting Insulin Level
NCT02115633,involves,fall risk
NCT02115633,involves,older adults
NCT02115633,involves,stroke survivors
NCT02115633,involves,Parkinson's disease
NCT02115633,evaluates,"Wearable ""Balance Booster"
NCT02115633,measures_primary,Gait Speed
NCT02115633,measures_secondary,Balance
NCT02115633,has_criteria,FGA score improvement
NCT02228733,evaluates,KBP-5074
NCT02228733,measures_primary,Area Under Curve (AUC)
NCT02228733,measures_secondary,plasma aldosterone
NCT02228733,measures_secondary,serum potassium
NCT02228733,measures_secondary,urine albumin levels
NCT02228733,has_criteria,BMI 19 ≤ BMI ≤ 30 kg/m2
NCT02228733,has_criteria,no significant medical history
NCT02228733,has_criteria,normal renal function
NCT02228733,has_criteria,good general health
NCT06003387,involves,Hemophilia B
NCT06003387,evaluates,CSL222
NCT06003387,measures_primary,Annualized Bleeding Rate
NCT06003387,measures_secondary,Treatment-emergent Adverse Events
NCT06003387,has_criteria,Pretreatment AAV5 Neutralizing Antibodies
NCT04065633,evaluates,PF-04965842
NCT04065633,measures_primary,number of subjects
NCT04065633,measures_secondary,Supine Blood pressure
NCT04065633,measures_secondary,pulse rate
NCT04065633,measures_secondary,oral temperature
NCT04065633,measures_secondary,QT interval
NCT04065633,measures_secondary,heart rate
NCT04065633,measures_secondary,QTc interval
NCT04065633,measures_secondary,PR interval
NCT04065633,measures_secondary,QRS complex
NCT04065633,has_criteria,Body mass index
NCT04065633,has_criteria,total body weight
NCT04065633,has_criteria,gastrectomy
NCT04065633,has_criteria,HIV infection
NCT04065633,has_criteria,hepatitis B
NCT04065633,has_criteria,hepatitis
NCT04065633,has_criteria,dermatological condition
NCT04065633,has_criteria,atopic dermatitis
NCT04065633,has_criteria,psoriasis
NCT04065633,has_criteria,tuberculosis
NCT04065633,has_criteria,chronic infections
NCT04065633,has_criteria,recurrent infections
NCT04065633,has_criteria,latent infections
NCT04065633,has_criteria,disseminated herpes zoster
NCT04065633,has_criteria,disseminated herpes simplex
NCT04065633,has_criteria,malignancies
NCT02597933,involves,Scleroderma Related Lung Fibrosis
NCT02597933,evaluates,Nintedanib
NCT02597933,measures_primary,Annual Rate of Decline in FVC
NCT02597933,measures_secondary,Modified Rodnan Skin Score
NCT02597933,measures_secondary,Saint George's Respiratory Questionnaire Total Score
NCT02597933,has_criteria,Baseline and up to 52 weeks
NCT02040233,involves,Heart Failure
NCT02040233,evaluates,BAY 1067197
NCT02040233,measures_primary,Left Ventricular Ejection Fraction
NCT02040233,measures_secondary,Heart Rate
NCT02040233,measures_secondary,Blood Pressure
NCT02040233,measures_secondary,Atrio-Ventricular Block
NCT02040233,has_criteria,Day 29
NCT01377233,involves,Schizophrenia
NCT01377233,evaluates,Zicronapine
NCT01377233,measures_primary,PANSS Total Score
NCT01377233,measures_secondary,CGI-S Change
NCT01377233,measures_secondary,CGI-I
NCT01377233,has_criteria,treatment-emergent adverse events
NCT03806933,involves,Glabellar Frown Lines
NCT03806933,evaluates,NT 201
NCT03806933,measures_primary,Duration of Effect
NCT03806933,measures_secondary,Adverse Event
NCT03806933,has_criteria,Treatment-emergent Adverse Event
NCT01478633,involves,Dementia of Alzheimer's type
NCT01478633,evaluates,Galantamine
NCT01478633,measures_primary,ADAS-J cog score
NCT01478633,measures_secondary,CGI-C
NCT01478633,has_criteria,probable Alzheimer's disease
NCT01478633,has_criteria,MMSE score 10 to 22
NCT01478633,has_criteria,donepezil 5 mg/day
NCT01478633,has_criteria,worsening cognitive function
NCT01478633,has_criteria,medically stable
NCT00603733,involves,Ulcerative Colitis
NCT00603733,evaluates,Pentasa
NCT00603733,measures_primary,Overall Improvement
NCT00603733,measures_secondary,Relapse
NCT00603733,has_criteria,Mild to moderate Ulcerative Colitis
NCT00421733,involves,Type 2 Diabetic Nephropathy
NCT00421733,evaluates,Paricalcitol Capsules
NCT00421733,measures_primary,Urine Albumin to Creatinine Ratio (UACR)
NCT00421733,measures_secondary,Albumin Levels
NCT00421733,has_criteria,Baseline (within 1 week prior to first treatment) through 24 weeks of treatment
NCT04488133,involves,Spinal Muscular Atrophy
NCT04488133,evaluates,Nusinersen
NCT04488133,measures_primary,Motor Milestones Score
NCT04488133,measures_secondary,Adverse Events
NCT04488133,measures_secondary,Serious Adverse Events
NCT04488133,measures_secondary,Clinical Laboratory Parameters
NCT04488133,measures_secondary,Electrocardiograms
NCT04488133,measures_secondary,Vital Signs
NCT04488133,has_criteria,WHO Criteria
NCT01320033,involves,Acne Vulgaris
NCT01320033,evaluates,CD2475/101
NCT01320033,evaluates,Placebo
NCT01320033,evaluates,Doxycycline
NCT01320033,measures_primary,Inflammatory lesion counts
NCT01320033,measures_secondary,Investigator Global Assessment
NCT01320033,has_criteria,Last Observation Carried Forward
NCT02395133,involves,Atopic Dermatitis
NCT02395133,evaluates,Dupilumab
NCT02395133,measures_primary,EASI-75 at Week 36
NCT02395133,measures_secondary,IGA Response
NCT02395133,has_criteria,Missing value at week 36
NCT00546754,involves,essential hypertension
NCT00546754,evaluates,Losartan 50 mg/Hydrochlorothiazide 12.5 mg
NCT00546754,evaluates,Valsartan 80 mg/Hydrochlorothiazide 12.5 mg
NCT00546754,measures_primary,Change in Systolic Blood Pressure
NCT00546754,measures_primary,Change in Diastolic Blood Pressure
NCT00546754,measures_secondary,Number of Patients Achieving Target Blood Pressure
NCT00546754,measures_secondary,Time to Achieve Target Blood Pressure
NCT00546754,measures_secondary,Change in Uric Acid
NCT00546754,measures_secondary,Change in Serum Highly Sensitive C-reactive Protein
NCT00546754,measures_secondary,Change in Gamma-Glutamyl Transpeptidase (Gamma-GT)
NCT00546754,has_criteria,Adult Patient 18 to 75 Years Of Age
NCT00546754,has_criteria,essential hypertension
NCT00546754,has_criteria,antihypertensive agent in monotherapy
NCT00546754,has_criteria,blood pressure > 140/90 mm Hg
NCT00546754,has_criteria,blood pressure > 130/80 mm Hg
NCT05603754,involves,Knee Osteoarthritis
NCT05603754,evaluates,Lorecivivint
NCT05603754,measures_primary,Change from baseline OA pain
NCT05603754,measures_secondary,WOMAC Function
NCT05603754,measures_secondary,OA disease activity
NCT05603754,has_criteria,Males and females 40-80 years
NCT03194633,involves,Chronic Kidney Disease
NCT03194633,involves,Hypertension
NCT03194633,evaluates,Nifedipine Gastrointestinal Therapeutic System
NCT03194633,measures_primary,Change in office SBP
NCT03194633,measures_secondary,Change in office DBP
NCT03194633,measures_secondary,Systolic blood pressure control rate
NCT03194633,measures_secondary,Diastolic blood pressure control rate
NCT03194633,measures_secondary,Adverse events
NCT03194633,has_criteria,eGFR >15 mL/min/1.73 m\*2
NCT03194633,has_criteria,age 18-70 years
NCT03194633,has_criteria,uncontrolled hypertension
NCT03194633,has_criteria,RASI treatment or contraindications
NCT03194633,has_criteria,no prior nifedipine GITS 60 mg
NCT04987333,evaluates,Efavaleukin Alfa
NCT04987333,measures_primary,Number of Participants
NCT04987333,measures_secondary,Treatment-emergent Adverse Events
NCT04987333,has_criteria,clinically significant changes
NCT03569033,involves,Viral Upper Respiratory Tract Infection
NCT03569033,evaluates,Gefapixant
NCT03569033,measures_primary,Awake Coughs Per Hour
NCT03569033,measures_secondary,Cough Severity VAS Score
NCT03569033,measures_secondary,Mean Total Daily CSD Score
NCT03569033,measures_secondary,Leicester Cough Questionnaire-Acute Score
NCT03569033,has_criteria,Induced Viral URTI
NCT06347133,involves,Hypertriglyceridemia
NCT06347133,evaluates,Plozasiran
NCT06347133,measures_primary,Percent Change in TG
NCT06347133,measures_secondary,Proportion of Participants achieving Fasting TG Levels <150 mg/dL
NCT06347133,measures_secondary,Number of Participants with Adverse Events
NCT06347133,measures_secondary,Incidence Rates of New-Onset Diabetes Mellitus
NCT06347133,measures_secondary,Incidence Rates of Worsening of Existing Diabetes
NCT06347133,measures_secondary,Change from Baseline in Hemoglobin A1c
NCT06347133,measures_secondary,Change from Baseline in Fasting Blood Glucose
NCT06347133,measures_secondary,Change from Baseline in C-peptide
NCT06347133,measures_secondary,Change from Baseline in HOMA-IR
NCT06347133,measures_secondary,Change from Baseline in Treatment-Emergent Adverse Events
NCT06347133,measures_secondary,Initiation of New Medication for Hyperglycemia
NCT01833533,involves,Chronic Hepatitis C Infection
NCT01833533,evaluates,ABT-450/r/ABT-267
NCT01833533,evaluates,ABT-333
NCT01833533,measures_primary,Sustained virologic response
NCT01833533,measures_secondary,Sustained virologic response
NCT01833533,has_criteria,HCV GT1a infection
NCT01621633,involves,Hepatic Impairment
NCT01621633,evaluates,LCZ696
NCT01621633,measures_primary,AUClast
NCT01621633,measures_primary,AUCinf
NCT01621633,measures_primary,Cmax
NCT01621633,measures_secondary,Adverse Events
NCT01621633,measures_secondary,Serious Adverse Events
NCT01621633,measures_secondary,Death
NCT01621633,has_criteria,Age 18-75 years
NCT01621633,has_criteria,Body weight ≥55 kg
NCT01621633,has_criteria,BMI 18-35 kg/m2
NCT01621633,has_criteria,Mild or moderate hepatic impairment
NCT01621633,has_criteria,No postural hypotension
NCT01621633,has_criteria,No hypersensitivity to LCZ696
NCT04751487,involves,Chronic Obstructive Pulmonary Disease
NCT04751487,evaluates,SAR440340/REGN3500/Itepekimab
NCT04751487,measures_primary,Annualized rate AECOPD
NCT04751487,measures_secondary,Change from baseline FEV1
NCT04751487,measures_secondary,Time to first AECOPD
NCT04751487,has_criteria,former smokers
NCT01020487,involves,Chronic Kidney Disease
NCT01020487,evaluates,Paricalcitol Capsules
NCT01020487,measures_primary,iPTH reductions
NCT01020487,measures_secondary,Calcium levels
NCT01020487,measures_secondary,Phosphorus levels
NCT01020487,has_criteria,Children Aged 10-16
NCT02795754,involves,Hematology parameters
NCT02795754,evaluates,GSK2838232
NCT02795754,measures_primary,absolute values
NCT02795754,measures_secondary,change from Baseline
NCT02795754,has_criteria,Baseline (Day-1)
NCT03381287,involves,Hypercholesterolemia
NCT03381287,evaluates,HTD1801
NCT03381287,measures_primary,Percent Change LDL-C
NCT03381287,measures_secondary,Percent Change Triglycerides
NCT03381287,measures_secondary,Percent Change FFA
NCT03381287,measures_secondary,Percent Change Lipoprotein-A
NCT03381287,has_criteria,BMI 25.0 to 45.0 kg/m2
NCT03381287,has_criteria,aged 18 to 70 years
NCT04072887,involves,COPD
NCT04072887,evaluates,QBW251
NCT04072887,measures_primary,Change from baseline FEV1
NCT04072887,measures_secondary,Evaluating Respiratory Symptoms
NCT04072887,has_criteria,smoking status at screening
NCT03607487,involves,Hidradenitis Suppurativa
NCT03607487,evaluates,INCB054707
NCT03607487,measures_primary,Proportion of Participants Achieving a Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit
NCT03607487,measures_secondary,Proportion of Participants Achieving an AN Count of 0 to 2 at Each Visit
NCT03607487,measures_secondary,Mean Change From Baseline in the Hidradenitis Suppurativa Pain Numeric Rating Scale (HS Pain NRS) Scores at Each Visit
NCT03607487,measures_secondary,Mean Change From Baseline in the Modified Sartorius Scale Score
NCT03607487,has_criteria,Up to 12 weeks
NCT04091087,involves,stasis dermatitis
NCT04091087,evaluates,Crisaborole
NCT04091087,measures_primary,Total Sign Score
NCT04091087,measures_secondary,Investigator's Static Global Assessment
NCT04091087,has_criteria,treatment success
NCT03629951,involves,Schizophrenia
NCT03629951,evaluates,oral antipsychotic
NCT03629951,measures_primary,Number of relapse
NCT03629951,measures_secondary,Clinical State
NCT03629951,has_criteria,Informed consent
NCT01575054,involves,Post-Stroke Lower Limb Spasticity
NCT01575054,evaluates,BOTOX®
NCT01575054,measures_primary,MAS-B ankle change
NCT01575054,measures_secondary,CGI by Physician score
NCT01575054,has_criteria,Baseline
NCT06175351,involves,Chronic Obstructive Pulmonary Disease
NCT06175351,evaluates,9MW1911
NCT06175351,measures_primary,Changes from baseline in FEV1
NCT06175351,measures_secondary,Time to first moderate to severe AECOPD
NCT06175351,measures_secondary,Annualized rate of moderate to severe AECOPD
NCT06175351,has_criteria,Baseline to week 24
NCT06064851,involves,Von Willebrand Disease
NCT06064851,evaluates,Transcutaneous Auricular Neurostimulation
NCT06064851,measures_primary,Menstrual blood loss
NCT06064851,measures_secondary,Quality of Life
NCT06064851,measures_secondary,Dysmenorrhea
NCT02634151,involves,Hypercholesterolemia
NCT02634151,evaluates,Gemcabene
NCT02634151,measures_primary,Percent Change LDL-C
NCT02634151,measures_secondary,Non-HDL-C
NCT02634151,measures_secondary,TC
NCT02634151,measures_secondary,TG
NCT02634151,measures_secondary,VLDL-C
NCT02634151,measures_secondary,HDL-C
NCT02634151,measures_secondary,Apolipoprotein B
NCT02634151,measures_secondary,Apolipoprotein A-I
NCT02634151,measures_secondary,Apolipoprotein A-II
NCT05089851,involves,Facial Lines
NCT05089851,evaluates,Onabotulinumtoxin A
NCT05089851,measures_primary,Investigator Clinical Grading
NCT05089851,measures_primary,Investigator Tolerability Assessment
NCT05089851,measures_primary,Incidence of Adverse Events
NCT05089851,measures_secondary,Self-Assessment Questionnaire
NCT05089851,has_criteria,healthy subjects
NCT01574651,involves,Chronic Obstructive Pulmonary Disease
NCT01574651,evaluates,QVA149
NCT01574651,measures_primary,SGRQ-C Total Score
NCT01574651,measures_secondary,Symptom scores
NCT01574651,has_criteria,Baseline
NCT00740051,involves,Type 2 Diabetes
NCT00740051,evaluates,BI 1356
NCT00740051,measures_primary,HbA1c Change
NCT00740051,measures_secondary,Fasting Plasma Glucose
NCT00740051,measures_secondary,Percentage of Patients
NCT00740051,has_criteria,Metformin intolerance
NCT01028651,involves,Portopulmonary Hypertension
NCT01028651,evaluates,Treprostinil
NCT01028651,measures_primary,mPAP less than 35 mmHg
NCT01028651,measures_primary,PVR less than 3 WU
NCT01028651,measures_secondary,systolic pulmonary arterial pressure
NCT01028651,measures_secondary,diastolic pulmonary arterial pressure
NCT01028651,measures_secondary,mean pulmonary arterial pressure
NCT01028651,measures_secondary,transpulmonary gradient
NCT01028651,measures_secondary,heart rate
NCT01028651,measures_secondary,cardiac output
NCT01028651,measures_secondary,arterial oxygen saturation
NCT01028651,measures_secondary,venous oxygen saturation
NCT01028651,measures_secondary,pulmonary vascular resistance
NCT01028651,measures_secondary,6-minute Walk Distance
NCT03745651,involves,Atopic Dermatitis
NCT03745651,evaluates,Ruxolitinib Cream
NCT03745651,measures_primary,IGA-TS at Week 8
NCT03745651,measures_secondary,EASI75 at Week 8
NCT03745651,measures_secondary,Itch NRS Score
NCT03745651,has_criteria,Baseline to Week 8
NCT02162251,involves,Alzheimer's Disease
NCT02162251,evaluates,Donepezil Hydrochloride
NCT02162251,evaluates,Memantine Hydrochloride
NCT02162251,measures_primary,Change from Baseline
NCT02162251,measures_secondary,MMSE Score
NCT02162251,has_criteria,diagnosed with Alzheimer's Disease
NCT02162251,has_criteria,administered donepezil hydrochloride
NCT02162251,has_criteria,administered memantine hydrochloride
NCT02162251,has_criteria,history of hypersensitivity
NCT03733353,involves,Psoriasis
NCT03733353,involves,Atopic Dermatitis
NCT03733353,evaluates,EDP1815
NCT03733353,measures_primary,Change from baseline
NCT03733353,measures_secondary,Adverse Events
NCT03733353,measures_secondary,Laboratory values
NCT03733353,measures_secondary,ECG parameters
NCT03733353,measures_secondary,Physical examination
NCT03733353,has_criteria,Body mass index
NCT02864953,involves,Severe Cerebral Edema
NCT02864953,evaluates,Intravenous BIIB093
NCT02864953,measures_primary,mRS 0-4 at Day 90
NCT02864953,measures_secondary,Time to All-Cause Death
NCT02864953,measures_secondary,Midline Shift at 72 Hours
NCT02864953,measures_secondary,Percentage of Participants With Adverse Events
NCT02864953,has_criteria,randomization up to Day 90
NCT01640951,involves,Chronic Plaque-type Psoriasis
NCT01640951,evaluates,Secukinumab
NCT01640951,measures_primary,PASI Score 75
NCT01640951,measures_secondary,PASI Score 50
NCT01640951,measures_secondary,PASI Score 90
NCT01640951,measures_secondary,PASI Score 100
NCT01640951,has_criteria,treatment emergent Adverse Event
NCT04185051,involves,Gastric Mucosal Integrity
NCT04185051,evaluates,JNJ-67953964
NCT04185051,measures_primary,Percentage of Participants
NCT04185051,measures_secondary,Gastroscopy Lanza Score
NCT04185051,has_criteria,Healthy Male and Female
NCT02386553,involves,Spinal Muscular Atrophy
NCT02386553,evaluates,Nusinersen
NCT02386553,measures_primary,Time to death or respiratory intervention
NCT02386553,measures_secondary,Percentage of participants developing clinically manifested SMA
NCT02386553,has_criteria,Genetically Diagnosed and Presymptomatic
NCT05677451,involves,CSU
NCT05677451,evaluates,LOU064
NCT05677451,measures_primary,Change from baseline in UAS7
NCT05677451,measures_secondary,Change fron baseline in ISS7
NCT05677451,measures_secondary,Change from baseline in HSS7
NCT05677451,has_criteria,Adolescents (12 - <18)
NCT03605251,involves,Rheumatoid Arthritis
NCT03605251,evaluates,TAS5315
NCT03605251,measures_primary,ACR20 response
NCT03605251,measures_secondary,ACR50 response
NCT03605251,measures_secondary,ACR70 response
NCT03605251,measures_secondary,DAS28-hs CRP remission
NCT03605251,measures_secondary,DAS28-ESR remission
NCT03605251,measures_secondary,CDAI remission
NCT03605251,measures_secondary,SDAI remission
NCT03605251,has_criteria,diagnosis of RA
NCT03605251,has_criteria,methotrexate treatment
NCT01534351,involves,Benign Prostatic Hyperplasia
NCT01534351,evaluates,Finasteride
NCT01534351,evaluates,Tamsulosin
NCT01534351,measures_primary,Percent Change IPSS
NCT01534351,measures_secondary,Prostate Volume
NCT01534351,measures_secondary,Adverse Events
NCT01534351,measures_secondary,Treatment Discontinuation
NCT01534351,has_criteria,BPH diagnosis
NCT03823287,involves,Neovascular Age-Related Macular Degeneration
NCT03823287,evaluates,Faricimab
NCT03823287,measures_primary,Change From Baseline in BCVA
NCT03823287,measures_secondary,Best Corrected Visual Acuity
NCT03823287,has_criteria,baseline BCVA
NCT06463587,involves,Generalized Myasthenia Gravis
NCT06463587,evaluates,Oral Cladribine
NCT06463587,measures_primary,MG-ADL Scale Score
NCT06463587,measures_secondary,QMG Scale Score
NCT06463587,measures_secondary,MGC Scale Score
NCT06463587,measures_secondary,MG-Qol15r Score
NCT06463587,has_criteria,National Cancer Institute Common Terminology Criteria for Adverse Events
NCT01106651,involves,Type 2 Diabetes Mellitus
NCT01106651,evaluates,Canagliflozin
NCT01106651,measures_primary,Change in HbA1c
NCT01106651,measures_secondary,Fasting Plasma Glucose
NCT01106651,measures_secondary,Body Weight
NCT01106651,measures_secondary,Total Fat
NCT01106651,has_criteria,55 to 80 Years of Age
NCT00764751,involves,Psoriasis Vulgaris
NCT00764751,evaluates,LEO 19123 Cream
NCT00764751,measures_primary,PASI score
NCT00764751,measures_secondary,Investigator's Global Assessment
NCT00764751,has_criteria,moderate or worse severity
NCT00630851,involves,Alzheimer's disease
NCT00630851,evaluates,Aricept
NCT00630851,measures_primary,ADCS-ADL-severe total score
NCT00630851,measures_secondary,SIB total score
NCT00630851,measures_secondary,NPI total score
NCT00630851,measures_secondary,MMSE total score
NCT00630851,measures_secondary,CGI-I score
NCT00630851,has_criteria,probable or possible Alzheimer's disease
NCT00630851,has_criteria,living in skilled nursing home
NCT02729051,involves,Chronic Obstructive Pulmonary Disease
NCT02729051,evaluates,Fluticasone Furoate/Umeclidinium Bromide/Vilanterol
NCT02729051,measures_primary,Change in FEV1
NCT02729051,measures_secondary,Percentage of Responders
NCT02729051,has_criteria,Modified Per Protocol
NCT06109051,involves,attention-deficit/hyperactivity disorder
NCT06109051,evaluates,Computerized Adaptive Test
NCT06109051,measures_primary,ADHD severity
NCT06109051,measures_secondary,ADHD symptoms and behaviors
NCT06109051,measures_secondary,quality of life
NCT06109051,has_criteria,adults 18 and over
NCT05692154,involves,Seasonal Allergic Rhinitis
NCT05692154,evaluates,Fexofenadine
NCT05692154,measures_primary,AUC of TNSS
NCT05692154,measures_secondary,AUC of TOSS
NCT05692154,has_criteria,2-day Pre-treatment
NCT03072953,involves,Pyoderma Gangrenosum
NCT03072953,evaluates,APD334
NCT03072953,measures_primary,Physician Global Assessments
NCT03072953,measures_secondary,Patient Global Assessments
NCT03072953,measures_secondary,Dermatology Life Quality Index
NCT03072953,measures_secondary,C-reactive Protein Levels
NCT03072953,has_criteria,18-80 years old
NCT05626751,involves,Diffuse Cutaneous Systemic Sclerosis
NCT05626751,evaluates,HZNP-HZN-825-301
NCT05626751,measures_primary,FVC % predicted
NCT05626751,measures_secondary,Incidence TEAEs
NCT05626751,measures_secondary,Incidence AESI
NCT05626751,measures_secondary,Concomitant medication
NCT05626751,measures_secondary,Vital signs
NCT05626751,measures_secondary,ECG measurements
NCT05626751,measures_secondary,Laboratory test results
NCT05626751,has_criteria,Clinically significant
NCT03095651,involves,Type 1 Diabetes Mellitus
NCT03095651,involves,Type 2 Diabetes Mellitus
NCT03095651,evaluates,MK-5160
NCT03095651,measures_primary,Maximal Glucose Infusion Rate
NCT03095651,measures_secondary,Maximum Plasma Concentration
NCT03095651,measures_secondary,Maximum Plasma Concentration of Glargine
NCT03095651,has_criteria,Up to 33 days
NCT03095651,has_criteria,Up to 12 days
NCT00751751,involves,Hypertension
NCT00751751,evaluates,Olmesartan Medoxomil
NCT00751751,evaluates,Losartan
NCT00751751,measures_primary,Diastolic blood pressure
NCT00751751,measures_secondary,Systolic blood pressure
NCT00751751,has_criteria,Age 65 years or older
NCT00751751,has_criteria,Mean sitting diastolic BP 100-114 mmHg
NCT00751751,has_criteria,Mean sitting systolic BP >=150 mmHg
NCT00751751,has_criteria,Secondary hypertension
NCT00751751,has_criteria,Malignant hypertension
NCT00751751,has_criteria,Severe heart failure
NCT00751751,has_criteria,Renal disease
NCT00751751,has_criteria,Myocardial infarction
NCT00751751,has_criteria,Hypersensitivity to study drugs
NCT00751751,has_criteria,Drug or alcohol abuse
NCT04376554,involves,Normal Human Intestinal Microbiota
NCT04376554,evaluates,Tebipenem
NCT04376554,measures_primary,Number of microorganisms
NCT04376554,measures_secondary,Types of microorganisms
NCT04376554,has_criteria,Oral administration
NCT02200653,involves,Hypertension
NCT02200653,evaluates,MICARDIS
NCT02200653,evaluates,COZAAR
NCT02200653,evaluates,LORZAAR
NCT02200653,measures_primary,Change in diastolic blood pressure
NCT02200653,measures_primary,Change in systolic blood pressure
NCT02200653,measures_secondary,24-hour mean blood pressure
NCT02200653,measures_secondary,morning mean blood pressure
NCT02200653,measures_secondary,daytime mean blood pressure
NCT02200653,measures_secondary,nighttime mean blood pressure
NCT02200653,measures_secondary,seated trough diastolic blood pressure
NCT02200653,measures_secondary,seated trough systolic blood pressure
NCT02200653,has_criteria,mean seated diastolic blood pressure
NCT02200653,has_criteria,24-mean DBP
NCT02200653,has_criteria,Age 18 years or older
NCT02200653,has_criteria,Ability to stop antihypertensive therapy
NCT02200653,has_criteria,written informed consent
NCT02200653,has_criteria,Pre-menopausal women
NCT02200653,has_criteria,surgically sterile
NCT02200653,has_criteria,nursing
NCT02200653,has_criteria,child-bearing potential
NCT02200653,has_criteria,acceptable means of birth control
NCT04804553,involves,Juvenile Psoriatic Arthritis
NCT04804553,evaluates,Apremilast
NCT04804553,measures_primary,ACR Pedi 30 Response
NCT04804553,measures_secondary,ACR Pedi 20
NCT04804553,has_criteria,30 percent improvement
NCT00463151,involves,Ulcerative Colitis
NCT00463151,evaluates,Rebamipide
NCT00463151,measures_primary,Clinical Improvement Rate
NCT00463151,measures_secondary,Clinical Remission
NCT00463151,measures_secondary,Mean Change From Baseline in Total DAI Score
NCT00463151,measures_secondary,Percentage of Subjects Showing Improvement in Each DAI Subscore
NCT00463151,measures_secondary,Mean Change From Baseline in Total Endoscopic Index (EI) Score
NCT00463151,has_criteria,Patients with active ulcerative colitis
NCT03151551,involves,Psoriatic Arthritis
NCT03151551,evaluates,Ixekizumab
NCT03151551,evaluates,Adalimumab
NCT03151551,measures_primary,ACR50 response
NCT03151551,measures_secondary,PASI100
NCT03151551,has_criteria,BSA≥3% & PASI=0 at baseline
NCT02202551,involves,Parkinson's disease
NCT02202551,involves,levodopa-induced dyskinesia
NCT02202551,evaluates,ADS-5102
NCT02202551,measures_primary,MDS-UPDRS (Parts I-III)
NCT02202551,measures_secondary,MDS-UPDRS (Part IV)
NCT02202551,has_criteria,Up to 101 weeks
NCT06125951,involves,Dementia Due to Alzheimer's Disease
NCT06125951,evaluates,Xanamem
NCT06125951,measures_primary,Change from Baseline to end of treatment
NCT06125951,measures_secondary,Incidence and severity of TEAEs
NCT06125951,has_criteria,Clinical Dementia Rating global score of 0.5 to 1.0
NCT06125951,has_criteria,Mini-mental state examination score of 18 to 26
NCT06125951,has_criteria,Magnetic resonance imaging or computerized tomography scan
NCT06125951,has_criteria,Positive plasma AD biomarker signature
NCT06125951,has_criteria,Cognitive impairment on a symbol coding test
NCT06125951,has_criteria,Stable symptomatic AD medications
NCT06125951,has_criteria,Consenting trial partner
NCT00343551,involves,Essential Hypertension
NCT00343551,evaluates,Aliskiren 300mg
NCT00343551,evaluates,Irbesartan 300mg
NCT00343551,evaluates,Ramipril 10 mg
NCT00343551,measures_primary,MADBP change
NCT00343551,measures_secondary,MASBP change
NCT00343551,has_criteria,Office Mean Sitting Diastolic Blood Pressure
NCT00343551,has_criteria,24-hr Mean Ambulatory Diastolic Blood Pressure
NCT00343551,has_criteria,absolute difference in blood pressure
NCT00343551,has_criteria,age 18 years or older
NCT00343551,has_criteria,post-menopausal
NCT04218851,involves,Invasive Aspergillosis
NCT04218851,evaluates,Posaconazole
NCT04218851,measures_primary,Treatment-related AEs
NCT04218851,measures_secondary,Favorable global clinical response
NCT04218851,measures_secondary,Relapse of invasive aspergillosis
NCT04218851,has_criteria,Modified 2008 EORTC/MSG disease definitions
NCT00529451,involves,Essential Hypertension
NCT00529451,evaluates,Aliskiren 300 mg
NCT00529451,evaluates,Aliskiren 150 mg
NCT00529451,evaluates,Aliskiren 75 mg
NCT00529451,evaluates,Ramipril 5 mg
NCT00529451,measures_primary,Change in msDBP
NCT00529451,measures_primary,Change in msSBP
NCT00529451,measures_secondary,Percentage of Patients Controlled
NCT00529451,measures_secondary,Percentage of Responders
NCT00529451,has_criteria,Baseline and Week 8
NCT04294654,involves,Depression
NCT04294654,involves,Dementia
NCT04294654,evaluates,Vortioxetine
NCT04294654,measures_primary,MADRS total score
NCT04294654,measures_secondary,DSST score
NCT04294654,measures_secondary,RAVLT score
NCT04294654,measures_secondary,IADL score
NCT04294654,has_criteria,baseline to Week 12
NCT03536754,involves,FSGS
NCT03536754,evaluates,CCX140-B
NCT03536754,measures_primary,UPCR at Week 12
NCT03536754,measures_secondary,Number of Participants
NCT03536754,has_criteria,Baseline to Week 12
NCT04445987,involves,Seborrheic Dermatitis
NCT04445987,evaluates,ARQ-154 Foam
NCT04445987,measures_primary,IGA score 0 or 1
NCT04445987,measures_secondary,Adverse Events
NCT04445987,measures_secondary,Serious Adverse Events
NCT01732211,involves,Chronic Pulmonary Sarcoidosis
NCT01732211,evaluates,PD 0360324
NCT01732211,measures_primary,Change From Baseline in % Predicted FVC
NCT01732211,measures_secondary,Chest X-ray Global Assessment Score
NCT01732211,measures_secondary,Change From Baseline in FVC
NCT01732211,measures_secondary,Change From Baseline Absolute in FVC (% Predicted)
NCT01732211,measures_secondary,Change From Baseline in Forced Expiratory Volume in 1 Second
NCT01732211,has_criteria,age
NCT06095128,involves,Ulcerative Colitis
NCT06095128,evaluates,Vedolizumab
NCT06095128,evaluates,Tofacitinib
NCT06095128,measures_primary,Clinical Remission
NCT06095128,measures_primary,Clinical Remission
NCT06095128,measures_primary,Clinical Remission
NCT06095128,measures_primary,Clinical Response
NCT06095128,has_criteria,Week 8
NCT06095128,has_criteria,Week 52
NCT06095128,has_criteria,Week 8
NCT06095128,has_criteria,Week 14
NCT06095128,has_criteria,Week 26
NCT02886728,involves,Rheumatoid Arthritis
NCT02886728,evaluates,Filgotinib
NCT02886728,evaluates,Methotrexate
NCT02886728,measures_primary,ACR20 response
NCT02886728,measures_secondary,HAQ-DI score
NCT02886728,has_criteria,MTX naive adults
NCT01244828,involves,Schizophrenia
NCT01244828,evaluates,Asenapine
NCT01244828,measures_primary,Change From Baseline in Weight
NCT01244828,measures_secondary,Change From Baseline in BMI
NCT01244828,measures_secondary,Number of Participants With Extrapyramidal Symptoms
NCT01244828,measures_secondary,Change From Baseline in HbA1c
NCT01244828,measures_secondary,Change From Baseline in Fasting Glucose
NCT01244828,measures_secondary,Change From Baseline in Insulin
NCT01244828,has_criteria,Multiple or/and High Dose Drugs
NCT06322628,involves,Nonalcoholic steatohepatitis
NCT06322628,evaluates,VSA006
NCT06322628,measures_primary,NASH Improvement
NCT06322628,measures_secondary,Liver fat fraction
NCT06322628,has_criteria,Chinese NASH Patients
NCT03042611,involves,Gastric Cancer
NCT03042611,evaluates,Rivocearnib
NCT03042611,measures_primary,Overall Survival
NCT03042611,measures_secondary,Progression-free Survival
NCT03042611,measures_secondary,Objective Response Rate
NCT03042611,measures_secondary,Disease Control Rate
NCT03042611,measures_secondary,Change From Baseline in Global Health Status/Quality of Life
NCT03042611,has_criteria,Day 1 (randomization) up to approximately 36 months
NCT03042611,has_criteria,Up to approximately 24 months
NCT05979311,involves,Human Immunodeficiency Virus (HIV)-1
NCT05979311,evaluates,Oral Once-daily 2 Drug Regimen
NCT05979311,evaluates,Oral Once-daily 3 Drug Regimen
NCT05979311,measures_primary,HIV-1 RNA <50 c/mL
NCT05979311,measures_secondary,HIV-1 RNA change from baseline
NCT05979311,measures_secondary,CD4+ cell count
NCT05979311,measures_secondary,CD4/CD8 ratio
NCT05979311,measures_secondary,HIV-1 Disease Progression
NCT05979311,measures_secondary,Time to virologic suppression
NCT05979311,measures_secondary,Virologic withdrawal
NCT05979311,measures_secondary,Treatment-emergent resistance
NCT05979311,measures_secondary,Renal Biomarkers- estimated glomerular filtration rate
NCT05979311,measures_secondary,Renal Biomarkers- urinary protein/creatinine
NCT05979311,measures_secondary,Renal Biomarker- Serum Cystatin C
NCT05979311,measures_secondary,Renal Biomarker- Serum Retinol Binding Protein (RBP)
NCT04788511,involves,Heart Failure
NCT04788511,involves,Obesity
NCT04788511,evaluates,Semaglutide
NCT04788511,measures_primary,KCCQ-CSS
NCT04788511,measures_secondary,Body Weight
NCT04788511,measures_secondary,6MWD
NCT04788511,has_criteria,uninterrupted time interval
NCT00446511,involves,Hypertension
NCT00446511,evaluates,Valsartan
NCT00446511,evaluates,Enalapril
NCT00446511,measures_primary,Change in msDBP
NCT00446511,measures_secondary,BP Control at Week 26
NCT00446511,measures_secondary,Change in 24-hour ABPM
NCT00446511,has_criteria,Non-CKD patients
NCT00446511,has_criteria,CKD patients
NCT02262728,involves,Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
NCT02262728,evaluates,Simeprevir
NCT02262728,measures_primary,SVR12
NCT02262728,measures_secondary,On-Treatment Virologic Response
NCT02262728,has_criteria,HCV RNA
NCT03333928,involves,Primary Sclerosing Cholangitis
NCT03333928,evaluates,HTD1801
NCT03333928,measures_primary,Absolute Change in ALP
NCT03333928,measures_secondary,Percentage of Subjects Who Achieve ALP of <1.5 x ULN at the End of Week 6
NCT03333928,has_criteria,Age 18-75 years
NCT04839328,involves,Plaque Psoriasis
NCT04839328,evaluates,Hemay005
NCT04839328,measures_primary,PASI75
NCT04839328,measures_secondary,sPGA
NCT04839328,has_criteria,Inclusion Criteria
NCT01309828,involves,Hypertension
NCT01309828,involves,Kidney Disease
NCT01309828,evaluates,Azilsartan Medoxomil
NCT01309828,evaluates,Chlorthalidone
NCT01309828,evaluates,Olmesartan Medoxomil
NCT01309828,evaluates,Hydrochlorothiazide
NCT01309828,measures_primary,Systolic Blood Pressure
NCT01309828,measures_primary,Diastolic Blood Pressure
NCT01309828,measures_secondary,Both Systolic and Diastolic Blood Pressure
NCT01309828,has_criteria,Target Blood Pressure
NCT02193828,involves,Dupuytren's Disease
NCT02193828,evaluates,AA4500
NCT02193828,measures_primary,Percent Change From Baseline
NCT02193828,measures_secondary,Change From Baseline in Consistency
NCT02193828,measures_secondary,Percent Change From Baseline in Hardness
NCT00923611,involves,Essential Hypertension
NCT00923611,evaluates,Fimasartan
NCT00923611,measures_primary,diastolic blood pressure
NCT00923611,measures_secondary,systolic blood pressure
NCT00923611,has_criteria,Mild to Moderate
NCT02828111,involves,Sporadic Nodular Basal Cell Carcinomas
NCT02828111,evaluates,Patidegib Gel
NCT02828111,measures_primary,GLI1 mRNA Levels
NCT02828111,measures_secondary,Tumor Size
NCT02828111,has_criteria,clinically diagnosed BCC 5 to 20 mm
NCT00219128,involves,High Blood Pressure
NCT00219128,evaluates,Aliskiren
NCT00219128,measures_primary,Change in diastolic blood pressure
NCT00219128,measures_secondary,Change in systolic blood pressure
NCT00219128,has_criteria,Essential hypertension
NCT00219128,has_criteria,Severe hypertension
NCT05143528,involves,Early Alzheimer's Disease
NCT05143528,evaluates,Nilotinib BE
NCT05143528,measures_primary,CDR-SB Score
NCT05143528,measures_secondary,ADAS-Cog 14
NCT05143528,measures_secondary,MMSE Score
NCT05143528,has_criteria,patient examination
NCT03569293,involves,Atopic Dermatitis
NCT03569293,evaluates,Upadacitinib
NCT03569293,measures_primary,EASI 75 at Week 16
NCT03569293,measures_secondary,vIGA-AD at Week 16
NCT03569293,has_criteria,Moderate to Severe
NCT06215911,involves,Chronic Heart Failure With Reduced Ejection Fraction
NCT06215911,evaluates,Tovinontrine
NCT06215911,measures_primary,Change in NT-proBNP
NCT06215911,measures_secondary,cGMP
NCT06215911,measures_secondary,BNP
NCT06215911,has_criteria,Baseline to Week 12
NCT05458011,involves,Migraine
NCT05458011,evaluates,Fremanezumab
NCT05458011,measures_primary,Monthly Average Number of Migraine Days
NCT05458011,measures_secondary,Headache Days of at Least Moderate Severity
NCT05458011,has_criteria,Baseline Period (Day -28 to Day -1)
NCT00576628,involves,Anemia
NCT00576628,evaluates,C.E.R.A.
NCT00576628,measures_primary,Mean Change in Hb
NCT00576628,measures_secondary,Percentage of Participants Maintaining Average Hb Concentration Within the Target Range of 11.0-13.0 g/dL
NCT00576628,measures_secondary,Mean Time Spent in Target Hb Range of 11.0 -13.0 g/dL During the Efficacy Evaluation Period
NCT00576628,measures_secondary,The Number of Participants Who Required Dose Adjustments During the Dose Titration Period
NCT00576628,measures_secondary,Time to Achievement of Response During the Efficacy Evaluation Period
NCT00576628,measures_secondary,Number of Participants With Red Blood Cells Transfusions
NCT00320528,involves,Attention-Deficit/Hyperactivity Disorder
NCT00320528,evaluates,Atomoxetine
NCT00320528,measures_primary,CHIP-CE Achievement
NCT00320528,measures_secondary,SNAP-IV
NCT00320528,measures_secondary,CGI-ADHD-Severity
NCT00320528,measures_secondary,CHIP-CE Satisfaction
NCT00320528,measures_secondary,CHIP-CE Comfort
NCT00320528,measures_secondary,CHIP-CE Resilience
NCT00320528,measures_secondary,CHIP-CE Risk Avoidance
NCT00320528,has_criteria,DSM-IV criteria
NCT04527328,involves,Cognitive Impairment
NCT04527328,evaluates,AKST1210
NCT04527328,measures_primary,Change from Baseline in Montreal Cognitive Assessment (MoCA)
NCT04527328,measures_secondary,Change From Baseline in Computer-based Cognitive Assessment (CogState) Composite Score
NCT04527328,has_criteria,Hemodialysis
NCT02354911,involves,Type 1 Diabetes
NCT02354911,evaluates,Autologous Immunoregulatory Dendritic Cells
NCT02354911,measures_primary,change in c-peptide AUC
NCT02354911,measures_secondary,adverse events
NCT02354911,measures_secondary,T-cells
NCT02354911,measures_secondary,dendritic cells
NCT02354911,measures_secondary,Fasting Plasma Glucose
NCT02354911,measures_secondary,Hemoglobin A1c
NCT02354911,has_criteria,8 hour fast
NCT00830128,involves,Fibromyalgia
NCT00830128,evaluates,Pregabalin
NCT00830128,measures_primary,Pain VAS Score
NCT00830128,measures_secondary,MOS Sleep Scale - Sleep Disturbance
NCT00830128,measures_secondary,MOS Sleep Scale - Snoring
NCT00830128,has_criteria,Up to 53 weeks
NCT01175811,involves,Type 2 Diabetes Mellitus
NCT01175811,evaluates,Insulin Intensification Therapies
NCT01175811,measures_primary,Change in HbA1c
NCT01175811,measures_secondary,Percentage of Participants
NCT01175811,has_criteria,Baseline
NCT03158311,involves,Asthma
NCT03158311,evaluates,QVM149
NCT03158311,evaluates,Salmeterol/Fluticasone/Tiotropium
NCT03158311,measures_primary,Change From Baseline in AQLQ Total Score
NCT03158311,measures_primary,Change From Baseline in FEV1
NCT03158311,measures_primary,Change From Baseline in ACQ-7 Total Score
NCT03158311,measures_secondary,Change From Baseline in AQLQ Total Score
NCT03158311,has_criteria,Baseline and Week 24
NCT03158311,has_criteria,Baseline
NCT03158311,has_criteria,Baseline
NCT04338711,evaluates,Modified Release (MR) formulation
NCT04338711,evaluates,Immediate Release (IR) solution
NCT04338711,measures_primary,AUCinf
NCT04338711,measures_primary,AUClast
NCT04338711,measures_primary,Cmax
NCT04338711,measures_primary,Tmax
NCT04338711,measures_secondary,Number of Participants with TEAEs
NCT04338711,measures_secondary,Serious Adverse Events (SAEs)
NCT04338711,has_criteria,Treatment-Emergent Adverse Events (Treatment Related)
NCT05276011,involves,Hip Osteoarthritis
NCT05276011,evaluates,TG-C
NCT05276011,measures_primary,Change in Hip Pain
NCT05276011,measures_secondary,Hip Disability
NCT05276011,has_criteria,Baseline to Month 12
NCT06488911,involves,Primary Biliary Cholangitis
NCT06488911,evaluates,Obeticholic Acid
NCT06488911,evaluates,Bezafibrate
NCT06488911,measures_primary,pruritus reduction
NCT06488911,measures_secondary,all-cause mortality
NCT06488911,measures_secondary,liver transplant
NCT06488911,measures_secondary,hepatic decompensation
NCT06488911,measures_secondary,MELD Score ≥15
NCT06488911,has_criteria,actively taking investigational product
NCT06488911,has_criteria,history or presence of other concomitant liver diseases
NCT05771428,involves,Alzheimer's disease
NCT05771428,evaluates,ABBV-552 Capsules
NCT05771428,measures_primary,Change in ADAS-Cog 14
NCT05771428,measures_secondary,
NCT05771428,has_criteria,Diagnosis of probable Alzheimer's disease
NCT06643728,involves,Obesity
NCT06643728,involves,Overweight
NCT06643728,evaluates,Bimagrumab
NCT06643728,evaluates,Tirzepatide
NCT06643728,measures_primary,Percent Change in Body Weight
NCT06643728,measures_secondary,Total Body Fat Mass
NCT06643728,measures_secondary,Body Weight Reduction
NCT06643728,measures_secondary,Waist Circumference
NCT06643728,measures_secondary,Body Mass Index
NCT06643728,measures_secondary,Waist-to-Height Ratio
NCT06643728,measures_secondary,Visceral Adipose Tissue
NCT06643728,measures_secondary,Total Body Lean Mass
NCT00658528,involves,Erosive Gastroesophageal Reflux Disease
NCT00658528,evaluates,Rabeprazole Extended-Release
NCT00658528,evaluates,Esomeprazole
NCT00658528,measures_primary,Endoscopically-confirmed Healing
NCT00658528,measures_secondary,Diary-recorded Sustained Resolution of Heartburn
NCT00658528,has_criteria,Los Angeles classification
NCT02534311,involves,Rheumatoid Arthritis
NCT02534311,evaluates,Subcutaneous Tocilizumab
NCT02534311,measures_primary,DAS28 change from baseline
NCT02534311,measures_secondary,DAS28 remission
NCT02534311,has_criteria,moderate to severe active RA
NCT01235728,involves,plaque-type psoriasis
NCT01235728,evaluates,MK-0873
NCT01235728,measures_primary,TLS Score change
NCT01235728,measures_secondary,Plasma concentrations
NCT01235728,has_criteria,BMI ≤36 kg/m^2
NCT04058028,involves,Systemic Lupus Erythematosus
NCT04058028,evaluates,AMG 570
NCT04058028,measures_primary,SRI-4 response
NCT04058028,measures_secondary,BICLA response
NCT04058028,measures_secondary,LLDAS response
NCT04058028,has_criteria,≥ 4-point decrease hSLEDAI
NCT04058028,has_criteria,no new BILAG 2004 A score
NCT04058028,has_criteria,no > 1 new BILAG B domain scores
NCT04058028,has_criteria,less than 0.3-point deterioration PGA
NCT04058028,has_criteria,no use of more than protocol allowed therapies
NCT04567628,involves,Crohn's Disease
NCT04567628,involves,Ulcerative Colitis
NCT04567628,evaluates,Vedolizumab
NCT04567628,measures_primary,Harvey-Bradshaw Index
NCT04567628,measures_secondary,Faecal Calprotectin
NCT04567628,measures_secondary,C-reactive Protein
NCT04567628,has_criteria,age
NCT04567628,has_criteria,sex
NCT04567628,has_criteria,disease type
NCT04567628,has_criteria,duration
NCT04567628,has_criteria,prior therapy
NCT04201093,involves,Parkinson's Disease
NCT04201093,measures_primary,Change From Baseline in MDS-UPDRS Parts II and III
NCT04201093,measures_secondary,Change From Baseline in MDS-UPDRS Part II
NCT04201093,measures_secondary,"Percentage of Responders with ""Much Improved"" or ""Very Much Improved"" on PGIC at endpoint"
NCT04201093,has_criteria,27 Weeks
NCT01611311,evaluates,BI 409306
NCT01611311,measures_primary,Maximum Measured Concentration
NCT01611311,measures_primary,Maximum Measured Concentration
NCT01611311,measures_primary,Area Under the Concentration-time Curve
NCT01611311,measures_primary,Area Under the Concentration-time Curve
NCT01611311,measures_secondary,Percentage of Subjects With Investigator Defined
NCT01611311,measures_secondary,Percentage of subjects with investigator defined
NCT01611311,has_criteria,From the first administration
NCT01893411,involves,Cerebral Palsy
NCT01893411,evaluates,Botulinum Toxin Type A
NCT01893411,measures_primary,Ashworth Scale Score
NCT01893411,measures_secondary,Investigator's Global Impression
NCT01893411,has_criteria,bilateral pes equinus
NCT06606483,involves,Obesity
NCT06606483,involves,Overweight
NCT06606483,evaluates,MDR-001
NCT06606483,measures_primary,Percent Change in Body Weight
NCT06606483,measures_secondary,Percentage of Study Participants Who Achieve ≥5% Body Weight Reduction at Week 24
NCT06606483,measures_secondary,Percentage of Study Participants Who Achieve ≥10% Body Weight Reduction at Week 24
NCT06606483,measures_secondary,Change in BMI (kg/m2)
NCT06606483,measures_secondary,Change in Waist Circumference
NCT06606483,measures_secondary,Change in hyperlipidemia (TC
NCT06606483,measures_secondary,Change in Blood Pressure (SBP
NCT06606483,measures_secondary,Change in Blood Glucose (HbA1c
NCT06606483,has_criteria,Subjects Who Are
NCT03850483,involves,Psoriasis
NCT03850483,evaluates,PF-06700841 Topical Cream
NCT03850483,measures_primary,PASI score at Week 12
NCT03850483,measures_secondary,Percentage of Participants With 75% Reduction From Baseline in PASI
NCT03850483,has_criteria,Baseline
NCT00904683,involves,Alzheimer's Disease
NCT00904683,evaluates,LY2062430
NCT00904683,measures_primary,Change from Baseline to Week 80 in ADAS-Cog14
NCT00904683,measures_secondary,Change from Baseline to Week 80 in CDR-SB Score
NCT00904683,measures_secondary,Change from Baseline to Week 80 in NPI Score
NCT00904683,measures_secondary,Change from Baseline to Week 80 in vMRI
NCT00904683,measures_secondary,Change from Baseline to Week 80 in MMSE Score
NCT00904683,measures_secondary,Change from Baseline to Week 80 in RUD-Lite Score
NCT00904683,measures_secondary,Change from Baseline to Week 80 in EQ-5D Proxy Score
NCT00904683,measures_secondary,Change from Baseline to Week 80 in QoL-AD Score
NCT00904683,measures_secondary,Change from Baseline to Week 80 in Plasma Amyloid Beta Levels
NCT00904683,measures_secondary,Change from Baseline to Week 80 in ADAS-Cog11 and ADAS-Cog12
NCT00904683,measures_secondary,Change from Baseline to Week 80 in ADCS-ADL Score
NCT00904683,has_criteria,Mini-Mental State Examination score of 16 through 26
NCT00904683,has_criteria,Modified Hachinski Ischemia Scale score of less than or equal to 4
NCT00904683,has_criteria,Geriatric Depression Scale score of less than or equal to 6
NCT00904683,has_criteria,magnetic resonance imaging (MRI) or computerized tomography (CT) scan in the last 2 years with no findings inconsistent with a diagnosis of AD
NCT00904683,has_criteria,concurrent AD treatment for at least 4 months at a stable dose for at least 2 months prior to randomization
NCT04414397,involves,Temple Hollowing
NCT04414397,evaluates,JUVÉDERM® VOLUMA® XC Injectable Gel
NCT04414397,measures_primary,Temple Hollowing Scale
NCT04414397,measures_secondary,Global Aesthetic Improvement Scale
NCT04414397,has_criteria,≥ 22 Years Old
NCT05837897,involves,Crohn's Disease
NCT05837897,evaluates,Vedolizumab
NCT05837897,measures_primary,Clinical Response
NCT05837897,measures_primary,Clinical Remission
NCT05837897,measures_primary,Endoscopic Response
NCT05837897,measures_secondary,PRO2 score
NCT05837897,has_criteria,Up to Week 14
NCT06604897,involves,Hypertension
NCT06604897,evaluates,Sacubitril/Valsartan
NCT06604897,measures_primary,Blood Pressure
NCT06604897,measures_secondary,Antihypertensive Medicines
NCT06604897,measures_secondary,Antihypertensive Drug Classes
NCT06604897,has_criteria,Systolic and diastolic blood pressure goals
NCT02301897,involves,Uterine Fibroids
NCT02301897,evaluates,Proellex
NCT02301897,measures_primary,Amenorrhea rate
NCT02301897,measures_secondary,PBAC Score
NCT02301897,has_criteria,Premenopausal Women
NCT04803305,involves,Advanced Cancer
NCT04803305,involves,Anorexia
NCT04803305,evaluates,Investigational New Drug
NCT04803305,evaluates,Placebo
NCT04803305,measures_primary,Appetite Score
NCT04803305,measures_secondary,Fatigue Score
NCT04803305,has_criteria,Baseline
NCT00629083,involves,Stress Urinary Incontinence
NCT00629083,evaluates,Bulking Agents
NCT00629083,measures_primary,Leakage reduction
NCT00629083,measures_secondary,Serious Adverse Events
NCT00629083,measures_secondary,Responder status
NCT00629083,measures_secondary,Quality of Life
NCT00629083,has_criteria,Female patients
NCT03929497,involves,Schizophrenia
NCT03929497,evaluates,Lu AF11167
NCT03929497,measures_primary,Change in BNSS
NCT03929497,measures_secondary,Change in PANSS
NCT03929497,has_criteria,Prominent Negative Symptoms
NCT06085183,involves,Renal Impairment
NCT06085183,evaluates,Indigotindisulfonate Sodium Injection
NCT06085183,measures_primary,conspicuity score
NCT06085183,measures_secondary,adverse events
NCT06085183,has_criteria,conspicuity score improvement
NCT02060383,involves,Cushing's Disease
NCT02060383,involves,Acromegaly
NCT02060383,evaluates,Pasireotide
NCT02060383,measures_primary,Change in HbA1c
NCT02060383,measures_secondary,Change in FPG
NCT02060383,has_criteria,HbA1c <7%
NCT02060383,has_criteria,HbA1c ≥7%
NCT01428583,involves,Chronic Noncancer Pain
NCT01428583,evaluates,Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules
NCT01428583,measures_primary,Clinical Opiate Withdrawal Scale (COWS) Score
NCT01428583,measures_secondary,Treatment-Emergent Adverse Events (AEs)
NCT01428583,has_criteria,Baseline up to end of study
NCT04460183,involves,COVID-19
NCT04460183,evaluates,RESP301
NCT04460183,measures_primary,Change in SpO2
NCT04460183,measures_secondary,Change in NEWS 2
NCT04460183,has_criteria,Hospitalized participants
NCT02191397,involves,Major Depressive Disorder
NCT02191397,evaluates,Bupropion Hydrochloride Extended-release Tablet
NCT02191397,evaluates,Escitalopram Oxalate Capsule
NCT02191397,measures_primary,HAMD-17 Total Score
NCT02191397,measures_secondary,Response Rate
NCT02191397,has_criteria,major protocol deviation
NCT03694197,evaluates,PRALUENT
NCT03694197,measures_primary,LDL-C change
NCT03694197,measures_secondary,Total-C change
NCT03694197,measures_secondary,Lp(a) change
NCT03694197,has_criteria,Adverse Events
NCT01611883,involves,Type 2 Diabetes
NCT01611883,involves,Hypercholesterolemia
NCT01611883,evaluates,Ezetimibe
NCT01611883,measures_primary,Change in HbA1c
NCT01611883,measures_secondary,Change in Glycoalbumin
NCT01611883,measures_secondary,Change in Fasting Plasma Glucose
NCT01611883,measures_secondary,Percentage of Participants With Adverse Event
NCT01611883,measures_secondary,Percentage of Participants With Changes in Diabetes Medications
NCT01611883,measures_secondary,Percent Change in LDL-C
NCT01611883,measures_secondary,Percent Change in TC
NCT01611883,measures_secondary,Percent Change in Triglycerides
NCT01611883,has_criteria,up to 24 weeks
NCT05632783,involves,Knee osteoarthritis
NCT05632783,evaluates,Chondroitin sulfate
NCT05632783,measures_primary,Safety Follow-up Period
NCT05632783,measures_secondary,Change in pain
NCT05632783,measures_secondary,WOMAC function
NCT05632783,measures_secondary,Subject's global evaluation
NCT05632783,has_criteria,Baseline to Week 24
NCT06378697,involves,Ankylosing Spondylitis
NCT06378697,evaluates,AK111
NCT06378697,measures_primary,ASAS20 response
NCT06378697,measures_secondary,ASAS40 response
NCT06378697,measures_secondary,ASAS5/6 response
NCT06378697,measures_secondary,ASDAS-CRP
NCT06378697,measures_secondary,SF-36 PCS
NCT06378697,measures_secondary,ASQoL scores
NCT06378697,measures_secondary,Treatment-emergent adverse events
NCT06378697,measures_secondary,Serious adverse events
NCT06378697,measures_secondary,Clinically significant examination results
NCT06378697,has_criteria,age ≥18 years old
NCT06378697,has_criteria,confirmed ankylosing spondylitis
NCT06060197,involves,MCT8 deficiency
NCT06060197,measures_primary,Economic burden
NCT06060197,measures_secondary,Health-related quality of life
NCT06060197,has_criteria,Caregiver's employment
NCT01868997,involves,Graves' Ophthalmopathy
NCT01868997,evaluates,Teprotumumab
NCT01868997,measures_primary,Responder Status
NCT01868997,measures_secondary,GO-QOL
NCT01868997,measures_secondary,Proptosis
NCT01868997,measures_secondary,CAS
NCT01868997,has_criteria,clinical activity score
NCT02671097,evaluates,Rosuvastatin
NCT02671097,evaluates,BAY1841788
NCT02671097,measures_primary,AUC(0-24)
NCT02671097,measures_primary,Cmax
NCT02671097,measures_secondary,Number of subjects
NCT02671097,has_criteria,Healthy subject
NCT02671097,has_criteria,Age: 45 to 65 years
NCT02671097,has_criteria,Race: White
NCT02671097,has_criteria,BMI: ≥18.0 and ≤29.9 kg/m\*2
NCT00844805,involves,Axial Spondyloarthritis
NCT00844805,involves,Ankylosing Spondylitis
NCT00844805,evaluates,Infliximab
NCT00844805,measures_primary,ASAS partial remission
NCT00844805,measures_secondary,Berlin MRI Spine Score
NCT00844805,measures_secondary,Sacroiliac Overall Score
NCT00844805,has_criteria,ASAS partial remission
NCT06090305,involves,Multiple Sclerosis
NCT06090305,evaluates,Levidex
NCT06090305,measures_primary,Global index score
NCT06090305,measures_secondary,Hamburg Quality of Life Questionnaire
NCT06090305,measures_secondary,Patient Health Questionnaire
NCT06090305,measures_secondary,Work and Social Assessment Scale
NCT06090305,measures_secondary,Multiple Sclerosis International Quality of Life
NCT06090305,measures_secondary,Generalized Anxiety Disorder Scale-7
NCT06090305,has_criteria,randomization
NCT04305197,involves,Systemic Lupus Erythematosus
NCT04305197,evaluates,ICP-022
NCT04305197,measures_primary,Ratio of Patients With Response
NCT04305197,measures_secondary,Occupancy rate of Bruton Tyrosine Kinase
NCT04305197,has_criteria,aged 18 to 75
NCT02047097,involves,Multiple Sclerosis
NCT02047097,evaluates,dimethyl fumarate
NCT02047097,measures_primary,Disease progression
NCT02047097,measures_secondary,MSIS-29 physical score
NCT02047097,has_criteria,EDSS physical functional system scores
NCT02820597,involves,Rhinitis
NCT02820597,evaluates,ClariFix Cryoablation
NCT02820597,measures_primary,Change in Rhinitis Symptom Severity
NCT02820597,measures_secondary,Change in Rhinitis Symptoms
NCT02820597,has_criteria,>21 years of age
NCT02820597,has_criteria,moderate to severe rhinorrhea
NCT02820597,has_criteria,nasal congestion for >3 months
NCT02141997,involves,Rheumatoid Arthritis
NCT02141997,evaluates,ABT-122
NCT02141997,measures_primary,ACR20 Response
NCT02141997,measures_secondary,ACR50 Response
NCT02141997,has_criteria,Inadequate response to Methotrexate
NCT05328297,involves,Bipolar Depression
NCT05328297,evaluates,JNJ-55308942
NCT05328297,measures_primary,MADRS Total Score
NCT05328297,measures_secondary,SHAPS Total Score
NCT05328297,has_criteria,specific single nucleotide polymorphism
NCT03058783,involves,Atopic Dermatitis
NCT03058783,evaluates,IDP-124 Lotion
NCT03058783,measures_primary,IGA 2-grade reduction
NCT03058783,measures_secondary,EASI 75
NCT03058783,has_criteria,Pediatric and Adult Subjects
NCT03534297,involves,Heart Failure
NCT03534297,evaluates,Dapansutrile Capsules
NCT03534297,measures_primary,Change in peak oxygen consumption
NCT03534297,measures_secondary,Left Ventricular Ejection Fraction
NCT03534297,measures_secondary,Left Ventricular Filling Pressure
NCT03534297,measures_secondary,Total body water
NCT03534297,measures_secondary,Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score
NCT03534297,measures_secondary,Kansas City Cardiomyopathy Questionnaire - Overall Summary Score
NCT03534297,has_criteria,Screening through Day 42 follow-up
NCT01919697,involves,Chronic Idiopathic Constipation
NCT01919697,evaluates,Plecanatide
NCT01919697,measures_primary,Number of TEAEs
NCT01919697,measures_secondary,Vital Signs
NCT01919697,has_criteria,Treatment period
NCT00327145,involves,Hypertension
NCT00327145,evaluates,Valsartan and Amlodipine
NCT00327145,measures_primary,Blood pressure
NCT00327145,measures_secondary,Diastolic blood pressure
NCT00327145,has_criteria,Age ≥18 years
NCT04033445,involves,Ulcerative Colitis
NCT04033445,evaluates,Guselkumab
NCT04033445,measures_primary,Clinical Response Week 12
NCT04033445,measures_primary,Clinical Remission Week 12
NCT04033445,measures_primary,IBDQ Remission Week 12
NCT04033445,measures_secondary,Symptomatic Remission Week 12
NCT04033445,measures_secondary,Endoscopic Healing Week 12
NCT04033445,measures_secondary,Histo-Endoscopic Mucosal Healing Week 12
NCT04033445,measures_secondary,Endoscopic Normalization Week 12
NCT04033445,has_criteria,Week 12
NCT04033445,has_criteria,Week 44
NCT04033445,has_criteria,Week 4
NCT03943147,involves,Lupus Nephritis
NCT03943147,evaluates,BMS-986165
NCT03943147,measures_primary,Number of Adverse Events
NCT03943147,measures_secondary,Clinically Significant ECG Abnormalities
NCT03943147,measures_secondary,Percent Change in Vital Signs
NCT03943147,measures_secondary,Abnormal Laboratory Parameters
NCT03943147,has_criteria,Baseline values at week 12
NCT04483947,involves,Non-alcoholic Steatohepatitis
NCT04483947,evaluates,AZD2693
NCT04483947,measures_primary,liver fat content
NCT04483947,measures_secondary,Alanine Aminotransferase
NCT04483947,measures_secondary,Aspartate Aminotransferase
NCT04483947,measures_secondary,Gamma Glutamyl Transferase
NCT04483947,measures_secondary,ELF score
NCT04483947,measures_secondary,plasma pharmacodynamic biomarker
NCT04483947,measures_secondary,disease-specific biomarkers
NCT04483947,measures_secondary,β-Hydroxybutyrate
NCT04483947,measures_secondary,lipid profile
NCT02654145,involves,Severe Eosinophilic Asthma
NCT02654145,evaluates,Omalizumab
NCT02654145,measures_primary,ACQ-5 score
NCT02654145,measures_secondary,SGRQ score
NCT02654145,has_criteria,latest available assessment
NCT00654745,involves,Type 2 Diabetes
NCT00654745,evaluates,Olmesartan
NCT00654745,measures_primary,Change in SBP
NCT00654745,measures_secondary,Change in DBP
NCT00654745,has_criteria,week 0 - week 12
NCT01718145,involves,Hepatitis C
NCT01718145,evaluates,Asunaprevir and Daclatasvir Combination Therapy
NCT01718145,evaluates,Telaprevir Therapy
NCT01718145,measures_primary,SVR12
NCT01718145,measures_secondary,hemoglobin < 10g/dL
NCT01718145,measures_secondary,rash-related dermatologic events
NCT01718145,measures_secondary,HCV RNA target detected
NCT01718145,measures_secondary,eRVR
NCT01718145,measures_secondary,Severe adverse events
NCT01718145,has_criteria,Japanese HCV Subjects
NCT00760747,involves,Attention Deficit/Hyperactivity Disorder
NCT00760747,evaluates,Atomoxetine
NCT00760747,measures_primary,ADHD-RS-IV Parent Version
NCT00760747,measures_secondary,Global Impression of Perceived Difficulties
NCT00760747,has_criteria,Baseline
NCT01451398,involves,Type 2 Diabetes Mellitus
NCT01451398,evaluates,Technosphere® Insulin
NCT01451398,evaluates,Technosphere Powder
NCT01451398,measures_primary,HbA1c at Week 24
NCT01451398,measures_secondary,Proportion of Responders
NCT01451398,measures_secondary,FPG Change
NCT01451398,measures_secondary,Proportion of Subjects
NCT01451398,measures_secondary,Time to Rescue
NCT01451398,measures_secondary,FEV1 Change
NCT01451398,measures_secondary,Incidence of Total Hypoglycemia
NCT01451398,measures_secondary,Incidence of Severe Hypoglycemia
NCT01451398,measures_secondary,Total Hypoglycemia Event Rate
NCT01451398,measures_secondary,Severe Hypoglycemia Event Rate
NCT01451398,measures_secondary,Mean 7-point Glucose Baseline Values
NCT01451398,measures_secondary,Mean 7-point Glucose Week 24 Values
NCT01451398,measures_secondary,Change in Body Weight
NCT01451398,has_criteria,HbA1c ≥ 7.5%
NCT02336698,involves,osteoarthritis
NCT02336698,evaluates,Fulranumab
NCT02336698,measures_primary,WOMAC pain score
NCT02336698,measures_secondary,WOMAC physical function score
NCT02336698,measures_secondary,Patient Global Assessment score
NCT02336698,measures_secondary,WOMAC Stiffness subscale score
NCT02336698,measures_secondary,daily numerical rating scale score
NCT02336698,measures_secondary,MOS Sleep subscale scores
NCT02336698,has_criteria,Baseline
NCT02157298,involves,Type 2 Diabetes
NCT02157298,evaluates,Dapagliflozin
NCT02157298,measures_primary,HbA1c Levels
NCT02157298,measures_secondary,Fasting Plasma Glucose
NCT02157298,measures_secondary,Total Body Weight
NCT02157298,measures_secondary,Total Mean Daily Insulin Dose
NCT02157298,measures_secondary,Proportion of Participants
NCT02157298,has_criteria,Informed consent
NCT02157298,has_criteria,Japanese Men or women
NCT02157298,has_criteria,Age ≥ 20 years
NCT02157298,has_criteria,Stable insulin dose
NCT00813098,involves,Non-Constipating Irritable Bowel Syndrome
NCT00813098,evaluates,LX1031
NCT00813098,measures_primary,relief of IBS pain
NCT00813098,measures_secondary,Change From Baseline
NCT00813098,has_criteria,Week 4
NCT02062645,involves,Hypertensive Patients
NCT02062645,evaluates,CVAA489
NCT02062645,measures_primary,Blood Pressure <140/90 mmHg
NCT02062645,measures_secondary,Sodium Intake
NCT02062645,has_criteria,Diagnosis of essential hypertension
NCT02062645,has_criteria,Newly diagnosed
NCT02062645,has_criteria,Previously untreated
NCT02062645,has_criteria,Currently untreated
NCT02062645,has_criteria,Written informed consent
NCT02062645,has_criteria,eGFR greater than 30 mL/min
NCT04633447,involves,Giant Cell Arteritis
NCT04633447,evaluates,Guselkumab
NCT04633447,measures_primary,GC-Free Remission
NCT04633447,measures_secondary,Normalization of ESR
NCT04633447,measures_secondary,Normalization of CRP
NCT04633447,measures_secondary,Normalization of ESR and CRP
NCT04633447,has_criteria,GC dose
NCT04633447,has_criteria,GCA disease flare
NCT06348498,involves,Coronary Heart Disease Complicating Chronic Heart Failure
NCT06348498,involves,Syndrome of Yang Deficiency with Blood Stasis
NCT06348498,evaluates,Jia Shen Tablets
NCT06348498,measures_primary,NT-proBNP
NCT06348498,measures_secondary,6-Minutes-Walking-Test
NCT06348498,measures_secondary,Echocardiogram results
NCT06348498,has_criteria,Baseline to weeks 4
NCT02120898,involves,Actinic Keratoses
NCT02120898,evaluates,Imiquimod Cream
NCT02120898,measures_primary,Complete Clearance Rate
NCT02120898,measures_secondary,Adverse Events
NCT02120898,has_criteria,untoward medical occurrence
NCT05081245,involves,Autism Spectrum Disorders
NCT05081245,evaluates,ML-004
NCT05081245,measures_primary,Change from Baseline
NCT05081245,measures_secondary,Clinician Global Impression of Improvement
NCT05081245,measures_secondary,Autism Behavior Inventory-Clinician Score
NCT05081245,measures_secondary,Aberrant Behavior Checklist 2-Irritability Subscale Score
NCT05081245,has_criteria,Baseline up to Day 110
NCT04656847,involves,Hypertension
NCT04656847,involves,CAD
NCT04656847,involves,Myocardial Infarction
NCT04656847,evaluates,Bisoprolol/Perindopril SPC
NCT04656847,measures_primary,Systolic BP reduction
NCT04656847,measures_primary,Diastolic BP reduction
NCT04656847,measures_secondary,Angina attacks
NCT04656847,measures_secondary,Lipid lowering therapy
NCT04656847,measures_secondary,LDL cholesterol
NCT04656847,has_criteria,SBP ≤140 mm Hg
NCT04656847,has_criteria,DBP ≤90 mm Hg
NCT04656847,has_criteria,Younger than 65 years
NCT04656847,has_criteria,Older than 65 years
NCT03853798,involves,Pyruvate Kinase Deficiency
NCT03853798,evaluates,AG-348
NCT03853798,measures_primary,Change from Baseline in Hb Concentration
NCT03853798,measures_secondary,Change from Baseline in Bilirubin
NCT03853798,measures_secondary,Change from Baseline in Lactate Dehydrogenase
NCT03853798,measures_secondary,Change from Baseline in Haptoglobin Levels
NCT03853798,measures_secondary,Change from Baseline in Reticulocyte Percentages
NCT03853798,measures_secondary,Change from Baseline in Number of Transfusion Events
NCT03853798,measures_secondary,Change from Baseline in Number of Red Blood Cell Units Transfused
NCT03853798,measures_secondary,Change from Baseline in Health-Related Quality of Life
NCT03853798,measures_secondary,Change from Baseline in HRQoL PRO Scores
NCT03853798,has_criteria,willing and able to comply
NCT01818245,evaluates,LY2605541
NCT01818245,measures_primary,AUC(0-∞)
NCT01818245,measures_secondary,Cmax
NCT01818245,has_criteria,≥18 to ≤55 years of age
NCT01818245,evaluates,LY2605541
NCT01818245,measures_primary,AUC(0-∞)
NCT01818245,measures_secondary,Cmax
NCT01818245,has_criteria,≥65 Years of Age
NCT01818245,evaluates,LY2605541
NCT01818245,measures_primary,Gtot
NCT01818245,measures_secondary,Rmax
NCT01818245,has_criteria,overtly healthy
NCT02484547,involves,Early Alzheimer's Disease
NCT02484547,evaluates,Aducanumab
NCT02484547,measures_primary,CDR-SB Score
NCT02484547,measures_secondary,MMSE Score
NCT02484547,measures_secondary,ADAS-Cog 13
NCT02484547,has_criteria,Baseline
NCT05442047,involves,Transthyretin (TTR) Amyloidosis
NCT05442047,evaluates,NNC6019-0001
NCT05442047,measures_primary,6-minute walk test
NCT05442047,measures_secondary,NT-proBNP
NCT05442047,measures_secondary,myocardial extracellular volume
NCT05442047,measures_secondary,KCCQ Clinical Summary Score
NCT05442047,measures_secondary,neuropathy impairment score
NCT05442047,measures_secondary,troponin I
NCT05442047,measures_secondary,global longitudinal strain
NCT05442047,has_criteria,heart disease
NCT04882098,involves,Psoriatic Arthritis
NCT04882098,evaluates,Guselkumab
NCT04882098,measures_primary,ACR 20 Response
NCT04882098,measures_secondary,Modified vdH-S score
NCT04882098,has_criteria,Baseline and Week 24
NCT03358147,involves,Persistant Asthma
NCT03358147,evaluates,PT001
NCT03358147,evaluates,Placebo
NCT03358147,evaluates,Spiriva® Respimat®
NCT03358147,measures_primary,Change From Baseline in FEV1
NCT03358147,measures_primary,AUC0-4
NCT03358147,measures_secondary,Rate of Asthma Exacerbations
NCT03358147,measures_secondary,Change From Baseline in ACQ-7
NCT03358147,measures_secondary,Change From Baseline in ACQ-5
NCT03358147,has_criteria,length of follow up
NCT04823247,involves,Psoriasis
NCT04823247,evaluates,Tildrakizumab
NCT04823247,measures_primary,WHO-5 Score
NCT04823247,measures_secondary,Physician Satisfaction
NCT04823247,measures_secondary,FamilyPso Score
NCT04823247,measures_secondary,DLQI-R Score
NCT04823247,measures_secondary,TSQM-9 Score
NCT04823247,measures_secondary,PBI 2.0 Score
NCT04823247,measures_secondary,WPAI:PSO Score
NCT04823247,measures_secondary,NRS Scores
NCT04823247,measures_secondary,PASI Score
NCT04823247,has_criteria,Patient with Psoriasis
NCT00954447,involves,Type 2 Diabetes
NCT00954447,evaluates,Linagliptin
NCT00954447,measures_primary,Change From Baseline in HbA1c
NCT00954447,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT00954447,has_criteria,categorical renal function impairment
NCT04037345,involves,Knee Osteoarthritis
NCT04037345,evaluates,SMUP-IA-01
NCT04037345,measures_primary,WOMAC total score
NCT04037345,measures_secondary,WOMAC subscales
NCT04037345,measures_secondary,VAS score
NCT04037345,measures_secondary,IKDC score
NCT04037345,has_criteria,Baseline
NCT02364947,involves,Alcohol Dependence
NCT02364947,evaluates,Nalmefene
NCT02364947,measures_primary,Change in HDDs
NCT02364947,measures_secondary,Change in TAC
NCT02364947,measures_secondary,Response Shift Drinking Risk Level
NCT02364947,measures_secondary,Response Low Drinking Risk Level
NCT02364947,measures_secondary,70% TAC Responder Rate
NCT02364947,measures_secondary,HDD Responder Rate
NCT02364947,measures_secondary,Change in CGI-S
NCT02364947,has_criteria,Alcohol Consumption
NCT01756898,involves,Atopic Dermatitis
NCT01756898,evaluates,ASB17061 Capsules
NCT01756898,measures_primary,EASI score
NCT01756898,measures_secondary,IGA responders
NCT01756898,has_criteria,Baseline up to 29 days
NCT01587898,involves,Anemia
NCT01587898,involves,Chronic Kidney Disease
NCT01587898,evaluates,investigational product
NCT01587898,measures_primary,Maximum Hgb Changes
NCT01587898,measures_secondary,Number of Participants
NCT01587898,measures_secondary,Percentage of Participants
NCT01587898,has_criteria,stable Hgb 8.5-11.0 g/dL
NCT02412098,involves,Hepatic Function
NCT02412098,evaluates,Eleclazine
NCT02412098,measures_primary,AUCinf of Eleclazine
NCT02412098,measures_primary,Cmax of Eleclazine
NCT02412098,measures_secondary,AUCinf of GS-623134
NCT02412098,measures_secondary,Cmax of GS-623134
NCT02412098,has_criteria,Treatment-emergent adverse events
NCT02412098,has_criteria,Clinical Laboratory Abnormalities
NCT05297045,involves,Type 2 Diabetes
NCT05297045,evaluates,RGT001-075
NCT05297045,measures_primary,Change in HbA1c
NCT05297045,measures_secondary,Fasting plasma glucose
NCT05297045,measures_secondary,Body weight
NCT05297045,measures_secondary,Body mass index
NCT05297045,measures_secondary,Waist circumference
NCT05297045,measures_secondary,Blood lipids
NCT05297045,measures_secondary,HbA1c <6.0%
NCT05297045,measures_secondary,Body weight loss
NCT05297045,measures_secondary,Adverse events
NCT05297045,measures_secondary,Systolic blood pressure
NCT05297045,measures_secondary,Diastolic blood pressure
NCT05297045,measures_secondary,Heart rate
NCT05297045,measures_secondary,Complete blood count
NCT05297045,measures_secondary,Serum sodium
NCT05297045,measures_secondary,Serum potassium
NCT05297045,measures_secondary,Serum total bilirubin
NCT03883945,involves,rosacea
NCT03883945,evaluates,Rosacea
NCT03883945,measures_primary,Inflammatory Lesion Counts
NCT03883945,measures_secondary,Erythema and Topography
NCT03883945,has_criteria,Healthy adults 18-65 years
NCT01479647,involves,healthy subjects
NCT01479647,evaluates,PH-797804
NCT01479647,measures_primary,peak plasma concentration
NCT01479647,measures_secondary,time to peak plasma concentration
NCT01479647,measures_secondary,area under the curve
NCT01479647,measures_secondary,terminal plasma half-life
NCT01479647,has_criteria,Body Mass Index 17.5 to 30.5 kg/m2
NCT01479647,has_criteria,total body weight >50 kg
NCT01479647,has_criteria,no clinically relevant abnormalities
NCT01479647,has_criteria,no clinically significant disease
NCT01479647,has_criteria,negative urine drug screen
NCT05074498,involves,Alzheimer's Disease
NCT05074498,evaluates,TB006
NCT05074498,measures_primary,Change From Baseline
NCT05074498,measures_secondary,Adverse Events
NCT05074498,has_criteria,Day 104
NCT05483998,evaluates,TLC-2716
NCT05483998,measures_primary,Plasma concentration
NCT05483998,measures_secondary,Number of subjects
NCT05483998,has_criteria,Healthy Participants
NCT03560245,involves,Alzheimer's Disease
NCT03560245,evaluates,Bryostatin
NCT03560245,measures_primary,Change in SIB Total Score
NCT03560245,measures_secondary,Changes in SIB Total Score
NCT03560245,has_criteria,Moderately Severe to Severe
NCT03022045,involves,Generalized Pustular Psoriasis
NCT03022045,involves,Erythrodermic Psoriasis
NCT03022045,evaluates,Risankizumab
NCT03022045,measures_primary,GPP Clinical Response
NCT03022045,measures_primary,EP Clinical Response
NCT03022045,has_criteria,Japanese Subjects
NCT04666298,involves,High Cardiovascular Risk
NCT04666298,involves,Elevated LDL-C
NCT04666298,evaluates,Inclisiran
NCT04666298,measures_primary,Percent Change From Baseline in LDL-C
NCT04666298,measures_secondary,Percent Change From Baseline in PCSK9
NCT04666298,measures_secondary,Absolute Change in LDL-C From Baseline
NCT04666298,measures_secondary,Proportion of Participants With LDL-C Greater Than 80% of Baseline Value
NCT04666298,has_criteria,LDL-C value greater than '0.8\*(LDL-C at Baseline - LDL-C at Day180...
NCT03025698,involves,Severe Aplastic Anemia
NCT03025698,evaluates,Eltrombopag
NCT03025698,measures_primary,Complete or partial response
NCT03025698,measures_secondary,Platelet response
NCT03025698,measures_secondary,Hematologic counts
NCT03025698,measures_secondary,RBC transfusion independence
NCT03025698,measures_secondary,Platelet transfusion independence
NCT03025698,measures_secondary,Bone marrow cellularity
NCT03025698,measures_secondary,Bone marrow morphology
NCT03025698,measures_secondary,Bone marrow cytogenetics
NCT03025698,has_criteria,Previously untreated or relapsed
NCT02024945,involves,Overactive Bladder Syndrome
NCT02024945,evaluates,Propiverine
NCT02024945,measures_primary,Quality of Life
NCT02024945,measures_secondary,Urination Urge
NCT02024945,measures_secondary,Incontinence episodes
NCT02024945,measures_secondary,Micturition Frequency
NCT02024945,has_criteria,Baseline visit
NCT01369498,involves,Myelofibrosis
NCT01369498,evaluates,Simtuzumab
NCT01369498,measures_primary,Bone Marrow Fibrosis Score
NCT01369498,measures_secondary,Hemoglobin
NCT01369498,measures_secondary,Platelet
NCT01369498,measures_secondary,Absolute Neutrophil Count
NCT01369498,has_criteria,Baseline; Week 24
NCT01360645,involves,Major Depressive Disorder
NCT01360645,evaluates,OPC-34712
NCT01360645,measures_primary,Change From Baseline
NCT01360645,measures_secondary,Sheehan Disability Scale Score
NCT01360645,has_criteria,Efficacy Sample
NCT05001945,involves,Hypertension
NCT05001945,evaluates,MLS-101
NCT05001945,measures_primary,Change in SBP
NCT05001945,measures_secondary,Change in DBP
NCT05001945,has_criteria,≥ 18 years old
NCT06276998,involves,Rheumatoid Arthritis
NCT06276998,evaluates,LNK01001 Capsule
NCT06276998,measures_primary,ACR20 Response
NCT06276998,measures_secondary,ACR50 Response
NCT06276998,measures_secondary,HAQ-DI
NCT06276998,has_criteria,20% improvement
NCT06276998,has_criteria,50% improvement
NCT06570798,involves,Autoimmune Diseases
NCT06570798,evaluates,Inebilizumab
NCT06570798,evaluates,Blinatumomab
NCT06570798,measures_primary,UPCR ≤ 0.5 mg/mg
NCT06570798,measures_primary,Remission in SLE
NCT06570798,measures_primary,LLDAS
NCT06570798,measures_secondary,SLEDAI-2K Score
NCT06570798,measures_secondary,UPCR
NCT06570798,measures_secondary,Anti-inebilizumab Antibody Formation
NCT06570798,measures_secondary,Anti-blinatumomab Antibody Formation
NCT04440345,involves,Overweight
NCT04440345,involves,Obesity
NCT04440345,evaluates,IBI362
NCT04440345,measures_primary,Number of adverse events
NCT04440345,measures_secondary,Anti-IBI362 Antibodies
NCT04440345,measures_secondary,Peak Plasma Concentration
NCT04440345,measures_secondary,Area under the plasma concentration
NCT04440345,measures_secondary,Fasting Blood Glucose
NCT04440345,measures_secondary,Glucagon
NCT04440345,measures_secondary,Insulin
NCT04440345,measures_secondary,C-peptide
NCT04440345,measures_secondary,Change in body weight
NCT04440345,has_criteria,stable body weight
NCT04440345,has_criteria,BMI ≥24 kg/m²
NCT04440345,has_criteria,BMI≥28 kg/m²
NCT05321498,involves,Mild Cognitive Impairment
NCT05321498,involves,Alzheimer's Disease
NCT05321498,evaluates,XPro1595
NCT05321498,measures_primary,EMACC score
NCT05321498,measures_secondary,Cogstate Composite score
NCT05321498,measures_secondary,myelin content
NCT05321498,measures_secondary,blood inflammatory and neurodegeneration biomarkers
NCT05321498,has_criteria,MCI with biomarkers of inflammation
NCT00497198,involves,Type 2 Diabetes
NCT00497198,evaluates,MCI-196
NCT00497198,measures_primary,Change From Baseline in Blood Glucose
NCT00497198,measures_secondary,Change From Baseline in Hemoglobin A1c
NCT00497198,measures_secondary,Change From Baseline in LDL-c
NCT00497198,has_criteria,fasting blood glucose levels
NCT00497198,has_criteria,HbA1c
NCT02472145,involves,Acute Myeloid Leukemia
NCT02472145,evaluates,Decitabine
NCT02472145,evaluates,Talacotuzumab
NCT02472145,measures_primary,Complete Response Rate
NCT02472145,measures_secondary,Overall Survival
NCT02472145,measures_secondary,Event-free Survival
NCT02472145,has_criteria,bone marrow blasts less than 5%
NCT02472145,has_criteria,absence of blasts with Auer rods
NCT02472145,has_criteria,absence of extramedullary disease
NCT02472145,has_criteria,absolute neutrophil count greater than 1.0\*10\^9/liter
NCT02472145,has_criteria,platelet count >100\*10\^9/L
NCT02472145,has_criteria,independence of red cell transfusions
NCT02472145,has_criteria,>25% absolute increase in bone marrow blast count
NCT02472145,has_criteria,bone marrow blasts greater than or equal to 5%
NCT02472145,has_criteria,reappearance of blasts in blood
NCT02472145,has_criteria,development of extramedullary disease
NCT02802345,involves,Idiopathic Pulmonary Fibrosis
NCT02802345,evaluates,Nintedanib
NCT02802345,measures_primary,Change From Baseline
NCT02802345,measures_secondary,Dyspnoea
NCT02802345,has_criteria,Lung Function Impairment
NCT02326298,involves,Plaque Psoriasis
NCT02326298,evaluates,Certolizumab Pegol
NCT02326298,measures_primary,PASI75 Response
NCT02326298,measures_secondary,PGA Clear or Almost Clear
NCT02326298,measures_secondary,PASI90 Response
NCT02326298,has_criteria,At least 75% improvement
NCT01872598,involves,Alzheimer's Disease
NCT01872598,evaluates,Masitinib
NCT01872598,measures_primary,ADCS-ADL score
NCT01872598,measures_secondary,ADAS-Cog score
NCT01872598,measures_secondary,MMSE score
NCT01872598,measures_secondary,CIBIC-plus score
NCT01872598,has_criteria,dementia of Alzheimer's type
NCT01872598,has_criteria,probable Alzheimer' disease
NCT01872598,has_criteria,MMSE 12 to 25
NCT01872598,has_criteria,cholinesterase inhibitors
NCT01872598,has_criteria,memantine
NCT01872598,has_criteria,no other cause of dementia
NCT01872598,has_criteria,no severe delusions or delirium
NCT06212245,involves,Neuromyelitis Optica Spectrum Disorders
NCT06212245,evaluates,Inebilizumab
NCT06212245,measures_primary,Percentage of NMOSD attack
NCT06212245,measures_secondary,Worsening in EDSS Score
NCT06212245,has_criteria,protocol-defined attack criteria
NCT00423098,involves,Lupus Nephritis
NCT00423098,evaluates,Enteric-coated Mycophenolate Sodium
NCT00423098,measures_primary,Complete Remission
NCT00423098,measures_secondary,Partial Remission
NCT00423098,measures_secondary,Prednisone Equivalent Corticosteroids
NCT00423098,measures_secondary,Moderate to Severe Flares
NCT00423098,has_criteria,urine protein/urine creatinine ratio
NCT00423098,has_criteria,urine sediment normalized
NCT00423098,has_criteria,serum creatinine within 10%
NCT04640298,involves,Osteoarthritis of Hip Joint
NCT04640298,evaluates,Cingal®
NCT04640298,measures_primary,NRS Pain on Walking
NCT04640298,measures_secondary,Lequesne Hip Index
NCT04640298,measures_secondary,Patient Global Assessment (PGA) Score
NCT04640298,measures_secondary,OMERACT-OARSI Responder Index
NCT04640298,has_criteria,6 months
NCT05110898,involves,Hypertension
NCT05110898,evaluates,Olmesartan + Indapamide
NCT05110898,measures_primary,Diastolic Blood Pressure Control
NCT05110898,measures_secondary,Systolic Blood Pressure Control
NCT05110898,measures_secondary,Proportion of systolic and diastolic treatment response
NCT05110898,measures_secondary,Systolic and diastolic blood pressure variation by ABPM exam
NCT05110898,measures_secondary,Patients responses to the treatment satisfaction questionnaire
NCT05110898,measures_secondary,Tolerability and occurrence of adverse events (AEs)
NCT05110898,has_criteria,Diastolic Blood Pressure (DBP)
NCT05110898,has_criteria,≥ 18 years
NCT05110898,has_criteria,Essential hypertension
NCT05110898,has_criteria,up to two anti-hypertensives
NCT02718898,involves,Genital Psoriasis
NCT02718898,evaluates,Ixekizumab
NCT02718898,measures_primary,sPGA of Genitalia (0
NCT02718898,measures_secondary,Overall sPGA (0
NCT02718898,measures_secondary,Genital Psoriasis Itch NRS
NCT02718898,measures_secondary,Sexual Activity Limited by Genital Psoriasis
NCT02718898,has_criteria,Genital Psoriasis Symptom Scale
NCT05394805,involves,Crohn's Disease
NCT05394805,evaluates,Adalimumab
NCT05394805,measures_primary,Clinical Remission
NCT05394805,measures_secondary,Serious Adverse Events
NCT05394805,measures_secondary,Serious Adverse Drug Reaction
NCT05394805,measures_secondary,Non-Serious Adverse Drug Reaction
NCT05394805,has_criteria,Moderate to Severe Active
NCT04607005,involves,Chronic Rhinosinusitis With Nasal Polyps
NCT04607005,involves,Eosinophilic Chronic Rhinosinusitis
NCT04607005,evaluates,Mepolizumab
NCT04607005,measures_primary,total endoscopic NP score
NCT04607005,measures_secondary,nasal obstruction VAS score
NCT04607005,measures_secondary,SNOT-22 total score
NCT04607005,has_criteria,Baseline (Day 0)
NCT00748098,involves,Restless Legs Syndrome
NCT00748098,evaluates,GSK1838262 Extended Release Tablets
NCT00748098,measures_primary,Wake Time During Sleep
NCT00748098,measures_secondary,Periodic Limb Movements
NCT00748098,measures_secondary,International Restless Legs Rating Scale
NCT00748098,has_criteria,Baseline
NCT05398198,involves,Asthma
NCT05398198,evaluates,GSK3923886 Inhalation Powder
NCT05398198,measures_primary,LRTS score change
NCT05398198,measures_secondary,URTS score change
NCT05398198,measures_secondary,FEV1 change
NCT05398198,measures_secondary,PEF change
NCT05398198,measures_secondary,Adverse events
NCT05398198,has_criteria,Day 22
NCT00627445,involves,Type 2 Diabetes
NCT00627445,evaluates,Biphasic Insulin Aspart 50
NCT00627445,measures_primary,Change in HbA1c
NCT00627445,measures_secondary,Change in 8-point plasma glucose
NCT00627445,measures_secondary,Change in prandial plasma glucose increment
NCT00627445,measures_secondary,Total increase in total daily insulin dose
NCT00627445,measures_secondary,Change in body weight
NCT00627445,measures_secondary,Number of hypoglycaemic episodes
NCT00627445,has_criteria,week 0
NCT00627445,has_criteria,week 16
NCT03596645,involves,Ulcerative Colitis
NCT03596645,evaluates,Golimumab
NCT03596645,measures_primary,Clinical Remission
NCT03596645,measures_secondary,Symptomatic Remission
NCT03596645,has_criteria,Pediatric Participants
NCT03160898,involves,Amyotrophic Lateral Sclerosis
NCT03160898,evaluates,CK-2127107
NCT03160898,measures_primary,Change From Baseline
NCT03160898,measures_secondary,ALSFRS-R Total Score
NCT03160898,measures_secondary,Slope of Muscle Strength Mega-score
NCT03160898,has_criteria,Baseline to Week 12
NCT04277598,involves,Diabetic Foot Ulcer
NCT04277598,evaluates,APO-2
NCT04277598,measures_primary,Wound area reduction
NCT04277598,measures_secondary,Wound size
NCT04277598,measures_secondary,Complete wound closure
NCT04277598,measures_secondary,Recurrence rate
NCT04277598,has_criteria,>50 % reduction
NCT03201445,involves,Inflammatory Bowel Disease
NCT03201445,evaluates,Filgotinib
NCT03201445,measures_primary,Sperm Concentration
NCT03201445,measures_secondary,Sperm Total Motility
NCT03201445,has_criteria,≥50% decrease
NCT04355845,evaluates,PF-06651600
NCT04355845,measures_primary,Sumatriptan AUC
NCT04355845,measures_secondary,Vital signs
NCT04355845,measures_secondary,Electrocardiogram
NCT04355845,measures_secondary,Lab tests
NCT04355845,measures_secondary,Adverse events
NCT04355845,has_criteria,Healthy participants
NCT04355845,has_criteria,BMI 17.5 to 30.5 kg/m2
NCT04355845,has_criteria,Total body weight >50 kg
NCT04355845,has_criteria,No clinically significant disease
NCT04355845,has_criteria,10-year ASCVD risk ≥7.5%
NCT04355845,has_criteria,No conditions affecting drug absorption
NCT04355845,has_criteria,No MAO-A inhibitors within 14 days
NCT01071798,involves,Rheumatoid Arthritis
NCT01071798,evaluates,Rituximab
NCT01071798,measures_primary,DAS28 Score
NCT01071798,measures_secondary,HAQ Disability Index
NCT01071798,measures_secondary,Percentage of Participants With a Treatment-Emergent Adverse Event
NCT01071798,has_criteria,Clinically Relevant Changes in HAQ-Score
NCT04652245,involves,seasonal allergic rhinitis
NCT04652245,evaluates,Dymista Allergen Chamber
NCT04652245,measures_primary,TNSS change from baseline
NCT04652245,measures_secondary,TOSS change from baseline
NCT04652245,has_criteria,written informed consent
NCT01376245,involves,COPD
NCT01376245,evaluates,Fluticasone Furoate/Vilanterol Inhalation Powder
NCT01376245,measures_primary,Change From Baseline in FEV1
NCT01376245,measures_secondary,Dyspnea Domain Score
NCT01376245,has_criteria,Asian Ancestry
NCT02043145,involves,Hyperhidrosis
NCT02043145,evaluates,BOTOX®
NCT02043145,measures_primary,Change From Baseline
NCT02043145,measures_secondary,Modified Ashworth Scale
NCT02043145,has_criteria,4 Years
NCT02745145,involves,Systemic sclerosis-interstitial lung disease
NCT02745145,evaluates,Abituzumab
NCT02745145,measures_primary,Change From Baseline in FVC
NCT02745145,measures_secondary,Dyspnea as Measured by TDI
NCT02745145,measures_secondary,Absolute Change From Baseline in SGRQ Total Score
NCT02745145,measures_secondary,Absolute Change From Baseline in mRSS
NCT02745145,has_criteria,Diffuse Cutaneous Skin Involvement
NCT01664598,involves,Rheumatoid Arthritis
NCT01664598,evaluates,Tocilizumab
NCT01664598,measures_primary,DAS28-ESR
NCT01664598,measures_secondary,SDAI
NCT01664598,has_criteria,Up to 112 weeks
NCT04057898,involves,Amyotrophic lateral sclerosis
NCT04057898,evaluates,MN-166
NCT04057898,measures_primary,ALSFRS-R score
NCT04057898,measures_secondary,muscle strength
NCT04057898,measures_secondary,quality of life
NCT04057898,measures_secondary,functional activity
NCT04057898,has_criteria,Baseline
NCT02569398,involves,Alzheimer's Dementia
NCT02569398,evaluates,Atabecestat
NCT02569398,measures_primary,Change From Baseline in PACC Score
NCT02569398,measures_secondary,Change From Baseline in CFI Score
NCT02569398,has_criteria,Asymptomatic at Risk
NCT03146845,involves,chronic ulcers
NCT03146845,evaluates,ALLEVYN Life Non-Bordered
NCT03146845,measures_primary,Change CWIS-PSDL Score
NCT03146845,measures_secondary,CWIS-WB
NCT03146845,measures_secondary,CWIS-SL
NCT03146845,measures_secondary,CWIS-GQ
NCT03146845,measures_secondary,CWIS-SQ
NCT03146845,has_criteria,6-week treatment period
NCT05155098,involves,Plaque Psoriasis
NCT05155098,involves,Psoriatic Arthritis
NCT05155098,involves,Ankylosing Spondylitis
NCT05155098,involves,Non-radiographic Axial Spondyloarthritis
NCT05155098,evaluates,Secukinumab
NCT05155098,measures_primary,Retention rate
NCT05155098,measures_secondary,Change in QoL
NCT05155098,measures_secondary,Treatment pattern
NCT05155098,measures_secondary,Work/school absenteeism
NCT05155098,measures_secondary,PASI 75
NCT05155098,has_criteria,Adult Patients
NCT03569098,involves,Hallux Abducto Valgus
NCT03569098,evaluates,Dysport
NCT03569098,measures_primary,NPRS Score at Week 8
NCT03569098,measures_secondary,mFFI Disability Subscale Score
NCT03569098,has_criteria,Baseline and Week 8
NCT01797445,involves,HIV-1
NCT01797445,evaluates,E/C/F/TAF
NCT01797445,evaluates,E/C/F/TDF
NCT01797445,measures_primary,HIV-1 RNA < 50 copies/mL
NCT01797445,measures_secondary,CD4+ Cell Count
NCT01797445,measures_secondary,Hip BMD
NCT01797445,measures_secondary,Spine BMD
NCT01797445,measures_secondary,Serum Creatinine
NCT01797445,has_criteria,Antiretroviral Treatment-Naive
NCT02759198,involves,Knee Osteoarthritis
NCT02759198,evaluates,YH23537
NCT02759198,measures_primary,Change From Baseline in VAS score
NCT02759198,measures_secondary,Western Ontario and McMaster Universities Index of Osteoarthritis (WOMAC) score
NCT02759198,measures_secondary,WOMAC subgroup(pain
NCT02759198,measures_secondary,Percentage From Baseline in WOMAC responder
NCT02759198,measures_secondary,Patient Global Impression of Change (PGIC)
NCT02759198,measures_secondary,Physician's Global Assessment of Response to Therapy (PGART)
NCT02759198,has_criteria,Signed Informed Consent
NCT02759198,has_criteria,Men and women ≥ 40 years of age
NCT02759198,has_criteria,Patients with knee osteoarthritis at one or both knee by ACR
NCT02759198,has_criteria,Patients with known or suspected secondary knee osteoarthritis
NCT05122598,involves,Early Alzheimer's Disease
NCT05122598,evaluates,Computerized Olfactory Training Program
NCT05122598,measures_primary,Logical Memory II
NCT05122598,measures_secondary,ADCS-PACC composite score
NCT05122598,has_criteria,Baseline|Logical Memory II
NCT03922945,involves,Obesity
NCT03922945,evaluates,VI-0521
NCT03922945,measures_primary,% Change in BMI
NCT03922945,measures_secondary,BMI Reduction at Week 56
NCT03922945,has_criteria,Aged 12-17 years
NCT03922945,has_criteria,BMI ≥ 95th percentile
NCT05593445,involves,Lichen Sclerosus
NCT05593445,evaluates,Ruxolitinib Cream
NCT05593445,measures_primary,ITCH4 at Week 12
NCT05593445,measures_secondary,CLISSCO at Week 12
NCT05593445,measures_secondary,Skin Pain NRS Score at Week 12
NCT05593445,has_criteria,Baseline; Week 12
NCT05226598,involves,Metastatic Non-Small Cell Lung Cancer
NCT05226598,evaluates,Pembrolizumab/Vibostolimab Coformulation
NCT05226598,evaluates,Pembrolizumab
NCT05226598,measures_primary,Overall Survival
NCT05226598,measures_secondary,Progression-Free Survival
NCT05226598,measures_secondary,Objective Response Rate
NCT05226598,measures_secondary,Change from Baseline in the Global Health Status/Quality of Life
NCT05226598,has_criteria,PD-L1 Tumor Proportion Score
NCT00872898,involves,Autism
NCT00872898,evaluates,Memantine
NCT00872898,measures_primary,Social Responsiveness Scale
NCT00872898,measures_secondary,Core Autism Treatment Scale-Improvement
NCT00872898,has_criteria,Baseline to Week 12
NCT01615198,involves,Essential Hypertension
NCT01615198,evaluates,LCZ696
NCT01615198,evaluates,Olmesartan
NCT01615198,measures_primary,Change From Baseline in Mean Sitting Systolic Blood Pressure
NCT01615198,measures_primary,Change From Baseline in Mean 24 Hour Ambulatory Systolic Blood Pressure
NCT01615198,measures_secondary,Change From Baseline in Mean Sitting Diastolic Blood Pressure
NCT01615198,measures_secondary,Change in Baseline in Mean 24 Hour Ambulatory Diastolic Blood Pressure
NCT03557398,involves,Vaginal Atrophy
NCT03557398,evaluates,HYDEAL-D Vaginal Pessaries
NCT03557398,measures_primary,Change of VHI score
NCT03557398,measures_secondary,Change of vaginal pH
NCT03557398,measures_secondary,Patient's perception of vulvovaginal symptoms
NCT03557398,measures_secondary,Improvement of sexual function
NCT03557398,has_criteria,Post-menopause Women
NCT02847598,involves,Cutaneous Lupus Erythematosus
NCT02847598,involves,Systemic Lupus Erythematosus
NCT02847598,evaluates,BIIB059
NCT02847598,evaluates,Litifilimab
NCT02847598,measures_primary,Active Joint Count
NCT02847598,measures_secondary,CLASI-A Score
NCT02847598,measures_secondary,CLASI-50 Response
NCT02847598,has_criteria,Baseline to Week 24
NCT02847598,has_criteria,Baseline to Week 16
NCT05516498,involves,Liver Cirrhosis
NCT05516498,evaluates,zibotentan and dapagliflozin
NCT05516498,measures_primary,Absolute change in HVPG
NCT05516498,measures_secondary,HVPG response
NCT05516498,measures_secondary,body weight
NCT05516498,measures_secondary,loop-diuretic equivalents use
NCT05516498,measures_secondary,total body water
NCT05516498,measures_secondary,body fat mass
NCT05516498,measures_secondary,systolic blood pressure
NCT05516498,measures_secondary,diastolic blood pressure
NCT05516498,has_criteria,Week 6
NCT00391898,involves,Parkinson's Disease
NCT00391898,evaluates,Levodopa/Carbidopa/Entacapone
NCT00391898,evaluates,Levodopa/Carbidopa
NCT00391898,measures_primary,UPDRS Part II Score
NCT00391898,measures_primary,UPDRS Part I Score
NCT00391898,measures_primary,UPDRS Part III Score
NCT00391898,measures_primary,UPDRS Part IV Score
NCT00391898,has_criteria,early wearing-off
NCT00835198,involves,Acne Vulgaris
NCT00835198,evaluates,Dapsone Gel 5% and Tretinoin Gel 0.025%
NCT00835198,evaluates,Tretinoin Gel 0.025%
NCT00835198,measures_primary,Change From Baseline
NCT00835198,measures_secondary,Investigator Global Assessment
NCT00835198,measures_secondary,Overall Disease Severity
NCT00835198,measures_secondary,Non-Inflammatory Lesion Counts
NCT00835198,has_criteria,Baseline
NCT03193398,involves,Major Depressive Disorder
NCT03193398,evaluates,BTRX-246040
NCT03193398,measures_primary,Change in MADRS
NCT03193398,measures_secondary,Change in MADRS-6
NCT03193398,measures_secondary,Change in HADS-A
NCT03193398,has_criteria,Week 8
NCT03117998,involves,Type 1 Diabetes Mellitus
NCT03117998,evaluates,REMD-477
NCT03117998,measures_primary,Change in Average Daily Insulin Use
NCT03117998,measures_secondary,Change From Baseline in AUC Glucose Concentrations
NCT03117998,measures_secondary,Continuous Glucose Monitoring (CGM) - Change in Average Daily 24-hour Glucose Concentration
NCT03117998,measures_secondary,Seven-Point Glucose Profile - Change in Average 24-h Glucose Concentrations
NCT03117998,measures_secondary,Summary of the Product of Average Daily 24-h Glucose Ratio and Daily Insulin Use Ratio
NCT03117998,measures_secondary,Change in Hemoglobin A1c From Baseline at Week 13
NCT03117998,has_criteria,repeated doses of REMD-477
NCT00535145,involves,Liver Disease
NCT00535145,evaluates,Paliperidone ER
NCT00535145,measures_primary,Incidence of Adverse Events
NCT00535145,measures_secondary,PANSS Change From Baseline
NCT00535145,measures_secondary,CGI-S Change From Baseline
NCT00535145,measures_secondary,PSP Change From Baseline
NCT00535145,has_criteria,Day 1 - Day 62
NCT00772577,involves,Hypertension
NCT00772577,evaluates,Aliskiren HCTZ
NCT00772577,evaluates,Ramipril
NCT00772577,measures_primary,Change in MSSBP
NCT00772577,measures_secondary,Change in MSDBP
NCT00772577,measures_secondary,Blood Pressure Control
NCT00772577,measures_secondary,Percentage of Responders
NCT00772577,measures_secondary,Change in MSPP
NCT00772577,has_criteria,BMI ≥ 30
NCT05026177,involves,Mild-to-Moderate Alzheimer's Disease
NCT05026177,evaluates,Simufilam
NCT05026177,measures_primary,Change from baseline
NCT05026177,measures_secondary,Change from baseline
NCT05026177,has_criteria,Baseline (Study Day 1) to Week 76
NCT04762277,involves,Hidradenitis Suppurativa
NCT04762277,evaluates,Spesolimab
NCT04762277,measures_primary,Percent Change From Baseline
NCT04762277,measures_secondary,Draining Fistula Count
NCT04762277,has_criteria,TNFi-naive population
NCT04762277,has_criteria,TNFi-failure population
NCT04916977,involves,Fabry Disease
NCT04916977,measures_primary,event-free survival
NCT04916977,measures_secondary,Comprehensive burden
NCT04916977,has_criteria,median Mainz Severity Score Index
NCT00406653,involves,Crohn's Disease
NCT00406653,evaluates,Abatacept
NCT00406653,measures_primary,CDAI-Defined Clinical Response
NCT00406653,measures_secondary,CDAI <150
NCT00406653,has_criteria,CDAI ≥220 and ≤450 points
NCT03394677,involves,Atopic Dermatitis
NCT03394677,evaluates,RVT-501 Topical Ointment
NCT03394677,measures_primary,Investigator Global Assessment
NCT03394677,measures_secondary,Eczema Area Severity Index
NCT03394677,measures_secondary,Peak Pruritus Numeric Rating Scale
NCT03394677,measures_secondary,Whole body surface area affected
NCT03394677,has_criteria,Pediatric Patients
NCT02898753,involves,Late-Onset Pompe Disease
NCT02898753,evaluates,VAL-1221
NCT02898753,measures_primary,Number of TEAEs
NCT02898753,measures_secondary,Infusion-Associated Reactions
NCT02898753,measures_secondary,Anti-VAL-1221 Antibodies
NCT02898753,measures_secondary,GAA Antibodies
NCT02898753,has_criteria,Ambulatory
NCT04187547,involves,Alzheimer's Disease
NCT04187547,evaluates,Tricaprilin
NCT04187547,measures_primary,Change From Baseline
NCT04187547,measures_secondary,TEAE incidence rate
NCT04187547,measures_secondary,Clinician's global impression
NCT04187547,measures_secondary,Dependence Scale
NCT04187547,measures_secondary,RUD-Lite
NCT04187547,measures_secondary,Disability Assessment for Dementia
NCT04187547,has_criteria,age 50 to 85
NCT04187547,has_criteria,MMSE score 14 to 26
NCT04187547,has_criteria,probable dementia
NCT01468077,involves,Rheumatoid Arthritis
NCT01468077,evaluates,RoActemra
NCT01468077,evaluates,Actemra
NCT01468077,measures_primary,Infusion Reaction
NCT01468077,measures_secondary,Discontinuing Tocilizumab
NCT01468077,measures_secondary,Liver Enzyme Values
NCT01468077,measures_secondary,Lipid Values
NCT01468077,has_criteria,Completed all visits
NCT04221477,involves,Lupus Nephritis
NCT04221477,evaluates,Obinutuzumab
NCT04221477,measures_primary,Complete Renal Response
NCT04221477,measures_secondary,Proteinuric Response
NCT04221477,measures_secondary,Overall Renal Response
NCT04221477,measures_secondary,Death or Renal-related Events
NCT04221477,measures_secondary,Estimated Glomerular Filtration Rate
NCT04221477,measures_secondary,Anti-dsDNA Titer
NCT04221477,measures_secondary,Complement C3
NCT04221477,measures_secondary,SLEDAI-2K
NCT04221477,measures_secondary,Fatigue
NCT04221477,measures_secondary,Adverse Events
NCT04221477,has_criteria,active proliferative LN
NCT06603077,involves,Hidradenitis Suppurativa
NCT06603077,evaluates,AVTX-009
NCT06603077,measures_primary,HiSCR75
NCT06603077,measures_secondary,HiSCR50
NCT06603077,measures_secondary,HiSCR90
NCT06603077,measures_secondary,IHS4 score
NCT06603077,measures_secondary,abscess and inflammatory nodule count
NCT06603077,measures_secondary,draining fistula count
NCT06603077,has_criteria,moderate to severe
NCT03563053,involves,AT
NCT03563053,evaluates,EryDex System
NCT03563053,measures_primary,Quality of Life
NCT03563053,measures_secondary,Clinical Global Impression of Change
NCT03563053,has_criteria,Baseline Visit
NCT04044547,involves,Parkinson's Disease
NCT04044547,evaluates,LY03003
NCT04044547,measures_primary,UPDRS part (Ⅲ) Total Score
NCT04044547,measures_secondary,Frequency of adverse events
NCT04044547,has_criteria,Hoehn & Yahr stage ≤3
NCT04044547,has_criteria,MMSE score ≥25
NCT04044547,has_criteria,Unified Parkinson's Disease Rating Scale (UPDRS) motor score (Part III) of ≤30 at Screening
NCT00078377,involves,narcolepsy
NCT00078377,evaluates,Armodafinil
NCT00078377,measures_primary,MWT sleep latency
NCT00078377,measures_secondary,CGI-C
NCT00078377,has_criteria,excessive sleepiness
NCT00078377,has_criteria,ICSD criteria
NCT00737477,involves,Chronic Kidney Disease
NCT00737477,evaluates,Mircera
NCT00737477,measures_primary,Hb in target range
NCT00737477,measures_secondary,Change in Hb
NCT00737477,measures_secondary,Time spent in target range
NCT05431153,evaluates,PF-07104091
NCT05431153,measures_primary,AUCinf of PF-07104091
NCT05431153,measures_primary,Cmax of PF-07104091
NCT05431153,measures_secondary,Number of Participants With TEAEs
NCT05431153,measures_secondary,Serious TEAEs
NCT05431153,has_criteria,treatment-emergent adverse events
NCT05431153,has_criteria,serious adverse events
NCT01041677,involves,Obesity
NCT01041677,evaluates,R256918
NCT01041677,measures_primary,Hepatic Triglyceride Content
NCT01041677,measures_secondary,Body weight
NCT01041677,measures_secondary,alanine aminotransferase
NCT01041677,measures_secondary,aspartate aminotransferase
NCT01041677,measures_secondary,fasting glucose
NCT01041677,measures_secondary,insulin
NCT01041677,measures_secondary,blood pressure
NCT01041677,measures_secondary,total cholesterol
NCT01041677,measures_secondary,HDL cholesterol
NCT01041677,measures_secondary,LDL cholesterol
NCT01041677,measures_secondary,triglycerides
NCT01041677,has_criteria,Liver fat content
NCT01041677,has_criteria,BMI
NCT01041677,has_criteria,fasting plasma glucose
NCT01041677,has_criteria,History of Obesity
NCT01041677,has_criteria,Diabetes Mellitus
NCT01041677,has_criteria,Weight reducing diet
NCT01041677,has_criteria,smoking habits
NCT02129777,involves,Plaque Psoriasis
NCT02129777,evaluates,Namilumab
NCT02129777,measures_primary,PASI75 Response
NCT02129777,measures_secondary,PASI75 Response
NCT02129777,has_criteria,Week 12
NCT06083753,involves,Relapsing-Remitting Multiple Sclerosis
NCT06083753,evaluates,PIPE-307
NCT06083753,measures_primary,binocular 2.5% LCLA
NCT06083753,measures_secondary,monocular 2.5% LCLA
NCT06083753,measures_secondary,Timed 25-Foot Walk Test
NCT06083753,measures_secondary,Nine-Hole Peg Test
NCT06083753,measures_secondary,Symbol Digital Modality Test
NCT06083753,measures_secondary,MRI measures
NCT06083753,measures_secondary,serum neurofilament light chain
NCT06083753,measures_secondary,blood concentration levels
NCT01553747,involves,Diarrhea-Predominant Irritable Bowel Syndrome
NCT01553747,evaluates,Eluxadoline
NCT01553747,measures_primary,Composite Responder
NCT01553747,measures_secondary,Daily Worst Abdominal Pain
NCT01553747,measures_secondary,Daily Stool Consistency
NCT01553747,has_criteria,≥30% improvement
NCT01305577,involves,Submental fat
NCT01305577,evaluates,Deoxycholic Acid Injection
NCT01305577,measures_primary,CR-SMFRS 1-grade Response
NCT01305577,measures_secondary,CR-SMFRS 2-grade Response
NCT01305577,measures_secondary,SSRS Response
NCT01305577,measures_secondary,Change From Baseline in CR-SMFRS Scores
NCT01305577,has_criteria,Baseline and 12 weeks after last treatment
NCT03562377,involves,atopic dermatitis
NCT03562377,evaluates,Tralokinumab
NCT03562377,measures_primary,IGA score
NCT03562377,measures_secondary,EASI
NCT03562377,measures_secondary,Anti-tetanus IgG
NCT03562377,measures_secondary,Anti-meningococcal IgG
NCT03562377,has_criteria,Investigator's Global Assessment
NCT03562377,has_criteria,Eczema Area and Severity Index
NCT01469377,involves,Major Depressive Disorder
NCT01469377,evaluates,Cariprazine
NCT01469377,measures_primary,MADRS Total Score
NCT01469377,measures_secondary,SDS Total Score
NCT01469377,has_criteria,Baseline to Week 8
NCT00502853,involves,Rheumatoid Arthritis
NCT00502853,evaluates,MabThera
NCT00502853,measures_primary,Synovitis Score
NCT00502853,measures_secondary,Bone Edema Score
NCT00502853,has_criteria,Patient With Rheumatoid Arthritis
NCT00394953,involves,Anemia
NCT00394953,evaluates,Mircera
NCT00394953,evaluates,Darbepoetin Alpha
NCT00394953,measures_primary,Hemoglobin decrease
NCT00394953,measures_secondary,Dose change
NCT00394953,measures_secondary,Laboratory abnormality
NCT00394953,has_criteria,Hemoglobin \>= 10.5 g/dL
NCT05428345,involves,Ulcerative Colitis
NCT05428345,involves,Crohn's Disease
NCT05428345,evaluates,Vedolizumab SC
NCT05428345,measures_primary,Clinical Response
NCT05428345,measures_primary,Clinical Remission
NCT05428345,measures_secondary,Serious Adverse Events
NCT05428345,measures_secondary,Adverse Drug Reactions
NCT05428345,measures_secondary,Serious Adverse Drug Reactions
NCT05428345,measures_secondary,Adverse Events of Special Interest
NCT05428345,measures_secondary,Unexpected Adverse Events
NCT05428345,measures_secondary,Unexpected ADRs
NCT05428345,has_criteria,Moderate to Severe
NCT03412747,involves,Chronic Plaque Psoriasis
NCT03412747,evaluates,Bimekizumab
NCT03412747,measures_primary,PASI90 response
NCT03412747,measures_secondary,Investigator's Global Assessment
NCT03412747,has_criteria,Adult Subjects
NCT04921345,involves,Atopic Dermatitis
NCT04921345,evaluates,Nemolizumab
NCT04921345,measures_primary,Eczema Area and Severity Index (EASI) Score
NCT04921345,measures_secondary,Absolute Change From Baseline in EASI Score
NCT04921345,has_criteria,Baseline through Week 52
NCT06490445,involves,Diabetic Peripheral Neuropathic Pain
NCT06490445,evaluates,Medical Cannabis Aerosol
NCT06490445,measures_primary,Change From Baseline
NCT06490445,measures_secondary,Neuropathic Pain Symptom Inventory
NCT06490445,measures_secondary,Brief Pain Inventory - Short Form
NCT06490445,measures_secondary,Weekly-mean 24-hour Average Pain Score
NCT06490445,has_criteria,Baseline up to Week 19
NCT01194245,involves,Type 1 Diabetes Mellitus
NCT01194245,evaluates,Prandial Insulins
NCT01194245,measures_primary,Glycosylated Hemoglobin A1C
NCT01194245,measures_secondary,Mean Daily Insulin Dose
NCT01194245,measures_secondary,Percentage of Participants Meeting Glucose Targets
NCT01194245,has_criteria,10-point glucose monitoring
NCT06647745,involves,T2DM
NCT06647745,involves,Essential Hypertension
NCT06647745,evaluates,THP-00101
NCT06647745,evaluates,THP-00102
NCT06647745,evaluates,THP-00103
NCT06647745,measures_primary,Changes in HbA1c
NCT06647745,measures_secondary,Changes in MSSBP
NCT06647745,measures_secondary,Changes in glycemic parameter
NCT06647745,measures_secondary,Changes in blood pressure
NCT03470545,involves,Obstructive Hypertrophic Cardiomyopathy
NCT03470545,evaluates,Mavacamten
NCT03470545,measures_primary,peak oxygen consumption
NCT03470545,measures_secondary,NYHA Functional Class
NCT03470545,has_criteria,NYHA Class II or III
NCT00095147,involves,Rheumatoid Arthritis
NCT00095147,evaluates,Abatacept
NCT00095147,evaluates,Infliximab
NCT00095147,evaluates,Methotrexate
NCT00095147,measures_primary,DAS28 Score
NCT00095147,measures_secondary,Death
NCT00095147,measures_secondary,Serious Adverse Events
NCT00095147,measures_secondary,Adverse Events
NCT00095147,has_criteria,immunomodulatory drugs
NCT03785145,involves,Lateral Canthal Lines
NCT03785145,evaluates,MT10109L
NCT03785145,measures_primary,≥ 2-grade improvement
NCT03785145,measures_secondary,Facial Line Satisfaction Questionnaire
NCT03785145,has_criteria,≥ 2 Grade Improvement
NCT05882045,involves,Obesity
NCT05882045,involves,Cardiovascular Disease
NCT05882045,evaluates,Retatrutide
NCT05882045,measures_primary,Percent Change Body Weight
NCT05882045,measures_secondary,Change from Baseline BMI
NCT05882045,measures_secondary,Change from Baseline Waist Circumference
NCT05882045,measures_secondary,Percent Change Total Cholesterol
NCT05882045,measures_secondary,Percent Change Triglycerides
NCT05882045,measures_secondary,Change from Baseline Systolic Blood Pressure
NCT05882045,measures_secondary,Change from Baseline Diastolic Blood Pressure
NCT05882045,measures_secondary,Change from Baseline Hemoglobin A1c
NCT05882045,measures_secondary,Percent Change Fasting Insulin
NCT05882045,measures_secondary,Change from Baseline SF-36v2
NCT05882045,measures_secondary,Steady State AUC
NCT05882045,has_criteria,Baseline to Week 80
NCT01597245,involves,Psoriasis
NCT01597245,evaluates,Ixekizumab
NCT01597245,measures_primary,sPGA 0
NCT01597245,measures_secondary,PASI75
NCT01597245,has_criteria,Moderate to Severe
NCT05562947,involves,Neovascular Age-Related Macular Degeneration
NCT05562947,evaluates,Port Delivery System With Ranibizumab
NCT05562947,measures_primary,Change from baseline BCVA
NCT05562947,measures_secondary,CPT at Week 36
NCT05562947,measures_secondary,CST at Week 36
NCT05562947,has_criteria,Baseline up to Week 40
NCT01421147,involves,Type 1 Diabetes
NCT01421147,evaluates,basal insulin injection
NCT01421147,measures_primary,Change From Baseline
NCT01421147,measures_secondary,Insulin Antibody Levels
NCT01421147,measures_secondary,Hemoglobin A1c
NCT01421147,has_criteria,time of basal insulin injection
NCT02688647,involves,Idiopathic Pulmonary Fibrosis
NCT02688647,evaluates,Belumosudil
NCT02688647,measures_primary,Changes in FVC
NCT02688647,measures_primary,FVC% Predicted
NCT02688647,measures_secondary,Percentages of Subjects With TEAEs
NCT02688647,measures_secondary,Percentages of Subjects With SAEs
NCT02688647,measures_secondary,TEAEs Leading to Discontinuation
NCT02688647,has_criteria,20 to 60 years
NCT01113047,involves,Hypertensive Patients
NCT01113047,evaluates,Aliskiren
NCT01113047,measures_primary,Diastolic blood pressure
NCT01113047,measures_secondary,Systolic blood pressure
NCT01113047,measures_secondary,Heart rate
NCT01113047,measures_secondary,Pulse pressure
NCT01113047,measures_secondary,Responder rates
NCT01113047,measures_secondary,Normalization rates
NCT01113047,has_criteria,Essential hypertension stage II
NCT01113047,has_criteria,Age >= 18 years old
NCT01113047,has_criteria,Male and female patients
NCT01113047,has_criteria,Severe hypertension
NCT01113047,has_criteria,Poorly controlled diabetes mellitus
NCT01113047,has_criteria,History of myocardial infarction
NCT01113047,has_criteria,Presence of heart failure
NCT05157945,involves,Depression
NCT05157945,evaluates,ALTO-300
NCT05157945,measures_primary,change in MADRS
NCT05157945,measures_primary,change in CGI-S
NCT05157945,has_criteria,signing of ICF
NCT00894647,involves,Actinic Keratosis
NCT00894647,evaluates,study cream
NCT00894647,measures_primary,Percent change AK lesion count
NCT00894647,measures_secondary,Complete clearance of AK lesions
NCT00894647,has_criteria,≥ 10 clinically typical AKs
NCT00894647,has_criteria,cryosurgery on 5 to 14 AKs
NCT00894647,has_criteria,healed cryosurgery lesions
NCT01592747,involves,Autism
NCT01592747,involves,Asperger's Disorder
NCT01592747,involves,Pervasive Developmental Disorder Not Otherwise Specified
NCT01592747,evaluates,Memantine
NCT01592747,measures_primary,Time to First LTR
NCT01592747,measures_secondary,Change From Baseline in CCC-2 Speech Subscale
NCT01592747,measures_secondary,Change From Baseline in CCC-2 Syntax Subscale
NCT01592747,has_criteria,Previously Treated With Memantine
NCT06277245,involves,Atopic Dermatitis
NCT06277245,evaluates,LNK01001 Capsule
NCT06277245,measures_primary,EASI-75 at Week 16
NCT06277245,measures_secondary,Investigator's Global Assessment
NCT06277245,measures_secondary,Worst-Itch Numeric Rating Scale
NCT06277245,has_criteria,Baseline and Week 16
NCT05630547,involves,Multiple Sclerosis
NCT05630547,evaluates,SAR443820
NCT05630547,measures_primary,sNfL levels
NCT05630547,measures_secondary,gadolinium enhancing T1 lesions
NCT05630547,measures_secondary,T2 hyperintense lesions
NCT05630547,measures_secondary,Time to onset of CDP
NCT05630547,measures_secondary,Time to onset of 9-HPT
NCT05630547,measures_secondary,Time to onset of T25-FW
NCT05630547,has_criteria,Male and Female Adults
NCT01795547,involves,Schizophrenia
NCT01795547,evaluates,Aripiprazole
NCT01795547,evaluates,Paliperidone Palmitate
NCT01795547,measures_primary,Quality of Life Scale
NCT01795547,measures_secondary,Investigator's Assessment Questionnaire
NCT01795547,measures_secondary,Clinical Global Impression - Severity of Illness
NCT01506947,involves,Calcitriol-resistant anemia
NCT01506947,evaluates,Parathyroid Hormone (PTH)
NCT01506947,measures_primary,Erythropoietin dose
NCT01506947,measures_secondary,SF-36 score
NCT01506947,has_criteria,serum hemoglobin levels
NCT02589847,involves,Recurrent Clostridium Difficile Infection
NCT02589847,evaluates,RBX2660
NCT02589847,measures_primary,CDI-diarrhea free
NCT02589847,measures_secondary,Quality of Life
NCT02589847,has_criteria,study treatment
NCT00369577,involves,schizophrenia
NCT00369577,involves,schizophreniform disorder
NCT00369577,involves,schizoaffective disorder
NCT00369577,evaluates,Staccato Loxapine
NCT00369577,measures_primary,PANSS-EC Change
NCT00369577,measures_secondary,BARS Change
NCT00369577,measures_secondary,CGI-I After Drug Administration
NCT00369577,has_criteria,age 18-65 years
NCT00369577,has_criteria,DSM-IV criteria
NCT00369577,has_criteria,PANSS-EC ≥14
NCT00369577,has_criteria,at least 1 item ≥4
NCT00810277,involves,Rheumatoid Arthritis
NCT00810277,evaluates,Tocilizumab
NCT00810277,measures_primary,DAS28 Remission
NCT00810277,measures_secondary,DAS28
NCT00810277,has_criteria,Inadequate response DMARDs
NCT03797677,involves,CF
NCT03797677,involves,MND
NCT03797677,evaluates,MN4000
NCT03797677,measures_primary,Patient satisfaction
NCT03797677,measures_secondary,Adherence to treatment
NCT03797677,has_criteria,ALS-FRS
NCT00504777,involves,Rheumatoid Arthritis
NCT00504777,evaluates,MabThera
NCT00504777,evaluates,Methotrexate
NCT00504777,measures_primary,Change From Baseline
NCT00504777,measures_secondary,ACR20/50/70 response
NCT00504777,measures_secondary,EULAR Category
NCT00504777,has_criteria,Anti-TNF Agents
NCT03615677,involves,Erosive Esophagitis
NCT03615677,evaluates,LXI-15028
NCT03615677,evaluates,Esomeprazole
NCT03615677,measures_primary,Endoscopic healing rate
NCT03615677,measures_secondary,Reflux Disease Questionnaire (RDQ) score
NCT03615677,measures_secondary,Gastro Esophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) score
NCT03615677,has_criteria,Informed consent
NCT03615677,has_criteria,Understand protocol
NCT03615677,has_criteria,Comply protocol
NCT00079677,involves,Obstructive Sleep Apnea/Hypopnea Syndrome
NCT00079677,evaluates,Armodafinil
NCT00079677,measures_primary,MWT sleep latency
NCT00079677,measures_secondary,CGI-C ratings
NCT00079677,has_criteria,excessive sleepiness
NCT00079677,has_criteria,nCPAP therapy
NCT00079677,has_criteria,18 to 65 years
NCT05707377,involves,Primary Membranous Nephropathy
NCT05707377,evaluates,Zanubrutinib
NCT05707377,measures_primary,Change from Baseline in UPCR
NCT05707377,measures_secondary,Number of Participants Achieving Complete Remission
NCT05707377,has_criteria,anti- phospholipase A2 receptor (PLA2R) antibody level reduced from baseline to less than 14 RU/ml.
NCT05707377,has_criteria,UPCR (based on 24-hour urine collection) ≤ 0.3
NCT05707377,has_criteria,stable eGFR (remains unchanged or decreases by \< 15% compared with the baseline)
NCT00351377,involves,Autoimmune Diseases
NCT00351377,evaluates,Mycophenolate Mofetil
NCT00351377,evaluates,Enteric-coated Mycophenolate Sodium
NCT00351377,measures_primary,GI Symptom Severity
NCT00351377,measures_secondary,GIQLI
NCT00351377,has_criteria,Baseline visit
NCT00351377,has_criteria,6-8 week visit
NCT05357677,involves,Postherpetic Neuralgia
NCT05357677,evaluates,SR419
NCT05357677,measures_primary,Daily Average Pain Score
NCT05357677,measures_secondary,Patient Global Impression of Change
NCT05357677,measures_secondary,Daily Sleep Interference Score
NCT05357677,has_criteria,Adult over 18 years old
NCT05357677,has_criteria,Neuropathic pain PHN
NCT05357677,has_criteria,DN4 score ≥4
NCT05357677,has_criteria,Average PI-NRS score ≥4 and ≤9
NCT05357677,has_criteria,Female non-pregnant non-lactating
NCT01139047,involves,healthy skin
NCT01139047,evaluates,MetroGel 1%
NCT01139047,evaluates,Finacea 15%
NCT01139047,measures_primary,tolerability scores
NCT01139047,measures_secondary,subject preference
NCT01139047,has_criteria,healthy adults
NCT01139047,has_criteria,healthy skin
NCT01139047,has_criteria,no allergy
NCT01124877,involves,Bipolar I Disorder
NCT01124877,evaluates,Oral Ziprasidone
NCT01124877,measures_primary,Change from Baseline
NCT01124877,measures_secondary,Adverse events
NCT01124877,has_criteria,received study medication
NCT00526877,involves,Schizophrenia
NCT00526877,involves,Schizoaffective Disorders
NCT00526877,evaluates,Long-acting Risperidone
NCT00526877,measures_primary,PANSS Total Score
NCT00526877,measures_secondary,PSP Scale Score
NCT00526877,measures_secondary,CGI Scale Score
NCT00526877,measures_secondary,SF-36 Quality of Life Score
NCT00526877,has_criteria,Screening
NCT03821077,involves,Allergic Rhinitis
NCT03821077,involves,Rhinoconjunctivitis
NCT03821077,involves,Asthma
NCT03821077,evaluates,Allergovac Poliplus
NCT03821077,measures_primary,Combined Symptom and Medication Score
NCT03821077,measures_secondary,Rhinoconjunctivitis Quality of Life Questionnaire
NCT03821077,has_criteria,Basal-12 months
NCT03821077,has_criteria,Total number
NCT03821077,has_criteria,Patient´s Tolerability assessment using a Likert-type scale
NCT03821077,has_criteria,Patient's perception of the improvement in their global status using a Likert-type scale
NCT00932477,involves,Dry eye
NCT00932477,evaluates,Artificial Tears
NCT00932477,measures_primary,Biomicroscopy Findings
NCT00932477,measures_secondary,Best-Corrected Visual Acuity
NCT00932477,measures_secondary,Ophthalmic Adverse Events
NCT00932477,has_criteria,Mild
NCT00932477,has_criteria,Uncontrolled systemic disease
NCT01230177,involves,Rheumatoid arthritis
NCT01230177,evaluates,Etanercept
NCT01230177,measures_primary,Change in DAS28-4
NCT01230177,measures_secondary,Disease Activity Score of 28 Joints
NCT01230177,has_criteria,28 joints count
NCT03155347,involves,Rheumatoid Arthritis
NCT03155347,evaluates,Tocilizumab
NCT03155347,measures_primary,ACR20 Response
NCT03155347,measures_secondary,Disease Activity Score
NCT03155347,has_criteria,Inadequate Response
NCT00853047,involves,Carcinoid Syndrome
NCT00853047,evaluates,Telotristat Etiprate
NCT00853047,measures_primary,Change in Bowel Movements
NCT00853047,measures_secondary,Stool Form
NCT00853047,measures_secondary,Sensation of Urgency
NCT00853047,measures_secondary,Cutaneous Flushing Episodes
NCT00853047,measures_secondary,Abdominal Pain
NCT01396447,involves,bipolar I disorder
NCT01396447,evaluates,Cariprazine
NCT01396447,measures_primary,Change From Baseline
NCT01396447,measures_secondary,Change From Baseline
NCT01396447,has_criteria,DSM-IV-TR criteria
NCT01964547,involves,Multiple Sclerosis
NCT01964547,evaluates,Sativex
NCT01964547,measures_primary,PASAT Total Score
NCT01964547,measures_secondary,BDI-II Total Score
NCT01964547,has_criteria,Score of 21 or over
NCT01892345,involves,Neuromyelitis optica
NCT01892345,evaluates,Eculizumab
NCT01892345,measures_primary,Adjudicated ARR
NCT01892345,measures_secondary,EDSS
NCT01892345,measures_secondary,Modified Rankin Scale
NCT01892345,measures_secondary,Hauser Ambulation Index
NCT06006247,involves,Early Parkinson's Disease
NCT06006247,evaluates,CVN424
NCT06006247,measures_primary,MDS-UPDRS Part II + Part III
NCT06006247,measures_secondary,Clinical Global Impression
NCT06006247,has_criteria,Baseline and Up to Week 12
NCT06111547,evaluates,TAK-279
NCT06111547,measures_primary,AUC0-t of TAK-279
NCT06111547,measures_primary,AUC0-inf of TAK-279
NCT06111547,measures_primary,Cmax of TAK-279
NCT06111547,measures_primary,AUCtau of TAK-279
NCT06111547,measures_primary,Cmax
NCT06111547,measures_secondary,Number of participants with TEAEs
NCT06111547,measures_secondary,Number of participants with serious TEAEs
NCT06111547,measures_secondary,Number of participants with AESI
NCT06111547,measures_secondary,Number of participants with clinically significant changes in ECG
NCT06111547,measures_secondary,Number of participants with clinically significant changes in vital signs
NCT06111547,measures_secondary,Number of participants with clinically significant changes in clinical laboratory parameters
NCT06111547,has_criteria,Healthy Chinese Adults
NCT01707147,involves,Type 2 Diabetes Mellitus
NCT01707147,evaluates,Trajenta
NCT01707147,measures_primary,Glycosylated Hemoglobin (HbA1c)
NCT01707147,measures_secondary,Fasting Plasma Glucose (FPG)
NCT01707147,has_criteria,Patients started on Trajenta
NCT01967147,involves,Dry Eye
NCT01967147,evaluates,Systane® Balance
NCT01967147,measures_primary,TFBUT at Day 35
NCT01967147,measures_secondary,TOSS Score at Day 35
NCT01967147,measures_secondary,OSDI Score at Day 35
NCT01967147,measures_secondary,IDEEL Treatment Effectiveness Score at Day 35
NCT01967147,has_criteria,One eye (study eye)
NCT01371747,involves,Hyperkalemia
NCT01371747,involves,Hypertension
NCT01371747,involves,Diabetic Nephropathy
NCT01371747,evaluates,Patiromer
NCT01371747,measures_primary,Change in Serum Potassium
NCT01371747,measures_secondary,Proportion of Participants
NCT01371747,has_criteria,serum potassium
NCT01395147,involves,Major Depressive Disorder
NCT01395147,evaluates,Lu AA21004
NCT01395147,measures_primary,Change from Baseline in MADRS
NCT01395147,measures_secondary,Number of Participants Reporting Adverse Events
NCT01395147,measures_secondary,Number of Participants With Markedly Abnormal Laboratory Values
NCT01395147,measures_secondary,Significant Change from Baseline in Body Weight
NCT01395147,measures_secondary,Change from Baseline in Vital Signs
NCT01395147,measures_secondary,Change from Baseline in Electrocardiograms
NCT01395147,measures_secondary,Clinically Significant Change From Baseline in Physical Examination Findings
NCT01395147,has_criteria,Baseline and Weeks 4
NCT01955161,involves,Alzheimer's Disease
NCT01955161,evaluates,Idalopirdine
NCT01955161,measures_primary,Change in Cognition
NCT01955161,measures_secondary,Change in Daily Functioning
NCT01955161,measures_secondary,Change in Global Impression
NCT01955161,measures_secondary,Change in Behavioural Disturbance
NCT01955161,has_criteria,Baseline to Week 24
NCT05084261,involves,Ulcerative Colitis
NCT05084261,evaluates,BT051
NCT05084261,measures_primary,clinical response
NCT05084261,measures_secondary,remission
NCT05084261,has_criteria,change from baseline
NCT00856661,involves,Acute Ischemic Stroke
NCT00856661,evaluates,Desmoteplase
NCT00856661,measures_primary,mRS Scores 0-2
NCT00856661,measures_secondary,NIHSS Scores <=1 or NIHSS Decrease >=8
NCT00856661,measures_secondary,Composite of mRS & NIHSS Response
NCT00856661,has_criteria,Day 90
NCT04014361,evaluates,LY3154885
NCT04014361,measures_primary,Maximum Concentration
NCT04014361,measures_secondary,Time to Maximum Plasma Concentration
NCT04014361,measures_secondary,Area Under the Concentration Versus Time Curve to Infinity
NCT06606561,involves,Knee Osteoarthritis
NCT06606561,evaluates,NANOVAE
NCT06606561,measures_primary,incidence of adverse events
NCT06606561,measures_secondary,Single Leg Stance Test
NCT06606561,measures_secondary,Timed Up and Go Test
NCT06606561,measures_secondary,Western Ontario and McMaster Universities Osteoarthritis Index
NCT06606561,has_criteria,subjects with KOA
NCT02349061,involves,Systemic Lupus Erythematosus
NCT02349061,evaluates,Ustekinumab
NCT02349061,measures_primary,SRI-4 response
NCT02349061,measures_secondary,Physician's Global Assessment
NCT02349061,has_criteria,SLEDAI-2K score
NCT02177461,involves,Blood Hypertension
NCT02177461,evaluates,Telmisartan
NCT02177461,evaluates,Enalapril
NCT02177461,measures_primary,Systolic blood pressure
NCT02177461,measures_secondary,Adverse events
NCT02177461,measures_secondary,Patient withdrawals
NCT02177461,has_criteria,Elderly patients
NCT01155661,involves,Major Depressive Disorder
NCT01155661,measures_primary,Suicidal Ideation
NCT01155661,measures_secondary,Sexual functioning
NCT03738761,involves,Hypertension
NCT03738761,evaluates,Perindopril/Amlodipine
NCT03738761,evaluates,Perindopril/Indapamide/Amlodipine
NCT03738761,measures_primary,Office normal BP
NCT03738761,measures_secondary,Responder rate
NCT03738761,measures_secondary,Mean absolute change
NCT03738761,measures_secondary,Mean relative change
NCT03738761,has_criteria,Office normal BP
NCT05528861,involves,Chronic Spontaneous Urticaria
NCT05528861,evaluates,Lirentelimab
NCT05528861,measures_primary,Absolute Change in UAS7
NCT05528861,measures_secondary,HSS7
NCT05528861,measures_secondary,ISS7
NCT05528861,has_criteria,≥18 years of age
NCT05528861,has_criteria,CSU diagnosis
NCT05528861,has_criteria,refractory to H1-AH
NCT02394561,involves,Psoriasis
NCT02394561,evaluates,secukinumab
NCT02394561,measures_primary,PASI 90 response
NCT02394561,measures_secondary,IGA 0/1
NCT02394561,measures_secondary,PASI 50
NCT02394561,measures_secondary,PASI 75
NCT02394561,measures_secondary,PASI 100
NCT02394561,measures_secondary,DLQI
NCT02394561,has_criteria,Moderate to Severe
NCT04556383,involves,Ulcerative Colitis
NCT04556383,evaluates,GB004
NCT04556383,measures_primary,Clinical Remission
NCT04556383,measures_secondary,Clinical Response
NCT04556383,measures_secondary,Histologic Remission
NCT04556383,has_criteria,Adult Subjects
NCT03227861,involves,Human Immunodeficiency Virus Type 1
NCT03227861,evaluates,(D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen
NCT03227861,measures_primary,HIV-1 RNA < 50 Copies/mL
NCT03227861,measures_secondary,CD4+ cell count
NCT03227861,has_criteria,safety stopping rules
NCT03372161,involves,lumbosacral radicular pain
NCT03372161,evaluates,Corticosteroid Lumbar Epidural Analgesia
NCT03372161,measures_primary,Mean Numeric Pain Rating Scale
NCT03372161,measures_secondary,Oswestry Disability Index Score
NCT03372161,has_criteria,Age 18 to 70 years
NCT05509361,involves,Psoriasis
NCT05509361,evaluates,AK101 Injection
NCT05509361,measures_primary,PASI 50
NCT05509361,measures_secondary,PASI 90
NCT05509361,has_criteria,Completed AK101-302 trial
NCT05424887,involves,Idiopathic Pulmonary Fibrosis
NCT05424887,evaluates,AK3280
NCT05424887,measures_primary,Progression-free survival
NCT05424887,measures_secondary,%FVC decrease
NCT05424887,measures_secondary,%DLco decrease
NCT05424887,has_criteria,absolute decrease 10%
NCT05424887,has_criteria,absolute decrease 15%
NCT05424887,has_criteria,Non-elective hospitalization
NCT05424887,has_criteria,Death
NCT03363854,involves,Atopic Dermatitis
NCT03363854,evaluates,Tralokinumab
NCT03363854,measures_primary,EASI at Week 16
NCT03363854,measures_secondary,Worst Daily Pruritus NRS
NCT03363854,measures_secondary,SCORAD at Week 16
NCT03363854,measures_secondary,DLQI at Week 16
NCT03363854,has_criteria,Investigator's Global Assessment
NCT00887354,involves,Low Bone Mass
NCT00887354,involves,Hip Fracture
NCT00887354,evaluates,Two Drugs
NCT00887354,measures_primary,Change in Lumbar Spine Areal Bone Mineral Density
NCT00887354,measures_secondary,Change in Areal Bone Mineral Density Measured at the Femoral Neck and Total Hip of the Non-Fractured Limb
NCT00887354,measures_secondary,Change From Baseline in Physical Component Summary of the Short Form-36 (SF-36) Questionnaire
NCT00887354,has_criteria,type of hip fracture
NCT00887354,has_criteria,glucocorticoids used at baseline
NCT00887354,has_criteria,duration of prior bisphosphonate use
NCT01190254,involves,Schizophrenia
NCT01190254,evaluates,Asenapine
NCT01190254,measures_primary,Change From Baseline in PANSS Total Score at Day 56
NCT01190254,measures_secondary,Change From Baseline in CGI-S Score at Day 56
NCT01190254,has_criteria,Baseline and Day 56
NCT04620733,involves,Primary Biliary Cholangitis
NCT04620733,evaluates,Seladelpar
NCT04620733,measures_primary,ALP <1.67 × ULN
NCT04620733,measures_primary,≥15% Reduction in ALP
NCT04620733,measures_primary,Total Bilirubin ≤ 1.0× ULN
NCT04620733,measures_secondary,Treatment-emergent Adverse Events
NCT04620733,measures_secondary,Serious TEAEs
NCT04620733,measures_secondary,Shift of ≥ 2 CTCAE Grades
NCT04620733,has_criteria,Inadequate Control to or Intolerance to Ursodeoxycholic Acid
NCT03371251,involves,Systemic Lupus Erythematosus
NCT03371251,evaluates,BOS161721
NCT03371251,measures_primary,SRI-4 Response
NCT03371251,measures_secondary,SLEDAI-2K score
NCT03371251,has_criteria,moderate to severe SLE
NCT06470451,involves,cutaneous T-cell lymphoma
NCT06470451,evaluates,Topical HyBryte™
NCT06470451,measures_primary,mCAILS score
NCT06470451,measures_secondary,Patch Lesion Response Rates
NCT06470451,measures_secondary,Plaque Lesion Response Rates
NCT06470451,has_criteria,clinical diagnosis of CTCL
NCT06470451,has_criteria,minimum of three lesions
NCT06470451,has_criteria,written informed consent
NCT00451451,involves,Relapsing-Remitting Multiple Sclerosis
NCT00451451,evaluates,Oral BG00012
NCT00451451,measures_primary,Annualized Relapse Rate
NCT00451451,measures_secondary,Number of New T2 Hyperintense Lesions
NCT00451451,measures_secondary,Number of New T1 Hypointense Lesions
NCT00451451,measures_secondary,Proportion of Subjects Relapsed
NCT00451451,has_criteria,EDSS score≤2.0
NCT01340651,involves,Myelofibrosis
NCT01340651,evaluates,Ruxolitinib (INCB018424)
NCT01340651,measures_primary,Overall Response
NCT01340651,measures_secondary,Spleen Volume
NCT01340651,has_criteria,splenomegaly ≥ 10 cm
NCT03765554,evaluates,PF-06700841
NCT03765554,measures_primary,Cmax of PF-06700841
NCT03765554,measures_primary,AUClast of PF-06700841
NCT03765554,measures_primary,Tmax of PF-06700841
NCT03765554,measures_primary,AUCinf of PF-06700841
NCT03765554,measures_secondary,Change from baseline in 12-Lead ECG parameters
NCT03765554,measures_secondary,Change from baseline in heart rate
NCT03765554,measures_secondary,Change from baseline in blood pressure
NCT03765554,measures_secondary,Change from baseline in pulse rate
NCT03765554,measures_secondary,Change from baseline in oral temperature
NCT03765554,measures_secondary,Number of participants with laboratory abnormalities
NCT03765554,measures_secondary,Number of participants with Treatment-Emergent Adverse Events
NCT03765554,measures_secondary,Number of participants with Serious Adverse Events
NCT03765554,measures_secondary,Number of participants with Discontinuation Due to AEs
NCT03765554,has_criteria,Healthy male
NCT03765554,has_criteria,Healthy female
NCT03765554,has_criteria,Age 18 to 55 years
NCT03765554,has_criteria,BMI 17.5 to 30.5 kg/m2
NCT00056654,involves,Prostate Cancer
NCT00056654,evaluates,Leuprolide Acetate
NCT00056654,measures_primary,ECOG performance status
NCT00056654,measures_secondary,symptom severity
NCT00056654,measures_secondary,prostate specific antigen
NCT00056654,measures_secondary,prostatic acid phosphatase
NCT00056654,has_criteria,Histological diagnosis of prostate cancer
NCT00056654,has_criteria,Need for androgen deprivation treatment
NCT00056654,has_criteria,Serum testosterone level ≥ 150 ng/dL
NCT00056654,has_criteria,Life expectancy of at least 18 months
NCT00056654,has_criteria,ECOG Performance status grades 0
NCT01907854,involves,Type 2 Diabetes
NCT01907854,evaluates,Liraglutide
NCT01907854,measures_primary,Change in HbA1c
NCT01907854,measures_secondary,Change in Body Weight
NCT01907854,measures_secondary,Change in Fasting Plasma Glucose
NCT01907854,measures_secondary,Change in Fasting Blood Lipids
NCT01907854,measures_secondary,Change in Systolic Blood Pressure
NCT01907854,measures_secondary,Change in Diastolic Blood Pressure
NCT01907854,measures_secondary,Subjects Who Achieve HbA1c Below 7.0%
NCT01907854,measures_secondary,Number of Treatment Emergent Adverse Events
NCT01907854,has_criteria,randomised subjects
NCT00411554,involves,Type 2 Diabetes Mellitus
NCT00411554,evaluates,Sitagliptin
NCT00411554,measures_primary,Change From Baseline in HbA1c
NCT00411554,measures_secondary,Change From Baseline in Fasting Plasma Glucose
NCT00411554,measures_secondary,Change From Baseline in 2 Hour Postprandial Glucose
NCT00411554,has_criteria,type 2 diabetes mellitus
NCT00411554,has_criteria,diet/exercise therapy
NCT03304054,involves,Myasthenia Gravis
NCT03304054,evaluates,Amifampridine Phosphate
NCT03304054,measures_primary,Change from baseline
NCT03304054,measures_secondary,Quantitative Myasthenia Gravis
NCT03304054,has_criteria,diagnos
NCT01582854,involves,Post-stroke Cognitive Impairment
NCT01582854,evaluates,Actovegin
NCT01582854,measures_primary,Change From Baseline in ADAS-cog+
NCT01582854,measures_secondary,Change From Baseline in ADAS-cog+
NCT01582854,has_criteria,Baseline ADAS-cog+ score
NCT06010654,involves,Generalized Anxiety Disorder
NCT06010654,evaluates,ANZEILAX
NCT06010654,measures_primary,GAD-7 scale
NCT06010654,measures_secondary,Beck Anxiety Inventory
NCT06010654,measures_secondary,Penn State Worry Questionnaire
NCT06010654,measures_secondary,Hospital Anxiety and Depression Scale
NCT06010654,has_criteria,severity of conditions
NCT00809354,involves,Osteoarthritis
NCT00809354,evaluates,Tanezumab
NCT00809354,measures_primary,Change From Baseline
NCT00809354,measures_secondary,Change From Baseline
NCT00809354,has_criteria,Knee or Hip
NCT04893551,involves,Relapsed
NCT04893551,evaluates,Tilvestamab (BGB149)
NCT04893551,measures_primary,Number of Participants
NCT04893551,measures_secondary,Laboratory Abnormalities
NCT04893551,measures_secondary,Vital Sign Abnormalities
NCT04893551,measures_secondary,Electrocardiogram Abnormalities
NCT04893551,measures_secondary,Physical Examinations Abnormalities
NCT04893551,measures_secondary,Concomitant Medication Use
NCT04893551,has_criteria,Screening
NCT01230853,involves,Alzheimer's disease
NCT01230853,evaluates,lecanemab
NCT01230853,measures_primary,safety and tolerability
NCT01230853,measures_secondary,safety and tolerability
NCT01230853,has_criteria,stable treatment
NCT02670551,involves,bipolar I disorder
NCT02670551,evaluates,Cariprazine
NCT02670551,measures_primary,Change From Baseline in MADRS Score
NCT02670551,measures_secondary,Change From Baseline in CGI-S Score
NCT02670551,has_criteria,DSM-5 criteria for bipolar I disorder
NCT05707351,involves,Hemophilia A
NCT05707351,evaluates,Adynovate
NCT05707351,measures_primary,Total Annualized Bleeding Rates
NCT05707351,measures_secondary,Number of Adynovate Infusions
NCT05707351,has_criteria,Previously Treated
NCT03439254,involves,Nonalcoholic Steatohepatitis
NCT03439254,evaluates,Obeticholic Acid
NCT03439254,measures_primary,Fibrosis improvement
NCT03439254,measures_secondary,Adverse Events
NCT03439254,has_criteria,Compensated Cirrhosis
NCT03728933,involves,Restless Legs Syndrome
NCT03728933,evaluates,Rotigotine Patch
NCT03728933,measures_primary,Change From Baseline
NCT03728933,measures_secondary,Clinical Global Impressions
NCT03728933,measures_secondary,Percentage of Participants
NCT03728933,has_criteria,Treatment Period
NCT01918033,involves,Perennial Allergic Rhinitis
NCT01918033,evaluates,Desloratadine
NCT01918033,measures_primary,Change From Baseline in TNSS
NCT01918033,measures_secondary,Number of Participants Experiencing an AE
NCT01918033,measures_secondary,Number of Participants Discontinuing Study Drug Due to an AE
NCT01918033,has_criteria,Nasal symptoms of sneezing
NCT01624233,involves,Psoriasis
NCT01624233,evaluates,Ixekizumab
NCT01624233,measures_primary,PASI improvement
NCT01624233,measures_secondary,Ctrough ss
NCT01624233,has_criteria,Japanese Participants
NCT00787254,involves,Gastric Ulcer
NCT00787254,involves,Duodenal Ulcer
NCT00787254,evaluates,Lansoprazole
NCT00787254,measures_primary,Number of participants
NCT00787254,measures_secondary,Lanza Score
NCT00787254,has_criteria,Nonsteroidal Anti-Inflammatory Drugs
NCT01968954,involves,Hyperlipidemia
NCT01968954,involves,Mixed Dyslipidemia
NCT01968954,evaluates,Bococizumab
NCT01968954,evaluates,PF-04950615
NCT01968954,evaluates,RN316
NCT01968954,measures_primary,Percent Change LDL-C
NCT01968954,measures_secondary,Percent Change TC
NCT01968954,measures_secondary,Percent Change Non HDL-C
NCT01968954,measures_secondary,Percent Change ApoB
NCT01968954,measures_secondary,Percent Change Lipoprotein(a)
NCT01968954,measures_secondary,Percent Change HDL-C
NCT01968954,measures_secondary,Percent Change Fasting LDL-C
NCT01968954,measures_secondary,Percent Change Fasting TG
NCT01968954,has_criteria,triglycerides level less than 200 mg/dL
NCT01968954,has_criteria,triglycerides level greater than or equal to 200 mg/dL
NCT01370733,involves,Major Depressive Disorder
NCT01370733,evaluates,Synchronized Transcranial Magnetic Stimulation
NCT01370733,measures_primary,HAM-D17 Total Score Change
NCT01370733,measures_secondary,HAM-D17 Total Score Change
NCT01370733,has_criteria,completed Week 6
NCT02253654,involves,Chronic Kidney Disease
NCT02253654,evaluates,Epoetin Alfa
NCT02253654,measures_primary,Hemoglobin percentage
NCT02253654,measures_secondary,Transfusion events
NCT02253654,has_criteria,Hemodialysis
NCT02760433,involves,Rheumatoid Arthritis
NCT02760433,evaluates,Olokizumab
NCT02760433,measures_primary,ACR20 response
NCT02760433,measures_secondary,Disease Activity Score 28-joint count (DAS28)
NCT02760433,measures_secondary,Health Assessment Questionnaire Disability Index (HAQ-DI)
NCT02760433,has_criteria,active disease
NCT03097133,involves,Major Depressive Disorder
NCT03097133,evaluates,Intranasal Esketamine
NCT03097133,measures_primary,Change From Baseline
NCT03097133,measures_secondary,CGI-SS-R Scale
NCT03097133,has_criteria,Imminent Risk for Suicide
NCT01127633,involves,Alzheimer's Disease
NCT01127633,evaluates,Solanezumab
NCT01127633,measures_primary,ADAS-Cog14
NCT01127633,measures_secondary,ADCS-ADL
NCT01127633,has_criteria,Baseline age
NCT06011733,involves,Plaque Psoriasis
NCT06011733,evaluates,Bimekizumab
NCT06011733,measures_primary,PASI90 response
NCT06011733,measures_secondary,PASI75 response
NCT06011733,has_criteria,Chinese Adult Study Participants
NCT01468233,involves,Hidradenitis Suppurativa
NCT01468233,evaluates,Adalimumab
NCT01468233,measures_primary,HiSCR at Week 12
NCT01468233,measures_secondary,Patient's Global Assessment of Skin Pain
NCT01468233,has_criteria,Hurley Stage
NCT02746133,involves,chronic kidney disease
NCT02746133,evaluates,Ketosteril
NCT02746133,has_criteria,pre-dialytic
NCT01616654,involves,Acne Vulgaris
NCT01616654,evaluates,CD5789
NCT01616654,measures_primary,Success Rate 1
NCT01616654,measures_secondary,Success Rate 2
NCT01616654,has_criteria,two-point reduction
NCT04072354,involves,Schizophrenia
NCT04072354,evaluates,Investigational Drug
NCT04072354,measures_primary,Change from Baseline in PANSS total score
NCT04072354,measures_secondary,Change from Baseline in CGI-S score
NCT04072354,has_criteria,Male or female subject between 13 to 65 years of age
NCT04072354,has_criteria,DSM-5 criteria for schizophrenia
NCT04072354,has_criteria,CGI-S score ≥ 4
NCT04072354,has_criteria,PANSS total score ≥ 80
NCT04072354,has_criteria,PANSS item score ≥ 4 on 2 or more of the following PANSS items: delusions
NCT04072354,has_criteria,acute exacerbation of psychotic symptoms
NCT04072354,has_criteria,marked deterioration of functioning in one or more areas
NCT06045754,involves,Crohn's Disease
NCT06045754,evaluates,Vedolizumab
NCT06045754,evaluates,Adalimumab
NCT06045754,evaluates,Ustekinumab
NCT06045754,measures_primary,Clinical Remission
NCT06045754,measures_secondary,PRO2 Remission
NCT06045754,has_criteria,CDAI score
NCT01729754,involves,Chronic Plaque Psoriasis
NCT01729754,evaluates,Tildrakizumab
NCT01729754,measures_primary,PASI-75 Response
NCT01729754,measures_secondary,PGA Score
NCT01729754,measures_secondary,Adverse Event
NCT01729754,has_criteria,Moderate-to-Severe
NCT06478433,involves,Adenectomy
NCT06478433,involves,Adenotonsillectomy
NCT06478433,evaluates,Device
NCT06478433,measures_primary,Lund-kennedy Score
NCT06478433,measures_secondary,QoL
NCT06478433,has_criteria,Patients aged 2 to 17 years
NCT06478433,has_criteria,Informed consent
NCT02633033,involves,Multiple Sclerosis Relapse
NCT02633033,evaluates,Acthar Gel
NCT02633033,measures_primary,MSIS-29v1 Physical
NCT02633033,measures_secondary,EDSS/FSS
NCT02633033,has_criteria,relapse during study period
NCT02495233,involves,Advanced Non-Small-Cell Lung Cancer
NCT02495233,evaluates,ASP2215
NCT02495233,evaluates,Erlotinib
NCT02495233,measures_primary,Objective Response Rate
NCT02495233,measures_secondary,AUC24
NCT02495233,measures_secondary,Cmax
NCT02495233,measures_secondary,Tmax
NCT02495233,measures_secondary,Ctrough
NCT06540833,involves,Psychosis Associated With Alzheimer's Disease
NCT06540833,evaluates,ITI-1284
NCT06540833,measures_primary,BEHAVE-AD psychosis subscale score
NCT06540833,measures_secondary,CGI-S score
NCT06540833,has_criteria,Week 6
NCT01663233,involves,Hypertension
NCT01663233,evaluates,LCZ696
NCT01663233,evaluates,Amlodipine
NCT01663233,measures_primary,Change in maSBP
NCT01663233,measures_primary,Change in maDBP
NCT01663233,measures_secondary,Change in msSBP
NCT01663233,measures_secondary,Change in msDBP
NCT01663233,measures_secondary,Change in PP
NCT01663233,measures_secondary,Number of Participants Achieving Systolic and Diastolic Blood Pressure Control
NCT01663233,has_criteria,Not Responding to Amlodipine
NCT02063854,evaluates,NE-58095 Tablets
NCT02063854,measures_primary,Percent Change BMD
NCT02063854,measures_secondary,Bone Turnover Marker
NCT02063854,has_criteria,Baseline and Month 12
NCT05462054,involves,STXBP1 Encephalopathy with Epilepsy
NCT05462054,measures_primary,Changes in seizure frequency
NCT05462054,measures_secondary,Changes in neurodevelopment parameters
NCT05462054,has_criteria,calendar age and VABS-II age-equivalent score
NCT02006654,involves,Alzheimer's Disease
NCT02006654,evaluates,Idalopirdine
NCT02006654,measures_primary,Change in Cognition
NCT02006654,measures_secondary,Change in Global Impression
NCT02006654,measures_secondary,Change in Daily Functioning
NCT02006654,measures_secondary,Change in Behavioural Disturbance
NCT02006654,has_criteria,Baseline and Week 24
NCT05514054,involves,Early Breast Cancer
NCT05514054,evaluates,Imlunestrant
NCT05514054,measures_primary,Invasive Disease-Free Survival
NCT05514054,measures_secondary,Distant Recurrence-Free Survival
NCT05514054,measures_secondary,Overall Survival
NCT05514054,measures_secondary,Pharmacokinetics
NCT05514054,measures_secondary,Change from Baseline in the EORTC QLQ-C30 Physical Functioning
NCT05514054,measures_secondary,Change from Baseline in the EORTC QLQ-C30 Role Functioning
NCT05514054,has_criteria,Randomization to recurrence or death
NCT00857233,involves,Alzheimer's Disease
NCT00857233,evaluates,Memantine
NCT00857233,measures_primary,Change from Baseline in the NPI total score.
NCT00857233,measures_secondary,Change from Baseline in the SIB total score.
NCT00857233,measures_secondary,CIBIC-plus
NCT00857233,has_criteria,Baseline and Week 24
NCT00706654,involves,Schizophrenia
NCT00706654,evaluates,Intramuscular Depot Formulation of Aripiprazole
NCT00706654,measures_primary,Time to Exacerbation
NCT00706654,measures_secondary,Percentage of Responders
NCT00706654,measures_secondary,Percentage of Patients Achieving Remission
NCT00706654,has_criteria,Exacerbation of Psychotic Symptoms/Impending Relapse Criteria
NCT00706654,has_criteria,Responder criteria
NCT00385736,involves,Ulcerative Colitis
NCT00385736,evaluates,Adalimumab
NCT00385736,measures_primary,Clinical Remission
NCT00385736,measures_secondary,Clinical Response
NCT00385736,measures_secondary,Mucosal Healing
NCT00385736,measures_secondary,Rectal Bleeding Subscore
NCT00385736,has_criteria,Mayo score <=2
NCT00386607,involves,High Blood Pressure
NCT00386607,evaluates,Aliskiren/Valsartan
NCT00386607,evaluates,Aliskiren
NCT00386607,evaluates,Valsartan
NCT00386607,evaluates,Hydrochlorothiazide
NCT00386607,measures_primary,Change From Baseline
NCT00386607,measures_secondary,Percentage of Patients
NCT00386607,has_criteria,Blood Pressure Control
NCT03518073,involves,Alzheimer's Disease
NCT03518073,evaluates,LY3303560
NCT03518073,measures_primary,Change from baseline
NCT03518073,measures_secondary,ADAS-Cog13 Score
NCT03518073,has_criteria,acetylcholinesterase inhibitor